,Generic Name,Trade Name,Date Designated,Orphan Designation,Orphan Designation Status,Date Designation Withdrawn or Revoked,FDA Orphan Approval Status,Approved Labeled Indication,Marketing Approval Date,Exclusivity End Date,"Exclusivity Protected Indication * (Shown for approvals from Jan. 1, 2013, to the present)",Sponsor Company,Sponsor Address 1,Sponsor Address 2,Sponsor City,Sponsor State,Sponsor Zip,Sponsor Country,CF Grid Key,GardName,GardId,Orphan
0,"Glycine, L-prolyl-L-prolyl-L-leucyl-L-seryl-L-glutaminyl-L-(i-circumflex plus/minus)-glutamyl-L-threonyl-L-phenylalanyl-L-seryl-L-(i-circumflex plus/minus)-aspartyl-L-leucyl-L-tryptophyl-L-lysyl-L-leucyl-L-leucyl-L-lysyl-L-lysyl-L-tryptophyl-L-lysyl-L-methionyl-L-arginyl-L-arginyl-L-asparaginyl-L-glutaminyl-L-phenylalanyl-L-tryptophyl-L-valyl-L-lysyl-L-valyl-L-glutaminyl-L-arginyl-",,3/21/2023,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Oncolyze, Inc.",845 UN Plaza,61b,New York City,New York,' 10017 ' ,United States,930422,multiple myeloma,"""gard:0007108""",
1,"N-[3-fluoro-4-[[1-methyl-6-(1H-pyrazol-4-yl)-1H-indazol-5-yl]oxy]phenyl]-1-(4-fluorophenyl)-1,2-dihydro-6-(1-methylethoxy)-2-oxo-3-pyridinecarboxamide",,5/16/2023,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Tyligand Bioscience (Shanghai) Limited,"No.3728 Jinke Road, Zhangjiang Hi-Tech Park","West wing, building 1",Shanghai,Shanghai,' 201203 ' ,China,937623,acute myeloid leukemia,"""gard:0012757""",
2,"(2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl]oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate",,6/22/2017,treatment of chronic myelomonocytic leukemia (cmml),Designated,,Not FDA Approved for Orphan Indication,,,,,Pharmavant 7 Sciences GmBH,Viaduktstr. 8,,Basel,,' 4051 ' ,Switzerland,581717,chronic myelomonocytic leukemia,"""gard:0008225""",
3,(S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin- 3-yl)methoxy)benzaldehyde,,5/16/2022,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Global Blood Therapeutics, Inc.",181 Oyster Point Blvd,,South San Francisco,California,' 94080 ' ,United States,877122,,,
4,1-(2-Nitro-imidazolyl)-3-[18F]fluoro-2-propanol;1H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole,,1/6/2016,"as a diagnostic for clinical management of soft tissue sarcoma, including rhabdomyosarcoma.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,' 33467 ' ,United States,509715,rhabdomyosarcoma,"""gard:0011951""",
5,"2-(2-{[2-(1H-benzimidazol-2-yl)ethyl]amino}ethyl)-N-[(3-fluoropyridin-2-yl)methyl]-1,3-oxazole-4-carboxamide trihydrochloride",,6/17/2019,treatment of beta-thalassemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vifor Pharma, Inc.",200 Cardinal Way,,Redwood City,California,' 94063 ' ,United States,688419,beta-thalassemia,"""gard:0000871""",
6,2-{[2-benzyl-4-(5-methyl-3H-imidazol-4-ylmethyl)-3-oxo-piperazine-1-carbonyl]- amino}-4methyl-pentanoic acid,,3/7/2023,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Prescient Therapeutics, LTD",Level 4,100 Albert Road,South Melbourne,VIC,' 03205 ' ,Australia,927422,lymphoma,"""gard:0020548""",
7,3-(5-cyano-4-(cyclopropylamino)pyridin-2-yl)-1-(6-formyl-5-((4-methyl-2-oxopiperazin-1-yl)methyl)pyridin-2-yl)-1-methylurea,,3/27/2023,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Wuxi Abbisko Biomedical Technology Co., Ltd.","Building E, Xingye Building, 97-1",Linghu Avenue,Wuxi,Jiangsu,' 214000 ' ,China,932323,soft tissue sarcoma,"""gard:0004898""",
8,"3-tert-butyl-N-{(1R)-1-[4-(6-{6-[4-({1-[4-(2,4-dioxo-1,3-diazinan-1-yl)phenyl]piperidin-4-yl}methyl)piperazin-1-yl]pyridin-3-yl}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-2-methylphenyl]ethyl}-1,2,4-oxadiazole-5-carboxamide",,12/5/2023,treatment of mantle cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,BeiGene USA Inc,"1840 Gateway Drive, 3rd Floor",,San Mateo,California,' 94404 ' ,United States,973323,lymphoma,"""gard:0020548""",
9,"a non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the human Methyl CpG Binding Protein 2B (MECP2B) cDNA under the control of a segment of the murine MECP2 promoter.",,4/17/2019,treatment of rett syndrome (rtt),Designated/Designation Withdrawn or Revoked,1/31/2022,Not FDA Approved for Orphan Indication,,,,,"Novartis Institute for BioMedical Research, Inc.",181 Massachusetts Avenue,,Cambridge,Massachusetts,' 02139 ' ,United States,681219,rett syndrome,"""gard:0005696""",
10,A potent negative allosteric modulator (NAM) of human alpha5-GABAA receptor,,1/31/2024,treatment of trigeminal neuralgia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shanghai SIMR Biotechnology Co., Ltd.","Building 26, 100 Banxia Road",Pudong New District,Shanghai,Shanghai,' 201318 ' ,China,951123,trigeminal neuralgia,"""gard:0007805""",
11,A recombinant plasmid-derived DNA-based vaccine targeting the E6 and E7 antigens of both HPV6 and HPV11,,7/28/2020,treatment of recurrent respiratory papillomatosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Inovio Pharmaceuticals, Inc.",660 West Germantown Pike,Suite 110,Plymouth Meeting,Pennsylvania,' 19462 ' ,United States,751220,recurrent respiratory papillomatosis,"""gard:0000111""",
12,Ac-Cys-Arg-Gly-Asp-Lys-Gly-Pro-Asp-Cys-NH2 (Cys:Cys disulfide linkage),,8/3/2023,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Lisata Therapeutics, Inc",110 Allen Road,Second Floor,Basking Ridge,New Jersey,' 07920 ' ,United States,952423,,,
13,Adeno-associated Virus Vector Expressing Human SERCA2a Gene,,12/6/2023,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Sardocor Corp.,"6 Tide Street, 2nd Floor",,Boston,Massachusetts,' 02210 ' ,United States,973523,muscular dystrophy,"""gard:0007922""",
14,allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting CD19 antigen,,2/16/2021,treatment of acute lymphoblastic leukemia,Designated/Designation Withdrawn or Revoked,2/20/2024,Not FDA Approved for Orphan Indication,,,,,"CRISPR Therapeutics, Inc.",610 Main Street,,Cambridge,Massachusetts,' 02139 ' ,United States,799420,acute lymphoblastic leukemia,"""gard:0000522""",
15,Aminouridyl phenoxypiperidinbenzyl butamide,,10/12/2021,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Anviron Corporation,4 Trouville,,Newport Coast,California,' 92657 ' ,United States,840521,,,
16,antibody drug conjugate comprised of an anti-B cell maturation (BCMA) IgG1 humanized antibody conjugated covalently to the dibenzocyclooctyne (DBCO) noncleavable linker maytansinoid warhead,,2/23/2021,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,802520,multiple myeloma,"""gard:0007108""",
17,apadamtase alfa,,9/28/2020,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Baxalta US Inc.,300 Shire Way,,Lexington,Massachusetts,' 02421 ' ,United States,768720,,,
18,ascorbic acid,,5/11/2009,treatment of charcot-marie-tooth disease type 1a.,Designated,,Not FDA Approved for Orphan Indication,,,,,Murigenetics SAS,Faculte de Medecine Timone,,13005 Marseille,,' ' ,France,280909,charcot-marie-tooth disease type 1,"""gard:0012433""",
19,autologous T-cells ex vivo modified with a lentiviral vector encoding a chimeric antigen receptor specific for CD1a,,9/5/2023,treatment of acute lymphoblastic leukemia/lymphoblastic lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,OneChain Immunotherapeutics S.L.,"Muntaner, 383, 3º-2ª",,Barcelona,,' 08021 ' ,Spain,958223,lymphoma,"""gard:0020548""",
20,Bcl-2 Family Protein Inhibitor,,12/19/2007,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,"Dept #PA72, Bldg. AP30-4",North Chicago,Illinois,' 60064 ' ,United States,251307,small cell lung cancer,"""gard:0009344""",
21,birtamimab,,2/17/2012,treatment of aa amyloidosis and al amyloidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Prothena Therapeutics Limited,Treasury Building,Lower Grand Canal Street,Dublin,2,' ' ,Ireland,361411,amyloidosis,"""gard:0018676""",
22,bosentan,Tracleer,10/6/2000,treatment of pulmonary arterial hypertension,Designated/Approved,,,Treatment of pulmonary arterial hypertension.,11/20/2001,11/20/2008,,Actelion Pharmaceuticals Ltd,1840 Gateway Drive,Suite 300,Cherry Hill,New Jersey,' 08002 ' ,United States,134200,pulmonary arterial hypertension,"""gard:0007501""",
23,bosentan,Tracleer,10/6/2000,treatment of pulmonary arterial hypertension,Designated/Approved,,,"Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability",9/5/2017,9/5/2024,"Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability",Actelion Pharmaceuticals Ltd,1840 Gateway Drive,Suite 300,Cherry Hill,New Jersey,' 08002 ' ,United States,134200,pulmonary arterial hypertension,"""gard:0007501""",
24,CDK inhibitor (CDKI) of CDK2/4/6,,3/3/2021,"treatment of patients with malignant gliomas (including glioblastoma, astrocytoma, and oligodendroglioma)",Designated,,Not FDA Approved for Orphan Indication,,,,,"Nuvation Bio, Inc.","1500 Broadway, Suite 1401",,New York,New York,' 10036 ' ,United States,805820,astrocytoma,"""gard:0012928""",
25,CRISPR/Cas13X RNA base-editing gene therapy drug targeting human OTOF Q829X mutation,,2/29/2024,treatment of otof q829x mutation-induced hearing loss,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cholgene Therapeutics, Inc.","651N. Broad Street, Suite 206",,Middletown,Delaware,' 19709 ' ,United States,990823,,,
26,DNA plasmid encoding the human transferrin gene,,9/25/2020,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"Eyevensys, Inc.",185 Alewife Brook Parkway,Suite 210,Cambridge,Massachusetts,' 02138 ' ,United States,766920,retinitis pigmentosa,"""gard:0005694""",
27,ezurpimtrostat,,1/18/2023,treatment of hepatocellular carcinoma (hcc),Designated,,Not FDA Approved for Orphan Indication,,,,,Genoscience Pharma,"10, rue d’Iéna",,Marseille,Provence,' 13006 ' ,France,922922,hepatocellular carcinoma,"""gard:0016773""",
28,Fc-fusion protein comprised of an anti-CXCR4 i-body tethered at its C-terminus to constant domains 2 and 3 of the Fc region of a mutated human IgG1,,2/22/2021,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,AdAlta Limited,15/2 Park Drive,,Bundoora,VIC,' 3083 ' ,Australia,800420,idiopathic pulmonary fibrosis,"""gard:0008609""",
29,Gallium-68 DOTANOC,,4/1/2020,diagnostic for the management of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",3651 FAU Blvd.,,Boca Raton,Florida,' 33467 ' ,United States,734120,neuroblastoma,"""gard:0007185""",
30,half-life extended bispecific T cell engager (BiTE®) antibody construct designed to target both CLDN18.2 and CD3,,7/31/2020,"treatment of gastric cancer, including cancer of gastroesophageal junction",Designated,,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,' 91320 ' ,United States,752720,,,
31,highly selective histone deacetylase 6 inhibitor,,3/17/2020,treatment of charcot-marie-tooth disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Chong Kun Dang Pharmaceutical Co., Ltd.","8, Chungjeong-ro, Seodaemun-gu,",,Seoul,,' ' ,South Korea,728619,,,
32,IgG1 antibody directed against the extra domain-B splice variant of fibronectin and conjugated to auristatin,,5/3/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Pyxis Oncology,"321 Harrison Avenue, Floor 11, Suite 1",,Boston,Massachusetts,' 02118 ' ,United States,936023,,,
33,"N-[(2R)-1-[(2S)-2-[(3-hydroxy-2-methyl-6-{[(3S)-3,5,12-trihydroxy-3-(2-hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl]oxy}oxan-4-yl)carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]pyridine-4-carboxamide",,9/1/2022,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Avacta Life Sciences Ltd.,"Scale Space, White City, Imperial College Campus",58 Wood Lane,London,,' W12 7RZ ' ,United Kingdom,887022,soft tissue sarcoma,"""gard:0004898""",
34,"N-[(2S)-1-[(3aS,6R,6aR)-6-Ethynyl-3-oxohexahydro-2H-furo[3,2-b]pyrrol-4-yl]-4-methyl-1-oxopentan-2-yl]-4-[5-fluoro-2-(4-methylpiperazin-1-yl)-1,3-thiazol-4-yl]benzamide hydrochloride",,4/15/2024,treatment of legg-calve-perthes disease (lcpd),Designated,,Not FDA Approved for Orphan Indication,,,,,Medivir AB,"Box 1086, Lunastigen 5, 2nd floor",,Huddinge,Huddinge,' Se-141 22 ' ,Sweden,952323,,,
35,"N-[4-[[2-(1,1-Dimethylethyl)phenyl]sulfonyl]phenyl]-2,3,4-trihydroxy-5-[[2-(1-methylethyl)phenyl]methyl]benzamide",,9/14/2020,treatment of retinoblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Oxular Ltd,Magadalen Centre,1 Robert Robinson Avenue,Oxford,,' OX4 4GA ' ,United Kingdom,764020,retinoblastoma,"""gard:0007563""",
36,nanatinostat and valganciclovir,,11/24/2021,"treatment of epstein barr virus-positive diffuse large b-cell lymphoma, not otherwise specified (ebv+ dlbcl, nos)",Designated,,Not FDA Approved for Orphan Indication,,,,,"Viracta Subsidiary, Inc.",2533 S. Coast Hwy 101,Suite 210,Cardiff,California,' 92007 ' ,United States,847721,lymphoma,"""gard:0020548""",
37,O-(2-[18F]fluoroethyl)-L-tyrosine,,10/5/2020,diagnostic for the management of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Telix Pharmaceuticals Limited (Telix),55 Flemington Road,Suite 401,North Melbourne,Victoria,' 3015 ' ,Australia,767920,,,
38,povidone iodine,,11/27/2017,treatment of endophthalmitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Veloce BioPharma LLC,7008 Lafayette Avenue,,Fort Washington,Pennsylvania,' 19034 ' ,United States,564916,endophthalmitis,"""gard:0020333""",
39,Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc),,1/18/2024,treatment of pancreatic cancer (pc),Designated,,Not FDA Approved for Orphan Indication,,,,,NeoImmuneTech,2400 Research Blvd,,Rockville,Maryland,' 20850 ' ,United States,866621,,,
40,recombinant serotype 9 adeno-associated virus encoding a codon-optimized human MECP2 gene,,10/7/2020,treatment for rett syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Taysha Gene Therapies,BioCenter at UT Southwestern,2280 Inwood Road,Dallas,Texas,' 75235 ' ,United States,770520,rett syndrome,"""gard:0005696""",
41,S-nitrosoglutathione reductase inhibitor,,1/13/2016,treatment of cystic fibrosis,Designated/Designation Withdrawn or Revoked,1/23/2018,Not FDA Approved for Orphan Indication,,,,,Alpine Immune Sciences,201 Elliott Ave. West,Suite 230,Seattle,Washington,' 98119 ' ,United States,435714,cystic fibrosis,"""gard:0006233""",
42,single chain urokinase plasminogen activator,,9/11/2014,treatment of empyema (pleural),Designated,,Not FDA Approved for Orphan Indication,,,,,"Lung Therapeutics, Inc.",P. O. Box 150183,,Austin,Texas,' 78715 ' ,United States,442514,,,
43,Small molecule mitofusin allosteric activator,,9/4/2020,treatment of charcot-marie-tooth disease type 2a,Designated,,Not FDA Approved for Orphan Indication,,,,,Mitochondria Emotion Inc.,"500 Boylston street, suite 1380",,Boston,Massachusetts,' 02116 ' ,United States,760320,,,
44,"((1r, 4r)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate)-Expanded cord blood",,12/13/2018,prevention of graft-versus-host-disease,Designated,,Not FDA Approved for Orphan Indication,,,,,ExCellThera Inc.,2950 chemin de Polythechnique,,Montreal,,' ' ,Canada,661418,,,
45,"((2S,5S)-5-(4-amino-5-(4-(2,3-difluorophenoxy)phenyl)imidazo[5,1-f][1,2,4]triazin-7-yl)tetrahydro-2H-pyran-2-yl)methanol",,10/2/2023,treatment of central nervous system lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Dizal (Jiangsu) Pharmaceutical Co., Ltd.","No. 199 Liangjing Road, Zhangjiang Hi-Tech Park",Pudong New Area,Shanghai,,' ' ,China,963823,lymphoma,"""gard:0020548""",
46,"((4-(3-benzyl-4-hydroxybenzyl)-3,5-dimethylphenoxy)methyl)phosphonic acid",,12/5/2016,treatment of x-linked adrenoleukodystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Viking Therapeutics, Inc.","9920 Pacific Heights Blvd, Suite 350",,San Diego,California,' 92121 ' ,United States,494215,leukodystrophy,"""gard:0006895""",
47,"((S)-3-(1-Cyclopentyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrazole-3-carboxamido)-5-(3,3-difluoropiperidin-1-yl)pentanoic acid hydrochloride)",,9/29/2022,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,APIE Therapeutics,"P.O. Box 13169, 2 Davis Dr.",,Research Triangle Park,North Carolina,' 27709 ' ,United States,903322,systemic sclerosis,"""gard:0009748""",
48,"((S)-3-(1-Cyclopentyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrazole-3-carboxamido)-5-(3,3-difluoropiperidin-1-yl)pentanoic acid hydrochloride)",,3/8/2022,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,APIE Therapeutics,P.O. Box 13169,2 Davis Dr.,Research Triangle Park,North Carolina,' 27709 ' ,United States,865821,idiopathic pulmonary fibrosis,"""gard:0008609""",
49,(+)-5-chloro-1-ethyl-3-(2-hydroxy-3-methoxybenzyl)-2-oxoindolin-3-yl dimethylcarbamate,,3/16/2021,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"MitoChem Therapeutics, Inc.",645 Meeting Street,,Charleston,South Carolina,' 29403 ' ,United States,806520,retinitis pigmentosa,"""gard:0005694""",
50,(+)-a-dihydrotetrabenazine,,3/30/2017,treatment pediatric patients with tourette's syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Adeptio Pharmaceuticals, Ltd",22 Bedford Row,WC1R 4JS,London,,' ' ,United Kingdom,498715,,,
51,(+)-alpha-dihydrotetrabenazine,,12/5/2018,treatment of huntington's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Adeptio Pharmaceuticals, Ltd",22 Bedford Row,WC1R 4JS,London,,' ' ,United Kingdom,607417,,,
52,(+)-Epicatechin,,4/6/2020,treatment of duchenne and becker muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Epirium Bio Inc.,"9171 Towne Centre Dr.,",Suite 270,San Diego,California,' 92122 ' ,United States,732020,duchenne and becker muscular dystrophy,"""gard:0018686""",
53,(+)N-hydroxy-N-(methylacylfulvene)urea,,11/28/2023,treatment of diffuse large b-cell lymphoma/high-grade b-cell lymphoma with myc and bcl2 rearrangements,Designated,,Not FDA Approved for Orphan Indication,,,,,Lantern Pharma,1920 McKinney Ave 7th floor,,Dallas,Texas,' 75201 ' ,United States,971823,lymphoma,"""gard:0020548""",
54,(+)N-hydroxy-N-(methylacylfulvene)urea,,1/3/2023,treatment of mantle cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Lantern Pharma,1920 McKinney Avenue Suite 700,,Dallas,Texas,' 75201 ' ,United States,904222,lymphoma,"""gard:0020548""",
55,"(+-)-9-(5-bromofuran-2-yl)-12,14-dimethyl-13,15-dioxo-17-phenyl-8-oxa-1,12,14-triazatetracyclo[8.7.0.02,7.011,16]heptadeca-2(7),3,5,10,16-pentaene-4-carboxylic acid",,10/19/2022,treatment of cholera,Designated,,Not FDA Approved for Orphan Indication,,,,,Vanda Pharmaceuticals Inc.,2200 Pennsylvania Avenue NW,Suite 300E,Washington,District of Columbia,' 20052 ' ,United States,906322,cholera,"""gard:0006043""",
56,"(+/-)-7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid",,3/31/2003,prevention of serious adverse events associated with vascular leak syndrome caused by interleukin-2 therapy,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Intarcia Therapeutics, Inc.",24650 Industrial Blvd,,Hayward,California,' 94545 ' ,United States,164102,,,
57,"(+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-cromen-7-ol",,1/10/2008,treatment of cholangiocarcinoma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Marshall Edwards, Inc.",11975 El Camino Real,Suite 101,San Diego,California,' 92130 ' ,United States,254407,cholangiocarcinoma,"""gard:0009304""",
58,"(+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-cromen-7-ol",,2/1/2008,treatment of stage iib through stage iv malignant melanoma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Marshall Edwards, Inc.",11975 El Camino Real,Suite 101,San Diego,California,' 92130 ' ,United States,252307,noma,"""gard:0004001""",
59,"(+/-)-cis-3-(4-hydroxyphenyl)-4-(4-methoxyphenyl)-3,4-dihydro-2H-cromen-7-ol",,1/10/2008,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Marshall Edwards, Inc.",11975 El Camino Real,Suite 101,San Diego,California,' 92130 ' ,United States,251707,,,
60,"(-)-(3aR,4S,7aR)-4-Hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester",,10/12/2011,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Stalicla SA,Campus Biotech Innovation Park,Avenue de Secheron 15,Geneve,,' 1202 ' ,Switzerland,353611,fragile x syndrome,"""gard:0006464""",
61,(-)-B-Elemene,,2/14/2023,treatment of glioblastoma multiforme (gbm),Designated,,Not FDA Approved for Orphan Indication,,,,,"Sichuan Honghe Biotechnology Co., Ltd.","No. 66, Jinghua East Road, Hexi Town, Jialing District",,Nanchong,Sichuan,' ' ,China,925022,glioblastoma,"""gard:0002491""",
62,(-)-epi-gallocatechin-3-gallate,,3/21/2024,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Merdury Biopharmaceutical Corporation,"15th Floor, No. 653 Bannan Road",Zhonghe District,New Taipei City,,' 235030 ' ,Taiwan,995324,muscular dystrophy,"""gard:0007922""",
63,(-)-Epigallocatechin 3-gallate,,4/29/2024,treatment of pouchitis,Designated,,Not FDA Approved for Orphan Indication,,,,,PharmassetX LLC,2900 Lake Vista Drive,,Louisville,Kentucky,' 40241 ' ,United States,999124,pouchitis,"""gard:0020510""",
64,(-)-Huperzine A,,12/12/2023,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Wanbangde Pharmaceutical Group Co, Ltd.","No. 28, North Baizhang Road, Chengdong Street",,Wenling,Zhejiang Province,' ' ,China,975423,myasthenia gravis,"""gard:0007122""",
65,(-)-Huperzine A,,6/7/2022,treatment of scn8a developmental and epileptic encephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Supernus Pharmaceuticals, Inc.",9715 Key West Avenue,,Rockville,Maryland,' 20850 ' ,United States,885322,,,
66,(-)-huperzine A,,6/15/2020,treatment of lennox-gastaut syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Supernus Pharmaceuticals, Inc.",9715 Key West Avenue,,Rockville,Maryland,' 20850 ' ,United States,744420,lennox-gastaut syndrome,"""gard:0009912""",
67,(-)-Huperzine A,,5/28/2024,treatment of neonatal hypoxic-ischemic encephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Wanbangde Pharmaceutical Group Co, Ltd.","No. 28, North Baizhang Road, Chengdong Street,",,Wenling,Zhejiang Province,' ' ,China,1003524,,,
68,"(1'R,6'R)-3-(Benzylamine)-6-hydroxy-3'-methyl-4-pentyl-6'-(prop-1-en-2-yl)-[1,1'-bi(cyclohexane)]-2',3,6-triene-2,5-dione",,7/6/2017,treatment of systemic scleroderma (ssc),Designated,,Not FDA Approved for Orphan Indication,,,,,Emerald Health Pharmaceuticals Inc.,5820 Nancy Ridge Drive,,San Diego,California,' 92121 ' ,United States,585717,scleroderma,"""gard:0018705""",
69,(1-hydroxy-2-oxopiperidin-3-yl)phosphonic acid,,8/9/2018,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,The University of Texas MD Anderson Cancer Center,1515 Holcombe Blvd #2,,Houston,Texas,' 77030 ' ,United States,646218,glioblastoma,"""gard:0002491""",
70,"(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-broethyl) diamidophosphate",,6/5/2013,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,EMD Serono,One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,396513,,,
71,"(1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate",,3/9/2012,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Threshold Pharmaceuticals, Inc.",170 Harbor Way,Suite 300,South San Francisco,California,' 94080 ' ,United States,365812,soft tissue sarcoma,"""gard:0004898""",
72,"(1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-caroxylic acid-phosphoric acid (1/1)",,6/8/2020,treatment of cutaneous variants of porphyria (which includes treatment and prevention of cutaneous manifestations of disease),Designated,,Not FDA Approved for Orphan Indication,,,,,"Mitsubishi Tanabe Pharma Development America, Inc.",525 Washington Blvd,Suite 400,Jersey City,New Jersey,' 07310 ' ,United States,645518,porphyria,"""gard:0010353""",
73,"(13E,14E,22R,6R)-35-fluoro-6-methyl-7-aza-1(5,3)-pyrazolo[1,5-a]pyrimidina-3(3,2)-pyridina-2(1,2)-pyrrolidinacyclooctaphan-8-one",,9/24/2018,treatment of solid tumors with neurotrophic tyrosine receptor kinase (ntrk)-fusion proteins,Designated/Designation Withdrawn or Revoked,12/1/2021,Not FDA Approved for Orphan Indication,,,,,"Bayer Healthcare Pharmaceuticals, Inc.",100 Bayer Blvd.,,Whippany,New Jersey,' 07981 ' ,United States,651318,,,
74,"(1E, 4E, 6E)-1-(3, 5-dimethoxyphenyl)- 7-(4-hydroxy-3, 5dimethoxyphenyl) hepta- 1, 4, 6-trien-3-one",,3/31/2022,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Agastiya Biotech,5256 South Mission Road,Suite 132,Bonsall,California,' 92003 ' ,United States,870822,acute myeloid leukemia,"""gard:0012757""",
75,"(1E, 4E, 6E)-1-(3, 5-dimethoxyphenyl)-7-(4-hydroxy-3, 5 dimethoxyphenyl) hepta-1, 4, 6-trien-3-one",,3/31/2022,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Agastiya Biotech,5256 South Mission Road,Suite 132,Bonsall,California,' 92003 ' ,United States,870922,,,
76,"(1E,4E,6E)-1-(3,5-dimethoxyphenyl)-7-(4-hydroxy-3,5dimethoxyphenyl)hepta-1,4,6-trien-3-one",,5/16/2022,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Agastiya Biotech,"5256 South Mission Road, Suite 132",,Bonsall,California,' 92003 ' ,United States,876722,glioblastoma,"""gard:0002491""",
77,"(1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione and [(1E,4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]",,8/23/2019,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Allianz Pharmascience Limited,"7F-2, No. 77, Section 2, Duan Hua",,South Road,Taipei,' ' ,Taiwan,704319,glioblastoma,"""gard:0002491""",
78,"(1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione and [(1E,4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]",,9/24/2019,treatment of spinocerebellar ataxia,Designated,,Not FDA Approved for Orphan Indication,,,,,AnnJi Pharmaceutical Co. Ltd.,"B405, 4F., No. 18, Siyuan, St.,",Zhongzheng Dist,Taipei City,,' 10087 ' ,Taiwan,701819,,,
79,"(1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione OR [(1E,4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]",,5/14/2019,treatment of huntington’s disease,Designated,,Not FDA Approved for Orphan Indication,,,,,AnnJi Pharmaceutical Co. Ltd.,"B405, 4F., No. 18, Siyuan St.",Zhongzheng District,Taipai City,,' 10087 ' ,Taiwan,686419,,,
80,"(1R,2R)-1,2-cyclohexane-diaminepyrophosphato-platinum(II)",,11/22/2017,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Phosplatin Therapeutics LLC,1350 6th Avenue,3rd Floor,New York,New York,' 10019 ' ,United States,613617,multiple myeloma,"""gard:0007108""",
81,"(1R,2R)-1,2-cyclohexane-diaminepyrophosphato-platinum(II)",,10/25/2018,treatment of thymoma and thymic carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Promontory Therapeutics, Inc.",1350 6th Avenue,3rd Floor,New York,New York,' 10019 ' ,United States,654818,thymic carcinoma,"""gard:0019695""",
82,"(1R,3R,4R,5S)-3-O-[2-O-benzoyl-3-O-(sodium(2S)-3-cyclohexyl-propanoate-",,2/17/2009,treatment of vaso-occlusive crisis in patients with sickle cell disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"GlycoMimetics, Inc.",9708 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,274608,,,
83,"(1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide",,2/8/2021,treatment of patients with paroxysmal nocturnal hemoglobinuria (pnh),Designated/Designation Withdrawn or Revoked,4/25/2024,Not FDA Approved for Orphan Indication,,,,,Alexion Pharmaceuticals Inc.,121 Seaport Blvd,,Boston,Massachusetts,' 02210 ' ,United States,722519,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
84,"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride",,8/10/2004,"treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult t-cell leukemia, and hairy cell leukemia",Designated,,Not FDA Approved for Orphan Indication,,,,,Mundipharma Research Ltd.,Cambridge Science Park,,Cambridge CB4 0GW,,' ' ,United Kingdom,190504,,,
85,"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride",,1/29/2004,treatment of t-cell non-hodgkin's lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Mundipharma Research Limited,Cambridge Science Park,Cambridge CB4 0GW,England,,' ' ,United Kingdom,172403,lymphoma,"""gard:0020548""",
86,"(1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-ribitol-hydrochloride",,8/13/2004,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Mundipharma Research Limited,Cambridge Science Park,Cambridge CB4 0GW,England,,' ' ,United Kingdom,190404,acute lymphoblastic leukemia,"""gard:0000522""",
87,"(1S)-6-chloro-1,3,4,9-tetrahydro-1-(4-methoxyphenyl)-2H-pyrido[3,4-b]indole-2-carboxylic acid, 4-chlorophenyl ester",,1/27/2020,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,' 07080 ' ,United States,720919,acute myeloid leukemia,"""gard:0012757""",
88,"(1S, 2S, 3R, 4R)-3-(5-Fluoro-2-(3-methyl-4-(4-methylpiperazin-1-yl)-phenylamino)-pyrimidin-4-ylamino)bicycle[2.2.1]hept-5-ene-2-carboxamide benzoate",,1/19/2010,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,299109,acute myeloid leukemia,"""gard:0012757""",
89,"(1S, 4R, 5R, 7S)-3, 4-dibenzyl-2-oxo-6, 8-dioxa- 3-azabyciclo [3.2.1] octane-7-carboxylic acid-L-lysine",,11/30/2018,treatment of neurotrophic keratopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Recordati Rare Diseases, SARL","Immeuble le ""Wilson""",70 Avenue du General de Gaulle,Puteaux,,' ' ,France,662818,neurotrophic keratopathy,"""gard:0019878""",
90,"(1S,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E)-33-(((2S,3S,4S,6R)-4-amino-3,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-1,3,4,7,9,11,17,37-octahydroxy-15,16,18,36-tetramethyl-14,39-dioxabicyclo[33. 3.1] nonatriaconta-19,21,23,25,27,29,31-heptaen-13-one",,6/24/2021,treatment of invasive aspergillosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Biosergen AS,7092 Tiller,,Trondheim,,' PB 217 ' ,Norway,803420,aspergillosis,"""gard:0005856""",
91,"(1S,3S)-3-((2-methyl-6-(1-methyl-5-(((methyl(propyl)carbamoyl)oxy)methyl)-1H-1,2,3-triazol-4-yl)pyridin-3-yl)oxy)cyclohexane-1-carboxylic acid",,12/17/2018,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,P.O. Box 4000,3551 Lawrenceville Road,Princeton,New Jersey,' 08540 ' ,United States,668018,idiopathic pulmonary fibrosis,"""gard:0008609""",
92,"(1S,3S)-3-amino-4-(difluoromethylene)cyclopentanecarboxylic acid hydrochloride, (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid hydrochloride",,9/15/2010,treatment of infantile spasms,Designated,,Not FDA Approved for Orphan Indication,,,,,"Catalyst Pharmaceuticals, Inc.",355 Alhambra Circle,Suite 1250,Coral Gables,Florida,' 33134 ' ,United States,300410,,,
93,"(2'R,3'S)-2'-hydroxy-N-carboxy-3'-amino-5'-methyl-hexanoic,N-tert-butyl ester, 13 ester 5B-20-epoxy-1B,2a,4a,7B,9a,10a,13a-heptahydroxy-4,10-diacetate-2-benzoate-(1""S)-7,9-acrolein acetal-11(15-1)-abeotaxane",,6/23/2014,treatment of progressive supranuclear palsy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cortice Biosciences, Inc.",1345 Avenue of the Americas,42nd Floor,New York,New York,' 10105 ' ,United States,436014,progressive supranuclear palsy,"""gard:0007471""",
94,"(2,2-diphenyl-tetrahydro-furan-3-yl-methyl)-dimethylamine hydrochloride",,5/18/2016,treatment of rett syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,Anavex Life Sciences Corporation,51 West 52nd Street,7th Floor,New York,New York,' 10019 ' ,United States,520816,rett syndrome,"""gard:0005696""",
95,(2-((2-chlorophenyl)(phenyl)amino)-N-(7-(hydroxyamino)-7-oxoheptyl)pyrimidine-5-carboxamide),,11/29/2016,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,4/30/2024,Not FDA Approved for Orphan Indication,,,,,"Acetylon Pharmaceuticals, Inc. (Celgene Subsidiary)",86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,544316,multiple myeloma,"""gard:0007108""",
96,"(2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1h-pyrazolo [4,3-c] pyridine-3,6(2h,5h)-dione)",,10/14/2015,treatment of systemic sclerosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Calliditas Therapeutics Suisse SA,Chemin des Aulx 16,,Plan-les-Ouates,,' 1228 ' ,Switzerland,493115,systemic sclerosis,"""gard:0009748""",
97,"(2-(6-(2-(4-cyclopropylpyrimidin-5-yl)-4-fluorophenoxy)-1,2,4-triazin-5-yl)-2,7-diazaspiro[3.5]nonan-7-yl)((1S,3aR,6aS)-octahydrocyclopenta[c]pyrrol-1-yl)methanone",,4/17/2023,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,BioNova Pharmaceuticals (Shanghai) Limited,"2889 Jinke Road, Chamtime Plaza, Building B, 9F Suite 901",,Shanghai,,' 201203 ' ,China,933923,acute myeloid leukemia,"""gard:0012757""",
98,"(2-Fluoro-5-trifluoromethoxy-phenyl)-carbamic acid 2-(2,6-dioxo-piperidin-3-yl)-3-oxo-2,3-dihydro-1H-isoindol-5-ylmethyl ester",,6/21/2023,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Monte Rosa Therapeutics, Inc.","321 Harrison Avenue, Suite 900",,Boston,Massachusetts,' 02118 ' ,United States,947423,small cell lung cancer,"""gard:0009344""",
99,(20S)-7-tert-butyldimethysilyl-10-hydroxycamptothecin,,7/13/2017,treatment of glioblastoma multiforme (gbm),Designated,,Not FDA Approved for Orphan Indication,,,,,"Vivacitas Oncology, Inc.",1990 North California Boulevard,8th Floor,Walnut Creek,California,' 94596 ' ,United States,586917,glioblastoma,"""gard:0002491""",
100,"(2M)-2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1- methyl-1H-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3- fluorobenzonitrile",,4/20/2023,treatment of mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mirati Therapeutics, Inc.",3545 Cray Ct.,,San Diego,California,' 92121 ' ,United States,934823,,,
101,"(2R,3R,4S)-2-(2-chloro-6-(3-chlorobenzylamino)-9H-purin-9-yl)tetrahydrothiophene-3,4-diol",,2/1/2021,treatment of primary biliary cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Future Medicine Co., Ltd.","Rm616, LH Business Growth Center, 54 Changeop-ro, Sujeong-gu",,Seongnam,Gyeonggi-do,' ' ,South Korea,796620,primary biliary cholangitis,"""gard:0007459""",
102,"(2R,3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol hydrogen chloride",,5/20/2021,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Daewoong Pharmaceutical Co., Ltd.","12, Bongeunsa-ro 114 gil, Gangnam-gu",,Seoul,,' 137-715 ' ,South Korea,817121,systemic sclerosis,"""gard:0009748""",
103,"(2R,3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piperidin-3-ol Hydrogen Chloride",,8/5/2019,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Daewoong Pharmaceutical Co., Ltd.","12, Bongeunsa-ro 114 gil",Gangnam-gu,Seoul,Korea,' ' ,South Korea,701419,idiopathic pulmonary fibrosis,"""gard:0008609""",
104,"(2R,4R)-1-(3-chloro-2-fluorobenzyl)-4-((3-fluoro-6-((5-methyl-1H-pyrazol-3-yl)amino)pyridin-2-yl)methyl)-2-methylpiperidine-4-carboxylic acid; 2- methylpropan-2-amine",,1/29/2020,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,724119,neuroblastoma,"""gard:0007185""",
105,(2S)-2-[(2S)-4-cyclohexyl-2-{[(2S)-1-(4-fluorobenzoyl)pyrrolidin-2-yl]formamido}butanamido]-N-(1-{[(1S)-1-{[(1S)-1-({1-[(1-{[2-({1-[(dimethylamino)methyl]cyclobutyl}carbamoyl)ethyl]carbamoyl}-1-methylethyl)carbamoyl]-1-methylethyl}carbamoyl)-3-methylbutyl,,7/19/2021,treatment of cutaneous leishmaniasis (old world and new world),Designated,,Not FDA Approved for Orphan Indication,,,,,Bacoba AG,Schloss Buonas 1,,Buonas,,' 6343 ' ,Switzerland,825621,leishmaniasis,"""gard:0006881""",
106,"(2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro- 1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid",,10/31/2012,treatment of primary biliary cirrhosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharmaceuticals, Inc.","One Main Street, 7th Floor",,Cambridge,Massachusetts,' 02142 ' ,United States,371012,,,
107,"(2S)-N-[(1S)-1-cyclohexyl-2-[(2S)-2-[4-(4-fluorobenzoyl)-1,3-thiazol-2-yl]pyrrolidin-1-yl]-2-oxoethyl]-2-(methylamino)propanamide",,6/28/2017,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Paul Maher, MD",10644 Weymouth Street,Suite 104,Bethesda,Maryland,' 20814 ' ,United States,582917,multiple myeloma,"""gard:0007108""",
108,"(2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide maleate",,10/22/2020,treatment of dermatomyositis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kezar Life Sciences, Inc.","4000 Shoreline Court, Suite 300",,South San Francisco,California,' 94080 ' ,United States,672018,dermatomyositis,"""gard:0006263""",
109,"(2S,3R)-N-[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide maleate",,10/21/2020,treatment of polymyositis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kezar Life Sciences, Inc.","4000 Shoreline Court, Suite 300",,South San Francisco,California,' 94080 ' ,United States,663518,polymyositis,"""gard:0007425""",
110,"(2S,3R,4R,5S)-2-(hydroxymethyl)-1-pentylpiperidine-3,4,5-triol",,8/1/2019,treatment of gm2 gangliosidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Idorsia Pharmaceuticals Ltd,91 Hegenheimermattweg,,Allschwil,Basel-Landschaft,' ' ,Switzerland,701719,gm2 gangliosidosis,"""gard:0021323""",
111,"(2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl]oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate",,6/21/2017,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,Pharmavant 7 Sciences GmBH,Viaduktstr. 8,,Basel,,' 4051 ' ,Switzerland,581817,acute myeloid leukemia,"""gard:0012757""",
112,"(2S,3S,4E,6S,7R,10R)-7,10-Dihydroxy-3,7-dimethyl-12-oxo-2-[(2E,4E,6R)-6-(pyridin-2-yl)hepta-2,4-dien-2-yl]oxacyclododec-4-en-6-yl 4-methylpiperazine-1-carboxylate",,6/27/2023,treatment of myelodysplastic syndrome (mds),Designated,,Not FDA Approved for Orphan Indication,,,,,"Hemavant Sciences, GmbH",Viaduktstrasse 8,,Basel,,' 4051 ' ,Switzerland,945423,myelodysplastic syndrome,"""gard:0007132""",
113,"(2S,4R)-1-((S)-2-(7-(4-((R)-3-((4-(N-(4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoyl)sulfamoyl)-2-((trifluoromethyl)sulfonyl)phenyl)amino)-4-(phenylthio)butyl)piperazin-1-yl)-7-oxoheptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide",,3/9/2022,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Dialectic Therapeutics, Inc.",3889 Maple Ave,STE 125,Dallas,Texas,' 75219 ' ,United States,865621,lymphoma,"""gard:0020548""",
114,"(2S,4R)-1-((S)-2-(7-(4-((R)-3-((4-(N-(4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoyl)sulfamoyl)-2-((trifluoromethyl)sulfonyl)phenyl)amino)-4-(phenylthio)butyl)piperazin-1-yl)-7-oxoheptanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-((S)-1-(4-(4-methylthiazol-5-yl)phenyl)ethyl)pyrrolidine-2-carboxamide",,12/5/2023,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Dialectic Therapeutics, Inc.","3889 Maple Ave, STE 125",,Dallas,Texas,' 75219 ' ,United States,973123,small cell lung cancer,"""gard:0009344""",
115,"(2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide",,12/14/2017,treatment of c3 glomerulopathy (c3g),Designated,,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc",300 George Street,,New Haven,Connecticut,' 06511 ' ,United States,617117,c3 glomerulopathy,"""gard:0017507""",
116,(2Z)-2-cyano-3-3hydroxy-N-[4-(trifluoromethly)phenyl]-2-hepten-6-ynamide,,1/10/2005,"prevention of acute rejection following kidney, heart, and liver transplantation",Designated,,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma US, Inc.",Three Parkway North,,Deerfield,Illinois,' 60015 ' ,United States,187004,,,
117,"(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide",,3/18/2011,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,NATCO Pharma Limited,Natco House,,Hyderabad 500033,,' ' ,India,337011,,,
118,"(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamide",,3/18/2011,treatment of chronic myelogenous leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,NATCO Pharma Limited,Natco House,,Hyderabad-500033,,' ' ,India,336911,,,
119,"(3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl amino) phenyl] benzamideNRC-AN-019",,3/18/2011,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,NATCO Pharma Limited,Natco House,,Hyderabad-500033,,' ' ,India,336811,,,
120,"(3beta,24S)-25,25,25-trifluoro-3-methyl-26,27-dinorergost-5-ene-3,24-diol",,10/16/2023,treatment of huntington’s disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Sage Therapeutics,215 First Street,,Cambridge,Massachusetts,' 02142 ' ,United States,919322,,,
121,"(3E,5E)-3,5-bis[(4-fluoro-3-nitrophenyl)methylidene]-1-(prop-2-enoyl)azepan-4-0ne",,4/30/2014,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,1/30/2023,Not FDA Approved for Orphan Indication,,,,,VivoLux AB,Uppsala Science Park,SE-751 83,Uppsala,,' ' ,Sweden,428714,multiple myeloma,"""gard:0007108""",
122,(3R)-3-Methyl-6-[2-({5-methyl-2-[4-(trifluoromethyl)phenyl]-1H-imidazol-1-yl}methyl)phenoxy]hexanoic acid hemisulfate,,3/28/2018,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.","1 Astellas Way, N4.203",,Northbrook,Illinois,' 60062 ' ,United States,633018,muscular dystrophy,"""gard:0007922""",
123,"(3R,3aS,9R,9aS,9bS)-3-((dimethylamino)methyl)-9-hydroxy-6,9-dimethyl-3,3a,4,5,7,8,9,9a-octahydroazuleno[4,5-b]furan-2(9bH)-one fumarate",,11/8/2017,treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,Accendatech USA Incorporated,3730 Kirby Drive,Suite 1200,Houston,Texas,' 77098 ' ,United States,610217,glioblastoma,"""gard:0002491""",
124,"(3S)-(+)-(5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one",,12/9/2015,treatment of fragile x syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,Centre National de la Recherche Scientifique (CNRS),3 Rue Michel-Ange,,Paris,,' ' ,France,497515,fragile x syndrome,"""gard:0006464""",
125,"(3S)-3-[(2S)-2-({N-[2-tert-butyl)phenyl]carbamoyl}carbonylamino) propanoylamino]-4-oxo-5-(2,3,5,6-tetrafluorophenoxy) pentanoci acid",,8/19/2003,treatment of patients undergoing solid organ transplantation.,Designated,,Not FDA Approved for Orphan Indication,,,,,Pfizer Global Research and Development,50 Pequot Avenue,,New London,Connecticut,' 06320 ' ,United States,169603,,,
126,"(3S)-3-[({1-(2-Chlorobenzyl)-4-hydroxy-5-methyl-2-oxo-1,2-dihydropyridin-3yl}amino)carbonyl]amino-3-(4-methylphenyl)propanoic acid monosodium salt",,4/25/2016,for mobilization of hematopoietic stem cells,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aviara Pharmaceuticals, Inc/",3331 Green Tree Park,,Houston,Texas,' 77027 ' ,United States,515216,,,
127,"(3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate",,6/15/2017,treatment of pediatric crohn's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,AbbVie,1 North Waukegan Road,,North Chicago,Illinois,' 60044 ' ,United States,575517,,,
128,"(4'aR,10'bR)-8'-chloro-1-[2-(1H-imidazol-1-yl)ethyl]-5',5'-dimethyl-4'a,10'b-dihydro-2'H,4'H,5'H-spiro[piperidine-4,3'-pyrano[3,2-c][1]benzopyran] diphosphate",,5/17/2022,treatment of brain cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Pharma America, Inc.",84 Waterford Drive,,Marlborough,Massachusetts,' 01752 ' ,United States,877322,,,
129,"(4R)-3-(4-fluoro-2-hydroxyphenyl)-4-methyl-4,5-dihydro- 1H-pyrazole-1-carboximidamide hydrochloride",,1/30/2024,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,AnaMar AB,Medicon Village,Scheeletorget 1,Lund,,' SE-223 81 ' ,Sweden,984523,systemic sclerosis,"""gard:0009748""",
130,"(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride",,9/4/2013,treatment of primary biliary cirrhosis,Designated/Designation Withdrawn or Revoked,4/20/2022,Not FDA Approved for Orphan Indication,,,,,"Mirum Pharmaceuticals, Inc.",950 Tower Lane,Suite 1050,Foster City,California,' 94404 ' ,United States,406113,,,
131,"(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride",,9/4/2013,treatment of primary sclerosing cholangitis,Designated/Designation Withdrawn or Revoked,4/20/2022,Not FDA Approved for Orphan Indication,,,,,"Mirum Pharmaceuticals, Inc.",950 Tower Lane,Suite 1050,Foster City,California,' 94404 ' ,United States,406213,sclerosing cholangitis,"""gard:0021868""",
132,"(4S)-4-ethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1-H-pyrano[3?,4?:6,7]-indolizino-[1,2-b]-quinoline-11-carbaldehyde O-(tert-butyl)-(E)-oxime",,11/29/2002,treatment malignant glioma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Sigma-Tau Research, Inc.",9841 Washingtonian Blvd,Suite 502,Gaithersburg,Maryland,' 20878 ' ,United States,161602,,,
133,"(5-(3-(2-amino-4-oxo-4,7-dihydro-3 H-pyrrolo[2,3- d]pyrimidin-6-yl)propyl)thiophene-2-carbonyl)- L-glutamic acid)",,3/30/2021,treatment of mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"FLAG Therapeutics, Inc.",9168 Wooden Road,,Raleigh,North Carolina,' 27617-8203 ' ,United States,806920,,,
134,"(5R)-5-ethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione",,5/17/2023,treatment of progressive myoclonic epilepsy-7,Designated,,Not FDA Approved for Orphan Indication,,,,,Autifony Therapeutics Ltd.,Gunnels Wood Road,,Stevenage,,' SG1 2FX ' ,United Kingdom,939923,progressive myoclonic epilepsy,"""gard:0007140""",
135,"(5S,8S, 10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5] diazocine-8-carboxyamide",,4/14/2016,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc., a business of Merck Healthcare KGaA",1 Technology Pl,,Rockland,Massachusetts,' 02370 ' ,United States,515315,ovarian cancer,"""gard:0007295""",
136,"(6-(4-((4-(1H-pyrazol-4-yl)phenyl)amino)pyrimidin-2-yl)-1-methyl-1H-indol-2-yl)(3,3-difluoroazetidin-1-yl)methanone",,5/8/2019,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Beijing Tide Pharmaceutical Co., Ltd",No.8 East Rongjing Street,Beijing Econnomic-technological Development Area (BDA),Beijing,,' ' ,China,683419,idiopathic pulmonary fibrosis,"""gard:0008609""",
137,"(6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl] amino-L-glyceroB-L-manno-heptopyranosyl]amino-9H-purine)",,2/21/2014,"parenteral treatment of painful, chronic, chemotherapy-induced peripheral neuropathy that is refractory to conventional analgesics",Designated/Designation Withdrawn or Revoked,2/16/2018,Not FDA Approved for Orphan Indication,,,,,"DARA Therapeutics, Inc.",8601 Six Forks Road,Suite 160 (Forum 1),Raleigh,North Carolina,' 27615 ' ,United States,385312,,,
138,(68-Ga)-Trivehexin,,5/8/2023,diagnostic for the management of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Radiopharm Theranostics, Inc.",C/O Vcorp Services LLC,701 S. Carson Street,Carson City,Nevada,' 89701 ' ,United States,921922,,,
139,"(6aR, 10aR)-3-(1¿,1¿-dimethylheptyl)-delta8-tetrahydro-cannabinol-9-carboxylic acid",,10/13/2015,treatment of cystic fibrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Corbus Pharmaceuticals, Inc.",500 River Ridge Drive,Second floor,Norwood,Massachusetts,' 02062 ' ,United States,493415,cystic fibrosis,"""gard:0006233""",
140,"(6aR, 10aR)-3-(1â¿¿,1â¿¿-dimethylheptyl)-Î¿8-tetrahydro-cannabinol-9-carboxylic acid",,6/10/2015,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Corbus Pharmaceuticals, Inc.",500 River Ridge Drive,Second Floor,Norwood,Massachusetts,' 02062 ' ,United States,480715,systemic sclerosis,"""gard:0009748""",
141,"(6R,S)5,10-methylene-tetrahydrofolic acid",,8/13/2004,for use in combination with 5-fluorouracil for the treatment of patients with pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Adventrx Pharmaceuticals, Inc.",6725 Mesa Ridge Road,Suite 100,San Diego,California,' 92121 ' ,United States,189304,,,
142,"(6S,9aS)-N-benzyl-6-(4-hydroxybenzyl)-4,7-dioxo-2-((3-(pyridin-2-yl)isoxazol-5-yl)methyl)-8-(quinolin-5-ylmethyl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide methane sulfonic acid",,6/7/2022,treatment of idiopathic pulmonary fribrosis (ipf),Designated,,Not FDA Approved for Orphan Indication,,,,,"3Plus2 Pharma, LLC",3904 Chapman Ct.,,Altadena,California,' 91001 ' ,United States,884022,,,
143,"(7S)-3-Amino-14-ethyl-11-fluoro-7-methyl-4-oxo-4,5,6,7,13,14-hexahydro-1,15-ethenopyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecine-12-carbonitrile",,5/25/2021,"treatment of gastric cancer, including gastroesophageal junction adenocarcinoma",Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol Myers Squibb,3401 Princeton Pike,,Lawrenceville,New Jersey,' 08648 ' ,United States,817821,noma,"""gard:0004001""",
144,"(7S)-N-(3-bromo-2-fluorophenyl)-7-[(4-methylpiperazin-1-yl)methyl]-7H,8H-[1,4]dioxino[2,3-g]quinazolin-4-amine",,6/21/2023,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Erasca, Inc.","3115 Merryfield Row, Suite 300",,San Diego,California,' 92121 ' ,United States,944323,,,
145,"(9-[N-(3-morpholinopropyl)-sulfonyl]-5,6-dihydro-5-oxo-11-H-indeno [1,2-c] isoquinoline methanesulfonic acid",,12/8/2004,prevention of post-operative complications of aortic anuerysm surgical repair,Designated,,Not FDA Approved for Orphan Indication,,,,,Inotek Pharmaceuticals Corporation,100 Cummings Center,,Beverly,Massachusetts,' 01915 ' ,United States,195404,,,
146,(E)-2-[[3-[(3-Methoxy-4-(prop-2-ynyloxy))phenyl]-1-oxo-2-propen-1-yl]amino]benzoic acid,,10/10/2023,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Certa Therapeutics Pty Ltd,"Level 9, 31 Queen St",,Melbourne,VIC,' 3000 ' ,Australia,965623,systemic sclerosis,"""gard:0009748""",
147,(E)-3-(6-Bromo-pyridin-2-yl)-2-cyano-N-((S)-1-phenyl-ethyl)-acryl amide,,2/1/2019,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Moleculin Biotech, Inc.","5300 Memorial Drive,",Suite 950,Houston,Texas,' 77007 ' ,United States,671018,glioblastoma,"""gard:0002491""",
148,(E)-N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalen-1-yloxy)methyl)oct-2-enediamide phosphate,,8/26/2019,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"CG Pharmaceuticals, Inc.","100-D, Bldg. D, Pine Grove Business Center",4 Orinda Way,Orinda,California,' 94563 ' ,United States,699019,,,
149,(E)-N¿-(1-(5-Chloro-2-hydroxy phenyl)Ethylidene)-3-((4-Methyl Piperazin-1-yl) Sulfonyl) Benzohydrazide Mesylate,,1/12/2017,treatment of ewing's sarcoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Salarius Pharmaceuticals,2450 Holcombe Boulevard,Suite J-608,Houston,Texas,' 77021 ' ,United States,571316,,,
150,"(E, Z)-4,5,9-trithiadodeca-1, 6, 11-triene 9-oxide (Ajoene)",,4/21/2016,treatment of pseudomonas aeruginosa pulmonary infections in cystic fibrosis patients,Designated/Designation Withdrawn or Revoked,4/17/2019,Not FDA Approved for Orphan Indication,,,,,Neem Biotech Ltd.,Units G & H,Roseheyworth Business Park,Blaenau Gwent,,' ' ,United Kingdom,516316,cystic fibrosis,"""gard:0006233""",
151,(H-L-Arginyl-L-Valyl-L-Isoleucyl-L-Arginyl-L-Alanyl-L-Cysteinyl-L-Leucyl-Glycyl-L-Valyl-Glycyl-L-Leucyl-L-Leucyl-Glycyl-L-Asparaginyl-L-Leucyl-D-Alanyl-Glycyl-L-Lysyl-amino-PEG12-propionic acid)2 (Disulfide bond at Cys),,12/13/2022,treatment of idiopathic pulmonary fibrosis (ipf),Designated,,Not FDA Approved for Orphan Indication,,,,,"CohBar, Inc.",1455 Adams Drive,Suite 2050,Menlo Park,California,' 94025 ' ,United States,914822,idiopathic pulmonary fibrosis,"""gard:0008609""",
152,"(N-(1¿,2-dihydroxy-[1,2¿-binapthalen]-4¿-yl)-4-methoxybenzenesulfonamide)",,3/14/2022,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tvardi Therapeutics, Inc.",2450 Holcombe Blvd. Suite X,,Houston,Texas,' 77021 ' ,United States,866721,hepatocellular carcinoma,"""gard:0016773""",
153,"(N-{2-[(6-{[(2,6-Dichloro-3,5-dimethoxyphenyl)carbamoyl](methyl)amino}pyrimidin-4- yl)amino]-5-(4-ethylpiperazin-1-yl)phenyl}prop-2-enamide)",,9/7/2017,treatment of hepatocellular carcinoma (hcc),Designated,,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.,200 Metro Blvd.,,Nutley,New Jersey,' 07110-6102 ' ,United States,597717,hepatocellular carcinoma,"""gard:0016773""",
154,(R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1- methylethyl) benzamide,,5/14/2024,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Spinogenix, Inc.",1901 Avenue of the Stars,Suite 200,Los Angeles,California,' 90067 ' ,United States,1001224,fragile x syndrome,"""gard:0006464""",
155,"(R)-(1-(4-fluorophenyl)-6-((4-(trifluoromethyl)phenyl)sulfonyl)-1,4,5,6,7,8-hexahydro-4aH-pyrazolo[3,4-g]isoquinolin-4a-yl)(pyridin-2-yl)methanone",,8/18/2020,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Corcept Therapeutics, Inc.",149 Commonwealth Drive,,Menlo Park,California,' 94025 ' ,United States,756420,amyotrophic lateral sclerosis,"""gard:0005786""",
156,"(R)-(3-(2'-cyclopropyl-3-(hydroxymethyl)-[1,1'-biphenyl]-4-yl) pyrrolidin-1-yl)(5-fluoropyridin-2-yl)methanone",,9/21/2023,treatment of olmsted syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Kamari Pharma Ltd.,Pinchas Sapir 3,Science Park,Ness Ziona,,' ' ,Israel,962223,,,
157,"(R)-1-(3,3-difluoro-1-methlypiperidin-4-yl)-8-(6-methoxypyridin-3-yl)-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one",,2/7/2023,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Wayshine Biopharm, INC","957 Ferndale Dr,",,Corona,California,' 92881 ' ,United States,924022,,,
158,(R)-1-phenylethyl-5-(4-biphenyl-4-cyclopropanecarboxylic acid)-3-methylisoxazole-4-yl carbamate sodium salt,,4/15/2011,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,P. O. Box 4000,,Princeton,New Jersey,' 08543 ' ,United States,327810,idiopathic pulmonary fibrosis,"""gard:0008609""",
159,"(R)-1-[4'-(5-chloro-3-{[(1-phenylethoxy)carbonyl] amino}thiophen-2-yl)-2'-methoxy-[1,1'-biphenyl]-4-yl]cyclopropanecarboxylic acid",,6/12/2023,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"HiLung, Inc.","46-29 Yoshida-Shimo'adachicho, Sakyo-ku",,Kyoto,Kansai,' 00000 ' ,Japan,942923,idiopathic pulmonary fibrosis,"""gard:0008609""",
160,"(R)-2-((1-(2-(4-methoxy-3-(2-morpholinoethoxy) phenyl)-5-methylthiazol-4-yl)ethyl)thio)pyrimidine-4,6-diamine",,11/9/2021,treatment of optic neuritis,Designated,,Not FDA Approved for Orphan Indication,,,,,Trethera Corporation,"13547 Ventura Boulevard, Suite 363",,Sherman Oaks,California,' 91423 ' ,United States,845721,,,
161,"(R)-2-((1-(2-(4-methoxy-3-(2-morpholinoethoxy) phenyl)-5-methylthiazol-4-yl)ethyl)thio)pyrimidine-4,6-diamine",,1/7/2021,treatment of acute disseminated encephalomyelitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Trethera Corporation,"13547 Ventura Boulevard, Suite 363",,Sherman Oaks,California,' 91423 ' ,United States,792220,acute disseminated encephalomyelitis,"""gard:0008639""",
162,"(R)-2-(5-cyano-2-(6-(methoxycarbonyl)-7-methyl-3-oxo-8-(3-(trifluoromethyl)phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidin-5-yl)phenyl)-N,N,N-trimethylethanaminium methanesulfonate dehydrate",,1/25/2017,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Chiesi Farmaceutici S.p.A.,26A Via Palermo,,Parma,Emilia-Romagna,' ' ,Italy,551216,cystic fibrosis,"""gard:0006233""",
163,"(R)-2-allyl-1-(7-ethyl-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-2-yl)-6-((4-(4-methylpiperazin-1-yl)phenyl)amino)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one",,10/14/2020,treatment of osteosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"K-Group Beta, Inc.","10835 Road to the Cure, Suite #205",,San Diego,California,' 92121 ' ,United States,772420,osteosarcoma,"""gard:0007284""",
164,"(R)-2-amino-N-((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide, tris hydrochloride",,10/3/2022,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,Stealth Biotherapeutics Inc.,140 Kendrick Street,Building C-West,Needham,Massachusetts,' 02494 ' ,United States,902322,amyotrophic lateral sclerosis,"""gard:0005786""",
165,"(R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl) butanamide",,7/27/2017,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",500 Warren Corporate Center Drive,,Warren,New Jersey,' 07059 ' ,United States,592517,amyotrophic lateral sclerosis,"""gard:0005786""",
166,"(R)-2-methyl-6-nitro-2-{4-[4-(4-trifluoromethoxyphenoxy)piperidin-1-yl]phenoxymethyl}-2,3-dihydroimidazo[2,1-b]oxazole",,7/12/2007,treatment of pulmonary tuberculosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Otsuka Pharmaceutical Company, Ltd","2-9, Kanda-Tsukasamachi",,Tokyo,,' ' ,Japan,244007,tuberculosis,"""gard:0007827""",
167,(R)-3-(1-cyclopropyl-3-(2-fluoro-4-(trifluoromethoxy)benzyl)ureido)piperidine-1-carboxamide,,4/24/2024,treatment of phenylketonuria,Designated,,Not FDA Approved for Orphan Indication,,,,,Jnana Therapeutics,6 Tide Street,,Boston,Massachusetts,' 02210 ' ,United States,902422,phenylketonuria,"""gard:0007383""",
168,"(R)-3-(5,5-dimethyl-4,5-dihydro-1,2,4-oxadiazol-3-yl)-N-(1-(2,3,5-trifluorophenyl) ethyl) pyrazolo[1,5-a] pyrimidin-5-amine hydrate",,9/19/2023,"treatment of alk-positive, ros1-positive, ntrk fusion-positive, or ltk positive non-small cell lung cancer",Designated,,Not FDA Approved for Orphan Indication,,,,,"TYK Medicines, Inc.","No.778 Huaxi Avenue, Changxing Economic Development Zone,",Block D,Huzhou,Zhejiang,' ' ,China,865721,small cell lung cancer,"""gard:0009344""",
169,(R)-3-[(4-{1-[1-(3-Carboxy-1-cyclopropyl-7-fluoro-9-methyl-4-oxo-4H-quinolizine-8-yl)-pyrrolidin-3-yl-cyclopropyl]-methylamino}-piperidin-1-ylimino)-methylenyl]-rifamycin,,1/14/2020,treatment of prosthetic joint infection,Designated,,Not FDA Approved for Orphan Indication,,,,,TenNor Therapeutics Limited,"218 Xinghu Street, Building B2, Suite 711",Suzhou Industrial Park,Suzhou,,' ' ,China,704419,,,
170,"(R)-3-[3-Fluoro-4-(1-methyl-1,4,5,6-tetrahydro-1,2,4-triazin-4-yl)phenyl]-5(R)-(hydroxymethyl)oxazolidin-2-one",,7/19/2017,treatment of tuberculosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"LigaChem Biosciences Inc.,","10, Gukjegwahak 10?ro, Yuseong?gu",,Daejon,Daedeok-gu,' 34002 ' ,South Korea,590317,tuberculosis,"""gard:0007827""",
171,"(R)-4-(3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enylmethyl]-piperazin-1-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride",,5/5/2008,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,257408,multiple myeloma,"""gard:0007108""",
172,"(R)-4-(3-morpholin-4-yl-l-phenylsulfanylmenthyl-propylamino)-N-(4-{4-[2-(4-chlorophenyl)-5,5-dimethylcyclohex-l-enylmethyl]-piperazin-l-yl}-benzoyl)-3-trifluoromethanesulfonylbenzenesulfonamide bis-hydrochloride",,12/19/2007,treatment of chronic lymphocytic leukemia,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,249107,,,
173,"(R)-5-(2-(2,5-difluorophenyl) pyrrolidin-1-yl)-3-(4-(trifluoromethyl)-1H-pyrazol-1-yl) pyrazolo[1,5-a] pyrimidine",,6/15/2022,treatment of neurotrophic tyrosine receptor kinase (ntrk) fusion-positive solid tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,Pyramid Biosciences,330 Bear Hill Road,Suite 302,Waltham,Massachusetts,' 02451 ' ,United States,827621,,,
174,"(R)-5-({4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl}methyl)-(5-2H)-1,3-thiazolidine-2,4-dione hydrochloride",,4/11/2022,treatment of x-linked adrenoleukodystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Poxel S.A.,259/261 Avenue Jean Jaures,,Lyon,,' F-69007 ' ,France,871522,leukodystrophy,"""gard:0006895""",
175,"(R)-6-((3,3-difluoro-1-methylpiperidine-4-yl)oxy-N-(3-ethynyl-2-fluorophenyl)-7-methoxyquinazolin-4-amine-,fumerate (2:1) (salt)",,7/24/2019,treatment of glioma (including glioblastoma and anaplastic astrocytoma),Designated,,Not FDA Approved for Orphan Indication,,,,,Wayshine Biopharm Inc.,"957 Ferndale Dr,",,Corona,California,' 92881 ' ,United States,695019,astrocytoma,"""gard:0012928""",
176,"(R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride",,11/19/2015,treatment of cholangiocarcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Basilea Pharmaceutical International Ltd.,Grenzacherstrasse 487,P.O. Box,Basel,,' ' ,Switzerland,497615,cholangiocarcinoma,"""gard:0009304""",
177,"(R)-6-(2-hydroxy-3-(4-(4-(trifluoromethyl)phenyl)piperazin- 1-yl)propoxy)-3,4-dihydroquinolin-2(1H)-one",,11/17/2020,treatment of subarachnoid hemorrhage,Designated,,Not FDA Approved for Orphan Indication,,,,,NeurOp Inc.,58 Edgewood Ave,,Atlanta,Georgia,' 30303 ' ,United States,781020,,,
178,(R)-Azasetron besylate,,8/16/2017,prevention of platinum-induced ototoxicity in pediatric patients,Designated,,Not FDA Approved for Orphan Indication,,,,,Sensorion SA,375 Rue du Professeur Joseph Blayac,,Montpellier,Languedoc-Roussillon,' ' ,France,593417,,,
179,"(R)-N-(1-(1-(1H-indazol-5-yl)-3-methyl-2,4-dioxo-1,3,8-triazaspiro[4,5]decan-8-yl)-3-methyl-1-oxobutan-2-yl)-2-fluoro-5-(trifluoromethyl)benzamide",,7/18/2019,treatment of idiopathic pulmonary fibrosis,Designated/Designation Withdrawn or Revoked,10/13/2020,Not FDA Approved for Orphan Indication,,,,,"X-Rx, Inc.",100 Beaver Street,,Waltham,Massachusetts,' 02453 ' ,United States,693119,idiopathic pulmonary fibrosis,"""gard:0008609""",
180,(R)-N-(3-(2-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propenamide hemi ethyl acetate solvate,,9/10/2020,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Dizal (Jiangsu) Pharmaceutical Co., Ltd.",199 Liangjing Road,Zhangjiang High-Tec Park,Shanghai,,' ' ,China,763220,lymphoma,"""gard:0020548""",
181,"(R)-N-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a] pyrimidin-3-yl)-4-((4-methylpiperazin-1-yl)methyl)benzamide sulfate hydrate",,5/17/2023,treatment of ntrk fusion-positive solid tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,Teligene US LLC,2060 D Avenida De Los Arboles 636,,Thousand Oaks,California,' 91362 ' ,United States,938623,,,
182,"(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide",,4/16/2021,treatment of myelodysplastic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Curis, Inc.","128 Spring Street, Building C, Suite 500",,Lexington,Massachusetts,' 02421 ' ,United States,810221,myelodysplastic syndrome,"""gard:0007132""",
183,"(R)-N-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide",,4/5/2021,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Curis, Inc.","128 Spring Street, Building C, Suite 500",,Lexington,Massachusetts,' 02421 ' ,United States,810321,acute myeloid leukemia,"""gard:0012757""",
184,(R)-N-[2-(6-chloro-5-methoxy-1H-indol-3-yl)propyl]acetamide,,10/3/2001,treatment of circadian rhythm sleep disorders in blind people with no light perception,Designated,,Not FDA Approved for Orphan Indication,,,,,"Phase 2 Discovery, Inc.","3130 Highland Avenue, Third Floor",,Cincinnati,Ohio,' 45219 ' ,United States,147501,,,
185,(R)-N-[2-(6-Chloro-methoxy-1H-indol-3yl)propyl]acetamide,,7/3/2003,treatment of neuroleptic-induced tardive dyskinesia in schizophrenia patients,Designated,,Not FDA Approved for Orphan Indication,,,,,"Phase 2 Discovery, Inc.",3130 Highland Ave.,Third Floor,Cincinnati,Ohio,' 45219 ' ,United States,157102,,,
186,"(R)-N2-(4-cyclopropyl-5-fluoro-6-methylpyridin-2-yl)-N4-(1, 5-dimethyl-1H-pyrazol-3-yl)-5-(3,4-dimethylpiperazin-1-yl) pyrimidine-2,4-diamine",,12/14/2021,treatment of malaria,Designated,,Not FDA Approved for Orphan Indication,,,,,Cadila Healthcare Limited,"Zydus Research Centre,","Survey No. 396/403, Sharkhej-Bavla N.H. No. 8A, Village Moraiya, Changodar,",Ahmedabad,Gujarat,' 382213 ' ,India,853221,malaria,"""gard:0006961""",
187,(R)-praziquantel,,6/27/2017,treatment of schistosomiasis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tongli Biomedical Co., Ltd. (TLB)",Guotaibei Road,"Room 401, Building D",Zhangjiagang,Jiangsu,' ' ,China,584317,schistosomiasis,"""gard:0009687""",
188,"(R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4-yl)pyridin-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate",,8/8/2019,treatment of fibrodysplasia ossificans progressiva,Designated,,Not FDA Approved for Orphan Indication,,,,,"Clementia Pharmaceuticals, Inc.","1000 De La Gauchetiere West, Suite 1200",,Montreal,,' ' ,Canada,698319,fibrodysplasia ossificans progressiva,"""gard:0006445""",
189,"(R,E)-3-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-1-(piperazin-1-yl)prop-2-en-1-on hemi-oxalate",,8/11/2022,treatment of solid tumors with the ntrk fusion gene,Designated,,Not FDA Approved for Orphan Indication,,,,,AUM Biosciences Pty Ltd.,10 Anson Rd #24-16A/B,International Plaza,Singapore,,' 079903 ' ,Singapore,894622,,,
190,"(RS)-baclofen, naltrexone and D-sorbitol",,3/17/2014,treatment of charcot-marie-tooth disease type 1a,Designated,,Not FDA Approved for Orphan Indication,,,,,Pharnext SA,"11, rue des Peupliers",,Issey-les-Moulineaux,,' ' ,France,422914,charcot-marie-tooth disease type 1,"""gard:0012433""",
191,(S)-1-((((1-Cyclohexylethyl)carbamoyl)oxy)methyl)-3-((2- nitrooxy)ethyl)carbamoyl)pyridin-1-ium iodide,,2/29/2024,prevention of delayed graft function in patients undergoing solid organ transplantation.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Unicycive Therapeutics, Inc.","4300 El Camino Real, Suite 210",,Los Altos,California,' 94022 ' ,United States,990223,,,
192,"(S)-1-((R)-3-amino-1-(4-((6-amino-9H-purin-9-yl)methyl)-6-(2,5-difluoro-4-methoxyphenyl)pyridin-3-yl)piperidin-3-yl)-2,2-difluoroethan-1-ol D-tartrate salt (1:1)",,6/8/2023,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,K36 Therapeutics Inc.,1 Main Street 13Fl,,Cambridge,Massachusetts,' 02142 ' ,United States,941323,multiple myeloma,"""gard:0007108""",
193,"(S)-1-(4-(1-(3,4,5-trimethyloxyphenyl)-1H-imidazol-4-ylamino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidine-2-carboxamide citrate",,8/29/2022,treatment of fibrodysplasia ossificans progressiva,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioCryst Pharmaceuticals, Inc.","4505 Emperor Blvd., Suite 200",Nottingham Hall,Durham,North Carolina,' 27703 ' ,United States,896622,fibrodysplasia ossificans progressiva,"""gard:0006445""",
194,"(S)-1-(6,7-Dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-yl)-N3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)-1H-1,2,4-triazole-3,5-diamine",,11/5/2014,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,BerGenBio AS,Jonas Lies vei 91,,Bergen,,' ' ,Norway,452314,acute myeloid leukemia,"""gard:0012757""",
195,"(S)-10-[(dimethylamino)methyl]-4-ethyl-9hydroxy-4-O-[a-(2"",4"",5"",7""-tetranitro-9""-fluorenylideneaminooxy)propionyl]- 1H-pyrano[3',4',6',7',] indolizino [1,2-B]-quinoline-3, 14-(4H, 12H)-dione, hydrochloride",,10/6/2010,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"TLC Biopharmaceuticals, Inc.",432 N Canal St,Suite 20,South San Francisco,California,' 94080 ' ,United States,317610,hepatocellular carcinoma,"""gard:0016773""",
196,"(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile",,1/26/2015,treatment of pemphigus vulgaris,Designated/Designation Withdrawn or Revoked,3/15/2018,Not FDA Approved for Orphan Indication,,,,,Almirall S.A.,"Ronda General Mitre, 151",,Barcelona,,' ' ,Spain,444614,pemphigus vulgaris,"""gard:0007355""",
197,"(S)-2-(1-((6-amino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl3,4-dihydropyrrolo[2,1-f][1,2,4]triazine-5-carbonitrile",,1/5/2017,treatment of epidermolysis bullosa acquisita,Designated/Designation Withdrawn or Revoked,3/15/2018,Not FDA Approved for Orphan Indication,,,,,"Almirall, S.A.","Ctra. Laurea Miro, 408-410",Sant Feliu de Llobregat,Barcelona,Catalunya,' ' ,Spain,548916,epidermolysis bullosa acquisita,"""gard:0006360""",
198,(S)-2-(1-(9H-purin-6-ylamino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one),,12/18/2017,treatment of peripheral t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Rhizen Pharmaceuticals SA,40 Rue Fritz-Courvoisier,,La Chaux-de-Fonds,Neuchâtel,' ' ,Switzerland,616417,lymphoma,"""gard:0020548""",
199,"(S)-2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy-1,1-d2)benzo[b]thiophen-7-yl)propanoic acid",,2/12/2024,treatment of autosomal dominant polycystic kidney disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Shanghai Alebund Pharmaceuticals Ltd.,"3rd Floor, Building 1, 400 Fangchun Road, Pilot Free Trade Zone",,Shanghai,,' ' ,China,986823,autosomal dominant polycystic kidney disease,"""gard:0010413""",
200,"(S)-3-((3-(1-((6-((3,4-dimethoxyphenyl)pryazin-2-yl)amino)ethyl)phenyl)carbamoyl)-5-methylpridin-1-ium",,11/17/2014,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,"GB002, Inc., a wholly-owned subsidiary of Gossamer Bio, Inc.",3013 Science Park Road,Suite 200,San Diego,California,' 92121 ' ,United States,441914,pulmonary arterial hypertension,"""gard:0007501""",
201,"(S)-3-((S)-2-(2-((2,6-difluorophenyl)amino)-2-oxoacetamido)propanamido-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid",,6/21/2017,treatment of primary sclerosing cholangitis (psc),Designated,,Not FDA Approved for Orphan Indication,,,,,Conatus Pharmaceuticals,16745 West Bernardo Drive,Suite 200,San Diego,California,' 92127 ' ,United States,583717,sclerosing cholangitis,"""gard:0021868""",
202,"(S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 4-(2-(5-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)-1H-indol-1-yl)ethyl)piperidine-1-carboxylate",,7/24/2019,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tarveda Therapeutics, Inc.",134 Coolidge Ave.,,Watertown,Massachusetts,' 02472 ' ,United States,694919,,,
203,"(S)-4,11-diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 4-(2-(5-(3-(2,4-dihydroxy-5-isopropylphenyl)-5-hydroxy-4H-1,2,4-triazol-4-yl)-1H-indol-1-yl)ethyl)piperidine-1-carboxylate",,10/10/2019,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tarveda Therapeutics, Inc.",134 Coolidge Ave.,,Watertown,Massachusetts,' 02472 ' ,United States,713419,small cell lung cancer,"""gard:0009344""",
204,"(S)-4,5-dihydro-2[2-hydroxy-3-(3,6,9-trioxadecyloxy)phenyl]-4-methyl-4-thiaxolecarboxylic acid",,2/4/2009,treatment of chronic iron overload in patients with transfusion-dependent anemias,Designated/Designation Withdrawn or Revoked,9/20/2018,Not FDA Approved for Orphan Indication,,,,,Shire Development LLC,300 Shire Way,,Lexington,Massachusetts,' 02421 ' ,United States,269408,,,
205,(S)-4-((1-Benzylpyrrolidin-3-yl)(methyl)amino)-2-fluoro-5-methyl-N-(thiazol-4-yl)benzenesulfonamide,,9/10/2020,"treatment of sodium channel, voltage-gated, type viii, alpha subunit (scn8a) developmental and epileptic encephalopathy syndrome",Designated,,Not FDA Approved for Orphan Indication,,,,,Neurocrine Biosciences Inc.,12780 El Camino Real,,San Diego,California,' 92130 ' ,United States,762220,,,
206,"(S)-4-methyl-5-((4-((2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1-(2-(4-(methylsulfonyl)piperazin-1-yl)propyl)-1H-indole-2-carbonitrile",,7/22/2019,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Kura Oncology,Clinical Development,55 Cambridge Parkway,Cambridge,Massachusetts,' 02142 ' ,United States,697819,acute myeloid leukemia,"""gard:0012757""",
207,"(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride",,11/17/2014,treatment of inherited mitochondrial respiratory chain diseases,Designated,,Not FDA Approved for Orphan Indication,,,,,Khondrion BV,Philips van Leydenlaan 15,,Ex Nijmegen,,' 6525 ' ,Netherlands,450714,,,
208,"(S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one",,4/29/2015,treatment of hodgkin lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,476215,lymphoma,"""gard:0020548""",
209,"(S)-7-(dimethylphosphoryl)-3-(2-((6,6-dimethylpiperidin-3-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)-1H-indole-6-carbonitrile",,9/12/2022,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Syros Pharmaceuticals,35 Cambridgepark Drive,Level 4,Cambridge,Massachusetts,' 02140 ' ,United States,898122,,,
210,"(S)-N-(1-(3-fluoro-2'-methoxy-[1,1'-biphenyl]-4-yl)-2-oxopiperidin-3-yl)-5-(pyridin-2-yl) thiophene-2-sulfonamide",,4/8/2024,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Amira Therapeutics, S.L.","Carrer Baldiri Reixac, 10-12",,Barcelona,Barcelona,' 08028 ' ,Spain,996524,soft tissue sarcoma,"""gard:0004898""",
211,"(S)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide",,1/18/2023,treatment of glioblastoma (gbm),Designated,,Not FDA Approved for Orphan Indication,,,,,Jubilant Therapeutics Inc.,"1430 US Highway 206, Suite 110",,Bedminster,New Jersey,' 07921 ' ,United States,923622,glioblastoma,"""gard:0002491""",
212,"(S)-N-(5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide",,1/18/2023,treatment of behcet’s disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ganzhou Hemay Pharmaceutical Co., Ltd.","West section of Lvyuan Avenue, West Zone,","Hi-tech Industrial Park, Xinfeng County",Ganzhou City,Jiangxi Province,' ' ,China,920522,,,
213,(S)-perillyl alcohol temozolomide,,11/12/2014,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"NeOnc Technologies, Inc.","8335 Sunset Blvd., #240",,Los Angeles,California,' 90069 ' ,United States,453314,,,
214,(s)-perillyl alcohol temozolomide carbamate,,7/27/2017,treatment of nasopharyngeal carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"NeOnc Technologies, Inc.","8335 Sunset Blvd., #240",,Los Angeles,California,' 90069 ' ,United States,575117,nasopharyngeal carcinoma,"""gard:0007163""",
215,(s)-perillyl alcohol temozolomide carbamate,,2/28/2017,treatment of intracranially located metastases from breast cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"NeOnc Technologies, Inc.","8335 Sunset Blvd., #240",,Los Angeles,California,' 90069 ' ,United States,557316,,,
216,(tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19,Kymriah (tisagenlecleucel),1/31/2014,for the treatment of acute lymphoblastic leukemia,Designated/Approved,,,Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse,8/30/2017,8/30/2024,Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse,Novartis Pharmaceuticals Corporation,"One Health Plaza,",Bldg 315 - Room 3650B,East Hanover,New Jersey,' 07936 ' ,United States,415113,acute lymphoblastic leukemia,"""gard:0000522""",
217,(UDU-stereoisomer of c-UJUun UNU-terminal UkUnhibitor),,3/28/2006,treatment of acute sensorineural hearing loss,Designated,,Not FDA Approved for Orphan Indication,,,,,Altamira Therapeutics Inc.,8 The Green,Suite 12455,Dover,Delaware,' 19901 ' ,United States,214905,,,
218,(Z)-3-fluoro-4-(quinolin-8-ylsulfonyl)but-2-en-1-amine,,7/10/2020,treatment of myelofibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Pharmaxis Ltd.,20 Rodborough Rd.,,Frenchs Forest,NSW,' ' ,Australia,747520,,,
219,1 8-(p[131I]-iodophenyl)octadecyl phosphocholine,,12/3/2014,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cellectar Biosciences, Inc.",3301 Agriculture Drive,,Madison,Wisconsin,' 53716 ' ,United States,455614,multiple myeloma,"""gard:0007108""",
220,"1'-{[5-(trifluoromethyl)-2-furyl]methyl}spiro[furo[2,3-f][1,3]benzodioxole-7,3'-indol]-2'(1'H)-one",,11/19/2012,treatment of erythromelalgia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Flexion Therapeutics, Inc.","10 Mall Road, Suite 301",,Burlington,Massachusetts,' 01803 ' ,United States,378012,,,
221,"1,1¿-(1, 12- Dodecanediyl)bis[cyclopropanecarboxamide]",,2/3/2022,treatment of congenital x-linked nephrogenic diabetes insipidus,Designated/Designation Withdrawn or Revoked,2/20/2024,Not FDA Approved for Orphan Indication,,,,,"NephroDI Therapeutics, Inc.","1606 Chestnut Street, Suite 3",,Philadelphia,Pennsylvania,' 19103 ' ,United States,859921,nephrogenic diabetes insipidus,"""gard:0007178""",
222,"1,2:5,6-Dianhdrogalactitol",,1/31/2012,treatment of malignant gliomas,Designated,,Not FDA Approved for Orphan Indication,,,,,"DelMar Pharmaceuticals, Inc.",3475 Edison Way,Suite R,Menlo Park,California,' 94025 ' ,United States,361311,,,
223,"1,2:5,6-dianhydrogalactitol",,3/10/2016,treatment of medulloblastoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"DelMar Pharmaceuticals, Inc.",3475 Edison Way,Suite R,Menlo Park,California,' 94025 ' ,United States,512515,medulloblastoma,"""gard:0007005""",
224,"1,2:5,6-dianhydrogalactitol",,4/19/2016,treatment of ovarian cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"DelMar Pharmaceuticals, Inc. (Clinical Operations)",3475 Edison Way,Suite R,Menlo Park,California,' 94025 ' ,United States,514915,ovarian cancer,"""gard:0007295""",
225,"1,2:5,6-dianhydrogalactitol",,12/14/2022,treatment of diffuse intrinsic pontine glioma (dipg),Designated,,Not FDA Approved for Orphan Indication,,,,,"Kintara Therapeutics, Inc.",9920 PACIFIC HEIGHTS BLVD.,Suite 150,San Diego,California,' 92121 ' ,United States,903822,diffuse intrinsic pontine glioma,"""gard:0013075""",
226,"1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio] butadiene",,8/3/2017,treatment of subarachnoid hemorrhage (sah),Designated,,Not FDA Approved for Orphan Indication,,,,,Edvince AB,Medicon Village,Scheelevägen 2,Lund,Skåne län,' ' ,Sweden,593217,,,
227,"1,4Lambda6, 3-Oxathiazinane-4,4-dione",,6/6/2022,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Geistlich Pharma North America,"902 Carnegie Center, Suite 360",,Princeton,New Jersey,' 08540 ' ,United States,883222,,,
228,"1,5-(Butylimino)-1,5 dideoxy,D-glucitol",,5/12/1998,treatment of fabry's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Oxford GlycoSciences,"10, The Quadrant",Abington Science Park,Abington,Oxfordshire,' ' ,United Kingdom,112198,,,
229,"1-(((Z)-hexadec-1-en-1-yl)oxy)-3-((2-oxido-1,3,2-oxazaphospholidin-2-yl)oxy)propan-2-yl (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate",,8/8/2019,treatment of rhizomelic chondrodysplasia punctata,Designated,,Not FDA Approved for Orphan Indication,,,,,"Med-Life Discoveries, LP",407-15 Innovation Boulevard,,Saskatoon,,' ' ,Canada,696219,rhizomelic chondrodysplasia punctata,"""gard:0013160""",
230,"1-((2S,4S)-2-((((S) -(4-bromophenoxy)(((S)-1-oxo-1-(((S)- pentan-2-yl)oxy)propan-2-yl)amino)phosphoryl)oxy)methyl)-1,3-dioxolan-4-yl)-2-oxo-1,2-dihydropyrimidin-4- aminium chloride",,5/4/2020,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Medivir AB,Box 1086s,,Huddinge,,' ' ,Sweden,745020,hepatocellular carcinoma,"""gard:0016773""",
231,"1-(11-dodecylamino-10-hydroxyundecyl)-3,7-dimethylxanthine hydrogen methanesulfonate",,1/18/2000,treatment of hormone refractory prostate carcinoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Cell Therapeutics, Inc.",201 Elliott Avenue West,Suite 400,Seattle,Washington,' 98119 ' ,United States,125899,noma,"""gard:0004001""",
232,"1-(2,8-Dimethyl-1-thia-3,8-diazaspiro[4.5]dec-3-yl)-3-(1H-indol-3-yl)propan-1-one",,4/6/2016,treatment of frontotemporal dementia.,Designated,,Not FDA Approved for Orphan Indication,,,,,Anavex Life Sciences Corp.,51 West 52nd Street,7th Floor,New York,New York,' 10019 ' ,United States,512615,frontotemporal dementia,"""gard:0008436""",
233,1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine,,6/24/2010,treatment of acute myelogenous leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Cyclacel Limited,Dundee Technopole,1 James Lindsay Place,Dundee,,' ' ,United Kingdom,263508,,,
234,1-(2-C-cyano-2-deoxy-B-D-arabino-pentafuranosyl)-N4-palmitoylcytosine,,6/24/2010,treatment of myelodysplastic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Cyclacel Limited,Dundee Technopole,1 James Lindsay Place,Dundee,,' ' ,United Kingdom,263408,myelodysplastic syndrome,"""gard:0007132""",
235,1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propane,,3/20/2017,treatment of infantile spasms,Designated,,Not FDA Approved for Orphan Indication,,,,,"Bio-Pharm Solutions, Co., Ltd.","6F, C Bldg., Advanced Institute of Convergence Technology","145 Gwanggyo-Ro, Yeongtong-Gu",Suwon,Gyeonggi-Do,' ' ,South Korea,555216,,,
236,1-(2-chlorophenyl)-1-(S)-hydroxy-2-(S)-carbamoyloxy-propane,,7/7/2016,treatment of status epilepticus,Designated,,Not FDA Approved for Orphan Indication,,,,,"Bio-Pharm Solutions Co., Ltd.",Advanced Institute of Convergence Technology,"6F, C Bldg",Yeongtong Suwon,Gyeonggi-do,' ' ,South Korea,528216,,,
237,"1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt",,9/28/2017,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,10/31/2022,Not FDA Approved for Orphan Indication,,,,,"Cardiff Oncology, Inc.",11055 Flintkote Avenue,,San Diego,California,' 92121 ' ,United States,602617,acute myeloid leukemia,"""gard:0012757""",
238,1-(2-Nitro-imidazolyl)-3-[18F]fluoro-2-propanol; 1H-1-(3-[18F]fluoro-2-hydroxypropyl0-2-nitroimidazole (18F-Misonidazole),,4/6/2016,diagnostic for management of glioma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,' 33467 ' ,United States,521116,,,
239,"1-(3-{4-[3,4-difluoro-2-(trifluoromethyl)phenyl]piperidine-1-carbonyl}-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridin-6-yl)ethan-1-one",,9/19/2017,treatment of stargardt disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Belite Bio, LLC",3210 Merryfield Row,,San Diego,California,' 92121 ' ,United States,601217,stargardt disease,"""gard:0000181""",
240,"1-(4-(benzylamino)-7,8-dihydro-5H-pyrano[4,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide",,7/8/2015,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,7/7/2017,Not FDA Approved for Orphan Indication,,,,,"Cleave Biosciences, Inc.",866 Malcolm Road,Suite 100,Burlingame,California,' 94010 ' ,United States,483815,multiple myeloma,"""gard:0007108""",
241,"1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one",,9/26/2013,management of postherpetic neuralgia,Designated/Designation Withdrawn or Revoked,3/10/2014,Not FDA Approved for Orphan Indication,,,,,Zalicus Pharmaceuticals Ltd.,245 First Street,,Cambridge,Massachusetts,' 02142 ' ,United States,387412,,,
242,"1-(4-Chloro-3,5-diphenyl-pyrazolo[3,4-c]pyridazin-1-yl)-2-methyl-propan-2-ol",,11/26/2019,treatment of usher syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Usher III Initiative, Inc.","191 N. Wacker Dr., Suite 1790",,Chicago,Illinois,' 60606 ' ,United States,711419,usher syndrome,"""gard:0007843""",
243,"1-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridine-3-yl}phenyl)-3-(3-fluorophenyl)urea)",,7/28/2011,treatment of acute myelogenous leukemia,Designated/Designation Withdrawn or Revoked,8/16/2014,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,337811,,,
244,1-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone,,8/31/2023,treatment of myelofibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Telios Pharma, Inc.",275 Shoreline Drive,Suite 325,Redwood City,California,' 94065 ' ,United States,957423,,,
245,1-(6-benzothiazolylsulfonyl)-5-chloro-1H-indole-2-butanoic acid,,3/31/2015,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Inventiva Pharma,50 rue de Dijon,,Daix 21121,,' ' ,France,470315,systemic sclerosis,"""gard:0009748""",
246,"1-(fluoro-18F)-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)benzo[d]thiazol-6-yl)oxy)propan-2-ol",,11/1/2017,a diagnostic for the management of progressive supranuclear palsy,Designated,,Not FDA Approved for Orphan Indication,,,,,Aprinoia Therapeutics,"17F, No. 3 Yuanqu Street",Nangang District,Taipei City,,' 11503 ' ,Taiwan,610917,progressive supranuclear palsy,"""gard:0007471""",
247,"1-118-signal regulatory protein alpha (human) fusion protein with immunoglobulin G1 (human Fc fragment), dimer",,3/8/2018,treatment of cutaneous t-cell lymphoma,Designated/Designation Withdrawn or Revoked,7/26/2022,Not FDA Approved for Orphan Indication,,,,,Trillium Therapeutics Inc.,2488 Dunwin Drive,,Mississauga,,' ' ,Canada,624917,lymphoma,"""gard:0020548""",
248,1-Cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea,,11/12/2009,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Astex Therapeutics Ltd,436 Cambridge Science Park,,Milton,Cambridge,' ' ,United Kingdom,291809,acute myeloid leukemia,"""gard:0012757""",
249,1-O-octadecyl-2-arachidonoyl-sn-glycerol-3-phosphoethanolamine,,3/29/2023,treatment of rett syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Institute of Rheological Functions of Food,"2241-1 Kubara, Hisayama-machi, Kasuya-gun",,Fukuoka,,' ' ,Japan,933223,rett syndrome,"""gard:0005696""",
250,"1-Pyrrolidinecarboximidamide, N-[imino[[4-(trifluoromethoxy)phenyl]amino]methyl]-, acetate (1:1)",,10/17/2022,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"ImmunoMet Therapeutics, Inc.",2450 Holcombe Blvd,JLABS at TMC,Houston,Texas,' 77021 ' ,United States,889822,,,
251,"1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy) methyl]benzene",,1/9/2012,treatment of poliovirus infection.,Designated,,Not FDA Approved for Orphan Indication,,,,,"ViroDefense, Inc.",155 Gibbs Street,Suite 529,Rockville,Maryland,' 20850 ' ,United States,357811,,,
252,"1-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl] ethanone",,2/19/2021,treatment of uveal melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Linnaeus Therapeutics, Inc.",30 Washington Avenue,Suite F,Haddonfield,New Jersey,' 08033 ' ,United States,801620,uveal melanoma,"""gard:0008621""",
253,"1-[(3aS,4R,9bR)-4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl] ethanone",,1/3/2023,treatment of stage iib to stage iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Linnaeus Therapeutics, Inc.","30 Washington Avenue, Suite F",,Haddonfield,New Jersey,' 08033 ' ,United States,918622,noma,"""gard:0004001""",
254,1-[12-(1 Carboxycyclopropyl) dodecyl] cyclopropane-1-carboxylic acid,,12/7/2022,treatment of congenital x-linked nephrogenic diabetes insipidus,Designated,,Not FDA Approved for Orphan Indication,,,,,"NephroDI Therapeutics, Inc.","1606 Chestnut Street, Suite 3",,Philadelphia,Pennsylvania,' 19103 ' ,United States,915322,nephrogenic diabetes insipidus,"""gard:0007178""",
255,"1-{2-[3-(3,4-Dichlorophenyl)ureido]-6-methyl-pyrimidin-4-yl}-amino-3(dimethylamino)propane Di methansulfonate",,8/2/2017,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Curtana Pharmaceuticals, Inc.",1624 Headway Circle,,Austin,Texas,' 78754 ' ,United States,599417,,,
256,1-{4-[2-(5-ethoxymethyl-2-methyl-phenylamino)-oxazol-5-yl]-phenyl}-imidazolidin-2-one,,8/1/2019,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,AB Science,"3, avenue George V",,Paris,,' ' ,France,695919,acute myeloid leukemia,"""gard:0012757""",
257,"1-{6-[(4-fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1H,2H,3H-pyrrolo[3,2-b]pyridin-1-yl}-2-[(2R,5R)-5-methyl-2-{[(3R)-3-methylmorpholin-4-yl]methyl}piperazin-1-yl]ethan-1-one, L-(+)-lactic acid salt",,8/28/2020,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Astex Pharmaceuticals, Inc.",4420 Rosewood Drive,Suite 200,Pleasanton,California,' 94588 ' ,United States,758020,lymphoma,"""gard:0020548""",
258,10 synthetic peptides targeting 5 tumor asociated antigens,,1/23/2013,treatment of non-small cell lung cancer in patients expressing hla-a2,Designated,,Not FDA Approved for Orphan Indication,,,,,Orphan Synergy Europe Pharma (OSE Pharma),OSE Pharma Pepiniere Paris Sante Cochin,29 bis rue du faubourg Saint Jacques,Paris,,' ' ,France,387212,small cell lung cancer,"""gard:0009344""",
259,"10,11-methylenedioxy-20(S)-camptothecin (10,11-MD-CPT)",,10/23/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Canget BioTekpharma, LLC",701 Ellicott Street,,Buffalo,New York,' 14203 ' ,United States,967123,,,
260,10-nitro-9(E)-octadec-9-enoic acid,,9/12/2019,treatment of pulmonary arterial hypertension,Designated/Designation Withdrawn or Revoked,2/26/2021,Not FDA Approved for Orphan Indication,,,,,"Complexa, Inc.",1055 Westlakes Dr,Suite 200,Berwyn,Pennsylvania,' 19312 ' ,United States,701019,pulmonary arterial hypertension,"""gard:0007501""",
261,111Indium pentetreotide,,6/10/1999,treatment of somatostatin receptor positive neuroendocrine tumors.,Designated,,Not FDA Approved for Orphan Indication,,,,,Louisiana State University Medical Center Foundation,1600 Canal St.,10th Floor,New Orleans,Louisiana,' 70112 ' ,United States,121198,,,
262,12-A-p21 RAS(5-21). 12-C-p21 RAS(5-21). 12-D-p21 RAS(5-21). 12-Rp21 RAS(5-21). 12-S-p21 RAS(5-21). 12-V-p21 RAS(5-21). 13-D-p21 RAS(5-21),,6/7/2011,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Targovax Solutions AS, a subsidiary of Targovax ASA",Vollsveien 19,,Lysaker,,' 1366 ' ,Norway,343011,,,
263,131-I-8H9 monoclonal antibody,,8/29/2016,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Y-mAbs Therapeutics, Inc.",750 3rd Avenue,9th Floor,New York,New York,' 10017 ' ,United States,535716,neuroblastoma,"""gard:0007185""",
264,131I-BC8 monoclonal antibody (Anti-CD45 murine monoclonal antibody radiolabeled with 131I,,3/28/2016,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,"Actinium Pharmaceuticals, Inc.",379 Thornall Avenue,6th Floor,Edison,New Jersey,' 08837 ' ,United States,510615,acute myeloid leukemia,"""gard:0012757""",
265,14-amino acid peptide derived from wound growth factor,,8/5/2010,prevention of delayed graft function in renal transplant recipients,Designated/Designation Withdrawn or Revoked,12/31/2014,Not FDA Approved for Orphan Indication,,,,,NephRx Corporation,4717 Campus Drive,,Kalamazoo,Michigan,' 49008 ' ,United States,311210,,,
266,14-amino acid peptide derived from wound growth factor,,8/16/2010,treatment of delayed graft function in renal transplant recipients,Designated/Designation Withdrawn or Revoked,12/31/2014,Not FDA Approved for Orphan Indication,,,,,NephRx Corporation,4717 Campus Drive,,Kalamazoo,Michigan,' 49008 ' ,United States,312410,,,
267,14-species commensal bacterial flora with prebiotics and postbiotic complex composed of gut microbiome modulating formulation,,4/29/2024,treatment of angelman syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Biom Pharmaceutical Corporation,2203 Industrial Blvd.,,Sarasota,Florida,' 34234 ' ,United States,999824,angelman syndrome,"""gard:0005810""",
268,"15(S)-hydroxy-(5Z,8Z,11Z,13E,17Z)-eicosapentaenoic acid ethyl ester",,12/17/2018,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Afimmune,Trintech Building,South County Business Park,Dublin,County Dublin,' ' ,Ireland,667918,idiopathic pulmonary fibrosis,"""gard:0008609""",
269,"15(S)-hydroxy-(5Z,8Z,11Z,13E,17Z)-eicosapentaenoic acid ethyl ester (15(S)-HEPE-EE)",,6/3/2022,treatment of sickle cell disease (scd),Designated,,Not FDA Approved for Orphan Indication,,,,,Afimmune,"Trintech Building, South County Business Park",Leopardstown,Dublin 18,,' ' ,Ireland,880022,,,
270,16 base single stranded peptide nucleic acid oligonucleotide ¿ 7 aminoacids peptide,,2/22/2018,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,BIOGENERA SpA,46 Via Marconi,,Porretta Terme (BO),Emilia-Romagna,' ' ,Italy,626018,small cell lung cancer,"""gard:0009344""",
271,16 base single stranded PNA oligonucleotide¿7 aminoacids peptide,,10/25/2017,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,BIOGENERA SpA,46 Via Marconi,,Porretta Terme (BO),Emilia-Romagna,' ' ,Italy,608517,neuroblastoma,"""gard:0007185""",
272,17 amino acid peptide,,1/29/2010,prevention of ischemia reperfusion injury in the lung during lung tranplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,Apeptico Forschung und Entwicklung GmbH (APEPTICO),Mariahilferstrabe 136,Top 1150,Vienna,,' ' ,Austria,298009,,,
273,17-a-hydroxyprogesterone caporate (oral formulation),,6/1/2015,prevention of preterm birth in women with a singleton pregnancy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Lipocine, Inc.",675 Arapeen Drive,Suite 202,Salt Lake City,Utah,' 84108 ' ,United States,445314,,,
274,17-allylamino-17-demethoxygeldanamycin (17-AGG),,9/3/2004,treatment of chronic myelogenous leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,Research & Development,5 Research Parkway,Wallingford,Connecticut,' 06492 ' ,United States,191304,,,
275,177-LU-DOTA-GlyGlyNle-CycMSHhex,,4/16/2015,treatment of stage iib through iv malignant melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"SolaranRx, Inc.","5901 Indian School Road, NE",,Albuquerque,New Mexico,' 87110 ' ,United States,470015,noma,"""gard:0004001""",
276,177Lu-tetraxetan-tetulomab,,5/14/2014,treatment of follicular lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Nordic Nanovector AS,Anniken Hagen,"Kjelsasveien 168B, NO-0884",Oslo,,' ' ,Norway,433014,lymphoma,"""gard:0020548""",
277,18-(p-[124I]-iodophenyl)octadecyl phosphocholine,,4/30/2014,diagnostic for the management of glioma,Designated/Designation Withdrawn or Revoked,7/2/2019,Not FDA Approved for Orphan Indication,,,,,"Cellectar Biosciences, Inc.",3301 Agriculture Drive,,Madison,Wisconsin,' 53716 ' ,United States,429514,,,
278,18-(p-[131]-iodophenyl)octadecyl phosphocholine,,3/15/2018,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cellectar Biosciences, Inc.",3301 Agriculture Drive,,Madison,Wisconsin,' 53716 ' ,United States,629018,neuroblastoma,"""gard:0007185""",
279,18-(p-[131I]-iodophenyl)octadecyl phosphocholine,,9/24/2018,treatment of osteosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cellectar Biosciences, Inc.",3301 Agriculture Drive,,Madison,Wisconsin,' 53716 ' ,United States,651018,osteosarcoma,"""gard:0007284""",
280,18-(p-[131I]-iodophenyl)octadecyl phosphocholine,,7/3/2018,treatment of ewing’s sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cellectar Biosciences, Inc.",3301 Agriculture Drive,,Madison,Wisconsin,' 53716 ' ,United States,646918,,,
281,18-(p-[131I]-iodophenyl)octadecyl phosphocholine,,12/23/2019,treatment of lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cellectar Biosciences, Inc.","100 Campus Drive, Suite 207",,Florham Park,New Jersey,' 07932 ' ,United States,716119,lymphoma,"""gard:0020548""",
282,18-(p-[131I]-iodophenyl)octadecyl phosphocholine,,5/8/2018,treatment of soft tissue sarcomas including rhabdomyosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cellectar Biosciences, Inc.",3301 Agriculture Drive,,Madison,Wisconsin,' 53716 ' ,United States,638418,rhabdomyosarcoma,"""gard:0011951""",
283,18-mer antisense oligonucleotide complementary to SCN1A mRNA,,8/5/2019,treatment of dravet syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Stoke Therapeutics, Inc.",45 Wiggins Ave,,Bedford,Massachusetts,' 01730 ' ,United States,695319,dravet syndrome,"""gard:0010430""",
284,18?mer antisense oligonucleotide complementary to OPA1 pre-mRNA,,7/29/2022,treatment of autosomal dominant optic atrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Stoke Therapeutics, Inc.",45 Wiggins Ave,,Bedford,Massachusetts,' 01730 ' ,United States,893822,autosomal dominant optic atrophy,"""gard:0011972""",
285,18F-meta-fluorobenzylguanidine,,8/21/2019,diagnostic for the management of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Innervate Radiopharmaceuticals, LLC",175 Elm Road,,Englewood,New Jersey,' 07631 ' ,United States,702419,neuroblastoma,"""gard:0007185""",
286,18Fluorine-N-3-Fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl) Nortropane,,1/26/2015,diagnostic to be used in the management of multiple system atrophy (msa),Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,' 33467 ' ,United States,451114,multiple system atrophy,"""gard:0007079""",
287,19 amino acid synthetic peptide NOS-enhancer,,7/26/2021,treatment of anterior ischemic optic neuropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Biozeus Biopharmaceutical SA,Rua Visconde de Pirajá 623 9°,"andar, Ipanema",Rio de Janeiro,RJ,' CEP 22410-003 ' ,Brazil,806120,,,
288,"1E,6E)-1,7-Bis(3,4-dimethoxyphenyl)-4-cyclobutylmethyl-1,6-heptadiene-3,5-dione or [(1E, 4Z,6E)-4-(cyclobutylmethyl)-1,7-bis(3,4-dimethoxyphenyl)-5-hydroxyhepta-1,4,6-trien-3-one]",,2/17/2016,treatment of spinal and bulbar muscular atrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,AnnJi Pharmaceutical Co. Ltd.,"B405, No. 18, Siyuan St., Zhongzheng Dist.",,Taipei City 100,,' ' ,Taiwan,509315,,,
289,2 dimethylbutyrate,,6/18/2008,treatment of beta thalassemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"HemaQuest Pharmaceuticals, Inc.",1001 Fourth Avenue,Suite 3317,Seattle,Washington,' 98154 ' ,United States,259608,,,
290,"2',3',5'-tri-o-acetyluridine",,1/13/2003,treatment of mitochondrial disease,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Repligen Corporation,41 Seyon Street,"Building 1, Suite 100",Waltham,Massachusetts,' 02453 ' ,United States,163202,mitochondrial disease,"""gard:0018887""",
291,2'-3'-dideoxyadenosine,,7/21/1987,treatment of aquired immunodeficiency syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"National Cancer Institute, Dct","NIH, Exec. Plaza N., Room 7-18",,Bethesda,Maryland,' 20892 ' ,United States,20587,,,
292,2'-deoxycytidine,,9/9/1996,as a host-protective agent in the treatment of acute myelogenous leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Grant, Steven M.D.","Massey Cancer Center, VCU",P.O. Box 980230,Richmond,Virginia,' 23298 ' ,United States,99996,,,
293,2'-O-(2-methoxyethyl) modified antisense oligonucleotide targeting PLP1 pre-mRNA,,9/15/2023,treatment of pelizaeus-merzbacher disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ionis Pharmaceuticals, Inc.",2855 Gazelle Court,,Carlsbad,California,' 92010 ' ,United States,960623,pelizaeus-merzbacher disease,"""gard:0004265""",
294,2'-O-(2-methoxyethyl) modified antisense oligonucleotide targeting UBE3A antisense transcript RNA,,5/26/2022,treatment of angelman syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ionis Pharmaceuticals, Inc.",2855 Gazelle Court,,Carlsbad,California,' 92010 ' ,United States,883522,angelman syndrome,"""gard:0005810""",
295,2'-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide targeting CD49d RNA,,10/21/2020,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Antisense Therapeutics Limited,6 Wallace Avenue Toorak,,Victoria,,' 3142 ' ,Australia,774720,muscular dystrophy,"""gard:0007922""",
296,2'-O-(2-methoxyethyl)phosphorothioate antisense oligonucleotide,,5/10/2016,treatment of acromegaly,Designated,,Not FDA Approved for Orphan Indication,,,,,Antisense Therapeutics Limited,6 Wallace Avenue,TOORAK VIC 3142,Trevose,,' ' ,Australia,517016,acromegaly,"""gard:0005725""",
297,2'-O-methyl phosphorothioate 5'-GCUAGGUUUACGGGACCUCU-3',,10/31/2012,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,LifeSplice Pharma LLC,1 Great Valley Parkway,Suite 20,Malvern,Pennsylvania,' 19355 ' ,United States,380012,amyotrophic lateral sclerosis,"""gard:0005786""",
298,"2'-O-methylphosphorothioate RNAoligonucleotide, 5'- m5CUGm5CUGm5CUGm5CUGm5CUGm5CUGm5CUG-3'""",,6/22/2021,treatment of spinocerebellar ataxia,Designated,,Not FDA Approved for Orphan Indication,,,,,Vico Therapeutics B.V.,J. H. Oortweg 21,,Leiden,,' 2333 CH ' ,Netherlands,821421,,,
299,"2,2'-{2-[1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diyl}diacetic acid (ixazomib citrate)",,3/9/2012,treatment of systemic light chain (al) amyloidosis.,Designated/Designation Withdrawn or Revoked,7/8/2020,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,361911,amyloidosis,"""gard:0018676""",
300,"2,2-dimethylbutanoic acid",,12/10/2020,treatment of methylmalonic acidemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"HemoShear Therapeutics, LLC",501 Locust Avenue,,Charlottesville,Virginia,' 22902 ' ,United States,751020,,,
301,"2,2-dimethylbutanoic acid",,12/10/2020,treatment of propionic acidemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"HemoShear Therapeutics, LLC",501 Locust Avenue,,Charlottesville,Virginia,' 22902 ' ,United States,746120,propionic acidemia,"""gard:0000467""",
302,"2,3,5-Trimethyl-6-nonyl-2,5-cyclohexadiene-1,4-dione",,4/26/2022,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",500 Warren Corporate Center Drive,,Warren,New Jersey,' 07059 ' ,United States,875722,amyotrophic lateral sclerosis,"""gard:0005786""",
303,"2,4 dinitrophenol",,9/8/2020,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mitochon Phannaceuticals, Inc.",970 Cross Lane,,Blue Bell,Pennsylvania,' 19422 ' ,United States,764820,amyotrophic lateral sclerosis,"""gard:0005786""",
304,"2,4-dinitrophenol",,2/11/2019,treatment of huntington disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mitochon Pharmaceuticals, Inc.",970 Cross Lane,,Blue Bell,Pennsylvania,' 19422 ' ,United States,672818,huntington disease,"""gard:0006677""",
305,"2,5,6,11,12,13-Hexahydro-2-methyl-11-(2-methylpropyl)-8-(2-pyrimidinylamino)-4H-indazolo[5,4-c]pyrrolo[3,4-c]carbazol-4-one mono(4-methylbenzenesulfonate)",,3/27/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Esanik Therapeutics, Inc.","2 W. Liberty Blvd., Suite 110",,Malvern,Pennsylvania,' 19355 ' ,United States,931223,,,
306,"2,5-dimethyl-3-[2-methyl-4-(methyloxy)phenyl]-N-[(1S)-1-(3-methyl-1,2,4-oxadiazol-5-",,1/15/2015,treatment of congenital adrenal hyperplasia (cah),Designated/Designation Withdrawn or Revoked,2/16/2016,Not FDA Approved for Orphan Indication,,,,,"Neurocrine Biosciences, Inc.",12780 El Camino Real,,San Diego,California,' 92130 ' ,United States,399713,congenital adrenal hyperplasia,"""gard:0001467""",
307,"2,6-Dichloro-N-(3-isobutyl-1,5-dimethyl-1H-pyrazol-4-yl)-4-(2-(piperazin-1-yl)pyridin-4-yl)benzenesulfonamide",,10/12/2022,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Pacylex Pharmaceuticals,"4560, 10230 Jasper Avenue",,Edmonton,Alberta,' T5J 46P ' ,Canada,904722,acute myeloid leukemia,"""gard:0012757""",
308,"2,7-bis(3-morpholinopropyl)-4-((2-(pyrrolidin-1-yl)ethyl)amino)-9-(4-(pyrrolidin-1-ylmethyl)phenyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone",,1/9/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Qualigen Therapeutics, Inc.","2042 Corte del Nogal, Suite B",,Carlsbad,California,' 92011 ' ,United States,917622,,,
309,"2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile",,6/8/2017,treatment of idiopathic pulmonary fibrosis.,Designated/Designation Withdrawn or Revoked,3/30/2021,Not FDA Approved for Orphan Indication,,,,,Galapagos NV,Generaal De Wittelaan,L11 A3,Mechelen,,' ' ,Belgium,570616,idiopathic pulmonary fibrosis,"""gard:0008609""",
310,"2-((2-fluoro-4-iodophenyl)amino)-N-(2-hydroxyethoxy)-1-methyl-1H-pyrrolo[2,3-b]pyridine-3-carboxamide",,8/12/2021,treatment of neurofibromatosis type 1,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nflection Therapeutics, Inc.",867 Boylston Street,5th Floor #1116,Boston,Massachusetts,' 02116 ' ,United States,746520,neurofibromatosis type 1,"""gard:0007866""",
311,"2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl) acetamide monohydrate",,11/20/2019,treatment of myelofibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Constellation Pharmaceuticals,"215 First Street, Suite 200",,Cambridge,Massachusetts,' 02142 ' ,United States,710219,,,
312,"2-(1,1-difluoroethyl)-5-methyl-N-[4-(pentafluoro-¿{6}-sulfanyl)phenyl]-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine",,8/18/2017,treatment of malaria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Paul Maher, MD",10644 Weymouth Street,Suite 104,Bethesda,Maryland,' 20814 ' ,United States,598417,malaria,"""gard:0006961""",
313,2-(2-chlorobenzylidene)hydrazinecarboximidamide acetate,,9/10/2015,treatment of charcot-marie tooth disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,InFlectis BioScience,21 rue de la Noue Bras de Fer,44200,Nantes,,' ' ,France,488415,,,
314,"2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-C]pyridine-3,6(2H,5H)-dione",,9/21/2010,treatment of idiopathic pulmonary fibrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Calliditas Therapeutics Suisse SA,Chemin des Aulx 14,,Plan-les-Ouates,,' 1228 ' ,Switzerland,316110,idiopathic pulmonary fibrosis,"""gard:0008609""",
315,"2-(2-chlorophenyl)-5-hydroxy-8-((3S,4R)-3-hydroxy-1-methylpiperidin-4-yl)-4-oxo-4H-chromen-7-yl dihydrogen phosphate",,3/14/2023,treatment of ewing sarcoma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Pharma America, Inc.",84 Waterford Drive,,Marlborough,Massachusetts,' 01752 ' ,United States,928322,,,
316,2-(2-phenylvinyl)-4-[-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt,,1/29/2010,treatment of acute myeloid leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"EntreMed, Inc.",9640 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,298609,acute myeloid leukemia,"""gard:0012757""",
317,2-(2-phenylvinyl)-4-[4-methylpiperazin-1-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt,,7/1/2014,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"CASI Pharmaceuticals, Inc.",9620 Medical Center Drive,Suite 300,Rockville,Maryland,' 20850 ' ,United States,437214,hepatocellular carcinoma,"""gard:0016773""",
318,2-(2-phenylvinyl)-4-[4-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-yl-amino)-pyrimidine L(+) tartrate salt,,12/22/2008,treatment of multiple myeloma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"EntreMed, Inc.",9640 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,270408,multiple myeloma,"""gard:0007108""",
319,2-(2-phenylvinyl)-4-[4-methylpiperazin-l-yl)]-6-(5-methyl-2H-pyrazol-3-ylamino)-pyrimidine L(+) tartrate salt,,3/18/2009,treatment of ovarian carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"EntreMed, Inc.",9640 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,277409,noma,"""gard:0004001""",
320,2-(2-{2-(2-{4-Benzothiazol-2- y1-phenoxy}-ethoxy]-ethoxy}-ethoxy}-ethanol,,5/24/2021,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,"Spinogenix, Inc","10210 Campus Point Drive, Suite 150",,San Diego,California,' 92121 ' ,United States,802820,amyotrophic lateral sclerosis,"""gard:0005786""",
321,"2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid",,8/16/2018,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"ASLAN Pharmaceuticals Pte, Ltd.",83 Clemenceau Avenue,#12-03,Singapore,,' ' ,Singapore,647118,acute myeloid leukemia,"""gard:0012757""",
322,"2-(3,7-Dimethyl-octa-2, 6-dienyl)¿6-ethylamino-3-hydroxy-5-pentyl-[1,4]benzoquinone",,2/1/2018,treatment of huntington’s disease (hd),Designated,,Not FDA Approved for Orphan Indication,,,,,Emerald Health Pharmaceuticals Inc.,5820 Nancy Ridge Drive,,San Diego,California,' 92121 ' ,United States,623717,,,
323,"2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-l-yl)-1-(1-(3-fluoro-2-(trifluoromethyl)isonicotinoyl)piperidin-4-yl)azetidin-3-yl)acetonitrile adipate",,1/26/2015,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,462014,,,
324,2-(3-amino-6-chloroquinolin-2-yl)-propan-2-ol,,4/17/2017,treatment of congenital ichthyosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Aldeyra Therapeutics,131 Hartwell Avenue,Suite 320,Lexington,Massachusetts,' 02421 ' ,United States,530116,ichthyosis,"""gard:0018985""",
325,"2-(3-diethylaminopropyl)-8,8-dipropyl-2-azaspiro [4,5] decan dimaleate",,12/2/2003,treatment of mulitple myeloma and associated bone resorption,Designated,,Not FDA Approved for Orphan Indication,,,,,"Callisto Pharmaceuticals, Inc.",2 Executive Drive,Suite 450,Somerset,New Jersey,' 08873 ' ,United States,167103,,,
326,"2-(3-Diethylaminopropyl)-8,8-dipropyl-2-azaspiro[4,5] decane dimaleate",,9/18/2006,treatment of carcinoid tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"Callisto Pharmaceuticals, Inc.",420 Lexington Avenue,,New York,New York,' 10170 ' ,United States,227706,,,
327,"2-(4-(((4-methoxyphenyl)thio)methyl)-1H-1,2,3-triazol-1-yl)-N,N-dimethylethan-1-aminium hydrochloride",,1/22/2024,treatment of retinal dystrophy associated with pde6 mutation,Designated,,Not FDA Approved for Orphan Indication,,,,,Miramoon Pharma SL,Av. Tolosa 72,,Donostia,,' 20018 ' ,Spain,908522,,,
328,"2-(4-(2,4-dichlorophenethyl)-3,6-dioxo-1-(2-(thiophen-2-yl)ethyl)piperazin-2-yl)-N-(2-(5-methoxy-1H-indol-3-yl)ethyl) acetamide",,12/14/2017,prevention of platinum-induced ototoxicity in pediatric patients,Designated/Designation Withdrawn or Revoked,11/22/2019,Not FDA Approved for Orphan Indication,,,,,Spiral Therapeutics,1467 Dolores Street,,San Francisco,California,' 94110 ' ,United States,618517,,,
329,"2-(4-(4-((1-(107- (4-(fluorophenyl)methoxy)-polyethyleneglycol36))-1H-1,2,3-triazol-4-yl)methoxy)-3,5- diiodophenoxy)-3,5-diiodophenyl)acetic acid",,11/5/2020,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,NanoPharmaceuticals LLC,1 Discovery Drive,,Rensselaer,New York,' 12144 ' ,United States,780420,acute myeloid leukemia,"""gard:0012757""",
330,"2-(4-(4-((1-(107-(4-(fluorophenyl)methoxy)-(polyethyleneglycol36))-1H-1,2,3-triazol-4-yl)methoxy)-3,5-diiodophenoxy)-3,5-diiodophenyl)acetic acid",,8/28/2020,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"NanoPharmaceuticals, LLC",1 Discovery Place,,Rensselaer,New York,' 12144 ' ,United States,759420,,,
331,"2-(4-(4-((1-(107-(4-(fluorophenyl)methoxy)-polyethyleneglycol36))-1H-1,2,3-triazol-4-yl)methoxy)-3,5-diiodophenoxy)-3,5-diiodophenyl)acetic acid",,8/28/2020,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"NanoPharmaceuticals, LLC",1 Discovery Place,,Rensselaer,New York,' 12144 ' ,United States,759520,,,
332,"2-(4-(4-((1-(107-(4-(guanidinomethyl)phenoxy)-(polyethyleneglycol36))-1H-1,2,3-triazol-4-yl)methoxy)-3,5-diiodophenoxy)-3,5-diiodophenyl)acetic acid",,8/28/2020,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"NanoPharmaceuticals, LLC",1 Discovery Place,,Rensselaer,New York,' 12144 ' ,United States,759320,neuroblastoma,"""gard:0007185""",
333,"2-(4-oxo-3-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid",,1/6/2022,treatment of sorbitol dehydrogenase deficiency (sord deficiency),Designated,,Not FDA Approved for Orphan Indication,,,,,Applied Therapeutics Inc.,"545 Fifth Avenue, Suite 1400",,New York,New York,' 10017 ' ,United States,777720,,,
334,"2-(4-oxo-3-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid",,5/23/2019,treatment of galactosemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Applied Therapeutics Inc.,"340 Madison Avenue, 19th Floor",,"New York,",New York,' 10173 ' ,United States,685219,galactosemia,"""gard:0002424""",
335,"2-(4-oxo-3-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid",,9/21/2020,treatment of phosphomannomutase 2 deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Applied Therapeutics Inc.,340 Madison Avenue,19th Floor,New York,New York,' 10173 ' ,United States,765620,,,
336,2-(4-Tert-butylphenyl)-1H-benzimidazole,,6/16/2022,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,"Tranquis Therapeutics, Inc.",3 Lagoon Dr #130,,Redwood City,California,' 94065 ' ,United States,884922,amyotrophic lateral sclerosis,"""gard:0005786""",
337,"2-(5-fluoro-2-methyl-1H-indol-3-yl)-1H-imidazo[4,5-f][1,10] phenanthroline",,6/1/2015,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aptose Biosciences, Inc.",5955 Airport Road,Suite 228,"Mississauga,",,' ' ,Canada,480415,acute myeloid leukemia,"""gard:0012757""",
338,"2-(6-(6-((6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)-6-methyl-N-(5-methyl-1Hpyrazol-3-yl)pyrimidin-4-amine fumarate",,11/15/2023,treatment of tissue-agnostic ret fusion-positive solid tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,Ellipses Pharma Ltd,10 Stratton Street,,London,England,' 00000 ' ,United Kingdom,944623,,,
339,2-(7-ethoxy-4-(3-fluorophenyl)-1-oxophthalazin-2(1H)-yl)-N-methyl-N-(2-methylbenzo[d]oxazol-6-yl)acetamide,,5/13/2015,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Flatley Discovery Lab,529 Main Street,Suite 115,Charlestown,Massachusetts,' 02129 ' ,United States,479115,cystic fibrosis,"""gard:0006233""",
340,2-(Piperazin-1-yl)ethyl 3-fluoro-5-(2-(3-(6-methylpyridin-2-yl)-4-(quinolin-4-yl)-1H-pyrazol-1-yl)acetamido)benzoate,,5/15/2024,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"AgomAb Spain, S.L.","Parque Empresarial de Touro, Parcelas 26-27","Fonte Diaz, Touro,",A Coruña,Galicia,' 15822 ' ,Spain,1002224,idiopathic pulmonary fibrosis,"""gard:0008609""",
341,"2-(trans-4-((3-(3-(trifluoromethyl)phenyl)imidazo[1,2-b]pyridazin6-yl)amino)cyclohexyl)propan-2-ol hydrochloride",,5/10/2022,treatment of myelofibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Pharma America, Inc.",84 Waterford Drive,,Marlborough,Massachusetts,' 01752 ' ,United States,874922,,,
342,"2-0-Butyryl-1-0-octyl-myo-inositol 3,4,5,6-tetrakisphosphate",,8/15/2003,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Inologic, Inc.","101 Elliott Ave., West",,Seattle,Washington,' 98119 ' ,United States,169003,cystic fibrosis,"""gard:0006233""",
343,2-0-desulfated heparin,,9/17/1993,treatment of cystic fibrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kennedy & Hoidal, M.D.'s",University Of Utah Medical Center,"50 North Medical Drive, Room 4R240",Salt Lake City,Utah,' 84132 ' ,United States,75593,cystic fibrosis,"""gard:0006233""",
344,"2-amino-1-[2-(4-fluoro-phenyl)-3-(4-fluoro-phenyl)amino)-8,8-dimethyl-5,6-dihydro-imidazo[1,2-a]pyrazin-7(8H)-yl)-ethanone diphosphate",,5/11/2017,treatment of malaria.,Designated,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,1 Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,568216,malaria,"""gard:0006961""",
345,"2-amino-2-[2-[2-chloro-4-[[3-(phenylmethoxy) phenyl] thio]phenyl]ethyl]1,3-propanediol hydrochloride",,10/6/2015,prevention of graft versus host disease.,Designated/Designation Withdrawn or Revoked,11/29/2017,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,491315,graft versus host disease,"""gard:0016642""",
346,"2-Amino-4-[11C]methylsulfanyl-butanoic acid, l-[S methyl[11C]methionine",,1/17/2017,diagnostic agent for the clinical management of medulloblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,' 33467 ' ,United States,566416,medulloblastoma,"""gard:0007005""",
347,"2-Amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1R,5S)-3-(tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1-yl)phenyl)nicotinamide fumarate dihydrate",,7/21/2020,treatment of fibrodysplasia ossificans progressiva,Designated,,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,750320,fibrodysplasia ossificans progressiva,"""gard:0006445""",
348,2-amino-N-({methyl-[(6-trifluoromethoxy-benzothiazol-2-ylcarbamoyl)-methyl]-carbamoyl}-methyl)-acetamide monohydrochloride,,5/18/2016,treatment of spinocerebellar ataxia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biohaven Pharmaceuticals, Inc.",215 Church Street,,New Haven,Connecticut,' 06510 ' ,United States,520016,,,
349,"2-butyl-9-methyl-8-(2H-1,2,3-triazol-2-yl)-9H-purin-6-amine A triazole purine analogue",,6/8/2022,treatment of non-24 sleep wake rhythm disorder (n24swrd) in blind individuals without light perception,Designated,,Not FDA Approved for Orphan Indication,,,,,Circadian Therapeutics Ltd.,Oxford Centre for Innovation,New Road,Oxford,,' OX1 1BY ' ,United Kingdom,811021,,,
350,2-Chloro-N6--(3-iodobenzyl)adenosine-5'-N-methyluronamide,,2/17/2012,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Can-Fite BioPharma Ltd.,10 Bareket Street,P. O. Box 7537,Petah-Tikva,,' ' ,Israel,363512,hepatocellular carcinoma,"""gard:0016773""",
351,2-chloroethyl-3-sarcosinamide-1-nitrosourea,,8/3/2001,treatment for malignant gliomas,Designated,,Not FDA Approved for Orphan Indication,,,,,"Lawrence Panasci, MD","Professor of Medicine, McGill University",3755 Cote Ste Catherine,"Montreal, Quebec H3T 1E2",,' ' ,Canada,146101,,,
352,2-chloroethyl-3-sarcosinamide-1-nitrosourea,,11/15/2001,treatment for malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Pangene Corporation,5500 Stewart Avenue,,Fremont,California,' 94538 ' ,United States,150601,,,
353,"2-hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate",,9/11/2019,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ategrin, Inc.","c/o 149 Bio, LLC, 1951 NW 7th Ave, Suite 600",,Miami,Florida,' 33136 ' ,United States,701219,,,
354,"2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2,2,2]octan-3-one",,4/11/2019,treatment of myelodysplastic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Aprea Therapeutics AB,Nobels Vag 3,,"Solna,",,' ' ,Sweden,673518,myelodysplastic syndrome,"""gard:0007132""",
355,2-hydroxypropyl-B-cyclodextrin,,2/18/2013,"treatment of niemann pick disease, type c.",Designated,,Not FDA Approved for Orphan Indication,,,,,Mandos LLC,9200 Sunset Blvd.,Suite 1010,West Hollywood,California,' 90069 ' ,United States,386412,,,
356,2-iminobiotin,,2/24/2009,treatment of perinatal asphyxia.,Designated,,Not FDA Approved for Orphan Indication,,,,,Neurophyxia B.V.,Onderwijsboulevard 219,,5223 DE 's-Hertogenbosch,,' ' ,Netherlands,275609,,,
357,"2-isopropyl-3H-naphtho[1,2-d]imidazole-4,5-dione",,4/16/2018,treatment of inherited mitochondrial respiratory chain disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Abliva AB,Medicon Village,,Lund,,' ' ,Sweden,621217,,,
358,2-methoxyestradiol,,4/11/2005,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,"PR Pharmaceuticals, Inc.",1716 Heath Parkway,,Fort Collins,Colorado,' 80524 ' ,United States,202905,pulmonary arterial hypertension,"""gard:0007501""",
359,2-methoxyestradiol,,4/4/2005,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"EntreMed, Inc.",Research Triangle Park Center,"4819 Emperor Blvd., Suite 400",Durham,North Carolina,' 27703 ' ,United States,201405,ovarian cancer,"""gard:0007295""",
360,2-methoxyestradiol,,7/10/2001,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"EntreMed, Inc.",Research Triangle Park Center,Suite 400,Durham,North Carolina,' 27703 ' ,United States,143801,multiple myeloma,"""gard:0007108""",
361,2-methoxyestradiol,,6/16/2006,treatment of multiforme glioblastoma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"EntreMed, Inc.",Research Triangle Park Center,"4819 Emperor Blvd., Suite 400",Durham,North Carolina,' 27703 ' ,United States,224006,glioblastoma,"""gard:0002491""",
362,"2-N,O-dimethylhydroxylamino-4,6-bispropylamino-s-triazine, hydrogen sulfate salt",,9/28/2022,treatment of apnea of prematurity,Designated,,Not FDA Approved for Orphan Indication,,,,,Enalare Therapeutics Inc.,161 Hodge Rd,,Princeton,New Jersey,' 08540 ' ,United States,853721,apnea of prematurity,"""gard:0019722""",
363,"2-O, 3-O, desulfated heparin",,12/21/2017,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Chimerix, Inc.",2505 Meridian Park,Suite 100,Durham,North Carolina,' 27713 ' ,United States,477815,acute myeloid leukemia,"""gard:0012757""",
364,"2-Pyrazinecarbonitrile, 5-[[5-2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino] monomesylate monohydrate",,4/9/2015,treatment of anal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Acrivon Therapeutics, Inc.","480 Arsenal Way, Suite 100",,Watertown,Massachusetts,' 02472 ' ,United States,472015,,,
365,"2-[(1,3-Benzoxazol-2-yl)amino]-N-[2-(2-hydroxyethoxy)ethyl]-1-methyl-1H-benzimidazole-5- carboxamide monophosphate",,9/1/2022,treatment of sickle cell disease,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,897122,,,
366,"2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate",,2/11/2019,treatment of esophageal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,673218,,,
367,"2-[(2S)-2-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-trifluoromethyl-4H-1,3-benzothiazin-4-one",,3/15/2018,treatment of tuberculosis (tb),Designated,,Not FDA Approved for Orphan Indication,,,,,Klinikum der Universität München,15 Marchioninistr.,,München,Bayern,' ' ,Germany,630318,tuberculosis,"""gard:0007827""",
368,"2-[(3-methyl-4-(2,2,2-trifluoroethoxy) pyridin-2-yl)methylsulfinyl] -1H-benzoimidazole",,8/27/2008,treatment of hepatocellular carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioQuant, Inc.",6330 Nancy Ridge Drive,,San Diego,California,' 92121 ' ,United States,264508,hepatocellular carcinoma,"""gard:0016773""",
369,"2-[(3-Methylbutyl)amino]-1,4-naphthalenedione",,10/12/2021,treatment of dravet syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Neuroene Therapeutics,"645 Meeting Street, 201-I",,Charleston,South Carolina,' 29403 ' ,United States,841521,dravet syndrome,"""gard:0010430""",
370,"2-[(3S)-2,6-dioxopiperidin-3-yl]-4-{[(2-fluoro-4-{[3-(morpholin-4-yl)azetidin-1-yl]methyl} phenyl) methyl]amino}-1H-isoindole-1,3(2H)-dione-hydrogen chloride (1/1)",,1/25/2023,treatment of follicular lymphoma (fl),Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Coporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,921022,lymphoma,"""gard:0020548""",
371,"2-[(4S)-6-(4-chlorophenyl)-1,7,8-trimethylthiophenol[3,2-f]1,2,4-triazolo[4,3-a]1,4-diazepin-4-yl]-N-[3-(4-methylpiperazinyl)propyl]acetamide",,9/29/2015,treatment of nuclear protein in testis (nut) midline carcinoma.,Designated/Designation Withdrawn or Revoked,8/22/2019,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc (a Roche Group Member)",1 DNA Way,M/S# 35-5e,South San Francisco,California,' 94080 ' ,United States,492615,noma,"""gard:0004001""",
372,"2-[(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thienol[3,2,-f]-[1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)-acetamide dihydrate",,7/16/2014,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,11/17/2020,Not FDA Approved for Orphan Indication,,,,,OncoEthix GmbH (Merck Subsidiary),Weystrasse 20,,Lucerne,,' ' ,Switzerland,433914,acute myeloid leukemia,"""gard:0012757""",
373,2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimadazole-4-carboxamide,,12/18/2007,treatment of malignant melanoma stages iib through iv.,Designated/Designation Withdrawn or Revoked,4/1/2022,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,246607,noma,"""gard:0004001""",
374,"2-[3-(2-chloro-4-{[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy}phenyl)-3-hydroxyazetidin-1-yl]pyridine-4-carboxylic acid¿2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1)",,10/25/2018,treatment of primary sclerosing cholangitis (psc),Designated,,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,658018,sclerosing cholangitis,"""gard:0021868""",
375,2-[4-(1-Methyl-4-pyridin-4-yl-lH-pyrazol-3-yl)-phenoxymethyl]-quinoline succinic acid,,6/2/2014,treatment of huntington's disease.,Designated/Designation Withdrawn or Revoked,4/2/2018,Not FDA Approved for Orphan Indication,,,,,Pfizer Inc.,445 Eastern Point Road,,Groton,Connecticut,' 06340 ' ,United States,429914,,,
376,2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid,,5/14/2013,treatment of patients with systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Horizon Therapeutics Ireland DAC,70 St. Stephen’s Green,,Dublin 2,,' D02 E2X4 ' ,Ireland,393813,systemic sclerosis,"""gard:0009748""",
377,2-[4-[[(2-R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate,,4/15/2015,treatment of patients with frederickson type i or v hyperlipoproteinemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"CymaBay Therapeutics, Inc.",7999 Gateway Blvd,Suite 130,Newark,California,' 94560 ' ,United States,470715,,,
378,2-[4-[[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]thio]-2-methylphenoxy]acetic acid (1:1) lysine dihydrate,,3/18/2015,treatment of homozygous familial hypercholesterolemia (hofh),Designated,,Not FDA Approved for Orphan Indication,,,,,"CymaBay Therapeutics, Inc.",7999 Gateway Blvd,Suite 130,Newark,California,' 94560 ' ,United States,429214,homozygous familial hypercholesterolemia,"""gard:0010416""",
379,"2-[[(4-Methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazol-5-ol or 5-O-desmethyl-omeprazole",,7/1/2022,treatment of multiple system atrophy (msa),Designated,,Not FDA Approved for Orphan Indication,,,,,Yoda Therapeutics Inc.,"4F-4, No. 305, Sec. 3, Zhongxiao E. Rd., Da' an Dist.",,Taipei,,' 106452 ' ,Taiwan,830021,multiple system atrophy,"""gard:0007079""",
380,2-[[3-({4-[(5-{2-[(3-Fluorophenyl)amino]-2-oxoethyl}-1H-pyrazol-3-yl)amino]-quinazolin-7-yl}propyl](ethyl)amino]ethyl dihydrogen phosphate trihydrate,,1/19/2010,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,' 19803 ' ,United States,298509,acute myeloid leukemia,"""gard:0012757""",
381,"2-{2,6-Dichloro-3-[(2,2-dimethyl-propionylamino)-methyl]-phenylamino}-6-(2,2-difluoroethoxy)-1-methyl-1H-benzoimidazole-5-carboxylic acid (trans-4-trifluoromethylcyclohexyl)-amide, hydrogensulfate",,2/28/2022,treatment for systemic sclerosis,Designated/Designation Withdrawn or Revoked,5/9/2024,Not FDA Approved for Orphan Indication,,,,,Gesynta Pharma AB,Fogdevreten 2A,,Solna,,' 171 65 ' ,Sweden,785320,systemic sclerosis,"""gard:0009748""",
382,"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid",,6/23/2015,treatment of malignant melanoma stages iib to iv.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Rgenix, Inc.",310 East 67th Street,Suite 1-12,New York,New York,' 10065 ' ,United States,483015,noma,"""gard:0004001""",
383,"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid",,6/16/2015,treatment of glioblastoma multiforme.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Rgenix, Inc.",310 East 67th Street,Suite 1-12,New York,New York,' 10065 ' ,United States,483215,glioblastoma,"""gard:0002491""",
384,"2-{3-[(3R)-3-({[2-chloro-3-(trifluoromethyl)phenyl]methyl}(2,2-diphenylethyl)amino)butoxy]phenyl}acetic acid",,6/16/2015,treatment of ovarian cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Rgenix, Inc.",310 East 67th Street,Suite 1-12,New York,New York,' 10065 ' ,United States,483115,ovarian cancer,"""gard:0007295""",
385,2-{4-[(9R)-9-Hydroxy-2-(3-hydroxy-3-methylbutyloxy)-9-(trifluoromethyl)-9H-fluoren-4-yl]-1H-pyrazol-1-yl}-2-methylpropanamide monohydrate,,1/23/2018,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,Akros Pharma Inc.,302 Carnegie Center,Suite 300,Princeton,New Jersey,' 08540 ' ,United States,620017,pulmonary arterial hypertension,"""gard:0007501""",
386,"2-{[(1r,4r)-4-(((4-chlorophenyl)(phenyl)carbamoyloxy)methyl)cyclohexy]methoxy} acetic acid",,8/28/2014,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,United Therapeutics Corporation,55 T.W. Alexander Drive,P.O. Box 14186,Research Triangle Park,North Carolina,' 27708 ' ,United States,440214,pulmonary arterial hypertension,"""gard:0007501""",
387,2-{[2-benzyl-4-(5-methyl-3H-imidazol-4-ylmethyl)-3-oxo-piperazine-1-carbonyl]- amino}-4methyl-pentanoic acid,,7/13/2022,treatment of peripheral t-cell lymphomas,Designated,,Not FDA Approved for Orphan Indication,,,,,"Prescient Therapeutics, LTD","Level 4, 100 Albert Road",,South Melbourne,VIC,' 3205 ' ,Australia,890422,lymphoma,"""gard:0020548""",
388,20% Lipid emulsion solution,,6/8/2017,treatment of local anesthetic systemic toxicity,Designated,,Not FDA Approved for Orphan Indication,,,,,ResQ Pharma,621 Rose Street,,Lincoln,Nebraska,' 68502 ' ,United States,522816,,,
389,20-alphaHydroxycholesterol,,8/31/2020,prevention of white matter injury in preterm infants less than or equal to 32 weeks gestational age,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tellus Therapeutics, Inc.",517 Summit Trail Drive,,Hillsborough,North Carolina,' 27278 ' ,United States,761620,,,
390,20-hydroxyecdysone,,5/10/2018,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Biophytis SA,14 Avenue de l’Opera,,Paris,,' ' ,France,639318,muscular dystrophy,"""gard:0007922""",
391,20-mer complementary to Akt mRNA,,12/10/2004,treatment of stomach cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Rexahn Corporation,9620 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,196104,,,
392,20-mer oligonucleotide complementary to Akt mRNA,,12/1/2004,treatment of renal cell carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Rexahn Corporation,9620 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,195704,renal cell carcinoma,"""gard:0013215""",
393,20-mer oligonucleotide complementary to Akt mRNA,,12/1/2004,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Rexahn Corporation,9620 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,195504,ovarian cancer,"""gard:0007295""",
394,20-mer oligonucleotide complementary to Akt mRNA,,12/8/2004,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Rexahn Corporation,9620 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,196204,,,
395,20-mer oligonucleotide complementary to Akt mRNA,,12/8/2004,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Rexahn Corporation,9620 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,196004,glioblastoma,"""gard:0002491""",
396,211At-4-astato-L-phenylalanine (4-[211At]APA),,8/28/2020,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Telix Pharmaceuticals Limited (Telix),55 Flemington Road,Suite 401,North Melbourne,Victoria,' 3015 ' ,Australia,758520,multiple myeloma,"""gard:0007108""",
397,225Ac-lintuzumab,,11/25/2014,treatment of acute myelogenous leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Actinium Pharmaceuticals, Inc.",379 Thornall Avenue,6th Floor,Edison,New Jersey,' 08837 ' ,United States,451714,,,
398,"24,25 dihydroxycholecalciferol",,2/27/1987,treatment of uremic osteodystrophy.,Designated,,Not FDA Approved for Orphan Indication,,,,,Lemmon Company,1510 Delp Drive,,Kulpsville,Pennsylvania,' 19443 ' ,United States,15786,,,
399,"2?(3,5?dichloro?4?([4?hydroxy?3?(propan?2?yl)phenyl]methyl)phenoxy)?N?methylacetamide",,7/22/2021,treatment of x-linked adrenoleukodystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Autobahn Therapeutics, Inc.",9880 Campus Point Drive Suite 370,,San Diego,California,' 92121 ' ,United States,827821,leukodystrophy,"""gard:0006895""",
400,2¿-O-(2-methoxyethyl) modified antisense oligonucleotide targeting exon 13 in the USH2A gene,,11/20/2017,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,ProQR Therapeutics IV B.V.,Zernikedreef 9,,Leiden,,' 2333 CK ' ,Netherlands,613017,retinitis pigmentosa,"""gard:0005694""",
401,2¿-O-(2-methoxyethyl) modified antisense oligonucleotide targeting glial fibrillary acidic protein pre mRNA,,9/18/2020,treatment of alexander disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Ionis Pharmaceuticals,2855 Gazelle Court,,Carlsbad,California,' 92010 ' ,United States,765520,alexander disease,"""gard:0005774""",
402,2¿-O-(2-methoxyethyl) modified antisense oligonucleotide targeting glycogen synthase 1 (GYS1) pre mRNA,,10/8/2020,treatment of lafora disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ionis Pharmaceuticals, Inc.",2855 Gazelle Court,,Carlsbad,California,' 92010 ' ,United States,771320,lafora disease,"""gard:0008214""",
403,"3', 3, Diseleno Dipropionic Acid",,8/9/2021,prevention of acute radiation syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Innovative Partners, Inc.",7947 BROOKSIDE CT,,Lake Worth,Florida,' 33467 ' ,United States,832321,acute radiation syndrome,"""gard:0021896""",
404,"3'-azido-2',3'dideoxyuridine",,11/20/1989,treatment of acquired immunodeficiency syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Berlex Laboratories, Inc.",1401 Harbor Bay Parkway,,Alameda,California,' 94501 ' ,United States,39889,acquired immunodeficiency,"""gard:0021359""",
405,"3,4 diaminopyridine and choline bitartrate",,4/30/2010,treatment of lambert-eaton myasthenic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,MS Therapeutics Limited,Beechy House,,Berkshire,,' ' ,United Kingdom,299909,lambert-eaton myasthenic syndrome,"""gard:0006851""",
406,"3,4-diaminopyridine",,3/30/2017,treatment of congenital myasthenic syndrome (cms),Designated,,Not FDA Approved for Orphan Indication,,,,,"Catalyst Pharmaceuticals, Inc.",355 Alhambra Circle,Suite 801,Coral Gables,Florida,' 33134 ' ,United States,556516,congenital myasthenic syndrome,"""gard:0011902""",
407,"3,4-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-5- carboxamide",,7/21/2021,treatment of gastrointestinal stromal tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cogent Biosciences, Inc.",200 Cambridge Park Drive,Suite 2500,Cambridge,Massachusetts,' 02140 ' ,United States,827121,gastrointestinal stromal tumor,"""gard:0008598""",
408,"3,5,3'-triiodothyroacetate",,9/20/2000,"treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid gland.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Elliot Danforth, Jr., M.D.",University of Vermont,84 Beartown Road,Underhill,Vermont,' 05489 ' ,United States,137200,noma,"""gard:0004001""",
409,"3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl((2S,3R,4R, 5R)-2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)-carbamimidoyl)pyrazine-2-carboxamide",,5/5/2020,treatment of primary ciliary dyskinesia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Parion Sciences, Inc.",2800 Meridian Parkway Suite 195,,Durham,North Carolina,' 27713 ' ,United States,746320,primary ciliary dyskinesia,"""gard:0004484""",
410,"3,5-diiodothyropropionic acid",,5/14/2013,treatment of allan-herndon-dudley syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Zarion Pharmaceuticals P/L,8 Grandview Grove,Sassafras 3787,Victoria,,' ' ,Australia,395613,allan-herndon-dudley syndrome,"""gard:0005617""",
411,"3,5-diiodothyropropionic acid",,7/28/2020,treatment of monocarboxylate transporter (mct) 8 deficiency (allan-herndon-dudley syndrome),Designated,,Not FDA Approved for Orphan Indication,,,,,"Prizm, LLC","3377 S. Price Road, Suite 3031",,Chandler,Arizona,' 85248 ' ,United States,764420,allan-herndon-dudley syndrome,"""gard:0005617""",
412,"3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole",,9/1/2022,treatment of multiple system atrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,' 19380 ' ,United States,898522,multiple system atrophy,"""gard:0007079""",
413,3-(1¿-butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-N-butylimide methyl ester,,12/6/2017,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Photolitec, LLC",6220 Creekhaven Drive,,East Amherst,New York,' 14051 ' ,United States,615317,,,
414,"3-(3,5-Dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one",,3/23/2000,treatment of von hippel-lindau disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sugen, Inc.",230 East Grand Ave.,,South San Francisco,California,' 94080 ' ,United States,127699,von hippel-lindau disease,"""gard:0007855""",
415,"3-(3,5-dimethyl-1H-2ylmethylene)-1,3-dihydro-indol-2-one",,9/11/1998,treatment of kaposi's sarcoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sugen, Inc.",230 East Grand Ave.,,South San Francisco,California,' 94080 ' ,United States,116398,,,
416,"3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-pyrazol-1-yl) propanoic acid",,4/22/2019,treatment of stargardt’s disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Stargazer Pharmaceuticals, Inc.",200 Clarendon Street,"45th Floor, Mailbox 30",Boston,Massachusetts,' 02116 ' ,United States,681519,,,
417,"3-(3-(3,5-Dimethyl-1H-pyrazol-4- yl)propoxy)-4-fluorobenzoic acid",,10/2/2018,treatment of transthyretin amyloidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"BridgeBio Pharma, Inc.",3160 Porter Drive,,Palo Alto,California,' 94301 ' ,United States,593117,amyloidosis,"""gard:0018676""",
418,"3-(4-((3-endo)-3-((5-cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4- yl)methoxy)-8-azabicyclo[3.2.1]octan-8-yl)-2-fluorophenyl)-1,2,4-oxadiazol-5(4H)-one",,9/13/2021,treatment of primary sclerosing cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cascade Pharmaceuticals, Inc","Building No. 6, Lane 908, Ziping Road,",Pudong New District,Shanghai,,' 201321 ' ,China,836821,sclerosing cholangitis,"""gard:0021868""",
419,"3-(4-(1,5-Napthrydine)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine)",,7/14/2015,treatment of fibrodysplasia ossificans progressiva.,Designated/Designation Withdrawn or Revoked,6/26/2019,Not FDA Approved for Orphan Indication,,,,,"La Jolla Pharmaceutical Company, Inc.",10182 Telesis Court,Suite 600,San Diego,California,' 92121 ' ,United States,484615,fibrodysplasia ossificans progressiva,"""gard:0006445""",
420,"3-(4-(8-fluoroquinoline)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine)",,7/14/2015,treatment of fibrodysplasia ossificans progressiva.,Designated/Designation Withdrawn or Revoked,6/26/2019,Not FDA Approved for Orphan Indication,,,,,"La Jolla Pharmaceutical Company, Inc.",10182 Telesis Court,Suite 600,San Diego,California,' 92121 ' ,United States,484915,fibrodysplasia ossificans progressiva,"""gard:0006445""",
421,"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride",,7/3/2017,treatment of hepatocellular carcinoma (hcc),Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,585117,hepatocellular carcinoma,"""gard:0016773""",
422,"3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride",,9/19/2016,treatment of diffuse large b-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,536816,lymphoma,"""gard:0020548""",
423,"3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5 f]indol-7-yl)-pyrrole-2,5-dione",,8/18/2017,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Actuate Therapeutics,1751 River Run,Suite 400,Fort Worth,Texas,' 76107 ' ,United States,598217,neuroblastoma,"""gard:0007185""",
424,"3-(5-Fluoro-benzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)-pyrrole-2,5-dione",,3/29/2016,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Actuate Therapeutics,1751 River Run,Suite 400,Fort Worth,Texas,' 76107 ' ,United States,513815,glioblastoma,"""gard:0002491""",
425,"3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxyl-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid",,3/2/2010,treatment of cystic fibrosis,Designated/Designation Withdrawn or Revoked,6/9/2017,Not FDA Approved for Orphan Indication,,,,,Vertex Pharmaceuticals Inc.,130 Waverly Street,,Cambridge,Massachusetts,' 02139 ' ,United States,301610,cystic fibrosis,"""gard:0006233""",
426,"3-([3,3-dibutyl-7-(methylsulfanyl)-1,1-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-1Lambda6,2,5-benzothiadiazepin-8-yl]oxy)propanoic acid",,11/15/2022,treatment of primary sclerosing cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Albireo AB,Arvid Wallgrens backe 20,,Göteborg,Göteborg,' 413 46 ' ,Sweden,910222,sclerosing cholangitis,"""gard:0021868""",
427,"3-Acetyl-1-cyclopentyl-7-{[(3S,4R)-3-hydroxyoxan-4-yl]amino }-4-methyl-1,6-naphthyridin-2(1H)-one",,2/18/2021,treatment of pulmonary arterial hypertension,Designated/Designation Withdrawn or Revoked,2/22/2023,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",235 East 42nd Street,,New York,New York,' 10017 ' ,United States,800720,pulmonary arterial hypertension,"""gard:0007501""",
428,3-aminopropyl-butyl phosphinic acid,,12/13/2016,treatment of succinic semialdehyde dehydrogenase deficiency.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Speragen, Inc.",13492 Research Boulevard,Suite 120-475,Austin,Texas,' 78750 ' ,United States,545416,succinic semialdehyde dehydrogenase deficiency,"""gard:0007695""",
429,3-aminopyridine-2-carboxaldehyde thiosemicarbazone,,11/8/2017,treatment of stage 1b to iv cervical cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"National Cancer Institute, Div of Cancer Treatment & Diagnosis (DCTD)",9609 Medical Center Drive,"Room 5-W520, MSC 9740",Rockville,Maryland,' 20850 ' ,United States,588817,,,
430,3-bromo-2-oxopropanoic acid,,5/1/2020,treatment of stage iib-iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"NewG Lab Pharma, Inc.",701 E Pratt St.,,Baltimore,Maryland,' 21202 ' ,United States,736920,noma,"""gard:0004001""",
431,3-bromopyruvate,,3/5/2013,treatment of liver and intrahepatic bile duct cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"KoDiscovery, LLC",Columbus Center,701 East Pratt Street,Baltimore,Maryland,' 21202 ' ,United States,390013,,,
432,3-bromopyruvate,,4/29/2014,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"PreScience Labs, LLC",9500 Reach Road,,Potomac,Maryland,' 20854 ' ,United States,430514,,,
433,3-bromopyruvic acid,,7/27/2022,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Ko Discovery LLC,701 East Pratt Street,Lab 4023,Baltimore,Maryland,' 21202 ' ,United States,894722,,,
434,3-chloro-4-fluorophenyl-[4-fluoro-4-[[(5-methylpyrimidin-2-ylmethyl)amino]methyl]piperidin-1yl]methanone,,10/25/2013,treatment of rett syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neurolixis, Inc.",3210 Merryfield Row,,San Diego,California,' 92121 ' ,United States,410613,rett syndrome,"""gard:0005696""",
435,3-fluoro-5-[5-(2-menthyl-thiazol-4-ylethylnyl)-pyridin-2-yl]-benzonitrile dihydrochloride,,7/28/2008,treatment of behavioral abnormalities associated with fragile x syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,Seaside Therapeutics,840 Memorial Drive,,Cambridge,Massachusetts,' 02139 ' ,United States,263608,fragile x syndrome,"""gard:0006464""",
436,3-pentylbenzenacetic acid sodium salt,,2/11/2015,treatment of idiopathic pulmonary fibrosis.,Designated/Designation Withdrawn or Revoked,2/18/2022,Not FDA Approved for Orphan Indication,,,,,Liminal BioSciences Limited,"Unit 1, Iconix Park, London Road",Sawston,Cambridge,,' CB22 3EG ' ,United Kingdom,464214,idiopathic pulmonary fibrosis,"""gard:0008609""",
437,3-pentylbenzeneacetic acid sodium salt,,2/28/2017,treatment of alström syndrome,Designated/Designation Withdrawn or Revoked,2/18/2022,Not FDA Approved for Orphan Indication,,,,,Liminal BioSciences Limited,"Unit 1, Iconix Park, London Road",Sawston,Cambridge,,' CB22 3EG ' ,United Kingdom,557016,alström syndrome,"""gard:0005787""",
438,"3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5-[(2-fluoro-4-iodophenyl)amino]-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione",,9/28/2021,treatment of familial adenomatous polyposis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Recursion Pharmaceuticals, Inc.",41 S. Rio Grande Street,,Salt Lake City,Utah,' 84101 ' ,United States,817621,familial adenomatous polyposis,"""gard:0006408""",
439,3-[2-(4-carbamimidoyl-phenylcarbamoyl)-5-methoxy-4-vinyl-phenyl]-6-(cyclopropylmethyl-carbamoyl)-pyridine-2-carboxylic acid,,12/23/2014,prevention of acute attacks of angioedema in individuals with hereditary angioedema,Designated/Designation Withdrawn or Revoked,2/22/2017,Not FDA Approved for Orphan Indication,,,,,"BioCryst Pharmaceuticals, Inc.",4505 Emperor Blvd,Suite 200200,Durham,North Carolina,' 27703 ' ,United States,457114,hereditary angioedema,"""gard:0005979""",
440,3-[3-(6-guanidino-1-oxoisoindolin-2yl) propanamido]-3-(pyridine-3yl) propanoic acid dihydrochloride,,1/17/2017,treatment of retinopathy of prematurity,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,' 33467 ' ,United States,566316,retinopathy of prematurity,"""gard:0005695""",
441,3-[4-(lH-imidazol-l-ylmethyl)phenyl]-5-(2-methylpropyl) thiophene-2-[(N-butyloxylcarbamate)-sulphonamide] sodium salt,,1/25/2017,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Vicore Pharma AB,Kornhamnstorg 53,,Stockholm,,' SE 111 27 ' ,Sweden,550816,idiopathic pulmonary fibrosis,"""gard:0008609""",
442,"3-[5-[(1R)-1-[bis(aziridin-1-yl(phosphoryloxy]ethyl]-2-nitrophenoxy]-N,N-dimethylbenzamide",,9/17/2018,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"OBI Pharma USA, Inc.","6020 Cornerstone Court W, Suite 200",,San Diego,California,' 92121 ' ,United States,650818,acute lymphoblastic leukemia,"""gard:0000522""",
443,"3-[5-[(1R)-1-[bis(aziridin-1-yl(phosphoryloxy]ethyl]-2-nitrophenoxy]-N,N-dimethylbenzamide",,7/3/2018,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"OBI Pharma USA, Inc.","6020 Cornerstone Court W, Suite 200",,San Diego,California,' 92121 ' ,United States,643218,hepatocellular carcinoma,"""gard:0016773""",
444,"3-{3-[4-(1-aminocyclobutyl)phenyl]-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl}cpyridin-2-amine bis-mesylate",,11/9/2015,treatment of proteus syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,497115,proteus syndrome,"""gard:0007475""",
445,"3alpha,6beta,7beta,12alpha-tetrahydroxy-5beta-cholan-24-oic acid",,10/22/2020,treatment of progressive familial intrahepatic cholestasis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Qing Bile Therapeutics, Inc.",5671 Trafalgar Street,,Vancouver,British Columbia,' V6N 1C2 ' ,Canada,777320,familial intrahepatic cholestasis,"""gard:0021119""",
446,4'-chloro-2'-cyano-N-(trans-4-hydroxy-4-methylcyclohexyl)-biphenyl-4-sulfonamide,,8/15/2022,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Modern Biosciences Ltd,"2nd Floor, 3 Pancras Square",,London,Greater London,' N1C 4AG ' ,United Kingdom,894922,idiopathic pulmonary fibrosis,"""gard:0008609""",
447,"4, 5 dibromorhodamine methyl ester",,10/30/2008,treatment of diffuse large b-cell lymphoma,Designated/Designation Withdrawn or Revoked,12/4/2020,Not FDA Approved for Orphan Indication,,,,,"Kiadis Pharma Canada, Inc.",2525 Marie Curie,,Saint-Laurent (Quebec),,' ' ,Canada,255507,lymphoma,"""gard:0020548""",
448,"4, 5 dibromorhodamine methyl ester",,10/30/2008,treatment of follicular lymphoma,Designated/Designation Withdrawn or Revoked,12/8/2020,Not FDA Approved for Orphan Indication,,,,,Kiadis Pharma Netherlands B.V.,Paasheuvelweg 25A,,Amsterdam,,' 1105 BP ' ,Netherlands,269808,lymphoma,"""gard:0020548""",
449,"4,4',4''-(Ethane-1,1,1- triyl)tris(2,6-diethoxyphenol)",,4/29/2022,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,Neuromagen Pharma Ltd.,Beer Sheva High Tech Park,P.O. Box 5316,Beer Sheva,Southern District,' 84561 ' ,Israel,872722,amyotrophic lateral sclerosis,"""gard:0005786""",
450,"4,5 dibromorhodamine methyl ester",,10/23/2007,for immune reconstitution and prevention of graft versus host disease following allogeneic hematopoietic stem cell transplantation.,Designated/Designation Withdrawn or Revoked,12/2/2021,Not FDA Approved for Orphan Indication,,,,,Kiadis Pharma Netherlands B.V.,Entrada 231 - 234,,Amsterdam,,' ' ,Netherlands,246307,graft versus host disease,"""gard:0016642""",
451,"4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol",,9/6/2016,treatment of angelman syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,Ovid Therapeutics,1460 Broadway,,New York,New York,' 10036 ' ,United States,533816,angelman syndrome,"""gard:0005810""",
452,"4,5-dibromorhodamine 123",,4/10/2003,treatment of chronic myelogenous leukemia,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Kiadis Pharma Canada, Inc.",2525 Marie-Curie,,Saint-Laurent (Quebec),,' ' ,Canada,166203,,,
453,"4,6,8-trihydroxy-10-(3,7,11-trimethyldodeca-2,6,10-trienyl)-5,10-dihydrodibenzo b,e][1,4]diazepin-11-one",,4/27/2009,treatment of malignant glioma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Thallion Pharmaceuticals, Inc.",7150 Alexander-Fleming,,Quebec,,' ' ,Canada,278709,,,
454,"4-(((3-chloro-1,4-dioxo-1,4 dihydronaphthalen-2-yl)amino)methyl)-N-(pyridine-3-yl)benzamide",,2/28/2019,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Sino-American Cancer Foundation,4978 Santa Anita Ave,Suite 104,Temple City,California,' 91780 ' ,United States,678619,multiple myeloma,"""gard:0007108""",
455,"4-((2S,4S)-4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl) benzoic acid",,5/18/2020,treatment of c3 glomerulopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,692819,c3 glomerulopathy,"""gard:0017507""",
456,"4-((3'R,4'S,5'R)-6''-chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamido)bicyclo [2.2.2]octane-1-carboxylic acid",,10/28/2020,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,' 20850 ' ,United States,778720,soft tissue sarcoma,"""gard:0004898""",
457,"4-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4- methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide, (2Z)-2-butenedioate (1:2), Sesquihydrate",,11/26/2019,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shanghai Fosun Pharmaceutical Development Co., Ltd.",16 Esquire Rd (Breas),,Billerica,Massachusetts,' 01862 ' ,United States,713619,acute myeloid leukemia,"""gard:0012757""",
458,4-((L-valyl)oxy)butanoic acid,,6/12/2019,treatment of narcolepsy,Designated,,Not FDA Approved for Orphan Indication,,,,,XWPharma Incorporated,"19F-1, No. 99, Sec. 1",Xintai 5th Road,New Taipei City,Xizhi District,' ' ,Taiwan,669418,narcolepsy,"""gard:0022460""",
459,4-(2-fluorophenyl)-6-methyl-2-(1-piperzinyl),,10/11/2006,treatment of chronic functional vomiting to include functional vomiting and cyclic vomiting syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Dynogen Pharmaceuticals, Inc.",52 Second Avenue,,Waltham,Massachusetts,' 02451 ' ,United States,199704,,,
460,"4-(3-(4-(1H-imidazo[4,5-b]pyridin-5-yl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one hydrochloride dihydrate",,1/9/2024,treatment of small cell lung cancer (sclc),Designated,,Not FDA Approved for Orphan Indication,,,,,"Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.","Room 102, 1F, Building 12, No.","1835 Duhui Road, Minhang District",Shanghai,,' 201108 ' ,China,981723,small cell lung cancer,"""gard:0009344""",
461,"4-(3-cyano-6-ethoxyquinolin-2-yl)-N- (2-fluorophenyl)-1,4-diazepane-1-carbothiomide",,5/26/2022,treatment of fragile x syndrome (fxs),Designated,,Not FDA Approved for Orphan Indication,,,,,"Neuronascent, Inc.","6030 Day Break Circle, A150 PMB244",,Clarksville,Maryland,' 21029 ' ,United States,880622,fragile x syndrome,"""gard:0006464""",
462,4-(3-Methanesulfonyl-phenyl)-1-propylpiperidine HCl,,12/12/2005,treatment of huntington's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Prilenia Therapeutics,"10 Hamenofin St., 3rd Floor",,Herzliya,,' ' ,Israel,213905,,,
463,"4-(4-((4-chloro-3-(trifluoromethyl)phenyl)sulfonyl)phenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione",,8/8/2019,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neuropore Therapies, Inc.","10835 Road to the Cure, Suite 230",,San Diego,California,' 92121 ' ,United States,704119,amyotrophic lateral sclerosis,"""gard:0005786""",
464,4-(4-Methoxy-phenylamino)-6-methylcarbamyl-quinoline-3-carboxylic acid,,3/24/2015,prevention of scarring post ab externo glaucoma surgery,Designated,,Not FDA Approved for Orphan Indication,,,,,Clanotech AB,Fogdevreten 2,,Solna,,' ' ,Sweden,468714,,,
465,4-(4-Methyl-piperazin-1-yl)-N-{6-[2-(4-trifluoromethyl-benzyloxy)-ethoxy]- 1H-indazol-3-yl}-benzamide hemioxalat,,12/14/2023,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Nerviano Medical Sciences S.r.l.,Viale Pasteur 10- CP11,,Nerviano (Milano),,' 20014 ' ,Italy,975723,acute myeloid leukemia,"""gard:0012757""",
466,"4-(5-(2-chlorophenyl)-3-methyl-2,10-dihydropyrazolo[4,3-b] pyrido[4,3-e][1,4]diazepin-8-yl) morpholine",,11/6/2019,treatment of cholangiocarcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"TransThera Sciences (Nanjing), Inc.","F3, Bld 9, Accelerator Phase 2","Biotech and Pharmaceutical Valley, Jiangbei New Area",Nanjing,,' 210032 ' ,China,711719,cholangiocarcinoma,"""gard:0009304""",
467,"4-(6-(4-(piperazin-1-yl)phenyl_pyrazolo[1,5-a]pyrimidin-3-yl)quinoline hydrochloride",,4/15/2013,treatment of fibrodysplasia ossificans progressiva,Designated/Designation Withdrawn or Revoked,6/26/2019,Not FDA Approved for Orphan Indication,,,,,"La Jolla Pharmaceutical Company, Inc.","10182 Telesis Court, Suite 600",,San Diego,California,' 92121 ' ,United States,393513,fibrodysplasia ossificans progressiva,"""gard:0006445""",
468,"4-(pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one",,5/4/2015,treatment of congenital long qt syndrome,Designated/Designation Withdrawn or Revoked,2/24/2017,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,446214,,,
469,"4-amino-1-[(1S,4R,5S)-2-fluoro-4,5-dihydroxy-3-(hydroxymethyl) cyclopent-2-en-1-yl] pyrimidin-2-one",,9/23/2014,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Processa Pharmaceuticals, Inc.","7380 Coca Cola Drive, Suite 106",,Hanover,Maryland,' 21076 ' ,United States,447314,,,
470,"4-amino-1-[(2R,3S,4S,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrothiophen-2-yl] pyrimidin-2(1H)-one",,8/1/2018,treatment of cholangiocarcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"FUJIFILM Pharmaceutical U.S.A., Inc.",1 Broadway,,Cambridge,Massachusetts,' 02142 ' ,United States,646118,cholangiocarcinoma,"""gard:0009304""",
471,"4-Amino-1-[5-O-[(2R, 4S)-2-oxido-4-(4-pyridinyl)-1, 3, 2-dioxaphosphorinan-2-yl]-b-D-arabinofuranosyl]-2(1H)-pyrimidinone",,8/22/2007,treatment of hepatocellular carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ligand Pharmaceuticals, Inc.",11085 N. Torrey Pines Road,Suite 300,LaJolla,California,' 92037 ' ,United States,228106,hepatocellular carcinoma,"""gard:0016773""",
472,4-Aminopyridine,,12/14/2005,treatment chronic functional motor and sensory deficits from guillain-barre syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Acorda Therapeutics, Inc.",420 Saw Mill River Road,,Ardsley,New York,' 10502 ' ,United States,214205,,,
473,4-aminosalicylic acid,,12/13/1989,treatment of mild to moderate ulcerative colitis in patients intolerant to sulfasalazine.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Beeken, Warren M.D.",University Of Vermont,Given C-317,Burlington,Vermont,' 05405 ' ,United States,37989,,,
474,4-aminosalicylic acid,,4/26/2006,treatment of acute flares in pediatric patients with ileo-cecal crohn's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jacobus Pharmaceutical Co., Inc.",37 Cleveland Lane,,Princeton,New Jersey,' 08540 ' ,United States,220506,,,
475,"4-benzyl-2-(a-naphtyl)-1,2,4-thiadiazolidine-3,5-dione",,10/13/2009,treatment of progressive supranuclear palsy,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"NOSCIRA, S.A.","Avda. de la Industria, 52",,Madrid,,' ' ,Spain,290109,progressive supranuclear palsy,"""gard:0007471""",
476,"4-Chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidin-4-ylcarbonyl)-3-pyridinyl]-3-(trifluoromethyl)benzenesulfonamide, sodium salt",,9/12/2018,treatment of focal segmental glomerulosclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"ChemoCentryx, Inc.",850 Maude Avenue,,Mountain View,California,' 94043 ' ,United States,604317,,,
477,"4-cholest-en-3-one, oxime",,12/1/2005,treatment of amyotrophic lateral sclerosis,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Trophos SA,"Parc scientifique de Lumigny, Case 931",,1322 Marseille cedex,,' ' ,France,214305,amyotrophic lateral sclerosis,"""gard:0005786""",
478,4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide monohydrochloride,,7/20/2006,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,6/4/2021,Not FDA Approved for Orphan Indication,,,,,"Johnson & Johnson Pharmaceutical Research & Dev,",920 U S Highway 202,P.O. Box 300,Raritan,New Jersey,' 08869 ' ,United States,224206,acute myeloid leukemia,"""gard:0012757""",
479,4-demethyl-4-cholesteryloxycarbonylpenclomedine,,9/19/2017,treatment of non-small cell lung cancer with cns metastases,Designated,,Not FDA Approved for Orphan Indication,,,,,"DEKK-TEC, Inc.",725 Topaz Street,,New Orleans,Louisiana,' 70124 ' ,United States,604017,small cell lung cancer,"""gard:0009344""",
480,"4-fluoro-5-((6-methylhexahydropyrrolo[3,4-b] pyrrol-5(1H)-yl) sulfonyl) isoquinoline",,2/5/2020,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"The National Institutes of Pharmaceutical R&D Co., Ltd","No. 27, Zhansimen Road","Shahe, Changping District",Beijing,,' ' ,China,727519,idiopathic pulmonary fibrosis,"""gard:0008609""",
481,"4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl",,9/29/2015,treatment of cerebral cavernous malformation.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Recursion Pharmaceuticals, LLC",383 S. Colorow Drive,,Salt Lake City,Utah,' 84108 ' ,United States,487815,,,
482,4-Hydroxy-4'-methyoxytolan,,5/1/2023,treatment of epidermolysis bullosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioMendics, LLC",4209 State Route 44,,Rootstown,Ohio,' 44272 ' ,United States,801220,,,
483,4-Methyl-3-quinolin-3-ylethynylbenzoic acid N'-(2-chloro-6- methylbenzoyl) hydrazide,,6/3/2019,treatment of chronic myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Sun Pharma Advanced Research Company Ltd.,"17/B, Mahal Industrial Estate",Mahakali Caves Road,Andheri (E),Mumbai,' ' ,India,687119,chronic myeloid leukemia,"""gard:0006105""",
484,4-methylpiperazine-1-carboxylic acid [1-(3-benzenesufonyl-1-phenethylallyl-carbamoyl)-2-phenylethyl] amide,,1/11/2017,treatment of chagas disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Center for Discovery & Innovation in Parasitic Diseases,"University of CA, San Francisco",9500 Gilman Drive,LaJolla,California,' 92093 ' ,United States,550316,,,
485,4-Methylumbelliferone,,3/13/2020,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,' 07670 ' ,United States,732620,,,
486,4-Methylumbelliferone,,3/30/2020,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,' 07670 ' ,United States,733820,hepatocellular carcinoma,"""gard:0016773""",
487,4-Methylumbelliferone,,4/20/2020,treatment of esophageal carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,' 07670 ' ,United States,735220,noma,"""gard:0004001""",
488,4-pyridinylmethyl 3(4-chlorophenyl)adamantine carboxamide,,11/2/2010,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,Apogee Biotechnology Corporation,Hershey Center for Applied Research,Suite 1016,Hummelstown,Pennsylvania,' 17036 ' ,United States,318110,,,
489,4-pyridinylmethyl 3(4-chlorophenyl)adamantine carboxamide,,3/30/2017,treatment of cholangiocarcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,RedHill Biopharma Ltd.,21 Ha'arba'a Street,,Tel Aviv-Yafo,Tel Aviv District,' ' ,Israel,559116,cholangiocarcinoma,"""gard:0009304""",
490,"4-[(2E)-1-Oxo-3-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-propen-1-yl]-1-piperazinecarboxamide",,2/8/2016,treatment of retinitis pigmentosa,Designated/Designation Withdrawn or Revoked,7/12/2017,Not FDA Approved for Orphan Indication,,,,,"Shire HGT, Inc.",300 Shire Way,,Lexington,Massachusetts,' 02421 ' ,United States,506615,retinitis pigmentosa,"""gard:0005694""",
491,"4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate",,8/17/2018,treatment of ryanodine receptor type 1-related myopathies,Designated,,Not FDA Approved for Orphan Indication,,,,,"ARMGO Pharma, Inc.",PMB #260,923 Saw Mill River Road,Ardsley,New York,' 10502 ' ,United States,558016,,,
492,"4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate",,5/5/2020,treatment of catecholaminergic polymorphic ventricular tachycardia,Designated,,Not FDA Approved for Orphan Indication,,,,,"ARMGO Pharma, Inc.",PMB #260,923 Saw Mill River Road,Ardsley,New York,' 10502 ' ,United States,736220,catecholaminergic polymorphic ventricular tachycardia,"""gard:0004421""",
493,"4-[(7-Methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)methyl]benzoic acid, hemifumarate",,11/18/2015,treatment of patients with duchenne muscular dystrophy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"ARMGO Pharma, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,501515,muscular dystrophy,"""gard:0007922""",
494,4-[131I]iodo-L-phenylalanine,,1/4/2011,treatment of glioma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Telix Pharmaceuticals (US) Inc.,10475 Crosspoint Boulevard,Suite 250,Indianapolis,Indiana,' 46256 ' ,United States,328710,,,
495,"4-[1]benzofuro[3,2-d]pyrimidin-4-yl-N-(1,3-benzodioxol-5-ylmethyl)piperazine-1-carbothioamide",,7/30/2008,"treatment, in combination with radiotherapy and temozolomide chemotherapy, of patients with glioblastoma multiforme.",Designated,,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd,,Dublin,California,' 94568 ' ,United States,262608,glioblastoma,"""gard:0002491""",
496,"4-[2-(3-Propyl-[1,2,4]0xadiazol-5-yl)-vinyl]-benzene-1,2-diol",,10/4/2011,treatment of chronic myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Piramal Enterprises Limited,1 Nirlon Complex,Goregaon (East),Mumbai,Maharashtra,' ' ,India,349611,chronic myeloid leukemia,"""gard:0006105""",
497,"4-[[(1S)-1-(4, 8-Dichloro-1-oxo-2-phenyl-3-isoquinolyl) ethyl] amino]-8H- pyrido[2,3-d] pyrimidin-5-one]",,10/11/2022,"treatment of peripheral t-cell lymphoma, not otherwise specified",Designated,,Not FDA Approved for Orphan Indication,,,,,"Boryung Co., LTD",Boryung Bldg,Changgyeonggung-ro 136,Seoul,Jongno-gu,' ##### ' ,South Korea,904122,lymphoma,"""gard:0020548""",
498,"4-[[(1S)-1-(4, 8-dichloro-1-oxo-2-phenyl-3-isoquinolyl) ethyl] amino]-8H-pyrido[2,3-d] pyrimidin-5-one]",,1/3/2024,treatment of angioimmunoblastic t-cell lymphoma (aitl),Designated,,Not FDA Approved for Orphan Indication,,,,,"Boryung Co., Ltd.",Changgyeonggung-ro 136,Boryung Bldg.,Jongno-gu,Seoul,' ' ,South Korea,915822,lymphoma,"""gard:0020548""",
499,"4-[[9-(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-trans-cyclohexanol",,9/23/2011,treatment of idiopathic pulmonary fibrosis,Designated/Designation Withdrawn or Revoked,6/16/2017,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,348911,idiopathic pulmonary fibrosis,"""gard:0008609""",
500,4-[[[4-(4-Chlorophenoxy)phenyl]sulfonyl]-methyl] tetrahydro-N-hydroxy-2H-pyran-4-carboxamide,,6/18/2008,prophylaxis of organ rejection in patients receiving allogeneic liver transplants,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Conatus Pharmaceuticals, Inc.",4365 Executive Drive,,San Diego,California,' 92121 ' ,United States,258308,,,
501,4-[[[4-[5-chloro-2-[[trans-4-[[(1R)-2-methoxy-1-methyl ethyl] amino] cyclohexyl] amino] -4-pyridinyl]-2-thiazolyl] amino] methyl] tetrahydro-2H-pyran-4-carbonitrile dimaleate,,12/20/2023,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"SELLAS Life Sciences Group, Inc.","7 Times Square, Suite 2503",,New York,New York,' 10036 ' ,United States,977523,lymphoma,"""gard:0020548""",
502,4-[[[4-[5-chloro-2-[[trans-4-[[(1R)-2-methoxy-1-methyl ethyl] amino] cyclohexyl] amino] -4-pyridinyl]-2-thiazolyl] amino] methyl] tetrahydro-2H-pyran-4-carbonitrile dimaleate,,10/10/2023,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,"SELLAS Life Sciences Group, Inc.","7 Times Square, Suite 2503",,New York,New York,' 10036 ' ,United States,965323,acute myeloid leukemia,"""gard:0012757""",
503,"4-{4-{[6-(4-Chlorophenyl)spiro[3.5]non-6-en-7-yl]methyl}-piperazin-1-yl}-N-{{3-nitro-4-[((2S)-1,4-dioxan-2-ylmethyl)amino]phenyl}sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide",,12/28/2020,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,' 20850 ' ,United States,787920,acute myeloid leukemia,"""gard:0012757""",
504,"4-{4-{[6-(4-Chlorophenyl)spiro[3.5]non-6-en-7-yl]methyl}-piperazin-1-yl}-N-{{3-nitro-4-[((2S)-1,4-dioxan-2-ylmethyl)amino]phenyl}sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide",,1/19/2021,treatment of follicular lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,' 20850 ' ,United States,796420,lymphoma,"""gard:0020548""",
505,"4-{[(2R,3S,4R,5S)-4-(4-Chloro-2-fluoro-phenyl)-3-(3-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid",,5/19/2014,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, A member of the Roche Group",F. Hoffmann-La Roche Ltd.,430 East 29th Street,New York,New York,' 10016 ' ,United States,429614,acute myeloid leukemia,"""gard:0012757""",
506,"4-{[4-Amino-3-(4-cyclohexylpiperazin-1-yl)-9,10-dioxo-9,10-dihydroanthracen-1-yl]amino}benzoic acid",,4/11/2018,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"VM Oncology, LLC",45535 Northport Loop East,,Fremont,California,' 94538 ' ,United States,633518,,,
507,4¿-(p-fluorobenzyl)tylosin A,,6/8/2017,treatment of onchocerciasis,Designated/Designation Withdrawn or Revoked,10/2/2023,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,Regulatory Affairs,1 Waukegan Road,North Chicago,Illinois,' 60044 ' ,United States,573016,onchocerciasis,"""gard:0007252""",
508,4¿-(p-fluorobenzyl)tylosin A,,6/6/2017,treatment of lymphatic filariasis,Designated/Designation Withdrawn or Revoked,10/2/2023,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,Regulatory Affairs,1 Waukegan Road,North Chicago,Illinois,' 60044 ' ,United States,572916,filariasis,"""gard:0018757""",
509,5'-CTATCTGUC*G1TTCTCTGU-3'.17 Na+,,3/31/2015,treatment of diffuse large b-cell lymphoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Idera Pharmaceuticals, Inc.",505 Eagleview Boulevard,Suite 212,Exton,Pennsylvania,' 19341 ' ,United States,472615,lymphoma,"""gard:0020548""",
510,5'-GCCATGGTTTTTTCTCAGG-3',,10/31/2012,prophylaxis for patients following documented or suspected exposure to ebolavirus,Designated/Designation Withdrawn or Revoked,2/14/2020,Not FDA Approved for Orphan Indication,,,,,"Sarepta Therapeutics, Inc.",215 First Street,,Cambridge,Massachusetts,' 02142 ' ,United States,347611,,,
511,"5'-O-(trans-9""-octadecenoyl)-1-beta-D-2'deoxy-2',2'-difluorocytidine",,12/7/2009,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Clovis Oncology, Inc.",5500 Flatiron Parkway,Suite 100,Boulder,Colorado,' 80301 ' ,United States,295909,,,
512,5(S)-(2'-hydroxy ethoxy)-20(S)-Camptothecin,,6/15/2007,treatment of osteosarcoma (bone cancer),Designated,,Not FDA Approved for Orphan Indication,,,,,"Dr. Reddy's Laboratories, Inc.",200 Somerset Corporate Blvd,"Building II, 7th Floor",Bridgewater,New Jersey,' 08807 ' ,United States,242107,osteosarcoma,"""gard:0007284""",
513,"5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(phenylmethyl)-a-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)- (9CI)",,10/11/2006,treatment of malignant gliomas,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Reata Pharmaceuticals, Inc.",1950 N. Stemmons Freeway,,Dallas,Texas,' 75207 ' ,United States,227606,,,
514,"5,5',5""-[Phosphinothioylidyne-tris(imino-2,1-ethanediyl)]tris[5-methylchelidoninium]trihydroide hexahydrochloride",,8/20/2003,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Now Pharm AG,"241, route d'Arlon",,Luxembourg,,' ' ,Luxembourg,169303,,,
515,"5,5-dimethyl-3-[2-(7-methylspiro[2H-benzofuran-3,1'-cyclopropane]-4-yl)oxypyrimidin-5-yl]imidazolidine-2,4-dione",,6/12/2017,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Autifony Therapeutics Limited,Gunnels Wood Road,Stevenage,,England,' ' ,United Kingdom,579217,fragile x syndrome,"""gard:0006464""",
516,"5,6-dibromo-4-nitro-2-(piperidin-4-yl)-1-(propan-2-yl)-1H-1,3-benzodiazole hydrochloride",,10/12/2021,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Stemline Therapeutics, Inc.","750 Lexington Avenue, 4th Floor",,New York,New York,' 10022 ' ,United States,840121,acute myeloid leukemia,"""gard:0012757""",
517,"5,6-dihydro-5-azacytidine",,5/11/1992,treatment of malignant mesothelioma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"ILEX Oncology, Inc.",4545 Horizon Hill Blvd.,,San Antonio,Texas,' 78229 ' ,United States,67292,,,
518,"5,7-Dichloro-2-((ethylamino)methyl)-8-hydroxy-3-methylquinazolin-4(3H)-one mesylate",,1/29/2019,treatment of multiple system atrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alterity Therapeutics, Limited",460 Bourke Street,,Melbourne,Victoria,' ' ,Australia,669118,multiple system atrophy,"""gard:0007079""",
519,"5,7-dichloro-2-dimethylaminomethyl-8-hydroxyquinoline hydrochloride",,9/4/2014,treatment of huntington's disease,Designated/Designation Withdrawn or Revoked,11/6/2019,Not FDA Approved for Orphan Indication,,,,,Prana Biotechnology Limited,"Level 2, 369 Royal Parade",,Parkville,Victoria,' ' ,Australia,353711,,,
520,"5,7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one",,6/18/2007,prevention of acute radiation syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Humanetics Corporation,1550 Utica Avenue South,Suite 770,Eden Prairie,Minnesota,' 55416 ' ,United States,241107,acute radiation syndrome,"""gard:0021896""",
521,"5-((4-(6-chlorothieno[2,3-d]pyrimidine-4-ylamino)piperidin-1-yl)methyl)-2-fluorobenzonitrile monofumurate",,10/21/2010,treatment of pulmonary arterial hypertension,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Forest Laboratories, Inc.",Harborside Financial Center,Plaza V,Jersey City,New Jersey,' 07311 ' ,United States,308510,pulmonary arterial hypertension,"""gard:0007501""",
522,"5-((S)-1-(3,5-bis(trifluoromethyl)phenoxy)ethyl)-3-hydroxycyclohex-2-en-1-one",,7/6/2022,amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,"Akava Therapeutics, LLC",755 Sheridan Road,,Winnetka,Illinois,' 60093 ' ,United States,886022,amyotrophic lateral sclerosis,"""gard:0005786""",
523,"5-(3,5-Dimethyl-4-hydroxybenzylamino)-3-(4-morpholin-4-yl-phenylamino)-1H-pyrazole-4-carboxylic acid amide",,12/7/2018,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Metagone Biotech Inc.,"3F., No. 11, Ln. 77, Xing-Ai Rd",Neihu Dist,Taipei,,' ' ,Taiwan,644218,idiopathic pulmonary fibrosis,"""gard:0008609""",
524,"5-(3,6-dibromo-9H-carbazol-9-yl)-N,N,N-trimethylpentan-1-aminium chloride",,11/21/2019,treatment of dercum’s disease (adiposis dolorosa),Designated,,Not FDA Approved for Orphan Indication,,,,,"Raziel Therapeutics, Inc.","High-Tech Village, Givat Ram Campus",Hebrew University,Jerusalem,,' ' ,Israel,688219,adiposis dolorosa,"""gard:0005750""",
525,"5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride",,4/18/2011,treatment of progressive supranuclear palsy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mithridion, Inc.",505 Science Drive,,Madison,Wisconsin,' 53711 ' ,United States,327510,progressive supranuclear palsy,"""gard:0007471""",
526,"5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)-pyridin-2-amine",,11/21/2016,treatment of primary central nervous system lymphoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Torqur AG, a subsidiary of Swiss Rockets AG",Rittergasse 3,,Basel,,' 4051 ' ,Switzerland,543116,lymphoma,"""gard:0020548""",
527,"5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine",,2/25/2019,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Molecure S.A. (previously OncoArendi S.A.),"101 Zwirki i Wigury street,",,Warsaw,,' 02-089 ' ,Poland,671618,idiopathic pulmonary fibrosis,"""gard:0008609""",
528,"5-(4-((2S,5S)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1H-1,2,4-triazol-3-amine",,1/14/2020,treatment of sarcoidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Molecure S.A. (previously OncoArendi S.A.),"101 Zwirki i Wigury street,",,Warsaw,,' 02-089 ' ,Poland,706419,sarcoidosis,"""gard:0007607""",
529,5-(4-carboxymethyl-phenylazo)-2-hydroxybenzoic acid disodium salt,,8/31/2017,treatment of pediatric ulcerative colitis (uc),Designated,,Not FDA Approved for Orphan Indication,,,,,"9 Meters Biopharma, Inc.",8480 Honeycutt Road,Suite 120,Raleigh,North Carolina,' 27615 ' ,United States,599917,,,
530,"5-(4-Cyclopropyl-1H-imidazol-l-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridin-2-yl)-4-methylbenzamide",,1/15/2015,treatment pulmonary arterial hypertension,Designated/Designation Withdrawn or Revoked,7/18/2017,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,459114,pulmonary arterial hypertension,"""gard:0007501""",
531,"5-(6,6-dimethyl-4-morpholino-8,9-dihydro-6H-[1,4]oxazino[3,4-e]purin-2-yl)pyrimidin-2-amine",,2/21/2018,treatment of glioblastoma multiforme (gbm),Designated,,Not FDA Approved for Orphan Indication,,,,,Kazia Therapeutics Limited,20 George Street,Suite 207,Hornsby,New South Wales,' ' ,Australia,624217,glioblastoma,"""gard:0002491""",
532,5-(ethylsulfonyl)-2-(naphthalen-2-yl)benzp[d]oxazole,,11/22/2011,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Summit (Oxford) Limited,136a Eastern Avenue,Milton Park,Abingdon,,' ' ,United Kingdom,351111,muscular dystrophy,"""gard:0007922""",
533,5-aminolevulinic acid,,11/12/2020,diagnostic for the visualization of tumor tissue in patients undergoing surgical resection for meningioma,Designated,,Not FDA Approved for Orphan Indication,,,,,NX Development Corp.,870 Corporate Drive,Suite 403,Lexington,Kentucky,' 40503 ' ,United States,710519,meningioma,"""gard:0007015""",
534,5-aminolevulinic acid,Gleolan,1/15/2013,visualization of malignant tissue during surgery for malignant glioma (who grades iii and iv),Designated/Approved,,,Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery,6/6/2017,6/6/2024,Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery,NX Development Corporation,1827 South Bayshore Lane,,Miami,Florida,' 33133 ' ,United States,387312,,,
535,5-Aminolevulinic Acid,,3/29/2021,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Hemerion Therapeutics,12 rue Denis Papin,NEO 2 - Building A,Villeneuve d’Ascq,,' 59650 ' ,France,811521,,,
536,5-aminolevulinic acid hydrochloride,,6/23/2022,treatment of malignant glioma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alpheus Medical, Inc.",3510 Hopkins Place N,,Oakdale,Minnesota,' 55128 ' ,United States,885522,,,
537,5-Arylnicotinamide ABCA1 inducer,,2/22/2023,treatment of alport syndrome (as),Designated,,Not FDA Approved for Orphan Indication,,,,,River 3 Renal Corp.,7550 Purple Sage,,Park City,Utah,' 84098 ' ,United States,925922,alport syndrome,"""gard:0005785""",
538,5-aza-2'-deoxycytidine,,8/3/1987,treatment of acute leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,' 94568 ' ,United States,20687,,,
539,"5-aza-2'-dexocytidine combined with 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-hydroxy-1,3-diazinan-2-one",,2/16/2017,treatment of thalassemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Novo Nordisk Inc.,800 Scudders Mill Rd.,P.O. Box 846,Plainsboro,New Jersey,' 08536 ' ,United States,555916,,,
540,"5-BROMO-N-(PROP-2-YN-1-YL)-2-(1H-1,2,4-TRIAZOL-1-YL) PYRIMIDINE-4,6-DIAMINE",,1/30/2024,treatment of prader-willi syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Palobiofarma S.L.,"Ave. Ernest LLuch 32, TCM2",,Mataro,Barcelona,' 08302 ' ,Spain,960323,prader-willi syndrome,"""gard:0005575""",
541,"5-Chloro-N-(3-cyclopropyl-5-(((3R,5S)-3,5-dimethylpiperazine-1-yl)methyl)phenyl)-4-(6-methyl-1H-indol-3-yl)pyrimidin-2-amine·monohydrate",,10/25/2018,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Aptose Biosciences Inc.,"12770 High Bluff Drive, Suite 120",,San Diego,California,' 92130 ' ,United States,657918,acute myeloid leukemia,"""gard:0012757""",
542,"5-cholesten-3ß, 25-diol 3-sulfate sodium salt (25HC3S)",,7/6/2017,treatment of primary sclerosing cholangitis (psc),Designated,,Not FDA Approved for Orphan Indication,,,,,DURECT Corporation,10260 Bubb Road,,Cupertino,California,' 95014 ' ,United States,586317,sclerosing cholangitis,"""gard:0021868""",
543,"5-fluoro-2-(6-fluoro-2-methyl-1H-benzo[d]imidazole-1-yl)-N4-(4-(trifluoromethyl)phenyl)pyrimidine-4,6-diamine",,2/13/2020,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",500 Warren Corporate Center Drive,,Warren,New Jersey,' 07059 ' ,United States,724319,soft tissue sarcoma,"""gard:0004898""",
544,"5-fluoro-2-(6-fluoro-2-methyl-1H-benzo[d]imidazole-1-yl)-N4-(4-(trifluoromethyl)phenyl)pyrimidine-4,6-diamine",,7/7/2020,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",500 Warren Corporate Center Drive,,Warren,New Jersey,' 07059 ' ,United States,755420,,,
545,"5-fluoro-4-(7''-fluoro-2''-methylspiro[cyclopentane-1,3''-indol]-5''-yl)-N-(5-(1-methylpiperidin-4-yl)pyridin-2-yl)pyrimidin-2-amine fumarate",,9/8/2020,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Gan & Lee Pharmaceuticals USA Corporation,520 US Highway 22 East,Suite 302,Bridgewater,New Jersey,' 08807 ' ,United States,760620,,,
546,5-hydroxymethyl-2-furfuraldehyde,,5/26/2006,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Baxalta US, Inc.",ONe Baxter Way,,Westlake Village,California,' 91362 ' ,United States,222406,,,
547,5-imino-13-deoxydoxorubicin HCl,,12/31/2015,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Monopar Therapeutics, Inc.",5 Revere Drive,Suite 200,Northbrook,Illinois,' 60062 ' ,United States,490315,soft tissue sarcoma,"""gard:0004898""",
548,5-iodo-2-pyrimidinone-2'-deoxyribose,,5/26/2006,treatment of malginant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hana Biosciences, Inc.",7000 Shoreline Court,Suite 370,South San Francisco,California,' 94080 ' ,United States,222606,,,
549,5-iodo-2-pyrimidinone-2¿deoxyribose,,6/25/2019,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shuttle Pharmaceuticals, LLC",1 Research Court,Suite 450,Rockville,Maryland,' 20850 ' ,United States,690919,glioblastoma,"""gard:0002491""",
550,"5-[(E)-2-(4-hydroxyphenyl)-ethenyl] benzene-1,3 diol",,3/13/2008,treatment of melas syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sirtris Pharmaceuticals, Inc.",200 Technology Square,,Cambridge,Massachusetts,' 02139 ' ,United States,241707,melas,"""gard:0007009""",
551,"5-[1-(2,6-Dichlorobenzyl)-piperidin-4-yl]methoxyquinazoline-2,4-diamine",,8/25/2009,treatment of spinal muscular atrophy,Designated/Designation Withdrawn or Revoked,8/16/2018,Not FDA Approved for Orphan Indication,,,,,CureSMA,925 Busse Avenue,,Elk Grove Village,Illinois,' 60007 ' ,United States,289509,,,
552,"5-[2-[(3,4-dichlorobenzoyl)amino]ethyl]-N-hydroxy-3-isoxazolecarboxamide",,11/8/2022,treatment of stage iib to iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Avstera Therapeutics Corp.,365 Phoenixville Pike,,Malvern,Pennsylvania,' 19355 ' ,United States,910122,noma,"""gard:0004001""",
553,5-[8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6yl]-2-pyrimidinamine,,2/10/2015,treatment of malignant mesothelioma,Designated/Designation Withdrawn or Revoked,3/8/2016,Not FDA Approved for Orphan Indication,,,,,"Verastem, Inc.",117 Kendrick Street,Suite 500,Needham,Massachusetts,' 02494 ' ,United States,463614,,,
554,"5-[[trans-4-[(trifluoromethoxy)phenyl]cyclohexyl]oxy]-1H-1,2,3-triazole-4-carboxylic acid",,6/8/2022,treatment of primary hyperoxaluria type 1,Designated/Designation Withdrawn or Revoked,5/31/2024,Not FDA Approved for Orphan Indication,,,,,BioMarin Pharmaceutical Inc.,105 Digital Drive,,Novato,California,' 94949 ' ,United States,882922,primary hyperoxaluria,"""gard:0016530""",
555,"5-{(1R,2R)-2-[(Cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride",,4/26/2018,treatment of kabuki syndrome,Designated/Designation Withdrawn or Revoked,5/27/2022,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",Takeda Parkway,,Deerfield,Illinois,' 60015 ' ,United States,635718,kabuki syndrome,"""gard:0006810""",
556,"5-{[(3R,4R)-1-(4-chloro-2,6-difluorophenyl)-3,4-dihydroxypiperidin-4-yl]methoxy}-8-fluoro-3,4-dihydroquinolin-2(1H)-one",,12/5/2016,treatment of active tuberculosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Otsuka Pharmaceutical Company, Ltd","2-9, Kanda-Tsukasamachi",,Tokyo,,' ' ,Japan,547216,tuberculosis,"""gard:0007827""",
557,"5-{[(5-amino-3,3-dihydroxyoxolan-2-yl)oxy][5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl}-N-(4-butylphenyl)-4,7-dimethyl-6-oxocyclohept-1-ene-1-carboxamide",,12/1/2020,treatment of tuberculosis,Designated,,Not FDA Approved for Orphan Indication,,,,,PAI Life Sciences Inc.,"1616 Eastlake Ave E, Suite 550",Attn: Darrick Carter,Seattle,Washington,' 98102 ' ,United States,783820,tuberculosis,"""gard:0007827""",
558,"5a8, monoclonal antibody to CD4",,12/20/1993,for use in post-exposure prophylaxis for occupational exposure to human immunodeficiency virus.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,' 02142 ' ,United States,70692,,,
559,"5¿-(4-fluorophenyl)-3¿-isopropyl-N-(4-(4-methylpiperazin-1-yl) phenyl)-1H,3¿H-[2,4¿-biimidazole]-4-carboxamide acetate",,2/1/2023,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,InSilico Medicine Hong Kong Limited,"Unit310, F3, Building 8W, Phase 2, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong",,Hong Kong,Hong Kong,' 999077 ' ,China,922822,idiopathic pulmonary fibrosis,"""gard:0008609""",
560,5¿-cEtG-sp-cEt5MeU-sp-cEt5MeU-sp-dT-sp-dA-sp-dT-sp-dT-sp-dA-sp-dT-sp-dA-sp-dG-sp-dG-sp-dG-sp-cEt5MeC-sp-cEt5MeU-sp-cEt5MeU-3¿,,8/5/2019,treatment of centronuclear myopathies,Designated,,Not FDA Approved for Orphan Indication,,,,,Dynacure SAS,300 Boulevard Sebastien Brant,,Illkirch Graffenstaden,,' ' ,France,702819,,,
561,"5ÿ¿ÿÿÿ¢ÿ¿ÿÿ¬""-GAATATTAACAIACTGACAAGTC-3ÿ¿ÿÿÿ¢ÿ¿ÿÿ¬""",,10/31/2012,prophylaxis following documented or suspected exposure to marburg virus,Designated/Designation Withdrawn or Revoked,2/14/2020,Not FDA Approved for Orphan Indication,,,,,"Sarepta Therapeutics, Inc.",215 First Street,,Cambridge,Massachusetts,' 02142 ' ,United States,347711,,,
562,"6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-2'H-spiro[cyclohexane-1,3'-imidazo[1,5a]pyridine]-1',5'-dione hydrochloride",,2/23/2017,treatment of diffuse large b-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,eFFECTOR Therapeutics,11180 Roselle Street,Suite A,San Diego,California,' 92121 ' ,United States,554516,lymphoma,"""gard:0020548""",
563,"6'-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)- paromamine sulfate",,11/3/2016,treatment of rett syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Eloxx Pharmaceuticals, Ltd.",Weizmann Science Park,7 Golda Meir Street,Ness Ziona,Center District,' ' ,Israel,541516,rett syndrome,"""gard:0005696""",
564,"6'-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)-paromamine sulfate",,7/31/2020,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"ELOXX Pharmaceuticals, Inc.",950 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,751820,cystic fibrosis,"""gard:0006233""",
565,"6'-(R)-methyl-5-O-(5-amino-5,6-dideoxy-alpha-L-talofuranosyl)-paromamine sulfate",,4/26/2018,treatment of cystinosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"ELOXX Pharmaceuticals, Inc.","950 Winter Street, North",,Waltham,Massachusetts,' 02451 ' ,United States,636218,cystinosis,"""gard:0006236""",
566,"6'-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-alpha-Ltalofuranosyl)-paromamine sulfate",,4/10/2024,treatment of alport syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Eloxx Pharmaceuticals Inc.,"480 Arsenal Way, Suite 130",,Watertown,Massachusetts,' 02472 ' ,United States,996224,alport syndrome,"""gard:0005785""",
567,"6,8-bis(benzylthio)octanoic acid",,1/25/2018,treatment of burkitt’s lymphoma (bl),Designated,,Not FDA Approved for Orphan Indication,,,,,"Cornerstone Pharmaceuticals, Inc.","9 Deerpark Drive, Suite J-5",,Monmouth Jct.,New Jersey,' 08852 ' ,United States,621617,lymphoma,"""gard:0020548""",
568,"6,8-bis-benzylsulfanyl-octanoic acid",,2/6/2006,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cornerstone Pharmaceuticals, Inc.",1 Duncan Drive,,Cranbury,New Jersey,' 08512 ' ,United States,216505,,,
569,"6,8-bis-benzylsulfanyl-octanoic acid",,8/22/2011,treatment of acute myeloid leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cornerstone Pharmaceuticals, Inc.",1 Duncan Drive,,Cranbury,New Jersey,' 08512 ' ,United States,349911,acute myeloid leukemia,"""gard:0012757""",
570,"6,8-bis-benzylsulfanyl-octanoic acid",,9/26/2013,treatment of myelodysplastic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cornerstone Pharmaceuticals, Inc.",1 Duncan Drive,,Cranbury,New Jersey,' 08512 ' ,United States,406813,myelodysplastic syndrome,"""gard:0007132""",
571,"6-((3S,4S)-4-Methyl-1-pyrimidin-2-ylmethyl-pyrrolidin-3-yl-1-(tetrahydro-pyran-4-yl)-1,5-dihydro-pryazolo[3,4-d]pyrimidin-4-one",,9/4/2014,treatment of sickle cell disease,Designated/Designation Withdrawn or Revoked,11/8/2022,Not FDA Approved for Orphan Indication,,,,,"Cardurion Pharmaceuticals, Inc.","78 Blanchard Road, Suite 200",,Burlington,Massachusetts,' 01803 ' ,United States,440514,,,
572,"6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile",,10/10/2018,treatment of pancreatic cancer.,Designated/Designation Withdrawn or Revoked,3/17/2023,Not FDA Approved for Orphan Indication,,,,,"Loxo Oncology, Inc.","701 Gateway Blvd, Suite 420",,"South San Francisco,",California,' 94080 ' ,United States,652318,,,
573,"6-(4-((1s,3s)-1-amino-3-hydroxycyclobutyl) phenyl)-1-ethyl-7- phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one L-Tartrate salt",,12/7/2022,treatment of hereditary hemorrhagic telangiectasia,Designated,,Not FDA Approved for Orphan Indication,,,,,Vaderis Therapeutics AG,Lichtstasse 35,Building WSJ-350,Basel,Basel,' CH-4056 ' ,Switzerland,914222,hereditary hemorrhagic telangiectasia,"""gard:0006626""",
574,"6-(4-((5-oxo-1,2,3,4,5,6-hexahydrobenzo[h][1,6]naphthyridin-8-yl)methyl)piperazin-1-yl)nicotinonitrile mono citrate",,3/2/2021,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Onconic Therapeutics,"1F, 12 Tehranro-26-gil",,Gangnam,Seoul,' 06236 ' ,South Korea,802220,,,
575,"6-(4-(4-(2,3-dichlorophenyl)-piperazin-1-yl)-butoxy)-2H-benzo[b][1,4]oxazin-3(4H)-one hydrochloride",,11/9/2016,treatment of pulmonary arterial hypertension (who group 1),Designated,,Not FDA Approved for Orphan Indication,,,,,"Reviva Pharmaceuticals, Inc.",3900 Freedom Circle,Suite 101,Santa Clara,California,' 95054 ' ,United States,541616,pulmonary arterial hypertension,"""gard:0007501""",
576,"6-(4-(4-(2,3-Dicholorophenyl) piperazin-1-yl) butoxy)-2H-benzo [b] [1,4] oxazin-3(4H)-one hydrochloride",,4/4/2018,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Reviva Pharmaceuticals, Inc.","1250 Oakmead Parkway, Suite 210",,Sunnyvale,California,' 94085 ' ,United States,633718,idiopathic pulmonary fibrosis,"""gard:0008609""",
577,6-(4-(tert-butyl)phenoxy)pyridin-3-amine hydrochloride,,2/23/2022,treatment of acute lymphoblastic leukemia (all),Designated,,Not FDA Approved for Orphan Indication,,,,,Cellestia Biotech AG,Hochbergerstrasse 60C,,Basel,Basel-Stadt,' 04057 ' ,Switzerland,862821,acute lymphoblastic leukemia,"""gard:0000522""",
578,"6-(R)-Methyl-5-O-(5-amino-5,6-dideoxy-a-L-talofuranosyl)- paromamine sulfate",,10/18/2016,treatment of mucopolysaccharidosis type 1 (mps i),Designated,,Not FDA Approved for Orphan Indication,,,,,"Eloxx Pharmaceuticals, Ltd.",Weizmann Science Park,7 Golda Meir Street,Ness Ziona,Center District,' ' ,Israel,540816,mucopolysaccharidosis type 1,"""gard:0010335""",
579,6-alpha-ethylchenodeoxycholic acid,,4/9/2008,treatment of primary sclerosing cholangitis,Designated/Designation Withdrawn or Revoked,2/14/2022,Not FDA Approved for Orphan Indication,,,,,"Intercept Pharmaceuticals, Inc.",18 Desbrosses Street,,New York,New York,' 10013 ' ,United States,259008,sclerosing cholangitis,"""gard:0021868""",
580,6-amino-5-chloro-N-[1R)-1-[5-[[[5-hloro-4-(trifluoromethyl)-2pyridinyl]amino]carbonyl]-2-thiazoyl]ethyl]-4-pyrimdinecarboxamide,,10/15/2013,treatment of stage iib-iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,410813,noma,"""gard:0004001""",
581,"6-Amino-9-[(3R)-1-(but-2-ynoyl)pyrrolidin-3-yl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one monohydrochloride",,6/5/2017,treatment of chronic lymphocytic leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 East Blaine Street,,Seattle,Washington,' 98102 ' ,United States,571116,,,
582,"6-Chloro-7-[4-[4-chlorophenyl)methyl]piperazin-1-yl]-2-(1,3-dimethylpyrazol-4-yl)-3H- imidazo[4,5-b]pyridine-3-ium fumarate",,3/1/2023,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,"Ellipses Pharma, Ltd.",10 Stratton Street,,London,Greater London,' W1J 8IG ' ,United Kingdom,927722,acute myeloid leukemia,"""gard:0012757""",
583,"6-ethoxy-7-methoxy-2-(2-methylsulfanylphenyl)-3,1-bensoxazin-4-one",,6/18/2015,treatment of netherton syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Sixera Pharma AB,Erik Dahlbergsgaten 11a2t,,Vastra Gotaland 41126,,' ' ,Sweden,481815,netherton syndrome,"""gard:0007182""",
584,"6-fluoro-(18F)-L-3,4-dihydroxyphenylalanine",,9/7/2016,a diagnostic for management of patients with lesch-nyhan syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,' 33467 ' ,United States,543716,lesch-nyhan syndrome,"""gard:0007226""",
585,"6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2- methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one",,5/23/2019,treatment of kras (kirsten rat sarcoma viral oncogene homolog) p.g12c-positive colorectal cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,1 Amgen Center Drive,Mail Stop 27-3-A,Thousand Oaks,California,' 91320 ' ,United States,654918,,,
586,"6-fluoro-9-methyl-9H-pyrido[3,4-b]-indole",,5/10/2021,treatment of sudden sensorineural hearing loss,Designated,,Not FDA Approved for Orphan Indication,,,,,AudioCure Pharma GmbH,Schlegelstr 9,,Berlin,,' 10115 ' ,Germany,797920,,,
587,6-hydroxymethylacylfulvene,,4/6/1999,treatment of histologically confirmed advanced or metastatic pancreatic cancer.,Designated/Designation Withdrawn or Revoked,5/12/2014,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.",300 Tice Blvd,,Woodcliff Lake,New Jersey,' 07677 ' ,United States,122198,,,
588,6-mercaptopurine oral liquid,,12/7/2009,treatment of acute lymphoblastic leukemia in the pediatric population,Designated,,Not FDA Approved for Orphan Indication,,,,,Orbona Pharma Ltd,Old Chambers,,Farnham,Surrey,' ' ,United Kingdom,286309,acute lymphoblastic leukemia,"""gard:0000522""",
589,"6-methoxy-3-(3',4',5'-trimethoxybenzoyl) indole",,5/11/2016,treatment of cholangiocarcinoma,Designated/Designation Withdrawn or Revoked,9/5/2023,Not FDA Approved for Orphan Indication,,,,,SynCore Biotechnology Co. Ltd.,"4F, 69 Dongxing Road",XinYi Dist,,Taipei City,' ' ,Taiwan,524516,cholangiocarcinoma,"""gard:0009304""",
590,6-thio-2'-deoxyguanosine,,5/2/2022,treatment of small cell lung cancer (sclc),Designated,,Not FDA Approved for Orphan Indication,,,,,"MAIA Biotechnology, Inc.","444 West Lake Street, Suite 1700",,Chicago,Illinois,' 60606 ' ,United States,872822,small cell lung cancer,"""gard:0009344""",
591,6-thio-2¿-deoxyguanosine,,11/8/2023,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"MAIA Biotechnology, Inc.","444 West Lake Street, Suite 1700",,Chicago,Illinois,' 60606 ' ,United States,968923,,,
592,6-thio-2¿-deoxyguanosine,,3/14/2022,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"MAIA Biotechnology, Inc.","444 West Lake Street, Suite 1700",,Chicago,Illinois,' 60606 ' ,United States,867621,hepatocellular carcinoma,"""gard:0016773""",
593,"6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3- tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one",,6/22/2020,treatment of beta-thalassemia,Designated/Designation Withdrawn or Revoked,1/27/2023,Not FDA Approved for Orphan Indication,,,,,"IMARA, Inc.",116 Huntington Avenue,6th Floor,Boston,Massachusetts,' 02116 ' ,United States,748620,beta-thalassemia,"""gard:0000871""",
594,"6-[(3S,4S-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imadazo[1,5-a]pyrazin-8-one",,1/31/2017,treatment of sickle cell disease (scd),Designated/Designation Withdrawn or Revoked,1/27/2023,Not FDA Approved for Orphan Indication,,,,,Imara Inc.,700 Technology Square,3rd Floor,Cambridge,Massachusetts,' 02139 ' ,United States,564316,,,
595,6-[18F] fluoro-L-m-tyrosine,,4/17/2019,diagnostic for the management of aromatic l-amino acid decarboxylase deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,' 33467 ' ,United States,686619,aromatic l-amino acid decarboxylase deficiency,"""gard:0000770""",
596,"6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-B-L-manno-heptopyranosyl]amino-9H-purine",,6/12/2014,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,2/16/2018,Not FDA Approved for Orphan Indication,,,,,"DARA Therapeutics, Inc.",8601 Six Forks Road,Suite 160 (Forum 1),Raleigh,North Carolina,' 27615 ' ,United States,434414,multiple myeloma,"""gard:0007108""",
597,6-{(1S)-1-[(2-Amino-6-fluoroquinolin-3-yl)oxy]ethyl}-5-(1H-pyrazol-1-yl)pyridin-2(1H)-one,,9/18/2020,treatment for sickle cell disease.,Designated/Designation Withdrawn or Revoked,4/6/2022,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",500 Arcola Road,,Collegeville,Pennsylvania,' 19426 ' ,United States,766020,,,
598,"6-{4-[l-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl}-N-(pyridin-4-yl)pyridine-2-carboxamide",,2/11/2016,treatment of glioblastoma multiforme (gbm).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Proximagen, LLC",505 Waterford Park,Hwy 169 North,Plymouth,Minnesota,' 55441 ' ,United States,503415,glioblastoma,"""gard:0002491""",
599,"6-{[(1R,2S)-2-aminocyclohexyl]amino-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate",,2/25/2019,treatment of follicular lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,671718,lymphoma,"""gard:0020548""",
600,"6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one monocitrate",,10/3/2017,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,606817,acute myeloid leukemia,"""gard:0012757""",
601,"6-{[(1R,2S)-2-aminocyclohexyl]amino}-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridine-3-one monocitrate",,2/14/2017,treatment of diffuse large b-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,556916,lymphoma,"""gard:0020548""",
602,"64-fluoro-36-methox-27-methyl-5-thia-4,8-diaza-2(4,6)-tieno[3,2-d]pyrimidine-3(3,5)-pyridina-1(2,5)-thiophena-6(1,3)-benzeneacyclononaphan-7-one 5,5-dioxide",,11/8/2022,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,AUM Biosciences,7265 Wisconsin Avenue,Cullen Building,Bethesda,Maryland,' 20814 ' ,United States,912422,neuroblastoma,"""gard:0007185""",
603,"7,8-dibromo-5,6-dihydro-9-methyl-2-(1-piperazinyl)-4H-imidazo[4,5,1-ij] quinoline hydrochloride",,3/26/2020,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Ryvu Therapeutics S.A.,Bobrzynskiego 14,,Krakow,,' ' ,Poland,733220,acute myeloid leukemia,"""gard:0012757""",
604,"7-(4-fluoro-2-methoxyphenyl)-6-methyl-N-(1-(piperidin-4-yl)-1H-pyrazol-4-yl) thieno [3,2-d]pyrimidin-2-amine semi-fumarate",,3/26/2018,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"MaxiNovel Pharmaceutical Co.,Ltd",Building A4-1005,181 Science Boulevard,Guangzhou,Guangdong Sheng,' ' ,China,629118,acute myeloid leukemia,"""gard:0012757""",
605,7-B-Hydroxy Cholesteryl-3-B-Oleate-Ester,,6/15/2011,treatment of gliomas.,Designated,,Not FDA Approved for Orphan Indication,,,,,Intsel Chimos SA,1 rue Royale,,91123 Saint-Cloud Cedex,,' ' ,France,343511,,,
606,"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one",,6/4/2018,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Chimerix, Inc.","2505 Meridian Parkway, Suite 100",,Durham,North Carolina,' 27713 ' ,United States,640218,,,
607,"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one*2HCl",,6/23/2016,treatment of glioblastoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Chimerix, Inc.","2505 Meridian Parkway, Suite 100",,Durham,North Carolina,' 27713 ' ,United States,527916,glioblastoma,"""gard:0002491""",
608,"7-benzyl-4-(2-methylbenzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4H)-one-2HCL",,2/7/2017,treatment of mantle cell lymphoma (mcl),Designated,,Not FDA Approved for Orphan Indication,,,,,"Chimerix, Inc.","2505 Meridian Parkway, Suite 100",,Durham,North Carolina,' 27713 ' ,United States,553316,lymphoma,"""gard:0020548""",
609,7-ethyl-10-hydroxycamptothecin (EHC),,4/13/2016,treatment of small cell lung cancer.,Designated/Designation Withdrawn or Revoked,2/21/2023,Not FDA Approved for Orphan Indication,,,,,"Nippon Kayaku Co., Ltd.","1-1, Marunouchi 2-chome",,Chiyoda,Tokyo,' ' ,Japan,513715,small cell lung cancer,"""gard:0009344""",
610,7-ethyl-10-hydroxycamptothecin and irinotecan hydrochloride trihydrate,,7/18/2023,treatment of small-cell lung carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,SN BioScience Inc.,"Na-422, LH Business Growth Center","54 Changup-ro, Sujeong-gu, Seongnam-si",Gyeonggi,Republic of Korea,' ' ,South Korea,949023,noma,"""gard:0004001""",
611,72 amino acid proprietary recombinant protein antagonist for the CXCR1 and CXCR2 receptors of interleukin-8,,6/4/2019,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Rise Biopharmaceutical Ltd.,"Room B405, Zhongguancun Shangdi Bio-medical Park","No.5 Kaituo Road, Haidian District",Beijing,Beijing,' ' ,China,660218,,,
612,"8 Cyclopentyl 1,3-dipropylxanthine",,3/24/1997,treatment of cystic fibrosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"SciClone Pharmaceuticals, Inc.",901 Mariner's Island Boulevard,,San Mateo,California,' 94404 ' ,United States,103997,cystic fibrosis,"""gard:0006233""",
613,"8-((6-iodobenzo[d][1,3]dioxol-5-yl)thio)-9-(2-(neopentylamino)ethyl)-9H-purin-6-amine, dihydrochloride salt",,6/6/2022,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Samus Therapeutics, Inc.",10 South Main Street,,Topsfield,Massachusetts,' 01983 ' ,United States,882822,,,
614,8-(1-Hydroxy-ethyl)-2-methoxy-3-(4-methoxy-benzyloxy)-benzo[c]chromen-6-one,,1/21/2015,treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,"Diffusion Pharmaceuticals, Inc.",2020 Avon Court,Suite 4,Charlottesville,Virginia,' 22902 ' ,United States,463714,glioblastoma,"""gard:0002491""",
615,"8-(6-iodobenzo[1,3]dioxol-5-ylsufanyl)-9-(3-isopropylamino propyl)adenine dihydrochloride",,5/16/2018,treatment of myelofibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Samus Therapeutics, Inc.",10 South Main Street,,Topsfield,Massachusetts,' 01983 ' ,United States,638018,,,
616,"8-bromo-2-(1-methylpiperidin-4-yl) amino)-4-(4-phenoxyphenyl) amino) pyrido[4,3-d] pyrimidin-5(6H)-one hydrochloride",,11/20/2018,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Oscotec Inc.,"Korea Bio-Park Bldg A, 9th Floor","700 Dawwangpangyo-ro, Bundang-gu",Seongnam-si,Gyeonggi-do,' ' ,South Korea,661018,acute myeloid leukemia,"""gard:0012757""",
617,8-methoxsalen,,6/22/1993,for use in conjunction with the uvar photopheresis to treat diffuse systemic sclerosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Mallinckrodt Hospital Products IP Limited,440 Route 22 East,,Bridgewater,New Jersey,' 08807 ' ,United States,74293,systemic sclerosis,"""gard:0009748""",
618,"8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naph-thyrin-3(2H)-one mono-hydrochloride",,9/3/2009,treatment of ovarian cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,291309,ovarian cancer,"""gard:0007295""",
619,"9-cis, 12-cis-11,11-d2-linoleic acid ethyl ester",,5/23/2016,treatment of friedreich's ataxia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Retrotope, Inc.",4300 El Camino Real,Suite 201,Los Altos,California,' 94022 ' ,United States,492315,,,
620,"9-cis,12-cis-11,11-D2-linoleic acid ethyl ester",,10/24/2017,treatment of pla2g6-associated neurodegeneration,Designated,,Not FDA Approved for Orphan Indication,,,,,"Retrotope, Inc.",4300 El Camino Real,Suite 201,Los Altos,California,' 94022 ' ,United States,607717,pla2g6-associated neurodegeneration,"""gard:0012567""",
621,9-cis-retinoic acid,,1/2/1997,prevention of retinal detachment due to proliferative vitreoretinopathy.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Allergan, Inc.",2525 Dupont Drive,P.O. Box 19534,Irvine,California,' 92623 ' ,United States,101296,vitreoretinopathy,"""gard:0019539""",
622,9-nitro-20-(S)-camptothecin,,5/15/2001,treatment of pediatric hiv infection/aids,Designated,,Not FDA Approved for Orphan Indication,,,,,"NovoMed Pharmaceuticals, Inc.",P.O. Box 900,,Germantown,Maryland,' 20875 ' ,United States,142201,,,
623,9-nitro-20-(S)-camptothecin,,9/16/1996,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,' 94568 ' ,United States,100196,,,
624,90Y-DOTA-tyr3-Octreotide,,1/20/2016,treatment of neuroendocrine tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"M. Sue O'Dorisio, MD, PhD","2519 JPP, 200 Hawkins Drive",,Iowa City,Iowa,' 52242 ' ,United States,504015,,,
625,90Y-hPAMA4,,1/29/2004,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,1/31/2017,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,178503,,,
626,"99mTc-HYNIC-[D-Phe1,Tyr3-Octreotide] trifluoroacetate",,12/5/2018,diagnostic for the management of neuroendocrine tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,Narodowe Centrum Badan Jadrowych,ul. Andrzeja Soltana 7,,Otwock,Masovian Voivodeship,' 05-400 ' ,Poland,661918,,,
627,a phosphoramidate oral prodrug of a unique 6-modified purine nucleotide,,12/18/2023,treatment of disease caused by dengue virus,Designated,,Not FDA Approved for Orphan Indication,,,,,Atea Pharmaceuticals Inc.,225 Franklin Street,Suite 2100,Boston,Massachusetts,' 02110 ' ,United States,976523,,,
628,"A (recombinant) disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13 (ADAMTS13) protein",,9/27/2023,treatment of thrombotic thrombocytopenic purpura (ttp),Designated,,Not FDA Approved for Orphan Indication,,,,,GC Biopharma Corp.,"107, Ihyeon-ro 30beon-gil, Giheung-gu",,Yongin-si,Gyeonggi-do,' 16924 ' ,South Korea,963423,thrombotic thrombocytopenic purpura,"""gard:0016659""",
629,"a B-cell maturation antigen (BCMA)-directed, genetically engineered T cell immunotherapy product derived from an autologous leukapheresis",,2/21/2023,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,908622,multiple myeloma,"""gard:0007108""",
630,"a bispecific antibody composed of a Light Chain and a Heavy Chain pair targeting HER2, and a Light Chain and a Heavy Chain pair targeting CD47",,12/7/2023,"treatment of patients with gastric cancer, including cancer of the gastroesophageal junction",Designated,,Not FDA Approved for Orphan Indication,,,,,"D3 Bio (Wuxi) Co., Ltd.","1101, Tower 1, No.6, Lane 38, Yuanshan Road, Pudong, Shanghai, China 200120",,Shanghai,,' 200120 ' ,China,974023,,,
631,"a bispecific antibody that binds human programmed death-ligand 1 (PD-L1; CD274) and 4-1BB (CD137, tumor necrosis factor receptor superfamily 9) proteins",,9/16/2022,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Antengene Biologics Limited,"Level 54, Hopewell Centre",183 Queen’s Road East,Wan Chai,Hong Kong,' ' ,China,899222,,,
632,"A CD47-binding, fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha (SIRPalpha) variant 1 (v1) genetically linked to a modified and inactive Fc domain of human IgG",,1/27/2022,treatment for gastric cancer and gastro-esophageal junction cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,ALX Oncology Inc.,323 Allerton Avenue,,South San Francisco,California,' 94080 ' ,United States,782220,,,
633,"A CD47-binding, fusion protein containing a high affinity engineered D1 domain of human signal regulatory protein alpha variant 1 genetically linked to a modified and inactive Fc domain of human IgG",,6/28/2022,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,ALX Oncology Inc.,323 Allerton Avenue,,South San Francisco,California,' 94080 ' ,United States,884522,acute myeloid leukemia,"""gard:0012757""",
634,a chemically modified full phosphorothioate-backbone anti-miR-17 oligonucleotide,,6/16/2022,autosomal dominant polycystic kidney disease (adpkd),Designated,,Not FDA Approved for Orphan Indication,,,,,Regulus Therapeutics Inc.,"4224 Campus Point Court, Suite 210",,San Diego,California,' 92121 ' ,United States,869322,autosomal dominant polycystic kidney disease,"""gard:0010413""",
635,a chemically modified full phosphorothioate-backboned anti-miR-17 oligonucleotide.,,7/28/2020,treatment of autosomal dominant polycystic kidney disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Regulus Therapeutics, Inc.",10628 Science Center Drive,Suite 225,San Diego,California,' 92121 ' ,United States,750820,autosomal dominant polycystic kidney disease,"""gard:0010413""",
636,A chimeric antigen receptor (CAR) immunotherapy directed against the target protein CD7,,2/8/2021,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"iCell Gene Therapeutics, LLC","25 Health Sciences Dr., Suite 118",,Stony Brook,New York,' 11790 ' ,United States,800320,acute lymphoblastic leukemia,"""gard:0000522""",
637,"a DMD exon 44 skipping PMO and a proprietary cyclic peptide, EEV, that is designed to enable robust muscle tissue uptake, high cellular internalization and endosomal escape of oligonucleotide therapeutics",,12/16/2022,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Entrada Therapeutics, Inc.",6 Tide Street,,Boston,Massachusetts,' 02210 ' ,United States,915222,muscular dystrophy,"""gard:0007922""",
638,A dual vector gene therapy product containing AAV8 vectors expressing the 5¿ and 3¿ portion of human otoferlin (OTOF) gene,,11/29/2022,treatment of otoferlin related hearing loss,Designated,,Not FDA Approved for Orphan Indication,,,,,Sensorion S.A.,375 rue du Professeur Joseph Blayac,,Montpellier,,' 34080 ' ,France,913222,,,
639,a Fab drug targeting the human TfR1 and conjugated to a PMO designed to bind to DMD exon 51,,3/21/2023,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Dyne Therapeutics, Inc.",1560 Trapelo Road,,Waltham,Massachusetts,' 02451 ' ,United States,929922,muscular dystrophy,"""gard:0007922""",
640,"a fixed-dose combination containing two active ingredients, senaparib and temozolomide",,8/3/2022,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"IMPACT Therapeutics, Inc.","12F, New Bund Times Square, 399 Haiyang West Rd.",Pudong District,Shanghai,,' ' ,China,895222,small cell lung cancer,"""gard:0009344""",
641,"a fourth generation activating chimeric receptor (ACR) natural killer (NK) cell therapy engineered with an NKG2D ACR, OX40 costimulatory domain, CD3zeta signaling moiety, and membrane bound IL-15 (mb-IL15)",,12/14/2021,treatment of acute myeloid lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nkarta, Inc.",1150 Veterans Blvd.,,South San Francisco,California,' 94080 ' ,United States,851121,lymphoma,"""gard:0020548""",
642,a fully human monoclonal antibody that binds and activates the Tie2 receptor,,2/21/2023,treatment of systemic capillary leak syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"PharmAbcine, Inc.","2F research building2, 1689 beon-gil",Yuseong-daero,Yuseong-gu,Daejeon,' 34047 ' ,South Korea,924722,systemic capillary leak syndrome,"""gard:0001084""",
643,a fully humanized immunoglobulin gamma 1 (IgG1) agonistic monoclonal antibody (mAb) that specifically targets and activates MuSK,,6/21/2023,treatment of congenital myasthenic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,argenx BV,Industriepark Zwijnaarde 7,,Zwijnaarde,East Flanders,' 9052 ' ,Belgium,944223,congenital myasthenic syndrome,"""gard:0011902""",
644,a fusion protein comprised of genetically engineered human serine peptidase inhibitor and human immunoglobulin G1 Fc,,12/21/2022,treatment of netherton syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Daiichi Sankyo, Inc.",211 Mount Airy Road,,Basking Ridge,New Jersey,' 07920 ' ,United States,915622,netherton syndrome,"""gard:0007182""",
645,a genetically modified Salmonella comprising of methioninase,,11/8/2022,treatment for osteosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Guangzhou Sinogen Pharmaceutical Co., Ltd.","No. 11 Kai Yuan Ave., Huangpu Dist.","Building C5, Room 101",Guangzhou,Guangdong,' 510530 ' ,China,910022,osteosarcoma,"""gard:0007284""",
646,a genetically modified salmonella comprising of methioninase,,12/14/2022,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Guangzhou Sinogen Pharmaceutical Co., Ltd.","No.11 Kai Yuan Ave., Huangpu Dist.","Building C5, Room 101",Guangzhou,Guangdong,' 510530 ' ,China,916722,hepatocellular carcinoma,"""gard:0016773""",
647,a genetically modified Salmonella comprising of methioninase,,8/28/2023,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Guangzhou Sinogen Pharmaceutical Co., Ltd.","No.11 Kai Yuan Ave., Huangpu Dist.","Building C5, Room 101",Guangzhou,Guangzhou,' 510530 ' ,China,957123,small cell lung cancer,"""gard:0009344""",
648,"a highly purified unmodified carbohydrate polymer which consists of (1,3) and (1,4)-beta-glycosidic linkages",,10/21/2020,treatment of osteosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,University Hospitals Cleveland Medical Center,"10532 Euclid Avenue, Walker 3000",,Cleveland,Ohio,' 44106 ' ,United States,774420,osteosarcoma,"""gard:0007284""",
649,a humanized aglycosylated IgG1 kappa monoclonal antibody targeting CD117 (cKit),,6/7/2021,conditioning treatment prior to hematopoietic stem cell transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jasper Therapeutics, Inc.","2200 Bridge Parkway, Suite #102",,Redwood City,California,' 94065 ' ,United States,820121,,,
650,a humanized anti-CD3/CD19 bispecific antibody,,2/26/2024,treatment of acute lymphocytic leukemia (all),Designated,,Not FDA Approved for Orphan Indication,,,,,"Curon Biopharmaceutical (Shanghai) Co., Limited","Room 103, No. 6, Lane. 898 Halei Road",Pilot Free Trade Zone,Shanghai,,' ' ,China,924222,,,
651,A Humanized Bispecific Antibody Neutralizing Both Sclerostin and Dickkopf-1,,10/20/2022,treatment of osteogenesis imperfecta (oi),Designated,,Not FDA Approved for Orphan Indication,,,,,Angitia Biopharmaceuticals Guangzhou Limited,"Room 202-302, Building 4, 188 Kaiyuan Avenue, Huangpu District",,Guangzhou,Guangdong,' 510530 ' ,China,883322,osteogenesis imperfecta,"""gard:0001017""",
652,a humanized IgG1kappa-agonistic anti-CD40 mAb,,8/3/2021,treatment of patients with soft tissue sarcoma (sts).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pyxis Oncology, Inc.",321 Harrison Avenue,"11th Floor, Suite 1",Boston,Massachusetts,' 02118 ' ,United States,830321,soft tissue sarcoma,"""gard:0004898""",
653,"a humanized IgG4 monoclonal antibody, produced in CHO cells, that binds to and inhibits the activated form of the classical complement pathway (CP) specific serine protease, C1s",,1/12/2023,treatment of autoimmune hemolytic anemia (aiha),Designated,,Not FDA Approved for Orphan Indication,,,,,Bioverativ USA Inc,225 Second Avenue,,Waltham,Massachusetts,' 02451 ' ,United States,892722,autoimmune hemolytic anemia,"""gard:0005870""",
654,"a humanized immunoglobulin G (IgG)1kappa monoclonal antibody targeting IL1RAP that has been designed to inhibit signal transduction from IL?1 alpha, IL?1beta, IL?33, IL?36 alpha, IL?36 beta, and IL?36 gamma",,9/5/2023,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Cantargia AB,Scheelevägen 27,,Lund,,' SE-223 63 ' ,Sweden,958323,systemic sclerosis,"""gard:0009748""",
655,a humanized immunoglobulin IgG1 antibody with a kappa light chain (LC) which has high selectivity and specificity for cancer-specific plectin,,10/19/2022,treatment of cholangiocarcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,ZielBio Incorporated,1317 Cartlon Ave,,Charlottesville,Virginia,' 22903 ' ,United States,900322,cholangiocarcinoma,"""gard:0009304""",
656,a humanized immunoglobulin IgG1 antibody with a kappa light chain (LC) with high selectivity and specificity for cancer-specific plectin,,11/3/2022,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,ZielBio Incorporated,1317 Carlton Ave,,Charlottesville,Virginia,' 22903 ' ,United States,908122,,,
657,"a humanized, immunoglobulin G subtype 4 anti-Amphiregulin monoclonal antibody",,2/16/2023,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pulmongene (Hong Kong) Co., Limited",9/F MW Tower No 111 Bonham Strand,Sheung Wan,Hong Kong,,' ' ,China,924422,idiopathic pulmonary fibrosis,"""gard:0008609""",
658,"A ligand binding moiety to MDM2, a chemical linker, and a ligand binding moiety to an E3 ligase that leads to MDM2 degradation.",,6/21/2023,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,Kymera Therapeutics,500 North Beacon St.,,Watertown,Massachusetts,' 02472 ' ,United States,946823,acute myeloid leukemia,"""gard:0012757""",
659,"a ligand binding moiety to STAT3, a chemical linker, and a ligand binding moiety to an E3 ligase that leads to STAT3 degradation",,5/31/2022,peripheral t-cell lymphoma (ptcl),Designated,,Not FDA Approved for Orphan Indication,,,,,Kymera Therapeutics,500 North Beacon St.,,Watertown,Massachusetts,' 02472 ' ,United States,879422,lymphoma,"""gard:0020548""",
660,"a ligand binding moiety to STAT3, a chemical linker, and a ligand binding moiety to an E3 ligase that leads to STAT3 degradation",,9/14/2022,treatment of cutaneous t-cell lymphoma (ctcl),Designated,,Not FDA Approved for Orphan Indication,,,,,Kymera Therapeutics,500 North Beacon St.,,Watertown,Massachusetts,' 02472 ' ,United States,879222,lymphoma,"""gard:0020548""",
661,A Lipid Nanoparticle Suspension of Akt-1 Antisense Oligonucleotide,,9/20/2023,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Zhejiang Haichang Biotech Co., Ltd.","Room 1109, West Zone Building 2, Lakeside Center, Xiasha Street, Qiantang New Area",,Hangzhou,Zhejiang,' 310012 ' ,China,961123,hepatocellular carcinoma,"""gard:0016773""",
662,"a liposomal formulation of CEBPA-51, an saRNA duplex in sucrose/phosphate buffer",,7/6/2021,treatment of hepatocellular carcinoma (hcc),Designated,,Not FDA Approved for Orphan Indication,,,,,"MiNA Alpha, Ltd",84 Wood Lane,,London,,' W12 0BZ ' ,United Kingdom,823821,hepatocellular carcinoma,"""gard:0016773""",
663,a live attenuated bioengineered Listeria monocytogenes cancer immunotherapy,,4/29/2014,treatment of stage ii to iv invasive cervical carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advaxis, Inc.",305 College Road East,,Princeton,New Jersey,' 08540 ' ,United States,429814,noma,"""gard:0004001""",
664,a long-acting interleukin-11 analog comprised of 178 amino acids covalently modified wiht a 40-kDa branched maleimide-polyethylene glycol at the added cysteine residue following the carboxy-terminal amino acid,,4/17/2019,treatment of acute radiation syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Bolder BioTechnology, Inc.","2425 55th Street, Suite 210",,Boulder,Colorado,' 80301 ' ,United States,680919,acute radiation syndrome,"""gard:0021896""",
665,a lyophilized modified oligonucleotide of 16 nucleotides conjugated to a molecule of oleic acid,,5/10/2022,treatment of myotonic dystrophy type 1,Designated,,Not FDA Approved for Orphan Indication,,,,,Arthex Biotech S.L.,"Carrer del Catedràtic Agustín Escardino, 9",,Paterna,Valencia,' 46980 ' ,Spain,874822,myotonic dystrophy,"""gard:0010419""",
666,a modified version of a leucine decarboxylase enzyme from Planctomycetaceae bacterium,,12/20/2022,treatment of maple syrup urine disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Codexis, Inc.",200 Penobscot Drive,,Redwood City,California,' 94063 ' ,United States,921222,maple syrup urine disease,"""gard:0003228""",
667,a modified version of methionine gamma-lyase (MGL) enzyme from the bacterium Pseudomonas entomophila,,1/18/2022,treatment of homocystinuria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Codexis, Inc.",200 Penobscot Drive,,Redwood City,California,' 94063 ' ,United States,856921,cystinuria,"""gard:0006237""",
668,a multiple substituted pyrimidoheterocycle small molecule inhibitor that covalently binds to the Switch II pocket of KRAS p.G12C and locks the oncogenic protein in its GDP-bound inactive form,,3/27/2023,treatment of patients with advanced pancreatic cancer harboring kras p.g12c mutant protein,Designated,,Not FDA Approved for Orphan Indication,,,,,"D3 Bio (Wuxi) Co., Ltd.","1101, Tower 1, No.6, Lane 38, Yuanshan Road, Pudong",,Shanghai,,' 200120 ' ,China,932223,,,
669,a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human MYBPC3 gene,,5/12/2021,treatment of hypertrophic cardiomyopathy (hcm) due to loss-of-function mutations in the mybpc3 gene encoding cardiac myosin-binding protein c,Designated,,Not FDA Approved for Orphan Indication,,,,,Tenaya Therapeutics,701 Oyster Point Blvd,Suite 500,South San Francisco,California,' 94080 ' ,United States,813221,,,
670,A native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 gene,,11/22/2022,treatment for arrhythmogenic right ventricular cardiomyopathy (arvc) due to pkp2 mutations.,Designated,,Not FDA Approved for Orphan Indication,,,,,Tenaya Therapeutics,171 Oyster Point Blvd,Suite 500,South San Francisco,California,' 94080 ' ,United States,911322,arrhythmogenic right ventricular cardiomyopathy,"""gard:0005847""",
671,a non-replicating recombinant adeno- associated virus serotype 9 (AAV9) based gene therapy vector containing the DNA of Streptococcus pyogenes Cas9 (SpCas9) protein and single guide RNA (sgRNA) designed to target the TATA-box of the PMP22 P1 promoter,,12/14/2023,treatment of charcot-marie-tooth disease type 1a,Designated,,Not FDA Approved for Orphan Indication,,,,,"ToolGen, Inc.","8F, 172, Magokjungang-ro",Gangseo-gu,Seoul,,' N/A ' ,South Korea,976023,charcot-marie-tooth disease type 1,"""gard:0012433""",
672,a non-replicating recombinant adeno-associated virus serotype 9 (AAV9) gene therapy vector containing the human adenosine triphosphate (ATP)-binding cassette (ABC) sub-family D member 1 (ABCD1) gene,,3/14/2022,treatment of adrenoleukodystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"SwanBio Therapeutics, Inc.",150 Monument Road,Suite 207,Bala Cynwyd,Pennsylvania,' 19004 ' ,United States,866121,leukodystrophy,"""gard:0006895""",
673,"a non-replicating recombinant adeno-associated virus serotype hu68 vector, containing a transgene encoding the human galactosylceramidase (GALC) enzyme",,10/22/2020,treatment of krabbe disease (globoid cell leukodystrophy),Designated,,Not FDA Approved for Orphan Indication,,,,,"Passage Bio, Inc.","Commerce Square Two, 2001 Market Street",,Philadelphia,Pennsylvania,' 19103 ' ,United States,776620,leukodystrophy,"""gard:0006895""",
674,a novel humanized bispecific XmAb® T cell recruiting antibody cross-reactive to human and nonhuman primate STEAP1 and CD3,,7/7/2020,treatment of ewing sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,Mail Stop: 27-3-F,Thousand Oaks,California,' 91320 ' ,United States,760020,,,
675,a novel synthetic small molecule inhibitor designed to target TEAD,,3/14/2022,treatment of mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Ikena Oncology,645 Summer St.,Suite 101,Boston,Massachusetts,' 02210 ' ,United States,866921,,,
676,a peptidomimetic protein peptide with sequence H-Gly-Arg-Arg-Ala-Ala-Pro-Gly-Arg-Aib-Gly-Gly-NH2,,4/8/2021,treatment of lennox- gastaut syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,CuroNZ Ltd,173 Cames Road,,Mangawhai,,' 0975 ' ,New Zealand,810621,,,
677,a phenylalanine consuming engineered bacteria,,5/8/2023,treatment of phenylketonuria (pku),Designated,,Not FDA Approved for Orphan Indication,,,,,"Synlogic Operating Company, Inc.","301 Binney Street, Suite 401",,Cambridge,Massachusetts,' 02142 ' ,United States,900622,phenylketonuria,"""gard:0007383""",
678,A plasmid encoding a rabies virus glycoprotein tag & lysosome-associated membrane glycoprotein 2 fusion protein gene and a mutant huntingtin small interfering RNA,,4/10/2023,treatment of huntington’s disease,Designated,,Not FDA Approved for Orphan Indication,,,,,ExoRNA Bioscience Nanjing Co. Ltd.,"Room 697, Building A, Phase I, Zhongdan Ecological Life","Science Industrial Park, No. 3-1, New Jinhu Road, Jiangbei New District",Nanjing,,' ' ,China,932623,,,
679,a polymer based prodrug of bortezomib,,10/12/2022,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Window Therapeutics, Inc",100 William Morrisey Blvd,010-3-187,Boston,Massachusetts,' 02151 ' ,United States,905222,multiple myeloma,"""gard:0007108""",
680,A potent and selective inhibitor of Gamma Secretase-mediated NOTCH signaling,,5/8/2019,treatment of adenoid cystic carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ayala Pharmaceuticals, Inc.","7 Oppenheimer St.,",,Rehovot,,' ' ,Israel,683819,noma,"""gard:0004001""",
681,a protein based on human alpha-1-antitrypsin (a1AT) with three mutations in the reactive center loop (RCL) conferring specificity for APC over other plasma proteases,,9/13/2022,treatment of hemophilia b,Designated,,Not FDA Approved for Orphan Indication,,,,,ApcinteX Limited,3rd Floor 1 Ashley Road,,Altrincham,Cheshire,' Wa14 2dt ' ,United Kingdom,898322,hemophilia,"""gard:0010418""",
682,A rAAV8 capsid containing a single-stranded DNA template encoding wild-type human coagulation factor IX protein and LNP1265: a lipid nanoparticle encapsulating a Cas9 mRNA and a single guide RNA,,12/20/2023,treatment of hemophilia b,Designated,,Not FDA Approved for Orphan Indication,,,,,Regeneron Pharmaceuticals Inc,777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,978123,hemophilia,"""gard:0010418""",
683,A recombinant adeno-associated viral (AAV) vector encoding the human otoferlin (hOTOF) gene.,,4/12/2021,treatment of otoferlin gene (otof)-mediated hearing loss,Designated,,Not FDA Approved for Orphan Indication,,,,,"Akouos, Inc.",645 Summer Street,Suite 200,Boston,Massachusetts,' 02210 ' ,United States,811221,,,
684,a recombinant adeno-associated virus pseudotyped with serotype 5 viral capsid encoding CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats associated protein 9) gene editing constructs,,7/23/2019,treatment of cep290 gene mutations including leber congenital amaurosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Editas Medicine,11 Hurley Street,,Cambridge,Massachusetts,' 02141 ' ,United States,693419,leber congenital amaurosis,"""gard:0000634""",
685,A recombinant adeno-associated virus serotype 9 (rAAV9) vector carrying a compact high-fidelity Cas12i (hfCas12Max) and a CRISPR RNA (crRNA) targeting human DMD exon 51 SD site,,1/4/2024,treatment of duchenne muscular dystrophy (dmd),Designated,,Not FDA Approved for Orphan Indication,,,,,"Cholgene Therapeutics, Inc.","54 Old Highway 22, Suite 220,",,Clinton,New Jersey,' 08809 ' ,United States,981023,muscular dystrophy,"""gard:0007922""",
686,a recombinant human IgG1 with minimized Fc effector function that selectively binds to BMP9 with high affinity and inhibits its interaction with Type II receptors on endothelial cells thereby blocking downstream signaling,,2/24/2023,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,Pfizer Inc.,66 Hudson Boulevard East,,New York,New York,' 10001 ' ,United States,925322,pulmonary arterial hypertension,"""gard:0007501""",
687,a recombinant human monoclonal antibody targeting hantavirus,,8/5/2021,treatment of hantavirus infection,Designated,,Not FDA Approved for Orphan Indication,,,,,Ichor Biologics,423 West 127th Street,,New York,New York,' 10027 ' ,United States,830721,,,
688,a recombinant humanized Fc effector function null IgG1 antibody with kappa light chains (IgG1) that selectively binds to E-selectin to inhibit binding to cellular proteins containing carbohydrate structures with a sialyl Lewis X (sLex) deter,,9/18/2020,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Pfizer Inc.,66 Hudson Boulevard East,,New York,New York,' 10001 ' ,United States,765320,,,
689,A recombinant humanized IgG1 monoclonal antibody targeting programmed death-ligand 1,,2/13/2020,treatment of nasopharyngeal carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Harbour BioMed US, Inc.","1 Broadway, 14th Floor, Cambridge, MA, 02142",,Cambridge,Massachusetts,' 02142 ' ,United States,723119,nasopharyngeal carcinoma,"""gard:0007163""",
690,"a recombinant, humanized single variable domain on a heavy chain (VHH) bispecific antibody that binds with high affinity to human properdin and human serum albumin",,8/21/2023,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,955723,,,
691,"A replication-defective, non-integrating herpes simplex virus type 1 vector expressing human cystic fibrosis transmembrane conductance regulator",,8/17/2020,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Krystal Biotech, Inc.",2100 Wharton Street,,Pittsburgh,Pennsylvania,' 15203 ' ,United States,755320,cystic fibrosis,"""gard:0006233""",
692,"A replication-defective, non-integrating herpes simplex virus type 1-based vector engineered to express full-length, functional human alpha-1 antitrypsin",,9/1/2023,treatment of alpha-1 antitrypsin deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Krystal Biotech, Inc.",2100 Wharton Street,Suite 701,Pittsburgh,Pennsylvania,' 15203 ' ,United States,958023,,,
693,A replication-deficient adeno-associated virus serotype 9 vector containing the ornithine transcarbamylase gene within the transposon and a lipid nanoparticle containing messenger RNA for the transposase,,7/24/2023,treatment of ornithine transcarbamylase deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Poseida Therapeutics, Inc.","9390 Towne Centre Drive, Ste 200",,San Diego,California,' 92121 ' ,United States,950023,ornithine transcarbamylase deficiency,"""gard:0008391""",
694,"A replication-incompetent, non-integrating Herpes simplex type 1 (HSV-1) vector expressing the human transglutaminase-1 (TGM-1) enzyme",,8/7/2018,treatment of tgm-1-deficient autosomal recessive congenital ichthyosis (arci),Designated,,Not FDA Approved for Orphan Indication,,,,,"Krystal Biotech, Inc.",2100 Wharton Street,,Pittsburgh,Pennsylvania,' 15203 ' ,United States,648718,autosomal recessive congenital ichthyosis,"""gard:0021106""",
695,a self-complementary adeno-associated virus serotype 9 expressing human codon-optimized CLN1 under control of CBh,,2/7/2018,treatment of neuronal ceroid lipofuscinosis type 1 (cln1),Designated,,Not FDA Approved for Orphan Indication,,,,,"Taysha Gene Therapies, Inc.",BioCenter at UT Southwestern,2280 Inwood Rd.,Dallas,Texas,' 75235 ' ,United States,628718,neuronal ceroid lipofuscinosis,"""gard:0010739""",
696,A self-complementary recombinant adeno-associated virus (scAAV) serotype 6 vector that expresses NeuroD1 under the control of the CMV promoter,,12/6/2023,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,NeuExcell Therapeutics Inc.,401 N Broad St. Suite M125,,Philadelphia,Pennsylvania,' 19108 ' ,United States,973823,,,
697,a single-stranded adeno-associated virus serotype 8 gene therapy containing codon optimized human alpha-1-iduronidase cDNA.,,10/22/2020,treatment of mucopolysaccharidosis type i (mps i),Designated,,Not FDA Approved for Orphan Indication,,,,,"Rain Bio, Inc.",8628 Valley Brook Drive,,Raleigh,North Carolina,' 27613 ' ,United States,774120,mucopolysaccharidosis,"""gard:0007065""",
698,A small molecule inhibitor of the pro-survival protein Myeloid Cell Leukemia sequence 1 (MCL 1),,2/15/2019,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,' 91320-1799 ' ,United States,675018,acute myeloid leukemia,"""gard:0012757""",
699,A small molecule messenger RNA (mRNA) degrader of MYB,,4/24/2024,treatment of adenoid cystic carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Remix Therapeutics,"100 Forge Rd., Suite 400",,Watertown,Massachusetts,' 02472 ' ,United States,998524,noma,"""gard:0004001""",
700,a small molecule tissue-nonspecific alkaline phosphatase inhibitor,,10/7/2019,treatment of pseudoxanthoma elasticum,Designated,,Not FDA Approved for Orphan Indication,,,,,"Daiichi Sankyo, Inc.",211 Mount Airy Road,,Basking Ridge,New Jersey,' 07920 ' ,United States,705419,pseudoxanthoma elasticum,"""gard:0009643""",
701,a strain of modified live probiotic bacterium Escherichia coli (E.coli) Nissle 1917 that has been modified to treat phenylketonuria by consuming phenylalanine within the gastrointestinal tract,,10/18/2017,treatment of phenylketonuria (pku),Designated,,Not FDA Approved for Orphan Indication,,,,,"Synlogic, Inc.","200 Sidney Street, Suite 320",,Cambridge,Massachusetts,' 02139 ' ,United States,608717,phenylketonuria,"""gard:0007383""",
702,a synthetic double-stranded RNA oligonucleotide conjugated to N-acetyl-D-galactosamine aminosugar residues,,3/16/2020,treatment of alpha-1 antitrypsin deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Dicerna Pharmaceuticals, Inc.",33 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,727619,,,
703,a synthetic PEGylated thrombopoietin (TPO) mimetic (TPOm) peptide with no sequence homology to endogenous,,5/24/2022,treatment of primary failure of platelet recovery (pfpr) or secondary failure of platelet recovery (sfpr) in patients who have undergone allogeneic hematopoietic stem cell transplant (hsct).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Janssen R&D, LLC",920 Route 202 South,PO Box 300,Raritan,New Jersey,' 08869 ' ,United States,878122,,,
704,a synthetic PEGylated thrombopoietin (TPO) mimetic (TPOm) peptide with no sequence homology to endogenous TPO,,5/26/2022,to treat patients undergoing myeloablative hematopoietic stem cell transplant conditioning to improve platelet recovery and reduce myeloablative bone marrow conditioning-related toxicities.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 US Highway 202,P.O. Box 300,Raritan,New Jersey,' 08869 ' ,United States,878222,,,
705,a synthetic peptide-oligonucleotide conjugate in which a phosphorodiamidate morpholino oligonucleotide is conjugated to a cell penetrating peptide,,8/1/2023,treatment of myotonic dystrophy type 1 (also known as steinert disease),Designated,,Not FDA Approved for Orphan Indication,,,,,PepGen Inc.,"321 Harrison Ave, 8th Floor",,Boston,Massachusetts,' 02118 ' ,United States,951523,myotonic dystrophy,"""gard:0010419""",
706,A therapeutic vaccine targeting the HPV16 E6/E7 proteins,,6/26/2020,treatment of hpv16-positive cervical cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,ISA Therapeutics BV,J.H. Oortweg 19,2333 CH Leiden,CH Leiden,,' ' ,Netherlands,744820,,,
707,A thienopyrimidine derivative that preferentially inhibits Phosphodiesterase 4B,,8/15/2022,treatment idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,,Ridgefield,Connecticut,' 06877 ' ,United States,896222,idiopathic pulmonary fibrosis,"""gard:0008609""",
708,"a tumor lysate-pulsed dendritic cell vaccine, enhanced by addition of a TLR 2, 4, 9 ligand adjuvant cocktail (Pam3cys, LPS, CpG ODN)",,10/25/2022,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,NovAccess Global,8584 E. Washington Street,#127,Chagrin Falls,Ohio,' 44023 ' ,United States,906622,,,
709,A-dmDT390-bisFv(UCHT1),,10/9/2014,treatment of cutaneous t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Angimmune, LLC",American Red Cross Holland Laboratory,15601 Crabbs Branch Way,Rockville,Maryland,' 20855 ' ,United States,448114,lymphoma,"""gard:0020548""",
710,a-Galactosidase A,,1/21/2003,treatment of fabry's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"iBio, Inc.",9 Innovation Way,Suite 100,Newark,Delaware,' 19711 ' ,United States,162302,,,
711,A10 & AS2-1 Antineoplaston,,9/3/2004,treatment for patients with brain stem glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Burzynski Research Institute, Inc.",9432 Old Katy Road,,Houston,Texas,' 77055 ' ,United States,189804,,,
712,"aadeno-associated viral vector, serotype 2, containing the human choroideremia gene encoding human Rab escort protein 1",,9/12/2013,treatment of choroideremia due to mutations in the human choroideremia gene (chm),Designated,,Not FDA Approved for Orphan Indication,,,,,"Sparks Therapeutics, Inc.",3737 Market Street,Suite 1300,Philadelphia,Pennsylvania,' 19104 ' ,United States,404713,choroideremia,"""gard:0006061""",
713,AAV-based engineered microRNA targeting conserved regions on the human PMP22 transcript,,10/4/2023,treatment of charcot-marie-tooth disease type 1a,Designated,,Not FDA Approved for Orphan Indication,,,,,Armatus Bio,1275 Kinnear Road,,Columbus,Ohio,' 43212 ' ,United States,964323,charcot-marie-tooth disease type 1,"""gard:0012433""",
714,AAV-G6Pase vector,,3/11/2013,treatment of glycogen storage disease type ia,Designated,,Not FDA Approved for Orphan Indication,,,,,"GlyGenix Therapeutics, Inc.",15 Research Drive,,Woodbridge,Connecticut,' 06443 ' ,United States,378912,glycogen storage disease,"""gard:0018973""",
715,AAV2.adalimumab,,6/22/2022,"treatment of non-infectious intermediate, posterior, or panuveitis or chronic non-infectious anterior uveitis",Designated,,Not FDA Approved for Orphan Indication,,,,,"Kriya Therapeutics, Inc.","1100 Island Drive, Suite 203",,Redwood City,California,' 94065 ' ,United States,884622,non-infectious anterior uveitis,"""gard:0021260""",
716,AAV2/8-SaCas9-sgRNA RHO-T17M,,6/7/2022,treatment of retinitis pigmentosa (rp),Designated,,Not FDA Approved for Orphan Indication,,,,,"Chigenovo Co., Ltd.","Room S-402, Building 1, Yard 9, Shengshengyuan Road,","Zhongguancun Life Science Park, Changping District",Beijing,,' ' ,China,866221,retinitis pigmentosa,"""gard:0005694""",
717,"AAV8/TTR-hFVa - Adeno Associated Virus, Serotype 8 with a transthyretin promotor and encoded transgene for human clotting Factor Va.",,10/27/2021,treatment of hemophilia a or hemophilia b with or without inhibitors,Designated,,Not FDA Approved for Orphan Indication,,,,,"GeneVentiv Therapeutics, Inc.",312 Buncombe Street,,Raleigh,North Carolina,' 27609 ' ,United States,843221,hemophilia,"""gard:0010418""",
718,AAV8_ABCA4 RNA Exon Editor,,11/22/2023,treatment of abca4-related retinopathies,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ascidian Therapeutics, Inc.",80 Guest Street; 4th Floor,,Boston,Massachusetts,' 02135 ' ,United States,970723,,,
719,AAV9 capsid encapsulating a bicistronic vector encoding for a unique combination of a recombinant human ?-glucocerebrosidase enzyme with the S1S3 variant of the N-acetylglucosamine-Phosphotransferase (S1S3 PTase),,10/21/2020,treatment of gaucher disease,Designated,,Not FDA Approved for Orphan Indication,,,,,M6P Therapeutics,20 S. Sarah Street,,St. Louis,Missouri,' 63108 ' ,United States,775220,gaucher disease,"""gard:0008233""",
720,AAV9 gene therapy encoding the Dok7 protein,,11/19/2020,treatment of congenital myasthenic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Amplo Biotechnology Inc.,"2637 E. Atlantic Ave., Ste 43644",,Pompano Beach,Florida,' 33062 ' ,United States,781220,congenital myasthenic syndrome,"""gard:0011902""",
721,AAV9 gene vector construct expressing the human Frataxin gene (scAAV9.CB.hFRXN isoform 1),,1/21/2021,treatment of friedreich`s ataxia (fa).,Designated/Designation Withdrawn or Revoked,1/31/2022,Not FDA Approved for Orphan Indication,,,,,"Novartis Institute for BioMedical Research, Inc.",181 Massachusetts Avenue,,Cambridge,Massachusetts,' 02139 ' ,United States,794920,,,
722,AAV9-Synapsin-Caveolin-1,,9/28/2022,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,"Eikonoklastes Therapeutics, Inc.","2356 Park Ave., #17",,Cincinnati,Ohio,' 45206-2725 ' ,United States,902122,amyotrophic lateral sclerosis,"""gard:0005786""",
723,abagovomab,,11/25/2003,treatment of epithelial ovarian cancer,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Menarini Ricerche S.p.A.,Via Tito Speri 10,Pomezia,Roma,,' ' ,Italy,171803,ovarian cancer,"""gard:0007295""",
724,abatacept,Orencia,12/26/2017,prevention of graft versus host disease,Designated/Approved,,,"prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor",12/15/2021,12/15/2028,prophylaxis of acute graft versus host disease (aGVHD) in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated-donor,Bristol-Myers Squibb Co.,P. O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,614117,graft versus host disease,"""gard:0016642""",
725,abatacept,,5/30/2013,treatment of type 1 diabetes mellitus patients with residual beta cell function,Designated,,Not FDA Approved for Orphan Indication,,,,,Orban Biotech LLC,64 Aspinwall Avenue,,Brookline,Massachusetts,' 02446 ' ,United States,395713,,,
726,Abatacept,,2/22/2017,treatment of giant cell arteritis,Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development,Marketed Products Development - Regulatory Strategy,P.O. Box 5326,Princeton,New Jersey,' 08543 ' ,United States,556316,giant cell arteritis,"""gard:0009615""",
727,abatacept,,2/22/2017,treatment of idiopathic inflammatory myopathy (iim),Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research & Development,Marketed Products Development - Regulatory Strategy,P.O. Box 5326,Princeton,New Jersey,' 08543 ' ,United States,556216,idiopathic inflammatory myopathy,"""gard:0009128""",
728,ABCA4 DNA nanoparticles,,10/28/2015,treatment of stargardt macular degeneration,Designated,,Not FDA Approved for Orphan Indication,,,,,"Copernicus Therapeutics, Inc.",11000 Cedar Avenue,,Cleveland,Ohio,' 44106 ' ,United States,494015,,,
729,abeotaxane inhibitor of microtubules,,10/7/2011,treatment of gliomas,Designated,,Not FDA Approved for Orphan Indication,,,,,Cortice Biosciences,1345 Avenue of the Americas,42nd Floor,New York,New York,' 10105 ' ,United States,352811,,,
730,abeotaxane inhibitor of microtubules,,4/18/2011,treatment of pediatric neuroblastoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Cortice Biosciences,1345 Avenue of the Americas,42nd Floor,New York,New York,' 10105 ' ,United States,335611,neuroblastoma,"""gard:0007185""",
731,Abetimus,,7/28/2000,treatment of lupus nephritis.,Designated,,Not FDA Approved for Orphan Indication,,,,,La Jolla Pharmaceutical Co.,6455 Nancy Ridge Dr.,,San Diego,California,' 92121 ' ,United States,133600,,,
732,Ac-225 alphavbeta3-IAC,,1/19/2022,treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,Advanced Imaging Projects,7947 Brookside Ct,,Lake Worth,Florida,' 33467 ' ,United States,838921,glioblastoma,"""gard:0002491""",
733,Ac-225-4-PHenylbutyryl-His-D-Phe-Arg-Trp-Gly-Lys(eAhx-DOTA)-NH2,,2/28/2019,treatment of uveal melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Modulation Therapeutics Incorporated,1 Medical Center Drive,MBRCC room 1817,Morgantown,West Virginia,' 26506 ' ,United States,675618,uveal melanoma,"""gard:0008621""",
734,Ac-Nle-cyclo-(Glu-His-D-Phe-Arg-Dap)-Trp-NH2,,6/3/2019,"treatment of non-infectious intermediate, posterior, pan, and chronic anterior uveitis",Designated,,Not FDA Approved for Orphan Indication,,,,,"Palatin Technologies, Inc.",4b Cedarbrook Drive,,Cranbury Township,New Jersey,' 08512 ' ,United States,670418,uveitis,"""gard:0019549""",
735,acadesine,,3/3/2011,treatment of chronic lymphocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Avanced In Vitro Cell Technologies, S.L.",(Advancell),,Barcelona,,' ' ,Spain,203105,,,
736,acadesine,,5/4/2011,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Advancell-Advanced In Vitro Cell Technologies S.A.,"Via Augusta 59, 3rd floor, door 313",,Barcelona,,' ' ,Spain,341011,multiple myeloma,"""gard:0007108""",
737,acalabrutinib,Calquence,9/21/2015,treatment of mantle cell lymphoma.,Designated/Approved,,,Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy,8/4/2022,,,"Acerta Pharma, LLC (a member of the AstraZeneca Group)",121 Oyster Point Boulevard,,South San Francisco,California,' 94080 ' ,United States,488915,lymphoma,"""gard:0020548""",
738,acalabrutinib,,5/13/2015,treatment of chronic lymphocytic leukemia (cll).,Designated/Approved,,,CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).,11/21/2019,11/21/2026,Indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).,"Acerta Pharma, LLC (a member of the AstraZeneca Group)",121 Oyster Point Boulevard,,South San Francisco,California,' 94080 ' ,United States,477415,,,
739,acalabrutinib,Calquence,5/13/2015,treatment of chronic lymphocytic leukemia (cll).,Designated/Approved,,,Treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),8/4/2022,,,"Acerta Pharma, LLC (a member of the AstraZeneca Group)",121 Oyster Point Boulevard,,South San Francisco,California,' 94080 ' ,United States,477415,,,
740,acalabrutinib,,10/22/2015,treatment of waldenstrom macroglobulinemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Acerta Pharma, LLC (a member of the AstraZeneca Group)",121 Oyster Point Boulevard,,South San Francisco,California,' 94080 ' ,United States,489015,,,
741,acalabrutinib,CALQUENCE,9/21/2015,treatment of mantle cell lymphoma.,Designated/Approved,,,treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy,10/31/2017,10/31/2024,treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy,"Acerta Pharma, LLC (a member of the AstraZeneca Group)",121 Oyster Point Boulevard,,South San Francisco,California,' 94080 ' ,United States,488915,lymphoma,"""gard:0020548""",
742,acamprosate,,3/25/2013,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Confluence Pharmaceuticals, LLC",Box 528,351 West 10th Street,Indianapolis,Indiana,' 46202 ' ,United States,392413,fragile x syndrome,"""gard:0006464""",
743,acazicolcept,,3/16/2020,prevention of acute graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Alpine Immune Sciences,201 Elliott Ave. West,Suite 230,Seattle,Washington,' 98119 ' ,United States,738919,graft versus host disease,"""gard:0016642""",
744,acazicolcept,,3/16/2020,treatment of acute graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Alpine Immune Sciences,201 Elliott Ave. West,Suite 230,Seattle,Washington,' 98119 ' ,United States,712619,graft versus host disease,"""gard:0016642""",
745,aceneuramic acid,,9/23/2011,treatment of hereditary inclusion body myopathy,Designated/Designation Withdrawn or Revoked,4/25/2018,Not FDA Approved for Orphan Indication,,,,,"Ultragenyx Pharmaceutical, Inc.",60 Leveroni Court,Suite 200,Novato,California,' 94949 ' ,United States,351511,,,
746,"acetic acid, propionic acid, and butyric acid",,10/22/2019,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"SFA Therapeutics, Inc.","610 Old York Rd, Suite 400",,Jenkintown,Pennsylvania,' 19046 ' ,United States,706219,hepatocellular carcinoma,"""gard:0016773""",
747,acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminyl-D-cystenyl-D-arginyl-D-arginyl-D-lysyl-D-asparaginylmaide disulfide,,11/24/2015,treatment of acute myeloid leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genus Oncology, LLC",2458 N. Racine Avenue,,Chicago,Illinois,' 60614 ' ,United States,494415,acute myeloid leukemia,"""gard:0012757""",
748,acetyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-arginyl-D-cysteinyl-D-glutaminyl-D-cysteinyl-D-arginyl-D-arginyl-D-lysyl-Dasparaginylamide disulfide,,2/18/2011,treatment of pancreatic cancer.,Designated/Designation Withdrawn or Revoked,3/14/2014,Not FDA Approved for Orphan Indication,,,,,"Genus Oncology, LLC",2458 N. Racine Avenue,,Chicago,Illinois,' 60614 ' ,United States,333311,,,
749,acetyl-l-carnitine,,7/24/2012,treatment of fragile x syndrome,Designated/Designation Withdrawn or Revoked,5/4/2017,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd.,Suite 500,Gaithersburg,Maryland,' 20878 ' ,United States,373112,fragile x syndrome,"""gard:0006464""",
750,acetyl-l-carnitine (ALC),,3/18/2011,treatment of rett syndrome,Designated/Designation Withdrawn or Revoked,5/4/2017,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd.,Suite 500,Gaithersburg,Maryland,' 20878 ' ,United States,329010,rett syndrome,"""gard:0005696""",
751,acetylcysteine,Acetadote,10/19/2001,for the intravenous treatment of moderate to severe acetaminophen overdose,Designated/Approved,,,"For the use of Acetadote(registered TM) Injection, administered intravenously within 8 to 10 hours after ingestion of a potentially heptotoxic quantity of acetaminophen, to prevent or lessen hepatic injur",1/23/2004,1/23/2011,,"Cumberland Pharmaceuticals, Inc.",209 10th Street South,Suite 332,Nashville,Tennessee,' 37203 ' ,United States,148401,,,
752,Acetylcysteine,,8/13/1987,intravenous treatment of patients presenting with moderate to severe acetaminophen overdose.,Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,P. O. Box 4000,,Princeton,New Jersey,' 08543 ' ,United States,20787,,,
753,acetylcysteine effervescent tablets for oral solution,Cetylev,2/24/2015,preventing hepatic injury from acetaminophin overdose,Designated/Approved,,,Indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion,1/29/2016,,,"Arbor Pharmaceuticals, Inc.",6 Concourse Parkway,Suite 1800,Atlanta,Georgia,' 30328 ' ,United States,401713,,,
754,Aconiazide,,6/20/1988,treatment of tuberculosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Lincoln Diagnostics,P.O. Box 1128,,Decatur,Illinois,' 62525 ' ,United States,28288,tuberculosis,"""gard:0007827""",
755,activated natural killer[aNK]),,3/15/2017,treatment of merkel cell carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"ImmunityBio, Inc.",9920 Jefferson Boulevard,,Culver City,California,' 90232 ' ,United States,562116,noma,"""gard:0004001""",
756,Active calcium sensing receptor antagonist derived from tetrahydropyrazolopyrimidine,,6/13/2017,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Centre Europe, Ltd.",61 Aldwych,,London,England,' ' ,United Kingdom,568816,pulmonary arterial hypertension,"""gard:0007501""",
757,ActRIIB-IgG1),,8/16/2010,treatment of duchenne muscular dystrophy,Designated/Designation Withdrawn or Revoked,7/12/2017,Not FDA Approved for Orphan Indication,,,,,"Acceleron Pharma, Inc.",128 Sidney St.,,Cambridge,Massachusetts,' 02139 ' ,United States,312310,muscular dystrophy,"""gard:0007922""",
758,acyclovir,,9/16/2010,treatment of herpetic keratitis,Designated/Designation Withdrawn or Revoked,9/19/2014,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline,One Franklin Plaza,,Philadelphia,Pennsylvania,' 19101 ' ,United States,313210,,,
759,acyclovir,,5/3/2016,treatment of herpetic keratitis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Cumulus Pharmaceuticals LLC,1712 Pioneer Avenue,Suite 1377,Cheyenne,Wyoming,' 82001 ' ,United States,513615,,,
760,acyclovir,Avaclyr,12/13/2010,treatment of acute herpetic keratitis caused by herpes simplex virus type 1 and 2,Designated/Approved,,,AVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus.,3/29/2019,3/29/2026,AVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus.,Fera Pharmaceuticals,134 Birch Hill Road,,Locust Valley,New York,' 11560 ' ,United States,325010,,,
761,Ad5/3-D24-granulocyte-macrophage colony stimulating factor (GMCSF)-encoding oncolytic adenovirus,,3/17/2014,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,12/20/2023,Not FDA Approved for Orphan Indication,,,,,"Targovax Solutions AS, a subsidiary of Targovax ASA",Vollsveien 19,,Lysaker,,' 1366 ' ,Norway,422814,ovarian cancer,"""gard:0007295""",
762,adagrasib,Krazati,6/7/2021,treatment for kras g12c positive non-small cell lung cancer,Designated/Approved,,,"Treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy",12/12/2022,12/12/2029,"Treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy","Mirati Therapeutics, Inc.",3545 Cray Court,,San Diego,California,' 92121 ' ,United States,756320,small cell lung cancer,"""gard:0009344""",
763,adalimumab,HUMIRA,5/13/2015,treatment of moderate to severe hidradenitis suppurativa (hurley stage 2 and hurley stage 3 disease),Designated/Approved,,,Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.,10/16/2018,10/16/2025,Treatment of moderate to severe hidradenitis suppurativa (HS) in adolescent patients 12 years of age and older.,"AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,446414,,,
764,adalimumab,Humira,3/21/2005,treatment of juvenile rheumatoid arthritis,Designated/Approved,,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.,2/21/2008,2/21/2015,,AbbVie Inc.,1 North Waukegan Road,Bldg. AP-30,North Chicago,Illinois,' 60064 ' ,United States,200905,,,
765,adalimumab,Humira,3/21/2005,treatment of juvenile rheumatoid arthritis,Designated/Approved,,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.,9/30/2014,9/30/2021,Treatment of polyarticular juvenile idiopathic arthritis in patients 2 to less than 4 years of age.,AbbVie Inc.,1 North Waukegan Road,Bldg. AP-30,North Chicago,Illinois,' 60064 ' ,United States,200905,,,
766,adalimumab,Humira,5/13/2014,"treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",Designated/Approved,,,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients",6/30/2016,6/30/2023,"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients","AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,318510,non-infectious anterior uveitis,"""gard:0021260""",
767,adalimumab,HUMIRA,10/19/2006,treatment of pediatric crohn's disease,Designated/Approved,,,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.",9/23/2014,9/23/2021,"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 through 16 years of age with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate.","AbbVie, Inc.",1 N. Waukegan Road,"Bldg AP30, Dept. PA77",North Chicago,Illinois,' 60064 ' ,United States,230306,,,
768,adalimumab,,7/10/2014,treatment of behcet's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Mucora,32b Eisenberg St,,Rehovot 7628810,,' ' ,Israel,436714,,,
769,adalimumab,Humira,5/11/2011,treatment of pediatric patients with ulcerative colitis,Designated/Approved,,,treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. Limitations of Use: The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers.,2/24/2021,2/24/2028,treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. Limitations of Use: The effectiveness of HUMIRA has not been established in patients who have lost response to or were intolerant to TNF blockers.,"AbbVie, Inc.",1 North Waukegan Rd,Dept PA72; Bldg AP30-4,North Chicago,Illinois,' 60064 ' ,United States,340911,,,
770,adalimumab,HUMIRA,5/13/2015,treatment of moderate to severe hidradenitis suppurativa (hurley stage 2 and hurley stage 3 disease),Designated/Approved,,,Treatment of moderate to severe hidradenitis suppurativa,9/9/2015,9/9/2022,Treatment of moderate to severe hidradenitis suppurativa,"AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,446414,,,
771,adalimumab,Humira,5/13/2014,"treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis",Designated/Approved,,,"Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older",9/28/2018,9/28/2025,"Treatment of non-infectious intermediate, posterior, and panuveitis in pediatric patients 2 years of age and older","AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,318510,non-infectious anterior uveitis,"""gard:0021260""",
772,"ADAMTS13, recombinant-krhn",,7/29/2008,"prevention of thrombotic thrombocytopenic purpura including its congential, acquired idiopathic and secondary forms.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,265208,thrombotic thrombocytopenic purpura,"""gard:0016659""",
773,"ADAMTS13, recombinant-krhn",Adzynma,7/29/2008,"treatment of thrombotic thrombocytopenic purpura including its congenital, acquired idiopathic, and secondary forms",Designated/Approved,,,prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP),11/9/2023,11/9/2030,prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP),"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,262208,thrombotic thrombocytopenic purpura,"""gard:0016659""",
774,aden-associated virus vector serotype 9 expressing human a-L-iduronidase,,9/29/2015,treatment of mucopolysaccharidosis type i (msp i).,Designated,,Not FDA Approved for Orphan Indication,,,,,"REGENXBIO, Inc.",9712 Medical Center Drive,Suite 100,Rockville,Maryland,' 20850 ' ,United States,492015,mucopolysaccharidosis,"""gard:0007065""",
775,Adenine,,12/22/2022,treatment of epidermolysis bullosa,Designated,,Not FDA Approved for Orphan Indication,,,,,Energenesis Biomedical Co. Ltd.,"6F-3, No.21, Ln.583, Ruiguang Rd.",Neihu Dist.,Taipei,,' 11492 ' ,Taiwan,917122,,,
776,Adeno Associate Virus carried Multi Characteristic Opsin,,12/30/2020,treatment of stargardt disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Nanoscope Therapeutics Inc.,"1312 Brown Trail, Ste A,",,Bedford,Texas,' 76022 ' ,United States,769620,stargardt disease,"""gard:0000181""",
777,adeno associated viral vector containing human ARSB gene,,3/17/2011,treatment of mucopolysaccharidosis type vi (mps vi; maroteaux-lamy syndrome),Designated,,Not FDA Approved for Orphan Indication,,,,,Fondazione Telethon,Via Guglielmo Saliceto,,5/a,,' ' ,Italy,335011,mucopolysaccharidosis,"""gard:0007065""",
778,adeno associated viral vector serotype rh.10 carrying the human SGSH and SUMF1 cDNAs,,5/6/2013,treatment of mucopolysaccharidosis type iiia (sanfilippo type a syndrome),Designated,,Not FDA Approved for Orphan Indication,,,,,Lysogene,52 rue La Boetie,,Paris,,' ' ,France,395813,mucopolysaccharidosis,"""gard:0007065""",
779,Adeno Associated Virus carried Multi Characteristic Opsin,,10/3/2017,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,Nanoscope Therapeutics Inc.,1312 Brown Trail,,Bedford,Texas,' 76022 ' ,United States,604217,retinitis pigmentosa,"""gard:0005694""",
780,Adeno Associated Virus Serotype 8 Encoding the Collagen Q Gene,,2/24/2020,treatment of collagen q congenital myasthenia,Designated,,Not FDA Approved for Orphan Indication,,,,,Amplo Biotechnology Inc.,"2637 E. Atlantic Blvd., #43644",,Pompano Beach,Florida,' 33062 ' ,United States,725219,,,
781,adeno associated virus with modified transthyretin and sequence encoding factor IX variant gene,,3/14/2014,treatment of hemophilia b,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,421814,hemophilia,"""gard:0010418""",
782,Adeno-associated vector expressing the human lipoprotein lipase protein,,5/21/2007,treatment of lipoprotein lipase deficiency,Designated/Designation Withdrawn or Revoked,6/12/2017,Not FDA Approved for Orphan Indication,,,,,uniQure B.V.,Meibergdreef 61,1100 DA,Amsterdam,,' ' ,Netherlands,240007,,,
783,adeno-associated viral (AAV) vector serotype rh. 10 encoding the human N-sulfoglycosamine sulphohydrolase cDNA (SGSH),,11/18/2015,treatment of mucopolysaccharidosis type iiia or sanfilippo type a syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,LYSOGENE,20 Rue Jacques Dulud,,Neuilly-sur-Seine,Île-de-France,' ' ,France,499115,mucopolysaccharidosis,"""gard:0007065""",
784,Adeno-associated viral 2/5 (AAV2/5) vector expressing the human KCNJ13 gene,,8/9/2021,treatment of inherited retinal dystrophy due to kcnj13 biallelic mutations,Designated,,Not FDA Approved for Orphan Indication,,,,,Hubble Therapeutics,536 Bay Rd.,,Duxbury,Massachusetts,' 02332 ' ,United States,743320,,,
785,adeno-associated viral serotype 2 vector under the regulatory control of a CMV promoter encoding the human tripeptidyl peptidase-1 (hTPP1) cDNA,,3/16/2016,treatment of cln2 disease (neuronal ceroid lipofuscinosis (ncl)) caused by tpp1 deficiency.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Spark Therapeutics, Inc.",3737 Market Street,Suite 1300,Philadelphia,Pennsylvania,' 19104 ' ,United States,518516,neuronal ceroid lipofuscinosis,"""gard:0010739""",
786,adeno-associated viral vector 9 delivering human Glutaryl-CoA Dehydrogenase (GCDH) gene,,5/26/2022,treatment of glutaric aciduria type i,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shanghai Vitalgen BioPharma Co., Ltd.","Building 2, No.11 Jia Lilue Road",Pudong New District,Shanghai,"Municipality, P.R. China",' ' ,China,881422,,,
787,adeno-associated viral vector 9-containing the human heparan-alpha-glucosaminide N-acetyltransferase (HGSNAT) gene (AAV9- HGSNAT),,1/16/2019,treatment of sanfilippo syndrome iiic (also known as mucopolysaccharidosis iiic/mps iiic),Designated,,Not FDA Approved for Orphan Indication,,,,,"Phoenix Nest, Inc.","710 6th Avenue, #2",,Brooklyn,New York,' 11215 ' ,United States,667518,mucopolysaccharidosis,"""gard:0007065""",
788,adeno-associated viral vector containing DNA encoding an RNAi targeting rhodopsin in combination with an adeno-associated viral vector containing DNA encoding a rhodopsin gene,,12/13/2012,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,Spark Therapeutics Ireland Ltd.,Smurfit Institute of Genetics,Trinity College,Dublin 2,,' ' ,Ireland,383412,retinitis pigmentosa,"""gard:0005694""",
789,adeno-associated viral vector containing modified U11 snRNA,,9/15/2010,treatment of duchenne muscular dystrophy.,Designated/Designation Withdrawn or Revoked,10/27/2023,Not FDA Approved for Orphan Indication,,,,,uniQure Inc.,113 Hartwell Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,288409,muscular dystrophy,"""gard:0007922""",
790,Adeno-associated viral vector containing the gene for human coagulation factor IX,,6/13/2001,intramuscular treatment of patients with moderate to severe hemophilia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Avigen, Inc.",1301 Harbor Bay Parkway,,Alameda,California,' 94502 ' ,United States,144401,hemophilia,"""gard:0010418""",
791,Adeno-associated viral vector containing the gene for human coagulation factor IX,,6/13/2001,intrahepatic treatment of patients with moderate to severe hemophilia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Avigen, Inc.",1301 Harbor Bay Parkway,,Alameda,California,' 94502 ' ,United States,145301,hemophilia,"""gard:0010418""",
792,Adeno-Associated Viral Vector encoding C1 Esterase Inhibitor,,8/22/2018,treatment of angioedema due to c1-inhibitor deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Adverum Biotechnologies, Inc.",800 Saginaw Drive,,Redwood City,California,' 94063 ' ,United States,648218,,,
793,Adeno-associated viral vector encoding human multidrug resistance protein 3A (MDR3A),,3/16/2020,treatment of progressive familial intrahepatic cholestasis,Designated,,Not FDA Approved for Orphan Indication,,,,,Vivet Therapeutics SAS,80 boulevard Haussmann,,Paris,Île-de-France,' ' ,France,729019,familial intrahepatic cholestasis,"""gard:0021119""",
794,Adeno-associated viral vector encoding the human ceroid lipofuscinosis neuronal type 2 (CLN2) gene,,7/12/2021,"treatment of neuronal ceroid lipofuscinosis type 2 (cln2) disease, batten disease",Designated,,Not FDA Approved for Orphan Indication,,,,,Lexeo Therapeutics,430 East 29th Str,14th Floor,New York,New York,' 10016 ' ,United States,825521,neuronal ceroid lipofuscinosis,"""gard:0010739""",
795,Adeno-associated viral vector encoding the human frataxin (FXN) gene,,6/24/2021,treatment of friedreich’s ataxia,Designated,,Not FDA Approved for Orphan Indication,,,,,Lexeo Therapeutics,430 East 29th Str,14th Floor,New York,New York,' 10016 ' ,United States,822221,,,
796,Adeno-associated viral vector expressing a cystic fibrosis transmembrane conductance regulator with a partial deletion in the R domain gene,,9/8/2020,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Spirovant Sciences, Inc.",3675 Market Street,2nd Floor,Philadelphia,Pennsylvania,' 19104 ' ,United States,760820,cystic fibrosis,"""gard:0006233""",
797,Adeno-Associated Viral Vector Expressing Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/dCas-based Gene Therapy consisting of a Single Guide RNA targeting the Human D4Z4 Locus and a messenger RNA encoding dCasONYX,,11/14/2023,treatement of facioscapulohumeral muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"EpiCrispr Biotechnologies, Inc.","7000 Shoreline Court, Suite 100",,South San Francisco,California,' 94080 ' ,United States,969623,muscular dystrophy,"""gard:0007922""",
798,Adeno-Associated Viral Vector Expressing Codon-optimized Human PCCA cDNA,,8/26/2020,treatment of propionic acidemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Mayo Clinic,200 First Street SW,,Rochester,Minnesota,' 55905 ' ,United States,759920,propionic acidemia,"""gard:0000467""",
799,Adeno-associated viral vector expressing human acid alpha glucosidase gene,,3/20/2007,treatment of pompe disease,Designated/Designation Withdrawn or Revoked,10/29/2020,Not FDA Approved for Orphan Indication,,,,,"Audentes Therapeutics, Inc.","101 Montgomery St., #2650",,San Francisco,California,' 94104 ' ,United States,237107,,,
800,Adeno-associated viral vector expressing human retinitis pigmentosa GTPase regulator-interacting protein 1 (AAV.Anc80.hRPGRIP1),,11/8/2021,rpgrip1 mutation-associated retinal dystrophies,Designated,,Not FDA Approved for Orphan Indication,,,,,Odylia Therapeutics,1447 Peachtree St. NE,,Atlanta,Georgia,' 30309 ' ,United States,849421,,,
801,adeno-associated viral vector expressing human retinoschisin-1 gene,,5/21/2007,treatment of x-linked juvenile retinoschisis (xlrs).,Designated,,Not FDA Approved for Orphan Indication,,,,,"TeamedOn International, Inc.","2275 Research Blvd, Suite 500",,Rockville,Maryland,' 20850 ' ,United States,238907,,,
802,Adeno-Associated Viral Vector Expressing Low-Density Lipoprotein Receptor,,1/31/2012,treatment of homozygous familial hypercholesterolemia,Designated,,Not FDA Approved for Orphan Indication,,,,,ReGenX Biosciences LLC,"750 17th Street, NW",Suite 1100,Washington,District of Columbia,' 20006 ' ,United States,359411,homozygous familial hypercholesterolemia,"""gard:0010416""",
803,adeno-associated viral vector expressing the human vascular endothelial growth factor gene,,12/31/2015,"treatment of critical limb ischemia in no-option patients where other procedures, grafts, or angioplasty are not indicated",Designated,,Not FDA Approved for Orphan Indication,,,,,"Integene International Holding, LLC",1951 NW 7th Avenue,Suite 300,Miami,Florida,' 33136 ' ,United States,482815,,,
804,Adeno-Associated Viral Vector Serotype 1 containing the human otoferlin gene,,8/11/2021,rescue of hearing function in patients diagnosed with congenital deafness due to biallelic mutations of the otof gene,Designated,,Not FDA Approved for Orphan Indication,,,,,"Decibel Therapeutics, Inc.",1325 Boylston Street,,Boston,Massachusetts,' 02215 ' ,United States,832721,,,
805,adeno-associated viral vector serotype 2 containing the human Rab escort protein 1 gene,,11/5/2014,treatment of choroideremia,Designated,,Not FDA Approved for Orphan Indication,,,,,Biogen,300 Binney Street,,Cambridge,Massachusetts,' 02142 ' ,United States,450514,choroideremia,"""gard:0006061""",
806,adeno-associated viral vector serotype 2 containing the human SLC6A3 gene,,1/24/2023,treatment of dopamine transporter deficiency syndrome (dtds),Designated,,Not FDA Approved for Orphan Indication,,,,,Bloomsbury Genetic Therapies Ltd.,30 Broad Street,Great Cambourne,Cambridge,,' CB23 6HJ ' ,United Kingdom,921422,,,
807,adeno-associated viral vector serotype 2.7m8 containing the chrimsonR-tdTomato gene,,1/25/2017,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,GenSight Biologics,74 Rue du Faubourg Saint-Antoine,,Paris,Île-de-France,' ' ,France,551516,retinitis pigmentosa,"""gard:0005694""",
808,Adeno-associated viral vector serotype 2.NN encoding the human cyclic nucleotide-gated channel subunit A1 gene,,8/17/2023,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,ViGeneron GmbH,Semmelweisstrasse 3,,Planegg,,' D-82152 ' ,Germany,954823,retinitis pigmentosa,"""gard:0005694""",
809,adeno-associated viral vector serotype 3B encoding shortened human ATP7B,,9/7/2017,treatment of wilson's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Vivet Therapeutics SAS,80 boulevard Haussmann,,Paris,Île-de-France,' ' ,France,601817,,,
810,Adeno-associated viral vector serotype 5 containing human ABCA4 gene,,9/30/2008,treatment of stargardt's disease.,Designated/Designation Withdrawn or Revoked,1/30/2014,Not FDA Approved for Orphan Indication,,,,,Fondazione Telethon,Via Guglielmo Saliceto,,5/a,,' ' ,Italy,267908,,,
811,adeno-associated viral vector serotype 5 encoding a microRNA targeted to human huntingtin gene,,9/27/2017,treatment of huntington's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,uniQure Inc.,113 Hartwell Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,525216,,,
812,Adeno-associated viral vector serotype 8 containing cDNA of the human PDE6A protein,,3/9/2020,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,Universitätsklinikum Tübingen (UKT),Geissweg 3,,Tübingen,,' ' ,Germany,728419,retinitis pigmentosa,"""gard:0005694""",
813,adeno-associated viral vector serotype 8 containing the human cardiac calsequestrin gene,,10/2/2014,treatment of catecholaminergic polymorphic ventricular tachycardia,Designated,,Not FDA Approved for Orphan Indication,,,,,Solid Biosciences Inc.,"500 Rutherford Ave, 3rd Floor",,Charlestown,Massachusetts,' 02129 ' ,United States,445614,catecholaminergic polymorphic ventricular tachycardia,"""gard:0004421""",
814,Adeno-associated viral vector serotype 8 containing the human RPGR gene,,9/27/2018,treatment of inherited retinal dystrophies due to defects in the rpgr gene,Designated,,Not FDA Approved for Orphan Indication,,,,,Biogen,300 Binney Street,,Cambridge,Massachusetts,' 02142 ' ,United States,632818,,,
815,adeno-associated viral vector serotype 9 (AAV9) carrying both HEXA and HEXB,,7/17/2020,treatment of gm2 gangliosidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Taysha Gene Therapies,BioCenter at UT Southwestern,2280 Inwood Road,Dallas,Texas,' 75235 ' ,United States,763120,gm2 gangliosidosis,"""gard:0021323""",
816,Adeno-associated viral vector serotype 9 (AAV9) containing human RPE65 gene,,3/30/2023,treatment of inherited retinal disease caused by rpe65 mutations,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cholgene Therapeutics, Inc.","54 Old Highway 22, Suite 220,",,Clinton,New Jersey,' 08809 ' ,United States,915422,,,
817,adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene,,12/27/2012,treatment of mucopolysaccharidosis type iiib (sanfilippo b syndrome),Designated,,Not FDA Approved for Orphan Indication,,,,,"Esteve Pharmaceuticals, S.A.",109 Passeig de la Zona Franca,4th Floor,Barcelona,Catalunya,' ' ,Spain,384712,mucopolysaccharidosis,"""gard:0007065""",
818,Adeno-associated viral vector serotype 9 containing the human NPC1 gene,,9/6/2023,"treatment of niemann-pick disease, type c",Designated,,Not FDA Approved for Orphan Indication,,,,,Bloomsbury Genetic Therapies Ltd.,30 Broad Street,Great Cambourne,Cambridge,,' CB23 6HJ ' ,United Kingdom,960023,,,
819,adeno-associated viral vector serotype 9 containing the human PLA2G6 gene,,9/15/2023,treatment of pla2g6-associated neurodegeneration,Designated,,Not FDA Approved for Orphan Indication,,,,,Bloomsbury Genetic Therapies Ltd.,30 Broad Street,Great Cambourne,Cambridge,,' CB23 6HJ ' ,United Kingdom,960923,pla2g6-associated neurodegeneration,"""gard:0012567""",
820,adeno-associated viral vector serotype 9 encoding a codon-optimized human SLC6A1 transgene,,7/17/2020,treatment of slc6a1-related disorder.,Designated,,Not FDA Approved for Orphan Indication,,,,,Taysha Gene Therapies,BioCenter at UT Southwestern,2280 Inwood Road,Dallas,Texas,' 75235 ' ,United States,766420,,,
821,Adeno-associated viral vector serotype 9 encoding human ATP7B,,12/7/2020,treatment of wilson's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Ultragenyx Pharmaceutical Inc.,840 Memorial Drive,,Cambridge,Massachusetts,' 02139 ' ,United States,784920,,,
822,adeno-associated viral vector serotype LK03 containing the human ornithine transcarbamylase gene,,8/8/2023,treatment of ornithine transcarbamylase deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Bloomsbury Genetic Therapies Ltd.,30 Broad Street,,Great Cambourne,Cambridge,' CB23 6HJ ' ,United Kingdom,952623,ornithine transcarbamylase deficiency,"""gard:0008391""",
823,adeno-associated viral vector type 9 with S1S3 gene encoding S1S3 variant of N-acetylglucosamine-1-phosphotransferase,,10/20/2020,treatment of mucolipidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,M6P Therapeutics,20 S. Sarah Street,,St. Louis,Missouri,' 63108 ' ,United States,774320,mucolipidosis,"""gard:0018975""",
824,Adeno-associated viral-based vector cystic fibrosis gene therapy,,2/15/1995,treatment of cystic fibrosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Targeted Genetics Corporation,"1100 Olive Way, Suite 100",,Seattle,Washington,' 98101 ' ,United States,84994,cystic fibrosis,"""gard:0006233""",
825,adeno-associated virus (AAV) serotype rh.10 expressing beta-galactosidase,,1/30/2017,treatment of gm1 gangliosidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Lysogene, Inc.",245 First Street,18th Floor,Cambridge,Massachusetts,' 02142 ' ,United States,560916,gangliosidosis,"""gard:0012510""",
826,adeno-associated virus (AAV) vector-based gene therapy delivering a therapeutic transgene of RJK002,,10/16/2023,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Rejukon Biopharm Inc.,"Building 22, Baijiatong, Lane 388, Shengrong","Road, Pudong New Area","Shanghai, China",,' ' ,China,966023,amyotrophic lateral sclerosis,"""gard:0005786""",
827,Adeno-associated virus (AAV)-based vector with an engineered capsid serotype SNY001 harboring human phenylalanine hydroxylase (hPAH) cDNA,,9/8/2023,treatment of phenylketonuria (pku),Designated,,Not FDA Approved for Orphan Indication,,,,,"Sanofi US Services, Inc.",55 Corporate Drive,,Bridgewater,New Jersey,' 08807 ' ,United States,958823,phenylketonuria,"""gard:0007383""",
828,adeno-associated virus (AAV2) capsid variant carrying a transgene encoding a codon-optimized human choroideremia (CHM) gene,,10/12/2017,treatment of choroideremia (chm),Designated,,Not FDA Approved for Orphan Indication,,,,,"4D Molecular Therapeutics, Inc.",5980 Horton Street,Suite 460,Emeryville,California,' 94608 ' ,United States,602217,choroideremia,"""gard:0006061""",
829,adeno-associated virus 2/8 expressing human BBS1 gene,,10/16/2020,treatment of bardet-biedl syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Axovia Therapeutics,1209 Orange Street,,Wilmington,Delaware,' 19801 ' ,United States,772920,bardet-biedl syndrome,"""gard:0006866""",
830,adeno-associated virus 2/9 expressing human BBS1 gene,,10/16/2020,treatment of bardet-biedl syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Axovia Therapeutics,1209 Orange Street,,Wilmington,Delaware,' 19801 ' ,United States,773020,bardet-biedl syndrome,"""gard:0006866""",
831,Adeno-associated virus 2/9 expressing human GALT gene (AAV2/9-hGALT),,9/28/2021,treatment of galactosemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jaguar Gene Therapy, LLC",Two Conway Park,"150 N. Field Drive, Suite 300",Lake Forest,Illinois,' 60045 ' ,United States,839921,galactosemia,"""gard:0002424""",
832,"Adeno-Associated Virus 9 human Propionyl-CoA Carboxylase, alpha subunit (AAV9-hPCCA)",,9/27/2021,treatment of propionic acidemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"National Institutes of Health, National Center for Advancing Translational Sciences",9800 Medical Center Dr.,,Rockville,Maryland,' 20850 ' ,United States,838121,propionic acidemia,"""gard:0000467""",
833,adeno-Associated Virus containing human Nuclear Hormone Receptor NR2E3 (AAV-hNR2E3) gene therapy,,7/23/2020,treatment of rho gene mutation associated retinal degenerative disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Ocugen Inc.,5 Great Valley Parkway,Suite 160,Malvern,Pennsylvania,' 19355 ' ,United States,722119,,,
834,Adeno-Associated Virus containing the gene for human Nuclear Hormone Receptor NR2E3 (AAV-hNR2E3),,8/7/2020,treatment of retinal dystrophies due to mutations in pde6b gene,Designated,,Not FDA Approved for Orphan Indication,,,,,Ocugen Inc.,5 Great Valley Parkway,Suite 160,Malvern,Pennsylvania,' 19355 ' ,United States,753920,,,
835,Adeno-Associated Virus containing the gene for human Nuclear Hormone Receptor NR2E3 (AAV-hNR2E3),,8/20/2019,treatment of cep290 mutation associated retinal disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Ocugen Inc.,5 Great Valley Parkway,Suite 160,Malvern,Pennsylvania,' 19355 ' ,United States,697519,,,
836,Adeno-associated virus delivered transgene of follistatin,,9/19/2016,treatment of inclusion body myositis,Designated,,Not FDA Approved for Orphan Indication,,,,,Milo Biotechnology,2322 Delaware Drive,,Cleveland Heights,Ohio,' 44106 ' ,United States,369612,inclusion body myositis,"""gard:0003896""",
837,adeno-associated virus gene therapy comprised of a transgene cassette encoding codon-optimzed human CFTR delta R,,2/5/2024,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"4D Molecular Therapeutics, Inc.",5858 Horton St. Suite 455,,Emeryville,California,' 94608 ' ,United States,986023,cystic fibrosis,"""gard:0006233""",
838,Adeno-Associated Virus Serotype 2 capsid variant (4D-C102) carrying a transgene encoding a codon-optimized human alpha-galactosidase A gene,,3/9/2020,treatment of fabry disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"4D Molecular Therapeutics, Inc.",5858 Horton St. Suite 455,,Emeryville,California,' 94608 ' ,United States,727119,fabry disease,"""gard:0006400""",
839,Adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and human factor 9 gene (SB-FIX),,9/1/2016,treatment of hemophilia b,Designated/Designation Withdrawn or Revoked,8/17/2022,Not FDA Approved for Orphan Indication,,,,,"Sangamo Therapeutics, Inc.",7000 Marina Boulevard,,Brisbane,California,' 94005 ' ,United States,535216,hemophilia,"""gard:0010418""",
840,adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human alpha-L-iduronidase (hIDUA) gene,,1/9/2017,treatment of mucopolysaccharidosis type i (mps i),Designated/Designation Withdrawn or Revoked,8/23/2023,Not FDA Approved for Orphan Indication,,,,,"Sangamo Therapeutics, Inc.",7000 Marina Boulevard,,Brisbane,California,' 94005 ' ,United States,546716,mucopolysaccharidosis,"""gard:0007065""",
841,Adeno-associated virus serotype 2/6 (rAAV2/6) vectors encoding zinc finger nucleases (ZFNs) and the human iduronate 2-sulfatase (hIDS) gene,,2/27/2017,treatment of mucopolysaccharidosis type ii,Designated/Designation Withdrawn or Revoked,8/23/2023,Not FDA Approved for Orphan Indication,,,,,"Sangamo Therapeutics, Inc.",7000 Marina Boulevard,,Brisbane,California,' 94005 ' ,United States,553416,mucopolysaccharidosis,"""gard:0007065""",
842,adeno-associated virus serotype 2/6 encoding a human alpha-galactosidase A cDNA,,10/21/2019,treatment of fabry disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sangamo Therapeutics, Inc.","501 Canal Blvd., Suite A100",,Richmond,California,' 94005 ' ,United States,707219,fabry disease,"""gard:0006400""",
843,adeno-associated virus serotype 5 (AAV5) vector containing the hSERPING cDNA sequence encoding human C1-esterase inhibitor (C1-INH),,12/20/2021,treatment of hereditary angioedema,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,' 94949 ' ,United States,852221,hereditary angioedema,"""gard:0005979""",
844,adeno-associated virus serotype 5 capsid containing the gene for human Nuclear Hormone Receptor NR2E3,,2/8/2019,treatment of nr2e3 mutation-associated retinal degenerative disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Ocugen Inc.,5 Great Valley Parkway,Suite 160,Malvern,Pennsylvania,' 19355 ' ,United States,652918,,,
845,Adeno-Associated Virus Serotype 5 capsid protein containing gene construct encoding human Retinoic Acid Receptor-Related Orphan Receptor Alpha,,4/26/2023,treatment of abca4-associated retinopathies,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ocugen, Inc.",11 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,920122,,,
846,Adeno-associated virus serotype 5 containing the human RDH12 gene,,12/18/2020,treatment of rdh12 mutation associated retinal dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,MeiraGTx UK II Limited,92 Britannia Walk,,London,,' N1 7NQ ' ,United Kingdom,786120,,,
847,Adeno-associated virus serotype 5 encoding human retinal guanylate cyclase 1 gene (AAV5-GUCY2D),,6/7/2021,treatment of retinal disease due to autosomal recessive mutations in the human retinal guanylate cyclase 1 (gucy2d) gene,Designated,,Not FDA Approved for Orphan Indication,,,,,Atsena Therapeutics Inc.,701 W Main Street,Suite 200,Durham,North Carolina,' 27701 ' ,United States,726919,,,
848,adeno-associated virus serotype 6 containing human LAMAN cDNA,,2/15/2018,treatment of alpha-mannosidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Stephen G. Kaler, MD",Eunice Kennedy Shriver NICHD,Porter Neuroscience Research Center II,Bethesda,Maryland,' 20892 ' ,United States,623417,alpha-mannosidosis,"""gard:0006968""",
849,adeno-associated virus serotype 8 expressing Cas9 gene and single guide RNA targeting R135W mutation in Rhodopsin gene,,7/14/2022,treatment of retinal dystrophy associated with r135w mutation in rhodopsin gene,Designated,,Not FDA Approved for Orphan Indication,,,,,"Chigenovo Co., Ltd.","Room S-402, Building 1, Yard 9, Shengshengyuan Road","Zhongguancun Life Science Park, Changping District",Beijing,,' ' ,China,890722,,,
850,Adeno-associated virus serotype 8 vector expressing B domain deleted codon optimized factor VIII,,9/18/2017,treatment of hemophilia a,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,603017,hemophilia,"""gard:0010418""",
851,Adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human SLC13A5 protein.,,1/4/2021,treatment of slc13a5 deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Taysha Gene Therapies,BioCenter at UT Southwestern,2280 Inwood Road,Dallas,Texas,' 75235 ' ,United States,789020,,,
852,Adeno-associated virus serotype 9 carrying the human Fukutin-Related protein gene and target sequence of the miR-208a,,1/31/2022,treatment of autosomal recessive disorder limb girdle muscular dystrophy r9 fkrp-related (lgmdr9),Designated,,Not FDA Approved for Orphan Indication,,,,,Atamyo Therapeutics,"1Bis, rue de l'Internationale",,Évry-Courcouronnes,,' 91000 ' ,France,858921,muscular dystrophy,"""gard:0007922""",
853,adeno-associated virus serotype 9 gene transfer vector expressing human AP4B1 cDNA,,2/16/2021,treatment of hereditary spastic paraplegia 47,Designated,,Not FDA Approved for Orphan Indication,,,,,BlackfinBio Limited,"24R Pleasant St, Unit 2",The Innovation Centre,Broomhall,Sheffield,' UK S14DP ' ,United Kingdom,802120,hereditary spastic paraplegia,"""gard:0006637""",
854,adeno-associated virus serotype 9 vector containing human Iduronate-2-sulfatase transgene,,7/16/2015,treatment of mucopolysaccharidosis type ii (hunter syndrome).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Esteve Pharmaceuticals, S.A.",109 Passeig de la Zona Franca,4th Floor,Barcelona,Catalunya,' ' ,Spain,486315,mucopolysaccharidosis,"""gard:0007065""",
855,Adeno-associated virus serotype 9 vector containing human Nacetylgalactosamine-6-sulfate sulfatase gene,,1/15/2020,treatment of mucopolysaccharidosis type iva (morquio a syndrome),Designated,,Not FDA Approved for Orphan Indication,,,,,"Esteve Pharmaceuticals, S.A.",109 Passeig de la Zona Franca,4th Floor,Barcelona,Catalunya,' ' ,Spain,725119,mucopolysaccharidosis,"""gard:0007065""",
856,Adeno-associated virus serotype 9 vector containing the human lysosome-associated membrane glycoprotein 2 isoform B transgene (AAV9.LAMP2B),,2/1/2019,treatment of danon disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Rocket Pharmaceuticals, Inc.",The Empire State Building,"350 Fifth Avenue, Suite 7530",New York,New York,' 10118 ' ,United States,670218,,,
857,Adeno-associated virus serotype 9 vector encoding the Dok7 protein,,1/23/2020,treatment of dok7 myasthenia,Designated,,Not FDA Approved for Orphan Indication,,,,,Amplo Biotechnology Inc.,"2637 E. Atlantic Blvd., #43644",,Pompano Beach,Florida,' 33062 ' ,United States,720119,,,
858,Adeno-associated virus serotype 9 vector with engineered transgene encoding the human CLN5 gene,,6/3/2020,treatment of neuronal ceroid lipofuscinosis type 5,Designated,,Not FDA Approved for Orphan Indication,,,,,Neurogene Inc.,"535 W 24th St,",5th Floor,New York,New York,' 10011 ' ,United States,740020,neuronal ceroid lipofuscinosis,"""gard:0010739""",
859,Adeno-associated virus serotype 9 virus particle containing viral DNA that includes an expression cassette containing the human NGLY1 gene coding sequence,,5/28/2021,treatment of ngly1 deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Grace Science, LLC",1142 Crane Street,Ste 4,Menlo Park,California,' 94025 ' ,United States,815921,,,
860,adeno-associated virus serotype 9/rh74 containing the human Capn3 gene and a target sequence of cardiac-specific microRNA,,1/4/2024,treatment of autosomal recessive disorder limb girdle muscular dystrophy r1 calpain-related (lgmdr1),Designated,,Not FDA Approved for Orphan Indication,,,,,Atamyo Therapeutics,"1Bis, rue de l'Internationale",,Evry Courcouronnes,,' 9100 ' ,France,980323,muscular dystrophy,"""gard:0007922""",
861,Adeno-associated virus serotype HSC15 expressing human arylsulfatase A,,8/11/2020,treatment of metachromatic leukodystrophy,Designated/Designation Withdrawn or Revoked,7/11/2023,Not FDA Approved for Orphan Indication,,,,,"Homology Medicines, Inc.",1 Patriots Park,,Bedford,Massachusetts,' 01730 ' ,United States,761420,leukodystrophy,"""gard:0006895""",
862,adeno-associated virus serotype rh.10 encoding for the human PKP2 gene (AAVrh.10hPKP2),,12/14/2023,treatment of arrhythmogenic cardiomyopathy due to a pkp2 pathogenic variant,Designated,,Not FDA Approved for Orphan Indication,,,,,"LEXEO Therapeutics, Inc.","345 Park Avenue South, 6th Floor",,New York,New York,' 10010 ' ,United States,975823,,,
863,Adeno-associated virus serotype rh.74 vector containing the human Plakophilin-2a transgene (AAVrh.74-PKP2a),,6/5/2023,treatment of pkp2-associated arrhythmogenic cardiomyopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Rocket Pharmaceuticals, Inc.",9 Cedarbrook Drive,,Cranbury,New Jersey,' 08512 ' ,United States,941023,,,
864,adeno-associated virus serotype rh10 encoding artificial anti-SOD1 miRNA,,6/11/2019,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,uniQure Biopharma BV,Paasheuvelweg 25A,P.O. Box 22506,Amsterdam,,' 1100 DA ' ,Netherlands,688119,amyotrophic lateral sclerosis,"""gard:0005786""",
865,Adeno-associated virus serotype rh10 vector encoding the human factor IX gene,,8/25/2015,treatment of hemophilia b.,Designated,,Not FDA Approved for Orphan Indication,,,,,Ultragenyx Pharmaceuticals,840 Memorial Drive,,Cambridge,Massachusetts,' 02139 ' ,United States,487615,hemophilia,"""gard:0010418""",
866,adeno-associated virus serotype rhesus 10 vector expressing the human galactocerebrosidase (GALC) gene,,2/10/2021,treatment of krabbe disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Forge Biologics, Inc.",3900 Gantz Road,,Grove City,Ohio,' 42123 ' ,United States,803220,krabbe disease,"""gard:0006844""",
867,Adeno-associated virus serotype SLB101 containing the human microdystrophin gene (h-muD5),,1/11/2024,treatment of duchenne muscular dystrophy (dmd),Designated,,Not FDA Approved for Orphan Indication,,,,,Solid Biosciences Inc.,"500 Rutherford Avenue, Third Floor",,Charlestown,Massachusetts,' 02129 ' ,United States,965523,muscular dystrophy,"""gard:0007922""",
868,adeno-associated virus transgene of follistatin,,11/19/2012,treatment of duchennes and becker's muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Milo Biotechnology,2322 Delaware Drive,,Cleveland Heights,Ohio,' 44106 ' ,United States,378512,muscular dystrophy,"""gard:0007922""",
869,adeno-associated virus type 2 encoding human aromatic L-amino acid decarboxylase,,11/14/2017,treatment of aromatic l-amino acid decarboxylase deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,University of California San Francisco,Department of Neurosurgery,1855 Folsom Street,San Francisco,California,' 94103 ' ,United States,613317,aromatic l-amino acid decarboxylase deficiency,"""gard:0000770""",
870,adeno-associated virus type 8 delivering a vector genome with human retinoschisin promoter (RS/IRBP) and the human retinoschisin cDNA (hRS),,11/16/2015,treatment of x-linked retinoschisis,Designated,,Not FDA Approved for Orphan Indication,,,,,"VegaVect, Inc.",6425 Penn Avenue,Suite 200,Pittsburgh,Pennsylvania,' 15206 ' ,United States,496015,x-linked retinoschisis,"""gard:0004690""",
871,adeno-associated virus vector carrying complementary deoxyribonucleic acid encoding the human long-wave-sensitive opsin 1 (AAV.7m8-L-opsin),,1/3/2022,treatment of blue cone monochromacy (x-linked incomplete achromatopsia),Designated,,Not FDA Approved for Orphan Indication,,,,,Blue Gen Therapeutics Foundation,"2108 N Street, Suite N",,Sacramento,California,' 95816 ' ,United States,854121,achromatopsia,"""gard:0015015""",
872,Adeno-associated Virus Vector Containing an Expression Cassette of the Human Factor VIII Transgene,,12/21/2022,treatment of hemophilia a,Designated,,Not FDA Approved for Orphan Indication,,,,,Belief BioMed Limited,"Unit 3A,12/F, Kaiser Centre, No. 18 Centre Street, Sai Ying Pun, Hong Kong, China",,Hong Kong,Hong Kong,' 999077 ' ,China,916022,hemophilia,"""gard:0010418""",
873,adeno-associated virus vector encoding human phenylalanine hydroxylase,,10/21/2019,treatment of phenylketonuria,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,' 94949 ' ,United States,707819,phenylketonuria,"""gard:0007383""",
874,adeno-associated virus vector expressing human 21-hydroxylase,,8/30/2018,treatment of congenital adrenal hyperplasia 21-hydroxylase deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Adrenas Therapeutics Inc,421 Kipling St,,Palo Alto,California,' 94301 ' ,United States,648918,congenital adrenal hyperplasia,"""gard:0001467""",
875,Adeno-associated virus vector expressing human iduronate-2-sulfatase,,3/28/2023,"treatment of mucopolysaccharidosis (mps) ii, also called hunter syndrome",Designated,,Not FDA Approved for Orphan Indication,,,,,"NeuroGT, Inc.",510 Meadowmont Village Circle #289,,Chapel Hill,North Carolina,' 27517 ' ,United States,932823,mucopolysaccharidosis,"""gard:0007065""",
876,adeno-associated virus vector serotype 9 expressing human sulfamidase,,6/1/2011,treatment of mucopolysaccharidosis type iiia (sanfilippo a syndrome).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Esteve Pharmaceuticals, S.A.",109 Passeig de la Zona Franca,4th Floor,Barcelona,Catalunya,' ' ,Spain,341611,mucopolysaccharidosis,"""gard:0007065""",
877,Adeno-associated viruses 8 (AAV8)-based gene therapy vector that expresses B domain-deleted human factor VIII under the control of human liver-specific promoters,,12/19/2023,treatment of hemophilia a,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gritgen Therapeutics Co., Ltd.","Unit E499, 5/F, Lecheng Plaza, Block II, Biomedical Industrial Park,","No. 218 Sangtian Street, Suzhou Industrial Park",Suzhou,Jiangsu Province,' ' ,China,976223,hemophilia,"""gard:0010418""",
878,Adenoassociated virus vector (AAV) carrying a modified AAV serotype 2 backbone and coding sequence of human thymidine phosphorylase preceded by a human thyroxin-binding globulin promoter,,9/4/2014,for the treatment of mitochondrial neurogastrointestinal encephalomyopathy (mngie),Designated,,Not FDA Approved for Orphan Indication,,,,,Columbia University Medical Center,Department of Neurology,"630 West 168th Street, P&S 4-423",New York,New York,' 10032 ' ,United States,441014,mitochondrial neurogastrointestinal encephalomyopathy,"""gard:0009920""",
879,Adenosine,,8/1/1989,for use in conjunction with bcnu in the treatment of brain tumors.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Medco Research, Inc.",8455 Beverly Boulevard,Suite 308,Los Angeles,California,' 90048 ' ,United States,32388,,,
880,Adenosine triphosphate type 1 competitive inhibitor of JAK2 V617F tyrosine kinase,,3/3/2011,"treatment of myeloproliferative disorders (polycythemia vera, essential throbocythemia, and myelofibrosis)",Designated,,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,334211,polycythemia,"""gard:0019466""",
881,Adenoviral vector expressing Herpes simplex virus thymidine kinase gene,,6/17/2005,treatment of malignant brain tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"Candel Therapeutics, Inc.",117 Kendrick Street,,Needham,Massachusetts,' 02494 ' ,United States,206105,,,
882,adenoviral vector expressing human papillomavirus (HPV) 6 and HPV 11 antigens,,3/17/2021,treatment of recurrent respiratory papillomatosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Precigen, Inc.",20358 Seneca Meadows Pkwy,,Germantown,Maryland,' 20876 ' ,United States,805520,recurrent respiratory papillomatosis,"""gard:0000111""",
883,adenoviral vector expressing the E.coli purine nucleoside phosphorylase gene and fludarabine,,6/8/2015,"intratumoral treatment of anatomically accessible oral and pharyngeal cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)",Designated,,Not FDA Approved for Orphan Indication,,,,,"GeoVax, Inc.","1900 Lake Park Drive, Suite 380",,Smyrna,Georgia,' 30080 ' ,United States,443814,,,
884,Adenoviral vector-RheoSwitch Therapeutic System-human interleukin 12 + veledimex,,7/23/2015,treatment of malignant glioma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ziopharm Oncology, Inc.",One First Avenue,Navy Yard Plaza,Boston,Massachusetts,' 02129 ' ,United States,486015,,,
885,adenovirus associated viral vector serotype 5 containing the human RPE65 gene,,3/10/2016,treatment of leber congenital amaurosis,Designated,,Not FDA Approved for Orphan Indication,,,,,MeiraGTx Limited,450 East 29th Street,15th Floor,New York,New York,' 10016 ' ,United States,511115,leber congenital amaurosis,"""gard:0000634""",
886,adenovirus associated viral vector serotype 5 containing the RPGR gene,,11/29/2016,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 US Highway,P.O. Box 300,Raritan,New Jersey,' 08869 ' ,United States,544816,retinitis pigmentosa,"""gard:0005694""",
887,adenovirus associated viral vector serotype 8 containing the human AIPL1 gene,,2/1/2018,"treatment of inherited retinal dystrophy due to defects in aipl1 gene, including leber congenital amaurosis, retinitis pigmentosa, and cone-rod dystrophy",Designated,,Not FDA Approved for Orphan Indication,,,,,MeiraGTx UK II Ltd,92 Britannia Walk,N1 7NQ,London,England,' ' ,United Kingdom,622217,retinitis pigmentosa,"""gard:0005694""",
888,adenovirus associated viral vector serotype 8 containing the human CNGB3 gene,,3/10/2016,treatment of achromatopsia due to mutations in the cngb3 gene.,Designated,,Not FDA Approved for Orphan Indication,,,,,MeiraGTx LLC,"450 East 29th Street, 14th Floor",,New York,New York,' 10016 ' ,United States,511615,achromatopsia,"""gard:0015015""",
889,adenovirus associated viral vector serotype 8 containing the human Cyclic Nucleotide Gated Channel Alpha 3 subunit (CNGA3) gene,,8/7/2018,treatment of achromatopsia due to cnga3 gene mutations.,Designated,,Not FDA Approved for Orphan Indication,,,,,MeiraGTx LLC,"450 East 29th Street, 14th Floor",,New York,New York,' 10016 ' ,United States,648118,achromatopsia,"""gard:0015015""",
890,adenovirus containing a human FAS-c gene,,4/2/2012,treatment of malignant glioma,Designated/Designation Withdrawn or Revoked,9/8/2022,Not FDA Approved for Orphan Indication,,,,,"Vascular Biogenics Ltd, (VBL Therapeutics)",8 HaSatat St.,,Modi’in,,' 7178106 ' ,Israel,364912,,,
891,"adenovirus delta 24-RGD, an oncolytic adenovirus genetically modified for treatment of glioma",,10/1/2014,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"DNAtrix, Inc.",3210 Merryfield Row,,San Diego,California,' 92121 ' ,United States,447214,,,
892,Adenovirus encoding the recombinant CD40 ligand,,4/19/2016,treatment of stage iib through iv melanoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Memgen LLC,12 Greenway Plaza,Suite 1100,Houston,Texas,' 77046 ' ,United States,516716,noma,"""gard:0004001""",
893,"Adenovirus serotype-5 (Ad5) vector that contains a modified non-oncogenic fused early 6 (E6) and early 7 (E7) gene of the human papillomavirus (HPV); (Ad5 [E1-, E2b-]-E6/E7)",,9/4/2014,treatment of human papillomavirus (hpv)-associated head and neck squamous cell carcinoma (hnscc),Designated,,Not FDA Approved for Orphan Indication,,,,,Etubics Corporation,410 West Harrison Street,Suite 100,Seattle,Washington,' 98119 ' ,United States,444514,noma,"""gard:0004001""",
894,adenovirus vaccine encoding reduced expression in immortalized cell protein,,7/14/2015,treatment of mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Momotaro-Gene Inc.,"1-12-1, Yanagi-machi",,Kita-ku,Okayama,' 700-0904 ' ,Japan,485315,,,
895,adenovirus-associated viral vector serotype 5 containing the human pde6B gene,,7/5/2016,treatment of retinitis pigmentosa due to pde6b gene mutations,Designated,,Not FDA Approved for Orphan Indication,,,,,eyeDNA Therapeutics,63 bis avenue Ledru-Rollin,,Paris,,' 75012 ' ,France,527216,retinitis pigmentosa,"""gard:0005694""",
896,adenovirus-associated viral vector serotype 5 containing the human RLBP1 gene,,6/12/2017,treatment of retinitis punctata albescens due to rlbp1 gene mutation,Designated,,Not FDA Approved for Orphan Indication,,,,,"HORAMA, SAS",9 Rue de l'Éperon,,Paris,Île-de-France,' ' ,France,579017,retinitis punctata albescens,"""gard:0016655""",
897,Adenovirus-based vector Factor VIII complementary DNA to somatic cells,,12/15/1999,treatment of hemophilia a.,Designated,,Not FDA Approved for Orphan Indication,,,,,GenStar Therapeutics Corporation,10835 Altman Row,Suite 150,San Diego,California,' 92121 ' ,United States,127499,hemophilia,"""gard:0010418""",
898,ADF-APO-CCN-GUC-K67-MET-MMP-MUC-RGS; HLA class I/II binding tumor associated peptides,,9/28/2012,treatment of renal cell carcinoma in hla-a*2 positive patients,Designated/Designation Withdrawn or Revoked,4/15/2016,Not FDA Approved for Orphan Indication,,,,,Immatics Biotechnologies GmbH,Paul-Ehrlich-Strasse 15,72072,Tubingen,,' ' ,Germany,378812,renal cell carcinoma,"""gard:0013215""",
899,adipose-derived mesenchymal stem cells in a hydrogel sheet,,10/25/2018,treatment of epidermolysis bullosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"Anterogen Co., Ltd.","405, Namsung Plaza",130 Digital-ro,Seoul,Seoul,' ' ,South Korea,658218,,,
900,"adoptive, anti-FLT3 chimeric antigen receptor T cell therapy generated through transduction of autologous T-cells with a self-inactivating human immunodeficiency virus-1 based lentiviral vector",,6/13/2019,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,' 91320 ' ,United States,688619,acute myeloid leukemia,"""gard:0012757""",
901,adult adherent bone marrow-derived multipotent stem cells,,7/6/2012,"treatment of mps-1, including hurler syndrome",Designated,,Not FDA Approved for Orphan Indication,,,,,"Athersys, Inc.",3201 Carnegie Avenue,,Cleveland,Ohio,' 44115 ' ,United States,372812,hurler syndrome,"""gard:0012559""",
902,adult hemogenic endothelial cells,,5/27/2015,treatment of aplastic anemia,Designated,,Not FDA Approved for Orphan Indication,,,,,HemoGenyx LLC,640 Elliott Street,Suite 108,Buffalo,New York,' 14203 ' ,United States,477715,aplastic anemia,"""gard:0020234""",
903,ADXS11-001,,8/12/2013,treatment of hpv-positive associated anal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advaxis, Inc.",305 College Road East,,Princeton,New Jersey,' 08540 ' ,United States,401813,,,
904,aerosolized beractant,,3/11/2013,treatment of respiratory distress syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Beena G. Sood, MD, MS",Wayne State University School of Medicine,Children's Hospital fo %i,Detroit,Michigan,' 48201 ' ,United States,390113,,,
905,Aerosolized pooled immune globulin,,1/3/1989,treatment of respiratory syncytial virus lower respiratory tract disease.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Pediatric Pharmaceuticals, Inc.",718 Bradford Avenue,,Westfield,New Jersey,' 07090 ' ,United States,33688,,,
906,AEZS-108 (LHRH-agonist linked to doxorubicin),,4/30/2010,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,7/27/2017,Not FDA Approved for Orphan Indication,,,,,Aeterna Zentaris,"100 Marketplace, Suite 203",25 Mountainview Blvd,Basking Ridge,New Jersey,' 07920 ' ,United States,304410,ovarian cancer,"""gard:0007295""",
907,afamelanotide,SCENESSE®,7/17/2008,treatment of erythropoietic porphyrias,Designated/Approved,,,SCENESSE® is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP),10/8/2019,10/8/2026,Indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).,Clinuvel Inc.,P. O. Box 94026,,Menlo Park,California,' 94026 ' ,United States,263208,porphyria,"""gard:0010353""",
908,afamelanotide,,12/11/2009,treatment of solar urticaria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Clinuvel, Inc.",30 Broad Street,Suites 1407 and 1408,New York,New York,' 10004 ' ,United States,292009,solar urticaria,"""gard:0019353""",
909,afamelanotide,,5/14/2014,treatment of familial benign chronic pemphigus (hailey-hailey disease),Designated,,Not FDA Approved for Orphan Indication,,,,,"Clinuvel, Inc.",40 Worth Street,10th Floor - Suite 1053,New York,New York,' 10013 ' ,United States,430014,familial benign chronic pemphigus,"""gard:0006559""",
910,afamelanotide,,2/4/2016,treatment of cutaneous variants of porphyria (which includes treatment and prevention of cutaneous manifestations of disease),Designated,,Not FDA Approved for Orphan Indication,,,,,Clinuvel Inc.,40 Worth Street,Suite 1053,New York,New York,' 10013 ' ,United States,502815,porphyria,"""gard:0010353""",
911,afatanib and palbociclib,,11/12/2020,treatment of chordoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc",5616 Hilltop Needmore Rd,,Fuquay Varina,North Carolina,' 27526 ' ,United States,781420,chordoma,"""gard:0001303""",
912,afatinib,Gilotrif,8/3/2015,treatment of non-small cell lung cancer with squamous histology.,Designated/Approved,,,"Treatment of patients with metastatic, squamous, non-small cell lung cancer progressing after platinum-based chemotherapy",4/15/2016,4/15/2023,"Treatment of patients with metastatic, squamous, non-small cell lung cancer progressing after platinum-based chemotherapy","Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,' 06877 ' ,United States,484115,small cell lung cancer,"""gard:0009344""",
913,afatinib,Gilotrif,12/3/2012,treatment of epidermal growth factor receptor (egfr) mutation-positive non-small cell lung cancer (nsclc).,Designated/Approved,,,GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.,1/12/2018,1/12/2025,GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations other than exon 19 deletions or exon 21 (L858R) substiution mutationas as detected by an FDA-approved test.,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,' 06877 ' ,United States,375712,small cell lung cancer,"""gard:0009344""",
914,afatinib,Gilotrif,12/3/2012,treatment of epidermal growth factor receptor (egfr) mutation-positive non-small cell lung cancer (nsclc).,Designated/Approved,,,First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.,7/12/2013,7/12/2020,First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,' 06877 ' ,United States,375712,small cell lung cancer,"""gard:0009344""",
915,afatinib,,6/4/2014,treatment of malignant brain and central nervous system tumors,Designated/Designation Withdrawn or Revoked,1/17/2023,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,' 06877 ' ,United States,433414,,,
916,afatinib,,7/9/2019,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,1/17/2023,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,' 06877 ' ,United States,690419,,,
917,aficamten,,1/5/2021,treatment of symptomatic hypertrophic cardiomyopathy (hcm),Designated,,Not FDA Approved for Orphan Indication,,,,,Cytokinetics Inc.,350 Oyster Point Blvd.,,South San Francisco,California,' 94080 ' ,United States,688819,,,
918,aflibercept,Eylea,7/23/2019,treatment of retinopathy of prematurity,Designated/Approved,,,treatment of retinopathy of prematurity (ROP),2/8/2023,2/8/2030,treatment of retinopathy of prematurity (ROP),"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,694319,retinopathy of prematurity,"""gard:0005695""",
919,agalsidase beta,Fabrazyme,1/19/1988,treatment of fabry's disease.,Designated/Approved,,,For use in patients with Fabry disease to reduce globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types,4/24/2003,4/24/2010,,Genzyme Corporation,One Kendall Square,,Cambridge,Massachusetts,' 02139 ' ,United States,15286,,,
920,agalsidase beta,Fabrazyme,1/19/1988,treatment of fabry's disease.,Designated/Approved,,,treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease,3/11/2021,3/11/2028,treatment of pediatric patients 2 years of age up to patients 8 years of age with confirmed Fabry disease,Genzyme Corporation,One Kendall Square,,Cambridge,Massachusetts,' 02139 ' ,United States,15286,,,
921,aganirsen,,11/7/2016,prevention of corneal graft rejection.,Designated,,Not FDA Approved for Orphan Indication,,,,,Gene Signal International SA,Route Cantonale,,Lausanne,Vaud,' ' ,Switzerland,500515,,,
922,Aggregated polymer of protein magnesium ammonium phospholinoleate-palmitoleate anhydride,,2/4/2020,treatment of schistosomiasis,Designated,,Not FDA Approved for Orphan Indication,,,,,Farmabrasilis,"Avenida Hélio Píres de Camargo, 181",,Valinhos,São Paulo,' ' ,Brazil,721319,schistosomiasis,"""gard:0009687""",
923,aglatimagene besadenovec,,4/8/2024,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Candel Therapeutics, Inc.","117 Kendrick Street, Suite 450",,Needham,Massachusetts,' 02494 ' ,United States,833121,,,
924,AI-RSA,,10/8/1992,treatment of autoimmune uveitis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"AutoImmune, Inc.",128 Spring Street,,Lexington,Massachusetts,' 02173 ' ,United States,60091,uveitis,"""gard:0019549""",
925,alanyl-glutamine dipeptide,,11/6/2017,prevention of complications associated with peritoneal dialysis (pd) treatment in end stage renal disease (esrd),Designated,,Not FDA Approved for Orphan Indication,,,,,Zytoprotec GmbH,28/2 Mariannengasse,,Vienna,Wien,' ' ,Austria,611617,,,
926,Albendazole,Albenza,1/17/1996,treatment of hydatid disease (cystic echinococcosis due to e. granulosus larvae or alveolar echinococcosis due to e. multilocularis larvae).,Designated/Approved,,,"Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.",6/11/1996,6/11/2003,,"Impax Laboratories, LLC",400 Crossing Boulevard,Third Floor,Bridgewater,New Jersey,' 08807 ' ,United States,94195,cystic echinococcosis,"""gard:0002764""",
927,Albendazole,Albenza,1/18/1996,"treatment of neurocysticercosis due to taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocys",Designated/Approved,,,"Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium.",6/11/1996,6/11/2003,,"Impax Laboratories, LLC",400 Crossing Boulevard,Third Floor,Bridgewater,New Jersey,' 08807 ' ,United States,94295,cysticercosis,"""gard:0008194""",
928,Albuterol,,3/12/2002,prevention of paralysis due to spinal cord injury,Designated,,Not FDA Approved for Orphan Indication,,,,,"MotoGen, Inc.",3 Pine View Road,,Mount Kisco,New York,' 10549 ' ,United States,152501,spinal cord injury,"""gard:0019109""",
929,Aldafermin,,12/21/2023,treatment of primary sclerosing cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,NGM Biopharmaceuticals Inc.,333 Oyster Point Boulevard,,South San Francisco,California,' 94080 ' ,United States,976723,sclerosing cholangitis,"""gard:0021868""",
930,Aldesleukin,,11/24/1998,for the treatment non-hodgkin's lymphoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Iovance Biotherapeutics, Inc.","825 Industrial Road, Suite 400",,San Carlos,California,' 94070 ' ,United States,116598,lymphoma,"""gard:0020548""",
931,Aldesleukin,,3/22/1989,treatment of primary immunodeficiency disease associated with t-cell defects.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Iovance Biotherapeutics, Inc.","825 Industrial Road, Suite 400",,San Carlos,California,' 94070 ' ,United States,28988,primary immunodeficiency,"""gard:0019813""",
932,Aldesleukin,,7/31/1998,treatment of acute myelogenous leukemia.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Chiron Corporation,4560 Horton Street,,Emeryville,California,' 94608 ' ,United States,113098,,,
933,Aldesleukin,Proleukin,9/14/1988,treatment of metastatic renal cell carcinoma.,Designated/Approved,,,Treatment of adults (>18 years old) with metastatic renal cell carcinoma.,5/5/1992,5/5/1999,,Chiron Corporation,4560 Horton Street,,Emeryville,California,' 94608 ' ,United States,29088,renal cell carcinoma,"""gard:0013215""",
934,aldesleukin,,7/6/2022,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,ILTOO Pharma,14 rue des Reculettes,,Paris,Ile-de-France,' 75013 ' ,France,854621,amyotrophic lateral sclerosis,"""gard:0005786""",
935,Aldesleukin,Proleukin,9/10/1996,treatment of metastatic melanoma.,Designated/Approved,,,Treatment of adults with metastatic melanoma.,1/9/1998,1/9/2005,,Chiron Corporation,4560 Horton Street,,Emeryville,California,' 94608 ' ,United States,100696,noma,"""gard:0004001""",
936,Aldesleukin,,4/22/2020,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Iovance Biotherapeutics, Inc.","825 Industrial Road, Suite 400",,San Carlos,California,' 94070 ' ,United States,742920,amyotrophic lateral sclerosis,"""gard:0005786""",
937,Aldoxorubicin,,6/29/2011,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"NantCell, Inc.",9920 Jefferson Boulevard,,Culver City,California,' 90232 ' ,United States,339711,soft tissue sarcoma,"""gard:0004898""",
938,aldoxorubicin,,9/24/2014,treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,"NantCell, Inc.",9920 Jefferson Boulevard,,Culver City,California,' 90232 ' ,United States,447014,glioblastoma,"""gard:0002491""",
939,aldoxorubicin,,9/24/2014,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"NantCell, Inc.",9920 Jefferson Boulevard,,Culver City,California,' 90232 ' ,United States,446914,small cell lung cancer,"""gard:0009344""",
940,aldoxorubicin,,9/24/2014,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"NantCell, Inc.",9920 Jefferson Boulevard,,Culver City,California,' 90232 ' ,United States,446814,ovarian cancer,"""gard:0007295""",
941,Aldoxorubicin,,4/18/2011,treatment of adenocarcinoma of the pancreas.,Designated,,Not FDA Approved for Orphan Indication,,,,,"NantCell, Inc.",9920 Jefferson Boulevard,,Culver City,California,' 90232 ' ,United States,337211,noma,"""gard:0004001""",
942,alectinib,Alecensa,1/27/2015,treatment of alk-positive non-small cell lung cancer,Designated/Approved,,,"ALECENSA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.",11/6/2017,11/6/2024,"Treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small-cell lung cancer (NSCLC) as detected by an FDA-approved test, excluding patients who have progressed on or are intolerant to crizotinib.","Hoffmann-La Roche, Inc. (c/o Genentech, Inc.)","1 DNA Way, MS #355E",,South San Francisco,California,' 94080 ' ,United States,462814,small cell lung cancer,"""gard:0009344""",
943,alectinib,Alecensa,1/27/2015,treatment of alk-positive non-small cell lung cancer,Designated/Approved,,,"adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors greater than or equal to 4 cm or node positive), as detected by an FDA-approved test",4/18/2024,4/18/2031,"adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors greater than or equal to 4 cm or node positive), as detected by an FDA-approved test","Hoffmann-La Roche, Inc. (c/o Genentech, Inc.)","1 DNA Way, MS #355E",,South San Francisco,California,' 94080 ' ,United States,462814,small cell lung cancer,"""gard:0009344""",
944,alectinib,Alecensa,1/27/2015,treatment of alk-positive non-small cell lung cancer,Designated/Approved,,,"ALECENSA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.",12/11/2015,12/11/2022,"Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), who have progressed on or are intolerant to crizotinib","Hoffmann-La Roche, Inc. (c/o Genentech, Inc.)","1 DNA Way, MS #355E",,South San Francisco,California,' 94080 ' ,United States,462814,small cell lung cancer,"""gard:0009344""",
945,Alefacept,,12/19/2007,for use as prophylaxis of rejection in patients receiving allogenic solid organ transplants.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,249307,,,
946,alemtuzumab,Campath,10/20/1997,treatment of chronic lymphocytic leukemia.,Designated/Approved,,,The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.,5/7/2001,5/7/2008,,Genzyme Corporation,4545 Horizon Hill Blvd.,,San Antonio,Texas,' 78229 ' ,United States,107197,,,
947,alendronate,,3/31/2003,treatment of osteogenesis imperfecta in pediatric patients 4 years of age and older,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharpe & Dohme Corp.",126 East Lincoln Ave.,RY 33-212,Rahway,New Jersey,' 07065 ' ,United States,166603,osteogenesis imperfecta,"""gard:0001017""",
948,Alendronate disodium,,2/13/2001,treatment of the bone manifestations of gaucher disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Richard J. Wenstrup, M.D.",Division of Human Genetics,Children's Hospital Research Foundation,Cincinnati,Ohio,' 45229 ' ,United States,140000,gaucher disease,"""gard:0008233""",
949,Alfentanil,,8/9/2005,treatment of painful hiv-associated neuropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cinergen, LLC",146 Medinah Drive,,Blue Bell,Pennsylvania,' 19422 ' ,United States,206405,,,
950,Alfentanil,,7/8/2005,management of postherpetic neuralgia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cinergen, LLC",146 Medinah Drive,,Blue Bell,Pennsylvania,' 19422 ' ,United States,206505,,,
951,alfimeprase,,9/20/2012,treatment of st-elevation myocardial infarcted patients who are undergoing primary percutaneous coronary intervention,Designated,,Not FDA Approved for Orphan Indication,,,,,"Niche Therapeutics, LLC",2009 Morton Avenue,,Ann Arbor,Michigan,' 48104 ' ,United States,370512,,,
952,algenpantucel-L,,10/21/2010,treatment of pancreatic cancer.,Designated/Designation Withdrawn or Revoked,12/4/2017,Not FDA Approved for Orphan Indication,,,,,NewLink Genetics Corporation,2503 S. Loop Drive,,Ames,Iowa,' 50010 ' ,United States,315810,,,
953,Alglucerase injection,Ceredase,3/11/1985,for replacement therapy in patients with gaucher's disease type i.,Designated/Approved,,,"Long-term enzyme replacement therapy for children, adolescents and adult patients with a confirmed diagnosis of Type I Gaucher disease who exhibit signs and symptoms that are severe enough to result in one or more of the following conditions: a) moderate-to-severe anemia; b) thrombocytopenia with bleeding tendency; c) bone disease; d) significant hepatomegaly or splenomegaly.",4/5/1991,4/5/1998,,Genzyme Corporation,One Kendall Square,,Cambridge,Massachusetts,' 02139 ' ,United States,5585,,,
954,Alglucerase injection,,7/21/1995,replacement therapy in patients with type ii and iii gaucher's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,One Kendall Square,,Cambridge,Massachusetts,' 02139 ' ,United States,91095,,,
955,alicaforsen,,6/24/2008,treatment of pouchitis.,Designated/Designation Withdrawn or Revoked,12/19/2023,Not FDA Approved for Orphan Indication,,,,,Bensen Therapeutics Limited,Atlantic House,10 Rose & Crown Walk,Saffron Walden,Essex,' ' ,United Kingdom,260808,pouchitis,"""gard:0020510""",
956,Alidornase alfa,,7/21/2020,treatment of sarcoidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"SarcoMed USA, Inc.",1300 Post Oak Boulevard,Suite 760,Houston,Texas,' 77056 ' ,United States,754820,sarcoidosis,"""gard:0007607""",
957,alirocumab,Praluent,6/15/2017,treatment of homozygous familial hypercholesterolemia,Designated/Approved,,,as an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C,4/1/2021,4/1/2028,as an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,580617,homozygous familial hypercholesterolemia,"""gard:0010416""",
958,alisertib,,5/14/2012,treatment of peripheral t-cell lymphoma,Designated/Designation Withdrawn or Revoked,6/14/2016,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,369112,lymphoma,"""gard:0020548""",
959,alisertib,,7/12/2013,treatment of small cell lung cancer,Designated/Designation Withdrawn or Revoked,5/8/2018,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,400313,small cell lung cancer,"""gard:0009344""",
960,alisertib,,9/19/2023,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Puma Biotechnology, Inc.","10880 W. Wilshire Blvd., Suite 2150",,Los Angeles,California,' 90024-4800 ' ,United States,961423,small cell lung cancer,"""gard:0009344""",
961,Alitretinoin,,4/10/1992,treatment of acute promyelocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ligand Pharmaceuticals, Inc.",10275 Science Center Dr.,,San Diego,California,' 92121 ' ,United States,66592,acute promyelocytic leukemia,"""gard:0000538""",
962,Alitretinoin,Panretin,3/24/1998,treatment of aids-related kaposi's sarcoma.,Designated/Approved,,,Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.,2/2/1999,2/2/2006,,Concordia Pharmaceuticals Inc.,Canewood Business Centre,5 Canewood Industrial Park,St Michael,,' BB11005 ' ,Barbados,110998,,,
963,alitretinoin,,1/12/2021,treatment of systemic (non-cutaneous) kaposi sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Galephar Pharmaceutical Research, Inc.",Carr 925 Km 6.1 Bo. Junquito,HC-04 BOX 4540,Humacao,Puerto Rico,' 00791 ' ,United States,708819,kaposi sarcoma,"""gard:0006814""",
964,"all-cis-docosa-4,7,10,13,16,19-hexaenoic acid",,5/21/2014,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"Celavista Mitobiogenesis, S.L.","Edi. SEDE, Parque Cien_fico Universidad UPV",,Leioa,Vizcaya,' 33156 ' ,Spain,432814,retinitis pigmentosa,"""gard:0005694""",
965,allantoin,,11/21/2002,treatment of skin blistering and erosions associated with inherited epidermolysis bullosa,Designated/Designation Withdrawn or Revoked,11/12/2020,Not FDA Approved for Orphan Indication,,,,,"Scioderm, Inc.",1007 Slater Road,Suite 170,Durham,North Carolina,' 27703 ' ,United States,151001,inherited epidermolysis bullosa,"""gard:0018992""",
966,allantoin (5-ureidohydantoin or glyoxyldiureide),,3/28/2024,treatment of epidermolysis bullosa,Designated,,Not FDA Approved for Orphan Indication,,,,,Paradigm Therapeutics,"465 West Coleman Blvd, Suite 202",,Mt. Pleasant,South Carolina,' 29464 ' ,United States,995224,,,
967,allogeneic ABCB5-positive limbal stem cells,,3/28/2019,treatment of limbal stem cell deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,RHEACELL GmbH & Co. KG,Im Neuenheimer Feld 517,,Heidelberg,Baden-Württemberg,' ' ,Germany,664518,limbal stem cell deficiency,"""gard:0020123""",
968,allogeneic anti-CD19 chimeric antigen receptor (CAR)-T cells,,7/2/2018,treatment of acute lymphoblastic leukemia (all),Designated,,Not FDA Approved for Orphan Indication,,,,,Imugene Limited,"Suite 12.01, Level 12","Blight House, 4-6 Bligh Street, Gadigal Country",Sydney,NSW,' 2000 ' ,Australia,606017,acute lymphoblastic leukemia,"""gard:0000522""",
969,Allogeneic bone marrow-derived mesenchymal stromal cells (MSCs),,12/2/2021,treatment of hypoplastic left heart syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Longeveron, Inc.","1951 NW 7th Ave., Suite 520",,Miami,Florida,' 33136 ' ,United States,849521,hypoplastic left heart syndrome,"""gard:0006739""",
970,Allogeneic CAR-T cells that is engineered to express a CAR targeting the B cell maturation antigen (BCMA),,11/22/2023,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Caribou Biosciences, Inc.","2929 7th Street, Suite 105",,Berkeley,California,' 94710 ' ,United States,947023,multiple myeloma,"""gard:0007108""",
971,allogeneic cardiosphere-derived cells,,4/21/2015,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Capricor, Inc.",8840 Wilshire Boulevard,2nd Floor,Beverly HIlls,California,' 90211 ' ,United States,474615,muscular dystrophy,"""gard:0007922""",
972,Allogeneic CD3+ T lymphocytes ex vivo expanded expressing the Vgamma9Vdelta2 T-cell receptor,,1/16/2020,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,TC BioPharm Ltd,"Maxim 1, 2 Parklands Way",,Motherwell,,' ' ,United Kingdom,684619,acute myeloid leukemia,"""gard:0012757""",
973,"allogeneic CD3-depleted, CD56-enriched activated natural killer-cell product",,3/16/2023,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Wugen, Inc.","4260 Forest Park Ave, Suite 100",,St. Louis,Missouri,' 63108-1110 ' ,United States,928922,acute myeloid leukemia,"""gard:0012757""",
974,"allogeneic cord blood cells, ex vivo modulated with 16,16 dimethyl prostaglandin E2 (dmPGE2)",,12/2/2010,"enhancement of stem cell engraftment through ex vivo treatment of human allogeneic hematopoietic stem cells (treatment of neuropenia, thrombocytopenia, lymphopenia, and anemia).",Designated,,Not FDA Approved for Orphan Indication,,,,,"Fate Therapeutics, Inc.",3535 General Atomics Court,,San Diego,California,' 92121 ' ,United States,321810,,,
975,allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 protein,,12/14/2021,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Vor Biopharma,100 Cambridgepark Dr.,Suite 400,Cambridge,Massachusetts,' 02140 ' ,United States,832621,acute myeloid leukemia,"""gard:0012757""",
976,allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting B-cell maturation antigen,,8/10/2020,treatment of multiple myeloma.,Designated/Designation Withdrawn or Revoked,7/17/2023,Not FDA Approved for Orphan Indication,,,,,"CRISPR Therapeutics, Inc.",610 Main Street,,Cambridge,Massachusetts,' 02139 ' ,United States,754120,multiple myeloma,"""gard:0007108""",
977,Allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting CD70 antigen,,6/8/2021,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"CRISPR Therapeutics, Inc.",610 Main Street,,Cambridge,Massachusetts,' 02139 ' ,United States,820421,lymphoma,"""gard:0020548""",
978,allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen-dsat,StrataGraft,5/21/2012,treatment of hospitalized patients with complex skin defects resulting from partial and full thickness skin burns requiring excision and grafting,Designated/Approved,,,Treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns),6/15/2021,6/15/2028,Treatment of adults with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated (deep partial-thickness burns),"Stratatech Corporation, a Mallinckrodt company",505 S. Rosa Road,Suite 169,Madison,Wisconsin,' 53719 ' ,United States,365312,,,
979,Allogeneic cytomegalovirus cytotoxic T lymphocytes,,8/31/2017,treatment of cytomegalovirus viremia and disease in immunocompromised patients,Designated,,Not FDA Approved for Orphan Indication,,,,,Memorial Sloan Kettering Cancer Center (MSKCC),1275 York Ave,,New York,New York,' 10065 ' ,United States,541416,,,
980,Allogeneic enriched variable delta 1 gamma delta T-cell therapy,,3/1/2021,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,GammaDelta Therapeutics Limited,West Works. 195 Wood Lane White City Place,,London,,' W12 7FQ ' ,United Kingdom,803620,acute myeloid leukemia,"""gard:0012757""",
981,allogeneic ex vivo expanded umbilical cord blood cells,,2/1/2010,for use as hematopoietic support in patients with chronic myeloid leukemia,Designated/Designation Withdrawn or Revoked,12/8/2014,Not FDA Approved for Orphan Indication,,,,,Gamida Cell - Teva Joint Venture,PO Box 34670,,,,' ' ,Israel,297609,chronic myeloid leukemia,"""gard:0006105""",
982,allogeneic ex vivo expanded unbilical cord blood cells,,2/1/2010,for use as hematopoietic support in patients with myelodysplastic syndromes,Designated/Designation Withdrawn or Revoked,12/9/2014,Not FDA Approved for Orphan Indication,,,,,Gamida Cell - Teva Joint Venture,PO Box 34670,,,,' ' ,Israel,299009,myelodysplastic syndrome,"""gard:0007132""",
983,Allogeneic ex vivo-generated natural killer cells from CD34+ umbilical cord blood progenitor cells,,9/30/2020,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Glycostem Therapeutics B.V.,Kloosterstraat 9,,AB Oss,,' 5349 ' ,Netherlands,768920,multiple myeloma,"""gard:0007108""",
984,allogeneic ex-vivo expanded placental adherent stromal cells,,2/18/2013,treatment of aplastic anemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Pluri Biotech Ltd.,MATAM Advanced Technology Park,Building # 5,Haifa,,' ' ,Israel,379512,aplastic anemia,"""gard:0020234""",
985,allogeneic ex-vivo expanded placental adherent stromal cells,,8/22/2011,treatment of thromboangiitis obliterans (buerger's disease),Designated,,Not FDA Approved for Orphan Indication,,,,,Pluri Biotech Ltd.,MATAM Advanced Technology Park,Building # 5,Haifa,,' ' ,Israel,348611,,,
986,allogeneic ex-vivo expanded placental adherent stromal cells,,12/29/2015,for the treatment of severe preeclampsia,Designated,,Not FDA Approved for Orphan Indication,,,,,Pluri Biotech Ltd.,MATAM Advanced Technology Park,Building # 5,Haifa,,' ' ,Israel,429114,preeclampsia,"""gard:0012924""",
987,allogeneic ex-vivo generated CD56+CD3-natural killer cells from CD34+ umbilical cord blood progenitor cells,,4/20/2016,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,IPD-Therapeutics BV,(Trading as Glycostem-Therapeutics),Molenstraat 110 5342 CC Oss,,,' ' ,Netherlands,455514,acute myeloid leukemia,"""gard:0012757""",
988,allogeneic Fecal Microbiota,,2/28/2018,treatment of graft-versus-host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,MaaT Pharma,317 Avenue Jean Jaurès,,Lyon-7E-Arrondissement,Auvergne-Rhône-Alpes,' ' ,France,627418,,,
989,Allogeneic gene edited BCMA-directed CAR T cells,,12/18/2019,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,11/21/2022,Not FDA Approved for Orphan Indication,,,,,"Precision BioSciences, Inc.",302 East Pettigrew Street,Suite A-100,Durham,North Carolina,' 27701 ' ,United States,715319,multiple myeloma,"""gard:0007108""",
990,allogeneic gene edited CD20-directed CAR (Chimeric Antigen Receptor) T cells,,9/11/2019,treatment of mantle cell lymphoma,Designated/Designation Withdrawn or Revoked,6/29/2022,Not FDA Approved for Orphan Indication,,,,,"Precision BioSciences, Inc.",302 East Pettigrew Street,Suite A-100,Durham,North Carolina,' 27701 ' ,United States,700519,lymphoma,"""gard:0020548""",
991,Allogeneic gene-edited CD19-directed CAR T cells/azercabtagene zapreleucel,,5/13/2020,treatment of mantle cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Imugene Limited,"Suite 12.01, Level 12","Blight House, 4-6 Bligh Street, Gadigal Country",Sydney,NSW,' 2000 ' ,Australia,738020,lymphoma,"""gard:0020548""",
992,allogeneic hematopoietic stem cell,,2/2/2010,"prevention (reduction) of transplant related mortality (trm, which is caused by graft versus host disease and/or infections) following mismatched (haploidentical) allogeneic hematopoietic stem cell transplantation.",Designated/Designation Withdrawn or Revoked,12/2/2021,Not FDA Approved for Orphan Indication,,,,,Kiadis Pharma Netherlands B.V.,Entrada 231 - 234,,Amsterdam,,' ' ,Netherlands,296709,graft versus host disease,"""gard:0016642""",
993,Allogeneic human aortic endothelial cells cultured in a porcine gelatin matrix,,4/3/2009,prevention of arteriovenous fistula or arteriovenous graft failure in patients with end satge renal disease receiving hemodialysis or preparing for hemodialysis,Designated/Designation Withdrawn or Revoked,3/14/2017,Not FDA Approved for Orphan Indication,,,,,Shire,300 Shire Way,,Lexington,Massachusetts,' 02421 ' ,United States,270108,,,
994,Allogeneic Human Pancreatic Islets of Langerhans,,7/22/2019,treatment of brittle type 1 diabetes,Designated,,Not FDA Approved for Orphan Indication,,,,,Hospital of the University of Pennsylvania (Penn Medicine),3400 Spruce Street,2 Ravdin Courtyard,Philadelphia,Pennsylvania,' 19104 ' ,United States,678919,,,
995,Allogeneic Human Pancreatic Islets of Langerhans,,6/4/2019,treatment of brittle type 1 diabetes,Designated,,Not FDA Approved for Orphan Indication,,,,,"University of California, San Francico",3333 California Street,3333 California Street,San Francisco,California,' 94118 ' ,United States,689619,,,
996,allogeneic human placental hematopoietic stem cell derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP),,2/14/2022,treatment of gastric/gastroesophageal junction cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Celularity Inc.,170 Park Avenue,,Florham Park,New Jersey,' 07932 ' ,United States,862521,,,
997,Allogeneic human retinal pigment epithelial cells on gelatin microcarriers,,7/18/1997,treatment of hoehn and yahr stage 3 and 4 parkinson's disease.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Bayer Healthcare Pharmaceuticals, Inc.",100 Bayer Boulevard,,Whippany,New Jersey,' 07981 ' ,United States,105797,,,
998,Allogeneic JC polyomavirus-specific T-cell therapy,,10/19/2022,treatment of progressive multifocal leukoencephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Cellevolve Bio Inc.,535 Mission St.,,San Francisco,California,' 94105 ' ,United States,906022,progressive multifocal leukoencephalopathy,"""gard:0007468""",
999,allogeneic mesenchymal stem cells derived neuronal regeneration promoting cells,,2/17/2022,treatment of charcot-marie-tooth disease type 1,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cellatoz Therapeutics, Inc.","17, Pangyo-ro 228 beon-gil, Bundang-gu",,Seongnam-si,Gyeonggi-do,' 13487 ' ,South Korea,862921,charcot-marie-tooth disease type 1,"""gard:0012433""",
1000,Allogeneic mesenchymoangioblast-derived mesenchymal stem cells,,3/26/2018,treatment of acute graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Cynata Therapeutics Limited,"Level 3, 62 Lygon Street",,Carlton,Victoria,' ' ,Australia,632018,graft versus host disease,"""gard:0016642""",
1001,Allogeneic motor neuron progenitor cells derived from human embryonic stem cells,,1/17/2014,treatment of amyotrophic lateral sclerosis,Designated/Designation Withdrawn or Revoked,11/22/2016,Not FDA Approved for Orphan Indication,,,,,Caladrius Biosciences,110 Allen Road,2nd Floor,Basking Ridge,New Jersey,' 07920 ' ,United States,415013,amyotrophic lateral sclerosis,"""gard:0005786""",
1002,Allogeneic multi-tumor-associated antigen-specific T cell product,,4/28/2020,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Marker Therapeutics, Inc.",3200 Southwest Freeway Suite 2240,,Houston,Texas,' 77027 ' ,United States,736320,acute myeloid leukemia,"""gard:0012757""",
1003,"Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpes virus-6, Epstein Barr virus, and adenovirus",,9/29/2021,treatment for virus-associated hemorrhagic cystitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"AlloVir, Inc.",2925 Richmond Avenue,Suite 1200,Houston,Texas,' 77098 ' ,United States,747920,,,
1004,allogeneic natural killer cells that originated from human cord blood mononuclear cells,,11/6/2023,treatment of patients with refractory/relapsed after at least 3 prior multiple myeloma treatment regimens or bcma based car-t therapy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cure Therapeutics, Inc.",114-6 Central town-ro,"Yeongtong-gu, Suwon-si, Gyeonggi-do",,,' 16506 ' ,South Korea,947723,multiple myeloma,"""gard:0007108""",
1005,Allogeneic peripheral blood mononuclear cells sensitized against patient alloantigens by mixed lymphocyte culture,,6/13/1997,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Applied Immunotherapeutics, LLC",14132 E. Firestone Boulevard,,Santa Fe Springs,California,' 90670 ' ,United States,104997,,,
1006,allogeneic processed thymus tissue-agdc,Rethymic,8/15/2003,treatment of congenital athymia,Designated/Approved,,,immune reconstitution in pediatric patients with congenital athymia,10/8/2021,10/8/2028,immune reconstitution in pediatric patients with congenital athymia,Enzyvant Therapeutics GmbH,Viaduktstrasse 8,CH-4051,Basel,,' ' ,Switzerland,172603,,,
1007,Allogeneic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor,,9/1/2004,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neurotech USA, Inc.",6 Blackstone Valley Place,,Lincoln,Rhode Island,' 02865 ' ,United States,189704,retinitis pigmentosa,"""gard:0005694""",
1008,allogeneic skin-derived ABCB5-positive mesenchymal stem cells,,5/1/2019,treatment of epidermolysis bullosa,Designated,,Not FDA Approved for Orphan Indication,,,,,RHEACELL GmbH & Co. KG,Im Neuenheimer Feld 517,,Heidelberg,Baden-Württemberg,' ' ,Germany,682719,,,
1009,allogeneic T cells genetically modified to express anti-B7-H3 chimeric antigen receptor (CAR),,2/16/2023,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"T-MAXIMUM Pharmaceutical (Suzhou) Co., Ltd.","Unit 318, Building A4, Biomedical Industrial Park, 218","Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu",Suzhou,Jiangsu,' ' ,China,925122,,,
1010,"Allogeneic T-cells cultured with anti-CD3 and IL-2; transduced with retroviral vector (SFCMM-3), expressing herpes simplex 1 virus-thymidine kinase (HSV-TK) and truncated low affinity nerve growth factor receptor; selected with anti-low affinity nerve gro",,1/28/2005,immunotherapy for acceleration of t-cell reconstitution in patients undergoing allogeneic hematopoietic stem cell transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,MolMed S.p.A.,Via Olgettina 58,,Milan,,' ' ,Italy,192304,,,
1011,Allogeneic Teazeled receptor-activated human white blood cells,,5/28/2024,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Second Life Therapeutics, Inc","180 Varick street, 6th floor",,New York,New York,' 10014 ' ,United States,1003624,,,
1012,Allogeneic Turbo Chimeric Antigen Receptor (Turbocar) T Cells Targeting B Cell Maturation Antigen,,4/26/2022,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Allogene Therapeutics,210 E Grand Ave,,South San Francisco,California,' 94080 ' ,United States,873022,multiple myeloma,"""gard:0007108""",
1013,Allogeneic umbilical cord blood (UCB) cell therapy product consisting of two cell fractions (CD34 enriched and CD34 depleted) derived from the same UCB unit,,4/11/2018,for the enhancement of cell engraftment in patients receiving hematopoietic stem cell transplantation (hsct),Designated,,Not FDA Approved for Orphan Indication,,,,,Magenta Therapeutics,"100 Technology Square, 5th Floor",,Cambridge,Massachusetts,' 02139 ' ,United States,635618,,,
1014,allogeneic umbilical cord mesenchymal stem cells,,5/3/2023,treatment of ocular graft-versus-host-disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Guangdong ProCapZoom Biosciences Co., Ltd.","Room 1901-1903, Unit 1, Building 2, No. 11, Guangpuzhong Road, Huangpu District",,Guangzhou,Guangdong,' 510000 ' ,China,932723,,,
1015,Allogeneic umbilical cord-derived mesenchymal stem cell drug,,8/5/2022,prevention of bronchopulmonary dysplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,Meribank Biotech Co. Ltd.,"7F., No. 2, Ln. 7, Wuquan Rd., Wugu Dist.",,New Taipei City,,' 248 ' ,Taiwan,893622,bronchopulmonary dysplasia,"""gard:0005962""",
1016,"allogeneic, expanded, engineered human umbilical cord E4ORF1+ CD31+ cells (E-CEL UVEC® cells)",,9/30/2020,prevention (reduction) of morbidity and mortality associated with hematopoietic stem cell transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,"Angiocrine Bioscience, Inc.",11575 Sorrento Valley Road,Suite 217,San Diego,California,' 92121 ' ,United States,767620,,,
1017,Allogenic Chimeric Antigen Receptor T Cells Targeting B Cell Maturation Antigen (BCMA),,8/10/2021,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Allogene Therapeutics,210 E Grand Ave,,South San Francisco,California,' 94080 ' ,United States,831421,multiple myeloma,"""gard:0007108""",
1018,Allogenic donor peripheral blood mononuclear cell-derived natural killer cells,,4/22/2024,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ingenium Therapeutics, Inc.","2FL, 17, Techno 2-ro",,Yuseong-gu,Daejeon,' 34012 ' ,South Korea,997224,acute myeloid leukemia,"""gard:0012757""",
1019,allogenic fetal mesenchymal stem cells,,5/6/2022,treatment of osteogenesis imperfecta,Designated,,Not FDA Approved for Orphan Indication,,,,,BOOST Pharma Aps,c/o Bio Innovation Institute,Ole Maaløes Vej 3,Copenhagen N,,' 2200 ' ,Denmark,873722,osteogenesis imperfecta,"""gard:0001017""",
1020,allogenic retinal epithelial cells transfected with plasmid vector expressing ciliary neurotrophic growth factor,,7/24/2012,treatment of macular telangiectasia type 2 (mactel),Designated,,Not FDA Approved for Orphan Indication,,,,,"Neurotech Pharmaceuticals, Inc.",900 Highland Corporate Drive,"Building #1, Suite #101",Cumberland,Rhode Island,' 02864 ' ,United States,368812,,,
1021,Allogenic spinal motor neuron precursor cell,,11/22/2023,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,"XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd","99 Jingu Road (Phase 3, Zone B), Building 3, Unit 201",Suzhou Industrial Park District,Suzhou,Jiangsu,' 215000 ' ,China,972223,amyotrophic lateral sclerosis,"""gard:0005786""",
1022,allogeniec Human Pancreatic Islets of Langerhans,,5/1/2019,treatment of brittle type 1 diabetes,Designated,,Not FDA Approved for Orphan Indication,,,,,"Diabetes Research Institute & Cell Transplant Center, Univ of Miami",1450 NW 10th Avenue,,Miami,Florida,' 33136 ' ,United States,685919,,,
1023,allopregnanolone,,4/20/2014,treatment of status epilepticus,Designated,,Not FDA Approved for Orphan Indication,,,,,Sage Therapeutics,215 First Street,Suite 220,Cambridge,Massachusetts,' 02142 ' ,United States,426114,,,
1024,allopregnanolone,,7/12/2013,"treatment of neimann-pick disease, type c",Designated/Designation Withdrawn or Revoked,6/26/2019,Not FDA Approved for Orphan Indication,,,,,"La Jolla Pharmaceutical Company, Inc.",10182 Telesis Court,"6th Floor, Suite 600",San Diego,California,' 92121 ' ,United States,399013,,,
1025,Allopurinol riboside,,12/4/1985,1. treatment of chagas' disease 2. treatment of cutaneous and visceral leishmaniasis,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Burroughs Wellcome Company,3030 Cornwallis Road,P.O. Box 12700,Research Triangle Park,North Carolina,' 27709 ' ,United States,10685,leishmaniasis,"""gard:0006881""",
1026,Allopurinol sodium,Aloprim for Injection,10/16/1992,"management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.",Designated/Approved,,,"Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.",5/17/1996,5/17/2003,,"Catalytica Pharmaceuticals, Inc",PO Box 1887,,Greenville,North Carolina,' 27835 ' ,United States,68392,lymphoma,"""gard:0020548""",
1027,Allopurinol sodium,,11/9/1987,ex-vivo preservation of cadaveric kidneys for transplantation,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Burroughs Wellcome Company,3030 Cornwallis Road,,Research Triangle Pk,North Carolina,' 27709 ' ,United States,22787,,,
1028,allosteric MEK 1/2 inhibitor,,11/3/2020,treatment of neurofibromatosis type 1,Designated,,Not FDA Approved for Orphan Indication,,,,,Pasithea Therapeutics Corp.,1111 Lincoln Road Suite 500,,Miami Beach,Florida,' 33139 ' ,United States,780120,neurofibromatosis type 1,"""gard:0007866""",
1029,Aloxistatin,,5/10/2022,treatment of gm1-gangliosidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,DORPHAN SA,Chemin de l’Eglise 7,,Epalinges,Vaud,' CH-1066 ' ,Switzerland,874322,gangliosidosis,"""gard:0012510""",
1030,alpelisib,Vijoice,11/18/2019,treatment of pik3ca-related overgrowth spectrum,Designated/Approved,,,Treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy,4/5/2022,4/5/2029,Treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,710819,,,
1031,Alpelisib,,3/21/2023,treatment of lymphatic malformations,Designated,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936-1080 ' ,United States,930022,,,
1032,alpelisib,Vijoice,11/18/2019,treatment of pik3ca-related overgrowth spectrum,Designated/Approved,,,treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy,4/24/2024,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,710819,,,
1033,"Alpha 1 anti-trypsin (AAT), human alpha 1 anti-trypsin, alpha 1 proteinase inhibitor",,7/25/2023,treatment of charcot-marie-tooth disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Ageronix SA,4 rue du Tir-au-Canon,,Carouge (Geneva),,' 1227 ' ,Switzerland,950423,,,
1034,alpha melanotropin,,9/2/2010,treatment of chronic beryllium disease,Designated,,Not FDA Approved for Orphan Indication,,,,,mondoBIOTECH Laboratories AG,Herrengasse 21,,Furstentum Liechtenstein,,' ' ,Germany,308910,chronic beryllium disease,"""gard:0000867""",
1035,alpha tocopherol and ascorbic acid,,3/28/2019,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,GenCo Pharmaceuticals LLC,371 Lake Surprise Road,,Cold Spring,New York,' 10516 ' ,United States,678719,fragile x syndrome,"""gard:0006464""",
1036,alpha-1 proteinase inhibitor (human),,7/31/2017,prevention of graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kamada, Ltd.",2 Holtzman Street,,Rehovot,,' ' ,Israel,590417,graft versus host disease,"""gard:0016642""",
1037,alpha-1 proteinase inhibitor (human),,10/23/2014,treatment of graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Kamada Ltd.,2 Holtsman Street,,Rehovot,Center District,' ' ,Israel,448014,graft versus host disease,"""gard:0016642""",
1038,alpha-1 proteinase inhibitor (human),,7/28/2011,treatment of patients with recent onset (,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kamada, Ltd.",2 Holtzman Street,,Rehovot,,' ' ,Israel,344111,,,
1039,Alpha-1-acid glycoprotein,,3/5/2004,treatment of cocaine overdose,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Bio Products Laboratory,Dagger Lane,,Borehamwood,,' ' ,United Kingdom,173103,,,
1040,Alpha-1-acid glycoprotein,,3/17/2004,treatment of tricyclic antidepressant poisoning,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Bio Products Laboratory,Dagger Lane,,Borehamwood,,' ' ,United Kingdom,172803,,,
1041,Alpha-1-antitrypsin (recombinant DNA Origin),,1/1/1984,as supplementation therapy for alpha-1-antitrypsin deficiency in the zz phenotype population.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Chiron Corporation,4560 Horton Street,,Emeryville,California,' 94608 ' ,United States,283,alpha-1-antitrypsin deficiency,"""gard:0005784""",
1042,alpha-CD39 IgG4 monoclonal antibody,,3/29/2021,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Coherus BioSciences, Inc.","333 Twin Dolphin drive, Suite 600",,Redwood City,California,' 94065 ' ,United States,808821,,,
1043,Alpha-galactosidase A,,6/22/1998,long-term enzyme replacement therapy for the treatment of fabry disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shire Human Genetic Therapies, Inc.",700 Main Street,,Cambridge,Massachusetts,' 02139 ' ,United States,112998,fabry disease,"""gard:0006400""",
1044,Alpha-galactosidase A,,7/20/1990,treatment of fabry's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Desnick, Robert J. M.D.",The Mount Sinai School Of Medicine,"Fifth Avenue at 100th Street, Box 1203",New York,New York,' 10029 ' ,United States,47190,,,
1045,Alpha-galactosidase A,,6/17/1991,treatment of alpha-galactosidase a deficiency (fabry's disease).,Designated,,Not FDA Approved for Orphan Indication,,,,,"David Calhoun, Ph.D.",Department of Chemistry,Convent Avenue & 138th Street,New York,New York,' 10031 ' ,United States,58691,,,
1046,alpha-L-iduronidase (IDUA) - ricin transport subunit B (RTB) lectin protein fusion,,7/1/2022,treatment of mucopolysaccharidosis type i (mps-i),Designated,,Not FDA Approved for Orphan Indication,,,,,BioStrategies LC,PO Box 2428,State University,Jonesboro,Arkansas,' 72467 ' ,United States,886222,mucopolysaccharidosis,"""gard:0007065""",
1047,Alpha-melanocyte stimulating hormone,,8/19/1997,prevention and treatment of intrinsic acute renal failure due to ischemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"National Institute of Diabetes, and Digestive and Kidney Diseases","National Institutes of Health, 31 Center Drive MSC","Building 31, Room 9N-222",Bethesda,Maryland,' 20892 ' ,United States,106497,,,
1048,Alpha-tocopherol quinone,,3/28/2006,treatment of inherited mitochondrial respiratory chain diseases,Designated,,Not FDA Approved for Orphan Indication,,,,,Penwest Pharmaceuticals Company,39 Old Ridgebury Road,Suite 11,Danbury,Connecticut,' 06810 ' ,United States,215205,,,
1049,alpha-tocotrienol quinone,,10/21/2010,treatment of inherited mitochondrial respiratory chain diseases,Designated/Designation Withdrawn or Revoked,9/2/2020,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,' 07080 ' ,United States,316310,,,
1050,alpha1 proteinase inhibitor (human),,1/29/2010,treatment of emphysema secondary to congenital alpha1-antitrypsin deficiency.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Grifols Therapeutics, Inc.",79 TW Alexander Drive,,Research Triangle Park,North Carolina,' 27709 ' ,United States,294309,,,
1051,Alpha1-antitrypsin(human),,4/3/2008,treatment of bronchiectasis,Designated,,Not FDA Approved for Orphan Indication,,,,,Kamada Ltd.,7 Sapir Street,,Ness Ziona,,' ' ,Israel,256508,,,
1052,Alpha1-proteinase inhibitor (human),,11/24/1999,for slowing the progression of emphysema in alpha1-antitrypsin deficient patients.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,CSL Behring L.L.C.,1020 First Ave.,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,124299,,,
1053,alpha1-proteinase inhibitor (human),,4/6/2012,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Grifols Therapeutics, Inc.",8368 US 70 BUS Hwy W.,,Clayton,North Carolina,' 27520 ' ,United States,368112,cystic fibrosis,"""gard:0006233""",
1054,alpha1-proteinase inhibitor (human),,2/20/2009,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,CSL Behring LLC,1020 First Avenue,P. O. Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,272908,cystic fibrosis,"""gard:0006233""",
1055,alpha1-proteinase inhibitor (human),,3/3/2015,treatment of type 1 diabetes mellitus patients with residual beta-cell function.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Grifols Therapeutics, Inc.",8368 US Business Hwy 70 West,,Clayton,North Carolina,' 27520 ' ,United States,418913,,,
1056,Alpha1-proteinase inhibitor (human),Prolastin,12/7/1984,for replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.,Designated/Approved,,,For chronic replacement therapy of individuals having congenital deficiency of alpha1- proteinase inhibitor with clinically demonstrable panacinar emphysema.,12/2/1987,12/2/1994,,Bayer Corporation,"Pharmaceutical Division, Biological Products",400 Morgan Lane,New Haven,Connecticut,' 06516 ' ,United States,3084,,,
1057,Alpha1-Proteinase Inhibitor (Human),,12/22/2004,inhalation therapy for the treatment of congential deficiency of alpha1-proteinase inhibitor.,Designated,,Not FDA Approved for Orphan Indication,,,,,Kamada Ltd.,7 Sapir Street,,Ness Ziona,,' ' ,Israel,190804,,,
1058,Alpha1-Proteinase Inhibitor (Human),,9/1/2004,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Kamada Ltd.,7 Sapir Street,,Ness Ziona,,' ' ,Israel,190704,cystic fibrosis,"""gard:0006233""",
1059,alpibectir and ethionamide fixed-dose combination drug,,11/6/2023,treatment of tuberculosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Bioversys SAS,c/o Institut Pasteur de Lille,1 Rue du Professuer Calmette,Lille,France,' 59000 ' ,France,968323,tuberculosis,"""gard:0007827""",
1060,Alprostadil,,10/20/1993,"treatment of severe peripheral arterial occlusive disease (critical limb ischemia) in patients where other procedures, grafts or angioplasty, are not indicated.",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Schwarz Pharma, Inc.",P.O. Box 2038,,Milwaukee,Wisconsin,' 53201 ' ,United States,70092,,,
1061,alprostadil,,11/6/2023,prevention of ischemia/reperfusion injury resulting from solid organ transplantation.,Designated,,Not FDA Approved for Orphan Indication,,,,,Institut Georges Lopez,Parc Tertiaire du Bois Dieu,1 Allee des Chevreuils,Lissieu,,' 69380 ' ,France,968723,,,
1062,Alrizomadlin,,7/14/2021,treatment of stage iii-iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,' 20850 ' ,United States,826021,noma,"""gard:0004001""",
1063,alrizomadlin,,3/17/2022,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,' 20850 ' ,United States,869522,neuroblastoma,"""gard:0007185""",
1064,alteplase,,1/27/2003,treatment of intraventricular hemorrhage associated with intracerebral hemorrhage,Designated,,Not FDA Approved for Orphan Indication,,,,,"Daniel F. Hanley, MD",Johns Hopkins University,"600 N. Wolfe St., Jefferson 1-109",Baltimore,Maryland,' 21287 ' ,United States,163502,,,
1065,alteplase,,10/20/2014,treatment of plastic bronchitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kathleen A Stringer, PharmD, FCCP - Professor",University of %i,428 Church St.,Ann Arbor,Michigan,' 48109 ' ,United States,431414,plastic bronchitis,"""gard:0021835""",
1066,altiratinib,,8/19/2014,treatment of glioblastoma multiforme.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Deciphera Pharmaceuticals, LLC",643 Massachusetts,Suite 200,Lawrence,Kansas,' 66044 ' ,United States,441714,glioblastoma,"""gard:0002491""",
1067,Altretamine,Hexalen,2/9/1984,treatment of advanced adenocarcinoma of the ovary.,Designated/Approved,,,Single agent palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent based combination.,12/26/1990,12/26/1997,,"Medimmune Oncology, Inc.",One Tower Bridge,"100 Front Street, Suite 400",West Conshohocken,Pennsylvania,' 19428 ' ,United States,983,noma,"""gard:0004001""",
1068,Alvelestat,,10/25/2021,treatment of alpha-1 antitrypsin deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Mereo Biopharma 4 Limited,1 Cavendish Place,,London,,' W1G 0QF ' ,United Kingdom,804020,,,
1069,Alvocidib,,4/13/2007,teatment of b-cell chronic lymphocytic leukemia (b-cll) or prolymphocytic leukemia arising from cll.,Designated/Designation Withdrawn or Revoked,1/25/2022,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Dainippon Pharma Oncology, Inc.",640 Memorial Drive,,Cambridge,Massachusetts,' 02139 ' ,United States,239607,b-cell chronic lymphocytic leukemia,"""gard:0006104""",
1070,alvocidib,,4/21/2014,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,1/25/2022,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Dainippon Pharma Oncology, Inc.",640 Memorial Drive,,Cambridge,Massachusetts,' 02139 ' ,United States,426214,acute myeloid leukemia,"""gard:0012757""",
1071,Amantadine HCl,,7/20/2015,treatment of levodopa-induced dyskinesia,Designated/Designation Withdrawn or Revoked,8/17/2018,Not FDA Approved for Orphan Indication,,,,,Osmotica Pharmaceutical Corporation,"Regulatory, Clinical Operations & Legal","Lumina Station #2, Suite 209-A",Wilmington,North Carolina,' 28403 ' ,United States,257608,,,
1072,Amantadine hydrochloride,Gocovri,4/9/2015,treatment of levodopa-induced dyskinesia,Designated/Approved,,,treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy with or without concomitant dopminergic medications,8/24/2017,8/24/2024,treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy with or without concomitant dopminergic medications,"Adamas Pharmaceuticals, Inc.",1900 Powell Street,Suite 750,Emeryville,California,' 94608 ' ,United States,413213,,,
1073,amatuximab,,9/28/2012,treatment of mesothelioma,Designated/Designation Withdrawn or Revoked,10/22/2021,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.,155 Tice Boulevard,,Woodcliff Lake,New Jersey,' 07677 ' ,United States,241607,,,
1074,ambrisentan,,12/23/2009,treatment of idiopathic pulmonary fibrosis,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 East Blaine Street,,Seattle,Washington,' 98102 ' ,United States,266908,idiopathic pulmonary fibrosis,"""gard:0008609""",
1075,ambrisentan,Letairis,7/16/2004,treatment of pulmonary arterial hypertension,Designated/Approved,,,Treatment of pulmonary arterial hypertension (WHO group I) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening,6/15/2007,6/15/2014,,Gilead Colorado,7575 West 103rd Avenue,Suite 102,Westminister,Colorado,' 80021 ' ,United States,183604,pulmonary arterial hypertension,"""gard:0007501""",
1076,ambrisentan/tadalafil fixed combination,,8/22/2016,treatment of pulmonary arterial hypertension,Designated/Designation Withdrawn or Revoked,8/15/2017,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,528316,pulmonary arterial hypertension,"""gard:0007501""",
1077,ambroxol,,6/29/2011,treatment of gaucher disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Zywie LLC,155 Lambert Drive,,Princeton,New Jersey,' 08540 ' ,United States,262308,gaucher disease,"""gard:0008233""",
1078,amifampridine,Firdapse,11/12/2009,treatment of lambert-eaton myasthenic syndrome,Designated/Approved,,,Treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older,9/29/2022,,,"Catalyst Pharmaceuticals, Inc.",355 Alhambra Circle,Suite 1250,Coral Gables,Florida,' 33134 ' ,United States,295309,lambert-eaton myasthenic syndrome,"""gard:0006851""",
1079,amifampridine,Firdapse,11/12/2009,treatment of lambert-eaton myasthenic syndrome,Designated/Approved,,,Treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults,11/28/2018,11/28/2025,Treatment of Lambert-Eaton myasthenic syndrome (LEMS),"Catalyst Pharmaceuticals, Inc.",355 Alhambra Circle,Suite 1250,Coral Gables,Florida,' 33134 ' ,United States,295309,lambert-eaton myasthenic syndrome,"""gard:0006851""",
1080,amifampridine,,12/18/1990,treatment of lambert-eaton myasthenic syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Catalyst Pharmaceuticals, Inc.",355 Alhambra Circle,Suite 801,Coral Gables,Florida,' 33134 ' ,United States,51590,lambert-eaton myasthenic syndrome,"""gard:0006851""",
1081,amifampridine phosphate,,8/31/2016,treatment of myasthenia gravis,Designated/Designation Withdrawn or Revoked,3/14/2024,Not FDA Approved for Orphan Indication,,,,,"Catalyst Pharmaceuticals, Inc.",355 Alhambra Circle,Suite 1250,Coral Gables,Florida,' 33134 ' ,United States,534916,myasthenia gravis,"""gard:0007122""",
1082,amifampridine phosphate,,3/3/2015,treatment of congenital myasthenic syndromes,Designated/Designation Withdrawn or Revoked,3/14/2024,Not FDA Approved for Orphan Indication,,,,,Catalyst Pharmaceuticals,"(dba Catalyst Pharmaceutical Partner, Inc)",Suite 1500,Coral Gables,Florida,' 33134 ' ,United States,464814,congenital myasthenic syndrome,"""gard:0011902""",
1083,Amifostine,Ethyol,5/12/1998,reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.,Designated/Approved,,,"Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands.",6/24/1999,6/24/2006,,"Medimmune Oncology, Inc.",One Tower Bridge,"100 Front Street, Suite 400",West Conshohocken,Pennsylvania,' 19428 ' ,United States,111698,,,
1084,Amifostine,Ethyol,5/30/1990,for use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.,Designated/Approved,,,To reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer.,12/8/1995,12/8/2002,,"Medimmune Oncology, Inc.",One Tower Bridge,"100 Front Street, Suite 400",West Conshohocken,Pennsylvania,' 19428 ' ,United States,42789,noma,"""gard:0004001""",
1085,Amifostine,,5/30/1990,for use as a chemoprotective agent for cisplatin in the treatment of metastatic melanoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.",Attn: Merav Edan,45 Great Valley Parkway,Malvern,Pennsylvania,' 19355 ' ,United States,42989,noma,"""gard:0004001""",
1086,Amifostine,,11/24/1998,for the reduction of the incidence and severity of toxicities associated with cisplatin administration.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.",Attn: Merav Edan,45 Great Valley Parkway,Malvern,Pennsylvania,' 19355 ' ,United States,116298,,,
1087,Amifostine,,5/30/1990,for use as a chemoprotective agent for cyclophosphamide in the treatment of advanced ovarian carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.",Attn: Merav Edan,45 Great Valley Parkway,Malvern,Pennsylvania,' 19355 ' ,United States,42889,noma,"""gard:0004001""",
1088,Amifostine,,10/4/1999,treatment of myelodysplastic syndromes.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Clinigen, Inc.",Attn: Merav Edan,45 Great Valley Parkway,Malvern,Pennsylvania,' 19355 ' ,United States,128399,myelodysplastic syndrome,"""gard:0007132""",
1089,amikacin sulfate,,1/5/2015,management of cystic fibrosis patients with pseudomonas aeruginosa lung infections,Designated,,Not FDA Approved for Orphan Indication,,,,,PlumeStars s.r.l.,Via Lago Scuro11,,Parma,,' ' ,Italy,458114,cystic fibrosis,"""gard:0006233""",
1090,Amiloride HCl solution for inhalation,,7/18/1990,treatment of cystic fibrosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Glaxo Wellcome Research and Development,5 Moore Drive,PO Box 13398,Research Triangle Park,North Carolina,' 27709 ' ,United States,48190,cystic fibrosis,"""gard:0006233""",
1091,Aminocaproic acid,,1/6/1995,for the topical treatment of traumatic hyphema of the eye.,Designated,,Not FDA Approved for Orphan Indication,,,,,Eastern Virginia Medical School,Department of Ophthalomology,"880 Kempsville Road, Suite 2500",Norfolk,Virginia,' 23502 ' ,United States,83294,,,
1092,Aminolevulinic acid hydrochloride,,9/9/2020,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"SonALAsense, Inc.",2600 Tenth Street,Suite 435,Berkeley,California,' 94710 ' ,United States,761520,,,
1093,aminolevulinic acid hydrochloride,,3/20/2007,treatment of esophageal dysplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,"DUSA Pharmaceuticals, Inc.",25 Upton Place,,Wilmington,Massachusetts,' 01887 ' ,United States,236807,,,
1094,Aminosalicylate sodium,,4/6/1993,treatment of crohn's disease.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Syncom Pharmaceuticals, Inc.",66 Hanover Road,,Florham Park,New Jersey,' 07932 ' ,United States,68592,,,
1095,Aminosalicylic acid,Paser Granules,2/19/1992,treatment of tuberculosis infections,Designated/Approved,,,Treatment of tuberculosis,6/30/1994,6/30/2001,,Jacobus Pharmaceutical Company,37 Cleveland Lane,P.O. Box 5290,Princeton,New Jersey,' 08540 ' ,United States,65792,tuberculosis,"""gard:0007827""",
1096,Aminosidine,,9/9/1994,treatment of visceral leishmaniasis (kala-azar).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kanyok, Thomas P. Pharm.D.",University of Illinois at Chicago College of Pharm,833 South Wood Street (m/c886) Rm. 176,Chicago,Illinois,' 60612 ' ,United States,83194,leishmaniasis,"""gard:0006881""",
1097,Aminosidine,,11/15/1993,treatment of mycobacterium avium complex.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kanyok, Thomas P. Pharm.D.",University Of Illinois At Chicago College of Pharm,833 South Wood Street (m/c886) Rm. 176,Chicago,Illinois,' 60612 ' ,United States,77193,,,
1098,Aminosidine,,5/14/1993,treatment of tuberculosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kanyok, Thomas P. Pharm.D.",University Of Illinois At Chicago College of Pharm,833 South Wood Street (m/c886) Rm. 176,Chicago,Illinois,' 60612 ' ,United States,74693,tuberculosis,"""gard:0007827""",
1099,aminosidine,,3/29/2005,treatment of visceral leishmaniasis,Designated,,Not FDA Approved for Orphan Indication,,,,,The Institute for One World Health,50 California Street,Suite 500,San Francisco,California,' 94111 ' ,United States,201705,leishmaniasis,"""gard:0006881""",
1100,Amiodarone,,8/17/1993,treatment of incessant ventricular tachycardia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Academic Pharmaceuticals, Inc.",21 N. Skokie Valley Highway,Suite G3,Lake Bluff,Illinois,' 60044 ' ,United States,70292,,,
1101,Amiodarone HCl,Cordarone,3/16/1994,for the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.,Designated/Approved,,,For initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy.,8/3/1995,8/3/2002,,Wyeth-Ayerst Laboratories,P.O. Box 8299,,Philadelphia,Pennsylvania,' 19101 ' ,United States,77293,,,
1102,Amisodin,,7/21/2021,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"PRG S&T Co., Ltd","9F, Sejung Tower, 252, Geumjeong-ro, Geumjeong-gu",,Busan,Busan,' 46274 ' ,South Korea,827921,amyotrophic lateral sclerosis,"""gard:0005786""",
1103,Amitriptyline,,5/27/2020,treatment of erythromelalgia,Designated,,Not FDA Approved for Orphan Indication,,,,,Algo Therapeutix S.A.S,49 rue des Nouvelles,,Suresnes,,' ' ,France,739620,,,
1104,amitriptyline and ketamine,,1/19/2010,treatment of postherpetic neuralgia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immune Pharmaceuicals, Inc.",Alexandria Center for LIfe Sciences,430 E. 29th St.,New York,New York,' 10016 ' ,United States,288809,,,
1105,ammonium 21-tungsto-9-antimoniate,,7/17/1985,treatment of acquired immunodeficiency syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Rhone-Poulenc Rorer Pharm.,500 Arcola Road,,Collegeville,Pennsylvania,' 19426 ' ,United States,7785,acquired immunodeficiency,"""gard:0021359""",
1106,Ammonium tetrathiomolybdate,,1/31/1994,treatment of wilson's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pipex Pharmaceuticals, Inc.",3930 Varsity Drive,,Ann Arbor,Michigan,' 48108 ' ,United States,79993,,,
1107,ammonium tetrathiomolybdate,,5/5/2008,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pipex Pharmaceuticals, Inc.",3930 Varsity Drive,,Ann Arbor,Michigan,' 48108 ' ,United States,254007,idiopathic pulmonary fibrosis,"""gard:0008609""",
1108,"Ammonium trichloro [dioxoethylene-O,O') tellurium (IV)",,11/9/1987,treatment of acquired immunodeficiency syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"NPDC-AS101, Inc.",783 Jersey Avenue,,New Brunswick,New Jersey,' 08901 ' ,United States,22387,acquired immunodeficiency,"""gard:0021359""",
1109,Amnion-derived Cellular Cytokine Solution,,4/26/2022,treatment of necrotizing enterocolitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Noveome Biotherapeutics, Inc.",100 Technology Drive,Suite 200,Pittsburgh,Pennsylvania,' 15219 ' ,United States,874022,necrotizing enterocolitis,"""gard:0009767""",
1110,Amonafide L-malate,,12/20/2006,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Xanthus Pharmaceuticals, Inc.",An Antisoma Group Company,300 Technology Square,Cambridge,Massachusetts,' 02139 ' ,United States,227506,acute myeloid leukemia,"""gard:0012757""",
1111,amphotericin B,,9/15/2010,treatment of visceral leishmaniasis.,Designated,,Not FDA Approved for Orphan Indication,,,,,iCo Therapeutics Inc.,760-777 Hornby Street,,Vancouver,,' ' ,Canada,315310,leishmaniasis,"""gard:0006881""",
1112,Amphotericin B,,12/26/2023,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"cystetic Medicines, Inc.",1403 Old Farm Road,,Champaign,Illinois,' 61821 ' ,United States,903022,cystic fibrosis,"""gard:0006233""",
1113,Amphotericin B inhalation powder,,12/15/2005,"prevention of pulmonary fungal infections in patients at risk for aspergillosis due to immunosuppressive therapy including those receiving organ or stem cell transplants, or treated with chemotherapy or radiation for hematologic malignancies",Designated/Designation Withdrawn or Revoked,12/14/2018,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,150 Industrial Road,,San Carlos,California,' 94070 ' ,United States,210805,aspergillosis,"""gard:0005856""",
1114,Amphotericin B lipid complex,,9/23/1996,treatment of invasive sporotrichosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"The Liposome Company, Inc.",One Research Way,,Princeton,New Jersey,' 08540 ' ,United States,97696,sporotrichosis,"""gard:0007692""",
1115,Amphotericin B lipid complex,Abelcet,12/5/1991,treatment of invasive fungal infections.,Designated/Approved,,,Treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy.,10/18/1996,10/18/2003,,"Liposome Company, Inc.",One Research Way,,Princeton,New Jersey,' 08540 ' ,United States,57891,,,
1116,Amphotericin B lipid complex,,8/21/1996,treatment of invasive protothecosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"The Liposome Company, Inc.",One Research Way,,Princeton,New Jersey,' 08540 ' ,United States,97796,,,
1117,Amphotericin B lipid complex,,5/6/1996,treatment of invasive coccidioidomycosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"The Liposome Company, Inc.",One Research Way,,Princeton,New Jersey,' 08540 ' ,United States,97396,coccidioidomycosis,"""gard:0009525""",
1118,Amphotericin B lipid complex,,6/27/1996,treatment of invasive candidiasis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"The Liposome Company, Inc.",One Research Way,,Princeton,New Jersey,' 08540 ' ,United States,96996,,,
1119,Amphotericin B lipid complex,,5/6/1996,treatment of invasive zygomycosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"The Liposome Company, Inc.",One Research Way,,Princeton,New Jersey,' 08540 ' ,United States,97096,zygomycosis,"""gard:0010224""",
1120,Ampreloxetine,,5/9/2023,treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Theravance Biopharma Ireland Limited,Ten Earlsfort Terrace,,Dublin 2,,' D02 T380 ' ,Ireland,936523,multiple system atrophy,"""gard:0007079""",
1121,amrubicin,,3/10/2008,treatment of small cell lung cancer,Designated/Designation Withdrawn or Revoked,1/20/2016,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,9225 Indian Creek Parkway,Suite 900,Overland Park,Kansas,' 66210 ' ,United States,255307,small cell lung cancer,"""gard:0009344""",
1122,Amsacrine,,12/7/1984,treatment of acute adult leukemia.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Warner-Lambert Company,2800 Plymouth Road,,Ann Arbor,Michigan,' 48106 ' ,United States,4584,,,
1123,"Amyl nitrite, sodium nitrite, sodium thiosulfate",,12/18/2006,treatment of cyanide poisoning,Designated,,Not FDA Approved for Orphan Indication,,,,,"Akorn, Inc.",2500 Millbrook Drive,,Buffalo Grove,Illinois,' 60089 ' ,United States,232506,cyanide poisoning,"""gard:0021938""",
1124,amylopectin,,3/24/2015,treatment of glycogen storage disease types ia and ib,Designated,,Not FDA Approved for Orphan Indication,,,,,"Voltera Pharmaceuticals, LLC",9322 SW 41st Ln,,Gainesville,Florida,' 32608 ' ,United States,469515,glycogen storage disease,"""gard:0018973""",
1125,an acetic acid diester of 2-deoxy-D-glucose,,8/29/2022,treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,"Moleculin Biotech, Inc.","5300 Memorial Drive, Suite 950",,Houston,Texas,' 77007 ' ,United States,896722,glioblastoma,"""gard:0002491""",
1126,"an ADC drug against CLDN18.2, containing a recombinant humanized anti-CLDN18.2 IgG1 monoclonal antibody and linker-payload MC-VC-PAB-MMAE",,11/30/2021,treatment of cholangiocarcinoma (intrahepatic bile duct cancer),Designated,,Not FDA Approved for Orphan Indication,,,,,LaNova Medicines Limited,"999 Cailun Road, Building 1, Floor 5",,Shanghai,,' 201203 ' ,China,849221,cholangiocarcinoma,"""gard:0009304""",
1127,an adeno-associated viral vector containing a codon-optimised human factor IX gene (AAV5-hFIXco),,12/22/2011,treatment of hemophilia b,Designated,,Not FDA Approved for Orphan Indication,,,,,"uniQure, B.V.",Meiberdreef 61,1100 DA,Amsterdam,,' ' ,Netherlands,357511,hemophilia,"""gard:0010418""",
1128,an adeno-associated viral vector delivering human FIX Padua gene,,12/14/2021,treatment of hemophilia b,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shanghai Vitalgen BioPharma Co., Ltd.","Building 2, No.11 Jia Lilue Road,",Pudong New District,Shanghai,,' CN201210 ' ,China,850921,hemophilia,"""gard:0010418""",
1129,An Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing FIX Padua (AAV8.ss-3xCRM8-TTRFIX_R338Lopt),,1/13/2020,treatment of hemophilia b,Designated/Designation Withdrawn or Revoked,10/20/2022,Not FDA Approved for Orphan Indication,,,,,Baxalta US Inc.,300 Shire Way,,Lexington,Massachusetts,' 02421 ' ,United States,717719,hemophilia,"""gard:0010418""",
1130,An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8,,7/31/2020,treatment of neuronal ceroid lipofuscinosis type 7,Designated/Designation Withdrawn or Revoked,3/22/2024,Not FDA Approved for Orphan Indication,,,,,Neurogene Inc.,"535 W 24th St,",5th Floor,New York,New York,' 10011 ' ,United States,751620,neuronal ceroid lipofuscinosis,"""gard:0010739""",
1131,An Adeno-associated Virus Vector Containing an Expression Cassette of the Human Factor IX Transgene,,8/15/2022,treatment of hemophilia b,Designated,,Not FDA Approved for Orphan Indication,,,,,Belief BioMed Limited,"Unit 3A,12/F, Kaiser Centre, No. 18 Centre Street, Sai Ying Pun, Hong Kong, China",,Hong Kong,Hong Kong,' 999077 ' ,China,895722,hemophilia,"""gard:0010418""",
1132,"an allogeneic, fratricide-resistant genetically modified T cell transduced with a 2nd generation 4-1BB-CD3z chimeric antigen receptor targeting human CD7",,12/8/2021,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Wugen, Inc.","4340 Duncan Ave, Suite 302",,St. Louis,Missouri,' 63110-1110 ' ,United States,849721,acute lymphoblastic leukemia,"""gard:0000522""",
1133,an anti-Claudin 18.2 and 4.1BB Bispecific Antibody,,3/1/2022,treatment of gastric cancer (gc) including cancer of the gastroesophageal junction (gej).,Designated,,Not FDA Approved for Orphan Indication,,,,,"I-Mab Biopharma, Co., Ltd","88 Shangke Road, Pudong New District","Suite 802, West Tower, Omni Vision Tech Park",Shanghai,Shangai,' 201210 ' ,China,828821,,,
1134,an anti-Claudin 18.2 monoclonal antibody conjugated with MMAE payload,,4/7/2022,"treatment of gastric cancer, including gastroesophageal junction",Designated,,Not FDA Approved for Orphan Indication,,,,,AstraZeneca,16192 Coastal Highway,,Lewes,Delaware,' 19958 ' ,United States,871122,,,
1135,An anti-Claudin18.2 monoclonal antibody conjugated with Duostatin-5 (DUO-5) payload,,1/22/2024,"treatment of gastric cancer, including cancer of the gastroesophageal junction (gej)",Designated,,Not FDA Approved for Orphan Indication,,,,,"Shandong Boan Biotechnology Co., Ltd.","No.39 Keji Avenue,",,Yantai Hi-Tech Zone,Shandong Province,' ' ,China,983523,,,
1136,"an antibiotic combination product consisting of 3 antimicrobial agents (clarithromycin, rifabutin, and clofazimine).",,10/13/2020,treatment for nontuberculous mycobacteria disease,Designated,,Not FDA Approved for Orphan Indication,,,,,RedHill Biopharma Ltd.,21 Ha'arba'a St.,,Tel-Aviv,,' 64739 ' ,Israel,770820,,,
1137,an antibody drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE,,5/26/2021,"treatment of gastric cancer, including gastroesophageal junction adenocarcinoma.",Designated,,Not FDA Approved for Orphan Indication,,,,,LaNova Medicines Limited,"999 Cailun Road, Building 1, Floor 5",,Shanghai,,' 201203 ' ,China,819121,noma,"""gard:0004001""",
1138,an antibody drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE,,5/26/2021,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,LaNova Medicines Limited,"999 Cailun Road, Building 1, Floor 5",,Shanghai,,' 201203 ' ,China,819021,,,
1139,"an antibody oligonucleotide conjugate (AOC), comprised of a human transferrin receptor 1 (TfR1) targeting, effector function null, humanized IgG1 antibody (AV01mAb) conjugated to one small interfering RNA (siRNA).",,7/21/2021,treatment of myotonic dystrophy type 1 (dm1),Designated,,Not FDA Approved for Orphan Indication,,,,,Avidity Biosciences,"10975 N. Torrey Pines Road, Ste. 150",,La Jolla,California,' 92037 ' ,United States,806820,myotonic dystrophy,"""gard:0010419""",
1140,"An antibody oligonucleotide conjugate, comprised of a human transferrin receptor 1 targeting, effector function null, humanized IgG1 antibody and a phosphorodiamidate morpholino oligonucleotide targeting exon 44 of the human DMD pre-mRNA",,8/10/2023,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Avidity Biosciences, Inc.","10578 Science Center Drive, Suite 125",,San Diego,California,' 92121 ' ,United States,952823,muscular dystrophy,"""gard:0007922""",
1141,"An antibody oligonucleotide conjugate, comprised of a human transferrin receptor 1 targeting, effector function null, humanized IgG1 antibody, a MCC maleimide linker, and a double-stranded siRNA oligonucleotide targeting DUX4",,2/13/2023,treatment of facioscapulohumeral muscular dystrophy (fshd),Designated,,Not FDA Approved for Orphan Indication,,,,,"Avidity Biosciences, Inc.","10578 Science Center Drive, Suite 125",,San Diego,California,' 92121 ' ,United States,924122,muscular dystrophy,"""gard:0007922""",
1142,an antibody-drug conjugate (ADC) (mAb/N-acetyl-y-calicheamicin),,7/29/2021,treatment of small cell lung cancer (sclc),Designated/Designation Withdrawn or Revoked,7/21/2023,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,829621,small cell lung cancer,"""gard:0009344""",
1143,an antisense oligonucleotide that has been developed to target expanded CAG repeats in messenger ribonucleic acid (mRNA),,7/27/2021,treatment of huntington’s disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Vico Therapeutics B.V.,J. H. Oortweg 21,,Leiden,,' 2333 CH ' ,Netherlands,828721,,,
1144,"An asymmetric immunoglobulin G1 (IgG1)-based, B-cell maturation antigen (BCMA) x CD3 T-cell bispecific monoclonal antibody",,8/28/2019,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,CELGENE INTERNATIONAL II SARL,c/o Celgene Corporation,86 Morris Avenue,Summit,New Jersey,' 07901 ' ,United States,698119,multiple myeloma,"""gard:0007108""",
1145,an autologous cell therapy product manufactured from tumor-infiltrating lymphocytes (TILs) that have been harvested from surgically resected tumor tissue and expanded ex vivo.,,4/26/2021,treatment of malignant melanoma stages iib to iv,Designated/Designation Withdrawn or Revoked,3/23/2023,Not FDA Approved for Orphan Indication,,,,,"Instil Bio, Inc.",3963 Maple Avenue,Suite 350,Dallas,Texas,' 75219 ' ,United States,812121,noma,"""gard:0004001""",
1146,An autologous chimeric antigen receptor (CAR) T-cell therapy engineered to express an antibody-derived single-chain variable fragment that recognizes C-type lectin-like molecule-1 (CLL-1),,9/27/2022,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,"Kite Pharma, Inc.",2400 Broadway,,Santa Monica,California,' 90404 ' ,United States,900522,acute myeloid leukemia,"""gard:0012757""",
1147,an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR,,5/17/2021,treatment of follicular lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC","920 U.S. Highway 202, P.O. Box 300",,Raritan,New Jersey,' 08869-0602 ' ,United States,814421,lymphoma,"""gard:0020548""",
1148,an autologous T-cell immunotherapy (ECT204),,1/31/2022,treatment of hepatocellular carcinoma (hcc),Designated,,Not FDA Approved for Orphan Indication,,,,,"Eureka Therapeutics, Inc.","5858 Horton Street, Suite 170",,Emeryville,California,' 94608 ' ,United States,859721,hepatocellular carcinoma,"""gard:0016773""",
1149,an autologous T-cell immunotherapy (ET140203),,10/7/2022,treatment of hepatoblastoma (hb),Designated,,Not FDA Approved for Orphan Indication,,,,,"Eureka Therapeutics, Inc.","5858 Horton Street, Suite 170",,Emeryville,California,' 94608 ' ,United States,902522,hepatoblastoma,"""gard:0002657""",
1150,an autologous T-cell immunotherapy (ET140203),,1/27/2022,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Eureka Therapeutics, Inc.","5858 Horton Street, Suite 170",,Emeryville,California,' 94608 ' ,United States,859621,hepatocellular carcinoma,"""gard:0016773""",
1151,"an autologous, epigenetically modified cell therapy product which contains expanded tumor-infiltrating lymphocytes (TIL)",,11/6/2023,treatment of stage iib-iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Lyell Immunopharma, Inc.",201 Haskins Way,,South San Francisco,California,' 94080 ' ,United States,925822,noma,"""gard:0004001""",
1152,"an encapsulated, engineered human ARPE-19 cell line that constitutively expresses the native human IL-2 cytokine (hIL 2)fcx v",,6/5/2023,treatment of mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Avenge Bio, Inc.",22 Strathmore Road,STE 241,Natick,Massachusetts,' 01760 ' ,United States,941423,,,
1153,"an IgG1 humanized antibody directed against Carcinoembryonic Antigen-related Cell Adhesion Molecule (CEACAM)1, 3 and 5",,2/22/2023,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Ymmunobio AG,Gartengasse 12,,Riehen,,' 4125 ' ,Switzerland,925422,hepatocellular carcinoma,"""gard:0016773""",
1154,an IgG1(Immunoglobulin G1) subclass antibody targeting CCR8(C-C Motif Chemokine Receptor 8),,12/18/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,LaNova Medicines Limited,"5th floor, No. 1 building",No.999 Cailun Road,Shanghai,Shanghai,' 201203 ' ,China,941123,,,
1155,An immunoglobulin subclass 1 (IgG1) human monoclonal antibody that targets the Marburg virus (MARV) glycoprotein,,11/22/2022,treatment of marburg virus disease (mvd) caused by infection with marburg virus (marv).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mapp Biopharmaceutical, Inc.",4921 Directors Place,Suite 100,San Diego,California,' 92121 ' ,United States,911222,,,
1156,"an injectable cancer vaccine consisting of a mixture of three synthetic peptides (alrefimotide, tapderimotide, and riletamotide)",,10/5/2023,treatment of mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Ultimovacs ASA,Ullernchausséen 64,,Oslo,,' 0379 ' ,Norway,964623,,,
1157,an oral inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1),,8/11/2023,treatment of mantle cell lymphoma (mcl),Designated,,Not FDA Approved for Orphan Indication,,,,,"Schrödinger, Inc.","1540 Broadway, 24th Floor",,New York,New York,' 10036 ' ,United States,955223,lymphoma,"""gard:0020548""",
1158,an orally bioavailable ALK inhibitor (a macrocyclic compound containing nitrogen heterocycles),,3/20/2023,"treatment of alk-positive, ros1-positive, and ltk-positive non-small cell lung cancer (nsclc)",Designated,,Not FDA Approved for Orphan Indication,,,,,"Nuvalent, Inc.",One Broadway,14th Floor,Cambridge,Massachusetts,' 02142 ' ,United States,929422,small cell lung cancer,"""gard:0009344""",
1159,an orally bioavailable ROS1 inhibitor (a macrocyclic compound containing nitrogen heterocycles),,2/21/2023,"treatment of ros1-positive, ltk-positive, and alk-positive non-small cell lung cancer",Designated,,Not FDA Approved for Orphan Indication,,,,,"Nuvalent, Inc.","One Broadway, 14th Floor",,Cambridge,Massachusetts,' 02142 ' ,United States,908322,small cell lung cancer,"""gard:0009344""",
1160,ANA-conjugated dactunomycin nanoemulsion,,7/7/2015,treatment of ewing sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"NanoSmart Pharmaceuticals, Inc.",27071 Cabot Road,Suite 104,Laguna Hills,California,' 92653 ' ,United States,481115,,,
1161,anacaulase-bcdb,NexoBrid,8/20/2003,"debridement of acute, deep dermal burns in hospitalized patients",Designated/Approved,,,eschar removal in adults with deep partial thickness (DPT) and/or full thickness (FT) thermal burns,12/28/2022,12/28/2029,eschar removal in hospitalized adults with deep partial thickness (DPT) and/or full thickness (FT) thermal burns,"MediWound, Ltd.",42 Hayarkon Street,,Yavne,,' ' ,Israel,156102,,,
1162,Anagrelide,,7/14/1986,treatment of thrombocytosis in chronic myelogenous leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,Roberts Pharmaceutical Corp.,Meridian Center II,Four Industrial Way West,Eatontown,New Jersey,' 07724 ' ,United States,14586,,,
1163,Anagrelide,,6/11/1985,treatment of polycythemia vera.,Designated,,Not FDA Approved for Orphan Indication,,,,,Roberts Pharmaceutical Corp.,Meridian Center II,Four Industrial Way West,Eatontown,New Jersey,' 07724 ' ,United States,6985,polycythemia,"""gard:0019466""",
1164,Anagrelide,Agrylin,1/27/1988,treatment of essential thrombocythemia.,Designated/Approved,,,Treatment of patients with essential thrombocythemia to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms.,3/14/1997,3/14/2004,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,20887,essential thrombocythemia,"""gard:0006594""",
1165,Anagrelide,,4/24/2023,treatment of gastrointestinal stromal tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,Sartar Therapeutics Oy,Terkko Health Hub,"Haartmaninkatu 4, Building 14",Helsinki,,' FI-00290 ' ,Finland,935223,gastrointestinal stromal tumor,"""gard:0008598""",
1166,anakinra,Kineret,8/19/2010,treatment of cryopyrin-associated periodic syndromes,Designated/Approved,,,Treatment of neonatal-onset multisystem inflammatory disease (NOMID),12/21/2012,12/21/2019,,Swedish Orphan Biovitrum AB (publ),SE-011276,,Stockholm,,' ' ,Sweden,312110,cryopyrin-associated periodic syndrome,"""gard:0010927""",
1167,anakinra,Kineret,6/29/2020,treatment of deficiency of il-1 receptor antagonist,Designated/Approved,,,treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA),12/18/2020,12/18/2027,treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA),Swedish Orphan Biovitrum AB (PUBL),Tomtebodavägen 23A,,Stockholm,,' ' ,Sweden,745420,,,
1168,"Ananain, comosain",,1/21/1992,for the enzymatic debridement of severe burns.,Designated,,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,One Kendall Square,,Cambridge,Massachusetts,' 02139 ' ,United States,63091,,,
1169,Anaritide acetate,,4/10/1992,improvement of early renal allograft function following renal transplantation.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Scios, Inc.",2450 Bayshore Parkway,,Mountain View,California,' 94043 ' ,United States,62291,,,
1170,Anaritide acetate,,8/27/1992,treatment of patients with acute renal failure.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Scios, Inc.",2450 Bayshore Parkway,,Mountain View,California,' 94043 ' ,United States,62391,,,
1171,Anatibant,,4/15/2005,treatment of patients having experienced a severe traumatic brain injury (glasgow coma scale 3 to 8) in order to decrease early mortality and improve long-term functional and neurological outcome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Xytis, Inc.",400 South El Camino Real,Suite 1200,San Mateo,California,' 94402 ' ,United States,153801,,,
1172,Ancestim,,7/5/1995,for use in combination with filgrastim to decrease the number of phereses required to collect peripheral blood progenitor cells capable of providing rapid multi-lineage hematopoietic reconstitution following myelosuppressive or myeloablative therapy.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,' 91320 ' ,United States,86594,,,
1173,Ancrod,,10/20/1989,to establish and maintain anticoagulation in heparin-intolerant patients undergoing cardiopulmonary bypass.,Designated,,Not FDA Approved for Orphan Indication,,,,,Knoll Pharmaceutical Company,"3000 Continental Dr., North",,Mt. Olive,New Jersey,' 07828 ' ,United States,37189,,,
1174,Andecaliximab,,3/19/2024,treatment of fibrodysplasia ossificans progressiva,Designated,,Not FDA Approved for Orphan Indication,,,,,ashibio Inc,2000 Sierra Point Parkway Suite 701,,"Brisbane,",California,' 94005 ' ,United States,994223,fibrodysplasia ossificans progressiva,"""gard:0006445""",
1175,anfibatide,,3/10/2016,treatment of thrombotic thrombocytopenic purpura.,Designated,,Not FDA Approved for Orphan Indication,,,,,Lee's Pharmaceutical (Hong Kong) Limited,"Unit 110-11, Bio-Informatics Centre",Hong Kong Science Park,"Shatin, Hong Kong",,' ' ,China,471215,thrombotic thrombocytopenic purpura,"""gard:0016659""",
1176,angiotensin (1-7),,8/30/2013,treatment of patients requiring stem cell transplantation to accelerate the mobilization of hematopoietic stem cells (cd34+) from the bone marrow to the peripheral blood when combined with a granulocyte colony-stimulating factor,Designated,,Not FDA Approved for Orphan Indication,,,,,"US Biotest, Inc.",231 Bonetti Drive,,San Luis Obispo,California,' 93401 ' ,United States,402713,,,
1177,Angiotensin (1-7),,9/1/2016,treatment of recessive dystrophic epidermolysis bullosa (rdeb).,Designated,,Not FDA Approved for Orphan Indication,,,,,Constant Therapeutics LLC,"303 Congress St, c/o Casner & Edwards",,Boston,Massachusetts,' 02210 ' ,United States,546416,dystrophic epidermolysis bullosa,"""gard:0002150""",
1178,Angiotensin (1-7),,11/26/2013,treatment of limb-girdle muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Constant Therapeutics LLC,"303 Congress St, c/o Casner & Edwards",,Boston,Massachusetts,' 02210 ' ,United States,412313,muscular dystrophy,"""gard:0007922""",
1179,Angiotensin (1-7),,2/8/2016,treatment of lama2-related muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Constant Therapeutics LLC,"303 Congress St, c/o Casner & Edwards",,Boston,Massachusetts,' 02210 ' ,United States,508815,muscular dystrophy,"""gard:0007922""",
1180,angiotensin (1-7)[A(1-7)],,7/25/2013,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Constant Therapeutics LLC,"303 Congress St, c/o Casner & Edwards",,Boston,Massachusetts,' 02210 ' ,United States,400813,muscular dystrophy,"""gard:0007922""",
1181,Angiotensin 1-7,,8/3/2001,treatment of myelodysplastic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tarix Pharmaceuticals, Ltd",12 Bow Street,,Cambridge,Massachusetts,' 02138 ' ,United States,144601,myelodysplastic syndrome,"""gard:0007132""",
1182,angiotensin 1-7,,6/17/2010,"to accelerate engraftment of hematopoietic cells (treatment of neutropenia, thrombocytopenia, lymphoma, and aneima)in hematopoietic stem cell transplants.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Tarix Pharmaceuticals, Ltd.",12 Bow Street,,Cambridge,Massachusetts,' 02138 ' ,United States,308810,lymphoma,"""gard:0020548""",
1183,Angiotensin 1-7,,2/16/2000,treatment of neutropenia associated with autologous bone marrow transplantation.,Designated,,Not FDA Approved for Orphan Indication,,,,,Tarix Pharmaceuticals Ltd,12 Bow Street,,Cambridge,Massachusetts,' 02138 ' ,United States,129999,,,
1184,angiotensin 1-7,,1/29/2010,treatment of sarcoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"W. Jeffrey Petty, MD",Wake Forest University Health Sciences,,Winston-Salem,North Carolina,' 27157 ' ,United States,295809,,,
1185,Angiotensin II type 2 receptor agonist,,7/3/2017,treatment of pediatric cardiomyopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Novopyxis, Inc.",1 Broadway,14th Floor,Cambridge,Massachusetts,' 02142 ' ,United States,575417,,,
1186,Angiotensin-(1-7),,9/13/2011,treatment of pulmonary arterial hypertension.,Designated,,Not FDA Approved for Orphan Indication,,,,,"US Biotest, Inc.",231 Bonetti Drive,,San Luis Obispo,California,' 93401 ' ,United States,345411,pulmonary arterial hypertension,"""gard:0007501""",
1187,anhydrous enol-oxaloacetate,,3/7/2018,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Terra Biological LLC,3830 Valley Centre Drive,Suite 705-561,San Diego,California,' 92130 ' ,United States,628018,hepatocellular carcinoma,"""gard:0016773""",
1188,anifrolumab,,12/14/2022,treatment of idiopathic inflammatory myopathies,Designated,,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,PO Box 8355,Wilmington,Delaware,' 19803 ' ,United States,876522,,,
1189,anifrolumab,,10/16/2013,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,,Wilmington,Delaware,' 19803 ' ,United States,299209,systemic sclerosis,"""gard:0009748""",
1190,anisina,,7/14/2015,treatment of neuroblastoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Novogen Ltd,16-20 Edgeworth David Avenue,,Hornsbsy,,' ' ,Australia,485815,neuroblastoma,"""gard:0007185""",
1191,Anlotinib,,6/19/2017,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advenchen Laboratories, LLC",887 Patriot Drive,Suite A,Moorpark,California,' 93021 ' ,United States,576017,soft tissue sarcoma,"""gard:0004898""",
1192,anlotinib hydrochloride,,12/31/2015,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advenchen Laboratories, LLC",887 Patriot Drive,Suite A,Moorpark,California,' 93021 ' ,United States,502715,ovarian cancer,"""gard:0007295""",
1193,ansuvimab,,3/30/2020,post-exposure prophylaxis against ebola virus infection,Designated,,Not FDA Approved for Orphan Indication,,,,,Emergent Manufacturing Operations Baltimore LLC,5901 East Lombard Street,,Baltimore,Maryland,' 21224 ' ,United States,730820,,,
1194,ansuvimab-zykl,EBANGA™,5/8/2019,treatment of ebola virus disease,Designated/Approved,,,"treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection",12/21/2020,12/21/2027,"treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection",Emergent Manufacturing Operations Baltimore LLC,5901 East Lombard Street,,Baltimore,Maryland,' 21224 ' ,United States,683019,,,
1195,antagonist of chemokine Ligand-2,,7/3/2017,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,12/17/2018,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",300 Technology Square,,Cambridge,Massachusetts,' 02139 ' ,United States,570416,,,
1196,"antagonist of the endosomal Toll-like receptors (TLRs) 7, 8, and 9",,12/23/2014,treatment of waldenstrom's macroglobulinemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Idera Pharmaceuticals, Inc.",505 Eagleview Boulevard,Suite 212,Exton,Pennsylvania,' 19341 ' ,United States,417813,,,
1197,anthrax immune globulin,,9/3/2009,treatment of inhalation anthrax disease,Designated/Designation Withdrawn or Revoked,5/19/2016,Not FDA Approved for Orphan Indication,,,,,"Emergent Biosolutions, Inc.",300 Professional Drive,,Gaithersburg,Maryland,' 20879 ' ,United States,288509,,,
1198,anthrax immune globulin (human),,7/29/2008,treatment of inhalational anthrax,Designated/Approved,,,Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs,3/24/2015,3/24/2022,Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs,Cangene Corp. - Emergent Biosolutions,155 Innovation Drive,R3T 5Y3,"Winnipeg, MB",,' ' ,Canada,263008,inhalational anthrax,"""gard:0020657""",
1199,Anthrax Vaccine Adsorbed,BioThrax,4/11/2014,for post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed bacillus anthracis exposure,Designated/Approved,,,"For post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs.",11/23/2015,11/23/2022,"For post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs.",Emergent BioDefense Operations Lansing LLC,300 Proessional Drive,,Gaithersburg,Maryland,' 20879 ' ,United States,424914,,,
1200,"Anthrax Vaccine Adsorbed, Adjuvanted",Cyfendus,8/19/2021,post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed bacillus anthracis exposure,Designated/Approved,,,post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs,7/20/2023,,,"Emergent Product Development Gaithersburg, Inc.",300 Professional Drive,,Gaitherburg,Maryland,' 20879 ' ,United States,832521,,,
1201,anti human Nogo-A human monoclonal antibody,,10/20/2008,treatment of acute spinal cord injury,Designated/Designation Withdrawn or Revoked,5/14/2019,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,268108,spinal cord injury,"""gard:0019109""",
1202,Anti pan T lymphocyte monoclonal antibody,,1/29/1986,1. for ex-vivo treatment to eliminate mature t cells from potential bone marrow grafts 2. for in-vivo treatment of bone marrow recipients to prevent graft rejection and graft versus host disease.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Xoma Corporation,2910 Seventh Street,,Berkeley,California,' 94710 ' ,United States,10985,graft versus host disease,"""gard:0016642""",
1203,Anti- FcgammaRIIB Monoclonal Antibody,,1/18/2022,treatment of follicular lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,BioInvent International AB,Ideon Science Park SE-223 70,,Lund,Lund,' ' ,Sweden,856621,lymphoma,"""gard:0020548""",
1204,anti-angiogenic peptide,,6/21/2017,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Almac Group,20 Seagoe Industrial Estate,,Craigavon,,' ' ,United Kingdom,523616,ovarian cancer,"""gard:0007295""",
1205,anti-Beta1 integrin monoclonal antibody,,1/13/2015,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"OncoSynergy, Inc.",380 Greenwich Avenue,,Greenwich,Connecticut,' 06830 ' ,United States,460114,ovarian cancer,"""gard:0007295""",
1206,Anti-Beta1 Integrin Monoclonal Antibody,,11/8/2021,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"OncoSynergy, Inc","850 Pacific Street, Unit 1802",,Stamford,Connecticut,' 06902 ' ,United States,845021,acute myeloid leukemia,"""gard:0012757""",
1207,anti-beta1 integrin monoclonal antibody,,8/7/2014,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"OncoSynergy, Inc.",380 Greenwich Avenue,,Greenwich,Connecticut,' 06830 ' ,United States,440614,glioblastoma,"""gard:0002491""",
1208,Anti-C1s Humanized IgG4 Monoclonal Antibody,,7/21/2021,treatment of chronic inflammatory demyelinating polyneuropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Sanofi Genzyme,50 Binney Street,,Cambridge,Massachusetts,' 02124 ' ,United States,810521,chronic inflammatory demyelinating polyneuropathy,"""gard:0006102""",
1209,Anti-CD19 Chimeric Antigen Receptor T-Cell Injection,,1/13/2022,"treatment of cd19+, relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (all)",Designated,,Not FDA Approved for Orphan Indication,,,,,Juventas Cell Therapy Ltd.,"Building 5, No. 8, Road 3 of Haitai Development Zone","Huayuan Industrial Part, Tianjin high-tech Area",Tianjin,Tianjin,' 300384 ' ,China,837621,acute lymphoblastic leukemia,"""gard:0000522""",
1210,"anti-CD23 IgG1, kappa monoclonal antibody",,2/12/2003,treatment of chronic lymphocytic leukemia,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Biogen IDEC, Inc.",,5200 Research Place,San Diego,California,' 92122 ' ,United States,160502,,,
1211,anti-CD3 mAb (SPV-T3a)-ricin A chain fusion protein and anti-CD7 mAb (WT1)-ricin A chain fusion protein,,9/13/2013,treatment of graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Philikos BV,Javastraat 122,,Nijmegen,,' 6524 ML ' ,Netherlands,405013,graft versus host disease,"""gard:0016642""",
1212,anti-CD30 Fc engineered humanized monoclonal antibody,,12/2/2008,treatment of hodgkin lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Xencor, Inc.",111 W. Lemon Avenue,,Monrovia,California,' 91016 ' ,United States,271208,lymphoma,"""gard:0020548""",
1213,Anti-CD45 monoclonal antibodies,,9/10/1990,prevention of acute graft rejection of human organ transplants.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Baxter Healthcare Corporation,1620 Waukegan Road,,Mcgaw Park,Illinois,' 60085 ' ,United States,48390,,,
1214,anti-CD47 monoclonal antibody,,7/30/2018,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,10/14/2021,Not FDA Approved for Orphan Indication,,,,,"Surface Oncology, Inc.","50 Hampshire St, 8th Floor",,Cambridge,Massachusetts,' 01239 ' ,United States,643718,multiple myeloma,"""gard:0007108""",
1215,Anti-CEA Sheep-human chimeric monoclonal antibody labeled w/iodine-131 (KAb201),,5/21/2003,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Avaant Pharmaceuticals India Ltd.,"3rd Floor, Neelkanth Commercial Centre",,Mumbai,,' ' ,India,168003,,,
1216,Anti-Claudin 18.2 Antibody consisting of a fully human monoclonal IgG1 antibody to the type 2 isoform of human Claudin 18 protein,,12/1/2020,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Leap Therapeutics, Inc.","47 Thorndike Street, Suite B-1",,Cambridge,Massachusetts,' 02141 ' ,United States,784020,,,
1217,"Anti-Claudin 18.2 antibody drug conjugate comprised of a Claudin 18.2 targeting monoclonal IgG1 antibody, a linker LND1002, and monomethyl auristatin E",,11/19/2020,treatment for gastric cancer including cancer of gastroesophageal junction,Designated,,Not FDA Approved for Orphan Indication,,,,,"Elevation Oncology, Inc.","888 7th Avenue, 12th Floor",,New York,New York,' 10106 ' ,United States,782320,,,
1218,Anti-Claudin 18.2 Antibody Drug Conjugate with MMAE and LND1002 linker,,5/5/2021,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Elevation Oncology, Inc.","888 7th Avenue, 12th Floor",,New York,New York,' 10106 ' ,United States,814521,,,
1219,anti-Claudin18.2 monoclonal antibody conjugated with Duostatin-5 payload,,12/21/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shandong Boan Biotechnology Co., Ltd.","No.39 Keji Avenue, Yantai Hi-Tech Zone, Shandong Province, P.R. China",,,,' ' ,China,978623,,,
1220,Anti-cytomegalovirus monoclonal antibodies,,5/2/1990,1. treatment of human cytomegalovirus infection in bone marrow and organ transplant patients 2. prevention of human cytomegalovirus infection in bone marrow and organ transplant patients,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Biomedical Research Institute,345 North Smith Avenue,,St. Paul,Minnesota,' 55102 ' ,United States,40489,,,
1221,Anti-cytomegalovirus monoclonal antibodies,,5/3/1990,1. treatment of human cytomegalovirus infection in patients diagnosed with aids 2. prevention of human cytomegalovirus infection in patients diagnosed with aids,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Biomedical Research Institute,345 North Smith Avenue,,St. Paul,Minnesota,' 55102 ' ,United States,41489,,,
1222,anti-EGFR VHH Fragment Fused to Cytosine Deaminase,,2/26/2020,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,4/12/2023,Not FDA Approved for Orphan Indication,,,,,"Lumosa Therapeutics Co., Ltd.","4F, No. 3-2, Park Street",Nangang District,Taipei,,' ' ,Taiwan,729119,,,
1223,anti-EGFRvIII x anti-CD3 bispecific T cell engager antibody construct,,4/2/2018,treatment of glioblastoma,Designated/Designation Withdrawn or Revoked,12/22/2022,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop: 27-3-F,Thousand Oaks,California,' 91320 ' ,United States,634718,glioblastoma,"""gard:0002491""",
1224,Anti-EphA1 monoclonal antibody conjugated to mcMMAF,,7/27/2009,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC",One MedImmune Way,,Gaithersburg,Maryland,' 20878 ' ,United States,288009,ovarian cancer,"""gard:0007295""",
1225,Anti-eTau Humanized IgG4 Monoclonal Antibody,,5/13/2015,treatment of progressive supranuclear palsy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",225 Binney Street,,Cambridge,Massachusetts,' 02142 ' ,United States,477515,progressive supranuclear palsy,"""gard:0007471""",
1226,Anti-fibroblast growth factor receptor 3 antigen-binding fragment (anti-FGFR3 Fab),,1/25/2022,treatment of achondroplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genzyme Corporation, a Sanofi Company",50 Binney Street,,Cambridge,Massachusetts,' 02142 ' ,United States,858121,achondroplasia,"""gard:0008173""",
1227,anti-HER2 bispecific antibody,,5/18/2016,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,9/27/2021,Not FDA Approved for Orphan Indication,,,,,Zymeworks Inc.,"1385 West 8th Street, Suite 540",,Vancouver,BC,' V6H 3V9 ' ,Canada,519516,ovarian cancer,"""gard:0007295""",
1228,Anti-HER2 bispecific antibody,,2/6/2017,"treatment of gastric cancer, including cancer of the gastroesophageal junction",Designated,,Not FDA Approved for Orphan Indication,,,,,Jazz Pharmaceuticals Ireland Limited,3170 Porter Drive,,Palo Alto,California,' 94304 ' ,United States,554716,,,
1229,anti-HER2 bispecific antibody drug conjugate,,7/6/2016,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,12/4/2018,Not FDA Approved for Orphan Indication,,,,,Zymeworks Inc.,18 West Mercer Street,Suite 370,Seattle,Washington,' 98119 ' ,United States,522616,ovarian cancer,"""gard:0007295""",
1230,anti-human epidermal growth factor receptor 2 (HER2) antibody drug conjugate,,2/1/2018,treatment of gastric cancer including cancer of gastroesophageal junction,Designated,,Not FDA Approved for Orphan Indication,,,,,"CSPC Dophen Corporation, subsidiary within CSPC Pharmaceutical Group",4070 Truxel Road,,Sacramento,California,' 95834 ' ,United States,620617,,,
1231,"anti-human transforming growth factor beta (TGF-Beta) monoclonal antibody (mAb), based on the amino acid sequence of the human monoclonal antibody fresolimumab (GC1008) with the exception of one serine to proline substitution",,10/15/2022,treatment of osteogenesis imperfecta,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sanofi Genzyme, A Sanofi Company",450 Water Street,,Cambridge,Massachusetts,' 02141 ' ,United States,904622,osteogenesis imperfecta,"""gard:0001017""",
1232,anti-inhibitor coagulant complex,FEIBA,4/12/2013,routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia a and b patients with inhibitors,Designated/Approved,,,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors,12/16/2013,12/16/2020,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors,"Baxalta US, Inc.",One Baxter Way,,West Lake Village,California,' 91362 ' ,United States,393913,hemophilia,"""gard:0010418""",
1233,anti-interferon-gamma Fab from goats,,11/18/2003,for the treatment of immunologic corneal allograft rejection,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Biotherapy, Inc.",6355 Topanga Canyon Blvd.,Suite 510,Woodland Hills,California,' 91367 ' ,United States,177103,,,
1234,anti-interleukin 21 (NNC0114-0006) in combination with liraglutide,,1/12/2017,treatment of type i diabetes mellitus with residual beta cell function.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.",800 Scudders Mill Road,P. O. Box 846,,New Jersey,' 08536 ' ,United States,529716,,,
1235,anti-Lewis Y humanized monoclonal antibody,,3/9/2012,treament of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Recepta Biopharma S.A.,"Rua Tabapua, 1123 cj.36",Itaim Bibi,Sao Paulo,,' ' ,Brazil,282409,ovarian cancer,"""gard:0007295""",
1236,Anti-LILRB4 humanized IgG1 monoclonal antibody,,10/21/2020,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immune-Onc Therapeutics, Inc.",795 San Antonio Road,,Palo Alto,California,' 94303 ' ,United States,773820,acute myeloid leukemia,"""gard:0012757""",
1237,Anti-nectin-4 IgG1 monoclonal antibody conjugated to monomethyl auristatin E,,4/30/2024,treatment of esophageal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mabwell (Shanghai) Bioscience Co., Ltd.","230 Cailun Road, China (Shanghai) Pilot Free Trade Zone","RM105, Building 2",Shanghai,,' ' ,China,1000124,,,
1238,anti-nogo-A monoclonal antibody,,7/7/2009,treatment of amyotrophic lateral sclerosis,Designated/Designation Withdrawn or Revoked,7/16/2015,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline,Glaxo Wellcome House,,"Greenford, Middlesex, UK UB6 0NN",,' ' ,United Kingdom,285709,amyotrophic lateral sclerosis,"""gard:0005786""",
1239,anti-sense oligonucleotide consisting of 2¿0-Me RNA with a phosphorothioate backbone,,9/23/2013,treatment of cystic fibrosis,Designated/Designation Withdrawn or Revoked,11/27/2020,Not FDA Approved for Orphan Indication,,,,,ProQR Therapeutics IV B.V.,Zernikedreef 9,,Leiden,,' 2333 CK ' ,Netherlands,403713,cystic fibrosis,"""gard:0006233""",
1240,anti-Siglec-15 monoclonal antibody on a human IgG1-Fc-silenced backbone,,5/29/2024,treatment of osteogenesis imperfecta,Designated,,Not FDA Approved for Orphan Indication,,,,,"NextCure, Inc.",9000 Virginia Manor Road,Suite 200,Beltsville,Maryland,' 20705 ' ,United States,987923,osteogenesis imperfecta,"""gard:0001017""",
1241,anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 single domain antibody,,8/29/2016,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Singh Biotechnology, LLC",4708 Rue Bordeaux,,Lutz,Florida,' 33558 ' ,United States,533616,,,
1242,Anti-STAT3 B VHH13 single domain antibody,,9/27/2017,treatment of osteosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Singh Biotechnology, LLC",4708 Rue Bordeaux,,Lutz,Florida,' 33558 ' ,United States,605917,osteosarcoma,"""gard:0007284""",
1243,Anti-T cell receptor murine monoclonal antibody,,4/3/2009,prophylaxis of acute rejection of solid organ transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tolera Therapeutics, Inc.",4717 Campus Drive #800,,Kalamazoo,Michigan,' 49008 ' ,United States,275709,,,
1244,"anti-T-lymphocyte immune globulin, rabbit",,9/12/2008,prophylaxis of acute allograft rejection in adult recipients in solid organ transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,Neovii Biotech GmbH,Am Haag 6 + 7,,Graefelfing,,' 82166 ' ,Germany,182503,,,
1245,"anti-T-lymphocyte immune globulin, rabbit",,3/26/2010,prevention of graft versus host disease (gvhd),Designated,,Not FDA Approved for Orphan Indication,,,,,Neovii Biotech GmbH,Am Haag 6 + 7,,Graefelfing,,' 82166 ' ,Germany,301810,graft versus host disease,"""gard:0016642""",
1246,Anti-tap-72 immunotoxin,,3/6/1987,treatment of metastatic colorectal adenocarcinoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Xoma Corporation,2910 Seventh Street,,Berkeley,California,' 94710 ' ,United States,17286,noma,"""gard:0004001""",
1247,"anti-TCR murine monoclonal antibody (MAb, type IgM)",,6/7/2010,treatment of patients 16 years of age and younger with immune-mediated t1dm and preserved pancreatic beta cell function,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tolera Therapeutics, Inc.",350 E. Michigan Avenue,,Kalamazoo,Michigan,' 49001 ' ,United States,293209,,,
1248,"anti-TCR murine monoclonal antibody (MAB, type IgM)",,1/12/2011,treatment of pediatric multiple sclerosis in patients less than or equal to 16 years of age,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tolera Therapeutics, Inc.",350 E. Michigan Ave.,,Kalamazoo,Michigan,' 49008 ' ,United States,329310,pediatric multiple sclerosis,"""gard:0010443""",
1249,Anti-tenascin 81C6 monoclonal antibody labeled w/ I 131,,10/4/2005,treatment of primary malignant brain tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"Bradmer Pharmaceuticals, Inc.",9900 Corporate Campus Drive,Suite 3000,Louisville,Kentucky,' 40223 ' ,United States,209405,,,
1250,anti-thymocyte globulin (rabbit),,9/21/2021,prophylaxis of graft-versus-host-disease,Designated/Designation Withdrawn or Revoked,6/8/2023,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,50 Binney Street,,Cambridge,Massachusetts,' 02142 ' ,United States,838821,,,
1251,anti-thymocyte Globulin (rabbit),,9/6/2000,treatment of myelodysplastic syndrome,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,A Sanofi Company,500 Kendall Street,Cambridge,Massachusetts,' 02142 ' ,United States,136800,myelodysplastic syndrome,"""gard:0007132""",
1252,anti-thymocyte globulin [rabbit],,5/25/2010,prophylaxis of acute organ rejection in patients receiving renal transplants,Designated,,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,308710,,,
1253,Anti-thymocyte serum,,6/2/1993,"treatment of allograft rejection, including solid organ (kidney, liver, heart, lung, and pancreas) and bone marrow transplantation.",Designated,,Not FDA Approved for Orphan Indication,,,,,Applied Medical Research,1600 Hayes Street,,Nashville,Tennessee,' 37203 ' ,United States,64491,,,
1254,Anti-transforming growth factor beta (TGF-ß) trap fusion protein,,3/25/2019,treatment of systemic sclerosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Formation Biologics,101 W 6th Street,Suite 501,Austin,Texas,' 8701 ' ,United States,678419,systemic sclerosis,"""gard:0009748""",
1255,anti-tumor necrosis factor (TNF) polyclonal antibody (bovine),,11/17/2014,treatment of pediatric ulcerative colitis (0 through 16 years of age),Designated,,Not FDA Approved for Orphan Indication,,,,,"Circle33, LLC",P. O. Box 11329,,Jackson,Wyoming,' 83002 ' ,United States,452414,,,
1256,"Anti-vascular endothelial growth factor, anti-hepatocyte growth factor Designed Ankyrin Repeat Protein",,12/23/2019,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Molecular Partners AG,Wagistrasse 14,,Zürich,Schlieren,' ' ,Switzerland,716519,multiple myeloma,"""gard:0007108""",
1257,Anti-von Willebrand Aptamer,,4/9/2008,treatment of thrombotic thrombocytopenic purpura,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Archemix Corporation,300 Third Street,,Cambridge,Massachusetts,' 02142 ' ,United States,256207,thrombotic thrombocytopenic purpura,"""gard:0016659""",
1258,antiangiogenic components extracted from marine cartilage,,10/16/2002,treatment of renal cell carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"AEterna Zentaris, Inc.",Dr. Claude Hariton,"Chief Medical Officer, VP, Cli",Quebec,,' ' ,Canada,159202,renal cell carcinoma,"""gard:0013215""",
1259,Antibody drug conjugate consisting of a humanized IgG1 anti-NaPi2b monoclonal antibody and monomethyl auristatin E,,7/29/2014,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,3/23/2016,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,440714,ovarian cancer,"""gard:0007295""",
1260,antibody drug conjugate consisting of fully human anti-guanylyl cyclase C monoclonal antibody linked to the cytotoxic drug monomethyl auristatin E,,7/21/2014,treatment of gastric cancer,Designated/Designation Withdrawn or Revoked,9/20/2016,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,437914,,,
1261,antibody drug conjugate of metal-binding motif-introduced trastuzumab antibody variant and monomethyl auristatin E,,7/30/2018,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alteogen, Inc.",62 Yuseong-daero 1628beon-gil,Yuseong-gu,Daejeon,Daejeon,' ' ,South Korea,643918,,,
1262,antibody drug conjugate targeting Claudin 18.2 (CLDN 18.2) consisting of a humanized monoclonal antibody against CLDN 18.2 and a conjugated linker-payload VC-MMAE (maleimidocaproyl-valine-citrulline-p-aminobenzylalcohol-Monomethyl Auristatin E),,5/22/2023,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Antengene (Hangzhou) Biologics Co., Ltd.","Room 218, Building 21, Hexiang Science and Technology Center","Xiasha Subdistrict, Qiantang New Area",Hangzhou,Zhejiang,' ' ,China,940123,,,
1263,Antibody drug conjugate targeting Claudin 18.2 (CLDN 18.2) consisting of a humanized monoclonal antibody against CLDN 18.2 and a conjugated linker-payload VC-MMAE (maleimidocaproyl-valine-citrulline-p-aminobenzylalcohol-Monomethyl Auristatin E),,5/16/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Antengene (Hangzhou) Biologics Co., Ltd.","Room 218, Building 21, Hexiang Science and Technology Center","Xiasha Subdistrict, Qiantang New Area",Hangzhou,Zhejiang,' ' ,China,937923,,,
1264,antibody drug conjugate targeting dipeptidase 3 (DPEP3),,1/8/2018,"treatment of dpep3-positive ovarian, fallopian tube, and primary peritoneal cancers",Designated/Designation Withdrawn or Revoked,1/10/2019,Not FDA Approved for Orphan Indication,,,,,"AbbVie Stemcentrx, LLC",1 North Waukegan Road,,Chicago,Illinois,' 60064 ' ,United States,555816,,,
1265,"Antibody-drug conjugate (ADC) comprising an anti-ROR1 monoclonal antibody (UC-961), a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker (mc-vc-PAB), and a monomethyl auristatin E (MMAE) cytotoxin.",,8/26/2020,treatment of mantle cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Merck Sharp & Dohme, LLC",126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,757520,lymphoma,"""gard:0020548""",
1266,antibody-drug conjugate comprised of a human aglycosylated anti-CD74 IgG1 antibody (SP7219) and two non-cleavable maytansinoid linker warheads,,10/10/2018,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sutro Biopharma, Inc.",111 Oyster Point,,South San Francisco,California,' 94080 ' ,United States,654118,multiple myeloma,"""gard:0007108""",
1267,Antibody-drug conjugate consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific for alpha-chain linked to SN-38 via a CL2A linker,,11/18/2020,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 The American Rd,,Morris Plains,New Jersey,' 07950 ' ,United States,781720,acute myeloid leukemia,"""gard:0012757""",
1268,antibody-drug conjugate of a humanized monoclonal antibody specific for CD6 conjugated to monomethyl auristatin E,,3/11/2024,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Abcon Therapeutics, Inc.",10000 Cedar Ave. GCIC Building,,Cleveland,Ohio,' 44106 ' ,United States,992523,lymphoma,"""gard:0020548""",
1269,Antiepilepsirine,,3/23/1989,treatment of drug resistant generalized tonic-clonic epilepsy in children and adults.,Designated,,Not FDA Approved for Orphan Indication,,,,,Children's Hospital,700 Children's Drive,,Columbus,Ohio,' 43205 ' ,United States,34588,,,
1270,Antihemophilic factor (human),Alphanate,1/5/1996,treatment of von willebrand's disease,Designated/Approved,,,For surgical and/or invasive procedures in patients with von Willebrand Disease (VWD) in whom desmopressin is either ineffective or contraindicated. It is not indicated for patients with severe VWD (Type 3) undergoing major surgery,1/31/2007,1/31/2014,,Grifols Biologicals Inc.,5555 Valley Boulevard,,Los Angeles,California,' 90032 ' ,United States,93895,,,
1271,Antihemophilic factor (recombinant),Kogenate,9/25/1989,prophylaxis and treatment of bleeding in individuals with hemophilia a or for prophylaxis when surgery is required in individuals with hemophilia a.,Designated/Approved,,,Treatment and prophylaxis of bleeding in patients with hemophilia A (not von Willebrand's disease),2/25/1993,2/25/2000,,Bayer Corporation,1884 Miles Avenue,,Elkhart,Indiana,' 46515 ' ,United States,39289,hemophilia,"""gard:0010418""",
1272,Antihemophilic factor (recombinant),"ReFacto, Xyntha",2/8/1996,for the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia a (congenital factor viii deficiency or classic hemophilia).,Designated/Approved,,,,3/6/2000,,,"Wyeth Pharmaceuticals, Inc.",P. O. Box 8299,,Philadelphia,Pennsylvania,' 19101 ' ,United States,94495,hemophilia,"""gard:0010418""",
1273,Antihemophilic factor (recombinant) formulated with sucrose reconstituted with liposome diluent,,4/29/2009,treatment of hemophilia a,Designated/Designation Withdrawn or Revoked,9/12/2014,Not FDA Approved for Orphan Indication,,,,,Bayer HealthCare LLC,555 Whiteplains Road,,Tarrytown,New York,' 10591 ' ,United States,280309,hemophilia,"""gard:0010418""",
1274,"antihemophilic factor (recombinant), Fc fusion protein",Eloctate,11/23/2010,treatment of hemophilia a,Designated/Approved,,,"Indicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.",6/6/2014,6/6/2021,"Treatment of adults and children with Hemophilia A (congenital Factor VIII deficiency) for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.","Bioverativ Therapeutics, Inc.",225 2nd Avenue,,Waltham,Massachusetts,' 02451 ' ,United States,321610,hemophilia,"""gard:0010418""",
1275,"antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl",Altuviiio,8/3/2017,treatment of hemophilia a,Designated/Approved,,,in adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and perioperative management of bleeding,2/22/2023,2/22/2030,in adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and perioperative management of bleeding,"Bioverativ Therapeutics, Inc.",225 Second Avenue,,Waltham,Massachusetts,' 02451 ' ,United States,591217,hemophilia,"""gard:0010418""",
1276,"antihemophilic factor (recombinant), porcine sequence",OBIZUR,3/16/2004,treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor viii,Designated/Approved,,,Treatment of bleeding episodes in adults with acquired hemophilia A.,10/23/2014,10/23/2021,Treatment of bleeding episodes in adults with acquired hemophilia A.,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,181403,,,
1277,"Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized",Humate-P,10/16/1992,treatment of patients with von willebrand's disease,Designated/Approved,,,"(1) In adult patients for treatment and prevention of bleeding in hemophilia A (classic hemophilia) and (2) in adult and pediatric patients for treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate.",4/1/1999,4/1/2006,,CSL Behring,1020 First Avenue,PO Box 61501,King Of Prussia,Pennsylvania,' 19406 ' ,United States,67992,,,
1278,Antimelanoma Antibody XMMME-001-DTPA 111 Indium,,11/14/1984,diagnostic use in imaging systemic and nodal melanoma metastasis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Xoma Corporation,2910 Seventh Street,,Berkeley,California,' 94710 ' ,United States,3484,noma,"""gard:0004001""",
1279,Antimelanoma Antibody XMMME-001-RTA,,11/14/1984,treatment of stage iii melanoma not amenable to surgical resection.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Xoma Corporation,2910 Seventh Street,,Berkeley,California,' 94710 ' ,United States,3584,noma,"""gard:0004001""",
1280,antimesothelin-ADC (antibody drug conjugate),,7/5/2012,treatment of mesothelioma,Designated/Designation Withdrawn or Revoked,9/6/2018,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",340 Changebridge Road,,Pine Brook,New Jersey,' 07058 ' ,United States,370112,,,
1281,"antineoplaston A10, antineoplaston AS2-1",,11/21/2008,treatment of gliomas,Designated,,Not FDA Approved for Orphan Indication,,,,,"Burzynski Research Institute, Inc.",9432 Old Katy Road,,Houston,Texas,' 77055 ' ,United States,267408,,,
1282,antinuclear antibody conjugated liposomal doxorubicin,,2/3/2015,treatment of ewing's sarcoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"NanoSmart Pharmaceuticals, Inc.",29442 Ponte Royal,,Laguna Niguel,California,' 92677 ' ,United States,455414,,,
1283,Antipyrine Test,,2/21/1985,for use as an index of hepatic drug-metabolizing capacity.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Upsher-Smith Laboratories, Inc",4905 23rd Avenue North,,Minneapolis,Minnesota,' 55447 ' ,United States,5284,,,
1284,Antisense 20-mer oligonucleotide complementary to R2 component of ribonucleotide reductase mRNA,,4/15/2005,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Lorus Therapeutics, Inc.",2 Meridan Road,,Toronto,,' ' ,Canada,203005,acute myeloid leukemia,"""gard:0012757""",
1285,antisense 20-mer phosphorothioate oligonucleotide [complementary to the coding region of R2 component of the human ribonucleotide reductase mRNA],,3/12/2003,treatment for renal cell carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Lorus Therapeutics, Inc",2 Meridan Road,,Toronto,,' ' ,Canada,165202,renal cell carcinoma,"""gard:0013215""",
1286,antisense oligonucleotide (ASO) binding SMN2 pre-mRNA,,1/22/2024,treatment of spinal muscular atrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Biogen,225 Binney Street,,Cambridge,Massachusetts,' 02142 ' ,United States,983323,,,
1287,antisense oligonucleotide complementary to the exonic splicer enhancer sequence at intron 26 of the centrosomal protein 290 pre-mRNA,,5/25/2016,treatment of leber's congenital amaurosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,ProQR Therapeutics IV B.V.,Zernikedreef 9,,Leiden,,' 2333 CK ' ,Netherlands,521316,,,
1288,antisense oligonucleotide consisting of 18 nucleotide residues with a sequence of 5¿-5MeC-5MeU-5MeU-5MeU-5MeC-5MeC-5MeU-5MeU-5MeC-A-5MeC-5MeU-G-5MeU- 5MeU-G-5MeC-A-3¿,,10/20/2022,treatment of cystic fibrosis patients carrying the w1282x cftr mutation,Designated,,Not FDA Approved for Orphan Indication,,,,,SpliSense Ltd.,"Biohouse Labs Jerusalem Bio Park, 1st Floor",Haddasah Ein Kerem,Jerusalem,Israel,' 9112101 ' ,Israel,881722,cystic fibrosis,"""gard:0006233""",
1289,Antisense oligonucleotide directed against connexin43,,4/27/2009,treatment of persistent corneal epithelial defects,Designated,,Not FDA Approved for Orphan Indication,,,,,Glaukos Corporation,1 Glaukos Way,,Aliso Viejo,California,' 92656 ' ,United States,279609,,,
1290,antisense oligonucleotide specific to the antisense transcript of UBE3A,,3/15/2018,treatment of angelman syndrome,Designated/Designation Withdrawn or Revoked,7/22/2019,Not FDA Approved for Orphan Indication,,,,,"GeneTx Biotherapeutics, LLC",1918 Sweetbriar Lane,,Darien,Illinois,' 60561 ' ,United States,630218,angelman syndrome,"""gard:0005810""",
1291,antisense oligonucleotide targeting exon 13 of the USH2A gene,,7/27/2017,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,ProQR Therapeutics IV B.V.,Zernikedreef 9,,Leiden,,' 2333 CK ' ,Netherlands,588917,retinitis pigmentosa,"""gard:0005694""",
1292,antisense oligonucleotide targeting exon 73 in the COL7A1 gene,,9/13/2017,treatment of dystrophic epidermolysis bullosa,Designated/Designation Withdrawn or Revoked,2/1/2024,Not FDA Approved for Orphan Indication,,,,,"Phoenicis Therapeutics, Inc.",66 Clubhouse Drive,,Hingham,Massachusetts,' 02043 ' ,United States,600217,dystrophic epidermolysis bullosa,"""gard:0002150""",
1293,antisense oligonucleotide targeting the c.7595-2144A>G mutation in intron 40 of the USH2A gene,,6/28/2017,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,ProQR Therapeutics IV B.V.,Zernikedreef 9,,Leiden,,' 2333 CK ' ,Netherlands,582317,retinitis pigmentosa,"""gard:0005694""",
1294,antisense oligonucleotide targeting the P23H mutation of the RHO gene,,11/18/2019,treatment of retinal dystrophy dut to the p23h gene mutation (retinitis pigmentosa),Designated,,Not FDA Approved for Orphan Indication,,,,,ProQR Therapeutics IV B.V.,Zernikedreef 9,,Leiden,,' 2333 CK ' ,Netherlands,709219,retinitis pigmentosa,"""gard:0005694""",
1295,antisense oligonucleotide targeting the U isoform of SNP rs362307,,6/16/2016,treatment of huntington's disease (prodromal stage huntington's disease and diagnosed huntington's disease),Designated/Designation Withdrawn or Revoked,8/9/2021,Not FDA Approved for Orphan Indication,,,,,Wave LIfe Sciences,733 Concord Avenue,,Cambridge,Massachusetts,' 02138 ' ,United States,525516,,,
1296,Antisense oligonucleotide targeting TUBB4A mRNA,,1/23/2024,treatment of tubb4a related isolated hypomyelination,Designated,,Not FDA Approved for Orphan Indication,,,,,SynaptixBio Ltd.,"9400 Garsington Road, Oxford Business Park",,Oxford,,' OX4 2HN ' ,United Kingdom,984323,,,
1297,Antithrombin III (human),Thrombate III,11/26/1984,for replacement therapy in congenital deficiency of at-iii for prevention and treatment of thrombosis and pulmonary emboli.,Designated/Approved,,,,12/30/1991,12/30/1998,,Bayer Corporation,"Pharmaceutical Division, Biological Products",400 Morgan Lane,New Haven,Connecticut,' 06516 ' ,United States,4084,,,
1298,Antithrombin III (human),ATnativ,2/8/1985,for the treatment of patients with hereditary antithrombin iii deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.,Designated/Approved,,,,12/13/1989,12/13/1996,,Pharmacia & Upjohn AB,Lindhagensgatan 133,,Stockholm,,' ' ,Sweden,5084,,,
1299,Antithrombin III (human) concentrate IV,,7/2/1985,for prophylaxis and treatment of thromboembolic episodes in patients with genetic at-iii deficiency.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Ave.,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,7185,,,
1300,Antithrombin III human,,1/2/1986,preventing or arresting episodes of thrombosis in patients with congenital at-iii deficiency and/or to prevent the occurrence of thrombosis in patients with at-iii deficiency who have undergone trauma or who are about to undergo surgery or parturition.,Designated,,Not FDA Approved for Orphan Indication,,,,,American National Red Cross,9312 Old Georgetown Road,,Bethesda,Maryland,' 20814 ' ,United States,11485,,,
1301,"Antivenin, crotalidae polyvalent immune Fab (ovine)",CroFab,1/12/1994,treatment of envenomations inflicted by north american crotalid snakes.,Designated/Approved,,,Treatment of minimal and moderate North American Crotalidae envenomation,10/2/2000,10/2/2007,,"Protherics, Inc.","1207 17th Ave. S., Suite 103",,Nashville,Tennessee,' 37212 ' ,United States,78993,noma,"""gard:0004001""",
1302,Antivenom (crotalidae) purified (avian),,2/12/1991,treatment of envenomation by poisonous snakes belonging to the crotalidae family.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ophidian Pharmaceuticals, Inc.",5445 East Cheryl Parkway,,Madison,Wisconsin,' 53711 ' ,United States,54690,noma,"""gard:0004001""",
1303,antroquinonol,,4/30/2015,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Golden Biotechnology Corporation,"10F, No. 9, Ln. 3, Sec. 1, Zhong-Zheng E. Rd",,New Taipei City 251,,' ' ,Taiwan,476315,acute myeloid leukemia,"""gard:0012757""",
1304,antroquinonol,,1/21/2015,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Golden Biotechnology Corp.,"10F., No. 9, Ln 3",Tamsui Dist.,New Taipei City 251,,' ' ,Taiwan,460814,,,
1305,antroquinonol,,7/23/2015,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Golden Biotechnology Corporation,"10F, No. 9, Ln. 3","Tamsui Dist.,",New Taipei City 251,,' ' ,Taiwan,488115,hepatocellular carcinoma,"""gard:0016773""",
1306,apatinib mesylate,,6/15/2017,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Elevar Therapeutics, Inc.",2825 E Cottonwood Parkway,Suite 180,Salt Lake City,Utah,' 84121 ' ,United States,579117,,,
1307,"APG-115, a novel orally available small molecule MDM2 inhibitor",,9/2/2020,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,' 20850 ' ,United States,762520,,,
1308,"APG-115, an orally bioavailable small molecule.",,9/14/2020,treatment of acute myeloid leukemia (aml).,Designated,,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,' 20850 ' ,United States,763020,acute myeloid leukemia,"""gard:0012757""",
1309,"APG-2575, a novel, orally active, selective and potent BCL-2 inhibitor",,10/14/2020,treatment for multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,' 20850 ' ,United States,772320,multiple myeloma,"""gard:0007108""",
1310,aphidicolin,,4/20/2016,treatment of ebola virus infection,Designated,,Not FDA Approved for Orphan Indication,,,,,Biospherics.net LLC,Department of Pharmaceutical Sciences,University of Kentucky,Nicholasville,Kentucky,' 40356 ' ,United States,472415,,,
1311,Apilimod,,8/29/2023,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,"AI Therapeutics, Inc.",530 Old Whitfield Street,,Guilford,Connecticut,' 06437 ' ,United States,741220,amyotrophic lateral sclerosis,"""gard:0005786""",
1312,apilimod dimesylate,,7/1/2019,treatment of follicular lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"AI Therapeutics, Inc.",530 Old Whitfield Street,,Guilford,Connecticut,' 06437 ' ,United States,691619,lymphoma,"""gard:0020548""",
1313,apolipoprotein E mimetic peptide,,12/3/2012,treatment of homozygous familial hypercholesterolemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"LipimetiX Development, LLC",5 Commonwealth Road,Suite 2A,Natick,Massachusetts,' 01760 ' ,United States,381712,homozygous familial hypercholesterolemia,"""gard:0010416""",
1314,apolipoprotein E mimetic peptide (AEM-28(R)-14),,8/7/2017,treatment of homozygous familial hypercholesterolemia (hofh),Designated,,Not FDA Approved for Orphan Indication,,,,,"LipimetiX Development, LLC",5 Commonwealth Road,Suite 2A,Natick,Massachusetts,' 01760 ' ,United States,596517,homozygous familial hypercholesterolemia,"""gard:0010416""",
1315,Apomorphine,,7/17/1995,treatment of the on-off fluctuations associated with late-stage parkinson's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pentech Pharmaceuticals, Inc.",1110 Lake Cook Rd.,Suite 257,Buffalo Grove,Illinois,' 60089 ' ,United States,89295,,,
1316,Apomorphine,,10/20/1997,for use as rescue treatment for early morning motor dysfunction in late-stage parkinson's disease.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Scherer DDS,Frankland Road,Swindon SN5 8RU,Wiltshire,,' ' ,United Kingdom,107997,,,
1317,Apomorphine HCl,Apokyn,4/22/1993,treatment of the on-off fluctuations associated with late-stage parkinson's disease.,Designated/Approved,,,"For the acute, intermittent treatment of hypomobility, ""off"" episodes (""end-of-dose-wearing-off"" and unpredictable :on/off"" episodes) associated with advanced Parkinson's disease",4/20/2004,4/20/2011,,"MDD US Operations, LLC, a subsidiary of Supernus Pharmaceuticals, Inc.",9715 Key West Avenue,,Rockville,Maryland,' 20850 ' ,United States,57591,,,
1318,Apomorphine hydrochloride,,5/23/2006,for the treatment of patients in a vegetative state or minimally conscious state for up to 12 months following a severe traumatic brain injury (traumatic or spontaneous),Designated,,Not FDA Approved for Orphan Indication,,,,,"NeuroHealing Pharmaceuticals, Inc.",50 Undine Road,,Newton,Massachusetts,' 02135 ' ,United States,204305,,,
1319,apomorphine palmitate,,6/4/2018,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Leukos Biotech,"Muntaner 383, 3°2°",,Barcelona,Catalonia,' ' ,Spain,640618,acute myeloid leukemia,"""gard:0012757""",
1320,apraglutide,,12/20/2018,treatment of short bowel syndrome (sbs),Designated,,Not FDA Approved for Orphan Indication,,,,,VectivBio AG,36 Aeschenvorstadt,,Basel,Basel-Stadt,' ' ,Switzerland,639518,short bowel syndrome,"""gard:0001502""",
1321,apraglutide,,5/25/2021,prevention of acute graft-versus-host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,VectivBio AG,Aeschenvorstadt 36,,Basel,,' 4051 ' ,Switzerland,817021,,,
1322,apremilast,OTEZLA®,1/17/2013,treatment of behcet's disease,Designated/Approved,,,OTEZLA is indicated for the treatment of adult patients with oral ulcers associated with Behçet¿s Disease.,7/19/2019,7/19/2026,For the treatment of adult patients with oral ulcers associated with Behçet¿s disease,Amgen Inc.,One Amgen Center Drive,Mailstop: 27-2-D,Thousand Oaks,California,' 91320 ' ,United States,384812,,,
1323,apremilast,,1/17/2018,treatment of pediatric patients with ulcerative colitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mailstop 27-2-D,Thousand Oaks,California,' 91320 ' ,United States,622417,,,
1324,Aprotinin,Trasylol,11/17/1993,"for prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary c",Designated/Approved,,,,12/29/1993,12/29/2000,,Bayer Corporation,Pharmaceutical Division,400 Morgan Lane,West Haven,Connecticut,' 06516 ' ,United States,66992,,,
1325,"APX005M,a 10 mg/mL preservative-free solution (pH 5.5) containing 25 mM sodium acetate, 248 mM trehalose, and 0.02% polysorbate 20 in water for injection in a singleuse, 20 mL Type 1 clear glass vials.",,10/5/2020,treatment of esophageal and gastroesophageal junction cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pyxis Oncology, Inc.","321 Harrison Avenue, 11th Floor, Suite 1",,Boston,Massachusetts,' 02118 ' ,United States,768220,,,
1326,AQ-13 (4-aminoquinoline analog),,9/12/2008,treatment of malaria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immtech Pharmaceuticals, Inc.",150 Fairway Drive,Suite 150,Vernon Hills,Illinois,' 60061 ' ,United States,266808,malaria,"""gard:0006961""",
1327,Arcitumomab,,5/10/1996,"diagnosis and localization of primary, residual, recurrent and metastatic medullary thyroid carcinoma.",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,96596,thyroid carcinoma,"""gard:0019763""",
1328,Arenegyr,,8/22/2008,treatment of malignant pleural mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,MolMed S.p.A.,Via Olgettina 58,,Milan,,' ' ,Italy,263908,pleural mesothelioma,"""gard:0007026""",
1329,Arginine butyrate,,3/9/2023,treatment of short bowel syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Baxter Healthcare Corporation,1 Baxter Parkway,,Deerfield,Illinois,' 60015 ' ,United States,928222,short bowel syndrome,"""gard:0001502""",
1330,Arginine butyrate,,5/25/1994,treatment of sickle cell disease and beta thalassemia.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Vertex Pharmaceuticals Inc.,130 Waverly Street,,Cambridge,Massachusetts,' 02139 ' ,United States,82094,,,
1331,Arginine butyrate,,4/7/1992,treatment of beta-hemoglobinopathies and beta-thalassemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Perrine, Susan P., M.D.",Boston University,Cancer Research Center,Boston,Massachusetts,' 02118 ' ,United States,66292,beta-thalassemia,"""gard:0000871""",
1332,Arginyl-Glutamine Dipeptide,,9/20/2022,prevention of retinopathy of prematurity,Designated,,Not FDA Approved for Orphan Indication,,,,,Infant Bacterial Therapeutics AB,Bryggargatan 10,,Sweden,Stockholm,' 111 21 ' ,Sweden,899822,retinopathy of prematurity,"""gard:0005695""",
1333,arimoclomol,,3/29/2005,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,KemPharm Denmark A/S,Ole Maaløes Vej 3,,Copenhagen,København,' 2200 ' ,Denmark,202705,amyotrophic lateral sclerosis,"""gard:0005786""",
1334,arimoclomol,,11/2/2017,treatment of inclusion body myositis,Designated,,Not FDA Approved for Orphan Indication,,,,,KemPharm Denmark A/S,Ole Maaloes Vej 3,,Copenhagen,København,' 2200 ' ,Denmark,611317,inclusion body myositis,"""gard:0003896""",
1335,arimoclomol citrate,,1/13/2015,"treatment of neimann-pick disease, type c",Designated,,Not FDA Approved for Orphan Indication,,,,,Zevra Denmark A/S,Ole Maaloes Vej 3,,Copenhagen,København,' 2200 ' ,Denmark,458814,,,
1336,Aripiprazole,,7/22/2019,treatment of n-glycanase 1 (ngly1) deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Perlara PBC,"2625 Alcatraz Ave, #435",,Berkeley,California,' 94705 ' ,United States,694219,,,
1337,aripiprazole,Abilify,1/25/2006,treatment of tourette's syndrome,Designated/Approved,,,Treatment of pediatric patients with Tourette's,12/12/2014,12/12/2021,Treatment of pediatric patients with Tourette's,Otsuka Pharmaceutical Development,and Commercialization,1st Floor,Princeton,New Jersey,' 08540 ' ,United States,207905,,,
1338,"ARQ 531, a reversible non-covalent ATP competitive inhibitor of BTK",,12/7/2020,treatment of chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll),Designated,,Not FDA Approved for Orphan Indication,,,,,"ArQule, Inc., a wholly owned subsidiary of Merck Sharp & Dohme, LLC",126 East Lincoln Ave,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,787120,lymphoma,"""gard:0020548""",
1339,arsenic,,11/2/2001,"treatment of acute myelocytic leukemia subtypes m0, m1, m2, m4, m5, m6 and m7",Designated/Designation Withdrawn or Revoked,4/26/2024,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,' 19380 ' ,United States,146001,,,
1340,arsenic trioxide,,7/30/2018,treatment of graft-versus-host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Medsenic,204 avenue de Colmar,,Strasbourg,Grand Est,' ' ,France,645318,,,
1341,Arsenic trioxide,,3/4/2005,treatment of malignant glioma,Designated/Designation Withdrawn or Revoked,4/26/2024,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,' 19380 ' ,United States,201305,,,
1342,arsenic trioxide,,6/13/2003,treatment of liver cancer,Designated/Designation Withdrawn or Revoked,4/26/2024,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,' 19380 ' ,United States,167303,,,
1343,Arsenic trioxide,,5/13/2003,treatment of chronic lymphocytic leukemia,Designated/Designation Withdrawn or Revoked,4/26/2024,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,' 19380 ' ,United States,167203,,,
1344,arsenic trioxide,,10/18/2001,treatment of chronic myeloid leukemia,Designated/Designation Withdrawn or Revoked,4/26/2024,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,' 19380 ' ,United States,145701,chronic myeloid leukemia,"""gard:0006105""",
1345,arsenic trioxide,,7/17/2000,treatment of myelodysplastic syndrome.,Designated/Designation Withdrawn or Revoked,4/26/2024,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,' 19380 ' ,United States,135200,myelodysplastic syndrome,"""gard:0007132""",
1346,Arsenic trioxide,,4/28/2000,treatment of multiple myeloma.,Designated/Designation Withdrawn or Revoked,4/26/2024,Not FDA Approved for Orphan Indication,,,,,"TEVA Branded Pharmaceutical Products R & D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,' 19380 ' ,United States,134700,multiple myeloma,"""gard:0007108""",
1347,Arsenic trioxide,Trisenox,3/3/1998,treatment of acute promyelocytic leukemia.,Designated/Approved,,,In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.,1/12/2018,1/12/2025,In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.,"Teva Branded Pharmaceutical Products R&D, Inc.",41 Moores Road,,Frazer,Pennsylvania,' 19355 ' ,United States,109697,acute promyelocytic leukemia,"""gard:0000538""",
1348,Arsenic trioxide,Trisenox,3/3/1998,treatment of acute promyelocytic leukemia.,Designated/Approved,,,"For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation of PML/RAR-alpha gene expression.",9/25/2000,9/25/2007,,"Teva Branded Pharmaceutical Products R&D, Inc.",41 Moores Road,,Frazer,Pennsylvania,' 19355 ' ,United States,109697,acute promyelocytic leukemia,"""gard:0000538""",
1349,arsenic trioxide capsule (oral),,11/2/2015,treatment of acute promyelocytic leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Syros Pharmaceuticals, Inc.","35 CambridgePark Drive, 4th Floor",,Cambridge,Massachusetts,' 02140 ' ,United States,496415,acute promyelocytic leukemia,"""gard:0000538""",
1350,artemether/lumefantrine,Coartem,8/31/2007,for the treatment of infections due to plasmodium falciparum or mixed infections including p. falciparum.,Designated/Approved,,,"Treatment of malaria in patients of 5 kg bodyweight or above with acute, uncomplicated malaria due to Plasmodium falciparum or mixed infections including P. falciparum",4/7/2009,4/7/2016,,Novartis Pharmaceuticals,Bldg 405/4051,One Health Plaza,East Hanover,New Jersey,' 07936 ' ,United States,245507,,,
1351,artemisone,,7/19/2017,treatment of malaria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Artemis Therapeutics, Inc.",18 East 16th Street,Suite 307,New York,New York,' 10003 ' ,United States,590117,malaria,"""gard:0006961""",
1352,artesunate,,3/28/2006,immediate treatment of malaria,Designated/Approved,,,Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be followed by a complete treatment course of an appropriate oral antimalarial regimen.,5/26/2020,5/26/2027,For the initial treatment of severe malaria in adult and pediatric patients to always be followed by a complete treatment course of an appropriate oral antimalarial regimen.,Amivas Inc.,"100 Tuscanney Drive, Suite B2",,Frederick,Maryland,' 21702 ' ,United States,221206,malaria,"""gard:0006961""",
1353,artesunate,,7/22/2019,treatment of malaria,Designated/Designation Withdrawn or Revoked,7/14/2021,Not FDA Approved for Orphan Indication,,,,,La Jolla Pharmaceutical Company,4550 Towne Centre Court,,"San Diego,",California,' 92121 ' ,United States,693719,malaria,"""gard:0006961""",
1354,Artesunate,,9/5/2017,treatment of malaria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Guilin Pharmaceutical Co., Ltd.",No. 43 Qilidian Road,,Guilin Guangxi,Shanghai Shi,' ' ,China,598517,malaria,"""gard:0006961""",
1355,Artesunate,,7/19/1999,treatment of malaria.,Designated,,Not FDA Approved for Orphan Indication,,,,,World Health Organization,Special Programme for Research and Training in Tro,"Via Appia ,",Geneva 27,,' ' ,Switzerland,125599,malaria,"""gard:0006961""",
1356,Arylalkyl 3-ketoindole,,12/26/2017,treatment of dengue virus infection,Designated,,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",125 Trenton-Harbourton Road,,Titusville,New Jersey,' 08560 ' ,United States,618217,,,
1357,arylsulfatase A (rhASA),,2/27/2008,treatment of metachromatic leukodystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,254207,leukodystrophy,"""gard:0006895""",
1358,asciminib,Scemblix,2/27/2017,treatment of chronic myelogenous leukemia,Designated/Approved,,,"Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs)",10/29/2021,10/29/2028,"Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs)",Novartis Pharmaceutical Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,556416,,,
1359,asciminib,Scemblix,2/27/2017,treatment of chronic myelogenous leukemia,Designated/Approved,,,Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation,10/29/2021,10/29/2028,Treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) with the T315I mutation,Novartis Pharmaceutical Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,556416,,,
1360,ascorbic acid,,7/30/2018,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Renovion, Inc.",112 South Duke Street,,Durham,North Carolina,' 27701 ' ,United States,645618,cystic fibrosis,"""gard:0006233""",
1361,ascorbic acid,,12/12/2016,treatment of lung dysfunction following lung transplant,Designated,,Not FDA Approved for Orphan Indication,,,,,"Renovion, Inc.",2 Briar Bridge Lane,,Chapel Hill,North Carolina,' 27516 ' ,United States,545816,,,
1362,ascorbic acid,Ascor,8/31/2007,treatment of scurvy,Designated/Approved,,,"for the treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administrtaion is not possible, insufficient or contraindicated",10/2/2017,10/2/2024,"for the treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administrtaion is not possible, insufficient or contraindicated",McGuff Pharmaceuticals Inc.,2921 W. MacArthur Blvd.,Suite 141,Santa Ana,California,' 92704 ' ,United States,243707,,,
1363,Asfotase alfa,Strensiq,9/12/2008,treatment of hypophosphatasia,Designated/Approved,,,For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP),10/23/2015,10/23/2022,For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP),"Alexion Pharmaceuticals, Inc.",100 College St.,,New Haven,Connecticut,' 06510 ' ,United States,266608,hypophosphatasia,"""gard:0006734""",
1364,aspacytarabine,,7/25/2022,treatment of myelodysplastic syndromes,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioSight, Ltd.","3 Hayarden St., Airport City",P.O.B.1083,Lod,,' 7019802 ' ,Israel,835821,myelodysplastic syndrome,"""gard:0007132""",
1365,asparaginase erwinia chrysanthemi (recombinant)-rywn,Rylaze,6/22/2021,treatment of acute lymphoblastic leukemia,Designated/Approved,,,As a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.,6/30/2021,,,Jazz Pharmaceuticals Ireland Limited,"Waterloo Exchange, Waterloo Road",Fifth floor,Dublin,,' D04 E5W7 ' ,Ireland,773420,acute lymphoblastic leukemia,"""gard:0000522""",
1366,aspirin for injection (acetylsalicylic acid),,9/18/2020,treatment of kawasaki disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Rhoshan Pharmaceuticals Inc.,"225 Wilmington-West Chester Pike, Suite 200",,Chadds Ford,Pennsylvania,' 19317 ' ,United States,764120,kawasaki disease,"""gard:0006816""",
1367,astuprotimut-R,,5/29/2009,treatment of mage-a3 positive non-small cell lung cancer,Designated/Designation Withdrawn or Revoked,3/11/2015,Not FDA Approved for Orphan Indication,,,,,"GlaxoSmithKline Biologicals, S.A.",Rue de I'Institut 89,,B-1330 Rixensart,,' ' ,Belgium,283709,small cell lung cancer,"""gard:0009344""",
1368,astuprotimut-R,,5/29/2009,treatment of mage-a3 positive stages iib to iv malignant melanoma,Designated/Designation Withdrawn or Revoked,10/9/2015,Not FDA Approved for Orphan Indication,,,,,"GlaxoSmithKline Biologicals, S.A.",Rue de l'Institut 89,,B-1330 Rixensart,,' ' ,Belgium,283809,noma,"""gard:0004001""",
1369,ataluren,,12/10/2014,treatment of mucopolysaccharidosis type i,Designated/Designation Withdrawn or Revoked,2/15/2018,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,' 07080 ' ,United States,455814,mucopolysaccharidosis,"""gard:0007065""",
1370,ataluren,,1/10/2005,treatment of muscular dystrophy resulting from premature stop mutations in the dystrohin gene,Designated,,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",500 Warren Corporate Center Drive,,Warren,New Jersey,' 07059 ' ,United States,197204,muscular dystrophy,"""gard:0007922""",
1371,ataluren,,9/1/2015,treatment of aniridia,Designated/Designation Withdrawn or Revoked,3/15/2023,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,' 07080 ' ,United States,490215,,,
1372,ataluren,,3/10/2008,treatment of spinal muscular atrophy,Designated/Designation Withdrawn or Revoked,3/15/2023,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,' 07080 ' ,United States,255907,,,
1373,ataluren,,9/1/2004,for use in the treatment of cystic fibrosis resulting fron a nonsense (premature stopcodon) mutation in the cystic bibrosis transmembrane conductance regulatory gene,Designated/Designation Withdrawn or Revoked,6/21/2017,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,' 07080 ' ,United States,192004,cystic fibrosis,"""gard:0006233""",
1374,atezolizumab,TECENTRIQ,10/13/2016,treatment of small cell lung cancer (sclc),Designated/Approved,,,"TECENTRIQ®, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)",3/18/2019,3/18/2026,"TECENTRIQ®, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)","Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,541216,small cell lung cancer,"""gard:0009344""",
1375,atezolizumab,Tecentriq,10/8/2020,treatment of soft tissue sarcoma,Designated/Approved,,,as a single agent for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS),12/9/2022,12/9/2029,treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic alveolar soft part sarcoma (ASPS),"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080-4990 ' ,United States,769320,soft tissue sarcoma,"""gard:0004898""",
1376,Atezolizumab,,1/7/2021,treatment of esophageal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Genentech Inc.,"1 DNA Way, MS #45-1A",,South San Francisco,California,' 94080-4990 ' ,United States,792320,,,
1377,Atezolizumab,,2/13/2017,"treatment of patients with stage iib, iic, iii, and iv melanoma",Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,MS 35-5E,South San Francisco,California,' 94080 ' ,United States,574817,noma,"""gard:0004001""",
1378,atezolizumab,TECENTRIQ®,2/13/2017,"treatment of stage llb, llc, lll and iv melanoma",Designated/Approved,,,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma,7/30/2020,7/30/2027,indicated in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma,"Genentech, Inc.",1 DNA Way,MS 35-5E,South San Francisco,California,' 94080 ' ,United States,550616,noma,"""gard:0004001""",
1379,atezolizumab + bevacizumab,Tecentriq and Avastin,1/8/2018,treatment of hepatocellular carcinoma (hcc),Designated/Approved,,,"TECENTRIQ, in combination with bevacizumab, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.",5/29/2020,5/29/2027,TECENTRIQ for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.,"Genentech, Inc.",1 DNA Way,MS 451A,South San Francisco,California,' 94080 ' ,United States,619317,hepatocellular carcinoma,"""gard:0016773""",
1380,atezolizumab + bevacizumab,Tecentriq and Avastin,1/8/2018,treatment of hepatocellular carcinoma (hcc),Designated/Approved,,,"AVASTIN, in combination with atezolizumab, for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.",5/29/2020,5/29/2027,AVASTIN for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.,"Genentech, Inc.",1 DNA Way,MS 451A,South San Francisco,California,' 94080 ' ,United States,619317,hepatocellular carcinoma,"""gard:0016773""",
1381,"ATI-450, an orally available small molecule inhibitor of the p38alpha mitogen activated protein kinase (MAPK)/MAPK-activated protein kinase 2 (MK2) inflammatory signaling pathway",,1/21/2021,treatment of cryopyrin-associated periodic syndrome,Designated/Designation Withdrawn or Revoked,1/3/2024,Not FDA Approved for Orphan Indication,,,,,Aclaris Theapeutics Inc.,"701 Lee Road, Suite 103",,Wayne,Pennsylvania,' 19087 ' ,United States,795720,cryopyrin-associated periodic syndrome,"""gard:0010927""",
1382,Atibuclimab,,9/21/2023,treatment of arrhythmogenic cardiomyopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Implicit Bioscience Ltd.,32 Logan Rd.,,Woolloongabba,Queensland,' 04102 ' ,Australia,962123,,,
1383,atidarsagene autotemcel,Lenmeldy,3/8/2018,treatment of the metachromatic leukodystrophy (including pre-symptomatic metachromatic leukodystrophy),Designated/Approved,,,"treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early juvenile (ESEJ) metachromatic leukodystrophy (MLD)",3/18/2024,3/18/2031,"treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early juvenile (ESEJ) metachromatic leukodystrophy (MLD)",Orchard Therapeutics Ltd.,245 Hammersmith Road,,London,,' W6 8PW ' ,United Kingdom,631518,leukodystrophy,"""gard:0006895""",
1384,"atoltivimab, maftivimab, and odesivimab-ebgn",INMAZEB™,7/14/2016,treatment of ebola virus infection,Designated/Approved,,,"treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection",10/14/2020,10/14/2027,"treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection","Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,536316,,,
1385,"atoltivimab, odesivimab and maftivimab",,12/23/2019,post-exposure prophylaxis against ebola virus infection,Designated,,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,714619,,,
1386,Atomoxetine hydrochloride,,8/26/2003,treatment of tourette's syndrome,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Eli Lilly & Company,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,173003,,,
1387,Atovaquone,,3/16/1993,treatment and suppression of toxoplasma gondii encephalitis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"GlaxoSmithKline, Inc.",5 Moore Drive,PO Box 13398,Research Triangle Park,North Carolina,' 27709 ' ,United States,66692,encephalitis,"""gard:0019357""",
1388,Atovaquone,Mepron,9/10/1990,treatment of aids associated pneumocystis carinii pneumonia.,Designated/Approved,,,For the acute oral treatment of mild to moderate Pneumocystis carinii pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole.,11/25/1992,11/25/1999,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,' 27709 ' ,United States,48890,,,
1389,Atovaquone,,3/16/1993,primary prophylaxis of hiv-infected persons at high risk for developing toxoplasma gondii encephalitis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"GlaxoSmithKline, Inc.",5 Moore Drive,PO Box 13398,Research Triangle Park,North Carolina,' 27709 ' ,United States,66792,encephalitis,"""gard:0019357""",
1390,Atovaquone,Mepron,8/14/1991,"prevention of pneumocystis carinii pneumonia (pcp) in high-risk, hiv-infected patients defined by a history of one or more episodes of pcp and/or a peripheral cd4+ (t4 helper/inducer) lymphocyte count less than or equal to 200/mm3.",Designated/Approved,,,Prevention of PCP in patients who are intolerant to trimethoprim-sulfamethoxazole.,1/5/1999,1/5/2006,,Glaxo Wellcome Research and Development,5 Moore Drive,PO Box 13398,Research Triangle Park,North Carolina,' 27709 ' ,United States,48990,,,
1391,Atrasentan,,9/29/2016,treatment of pediatric nephrotic syndrome,Designated/Designation Withdrawn or Revoked,10/1/2018,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,Regulatory Affairs,1 North Waukegan Road,North Chicago,Illinois,' 60044 ' ,United States,537116,c syndrome,"""gard:0005978""",
1392,Attenuated autologous cancer cells and granulocyte macrophage colony stimulating factor in combination with activated autologous blood derived T-cells,,4/27/2007,treatment of primary central nervous system malignancies,Designated,,Not FDA Approved for Orphan Indication,,,,,"TVAX Biomedical, LLC",8006 Reeder Street,,Lenexa,Kansas,' 66214 ' ,United States,239307,,,
1393,Attenuated Salmonella typhimurium containing the gene for human interleukin-2 (IL-2),,5/17/2022,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Salspera Inc.,3510 Hopkins Place N,,Oakdale,Minnesota,' 55128 ' ,United States,877922,,,
1394,auranofin,,4/30/2010,treatment of amebiasis,Designated,,Not FDA Approved for Orphan Indication,,,,,Ctr for Discovery & Innovation in Parasitic Diseas,"U. of CA, San Francisco","QB3, Byers Hall 508B",San Francisco,California,' 94158 ' ,United States,305210,,,
1395,Autologous Activated T Lymphocytes (ATL),,3/28/2018,treatment of hepatocellular carcinoma (hcc),Designated,,Not FDA Approved for Orphan Indication,,,,,Lukas Biomedical Inc.,"3F, No. 2, Ln. 265, Sec. 4, Xin-Yi Rd",,Da’an,Taipei City,' ' ,Taiwan,631218,hepatocellular carcinoma,"""gard:0016773""",
1396,autologous adipose derived mesenchymal stromal cells,,10/22/2014,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Mayo Clinic,200 First Street SW,,Rochester,Minnesota,' 55905 ' ,United States,427014,amyotrophic lateral sclerosis,"""gard:0005786""",
1397,autologous adipose tissue derived mesenchymal stem cells,,5/4/2016,treatment of buerger's disease (thromboangiitis obliterans).,Designated,,Not FDA Approved for Orphan Indication,,,,,Biostar Stem Cell Research Institute,"305 Lotte IT Castle 2,",550-1 Gasan-dong,Seoul,,' ' ,South Korea,518116,,,
1398,autologous adult bone marrow-derived and unexpanded CD133+ hematopoietic stem cells (CD133+ BMDSCs) mobilized from peripheral blood (PB),,2/1/2019,treatment of women with infertility and a thin endometrium seeking pregnancy,Designated,,Not FDA Approved for Orphan Indication,,,,,Asherman Therapy S.L.U.,Ronda Narcís Monturiol Estarriol,"nº11 Parcela B, Edificio Europark",Valencia,,' ' ,Spain,613117,,,
1399,Autologous adult live cultured osteoblasts,,12/20/2018,treatment of osteonecrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Regrow Biosciences Pvt. Ltd.,"2 ABC, Acme Plaza",Andheri Kurla Road,Mumbai,Maharashtra,' ' ,India,664218,osteonecrosis,"""gard:0021657""",
1400,autologous anti-CD19 CAR T cell immunotherapy,,4/24/2024,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kyverna Therapeutics, Inc.","5980 Horton Street, Suite 550",,Emeryville,California,' 94608 ' ,United States,999024,myasthenia gravis,"""gard:0007122""",
1401,autologous anti-CD19 chimeric antibody receptor T cells designed to deplete CD19+ B cells,,1/31/2024,treatment of idiopathic inflammatory myopathies (iim),Designated,,Not FDA Approved for Orphan Indication,,,,,"Cabaletta Bio, Inc","2929 Arch Street, Suite 600",,Philadelphia,Pennsylvania,' 19104 ' ,United States,985523,,,
1402,autologous anti-CD19 Chimeric Antigen Receptors (CAR)-T cells expressing a short hairpin RNA (shRNA) against interleukin-6 (IL-6) (also termed ssCART-19 cells),,7/11/2022,treatment of acute lymphocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Unicar Bio-Therapy, Ltd","No. 780, Cailun Road, Pudong New Area ","Room I, 3rd Floor ",Shanghai ,shanghai,' 201208 ' ,China,860221,,,
1403,Autologous Anti-CD22 CAR T-Cells,,9/14/2020,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Center for Cancer Research, National Cancer Institute",National Institutes of Health,,Bethesda,Maryland,' 20892 ' ,United States,762620,acute lymphoblastic leukemia,"""gard:0000522""",
1404,autologous anti-CLL-1 CAR T-cell therapy,,11/23/2021,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Guangzhou Bio-gene Technology Co., Ltd","206 Kaiyuan Blvd, Huangpu District",,Guangzhou,Guangdong,' 510530 ' ,China,847421,acute myeloid leukemia,"""gard:0012757""",
1405,autologous antigen presenting cells pulsed with autologous tumor Ig idiotype,,4/18/2002,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Dendreon Corporation,3005 First Avenue,,Seattle,Washington,' 98121 ' ,United States,153701,multiple myeloma,"""gard:0007108""",
1406,Autologous auricular cartilage construct for subcutaneous implantation,,11/6/2019,treatment of microtia (including anotia),Designated,,Not FDA Approved for Orphan Indication,,,,,"PrintBio, Inc.",51-36 35th Street,,Long Island City,New York,' 11101 ' ,United States,714219,anotia,"""gard:0016835""",
1407,Autologous B cell-derived ex vivo gene edited cell therapy comprised of expanded/differentiated B lymphocyte lineage genetically engineered to express and secrete factor IX,,5/15/2024,treatment of hemophilia b,Designated,,Not FDA Approved for Orphan Indication,,,,,"Be BioPharma, Inc.","One Kendall Sq, B200, 3rd Floor",,Cambridge,Massachusetts,' 02139 ' ,United States,1001524,hemophilia,"""gard:0010418""",
1408,autologous B cells engineered to secrete intact alpha-galactosidase A enzyme,,9/19/2023,treatment of fabry disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Walking Fish Therapeutics,"450 East Jamie Court, Suite 300",,San Francisco,California,' 94080 ' ,United States,961323,fabry disease,"""gard:0006400""",
1409,Autologous blood derived natural killer cells,,9/14/2020,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"CHA Biotech. Co., Ltd","335, Pangyo-r",Bundang-gu,Seongnam-si,Gyeonggi-do,' 13488 ' ,Republic of Korea,764520,,,
1410,Autologous blood outgrowth endothelial cells transduced with lentiviral vector to restore factor VIII function,,10/30/2023,treatment of hemophilia a,Designated,,Not FDA Approved for Orphan Indication,,,,,Sernova Corp,700 Collip Circle Suite 114,,London,Ontario,' N6G 4X8 ' ,Canada,967423,hemophilia,"""gard:0010418""",
1411,"autologous bone marrow CD34+ cells transduced ex vivo with a self activating HIV-1 -based lentiviral vector, EFS-ADA",,10/21/2014,treatment of adenosine deaminase deficient severe combined immunodeficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Donald B. Kohn, M.D.","Box 957243, 610 Charles E. Young Drive East","3161 Terasaki Life Sciences Building, UCLA",Los Angeles,California,' 90095 ' ,United States,449114,severe combined immunodeficiency,"""gard:0007628""",
1412,autologous CAR-T cell targeting HER2 and IL13Ralpha2 that simultaneously secrete CD3 EGFR/EGFRvIII bispecific T cell engagers,,1/18/2024,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shanghai Simnova Biotechnology Co., Ltd.","Building 16, Lane 118, Furonghua Road",Pudong New Area,Shanghai,Shanghai,' 201200 ' ,China,982723,,,
1413,autologous CD3+ T cell product transduced with transgene constructs expressing anti-human mesothelin (MSLN) CAR and self-secreting anti-human PD-1 nanobody,,5/16/2023,treatment of mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shanghai Cell Therapy Group Pharmaceutical Technology Co., Ltd.","118 Yuanmin Road, Jiading District, Shanghai, China.",,Shanghai,Shanghai,' 201805 ' ,China,937323,,,
1414,"Autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane bound Interleukin-15, and a truncated form of human HER1t (kill switch) on the cell surface.",,12/31/2019,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Precigen,20358 Seneca Meadows Parkway,,Germantown,Maryland,' 20876 ' ,United States,717019,acute myeloid leukemia,"""gard:0012757""",
1415,Autologous CD3+ T cells transduced with retroviral vector containing a chimeric antigen receptor directed against CD19 (Autologous CD3+ T cells containing CD19 chimeric antigen receptor),,11/13/2014,treatment of acute lymphoblastic leukemia (all),Designated/Designation Withdrawn or Revoked,10/12/2018,Not FDA Approved for Orphan Indication,,,,,"Juno Therapeutics, Inc.","307 Westlake Ave. N., St. 300",,Seattle,Washington,' 98109 ' ,United States,452814,acute lymphoblastic leukemia,"""gard:0000522""",
1416,autologous CD34+ bone marrow derived stem cells transduced with a self-inactivating gammaretroviral vector encoding the human IL2RG (yc),,1/15/2015,treatment of severe combined immune deficiency-x1,Designated,,Not FDA Approved for Orphan Indication,,,,,Boston Children's Hospital,Div. of Hematology/Oncology,Karp 08215,Boston,Massachusetts,' 02115 ' ,United States,458514,,,
1417,Autologous CD34+ cell enriched haematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding for human Interferon-alpha2 cDNA (Temferon),,3/1/2023,treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,Genenta Sciences,430 East 29th Street,,New York,New York,' 10016 ' ,United States,927322,glioblastoma,"""gard:0002491""",
1418,autologous CD34+ cell enriched hematopoietic stem cells genetically modified ex vivo with a lentiviral vector to contain codon-optimized complementary deoxyribonucleic acid that encodes human beta-glucocerebrosidase,,9/25/2019,treatment of gaucher disease,Designated/Designation Withdrawn or Revoked,9/8/2023,Not FDA Approved for Orphan Indication,,,,,"AVROBIO, Inc.",One Kendall Square,Building 300,Cambridge,Massachusetts,' 02139 ' ,United States,702319,gaucher disease,"""gard:0008233""",
1419,autologous CD34+ cell- enriched population transduced with lentiviral vector encoding the codon-optimized human alpha-galactosidase A complementary deoxyribonucleic acid sequence.,,12/17/2018,treatment of fabry disease,Designated/Designation Withdrawn or Revoked,9/8/2023,Not FDA Approved for Orphan Indication,,,,,"AVROBIO, Inc.",One Kendall Square,Building 300,Cambridge,Massachusetts,' 02139 ' ,United States,664318,fabry disease,"""gard:0006400""",
1420,Autologous CD34+ cells edited with CRISPR/Cas9 and transduced with an adeno-associated virus vector serotype 6 containing the codon-optimized version of PKLR gene,,3/7/2023,treatment of pyruvate kinase deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Consorcio Centro de Investigación Biomédica en Red (CIBER),"C/ Monforte de Lemos, 3-5 Pabellón 11, Planta 0",,Madrid,Madrid,' 28029 ' ,Spain,901022,,,
1421,autologous CD34+ Cells Enriched with Blood Derived Mitochondria,,2/26/2019,treatment of pearson syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Minovia Therapeutics Ltd.,3 Hasadna Street,,Tirat,HaCarmel,' ' ,Israel,673118,pearson syndrome,"""gard:0007343""",
1422,Autologous CD34+ cells transduced with a lentiviral vector that encodes for the human NCF1 cDNA sequence,,3/1/2023,treatment of chronic granulomatous disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Somagenetix AG,In der Breiti,,Zurich,Zurich,' 8047 ' ,Switzerland,927622,chronic granulomatous disease,"""gard:0006100""",
1423,Autologous CD34+ cells transduced with gamma globin lentiviral vector,,1/14/2020,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Cincinnati Children’s Hospital Medical Center,"3333 Burnet Avenue, MLC 11027",,Cincinnati,Ohio,' 45229 ' ,United States,720419,,,
1424,Autologous CD34+ cells transfected with lentiviral vector containing the human WAS cDNA (Telethon 003),,4/30/2010,treatment of wiskott aldrich syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Fondazione Telethon ETS,Via Varese 16/B,,Rome,,' 00185 ' ,Italy,304310,h syndrome,"""gard:0010239""",
1425,Autologous CD34+ enriched cell population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human gp91phox gene,,1/16/2020,treatment of x-linked chronic granulomatous disease (x-cgd),Designated,,Not FDA Approved for Orphan Indication,,,,,Orchard Therapeutics (Europe) Limited,245 Hammersmith Road,,London,,' W6 8PW ' ,United Kingdom,718919,chronic granulomatous disease,"""gard:0006100""",
1426,Autologous CD34+ enriched cell population that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene,,6/22/2020,treatment of mucopolysaccharidosis type i (mps-i),Designated,,Not FDA Approved for Orphan Indication,,,,,Orchard Therapeutics (Europe) Limited,245 Hammersmith Road,,London,,' W6 8PW ' ,United Kingdom,750120,mucopolysaccharidosis,"""gard:0007065""",
1427,autologous CD34+ enriched cells transduced with a lentiviral vector containing RNA resulting in codon-optimized cDNA encoding for functional human cystinosin,,3/4/2020,treatment of cystinosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936-1080 ' ,United States,727319,cystinosis,"""gard:0006236""",
1428,Autologous CD34+ hematopoietic stem and progenitor cells edited by CRISPR/CAS12a at the HBG1 and HBG2 promoters,,4/26/2023,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Editas Medicine, Inc.",11 Hurley Street,,Cambridge,Massachusetts,' 02141 ' ,United States,762920,,,
1429,autologous CD34+ hematopoietic stem and progenitor cells edited by CRISPR/Cas12a ribonucleoprotein (RNP) at the HBG1 and HBG2 promoters,,5/4/2022,treatment of beta thalassemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Editas Medicine, Inc.",11 Hurley Street,,Cambridge,Massachusetts,' 02141 ' ,United States,874122,,,
1430,Autologous CD34+ hematopoietic stem and progenitor cells modified ex vivo with a lentiviral vector that restores endogenously regulated expression of WASp,,10/18/2023,treatment of wiskott-aldrich syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,ImmunoVec,570 Westwood Plaza Building 114,,Los Angeles,California,' 90095 ' ,United States,925222,h syndrome,"""gard:0010239""",
1431,autologous CD34+ hematopoietic stem and progenitor cells modified ex-vivo with a lentiviral vector that restores expression of Gp91phox,,4/7/2021,treatment of chronic granulomatous disease,Designated,,Not FDA Approved for Orphan Indication,,,,,ImmunoVec,570 Westwood Plaza Building 114,,Los Angeles,California,' 90095 ' ,United States,810721,chronic granulomatous disease,"""gard:0006100""",
1432,autologous CD34+ hematopoietic stem and progenitor cells modified ex-vivo with a lentiviral vector which restores endogenously regulated expression of FOXP3,,4/27/2021,treatment of immune dysregulation polyendocrinopathy x-linked (ipex) syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,ImmunoVec,570 Westwood Plaza Building 114,,Los Angeles,California,' 90095 ' ,United States,815321,polyendocrinopathy,"""gard:0019800""",
1433,autologous CD34+ hematopoietic stem and progenitor cells transduced with lentiviral vector containing the human DCLRE1C complementary DNA,,6/20/2023,treatment of patients with artemis-deficient severe combined immunodeficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Morton J Cowan, M.D.","Department of Pediatrics, Division of Allergy, Immunology and Blood and Marrow Transplantation, UCSF and UCSF Benioff Children’s Hospital","Mission Hall, Floor 4, 550 16th Street",San Francisco,California,' 94143-0434 ' ,United States,943923,severe combined immunodeficiency,"""gard:0007628""",
1434,Autologous CD34+ hematopoietic stem and progenitor cells transfected with zinc finger nuclease messenger RNAs SB-mRENH1 and SB-mRENH2,,6/11/2019,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sangamo Therapeutics, Inc.","501 Canal Blvd., Suite A100",,Richmond,Massachusetts,' 94005 ' ,United States,674318,,,
1435,autologous CD34+ hematopoietic stem and progenitor cells transfected with zinc finger nuclease messenger RNAs SB-mRENH1 and SB-mRENH2,,6/4/2019,treatment of beta-thalassemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sangamo Therapeutics, Inc.","501 Canal Blvd., Suite A100",,Richmond,California,' 94005 ' ,United States,673618,beta-thalassemia,"""gard:0000871""",
1436,autologous CD34+ hematopoietic stem and progenitor cells with a HBB gene corrected by CRISPR/Cas9 in combination with a gcSCD-AAV6 vector,,11/23/2021,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Graphite Bio, Inc.","201 Haskins Way, Suite 210",,South San Francisco,California,' 94080 ' ,United States,846821,,,
1437,Autologous CD34+ hematopoietic stem cells transduced with an hCD11b lentiviral vector encoding for the human N-sulfoglucosamine sulfohydrolase (SGSH) gene,,5/3/2017,treatment of mucopolysaccharidosis iiia,Designated,,Not FDA Approved for Orphan Indication,,,,,Orchard Therapeutics Ltd.,245 Hammersmith Road,,London,,' W6 8PW ' ,United Kingdom,562516,mucopolysaccharidosis,"""gard:0007065""",
1438,Autologous CD4+/CD8+ T cells expressing a BCMA-specific chimeric antigen receptor (CAR),,9/28/2017,treatment of multiple myeloma (mm),Designated,,Not FDA Approved for Orphan Indication,,,,,"Juno Therapeutics, Inc.",400 Dexter Avenue North,Suite 1200,Seattle,Washington,' 98109 ' ,United States,606117,multiple myeloma,"""gard:0007108""",
1439,autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor and a truncated epidermal growth factor receptor,,9/7/2016,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Juno Therapeutics, Inc.",400 Dexter Avenue North,Suite 1200,Seattle,Washington,' 98109 ' ,United States,533416,acute lymphoblastic leukemia,"""gard:0000522""",
1440,autologous CD4+/CD8+ T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19,,11/6/2014,treatment of acute lymphoblastic leukemia (inclusive of b-cell acute lymphoblastic leukemia),Designated/Designation Withdrawn or Revoked,10/12/2018,Not FDA Approved for Orphan Indication,,,,,"Juno Therapeutics, Inc.",400 Dexter Avenue N,400 Dexter Avenue N,Seattle,Washington,' 98109 ' ,United States,450614,acute lymphoblastic leukemia,"""gard:0000522""",
1441,Autologous CD4+/CD8+ T cells transduced with lentiviral vector directed against MAGE-A4 antigen,,3/23/2023,treatment of stage iib to iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,TCRx Therapeutics Ltd.,"Bldg B, 3-1 Xinjinhu Lu",Floor 6,Nanjing,Jiangsu,' 210031 ' ,China,930822,noma,"""gard:0004001""",
1442,autologous CD4+CD25hiFoxP3+regulatory T cells,,11/19/2013,prevention of graft rejection following solid organ transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,iREG Medical AB,"Tallmov 2A,",,Uppsala,,' ' ,Sweden,409613,,,
1443,autologous cell therapy product manufactured from tumor-infiltrating lymphocytes that have been harvested from surgically resected tumor tissue and expanded ex vivo,,11/28/2022,treatment of stage ib2 (tumor size >2 cm) to stage iv cervical cancer,Designated/Designation Withdrawn or Revoked,3/23/2023,Not FDA Approved for Orphan Indication,,,,,"Instil Bio, Inc.",3963 Maple Avenue,Suite 350,Dallas,Texas,' 75219 ' ,United States,851621,,,
1444,Autologous Chimeric Antigen Receptor (CAR) Modified Recombinant T Cells Targeting EGFRvIII,,5/9/2023,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Beijing DCTY® Biotech Co., Ltd.",Building 4 No. 86 Shuangying West Road,,Beijing,Beijing,' 102200 ' ,China,937123,,,
1445,Autologous chimeric antigen receptor (CAR) T cells targeting B7-H3,,3/18/2022,treatment for neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,PersonGen BioTherapeutics (Suzhou) Co. Ltd.,218 Xinghu St. BioBay Build. B1,Suite 412 SIP,Suzhou,Jiangsu,' 215125 ' ,China,871822,neuroblastoma,"""gard:0007185""",
1446,autologous chimeric antigen receptor (CAR) T cells targeting CD7,,8/31/2023,treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Hebei Senlang Biotechnology Co. Ltd.,"Room 512 and 513, Building 1, No.136 Yellow River Avenue",Shijiazhuang High-tech Development Zone,Shijiazhuang,Hebei,' 050000 ' ,China,957723,lymphoma,"""gard:0020548""",
1447,autologous chimeric antigen receptor (CAR) T cells targeting intercellular adhesion molecule-1 (ICAM-1),,4/9/2019,"treatment of anaplastic thyroid cancer, medullary thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer",Designated,,Not FDA Approved for Orphan Indication,,,,,"AffyImmune Therapeutics, Inc.",12 Michigan Dr.,,Natick,Massachusetts,' 01760 ' ,United States,634518,,,
1448,Autologous chimeric antigen receptor (CAR)-positive T cells targeting cluster of differentiation 19 (CD19) and B cell maturation antigen (BCMA),,11/4/2021,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gracell Biopharmaceuticals, Inc.",530 Lytton Avenue,2nd Floor,Palo Alto,California,' 94301 ' ,United States,845421,multiple myeloma,"""gard:0007108""",
1449,Autologous Claudin 18.2 specific chimeric antigen receptor (CAR)-T cell therapy,,7/18/2022,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Suzhou Immunofoco Biotechnology Co., Ltd","Unit 504-506, Bldg A3, Creative Industry Park, Xinghu Street",,Suzhou Industrial Park,Jiangsu Province,' ' ,China,892622,,,
1450,Autologous Claudin18.2-targeted CAR-T cells,,11/22/2022,treatment of gastric cancer (gc) including gastroesophageal junction (gej) cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Legend Biotech USA, Inc.",2101 Cottontail Lane,,Somerset,New Jersey,' 08873 ' ,United States,912522,,,
1451,autologous cluster of differentiation 34 positive (CD34+) hematopoietic stem/progenitor cells transduced with the LVMWAS lentiviral vector encoding the human Wiskott-Aldrich Syndrome protein,,3/20/2024,treatment of wiskott-aldrich syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,978223,h syndrome,"""gard:0010239""",
1452,Autologous cultured endothelial cells on a donor human corneal disk,,6/1/2007,"treatment of fuch's dystrophy, pseudophakic bullous keratopathy, and bullous keratopathy",Designated,,Not FDA Approved for Orphan Indication,,,,,"Cellular Bioengineering, Inc.",1946 Young Street,,Honolulu,Hawaii,' 96826 ' ,United States,235206,,,
1453,Autologous Cytokine-Induced Killer Cells (Cytokine-Induced Killer Cells Plus Cytotoxic T Lymphocytes),,8/1/2018,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Green Cross Cell Corporation,"4, 6th floor, SJ Technovile 278","Beotkkot-ro, Geumcheon-gu",Seoul,Seoul,' ' ,South Korea,645818,glioblastoma,"""gard:0002491""",
1454,Autologous Cytokine-Induced Killer Cells (Cytokine-Induced Killer Cells plus Cytotoxic T Lymphocytes),,6/21/2018,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,GC Cell Corporation,"4, 6th floor, SJ Technovile 278","Beotkkot-ro, Geumcheon-gu",Seoul,Seoul,' ' ,South Korea,642418,hepatocellular carcinoma,"""gard:0016773""",
1455,autologous Cytokine-Induced Killer Cells (Cytokine-induced Killer Cells plus Cytotoxic T Lymphocytes),,9/10/2018,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,Green Cross Cell Corporation,"4, 6th floor, SJ Technovile 278","Beotkkot-ro, Geumcheon-gu",Seoul,Seoul,' ' ,South Korea,649218,,,
1456,Autologous delta-like-ligand 3 (DLL3)-targeted chimeric antigen receptor (CAR) T-cells,,6/21/2023,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Legend Biotech USA, Inc.",2101 Cottontail Lane,,Somerset,New Jersey,' 08873 ' ,United States,944523,small cell lung cancer,"""gard:0009344""",
1457,Autologous dendritic cell/tumor antigens,,9/27/2016,treatment of glioblastoma multiforme (gbm),Designated,,Not FDA Approved for Orphan Indication,,,,,"Ever Supreme Bio Technology, Co. Ltd.","Rm. A,B, 10F, No.573, Sec.2, Taiwan Blvd, West District",,,Taichung City,' ' ,Taiwan,537016,glioblastoma,"""gard:0002491""",
1458,Autologous dendritic cells ex vivo incubated with zebularine and factor VIII,,9/24/2018,treatment to reduce factor viii neutralizing antibodies (inhibitors),Designated,,Not FDA Approved for Orphan Indication,,,,,Idogen AB,2 Scheelevägen,,,Skåne län,' ' ,Sweden,603717,,,
1459,autologous dendritic cells pulsed with allogeneic tumor cell lysate,,5/6/2014,treatment of malignant mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Amphera BV,Onderwijs Blvd 219,5223 DE's-Hertogenbosch,,,' ' ,Netherlands,430214,,,
1460,Autologous dendritic cells pulsed with autologous antigens from primay malignant brain tumor cells,,11/29/2002,treatment of primary brain malignant cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Northwest Biotherapeutics, Inc.",22322 20th Avenue SE,Suite 150,Bothell,Washington,' 98021 ' ,United States,162902,,,
1461,autologous dendritic cells pulsed with hepatitis B virus antigens,,10/25/2018,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jiangsu Antae Biological Technology Co., Ltd.","No. 1, G01 Medical City of China Avenue,",,Taizhou,Jiangsu Province,' ' ,China,656718,hepatocellular carcinoma,"""gard:0016773""",
1462,Autologous dendritic cells pulsed with recombinant human fusion protein (mucin1- glutathione S transferase) coupled to oxidized polymannose,,9/13/2010,treatment of ovarian cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,Prima Biomed Ltd.,1233 High Street,Suite 1,Armadale,Victoria,' ' ,Australia,315510,ovarian cancer,"""gard:0007295""",
1463,Autologous Desmoglein 3 (DSG3) Chimeric Autoantibody Receptor-directed (CAAR) T cells,,1/28/2020,treatment of pemphigus vulgaris,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cabaletta Bio, Inc.","2929 Arch Street, Suite 600",,Philadelphia,Pennsylvania,' 19104 ' ,United States,720519,pemphigus vulgaris,"""gard:0007355""",
1464,Autologous DNP-conjugated tumor vaccine,,2/23/1999,for adjuvant therapy in melanoma patients with surgically resectable lymph node metastasis (stage iii and limited stage iv disease).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Avax Technologies, Inc.",9200 Indian Creek Parkway,"Building 9, Suite 200",Overland Park,Kansas,' 66210 ' ,United States,119498,noma,"""gard:0004001""",
1465,Autologous Engineered Skin Substitute,,6/1/2012,treatment of hospitalized patients with deep partial and full thickness burns requiring grafting.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Amarantus BioScience Holdings, Inc.",655 Montgomery St.,Suite 900,San Francisco,California,' 94111 ' ,United States,356211,,,
1466,autologous engineered T-cell product that targets B-cell maturation antigen (BCMA),,9/10/2018,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,2/12/2019,Not FDA Approved for Orphan Indication,,,,,"Kite Pharma, Inc.",2225 Colorado Avenue,,Santa Monica,California,' 90404 ' ,United States,648418,multiple myeloma,"""gard:0007108""",
1467,autologous enriched T cells transduced with a lentiviral vector to express an anti-CD19 Chimeric Antigen Receptor,,11/4/2019,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Autolus Incorporated, US subsidiary of Autolus Limited",805 King Farm Boulevard,Suite 550,Rockville,Maryland,' 20850 ' ,United States,708319,acute lymphoblastic leukemia,"""gard:0000522""",
1468,Autologous enriched T-cells genetically modified with a retroviral vector to express two chimeric antigen receptors (CARs) targeting cluster of differentiation (CD) 19 and CD 22.,,4/17/2019,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Autolus Limited,Forest House,58 Wood Lane,London,,' ' ,United Kingdom,680119,acute lymphoblastic leukemia,"""gard:0000522""",
1469,Autologous EpCAM specific CAR-T cell injection,,8/16/2023,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Suzhou Immunofoco Biotechnology Co., Ltd","Unit 504-506, Bldg A3, Creative Industry Park, Xinghu Street",,Suzhou Industrial Park,Jiangsu Province,' ' ,China,954223,,,
1470,autologous Epstein-Barr specific T-cells,,5/31/2017,treatment of post-transplant lymphoproliferative disorder,Designated,,Not FDA Approved for Orphan Indication,,,,,BCM Center for Cell and Gene Therapy,"1102 Bates Avenue, Suite 1770.04",,Houston,Texas,' 77030 ' ,United States,567416,,,
1471,autologous Epstein-Barr virus specific T-cells,,3/9/2015,treatment of epstein-barr virus positive non-hodgkin lymphomas.,Designated,,Not FDA Approved for Orphan Indication,,,,,BCM Center for Cell and Gene Therapy,"1102 Bates Avenue, Suite 1770.04",,Houston,Texas,' 77030 ' ,United States,421513,lymphoma,"""gard:0020548""",
1472,autologous ex vivo expanded CD4+-enriched leukocytes treated with the de-methylating agent 5-aza-2â??-deoxycytidine,,9/13/2013,treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,CytoVac A/S,Science & Technology Park Scion DTU,,Horsholm,,' ' ,Denmark,405513,glioblastoma,"""gard:0002491""",
1473,autologous ex vivo expanded polyclonal CD4+CD25+CD1271o/-FOXP3+ Regulatory T cells,,5/10/2016,treatment of type 1 diabetes mellitus with residual beta cell function,Designated/Designation Withdrawn or Revoked,5/25/2021,Not FDA Approved for Orphan Indication,,,,,Caladrius Biosciences,110 Allen Road,2nd Floor,Basking Ridge,New Jersey,' 07920 ' ,United States,519716,,,
1474,autologous ex vivo expanded polyclonal CD4plusCD25plusCD127 lo/- FOXP3plus regulatory T cells (CELZ-101),,3/5/2024,prevention of allograft rejection in patients undergoing pancreatic islet cell transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,"Creative Medical Technology Holdings, Inc",211 E. Osborn Rd.,,Phoenix,Arizona,' 85012 ' ,United States,940723,,,
1475,Autologous ex-vivo CRISPR/Cas9 engineered Wilms¿ tumor 1-specific T-cell receptor T cells,,3/9/2022,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,5/8/2023,Not FDA Approved for Orphan Indication,,,,,"Intellia Therapeutics, Inc.",40 Erie Street,,Cambridge,Massachusetts,' 02139 ' ,United States,865021,acute myeloid leukemia,"""gard:0012757""",
1476,Autologous ex-vivo-expanded peripheral polyclonal lymphocytes enriched in activated natural killer cells,,8/25/2020,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,XNK Therapeutics AB,Hälsovägen 7,,Huddinge Municipality,Stockholm County,' ' ,Sweden,639218,multiple myeloma,"""gard:0007108""",
1477,autologous genetically engineered T cells that express a single-domain antibody that recognizes human mesothelin fused to the cluster of differentiation 3e subunit of the T cell receptor,,2/1/2019,treatment of mesothelioma,Designated/Designation Withdrawn or Revoked,1/16/2024,Not FDA Approved for Orphan Indication,,,,,"TCR2 Therapeutics, Inc., a wholly owned subsidiary of Adaptimmune Therapeutics plc",100 Binney Street,Suite 710,Cambridge,Massachusetts,' 02142 ' ,United States,670718,,,
1478,Autologous genetically modified CD34+ hematopoietic cells transduced with a lentiviral vector (LV-EFS-TCIRG1-WPRE) that encodes for the human TCIRG1 transgene,,2/28/2019,treatment of infantile malignant osteopetrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Rocket Pharmaceuticals, Inc.",The Empire State Building,"350 Fifth Avenue, Suite 7530",New York,New York,' 10118 ' ,United States,679919,,,
1479,autologous genetically modified human dermal fibroblasts,,6/10/2014,treatment of dystrophic epidermolysis bullosa.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Castle Creek Biosciences, LLC",405 Eagleview Blvd,,Exton,Pennsylvania,' 19341 ' ,United States,434614,dystrophic epidermolysis bullosa,"""gard:0002150""",
1480,autologous glioma tumor cells treated with 18-mer oligodeoxynucleotide sequence complementary to insulin-like growth factor type 1 receptor (IGF-1R) codons 2-7 in the IG-1R gene,,10/11/2017,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Imvax, Inc.","601 Walnut Street, Suite 440",,Philadelphia,Pennsylvania,' 19106 ' ,United States,546916,,,
1481,autologous human adipose perivascular stromal cells genetically modified to secrete soluble Tumor Necrosis Factor-related Apoptosis-inducing Ligand (sTRAIL),,5/22/2018,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Rigenerand Srl,"4, Via Maestri del Lavoro",,,Medolla (Modena),' ' ,Italy,638218,,,
1482,"autologous human CD34+ hematopoietic stem and progenitor cells (HSPCs), derived from G-CSF/plerixafor mobilized peripheral blood stem cells (PBSCs) of patients with Danon disease (DD)",,4/23/2024,treatment of danon disease (dd),Designated,,Not FDA Approved for Orphan Indication,,,,,Papillon Therapeutics,3210 Merryfield Row,,San Diego,California,' 92121 ' ,United States,998224,,,
1483,autologous human peripheral blood mononuclear cells incubated ex vivo with protein TBX-4000 (Tat-MYC),,10/16/2017,treatment of malignant melanoma stages iib to iv,Designated,,Not FDA Approved for Orphan Indication,,,,,"Taiga Biotechnologies, Inc.",12635 Montview Boulevard,Fitzsimmons BBioscience Park Center,Aurora,Colorado,' 80045 ' ,United States,607517,noma,"""gard:0004001""",
1484,"Autologous human regulatory T cells transduced with a retroviral vector encoding an FVIII C2 T cell receptor (TCR), which specifically binds FVIII C2 2213-2227 epitope in the context with HLA DRB1*01:01",,9/26/2023,treatment of hemophilia a with inhibitors,Designated,,Not FDA Approved for Orphan Indication,,,,,"TeraImmune, Inc.",20400 Century Blvd,STE 125,Germantown,Maryland,' 20874 ' ,United States,930222,hemophilia,"""gard:0010418""",
1485,Autologous incubated macrophage,,9/3/2004,therapy to improve the motor and sensory neurological outcome in acute cases of spinal cord injury,Designated,,Not FDA Approved for Orphan Indication,,,,,"Proneuron Biotechnologies, Inc.",2029 Century Park East,Sixth Floor,Los Angeles,California,' 90067 ' ,United States,186704,spinal cord injury,"""gard:0019109""",
1486,autologous logic-gated Tmod chimeric antigen receptor (CAR) T cells expressing a carcinoembryonic antigen targeted CAR activator and a human leukocyte antigen serotype A*02 (HLA-A*02) targeted blocker,,2/22/2024,treatment of germline heterozygous hla-a*02(+) patients with colorectal cancer that expresses cea and has lost hla a*02 expression,Designated,,Not FDA Approved for Orphan Indication,,,,,"A2 Biotherapeutics, Inc.","30301 Agoura Road, Suite 210",,Agoura Hills,California,' 91301 ' ,United States,989623,,,
1487,"autologous lymphocytes depleted ex vivo of immunoreactive T cells using 4,5",,4/3/2008,treatment of chronic graft versus host disease,Designated/Designation Withdrawn or Revoked,12/8/2020,Not FDA Approved for Orphan Indication,,,,,Kiadis Pharma Netherlands B.V.,Paasheuvelweg 25A,,Amsterdam,,' 1105 BP ' ,Netherlands,255607,graft versus host disease,"""gard:0016642""",
1488,Autologous lymphoma-derived immunoglobulin idiotype antigen vaccine conjugated to keyhole limpet hemocyanin,,10/18/2011,treatment of waldenstrom's macroglobulinemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biovest International, Inc.",324 S. Hyde Park Avenue,Suite 350,Tampa,Florida,' 33606 ' ,United States,354111,,,
1489,"Autologous modified RNA transfected myeloid cells that express a fusion protein composed of humanized scFv that recognizes human CD5, a CD8 alpha transmembrane domain, and Fc gamma and PI3K intracellular signaling domains (CD5-ATAK-Fcy-PI3K Myeloid Cells)",,3/16/2020,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Myeloid Therapeutics, Inc.",One Kendall Square,"Bld 200, Ste 101",Cambridge,Massachusetts,' 02139 ' ,United States,730320,lymphoma,"""gard:0020548""",
1490,autologous mononuclear cells derived from umbilical cord blood,,7/13/2017,treatment of severe pediatric congenital heart disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Timothy Nelson, MD, PhD",Mayo Clinic,Hypoplastic Left Heart Syndrome Program,Rochester,Minnesota,' 55902 ' ,United States,583817,,,
1491,Autologous multi-tumor-associated antigen-specific T cell product (MultiTAA-specific T cell product),,1/18/2022,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Marker Therapeutics, Inc.",3200 Southwest Freeway Suite 2240,,Houston,Texas,' 77027 ' ,United States,775620,,,
1492,autologous Muscle-Specific tyrosine Kinase Autoantibody Receptor T cells (MuSK-CAART),,10/7/2022,treatment of muscle-specific tyrosine kinase (musk) myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cabaletta Bio, Inc","2929 Arch Street, Suite 600",,Philadelphia,Pennsylvania,' 19104 ' ,United States,903422,myasthenia gravis,"""gard:0007122""",
1493,autologous neo-uninary conduit,,6/7/2011,treatment of bladder dysfunction requiring incontinent urinary diversion.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tengion, Inc.",2900 Potshop Lane,,East Norriton,Pennsylvania,' 19403 ' ,United States,332410,,,
1494,Autologous olfactory neural progenitors,,2/1/2008,"treatment of spinal cord injury patients with asia impairment grades a, b, or c",Designated,,Not FDA Approved for Orphan Indication,,,,,"RhinoCyte, Inc.",201 E. Jefferson Street,,Louisville,Kentucky,' 40202 ' ,United States,246207,spinal cord injury,"""gard:0019109""",
1495,autologous olfactory neural progenitors,,12/31/2008,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"RhinoCyte, Inc.",201 E. Jefferson Street,,Louisville,Kentucky,' 40202 ' ,United States,260108,amyotrophic lateral sclerosis,"""gard:0005786""",
1496,Autologous or allogeneic limbal epithelial stem cells expanded ex vivo on human amniotic membrane,,7/14/2005,treatment of ocular surface diseases that are characterized by total limbal stem cell deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"TissueTech, Inc.",7000 SW 97th Avenue,,Miami,Florida,' 33173 ' ,United States,198004,limbal stem cell deficiency,"""gard:0020123""",
1497,autologous osteogenic cells cultured from adipose tissue derived stem cells embedded in extracellular matrix with demineralized bone matrix.,,6/30/2016,treatment of congenital pseudarthrosis of the tibia,Designated/Designation Withdrawn or Revoked,6/15/2020,Not FDA Approved for Orphan Indication,,,,,Novadip Biosciences,11 Granbonpré,,Mont-Saint-Guibert,Région wallonne,' ' ,Belgium,525316,,,
1498,Autologous Osteogenic Stem Cells,,9/9/2020,treatment of congenital pseudarthrosis of long bones,Designated,,Not FDA Approved for Orphan Indication,,,,,Novadip Biosciences,265 Streaker Road,,Sykesville,Maryland,' 21784 ' ,United States,761220,,,
1499,autologous patients¿ CD4+ T cells that have been subjected to lentivirus mediated gene transfer of healthy FOXP3,,10/26/2020,treatment of immune dysregulation polyendocrinopathy enteropathy x-linked (ipex) syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Stanford University,"265 Campus Dr., Office G3039",Lorry I Lokey Stem Cell Research Building,Stanford,California,' 94305-5101 ' ,United States,776420,polyendocrinopathy,"""gard:0019800""",
1500,autologous peripheral blood mononuclear cells manipulated ex vivo to produce macrophages with markedly reduced signal-regulatory protein alpha (SIRPalpha) expression,,11/6/2023,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,SIRPant Immunotherapeutics,1590 Bunker Court,,Chambersburg,Pennsylvania,' 17202-8040 ' ,United States,968523,lymphoma,"""gard:0020548""",
1501,Autologous stromal vascular cell fraction from adipose tissue (central facitily processed),,11/9/2016,treatment of impaired hand function due to systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Lorem Cytori USA, Inc.",3020 Callan Road,,San Diego,California,' 92121 ' ,United States,539816,systemic sclerosis,"""gard:0009748""",
1502,Autologous synthetic NKG2D receptor armored CLDN18.2 specific CAR-T cell injection,,8/28/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Suzhou Immunofoco Biotechnology Co., Ltd","Unit 504-506, Bldg A3, Creative Industry Park, Xinghu Street",,Suzhou Industrial Park,Jiangsu Province,' ' ,China,957023,,,
1503,Autologous synthetic NKG2D receptor armored CLDN18.2 specific CAR-T cell injection,,8/15/2023,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Suzhou Immunofoco Biotechnology Co., Ltd","Unit 504-506, Bldg A3, Creative Industry Park, Xinghu Street",,Suzhou Industrial Park,Jiangsu Province,' ' ,China,954323,,,
1504,autologous T cells expressing a transmembrane chimeric antigen receptor (CAR) to target anti-delta-like ligand 3,,12/18/2019,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,1 Amgen Center Drive,Mail Stop 27-3-A,Thousand Oaks,California,' 91320 ' ,United States,664618,small cell lung cancer,"""gard:0009344""",
1505,Autologous T cells expressing anti-B cell maturation agent chimeric antigen receptor,,8/16/2023,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nexcella, Inc.","11400 W. Olympic Blvd, Ste 200",,Los Angeles,California,' 90064 ' ,United States,955023,multiple myeloma,"""gard:0007108""",
1506,Autologous T cells expressing anti-B cell maturation agent chimeric antigen receptor,,9/19/2023,treatment of amyloid light chain (al) amyloidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nexcella, Inc.","11400 W. Olympic Blvd, Suite 200",,Los Angeles,California,' 90064 ' ,United States,960523,amyloidosis,"""gard:0018676""",
1507,Autologous T cells genetically engineered to express an anti-mesothelin killer immunoglobulin-like receptor-chimeric antigen receptor (KIR-CAR),,9/27/2022,treatment of mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Verismo Therapeutics,"3675 Market Street, Suite 200",,Philadelphia,Pennsylvania,' 19104 ' ,United States,900722,,,
1508,autologous T cells genetically modified to express CD123 specific hinge-optimized CD28-costimulatory chimeric receptor and a truncated human epidermal growth factor receptor,,12/17/2018,treatment of blastic plasmacytoid dendritic cell neoplasm,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mustang Bio, Inc.",377 Plantation Street,,Worcester,Massachusetts,' 01605 ' ,United States,663118,,,
1509,autologous T cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD123,,4/26/2022,treatment of blastic plasmacytoid dendritic cell neoplasm,Designated,,Not FDA Approved for Orphan Indication,,,,,INSERM UMR 1098,University Bourgogne Franche-Comté 8,"rue du Docteur Jean-François-Xavier Girod, BP1937",Besançon Cedex,,' 25020 ' ,France,873222,,,
1510,"autologous T cells transduced with lentiviral vector encoding a G protein-coupled receptor class C, group 5, member D (GPRC5D)-specific chimeric antigen receptor",,6/21/2023,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","400 Dexter Avenue N, Suite 1200",,Seattle,Washington,' 98109 ' ,United States,945023,multiple myeloma,"""gard:0007108""",
1511,autologous T cells transduced with lentivirus to express a fully human anti-CD19 single chain variable fragment,,3/19/2024,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cabaletta Bio, Inc.","2929 Arch Street, Suite 600",,Philadelphia,Pennsylvania,' 19104 ' ,United States,993823,systemic sclerosis,"""gard:0009748""",
1512,Autologous T cells transduced with natural T cell receptor (TCR) that recognizes the HLA-A-restricted HBsAg epitope,,12/27/2023,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,SCG Cell Therapy Pte. Ltd.,"138 Depot Road, #04-02",,,,' 109683 ' ,Singapore,979523,hepatocellular carcinoma,"""gard:0016773""",
1513,autologous T cells transduced with retroviral vector encoding a hepatitis B virus antigen-specific T cell receptor,,7/3/2017,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Lion TCR Pte. Ltd.,11-07/08 Maxwell House,,20 Maxwell Road,,' ' ,Singapore,579517,hepatocellular carcinoma,"""gard:0016773""",
1514,Autologous T cells transfected with mRNA encoding hepatitis B virus antigen-specific T cell receptor,,7/3/2017,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Lion TCR Pte. Ltd.,11-07/08 Maxwell House,20 Maxwell Road,Singapore,,' ' ,Singapore,579417,hepatocellular carcinoma,"""gard:0016773""",
1515,Autologous T cells transfected with PiggyBac transposon plasmid vector expressing B-cell maturation antigen (CAR-T cells),,5/8/2019,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Poseida Therapeutics, Inc.","4242 Campus Point Court, Suite 700",,San Diego,California,' 92121 ' ,United States,684019,multiple myeloma,"""gard:0007108""",
1516,autologous T lymphocyte enriched population cultured in the rpesence of phosphatidylinositol 3-kinase inhibitor (bb007) that contains cells transduced with an anti-human B cell maturation antigen (BCMA02) chimeric antigen receptor (CAR) lentiviral vector,,10/5/2017,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"bluebird bio, Inc.",60 Binney Street,,Cambridge,Massachusetts,' 02142 ' ,United States,604417,multiple myeloma,"""gard:0007108""",
1517,Autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturation antigen with 4-1BB and CD3-zeta intracellular signaling domains,,2/26/2020,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Arcellx, Inc.","25 West Watkins Mill Road, Suite A",,Gaithersburg,Maryland,' 20878 ' ,United States,725919,multiple myeloma,"""gard:0007108""",
1518,autologous T-cells expressing a chimeric antigen receptor directed against B-Cell maturation antigen,,11/8/2022,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cartesian Therapeutics, Inc.","704 Quince Orchard Road, Suite 210",,Gaithersburg,Maryland,' 20878 ' ,United States,909722,myasthenia gravis,"""gard:0007122""",
1519,"autologous T-cells genetically modified to express a CD123-specific, hinge-optimized, CD28-costimulatory chimeric receptor and a truncated human epidermal growth factor receptor",,7/22/2019,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mustang Bio, Inc.",377 Plantation Street,,Worcester,Massachusetts,' 01605 ' ,United States,693319,acute myeloid leukemia,"""gard:0012757""",
1520,Autologous T-cells genetically modified using a lentiviral vector encoding for CD19 CD3e TRuC,,5/11/2020,treatment of acute lymphoblastic leukemia,Designated/Designation Withdrawn or Revoked,3/17/2023,Not FDA Approved for Orphan Indication,,,,,"TCR2 Therapeutics, Inc.",100 Binney Street,Suite 710,Cambridge,Massachusetts,' 02142 ' ,United States,737420,acute lymphoblastic leukemia,"""gard:0000522""",
1521,Autologous T-Cells transduced with a lentiviral vector (LVV) expressing CD20-specific chimeric antigen receptor (CAR) gene (CD20 CAR-T Cells),,6/16/2022,treatment of waldenstrom macroglobulinemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mustang Bio, Inc.",377 Plantation Street,,Worcester,Massachusetts,' 01605 ' ,United States,885022,,,
1522,"autologous tumor cells fused with polyethylene glycol to human allogeneic FO-1, DNA plasmid transfected tumor cell line",,5/6/2015,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sebastiano Gattoni-Celli, MD",Med. University of SC- Dept of Radiation Oncology,114 Doughty St.,Charleston,South Carolina,' 29403 ' ,United States,456914,glioblastoma,"""gard:0002491""",
1523,autologous tumor infiltrating lymphocytes (TIL),,4/30/2018,treatment of cervical cancer with a tumor size greater than 2 cm. in diameter,Designated,,Not FDA Approved for Orphan Indication,,,,,"Iovance Biotherapeutics, Inc.",999 Skyway Road,Suite 150,San Carlos,California,' 94070 ' ,United States,601517,,,
1524,autologous tumor-derived gp96 heat shock protein-peptide complex,,7/11/2002,treatment of metastatic melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Agenus, Inc.",3 Forbes Rd.,,l,Massachusetts,' 02421 ' ,United States,154202,noma,"""gard:0004001""",
1525,autologous tumor-derived gp96 heat shock protein-peptide complex,,5/10/2002,treatment of renal cell carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Agenus, Inc.",3 Forbes Rd.,,Lexington,Massachusetts,' 02421 ' ,United States,150201,renal cell carcinoma,"""gard:0013215""",
1526,autologous umbilical cord blood,,7/24/2012,treatment of pediatric (0-16 yrs old inclusive) cerebral palsy due to acquired brain injury,Designated,,Not FDA Approved for Orphan Indication,,,,,Duke University,2301 Erwin Road,,Durham,North Carolina,' 27710 ' ,United States,372312,,,
1527,autologus CD34+ cells transfected with retroviral vector containing adenosine deaminase gene,,8/26/2009,treatment of severe combined immunodeficiency due to adenosine deaminase deficiency.,Designated,,Not FDA Approved for Orphan Indication,,,,,Fondazione Telethon ETS,245 Hammersmith Road,Via Varese 16/B,Rome,,' 00185 ' ,Italy,286209,severe combined immunodeficiency,"""gard:0007628""",
1528,Autolymphocyte therapy,,7/12/1994,treatment of renal cell carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Cytogen Corporation,600 College Road East,CN 5308,Princeton,New Jersey,' 08540 ' ,United States,79593,renal cell carcinoma,"""gard:0013215""",
1529,Autotaxin inhibitor,,1/14/2019,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Bridge Biotherapeutics, Inc","253 Pangyo-ro, Bundang-gu","Suite 903-2, Building B, Pangyo Innovalley",Seongnam-si,Gyeonggi-do,' ' ,South Korea,665918,idiopathic pulmonary fibrosis,"""gard:0008609""",
1530,avacopan,Tavneos,6/2/2014,"treatment of anti-neutrophil cytoplasmic autoantibodies associated vasculitides (granulomatosis with polyangiitis or wegener's granulomatosis, microscopic polyangiitis, and churg-strauss syndrome)",Designated/Approved,,,As an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids,10/7/2021,10/7/2028,As an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]),"ChemoCentryx, Inc.","835 Industrial Road, Suite 600",,San Carlos,California,' 94070 ' ,United States,432014,granulomatosis with polyangiitis,"""gard:0007880""",
1531,avacopan,,3/20/2017,treatment of c3 glomerulopathy,Designated/Designation Withdrawn or Revoked,2/5/2024,Not FDA Approved for Orphan Indication,,,,,"ChemoCentryx, Inc.",850 Maude Avenue,,Mountain View,California,' 94043 ' ,United States,559016,c3 glomerulopathy,"""gard:0017507""",
1532,avacopan,,11/17/2014,treatment of atypical hemolytic uremic syndrome,Designated/Designation Withdrawn or Revoked,2/5/2024,Not FDA Approved for Orphan Indication,,,,,"ChemoCentryx, Inc.",850 Maude Avenue,,Mountain View,California,' 94043 ' ,United States,443714,hemolytic uremic syndrome,"""gard:0022233""",
1533,avadomide,,3/12/2018,treatment of follicular lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,629418,lymphoma,"""gard:0020548""",
1534,avalglucosidase alfa-ngpt,Nexviazyme,11/19/2013,treatment of pompe disease,Designated/Approved,,,Treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency),8/6/2021,,,"Genzyme Corporation, a Sanofi Company",50 Binney Street,,Cambridge,Massachusetts,' 02142 ' ,United States,411913,,,
1535,avapritinib,Ayvakit,1/6/2016,treatment of gastrointestinal stromal tumors,Designated/Approved,,,"Treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations",1/9/2020,1/9/2027,"Treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations",Blueprint Medicines Corporation,45 Sidney Street,Suite 200,Cambridge,Massachusetts,' 02139 ' ,United States,500415,gastrointestinal stromal tumor,"""gard:0008598""",
1536,avapritinib,Ayvakit,1/21/2016,treatment of mastocytosis,Designated/Approved,,,"Treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).",6/16/2021,6/16/2028,"Treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).",Blueprint Medicines Corporation,45 Sidney Street,,Cambridge,Massachusetts,' 02139 ' ,United States,506515,mastocytosis,"""gard:0006987""",
1537,avapritinib,Ayvakit,1/21/2016,treatment of mastocytosis,Designated/Approved,,,treatment of adult patients with indolent systemic mastocytosis (ISM),5/22/2023,5/22/2030,treatment of adult patients with indolent systemic mastocytosis (ISM),Blueprint Medicines Corporation,45 Sidney Street,,Cambridge,Massachusetts,' 02139 ' ,United States,506515,mastocytosis,"""gard:0006987""",
1538,avasimibe,,5/16/2023,treatment of prader-willi syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,EFIL BioScience Inc.,"#601, Bando Ivyvalley","686 Chenggyesan-ro, Soojeong-gu",Seongnam,Gyeonggi-do,' 13105 ' ,South Korea,938123,prader-willi syndrome,"""gard:0005575""",
1539,avatrombopag maleate,,12/19/2019,treatment of chemotherapy-induced thrombocytopenia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sobi, Inc.",240 Leigh Farm Road,Suite 245,Durham,North Carolina,' 27707 ' ,United States,699419,,,
1540,avatrombopag maleate,,9/1/2011,treatment of idiopathic thrombocytopenic purpura,Designated/Approved,,,DOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment,6/26/2019,6/26/2026,For the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment,"Sobi, Inc.",240 Leigh Farm Road,Suite 245,Durham,North Carolina,' 27707 ' ,United States,325110,,,
1541,avelumab,,10/11/2017,treatment of gastric cancer (gc) including cancer of the gastroesophageal junction (gej),Designated,,Not FDA Approved for Orphan Indication,,,,,"EMD Serono Research & Development Institute, Inc.",45A Middlesex Turnpike,,Billerica,Massachusetts,' 01821 ' ,United States,604117,,,
1542,avelumab (Recombinant human monoclonal IgG1 antibody against programmed death ligand-1),Bavencio,9/21/2015,treatment of merkel cell carcinoma.,Designated/Approved,,,Treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma,3/23/2017,3/23/2024,Treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma,"EMD Serono Research and Development Institute, Inc.",45A Middlesex Turnpike,,Billerica,Massachusetts,' 01821 ' ,United States,491815,noma,"""gard:0004001""",
1543,avexitide,,12/8/2016,treatment of hyperinsulinemic hypoglycemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Eiger BioPharmaceuticals, Inc.",350 Cambridge Avenue,Suite 350,Palo Alto,California,' 94306 ' ,United States,522116,,,
1544,avicin d,,3/24/2015,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Avicin Therapeutics Ltd.,Westpark Corporate Center,4634 S. Alston Avenue,Durham,North Carolina,' 27713 ' ,United States,467714,multiple myeloma,"""gard:0007108""",
1545,aviptadil,,2/22/2005,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,Mondobiotech Laboratories AG,Herrengasse 21,,Furstentum Liechtenstein,,' ' ,Germany,180903,pulmonary arterial hypertension,"""gard:0007501""",
1546,Aviptadil,,7/23/2020,treatment of sarcoidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,AdVita Lifescience GmbH,Alte Bundesstraße 20,,Gundelfingen,,' 79194 ' ,Germany,751520,sarcoidosis,"""gard:0007607""",
1547,Avutometinib,,3/5/2024,treatment of low grade serous ovarian cancer (lgsoc),Designated,,Not FDA Approved for Orphan Indication,,,,,"Verastem, Inc",117 Kendrick St #500,,Needham,Massachusetts,' 02494 ' ,United States,891422,ovarian cancer,"""gard:0007295""",
1548,Avutometinib; defactinib,,3/5/2024,treatment of low grade serous ovarian cancer (lgsoc),Designated,,Not FDA Approved for Orphan Indication,,,,,"Verastem, Inc.",117 Kendrick Street,Suite 500,Needham,Massachusetts,' 02494 ' ,United States,991323,ovarian cancer,"""gard:0007295""",
1549,axatilimab,,4/7/2021,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Syndax Pharmaceuticals, Inc.",35 Gatehouse Drive,"Building D, Floor 3",Waltham,Massachusetts,' 02451 ' ,United States,807821,idiopathic pulmonary fibrosis,"""gard:0008609""",
1550,axatilimab,,3/29/2021,treatment of chronic graft versus host disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,732320,graft versus host disease,"""gard:0016642""",
1551,axicabtagene ciloleucel,,3/24/2020,treatment of nodal marginal zone lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kite Pharma, Inc.",2400 Broadway,,Santa Monica,California,' 90404 ' ,United States,740320,lymphoma,"""gard:0020548""",
1552,axicabtagene ciloleucel,,3/23/2020,treatment of extranodal marginal zone lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kite Pharma, Inc.",2400 Broadway,,Santa Monica,California,' 90404 ' ,United States,735920,lymphoma,"""gard:0020548""",
1553,axicabtagene ciloleucel,Yescarta,4/25/2016,treatment of follicular lymphoma.,Designated/Approved,,,"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma",10/18/2017,10/18/2024,"Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma)","Kite Pharma, Inc.",2400 Broadway,,Santa Monica,California,' 90404 ' ,United States,515615,lymphoma,"""gard:0020548""",
1554,axicabtagene ciloleucel,Yescarta,3/27/2014,treatment of diffuse large b-cell lymphoma,Designated/Approved,,,"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma",10/18/2017,10/18/2024,"Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma)","Kite Pharma, Inc.",2400 Broadway,,Santa Monica,California,' 90404 ' ,United States,423914,lymphoma,"""gard:0020548""",
1555,axicabtagene ciloleucel,Yescarta,4/25/2016,treatment of follicular lymphoma.,Designated/Approved,,,Treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy,3/5/2021,3/5/2028,"Treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy, excluding patients with diffuse large B-cell lymphoma arising from follicular lymphoma.","Kite Pharma, Inc.",2400 Broadway,,Santa Monica,California,' 90404 ' ,United States,515615,lymphoma,"""gard:0020548""",
1556,axicabtagene ciloleucel,Yescarta,4/20/2016,treatment of primary mediastinal b-cell lymphoma.,Designated/Approved,,,"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma",10/18/2017,10/18/2024,"Treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, treatment of adult patients with relapsed or refractory DLBCL arising from follicular lymphoma after two or more lines of systemic therapy, and treatment of adult patients with relapsed or refractory primary mediastinal B-cell lymphoma after two or more lines of systemic therapy (not including treatment of patients with primary central nervous system lymphoma)","Kite Pharma, inc.",2400 Broadway,,Santa Monica,California,' 90404 ' ,United States,515915,lymphoma,"""gard:0020548""",
1557,axicabtagene ciloleucel,Yescarta,3/27/2014,treatment of diffuse large b-cell lymphoma,Designated/Approved,,,Treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Limitations of Use: Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.,4/1/2022,4/1/2029,"treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy, treatment of adult patients with DLBCL arising from follicular lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy, and treatment of adult patients with primary mediastinal B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy (not including treatment of patients with primary central nervous system lymphoma and excluding patients covered by the indication that received marketing approval on October 18, 2017 for Yescarta)","Kite Pharma, Inc.",2400 Broadway,,Santa Monica,California,' 90404 ' ,United States,423914,lymphoma,"""gard:0020548""",
1558,axicabtagene ciloleucel,Yescarta,4/25/2016,treatment of follicular lymphoma.,Designated/Approved,,,Treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Limitations of Use: Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.,4/1/2022,4/1/2029,"treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy, treatment of adult patients with DLBCL arising from follicular lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy, and treatment of adult patients with primary mediastinal B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy (not including treatment of patients with primary central nervous system lymphoma and excluding patients covered by the indication that received marketing approval on October 18, 2017 for Yescarta)","Kite Pharma, Inc.",2400 Broadway,,Santa Monica,California,' 90404 ' ,United States,515615,lymphoma,"""gard:0020548""",
1559,axicabtagene ciloleucel,Yescarta,4/20/2016,treatment of primary mediastinal b-cell lymphoma.,Designated/Approved,,,Treatment of adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Limitations of Use: Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.,4/1/2022,4/1/2029,"treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy, treatment of adult patients with DLBCL arising from follicular lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy, and treatment of adult patients with primary mediastinal B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy (not including treatment of patients with primary central nervous system lymphoma and excluding patients covered by the indication that received marketing approval on October 18, 2017 for Yescarta)","Kite Pharma, inc.",2400 Broadway,,Santa Monica,California,' 90404 ' ,United States,515915,lymphoma,"""gard:0020548""",
1560,axitinib,,5/31/2007,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",10646 Science Center Drive,,San Diego,California,' 92121 ' ,United States,240607,,,
1561,azacitidine,Vidaza,12/3/2001,treatament of myelodysplastic syndromes,Designated/Approved,,,"Treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia and requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia",5/19/2004,5/19/2011,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,150101,myelodysplastic syndrome,"""gard:0007132""",
1562,Azacitidine,ONUREG,6/18/2008,treatment of acute myeloid leukemia,Designated/Approved,,,ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy,9/1/2020,9/1/2027,ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy,Bristol-Myers Squibb,86 Morris Ave,,Summit,New Jersey,' 07901 ' ,United States,257008,acute myeloid leukemia,"""gard:0012757""",
1563,azacitidine,Vidaza,7/28/2021,treatment of juvenile myelomonocytic leukemia,Designated/Approved,,,Treatment of pediatric patients aged one month and older with newly diagnosed juvenile myelomonocytic leukemia (JMML),5/20/2022,5/20/2029,Treatment of pediatric patients aged one month and older with newly diagnosed juvenile myelomonocytic leukemia (JMML),Celgene Corporation (a Bristol-Myers Squibb Company),86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,829021,juvenile myelomonocytic leukemia,"""gard:0009884""",
1564,Azathioprine,,9/14/1999,treatment of oral manifestations of graft-versus-host disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Oral Solutions, Inc.","787 Seventh Ave., 48th Floor",,New York,New York,' 10019 ' ,United States,128099,,,
1565,azeliragon,,5/16/2024,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Cantex Pharmaceuticals,1792 Bell Tower Lane,,Weston,Florida,' 33326 ' ,United States,1002124,,,
1566,azeliragon,,12/20/2022,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Cantex Pharmaceuticals,2536 Royal Palm Way,,Weston,Florida,' 33327 ' ,United States,915922,glioblastoma,"""gard:0002491""",
1567,azithromycin,,6/6/2022,prevention of bronchopulmonary dysplasia in neonates.,Designated,,Not FDA Approved for Orphan Indication,,,,,Iorek Pharma Limited,102 High Street,,GODALMING,England,' GU7 1DS ' ,United Kingdom,881322,bronchopulmonary dysplasia,"""gard:0005962""",
1568,aztreonam,,5/15/2009,improvement of respiratory symptoms in patients with bronchiectasis and gram-negative bacteria in the airways.,Designated/Designation Withdrawn or Revoked,9/12/2014,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",2025 1st Avenue,,Seattle,Washington,' 98121 ' ,United States,266208,,,
1569,aztreonam,Cayston,3/12/2002,inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis,Designated/Approved,,,To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa,2/22/2010,2/22/2017,,"Gilead Sciences, Inc.",199 East Blaine St,,Seattle,Washington,' 98102 ' ,United States,155002,cystic fibrosis,"""gard:0006233""",
1570,Azurin-p28,,12/2/2015,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"CDG Therapeutics, Inc.",840 South Wood Street,M/C 820,Chicago,Illinois,' 60612 ' ,United States,507415,,,
1571,B Lymphocyte Stimulator,,2/21/2001,treatment of common variable immunodeficiency (cvid),Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Human Genome Sciences, Inc.",9410 Key West Avenue,,Rockville,Maryland,' 20850 ' ,United States,140600,common variable immunodeficiency,"""gard:0006140""",
1572,Bacillus Calmette-Guerin vaccine,,8/9/2006,treatment of stage iib through iv metastatic melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,OncoVac Corporation,P. O. Box 970,,Pacific Palisades,California,' 90272 ' ,United States,223806,noma,"""gard:0004001""",
1573,Bacillus subtilis oxalate decarboxylase,,2/29/2016,treatment of pediatric hyperoxaluria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Allena Pharmaceuticals, Inc.",1 Executive Park Drive,Suite 202,Newton,Massachusetts,' 02462 ' ,United States,508015,,,
1574,Bacillus subtilis oxalate decarboxylase,,6/12/2017,treatment of primary hyperoxaluria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Allena Pharmaceuticals, Inc.",1 Executive Park Drive,Suite 202,Newton,Massachusetts,' 02462 ' ,United States,578917,primary hyperoxaluria,"""gard:0016530""",
1575,Bacillus thuringiensis crystal protein (Cry5B),,3/7/2018,"treatment of gastroinstestinal infections caused by ascaris lumbricoides (roundworm), trichuris trichiura (whipworm), ancylostoma duodenale, necator americanus, and ancylostoma ceylanicum (hookworms)",Designated,,Not FDA Approved for Orphan Indication,,,,,University of Massachusetts Medical School,373 Plantation Street,"Two Biotech, Suite 219",Worcester,Massachusetts,' 01605 ' ,United States,562816,,,
1576,Bacitracin,,3/13/1984,treatment of antibiotic-associated pseudomembranous enterocolitis caused by toxins a and b elaborated by clostridium difficile.,Designated,,Not FDA Approved for Orphan Indication,,,,,"A. L. Laboratories, Inc.",One Executive Drive,P.O. Box 1399,Fort Lee,New Jersey,' 07024 ' ,United States,1284,,,
1577,baclofen,Lioresal Intrathecal,11/10/1987,"treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy).",Designated/Approved,,,Management of severe spasticity of spinal cord origin in patients who are unresponsive to oral baclofen therapy or experience intolerable CNS side effects at effective doses.,6/25/1992,6/25/1999,,"Medtronic, Inc.",800 53rd Avenue N.E.,,Minneapolis,Minnesota,' 55432 ' ,United States,23987,spinal cord injury,"""gard:0019109""",
1578,baclofen,,12/2/2003,treatment of dystonia,Designated,,Not FDA Approved for Orphan Indication,,,,,Medtronic Neurological,710 Medtronic Parkway NE,,Minneapolis,Minnesota,' 55432 ' ,United States,174703,,,
1579,baclofen,,10/28/2015,treatment of complex regional pain syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Piramal Critical Care, Inc.",261 Brodhead Road,Suite 221,Bethlehem,Pennsylvania,' 18017 ' ,United States,493915,complex regional pain syndrome,"""gard:0004647""",
1580,Baclofen,,9/26/1994,treatment of spasticity associated with cerebral palsy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Medtronic, Inc.",800 53rd Avenue N.E.,P.O. 1250,Minneapolis,Minnesota,' 55440 ' ,United States,80494,,,
1581,baclofen,OZOBAX,12/16/1991,treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.,Designated/Approved,,,"Treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. OZOBAX may also be of some value in patients with spinal cord injuries and other spinal cord diseases.",9/18/2019,,,"Metacel Pharmaceuticals, LLC",244 E Washington Street,,Athens,Georgia,' 30601 ' ,United States,64091,spinal cord injury,"""gard:0019109""",
1582,baclofen,,12/31/2020,prevention of baclofen withdrawal syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Saol Therapeutics Research Limited,"Peter Street, Unit G04",Adelaide Chambers,Dublin,,' 8 ' ,Ireland,685619,,,
1583,Bacteriophage,,10/14/2020,treatment for prosthetic joint infection,Designated,,Not FDA Approved for Orphan Indication,,,,,"Adaptive Phage Therapeutics, Inc.",22 Firstfield Road; Suite 125,,Gaithersburg,Maryland,' 20878 ' ,United States,772020,,,
1584,bacterium Bacteroides thetaiotaomicron,,9/26/2013,treatment of active crohn's disease in the pediatric population,Designated/Designation Withdrawn or Revoked,4/21/2023,Not FDA Approved for Orphan Indication,,,,,4D Pharma Research Ltd,Life Sciences Innovation Bldg,Cornhill Road,Scotland,,' ' ,United Kingdom,308110,,,
1585,Balipodect,,6/19/2019,treatment of cdkl5 deficiency disorder,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,689219,,,
1586,Balipodect,,6/13/2019,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,689319,fragile x syndrome,"""gard:0006464""",
1587,Balsalazide disodium,Colazal,8/12/2005,treatment of pediatric patients with ulcerative colitis,Designated/Approved,,,Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established.,12/20/2006,12/20/2013,,"Salix Pharmaceuticals, Inc.",400 Somerset Corporate Blvd,,Bridgewater,New Jersey,' 08807 ' ,United States,208205,,,
1588,Bardoxolone,,8/6/2008,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Reata Pharmaceuticals, Inc.",2801 Gateway Drive,,Irving,Texas,' 75063 ' ,United States,264108,,,
1589,bardoxolone,,3/30/2015,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,"Reata Pharmaceuticals, Inc.",2801 Gateway Dr.,Suite 150,Irving,Texas,' 75063 ' ,United States,456114,pulmonary arterial hypertension,"""gard:0007501""",
1590,bardoxolone methyl,,6/3/2019,treatment of autosomal dominant polycystic kidney disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Reata Pharmaceuticals, Inc.",2801 Gateway Dr.,Suite 150,Irving,Texas,' 75063 ' ,United States,687219,autosomal dominant polycystic kidney disease,"""gard:0010413""",
1591,bardoxolone methyl,,7/3/2017,treatment of alport syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Reata Pharmaceuticals, Inc.",2801 Gateway Dr.,Suite 150,Irving,Texas,' 75063 ' ,United States,568016,alport syndrome,"""gard:0005785""",
1592,baricitinib,,11/2/2017,treatment of pediatric systemic lupus erythematosus,Designated/Designation Withdrawn or Revoked,5/6/2022,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,610017,pediatric systemic lupus erythematosus,"""gard:0019219""",
1593,Basiliximab,Simulect,12/12/1997,prophylaxis of solid organ rejection.,Designated/Approved,,,Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.,5/12/1998,5/12/2005,,Novartis Pharmaceuticals Corporation,59 Route 10,,East Hanover,New Jersey,' 07936 ' ,United States,109197,,,
1594,basimglurant,,3/9/2012,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,333211,fragile x syndrome,"""gard:0006464""",
1595,batiraxcept,,2/22/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aravive, Inc.","3730 Kirby Drive, Suite 1200",,Houston,Texas,' 77098 ' ,United States,925522,,,
1596,BCL-005 (fused (hybrid) melanoma-dendritic cells),,10/21/2010,treatment of stage iib to iv melanoma in hla-a2 positive patients,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Brucells SA,Rue de Ransbeekstraat 310,,Brussel,,' ' ,Belgium,314610,noma,"""gard:0004001""",
1597,BCX9930 is a small molecule inhibitor of human complement factor D.,,8/28/2020,treatment of paroxysmal nocturnal hemoglobinuria,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioCryst Pharmaceuticals, Inc.",4505 Emperor Blvd.,,Durham,North Carolina,' 27703 ' ,United States,758220,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
1598,beclomethasone,,3/4/2009,treatment of pediatriac patients with ulcerative colitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aptalis Pharma US, Inc.",100 Somerset corporate Blvd,,Bridgewater,New Jersey,' 08807 ' ,United States,274908,,,
1599,"beclomethasone 17,21-dipropionate",,11/19/2012,prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster,Designated,,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc","29 Emmons Drive, Suite B-10",,Princeton,New Jersey,' 08540 ' ,United States,356311,,,
1600,"beclomethasone 17,21-dipropionate",,7/24/2009,treatment of gastrointestinal symptoms with chronic graft versed host disease in patients undergoing allogenic hematopoietic cell transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.",29 Emmons Drive,Suite B-10,Princeton,New Jersey,' 08540 ' ,United States,285609,,,
1601,"beclomethasone 17,21-dipropionate",,8/28/2001,prevention of gastrointestinal graft-versus-host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.",29 Emmons Drive,Suite B-10,Princeton,New Jersey,' 08540 ' ,United States,146501,,,
1602,"beclomethasone 17,21-diproprionate",,12/18/2007,treatment of pediatric patients with crohn disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.",29 Emmons Drive,Suite B-10,Princeton,New Jersey,' 08540 ' ,United States,144201,,,
1603,beclomethasone dipropionate,,3/27/1998,for oral administration in the treatment of intestinal graft-versus-host disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.",29 Emmons Drive,Suite B-10,Princeton,New Jersey,' 08540 ' ,United States,111198,,,
1604,bedaquiline,SIRTURO,1/10/2005,treatment of active tuberculosis,Designated/Approved,,,Part of combination therapy in adults (greater than or equal to 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB).,12/28/2012,12/28/2019,,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,' 08869 ' ,United States,199304,tuberculosis,"""gard:0007827""",
1605,bedaquiline,SIRTURO,1/10/2005,treatment of active tuberculosis,Designated/Approved,,,SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (12 to less than 18 years of age and weighing at least 30 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided.,8/9/2019,8/9/2026,As part of combination therapy in the treatment of pediatric patients (12 to less than 18 years of age and weighing at least 30 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB),"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,' 08869 ' ,United States,199304,tuberculosis,"""gard:0007827""",
1606,Bedaquiline,,7/27/2017,treatment of nontuberculosis mycobacteria infection,Designated,,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",125 Trenton-Harbourton Road,,Titusville,New Jersey,' 08560 ' ,United States,589917,tuberculosis,"""gard:0007827""",
1607,bedaquiline,SIRTURO,1/10/2005,treatment of active tuberculosis,Designated/Approved,,,SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided.,5/27/2020,5/27/2027,As part of combination therapy in the treatment of pediatric patients 5 years and older to less than 12 years of age and weighing at least 15 kg with pulmonary multi-drug resistant tuberculosis (MDR-TB),"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,' 08869 ' ,United States,199304,tuberculosis,"""gard:0007827""",
1608,begelomab,,8/20/2021,treatment of dermatomyositis,Designated,,Not FDA Approved for Orphan Indication,,,,,ADIENNE SA,Via Zurigo 46,,Lugano,Europe,' 6900 ' ,Switzerland,833021,dermatomyositis,"""gard:0006263""",
1609,belantamab mafodotin-blmf,BLENREP,6/22/2017,treatment of multiple myeloma,Designated/Approved,,,"for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent (indication withdrawn)",8/5/2020,2/6/2023,"for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent (indication withdrawn)",GlaxoSmithKline Intellectual Property Development Ltd.,980 GREAT WEST ROAD,,BRENTFORD,MIDDLESEX,' TW89GS ' ,United Kingdom,590517,multiple myeloma,"""gard:0007108""",
1610,belatacept,Nulojix,2/20/2008,prophylaxis of organ rejection in renal allograft recipients,Designated/Approved,,,Prophylaxis of organ rejection in adult patients receiving kidney transplants,6/15/2011,6/15/2018,,Bristol-Myers Squibb Company,P. O. Box 4000,,Princeton,New Jersey,' 08543 ' ,United States,253907,,,
1611,belimumab,,1/24/2023,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,GSK LLC,"2929 Walnut St, Suite 1700",,Philadelphia,Pennsylvania,' 19112 ' ,United States,921522,systemic sclerosis,"""gard:0009748""",
1612,Belinostat,Beleodaq,9/3/2009,treatment of peripheral t-cell lymphoma (ptcl).,Designated/Approved,,,Treatment of patients with relapsed or refractory peripheral T-cell lymphoma,7/3/2014,7/3/2021,Treatment of patients with relapsed or refractory peripheral T-cell lymphoma,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,' 08520 ' ,United States,289309,lymphoma,"""gard:0020548""",
1613,beloranib,,1/15/2013,treatment of prader-willi syndrome,Designated/Designation Withdrawn or Revoked,2/1/2017,Not FDA Approved for Orphan Indication,,,,,"Zafgen, Inc.",175 Portland Street,4th Floor,Boston,Massachusetts,' 02114 ' ,United States,385012,prader-willi syndrome,"""gard:0005575""",
1614,belumosudil,Rezurock,10/5/2017,treatment of graft versus host disease (gvhd),Designated/Approved,,,Treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy,7/16/2021,7/16/2028,Treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy,"Kadmon Pharmaceuticals, LLC","55 Cambridge Parkway, Suite 300E",,Cambridge,Massachusetts,' 02142 ' ,United States,606717,graft versus host disease,"""gard:0016642""",
1615,Belumosudil,,9/4/2020,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Kadmon Corporation,450 East 29th Street,,New York,New York,' 10016 ' ,United States,760520,systemic sclerosis,"""gard:0009748""",
1616,belzutifan,Welireg,6/24/2020,treatment of von hippel-lindau disease,Designated/Approved,,,"Treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery",8/13/2021,8/13/2028,"Treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery","Merck Sharp & Dohme, LLC",126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,745820,von hippel-lindau disease,"""gard:0007855""",
1617,bempedoic acid,,4/5/2021,treatment of homozygous familial hypercholesterolemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Esperion Therapeutics, Inc.","3891 Ranchero Drive, Suite 150",,Ann Arbor,Michigan,' 48108 ' ,United States,812621,homozygous familial hypercholesterolemia,"""gard:0010416""",
1618,bempegaldesleukin,,4/17/2020,treatment of stage iib to stage iv melanoma,Designated/Designation Withdrawn or Revoked,5/9/2022,Not FDA Approved for Orphan Indication,,,,,Nektar Therapeutics,"455 Mission Bay Blvd, South",,San Francisco,California,' 94158 ' ,United States,732720,noma,"""gard:0004001""",
1619,bendamustine,,6/22/2017,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Paul Maher, MD",10644 Weymouth Street,Suite 104,Bethesda,Maryland,' 20814 ' ,United States,584417,multiple myeloma,"""gard:0007108""",
1620,bendamustine for 50 ml admixture,Bendeka,7/2/2014,treatment of chronic lymphocytic leukemia,Designated/Approved,,,Treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.,12/7/2015,12/7/2022,Treatment of patients with CLL,"Eagle Pharmaceuticals, Inc.",50 Tice Blvd,Suite 315,Woodcliff Lake,New Jersey,' 07677 ' ,United States,431814,,,
1621,bendamustine for 50ml admixture,Bendeka,7/2/2014,"treatment of follicular lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoma tissue (malt), and nodal marginal zone lymphoma (collectively",Designated/Approved,,,Treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.,12/7/2015,12/7/2022,Treatment of patients with indolent B-cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab containing regimen,"Eagle Pharmaceuticals, Inc.",50 Tice Blvd,Suite 315,Woodcliff Lake,New Jersey,' 07677 ' ,United States,430314,lymphoma,"""gard:0020548""",
1622,Bendamustine hydrochloride,Treanda,8/17/2007,treatment of chronic lymphocytic leukemia,Designated/Approved,,,Treatment of patients with chronic lymphocytic leukemia,3/20/2008,3/20/2015,,"Cephalon, Inc.",41 Moores Road,,Frazer,Pennsylvania,' 19355 ' ,United States,244807,,,
1623,bendamustine hydrochloride,Treanda,11/26/2013,"treatment of follicular lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoma tissue (malt), and nodal marginal zone lymphoma (collectively",Designated/Approved,,,Treatment of Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.,10/31/2008,10/31/2015,,"Cephalon, Inc.",A wholly owned subsidiary of Teva Pharmaceuticals,PO Box 4011,Frazer,Pennsylvania,' 19355 ' ,United States,253107,lymphoma,"""gard:0020548""",
1624,bendamustine hydrochloride with betadex sulfobutyl ether sodium,,9/10/2013,treatment of chronic lymphocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,BendaRx Corp.,1000 De La Gauchetiere W,Ste 2400,Montréal,,' ' ,Canada,386612,,,
1625,Bendamustine oral doseage formulation,,11/5/2015,treatment of chronic lymphocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Exinda Theapeutics LLC,"3941 Park Drive, Suite 20-740",,El Dorado Hills,California,' 95762 ' ,United States,486215,,,
1626,benralizumab,,8/26/2019,treatment of eosinophilic esophagitis,Designated/Designation Withdrawn or Revoked,8/16/2023,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P.O. Box 8355,Wilmington,Delaware,' 19803 ' ,United States,670018,,,
1627,Benralizumab,,11/1/2021,treatment of eosinophilic gastroenteritis,Designated,,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P.O. Box 8355,Wilmington,Delaware,' 19803 ' ,United States,838521,eosinophilic gastroenteritis,"""gard:0009142""",
1628,Benralizumab,,11/1/2021,treatment of eosinophilic gastritis (eg),Designated,,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P.O. Box 8355,Wilmington,Delaware,' 19803 ' ,United States,828221,,,
1629,benralizumab,,11/21/2018,treatment of eosinophilic granulomatosis with polyangiitis,Designated,,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,P. O. Box 8355,1800 Concord Pike,Wilmington,Delaware,' 19803 ' ,United States,660018,granulomatosis with polyangiitis,"""gard:0007880""",
1630,benralizumab,,2/1/2019,treatment of hypereosinophilic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,P. O. Box 8355,1800 Concord Pike,Wilmington,Delaware,' 19803 ' ,United States,670518,c syndrome,"""gard:0005978""",
1631,"Benzeneacetamide, 2-[2-[2-[[2-methoxy-4-(1-methyl-4-piperidinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]ethyl]-",,5/18/2020,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Amplia Therapeutics,55 Flemington Road,Suite 226,North Melbourne,VIC,' ' ,Australia,742020,idiopathic pulmonary fibrosis,"""gard:0008609""",
1632,"benzeneacetamide, 2-[2-[2-[[2-methoxy-4-(1-methyl-4-piperidinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]ethyl]-",,3/23/2020,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Amplia Therapeutics,55 Flemington Road,Suite 226,North Melbourne,VIC,' ' ,Australia,730620,,,
1633,benznidazole,,7/5/2017,treatment of chagas disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Taran Therapeutics, Inc.","5 Haines Cove Drive, Suite 2",,Toms River,New Jersey,' 08753-6810 ' ,United States,586517,,,
1634,benznidazole,,4/14/2014,treatment of chagas disease,Designated/Approved,,,"Treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi, in pediatric patients 2 to 12 years of age.",8/29/2017,8/29/2024,"Treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi, in pediatric patients 2 to 12 years of age.","Chemo Research, S.L.",Edificio Nectar,"c/Quintanapalla, 2, 3 planta",Madrid,,' ' ,Spain,425214,,,
1635,benzoate,,7/6/2012,treatment of pediatric schizophrenia,Designated,,Not FDA Approved for Orphan Indication,,,,,SyneuRx International (Taiwan) Corp.,1380 S. Marengo Ave,,Pasadena,California,' 91106 ' ,United States,365712,,,
1636,Benzoate and phenylacetate,Ucephan,1/21/1986,"for adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency.",Designated/Approved,,,,12/23/1987,12/23/1994,,ImmunexImmunex,2525 McGaw Avenue,P.O. Box 19791,Irvine,California,' 92623 ' ,United States,11385,,,
1637,benzoate/phenylacetate,Ammonul,11/22/1993,treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.,Designated/Approved,,,Adjunctive therapy in the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.,2/17/2005,2/17/2012,,Medicis Pharmaceutical Corp.,8125 N. Hayden Road,,Scottsdale,Alaska,' 85258 ' ,United States,77993,,,
1638,"Benzophenone-3, octylmethoxycinnamate, avobenzone, titanium dioxide, zinc oxide",,8/13/2001,for the prevention of visible light induced skin photosensitivity as a result of porfimer sodium photodynamic therapy,Designated,,Not FDA Approved for Orphan Indication,,,,,Fallien Cosmeceuticals Ltd.,677 W. Dekalb Pike,,King of Prussia,Pennsylvania,' 19406 ' ,United States,142401,,,
1639,Benzydamine hydrochloride,,5/18/1998,prophylactic treatment of oral mucositis resulting from radiation therapy for head and neck cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Angelini Pharmaceuticals, Inc.",70 Grand Avenue,,River Edge,New Jersey,' 07661 ' ,United States,111898,,,
1640,Benzyl ethyl aminoazobenzene quaternary ammonium,,3/17/2022,treatment of retinitis pigmentosa (rp),Designated,,Not FDA Approved for Orphan Indication,,,,,"Kiora Pharmaceuticals, Inc.",1371 East 2100 South,Suite 200,Salt Lake City,Utah,' 84105 ' ,United States,868421,retinitis pigmentosa,"""gard:0005694""",
1641,"Benzylpenicillin, benzylpenicilloic, benzylpenilloic acid",,9/28/1987,assessing the risk of administrating penicillin when it is the preferred drug of choice in adult patients who have previously received penicillin and have a history of clinical sensitivity.,Designated,,Not FDA Approved for Orphan Indication,,,,,AllerQuest LLC,836 Farmington Avenue,Suite 207,West Hanford,Connecticut,' 06119 ' ,United States,18787,,,
1642,Beractant,,12/20/1993,"treatment of full-term newborn infants with respiratory failure caused by meconium aspiration syndrome, persistent pulmonary hypertension of the newborn, or pneumonia and sepsis.",Designated,,Not FDA Approved for Orphan Indication,,,,,Ross Laboratories,625 Cleveland Avenue,,Columbus,Ohio,' 43215 ' ,United States,76793,meconium aspiration syndrome,"""gard:0010494""",
1643,Beractant,Survanta intratracheal suspension,2/5/1986,treatment of neonatal respiratory distress syndrome,Designated/Approved,,,"Treatment of (""rescue"") of premature infants with RDS confirmed by x-ray and requiring mechanical ventilation",7/1/1991,7/1/1998,,Ross Laboratories,625 Cleveland Avenue,,Columbus,Ohio,' 43215 ' ,United States,10885,,,
1644,Beractant,Survanta intratracheal suspension,2/5/1986,treatment of neonatal respiratory distress syndrome,Designated/Approved,,,Prevention of RDS (hyaline membrane disease) in premature infants less than 1250 grams birthweight or with evidence of surfactant deficiency,7/2/1991,7/2/1998,,Ross Laboratories,625 Cleveland Avenue,,Columbus,Ohio,' 43215 ' ,United States,10885,,,
1645,Beraprost,,4/29/1999,"treatment of pulmonary arterial hypertension associated with any new york heart association classification (class i, ii, iii, or iv).",Designated/Designation Withdrawn or Revoked,4/2/2020,Not FDA Approved for Orphan Indication,,,,,"LungRx, Inc.",1040 Spring Street,,Silver Spring,Maryland,' 20910 ' ,United States,123099,pulmonary arterial hypertension,"""gard:0007501""",
1646,beraprost sodium 314d,,12/22/2011,treatment of pulmonary arterial hypertension,Designated/Designation Withdrawn or Revoked,1/17/2020,Not FDA Approved for Orphan Indication,,,,,Lung Biotechnology PBC,1040 Spring Street,,Silver Spring,Maryland,' 20910 ' ,United States,355711,pulmonary arterial hypertension,"""gard:0007501""",
1647,berbamine,,11/29/2021,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,IsoQ Therapeutics Inc.,2140 S. Dupont Hwy,,Camden,Delaware,' 19934 ' ,United States,848121,lymphoma,"""gard:0020548""",
1648,berberine ursodeoxycholate,,8/29/2016,treatment of primary sclerosing cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,HighTide Biopharma Pty. Ltd.,1 Melissa Street,,Mount Waverley,Victoria,' ' ,Australia,509915,sclerosing cholangitis,"""gard:0021868""",
1649,beremagene geperpavec-svdt,Vyjuvek,11/2/2017,treatment of dystrophic epidermolysis bullosa,Designated/Approved,,,treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene,5/19/2023,5/19/2030,treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene,"Krystal Biotech, Inc.",2100 Wharton Street,Suite 701,Pittsburgh,Pennsylvania,' 15203 ' ,United States,558816,dystrophic epidermolysis bullosa,"""gard:0002150""",
1650,berotralstat,ORLADEYO™,11/1/2017,treatment of c1-inhibitor-dependent angioedema (including prevention and treatment of attacks),Designated/Approved,,,prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older,12/3/2020,12/3/2027,prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older,"BioCryst Pharmaceuticals, Inc.",4505 Emperor Blvd,Suite 200,Durham,North Carolina,' 27703 ' ,United States,607617,,,
1651,bertilimumab,,8/17/2018,treatment of bullous pemphigoid,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,578517,bullous pemphigoid,"""gard:0005972""",
1652,Berubicin,,6/9/2020,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"CNS Pharmaceuticals, Inc.",2100 West Loop South,Suite 900,Houston,Texas,' 77027 ' ,United States,748420,,,
1653,besilesomab-CHX-A¿-DTPA-90Y,,3/28/2022,conditioning treatment prior to hematopoietic stem cell transplant,Designated,,Not FDA Approved for Orphan Indication,,,,,"Telix Pharmaceuticals (US), Inc.","12 Municipal Drive, Suite 330",,Fishers,Indiana,' 46038 ' ,United States,869222,,,
1654,Beta alethine,,3/24/1997,treatment of metastatic melanoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Dovetail Technologies, Inc.","Bldg. 337, Paint Branch Drive",,College Park,Maryland,' 20742 ' ,United States,103397,noma,"""gard:0004001""",
1655,Beta alethine,,3/24/1997,treatment of multiple myeloma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Dovetail Technologies, Inc.","Bldg. 337, Paint Branch Drive",,College Park,Maryland,' 20742 ' ,United States,103297,multiple myeloma,"""gard:0007108""",
1656,Beta-Lapachone,,3/28/2022,treatment of primary sclerosing cholangitis (psc),Designated,,Not FDA Approved for Orphan Indication,,,,,"Curome Biosciences Co., Ltd.","Gwanggyo Business Center 5F(#508),","156, Gwanggyo-ro, Yeongtong-Gu",Suwon-si,Gyeonggi-do,' 16506 ' ,South Korea,812821,sclerosing cholangitis,"""gard:0021868""",
1657,Beta-nicotinamide mononucleotide,,12/14/2023,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,LGD SARL,31 Impasse Leon Foucault,,Velaux,VELAUX,' 13880 ' ,France,975923,,,
1658,Betahistine dihydrochloride,,11/8/2007,treatment of obesity associated with prader willi syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Altamira Therapeutics Inc.,"254 Chapman Rd, Ste 208 #15392",,Newark,Delaware,' 19702 ' ,United States,247407,,,
1659,Betaine,Cystadane,5/16/1994,treatment of homocystinuria.,Designated/Approved,,,Treatment of homocystinuria to decrease elevated homocysteine blood levels.,10/25/1996,10/25/2003,,Orphan Europe SARL,70 Avenue du Général de Gaulle,,Puteaux,Île-de-France,' ' ,France,81794,cystinuria,"""gard:0006237""",
1660,betamethasone,,10/7/2015,treatment of ataxia telangiectasia.,Designated,,Not FDA Approved for Orphan Indication,,,,,Acasti Pharma Inc.,"3009 Boulevard De la Concorde E., Suite 102",,Laval,Quebec,' H7E 2B5 ' ,Canada,492415,,,
1661,Bethanidine sulfate,,9/20/1988,treatment of primary ventricular fibrillation.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Medco Research, Inc.",8455 Beverly Blvd.,Suite 308,Los Angeles,California,' 90048 ' ,United States,26087,,,
1662,Bethanidine sulfate,,11/24/1989,prevention of recurrence of primary ventricular fibrillation.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Medco Research, Inc.",8455 Beverly Blvd.,Suite 308,Los Angeles,California,' 90048 ' ,United States,32588,,,
1663,betibeglogene autotemcel,Zynteglo,3/18/2013,treatment of b-thalassemia major and intermedia,Designated/Approved,,,Treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell (RBC) transfusions,8/17/2022,8/17/2029,Treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell (RBC) transfusions,"bluebird bio, Inc.",455 Grand Union Blvd,,Somerville,Massachusetts,' 02145 ' ,United States,390513,,,
1664,Betulinic acid,,8/9/2007,topical treatment of metastatic melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Life Sciences, Inc. (ALS)",1440 Davey Road,,Woodridge,Illinois,' 60517 ' ,United States,244107,noma,"""gard:0004001""",
1665,Bevacizumab,,10/12/2022,treatment of hereditary hemorrhagic telangiectasia,Designated,,Not FDA Approved for Orphan Indication,,,,,Laboratoires Delbert SAS,49 rue Rouelle,,Paris,,' 75015 ' ,France,904822,hereditary hemorrhagic telangiectasia,"""gard:0006626""",
1666,bevacizumab,,1/27/2016,treatment of mesothelioma,Designated/Designation Withdrawn or Revoked,1/3/2020,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,505115,,,
1667,bevacizumab,,11/20/2009,in combination with a platinum and 5-fu or capecitabine for the treatment of stomach cancer.,Designated/Designation Withdrawn or Revoked,1/3/2020,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,294409,,,
1668,bevacizumab,,10/13/2009,treatment of melanoma stages iib through iv as part of a combination chemotherapy regimen,Designated/Designation Withdrawn or Revoked,1/3/2020,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,291709,noma,"""gard:0004001""",
1669,bevacizumab,,10/20/2004,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,1/3/2020,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.","1 DNA Way, MS #242",,South San Francisco,California,' 94080 ' ,United States,193704,,,
1670,bevacizumab,Avastin,5/26/2006,treatment of malignant glioma,Designated/Approved,,,Treatment of glioblastoma with progressive disease following prior therapy,5/5/2009,5/5/2016,,"Genentech, Inc.","1 DNA Way, MS 241B",,South San Francisco,California,' 94080 ' ,United States,222906,,,
1671,bevacizumab,Avastin,2/9/2006,therapeutic treatment of patients with ovarian cancer,Designated/Approved,,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",11/14/2014,11/14/2021,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,216405,ovarian cancer,"""gard:0007295""",
1672,bevacizumab,Avastin,2/9/2006,therapeutic treatment of patients with ovarian cancer,Designated/Approved,,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.",12/6/2016,12/6/2023,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian cancer.","Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,216405,ovarian cancer,"""gard:0007295""",
1673,bevacizumab,Avastin,11/6/2003,treatment of renal cell carcinoma,Designated/Approved,,,Treatment of renal cell carcinoma in combination with interferon alfa,7/31/2009,7/31/2016,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,172903,renal cell carcinoma,"""gard:0013215""",
1674,bevacizumab,,10/21/2010,treatment of hereditary hemorrhagic telangiectasia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Terence M. Davidson, MD",UCSD Medical Center,,San Diego,California,' 92103 ' ,United States,317510,hereditary hemorrhagic telangiectasia,"""gard:0006626""",
1675,bevacizumab,Avastin,11/23/2010,treatment of fallopian tube carcinoma,Designated/Approved,,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens.",11/14/2014,11/14/2021,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent fallopian tube cancer who have received no more than 2 prior chemotherapy regimens.","Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,318010,noma,"""gard:0004001""",
1676,bevacizumab,Avastin,11/2/2010,treatment of primary peritoneal carcinoma.,Designated/Approved,,,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens",11/14/2014,11/14/2021,"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent primary peritoneal cancer who received no more than 2 prior chemotherapy regimens","Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,317810,primary peritoneal carcinoma,"""gard:0020103""",
1677,bevacizumab,Avastin,11/2/2010,treatment of primary peritoneal carcinoma.,Designated/Approved,,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitiverecurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.",6/13/2018,6/13/2025,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV primary peritoneal cancer following initial surgical resection.","Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,317810,primary peritoneal carcinoma,"""gard:0020103""",
1678,bevacizumab,,3/10/2016,treatment of coat's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"MicroSert, Ltd.",Bar Yehuda Street,,Nesher,Haifa District,' ' ,Israel,512215,,,
1679,bevacizumab,Avastin,2/9/2006,therapeutic treatment of patients with ovarian cancer,Designated/Approved,,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitiverecurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.",6/13/2018,6/13/2025,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian cancer following initial surgical resection.","Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,216405,ovarian cancer,"""gard:0007295""",
1680,bevacizumab,Avastin,11/23/2010,treatment of fallopian tube carcinoma,Designated/Approved,,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.",12/6/2016,12/6/2023,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent fallopian tube cancer.","Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,318010,noma,"""gard:0004001""",
1681,bevacizumab,Avastin,11/2/2010,treatment of primary peritoneal carcinoma.,Designated/Approved,,,"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.",12/6/2016,12/6/2023,"Either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent primary peritoneal cancer.","Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,317810,primary peritoneal carcinoma,"""gard:0020103""",
1682,bevacizumab,Avastin,11/23/2010,treatment of fallopian tube carcinoma,Designated/Approved,,,"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitiverecurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.",6/13/2018,6/13/2025,"In combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV fallopian tube cancer following initial surgical resection.","Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,318010,noma,"""gard:0004001""",
1683,Bevantolol,,6/24/2021,treatment of huntington's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,SOM Innovation Biotech S.A.,"Baldiri Reixac, 4",,Barcelona,Barcelona,' 08028 ' ,Spain,822821,,,
1684,Bexarotene,Targretin,6/18/1999,treatment of cutaneous t-cell lymphoma.,Designated/Approved,,,Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.,12/29/1999,12/29/2006,,"Eisai, Inc.",300 Tice Blvd,,Woodcliff Lake,New Jersey,' 07677 ' ,United States,124699,lymphoma,"""gard:0020548""",
1685,Bexmarilimab,,8/24/2023,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Faron Pharmaceuticals Ltd.,Joukahaisenkatu 6,,Turku,,' FI-20520 ' ,Finland,956623,acute myeloid leukemia,"""gard:0012757""",
1686,bezafibrate,,7/24/2013,for therapeutic treatment of barth syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Barth Sydrome Foundation, Inc.",P. O. Box 618,,Larchmont,New York,' 10538 ' ,United States,400013,h syndrome,"""gard:0010239""",
1687,Bezuclastinib,,3/17/2023,treatment of mastocytosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cogent Biosciences, Inc.",275 Wyman Street,3rd Floor,Waltham,Massachusetts,' 02451 ' ,United States,929722,mastocytosis,"""gard:0006987""",
1688,bi-shRNA furin and GMCSF Autologous Tumor Cell Vaccine,,10/22/2014,treatment of ewing's sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gradalis, Inc.",2545 Golden Bear Drive #110,,Carrolton,Texas,' 75006 ' ,United States,442114,,,
1689,bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine,,2/17/2012,treatment of stage iib to iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gradalis, Inc.",2545 Golden Bear Drive #110,,Carrolton,Texas,' 75006 ' ,United States,356611,noma,"""gard:0004001""",
1690,bi-shRNAfurin and granulocyte macrophage colony stimulating factor augmented autologus tumor cell vaccine,,4/18/2011,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gradalis, Inc.",2545 Golden Bear Drive,,Carrollton,Texas,' 75006 ' ,United States,336011,ovarian cancer,"""gard:0007295""",
1691,bi-specific fragment crystallizable region (Fc) fusion protein containing cluster of differentiation 80 ectodomain as an N-terminal moiety and interleukin-2 variant as a C-terminal moiety conjugated with human immunoglobulin G4 Fc,,10/17/2022,treatment of merkel cell carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"GI Innovation, Inc.","A-1116 Tera Tower, 167, Songpa-daero",,Songpa-gu,Seoul,' 05855 ' ,South Korea,905422,noma,"""gard:0004001""",
1692,bicarbonate infusate,Normocarb HF,8/9/2005,use in the management of patients undergoing continuous renal replacement therapy with hemofiltration,Designated/Approved,,,Use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace water and to correct electrolytes and acid-base imbalances in adults and children,7/26/2006,7/26/2013,,"Dialysis Solutions, Inc.",14 Emmett Place,,Whitby,,' ' ,Canada,198904,,,
1693,"bicistronic messenger ribonucleic acid (mRNA) encoding for ZF-DNMT and ZF-KRAB proteins, encapsulated in a lipid nanoparticle (LNP)",,10/31/2022,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Omega Therapeutics, Inc.","20 Acorn Park Drive, Suite 400",,Cambridge,Massachusetts,' 02140 ' ,United States,907422,hepatocellular carcinoma,"""gard:0016773""",
1694,"bictegravir, emtricitabine, and tenofovir alafenamide",Biktarvy,5/17/2017,treatment of human immunodeficiency virus type 1 infection in pediatric patients,Designated/Approved,,,as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg: (1) who have no antiretroviral treatment history or (2) to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir,2/23/2024,2/23/2031,treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients weighing at least 14 kg to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir and with known or suspected substitutions associated with resistance to emtricitabine,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,559316,,,
1695,"bictegravir, emtricitabine, and tenofovir alafenamide",Biktarvy,5/17/2017,treatment of human immunodeficiency virus type 1 infection in pediatric patients,Designated/Approved,,,BIKTARVY® is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral with no history of treatment failure and no known substitutions associated with resistance to the individual components o,6/18/2019,6/18/2026,As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral with no history of treatment failure and no known substitutions associated with resistance to the individual components of,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,559316,,,
1696,"bictegravir, emtricitabine, and tenofovir alafenamide",Biktarvy,5/17/2017,treatment of human immunodeficiency virus type 1 infection in pediatric patients,Designated/Approved,,,As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy,10/7/2021,10/7/2028,As a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients weighing 14 kg to less than 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Biktarvy,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,559316,,,
1697,bifidobacterium infantis 35624,,3/24/2008,treatment of pediatric ulcerative colitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Alimentary Health Limited,"Cork Airport Business Park, Building 2800",,Cork,,' ' ,Ireland,255107,,,
1698,bifidobacterium longum infantis 35624,,1/16/2003,treatment of pediatric crohn's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Alimentary Health Limited,"Guardwell, Kinsale",,Cork,,' ' ,Ireland,161902,,,
1699,"bilayer, engineered collagen hydrogel-based skin graft composed of autologous keratinocytes and fibroblasts",,9/6/2016,treatment of partial deep dermal and full thickness burn wounds,Designated,,Not FDA Approved for Orphan Indication,,,,,Curtiss AG,Grabenstrasse 11,,Schlieren,,' 8952 ' ,Switzerland,532816,,,
1700,bimagrumab,,6/18/2012,treatment of inclusion body myositis,Designated/Designation Withdrawn or Revoked,8/13/2018,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,369012,inclusion body myositis,"""gard:0003896""",
1701,Bindarit,,2/3/1998,treatment of lupus nephritis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Angelini Pharmaceuticals, Inc.",70 Grand Avenue,Suite 109,River Edge,New Jersey,' 07661 ' ,United States,110097,,,
1702,binimetinib,,11/19/2013,treatment stage iib-iv melanoma.,Designated/Designation Withdrawn or Revoked,11/15/2022,Not FDA Approved for Orphan Indication,,,,,"Array BioPharma Inc., a wholly-owned subsidiary of Pfizer Inc.",125 Cambridge Park Drive,Suite 301,Cambridge,Massachusetts,' 02140 ' ,United States,411513,noma,"""gard:0004001""",
1703,binimetinib,,7/31/2014,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,11/15/2022,Not FDA Approved for Orphan Indication,,,,,"Array BioPharma Inc., a wholly-owned subsidiary of Pfizer Inc.",3200 Walnut Street,,Boulder,Colorado,' 80301 ' ,United States,440414,ovarian cancer,"""gard:0007295""",
1704,Bio-engineered oral mucosal tissue,,4/27/2006,for use as a graft for restoring a cornea-like epithelial phenotype to substitute for the normal corneal epithelium that is lost in patients due to total limbal stem cell deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"TissueTech, Inc.",7000 SW 97th Avenue,,Miami,Florida,' 33173 ' ,United States,219806,limbal stem cell deficiency,"""gard:0020123""",
1705,Bioartificial liver system utilizing encapsulated human Hep G2 hepatoblastoma cells in a fluidised bed bioreactor (BAL).,,9/9/2020,treatment of acute liver failure.,Designated,,Not FDA Approved for Orphan Indication,,,,,ESPL Regulatory Consulting Limited,"River House, Unit 4D,","Blackpool Retail Park, Blackpool, Co. Cork",Cork,Munster,' ' ,Ireland,761120,acute liver failure,"""gard:0019112""",
1706,Bioartificial liver system utilizing xenogenic hepatocytes in a hollow fiber bioreactor cartridge (BAL),,2/11/2002,treatment of patients with acute liver failure presenting with encephalopathy deteriorating beyond parson's grade 2,Designated,,Not FDA Approved for Orphan Indication,,,,,"Excorp Medical, Inc.",Suite 235,7200 Hudson Blvd.,Oakdale,Minnesota,' 55128 ' ,United States,136600,acute liver failure,"""gard:0019112""",
1707,Biocompatible polymeric PLGA nanofiber membrane containing the active substance 7-ethyl-10-hydroxycamptothecin,,10/13/2021,treatment of soft tissue sarcoma (sts),Designated,,Not FDA Approved for Orphan Indication,,,,,Cebiotex S.L.,"Plaça Pau Vila, 1; Block A, 3rd Floor",Barcelona Tech City,Barcelona,,' 08039 ' ,Spain,840021,soft tissue sarcoma,"""gard:0004898""",
1708,Biotin,,9/8/2020,treatment of charcot-marie-tooth disease,Designated,,Not FDA Approved for Orphan Indication,,,,,MedDay Pharmaceuticals,6880 Commerce Blvd.,,Canton,Michigan,' 48187 ' ,United States,760720,,,
1709,Biphenyl-substituted L-ido configured deoxynojirimycin derivative,,1/31/2022,treatment of gm2 gangliosidoses (tay-sachs disease and sandhoff disease),Designated,,Not FDA Approved for Orphan Indication,,,,,Azafaros BV,JH Oortweg 21,,Leiden,CH,' 2333 ' ,Netherlands,859521,tay-sachs disease,"""gard:0007737""",
1710,biphenyl-substituted L-ido configured deoxynojirimycin derivative,,3/7/2022,treatment of niemann pick disease type c,Designated,,Not FDA Approved for Orphan Indication,,,,,Azafaros BV,JH Oortweg 21,,Leiden,,' 2333 ' ,Netherlands,865321,,,
1711,birch triterpenes,Filsuvez,8/7/2014,treatment of epidermolysis bullosa,Designated/Approved,,,Treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older,12/18/2023,12/18/2030,Treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older,Chiesi Farmaceutici S.p.A.,Via Palermo 26/A,,Parma,Emilia Romagna,' 43122 ' ,Italy,438114,,,
1712,Bis(4-fluorophenyl)phenylacetamide,,3/2/2000,treatment of sickle cell disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,ICAgen Inc.,Ion Channel Advances,PO Box 14487,Durham,North Carolina,' 27709 ' ,United States,131999,,,
1713,"Bis-(3-deoxy-3-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-B-D-galactopyranosyl) sulfane",,8/25/2020,treatment of idiopathic pulmonary fibrosis,Designated/Designation Withdrawn or Revoked,10/20/2023,Not FDA Approved for Orphan Indication,,,,,Galecto Biotech AB,Ole Maaloes Vej 3,,Copenhagen N,,' ' ,Denmark,757320,idiopathic pulmonary fibrosis,"""gard:0008609""",
1714,bis-choline tetrathiomolybdate,,6/5/2017,treatment of amyotrophic lateral sclerosis (als),Designated/Designation Withdrawn or Revoked,6/10/2022,Not FDA Approved for Orphan Indication,,,,,Alexion Pharmaceutical Inc.,121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,569516,amyotrophic lateral sclerosis,"""gard:0005786""",
1715,bis-choline tetrathiomolybdate,,4/6/2020,treatment of primary biliary cholangitis,Designated/Designation Withdrawn or Revoked,9/12/2022,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,733720,primary biliary cholangitis,"""gard:0007459""",
1716,bis-cyclopropylcarbamoyl-bis-indanedione sulfone,,9/15/2021,treatment of heparin induced thrombocytopenia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Fox Chase Chemical Diversity Center, Inc.",3805 Old Easton Road,,Doylestown,Pennsylvania,' 18902 ' ,United States,837021,,,
1717,bisantrene HCl,,2/14/2014,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Race Oncology, Ltd",50 Kings Park Road,Level 2,West Perth,WA,' ' ,Australia,419613,acute myeloid leukemia,"""gard:0012757""",
1718,"Bismuth-1,2-ethanedithiol; 1,2-Bis-((1,3-dithia-2-bismolan)-2-yl) thioethane",,8/21/2019,treatment (management) of pulmonary infections in patients with cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Microbion Corporation,1102 West Babcock Street,Suite B,Bozeman,Montana,' 59715 ' ,United States,621817,cystic fibrosis,"""gard:0006233""",
1719,bispecific anti-GD2/anti-B7-H3 monoclonal antibody,,2/26/2024,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Invenra Inc.,5510 Element Way Suite 400,,Madison,Wisconsin,' 53719 ' ,United States,990123,neuroblastoma,"""gard:0007185""",
1720,bispecific antibody (monoclonal antibody),,8/8/2013,treatment of her2-expressing adenocarcinoma of the esophagus,Designated/Designation Withdrawn or Revoked,2/15/2022,Not FDA Approved for Orphan Indication,,,,,"Elevation Oncology, Inc.",888 7th Avenue,Suite 30,New York,New York,' 10106 ' ,United States,401113,adenocarcinoma of the esophagus,"""gard:0016927""",
1721,bispecific antibody (monoclonal antibody),,8/8/2013,treatment of her2-expressing advanced adenocarcinoma of the stomach and gastroesophageal junction,Designated/Designation Withdrawn or Revoked,2/15/2022,Not FDA Approved for Orphan Indication,,,,,"Elevation Oncology, Inc.",888 7th Avenue,Suite 30,New York,New York,' 10106 ' ,United States,401413,noma,"""gard:0004001""",
1722,Bispecific antibody 520c9x22,,10/5/1993,for in vivo serotherapy of patients with ovarian cancer.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Medarex, Inc.",67 Beaver Avenue,,Annandale,New Jersey,' 08801 ' ,United States,72492,ovarian cancer,"""gard:0007295""",
1723,Bispecific antibody against Claudin 18.2 and cluster of differentiation 47 (CD47),,6/13/2022,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Phanes Therapeutics, Inc.",11535 Sorrento Valley Rd Suite 400,,San Diego,California,' 92121 ' ,United States,888122,,,
1724,Bispecific antibody against CLDN18.2 and T cell receptor complex CD3,,5/3/2023,treatment of gastric/gej cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,936323,,,
1725,bispecific antibody against CLDN18.2 and T cell receptor complex CD3,,6/3/2024,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.",2375 Waterview Drive,,Northbrook,Illinois,' 60062 ' ,United States,943723,,,
1726,Bispecific Antibody against DLL3 and CD47,,6/6/2022,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Phanes Therapeutics, Inc.","11535 Sorrento Valley Road, Suite 400",,San Diego,California,' 92121 ' ,United States,880922,small cell lung cancer,"""gard:0009344""",
1727,bispecific antibody drug conjugate (ADC) comprised of a humanized anti-CD33 and a humanized anti-CD7 Fab chemically linked to form a bi-Fab and conjugated to maleimidocaproyl monomethylauristatin F (mcMMAF),,4/15/2024,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,BiVictriX Therapeutics plc.,"Mereside, Alderley Park",,Alderley Edge,Cheshire,' SK10 4TG ' ,United Kingdom,997724,acute myeloid leukemia,"""gard:0012757""",
1728,bispecific Antibody simultaneously targeting CD38 and CD3,,9/11/2019,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ichnos Sciences, Inc.",One World Trade Center,"76th Floor, Suite D",New York,New York,' 10007 ' ,United States,700119,multiple myeloma,"""gard:0007108""",
1729,bispecific antibody targeting interleukin 4 (IL-4) and interleukin 13 (IL-13),,9/14/2011,treatment of idiopathic pulmonary fibrosis.,Designated/Designation Withdrawn or Revoked,2/21/2018,Not FDA Approved for Orphan Indication,,,,,"Sanofi US Services, Inc., A SANOFI COMPANY",55 Corporate Drive,Mailstop: 55C-300,Bridgewater,New Jersey,' 08807 ' ,United States,342811,idiopathic pulmonary fibrosis,"""gard:0008609""",
1730,bispecific T cell engager antibody construct with a half-life extension Fc moiety capable of binding to the neonatal Fc receptor,,9/11/2019,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop 17-1-A,Thousand Oaks,California,' 91320 ' ,United States,655818,acute myeloid leukemia,"""gard:0012757""",
1731,bispecific T-cell engager (BiTE) antibody targeting CD33 and CD3,,7/1/2019,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop 17-1-A,Thousand Oaks,California,' 91320 ' ,United States,691519,acute myeloid leukemia,"""gard:0012757""",
1732,Bispecific T-cell engager (BiTE) containing two single-chain variable fragment (scFv) domains directed against the B cell maturation antigen (BCMA) surface receptor on tumor cells and the cluster of differentiation 3 (CD3) receptor on T-cells,,2/8/2019,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,' 91320 ' ,United States,669618,multiple myeloma,"""gard:0007108""",
1733,bispecific T-cell engager antibody with a single chain Fc moiety that binds to B cell maturation antigen surface receptor and CD3,,10/10/2018,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop: 27-3-F,Thousand Oaks,California,' 91320 ' ,United States,644818,multiple myeloma,"""gard:0007108""",
1734,"bispecific, biparatopic antibody targeting CD38 and CD47",,2/27/2023,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Ichnos Sciences SA,"Chemin de la Combeta, 5",,La Chaux-de-Fonds,Neuchatel,' 02300 ' ,Switzerland,926822,multiple myeloma,"""gard:0007108""",
1735,bitopertin,,12/22/2022,treatment of erythropoietic protoporphyria,Designated,,Not FDA Approved for Orphan Indication,,,,,Disc Medicine,321 Arsenal Street,Suite 101,Watertown,Massachusetts,' 02472 ' ,United States,916222,porphyria,"""gard:0010353""",
1736,bitopertin,,8/16/2017,treatment of ß-thalassemia,Designated/Designation Withdrawn or Revoked,8/9/2018,Not FDA Approved for Orphan Indication,,,,,Hoffmann-La Roche Inc.,"c/o Genentech, Inc.",1 DNA Way,South San Francisco,California,' 94080 ' ,United States,596717,,,
1737,bivalent anti-human myostatin adnectin-IgG1,,2/10/2015,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,450914,muscular dystrophy,"""gard:0007922""",
1738,Bivalent cytomeglaovirus gB/pp65 enveloped virus-like particles,,6/17/2022,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"VBI Vaccines, Inc.",American Twine Office Park,"160 Second Street, Floor 3",Cambridge,Massachusetts,' 02142 ' ,United States,886322,glioblastoma,"""gard:0002491""",
1739,bivalirudin,,11/2/2005,for use as an anticoagulant in patients with or at risk of heparin-induced thrombocytopenia/heparin-induced thrombocytopenia thrombosis syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,The Medicines Company,8 Sylvan Way,,Parsippany,New Jersey,' 07054 ' ,United States,200204,heparin-induced thrombocytopenia,"""gard:0002650""",
1740,blarcamesine,,11/3/2022,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Anavex Life Sciences Corp.,"630 5th Avenue, 20th Floor",,New York,New York,' 10111 ' ,United States,908022,fragile x syndrome,"""gard:0006464""",
1741,Bleomycin,,12/20/2010,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,CIRJ Company Ltd.,1800 Loma Vista St.,,Pasadena,California,' 91004 ' ,United States,326510,,,
1742,Bleomycin,,2/9/1999,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genetronics, Inc.",11199 Sorrento Valley Rd.,,San Diego,California,' 92121 ' ,United States,118498,,,
1743,Bleomycin sulfate,Blenoxane,9/17/1993,treatment of malignant pleural effusion.,Designated/Approved,,,Treatment of malignant pleural effusion.,2/20/1996,2/20/2003,,Bristol-Myers Squibb Pharmaceutical Research Institute,P.O. Box 4000,,Princeton,New Jersey,' 08543 ' ,United States,76193,,,
1744,blinatumomab,,2/6/2006,"treatment of indolent b-cell lymphoma, excluding cll and nhl with cns involvement",Designated,,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,' 91230 ' ,United States,203405,lymphoma,"""gard:0020548""",
1745,Blinatumomab,,5/16/2008,treatment of chronic lymphocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,' 91230 ' ,United States,261708,,,
1746,blinatumomab,,5/16/2008,treatment for hairy cell leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,' 91230 ' ,United States,261808,,,
1747,blinatumomab,,5/16/2008,treatment of prolymphocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,' 91230 ' ,United States,261908,,,
1748,blinatumomab,Blincyto,5/16/2008,treatment of acute lymphocytic leukemia,Designated/Approved,,,Treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).,12/3/2014,12/3/2021,Treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).,"Amgen, Inc.",One Amgen Center Dr.,Mail Stop 17-2-A,Thousand Oaks,California,' 91320 ' ,United States,255707,,,
1749,blinatumomab,Blincyto,5/16/2008,treatment of acute lymphocytic leukemia,Designated/Approved,,,treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children,7/11/2017,7/11/2024,treatment of Philadelphia chromosome-positive relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children,"Amgen, Inc.",One Amgen Center Dr.,Mail Stop 17-2-A,Thousand Oaks,California,' 91320 ' ,United States,255707,,,
1750,blinatumomab,Blincyto,5/16/2008,treatment of acute lymphocytic leukemia,Designated/Approved,,,treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL),8/30/2016,8/30/2023,treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in patients weighing less than 45 kg,"Amgen, Inc.",One Amgen Center Dr.,Mail Stop 17-2-A,Thousand Oaks,California,' 91320 ' ,United States,255707,,,
1751,blinatumomab,,7/6/2017,treatment of diffuse large b-cell lymphoma (dlbcl),Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,1 Amgen Center Drive,,Thousand Oaks,California,' 91320 ' ,United States,585917,lymphoma,"""gard:0020548""",
1752,blinatumomab,Blincyto,5/16/2008,treatment of acute lymphocytic leukemia,Designated/Approved,,,BLINCYTO® is indicated for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children.,3/29/2018,3/29/2025,For the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children,"Amgen, Inc.",One Amgen Center Dr.,Mail Stop 17-2-A,Thousand Oaks,California,' 91320 ' ,United States,255707,,,
1753,blisibimod,,8/7/2017,treatment of patients with immunoglobulin a nephropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Anthera Pharmaceuticals, Inc.",25801 Industrial Boulevard,Suite B,Hayward,California,' 94545 ' ,United States,560216,,,
1754,BMEDA-chelated Rhenium-186 nanoliposomes,,8/26/2020,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,University of Texas Health Science Center at San Antonio,7979 Wurzbach Rd.,Suite Z416,San Antonio,Texas,' 78229 ' ,United States,757420,glioblastoma,"""gard:0002491""",
1755,BMEDA-chelated Rhenium-186 nanoliposomes,,11/2/2023,treatment of breast cancer with leptomeningeal metastases (lm),Designated,,Not FDA Approved for Orphan Indication,,,,,"Plus Therapeutics, Inc.",4200 Marathon Blvd. # 200,,Austin,Texas,' 78756 ' ,United States,876022,,,
1756,BN-Brachyury; a heterologous prime/boost therapeutic cancer vaccine composed of MVA-BN-Brachyury (prime) and FPV-Brachyury (boost),,4/30/2018,treatment of chordoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Bavarian Nordic A/S,3025 Carrington Mill Boulevard,Suite 100,Morrisville,North Carolina,' 27560 ' ,United States,634818,chordoma,"""gard:0001303""",
1757,bomedemstat,,2/7/2017,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,"Merck & Co., Inc.","126 E. Lincoln Avenue, PO Box 2000",RY34B-332,Rahway,New Jersey,' 07065-0900 ' ,United States,553716,acute myeloid leukemia,"""gard:0012757""",
1758,bomedemstat,,11/7/2018,treatment of essential thrombocythemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Merck & Co., Inc.","126 E. Lincoln Avenue, PO Box 2000",RY34B-332,Rahway,New Jersey,' 07065-0900 ' ,United States,660418,essential thrombocythemia,"""gard:0006594""",
1759,bomedemstat,,6/26/2017,treatment of myelofibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Merck & Co., Inc.","126 E. Lincoln Avenue, PO Box 2000",RY34B-332,Rahway,New Jersey,' 07065-0900 ' ,United States,565516,,,
1760,Bone Marrow Derived Mesenchymal Stem Cell Secretome,,5/24/2021,treatment of persistent corneal epithelial defects,Designated,,Not FDA Approved for Orphan Indication,,,,,"Combangio, Inc.","1440 O’Brien Drive, Suite D",,Menlo Park,California,' 94025 ' ,United States,743520,,,
1761,Bone marrow-derived mononuclear cells,,5/17/2010,treatment of thromboangiitis obliterans (buerger's disease),Designated,,Not FDA Approved for Orphan Indication,,,,,t2cure GmbH,Kennedyallee 93,,60596 Frankfurt am Main,,' ' ,Germany,307310,,,
1762,bortezomib,Velcade,1/15/2003,treatment of multiple myeloma,Designated/Approved,,,Treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy,5/13/2003,5/13/2010,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,163002,multiple myeloma,"""gard:0007108""",
1763,bortezomib,,2/3/2015,treatment of acute lymphoblastic leukemia,Designated/Designation Withdrawn or Revoked,7/16/2018,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,464014,acute lymphoblastic leukemia,"""gard:0000522""",
1764,bortezomib,Velcade,5/30/2012,treatment of mantle cell lymphoma.,Designated/Approved,,,Treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.,12/8/2006,12/8/2013,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,226106,lymphoma,"""gard:0020548""",
1765,bortezomib,Velcade,1/15/2003,treatment of multiple myeloma,Designated/Approved,,,First-line therapy of multiple myeloma.,6/20/2008,6/20/2015,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,163002,multiple myeloma,"""gard:0007108""",
1766,bortezomib,Velcade,5/30/2012,treatment of mantle cell lymphoma.,Designated/Approved,,,Treatment of patients with mantle cell lymphoma.,10/8/2014,10/8/2021,Treatment of patients with mantle cell lymphoma who have not received at least 1 prior therapy,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,226106,lymphoma,"""gard:0020548""",
1767,bortezomib,,1/4/2011,treatment of follicular non-hodgkin lymphoma,Designated/Designation Withdrawn or Revoked,7/16/2018,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,328610,lymphoma,"""gard:0020548""",
1768,bortezomib,Velcade,1/15/2003,treatment of multiple myeloma,Designated/Approved,,,Treatment of multiple myeloma patients who have received at least one prior therapy,3/25/2005,3/25/2012,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,163002,multiple myeloma,"""gard:0007108""",
1769,bortezomib,,7/5/2016,treatment of neurofibromatosis type 2 (nf2),Designated,,Not FDA Approved for Orphan Indication,,,,,BioXcel Corporation,780 East Main Street,Suite 2,Branford,Connecticut,' 06405 ' ,United States,525816,neurofibromatosis type 2,"""gard:0007193""",
1770,bosentan,,6/7/2010,reduction of the number (treatment) of new digital ulcers in patients with systemic sclerosis,Designated/Designation Withdrawn or Revoked,9/2/2014,Not FDA Approved for Orphan Indication,,,,,Actelion Ltd.,Gewerbestrasse 16,,Allschwil,,' ' ,Switzerland,292209,systemic sclerosis,"""gard:0009748""",
1771,bosentan,,9/30/2008,treatment of idiopathic pulmonary fibrosis,Designated/Designation Withdrawn or Revoked,9/26/2013,Not FDA Approved for Orphan Indication,,,,,Actelion Pharmaceuticals Ltd,Gewerbestrasse 16,,Allschwil,,' ' ,Switzerland,267608,idiopathic pulmonary fibrosis,"""gard:0008609""",
1772,bosutinib,Bosulif,2/24/2009,treatment of chronic myelogenous leukemia,Designated/Approved,,,BOSULIF is indicated for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML).,12/19/2017,12/19/2024,Treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).,PF PRISM C.V.,Rivium Westlaan 142,,Capelle aan den IJssel,,' 2909 LD ' ,Netherlands,274808,,,
1773,bosutinib,Bosulif,2/24/2009,treatment of chronic myelogenous leukemia,Designated/Approved,,,"Treatment of adult patients with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy",9/4/2012,9/4/2019,,PF PRISM C.V.,Rivium Westlaan 142,,Capelle aan den IJssel,,' 2909 LD ' ,Netherlands,274808,,,
1774,bosutinib,Bosulif,2/24/2009,treatment of chronic myelogenous leukemia,Designated/Approved,,,"treatment of pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy",9/26/2023,9/26/2030,"treatment of pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy",PF PRISM C.V.,Rivium Westlaan 142,,Capelle aan den IJssel,,' 2909 LD ' ,Netherlands,274808,,,
1775,Botulinum toxin type A,Botox,3/22/1984,treatment of strabismus and blepharospasms,Designated/Approved,,,Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above),12/30/1989,12/30/1996,,"Allergan, Inc.",2525 Dupont Drive,P.O. Box 19534,Irvine,California,' 92713 ' ,United States,483,,,
1776,Botulinum toxin type A,Botox,3/22/1984,treatment of strabismus and blepharospasms,Designated/Approved,,,Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above),12/29/1989,12/29/1996,,"Allergan, Inc.",2525 Dupont Drive,P.O. Box 19534,Irvine,California,' 92713 ' ,United States,483,,,
1777,botulinum toxin type A,Botox,12/6/1991,treatment of dynamic muscle contracture in pediatric cerebral palsy patients,Designated/Approved,,,BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age.,6/20/2019,6/20/2026,For the treatment of upper limb spasticity in pediatric cerebral palsy patients 2 to 17 years of age,"Allergan, Inc.",2525 Dupont Drive,T1-2A,Irvine,California,' 92623 ' ,United States,56591,,,
1778,Botulinum toxin type A,,9/15/1992,treatment of synkinetic closure of the eyelid associated with vii cranial nerve aberrant regeneration.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Botulinum Toxin Research Associates, Inc.",1261 Furnace Brook Parkway,,Quincy,Massachusetts,' 02169 ' ,United States,64591,,,
1779,Botulinum toxin type A,,12/5/1991,treatment of essential blepharospasm.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharmaceuticals, Inc.",106 Allen Road,3rd Floor,Basking Ridge,New Jersey,' 07920 ' ,United States,60891,,,
1780,Botulinum toxin type A,Botox,8/20/1986,treatment of cervical dystonia.,Designated/Approved,,,Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.,12/21/2000,12/21/2007,,"Allergan, Inc.",2525 Dupont Drive,P.O. Box 19534,Irvine,California,' 92623 ' ,United States,9885,,,
1781,Botulinum toxin type A,Dysport,10/20/1999,treatment of dynamic muscle contractures in pediatric cerebral palsy patients.,Designated/Approved,,,Treatment of lower limb spasticity in pediatric patients 2 years of age and older,7/29/2016,7/29/2023,Treatment of lower limb spasticity in pediatric cerebral palsy patients 2 years of age and older,"Ipsen Biopharmaceuticals, Inc.",650 East Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,128299,,,
1782,Botulinum toxin type A,,3/23/1989,treatment of essential blepharospasm.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Porton International, Inc.","1155 15th Street, N.W., #315",,Washington,District of Columbia,' 20005 ' ,United States,35789,,,
1783,Botulinum toxin type A,,8/12/1998,treatment of spasmodic torticollis (cervical dystonia).,Designated,,Not FDA Approved for Orphan Indication,,,,,Ipsen Biopharm Limited,1 Bath Road,Maidenhead,"Berkshire, SL6 4UH",,' ' ,United Kingdom,114198,,,
1784,Botulinum toxin type B,Myobloc,1/16/1992,treatment of cervical dystonia.,Designated/Approved,,,Treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.,12/8/2000,12/8/2007,,"Soltice Neurosciences, LLC",4010 Dupont Circle,Suite L-07,Louisville,Kentucky,' 40207 ' ,United States,64791,,,
1785,Botulinum toxin type F,,10/24/1991,treatment of spasmodic torticollis (cervical dystonia).,Designated,,Not FDA Approved for Orphan Indication,,,,,Ipsen Limited,27 Maple Street,,Milford,Massachusetts,' 01757 ' ,United States,61091,,,
1786,"botulism antitoxin heptavalent (A, B, C, D, E, F, G) (Equine)",,6/29/2011,treatment of botulism.,Designated/Approved,,,"Treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin (BoNT) serotypes A, B, C, D, E, F or G in adults and pediatric patients.",3/22/2013,3/22/2020,"Treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients",Cangene Corporation,155 Innovation Drive,,Winnipeg,,' ' ,Canada,345011,botulism,"""gard:0000943""",
1787,Botulism immune globulin,BabyBIG,1/31/1989,treatment of infant botulism.,Designated/Approved,,,Indicated for treatment of infant botulism caused by type A or type B Clostridium botulinum.,10/23/2003,10/23/2010,,California Department of Health Services,2151 Berkeley Way,,Berkeley,California,' 94704 ' ,United States,34488,infant botulism,"""gard:0020150""",
1788,Bovine colostrum,,11/19/1990,treatment of aids-related diarrhea.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hastings, Donald DVM",1030 North Parkview Drive,,Bismarck,North Dakota,' 58501 ' ,United States,55190,,,
1789,"Bovine immunoglobulin concentrate, Cryptosporidium parvum",,3/1/1994,treatment and symptomatic relief of cryptosporidium parvum infection of the gastrointestinal tract in immunocompromised patients.,Designated,,Not FDA Approved for Orphan Indication,,,,,"GalaGen, Inc.",4001 Lexington Avenue North,,Arden Hills,Minnesota,' 55126 ' ,United States,78293,,,
1790,bovine lactoferrin,,2/19/2015,prevention of late-onset sepsis in very low birth weight infants,Designated,,Not FDA Approved for Orphan Indication,,,,,"Metrodora Therapeutics, LLC",2502 Avenue I,,Brooklyn,New York,' 11210 ' ,United States,460514,,,
1791,bovine lactoferrin,,2/23/2015,prevention of necrotizing enterocolitis in very low birth weight infants (birth weight less than or equal to 1500 grams),Designated,,Not FDA Approved for Orphan Indication,,,,,"Metrodora Therapeutics, LLC",2502 Avenue I,,Brooklyn,New York,' 11210 ' ,United States,460714,necrotizing enterocolitis,"""gard:0009767""",
1792,Bovine whey protein concentrate,,9/30/1993,treatment of cryptosporidiosis caused by the presence of cryptosporidium parvum in the gastrointestinal tract of patients who are immunodeficient/immunocompromised or immunocompetent.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biomune Systems, Inc.","540 Arapeen Drive, Suite 202",,Salt Lake City,Utah,' 84108 ' ,United States,76593,,,
1793,branaplam,,1/23/2018,treatment of spinal muscular atrophy (sma),Designated/Designation Withdrawn or Revoked,1/16/2024,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,1 Health Plaza,Office #310-2132B,East Hanover,New Jersey,' 07936 ' ,United States,620117,,,
1794,Branaplam,,10/19/2020,treatment of huntington’s disease,Designated/Designation Withdrawn or Revoked,1/16/2024,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936-1080 ' ,United States,773320,,,
1795,Branched chain amino acids,,12/23/1988,treatment of amyotrophic lateral sclerosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Mount Sinai Medical Center,One Gustave L. Levy Place,,New York,New York,' 10029 ' ,United States,33588,amyotrophic lateral sclerosis,"""gard:0005786""",
1796,brentuximab vedotin,Adcetris,10/23/2008,"treatment of peripheral t-cell lymphoma, including anaplastic large cell lymphoma, peripheral t-cell lymphoma not otherwise specified, angioimmunoblastic t-cell lymphoma, adult t-cell leukemia/lymphoma, enteropathy-associated t-cell lymphoma, and extranod",Designated/Approved,,,"ADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone",11/16/2018,11/16/2025,"ADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone",Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,268908,lymphoma,"""gard:0020548""",
1797,brentuximab vedotin,Adcetris,10/23/2008,"treatment of peripheral t-cell lymphoma, including anaplastic large cell lymphoma, peripheral t-cell lymphoma not otherwise specified, angioimmunoblastic t-cell lymphoma, adult t-cell leukemia/lymphoma, enteropathy-associated t-cell lymphoma, and extranod",Designated/Approved,,,The treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen,8/19/2011,8/19/2018,,Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,268908,lymphoma,"""gard:0020548""",
1798,brentuximab vedotin,,11/13/2018,treatment of extranodal nk/t-cell lymphoma (enktl),Designated/Designation Withdrawn or Revoked,2/25/2019,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,656818,lymphoma,"""gard:0020548""",
1799,brentuximab vedotin,,4/15/2013,"treatment of patients with peripheral t-cell lymphoma, not otherwise specified",Designated/Designation Withdrawn or Revoked,2/25/2019,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,394013,lymphoma,"""gard:0020548""",
1800,brentuximab vedotin,Adcetris,1/30/2007,treatment of hodgkin's lymphoma,Designated/Approved,,,"treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide",11/10/2022,11/10/2029,treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL),Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,235606,lymphoma,"""gard:0020548""",
1801,Brentuximab vedotin,,2/6/2017,treatment of cutaneous t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,550916,lymphoma,"""gard:0020548""",
1802,brentuximab vedotin,Adcetris,11/19/2012,treatment of mycosis fungoides,Designated/Approved,,,Treatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy,11/9/2017,11/9/2024,Treatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy,Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,362611,,,
1803,brentuximab vedotin,,7/7/2016,treatment of enteropathy-associated t-cell lymphoma.,Designated/Designation Withdrawn or Revoked,2/25/2019,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,528716,lymphoma,"""gard:0020548""",
1804,Brentuximab vedotin,Adcetris,9/7/2016,treatment of primary cutaneous cd30-positive t-cell lymphoproliferative disorders,Designated/Approved,,,For adult patients with primary cutaneous anaplastic large cell lymphoma who have received prior systemic therapy,11/9/2017,11/9/2024,For adult patients with primary cutaneous anaplastic large cell lymphoma who have received prior systemic therapy,Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,536516,,,
1805,brentuximab vedotin,,1/31/2014,treatment of patients with diffuse large b-cell lymphoma.,Designated/Designation Withdrawn or Revoked,3/12/2018,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,418713,lymphoma,"""gard:0020548""",
1806,brentuximab vedotin,Adcetris,1/30/2007,treatment of hodgkin's lymphoma,Designated/Approved,,,Treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.,8/17/2015,8/17/2022,Treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.,Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,235606,lymphoma,"""gard:0020548""",
1807,brentuximab vedotin,,9/13/2013,treatment of patients with angioimmunoblastic t-cell lymphoma,Designated/Designation Withdrawn or Revoked,2/25/2019,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,404913,lymphoma,"""gard:0020548""",
1808,brentuximab vedotin,Adcetris,1/30/2007,treatment of hodgkin's lymphoma,Designated/Approved,,,The treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates,8/19/2011,8/19/2018,,Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,235606,lymphoma,"""gard:0020548""",
1809,brentuximab vedotin,Adcetris,1/30/2007,treatment of hodgkin's lymphoma,Designated/Approved,,,"ADCETRIS® is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.",3/20/2018,3/20/2025,"ADCETRIS® is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy.",Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,235606,lymphoma,"""gard:0020548""",
1810,brentuximab vedotin,,5/23/2016,treatment of adult t-cell leukemia/lymphoma,Designated/Designation Withdrawn or Revoked,2/25/2019,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,521716,lymphoma,"""gard:0020548""",
1811,Brevenal,,4/2/2018,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Silurian Pharmaceuticals, Inc.",6490 Doyle Street,,Emeryville,California,' 94608 ' ,United States,632318,cystic fibrosis,"""gard:0006233""",
1812,brexucabtagene autoleucel,,4/20/2016,treatment of chronic lymphocytic leukemia.,Designated/Designation Withdrawn or Revoked,1/21/2022,Not FDA Approved for Orphan Indication,,,,,"Kite Pharma, Inc.",2225 Colorado Avenue,,Santa Monica,California,' 90404 ' ,United States,516015,,,
1813,brexucabtagene autoleucel,TECARTUS™,4/28/2016,treatment of mantle cell lymphoma,Designated/Approved,,,TECARTUS¿ is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL),7/24/2020,7/24/2027,TECARTUS¿ is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL),"Kite Pharma, Inc.",199 E Blaine St,,Seattle,Washington,' 98102 ' ,United States,515715,lymphoma,"""gard:0020548""",
1814,brexucabtagene autoleucel,Tecartus,4/20/2016,treatment of acute lymphoblastic leukemia,Designated/Approved,,,Treatment of adult patients with relapsed or refractory B-cell precursor acute lymphomblastic leukemia (ALL),10/1/2021,10/1/2028,Treatment of adult patients with relapsed or refractory B-cell precursor acute lymphomblastic leukemia (ALL),"Kite Pharma, Inc.",2225 Colorado Avenue,,Santa Monica,California,' 90404 ' ,United States,515815,acute lymphoblastic leukemia,"""gard:0000522""",
1815,brigatinib,Alunbrig,4/28/2016,"treatment of anaplastic lymphoma kinase-positive (alk+), c-ros 1 oncogene positive (ros1+), or epidermal growth factor receptor positive (egfr+) non-small cell lung cancer (nsclc).",Designated/Approved,,,ALUNBRIG (brigatinib) is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.,5/22/2020,5/22/2027,"For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test, not including patients who have progressed on or are intolerant to crizotinib.","Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,505415,lymphoma,"""gard:0020548""",
1816,brigatinib,Alunbrig,4/28/2016,"treatment of anaplastic lymphoma kinase-positive (alk+), c-ros 1 oncogene positive (ros1+), or epidermal growth factor receptor positive (egfr+) non-small cell lung cancer (nsclc).",Designated/Approved,,,Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib,4/28/2017,4/28/2024,Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,505415,lymphoma,"""gard:0020548""",
1817,brilliant blue G,,12/16/2009,for use in ophthalmic surgery to aid in the removal of the inner limiting membrane of the eye.,Designated/Designation Withdrawn or Revoked,2/9/2021,Not FDA Approved for Orphan Indication,,,,,Fluoron GmbH,Biberkopfweg 1,,,,' ' ,Germany,257908,,,
1818,Brilliant Blue G Ophthalmic Solution 0.025%,DORC ILM-Blue,7/31/2012,for use as an aid in ophthalmic surgery by selectively staining the internal limiting membrane,Designated/Approved,,,TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is indicated to selectively stain the internal limiting membrane (ILM).,12/20/2019,12/20/2026,Indicated to selectively stain the internal limiting membrane (ILM),Dutch Ophthalmic Research Center International BV,P.O. Box 43,,Zuidland,,' ' ,Netherlands,341811,,,
1819,brimonidine,,8/3/2017,treatment of ocular graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ocugen, Inc.",5 Great Valley Parkway,Suite 160,Malvern,Pennsylvania,' 19355 ' ,United States,564016,graft versus host disease,"""gard:0016642""",
1820,Brimonidine,,2/7/2000,treatment of anterior ischemic optic neuropathy.,Designated,,Not FDA Approved for Orphan Indication,,,,,AbbVie,2525 Dupont Dr.,,Irvine,California,' 92612 ' ,United States,125699,,,
1821,brincidofovir,Tembexa,6/5/2018,treatment of smallpox,Designated/Approved,,,"Treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates",6/4/2021,6/4/2028,"Treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates",Emergent BioDefense Operations Lansing LLC,3500 North Martin Luther King Jr. Blvd.,,Lansing,Michigan,' 48906 ' ,United States,640518,,,
1822,brivanib alaninate,,3/18/2011,treatment of hepatocellular carcinoma,Designated/Designation Withdrawn or Revoked,6/27/2014,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb,P. O. Box 4000,,Princeton,New Jersey,' 08543 ' ,United States,336311,hepatocellular carcinoma,"""gard:0016773""",
1823,brivaracetam,,12/3/2019,treatment of childhood absence epilepsy,Designated,,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.",1950 Lake Park Drive,Building 2100,Smyrna,Georgia,' 30080 ' ,United States,711119,childhood absence epilepsy,"""gard:0016667""",
1824,brivaracetam,,10/5/2005,treatment of symptomatic myoclonus,Designated,,Not FDA Approved for Orphan Indication,,,,,"UCB Pharma, Inc.",1950 Lake Park Drive,,Smyra,Georgia,' 30080 ' ,United States,207305,,,
1825,brivaracetam,,12/3/2019,treatment of juvenile absence epilepsy,Designated,,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.",1950 Lake Park Drive,Building 2100,Smyrna,Georgia,' 30080 ' ,United States,724019,juvenile absence epilepsy,"""gard:0002162""",
1826,Brivudin,,11/15/2007,adjunct treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"SciClone Pharmaceuticals, Inc.",901 Mariner's Island Blvd.,,San Mateo,California,' 94404 ' ,United States,247807,,,
1827,brodalumab,,10/11/2022,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Bausch Health,400 Somerset Corporate Blvd,,Bridgewater,New Jersey,' 08807 ' ,United States,904322,systemic sclerosis,"""gard:0009748""",
1828,Brogidirsen,,7/31/2023,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"NS Pharma, Inc.","140 East Ridgewood Avenue, Suite 280S",,Paramus,New Jersey,' 07652 ' ,United States,950823,muscular dystrophy,"""gard:0007922""",
1829,bromelain + acetylcysteine,,12/27/2018,treatment of pseudomyxoma peritonei with bromelain and acetylcysteine,Designated,,Not FDA Approved for Orphan Indication,,,,,MUCPharm Pty Ltd.,13/53 High Street,,Malvern,Victoria,' ' ,Australia,664418,pseudomyxoma peritonei,"""gard:0007488""",
1830,Bromhexine,,5/15/1989,treatment of mild to moderate keratoconjunctivitis sicca in patients with sjogren's syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.","900 Ridgebury Road, Box 368",,Ridgefield,Connecticut,' 06877 ' ,United States,34789,,,
1831,bromodomain and Extra-Terminal (BET) Inhibitor,,4/5/2017,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,5/10/2022,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,561016,acute myeloid leukemia,"""gard:0012757""",
1832,bromophenoxyazole propanoic acid,,9/12/2022,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,"NMD Pharma, INCUBA",Palle Juul-Jensens Boulevard 82,,Aarhus,Midtjylland,' 8200 ' ,Denmark,859421,myasthenia gravis,"""gard:0007122""",
1833,Broxuridine,,9/18/1995,radiation sensitizer in the treatment of primary brain tumors.,Designated,,Not FDA Approved for Orphan Indication,,,,,"NeoPharm, Inc.","225 East Deerpath, Suite 250",,Lake Forest,Illinois,' 60045 ' ,United States,91295,,,
1834,Bruton's tyrosine kinase inhibitor,,2/10/2014,treatment of chronic lymphocytic leukemia,Designated/Designation Withdrawn or Revoked,1/6/2015,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,400 Connell Drive,Suite 700,Berkeley Heights,New Jersey,' 07922 ' ,United States,408313,,,
1835,bryostatin 1,,3/31/2015,treatment of fragile x syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Synaptogenix, Inc.",50 Park Place,Suite 1401,Newark,New Jersey,' 07102 ' ,United States,471415,fragile x syndrome,"""gard:0006464""",
1836,bryostatin-1,,12/3/2001,for use in combination with paclitaxel in the treatment of esophageal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"GPC Biotech, Inc.",610 Lincoln Street,,Waltham,Massachusetts,' 02451 ' ,United States,148201,,,
1837,bucillamine,,10/22/2015,treatment of cystinuria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Revive Therapeutics, Ltd.",5 Director Court,Suite 105,Vaughan,,' ' ,Canada,493615,cystinuria,"""gard:0006237""",
1838,bucillamine,,2/15/2022,prevention of ischemia-reperfusion injury during liver transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,Revive Therapeutics Inc.,82 Richmond Street East,,Toronto,Ontario,' M5C 1P1 ' ,Canada,862021,,,
1839,budesonide,,2/11/2019,treatment of primary biliary cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Calliditas Therapeutics AB,Kungsbron 1,,Stockholm,Stockholms län,' SE-111 22 ' ,Sweden,673818,primary biliary cholangitis,"""gard:0007459""",
1840,budesonide,,5/6/2013,treat of ulcerative colitis in pediatric patients aged 0 through 16 years.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Santarus, Inc.","3611 Valley Centre Drive, Suite 400",,San Diego,California,' 92130 ' ,United States,394613,,,
1841,budesonide,Tarpeyo,5/17/2010,to slow the progression of immunoglobulin a nephropathy & delay kidney failure in patients affected by the disease.,Designated/Approved,,,"to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) > or = 1.5 g/g",12/15/2021,12/15/2028,"to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) > or = 1.5 g/g",Calliditas Therapeutics AB,Kungsbron 1,,Stockholm,,' SE-111 22 ' ,Sweden,305710,,,
1842,budesonide,Tarpeyo,5/17/2010,to slow the progression of immunoglobulin a nephropathy & delay kidney failure in patients affected by the disease.,Designated/Approved,,,to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression,12/20/2023,12/20/2030,"to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression, excluding the use provided for in the indication approved on December 15, 2021",Calliditas Therapeutics AB,Kungsbron 1,,Stockholm,,' SE-111 22 ' ,Sweden,305710,,,
1843,budesonide,Eohilia,12/20/2006,treatment of patients with eosinophilic esophagitis,Designated/Approved,,,treatment for 12 weeks in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE),2/9/2024,2/9/2031,treatment of adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE),"Takeda Pharmaceuticals U.S.A., Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,227406,,,
1844,budesonide,,2/1/2019,treatment of autoimmune hepatitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Calliditas Therapeutics AB,Kungsbron 1,,Stockholm,,' SE-111 22 ' ,Sweden,670118,autoimmune hepatitis,"""gard:0005871""",
1845,budesonide,,5/8/2018,treatment of eosinophilic esophagitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Dr. Falk Pharma GmbH,Leinenweberstrasse 5,,Freiburg,,' 79108 ' ,Germany,634418,,,
1846,Budoprutug,,1/12/2023,treatment of membranous nephropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tenet Medicines, Inc.",2525 Smith Street,,Scotch Plains,New Jersey,' 07076 ' ,United States,807621,,,
1847,Buffered intrathecal electrolyte/dextrose injection,Elliotts B Solution,8/24/1994,for use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment meningeal leukemia and lymphocytic lymphoma,Designated/Approved,,,For the intrathecal administration of methotrexate and cytarabine for the prevention or treatment of meningeal leukemia and lymphocytic lymphoma.,9/27/1996,9/27/2003,,"Lukare Medical, LLC",4 Julia Court,P. O. Box 782,Scotch Plains,New Jersey,' 07076 ' ,United States,83994,lymphoma,"""gard:0020548""",
1848,Buffered Ursodeoxycholic Acid,,9/3/2004,treatment of pruritus in patients with alagille syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Digestive Care, Inc.",1120 Win Drive,,Bethlehem,Pennsylvania,' 18017 ' ,United States,191204,alagille syndrome,"""gard:0000804""",
1849,bulevirtide,,3/31/2015,treatment of hepatitis d virus infection.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,470915,,,
1850,bupivacaine,,6/18/2008,relief of persistent pain associated with postherpetic neuralgia,Designated,,Not FDA Approved for Orphan Indication,,,,,DURECT Corporation,10260 Bubb Road,,Cupertino,California,' 95014 ' ,United States,237207,,,
1851,bupivacaine hydrochloride,,5/31/2016,treatment of pain associated with postherpetic neuralgia.,Designated,,Not FDA Approved for Orphan Indication,,,,,Acasti Pharma Inc.,"3009 Boulevard De la Concorde E., Suite 102",,Laval,Quebec,' H7E 2B5 ' ,Canada,510515,,,
1852,buprenorphine,,5/25/2022,treatment of opioid withdrawal syndrome in the pediatric population,Designated,,Not FDA Approved for Orphan Indication,,,,,Chiesi Farmaceutici S.p.A.,Via Palermo 26/A,,Parma,,' 43122 ' ,Italy,541116,,,
1853,Buprenorphine hydrochloride,,6/15/1994,treatment of opiate addiction in opiate users.,Designated/Designation Withdrawn or Revoked,11/7/2019,Not FDA Approved for Orphan Indication,,,,,"Indivior, Inc.",10710 Midlothian Turnpike,Suite 125,North Chesterfield,Virginia,' 23235 ' ,United States,75293,,,
1854,Buprenorphine hydrochloride,,6/15/1994,treatment of opiate addiction in opiate users.,Designated/Designation Withdrawn or Revoked,11/7/2019,Not FDA Approved for Orphan Indication,,,,,"Indivior, Inc.",10710 Midlothian Turnpike,Suite 125,North Chesterfield,Virginia,' 23235 ' ,United States,75293,,,
1855,buprenorphine in combination with naloxone,Suboxone,10/27/1994,treatment of opiate addiction in opiate users,Designated/Approved,,,Treatment of opioid dependence in patients 16 years of age or older,10/8/2002,10/8/2009,,"Indivior, Inc.",10710 Midlothian Turnpike,Suite 430,Richmond,Virginia,' 23235 ' ,United States,79093,,,
1856,burosumab-twza,Crysvita,12/14/2009,treatment of x-linked hypophosphatemia (formerly known as vitamin d-resistant rickets),Designated/Approved,,,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.,9/27/2019,9/27/2026,For the treatment of X-linked hypophosphatemia (XLH) in pediatric patients 6 months of age to less than 1 year of age,"Kyowa Kirin, Inc.",135 US Highway 202/206,Suite 6,Bedminster,New Jersey,' 07921 ' ,United States,296109,x-linked hypophosphatemia,"""gard:0012943""",
1857,burosumab-twza,Crysvita,6/15/2017,treatment of tumor-induced osteomalacia (tio) syndrome,Designated/Approved,,,Crysvita (burosumab-twza) is indicated for the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized.,6/18/2020,6/18/2027,For the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older,"Kyowa Kirin, Inc.",135 US Highway 202 206,Suite 6,Bedminster Township,New Jersey,' 07921 ' ,United States,576217,,,
1858,burosumab-twza,Crysvita,12/14/2009,treatment of x-linked hypophosphatemia (formerly known as vitamin d-resistant rickets),Designated/Approved,,,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older,4/17/2018,4/17/2025,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older,"Kyowa Kirin, Inc.",135 US Highway 202/206,Suite 6,Bedminster,New Jersey,' 07921 ' ,United States,296109,x-linked hypophosphatemia,"""gard:0012943""",
1859,Busulfan,,3/5/2001,intrathecal therapy for neoplastic meningitis,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Boulevard,,Dublin,California,' 94568 ' ,United States,140700,,,
1860,Busulfan,,7/7/1997,treatment of primary brain malignancies.,Designated,,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,' 94568 ' ,United States,105897,,,
1861,busulfan,,11/25/2002,preparative therapy for pediatric patients undergoing bone marrow transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,' 94568 ' ,United States,160402,,,
1862,Busulfan,Busulfex,7/28/1994,as preparative therapy in the treatment of malignancies with bone marrow transplantation.,Designated/Approved,,,For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.,2/4/1999,2/4/2006,,"Otsuka Pharmaceutical Company, Ltd","2-9, Kanda-Tsukasamachi",,Tokyo,,' ' ,Japan,83094,,,
1863,Busulfan,,4/21/1994,for use as preparative therapy for malignancies treated with bone marrow transplantation.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sparta Pharmaceuticals, Inc.",111 Rock Road,,Horsham,Pennsylvania,' 19044 ' ,United States,81694,,,
1864,Buthionine sulfoxamine,,10/5/2005,for use in children as a modulator of chemotherapy for the treatment of pediatric patients with neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,USC-CHLA Institute for Pediatric Clinical Research,Children's Hospital Los Angeles,MS 55,Los Angeles,California,' 90027 ' ,United States,209705,neuroblastoma,"""gard:0007185""",
1865,Buthionine sulfoxamine,,10/5/2005,use as a modulator of chemotherapy for the treatment of pediatric patients with primary malignant brain tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,USC-CHLA Institute for Pediatric Clinical Research,Children's Hospital Los Angeles,MS 55,Los Angeles,California,' 90027 ' ,United States,213205,,,
1866,butyl ((2-(5-((1H-imidazol-1-yl)methyl)pyridin-2-yl)-4-(trifluoromethoxy)phenyl)sulfonyl) carbamate,,11/2/2020,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Capacity Bio Inc.,"231 Bonetti Dr., Suite 240",,San Luis Obispo,California,' 93401 ' ,United States,779020,amyotrophic lateral sclerosis,"""gard:0005786""",
1867,butylidenephthalide,,8/5/2015,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Everfront Biotech, Inc.","11F., No. 31, Ln. 169, Kangning St.",,New Taipei City 221,,' ' ,Taiwan,485715,,,
1868,Butyrylcholinesterase,,9/30/1992,treatment of post-surgical apnea.,Designated,,Not FDA Approved for Orphan Indication,,,,,Shire Laboratories Inc.,1550 East Gude Drive,,Rockville,Maryland,' 20850 ' ,United States,69192,,,
1869,Butyrylcholinesterase,,3/25/1992,for the reduction and clearance of toxic blood levels of cocaine encountered during a drug overdose.,Designated,,Not FDA Approved for Orphan Indication,,,,,Shire Laboratories Inc.,1550 East Gude Drive,,Rockville,Maryland,' 20850 ' ,United States,63591,,,
1870,"c-KIT-targeting, dendrimer-linked phosphorodiamidate morpholino oligonucleotide",,3/10/2022,treatment of mastocytosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hoth Therapeutics, Inc",One Rockefeller Plaza,Suite 1039,New York,New York,' 10020 ' ,United States,866521,mastocytosis,"""gard:0006987""",
1871,c-myb antisense oligodeoxynucleotide,,2/22/2005,treatment of chronic myelogenous leukemia,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Genta, Inc.",Two Connell Drive,,Berkeley Heights,New Jersey,' 07922 ' ,United States,198504,,,
1872,C-type natriuretic peptide conjugated to a multi-arm polyethylene glycol carrier molecule through a cleavable linker,,2/27/2019,treatment of achondroplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,Ascendis Pharma Growth Disorders A/S,Tuborg Boulevard 5,DK-2900,Hellerup,,' ' ,Denmark,673418,achondroplasia,"""gard:0008173""",
1873,C1 esterase inhibitor (human),Cinryze,7/16/2004,treatment of angioedema,Designated/Approved,,,"CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years old and above) with Hereditary Angioedema (HAE).",6/20/2018,6/20/2025,CINRYZE (C1 esterase inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in pediatric patients ages 6-11 with Hereditary Angioedema (HAE).,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,185804,,,
1874,C1 esterase inhibitor (human),Cinryze,7/16/2004,treatment of angioedema,Designated/Approved,,,Routine prophylaxis against angioedema attacks in patients with Hereditary Angioedema (HAE),10/10/2008,10/10/2015,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,185804,,,
1875,C1 esterase inhibitor (human),,8/21/1996,treatment and prevention of angioedema caused by c1-esterase inhibitor deficiency.,Designated,,Not FDA Approved for Orphan Indication,,,,,Alpha Therapeutic Corporation,5555 Valley Boulevard,,Los Angeles,California,' 90032 ' ,United States,95296,,,
1876,C1 esterase inhibitor (Human),,11/30/2016,treatment of acute antibody mediated rejection following kidney transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,510415,,,
1877,C1 esterase inhibitor (human),Berinert,10/16/1992,prevention and/or treatment of acute attacks of hereditary angioedema.,Designated/Approved,,,Treatment of acute attacks of hereditary angioedema.,10/8/2009,10/8/2016,,CSL Behring LLC,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,67592,hereditary angioedema,"""gard:0005979""",
1878,C1 esterase inhibitor subcutaneous (human),Haegarda,10/16/1992,prevention and/or treatment of acute attacks of hereditary angioedema.,Designated/Approved,,,For routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients.,6/22/2017,6/22/2024,For routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients.,CSL Behring LLC,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,67592,hereditary angioedema,"""gard:0005979""",
1879,C1 esterase inhibitor subcutaneous (human),Haegarda,10/16/1992,prevention and/or treatment of acute attacks of hereditary angioedema.,Designated/Approved,,,HAEGARDA is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) (C1-INH) indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older,9/24/2020,,,CSL Behring LLC,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,67592,hereditary angioedema,"""gard:0005979""",
1880,"C1 esterase inhibitor, human",,4/5/2018,treatment of antibody mediated rejection (amr) of solid organ transplants,Designated,,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,602117,,,
1881,C1-esterase inhibitor (recombinant),RUCONEST,2/23/1999,treatment of (acute attacks of) angioedema caused by hereditary or acquired c1-esterase inhibitor deficiency.,Designated/Approved,,,Treatment of acute attacks of hereditary angioedema (HAE) in adult and adolescent patients.,7/16/2014,7/16/2021,Treatment of acute attacks of hereditary angioedema (HAE) in adult and adolescent patients.,Pharming Group N.V.,P. O. Box 451 Darwinweg 24,,Leiden,,' ' ,Netherlands,123599,,,
1882,C1-inhibitor,,8/30/1990,treatment of acute attacks of angioedema.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Baxter Healthcare Corp.,Hyland Division (Baxter Hyland),550 North Brand Blvd.,Glendale,California,' 91203 ' ,United States,46490,,,
1883,C1-inhibitor,,8/30/1990,"prevention of acute attacks of angioedema, including short-term prophylaxis for patients requiring dental or other surgical procedures.",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Baxter Healthcare Corp.,Hyland Division (Baxter Hyland),550 North Brand Blvd.,Glendale,California,' 91203 ' ,United States,46590,,,
1884,C20-D3-retinyl acetate,,9/16/2010,treatment of stargardt's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alkeus pharmaceuticals, Inc.",2103 Massachusetts Avenue,,Cambridge,Massachusetts,' 02140 ' ,United States,317210,,,
1885,C21H27O10P,,3/30/2015,treatment of gastric cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Minneamrita Therapeutics, LLC",6 Hickory Court,,Rock Island,Illinois,' 61201 ' ,United States,471615,,,
1886,C24H28N8O7S2,,4/2/2015,treatment of diffuse large b-cell lymphoma (dlbcl).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Curis, Inc.",4 Maguire Road,,Lexington,Massachusetts,' 02421 ' ,United States,467814,lymphoma,"""gard:0020548""",
1887,C66H100N6O27,,3/11/2013,treatment of of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"GenSpera, Inc.",2511 North Loop 1604 W,Suite 204,San Antonio,Texas,' 78258 ' ,United States,389613,hepatocellular carcinoma,"""gard:0016773""",
1888,Cabiralizumab,,1/11/2016,treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor,Designated/Designation Withdrawn or Revoked,5/15/2020,Not FDA Approved for Orphan Indication,,,,,"Five Prime Therapeutics, Inc.",111 Oyster Point Boulevard,,South San Francisco,California,' 94080 ' ,United States,502315,tenosynovial giant cell tumor,"""gard:0007396""",
1889,cabozantinib,,6/5/2024,treatment of pancreatic neuroendocrine tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"Exelixis, Inc.",1851 Harbor Bay Parkway,,Alameda,California,' 94502 ' ,United States,1004024,,,
1890,cabozantinib,Cabometyx,11/29/2010,"treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.",Designated/Approved,,,Treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible,9/17/2021,9/17/2028,Treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible,"Exelixis, Inc.",1851 Harbor Bay Parkway,,Alameda,California,' 94502 ' ,United States,297109,thyroid carcinoma,"""gard:0019763""",
1891,cabozantinib,CABOMETYX,3/2/2017,treatment of hepatocellular carcinoma.,Designated/Approved,,,CABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.,1/14/2019,1/14/2026,CABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.,"Exelixis, Inc.",1851 Harbor Bay Parkway,,Alameda,California,' 94502 ' ,United States,552916,hepatocellular carcinoma,"""gard:0016773""",
1892,cabozantinib,Cometriq,11/29/2010,"treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.",Designated/Approved,,,"Treatment of progressive, metastatic medullary thyroid cancer (MTC).",11/29/2012,11/29/2019,,"Exelixis, Inc.",1851 Harbor Bay Parkway,,Alameda,California,' 94502 ' ,United States,297109,thyroid carcinoma,"""gard:0019763""",
1893,cadazolid,,8/8/2017,treatment of clostridium difficile infection in pediatric patients,Designated/Designation Withdrawn or Revoked,5/14/2021,Not FDA Approved for Orphan Indication,,,,,Actelion Pharmaceuticals Ltd,16 Gewerbestrasse,,Allschwil,Basel-Landschaft,' ' ,Switzerland,592917,,,
1894,Caffeine,Cafcit,9/20/1988,treatment of apnea of prematurity.,Designated/Approved,,,Short term treatment of apnea of prematurity in infants between 28 and less than 33 weeks gestational age.,9/21/1999,9/21/2006,,"O.P.R. Development, L.P.",1501 Wakarusa Drive,,Lawrence,Kansas,' 66047 ' ,United States,31288,apnea of prematurity,"""gard:0019722""",
1895,caffeine and sodium benzoate,,8/22/2012,treatment of seizure prolongation in patients undergoing electroconvulsive therapy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",One Luitpold Drive,P. O. Box 9001,Shirley,New York,' 11967 ' ,United States,367512,,,
1896,Caflanone,,9/25/2019,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Flavocure Biotech,701 East Pratt Street,Suite 2033,Baltimore,Maryland,' 21202 ' ,United States,702719,,,
1897,Calcitonin salmon nasal spray,,10/29/1990,treatment of symptomatic paget's disease (osteitis deformans).,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Sandoz Pharmaceuticals Corp.,59 Route 10,,East Hanover,New Jersey,' 07936 ' ,United States,48290,,,
1898,Calcitonin-human for injection,Cibacalcin,1/20/1987,treatment of symptomatic paget's disease (osteitis deformans).,Designated/Approved,,,,10/31/1986,10/31/1993,,Novartis Pharmaceutical Corporation,59 Route 10,,East Hanover,New Jersey,' 07936 ' ,United States,13186,,,
1899,Calcium acetate,,6/27/1989,treatment of hyperphosphatemia in end stage renal disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Pharmedic Company,"28101 Ballard Road, Suite F",,Lake Forest,Illinois,' 60045 ' ,United States,36489,,,
1900,Calcium acetate,Phos-Lo,12/22/1988,treatment of hyperphosphatemia in end stage renal failure.,Designated/Approved,,,,12/10/1990,12/10/1997,,Fresenius Medical Care North America,920 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,31588,,,
1901,calcium benzoate and risperidone,,12/20/2010,treatment of pediatric patients with schizophrenia,Designated,,Not FDA Approved for Orphan Indication,,,,,"University of California, Los Angeles",Dept. of Psychiarty,"HH212, 1000 W. Carson Street",Torrance,California,' 90509 ' ,United States,326110,,,
1902,Calcium carbonate,,6/6/1990,treatment of hyperphosphatemia in patients with end stage renal disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"R & D Laboratories, Inc.",4204 Glencoe Avenue,,Marina Del Rey,California,' 90292 ' ,United States,42189,,,
1903,Calcium gluconate,,11/20/1997,for use as a wash for hydrofluoric acid spills on human skin.,Designated,,Not FDA Approved for Orphan Indication,,,,,Calgonate Corp.,3310 South Ocean Blvd,Unit 132,Highland Beach,Florida,' 33487 ' ,United States,108997,,,
1904,Calcium gluconate gel,,5/21/1991,for use in the emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.,Designated,,Not FDA Approved for Orphan Indication,,,,,Calgonate Corporation,3310 South Ocean Blvd,Unit 132,Highland Beach,Florida,' 33487 ' ,United States,6485,,,
1905,Calcium gluconate gel 2.5%,,9/10/1990,emergency topical treatment of hydrogen fluoride (hydrofluoric acid) burns.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Paddock Laboratories, Inc.",3940 Quebec Avenue North,,Minneapolis,Minnesota,' 55427 ' ,United States,46290,,,
1906,"calcium, magnesium, potassium, and sodium oxybates",Xywav,7/31/2019,treatment of idiopathic hypersomnia,Designated/Approved,,,Treatment of idiopathic hypersomnia (IH) in adults,8/12/2021,8/12/2028,Treatment of idiopathic hypersomnia (IH) in adults,Jazz Pharmaceuticals Ireland Limited,5th Floor Waterloo Exchange,Waterloo Road,Dublin,,' ' ,Ireland,694619,idiopathic hypersomnia,"""gard:0008737""",
1907,"calcium, magnesium, potassium, and sodium oxybates",Xywav,11/7/1994,treatment of narcolepsy.,Designated/Approved,,,XYWAV is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.,7/21/2020,7/21/2027,XYWAV is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.,Jazz Pharmaceuticals Ireland Limited,5th Floor Waterloo Exchange,Waterloo Road,Dublin 4,,' D04 E5W7 ' ,Ireland,85894,narcolepsy,"""gard:0022460""",
1908,calfactant,Infasurf,6/7/1985,treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.,Designated/Approved,,,Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.,7/1/1998,,,ONY Biotech Inc.,1576 Sweet Home Road,,Amherst,New York,' 14228 ' ,United States,6285,,,
1909,calfactant,,9/5/2000,treatment of acute respiratory distress syndrome (ards),Designated,,Not FDA Approved for Orphan Indication,,,,,"ONY, Inc.",Baird Research Park,Suite 114,Amherst,New York,' 14228 ' ,United States,136400,,,
1910,calmangafodipir,,3/15/2019,treatment of acetaminophen overdose.,Designated,,Not FDA Approved for Orphan Indication,,,,,Egetis Therapeutics AB,Grev Turegatan 11c,,Stockholm,,' ' ,Sweden,676418,,,
1911,calpurbatug,,4/12/2024,treatment of prosthetic joint infection,Designated,,Not FDA Approved for Orphan Indication,,,,,Trellis Bioscience Inc.,702 Marshall St.,Ste 614,Redwood City,California,' 94063 ' ,United States,997624,,,
1912,Cambritaxestat,,2/28/2024,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,iOnctura BV,"Avenue de Sécheron, 15, CH-1202 Geneva, Switzerland",,Geneva,,' CH-1202 ' ,Switzerland,990523,,,
1913,camostat,,5/18/2011,treatment of chronic pancreatitis,Designated,,Not FDA Approved for Orphan Indication,,,,,NIXS Corporation,"Nichi-Iko Pharmaceutical Co., Ltd.",7th Floor - NOF Nihonbashi Honcho Bldg,Tokyo,,' ' ,Japan,338211,,,
1914,Camoteskimab,,2/14/2024,treatment of still’s disease including adult-onset still’s disease and systemic juvenile idiopathic arthritis,Designated,,Not FDA Approved for Orphan Indication,,,,,Apollo Therapeutics Inc.,"33 Arch Street, 17th Floor",,Boston,Massachusetts,' 02110 ' ,United States,961623,juvenile idiopathic arthritis,"""gard:0018677""",
1915,camrelizumab,,4/27/2021,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jiangsu Hengrui Medicine Co., Ltd",7 Kunlunshan Road,Economic and Technological Development Zone,Lianyungang,Jiangsu,' ' ,China,675718,hepatocellular carcinoma,"""gard:0016773""",
1916,canakinumab,,3/24/2021,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936-1080 ' ,United States,805920,,,
1917,canakinumab,Ilaris,9/4/2012,treatment of tnf-receptor associated periodic syndrome (traps),Designated/Approved,,,Indicated for the treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients,9/23/2016,9/23/2023,Indicated for treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,376912,c syndrome,"""gard:0005978""",
1918,canakinumab,ILARIS,12/5/2013,treatment of familial mediterranean fever,Designated/Approved,,,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients,9/23/2016,9/23/2023,Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,412813,familial mediterranean fever,"""gard:0006421""",
1919,canakinumab,ILARIS,12/5/2013,treatment of hyperimmunoglobulinemia d and periodic fever syndrome,Designated/Approved,,,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients,9/23/2016,9/23/2023,Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,412913,periodic fever syndrome,"""gard:0019812""",
1920,canakinumab,ILARIS,9/30/2008,treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.,Designated/Approved,,,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.,5/9/2013,5/9/2020,Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 through 16 years.,Novartis Pharmaceuticals Corporation,One Health Plaza,Bldg 135-566G,East Hanover,New Jersey,' 07936 ' ,United States,260408,,,
1921,canakinumab,Ilaris,12/18/2007,treatment of cryopyrin-associated periodic syndromes,Designated/Approved,,,"Treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older.",6/17/2009,6/17/2016,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,250507,cryopyrin-associated periodic syndrome,"""gard:0010927""",
1922,canakinumab,,7/31/2017,treatment of adult-onset still's disease,Designated/Approved,,,"ILARIS is indicated for the treatment of active Still¿s disease, including Adult-Onset Still¿s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.",6/16/2020,6/16/2027,For the treatment of active adult-onset Still¿s Disease (AOSD).,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,591317,,,
1923,"cancer vaccine consisting of p719-20, p728, and p725 synthetic peptides representing fragments of the hTERT subunit",,12/2/2021,treatment of stage iib - iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Ultimovacs ASA,Ullernchausséen 64,,Oslo,,' 0379 ' ,Norway,818321,noma,"""gard:0004001""",
1924,cannabidiol,Epidiolex,11/14/2013,treatment of dravet syndrome,Designated/Approved,,,EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older.,9/28/2018,9/28/2025,EPIDIOLEX is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older.,GW Research Ltd.,Sovereign House,Histon,Cambridge,,' ' ,United Kingdom,409313,dravet syndrome,"""gard:0010430""",
1925,cannabidiol,,6/23/2014,treatment of lennox-gastaut syndrome,Designated/Designation Withdrawn or Revoked,9/6/2018,Not FDA Approved for Orphan Indication,,,,,"Insys Development Company, Inc.",1333 S. Spectrum Blvd,Suite 100,Chandler,Alaska,' 85286 ' ,United States,438214,lennox-gastaut syndrome,"""gard:0009912""",
1926,cannabidiol,,7/1/2014,treatment of dravet syndrome,Designated/Designation Withdrawn or Revoked,9/6/2018,Not FDA Approved for Orphan Indication,,,,,"Insys Development Company, Inc.",1333 S. Spectrum Blvd,Suite 100,Chandler,Alaska,' 85286 ' ,United States,439414,dravet syndrome,"""gard:0010430""",
1927,cannabidiol,,4/22/2015,treatment of neonatal hypoxic ischemic encephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,GW Pharma Ltd.,15 T.W. Alexander Drive,P. O. Box 13547,Research Triangle Park,North Carolina,' 27709 ' ,United States,471815,,,
1928,cannabidiol,,6/13/2016,treatment of infantile spasms,Designated,,Not FDA Approved for Orphan Indication,,,,,GW Research Ltd.,Sovereign House,Histon,Cambridge,,' ' ,United Kingdom,521416,,,
1929,cannabidiol,Epidiolex,2/27/2014,treatment of lennox-gastaut syndrome,Designated/Approved,,,EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older.,9/28/2018,9/28/2025,EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.,GW Research Ltd.,Sovereign House,Histon,Cambridge,,' ' ,United Kingdom,421213,lennox-gastaut syndrome,"""gard:0009912""",
1930,cannabidiol,,12/12/2022,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Transpire Bio Inc.,"8201 Peters Road, Suite 1000",,Plantation,Florida,' 33324 ' ,United States,914322,glioblastoma,"""gard:0002491""",
1931,cannabidiol,,11/17/2014,treatment of pediatric schizophrenia (pediatrics is defined as 0 through 16 years of age),Designated,,Not FDA Approved for Orphan Indication,,,,,"Benuvia Therapeutics, LLC",3950 N. Mays Street,,Round Rock,Texas,' 78655 ' ,United States,452614,,,
1932,Cannabidiol,,2/10/2022,treatment of chromosome 15q11.2-13.1 duplication syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Radius Pharmaceuticals, Inc.",22 Boston Warf Road 7th Floor,,Boston,Massachusetts,' 02210 ' ,United States,860921,n syndrome,"""gard:0003902""",
1933,Cannabidiol,,2/9/2022,treatment of angelman syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Radius Pharmaceuticals, Inc.",22 Boston Warf Road 7th Floor,,Boston,Massachusetts,' 02210 ' ,United States,860821,angelman syndrome,"""gard:0005810""",
1934,cannabidiol,,9/24/2014,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Benuvia Therapeutics, LLC",3950 N. Mays Street,,Round Rock,Texas,' 78665 ' ,United States,450814,,,
1935,cannabidiol,,8/20/2014,treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,"Benuvia Therapeutics, LLC",3950 N. Mays Street,,Round Rock,Texas,' 78665 ' ,United States,444814,glioblastoma,"""gard:0002491""",
1936,cannabidiol,,7/23/2015,treatment of infantile spasms,Designated,,Not FDA Approved for Orphan Indication,,,,,"Radius Pharmaceuticals, Inc.",950 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,486115,,,
1937,cannabidiol,,7/14/2015,prevention of graft versus host disease (gvhd).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kalytera Therapeutics Israel, Ltd.",Technological Building,Road 4 Katzrin,Qatsrin,,' ' ,Israel,482315,graft versus host disease,"""gard:0016642""",
1938,cannabidiol,Epidiolex,4/19/2016,treatment of tuberous sclerosis complex.,Designated/Approved,,,"treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older",7/31/2020,7/31/2027,treatment of seizures associated with tuberous sclerosis complex (TSC) in patients 1 year of age and older,GW Research Ltd.,Sovereign House,Histon,Cambridge,,' ' ,United Kingdom,510716,tuberous sclerosis complex,"""gard:0007830""",
1939,Cannabidiol,,9/16/2020,treatment of 22q.11.2 deletion syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Zynerba Pharmaceuticals, Inc.",80 West Lancaster Avenue,Suite 300,Devon,Pennsylvania,' 19333 ' ,United States,763820,n syndrome,"""gard:0003902""",
1940,cannabidiol,,11/29/2016,treatment of graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kalytera Therapeutics Israel, Ltd.",Technological Building,Road 4 Katzrin,Qatsrin,,' ' ,Israel,545316,graft versus host disease,"""gard:0016642""",
1941,cannabidiol,,8/21/2020,treatment of prader willi syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Radius Pharmaceuticals, Inc.",950 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,538916,,,
1942,cannabidiol,,11/5/2018,prevention of ischemia/reperfusion injury resulting from solid organ transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,Revive Therapeutics Ltd.,5 Director Court,Suite 105,Vaughan,,' ' ,Canada,656618,,,
1943,cannabidiol,EPIDIOLEX,11/14/2013,treatment of dravet syndrome,Designated/Approved,,,"treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older.",7/31/2020,7/31/2027,treatment of seizures associated with Dravet syndrome (DS) in patients between 1 and 2 years of age,GW Research Ltd.,Sovereign House,Histon,Cambridge,,' ' ,United Kingdom,409313,dravet syndrome,"""gard:0010430""",
1944,cannabidiol,EPIDIOLEX,2/27/2014,treatment of lennox-gastaut syndrome,Designated/Approved,,,"treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex (TSC) in patients 1 year of age and older.",7/31/2020,7/31/2027,treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients between 1 and 2 years of age,GW Research Ltd.,Sovereign House,Histon,Cambridge,,' ' ,United Kingdom,421213,lennox-gastaut syndrome,"""gard:0009912""",
1945,cannabidiol,,2/23/2016,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Zynerba Pharmaceuticals, Inc.",80 West Lancaster Avenue,Suite 300,Devon,Pennsylvania,' 19333 ' ,United States,488315,fragile x syndrome,"""gard:0006464""",
1946,cannabidiol,,4/28/2020,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Diverse Biotech, Inc.","3805 Old Easton Road, Suite 111",,Doylestown,Pennsylvania,' 18902 ' ,United States,736020,glioblastoma,"""gard:0002491""",
1947,cannabidiol,,8/15/2019,treatment of childhood absence epilepsy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Radius Pharmaceuticals, Inc.",950 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,696519,childhood absence epilepsy,"""gard:0016667""",
1948,cannabidiol,,4/20/2020,treatment of epidermolysis bullosa,Designated,,Not FDA Approved for Orphan Indication,,,,,Tetra Bio-Pharma Inc.,365 St.-Jean Street,Suite 122,Longueuil,,' ' ,Canada,734620,,,
1949,Cannabidiol,,2/14/2024,treatment of pericarditis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Cardiol Therapeutics Inc.,"2265 Upper Middle Road East, Suite 602",,Oakville,Ontario,' L6H 0G5 ' ,Canada,936823,,,
1950,cannabidiol,,6/25/2018,treatment of autoimmune hepatitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Revive Therapeutics Ltd.,5 Director Court,Suite 105,Vaughan,,' ' ,Canada,609617,autoimmune hepatitis,"""gard:0005871""",
1951,cannabidiol,,12/21/2017,treatment of dravet syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"AXIUM Pharmaceuticals, Inc.",265 Eastchester Drive,"Suite 133, #201",High Point,North Carolina,' 27262 ' ,United States,617417,dravet syndrome,"""gard:0010430""",
1952,Cannabidiol,,3/22/2021,treatment of angelman syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Biom Therapeutics,2203 Industrial Blvd.,,Sarasota,Florida,' 34239 ' ,United States,806620,angelman syndrome,"""gard:0005810""",
1953,cannabidiol (CBD),,10/24/2017,treatment of lennox-gastaut syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"AXIUM Pharmaceuticals, Inc.",265 Eastchester Drive,"Suite 133, #201",High Point,North Carolina,' 27262 ' ,United States,610117,lennox-gastaut syndrome,"""gard:0009912""",
1954,cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC),,1/8/2018,treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,"AXIUM Pharmaceuticals, Inc.",265 Eastchester Drive,"Suite 133, #201",High Point,North Carolina,' 27262 ' ,United States,620417,glioblastoma,"""gard:0002491""",
1955,Cannabidiol acid methyl ester (CBDA-ME),,1/3/2023,treatment of prader-willi syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,EPM Group Inc.,1600 Webster Street #407,,San Francisco,California,' 94115 ' ,United States,920722,prader-willi syndrome,"""gard:0005575""",
1956,Cannabidiol and delta-9-tetrahydrocannabinol,,3/15/2018,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"AXIUM Pharmaceuticals, Inc.",265 Eastchester Drive,"Suite 133, #201",High Point,North Carolina,' 27262 ' ,United States,628818,amyotrophic lateral sclerosis,"""gard:0005786""",
1957,cannabidiol covalently linked to temozlomide,,8/14/2020,treatment of malignant glioma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Diverse Biotech, Inc.",3805 Old Easton Road,Suite 111,Doylestown,Pennsylvania,' 18902 ' ,United States,755620,,,
1958,cannabidiol oral solution (CBD-OS),,6/7/2021,treatment of epilepsy with myoclonic-atonic seizures,Designated,,Not FDA Approved for Orphan Indication,,,,,GW Research Ltd,5750 Fleet Street Suite 200,Sovereign House,Histon,Cambridge,' CB24 9BZ ' ,United Kingdom,819221,,,
1959,Cannabidivarin,,6/6/2017,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,GW Research Ltd.,Sovereign House,Histon,Cambridge,,' ' ,United Kingdom,572416,fragile x syndrome,"""gard:0006464""",
1960,cannabidivarin,,11/30/2016,treatment of rett syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,GW Research Ltd.,Sovereign House,Histon,Cambridge,,' ' ,United Kingdom,549216,rett syndrome,"""gard:0005696""",
1961,cantharidin,,7/24/2012,"treatment of perforating diseases, including kyrle's disease, reactive perforating collangenosis, perforating folliculitis and elastosis perforans serpiginosa",Designated,,Not FDA Approved for Orphan Indication,,,,,"Orenova Group, LLC",10 New King Street,Suite 106,White Plains,New York,' 10604 ' ,United States,359311,elastosis perforans serpiginosa,"""gard:0010103""",
1962,cantrixil,,4/20/2015,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Vivesto AB,Vallongatan 1,,Uppsala,,' ' ,Sweden,474815,ovarian cancer,"""gard:0007295""",
1963,Caplacizumab,CABLIVI,4/14/2009,treatment of thrombotic thrombocytopenic purpura,Designated/Approved,,,"CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.",2/6/2019,2/6/2026,"CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.","Ablynx, a wholly owned subsidiary of Sanofi Group",55 Corporate Drive,,Bridgewater,New Jersey,' 08807 ' ,United States,277909,thrombotic thrombocytopenic purpura,"""gard:0016659""",
1964,capmatinib,,3/15/2019,treatment of non-small cell lung cancer with met genomic tumor aberrations,Designated/Approved,,,Tabrecta (capmatinib) is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.,5/6/2020,5/6/2027,For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,644518,small cell lung cancer,"""gard:0009344""",
1965,caprine hyperimmune serum against HIV lysate,,2/14/2014,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Aimsco Ltd.,3 Beeston Place,Belgravia,London,,' SW1W OJJ ' ,United Kingdom,420313,systemic sclerosis,"""gard:0009748""",
1966,caprine hyperimmune serum against HIV lysate,,10/28/2009,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Aimsco Ltd.,3 Beeston Place,Belgravia,London,,' SW1W OJJ ' ,United Kingdom,291109,amyotrophic lateral sclerosis,"""gard:0005786""",
1967,Capsaicin,,8/3/2005,treatment of postherpetic neuralgia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"TheraQuest Biosciences, LLC",146 Medinah Drive,,Blue Bell,Pennsylvania,' 19422 ' ,United States,205705,,,
1968,capsaicin,,5/2/2003,treatment of painful hiv-associated neuropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Averitas Pharma, Inc.",360 Mount Kemble Avenue,,Morristown,New Jersey,' 07960 ' ,United States,165502,,,
1969,capsaicin,,9/29/2006,treatment of intermetatarsal neuroma (morton's neuroma) that does not respond to conservative treatment and requires either neurectomy or neurolysis,Designated,,Not FDA Approved for Orphan Indication,,,,,Centrexion Corporation,509 S. Exeter Street,Suite 202,Baltimore,Maryland,' 21202 ' ,United States,222506,,,
1970,capsaicin,,10/23/2002,treatment of erythromelalgia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Averitas Pharma, Inc.",360 Mount Kemble Avenue,,Morristown,New Jersey,' 07960 ' ,United States,158202,,,
1971,capsaicin,Qutenza,5/22/2009,management of neuropathic pain in patients with postherpetic neuralgia,Designated/Approved,,,Management of neuropathic pain associated with postherpetic neuralgia,11/16/2009,11/16/2016,,"Averitas Pharma, Inc.",360 Mount Kemble Avenue,,Morristown,New Jersey,' 07960 ' ,United States,269508,,,
1972,CAR-T cell engager protein that links the CD19-directed CAR-T cell to a B cell antigen CD20,,2/20/2024,treatment of mantle cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Aleta Biotherapeutics,27 Strathmore Rd,,Natick,Massachusetts,' 01760 ' ,United States,938723,lymphoma,"""gard:0020548""",
1973,"carbamic acid, [[4-[[3-[[4-[1-(4-hydroxyphenyl)-1-methyl-ethyl]phenoxy]methyl]phenyl]methoxy]-phenyl]iminomethyl]-,ethyl ester",,1/15/2002,management of cystic fibrosis,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc",900 Ridgebury Road,P.O. Box 368,Ridgefield,Connecticut,' 06877 ' ,United States,148601,cystic fibrosis,"""gard:0006233""",
1974,carbenoxolone,,7/2/2014,treatment of huntington's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Oxalys Pharmaceuticals, Inc.",4 Mollard Road,,Toronto,,' ' ,Canada,429414,,,
1975,carbetocin (nasal spray),,4/11/2014,treatment of prader willi syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Acadia Pharmaceuticals Inc.,"12830 El Camino Real, Suite 400",,San Diego,Illinois,' 92310 ' ,United States,423014,,,
1976,carbon dioxide,,12/17/2015,treatment of trigeminal neuralgia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Capnia, Inc.",3 Twin Dolphin Drive,Suite 160,Redwood City,California,' 94065 ' ,United States,465114,trigeminal neuralgia,"""gard:0007805""",
1977,carbon monoxide,,8/16/2016,treatment of idiopathic pulmonary fibrosis (ipf).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Proterris, Inc.",197 West Springfield Street,,Boston,Massachusetts,' 02118 ' ,United States,530816,idiopathic pulmonary fibrosis,"""gard:0008609""",
1978,carbon monoxide,,6/24/2008,for use in the reduction of the incidence and severity of delayed graft function in patients undergoing solid organ transplanation.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,INO Therapeutics,Perryville III Corporate Park,P. O. Box 9001,Hampton,New Jersey,' 08827 ' ,United States,241807,,,
1979,carbon monoxide,,9/28/2012,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hillhurst Biopharmaceuticals, Inc.",2029 Verdugo Blvd,Suite 125,Montrose,California,' 91020 ' ,United States,379612,,,
1980,carbon monoxide,,4/14/2020,prevention of primary graft dysfunction in transplant recipients receiving a lung or heart+ lung transplant.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Proterris, Inc.",197 West Springfield Street,,Boston,Massachusetts,' 02118 ' ,United States,733620,,,
1981,carbon monoxide,,8/1/2018,prevention of delayed graft function in renal transplant recipients,Designated,,Not FDA Approved for Orphan Indication,,,,,"Proterris, Inc.",197 West Springfield Street,,Boston,Massachusetts,' 02118 ' ,United States,573917,,,
1982,carboplatin,,12/28/2023,treatment of malignant glioma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Carthera,"Immeuble Weitz, 1 place Vaclav Havel",,Lyon,,' 69007 ' ,France,980123,,,
1983,Carbovir,,12/13/1989,treatment of persons with aids and in patients with symptomatic hiv infection and a cd4 count less than 200/mm3.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,' 27709 ' ,United States,41189,,,
1984,carboxy pyrrolidine hexanoyl pyrrolidine carboxylate,,2/10/2015,treatment of al amyloidosis,Designated/Designation Withdrawn or Revoked,2/14/2019,Not FDA Approved for Orphan Indication,,,,,"Glaxo Group Limited, England d/b/a GlaxoSmithKline",980 Great West Road,,"Middlesex, TW8 9GS",,' ' ,United Kingdom,462614,amyloidosis,"""gard:0018676""",
1985,carboxyamidotriazole orotate,,5/10/2018,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tactical Therapeutics, Inc.","48 Wall Street, 12th Floor",,New York,New York,' 10005 ' ,United States,637318,,,
1986,cardiotrophin-1,,9/13/2011,treatment of acute liver failure,Designated,,Not FDA Approved for Orphan Indication,,,,,"Digna Biotech, S.L.",Calloe ORENSE No. 85,2nd Floor,Madrid,,' ' ,Spain,350711,acute liver failure,"""gard:0019112""",
1987,cardiotrophin-1,,6/24/2008,to protect the liver from ischemia-reperfusion injury inherent to the procedure of transplantation.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Digna Biotech, S.L.",Calloe ORENSE No. 85,2nd Floor,Madrid,,' ' ,Spain,244907,,,
1988,cardiotrophin-1,,10/16/2014,prevention of ischemia-reperfusion injury in kidney transplant recipients,Designated,,Not FDA Approved for Orphan Indication,,,,,"Digna Biotech, S.L.",Calloe ORENSE No. 85,2nd Floor,Madrid,,' ' ,Spain,432714,,,
1989,carfilzomib,Kyprolis,1/18/2008,treatment of multiple myeloma,Designated/Approved,,,treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with daratumumab and hyaluronidase-fihj and dexamethasone,11/30/2021,,,"Onyx Therapeutics, Inc.",249 East Grand Avenue,,South San Francisco,California,' 94080 ' ,United States,252507,multiple myeloma,"""gard:0007108""",
1990,carfilzomib,Kyprolis,1/18/2008,treatment of multiple myeloma,Designated/Approved,,,Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.,7/20/2012,7/20/2019,,"Onyx Therapeutics, Inc.",249 East Grand Avenue,,South San Francisco,California,' 94080 ' ,United States,252507,multiple myeloma,"""gard:0007108""",
1991,carfilzomib,Kyprolis,1/18/2008,treatment of multiple myeloma,Designated/Approved,,,Treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with daratumumab and dexamethasone.,8/20/2020,,,"Onyx Therapeutics, Inc.",249 East Grand Avenue,,South San Francisco,California,' 94080 ' ,United States,252507,multiple myeloma,"""gard:0007108""",
1992,carfilzomib,,1/21/2021,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,' 91320-1799 ' ,United States,795120,acute lymphoblastic leukemia,"""gard:0000522""",
1993,carfilzomib,Kyprolis,1/18/2008,treatment of multiple myeloma,Designated/Approved,,,Treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with isatuximab and dexamethasone,6/30/2022,,,"Onyx Therapeutics, Inc.",249 East Grand Avenue,,South San Francisco,California,' 94080 ' ,United States,252507,multiple myeloma,"""gard:0007108""",
1994,carglumic acid,Carbaglu,6/17/2014,treatment of organic acidemias,Designated/Approved,,,in pediatric and adult patients as adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA),1/22/2021,1/22/2028,in pediatric and adult patients as adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA),Recordati Rare Diseases,Immeuble Le Wilson,70 avenue du General de Gaulle,Puteaux,,' ' ,France,352111,,,
1995,carglumic acid,Carbaglu,1/20/1998,treatment of n-acetylglutamate synthetase deficiency.,Designated/Approved,,,As an adjunctive therapy for the treatment of acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS) and as manitenance therapy for chronic hyperammonemia due to NAGS deficiency,3/18/2010,3/18/2017,,Orphan Europe SARL,Immeuble Le Wilson,70 avenue du General de Gaulle,Puteaux,,' ' ,France,109997,,,
1996,carisbamate,,8/2/2017,treatment of lennox-gastaut syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"SK Life Sciences, Inc.",22-10 New Jersey 208 South,,Fair Lawn,New Jersey,' 07410 ' ,United States,594117,lennox-gastaut syndrome,"""gard:0009912""",
1997,carisbamate,,3/16/2012,management of patients with infantile spasms,Designated,,Not FDA Approved for Orphan Indication,,,,,"SK Life Science, Inc.",22-10 Route 208 South,,Fair Lawn,New Jersey,' 07410 ' ,United States,362511,,,
1998,carlumab,,10/24/2006,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,2/22/2021,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",200 Great Valley PArkway,,Malvern,Pennsylvania,' 19355 ' ,United States,231506,,,
1999,carlumab,,11/8/2007,treatment of idiopathic pulmonary fibrosis,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.",200 Great Vallley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,250007,idiopathic pulmonary fibrosis,"""gard:0008609""",
2000,Carmustine,,2/18/2021,treatment prior to hematopoietic stem cell transplantation in patients with relapsed or refractory non-hodgkin lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Vivus LLC,"900 East Hamilton Avenue, Suite 550",,Campbell,California,' 95008 ' ,United States,801420,lymphoma,"""gard:0020548""",
2001,carmustine,,10/11/2017,conditioning treatment prior to hematopoietic progenitor cell transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,ADIENNE S.A.,"Via Zurigo, 46",,Lugano,,' ' ,Switzerland,606517,,,
2002,Carmustine,,7/3/2000,treatment of intracranial malignancies.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Direct Therapeutics, Inc.",460 Seaport Court,Suite 220,Redwood,California,' 94063 ' ,United States,134500,,,
2003,Cascara sagrada fluid extract,,3/21/1989,treatment of oral drug overdosage to speed lower bowel evacuation.,Designated,,Not FDA Approved for Orphan Indication,,,,,Intramed Corporation,102 Tremont Way,,Augusta,Georgia,' 30907 ' ,United States,34288,,,
2004,casimersen,Amondys 45,6/4/2019,treatment of duchenne muscular dystrophy,Designated/Approved,,,treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping,2/25/2021,2/25/2028,treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping,"Sarepta Therapeutics, Inc.",215 First Street,,Cambridge,Massachusetts,' 02142 ' ,United States,690019,muscular dystrophy,"""gard:0007922""",
2005,CaspaCIDe System (combination product) consisting of allogeneic T Cell genetically modified to contain an inducible caspase 9 gene and Rimiducid,,2/18/2016,replacement t-cell therapy for the treatment of immunodeficiency and graft versus host disease after allogeneic hematopoietic stem cell transplant,Designated/Designation Withdrawn or Revoked,4/4/2022,Not FDA Approved for Orphan Indication,,,,,"Bellicum Pharmaceuticals, Inc.",2130 West Holcombe Boulevard,,Houston,Texas,' 77030 ' ,United States,496915,graft versus host disease,"""gard:0016642""",
2006,catumaxomab,,7/1/2009,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neoviibiotech North America, Inc.",920 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,284509,,,
2007,Catumaxomab,,6/9/2006,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neoviibiotech North America, Inc.",920 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,223406,ovarian cancer,"""gard:0007295""",
2008,Caveolin-1 Scaffolding Domain 7-Mer,,9/9/2020,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Lung Therapeutics, Inc.","2801 Via Fortuna, Suite 425",,Austin,Texas,' 78746 ' ,United States,761920,idiopathic pulmonary fibrosis,"""gard:0008609""",
2009,cavrotolimod,,3/1/2021,treatment of merkel cell carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Exicure, Inc.","2430 N. Halsted Street, 4th Floor",,Chicago,Illinois,' 60614 ' ,United States,677419,noma,"""gard:0004001""",
2010,CD20-CD47 bispecific fusion protein,,6/8/2022,treatment of burkitt lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Conjupro Biotherapeutics, Inc.","302 Carnegie Center, Ste 100",,Princeton,New Jersey,' 08540 ' ,United States,883922,lymphoma,"""gard:0020548""",
2011,CD200 activation receptor ligand (CD200AR-L),,8/29/2023,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,OX2 Therapeutics,"1200 Washington Ave. South, Suite 260",,Minneapolis,Minnesota,' 55415 ' ,United States,962023,,,
2012,CD3 and B-cell maturation antigen T-cell engaging bispecific antibody,,10/17/2019,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"TeneoOne, Inc.",1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,706319,multiple myeloma,"""gard:0007108""",
2013,CD30-Targeted Genetically-modified Autologous T-cell immunotherapy,,1/29/2024,treatment of anaplastic large cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Wu Han Bio-raid Biotech Co., Ltd.","388 Gaoxin 2nd Road, East Lake New Technology Development Zone, Wuhan City Floor 4, Building 3, Phase 3.1",Wuhan optical Valley International Bio-pharmaceutical Enterprise Accelerator Floor 5-1,Wuhan,Hubei,' ' ,China,985223,lymphoma,"""gard:0020548""",
2014,CD34+ cells that have been transduced in vitro with a lentiviral vector carrying a codon-optimized sequence for expressing the wild type RPS19 protein,,10/21/2020,treatment diamond-blackfan anemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Apriligen LLC,"200 Central Park South, Suite 12Q",,New York,New York,' 10019 ' ,United States,774520,,,
2015,CD34+ hematopoietic stem and progenitor cells with CD3+ T-cells,,6/25/2019,prevention of graft rejection following solid organ transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,"Medeor Therapeutics, Inc.","1 Tower Place, 9th Floor",,South San Francisco,California,' 94080 ' ,United States,690519,,,
2016,CD4 human truncated 369 AA polypeptide,,11/21/1989,treatment of acquired immunodeficiency syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,SmithKline Beecham,"Route 23 & Woodmont Ave., P.O. Box 1510",,King Of Prussia,Pennsylvania,' 19406 ' ,United States,38889,acquired immunodeficiency,"""gard:0021359""",
2017,CD4-mediated activated regulatory T cells,,11/27/2017,treatment of graft-versus-host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"ActiTrexx GmbH, University Medical Center of Johannes Gutenberg-University",1 Langenbeckstraße,"1, Building 401",Mainz,Rheinland-Pfalz,' 55131 ' ,Germany,613517,,,
2018,CD40/CD80/CD86 modified autologous dendritic cell therapy,,12/20/2013,treatment type 1 diabetes mellitus patients with residual beta cell function,Designated,,Not FDA Approved for Orphan Indication,,,,,"DiaVacs, Inc.",410 Tower Drive,,Edgewater,New Jersey,' 07020 ' ,United States,396613,,,
2019,CD5-T lymphocyte immunotoxin,,8/27/1987,treatment of graft versus host disease and/or rejection in patients who have received bone marrow transplants.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Xoma Corporation,2910 Seventh Street,,Berkeley,California,' 94710 ' ,United States,19587,graft versus host disease,"""gard:0016642""",
2020,CD71 Binding Centyrin-GYS1 siRNA,,8/1/2022,treatment of pompe disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Aro Biotherapeutics Company,"601 Walnut Street, Suite 740",,Philadelphia,Pennsylvania,' 19106 ' ,United States,899122,,,
2021,CDC-like kinase inhibitor of the Wnt Pathway,,12/17/2018,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biosplice Therapeutics, Inc.",9360 Towne Centre Drive,,San Diego,California,' 92121 ' ,United States,662318,,,
2022,Ceclazepide,,5/12/2016,treatment of gastric neuroendocrine tumors (gastric nets).,Designated/Designation Withdrawn or Revoked,2/6/2023,Not FDA Approved for Orphan Indication,,,,,Trio Medicines Ltd.,Pavillion View,19 New Road,Brighton,,' ' ,United Kingdom,520116,,,
2023,cedazuridine and decitabine,Inqovi,8/21/2019,treatment of myelodysplastic syndromes (including chronic myelomonocytic leukemia),Designated/Approved,,,"Indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.",7/7/2020,7/7/2027,"Indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.","Astex Pharmaceuticals, Inc.",4420 Rosewood Drive,Suite 200,Pleasanton,California,' 94588 ' ,United States,697019,chronic myelomonocytic leukemia,"""gard:0008225""",
2024,cediranib,,12/13/2010,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,National Institutes of Health,National Cancer Institute,9609 Medical Center Dr.,Bethesda,Maryland,' 20892 ' ,United States,310510,glioblastoma,"""gard:0002491""",
2025,Ceftriaxone sodium,,3/28/2006,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Mass General Hospital,"Merit E. Cudkowicz, MD, MSc","Building 149 13th Street, Room 2274",Charlestown,Massachusetts,' 02129 ' ,United States,218606,amyotrophic lateral sclerosis,"""gard:0005786""",
2026,celastrol,,4/10/2024,treatment of prader-willi syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"ERX Pharmaceuticals, Inc.","245 Main St, 2nd Floor",,Cambridge,Massachusetts,' 02142 ' ,United States,858421,prader-willi syndrome,"""gard:0005575""",
2027,Celecoxib,,7/30/2020,treatment of hemophilic arthropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Upex-Med Co., Ltd.","Rm1117, Geumgangpenterium IT Tower B","Hagui-ro 282, Dongan-gu, Anyang-si,",Gyeonggi-do,,' ' ,South Korea,751420,,,
2028,Celecoxib oral liquid suspension,,1/5/2017,treatment of pediatric juvenile idiopathic arthritis,Designated,,Not FDA Approved for Orphan Indication,,,,,"NuBioPharma, LLC",111 Dennis Drive,Suite 121,Sanford,North Carolina,' 27330 ' ,United States,549716,juvenile idiopathic arthritis,"""gard:0018677""",
2029,celiprolol,,1/5/2015,treatment of ehlers-danlos syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Acer Therapeutics, Inc.",222 Third Street,Suite 2240,Cambridge,Massachusetts,' 02142 ' ,United States,456714,ehlers-danlos syndrome,"""gard:0006322""",
2030,cell based therapeutic composed of allogeneic donor apoptotic cells,,3/18/2013,prevention of graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Enlivex Therapeutics Ltd.,POB 12167,Hadassah Ein Kerem,Jerusalem,,' ' ,Israel,390213,graft versus host disease,"""gard:0016642""",
2031,Cell-penetrating activating transcription factor 5 mimetic,,4/30/2018,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sapience Therapeutics, Inc","520 White Plains Road, 2nd Floor",,Tarrytown,New York,' 10591 ' ,United States,637418,acute myeloid leukemia,"""gard:0012757""",
2032,cell-penetrating CCAAT-enhancer-binding protein ß antagonist,,2/5/2020,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sapience Therapeutics, Inc",500 Mamaroneck Avenue,Suite 320,Harrison,New York,' 10528 ' ,United States,723419,,,
2033,Cell-penetrating dominant-negative activating transcription factor 5,,3/20/2017,treatment of glioma,Designated/Designation Withdrawn or Revoked,5/7/2018,Not FDA Approved for Orphan Indication,,,,,"Sapience Therapeutics, Inc",500 Mamaroneck Avenue,Suite 320,Harrison,New York,' 10528 ' ,United States,560116,,,
2034,Cells produced using the AastromReplicelle System and SC-I Therapy Kit,,7/10/2002,for use in patients receiving high dose chemotherapy who are unable to generate an acceptable dose of peripheral blood stem cells and who have a sufficient bone marrow aspirate without morphological evidence of tumor,Designated,,Not FDA Approved for Orphan Indication,,,,,Aastrom Biosciences Incorporated,P.O. Box 376,,Ann Arbor,Michigan,' 48106 ' ,United States,153401,,,
2035,cellspan esophageal implant,,11/29/2016,"restore the structure and function of the esophagus subsequent to esophageal damage due to cancer, injury, or congenital abnormality",Designated,,Not FDA Approved for Orphan Indication,,,,,"Biostage, Inc.",84 October Hill Road,Suite 11,Holliston,Massachusetts,' 01746 ' ,United States,542816,,,
2036,cemdisiran,,2/10/2022,treatment of paroxysmal nocturnal hemoglobinuria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharamecuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,861721,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
2037,cemdisiran,,7/5/2023,treatment of myasthenia gravis (mg),Designated,,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharamecuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,837421,myasthenia gravis,"""gard:0007122""",
2038,cemiplimab-rwlc,,8/19/2021,treatment of stage ia2 to stage iv cervical cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,671518,,,
2039,cenegermin-bkbj,Oxervate,6/23/2014,treatment of neurotrophic keratitis,Designated/Approved,,,Treatment of neurotrophic keratitis,8/22/2018,8/22/2025,Treatment of neurotrophic keratitis,Dompe S.p.A.,Via S. Martino 12-12/A,,Milan,,' ' ,Italy,436214,,,
2040,cenersen,,6/18/2008,treatment of stage iib through iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.",1001 Twelve Oaks Center Drive,Suite 1002,Wayzata,Minnesota,' 55391 ' ,United States,224506,noma,"""gard:0004001""",
2041,cenersen,,2/27/2008,treatment of chronic lymphocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.",1001 Twelve Oaks Center Drive,Suite 1002,Wayzata,Minnesota,' 55391 ' ,United States,252807,,,
2042,cenersen,,5/8/2006,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Eleos, Inc.",1001 Twelve Oaks Center Drive,Suite 1002,Wayzata,Minnesota,' 55391 ' ,United States,220906,acute myeloid leukemia,"""gard:0012757""",
2043,Centruroides immune F(ab)2,Anascorp,6/12/2000,treatment of scorpion envenomations requiring medical attention.,Designated/Approved,,,Treatment of clinical signs of scorpion envenomation,8/4/2011,8/4/2018,,"Rare Disease Therapeutics, Inc.",12975 Brookprinter Drive,Suite 170,Poway,California,' 92064 ' ,United States,135900,scorpion envenomation,"""gard:0021939""",
2044,Cepharanthine,,1/14/2021,treatment of esophageal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Sairiyo Therapeutics Inc.,"77 King Street West, Suite 2905",,Toronto,Ontario,' M5K 1H1 ' ,Canada,794320,,,
2045,Cepharanthine,,9/22/2020,treatment of immune thrombocytopenia (itp),Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenafly,New Jersey,' 07670 ' ,United States,766520,immune thrombocytopenia,"""gard:0005194""",
2046,ceramide,,11/13/2018,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.",1981 Pine Hall Road,,State College,Pennsylvania,' 16801 ' ,United States,660618,,,
2047,ceramide,,8/8/2016,treatment of liver cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.",1981 Pine Hall Road,,State College,Pennsylvania,' 16801 ' ,United States,531416,,,
2048,ceramide,,12/18/2018,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Keystone Nano, Inc.",1981 Pine Hall Road,,State College,Pennsylvania,' 16801 ' ,United States,662618,acute myeloid leukemia,"""gard:0012757""",
2049,cerdulatinib,,9/21/2018,treatment of peripheral t-cell lymphoma (ptcl).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Portola Pharmaceuticals, Inc.",270 East Grand Avenue,,South San Francisco,California,' 94080 ' ,United States,651118,lymphoma,"""gard:0020548""",
2050,cereblon E3 ubiquitin ligase modulating agent,,8/10/2021,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"C4 Therapeutics, Inc.",490 Arsenal Way,Suite 200,Watertown,Massachusetts,' 02742 ' ,United States,831921,multiple myeloma,"""gard:0007108""",
2051,cereblon enzyme 3 (E3) ligase modulating agent,,3/25/2021,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation (a Bristol-Myers Squibb Company),86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,808421,acute myeloid leukemia,"""gard:0012757""",
2052,cereblon enzyme 3 (E3) ubiquitin ligase modulating agent,,5/14/2019,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,685019,multiple myeloma,"""gard:0007108""",
2053,ceritinib,ZYKADIA,9/27/2013,treatment of patients with non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase(alk)-positive,Designated/Approved,,,ZYKADIA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic nonsmall cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.,4/29/2014,4/29/2021,Treatment of patients with anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,405213,lymphoma,"""gard:0020548""",
2054,ceritinib,ZYKADIA,9/27/2013,treatment of patients with non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase(alk)-positive,Designated/Approved,,,Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test,5/26/2017,5/26/2024,Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,405213,lymphoma,"""gard:0020548""",
2055,Cerium dioxide nanoparticles,,3/26/2020,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Cerion Nanomaterials,1 Blossom Road,,Rochester,New York,' 14610 ' ,United States,731920,amyotrophic lateral sclerosis,"""gard:0005786""",
2056,cerliponase alfa,Brineura,4/1/2013,treatment of neuronal ceroid lipofuscinosis type 2,Designated/Approved,,,"To slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.",4/27/2017,4/27/2024,"To slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.","BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,' 94949 ' ,United States,391913,neuronal ceroid lipofuscinosis,"""gard:0010739""",
2057,certepetide,,3/28/2024,treatment of osteosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Lisata Therapeutics, Inc",110 Allen Road,Second Floor,Basking Ridge,New Jersey,' 07920 ' ,United States,996324,osteosarcoma,"""gard:0007284""",
2058,certepetide,,1/29/2019,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Lisata Therapeutics, Inc.","110 Allen Road, Second Floor",,Basking Ridge,New Jersey,' 07920 ' ,United States,669518,,,
2059,cethromycin,,9/9/2009,prophylactic treatment of tularemia due to francisella tularensis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Life Sciences, Inc.",1440 Davey Road,,Woodridge,Illinois,' 60517 ' ,United States,288909,tularemia,"""gard:0000396""",
2060,cethromycin,,2/28/2007,prophylactic treatment of patients exposed to inhalation anthrax.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced LIfe Sciences, Inc.",1440 Davey Road,,Woodridge,Illinois,' 60517 ' ,United States,235906,,,
2061,cethromycin,,9/9/2009,prophylactic treatment of plague due to yersinia pestis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Life Sciences, Inc.",1440 Davey Road,,Woodridge,Illinois,' 60517 ' ,United States,289009,plague,"""gard:0018702""",
2062,Cetiedil citrate injection,,12/22/1988,treatment of sickle cell disease crisis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Baker Cummins Pharmaceuticals, Inc.",,,,,' ' ,,31488,,,
2063,cetuximab,,6/15/2007,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,ImClone Systems Incorporated,33 ImClone Drive,,Branchburg,New Jersey,' 08876 ' ,United States,237907,,,
2064,cetuximab,Erbitux,7/3/2000,treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor,Designated/Approved,,,"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed",3/1/2006,3/1/2013,,ImClone Systems Incorporated,33 ImClone Drive,,Branchburg,New Jersey,' 08876 ' ,United States,132700,,,
2065,Cevidoplenib,,3/20/2024,treatment of primary immune thrombocytopenia (itp),Designated,,Not FDA Approved for Orphan Indication,,,,,Oscotec Inc.,"Korea Bio-Park, Building A, 9th Floor","700 Daewangpangyo-ro, Bundan-gu",Seongnam-si,Gyeonggi-do,' 13488 ' ,South Korea,994823,immune thrombocytopenia,"""gard:0005194""",
2066,cevostamab,,2/3/2021,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,799220,multiple myeloma,"""gard:0007108""",
2067,Chaenomelis Fructus Extract,,11/29/2023,treatment of bag3-related myofibrillar myopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Centre for Chinese Herbal Medicine Drug Development Limited,"Units 201-3 & 205-7, 2/F, 15W BLDG, 15 Science Park West Avenue","Hong Kong Science Park, Shatin",Hong kong,Hong Kong,' 000000 ' ,China,972723,myofibrillar myopathy,"""gard:0010529""",
2068,Chelating agent delivering Holmium-166,,2/10/1999,treatment of multiple myeloma.,Designated,,Not FDA Approved for Orphan Indication,,,,,NeoRx Corporation,410 W. Harrison Street,,Seattle,Washington,' 98119 ' ,United States,119998,multiple myeloma,"""gard:0007108""",
2069,chelmab-y or chelamusab-Y,,4/24/1990,treatment of ovarian cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,Cytogen Corporation,600 College Road East,,Princeton,New Jersey,' 08540 ' ,United States,41689,ovarian cancer,"""gard:0007295""",
2070,Chemically induced photoreceptor-like cells,,2/18/2021,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"CiRC Biosciences, Inc.","330 N Wabash Avenue, Suite 3500",,Chicago,Illinois,' 60611 ' ,United States,801020,retinitis pigmentosa,"""gard:0005694""",
2071,chemically modified recombinant sulfamidase,,6/28/2017,treatment of mucopolysaccharidosis type iiia (mps iiia),Designated,,Not FDA Approved for Orphan Indication,,,,,Swedish Orphan Biovitrum AB (publ),DÄNSKEBO,,Linköping SV,Östergötlands län,' ' ,Sweden,583617,mucopolysaccharidosis,"""gard:0007065""",
2072,chemically synthesized molecule which is composed of two binding sites (a CD38 binder and a universal antibody binding terminus binder) connected by a linker chain.,,8/31/2020,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Kleo Pharmaceuticals,25 Science Park,,New Haven,Connecticut,' 06511 ' ,United States,758820,multiple myeloma,"""gard:0007108""",
2073,Chenodeoxycholic acid,,1/29/2004,treatment of cerebrotendinous xanthomatosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Dr. Falk Pharma GmbH,Leinenweberstrasse 5,,Freiburg,,' ' ,Germany,175303,cerebrotendinous xanthomatosis,"""gard:0005622""",
2074,chenodeoxycholic acid,,2/12/2007,treatment of cerebrotendinous xanthomatosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.",9841 Washingtonian Boulevard,Suite 500,Gaithersburg,Maryland,' 20878 ' ,United States,235406,cerebrotendinous xanthomatosis,"""gard:0005622""",
2075,chenodiol,,3/22/2010,treatment of cerebrotendinous xanthomatosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mirum Pharmaceuticals, Inc.","950 Tower Lane, Suite 1050",,Foster City,California,' 94404 ' ,United States,300510,cerebrotendinous xanthomatosis,"""gard:0005622""",
2076,chenodiol,Chenix,9/21/1984,"for patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age",Designated/Approved,,,,7/28/1983,7/28/1990,,Solvay,901 Sawyer Road,,Marietta,Georgia,' 30062 ' ,United States,3384,,,
2077,chiauranib,,9/2/2021,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shenzhen Chipscreen Biosciences Co., Ltd.","2-601, BIO-Incubator, Gaoxin C, 1st Ave.,","Hi-Tech Industrial Park, Nanshan District",Shenzhen,Guangdong,' 518057 ' ,China,836221,small cell lung cancer,"""gard:0009344""",
2078,Chimeric (human-murine) G250 IgG monoclonal antibody,,7/24/2000,treatment of renal cell carcinoma.,Designated/Designation Withdrawn or Revoked,4/24/2014,Not FDA Approved for Orphan Indication,,,,,Wilex Biotechnology GmbH,Grillparzerstrasse 10B,,81675 Munich,,' ' ,Germany,133300,renal cell carcinoma,"""gard:0013215""",
2079,chimeric Antigen Receptor (CAR) directed against the target protein CD5,,10/16/2017,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,iCell Gene Therapeutics,25 Health Sciences Drive,Suite 118,Stony Brook,New York,' 11793 ' ,United States,577717,acute lymphoblastic leukemia,"""gard:0000522""",
2080,chimeric antigen receptor (CAR) modified recombinant T cells targeting B7-H3,,6/21/2023,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Fuzhou Tcelltech Biological Science and Technology Inc.,Haixi High-Tech Industrial Zone,"Room A-504, Building 10, Innovation Park",Fuzhou,Fujian,' 350108 ' ,China,945323,,,
2081,Chimeric antigen receptor (CAR)-T cell therapy targeting G protein-coupled receptor class-C group-5 member-D (GPRC5D).,,10/24/2022,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"OriCell Therapeutics, Inc.","3F Bldg 1, No. 1227 Zhangheng Rd,",Pudong,Shanghai,,' 201203 ' ,China,907222,multiple myeloma,"""gard:0007108""",
2082,chimeric antigen receptor directed against the target protein CD4 lentivirally transfected T cells,,7/28/2016,treatment of peripheral t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,iCell Gene Therapeutics,25 Health Sciences Drive,Suite 118,Stony Brook,New York,' 11793 ' ,United States,522216,lymphoma,"""gard:0020548""",
2083,Chimeric Antigen Receptor immunotherapy directed against CLL-1 and CD33,,2/2/2021,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"iCell Gene Therapeutics, LLC","25 Health Sciences Dr., Suite 118",,Stony Brook,New York,' 11790 ' ,United States,798220,acute myeloid leukemia,"""gard:0012757""",
2084,Chimeric Antigen Receptor T Cells targeting CD7,,11/9/2021,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,PersonGen BioTherapeutics (Suzhou) Co. Ltd.,218 Xinghu St. BioBay Build.B1 Suite412 SIP,,Suzhou City,Jiangsu Province,' ' ,China,845121,acute lymphoblastic leukemia,"""gard:0000522""",
2085,chimeric fusion protein of recombinant human alpha-N-acetylglucosaminidase and human insulin-like growth factor 2,,11/25/2014,"treatment of mucopolysaccharidosis iii type b (mps iiib, sanfilippo syndrome type b)",Designated,,Not FDA Approved for Orphan Indication,,,,,Allievex Corporation,P.O. Box 1056,,Marblehead,Massachusetts,' 01945 ' ,United States,450014,sanfilippo syndrome type b,"""gard:0007072""",
2086,chimeric IgG4 monoclonal antibody targeting CD14,,1/11/2021,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Implicit Bioscience Ltd.,32 Logan Rd,Woolloongabba,,Queensland,' ' ,Australia,650418,amyotrophic lateral sclerosis,"""gard:0005786""",
2087,Chimeric locked nucleic acid and ribonucleic-deoxyribonucleic antisense oligonucleotide specific for the human UBE3A-antisense transcript,,8/28/2019,treatment of angelman syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Ultragenyx Pharmaceutical Inc.,"60 Leveroni Court, Suite 200",,Novato,California,' 94949 ' ,United States,702619,angelman syndrome,"""gard:0005810""",
2088,Chimeric M-T412 (human-murine) IgG monoclonal anti-CD4,,6/5/1991,treatment of multiple sclerosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,54490,,,
2089,"chimeric monoclonal antibodies, c-alphaStx2",,10/4/2005,for treatment of shiga-toxin producing bacterial infection,Designated,,Not FDA Approved for Orphan Indication,,,,,Taro Pharmaceuticals Inc.,130 East Drive,,Brampton,,' ' ,Canada,208105,,,
2090,chimeric monoclonal antibody against Claudin 6,,3/18/2013,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,3/15/2021,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,390613,ovarian cancer,"""gard:0007295""",
2091,chimeric monoclonal antibody against claudin-18 splice variant 2,,9/26/2013,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Astellas Pharma Global Development Inc.,1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,407813,,,
2092,Chimeric monoclonal antibody to CD30 (anti-CD30 antibody),,2/18/2004,treatment of cd30 positive t-cell lymphomas,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,178203,lymphoma,"""gard:0020548""",
2093,Chimeric monoclonal antibody to CD30 (anti-CD30 antibody),,7/18/2003,treatment of hodgkin's disease,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc","21823 30th Drive, Southeast",,Bothell,Washington,' 98021 ' ,United States,171303,,,
2094,chimeric monoclonal antibody to claudin 18 splice variant 2,,11/20/2012,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Astellas Pharma Global Development Inc.,1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,383312,,,
2095,Chimeric monoclonal antibody to mesothelin,,10/31/2006,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,2/15/2016,Not FDA Approved for Orphan Indication,,,,,"Morphotek, Inc.",210 Welsh Pool Road,,Exton,Pennsylvania,' 19341 ' ,United States,231606,,,
2096,chimeric murine/human IgG1 monoclonal antibody to human interleukin-3 receptor alpha chain,,4/3/2009,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,CSl Limited,45 Poplar Road,,Parkville,Victoria,' ' ,Australia,277309,acute myeloid leukemia,"""gard:0012757""",
2097,"Chimeric, humanized monoclonal antibody to staphylococcus",,8/3/2000,prophylaxis of staphylococcus epidermidis sepsis in low birth weight (1500 grams or less) infants.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biosynexus, Inc.",9298 Gaither Road,,Rockville,Maryland,' 20877 ' ,United States,132099,,,
2098,Chlorhexidine gluconate mouthrinse,,8/18/1986,for use in the amelioration of oral mucositis associated with cytoreductive therapy used in conditioning patients for bone marrow transplantation therapy.,Designated,,Not FDA Approved for Orphan Indication,,,,,Procter & Gamble Company,Sharon Wood Technical Center,11370 Reed Hartman Highway,Cincinnati,Ohio,' 45241 ' ,United States,13086,,,
2099,chlorobutanol/propylene glycol/hydrochloric acid,,2/18/1997,treatment of patulous eustachian tube,Designated,,Not FDA Approved for Orphan Indication,,,,,Ear Foundation,"2420 Castillo Street, Suite 100",,Santa Barbara,California,' 93105 ' ,United States,98896,,,
2100,chloropyramine,,10/22/2010,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"CurFAKtor Pharmaceuticals, LLC",14 Rock Dove Lane,,Orchard Park,New York,' 14127 ' ,United States,321110,,,
2101,chloroquine,,5/20/2015,treatment of glioblastoma multiforme.,Designated,,Not FDA Approved for Orphan Indication,,,,,"DualTpharma B.,V.",Boschstraat 111-D01,,Maastricht,,' ' ,Netherlands,475015,glioblastoma,"""gard:0002491""",
2102,Chlorotoxin,,12/18/2007,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.,200 Metro Blvd.,,Nutley,New Jersey,' 07110-6102 ' ,United States,250407,,,
2103,chlorotoxin,,12/2/2008,"treatment of stage iib, iic, iii & iv melanoma",Designated,,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.,200 Metro Blvd.,,Nutley,New Jersey,' 07110-6102 ' ,United States,264008,noma,"""gard:0004001""",
2104,chlorotoxin conjugated to indocyanine green dye,,6/23/2015,diagnostic for the management of primary malignant brain and cns tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"Blaze Bioscience, Inc.","530 Fairview Avenue, North",Suite 1400,Seattle,Washington,' 98109 ' ,United States,482615,,,
2105,CHO cell line produced human alpha-1 antitrypsin (CHO-AAT) protein,,10/19/2020,treatment of alpha-1 antitrypsin deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Caravella Biopharma SA,Route de l’Ile-aux-Bois 1A,,Monthey,,' 1870 ' ,Switzerland,773920,,,
2106,cholera toxin B subunit,,11/16/2017,treatment of ulcerative colitis in pediatric patients,Designated,,Not FDA Approved for Orphan Indication,,,,,Aliment Wellness LLC,9462 Brownsboro Road,Suite 340,Louisville,Kentucky,' 40241 ' ,United States,603817,,,
2107,"cholest-4-en-3-one, oxime",,2/17/2009,treatment of spinal muscular atrophy.,Designated/Designation Withdrawn or Revoked,3/4/2019,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",A Roche Group Member,1 DNA Way,South San Francisco,California,' 94080 ' ,United States,273108,,,
2108,cholesterol 24S-hydroxylase inhibitor,,11/29/2017,treatment of dravet syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",Takeda Parkway,,Deerfield,Illinois,' 60015 ' ,United States,614917,dravet syndrome,"""gard:0010430""",
2109,cholesterol 24S-hydroxylase inhibitor,,12/6/2017,treatment of lennox-gastaut syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",Takeda Parkway,,Deerfield,Illinois,' 60015 ' ,United States,615817,lennox-gastaut syndrome,"""gard:0009912""",
2110,cholic acid,Cholbam,7/18/2003,treatment of inborn errors of cholesterol and bile acid synthesis and metabolism,Designated/Approved,,,Treatment of bile acid synthesis disorders due to single enzyme defects,3/17/2015,3/17/2022,Treatment of bile acid synthesis disorders due to single enzyme defects,"Mirum Pharmaceuticals, Inc.","950 Tower Lane, Suite 1050",,Foster City,California,' 94404 ' ,United States,170503,,,
2111,Choline chloride,,7/20/2006,prevention and/or treatment of choline deficiency in patients on long-term parenteral nutrition,Designated,,Not FDA Approved for Orphan Indication,,,,,"Protara Therapeutics, Inc.",1 Little West 12th Street,Suite 254,New York,New York,' 10014 ' ,United States,225206,,,
2112,Choline chloride,,2/10/1994,"treatment of choline deficiency, specifically the choline deficiency, hepatic steatosis, and cholestasis, associated with long-term parenteral nutrition.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Protara Therapeutics, Inc.","345 Park Avenue South, 3rd Floor",,New York,New York,' 10010 ' ,United States,76993,,,
2113,choline tetrathiomolybdate,,8/25/2011,treatment of wilson's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Alexion Pharmaceutical Inc.,121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,346511,,,
2114,Chondrocyte-alginate gel suspension,,12/1/1997,for use in correcting vesicoureteral reflux in the pediatric population.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Curis, Inc.",61 Moulton Street,,Cambridge,Massachusetts,' 02138 ' ,United States,107697,,,
2115,Chondroitinase,,2/9/1995,treatment of patients undergoing vitrectomy.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Bausch & Lomb Pharmaceuticals, Inc.",8500 Hidden River Pkwy.,,Tampa,Florida,' 33637 ' ,United States,87794,,,
2116,chromium picolinate and chromium histidinate,,12/22/2014,treatment of pediatic polycystic ovary syndrome (0 through 16 years of age),Designated,,Not FDA Approved for Orphan Indication,,,,,"JDS Therapeutics, LLC",3 Manhattanville Rd,Suite 201,Purchase,New York,' 10577 ' ,United States,456814,,,
2117,chrysoeriol,,6/22/2017,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Flavocure Biotech,701 East Pratt Street,Suite 2033,Baltimore,Maryland,' 21202 ' ,United States,582017,acute myeloid leukemia,"""gard:0012757""",
2118,cicletanine hydrochloride,,6/24/2008,treatment for pulmonary arterial hypertension.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,261608,pulmonary arterial hypertension,"""gard:0007501""",
2119,Ciclopirox,,4/17/2018,treatment of congenital erythropoietic porphyria,Designated,,Not FDA Approved for Orphan Indication,,,,,Atlas Molecular Pharma S.L.,Parque Tecnológico de Bizkaia,Building 800,Derio,,' ' ,Spain,629718,porphyria,"""gard:0010353""",
2120,cilengitide,,5/27/2005,treatment of malignant glioma,Designated/Designation Withdrawn or Revoked,8/15/2013,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,205205,,,
2121,Ciliary neurotrophic factor,,1/30/1992,treatment of amyotrophic lateral sclerosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Regeneron Pharmaceuticals Inc,777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,63691,amyotrophic lateral sclerosis,"""gard:0005786""",
2122,"Ciliary neurotrophic factor, recombinant human",,4/2/1992,treatment of spinal muscular atrophies.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Syntex-Synergen Neuroscience,3200 Walnut Street,,Boulder,Colorado,' 80301 ' ,United States,66392,,,
2123,"Ciliary neurotrophic factor, recombinant human",,5/8/1992,"treatment of motor neuron disease (including amyotrophic lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and primary lateral sclerosis).",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Syntex-Synergen Neuroscience,3200 Walnut Street,,Boulder,Colorado,' 80301 ' ,United States,66492,progressive muscular atrophy,"""gard:0021891""",
2124,ciltacabtagene autoleucel,Carvykti,2/1/2019,treatment of multiple myeloma (mm),Designated/Approved,,,"treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide",4/5/2024,4/5/2031,"treatment of adult patients with relapsed or refractory multiple myeloma, who have received 1, 2, or 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide, or who have received 4 or more prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, but not including an anti-CD38 monoclonal antibody, and are refractory to lenalidomide","Janssen Research & Development, LLC",920 US Highway 202,,Raritan,New Jersey,' 08869 ' ,United States,672118,multiple myeloma,"""gard:0007108""",
2125,ciltacabtagene autoleucel,Carvykti,2/1/2019,treatment of multiple myeloma (mm),Designated/Approved,,,"Treatment of adult patients with relapsed or refractory multiple myeloma, after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody",2/28/2022,2/28/2029,"Treatment of adult patients with relapsed or refractory multiple myeloma, after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody","Janssen Research & Development, LLC",920 US Highway 202,,Raritan,New Jersey,' 08869 ' ,United States,672118,multiple myeloma,"""gard:0007108""",
2126,cinacalcet,Sensipar,4/30/2010,"treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery",Designated/Approved,,,"Treatment of hypercalcemia in adult patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy.",11/21/2014,11/21/2021,"Treatment of less severe hypercalcemia (serum calcium >11.2 mg/dl and <= 12.5 mg/dl) in adult patients with primary hyperparathyroidism (HPT) for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy.","Amgen, Inc.",One Amgen Center Drive,"Bldg 17, 1A-4-4, Mail Stop 17-1-B",Thousand Oaks,California,' 91320 ' ,United States,165102,,,
2127,cinacalcet,Sensipar,4/30/2010,"treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery",Designated/Approved,,,Treatment of severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy,2/25/2011,2/25/2018,,"Amgen, Inc.",One Amgen Center Drive,"Bldg 17, 1A-4-4, Mail Stop 17-1-B",Thousand Oaks,California,' 91320 ' ,United States,165102,,,
2128,cinacalcet,Sensipar,5/12/2003,treatment of hypercalcemia in patients with parathyroid carcinoma,Designated/Approved,,,Treatment of hypercalcemia in patients with parathyroid carcinoma,3/8/2004,3/8/2011,,"Amgen, Inc.",,One Amgen Center Drive,Thousand Oaks,California,' 91320 ' ,United States,163402,thyroid carcinoma,"""gard:0019763""",
2129,cinacalcet,,9/7/2016,treatment of secondary hyperparathyroidism (hpt) in pediatric patients with chronic kidney disease receiving dialysis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,"Bldg 17, 1A-4-4, Mail Stop 17-1-B",Thousand Oaks,California,' 91320 ' ,United States,511315,,,
2130,Cinnamtannin B-1,,2/5/2024,treatment of osteosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"GTS Biotech, LLC",4922 Port Royal Rd,Suite C-8,Spring Hill,Tennessee,' 37174 ' ,United States,986523,osteosarcoma,"""gard:0007284""",
2131,cinrebafusp,,6/22/2021,treatment of gastric cancer including cancer of the gastroesophageal junction,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Pieris Pharmaceuticals, Inc.",255 State Street,9th Floor,Boston,Massachusetts,' 02109 ' ,United States,821221,,,
2132,cintredekin besudotox,,11/2/2001,treatment of malignant glioma,Designated/Designation Withdrawn or Revoked,11/2/2015,Not FDA Approved for Orphan Indication,,,,,"Insys Development Company, Inc.","1333 South Sprectum Blvd, Suite 100",,Chandler,Alaska,' 85286 ' ,United States,149801,,,
2133,Cintredekin Besudotox,,4/30/2010,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Insys Development Company, Inc.","1333 South Sprectum Blvd, Suite 100",,Chandler,Alaska,' 85286 ' ,United States,305110,idiopathic pulmonary fibrosis,"""gard:0008609""",
2134,cipaglucosidase alfa-atga and miglustat,Pombiliti and Opfolda,9/13/2017,treatment of pompe disease,Designated/Approved,,,"in combination with Opfolda, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing greater than or equal to 40 kg and who are not improving on their current enzyme replacement therapy (ERT)",9/28/2023,,,"Amicus Therapeutics, Inc.",47 Hulfish Street,,Princeton,New Jersey,' 08542 ' ,United States,601617,,,
2135,cipaglucosidase alfa-atga and miglustat,Pombiliti and Opfolda,9/13/2017,treatment of pompe disease,Designated/Approved,,,"in combination with Pombiliti, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing greater than or equal to 40 kg and who are not improving on their current enzyme replacement therapy (ERT)",9/28/2023,,,"Amicus Therapeutics, Inc.",47 Hulfish Street,,Princeton,New Jersey,' 08542 ' ,United States,601617,,,
2136,Cipargamin,,7/27/2017,treatment of malaria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Paul Maher, MD",10644 Weymouth Street,Suite 104,Bethesda,Maryland,' 20814 ' ,United States,595417,malaria,"""gard:0006961""",
2137,cipargamin,,5/1/2020,treatment of malaria,Designated,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,Bldg. 315 / 1650D,East Hanover,New Jersey,' 07936 ' ,United States,746820,malaria,"""gard:0006961""",
2138,ciprofloxacin,,6/1/2011,the management of bronchiectasis,Designated,,Not FDA Approved for Orphan Indication,,,,,Savara Inc.,"1717 Langhorne Newtown Road, Suite 300",,Langhorne,Pennsylvania,' 19047 ' ,United States,339911,,,
2139,ciprofloxacin DPI,,2/2/2010,management of pulmonary infection due to pseudomonas aeruginosa in cystic fibrosis patients,Designated/Designation Withdrawn or Revoked,9/7/2018,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",P. O. Box 1000,,Montville,New Jersey,' 07045 ' ,United States,297209,cystic fibrosis,"""gard:0006233""",
2140,ciprofloxacin dry powder inhaler,,4/17/2014,treatment of non-cystic fibrosis bronchiectasis,Designated/Designation Withdrawn or Revoked,9/7/2018,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",P. O. Box 1000,,Montville,New Jersey,' 07045 ' ,United States,422314,cystic fibrosis,"""gard:0006233""",
2141,cirmtuzumab,,6/22/2020,treatment of mantle cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Oncternal Therapeutics, Inc.",12230 El Camino Real,Suite 300,SanDiego,California,' 92130 ' ,United States,744220,lymphoma,"""gard:0020548""",
2142,cirmtuzumab,,6/22/2020,treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Oncternal Therapeutics, Inc.",12230 El Camino Real,Suite 300,SanDiego,California,' 92130 ' ,United States,744120,lymphoma,"""gard:0020548""",
2143,"cis-adamantane-2-spiro-3'-8'-[4'-[2'-(4'-morpholinyl)ethoxy]phenyl]-1',2,'4'-trioxaspiro[4.5] decane mesylate",,1/19/2010,"treatment of malaria caused by plasmodium falciparum, plasmodium vivax, plasmodium ovale, or plasmodium malariae",Designated,,Not FDA Approved for Orphan Indication,,,,,Medicines for Malaria Venture (MMV),International Centre Cointrin,P. O. Box 1826,CH-1215 Geneva 15,,' ' ,Switzerland,297309,malaria,"""gard:0006961""",
2144,Cis-diamminedichloroplatinum (II) polyethylene glycol-polyglutamate (cis platinum PEG-pGlu) polymeric micelles,,7/27/2017,treatment of biliary tract carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"NanoCarrier Co., Ltd",Chuou 144-15,226-39 Wakashiba,Kashiwa,Chiba,' ' ,Japan,588717,noma,"""gard:0004001""",
2145,"cis-diamminedichloroplatinum(II) (CDDP), vinblastine sulfate, 8-((2-hydroxybenzoyl)amino)octanoate (SHAO-FA)",,6/13/2022,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Intensity Therapeutics, Inc.","61 Wilton Road, 3rd Floor",,Westport,Connecticut,' 06880 ' ,United States,867921,soft tissue sarcoma,"""gard:0004898""",
2146,Cisplatin,,9/6/2016,treatment of anal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Privo Technologies,13 Bristol Street,Unit #1,Cambridge,Massachusetts,' 02141 ' ,United States,536616,,,
2147,Cisplatin ChemoThin Wafer,,11/3/2015,"treatment of anatomically accessible oral cancers (lip, tongue, gum, floor of mouth, salivary gland, and other oral cavity)",Designated,,Not FDA Approved for Orphan Indication,,,,,Privo Technologies,13 Bristol Street,Unit #1,Cambridge,Massachusetts,' 02141 ' ,United States,447514,,,
2148,Cisplatin in liposomal formulation,,3/20/2007,treatment of osteosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Eleison Pharmaceuticals LLC,103 Carnegie Center,Suite 300,Princeton,New Jersey,' 08540 ' ,United States,238607,osteosarcoma,"""gard:0007284""",
2149,Cisplatin loaded hyaluronate film for implant,,5/2/2017,treatment of mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,PlumeStars s.r.l.,Via Lago Scuro11,,Parma,,' ' ,Italy,557716,,,
2150,Cisplatin transmucosal system,,7/13/2022,treatment of carcinoma in situ (cis) of the anterior 2/3 of the oral cavity,Designated,,Not FDA Approved for Orphan Indication,,,,,Privo Technologies,200 Corporate Place Suite 6b,,Peabody,Massachusetts,' 01960 ' ,United States,783620,noma,"""gard:0004001""",
2151,Cisplatin/epinephrine,,4/3/2000,treatment of squamous cell carcinoma of the head and neck.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Matrix Pharmaceutical, Inc.",34700 Campus Drive,,Fremont,California,' 94555 ' ,United States,133200,noma,"""gard:0004001""",
2152,Cisplatin/epinephrine,,9/7/2000,treatment of metastatic malignant melanoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Matrix Pharmaceutical, Inc.",34700 Campus Drive,,Fremont,California,' 94555 ' ,United States,134800,noma,"""gard:0004001""",
2153,citric acid,,8/30/2021,treatment of hyperammonemia in inborn errors of metabolism,Designated,,Not FDA Approved for Orphan Indication,,,,,Versantis AG,Technoparkstrasse 1,,Zürich,,' ' ,Switzerland,731120,,,
2154,citric acid monohydrate,,6/21/2017,treatment of acute-on-chronic liver failure,Designated,,Not FDA Approved for Orphan Indication,,,,,Versantis AG,7 Otto-Stern-Weg,HPL D16.2,Zürich,Zürich,' ' ,Switzerland,583217,,,
2155,"Citric acid, glucono-delta-lactone and magnesium carbonate",Renacidin Irrigation,8/28/1989,treatment of renal and bladder calculi of the apatite or struvite variety.,Designated/Approved,,,,10/2/1990,10/2/1997,,"United-Guardian, Inc.",P.O. Box 2500,,Smithtown,New York,' 11787 ' ,United States,40189,,,
2156,civamide,,12/9/2002,treatment of postherpetic neuralgia of the trigeminal nerve,Designated,,Not FDA Approved for Orphan Indication,,,,,"Winston Laboratories, Inc.","100 Fairway Drive, Suite 134",,Vernon Hills,Illinois,' 60061 ' ,United States,159102,,,
2157,civamide,,2/17/2009,treatment of postherpetic neuralgia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Winston Laboratories, Inc.",100 Fairway Drive,,Vernon Hills,Illinois,' 60061 ' ,United States,272308,,,
2158,"Cl-CAR-135 (FLT3 CAR), RRV-FLT3-CAR-tCD19 transduced autologous T cells derived from patients with acute myeloid leukemia",,7/31/2020,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Cytoimmune Therapeutics,1333 S Mayflower Avenue,,Monrovia,California,' 91016 ' ,United States,752420,acute myeloid leukemia,"""gard:0012757""",
2159,cladribine,,3/19/2015,treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder,Designated,,Not FDA Approved for Orphan Indication,,,,,Chord Therapeutics S.a.r.l.,15 Avenue De Secheron,,Geneva,,' ' ,Switzerland,467214,neuromyelitis optica spectrum disorder,"""gard:0006267""",
2160,Cladribine,,4/19/1994,treatment of the chronic progressive form of multiple sclerosis.,Designated/Designation Withdrawn or Revoked,7/30/2021,Not FDA Approved for Orphan Indication,,,,,"Johnson & Johnson Pharmaceutical R & D, LLC",920 Route 202,PO Box 300,Raritan,New Jersey,' 08869 ' ,United States,77793,,,
2161,cladribine,,6/14/2023,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",1 Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,943223,myasthenia gravis,"""gard:0007122""",
2162,Cladribine,Leustatin Injection,11/15/1990,treatment of hairy cell leukemia.,Designated/Approved,,,,2/26/1993,2/26/2000,,R. W. Johnson Pharmaceutical Research Institute,"Route 202, P.O. Box 300",,Raritan,New Jersey,' 08869 ' ,United States,51690,,,
2163,Cladribine,,4/19/1993,treatment of non-hodgkin's lymphoma.,Designated/Designation Withdrawn or Revoked,2/9/2015,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,' 08869 ' ,United States,68092,lymphoma,"""gard:0020548""",
2164,cladribine,,12/31/1990,treatment of chronic lymphocytic leukemia,Designated/Designation Withdrawn or Revoked,2/9/2015,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,' 08869 ' ,United States,54190,,,
2165,Cladribine,,7/20/1990,treatment of acute myeloid leukemia.,Designated/Designation Withdrawn or Revoked,2/9/2015,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,' 08869 ' ,United States,47990,acute myeloid leukemia,"""gard:0012757""",
2166,"clarithromycin, rifabutin, clofazimine",,4/26/2011,treatment of pediatric crohn's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,RedHill Biopharma Ltd.,21 Ha'arba'a Street,Tel Aviv-Yafo,Tel Aviv District,,' 6473921 ' ,Israel,338811,,,
2167,clazakizumab,,8/8/2019,treatment of chronic antibody-mediated rejection in kidney transplant recipients,Designated,,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,P.O. Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,612317,,,
2168,clazosentan,,2/16/2006,treatment of cerebral vasospasm following subarachnoid hemorrhage,Designated/Designation Withdrawn or Revoked,9/19/2023,Not FDA Approved for Orphan Indication,,,,,Idorsia Pharmaceuticals US Inc.,1820 Chapel Avenue West,Suite 150,Cherry Hill,New Jersey,' 08002 ' ,United States,217105,,,
2169,Clemizole,,10/14/2021,treatment of lennox-gastaut syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Epygenix Therapeutics, Inc.",140 E Ridgewood Avenue,"Suite 415, South Tower",Paramus,New Jersey,' 07652 ' ,United States,841821,lennox-gastaut syndrome,"""gard:0009912""",
2170,clemizole,,4/19/2017,treatment of dravet syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Epygenix Therapeutics, Inc.",140 East Ridgewood Avenue,Suite 415 South Tower,Paramus,New Jersey,' 07652 ' ,United States,566116,dravet syndrome,"""gard:0010430""",
2171,Clemizole Hydrochloride,,4/26/2022,treatment of ohtahara syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Epygenix Therapeutics, Inc.","630 W Germantown Pike, Suite 215",,Plymouth Meeting,Pennsylvania,' 19462 ' ,United States,852621,,,
2172,clenbuterol,,10/27/2014,adjunctive therapy with enzyme replacement therapy in the treatment of pompe disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Duke University Medical Center,Department of Pediatrics,Box 103856,Durham,North Carolina,' 27710 ' ,United States,451614,,,
2173,Clenbuterol,,1/9/2017,treatment of pompe disease (glycogen storage disease type ii),Designated,,Not FDA Approved for Orphan Indication,,,,,"Dwight D. Koeberl, MD, PhD",Duke University Medical Center,"Pediatrics Dept., Div. of Genetics",Durham,North Carolina,' 27710 ' ,United States,546316,glycogen storage disease,"""gard:0018973""",
2174,clenbuterol,,10/2/2018,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Duke University Medical Center,Department of Pediatrics,Box 103856,Durham,North Carolina,' 27710 ' ,United States,653918,amyotrophic lateral sclerosis,"""gard:0005786""",
2175,clervonafusp alfa,,10/4/2018,treatment of pompe disease,Designated/Designation Withdrawn or Revoked,6/22/2020,Not FDA Approved for Orphan Indication,,,,,"Valerion Therapeutics, LLC",100 Main Street,,Concord,Massachusetts,' 01742 ' ,United States,651518,,,
2176,Clindamycin,,10/28/1988,treatment of pneumocystis carinii pneumonia associated with aids patients.,Designated,,Not FDA Approved for Orphan Indication,,,,,Pharmacia & Upjohn,7000 Portage Road,Unit 0633-298-113,Kalamazoo,Michigan,' 49001 ' ,United States,26988,,,
2177,Clindamycin,,10/28/1988,prevention of pneumocystis carinii pneumonia in aids patients.,Designated,,Not FDA Approved for Orphan Indication,,,,,Pfizer Inc.,235 East 42nd Street,,New York,New York,' 10017 ' ,United States,27088,,,
2178,Clindamycin hydrochloride,,8/9/2006,treatment of sarcoidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Autoimmunity Research Foundation,"Autoimmunity Research, Inc.",,Thousand Oaks,California,' 91360 ' ,United States,213405,sarcoidosis,"""gard:0007607""",
2179,clobazam,Onfi,12/18/2007,treatment of lennox-gastaut syndrome,Designated/Approved,,,Adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome inpatients 2 years of age or older,10/21/2011,10/21/2018,,"Lundbeck, Inc.",Four Parkway North,,Deerfield,Illinois,' 60015 ' ,United States,248307,lennox-gastaut syndrome,"""gard:0009912""",
2180,clofarabine,,1/24/2019,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Boyen Therapeutics, Inc.","333 Section 1, Keelung Road",Suite 1212,Taipei,Taipei,' 110208 ' ,Taiwan,668118,acute myeloid leukemia,"""gard:0012757""",
2181,clofarabine,Clolar,2/7/2002,treatment of acute lymphoblastic leukemia,Designated/Approved,,,Treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,12/28/2004,12/28/2011,,Genzyme Corporation,4545 Horizon Hill Blvd.,,San Antonio,Texas,' 78229 ' ,United States,153201,acute lymphoblastic leukemia,"""gard:0000522""",
2182,clofarabine,,3/14/2002,treatment of acute myelogenous leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genzyme Corp (Ilex Products, Inc.)",4545 Horizon Hill Blvd.,,San Antonio,Texas,' 78229 ' ,United States,154802,,,
2183,clofazimine,,8/17/2018,treatment of pulmonary nontuberculous mycobacterial infections,Designated,,Not FDA Approved for Orphan Indication,,,,,MannKind Corporation,1 Casper Street,,Danbury,Connecticut,' 06810 ' ,United States,646318,,,
2184,Clofazimine,Lamprene,6/11/1984,"treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum.",Designated/Approved,,,,12/15/1986,12/15/1993,,Novartis Pharmaceutical Corporation,59 Route 10,,East Hanover,New Jersey,' 07936 ' ,United States,2684,leprosy,"""gard:0006886""",
2185,clofazimine,,10/18/2023,treatment of non-tuberculous mycobacterial infections,Designated,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936-1080 ' ,United States,966923,,,
2186,clofazimine,,6/25/2014,treatment of active tuberculosis,Designated/Designation Withdrawn or Revoked,6/21/2022,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,436314,tuberculosis,"""gard:0007827""",
2187,Clonazepam,,8/4/1994,treatment of hyperekplexia (startle disease).,Designated/Designation Withdrawn or Revoked,1/30/2024,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,82794,hyperekplexia,"""gard:0021281""",
2188,Clonazepam Intranasal Spray,,12/19/2007,treatment of recurrent acute repetitive seizures,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jazz Pharmaceuticals, Inc.",3180 Porter Drive,,Palo Alto,California,' 94304 ' ,United States,243507,,,
2189,Clonidine,Duraclon,1/24/1989,"for continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates.",Designated/Approved,,,In combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone.,10/2/1996,10/2/2003,,"Roxane Laboratories, Inc.",PO Box 16532,,Columbus,Ohio,' 43216 ' ,United States,34388,,,
2190,Clotrimazole,,6/14/2005,topical treatment of children and adults with pouchitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"AesRx, LLC",275 Grove Street,Suite 2-400,Newton,Massachusetts,' 02466 ' ,United States,204005,pouchitis,"""gard:0020510""",
2191,Clotrimazole,,4/24/1995,treatment of sickle cell disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Brugnara, Carlo M.D.",The Children's Hospital,"300 Longwood Avenue, Bader 760",Boston,Massachusetts,' 02115 ' ,United States,88094,,,
2192,Clotrimazole,,3/13/2006,treatment of huntington's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"EnVivo Pharmaceuticals, Inc.",480 Arsenal Street,,Watertown,Massachusetts,' 02472 ' ,United States,216705,,,
2193,clotrimazole otic solution,,5/10/2016,treatment of fungal otitis externa (otomycosis),Designated,,Not FDA Approved for Orphan Indication,,,,,Laboratorios SALVAT S.A.,"C/ Gall, 30-36",Esplugues de Llobregat,Barcelona,Catalunya,' ' ,Spain,520516,,,
2194,clustered regularly interspaced short palindromic repeats CRISPR/ Cas9-based gene therapy consisting of a single guide RNA targeting the human TTR gene and a messenger RNA encoding Cas9,,10/19/2021,treatment of transthyretin amyloidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Intellia Therapeutics, Inc.",40 Erie Street,,Cambridge,Massachusetts,' 02139 ' ,United States,842521,amyloidosis,"""gard:0018676""",
2195,CNDO-109-activated allogeneic natural killer cells,,6/18/2012,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Fortress Biotech, Inc.",2 Gansevoort Street,9th Floor,New York,New York,' 10014 ' ,United States,371512,acute myeloid leukemia,"""gard:0012757""",
2196,co-packaged combination of pocapavir and imocitrelvir,,2/20/2024,treatment of poliovirus infection,Designated,,Not FDA Approved for Orphan Indication,,,,,ViroDefense Inc.,"5425 Wisconsin Avenue, Suite 600",,Chevy Chase,Maryland,' 20815 ' ,United States,989223,,,
2197,Coagulation factor IX,Mononine,6/27/1989,replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia b.,Designated/Approved,,,"Prevention and control of bleeding in factor IX deficiency, also known as hemophilia B or Christmas disease.",8/20/1992,8/20/1999,,Armour Pharmaceutical Company,"500 Arcola Road, P.O. Box 1200",,Collegeville,Pennsylvania,' 19426 ' ,United States,36189,hemophilia,"""gard:0010418""",
2198,Coagulation Factor IX (human),AlphaNine,7/5/1990,"for use as replacement therapy in patients with hemophilia b for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis.",Designated/Approved,,,,12/31/1990,12/31/1997,,Alpha Therapeutic Corporation,5555 Valley Boulevard,,Los Angeles,California,' 90032 ' ,United States,45890,hemophilia,"""gard:0010418""",
2199,Coagulation Factor IX (recombinant),BeneFix,10/3/1994,treatment of hemophilia b,Designated/Approved,,,"For the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency and Christmas disease), including control and prevention of bleeding in surgical settings.",2/11/1997,2/11/2004,,"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.",235 E. 42nd St 219/9/1,,New York,New York,' 10017 ' ,United States,82294,hemophilia,"""gard:0010418""",
2200,Coagulation Factor IX (recombinant),BeneFix,10/3/1994,treatment of hemophilia b,Designated/Approved,,,Routine prophylaxis to reduce the frequency of bleeding episodes in patients 16 years of age and older with hemophilia B (congenital factor IX deficiency or Christmas disease).,6/26/2020,,,"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.",235 E. 42nd St 219/9/1,,New York,New York,' 10017 ' ,United States,82294,hemophilia,"""gard:0010418""",
2201,Coagulation Factor IX (recombinant),BeneFix,10/3/1994,treatment of hemophilia b,Designated/Approved,,,Routine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hemophilia B (congenital factor IX deficiency or Christmas disease),10/5/2021,,,"Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.",235 E. 42nd St 219/9/1,,New York,New York,' 10017 ' ,United States,82294,hemophilia,"""gard:0010418""",
2202,"Coagulation factor IX (recombinant), Fc fusion protein",ALPROLIX,10/30/2008,control and prevention of hemorrhagic episodes in patients with hemophilia b (congenital factor ix deficiency or christmas disease),Designated/Approved,,,"Adults and children with Hemophilia B for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.",3/28/2014,3/28/2021,"Adults and children with Hemophilia B for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.","Bioverativ Therapeutics, Inc.",225 2nd Avenue,,Waltham,Massachusetts,' 02451 ' ,United States,261508,hemophilia,"""gard:0010418""",
2203,"Coagulation Factor IX (Recombinant), GlycoPEGylated",Rebinyn,3/18/2013,routine prophylactic administration for prevention of bleeding in patients with hemophilia b (christmas disease),Designated/Approved,,,Routine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hemophilia B (congenital Factor IX deficiency),7/29/2022,,,"Novo Nordisk, Inc.",100 College Road West,,Princeton,,' 08540 ' ,United States,276509,hemophilia,"""gard:0010418""",
2204,coagulation factor IX (recombinant); coagulation factor IX (recombinant),RIXUBIS; RIXUBIS,10/31/2012,prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia b (routine prophylaxis in patients where there is no evidence or suspicion of bleeding),Designated/Approved,,,"Adults and children with Hemophilia B for (1) control and prevention of bleeding episodes, (2) perioperative management, and (3) routine prophylaxis",9/12/2014,9/12/2021,Children with hemophilia B for routine prophylaxis.,"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,377412,hemophilia,"""gard:0010418""",
2205,coagulation factor IX (recombinant); coagulation factor IX (recombinant),RIXUBIS; RIXUBIS,10/31/2012,prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia b (routine prophylaxis in patients where there is no evidence or suspicion of bleeding),Designated/Approved,,,"Adults with Hemophilia B for (1) control and prevention of bleeding episodes, (2) perioperative management, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes.",6/26/2013,6/26/2020,Adults with Hemophilia B for routine prophylaxis to prevent or reduce the frequency of bleeding episodes.,"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,377412,hemophilia,"""gard:0010418""",
2206,Coagulation factor VIIa (recombinant),NovoSeven,7/21/2004,prevention of bleeding episodes in patients with acquired inhibitors to factor viii or factor ix,Designated/Approved,,,Prevention of bleeding in surgical interventions or invasive procedures in patients with acquired hemophilia,10/13/2006,10/13/2013,,"Novo Nordisk, Inc.",100 Overlook Center,Suite 200,Princeton,New Jersey,' 08540 ' ,United States,190104,,,
2207,Coagulation Factor VIIa (Recombinant),,10/3/2006,treatment of bleeding in patients experiencing intracranial hemorrhage.,Designated/Designation Withdrawn or Revoked,2/20/2014,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.",P. O. Box 846,,Plainsboro,New Jersey,' 08536 ' ,United States,192404,,,
2208,Coagulation factor VIIa (recombinant),NovoSeven,9/10/2004,prevention of bleeding episodes in patients with congenital factor vii deficiency,Designated/Approved,,,Prevention of bleeding in surgical interventions or invasive procedures in patients with congenital F VII deficiency,7/11/2005,7/11/2012,,"Novo Nordisk, Inc.",100 Overlook Center,Suite 200,Princeton,New Jersey,' 08540 ' ,United States,189904,congenital factor vii deficiency,"""gard:0002238""",
2209,Coagulation Factor VIIa (Recombinant),NovoSeven,7/16/2004,treatment of bleeding episodes in patients with acquired inhibitors to factor viii or factor ix,Designated/Approved,,,Treatment of bleeding episodes in surgical interventions or invasive procedures in patients with acquired hemophilia,10/13/2006,10/13/2013,,"Novo Nordisk, Inc.",100 Overlook Center,Suite 200,Princeton,New Jersey,' 08540 ' ,United States,186204,,,
2210,Coagulation factor VIIa (recombinant),NovoSeven,6/18/2004,"prevention of bleeding episodes in patients with hemophilia a or b, with or without inhibitors",Designated/Approved,,,Prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX,8/12/2005,8/12/2012,,"Novo Nordisk, Inc.",100 Overlook Center,Suite 200,Princeton,New Jersey,' 08540 ' ,United States,186104,hemophilia,"""gard:0010418""",
2211,coagulation factor VIIa (recombinant),NovoSeven RT,6/18/2004,treatment of bleeding episodes in glanzmann's thrombasthenia,Designated/Approved,,,"Treatment of bleeding episodes and peri-operative management in adults and children with Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.",7/2/2014,7/2/2021,"Treatment of bleeding episodes and peri-operative management in adults and children with Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets.",Novo Nordisk Inc.,800 Scudders Mill Rd.,,Plainsboro,New Jersey,' 08536 ' ,United States,186004,,,
2212,Coagulation factor VIIa (recombinant),,6/18/2004,prevention of bleeding episodes in glanzmann's thrombasthenia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.",100 College Road West,,Princeton,New Jersey,' 08540 ' ,United States,190004,,,
2213,Coagulation factor VIIa (recombinant),NovoSeven,9/10/2004,treatment of bleeding episodes in patients with congenital factor vii deficiency,Designated/Approved,,,Treatment of bleeding episodes in patients with Factor VII Deficiency,7/11/2005,7/11/2012,,"Novo Nordisk, Inc.",100 Overlook Center,Suite 200,Princeton,New Jersey,' 08540 ' ,United States,185904,congenital factor vii deficiency,"""gard:0002238""",
2214,Coagulation factor VIIa (recombinant),NovoSeven,6/6/1988,treatment of bleeding episodes in hemophilia a or b patients with inhibitors to factor viii or factor ix.,Designated/Approved,,,Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.,3/25/1999,3/25/2006,,"Novo Nordisk, Inc.",100 Overlook Center,Suite 200,Princeton,New Jersey,' 08540 ' ,United States,26588,hemophilia,"""gard:0010418""",
2215,Coagulation factor X (human),COAGADEX,11/8/2007,treatment of hereditary factor x deficiency,Designated/Approved,,,COAGADEX is indicated in adults and children with hereditary Factor X deficiency for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and perioperative management of bleeding in patients with mild and moderate hereditary Factor X deficiency.,9/21/2018,9/21/2025,Coagadex is indicated for routine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hereditary Factor X deficiency; on-demand treatment and control of bleeding episodes in children under the age of 12 years with hereditary Factor X deficiency; perioperative management of bleeding in children under the age of 12 years with mild hereditary factor X deficiency; perioperative management of bleeding in adults and children with moderate hereditary Factor X deficiency,Bio Products Laboratory Limited,Dagger Lane,,Elstree,Hertfordshire,' ' ,United Kingdom,246907,,,
2216,Coagulation factor X (human),COAGADEX,11/8/2007,treatment of hereditary factor x deficiency,Designated/Approved,,,Treatment of adults and adolescents (aged 12 years and above) with hereditary Factor X deficiency for on-demand treatment and control of bleeding episodes and perioperative management of bleeding in patients with mild hereditary Factor X deficiency,10/20/2015,10/20/2022,Treatment of adults and adolescents (aged 12 years and above) with hereditary Factor X deficiency for on-demand treatment and control of bleeding episodes and perioperative management of bleeding in patients with mild hereditary Factor X deficiency,Bio Products Laboratory Limited,Dagger Lane,,Elstree,Hertfordshire,' ' ,United Kingdom,246907,,,
2217,Coagulation factor X (human),Coagadex,11/8/2007,treatment of hereditary factor x deficiency,Designated/Approved,,,"in adults and children with hereditary Factor X deficiency for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and perioperative management of bleeding in patients with mild, moderate, and severe hereditary Factor X deficiency",4/14/2023,4/14/2030,perioperative management of bleeding in adults and children with severe hereditary Factor X deficiency,Bio Products Laboratory Limited,Dagger Lane,,Elstree,Hertfordshire,' ' ,United Kingdom,246907,,,
2218,Coagulation Factor X Human,,11/21/2023,treatment of acquired factor x deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Bio Products Laboratory Limited,Dagger Lane,Elstree,Borehamwood,,' WD6 3BX ' ,United Kingdom,970823,acquired factor x deficiency,"""gard:0022410""",
2219,"Coagulation factor Xa (recombinant), inactivated-zhzo",ANDEXXA,2/23/2015,for reversing the anticoagulant effect of direct or indirect factor xa inhibitors in patients experiencing a serious uncontrolled bleeding event or who require urgent or emergent surgery,Designated/Approved,,,"Coagulation factor Xa (recombinant), inactivated-zhzo is indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding",5/3/2018,5/3/2025,"Coagulation factor Xa (recombinant), inactivated-zhzo is indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding","Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,437414,,,
2220,coagulation factor XIII A-subunit (recombinant),TRETTEN,11/6/2003,prophylaxis of bleeding associated with congential factor xiii deficiency,Designated/Approved,,,Routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency.,12/23/2013,12/23/2020,Routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency.,"Novo Nordisk, Inc.",800 Scudders Mill Rd.,,Plainsboro,New Jersey,' 08536 ' ,United States,174803,,,
2221,cobicistat,Tybost®,6/15/2017,treatment of human immunodeficiency virus type 1 (hiv-1) infection in pediatric patients,Designated/Approved,,,TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir in combination with other antiretroviral agents in the treatment of HIV-1 infection in pediatric patients weighing at least 35 kg,8/22/2019,8/22/2026,Indicated to increase systemic exposure of atazanavir in combination with other antiretroviral agents in the treatment of HIV-1 infection in pediatric patients weighing at least 35 kg.,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,577917,,,
2222,cobicistat,Tybost®,6/15/2017,treatment of human immunodeficiency virus type 1 (hiv-1) infection in pediatric patients,Designated/Approved,,,TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection in pediatric patients weighing at least 35 kg coadminstered with atazanavir or weighing at least 40 kg coadministered with darunavir.,10/3/2019,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,577917,,,
2223,cobimetinib,Cotellic,4/26/2021,treatment for histiocytic neoplasms,Designated/Approved,,,as a single agent for the treatment of adult patients with histiocytic neoplasms,10/28/2022,10/28/2029,treatment of adult patients with histiocytic neoplasms,"Genentech, Inc.",1 DNA Way MS#451b,,South San Francisco,California,' 94080 ' ,United States,752820,,,
2224,cobimetinib,,1/31/2014,"treatment of stage iib, iic, iii, and iv melanoma with brafv600 mutation",Designated/Approved,,,"For the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, in combination with vemurafenib. Limitations of Use: COTELLIC is not indicated for treatment of patients with wild-type BRAF melanoma.",11/10/2015,11/10/2022,"For the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, in combination with vemurafenib. COTELLIC is not indicated for treatment of patients with wild-type BRAF melanoma","Genentech, Inc.","1 DNA Way, MS 241A",,South San Francisco,California,' 94080 ' ,United States,419513,noma,"""gard:0004001""",
2225,cobiprostone,,11/14/2002,treatment of cystic fibrosis,Designated/Designation Withdrawn or Revoked,4/29/2015,Not FDA Approved for Orphan Indication,,,,,"Sucampo Pharma Americas, LLC.",4520 East-West Highway,Suite 300,Bethesda,Maryland,' 20814 ' ,United States,158302,cystic fibrosis,"""gard:0006233""",
2226,cobitolimod,,8/8/2017,treatment of ulcerative colitis in pediatric patients,Designated/Designation Withdrawn or Revoked,5/28/2024,Not FDA Approved for Orphan Indication,,,,,InDex Pharmaceuticals AB,23a Tomtebodavägen,,Hagalund,Stockholms län,' ' ,Sweden,594417,,,
2227,cobomarsen,,7/21/2020,treatment of t-cell lymphoma,Designated/Designation Withdrawn or Revoked,2/25/2022,Not FDA Approved for Orphan Indication,,,,,"Viridian Therapeutics, Inc.",6200 Lookout Road,Suite 100,Boulder,Colorado,' 80301 ' ,United States,748520,lymphoma,"""gard:0020548""",
2228,coccidioidin SD Skin Test Antigen,,12/19/2007,for the diagnosis of coccidioidomycosis,Designated/Approved,,,"For the detection of delayed type hypersensitivity to C. immitis in individuals, 18-64 years of age, with a history of pulmonary coccidioidomy-cosis",7/29/2011,,,"Allermed Labortories, Inc.",7203 Convoy Court,,San Diego,California,' 92111 ' ,United States,246007,coccidioidomycosis,"""gard:0009525""",
2229,Coenzyme Q10,,3/5/2001,treatment of huntington's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Integrative Therapeutics, Inc.",825 Challenger Drive,,Green Bay,Wisconsin,' 54311 ' ,United States,138700,,,
2230,coenzyme Q10 and d-alpha-tocopherol,,3/14/2011,treatment of friedreich's ataxia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,' 59718 ' ,United States,335111,,,
2231,Colchicine,,12/9/1985,for arresting the progression of neurologic disability caused by chronic progressive multiple sclerosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Pharmacontrol Corporation,"661 Palisade Ave., P.O. Box 931",,Englewood Cliffs,New Jersey,' 07632 ' ,United States,11085,,,
2232,Colchicine,,9/25/2007,treatment of behcet's syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"AR Scientific, Inc.",1100 Orthodox Street,,Philadelphia,Pennsylvania,' 19124 ' ,United States,245707,,,
2233,colchicine,Colcrys,9/25/2007,treatment of familial mediterranean fever,Designated/Approved,,,Treatment of familial Mediterranean fever,7/29/2009,7/29/2016,,"AR Holding Company, Inc.",1100 Orthodox Street,,Philadelphia,Pennsylvania,' 19124 ' ,United States,245807,familial mediterranean fever,"""gard:0006421""",
2234,"Colfosceril palmitate, cetyl alcohol, tyloxapol",Exosurf Neonatal for Intratracheal Suspension,10/20/1989,"1. prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less 2. treatment of established hyaline membrane disease at all gestational ages",Designated/Approved,,,"Prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages",8/2/1990,8/2/1997,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,' 27709 ' ,United States,14886,,,
2235,"Colfosceril palmitate, cetyl alcohol, tyloxapol",,1/11/1993,treatment of adult respiratory distress syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline,5 Moore Drive,P.O. Box 13398,Research Triangle Park,North Carolina,' 27709 ' ,United States,68492,,,
2236,colistimethate sodium,,3/19/2020,treatment of respiratory infection in patients with cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"EnBiotix, Inc.",197 W. Springfield St.,,Boston,Massachusetts,' 02118 ' ,United States,672418,cystic fibrosis,"""gard:0006233""",
2237,collagenase clostridium histolyticum,XIAFLEX,3/12/1996,treatment of peyronie's disease.,Designated/Approved,,,Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.,12/6/2013,12/6/2020,Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.,"Auxilium Pharmaceuticals, Inc.",640 Lee Road,,Chesterbrook,Pennsylvania,' 19087 ' ,United States,95496,,,
2238,collagenase clostridium histolyticum,Xiaflex,5/23/1996,treatment of advanced (involutional or residual stage) dupuytren's disease,Designated/Approved,,,Treatment of adult patients with Dupuytren's contracture with a palpable cord,2/2/2010,2/2/2017,,"Auxilium Pharmaceuticals, Inc.",40 Valley Stream Parkway,,Malvern,Pennsylvania,' 19335 ' ,United States,92595,,,
2239,combination of 7-ethtyl-10-hydroxycamptothecin and irinotecan hydrochloride trihydrate,,2/26/2024,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,SN BioScience Inc.,"Na-422, LH Business Growth Center,","54 Changup-ro, Sujeong-gu",Seongnam-si,Gyeonggi,' ' ,South Korea,989523,,,
2240,"Combination of an inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium)",,10/13/2016,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Yisheng US Biopharma, Inc.",11 Firstfield Road,Suite A,Gaithersburg,Maryland,' 20878 ' ,United States,539916,hepatocellular carcinoma,"""gard:0016773""",
2241,combination of disulfiram and copper gluconate,,5/18/2016,treatment of glioblastoma multiforme.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cantex Pharmaceuticals, Inc.",1792 Bell Tower Lane,,Weston,Florida,' 33326 ' ,United States,522516,glioblastoma,"""gard:0002491""",
2242,Combination of nivolumab and ipilimumab,,10/9/2014,treatment of stage iib to stage iv melanoma,Designated/Approved,,,"Treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma",9/30/2015,9/30/2022,"Treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma",Bristol-Myers Squibb Company,5 Research Parkway,,Wallingford,Connecticut,' 06492 ' ,United States,445014,noma,"""gard:0004001""",
2243,combination of p-Tolylmethylcarbinol nicotinic acid ester and a-naphthylacetic acid,,3/30/2020,treatment of primary biliary cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,' 07670 ' ,United States,731020,primary biliary cholangitis,"""gard:0007459""",
2244,combination Resveratrol and Curcumin,,2/27/2024,treatment of patients with dercum's disease (adiposis dolorosa),Designated,,Not FDA Approved for Orphan Indication,,,,,"Caliway Biopharmaceuticals Co., Ltd.","32F-9, No.99, Sec. 1, Xintai 5th Rd.",Xizhi Dist.,New Taipei City,,' 221 ' ,Taiwan,825321,adiposis dolorosa,"""gard:0005750""",
2245,combinatorial regimen of LV305 (lentiviral vector encoding NY-ESO-1 gene) and G305 (NY-ESO-1 recombinant protein plus GLA-SE),,5/2/2016,treatment of soft tissue sarcoma,Designated/Designation Withdrawn or Revoked,8/13/2019,Not FDA Approved for Orphan Indication,,,,,Immune Design Corp.,1616 Eastlake Ave. E,Suite 310,Seattle,Washington,' 98102 ' ,United States,467914,soft tissue sarcoma,"""gard:0004898""",
2246,combretastatin A 1 diphosphate,,11/19/2012,treatment of acute myelogenous leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mateon Therapeutics, Inc.",701 Gateway Blvd,Suite 210,South San Francisco,California,' 94080 ' ,United States,382412,,,
2247,Combretastatin A4 Phosphate,,7/23/2003,"treatment of anaplastic thyroid cancer, medullary thyroid cancer, and stage iv papillary or follicular thyroid cancer",Designated,,Not FDA Approved for Orphan Indication,,,,,"Mateon Therapeutics, Inc.",701 Gateway Boulevard,Suite 210,South San Francisco,California,' 94080 ' ,United States,167503,,,
2248,Combretastatin A4 phosphate,,5/8/2006,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mateon Therapeutics, Inc.",701 Gateway Blvd,Suite 210,South San Francisco,California,' 94080 ' ,United States,217805,ovarian cancer,"""gard:0007295""",
2249,competetive small molecule inhibitor of the enzyme O-GlcNAcase,,3/10/2016,treatment of progressive supranuclear palsy.,Designated/Designation Withdrawn or Revoked,8/14/2017,Not FDA Approved for Orphan Indication,,,,,"Merck & Company, Inc.",126 East Lincoln Avenue,P. O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,512815,progressive supranuclear palsy,"""gard:0007471""",
2250,competitive and reversible small molecule inhibitor of the O-linked-B-N-acetylglucosaminidase enzyme,,7/10/2018,treatment of progressive supranuclear palsy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ferrer Internacional, S.A.","Gran Vía Carlos III, 94",,Barcelona,,' E-08028 ' ,Spain,644318,progressive supranuclear palsy,"""gard:0007471""",
2251,complement factor H,,12/7/2009,treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,LFB Biotechnologies S.A.,"3, avenue des Tropiques",,Courtaboeuf Cedex,,' ' ,France,260308,hemolytic uremic syndrome,"""gard:0022233""",
2252,concizumab,,10/22/2018,treatment of hemophilia a,Designated,,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.",P.O Box 846,,Plainsboro,New Jersey,' 08536 ' ,United States,653618,hemophilia,"""gard:0010418""",
2253,concizumab,,7/22/2019,treatment of hemophilia b,Designated,,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.",P.O Box 846,,Plainsboro,New Jersey,' 08536 ' ,United States,663618,hemophilia,"""gard:0010418""",
2254,conditionally active biologics-anti-ROR2-antibody drug conjugate consisting of a humanized IgG1 antibody specific for ROR2 tyrosine kinase conjugated to a peptide linker coupled with monomethyl auristatin E,,12/18/2018,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,BioAtla LLC,11085 Torreyana Road,Suite 100,San Diego,California,' 92121 ' ,United States,663018,soft tissue sarcoma,"""gard:0004898""",
2255,conditionally-replicative CD40L-expressing adenovirus,,12/8/2022,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Adze Biotechnology, Inc.","2332 Galiano Street, Second Floor",,Coral Gables,Florida,' 33134 ' ,United States,914922,,,
2256,Conjugate of a dengue virus specific small chemical ligand and an amphiphilic PEG based polymer,,8/6/2013,treatment of dengue fever (includes dengue hemorrhagic fever and dengue shock syndrome),Designated,,Not FDA Approved for Orphan Indication,,,,,NanoViricides Incorporated,"135 Wood Street, Suite 205",,West Haven,Connecticut,' 06516 ' ,United States,402313,ck syndrome,"""gard:0017210""",
2257,conjugate of human transferrin and a mutant diphtheria toxin (CRM 107),,12/3/2001,treatment of malignant tumors of the central nervous system,Designated,,Not FDA Approved for Orphan Indication,,,,,Xenova Biomedix Limited,957 Budkingham Avenue,Slough,Berkshire,,' ' ,United Kingdom,150901,,,
2258,conjugated bile acids,,7/18/2003,treatment of steatorrhea in patients with short bowel syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jarrow Formulas, Inc.",1824 S. Robertson Blvd.,,Los Angeles,California,' 90035 ' ,United States,151301,short bowel syndrome,"""gard:0001502""",
2259,Contulakin-G,,7/7/2005,intrathecal treatment of neuropathic pain associated with spinal cord injury,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cognetix, Inc.",421 Wakara Way,,Salt Lake City,Utah,' 84108 ' ,United States,205505,spinal cord injury,"""gard:0019109""",
2260,copanlisib,,2/7/2017,treatment of splenic marginal zone lymphoma,Designated/Designation Withdrawn or Revoked,3/28/2024,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Boulevard,P. O. Box 915,Hanover,New Jersey,' 07981 ' ,United States,552616,lymphoma,"""gard:0020548""",
2261,copanlisib,,4/16/2021,treatment of patients with small lymphocytic lymphoma (sll),Designated/Designation Withdrawn or Revoked,3/28/2024,Not FDA Approved for Orphan Indication,,,,,Bayer HealthCare Pharmaceuticals Inc.,100 Bayer Blvd,P.O.Box 915,Whippany,New Jersey,' 07981-0915 ' ,United States,811321,lymphoma,"""gard:0020548""",
2262,copanlisib,,5/3/2021,treatment of patients with lymphoplasmacytoid lymphoma (lpl)/ waldenstrom macroglobulinemia (wm),Designated/Designation Withdrawn or Revoked,3/28/2024,Not FDA Approved for Orphan Indication,,,,,Bayer HealthCare Pharmaceuticals Inc.,100 Bayer Blvd,P.O.Box 915,Whippany,New Jersey,' 07981-0915 ' ,United States,811421,lymphoma,"""gard:0020548""",
2263,copanlisib,ALIQOPA,2/5/2015,treatment of follicular lymphoma,Designated/Approved,,,Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies,9/14/2017,9/14/2024,Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies,Bayer US LLC,100 Bayer Boulevard,P. O. Box 915,Hanover,New Jersey,' 07981 ' ,United States,463314,lymphoma,"""gard:0020548""",
2264,copanlisib,,2/7/2017,treatment of extranodal marginal zone lymphoma,Designated/Designation Withdrawn or Revoked,3/28/2024,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Boulevard,P. O. Box 915,Hanover,New Jersey,' 07981 ' ,United States,552416,lymphoma,"""gard:0020548""",
2265,copanlisib,,2/7/2017,treatment of nodal marginal zone lymphoma,Designated/Designation Withdrawn or Revoked,3/28/2024,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Boulevard,P. O. Box 915,Hanover,New Jersey,' 07981 ' ,United States,552516,lymphoma,"""gard:0020548""",
2266,copper Cu 64 dotatate,Detectnet,5/18/2016,diagnostic for the management of neuroendocrine tumors.,Designated/Approved,,,indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients,9/3/2020,9/3/2027,indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients,RadioMedix Inc.,"9701 Richmond Avenue, Suite 222",,Houston,Texas,' 77042 ' ,United States,520716,,,
2267,copper histidinate,,5/14/2012,treatment of menkes disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sentynl Therapeutics, Inc.","420 Stevens Ave., Suite 200",,Solana Beach,California,' 92075 ' ,United States,366312,menkes disease,"""gard:0001521""",
2268,copper sulfate,,10/26/2017,treatment of keratoconus,Designated,,Not FDA Approved for Orphan Indication,,,,,Glaukos Corporation,One Glaukos Way,,Aliso Viejo,California,' 92656 ' ,United States,586117,,,
2269,Cordycepin,,7/5/2007,treatment of tdt-positive acute lymphocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"OncoVista, Inc.",14785 Omicron Drive,,San Antonio,Texas,' 78245 ' ,United States,242507,,,
2270,corifungin,,7/6/2011,treatment of visceral leishmaniasis,Designated,,Not FDA Approved for Orphan Indication,,,,,Sandler Center for Drug Discovery,"University of CA, San Francisco",1700 4th Street,San Francisco,California,' 94158 ' ,United States,342211,leishmaniasis,"""gard:0006881""",
2271,corifungin,,8/22/2011,treatment of amebic meningoencephalitis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Ctr for Discovery & Innovation in Parasitic Diseas,"University of CA, San Francisco","Byers Hall Room 508B, QB3",San Francisco,California,' 94158 ' ,United States,348811,encephalitis,"""gard:0019357""",
2272,Corneal Endothelial Cells Substitute derived from human allogeneic iPS Cells,,12/20/2023,treatment of bullous keratopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cellusion, Inc.","#801, 8-6 Nihonbashi-Kobunacho, Chuo-ku,",,Tokyo,,' 103-0024 ' ,Japan,975623,,,
2273,Corticorelin ovine triflutate,Acthrel,11/24/1989,for use in differentiating pituitary and ectopic production of acth in patients with acth-dependent cushings syndrome.,Designated/Approved,,,To differentiate between pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.,5/23/1996,5/23/2003,,"Ferring Laboratories, Inc.","400 Rella Boulevard, Suite 201",,Suffern,New York,' 10901 ' ,United States,35089,,,
2274,Corticotropin (ACTH) porcine (synthetic),,6/21/2023,treatment of membranous nephropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cerium Pharmaceuticals, Inc.",312 Main Street,Suite 200,Gaithersburg,Maryland,' 20878 ' ,United States,828921,,,
2275,corticotropin-releasing factor receptor-1 antagonist containing an unfused thiazole ring,,11/8/2017,treatment of congenital adrenal hyperplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,Spruce Biosciences,548 Market Street,Suite 74598,San Francisco,California,' 94104 ' ,United States,612217,congenital adrenal hyperplasia,"""gard:0001467""",
2276,"Corticotropin-releasing factor, human",,4/6/1998,treatment of peritumoral brain edema.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neurobiological Technologies, Inc.",1387 Marina Way South,,Richmond,California,' 94804 ' ,United States,108097,,,
2277,cosyntropin,,8/2/2017,treatment of infantile spasms.,Designated,,Not FDA Approved for Orphan Indication,,,,,"West Therapeutic Development, LLC",540 Ziegler Drive,,Grayslake,Illinois,' 60030 ' ,United States,594017,,,
2278,cosyntropin,,7/6/2017,treatment of duchenne muscular dystrophy.,Designated/Designation Withdrawn or Revoked,2/9/2021,Not FDA Approved for Orphan Indication,,,,,Mallinckrodt ARD Inc.,675 McDonnell Boulevard,,Hazelwood,Missouri,' 63042 ' ,United States,545216,muscular dystrophy,"""gard:0007922""",
2279,cotsiranib,,11/29/2017,treatment of cholangiocarcinoma (cca),Designated,,Not FDA Approved for Orphan Indication,,,,,"Sirnaomics, Inc.",401 Professional Drive,Suite 280,Gaithersburg,Maryland,' 20879 ' ,United States,614817,cholangiocarcinoma,"""gard:0009304""",
2280,Cotsiranib,,6/15/2017,treatment of primary sclerosing cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sirnaomics, Inc.",401 Professional Drive,Suite 280,Gaithersburg,Maryland,' 20879 ' ,United States,580717,sclerosing cholangitis,"""gard:0021868""",
2281,Coumarin,,12/22/1994,treatment of renal cell carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Drossapharm LTD,Ariesheim,,Basel,,' ' ,Switzerland,84294,renal cell carcinoma,"""gard:0013215""",
2282,Coversin,,9/8/2016,treatment of paroxysmal nocturnal hemoglobinuria,Designated,,Not FDA Approved for Orphan Indication,,,,,Akari Therapeutics Plc,24 West 40th Street,8th Floor,New York,New York,' 10018 ' ,United States,533916,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
2283,Coxsackievirus A21,,12/15/2005,"treatment of stage ii (t4), stage iii, and stage iv melanoma",Designated,,Not FDA Approved for Orphan Indication,,,,,"Viralytics Limited, a wholly owned subsidiary of Merck Sharp & Dohme, LLC",P. O. Box 1045,"Unit 8/33 Ryde Road,","Pymble,",NSW,' ' ,Australia,212105,noma,"""gard:0004001""",
2284,Creatine,,10/11/2005,treatment of huntington's disease,Designated/Designation Withdrawn or Revoked,4/13/2017,Not FDA Approved for Orphan Indication,,,,,"Marathon Pharmaceuticals, LLC",1033 Skokie Blvd,Suite 600,Northbrook,Illinois,' 60062 ' ,United States,210005,,,
2285,creatine,,2/12/2002,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Avicena Group, Inc.",580 California St.,Suite 1600,San Francisco,California,' 94104 ' ,United States,152701,amyotrophic lateral sclerosis,"""gard:0005786""",
2286,crenolanib,,3/18/2011,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"AROG Pharmaceuticals, LLC",12400 Coit Road,Suite 570,Dallas,Texas,' 75251 ' ,United States,335911,soft tissue sarcoma,"""gard:0004898""",
2287,crenolanib,,10/31/2012,treatment of acute myelogenous leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"AROG Pharmaceuticals, LLC",12400 Coit Road,Suite 570,Dallas,Texas,' 75251 ' ,United States,363812,,,
2288,crenolanib,,10/21/2019,"treatment of gastric cancer, including cancer of the gastroesophageal junction",Designated,,Not FDA Approved for Orphan Indication,,,,,"AROG Pharmaceuticals, Inc.","5420 LBJ Freeway, Suite 410",,Dallas,Texas,' 75240 ' ,United States,706819,,,
2289,crenolanib besylate,,12/20/2010,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"AROG Pharmaceuticals, LLC",Two Lincoln Centre,Suite 410,Dallas,Texas,' 75240 ' ,United States,320910,,,
2290,cridanimod,,1/12/2011,treatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Xenetic Biosciences, Inc.",99 Hayden Avenue,Suite 230,Lexington,Massachusetts,' 02421 ' ,United States,328910,,,
2291,crinecerfont,,3/15/2019,treatment of congenital adrenal hyperplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neurocrine Biosciences, Inc.",12780 El Camino Real,,San Diego,California,' 92130 ' ,United States,639018,congenital adrenal hyperplasia,"""gard:0001467""",
2292,Crisdesalazine,,10/24/2022,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"GNT Pharma Co., Ltd.",23 Yonggu-daero 1855beon-gil,"Giheng-gu,",Yongin-si,Gyeonggi-do,' 17096 ' ,South Korea,907322,amyotrophic lateral sclerosis,"""gard:0005786""",
2293,crizanlizumab,ADAKVEO,7/22/2008,treatment of sickle cell disease,Designated/Approved,,,ADAKVEO® is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.,11/15/2019,11/15/2026,Indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.,Novartis Pharmaceuticals Corporation,One Health Plaza,Building 337 B11.3D,East Hanover,New Jersey,' 07936- ' ,United States,259708,,,
2294,crizotinib,Xalkori,9/13/2010,"treatment of alk-positive, met-positive, or ros-positive non-small cell lung cancer",Designated/Approved,,,Treatment of patients with metastatic NSCLC whose tumors are ROS1-positive,3/11/2016,3/11/2023,Treatment of patients with metastatic NSCLC whose tumors are ROS1-positive,"Pfizer, Inc.",66 Hudson Boulevard East,,New York,New York,' 10001 ' ,United States,310610,small cell lung cancer,"""gard:0009344""",
2295,crizotinib,Xalkori,9/13/2010,"treatment of alk-positive, met-positive, or ros-positive non-small cell lung cancer",Designated/Approved,,,Treatment of patients with locally advanced or metastatic non-small cell lungcancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDAapprovedtest,8/26/2011,8/26/2018,,"Pfizer, Inc.",66 Hudson Boulevard East,,New York,New York,' 10001 ' ,United States,310610,small cell lung cancer,"""gard:0009344""",
2296,crizotinib,Xalkori,12/20/2021,treatment of inflammatory myofibroblastic tumor,Designated/Approved,,,"treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive",9/7/2023,,,Pfizer Inc.,10646 Science Center Drive,,San Diego,California,' 92121 ' ,United States,834721,inflammatory myofibroblastic tumor,"""gard:0007146""",
2297,crizotinib,Xalkori,9/28/2012,treatment of anaplastic large cell lymphoma,Designated/Approved,,,"treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive",9/7/2023,,,"Pfizer, Inc.",10646 Science Center Drive,,San Diego,California,' 92121 ' ,United States,379712,lymphoma,"""gard:0020548""",
2298,crizotinib,Xalkori,9/13/2010,"treatment of alk-positive, met-positive, or ros-positive non-small cell lung cancer",Designated/Approved,,,treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test,9/7/2023,,,"Pfizer, Inc.",66 Hudson Boulevard East,,New York,New York,' 10001 ' ,United States,310610,small cell lung cancer,"""gard:0009344""",
2299,crizotinib,Xalkori,9/28/2012,treatment of anaplastic large cell lymphoma,Designated/Approved,,,"treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive",1/14/2021,1/14/2028,"treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.","Pfizer, Inc.",10646 Science Center Drive,,San Diego,California,' 92121 ' ,United States,379712,lymphoma,"""gard:0020548""",
2300,crizotinib,Xalkori,12/20/2021,treatment of inflammatory myofibroblastic tumor,Designated/Approved,,,"Treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive",7/14/2022,7/14/2029,"Treatment of adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive",Pfizer Inc.,10646 Science Center Drive,,San Diego,California,' 92121 ' ,United States,834721,inflammatory myofibroblastic tumor,"""gard:0007146""",
2301,crizotinib,,10/31/2012,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",66 Hudson Boulevard East,,New York,New York,' 10001 ' ,United States,379812,neuroblastoma,"""gard:0007185""",
2302,crofelemer,,8/2/2017,treatment of short bowel syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Napo Pharmaceuticals, Inc.",201 Mission Street,Suite 2375,San Francisco,California,' 94105 ' ,United States,592017,short bowel syndrome,"""gard:0001502""",
2303,crofelemer,,2/27/2023,treatment of microvillus inclusion disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Napo Pharmaceuticals Inc.,"200 Pine Street, Suite 400",,San Francisco,California,' 94104 ' ,United States,897722,microvillus inclusion disease,"""gard:0007039""",
2304,Cromolyn sodium,Gastrocrom,3/8/1984,treatment of mastocytosis.,Designated/Approved,,,,12/22/1989,12/22/1996,,Fisons Corporation,"755 Jefferson Rd., P.O. Box 1710",,Rochester,New York,' 14603 ' ,United States,1183,mastocytosis,"""gard:0006987""",
2305,Cromolyn sodium 4% ophthalmic solution,Opticrom 4% ophthalmic solution,7/24/1985,treatment of vernal keratoconjunctivitis.,Designated/Approved,,,,10/3/1984,10/3/1991,,Fisons Corporation,755 Jefferson Rd.,P.O. Box 1710,Rochester,New York,' 14603 ' ,United States,8285,vernal keratoconjunctivitis,"""gard:0007854""",
2306,cromolyn sodium for inhalation,,12/9/2015,treatment of mastocytosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Patara Pharma, LLC",11455 El Camino Real,Suite 460,San Diego,California,' 92130 ' ,United States,497415,mastocytosis,"""gard:0006987""",
2307,cromolyn solution,,4/11/2019,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Respivant Sciences, Inc.","11455 El Camino Real, Suite 460",,San Diego,California,' 92130 ' ,United States,602817,idiopathic pulmonary fibrosis,"""gard:0008609""",
2308,crotalidae immune F(ab')2 (equine),Anavip,1/29/2004,treatment of envenomation by crotaline snakes,Designated/Approved,,,Management of adult and pediatric patients with North American rattlesnake envenomation,5/6/2015,5/6/2022,Management of adult and pediatric patients with North American rattlesnake envenomation,"Rare Disease Therapeutics, Inc.",12975 Brookprinter Place,Suite 170,Poway,California,' 92064 ' ,United States,177503,noma,"""gard:0004001""",
2309,crotalidae immune F(ab')2 (equine),Anavip,1/29/2004,treatment of envenomation by crotaline snakes,Designated/Approved,,,For the management of adult and pediatric patients with North American Pit Viper envenomation,4/1/2021,,,"Rare Disease Therapeutics, Inc.",12975 Brookprinter Place,Suite 170,Poway,California,' 92064 ' ,United States,177503,noma,"""gard:0004001""",
2310,cryopreserved human umbilical cord,,1/8/2018,treatment of spina bifida,Designated,,Not FDA Approved for Orphan Indication,,,,,"TissueTech, Inc.",7300 Corporate Center Drive,Suite 700,Miami,Florida,' 33126 ' ,United States,611717,,,
2311,Cryptosporidium hyperimmune bovine colostrum IgG concentrate,,12/30/1991,treatment of diarrhea in aids patients caused by infection with cryptosporidium parvum.,Designated,,Not FDA Approved for Orphan Indication,,,,,ImmuCell Corporation,56 Evergreen Drive,,Portland,Maine,' 04103 ' ,United States,62591,,,
2312,CT-2584 mesylate,,4/16/1999,treatment of malignant mesothelioma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Cell Therapeutics, Inc.",501 Elliott Ave. West,Suite 400,Seattle,Washington,' 98119 ' ,United States,124899,,,
2313,CT-2584 Mesylate,,4/16/1999,treatment of adult soft tissue sarcoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Cell Therapeutics, Inc.",501 Elliott Ave. West,Suite 400,Seattle,Washington,' 98119 ' ,United States,121798,soft tissue sarcoma,"""gard:0004898""",
2314,Cu-64 anti CD99,,1/5/2021,diagnostic for the clinical management of ewing sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",9429 Harding Ave,,Surfside,Florida,' 33154 ' ,United States,790520,,,
2315,cudetaxestat,,10/12/2021,treatment of systemic sclerosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Blade Therapeutics, Inc.",442 Littlefield Avenue,,South San Francisco,California,' 94080 ' ,United States,841021,systemic sclerosis,"""gard:0009748""",
2316,"Cultured human retinal pigment epithelial cell line (ARPE-19) genetically modified with a non-viral vector to express B domain deleted human factor VIII protein, encapsulated within two-layer modified alginate spheres",,8/21/2019,treatment of hemophilia a,Designated/Designation Withdrawn or Revoked,9/29/2022,Not FDA Approved for Orphan Indication,,,,,"Sigilon Therapeutics, Inc.","100 Binney Street, STE 600",,Cambridge,Massachusetts,' 02142 ' ,United States,697219,hemophilia,"""gard:0010418""",
2317,"Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express Human alpha-galactosidase A (h alpha-Gal A), encapsulated within two-layer modified alginate spheres",,3/2/2021,treatment of alpha-galactosidase a deficiency (fabry’s disease),Designated/Designation Withdrawn or Revoked,12/18/2023,Not FDA Approved for Orphan Indication,,,,,"Sigilon Therapeutics, Inc.","100 Binney Street, STE 600",,Cambridge,Massachusetts,' 02142 ' ,United States,805720,,,
2318,"Cultured human retinal pigment epithelial cells (ARPE-19) genetically modified with a non-viral vector to express human native alpha-L-iduronidase enzyme (hIDUA), encapsulated within two-layer modified alginate spheres",,12/14/2020,mucopolysaccharidosis i (mps i; alpha-l-iduronidase deficiency),Designated/Designation Withdrawn or Revoked,12/14/2022,Not FDA Approved for Orphan Indication,,,,,"Sigilon Therapeutics, Inc.","100 Binney Street, STE 600",,Cambridge,Massachusetts,' 02142 ' ,United States,786420,mucopolysaccharidosis,"""gard:0007065""",
2319,cultured skin substitute (CSS),,8/22/2016,treatment of burns requiring skin grafting.,Designated,,Not FDA Approved for Orphan Indication,,,,,Regenicin Inc.,10 High Court,,Little Falls,New Jersey,' 07424 ' ,United States,532116,,,
2320,cusatuzumab,,1/14/2019,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,OncoVerity,12635 E. Montview Blvd.,,Aurora,Colorado,' 80045 ' ,United States,614717,acute myeloid leukemia,"""gard:0012757""",
2321,Cutamesine dihydrochloride,,12/5/2023,treatment of alpha-thalassemia x-linked disability (atrx) syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioPharma Global, a division of Pace Life Sciences",2665 Long Lake Road,Suite 300,Roseville,Minnesota,' 55113 ' ,United States,973623,alpha-thalassemia,"""gard:0000621""",
2322,"Cyclo {{(E,Z)-(2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)nona-6,8-dienoyl}-L-2-aminobytyrl-N-methyl-glycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl}",,12/20/2006,"treatment and chronic control of non-infectious posterior, intermediate and pan-uveitis",Designated,,Not FDA Approved for Orphan Indication,,,,,"Lux Biosciences, Inc.",Hoarborside Financial Center,"Plaza 10, 14th Floor",Jersey City,New Jersey,' 07302 ' ,United States,227806,uveitis,"""gard:0019549""",
2323,cyclo(-L-Glycyl-L-2-Allylproline),,10/9/2019,treatment of angelman syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neuren Pharmaceuticals, Ltd.","Ste 201, 697 Burke Rd",,Camberwel,,' ' ,Australia,705719,angelman syndrome,"""gard:0005810""",
2324,Cyclo(-L-Glycyl-L-2-Allylproline),,10/15/2019,treatment of pitt-hopkins syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neuren Pharmaceuticals, Ltd.","Ste 201, 697 Burke Rd",,Camberwel,,' ' ,Australia,706119,pitt-hopkins syndrome,"""gard:0004372""",
2325,Cyclo(-L-Glycyl-L-2-Allylproline),,10/15/2019,treatment of phelan-mcdermid syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neuren Pharmaceuticals, Ltd.","Ste 201, 697 Burke Rd",,Camberwel,,' ' ,Australia,706019,,,
2326,"cyclo(-y-aminobutyryl-L-phenylalanyl-L-tryptophanyl-D-tryptophanyl-L-lysyl-L-threonly-L-phenylalanyl-N-3-carboxypropyl)-glycine amide, acetate salt",,6/24/2013,treatment of acromegaly,Designated,,Not FDA Approved for Orphan Indication,,,,,"Xeris Pharmaceuticals, lnc.","1375 West Fulton Street, Suite 1300",,Chicago,Illinois,' 60607 ' ,United States,397713,acromegaly,"""gard:0005725""",
2327,cyclocreatine,,6/18/2012,treatment of creatine transporter deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Lumos Pharma,4200 Marathon Blvd.,Suite 200,Austin,Texas,' 78756 ' ,United States,362711,,,
2328,cyclocreatine phosphate,,1/17/2018,prevention of ischemic injury to enhance cardiac graft recovery and survival in heart transplantation.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nour Heart Therapeutics, LLC","121 Locust Street, SW",,Vienna,Virginia,' 22180 ' ,United States,495115,,,
2329,cyclophosphamide,,6/17/2011,prevention of graft versus host disease following allogeneic hematopoietic stem cell transplant,Designated,,Not FDA Approved for Orphan Indication,,,,,"Accentia Biopharmaceuticals, Inc.",324 S. Hyde Park Avenue,,Tampa,Florida,' 33606 ' ,United States,343611,graft versus host disease,"""gard:0016642""",
2330,cyclophosphamide,,6/7/2011,treatment of systemic sclerosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Accentia Biopharmaceuticals, Inc.","324 South Hyde Avenue, Suite 350",,Tampa,Florida,' 33606 ' ,United States,333911,systemic sclerosis,"""gard:0009748""",
2331,Cyclosporin A,,10/29/2004,treatment of amyotrophic lateral sclerosis and its variants,Designated,,Not FDA Approved for Orphan Indication,,,,,"Maas Biolab,LLC",Tecnology Ventures Corporation Technopolis,"1155 University Blvd., SE",Albuquerque,New Mexico,' 87106 ' ,United States,194704,amyotrophic lateral sclerosis,"""gard:0005786""",
2332,cyclosporine,,2/17/2009,treatment of graft-versus-host disease,Designated/Designation Withdrawn or Revoked,3/1/2019,Not FDA Approved for Orphan Indication,,,,,Sigmoid Pharma Limited,Dublin City University,,Dublin,,' ' ,Ireland,275108,,,
2333,cyclosporine,,2/17/2009,prophylaxis of graft-versus-host disease,Designated/Designation Withdrawn or Revoked,3/1/2019,Not FDA Approved for Orphan Indication,,,,,Sigmoid Pharma Limited,Dublin City University,,Dublin,,' ' ,Ireland,273308,,,
2334,cyclosporine,Verkazia,5/4/2007,treatment of vernal keratoconjunctivitis,Designated/Approved,,,Treatment of vernal keratoconjunctivitis (VKC) in children and adults,6/23/2021,6/23/2028,Treatment of vernal keratoconjunctivitis (VKC) in children and adults,"Harrow Eye, LLC",102 Woodmont Blvd Ste 610,,Nashville,Tennessee,' 37205-2221 ' ,United States,239907,vernal keratoconjunctivitis,"""gard:0007854""",
2335,Cyclosporine,,11/25/2003,prophylaxis of organ rejection in patients receiving allogeneic lung transplant,Designated,,Not FDA Approved for Orphan Indication,,,,,"APT Pharmaceuticals, Inc.",700 Airport Blvd.,Suite 350,Burlingame,California,' 94010 ' ,United States,180103,,,
2336,Cyclosporine,,11/25/2003,treatment of acute rejection in patients requiring allogenic lung transplants,Designated,,Not FDA Approved for Orphan Indication,,,,,"APT Pharmaceuticals, Inc.",700 Airport Blvd.,Suite 350,Burlingame,California,' 94010 ' ,United States,176303,,,
2337,cyclosporine 2% ophthalmic ointment,,8/1/1991,"for use in corneal melting syndromes of known or presumed immunologic etiopathogenesis, including mooren's ulcer",Designated,,Not FDA Approved for Orphan Indication,,,,,"Allergan, Inc.",2525 Dupont Drive,P. O. Box 19534,Irvine,California,' 92612 ' ,United States,58991,,,
2338,cyclosporine 2% ophthalmic ointment,,8/1/1991,treatment of patients at high risk of graft rejection following penetrating keratoplasty,Designated,,Not FDA Approved for Orphan Indication,,,,,"Allergan, Inc.",2525 Dupont Drive,P. O. Box 19534,Irvine,California,' 92612 ' ,United States,51790,,,
2339,cyclosporine A,,4/9/2008,treatment of herpes simplex virus stromal keratitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Santen SAS,1 rue Pierre Fontaine,,91058 Evry cedex,,' ' ,France,254807,herpes simplex virus stromal keratitis,"""gard:0019879""",
2340,cyclosporine A,,9/30/2008,prevention of corneal graft rejection,Designated,,Not FDA Approved for Orphan Indication,,,,,Santen SAS,Batiment Genavenir IV,,F-91058-Evry cedex,,' ' ,France,254907,,,
2341,Cyclosporine A implant,,1/8/2007,for the prevention of acute rejection in cornea transplant patients,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Lux Biosciences, Inc.",Harborside Financial Center,"Plaza 10, 14th Floor",Jersey City,New Jersey,' 07302 ' ,United States,224106,,,
2342,Cyclosporine in combination with omega-3 polyunsaturated fatty acids,,12/6/2000,prevention of solid organ graft rejection.,Designated,,Not FDA Approved for Orphan Indication,,,,,RTP Pharma Corporation,200 Westpark Corporate Center,4364 South Alston Avenue,Durham,North Carolina,' 27713 ' ,United States,138500,,,
2343,Cyclosporine ophthalmic,,11/9/1988,treatment of severe keratoconjunctivitis sicca associated with sjogren's syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,University Of Georgia,College Of Veterinary Medicine,Department of Small Animal Medicine,Athens,Georgia,' 30602 ' ,United States,29988,,,
2344,cyclosporine; ciclosporin,,11/23/2010,treatment of moderate to severe traumatic brain injury.,Designated,,Not FDA Approved for Orphan Indication,,,,,Abliva AB,Medicon Village,SE-223 81,Lund,,' ' ,Sweden,319710,,,
2345,Cyclo{-Asn-Leu-d-Phe-Al[(N5-acetyl-N5-hydroxy-Orn)-(N5-acetyl-N5-hydroxy-Orn)-(N5-hydroxy-Orn)]-} . Al(III),,12/29/2015,treatment of invasive aspergillosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Basilea Pharmaceutica International, Ltd., Allschwil",Hegenheimermattweg 167b,,Allschwil,,' 4123 ' ,Switzerland,498415,aspergillosis,"""gard:0005856""",
2346,Cyproterone acetate,,10/26/1984,treatment of severe hirsutism.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Berlex Laboratories, Inc.",300 Fairfield Road,,Wayne,New Jersey,' 07470 ' ,United States,3884,,,
2347,Cys-His-Ala-Val-Cys,,2/14/2008,"for use in conjunction with melphalen for the treatment of malignant melanoma, ajcc stages iib, iic, iii and iv",Designated,,Not FDA Approved for Orphan Indication,,,,,"Adherex Technologies, Inc.",4620 Creekstone Drive,,Durham,North Carolina,' 27703 ' ,United States,252607,noma,"""gard:0004001""",
2348,cysteamine,,5/9/2008,treatment of huntington's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Horizon Therapeutics USA, Inc.",150 S. Saunders Road,Suite 100,Lake Forest,Illinois,' 60045 ' ,United States,258008,,,
2349,Cysteamine,Cystagon,1/25/1991,treatment of nephropathic cystinosis.,Designated/Approved,,,Treatment of nephropathic cystinosis in adults and children.,8/15/1994,8/15/2001,,"Mylan Laboratories, Inc.",781 Chestnut Ridge Road,P.O. Box 4310,Morgantown,West Virginia,' 26504 ' ,United States,55690,cystinosis,"""gard:0006236""",
2350,cysteamine,,9/11/2013,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Horizon Therapeutics USA, Inc.",150 S. Saunders Road,,Lake Forest,Illinois,' 60045 ' ,United States,404613,,,
2351,Cysteamine,,5/1/1986,treatment of nephropathic cystinosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Thoene, Jess G., M.D.",University of Michigan Medical School,"300 NIB, 1192 SE",Ann Arbor,Michigan,' 48109 ' ,United States,13986,cystinosis,"""gard:0006236""",
2352,Cysteamine,,9/11/2014,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,NovaBiotics Ltd.,Cruickshank Building,,Craibstone,Aberdeen,' ' ,United Kingdom,368712,cystic fibrosis,"""gard:0006233""",
2353,cysteamine,,8/6/2008,treatment of neuronal ceroid lipofuscinoses (batten disease),Designated,,Not FDA Approved for Orphan Indication,,,,,"Raptor Pharmaceuticals, Inc.",9 Commercial Blvd.,Suite 200,Novato,California,' 94949 ' ,United States,262408,,,
2354,cysteamine enteric coated,PROCYSBI,10/24/2006,treatment of cystinosis,Designated/Approved,,,PROCYSBI is indicated for the treatment of nephropathic cystinosis in adult and pediatric patients 2 years of age and older.,8/14/2015,8/14/2022,Treatment of nephropathic cystinosis in pediatric patients 2 years of age to less than 6 years of age.,"Horizon Therapeutics USA, Inc.",150 S. Saunders Road,Suite 100,Lake Forest,Illinois,' 60045 ' ,United States,231006,cystinosis,"""gard:0006236""",
2355,cysteamine enteric coated,PROCYSBI,10/24/2006,treatment of cystinosis,Designated/Approved,,,PROCYSBI is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.,2/14/2020,,,"Horizon Therapeutics USA, Inc.",150 S. Saunders Road,Suite 100,Lake Forest,Illinois,' 60045 ' ,United States,231006,cystinosis,"""gard:0006236""",
2356,cysteamine enteric coated,PROCYSBI,10/24/2006,treatment of cystinosis,Designated/Approved,,,PROCYSBI is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.,12/22/2017,12/22/2024,Treatment of nephropathic cystinosis in pediatric patients 1 year of age to less than 2 years of age.,"Horizon Therapeutics USA, Inc.",150 S. Saunders Road,Suite 100,Lake Forest,Illinois,' 60045 ' ,United States,231006,cystinosis,"""gard:0006236""",
2357,cysteamine enteric coated,PROCYSBI,10/24/2006,treatment of cystinosis,Designated/Approved,,,PROCYSBI is indicated for the management of nephropathic cystinosis in adults and children ages 6 years and older.,4/30/2013,4/30/2020,Management of nephropathic cystinosis in adults and children ages 6 years and older.,"Horizon Therapeutics USA, Inc.",150 S. Saunders Road,Suite 100,Lake Forest,Illinois,' 60045 ' ,United States,231006,cystinosis,"""gard:0006236""",
2358,Cysteamine hydrochloride,Cystaran,8/19/1997,treatment of corneal cystine crystal accumulation in cystinosis patients.,Designated/Approved,,,Treatment of corneal cystine crystal accumulation in patients with cystinosis,10/2/2012,10/2/2019,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd,Suite 500,Gaithersburg,Maryland,' 20878 ' ,United States,105997,cystinosis,"""gard:0006236""",
2359,"cysteine conjugated antibody drug conjugate, where the monomethyl auristatin E linker/payload is conjugated to a monoclonal antibody intermediate, an IgG1 molecule",,4/24/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"TORL Biotherapeutics, LLC",6100 Bristol Parkway,,Culver,California,' 90230 ' ,United States,935723,,,
2360,"cysteine conjugated antibody drug conjugate, where the monomethyl auristatin E linker/payload is conjugated to an anti-CLDN18.2 monoclonal antibody intermediate, an IgG1 molecule",,5/3/2023,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"TORL Biotherapeutics, LLC",6100 Bristol Parkway,,Culver,California,' 90230 ' ,United States,935623,,,
2361,Cystic fibrosis gene therapy,,6/30/1992,treatment of cystic fibrosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,One Mountain Rd.,P.O. Box 9322,Framingham,Massachusetts,' 01701 ' ,United States,66192,cystic fibrosis,"""gard:0006233""",
2362,Cystic fibrosis Tr gene therapy (recombinant adenovirus),,3/9/1995,treatment of cystic fibrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"GenVec, Inc.",12111 Parklawn Drive,,Rockville,Maryland,' 20852 ' ,United States,87694,cystic fibrosis,"""gard:0006233""",
2363,Cystic fibrosis transmembrane conductance regulator,,1/14/1992,for cystic fibrosis transmembrane conductance regulator protein replacement therapy in cystic fibrosis patients.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,One Mountain Road,P.O. Box 9322,Framingham,Massachusetts,' 01701 ' ,United States,63891,cystic fibrosis,"""gard:0006233""",
2364,Cystic fibrosis transmembrane conductance regulator gene,,1/8/1993,treatment of cystic fibrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genetic Therapy, Inc.",938 Clopper Road,,Gaithersburg,Maryland,' 20878 ' ,United States,70492,cystic fibrosis,"""gard:0006233""",
2365,cystic fibrosis transmembrane conductance regulator protein corrector (VX-121)/tezacaftor/deutivacaftor,,10/26/2020,treatment of cystic fibrosis (cf),Designated,,Not FDA Approved for Orphan Indication,,,,,Vertex Pharmaceuticals Incorporated,50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,777220,cystic fibrosis,"""gard:0006233""",
2366,Cytarabine liposomal,DepoCyt,6/2/1993,treatment of neoplastic meningitis.,Designated/Approved,,,Intrathecal treatment of lymphomatous meningitis.,4/1/1999,4/1/2006,,"Pacira Pharmaceuticals, Inc.",10450 Science Center Drive,,San Diego,California,' 92121 ' ,United States,73393,,,
2367,cytarabine liposome,,1/30/2007,treatment of gliomas,Designated,,Not FDA Approved for Orphan Indication,,,,,"Bruce Frankel, MD",Medical University of South Carolina,"96 Jonathan Lucas Street, Suite 428 CSB",Charleston,South Carolina,' 29425 ' ,United States,234806,,,
2368,cytarabine-beta-L-aspartic acid,,5/14/2019,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,BioSight Ltd.,1 Hayarden St.,P.O.B 1083,Airport City,Lod,' ' ,Israel,684419,acute myeloid leukemia,"""gard:0012757""",
2369,Cytarabine:daunorubicin liposome injection; daunorubicin and cytarabine (liposome); daunorubicin and cytarabine liposome for injection,VYXEOS ; Vyxeos ; Vyxeos,8/22/2008,treatment of acute myeloid leukemia,Designated/Approved,,,Treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC),8/3/2017,8/3/2024,Treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC),"Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company)",3170 Porter Drive,,Palo Alto,California,' 94304 ' ,United States,265808,acute myeloid leukemia,"""gard:0012757""",
2370,Cytarabine:daunorubicin liposome injection; daunorubicin and cytarabine (liposome); daunorubicin and cytarabine liposome for injection,VYXEOS ; Vyxeos ; Vyxeos,8/22/2008,treatment of acute myeloid leukemia,Designated/Approved,,,treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients ages 1 year and older,3/30/2021,3/30/2028,treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in pediatric patients ages 1 year and older,"Celator Pharmaceuticals, Inc. (a Jazz Pharmaceuticals Company)",3170 Porter Drive,,Palo Alto,California,' 94304 ' ,United States,265808,acute myeloid leukemia,"""gard:0012757""",
2371,"cytochrome C, flavin mononucleotide and thiamin diphosphate",,6/17/2011,treatment of mitochondrial disorders,Designated,,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,' 59718 ' ,United States,342311,,,
2372,cytochrome P450 isoform 2B1 gene transfected human embryonic kidney 293 cells encapsulated in polymeric cellulose sulphate,,12/17/2014,treatment of pancreatic cancer in combination with ifosfamide,Designated,,Not FDA Approved for Orphan Indication,,,,,"PharmaCyte Biotech, Inc.",23046 Avenida de la Carlota,Suite 600,Laguna Hills,California,' 92652 ' ,United States,457014,,,
2373,Cytomegalovirus DNA Vaccine w/Copolymer/Benzalkonium Chloride,,9/23/2006,"for use in prevention of clinically significant cmv viremia, cmv disease and associated complications in at-risk hematopoietic cell transplant and solid organ transplant populations",Designated,,Not FDA Approved for Orphan Indication,,,,,Vical Inc.,10390 Pacific Center Court,,San Diego,California,' 92121 ' ,United States,194504,,,
2374,Cytomegalovirus DNA vaccine with plasmids expressing pp65 and gB genes,,6/3/2005,"prevention of clinically significant cytomegalovirus (cmv) viremia, cmv disease and associated complications in at-risk hematopoietic cell transplant and solid transplant populations",Designated,,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,193104,,,
2375,Cytomegalovirus immune globulin (human),CytoGam,8/3/1987,prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.,Designated/Approved,,,"#1) Attenuation of primary CMV disease associated with kidney transplant recipients who are seronegative for CMV and who receive a kidney from a CMV seropositve donor; #2) Prophylaxis of CMV disease associated transplantation of kidney (all other), lung, liver, pancreas and heart.",12/4/1998,12/4/2005,,CSL Behring LLC,1020 First Avenue,P. O. Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,15386,,,
2376,Cytomegalovirus immune globulin intravenous (human),,1/28/1991,for use in conjunction with ganciclovir sodium for the treatment of cytomegalovirus pneumonia in bone marrow transplant patients.,Designated,,Not FDA Approved for Orphan Indication,,,,,Bayer Corporation,"Pharmaceutical Division, Biological Products",400 Morgan Lane,New Haven,Connecticut,' 06516 ' ,United States,52190,,,
2377,cytomegalovirus specific cytotoxic T lymphocytes,,1/5/2017,treatment of cytomegalovirus infection in severely immunocompromised patients,Designated,,Not FDA Approved for Orphan Indication,,,,,"ViraCyte, LLC","33 - 5th Avenue, NW",Suite 700,New Brighton,Minnesota,' 55112 ' ,United States,418613,,,
2378,"D,L-3-hydroxybutyrate",,11/3/2020,treatment of multiple acyl-coa dehydrogenase deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Orpha Labs, AG",Haldenstrasse 5,,Baar,,' CH-6340 ' ,Switzerland,779220,acyl-coa dehydrogenase deficiency,"""gard:0021318""",
2379,D-amino acid oxidase inhibitor,,12/6/2017,treatment of friedreich's ataxia (frda),Designated/Designation Withdrawn or Revoked,11/29/2019,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",Takeda Parkway,,Deerfield,Illinois,' 60015 ' ,United States,615417,,,
2380,D-beta-hydroxybutyrate,,3/18/2024,treatment of fatty acid oxidation disorders,Designated,,Not FDA Approved for Orphan Indication,,,,,Aimmune Nestle US R&D LLC,1007 US Hwy 202/206,,Bridgewater,New Jersey,' 08807 ' ,United States,993723,,,
2381,D-Galactose,,1/14/2019,treatment of phosphoglucomutase 1 deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"AUG Therapeutics, LLC",1 Broadway,,Cambridge,Massachusetts,' 02142 ' ,United States,666818,,,
2382,D-mannitol and L-proline,,4/20/2009,treatment of cockayne syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,DNage B.V.,Darwinweg 24,,Leiden,,' ' ,Netherlands,277009,cockayne syndrome,"""gard:0006122""",
2383,D-mannose,,1/14/2019,treatment of mannose phosphate isomerase deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"AUG Therapeutics, LLC",1 Broadway,,Cambridge,Massachusetts,' 02142 ' ,United States,666918,,,
2384,d-methadone,,6/2/2016,treatment of postherpetic neuralgia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Relmada Therapeutics, Inc.",750 Third Avenue,9th Floor,New York,New York,' 10017 ' ,United States,499915,,,
2385,D-peptide,,2/4/2011,treatment of acute myelogenous leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immune System Key, Ltd",POB 23365,,Jerusalem,,' ' ,Israel,331210,,,
2386,D-peptide of the sequence AKRHHGYKRKFH - NH2,,10/23/2002,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Demegen, Inc.",100 Technology Drive,Suite 440 B,Pittsburgh,Pennsylvania,' 15219 ' ,United States,156502,cystic fibrosis,"""gard:0006233""",
2387,D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-Nh2 (disulfide bridge: 2-6) acetate,,3/19/2009,"treatment of melanoma, stages iib through iv",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Thallion Pharmaceuticals, Inc.",7150 Alexander-Fleming,,Quebec,,' ' ,Canada,277709,noma,"""gard:0004001""",
2388,D-tagatose,,1/19/2017,treatment of prader-willi syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Biospherics.net LLC,Department of Pharmaceutical Sciences,University of Kentucky,Nicholasville,Kentucky,' 40356 ' ,United States,459614,prader-willi syndrome,"""gard:0005575""",
2389,"d6-tetrabenazine, deutetrabenazine",Austedo,11/5/2014,treatment of huntington's disease,Designated/Approved,,,Treatment of chorea associated with Huntington¿s disease,4/3/2017,4/3/2024,Treatment of chorea associated with Huntington¿s disease,"Teva Branded Pharmaceutical Products R&D, Inc.",3333 N. Torrey Pines Court,Suite 400,La Jolla,California,' 92037 ' ,United States,383212,,,
2390,D9-ivacaftor,,1/18/2017,treatment of cystic fibrosis (cf),Designated,,Not FDA Approved for Orphan Indication,,,,,"Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,551016,cystic fibrosis,"""gard:0006233""",
2391,dabrafenib,Tafinlar,2/8/2016,treatment of malignant glioma with braf v600 mutation,Designated/Approved,,,"in combination with trametinib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy",3/16/2023,3/16/2030,treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936-1080 ' ,United States,506415,,,
2392,dabrafenib,TAFINLAR,1/12/2011,treatment braf v600 mutation positive stage iib through iv melanoma,Designated/Approved,,,Treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA approved test.,5/29/2013,5/29/2020,Treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA approved test.,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,329610,noma,"""gard:0004001""",
2393,Dabrafenib,,10/19/2020,treatment of kabuki syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Rescindo Therapeutics Inc.,1034 Kennicott Ave,,Cary,North Carolina,' 27513 ' ,United States,775820,kabuki syndrome,"""gard:0006810""",
2394,dabrafenib,,10/20/2014,treatment of patients with braf mutation positive non-small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,1 Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,448214,small cell lung cancer,"""gard:0009344""",
2395,dabrafenib and trametinib,Mekinist,10/29/2015,treatment of patients with braf mutation positive non-small cell lung cancer.,Designated/Approved,,,"Mekinist in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.",6/22/2017,6/22/2024,"Mekinist in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test; AND Tafinlar in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.",Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,495915,small cell lung cancer,"""gard:0009344""",
2396,dabrafenib and trametinib,Tafinlar(r) Capsules a nd Mekinist(r) Tablets,9/1/2016,treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a braf v600 mutation.,Designated/Approved,,,"TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options",5/4/2018,5/4/2025,"MEKINIST (trametinib) and TAFINLAR (dabrafenib) in combination, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options",Novartis Pharmaceuticals Corporation,1 Health Plaza,Building 337,East Hanover,New Jersey,' 07936 ' ,United States,521616,,,
2397,dabrafenib and trametinib,Tafinlar(r) Capsules a nd Mekinist(r) Tablets,9/1/2016,treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a braf v600 mutation.,Designated/Approved,,,"MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options",5/4/2018,5/4/2025,"MEKINIST (trametinib) and TAFINLAR (dabrafenib) in combination, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options",Novartis Pharmaceuticals Corporation,1 Health Plaza,Building 337,East Hanover,New Jersey,' 07936 ' ,United States,521616,,,
2398,dacetuzumab,,8/13/2004,treatment of multiple myeloma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,188004,multiple myeloma,"""gard:0007108""",
2399,dacetuzumab,,10/6/2005,treatment of chronic lymphocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,209305,,,
2400,Daclizumab,Zenapax,3/5/1993,prevention of acute renal allograft rejection.,Designated/Approved,,,"Prophylaxis of acute organ rejection in patients receiving renal transplants, to be used as a part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.",12/10/1997,12/10/2004,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,67692,,,
2401,dacomitinib,VIZIMPRO,3/3/2015,"treatment of non-small cell lung cancer with egfr, her2, her4, or ddr2 mutations.",Designated/Approved,,,For the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R,9/27/2018,9/27/2025,For the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R,"Pfizer, Inc.",66 Hudson Boulevard East,,New York,New York,' 10001 ' ,United States,435114,small cell lung cancer,"""gard:0009344""",
2402,dalbavancin,,3/30/2015,treatment of acute osteomyelitis in children (0 through 16 years of age),Designated,,Not FDA Approved for Orphan Indication,,,,,Durata Therapeutics International B.V.,"Spaces Zuidas II, Kantoor 4.03",,Amsterdam,,' ' ,Netherlands,459714,,,
2403,Dalcinonacog Alfa,,9/20/2017,treatment for hemophilia b,Designated,,Not FDA Approved for Orphan Indication,,,,,GC Biopharma Corp.,"107 Ihyeon-ro 30 beong-gil, Giheung-gu",,Yongin-si,Gyeonggi-do,' 94080 ' ,South Korea,596217,hemophilia,"""gard:0010418""",
2404,dalfampridine,Ampyra,6/2/1987,relief of symptoms of multiple sclerosis,Designated/Approved,,,Treatment to improve walking in patients with multiple sclerosis,1/22/2010,1/22/2017,,Acorda Therapeutics,15 Skyline Dr.,,Hawthorne,New York,' 10532 ' ,United States,18186,,,
2405,dalfampridine,,11/25/2019,treatment of transverse myelitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Magnum Therapeutics,243 W. 259th Street,,Riverdale,New York,' 10471 ' ,United States,713019,,,
2406,danicopan,Voydeya,11/2/2017,treatment of paroxysmal nocturnal hemoglobinuria,Designated/Approved,,,add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH),3/29/2024,3/29/2031,treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH),"Alexion Pharmaceuticals, Inc",300 George Street,,New Haven,Connecticut,' 06511 ' ,United States,512715,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
2407,dantrolene,,12/12/2019,treatment of organophosphate exposure,Designated,,Not FDA Approved for Orphan Indication,,,,,"Eagle Pharmaceuticals, Inc.",50 Tice Blvd,Suite 315,Woodcliff Lake,New Jersey,' 07677 ' ,United States,713319,,,
2408,dantrolene sodium,,9/25/2012,treatment of heat stroke,Designated,,Not FDA Approved for Orphan Indication,,,,,"Eagle Pharmaceuticals, Inc.",50 Tice Blvd,Suite 315,Woodcliff Lake,New Jersey,' 07677 ' ,United States,377512,,,
2409,Dantrolene sodium,,12/14/1987,treatment of the neuroleptic malignant syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Norwich Eaton Pharmaceuticals,P.O. Box 191,,Norwich,New York,' 13815 ' ,United States,23287,neuroleptic malignant syndrome,"""gard:0007195""",
2410,dantrolene sodium,,2/17/2016,treatment of wolfram syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Washington University in St. Louis,660 S. Euclid Avenue,Campus Box 8127,St. Louis,Missouri,' 63110 ' ,United States,474515,wolfram syndrome,"""gard:0007898""",
2411,dantrolene sodium suspension for injection,RYANODEX,8/16/2013,treatment of malignant hyperthermia syndrome,Designated/Approved,,,Treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.,7/22/2014,7/22/2021,Treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.,"Eagle Pharmaceuticals, Inc.",50 Tice Blvd,Suite 315,Woodcliff Lake,New Jersey,' 07677 ' ,United States,179703,,,
2412,Dapsone,,11/7/1994,prophylaxis of toxoplasmosis in severely immunocompromised patients with cd4 counts below 100.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jacobus Pharmaceutical Company, Inc.",37 Cleveland Lane,P.O. Box 5290,Princeton,New Jersey,' 08540 ' ,United States,85694,,,
2413,Dapsone USP,,1/8/1992,for the combination treatment of pneumocystis carinii pneumonia in conjunction with trimethoprim.,Designated,,Not FDA Approved for Orphan Indication,,,,,Jacobus Pharmaceutical Company,37 Cleveland Lane,P.O. Box 5290,Princeton,New Jersey,' 08540 ' ,United States,61291,,,
2414,Dapsone USP,,12/24/1991,prophylaxis for pneumocystis carinii pneumonia.,Designated,,Not FDA Approved for Orphan Indication,,,,,Jacobus Pharmaceutical Company,37 Cleveland Lane,P.O. Box 5290,Princeton,New Jersey,' 08540 ' ,United States,61191,,,
2415,daratumumab,,9/5/2017,treatment of systemic amyloid light-chain (al) amyloidosis,Designated/Designation Withdrawn or Revoked,10/5/2021,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,' 08869 ' ,United States,536216,amyloidosis,"""gard:0018676""",
2416,daratumumab,Darzalex,5/6/2013,treatment of multiple myeloma,Designated/Approved,,,"DARZALEX is indicated in combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; and in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor; and as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.",5/7/2018,5/7/2025,"In combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant","Janssen Biotech, Inc.",920 Route 202 South,PO Box 300,Raritan,New Jersey,' 08869 ' ,United States,397113,multiple myeloma,"""gard:0007108""",
2417,daratumumab,Darzalex,5/6/2013,treatment of multiple myeloma,Designated/Approved,,,"Treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT) and in patients with relapsed or refractory multiple myeloma who have received at least 1 prior therapy; in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with bortezomib, thalidomide and dexamethasone in newly diagnosed patients who are eligible for ASCT; in combination with bortezomib and dexamethasone in patients who have received at least 1 prior therapy; in combination with pomalidomide and dexamethasone in patients who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor (PI); and as monotherapy, in patients who have received at least 3 prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immodulatory agent.",9/26/2019,9/26/2026,"Indicated for the treatment of adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant","Janssen Biotech, Inc.",920 Route 202 South,PO Box 300,Raritan,New Jersey,' 08869 ' ,United States,397113,multiple myeloma,"""gard:0007108""",
2418,daratumumab,Darzalex,5/6/2013,treatment of multiple myeloma,Designated/Approved,,,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent,11/16/2015,11/16/2022,For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent,"Janssen Biotech, Inc.",920 Route 202 South,PO Box 300,Raritan,New Jersey,' 08869 ' ,United States,397113,multiple myeloma,"""gard:0007108""",
2419,daratumumab,Darzalex,5/6/2013,treatment of multiple myeloma,Designated/Approved,,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor; and as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.",6/16/2017,6/16/2024,"In combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, not including any overlap with the exclusivity awarded for the 2015 approval for the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and immunomodulary agent or are double refractory to a proteasome inhibitor and immunomodulatory agent.","Janssen Biotech, Inc.",920 Route 202 South,PO Box 300,Raritan,New Jersey,' 08869 ' ,United States,397113,multiple myeloma,"""gard:0007108""",
2420,daratumumab,Darzalex,5/6/2013,treatment of multiple myeloma,Designated/Approved,,,"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.",11/21/2016,11/21/2023,"DARZALEX in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.","Janssen Biotech, Inc.",920 Route 202 South,PO Box 300,Raritan,New Jersey,' 08869 ' ,United States,397113,multiple myeloma,"""gard:0007108""",
2421,daratumumab,Darzalex,5/6/2013,treatment of multiple myeloma,Designated/Approved,,,DARZALEX is indicated for the treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.,6/27/2019,,,"Janssen Biotech, Inc.",920 Route 202 South,PO Box 300,Raritan,New Jersey,' 08869 ' ,United States,397113,multiple myeloma,"""gard:0007108""",
2422,daratumumab,,11/9/2015,treatment of diffuse large b-cell lymphoma.,Designated/Designation Withdrawn or Revoked,9/20/2021,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring hOuse,Pennsylvania,' 19477 ' ,United States,496815,lymphoma,"""gard:0020548""",
2423,daratumumab,Darzalex,5/6/2013,treatment of multiple myeloma,Designated/Approved,,,Treatment of adult patients with multiple myeloma in combination with carfilzomib and dexamethasone in patients who have received one to three prior lines of therapy,8/20/2020,,,"Janssen Biotech, Inc.",920 Route 202 South,PO Box 300,Raritan,New Jersey,' 08869 ' ,United States,397113,multiple myeloma,"""gard:0007108""",
2424,daratumumab,,8/20/2015,treatment of mantle cell lymphoma.,Designated/Designation Withdrawn or Revoked,9/20/2021,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring House,Pennsylvania,' 19477 ' ,United States,488615,lymphoma,"""gard:0020548""",
2425,daratumumab,,8/6/2015,treatment of follicular lymphoma,Designated/Designation Withdrawn or Revoked,9/20/2021,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring House,Pennsylvania,' 19477 ' ,United States,487415,lymphoma,"""gard:0020548""",
2426,daratumumab and hyaluronidase-fihj,Darzalex Faspro,10/6/2020,treatment of light-chain (al) amyloidosis,Designated/Approved,,,"in combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis",1/15/2021,1/15/2028,treatment of adult patients with newly diagnosed light chain (AL) amyloidosis,"Janssen Research & Development, LLC",1400 McKean Road,PO Box 776,Spring House,Pennsylvania,' 19477 ' ,United States,769220,amyloidosis,"""gard:0018676""",
2427,Darinaparsin,,9/13/2010,treatment of peripheral t-cell lymphoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Solasia Pharma K.K.,"3F, Shiodome Building",,Toyko 105-0022,,' ' ,Japan,313810,lymphoma,"""gard:0020548""",
2428,Daromun,,7/10/2018,treatment of melanoma stages iib through iv.,Designated,,Not FDA Approved for Orphan Indication,,,,,Philogen S.p.A.,La Lizza 7,I-53100 Siena,Siena,Tuscany,' ' ,Italy,640018,noma,"""gard:0004001""",
2429,darovasertib,,4/27/2022,treatment of uveal melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,IDEAYA Biosciences Inc.,7000 Shoreline Court,Suite 350,South San Francisco,California,' 94080 ' ,United States,873322,uveal melanoma,"""gard:0008621""",
2430,darvadstrocel,,2/22/2022,treatment of anal fistulas in patients without crohn's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc. (Millennium)",40 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,784320,anal fistula,"""gard:0020568""",
2431,Dasatinib,Sprycel,11/18/2005,treatment of philadelphia-positive acute lymphoblastic leukemia,Designated/Approved,,,SPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.,12/21/2018,12/21/2025,SPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.,Bristol-Myers Squibb Company,P. O Box 5326,Mailstop C 4065,Princeton,New Jersey,' 08542 ' ,United States,214605,acute lymphoblastic leukemia,"""gard:0000522""",
2432,dasatinib,,11/29/2022,treatment of acute lymphoblastic leukemia (all),Designated,,Not FDA Approved for Orphan Indication,,,,,Xspray Pharma AB,Råsundavägen 12,,Solna,,' 16967 ' ,Sweden,809121,acute lymphoblastic leukemia,"""gard:0000522""",
2433,dasatinib,Sprycel,11/28/2005,treatment of chronic myelogenous leukemia,Designated/Approved,,,Treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase,11/9/2017,11/9/2024,Treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase,Bristol-Myers Squibb Company,"3401 Princeton Pike, B-3043C",,Lawrence Township,New Jersey,' 08648 ' ,United States,212405,,,
2434,dasatinib,,6/16/2022,treatment of chronic myeloid leukemia (cml),Designated,,Not FDA Approved for Orphan Indication,,,,,Xspray Pharma AB,Råsundavägen 12,,Solna,,' 16967 ' ,Sweden,809221,chronic myeloid leukemia,"""gard:0006105""",
2435,dasatinib,Phyrago,10/5/2021,treatment of acute lymphoblastic leukemia,Designated/Approved,,,treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy,12/5/2023,,,"Nanocopoeia, LLC",639 Campus Drive,,New Brighton,Minnesota,' 55112 ' ,United States,750520,acute lymphoblastic leukemia,"""gard:0000522""",
2436,dasatinib,Phyrago,10/5/2021,treatment of chronic myelogenous leukemia,Designated/Approved,,,"treatment of adult patients with: newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase; or chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib",12/5/2023,,,"Nanocopoeia, LLC",639 Campus Drive,,New Brighton,Minnesota,' 55112 ' ,United States,750420,,,
2437,Dasatinib,,10/26/2020,treatment of noonan syndrome-associated hypertrophic cardiomyopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"IGIA Pharmaceuticals, Inc.",1125 Boone Aire Road,,Florence,Kentucky,' 41042 ' ,United States,775320,noonan syndrome,"""gard:0010955""",
2438,Dasatinib,Sprycel,11/18/2005,treatment of philadelphia-positive acute lymphoblastic leukemia,Designated/Approved,,,Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy,6/28/2006,6/28/2013,,Bristol-Myers Squibb Company,P. O Box 5326,Mailstop C 4065,Princeton,New Jersey,' 08542 ' ,United States,214605,acute lymphoblastic leukemia,"""gard:0000522""",
2439,dasatinib,Sprycel,11/28/2005,treatment of chronic myelogenous leukemia,Designated/Approved,,,Treatment of adults with chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib,6/28/2006,6/28/2013,,Bristol-Myers Squibb Company,"3401 Princeton Pike, B-3043C",,Lawrence Township,New Jersey,' 08648 ' ,United States,212405,,,
2440,dasatinib monolauryl sulfate,,11/3/2022,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Handa Oncology, LLC","2025 Gateway Place, Suite 480",,San Jose,California,' 95110 ' ,United States,888722,acute lymphoblastic leukemia,"""gard:0000522""",
2441,dasatinib monolauryl sulfate,,3/17/2022,treatment of chronic myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Handa Oncology, LLC","1732 N. First Street, Suite 200",,San Jose,California,' 95112 ' ,United States,869722,chronic myeloid leukemia,"""gard:0006105""",
2442,dasiglucagon,,8/10/2017,treatment of hypoglycemia in patients with congenital hyperinsulinism (ch),Designated,,Not FDA Approved for Orphan Indication,,,,,Zealand Pharma A/S,36 Smedeland,,Glostrup,,' ' ,Denmark,569416,,,
2443,dasiprotimut-T,,10/28/2009,treatment of follicular lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biovest International, Inc.",324 S. Hyde Park Avenue,Suite 350,Tampa,Florida,' 33606 ' ,United States,291909,lymphoma,"""gard:0020548""",
2444,dasiprotimut-T,,6/17/2010,treatment of mantle cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biovest International, Inc.",324 S. Hyde Park Avenue,Suite 350,Tampa,Florida,' 33606 ' ,United States,309710,lymphoma,"""gard:0020548""",
2445,DAsn-Ile-Pro-Nva-Leu-Tyr-DSer-Phe-Ala-DSer,,2/8/2024,treatment of duchenne muscular dystrophy (dmd),Designated,,Not FDA Approved for Orphan Indication,,,,,"Allysta Pharmaceuticals, Inc.",500 108th Avenue NE,Suite 1100,Bellevue,Washington,' 98004 ' ,United States,987423,muscular dystrophy,"""gard:0007922""",
2446,daunorubicin citrate liposome,,4/15/2013,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,11/18/2015,Not FDA Approved for Orphan Indication,,,,,Galen Limited,Seagoe Industrial Estate,,"Graigavon, BT63 5UA",,' ' ,United Kingdom,393413,acute myeloid leukemia,"""gard:0012757""",
2447,Daunorubicin citrate liposome injection,DaunoXome,5/14/1993,treatment of patients with advanced hiv-associated kaposi's sarcoma.,Designated/Approved,,,"First line cytotoxic therapy for advanced, HIV related Kaposi's sarcoma.",4/8/1996,4/8/2003,,"NeXstar Pharmaceuticals, Inc.",650 Cliffside Drive,,San Dimas,California,' 91773 ' ,United States,73693,,,
2448,Daunorubicin liposomal,,9/5/2008,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Diatos USA, LLC",15310 Amberly Drive,,Tampa,Florida,' 33647 ' ,United States,266508,acute myeloid leukemia,"""gard:0012757""",
2449,davunetide,,12/7/2009,treatment of progressive supranuclear palsy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Allon Therapeutics, Inc.",506-1168 Hamilton Street,,Vancouver,,' ' ,Canada,293909,progressive supranuclear palsy,"""gard:0007471""",
2450,davunetide,,2/22/2018,treatment of activity-dependent neuroprotective protein (adnp) syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Ramot at Tel Aviv University Ltd.,PO Box 39296,,Tel-Aviv,,' 6139201 ' ,Israel,624317,,,
2451,daxibotulinumtoxinA-lanm,Daxxify,11/16/2017,treatment of cervical dystonia,Designated/Approved,,,treatment of cervical dystonia in adult patients,8/11/2023,,,"Revance Therapeutics, Inc.",7555 Gateway Boulevard,,Newark,California,' 94560 ' ,United States,579317,,,
2452,DCVAC OvCa,,5/14/2013,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,8/29/2022,Not FDA Approved for Orphan Indication,,,,,SOTIOS a.s.,"Jankovcova 1518/2, 170 00",,Prague,,' 7 ' ,Czech Republic,393213,ovarian cancer,"""gard:0007295""",
2453,DEAE-rebeccamycin,,3/1/2004,treatment of bile duct tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,Helsinn Healthcare SA,"Via Pian Scairolo, 6912 Pazzallo",,Lugano,,' ' ,Switzerland,179903,,,
2454,decitabine,,8/4/2006,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,4/3/2015,Not FDA Approved for Orphan Indication,,,,,Otsuka Pharmaceutical Development &,"Commercialization, Inc.",508 Carnegie Center Drive,Princeton,New Jersey,' 08540 ' ,United States,227106,acute myeloid leukemia,"""gard:0012757""",
2455,decitabine,,9/9/2002,treatment of sickle cell anemia,Designated/Designation Withdrawn or Revoked,4/3/2015,Not FDA Approved for Orphan Indication,,,,,Otsuka Pharmaceutical Development &,"Commercialization, Inc.",508 Carnegie Center Drive,Princeton,New Jersey,' 08540 ' ,United States,159702,sickle cell anemia,"""gard:0008614""",
2456,decitabine,,3/8/1999,treatment of chronic myelogenous leukemia.,Designated/Designation Withdrawn or Revoked,4/3/2015,Not FDA Approved for Orphan Indication,,,,,Otsuka Pharmaceutical Development &,"Commercialization, Inc.",508 Carnegie Center Drive,Princeton,New Jersey,' 08540 ' ,United States,123399,,,
2457,decitabine,Dacogen,3/8/1999,treatment of myelodysplastic syndromes.,Designated/Approved,,,"for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups",5/2/2006,5/2/2013,,Otsuka Pharmaceutical Development,"and Commercialization, Inc.",508 Carnegie Center Drive,Princeton,New Jersey,' 08540 ' ,United States,122298,myelodysplastic syndrome,"""gard:0007132""",
2458,decitabine and tetrahydrouridine,,9/19/2016,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Novo Nordisk Inc.,800 Scudders Mill Rd.,P.O. Box 846,Plainsboro,New Jersey,' 08536 ' ,United States,537716,,,
2459,defactinib,,2/12/2015,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Verastem, Inc.",117 Kendrick Street,Suite 500,Needham,Massachusetts,' 02494 ' ,United States,463514,ovarian cancer,"""gard:0007295""",
2460,deferasirox,Exjade; Jadenu Sprinkles,2/24/2015,treatment of chronic iron overload in alpha-thalassemia,Designated/Approved,,,Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and serum ferritin greater than 300 mcg/L.,1/23/2013,1/23/2020,Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and serum ferritin greater than 300 mcg/L.,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,354411,alpha-thalassemia,"""gard:0000621""",
2461,Deferasirox,Exjade; Jadenu Sprinkles,11/21/2002,treatment of chronic iron overload in patients with transfusion-dependent anemias,Designated/Approved,,,Treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age or older,11/2/2005,11/2/2012,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Hampshire,' 07936 ' ,United States,161002,,,
2462,Deferasirox,Exjade; Jadenu Sprinkles,11/21/2002,treatment of chronic iron overload in patients with transfusion-dependent anemias,Designated/Approved,,,treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older,5/18/2017,,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Hampshire,' 07936 ' ,United States,161002,,,
2463,deferasirox,Exjade; Jadenu Sprinkles,2/24/2015,treatment of chronic iron overload in alpha-thalassemia,Designated/Approved,,,Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L.,5/18/2017,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,354411,alpha-thalassemia,"""gard:0000621""",
2464,deferiprone,Ferriprox,12/12/2001,treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy,Designated/Approved,,,treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes; and treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with sickle cell disease or other anemias,4/30/2021,4/30/2028,"treatment of transfusional iron overload in adult patients with thalassemia syndromes excluding adult patients covered by the indication for thalassemia syndromes approved on October 14, 2011; treatment of transfusional iron overload in pediatric patients 8 years of age and older with thalassemia syndromes; and treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with sickle cell disease or other anemias","Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,' 27518 ' ,United States,150701,,,
2465,deferiprone,Ferriprox,12/12/2001,treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy,Designated/Approved,,,Ferriprox (deferiprone) is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate.,5/19/2020,,,"Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,' 27518 ' ,United States,150701,,,
2466,deferiprone,Ferriprox,12/12/2001,treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy,Designated/Approved,,,treatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with thalassemia syndromes; and treatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with sickle cell disease or other anemias,4/30/2021,4/30/2028,"treatment of transfusional iron overload in adult patients with thalassemia syndromes excluding adult patients covered by the indication for thalassemia syndromes approved on October 14, 2011; treatment of transfusional iron overload in pediatric patients 3 years of age and older with thalassemia syndromes; and treatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with sickle cell disease or other anemias","Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,' 27518 ' ,United States,150701,,,
2467,deferiprone,,9/1/2011,treatment of superficial siderosis,Designated/Designation Withdrawn or Revoked,2/9/2022,Not FDA Approved for Orphan Indication,,,,,"Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,' 27518 ' ,United States,340011,superficial siderosis,"""gard:0009484""",
2468,deferiprone,Ferriprox,12/12/2001,treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy,Designated/Approved,,,Treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate,10/14/2011,10/14/2018,,"Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,' 27518 ' ,United States,150701,,,
2469,deferiprone,,6/15/2017,treatment of neurodegeneration with brain iron accumulation (nbia),Designated/Designation Withdrawn or Revoked,1/18/2022,Not FDA Approved for Orphan Indication,,,,,"Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,' 27518 ' ,United States,581217,neurodegeneration with brain iron accumulation,"""gard:0011899""",
2470,deferiprone,,7/31/2008,treatment of friedreich's ataxia,Designated/Designation Withdrawn or Revoked,2/9/2022,Not FDA Approved for Orphan Indication,,,,,"Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,' 27518 ' ,United States,264308,,,
2471,Deferitrin,,4/14/2004,treatment of iron overload,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,153 Second Avenue,,Waltham,Massachusetts,' 02451 ' ,United States,178603,,,
2472,deferoxamine,,3/15/2019,treatment of sickle cell leg ulcers,Designated,,Not FDA Approved for Orphan Indication,,,,,Theris Medical,604 Fifth Avenue,Suite D,Redwood City,California,' 94063 ' ,United States,633618,,,
2473,deferoxamine starch conjugate,,12/21/1998,treatment of chronic iron overload resulting from conventional transfusional treatment of beta-thalassemia major and sickle cell anemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biomedical Frontiers, Inc.","108710th Ave., S.E.",,Minneapolis,Minnesota,' 55414 ' ,United States,117698,beta-thalassemia major,"""gard:0017162""",
2474,deferoxamine starch conjugate,,1/28/2005,treatment of acute iron poisoning,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biomedical Frontiers, Inc.","1087 10th Avenue, SE",,Minneapolis,Minnesota,' 55414 ' ,United States,197704,,,
2475,defibrotide,,5/14/2020,prevention of acute graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Jazz Pharmaceuticals Ireland Limited,5th Floor Waterloo Exchange,Waterloo Road,Dublin,,' ' ,Ireland,738720,graft versus host disease,"""gard:0016642""",
2476,Defibrotide,,7/5/1985,treatment of thrombotic thrombocytopenic purpura.,Designated,,Not FDA Approved for Orphan Indication,,,,,Crinos International,Via Belvedere 1,,"Villa Guardia, Italy",,' 22079 ' ,United States,7285,thrombotic thrombocytopenic purpura,"""gard:0016659""",
2477,defibrotide,Defitelio,5/21/2003,for the treatment of hepatic veno-occlusive disease,Designated/Approved,,,"For the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).",3/30/2016,3/30/2023,"For the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT).","Jazz Pharmaceuticals, Inc.",3180 Porter Drive,,Palo Alto,California,' 94304 ' ,United States,168803,hepatic veno-occlusive disease,"""gard:0013004""",
2478,defibrotide,,1/8/2007,for the prevention of hepatic veno-occlusive disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jazz Pharmaceuticals, Inc.",3180 Porter Drive,,Palo Alto,California,' 94304 ' ,United States,228406,hepatic veno-occlusive disease,"""gard:0013004""",
2479,deflazacort,,9/16/2010,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,University of Rochester Medical Center,1351 Mt. Hope Avenue,Suite 203,Rochester,New York,' 14620 ' ,United States,315110,muscular dystrophy,"""gard:0007922""",
2480,deflazacort,,10/22/2015,treatment of pediatric (0 through 16 years of age) juvenile idiopathis arthritis (jia) international league of associations for rheumatology (ilar) categories excluding systemic jia.,Designated/Designation Withdrawn or Revoked,11/22/2019,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,' 07080 ' ,United States,491715,,,
2481,deflazacort,Emflaza,8/16/2013,treatment of duchenne muscular dystrophy,Designated/Approved,,,Treatment of Duchenne Muscular Dystrophy in patients 5 years of age and older,2/9/2017,2/9/2024,Treatment of Duchenne Muscular Dystrophy in patients 5 years of age and older,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,' 07080 ' ,United States,403413,muscular dystrophy,"""gard:0007922""",
2482,deflazacort,Emflaza,8/16/2013,treatment of duchenne muscular dystrophy,Designated/Approved,,,EMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.,6/7/2019,6/7/2026,For the treatment of Duchene muscular dystrophy in patients 2 years of age to less than 5 years of age,"PTC Therapeutics, Inc.",100 Corporate Court,,South Plainfield,New Jersey,' 07080 ' ,United States,403413,muscular dystrophy,"""gard:0007922""",
2483,Degrader of Lysine-specific histone demethylase 1A and REST Corepressor 1,,1/25/2023,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Beactica Therapeutics AB,Virdings allé 2,,Uppsala,,' 754 50 ' ,Sweden,920922,glioblastoma,"""gard:0002491""",
2484,dehydrated alcohol,,3/16/2012,treatment of trigeminal neuralgia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",One Luitpold Drive,P. O. Box 9001,Shirley,New York,' 11967 ' ,United States,361611,trigeminal neuralgia,"""gard:0007805""",
2485,Dehydrated alcohol,,7/10/2020,treatment of methanol poisoning,Designated,,Not FDA Approved for Orphan Indication,,,,,Eton Pharmaceuticals,21925 W. Field Pkwy,Suite 235,Deer Park,Illinois,' 60010 ' ,United States,746720,methanol poisoning,"""gard:0018804""",
2486,dehydrated alcohol,Ablysinol,9/11/2013,treatment of hypertrophic obstructive cardiomyopathy,Designated/Approved,,,ABLYSINOL® is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy.,6/21/2018,6/21/2025,ABLYSINOL® is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy.,"Belcher Pharmaceuticals, LLC",6911 Bryan Dairy Road,,Largo,Florida,' 33777 ' ,United States,402513,,,
2487,Dehydroepiandrosterone,,7/13/1994,treatment of systemic lupus erythematosus (sle) and the reduction in the use of steroids in steroid-dependent sle patients.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline,P. O. Box 13398,Five Moore Drive,Research Triangle Park,North Carolina,' 27709 ' ,United States,83794,systemic lupus erythematosus,"""gard:0018695""",
2488,Dehydroepiandrosterone (DHEA),,8/19/2003,replacement therapy in individuals with adrenal insufficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Paladin Labs, Inc.","6111 Royalmount Avenue, Suite 102",,Montreal,,' ' ,Canada,172303,,,
2489,Dehydroepiandrosterone sulfate sodium,,1/29/1997,treatment of serious burns requiring hospitalization.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pharmadigm, Inc.",2401 Foothill Drive,,Salt Lake City,Utah,' 84109 ' ,United States,102196,,,
2490,Dehydroepiandrosterone sulfate sodium,,1/28/1997,to accelerate the re-epithelialization of donor sites in those hospitalized burn patients who must undergo autologous skin grafting.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pharmadigm, Inc.",2401 Foothill Drive,,Salt Lake City,Utah,' 84109 ' ,United States,101996,,,
2491,delandistrogene moxeparvovec-rokl,Elevidys,6/21/2018,treatment of duchenne muscular dystrophy,Designated/Approved,,,treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene,6/22/2023,6/22/2030,treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene,"Sarepta Therapeutics, Inc.",215 First Street,,Cambridge,Massachusetts,' 02142 ' ,United States,641318,muscular dystrophy,"""gard:0007922""",
2492,delta-9-tetrahydrocannabinol,,11/27/2019,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Tetra Bio-Pharma Inc.,365 St.-Jean Street,Suite 122,Longueuil,,' ' ,Canada,652218,hepatocellular carcinoma,"""gard:0016773""",
2493,delta-9-tetrahydrocannabinol and cannabidiol,,4/14/2020,treatment of epidermolysis bullosa,Designated,,Not FDA Approved for Orphan Indication,,,,,Tetra Bio-Pharma Inc.,365 St.-Jean Street,Suite 122,Longueuil,,' ' ,Canada,734820,,,
2494,delta-9-tetrahydrocannabinol and cannabidiol,,1/29/2019,treatment of huntington's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,MMJ International Holdings,1895 Preston White Drive,Suite 101,Reston,Virginia,' 20191 ' ,United States,668918,,,
2495,delta-9-tetrahydrocannabinol and cannabidiol,,3/7/2018,treatment of complex regional pain syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,PhytoPain Pharma Inc.,9315-4466 Quebec Inc,1230 Boise Street,Boucherville,,' ' ,Canada,549616,complex regional pain syndrome,"""gard:0004647""",
2496,delta-9-tetrahydrocannibinol and cannabidiol,,12/3/2015,treatment of glioma.,Designated,,Not FDA Approved for Orphan Indication,,,,,GW Research Ltd.,Sovereign House,Histon,Cambridge,,' ' ,United Kingdom,498215,,,
2497,demcizumab,,4/30/2014,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,7/31/2017,Not FDA Approved for Orphan Indication,,,,,"OncoMed Pharmaceuticals, Inc.",800 Chesapeake Drive,,Redwood City,California,' 94063 ' ,United States,427314,,,
2498,Denatonium acetate monohydrate,,6/8/2023,treatment of prader willi syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aardvark Therapeutics, Inc.","4747 Executive Drive, Suite 1020",,San Diego,California,' 92121 ' ,United States,942123,,,
2499,Dendritic cell/tumor cell fusion vaccine + recombinant human interleukin 12,,1/25/2017,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,CyTIX Inc.,"7F Terada Bldg, 2-3-3 Shibakoen",,Minato-ku,Tokyo,' ' ,Japan,552316,,,
2500,"dendritic cells pulsed with synthetic peptides derived from antigens MAGE1, HER-2, AIM-2,TRP-2, gp100 and interleukin-13 receptor alpha",,6/7/2010,treatment of glioblastoma or brain stem glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,ImmunoCellular Therapeutics Ltd.,21900 Burbank Blvd,,Woodland Hills,California,' 91367 ' ,United States,308010,glioblastoma,"""gard:0002491""",
2501,dendritic hybrid cell vaccine,,9/23/2011,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Orbis Health Solutions, LLC",111 Smith Hines Road,Suite E & F,Greenville,South Carolina,' 29607 ' ,United States,351011,neuroblastoma,"""gard:0007185""",
2502,"dendritic-cell targeting, lentiviral vector encoding the NY-ESO-1 gene",,1/6/2016,treatment of soft tissue sarcoma.,Designated/Designation Withdrawn or Revoked,8/13/2019,Not FDA Approved for Orphan Indication,,,,,Immune Design Corp.,1616 Eastlake Ave. E,Suite 310,Seattle,Washington,' 98102 ' ,United States,497915,soft tissue sarcoma,"""gard:0004898""",
2503,denileukin diftitox,,7/12/2013,treatment of cutaneous t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Citius Pharmaceuticals, Inc.","11 Commerce Drive, 1st Floor",,Cranford,New Jersey,' 07016 ' ,United States,341311,lymphoma,"""gard:0020548""",
2504,denileukin diftitox,,6/29/2011,treatment of peripheral t-cell lymphoma (ptcl),Designated,,Not FDA Approved for Orphan Indication,,,,,"Citius Pharmaceuticals, Inc.","11 Commerce Drive, 1st Floor",,Cranford,New Jersey,' 07016 ' ,United States,342611,lymphoma,"""gard:0020548""",
2505,denileukin diftitox,,4/30/2010,treatment of peripheral t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.",300 Tice Boulevard,,Woodcliff Lake,New Jersey,' 07677 ' ,United States,302010,lymphoma,"""gard:0020548""",
2506,denileukin diftitox,Ontak,8/21/1996,treatment of patients with cutaneous t-cell lymphoma,Designated/Approved,,,Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.,2/5/1999,2/5/2006,,"Eisai, Inc.",300 Tice Boulevard,,Woodcliff Lake,New Jersey,' 07677 ' ,United States,99396,lymphoma,"""gard:0020548""",
2507,denosumab,XGEVA,9/11/2013,treatment of hypercalcemia in malignancy,Designated/Approved,,,To treat hypercalcemia of malignancy refractory to biphosphonate therapy.,12/5/2014,12/5/2021,To treat hypercalcemia of malignancy refractory to biphosphonate therapy.,"Amgen, Inc.",One Amgen Center Drive,MS 17-2-C,Thousand Oaks,California,' 91320 ' ,United States,404213,,,
2508,denosumab,Xgeva,12/20/2010,treatment of patients with giant cell tumor of bone,Designated/Approved,,,Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.,6/13/2013,6/13/2020,Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,' 91320 ' ,United States,324110,giant cell tumor of bone,"""gard:0013046""",
2509,denosumab,,2/2/2021,treatment of osteogenesis imperfecta,Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop: 27-2-D,Thousand Oaks,California,' 91320-1799 ' ,United States,798920,osteogenesis imperfecta,"""gard:0001017""",
2510,deoxynucleogen,,9/10/2019,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"CLS Therapeutics, Inc",101 6th Ave,,New York,New York,' 10013 ' ,United States,699519,,,
2511,deoxythymidine monophosphate and deoxycytidine monophosphate,,7/7/2016,treatment of thymidine kinase 2 deficiency.,Designated,,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.","1950 Lake Park Drive, Bldg 2100",,Smyrna,Georgia,' 30080 ' ,United States,532716,,,
2512,"Derivative of 6-[2-(pyridin-2-yl)phenoxy]methyl}-1,2,3,4-tetrahydroisoquinoline",,3/9/2024,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,,Ridgefield,Connecticut,' 06877 ' ,United States,990923,systemic sclerosis,"""gard:0009748""",
2513,Dermagraft,,12/13/2010,treatment of epidermolysis bullosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shire Regenerative Medicine, Inc.",11095 Torreyana Road,subsidiary of Shire Pharmaceuticals.,San Diego,California,' 92121 ' ,United States,327010,,,
2514,Deslorelin,,11/5/1987,treatment of central precocious puberty.,Designated,,Not FDA Approved for Orphan Indication,,,,,Roberts Pharmaceutical Corp.,Meridian Center II,Four Industrial Way West,Eatontown,New Jersey,' 07724 ' ,United States,16086,central precocious puberty,"""gard:0016546""",
2515,Desmoglein 3 synthetic peptide (PI-0824),,10/26/2004,treatment of pemphigus vulgaris,Designated,,Not FDA Approved for Orphan Indication,,,,,"Peptimmune, Inc.",64 Sidney Street,,Cambridge,Massachusetts,' 02139 ' ,United States,190904,pemphigus vulgaris,"""gard:0007355""",
2516,Desmopressin acetate,,1/22/1991,treatment of mild hemophilia a and von willebrand's disease.,Designated/Approved,,,Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%.,3/7/1994,3/7/2001,,"Ferring Pharmaceuticals, Inc.",100 Interpace Parkway,,Parsippany-Troy Hills,New Jersey,' 07054 ' ,United States,51490,mild hemophilia a,"""gard:0017061""",
2517,deuterated S-lisofylline,,6/18/2018,treatment of necrobiosis lipoidica,Designated,,Not FDA Approved for Orphan Indication,,,,,Processa Pharmaceuticals Inc,7380 Coca Cola Drive,Suite 106,Hanover,Maryland,' 21076 ' ,United States,640918,necrobiosis lipoidica,"""gard:0013040""",
2518,deutetrabenazine,,1/13/2015,treatment of tourette syndrome in the pediatric population (defined as 0 through 16 years of age),Designated,,Not FDA Approved for Orphan Indication,,,,,TEVA Pharmaceuticals,3366 North Torrey Pines Court,Suite 225,LaJolla,California,' 92037 ' ,United States,442314,,,
2519,devimistat,,6/24/2021,treatment of liver and intrahepatic bile duct cancer (also known as biliary tract cancer; cholangiocarcinomas of the bile duct and the gall bladder),Designated,,Not FDA Approved for Orphan Indication,,,,,"Cornerstone Pharmaceuticals, Inc.",1 Duncan Drive,,Cranbury,New Jersey,' 08512 ' ,United States,808021,cholangiocarcinoma,"""gard:0009304""",
2520,Devimistat,,10/26/2020,treatment of relapsed or refractory clear cell sarcoma of the soft tissues.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cornerstone Pharmaceuticals, Inc.",1 Duncan Drive,,Cranbury,New Jersey,' 08512 ' ,United States,777920,,,
2521,devimistat,,2/28/2018,treatment of peripheral t-cell lymphoma (ptcl),Designated,,Not FDA Approved for Orphan Indication,,,,,"Cornerstone Pharmaceuticals, Inc.",9 Deerpark Drive,Suite J-5,"Monmouth Jct.,",New Jersey,' 08852 ' ,United States,623117,lymphoma,"""gard:0020548""",
2522,dexamethasone,,3/26/2018,treatment of multiple myeloma (mm),Designated/Approved,,,HEMADY is indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma,10/3/2019,10/3/2026,Indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma (MM).,Dexcel Pharma Technologies Ltd,Dexcel Street,,Or Akiva,Haifa District,' ' ,Israel,626318,multiple myeloma,"""gard:0007108""",
2523,dexamethasone,,2/26/2019,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Fera Pharmaceuticals,134 Birch Hill Road,,Locust Valley,New York,' 11560 ' ,United States,674718,multiple myeloma,"""gard:0007108""",
2524,dexamethasone,,1/26/2021,prevention of proliferative vitreoretinopathy (pvr),Designated,,Not FDA Approved for Orphan Indication,,,,,"TherOptix, Inc.","689 Main Street, #305",,Walpole,Massachusetts,' 02081 ' ,United States,795620,vitreoretinopathy,"""gard:0019539""",
2525,dexamethasone intravitreal implant,Ozurdex,9/11/1998,"treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis",Designated/Approved,,,For treatment of non-infectious uveitis affecting the posterior segment of the eye,9/24/2010,9/24/2017,,Allergan,2525 Dupont Drive,,Irvine,California,' 92623 ' ,United States,115298,uveitis,"""gard:0019549""",
2526,dexamethasone phosphate,,12/2/2008,treatment of corneal graft rejection.,Designated,,Not FDA Approved for Orphan Indication,,,,,"EyeGate Pharmaceuticals, Inc.",100 Beaver Street,,Waltham,Massachusetts,' 02453 ' ,United States,270608,,,
2527,dexamethasone sodium phosphate encapsulated in autologous erythrocytes,,7/24/2012,treatment of ataxia-telangiectasia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Quince Therapeutics, S.p.A.","Via Meucci, 3",,Bresso,MI,' 20091 ' ,Italy,373212,ataxia-telangiectasia,"""gard:0005862""",
2528,dexanabinol,,8/11/2004,for the attenuation or amelioration of the long-term neurological sequelae associated with moderate and severe traumatic brain injury,Designated,,Not FDA Approved for Orphan Indication,,,,,Pharmos Corporation,99 Wood Avenue,Suite 311,Iselin,New Jersey,' 08830 ' ,United States,179803,moderate and severe traumatic brain injury,"""gard:0019108""",
2529,dexpramipexole,,10/11/2007,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Knopp Biosciences LLC,2100 Wharton Street,Suite 615,Pittsburgh,Pennsylvania,' 15203 ' ,United States,247107,amyotrophic lateral sclerosis,"""gard:0005786""",
2530,Dexpramipexole,,4/22/2019,treatment of hypereosinophilic syndrome (hes),Designated,,Not FDA Approved for Orphan Indication,,,,,Areteia Therapeutics,"1200 Morris Turnpike, Suite 3005",,Short Hills,New Jersey,' 07078 ' ,United States,681319,c syndrome,"""gard:0005978""",
2531,dexrazoxane,Totect(r),3/25/2004,treatment of anthracycline extravasation during chemotherapy,Designated/Approved,,,Treatment of extravasation resulting from IV anthracycline chemotherapy,9/6/2007,9/6/2014,,"Clinigen, Inc.",790 Township Line Road,Suite 120,Yardley,Pennsylvania,' 19067 ' ,United States,181103,,,
2532,Dexrazoxane,Zinecard,12/17/1991,for the prevention of cardiomyopathy associated with doxorubicin administration.,Designated/Approved,,,Cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative dose of 300mg/m2.,5/26/1995,5/26/2002,,Pharmacia & Upjohn,7000 Portage Road,,Kalamazoo,Michigan,' 49001 ' ,United States,63291,,,
2533,dexrazoxane hydrochloride,,8/19/2014,prevention of cardiomyopathy for chilren and adolescents 0 through 16 years of age treated with anthracyclines,Designated,,Not FDA Approved for Orphan Indication,,,,,"Satiscor, LLC",45 Marine Road,,Boston,Massachusetts,' 02127 ' ,United States,441314,,,
2534,dextran 1,,3/21/2003,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,BCY LifeSciences Inc.,160 Eglinton Ave. East,Suite 600,Toronto,,' ' ,Canada,157602,cystic fibrosis,"""gard:0006233""",
2535,Dextran 70,,3/5/1990,treatment of recurrent corneal erosion unresponsive to conventional therapy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Holles Laboratories, Inc.",30 Forest Notch,,Cohasset,Massachusetts,' 02025 ' ,United States,42689,,,
2536,Dextran and deferoxamine,,3/8/1991,treatment of acute iron poisoning.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biomedical Frontiers, Inc.",1095 10th Avenue S.E.,,Minneapolis,Minnesota,' 55414 ' ,United States,52290,,,
2537,"Dextran sulfate (inhaled, aerosolized)",,10/5/1990,for use as an adjunct to the treatment of cystic fibrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kennedy & Hoidal, M.D.'s",University Of Utah Medical Center,"50 North Medical Drive, Room 4R240",Salt Lake City,Utah,' 84132 ' ,United States,50690,cystic fibrosis,"""gard:0006233""",
2538,Dextran sulfate sodium,,11/19/1987,treatment of aquired immunodeficiency syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ueno Fine Chemicals Industry, Ltd.","2-31 Koraibashi, Higashi-ku",,Osaka 541,,' ' ,Japan,23187,,,
2539,"Dextran-coated, nanoparticle-conjugated stabilized synthetic antisense oligonucleotide targeting miR-10b",,2/27/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"TransCode Therapeutics, Inc.",6 Liberty Square #2382,,Boston,Massachusetts,' 02109 ' ,United States,926622,,,
2540,dextromethadone hydrochloride,,9/13/2021,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Relmada Therapeutics, Inc.",880 Third Avenue,12th Floor,New York,New York,' 10022 ' ,United States,836721,amyotrophic lateral sclerosis,"""gard:0005786""",
2541,dextromethorphan hydrobromide/quinidine sulfate,,2/14/2017,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,Avanir Pharmaceuticals,30 Enterprise,Suite 400,Aliso Viejo,California,' 92656 ' ,United States,556716,amyotrophic lateral sclerosis,"""gard:0005786""",
2542,DHA-paclitaxel,,10/10/2002,treatment of metastatic malignant melanoma,Designated/Designation Withdrawn or Revoked,8/27/2015,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",1000 Madison Ave,,Norristown,Pennsylvania,' 19403 ' ,United States,153001,noma,"""gard:0004001""",
2543,DHA-paclitaxel,,9/25/2001,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,8/27/2015,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",One Luitpold Drive,,Shirley,New York,' 11976 ' ,United States,147801,,,
2544,DHA-paclitaxel,,5/1/2003,treatment of adenocarcinoma of the stomach or lower esophagus,Designated/Designation Withdrawn or Revoked,8/26/2015,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",1000 Madison Ave,,Norristown,Pennsylvania,' 19403 ' ,United States,153301,noma,"""gard:0004001""",
2545,di-deuterated linoleic acid,,1/28/2020,treatment of progressive supranuclear palsy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Retrotope, Inc.",4300 El Camino Real,Suite 201,Los Altos,California,' 94022 ' ,United States,721019,progressive supranuclear palsy,"""gard:0007471""",
2546,diacerein,,10/15/2014,treatment of epidermolysis bullosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"TWi Biotechnology, Inc.","8F, No.41, Lane 221, Kang Chien Rd.",Nei Hu Dist,Taipei,,' ' ,Taiwan,448614,,,
2547,Diacerein,,11/2/2018,treatment of epidermolysis bullosa,Designated,,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,' ' ,Italy,660318,,,
2548,diacetyl(N(4)-methylthiosemicarbazonato) copper (II),,12/18/2017,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,Collaborative Medicinal Development Pty. Ltd. (CMD),c/o Shaw Downie,Level 11,Sydney,New South Wales,' ' ,Australia,611117,amyotrophic lateral sclerosis,"""gard:0005786""",
2549,Dianeal peritoneal dialysis solution with 1.1% amino acids,,6/11/1992,for use as a nutritional supplement for the treatment of malnourishment in patients undergoing continuous ambulatory peritoneal dialysis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Baxter Healthcare Corporation,1620 Waukegan Road,,McGaw Park,Illinois,' 60085 ' ,United States,64191,,,
2550,diannexin,,10/28/2009,prevention of ischemia-reperfusion injury in solid organ transplants,Designated,,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.",Three Parkway North,,Deerfield,Illinois,' 60015 ' ,United States,294109,,,
2551,diazepam,Libervant,11/10/2016,"treatment of selected, refractory patients with epilepsy who are on stable regimens of antiepileptic drugs (aed) and who require intermittent use of diazepam to control bouts of increased seizure activity (acute repetitive seizures)",Designated/Approved,,,"acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient¿s usual seizure pattern in patients with epilepsy 2 to 5 years of age",4/26/2024,,,Aquestive Therapeutics,30 Technology Drive South,,Warren,New Jersey,' 07059 ' ,United States,543516,,,
2552,diazepam,,5/23/2018,treatment of dravet syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Xeris Pharmaceutical, Inc.","1375 West Fulton Street, Suite 1300",,Chicago,Illinois,' 60607 ' ,United States,638118,dravet syndrome,"""gard:0010430""",
2553,diazepam (intranasal),,7/31/2012,management of patients with acute repetitive seizures,Designated,,Not FDA Approved for Orphan Indication,,,,,SK Life Sciences Inc.,22-10 New Jersey 208,,Fair Lawn,New Jersey,' 07410 ' ,United States,334911,,,
2554,diazepam (intranasal),VALTOCO,11/16/2015,management of acute repetitive seizures,Designated/Approved,,,"Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient¿s usual seizure pattern in patients with epilepsy 6 years of age and older.",1/10/2020,1/10/2027,"Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient¿s usual seizure pattern in patients with epilepsy 6 years of age and older.","Neurelis Pharmaceuticals, Inc.",11682 El Camino Reall,Suite 255,San Diego,California,' 92130 ' ,United States,382512,,,
2555,diazepam auto-injector,,5/30/2013,"management of selected, refractory patients with epilepsy on stable regimens of antiepileptic drugs, who require intermittent use of diazepam to control bouts of increased seizure activity",Designated,,Not FDA Approved for Orphan Indication,,,,,"Meridian Medical Technologies, Inc.","6350 Stevens Forest Rd, Suite 301",,Columbia,Maryland,' 21046 ' ,United States,384112,,,
2556,diazepam subcutaneous injection,,5/26/2016,treatment of acute repetitive seizures.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Xeris Pharmaceuticals, Inc.","1375 West Fulton Street, Suite 1300",,Chicago,Illinois,' 60607 ' ,United States,518316,,,
2557,Diazepam viscous solution for rectal administration,Diastat,2/25/1992,"for the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (aeds), who require intermittent use of diazepam to control bouts of increased seizure activity.",Designated/Approved,,,,7/29/1997,7/29/2004,,Valeant Pharmaceuticals,3300 Hyland Avenue,,Costa Mesa,California,' 92626 ' ,United States,61591,,,
2558,Diaziquone,,11/10/1983,treatment of primary brain malignancies (grade iii and iv astrocytomas).,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Warner-Lambert Company,"2800 Plymouth Rd., P.O. Box 1047",,Ann Arbor,Michigan,' 48106 ' ,United States,383,astrocytoma,"""gard:0012928""",
2559,diazoxide,,12/3/2012,treatment of prader willi syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sedogen, LLC",1701 East Lake Avenue,Suite260,Glenview,Illinois,' 60025 ' ,United States,383712,,,
2560,Diazoxide choline,,5/26/2021,treatment of glycogen storage disease type 1,Designated,,Not FDA Approved for Orphan Indication,,,,,"Soleno Therapeutics, Inc.",203 Redwood Shores Parkway,Suite 500,Redwood City,California,' 94065 ' ,United States,818621,glycogen storage disease,"""gard:0018973""",
2561,diazoxide choline,,5/13/2014,treatment of prader-willi syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Soleno Therapeutics, Inc.",1235 Radio Road,Suite 110,Redwood City,California,' 94065 ' ,United States,428214,prader-willi syndrome,"""gard:0005575""",
2562,dichlorphenamide,,9/2/2010,treatment of primary periodic paralyses,Designated/Approved,,,"Treatment of primary hyperkalemic periodic paralysis, primary hypokalemic period paralysis, and related variants",8/7/2015,8/7/2022,"Treatment of primary hyperkalemic periodic paralysis, primary hypokalemic period paralysis, and related variants","Xeris Pharmaceuticals, Inc.","180 N La Salle Street, Suite 1600",,Chicago,Illinois,' 60601 ' ,United States,314210,,,
2563,Dideoxyinosine,,6/22/1988,treatment of acquired immunodeficiency syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb,2400 West Lloyd Expressway,,Evansville,Indiana,' 47721 ' ,United States,29488,acquired immunodeficiency,"""gard:0021359""",
2564,Diethyldithiocarbamate,,4/3/1986,treatment of aids.,Designated,,Not FDA Approved for Orphan Indication,,,,,Connaught Laboratories,"Route 611, P.O. Box 187",,Swiftwater,Pennsylvania,' 18370 ' ,United States,13286,,,
2565,diethylenetriaminepentaacetate (DPTA),,4/14/2004,"for treatment of patients with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination.",Designated,,Not FDA Approved for Orphan Indication,,,,,CIS-US,10 DeAngelo Drive,,Bedford,Massachusetts,' 01730 ' ,United States,180203,,,
2566,Diethylenetriaminepentaacetic acid (DTPA),,4/28/2004,"treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination.",Designated/Approved,,,"Treatment of internal contamination with plutonium, americium or curium",8/11/2004,8/11/2011,,Hameln Pharmaceuticals gmbh,Langes Feld 13,,Hameln,,' ' ,Germany,186804,,,
2567,Diethylnorspermine (DENSPM),,5/25/2004,treatment for hepatocellular carcinoma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,153 Second Avenue,,Waltham,Massachusetts,' 02451 ' ,United States,182803,hepatocellular carcinoma,"""gard:0016773""",
2568,diferuloylmethane,,6/13/2003,treatment of cystic fibrosis,Designated/Designation Withdrawn or Revoked,1/19/2018,Not FDA Approved for Orphan Indication,,,,,"Allertein Therapeutics, LLC",640 Sasco Hill Road,,Fairfield,Connecticut,' 06824 ' ,United States,167603,cystic fibrosis,"""gard:0006233""",
2569,difluprednate,Durezol,9/30/2008,treatment of endogenous and traumatic anterior uveitis and panuveitis.,Designated/Approved,,,Treatment of endogenous anterior uveitis,6/13/2012,6/13/2019,,Alcon Pharmaceuticals. Ltd.,Route Des Arsenaux 41,(P.O. Box 61),Fribourg,,' ' ,Switzerland,265608,uveitis,"""gard:0019549""",
2570,digitoxin,,10/18/2001,treatment of soft tissue sarcomas,Designated,,Not FDA Approved for Orphan Indication,,,,,SimRx Advisors LLC,247 West 87th Street,Suite 7G,New York,New York,' 10024 ' ,United States,149701,soft tissue sarcoma,"""gard:0004898""",
2571,digitoxin,,11/2/2001,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,SimRx Advisors LLC,247 West 87th Street,Suite 7G,New York,New York,' 10024 ' ,United States,149601,ovarian cancer,"""gard:0007295""",
2572,digitoxin,,5/27/2005,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Silver Pharmaceuticals,350 Seven Locks Road,Suite 211,Rockville,Maryland,' 20854 ' ,United States,205005,cystic fibrosis,"""gard:0006233""",
2573,digoxin immune fab (ovine),,2/3/2012,treatment of severe preeclampsia and eclampsia,Designated,,Not FDA Approved for Orphan Indication,,,,,"AMAG Pharmaceuticals, Inc.",1100 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,343911,preeclampsia,"""gard:0012924""",
2574,Digoxin immune FAB (Ovine),Digibind,11/1/1984,treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.,Designated/Approved,,,,4/22/1986,4/22/1993,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,' 27709 ' ,United States,2584,,,
2575,Digoxin immune fab(ovine),,3/11/1985,"treatment of life-threatening acute cardiac glycoside intoxication manifested by conduction disorders, ectopic ventricular activity and (in some cases) hyperkalemia.",Designated,,Not FDA Approved for Orphan Indication,,,,,Boehringer Mannheim Corp.,1301 Piccard Drive,,Rockville,Maryland,' 20850 ' ,United States,5685,,,
2576,dihydroartemisinin and piperaquine,,1/8/2007,"treatment of uncomplicated malaria caused by ""plasmodium falciparum,"" plasmodium vivax,"" plasmodium malariae,"" or ""plasmodium ovale.""",Designated,,Not FDA Approved for Orphan Indication,,,,,Alfasigma S.p.A,223 Viale Sarca,,Milano,Lombardia,' ' ,Italy,234006,malaria,"""gard:0006961""",
2577,Dihydrotestosterone,,2/5/1996,treatment of weight loss in aids patients with hiv-associated wasting.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Besins Internaitonal, US Inc.",610 Herndon Parkway,Suite 750,Herndon,Virginia,' 20170 ' ,United States,93995,,,
2578,Dihydrotestosterone Gel,,7/9/2020,treatment of micropenis,Designated,,Not FDA Approved for Orphan Indication,,,,,Besins Healthcare Ireland Ltd.,16 Pembroke Street Upper,DO2HE63,Dublin 2,,' ' ,Ireland,747120,,,
2579,dihydroxyphenylalanine F 18/Fluorodopa (F18),,1/22/2018,diagnostic for the management of congenital hyperinsulinism,Designated,,Not FDA Approved for Orphan Indication,,,,,Society of Nuclear Medicine and Molecular Imaging,1850 Samuel Morse Drive,,Reston,Virginia,' 20190 ' ,United States,621017,,,
2580,Dilanubicel,,7/9/2018,reduction of morbidity and mortality associated with hematopoietic stem cell transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nohla Therapeutics, Inc.",1616 Fairview Avenue East,Suite 100,Seattle,Washington,' 98102 ' ,United States,642818,,,
2581,Dilanubicel,,2/26/2024,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Deverra Therapeutics,"1600 Fairview Avenue East, Suite 300",,Seattle,Washington,' 98102 ' ,United States,989823,acute myeloid leukemia,"""gard:0012757""",
2582,dimebon,,5/12/2009,treatment of huntington's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Medivation, Inc.",201 Spear Street,,San Francisco,California,' 94105 ' ,United States,282309,,,
2583,Dimerizing drug that binds to mutated Fas protein/drug-binding domain fusion protein (FKBP),,11/24/1999,treatment of acute graft-versus-host disease in patients undergoing bone marrow transplantation.,Designated/Designation Withdrawn or Revoked,10/24/2023,Not FDA Approved for Orphan Indication,,,,,"Bellicum Pharmaceuticals, Inc.",6400 Fannin Street,Suite 2300,Houston,Texas,' 77030 ' ,United States,126299,,,
2584,dimethyl fumarate,,9/11/2013,treatment of friedreich's ataxia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ixchel Pharma, LLC",608 12th Street,,Davis,California,' 95616 ' ,United States,406713,,,
2585,dimethyl sulfoxide,,5/9/2008,for use in combination with antimicrobial drugs for the treatment of drug resistant tuberculosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Abela Pharmaceuticals, Inc.",21581 Midcrest Drive,,Lake Forest,California,' 92630 ' ,United States,254707,tuberculosis,"""gard:0007827""",
2586,Dimethyl sulfoxide,,6/6/1986,treatment of cutaneous manifestations of scleroderma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Research Industries Corp.,,,,,' ' ,,14986,scleroderma,"""gard:0018705""",
2587,Dimethyl sulfoxide,,11/22/1994,"treatment of increased intracranial pressure in patients with severe, closed-head injury, also known as traumatic brain coma, for whom no other effective treatment is available.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Abela Pharmaceuticals, Inc.",21581 Midcrest Drive,,Lake Forest,California,' 92630 ' ,United States,81394,,,
2588,dimethylaminomicheliolide Fumarate,,11/3/2022,treatment of diffuse midline glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Accendatech AU Pty Ltd.,"Suite 2903, 201 Elizabeth Street",,Sydney,Sydney,' 2000 ' ,Australia,842721,,,
2589,Dimethylsulfoxide,,4/15/1997,topical treatment for the prevention of soft tissue injury following extravastion of cytotoxic drugs.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cancer Technologies, Inc.",7301 East 22nd Street,Suite 10E,Tucson,Alaska,' 85710 ' ,United States,104097,,,
2590,Dimethylsulfoxide,,4/6/1998,treatment of palmar-plantar erythrodysethesia syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cancer Technologies, Inc.",7301 East 22nd Street,Suite 10E,Tucson,Alaska,' 85710 ' ,United States,108697,,,
2591,dimethyltryptamine,,4/27/2021,prevention of ischemia-reperfusion injury in patients undergoing solid organ transplantation.,Designated,,Not FDA Approved for Orphan Indication,,,,,Sairiyo Therapeutics Inc.,"77 King Street West, Suite 2905",,Toronto,Ontario,' M5K 1H1 ' ,Canada,813521,,,
2592,dinaciclib,,8/25/2011,treatment of chronic lymphocytic leukemia.,Designated/Designation Withdrawn or Revoked,2/4/2022,Not FDA Approved for Orphan Indication,,,,,Merck Sharp & Dohme Ltd.,"Hertford Road, Hoddesdon",,Hertfordshire,,' ' ,United Kingdom,347211,,,
2593,dinutuximab,Unituxin,12/20/2010,treatment of neuroblastoma,Designated/Approved,,,"For use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy",3/10/2015,3/10/2022,"For use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy",United Therapeutics Corporation,55 TW Alexander Drive,,Research Triangle Park,North Carolina,' 27709 ' ,United States,324210,neuroblastoma,"""gard:0007185""",
2594,diosmin,,5/15/2018,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Primus Pharmaceuticals, Inc.",7373 North Scottsdale Road,Suite B-200,Scottsdale,Alaska,' 85253 ' ,United States,582417,systemic sclerosis,"""gard:0009748""",
2595,Dipalmitoylphosphatidylcholine /phosphatidylglycerol,,7/28/1988,prevention and treatment of neonatal respiratory distress syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Forum Products, Inc.",33 Flying Point Road,,Southampton,New York,' 11968 ' ,United States,29688,,,
2596,diphenylcyclopenone,,6/13/2003,treatment of chronic severe forms of alopecia areata (alopecia totalis [at]/alopecia universalis [au]),Designated,,Not FDA Approved for Orphan Indication,,,,,"Lloyd E. King, Jr.",1900 Patterson Street,Suite 104,Nashville,Tennessee,' 37203 ' ,United States,164502,alopecia,"""gard:0018995""",
2597,Diphenylcyclopropenone gel,,4/15/2015,treatment of malignant melanoma stage iib to iv,Designated,,Not FDA Approved for Orphan Indication,,,,,RXi Pharmaceuticals Corp.,257 Simarano Drive,Suite 101,Marlborough,Massachusetts,' 01752 ' ,United States,473615,noma,"""gard:0004001""",
2598,dipraglurant,,12/29/2015,treatment of levodopa-induced dyskinesias,Designated,,Not FDA Approved for Orphan Indication,,,,,Addex Pharma SA,Chemin des Aulx 14,1228 Plan-Les-Ouates,Geneva,,' ' ,Switzerland,485215,,,
2599,Disaccharide tripeptide glycerol dipalmitoyl,,3/1/1990,treatment of pulmonary and hepatic metastases in patients with colorectal adenocarcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"ImmunoTherapeutics, Inc.",3505 Riverview Circle,,Moorhead,Minnesota,' 56560 ' ,United States,39789,noma,"""gard:0004001""",
2600,disitamab vedotin,,9/10/2018,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Seagen Inc.,21823 30th Drive SE,,Bothell,Washington,' 98021 ' ,United States,649418,,,
2601,Disodium clodronate,,6/16/1993,treatment of hypercalcemia of malignancy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Discovery Experimental & Development, Inc.",29949 S.R. 54 West,,Wesley Chapel,Florida,' 33543 ' ,United States,72292,,,
2602,Disodium clodronate tetrahydrate,,3/5/1990,treatment of increased bone resorption due to malignancy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Anthra Pharmaceuticals, Inc.","103 Carnegie Center, Suite 102",,Princeton,New Jersey,' 08540 ' ,United States,40689,,,
2603,Disodium silibinin dihemisuccinate,,7/10/1986,treatment of hepatic intoxication by amanita phalloides (mushroom poisoning).,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Pharmaquest Corporation,4470 Redwood Highway,,San Rafael,California,' 94903 ' ,United States,15086,,,
2604,Disufenton sodium,,8/14/2020,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Oblato, Inc.",116 Village Boulevard,Suite 200,Princeton,New Jersey,' 08540 ' ,United States,757820,,,
2605,disufenton sodium,,8/22/2016,treatment of glioblastoma multiforme,Designated/Designation Withdrawn or Revoked,9/9/2020,Not FDA Approved for Orphan Indication,,,,,"Oblato, Inc.",116 Village Boulevard,,Princeton,New Jersey,' 08540 ' ,United States,531616,glioblastoma,"""gard:0002491""",
2606,"disulfide-stabilized single-chain variable region fragment of the anti-EGFR wild type/EGFRvIII dual specificity monoclonal antibody with variable fragments fused to a truncated version of the Pseudomonas exotoxin A, PE38, and KDEL",,9/19/2016,treatment of glioma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Darell D. Bigner, MD, PhD",Duke University Medical Center,Oreuss Laboratory -Brain Tumor Research,Durham,North Carolina,' 27710 ' ,United States,519816,,,
2607,Disulfiram and Copper,,10/8/2020,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cantex Pharmaceuticals, Inc.",1792 Bell Tower Lane,,Weston,Florida,' 33326 ' ,United States,771520,multiple myeloma,"""gard:0007108""",
2608,DL-3-n-butylphthalide,,2/28/2018,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,"CSPC NBP Pharmaceutical Co, Ltd, subsidiary of CSPC Pharma Group",No. 88 Yangzi Road,,Shijiazhuang Shi,Hebei Sheng,' ' ,China,623217,amyotrophic lateral sclerosis,"""gard:0005786""",
2609,DNA plasmid encoding the acetylcholine receptor,,4/18/2011,treatment of myasthenia gravis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Bayhill Therapeutics,1804 Embarcadero Rd.,Suite 201,Palo Alto,California,' 94303 ' ,United States,337711,myasthenia gravis,"""gard:0007122""",
2610,DNA plasmid expressing diphtheria toxin triggered by the presence of oncofetal gen H19,,8/20/2009,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioCancell Therapeutics USA, Inc.",1 Kendall Square,"Building 1400, Suite 14303",Cambridge,Massachusetts,' 02139 ' ,United States,287009,ovarian cancer,"""gard:0007295""",
2611,DNA plasmid vector (pCK-HGFX7) expressing human hepatocyte growth factor,,2/6/2014,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Helixmith Co., Ltd.",10390 Pacific Center Court,,San Diego,California,' 92121 ' ,United States,417013,amyotrophic lateral sclerosis,"""gard:0005786""",
2612,DNA Plasmid Vector encoding IL-12 (pUMVC3-hIL-12-NGVL331),,6/6/2017,"treatment of stage iib, iic, iii, and iv melanoma (which includes use in combination with pembrolizumab)",Designated,,Not FDA Approved for Orphan Indication,,,,,OncoSec Medical Incorporated,5820 Nancy Ridge Drive,,San Diego,California,' 92121 ' ,United States,568316,noma,"""gard:0004001""",
2613,DNA plasmid vector expressing eIF5Ak50,,12/13/2010,treatment of multiple myeloma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Senesco Technologies, Inc.",303 George Street,,New Brunswick,New Jersey,' 08901 ' ,United States,324910,multiple myeloma,"""gard:0007108""",
2614,"DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the nastive eIF5A mRNA, and PEI (polyethyleneimine)",,7/24/2012,treatment of diffuse large b cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Senesco Technologies, Inc.",721 Route 202/206,Suite 130,Bridgewater,New Jersey,' 08807 ' ,United States,373712,lymphoma,"""gard:0020548""",
2615,"DNA plasmid vector expressing eIF5Ak50R protein, siRNA directed against the native eIF5A mRNA, and PEI (polyethyleneimine)",,7/24/2012,treatment of mantle cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Senesco Technologies, Inc.",721 Route 202/206,Suite 130,Bridgewater,New Jersey,' 08807 ' ,United States,373612,lymphoma,"""gard:0020548""",
2616,DNA plasmid vector expressing human IL-12 gene,,4/4/2005,treatment of ovarian cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Imunon, Inc.",997 Lenox Drive,Suite 100,Lawrenceville,New Jersey,' 08068 ' ,United States,198304,ovarian cancer,"""gard:0007295""",
2617,"DNA, (Cm-Gm-Gm-Gm-G-T-G-T-G-G-G-T-T-C-G-T-C-G-T-T-A-G-C-T-T-G-A-T-T-T-G-G-C-A-G-C-Um-Gm-Cm-Cm-(3'¿3')-dT), 5'-ester with [[5-(phosphoonoxy) pentyl] amino] carbonyl-oxy-1, 2-ethanediyl, sodium salt",,8/19/2019,treatment of osteogenesis imperfecta,Designated,,Not FDA Approved for Orphan Indication,,,,,Aptacure Therapeutics Limited,"West Wing 2/F, 822 Lai Chi Kok Road",Cheung Sha Wan,Kowloon,,' ' ,,696619,osteogenesis imperfecta,"""gard:0001017""",
2618,"DNA, (Cm-Gm-Gm-Gm-G-T-G-T-G-G-G-T-T-C-G-T-C-G-T-T-A-G-C-T-T-G-A-T-T-T-G-G-C-A-G-C-Um-Gm-Cm-Cm-(5'->3')-dT), 5'-ester with (29S)-29-(tert-butoxycarbonyl)-1-((hydroxyphosphoryl)oxy)-8,17,26,31-tetraoxo-10,13,19,22-tetraoxa-7,16,25,30-tetraazaoctatetracontan-48-oic acid",,11/3/2022,treatment of osteogenesis imperfecta,Designated,,Not FDA Approved for Orphan Indication,,,,,Aptacure Therapeutics Limited,"M13, 1/F, Unit 101-103, Building 15 of Hong Kong Science Park",No. 15 Science Park West Avenue,Pak Shek Kok,New Territories,' ' ,Hong Kong,908722,osteogenesis imperfecta,"""gard:0001017""",
2619,"DNA, (Cm-Gm-Gm-Gm-G-T-G-T-G-G-G-T-T-C-G-T-C-G-T-T-A-G-C-T-T-G-A-T-T-T-G-G-C-A-G-C-Um-Gm-Cm-Cm-(5'->3')-idT), 5'-ester with (29S)-29-carboxy-8,17,26,31-tetraoxo-10,13,19,22-tetraoxa-7,16,25,30-tetraazaoctatetracontan-48-oic acid",,2/21/2024,treatment of x-linked hypophosphatemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Aptacure Therapeutics Limited,"M13, 1/F, Unit 101-103, Building 15 of Hong Kong Science Park,",No. 15 Science Park West Avenue,Pak Shek Kok,New Territories,' ' ,Hong Kong,989423,x-linked hypophosphatemia,"""gard:0012943""",
2620,"DNA-lipid complex (DMRIE/DOPE)/plasmid vector (VCL-1102, Vical) expressing human interleukin-2",,4/28/2000,treatment of renal cell carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Vical Incorporated,9373 Towne Center Dr.,Suite 100,San Diego,California,' 92121 ' ,United States,134400,renal cell carcinoma,"""gard:0013215""",
2621,DNP-Modified autologous tumor vaccine,,9/21/2000,adjuvant therapy for the treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"AVAX Technologies, Inc.",9200 Indian Creek Parkway,"Building 9, Suite 200",Overland Park,Kansas,' 66210 ' ,United States,138000,ovarian cancer,"""gard:0007295""",
2622,docarpamine,,4/14/2020,treatment of ascites due to all etiologies except cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Martin Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,' 10279 ' ,United States,701519,,,
2623,Docetaxel albumin bound,,7/20/2022,treatment of gastric cancer including cancer of gastroesophageal junction,Designated,,Not FDA Approved for Orphan Indication,,,,,"Conjupro Biotherapeutics, Inc.","302 Carnegie Center, Ste 100",,Princeton,New Jersey,' 08540 ' ,United States,892322,,,
2624,docetaxel encapsulated in an albumin-stabilized liposome,,9/12/2018,treatment of small cell lung cancer (sclc),Designated,,Not FDA Approved for Orphan Indication,,,,,"Plus Therapeutics, Inc.",12500 Network Blvd #207,,San Antonio,Texas,' 78249 ' ,United States,649918,small cell lung cancer,"""gard:0009344""",
2625,docosahexaenoic acid,,6/1/2015,treatment of short bowel syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Micelle BioPharma, Inc.","3874 Fiscal Ct., #200",,Riviera Beach,Florida,' 33404 ' ,United States,450214,short bowel syndrome,"""gard:0001502""",
2626,docosahexaenoic acid,,4/27/2015,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Micelle BioPharma, Inc.","3874 Fiscal Ct., #200",,Riviera Beach,Florida,' 33404 ' ,United States,454314,,,
2627,"docosahexaenoic acid, DHA",,12/17/2014,treatment of primary sclerosing cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Micelle BioPharma, Inc.","3874 Fiscal Ct., #200",,Riviera Beach,Florida,' 33404 ' ,United States,456414,sclerosing cholangitis,"""gard:0021868""",
2628,docosahexanoic acid-paclitaxel,,3/5/2001,treatment of hormone-refractory prostate cancer.,Designated/Designation Withdrawn or Revoked,8/26/2015,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",One Luitpold Drive,,Shirley,New York,' 11976 ' ,United States,141701,,,
2629,dodecafluoropentane emulsion,,2/11/2016,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,NuvOx Pharma,1635 East 18th Street,,Tucson,Alaska,' 85719 ' ,United States,507515,,,
2630,dodecafluoropentane emulsion (DDFPe),,12/2/2015,radiosensitizer to be used during radiation treatment of glioblastoma multiforme (gbm).,Designated,,Not FDA Approved for Orphan Indication,,,,,NuvOx Pharma,1635 East 18th Street,,Tucson,Alaska,' 85719 ' ,United States,497715,glioblastoma,"""gard:0002491""",
2631,Dodecyl Creatine Ester,,3/9/2021,treatment of creatine transporter deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,CERES BRAIN Therapeutics,Paris Biotech Santé,"24, rue du Faubourg Saint Jacques",Paris,,' 75014 ' ,France,803720,,,
2632,domperidone,,9/2/2011,"treatment of hypoprolactinemia in breastfeeding mothers, and in some hypoprolactinemic conditions following the use of cabergoline or bromocriptine in mothers who wish to initiate or return to breastfeeding",Designated,,Not FDA Approved for Orphan Indication,,,,,Texas Tech University Health Sciences Center,1400 S Coulter St.,,Amarillo,Texas,' 79106 ' ,United States,336111,,,
2633,donidalorsen,,9/19/2023,treatment of hereditary angioedema,Designated,,Not FDA Approved for Orphan Indication,,,,,Ionis Pharmaceuticals,2855 Gazelle Court,,Carlsbad,California,' 92010 ' ,United States,961723,hereditary angioedema,"""gard:0005979""",
2634,donislecel-jujn,Lantidra,2/1/2017,treatment of brittle type 1 diabetes,Designated/Approved,,,treatment of adults with Type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe hypoglycemia despite intensive diabetes management and education (exclusivity waived),6/28/2023,,,CellTrans Inc.,2201 W. Campbell Park Drive,,Chicago,Illinois,' 60612 ' ,United States,549916,,,
2635,dopamine hydrochloride,,10/24/2017,prevention of intraventricular hemorrhage in hypotensive premature neonates,Designated,,Not FDA Approved for Orphan Indication,,,,,"Brepco Biopharma, Ltd.",1785 Old Mill Road,,Bethlehem,Pennsylvania,' 18015 ' ,United States,578817,,,
2636,doranidazole,,11/30/2018,radiosensitizer to be used during radiation treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shuttle Pharmaceuticals, Inc.",1 Research Court,Suite 450,Rockville,Maryland,' 20850 ' ,United States,665218,,,
2637,Doripenem,,7/16/2004,treatment of bronchopulmonary infection in patients with cystic fibrosis who are colonized with pseudomonas aeruginosa or burkholderia cepacia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shionogi, Inc.",300 Campus Drive,Suite 300,Florham Park,New Jersey,' 07932 ' ,United States,188104,cystic fibrosis,"""gard:0006233""",
2638,Dornase alfa,Pulmozyme,1/16/1991,to reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.,Designated/Approved,,,In conjunction with standard therapies in the management of cystic fibrosis patients to reduce the frequency of respiratory infections requiring parenteral antibiotics and to improve pulmonary function.,12/30/1993,12/30/2000,,"Genentech, Inc.",460 Point San Bruno Boulevard,,South San Francisco,California,' 94080 ' ,United States,48090,cystic fibrosis,"""gard:0006233""",
2639,dornase alfa,,6/4/2019,treatment of sarcoidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"SarcoMed USA, LLC",1300 Post Oak Boulevard,Suite 760,Houston,Texas,' 77056 ' ,United States,616617,sarcoidosis,"""gard:0007607""",
2640,Dornase alpha,,12/14/2021,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Xenetic Biosciences, Inc.","40 Speen Street, Suite 102",,Framingham,Massachusetts,' 01701 ' ,United States,851921,,,
2641,double stranded oligomer AD00370 RNA interference-based liver targeted therapeutic,,6/9/2015,treatment of alpha-1 antitrypsin deficiency,Designated/Designation Withdrawn or Revoked,3/7/2017,Not FDA Approved for Orphan Indication,,,,,Arrowhead Research Corporation,225 South Lake Avenue,Suite 1050,Pasadena,California,' 91101 ' ,United States,480515,,,
2642,double stranded oligomer ADS-001 RNA interference-based liver targeted therapeutic,,2/14/2018,treatment of alpha-1 antitrypsin deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Takeda Development Center Americas Inc.,95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,623617,,,
2643,Double stranded oligomer ARO-APOC3 RNA interference-based liver targeted therapeutic,,6/20/2019,treatment of familial chylomicronemia syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Arrowhead Pharmaceuticals, Inc.",177 East Colorado Boulevard,Suite 700,Pasadena,California,' 91105 ' ,United States,690119,familial chylomicronemia syndrome,"""gard:0006414""",
2644,Double stranded oligomer RNA interference-based liver targeted therapeutic directed against the ANGPTL3 gene,,7/15/2019,treatment of homozygous familial hypercholesterolemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Arrowhead Pharmaceuticals, Inc.",177 East Colorado Boulevard,Suite 700,Pasadena,California,' 91105 ' ,United States,692719,homozygous familial hypercholesterolemia,"""gard:0010416""",
2645,double stranded RNA which targets the mutated KRAS oncogene,,1/26/2015,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Silenseed Ltd,Goldyne Savad Institute of Gene Therapy,,Jerusalem,,' 9112001 ' ,Israel,463214,,,
2646,double stranded small interfering RNA composed of a CLCN7G215R allele-specific siRNA,,5/8/2023,treatment of autosomal dominant osteopetrosis (ado),Designated,,Not FDA Approved for Orphan Indication,,,,,SiSaf Ltd.,3 Huxley Rd,,Guildford,,' GU2 7RE ' ,United Kingdom,936723,,,
2647,Double-stranded DNA plasmid carrying the gene for the diphtheria toxin A (DT-A) chain,,8/6/2010,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioCancell Therapeutics USA, Inc.",1 Kendall Square,"Building 1400, Suite 14303",Cambridge,Massachusetts,' 02139 ' ,United States,297809,,,
2648,Double-stranded small-interfering ribonucleic acid (siRNA) comprised of an antisense strand complementary to a targeted sequence within human PMP22 messenger RNA and a nucleotide sense strand linked to a fatty acid motif,,5/22/2023,treatment of charcot-marie-tooth disease type 1a,Designated,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936-1080 ' ,United States,940323,charcot-marie-tooth disease type 1,"""gard:0012433""",
2649,dovitinib,,9/26/2013,treatment of adenoid cystic carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Oncology Venture ApS,1 Venlighedsvej,,Hørsholm,,' ' ,Denmark,388012,noma,"""gard:0004001""",
2650,Dovitinib,,10/3/2006,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,210105,multiple myeloma,"""gard:0007108""",
2651,dovitinib,,10/11/2023,treatment of osteosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Oncoheroes Biosciences Inc.,62 Cypress St. #5,,Brookline,Massachusetts,' 02445 ' ,United States,905922,osteosarcoma,"""gard:0007284""",
2652,dovramilast,,10/31/2023,treatment of leprosy (hansen disease).,Designated,,Not FDA Approved for Orphan Indication,,,,,Medicines Development for Global Health,18 Kavanagh Street,Level 1,Southbank,Victoria,' 3006 ' ,Australia,967823,leprosy,"""gard:0006886""",
2653,doxofylline,,2/14/2014,treatment of bronchiectasis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alitair Pharmaceuticals, Inc.",55 Madison Avenue,Suite 400,Morristown,New Jersey,' 07960 ' ,United States,399413,,,
2654,doxorubicin,,8/25/2009,treatment of hepatocellular carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Delcath Systems, Inc.",1301 6th Avenue,43rd Floor,New York,New York,' 10019 ' ,United States,286109,hepatocellular carcinoma,"""gard:0016773""",
2655,doxorubicin,,4/6/2015,treatment of cutaneous t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Louis D. Falo, Jr.","University of Pittsburgh, Dep. of Dermatology",3500 Fifth Avenue,Pittsburgh,Pennsylvania,' 15213 ' ,United States,469215,lymphoma,"""gard:0020548""",
2656,Doxorubicin,,6/8/2021,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Bionaut Labs,"3767 Overland Avenue, Suite 114",,Los Angeles,California,' 90046 ' ,United States,820821,,,
2657,doxorubicin HCL liposome injection,Doxil,12/29/2004,treatment of multiple myeloma,Designated/Approved,,,For use in combination with bortezomib for the treatment of patients with multiple myeloma who have not previously received bortezomib and have at least one prior therapy.,5/17/2007,5/17/2014,,Johnson & Johnson Pharmaceutical Research & Dev.,"920 US Highway 202, P. O. Box 300",,Raritan,,' 08869 ' ,United States,191704,multiple myeloma,"""gard:0007108""",
2658,Doxorubicin HCl with pluronic L-61 and pluronic F-127,,10/7/2005,treatment of esophageal carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Supratek Pharma Inc.,6100 Royalmount Avenue,,Montreal,,' ' ,Canada,210705,noma,"""gard:0004001""",
2659,Doxorubicin liposome,Doxil,11/4/1998,treatment of ovarian cancer.,Designated/Approved,,,"Treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel- and platinium-based chemotherapy regimens. Refractory disease is defined as disease that has progressed while on treatment, or within 6 months of completing treatment.",6/28/1999,6/28/2006,,Alza Corporation,1550 Plymouth St.,PO Box 7210,Mountain View,California,' 94039 ' ,United States,117398,ovarian cancer,"""gard:0007295""",
2660,doxorubicin nanoparticles,,3/14/2005,treatment of hepatocellular carcinoma,Designated/Designation Withdrawn or Revoked,5/28/2019,Not FDA Approved for Orphan Indication,,,,,Onxeo SA,"49 Boulevard du general Martial Valin, 75015",,Paris,,' ' ,France,199904,hepatocellular carcinoma,"""gard:0016773""",
2661,doxorubicin with pluronics F-127 and L-61,,2/20/2008,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Supratek Pharma, Inc.",6100 Royalmount Avenue,,Montreal,,' ' ,Canada,248107,,,
2662,DPX-Survivac,,7/14/2015,treatment of ovarian cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immunovaccine Technologies, Inc.",1344 Summer Street,,Halifax,,' ' ,Canada,481615,ovarian cancer,"""gard:0007295""",
2663,Dronabinol,Marinol,1/15/1991,for the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of aids.,Designated/Approved,,,Treatment of anorexia associated with weight loss in patients with AIDS.,12/22/1992,12/22/1999,,"Unimed Pharmaceuticals, Inc.",901 Sawyer Rd.,,Marietta,Georgia,' 30062 ' ,United States,54890,,,
2664,droxidopa,NORTHERA,1/17/2007,"treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy.",Designated/Approved,,,"Treatment of orthostatic dizziness, lightheadedness, or the ""feeling that you are about to black out"" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.",2/18/2014,2/18/2021,"Treatment of orthostatic dizziness, lightheadedness, or the ""feeling that you are about to black out"" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy.",Lundbeck LLC,"3530 Toringdon Way, Suite 200",,Charlotte,North Carolina,' 28277 ' ,United States,229506,,,
2665,"drug component, inhaled nitric oxide, of the inhaled nitric oxice/INOpulse® Device combination product",,9/10/2019,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Bellerophon Therapeutics,184 Liberty Corner Road,Suite 302,Warren,New Jersey,' 07059 ' ,United States,621517,idiopathic pulmonary fibrosis,"""gard:0008609""",
2666,DTPA[Indium-111]-dinutuximab-IRDye800CW,,7/31/2023,diagnostic for the management of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,University of Pittsburgh,4200 Fifth Ave,,Pittsburgh,Pennsylvania,' 15260 ' ,United States,951023,neuroblastoma,"""gard:0007185""",
2667,"Dual antibody including HBV-Ab 17, libivirumab, and HBV-Ab 19, exbivirumab",,7/15/2003,for the prevention of hepatitis b virus (hbv) reinfection in patients who have received a liver transplantation,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Cubist Pharmaceuticals,65 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,171103,,,
2668,dual E-selectin and C-X-C chemokine receptor Type 4 (CXCR4) antagonist that targets both E-selectin and CXCR4,,1/27/2020,treatment of osteosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"GlycoMimetics, Inc.",9708 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,721819,osteosarcoma,"""gard:0007284""",
2669,Dual recombinant adeno-associated viral vectors encoding the human otoferlin gene,,12/21/2023,treatment of otoferlin-mediated hearing loss,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shanghai Refreshgene Therapeutics Co., Ltd.","Room 2001, Building 7-5, Free Trade No.1 Park, 160 Basheng Road",Waigaoqiao Free Trade Zone,Shanghai,Shanghai,' 200131 ' ,China,977923,,,
2670,dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL),,12/13/2017,treatment of diffuse large b-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"KAHR Medical, LTD",P. O. Box 12000,,Jerusalem,Jerusalem District,' ' ,Israel,517316,lymphoma,"""gard:0020548""",
2671,dupilumab,Dupixent,9/5/2017,treatment of eosinophilic esophagitis,Designated/Approved,,,"Treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE)",5/20/2022,5/20/2029,"Treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (EoE)","Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,599317,,,
2672,dupilumab,Dupixent,9/5/2017,treatment of eosinophilic esophagitis,Designated/Approved,,,"treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE)",1/25/2024,1/25/2031,treatment of pediatric patients aged 1 year and older weighing at least 15 kg who are less than 12 years of age or less than 40 kg in weight with eosinophilic esophagitis (EoE),"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,599317,,,
2673,dupilumab,,8/21/2019,treatment of bullous pemphigoid,Designated,,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,697319,bullous pemphigoid,"""gard:0005972""",
2674,Duramycin,,12/11/1997,treatment of cystic fibrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Lantibio, Inc.",100 Europa Drive,Suite 421,Chapel Hill,North Carolina,' 27517 ' ,United States,107897,cystic fibrosis,"""gard:0006233""",
2675,durvalumab,Imfinzi,1/15/2020,treatment of hepatocellular carcinoma,Designated/Approved,,,In combination with tremelimumab-actl for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC),10/21/2022,10/21/2029,treatment of adult patients with unresectable hepatocellular carcinoma (uHCC),AstraZeneca Pharmaceuticals LP,1800 Concord Pike,,Wilmington,Delaware,' 19803 ' ,United States,721519,hepatocellular carcinoma,"""gard:0016773""",
2676,durvalumab,Imfinzi,12/10/2020,treatment of biliary tract cancer,Designated/Approved,,,"In combination with gemcitabine and cisplatin, for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC)",9/2/2022,9/2/2029,treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC),AstraZeneca Pharmaceuticals LP,1800 Concord Pike,,Wilmington,Delaware,' 19803 ' ,United States,785220,,,
2677,durvalumab,,10/12/2023,"treatment of gastric cancer, including gastroesophageal junction cancer",Designated,,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals,1800 Concord Pike,,Wilmington,Delaware,' 19803 ' ,United States,965823,,,
2678,durvalumab,IMFINZI,7/10/2019,treatment of small cell lung cancer,Designated/Approved,,,"IMFINZI is indicated for use, in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).",3/27/2020,3/27/2027,"Indicated in combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).",AstraZeneca Pharmaceuticals LP,1800 Concord Pike,,Wilmington,Delaware,' 19803 ' ,United States,691319,small cell lung cancer,"""gard:0009344""",
2679,dusquetide,,8/10/2016,treatment of macrophage activation syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.",29 Emmons Drive,Suite B-10,Princeton,New Jersey,' 08540 ' ,United States,528016,macrophage activation syndrome,"""gard:0012124""",
2680,duvelisib,COPIKTRA,8/1/2013,treatment of follicular lymphoma,Designated/Approved,,,Treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior therapies (Indication withdrawn),9/24/2018,12/17/2021,Treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior therapies (Indication withdrawn),"Secura Bio, Inc.",1995 Village Center Cir.,Suite 128,Las Vegas,Nevada,' 89134-6360 ' ,United States,399913,lymphoma,"""gard:0020548""",
2681,duvelisib,COPIKTRA,4/15/2013,treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma,Designated/Approved,,,Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies,9/24/2018,9/24/2025,Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies,"Secura Bio, Inc.",1995 Village Center Cir.,,Las Vegas,Nevada,' 89134-6360 ' ,United States,394413,lymphoma,"""gard:0020548""",
2682,duvelisib,,10/2/2019,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Secura Bio, Inc.",1995 Village Center Cir.,,Las Vegas,Nevada,' 89134-6360 ' ,United States,703019,lymphoma,"""gard:0020548""",
2683,duvoglustat hydrochloride,,6/18/2007,treatment of pompe disease,Designated/Designation Withdrawn or Revoked,7/31/2018,Not FDA Approved for Orphan Indication,,,,,"Amicus Therapeutics, Inc",1 Cedarbrook Drive,,Cranbury,New Jersey,' 08512 ' ,United States,238507,,,
2684,Dynamine,,2/5/1990,treatment of lambert eaton myasthenic syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,Mayo Foundation,200 First Street Southwest,,Rochester,Minnesota,' 55905 ' ,United States,43189,c syndrome,"""gard:0005978""",
2685,Dynamine,,10/16/1991,treatment of hereditary motor and sensory neuropathy type i (charcot-marie-tooth disease).,Designated,,Not FDA Approved for Orphan Indication,,,,,Mayo Foundation,200 First Street Southwest,,Rochester,Minnesota,' 55905 ' ,United States,56090,,,
2686,Dystrophin Expressing Chimeric Cells derived from allogenic normal human myoblast and autologous DMD myoblast from Duchenne muscular dystrophy affected donor,,8/5/2020,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Dystrogen Therapeutics Corporation,1415 W 37th Street,,Chicago,Illinois,' 60609 ' ,United States,758720,muscular dystrophy,"""gard:0007922""",
2687,E-selectin antagonist,,5/13/2015,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,"GlycoMimetics, Inc.",401 Professional Drive,Suite 250,Gaithersburg,Maryland,' 20879 ' ,United States,475315,acute myeloid leukemia,"""gard:0012757""",
2688,E-selectin/Adeno-Associated Virus (E-sel/AAV2) Gene Therapy,,10/12/2021,treatment of buerger disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Ambulero Inc,1951 NW 7th Avenue,Suite 6000,Miami,Florida,' 33136 ' ,United States,840421,buerger disease,"""gard:0005969""",
2689,EBV-induced natural T cell [EBViNT Cell],,9/27/2022,"treatment of extranodal nk/t cell lymphoma, nasal-type",Designated,,Not FDA Approved for Orphan Indication,,,,,Eutilex Co. Ltd,"Suite 408, Gasan digital 1-Ro 58",,Seoul,"Geumcheon-gu, Seoul,",' 08591 ' ,South Korea,900922,lymphoma,"""gard:0020548""",
2690,ecallantide,Kalbitor,2/4/2003,treatment of angioedema,Designated/Approved,,,Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older,3/28/2014,3/28/2021,Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 through 15 years of age.,"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,160802,,,
2691,ecallantide,Kalbitor,2/4/2003,treatment of angioedema,Designated/Approved,,,Treatment of acute attacks of hereditary angioedema in patients 16 years of age and older,12/1/2009,12/1/2016,,"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,160802,,,
2692,echinomycin,,1/5/2017,treatment of graft-versus-host disease (gvhd),Designated,,Not FDA Approved for Orphan Indication,,,,,"OncoC4, Inc.",9640 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,549016,,,
2693,echinomycin,,5/21/2015,treatment of acute myeloid leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"OncoC4, Inc.",9640 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,479815,acute myeloid leukemia,"""gard:0012757""",
2694,Echothiophate iodide,,4/11/2022,treatment of stargardt disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Fera Pharmaceuticals, LLC",134 Birch Hill Road,,Locust Valley,New York,' 11560 ' ,United States,871422,stargardt disease,"""gard:0000181""",
2695,echothiophate iodide,,6/2/2014,treatment of stargardt's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Makindus, Inc.",3805 Old Easton Road,,Doylestown,Pennsylvania,' 18902 ' ,United States,430914,,,
2696,ecopipam hydrochloride,,9/29/2010,treatment of pediatric patients with tourette's syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Emalex Biosciences, Inc.","1033 Skokie Bulevard, Suite 600",,Northbrook,Illinois,' 60062 ' ,United States,308210,,,
2697,ecopipam hydrochloride,,7/21/2009,symptomatic treatment of self injurious behaviors in patients with lesch-nyhan disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Emalex Biosciences, Inc.","1033 Skokie Bulevard, Suite 600",,Northbrook,Illinois,' 60062 ' ,United States,284109,,,
2698,eculizumab,Soliris,6/24/2013,treatment of neuromyelitis optica,Designated/Approved,,,Soliris is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.,6/27/2019,6/27/2026,For the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,398713,,,
2699,eculizumab,,9/28/2022,treatment of guillain barre syndrome (gbs),Designated,,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Blvd.,,Boston,Massachusetts,' 02210 ' ,United States,902222,,,
2700,Eculizumab,,9/21/2000,treatment of dermatomyositis,Designated/Designation Withdrawn or Revoked,12/15/2021,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,136100,dermatomyositis,"""gard:0006263""",
2701,eculizumab,Soliris,8/20/2003,treatment of paroxysmal nocturnal hemoglobinuria,Designated/Approved,,,Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis,3/16/2007,3/16/2014,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,173203,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
2702,eculizumab,,1/10/2014,prevention of delayed graft function after renal transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,417213,,,
2703,eculizumab,Soliris,4/29/2009,treatment of atypical hemolytic uremic syndrome,Designated/Approved,,,For the treatment of atypical Hemolytic Uremic Syndrome (aHUS),9/23/2011,9/23/2018,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,279509,hemolytic uremic syndrome,"""gard:0022233""",
2704,eculizumab,,10/18/2011,treatment of shiga-toxin producing escherichia coli hemolytic uremic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,354511,hemolytic uremic syndrome,"""gard:0022233""",
2705,eculizumab,Soliris,6/12/2014,treatment of myasthenia gravis,Designated/Approved,,,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive,10/23/2017,10/23/2024,for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,434214,myasthenia gravis,"""gard:0007122""",
2706,eculizumab,,3/5/2001,treatment of idiopathic membranous glomerular nephropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,138800,,,
2707,edaravone,Radicava ORS,5/12/2015,treatment of amyotrophic lateral sclerosis,Designated/Approved,,,Treatment of amyotrophic lateral sclerosis (ALS),5/12/2022,5/12/2029,Treatment of amyotrophic lateral sclerosis (ALS),Mitsubishi Tanabe Pharma Corporation,"17-10, Nihonbashi-Koamicho",,Tokyo,,' ' ,Japan,478215,amyotrophic lateral sclerosis,"""gard:0005786""",
2708,edaravone,Radicava,5/12/2015,treatment of amyotrophic lateral sclerosis,Designated/Approved,,,Treatment of amyotrophic lateral sclerosis (ALS),5/5/2017,5/5/2024,Treatment of amyotrophic lateral sclerosis (ALS),Mitsubishi Tanabe Pharma Corporation,"17-10, Nihonbashi-Koamicho",,Tokyo,,' ' ,Japan,478215,amyotrophic lateral sclerosis,"""gard:0005786""",
2709,edaravone,,11/4/2021,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Suzhou Auzone Biological Technology Co., Ltd","Room 406, A7 Building, BioBay, No. 218 Xinghu Street",Suzhou Industrial Park,Suzhou,Jiangsu,' 215000 ' ,China,847021,amyotrophic lateral sclerosis,"""gard:0005786""",
2710,edaravone,,3/12/2015,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Treeway B.V.,Sevillaweg 142,,Rotterdam,,' ' ,Netherlands,465514,amyotrophic lateral sclerosis,"""gard:0005786""",
2711,Edaravone and (+)-Borneol,,8/11/2020,treatment of amyotrophic lateral sclerosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Yantai Yenepharma. Co., Ltd","Inner No. 2, No.32 Zhujiang Road",Yantai Economic and Technological Development Zone,Yantai,Shandong Province,' 264006 ' ,China,754420,amyotrophic lateral sclerosis,"""gard:0005786""",
2712,Edasalonexent,,11/17/2014,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Catabasis Pharmaceuticals, Inc.","One Kendall Square, Suite B14202",Suite B14202,Cambridge,Massachusetts,' 02139 ' ,United States,453714,muscular dystrophy,"""gard:0007922""",
2713,Edited allogeneic chimeric antigen receptor T Cells (CAR-T),,9/1/2022,treatment of follicular lymphoma (fl),Designated,,Not FDA Approved for Orphan Indication,,,,,"Caribou Biosciences, Inc.",2929 7th Street,Suite 105,Berkeley,California,' 94710 ' ,United States,899022,lymphoma,"""gard:0020548""",
2714,Edotreotide,,7/28/2005,treatment of somatostatin receptor-positive neuroendocrine gastroenteropancreatic tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"Molecular Insight Pharmaceuticals, Inc. (Progenics Subsidiary)",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,160902,,,
2715,Edralbrutinib,,4/24/2023,treatment of neuromyelitis optica spectrum disorder,Designated,,Not FDA Approved for Orphan Indication,,,,,Reistone Biopharma Company Limited,"No. 298 Xiangke Road, Youyue Plus, 2nd Floor, #203, Pudong",,Shanghai,Shanghai,' 21210 ' ,China,935023,neuromyelitis optica spectrum disorder,"""gard:0006267""",
2716,efaproxiral,,7/28/2004,adjunct to whole brain radiation therapy for the treatment of brain metastases in patients with breast cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Allos Therapeutics, Inc.",11080 CirclePoint Road,Suite 200,Westminster,Colorado,' 80020 ' ,United States,158802,,,
2717,Efdispo,,1/15/2013,treatment of ewings sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"TDP Biotherapeutics, Inc.",113 Summer Walk Drive,,Gaithersburg,Maryland,' 20878 ' ,United States,386912,,,
2718,efgartigimod,,2/1/2019,treatment of primary immune thrombocytopenia (itp),Designated,,Not FDA Approved for Orphan Indication,,,,,argenx BVBA,7 Industriepark-Zwijnaarde,,Gent,Vlaanderen,' ' ,Belgium,633218,immune thrombocytopenia,"""gard:0005194""",
2719,efgartigimod alfa and hyaluronidase-qvfc,Vyvgart Hytrulo,7/27/2022,treatment of myasthenia gravis,Designated/Approved,,,treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive,6/20/2023,6/20/2030,treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive,argenx BV,Industriepark Zwijnaarde 7,,Zwijnaarde,Ghent,' 9052 ' ,Belgium,825421,myasthenia gravis,"""gard:0007122""",
2720,efgartigimod alfa-fcab,Vyvgart,9/20/2017,treatment of myasthenia gravis,Designated/Approved,,,treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive,12/17/2021,12/17/2028,treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive,argenx BV,Industriepark Zwijnaarde 7,,Zwijnaarde,,' 9052 ' ,Belgium,527316,myasthenia gravis,"""gard:0007122""",
2721,efgartigimod coformulated with recombinant human hyaluronidase PH20 (rHuPH20),,11/8/2021,treatment of chronic inflammatory demyelinating polyneuropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,argenx BV,Industriepark Zwijnaarde 7,,Zwijnaarde,East Flanders,' 9052 ' ,Belgium,851421,chronic inflammatory demyelinating polyneuropathy,"""gard:0006102""",
2722,eflornithine,Iwilfin,11/22/2017,treatment of neuroblastoma,Designated/Approved,,,"to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy",12/13/2023,12/13/2030,"to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy","USWM, LLC",4441 Springdale Rd,,Louisville,Kentucky,' 40241 ' ,United States,613217,neuroblastoma,"""gard:0007185""",
2723,eflornithine,,2/4/2011,treatment of familial adenomatous polyposis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Panbela Therapeutics, Inc.","712 Vista Blvd., #305",,Waconia,Minnesota,' 55387 ' ,United States,321210,familial adenomatous polyposis,"""gard:0006408""",
2724,Eflornithine,,9/29/2006,treatment of anaplastic glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Orbus Therapeutics, Inc.",1043 Via Tornasol,,Aptos,California,' 95003 ' ,United States,229306,,,
2725,eflornithine,,12/14/2016,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Panbela Therapeutics, Inc.","712 Vista Blvd., #305",,Waconia,Minnesota,' 55387 ' ,United States,547716,,,
2726,eflornithine,,11/23/2010,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Cancer Prevention Pharmaceuticals,1760 E. River Road,Suite 250,Tucson,Alaska,' 85718 ' ,United States,319610,neuroblastoma,"""gard:0007185""",
2727,Eflornithine HCl,,4/18/1986,treatment of pneumocystis carinii pneumonia in aids patients.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Marion Merrell Dow, Inc.",P.O. Box 9627,,Kansas City,Missouri,' 64134 ' ,United States,13686,,,
2728,eflornithine + sulindac,,1/8/2018,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Panbela Therapeutics, Inc.","712 Vista Blvd., #305",,Waconia,Minnesota,' 55387 ' ,United States,619917,,,
2729,eflornithine HCL,,4/7/2015,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Panbela Therapeutics, Inc.","712 Vista Blvd., #305",,Waconia,Minnesota,' 55387 ' ,United States,472715,,,
2730,eflornithine HCl,,3/11/2024,treatment of bachmann-bupp syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Orbus Therapeutics, Inc.",2479 East Bayshore Road,Suite 105,Palo Alto,California,' 94303 ' ,United States,992323,,,
2731,Eflornithine HCl,Ornidyl,4/23/1986,treatment of trypanosoma brucei gambiense infection (sleeping sickness).,Designated/Approved,,,,11/28/1990,11/28/1997,,Hoechst Marion Roussel,P.O. Box 9627,,Kansas City,Missouri,' 64134 ' ,United States,13586,,,
2732,eflornithine plus sulindac,,1/22/2013,treatment of familial adenomatous polyposis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Panbela Therapeutics, Inc.",712 Vista Blvd #305,,Waconia,Minnesota,' 55387 ' ,United States,387012,familial adenomatous polyposis,"""gard:0006408""",
2733,efmitermant alfa,,2/28/2019,treatment of charcot-marie-tooth disease,Designated/Designation Withdrawn or Revoked,4/2/2020,Not FDA Approved for Orphan Indication,,,,,Acceleron Pharma Inc.,128 Sidney Street,,Cambridge,Massachusetts,' 02139 ' ,United States,674918,,,
2734,efzofitimod,,4/12/2022,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,aTyr Pharma Inc.,"3545 John Hopkins Court, Suite 250",,San Diego,California,' 92121 ' ,United States,870022,systemic sclerosis,"""gard:0009748""",
2735,eicosapentaenoic acid,,3/8/2011,treatment of familial adenomatous polyposis,Designated,,Not FDA Approved for Orphan Indication,,,,,S.L.A. Pharma Ltd. (UK),Elite House,,"Leavesden, Watford",,' ' ,United Kingdom,283409,familial adenomatous polyposis,"""gard:0006408""",
2736,elacytarabine,,6/18/2008,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,Clavis Pharma ASA,Parkveien 53 B,,Oslo,,' ' ,Norway,259408,acute myeloid leukemia,"""gard:0012757""",
2737,eladocagene exuparvovec,,6/8/2016,treatment of aromatic l-amino acid decarboxylase deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",500 Warren Corporate Center Drive,,Warren,New Jersey,' 07059 ' ,United States,526916,aromatic l-amino acid decarboxylase deficiency,"""gard:0000770""",
2738,elafibranor,,7/25/2019,treatment of primary biliary cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Ipsen Bioscience Inc.,"One Main Street, 7th Floor",,Cambridge,Massachusetts,' 02142 ' ,United States,693919,primary biliary cholangitis,"""gard:0007459""",
2739,elamipretide,,3/22/2018,treatment of barth syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Stealth Biotherapeutics, Inc.",140 Kendrick Street,Building C-West,Needham,Massachusetts,' 02494 ' ,United States,607817,h syndrome,"""gard:0010239""",
2740,elamipretide,,4/2/2018,treatment of leber’s hereditary optic neuropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Stealth BioTherapeutics Inc.,140 Kendrick Street,Building C-West,Needham,Massachusetts,' 02494 ' ,United States,609417,hereditary optic neuropathy,"""gard:0019540""",
2741,elamipretide,,9/5/2017,treatment of primary mitochondrial myopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Stealth BioTherapeutics,140 Kendrick Street,Building C-West,Needham,Massachusetts,' 02494 ' ,United States,597417,mitochondrial myopathy,"""gard:0020371""",
2742,elamipretide,,3/22/2022,treatment of friedreich’s ataxia (frda),Designated,,Not FDA Approved for Orphan Indication,,,,,"Stealth Biotherapeutics, Inc.","275 Grove Street, Suite 3-107",,Newton,Massachusetts,' 02466 ' ,United States,794420,,,
2743,Elamipretide HCl,,5/10/2022,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Stealth Biotherapeutics Inc.,140 Kendrick Street,Building C-West,Needham,Massachusetts,' 02494 ' ,United States,874722,muscular dystrophy,"""gard:0007922""",
2744,elapegademase-lvlr,Revcovi,3/19/2015,treatment of adenosine deaminase deficiency in patients with severe combined immunodeficiency.,Designated/Approved,,,Treatment of Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID).,10/5/2018,10/5/2025,treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.,Chiesi USA Inc.,175 Regency Woods Place,Suite 600,Cary,North Carolina,' 27518 ' ,United States,467514,severe combined immunodeficiency,"""gard:0007628""",
2745,Elcatonin,,9/25/1995,intrathecal treatment of intractable pain.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Innapharma, Inc.",10 Mountainview Road,,Upper Saddle River,New Jersey,' 07458 ' ,United States,81594,,,
2746,electrokinetically altered saline solution with an elevated dissolved oxygen concentration,,7/10/2017,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,Revalesio Corporation,1202 East D Street,,Tacoma,Washington,' 98421 ' ,United States,581017,amyotrophic lateral sclerosis,"""gard:0005786""",
2747,Elemene Emulsion Injection,,8/29/2022,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Dalian Holley Kingkong Pharmaceutical Co., Ltd.","No.8, Chengen Street, Jinzhou District",,Dalian,Liaoning,' ' ,China,897322,,,
2748,Elesclomol,,12/18/2007,treatment of metastatic melanoma in combination with paclitaxel,Designated,,Not FDA Approved for Orphan Indication,,,,,Synta Pharmaceuticals Corporation,45 Hartwell Ave.,,Lexington,Massachusetts,' 02421 ' ,United States,243607,noma,"""gard:0004001""",
2749,Elesclomol copper,,8/3/2023,treatment of menkes disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Engrail Therapeutics, Inc.",12750 High Bluff Drive,,San Diego,California,' 92130 ' ,United States,952123,menkes disease,"""gard:0001521""",
2750,"elexacaftor, tezacaftor, and ivacaftor; ivacaftor",Trikafta,8/29/2018,treatment of cystic fibrosis,Designated/Approved,,,treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data,12/21/2020,12/21/2027,treatment of cystic fibrosis in patients aged 12 years and older who have a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive based on in vitro data.,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,647618,cystic fibrosis,"""gard:0006233""",
2751,"elexacaftor, tezacaftor, and ivacaftor; ivacaftor",Trikafta,8/29/2018,treatment of cystic fibrosis,Designated/Approved,,,Treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data,6/8/2021,6/8/2028,Treatment of cystic fibrosis (CF) in patients aged 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,647618,cystic fibrosis,"""gard:0006233""",
2752,"elexacaftor, tezacaftor, and ivacaftor; ivacaftor",Trikafta,8/29/2018,treatment of cystic fibrosis,Designated/Approved,,,TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene,10/21/2019,10/21/2026,Indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,647618,cystic fibrosis,"""gard:0006233""",
2753,"elexacaftor, tezacaftor, and ivacaftor; ivacaftor",Trikafta,8/29/2018,treatment of cystic fibrosis,Designated/Approved,,,treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data,4/26/2023,4/26/2030,treatment of cystic fibrosis (CF) in patients aged 2 years to less than 6 years who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro data,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,647618,cystic fibrosis,"""gard:0006233""",
2754,elezanumab,,3/17/2020,treatment of acute spinal cord injury,Designated,,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,,North Chicago,Illinois,' 60044 ' ,United States,729419,spinal cord injury,"""gard:0019109""",
2755,eliglustat,CERDELGA,9/17/2008,treatment of type i gaucher disease,Designated/Approved,,,"Long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.",8/19/2014,8/19/2021,"Long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test.",Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,265408,gaucher disease,"""gard:0008233""",
2756,Eliglustat Tartrate,,9/2/2021,"treatment of gaucher disease type 1 patients who are cyp2d6 ultra-rapid metabolizers and patients whose cyp2d6 genotype cannot be determined (i.e., indeterminate metabolizers).",Designated,,Not FDA Approved for Orphan Indication,,,,,"Kashiv Biosciences, LLC",20 New England Avenue,,Piscataway,New Jersey,' 08854 ' ,United States,816821,gaucher disease,"""gard:0008233""",
2757,elivaldogene autotemcel,Skysona,4/19/2012,treatment of adrenoleukodystrophy,Designated/Approved,,,"To slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD)",9/16/2022,9/16/2029,"To slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD)","bluebird bio, Inc.",455 Grand Union Blvd,,Somerville,Massachusetts,' 02145 ' ,United States,368212,leukodystrophy,"""gard:0006895""",
2758,elosulfase alfa,Vimizim,5/15/2009,use in the treatment of mucopolysaccharidosis (mps) type iv a (morquio a syndrome),Designated/Approved,,,Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome),2/14/2014,2/14/2021,Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome),BioMarin Pharmaceutical Inc.,105 Digital Drive,,Novato,California,' 94949 ' ,United States,280809,mucopolysaccharidosis,"""gard:0007065""",
2759,elotuzumab,Empliciti,9/1/2011,treatment of multiple myeloma,Designated/Approved,,,EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.,11/6/2018,11/6/2025,"Indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, excluding adult patients covered by Empliciti¿s previously approved indication for multiple myeloma.",Bristol-Myers Squibb Co.,P.O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,348411,multiple myeloma,"""gard:0007108""",
2760,elotuzumab,Empliciti,9/1/2011,treatment of multiple myeloma,Designated/Approved,,,Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies,11/30/2015,11/30/2022,Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies,Bristol-Myers Squibb Co.,P.O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,348411,multiple myeloma,"""gard:0007108""",
2761,elraglusib,,7/18/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Actuate Therapeutics, Inc.","1751 River Run, Suite 400",,Fort Worth,Texas,' 76107 ' ,United States,949823,,,
2762,elranatamab-bcmm,Elrexfio,10/12/2021,treatment of multiple myeloma,Designated/Approved,,,"treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody",8/14/2023,8/14/2030,"treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody",Pfizer Inc.,66 Hudson Boulevard East,,New York,New York,' 10001 ' ,United States,840721,multiple myeloma,"""gard:0007108""",
2763,Eltanexor,,1/19/2022,treatment of myelodysplastic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Karyopharm Therapeutics, Inc.","85 Wells Ave,",,"Newton,",Massachusetts,' 02459 ' ,United States,857421,myelodysplastic syndrome,"""gard:0007132""",
2764,eltoprazine HCl,,2/8/2016,treatment of levodopa-induced dyskinesia associated with parkinson's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Amarantus BioScience Holdings, Inc.",655 Montgomery St.,Suite 900,San Francisco,California,' 94111 ' ,United States,504215,,,
2765,eltrombopag,Promacta,11/8/2013,treatment of aplastic anemia,Designated/Approved,,,Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.,8/26/2014,8/26/2021,Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,410213,aplastic anemia,"""gard:0020234""",
2766,eltrombopag,Promacta,11/8/2013,treatment of aplastic anemia,Designated/Approved,,,PROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia.,11/16/2018,11/16/2025,PROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia.,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,410213,aplastic anemia,"""gard:0020234""",
2767,eltrombopag,Promacta,5/5/2008,treatment of idiopathic thrombocytopenia purpura,Designated/Approved,,,"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy",11/20/2008,11/20/2015,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,251907,,,
2768,Emapalumab,,9/25/2020,prevention of graft failure following hematopoietic stem cell transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,Sobi AG,12 Chemin des Aulx,Plan-Les-Ouates,Geneva,,' 1228 ' ,Switzerland,766720,,,
2769,Emapalumab-lzsg,GAMIFANT™,3/26/2010,treatment of hemophagocytic lymphohistiocytosis,Designated/Approved,,,"GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.",11/20/2018,11/20/2025,"GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.",Swedish Orphan Biovitrum AB,SE-112,75 Stockholm,Stockholm,,' ' ,Sweden,302910,,,
2770,emeramide,,4/6/2012,treatment of mercury toxicity,Designated,,Not FDA Approved for Orphan Indication,,,,,NBMI Science Limited,c/o Philip Lee Solicitors,119 Burnside Drive,Nicholasville,,' ' ,Ireland,367312,,,
2771,emicizumab-kxwh,Hemlibra,1/10/2014,treatment of hemophilia a,Designated/Approved,,,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors,11/16/2017,11/16/2024,Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors,Genentech,1 DNA Way,MS 355e,South San Francisco,California,' 94080 ' ,United States,416913,hemophilia,"""gard:0010418""",
2772,emicizumab-kxwh,Hemlibra,1/10/2014,treatment of hemophilia a,Designated/Approved,,,HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.,10/4/2018,10/4/2025,HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors.,Genentech,1 DNA Way,MS 355e,South San Francisco,California,' 94080 ' ,United States,416913,hemophilia,"""gard:0010418""",
2773,emixustat,,1/4/2017,treatment of stargardt disease (stgd),Designated,,Not FDA Approved for Orphan Indication,,,,,Acucela Inc.,1301 2nd Avenue,Suite 4200,Seattle,Washington,' 98101 ' ,United States,548816,stargardt disease,"""gard:0000181""",
2774,emodepside,,9/13/2016,"treatment of onchocerhiasis (""river blindness"") caused by the filarial nematode onchocerca volvulus",Designated,,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Boulevard,P. O. Box 915,Whippany,New Jersey,' 07981 ' ,United States,535416,,,
2775,empasiprubart,,6/5/2024,treatment of multifocal motor neuropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,argenx BV,Industriepark Zwijnaarde 7,,Zwijnaarde (Ghent),,' 9052 ' ,Belgium,1005024,multifocal motor neuropathy,"""gard:0011011""",
2776,emricasan,,11/20/2013,treatment of liver transplant recipients with reestablished fibrosis to delay the progression to cirrhosis and end stage liver disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Conatus Pharmaceuticals Inc.,16745 W. Bernardo Drive,Suite 200,San Diego,California,' 92127 ' ,United States,396113,,,
2777,emtricitabine and tenofovir alafenamide,Descovy,6/6/2017,treatment of hiv-1 infection in pediatric patients under 12 years of age,Designated/Approved,,,"DESCOVY, indicated in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg and also indicated, in combination with other antiretroviral agents other than protease inhibitors that require a CYP3A inhibitor, for the treatment of HIV-1 infection in pediatric patients weighing at least 25 kg and less than 35 kg.",9/28/2017,9/28/2024,"¿ In combination with other antiretroviral agents, for the treatment of HIV-1 infection in pediatric patients under 12 years of age weighing at least 35kg; and ¿ In combination with other antiretroviral agents other than protease inhibitors that require a CYP3A inhibitor, for the treatment of HIV-1 infection in pediatric patients under 12 years of age weighing at least 25kg and less than 35kg","Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,569716,,,
2778,emtricitabine and tenofovir alafenamide,Descovy,6/6/2017,treatment of hiv-1 infection in pediatric patients under 12 years of age,Designated/Approved,,,Treatment of HIV-1 infection in pediatric patients weighing at least 14 kg and less than 35 kg in combination with other antiretroviral agents other than protease inhibitors that require a CYP3A inhibitor,1/7/2022,1/7/2029,Treatment of HIV-1 infection in pediatric patients under 12 years of age weighing at least 14 kg to less than 25 kg,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,569716,,,
2779,Enadoline hydrochloride,,1/28/1997,treatment of severe head injury.,Designated,,Not FDA Approved for Orphan Indication,,,,,Warner-Lambert Company,Parke-Davis Pharmaceutical Research Division,2800 Plymouth Road,Ann Arbor,Michigan,' 48105 ' ,United States,102496,,,
2780,enalapril maleate (powder for oral solution),,1/30/2013,treatment of hypertension in pediatric patients,Designated/Designation Withdrawn or Revoked,4/28/2016,Not FDA Approved for Orphan Indication,,,,,"Silvergate Pharmaceuticals, Inc.",5371 Gordon Way,,Dublin,Ohio,' 43017 ' ,United States,376712,,,
2781,enasidenib,Idhifa,6/12/2014,treatment of acute myelogenous leukemia,Designated/Approved,,,Treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test,8/1/2017,8/1/2024,Treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test,Celgene Corporation,9225 Indian Creek Parkway,Suite 900,Overland Park,Kansas,' 66210 ' ,United States,434514,,,
2782,Encaleret sulfate,,11/24/2020,treatment for autosomal dominant hypocalcemia type 1 (adh1),Designated,,Not FDA Approved for Orphan Indication,,,,,"Calcilytix Therapeutics, Inc.","1800 Owens Street, Suite C-1200",,San Francisco,California,' 94014 ' ,United States,782120,autosomal dominant hypocalcemia,"""gard:0002877""",
2783,Encapsulated porcine islet preparation,,7/5/1995,treatment of type i diabetic patients who are already on immunosuppression.,Designated,,Not FDA Approved for Orphan Indication,,,,,VivoRx,2825 Santa Monica Blvd.,2nd Floor,Santa Monica,California,' 90404 ' ,United States,90195,,,
2784,encapsulated rapamycin,,3/15/2019,treatment of familial adenomatous polyposis,Designated,,Not FDA Approved for Orphan Indication,,,,,Emtora Biosciences Inc,16601 Blanco Road,Suite 120,San Antonio,Texas,' 78232 ' ,United States,678319,familial adenomatous polyposis,"""gard:0006408""",
2785,enchochleate amphotericin B,,1/10/2014,treatment of visceral leishmaniasis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Matinas BioPharma Nanotechnologies, Inc","1545 Route 206 South, Suite 302",,Bedminister,New Jersey,' 07921 ' ,United States,416113,leishmaniasis,"""gard:0006881""",
2786,encochleated amikacin,,3/3/2016,treatment of non-tuberculous mycobacteria (ntm) infections,Designated,,Not FDA Approved for Orphan Indication,,,,,"Matinas BioPharma Nanotechnologies, Inc","1545 Route 206 South, Suite 302",,Bedminster Township,New Jersey,' 07921 ' ,United States,507715,,,
2787,Encochleated oral Amphotericin B suspension,,10/3/2019,treatment of cryptococcosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Matinas BioPharma Nanobiotechnologies, Inc.",1545 Route 206 South,Suite 302,Bedminster Township,New Jersey,' 07921 ' ,United States,703119,cryptococcosis,"""gard:0006218""",
2788,encorafenib,,11/19/2013,treatment of stage iib-iv melanoma positive for braf mutation,Designated/Designation Withdrawn or Revoked,7/6/2022,Not FDA Approved for Orphan Indication,,,,,"Array BioPharma Inc., a wholly-owned subsidiary of Pfizer Inc.",125 Cambridge Park Drive,Suite 301,Cambridge,Massachusetts,' 02140 ' ,United States,411413,noma,"""gard:0004001""",
2789,encorafenib,Braftovi,9/8/2021,treatment of braf-mutant non-small cell lung cancer,Designated/Approved,,,"in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test",10/11/2023,10/11/2030,"treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test",Array BioPharma Inc. (a wholly owned subsidiary of Pfizer Inc.),445 Eastern Point Road,,Groton,Connecticut,' 06340-5146 ' ,United States,788820,small cell lung cancer,"""gard:0009344""",
2790,encorafenib + binimetinib,,11/19/2013,treatment of stage iib-iv melanoma positive for the braf mutation.,Designated/Approved,,,"MEKTOVI® is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test",6/27/2018,6/27/2025,"BRAFTOVI¿ (encorafenib) and MEKTOVI® (binimetinib) indicated, in combination, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.","Array BioPharma, Inc.",100 Cambridgepark Drive,Suite 505,Cambridge,Massachusetts,' 02140 ' ,United States,411613,noma,"""gard:0004001""",
2791,encorafenib + binimetinib,,11/19/2013,treatment of stage iib-iv melanoma positive for the braf mutation.,Designated/Approved,,,"BRAFTOVI¿ is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test",6/27/2018,6/27/2025,"BRAFTOVI¿ (encorafenib) and MEKTOVI® (binimetinib) indicated, in combination, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.","Array BioPharma, Inc.",100 Cambridgepark Drive,Suite 505,Cambridge,Massachusetts,' 02140 ' ,United States,411613,noma,"""gard:0004001""",
2792,Endothelin receptor B antagonist,,1/21/2016,treatment of malignant melanoma stages iib to iv.,Designated,,Not FDA Approved for Orphan Indication,,,,,"ENB Therapeutics, LLC",166 5th Avenue,2nd Floor,New York,New York,' 10010 ' ,United States,506215,noma,"""gard:0004001""",
2793,EnGeneIC delivery vehicles loaded with doxorubicin and targeted to tumor with sequences from Vectibix and mouse monoclonal antibody,,2/14/2017,treatment glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,EnGeneIC Ltd,25 Sirius Road,Building 2,Lane Cove West,New South Wales,' ' ,Australia,553116,glioblastoma,"""gard:0002491""",
2794,Engineered cationic antibiotic peptide,,7/1/2020,treatment of prosthetic joint infections,Designated,,Not FDA Approved for Orphan Indication,,,,,"Peptilogics, Inc.","2730 Sidney Street, Suite 300",,Pittsburgh,Pennsylvania,' 15203 ' ,United States,723219,,,
2795,Engineered variant of recombinant human fibroblast growth factor 19,,2/6/2014,treatment of primary biliary cirrhosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"NGM Biopharmaceuticals, Inc.",630 Gateway Blvd,,South San Francisco,California,' 94080 ' ,United States,415813,,,
2796,Enhanced delivery peptide-oligonucleotide conjugate for Duchenne Muscular Dystrophy Exon 51,,3/7/2024,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,PepGen Inc.,"321 Harrison Ave, 8th Floor",,Boston,Massachusetts,' 02118 ' ,United States,991923,muscular dystrophy,"""gard:0007922""",
2797,eniluracil,,12/15/2005,treatment of hepatocellular carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Adherex Technologies, Inc.",501 Eastowne Drive,Suite 140,Chapel Hill,North Carolina,' 27514 ' ,United States,211505,hepatocellular carcinoma,"""gard:0016773""",
2798,enisoprost,,10/20/1989,1. for use with cyclosporine in organ transplant recipients to reduce acute transplant rejection 2. for use in organ transplant patients to diminish the nephrotoxicity induced by cyclosporine.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,G.D. Searle & Company,4901 Searle Parkway,,Skokie,Illinois,' 60077 ' ,United States,37289,,,
2799,enriched CD34+ hematopoietic stem and progenitor cells / highly purified CD34-CD25+CD4+CD127-regulatory T cells / conventional T cells (Orca-T),,1/30/2024,prevention of graft-versus-host disease and/or death in patients undergoing hematopoietic stem cell transplant.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Orca Biosystems, Inc.","3400 Business Drive, Suite C",,Sacramento,California,' 94025 ' ,United States,985423,,,
2800,Enriched CD34+ hematopoietic stem and progenitor cells/highly puridied CD34-CD25+CD4+CD127-regulatory T cells/conventional T cells,,7/1/2020,treatment to enhance cell engraftment in patients receiving hematopoietic stem cell transplant.,Designated/Designation Withdrawn or Revoked,2/1/2024,Not FDA Approved for Orphan Indication,,,,,Orca Biosystems Inc.,"3475 Edison Way, Suite B",,Menlo Park,California,' 94025 ' ,United States,746020,,,
2801,ensituximab,,10/21/2010,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neogenix Oncology, Inc.",9700 Great Seneca Highway,,Rockville,Maryland,' 20850 ' ,United States,320210,,,
2802,entolimod,,11/23/2010,prevention of death following a potentially lethal dose of total body irradiation during or after a radiation disaster,Designated,,Not FDA Approved for Orphan Indication,,,,,"Statera BioPharma, Inc.",2537 Research Boulevard,Suite 201,Ft. Collins,Colorado,' 80526 ' ,United States,310910,,,
2803,entospletinib,,6/15/2017,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kronos Bio, Inc.","1300 S. El Camino Real, Suite 400",,San Mateo,California,' 94402 ' ,United States,569616,acute myeloid leukemia,"""gard:0012757""",
2804,entospletinib,,4/14/2014,treatment of chronic lymphocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kronos Bio, Inc.","1300 S. El Camino Real, Suite 400",,San Mateo,California,' 94402 ' ,United States,426714,,,
2805,entospletinib,,8/10/2017,prevention of chronic graft-versus-host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kronos Bio, Inc.","1300 S. El Camino Real, Suite 400",,San Mateo,California,' 94402 ' ,United States,510115,,,
2806,entrectinib,,12/22/2014,treatment of neuroblastoma,Designated/Designation Withdrawn or Revoked,1/7/2020,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,MS#241A,South San Francisco,California,' 94080 ' ,United States,462414,neuroblastoma,"""gard:0007185""",
2807,entrectinib,ROZLYTREK,2/3/2015,"treatment of trka-positive, trkb-positive, trkc-positive ros1-positive or alk-positive non-small cell lung cancer",Designated/Approved,,,ROZLYTREK is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.,8/15/2019,8/15/2026,For the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.,"Genentech, Inc.",1 DNA Way,MS#241A,South San Francisco,California,' 94080 ' ,United States,462914,small cell lung cancer,"""gard:0009344""",
2808,entrectinib,Rozlytrek,7/5/2017,treatment of ntrk fusion-positive solid tumors,Designated/Approved,,,"treatment of adult and pediatric patients older than 1 month of age with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy",10/20/2023,10/20/2030,"treatment of pediatric patients older than 1 month up to 12 years of age with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy","Genentech, Inc.",1 DNA Way,MS#241A,South San Francisco,California,' 94080 ' ,United States,587117,,,
2809,entrectinib,Rozlytrek,7/5/2017,treatment of ntrk fusion-positive solid tumors,Designated/Approved,,,"ROZLYTREK is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have either progressed following treatment or have no satisfactory alternative therapy",8/15/2019,8/15/2026,"For the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have either progressed following treatment or have no satisfactory alternative therapy.","Genentech, Inc.",1 DNA Way,MS#241A,South San Francisco,California,' 94080 ' ,United States,587117,,,
2810,envafolimab,,6/28/2021,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tracon Pharmaceuticals, Inc.",4350 LaJolla Village Dr.,Suite 800,San Diego,California,' 92122 ' ,United States,745320,soft tissue sarcoma,"""gard:0004898""",
2811,Envafolimab,,1/16/2020,treatment of biliary tract cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"3D Medicines (Sichuan) Co., Ltd","64-66, Jiaogui Second Lane, Jinniu District",,Chengdu,Sichuan,' ' ,China,718819,,,
2812,enzastaurin,,3/4/2009,treatment of diffuse large b-cell lymphoma,Designated/Designation Withdrawn or Revoked,11/16/2023,Not FDA Approved for Orphan Indication,,,,,Denovo Biopharma LLC,6331 Nancy Ridge Drive,,San Diego,California,' 92121 ' ,United States,277209,lymphoma,"""gard:0020548""",
2813,Enzastaurin,,9/19/2005,treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,Denovo Biopharma LLC,6331 Nancy Ridge Drive,,San Diego,California,' 92121 ' ,United States,208505,glioblastoma,"""gard:0002491""",
2814,enzastaurin,,12/7/2021,treatment of ehlers-danlos syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aytu BioPharma, Inc.","373 Inverness Parkway, Suite 206",,Englewood,Colorado,' 80112 ' ,United States,849821,ehlers-danlos syndrome,"""gard:0006322""",
2815,enzyme transport vehicle specific for the transferrin receptor fused to iduronate 2-sulfatase,,2/19/2019,treatment of mucopolysaccharidosis type ii,Designated,,Not FDA Approved for Orphan Indication,,,,,Denali Therapeutics Inc.,"151 Oyster Point Blvd, Second Floor",,South San Francisco,California,' 94080 ' ,United States,671118,mucopolysaccharidosis,"""gard:0007065""",
2816,epacadostat,,2/11/2016,treatment of stage iib-iv melanoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,493015,noma,"""gard:0004001""",
2817,epalrestat,,3/26/2020,"treatment of phosphomannomutase-2 deficiency, a congenital disorder of glycosylation",Designated,,Not FDA Approved for Orphan Indication,,,,,Maggie's Pearl,903 Independence Street,,Sturgis,Michigan,' 49091 ' ,United States,735820,congenital disorder of glycosylation,"""gard:0010307""",
2818,epcoritamab,,3/1/2022,treatment of follicular lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genmab US, Inc.",777 Scudders Mill Road,"Bldg. 2, 4th Floor",Plainsboro,New Jersey,' 08536 ' ,United States,865921,lymphoma,"""gard:0020548""",
2819,epetraborole hydrochloride,,2/9/2022,treatment of infections caused by nontuberculous mycobacteria (ntm),Designated,,Not FDA Approved for Orphan Indication,,,,,"AN2 Therapeutics, Inc.",P.O. Box 418,,Menlo Park,California,' 94026 ' ,United States,860621,,,
2820,Epidermal growth factor (human),,3/6/1985,for promotion of cutaneous wound healing in extreme burn treatment protocols.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Ethicon, Inc.",P.O. Box 151,,Somerville,New Jersey,' 08876 ' ,United States,5485,,,
2821,Epidermal growth factor (human),,10/5/1987,for acceleration of corneal epithelial regeneration and the healing of stromal tissue in the condition of non-healing corneal defects.,Designated,,Not FDA Approved for Orphan Indication,,,,,Chiron Vision,500 Iolab Drive,,Claremont,California,' 91711 ' ,United States,14386,,,
2822,epidermal stem cells genetically modified with a gamma-retroviral (rv) vector expressing the full-length LAMB3 cDNA,,11/5/2020,treatment of epidermolysis bullosa,Designated,,Not FDA Approved for Orphan Indication,,,,,Holostem S.r.l.,Via Glauco Gottardi 100,,Modena,,' 41125 ' ,Italy,780320,,,
2823,Epirubicin,,11/28/2023,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Beijing Inno Medicine Co., Ltd.","No.101-301, 3/F, Building 9, No.4,","Xishan Creative Park, Haidian District",Beijing,,' ' ,China,971923,,,
2824,Epirubicin,Ellence,9/14/1999,treatment of breast cancer.,Designated/Approved,,,Component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.,9/15/1999,9/15/2006,,Pharmacia & Upjohn Company,0634-298-113,7000 Portage Rd.,Kalamazoo,Michigan,' 49001 ' ,United States,121498,,,
2825,epirubicin-conjugated polymer micelles,,7/13/2017,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"NanoCarrier Co., Ltd",Chuou 144-15,226-39 Wakashiba,Kashiwa,Chiba,' ' ,Japan,588517,soft tissue sarcoma,"""gard:0004898""",
2826,Episcleral Topotecan,,7/24/2019,treatment of retinoblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Targeted Therapy Technologies, LLC., DBA: 3T Ophthalmics",3972 Barranca Parkway,Suite J-185,Irvine,California,' 92606 ' ,United States,694519,retinoblastoma,"""gard:0007563""",
2827,Epitalon,,9/2/2010,treatment of retinitis pigmentosa,Designated/Designation Withdrawn or Revoked,1/6/2016,Not FDA Approved for Orphan Indication,,,,,BioDiem Ltd,"Level 10, South Tower",Victoria 3000,Melbourne,,' ' ,Australia,312010,retinitis pigmentosa,"""gard:0005694""",
2828,eplontersen,Wainua,1/6/2022,treatment of transthyretin-mediated amyloidosis,Designated/Approved,,,Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults,12/21/2023,12/21/2030,Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults,"Ionis Pharmaceuticals, Inc.",2855 Gazelle Ct,,Carlsbad,California,' 92010 ' ,United States,827521,amyloidosis,"""gard:0018676""",
2829,Epoetin alfa,Epogen,7/1/1991,treatment of anemia associated with hiv infection or hiv treatment.,Designated/Approved,,,Treatment of AZT-induced anemia in HIV infected patients.,12/31/1990,12/31/1997,,"Amgen, Inc.",1840 Dehavilland Drive,,Thousand Oaks,California,' 91320 ' ,United States,56490,,,
2830,Epoetin alfa,,12/20/1993,treatment of myelodysplastic syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Johnson & Johnson Pharmaceutical Research & Dev.,",920 U.S. Highway,"Route 202, P.O. Box 300",Raritan,New Jersey,' 08869 ' ,United States,78793,myelodysplastic syndrome,"""gard:0007132""",
2831,Epoetin alfa,Epogen,4/10/1986,treatment of anemia associated with end stage renal disease.,Designated/Approved,,,"Treatment of anemia associated with chronic renal failure, including patients on dialysis (end stage renal disesae) and patients not on dialysis",6/1/1989,6/1/1996,,"Amgen, Inc.",1840 Dehavilland Drive,,Thousand Oaks,California,' 91320 ' ,United States,12486,,,
2832,Epoetin alpha,,3/7/1989,treatment of hiv associated anemia related to hiv infection or hiv treatment.,Designated,,Not FDA Approved for Orphan Indication,,,,,R. W. Johnson Pharmaceutical Research Institute,"Route 202, P.O. Box 300",,Raritan,New Jersey,' 08869 ' ,United States,32688,,,
2833,Epoetin alpha,,8/27/1987,treatment of anemia associated with end stage renal disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,R. W. Johnson Pharmaceutical Research Institute,Route 202 South,P.O. Box 300,Raritan,New Jersey,' 08869 ' ,United States,17186,,,
2834,Epoetin alpha,,7/21/1988,treatment of anemia of prematurity in preterm infants.,Designated/Designation Withdrawn or Revoked,10/28/2013,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring House,Pennsylvania,' 19477 ' ,United States,21987,,,
2835,Epoetin beta,,10/22/1987,treatment of anemia associated with end stage renal disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Chugai-USA, Inc.",3780 Hawthorn Court,,Waukegan,Illinois,' 60087 ' ,United States,22987,,,
2836,Epoprostenol,,3/29/1984,replacement of heparin in patients requiring hemodialysis and who are at risk of hemmorrage,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,' 27709 ' ,United States,783,,,
2837,epoprostenol,Flolan,3/22/1999,treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.,Designated/Approved,,,treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases.,4/14/2000,4/14/2007,,GlaxoSmithKline,2301 Renaissance Blvd,P. O. Box 61540,King of Prussia,Pennsylvania,' 19406 ' ,United States,121698,,,
2838,Epoprostenol,Flolan,9/25/1985,treatment of primary pulmonary hypertension.,Designated/Approved,,,Long-term intravenous treatment of primary pulmonary hypertension in NYHA Class III and Class IV patients.,9/20/1995,9/20/2002,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,' 27709 ' ,United States,8785,,,
2839,Epoprostenol,,10/29/1984,replacement of heparin in patients requiring hemodialysis and who are at increased risk of hemorrhage.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Upjohn Company,301 Henrietta Street,,Kalamazoo,Michigan,' 49001 ' ,United States,2884,,,
2840,epoprostenol,,4/20/2020,treatment of frostbite,Designated,,Not FDA Approved for Orphan Indication,,,,,"LutaFlo Therapeutics, LLC","102 N Water St, Suite 612",,Milwaukee,Wisconsin,' 53202 ' ,United States,705119,,,
2841,epratuzumab,,7/13/1998,treatment of non-hodgkin's lymphoma,Designated/Designation Withdrawn or Revoked,5/15/2019,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,113298,lymphoma,"""gard:0020548""",
2842,epratuzumab,,9/30/2008,treatment of acute lymphoblastic leukemia,Designated/Designation Withdrawn or Revoked,2/4/2020,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,260908,acute lymphoblastic leukemia,"""gard:0000522""",
2843,eprenetapopt,,4/7/2021,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aprea Therapeutics, Inc.",535 Boylston Street,2nd Floor,Boston,Massachusetts,' 02116 ' ,United States,797420,acute myeloid leukemia,"""gard:0012757""",
2844,eprodisate,,4/6/1999,treatment of secondary amyloidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"C. T. Development America, Inc.",663 Fifth Avenue,7th Floor,New York,New York,' 10022 ' ,United States,118998,amyloidosis,"""gard:0018676""",
2845,Epstein Barr Virus specific cytotoxic T lymphocytes,,12/27/2006,prevention and treatment of ebv-post transplant lymphoproliferative disease after hematopoietic stem cell transplant or solid organ transplant.,Designated/Designation Withdrawn or Revoked,4/24/2015,Not FDA Approved for Orphan Indication,,,,,Center for Cell and Gene Therapy,Feigin Center,Suite 1120,Houston,Texas,' 77030 ' ,United States,223906,,,
2846,Epstein-Barr Virus envelope glycoprotein 350 (gp350)-directed genetically modified autologous chimeric antigen receptor (CAR)-T cells,,5/31/2023,treatment of nasopharyngeal carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Biosyngen Pte. Ltd.,"31 Rochester Drive, #02-57/58, Park Avenue Rochester",,,Singapore,' 138637 ' ,Singapore,940623,nasopharyngeal carcinoma,"""gard:0007163""",
2847,Epstein-Barr virus-specific autologous cytotoxic T lymphocytes,,6/12/2014,treatment of epstein-barr virus positive head and neck cancers (which includes nasopharyngeal carcinoma),Designated/Designation Withdrawn or Revoked,5/9/2022,Not FDA Approved for Orphan Indication,,,,,Tessa Therapeutics Pte.,8 Temasek Blvd #24-02,,Suntec Tower Three,,' ' ,Singapore,434714,nasopharyngeal carcinoma,"""gard:0007163""",
2848,eptifibatide and iloprost,,4/20/2012,treatment of purpura fulminans,Designated,,Not FDA Approved for Orphan Indication,,,,,Thrombologic,COBIS/Ole Maaloesvej 3,,2200 Copenhagen,,' ' ,Denmark,364012,,,
2849,erdosteine,,12/20/2013,treatment of bronchiectasis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alitair Pharmaceuticals, Inc.",55 Madison Avenue,Suite 400,Morristown,New Jersey,' 07960 ' ,United States,417413,,,
2850,eribulin mesylate,Halaven,5/14/2012,treatment of soft tissue sarcoma,Designated/Approved,,,Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen,1/28/2016,1/28/2023,Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen,Eisai Inc.,200 Metro Blvd.,,Nutley,New Jersey,' 07110-6102 ' ,United States,367112,soft tissue sarcoma,"""gard:0004898""",
2851,Erlotinib Hydrochloride,,7/18/2003,treatment of malignant gliomas,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,172003,,,
2852,Erwinia L-asparaginase,Erwinase,7/30/1986,treatment of acute lymphocytic leukemia.,Designated/Approved/Designation Withdrawn or Revoked,5/10/2021,,Treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.,11/18/2011,11/18/2018,,"Jazz Pharmaceuticals, Inc.",3180 Porter Drive,,Palo Alto,California,' 94304 ' ,United States,15186,,,
2853,Erwinia L-asparaginase,,1/25/1985,for use as an alternative to e. coli asparaginase in those situations where repeat courses of asparaginase therapy for acute lymphoblastic leukemia are required or where allergic reactions force the discontinuance of the e. coli preparation.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Lyphomed, Inc.",,,,,' ' ,,4684,acute lymphoblastic leukemia,"""gard:0000522""",
2854,"Erythropoietin (human, recombinant)",,11/19/1987,treatment of anemia associated with end stage renal disease.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Organon Teknika Corporation,,,,,' ' ,,18987,,,
2855,Erythropoietin (recombinant human),,8/19/1987,treatment of anemia associated with end stage renal disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,McDonnell Douglas Corp,"P.O. Box 516, 107/2 MS10",,St. Louis,Missouri,' 63166 ' ,United States,17886,,,
2856,esomeprazole,,5/15/2019,treatment of eosinophilic esophagitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Adare Pharmaceuticals US, L.P.",Princeton Pike Corporate Center,"1200 Lenox Drive, Suite 100",Lawrenceville,New Jersey,' 08648 ' ,United States,684119,,,
2857,estetrol,,3/28/2019,treatment of neonatal hypoxic ischemic encephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Mithra Pharmaceuticals S.A.,5-7 Rue St Georges,,Liège,,' ' ,Belgium,678119,,,
2858,estradiol Gel,,10/31/2006,estrogen replacement therapy in females with turner syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ascend Therapeutics US, LLC",15 Mount Kemble Avenue,,Morristown,New Jersey,' 07960 ' ,United States,231706,turner syndrome,"""gard:0007831""",
2859,etanercept,Enbrel,10/27/1998,reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.,Designated/Approved,,,Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older,5/27/1999,5/27/2006,,Immunex Corporation,One Amgen Center Drive,,Thousand Oaks,California,' 91320 ' ,United States,116198,,,
2860,Etanercept,,4/6/1999,treatment of wegener's granulomatosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation,51 University Street,,Seattle,Washington,' 98101 ' ,United States,122999,,,
2861,etaracizumab,,4/14/2004,"for the treatment of of stage iib, stage iic, stage iii and stage iv melanoma",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC",One MedImmune Way,,Gaithersburg,Maryland,' 20878 ' ,United States,178403,noma,"""gard:0004001""",
2862,etarfolatide,,2/16/2000,for the identification of ovarian carcinomas,Designated,,Not FDA Approved for Orphan Indication,,,,,"Endocyte, Inc.",3000 Kent Ave.,Suite A1-100,West Lafayette,Indiana,' 47906 ' ,United States,131399,noma,"""gard:0004001""",
2863,etavopivat,,2/19/2020,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"FORMA Therapeutics, Inc.",300 North Beacon Street,Suite 501,Watertown,Massachusetts,' 02472 ' ,United States,728919,,,
2864,etelcalcetide,,5/31/2017,treatment of pediatric hyperparathyroidism,Designated,,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",1 Amgen Center Drive,,Thousand Oaks,California,' 91320 ' ,United States,567616,,,
2865,eteplirsen,Exondys 51,10/23/2007,treatment of duchenne muscular dystrophy.,Designated/Approved,,,Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping,9/19/2016,9/19/2023,Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping,"Sarepta Therapeutics, Inc.",215 First Street,Suite 415,Cambridge,Massachusetts,' 02142 ' ,United States,248407,muscular dystrophy,"""gard:0007922""",
2866,Ethanol gel,,3/29/2006,treatment of congenital venous malformations,Designated/Designation Withdrawn or Revoked,7/15/2015,Not FDA Approved for Orphan Indication,,,,,Orfagen,CRDPF - LANGLADE,,Toulouse,Cedex,' ' ,France,212205,,,
2867,Ethanol gel,,3/13/2006,treatment of congenital lymphatic malformations,Designated/Designation Withdrawn or Revoked,7/15/2015,Not FDA Approved for Orphan Indication,,,,,Orfagen,CRDPF - LANGLADE,,Toulouse,Cedex,' ' ,France,212505,,,
2868,ethanolamine,,1/17/2014,prophylactic use in pediatric patients (age 0 through 16 years) with esophageal varices that are at risk of bleeding to obliterate varices and to prevent bleeding,Designated,,Not FDA Approved for Orphan Indication,,,,,"QOL Medical, LLC","4445 North Highway A1A, 241",,Vero Beach,Florida,' 32963 ' ,United States,416713,,,
2869,Ethanolamine oleate,Ethamolin,3/22/1984,"treatment of patients with esophageal varices that have recently bled, to prevent rebleeding.",Designated/Approved,,,,12/22/1988,12/22/1995,,QOL Medical,"4445 North Highway A1A, 241",,Vero Beach,Florida,' 32963 ' ,United States,1484,,,
2870,"Ethenesulfonamide, 2-[(2R)-1,2-dimethyl-2- pyrrolidinyl]-N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4- yl)amino]carbonyl]-, (1E)-",,3/17/2023,treatment of cryopyrin associated periodic syndromes (caps),Designated,,Not FDA Approved for Orphan Indication,,,,,Zydus Therapeutics Inc.,73C Route 31 North,,Pennington,New Jersey,' 08534 ' ,United States,929522,c syndrome,"""gard:0005978""",
2871,"Ethinyl Estradiol, USP",,6/22/1988,treatment of turner's syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Bio-Technology General Corp.,"70 Wood Avenue, South",,Iselin,New Jersey,' 08830 ' ,United States,28788,,,
2872,ethiodized oil injection,Lipiodol,9/26/2013,management of patients with known hepatocellular carcinoma (hcc),Designated/Approved,,,Selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC),4/4/2014,4/4/2021,Selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC),Guerbet LLC,"120 West 7th St., Suite 108",,Bloomington,Indiana,' 47404 ' ,United States,400113,hepatocellular carcinoma,"""gard:0016773""",
2873,Ethiofos,,8/1/1989,use as a chemoprotective agent for cisplatin and cyclophosphamide in the treatment of ovarian cancer.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,U.S. Bioscience,100 Front Street,,West Conshohocken,Pennsylvania,' 19428 ' ,United States,24187,ovarian cancer,"""gard:0007295""",
2874,"Ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate",,5/13/1998,treatment of crohn's disease.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Tap Holdings Inc.,2355 Waukegan Road,,Deerfield,Illinois,' 60015 ' ,United States,112698,,,
2875,Ethyl eicosapentaenoate,,4/6/2000,treatment of huntington's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Laxdale Ltd.,"Kings Park House, Laurelhill Business Park",Polmaise Road,Stirling,,' ' ,United Kingdom,134300,,,
2876,Etidronate disodium,Didronel,3/21/1986,treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.,Designated/Approved,,,,4/21/1987,4/21/1994,,"MGI Pharma, Inc.",5775 West Old Shakoppe Rd.,Suite 100,Bloomington,Minnesota,' 55437 ' ,United States,12185,,,
2877,Etidronate disodium,,5/2/1991,prevention of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"MGI Pharma, Inc.",6300 West Old Shakoppe Rd.,Suite 110,Bloomington,Minnesota,' 55438 ' ,United States,49890,,,
2878,Etidronate disodium,,5/2/1991,treatment of degenerative metabolic bone disease occurring in patients who require long term (6 months or greater) total parenteral nutrition.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"MGI Pharma, Inc.",6300 West Old Shakoppe Rd.,Suite 110,Bloomington,Minnesota,' 55438 ' ,United States,49790,,,
2879,Etiocholanedione,,11/3/1995,treatment of aplastic anemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,' 94568 ' ,United States,92695,aplastic anemia,"""gard:0020234""",
2880,Etiocholanedione,,5/7/1996,treatment of prader-willi syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,' 94568 ' ,United States,95896,prader-willi syndrome,"""gard:0005575""",
2881,etirinotecan pegol,,4/18/2011,treatment of ovarian cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,Nektar Therapeutics,"455 Mission Bay Blvd, South",,San Francisco,California,' 94158 ' ,United States,338011,ovarian cancer,"""gard:0007295""",
2882,etoposide toniribate,,2/11/2019,treatment of biliary tract cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,CellAct Pharma GmbH,Otto-Hahn str. 15,,Dortmund,,' 44227 ' ,Germany,671318,,,
2883,etranacogene dezaparvovec-drlb,Hemgenix,4/17/2019,treatment of hemophilia b,Designated/Approved,,,"Treatment of adults with Hemophilia B (congenital Factor IX deficiency) who: currently use Factor IX prophylaxis therapy, or; have current or historical life-threatening hemorrhage, or; have repeated, serious spontaneous bleeding episodes",11/22/2022,11/22/2029,"Treatment of adults with Hemophilia B (congenital Factor IX deficiency) who: currently use Factor IX prophylaxis therapy, or; have current or historical life-threatening hemorrhage, or; have repeated, serious spontaneous bleeding episodes",CSL Behring LLC,1020 First Avenue,P.O. Box 61501,King of Prussia,Pennsylvania,' 19406-0901 ' ,United States,632918,hemophilia,"""gard:0010418""",
2884,Etrasimod L-arginine,,6/8/2021,treatment of eosinophilic esophagitis (eoe),Designated,,Not FDA Approved for Orphan Indication,,,,,"Arena Pharmaceuticals, Inc.",6154 Nancy Ridge Drive,,San Diego,California,' 92121 ' ,United States,723019,,,
2885,etrolizumab,,8/22/2016,treatment of pediatric patients with ulcerative colitis,Designated/Designation Withdrawn or Revoked,12/15/2022,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 Dna Way,,South San Francisco,California,' 94080 ' ,United States,531116,,,
2886,etrolizumab,,7/13/2017,treatment of pediatric crohn's disease.,Designated/Designation Withdrawn or Revoked,12/15/2022,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 Dna Way,,South San Francisco,California,' 94080 ' ,United States,531216,,,
2887,"Eubacterial Spores, Purified Suspension, Encapsulated",,11/27/2017,treatment of pediatric ulcerative colitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Seres Therapeutics, Inc.",200 Sidney Street,,Cambridge,Massachusetts,' 02139 ' ,United States,617517,,,
2888,everolimus,Afinitor,6/8/2009,"treatment of tuberous sclerosis complex including tsc-associated subependymal giant cell astrocytoma (sega), tsc-associated angiomyolipoma and tsc-associated lymphangioleiomyomatosis (lam)",Designated/Approved,,,Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection,10/29/2010,10/29/2017,,Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,' 07936 ' ,United States,283609,astrocytoma,"""gard:0012928""",
2889,everolimus,Afinitor,6/8/2009,"treatment of tuberous sclerosis complex including tsc-associated subependymal giant cell astrocytoma (sega), tsc-associated angiomyolipoma and tsc-associated lymphangioleiomyomatosis (lam)",Designated/Approved,,,Treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery.,4/26/2012,4/26/2019,,Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,' 07936 ' ,United States,283609,astrocytoma,"""gard:0012928""",
2890,everolimus,Afinitor,6/8/2009,"treatment of tuberous sclerosis complex including tsc-associated subependymal giant cell astrocytoma (sega), tsc-associated angiomyolipoma and tsc-associated lymphangioleiomyomatosis (lam)",Designated/Approved,,,For the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures.,4/10/2018,4/10/2025,For the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures.,Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,' 07936 ' ,United States,283609,astrocytoma,"""gard:0012928""",
2891,everolimus,,7/23/2012,treatment of hepatocellular carcinoma,Designated/Designation Withdrawn or Revoked,10/12/2018,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,' 07936 ' ,United States,374012,hepatocellular carcinoma,"""gard:0016773""",
2892,everolimus,Afinitor,2/14/2008,treatment of neuroendocrine tumors,Designated/Approved,,,"Treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease; and treatment of adult patients with progressive, well-differentiated, non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin, with unresectable, locally advanced or metastatic disease.",2/26/2016,2/26/2023,"Treatment of adult patients with progressive, well-differentiated, non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) (excluding pancreatic) or lung origin, with unresectable, locally advanced or metastatic disease.",Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,' 07936 ' ,United States,254107,,,
2893,everolimus,,6/2/2014,treatment of diffuse large b-cell lymphoma,Designated/Designation Withdrawn or Revoked,10/12/2018,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,' 07936 ' ,United States,431214,lymphoma,"""gard:0020548""",
2894,everolimus,Afinitor,2/14/2008,treatment of neuroendocrine tumors,Designated/Approved,,,"Treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease.",5/5/2011,5/5/2018,,Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,' 07936 ' ,United States,254107,,,
2895,everolimus,,5/24/2011,treatment of gastric cancer,Designated/Designation Withdrawn or Revoked,6/18/2014,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,' 07936 ' ,United States,340111,,,
2896,everolimus,,9/16/2010,treatment of waldenstrom macroglobulinemia (also known as lymphoplasmacytic lymphoma),Designated/Designation Withdrawn or Revoked,6/18/2014,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,' 07936 ' ,United States,315410,lymphoma,"""gard:0020548""",
2897,everolimus ointment,,9/10/2015,topical treatment of tuberous sclerosis complex-related skin lesions,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aucta Pharmaceuticals, LLC",675 US Highway One,,North Brunswick,New Jersey,' 08902 ' ,United States,489715,tuberous sclerosis complex,"""gard:0007830""",
2898,evinacumab-dgnb,Evkeeza,2/8/2016,treatment of homozygous familial hypercholesterolemia,Designated/Approved,,,"as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholesterolemia (HoFH)",3/21/2023,3/21/2030,"as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of pediatric patients, aged 5 years to less than 12 years, with homozygous familial hypercholesterolemia (HoFH)","Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591-6707 ' ,United States,507815,homozygous familial hypercholesterolemia,"""gard:0010416""",
2899,evinacumab-dgnb,Evkeeza,2/8/2016,treatment of homozygous familial hypercholesterolemia,Designated/Approved,,,"adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH)",2/11/2021,2/11/2028,"adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH)","Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591-6707 ' ,United States,507815,homozygous familial hypercholesterolemia,"""gard:0010416""",
2900,evolocumab,Repatha,9/12/2013,treatment of homozygous familial hypercholesterolemia,Designated/Approved,,,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.",8/27/2015,8/27/2022,"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C.",Amgen Inc.,One Amgen Center Drive,M/S 17 2 B,Thousand Oaks,California,' 91320 ' ,United States,404113,homozygous familial hypercholesterolemia,"""gard:0010416""",
2901,evolocumab,Repatha,9/12/2013,treatment of homozygous familial hypercholesterolemia,Designated/Approved,,,"As an adjunct to other low-density lipoprotein cholesterol (LDL-C)-lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C",9/24/2021,9/24/2028,to reduce LDL-C in pediatric patients aged 10 to less than 13 years with homozygous familial hypercholesterolemia (HoFH),Amgen Inc.,One Amgen Center Drive,M/S 17 2 B,Thousand Oaks,California,' 91320 ' ,United States,404113,homozygous familial hypercholesterolemia,"""gard:0010416""",
2902,ex vivo cultured adult human mesenchymal stem cells,,12/14/2005,treatment of acute graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mesoblast, Inc.",505 Fifth Avenue,Third Floor,New York,New York,' 10017 ' ,United States,214805,graft versus host disease,"""gard:0016642""",
2903,ex vivo cultured human mesenchymal stromal cells,,5/8/2014,prevention of graft rejection following solid organ transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,iCell Science AB,Tallmov. 2A,756 45,Uppsala,,' ' ,Sweden,428814,,,
2904,ex vivo expanded allogeneic cord blood-derived NK cells that have been genetically modified to express a HER2-directed CAR and secrete IL-15,,3/7/2023,treatment of gastric and gastroesophageal junction cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Artiva Biotherapeutics, Inc.",5505 Morehouse Drive,Suite 100,San Diego,California,' 92121 ' ,United States,927822,,,
2905,ex vivo expanded autologous human corneal epithelial cells containing stem cells,,4/26/2018,treatment of limbal stem cell deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Holostem S.r.l.,Via Glauco Gottardi 100,,Modena,,' 41125 ' ,Italy,632218,limbal stem cell deficiency,"""gard:0020123""",
2906,"ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate?2? sulfatase (IDS) enzyme to subjects with Hunter syndrome",,11/24/2021,"treatment of hunter syndrome (mucopolysaccharidosis type ii, mps ii)",Designated/Designation Withdrawn or Revoked,9/8/2023,Not FDA Approved for Orphan Indication,,,,,"AVROBIO, Inc.","100 Technology Square, 6th Floor",,Cambridge,Massachusetts,' 02139 ' ,United States,848221,mucopolysaccharidosis,"""gard:0007065""",
2907,Ex-vivo conditioned medium from cultured adult human mesenchymal stem cells,,8/15/2022,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Summa Bio-Solutions Inc.,500 8th Avenue,Suite 110,Fort Worth,Texas,' 76104 ' ,United States,895522,idiopathic pulmonary fibrosis,"""gard:0008609""",
2908,ex-vivo cultered adult human mesenchymal stem cells,,4/30/2010,treatment of type 1 diabetes patients with residual beta cell function,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mesoblast, Inc.",505 Fifth Avenue,Third Floor,New York,New York,' 10017 ' ,United States,284009,,,
2909,ex-vivo expanded autologous bone marrow-derived mesenchymal stem cells,,12/20/2010,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"TCA Cellular Therapy, LLC",101 Judge Tanner Blvd.,,Covington,Louisiana,' 70433 ' ,United States,328810,amyotrophic lateral sclerosis,"""gard:0005786""",
2910,ex-vivo expanded placental adherent stromal cells,,9/20/2017,treatment of acute radiation syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Pluri Biotech Ltd.,MATAM Advanced Technology Park,Building # 5,Haifa,,' ' ,Israel,599117,acute radiation syndrome,"""gard:0021896""",
2911,ex-vivo expanded placental adherent stromal cells,,9/24/2018,"treatment of graft failure and incomplete hematopoietic recovery, following hematopoietic cell transplantation (hct)",Designated,,Not FDA Approved for Orphan Indication,,,,,Pluri Biotech Ltd.,MATAM Advanced Technology Park,Building # 5,Haifa,,' ' ,Israel,626418,,,
2912,ex-vivo-expanded autologous keratinocytes transduced with retroviral vector containing the human COL7A1 gene.,,5/24/2017,treatment of dystrophic epidermolysis bullosa,Designated,,Not FDA Approved for Orphan Indication,,,,,Abeona Therapeutics,6555 Carnegie Blvd,Suite 401,Cleveland,Ohio,' 44103 ' ,United States,568716,dystrophic epidermolysis bullosa,"""gard:0002150""",
2913,exagamglogene autotemcel,Casgevy,5/11/2020,treatment of sickle cell disease,Designated/Approved,,,treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs),12/8/2023,12/8/2030,treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs),Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,715519,,,
2914,exagamglogene autotemcel,Casgevy,4/28/2020,treatment of beta-thalassemia,Designated/Approved,,,treatment of patients aged 12 years and older with transfusion-dependent beta-thalassemia (TDT),1/16/2024,1/16/2031,treatment of patients aged 12 years and older with transfusion-dependent beta-thalassemia (TDT),Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,714319,beta-thalassemia,"""gard:0000871""",
2915,Excindogen,,9/23/2020,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,CarcinEx Inc.,820 Grape St.,,Denver,Colorado,' 80220 ' ,United States,768020,,,
2916,"EXE-346, a Live Biotherapeutic Product (LBP), contains eight strains of probiotic bacteria.",,11/2/2020,treatment of pouchitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"ExeGi Pharma, LLC.",90 Church St.,,Rockville,Maryland,' 20850 ' ,United States,778120,pouchitis,"""gard:0020510""",
2917,Exemestane,Aromasin,9/19/1991,treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.,Designated/Approved,,,Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.,10/21/1999,10/21/2006,,Pharmacia & Upjohn,7000 Portage Road,Mail Stop: 0636-298-113,Kalamazoo,Michigan,' 49001 ' ,United States,60191,,,
2918,exenatide,,5/16/2017,treatment of idiopathic intracranial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,Boyd Consultants Ltd,"6th Floor, South Bank House, Barrow Street",,Dublin,,' 4 ' ,Ireland,530516,idiopathic intracranial hypertension,"""gard:0004561""",
2919,exendin-(9-39),,6/1/2011,treatment of congential hyperinsulinenic hypoglycemia and other causes of hyperinsulinemic hypoglycemia in adults and children,Designated/Designation Withdrawn or Revoked,2/14/2024,Not FDA Approved for Orphan Indication,,,,,The Children's Hospital of Philadelphia,Children's Hospital of Phil. Research Institute,Abramson Research Center,Philadelphia,Pennsylvania,' 19104 ' ,United States,321310,,,
2920,Exisulind,,2/14/1994,for the suppression and control of colonic adenomatous polyps in the inherited disease adenomatous polyposis coli.,Designated,,Not FDA Approved for Orphan Indication,,,,,"OSI Pharmaceuticals, Inc.",41 Pinelawn Road,,Melville,New York,' 11747 ' ,United States,79293,noma,"""gard:0004001""",
2921,Exon 44 specific phosphorothioate oligonucleotide,,11/5/2009,treatment of duchenne muscular dystrophy in patients who have a mutation correctable by skipping of exon 44of the dystrophin gene.,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,' 94949 ' ,United States,288309,muscular dystrophy,"""gard:0007922""",
2922,Exon 45 specific phosphorothioate oligonucleotide,,1/23/2013,treatment of duchenne muscular dystrophy patients bearing mutations that can be corrected by skipping exon 45,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,' 94949 ' ,United States,384512,muscular dystrophy,"""gard:0007922""",
2923,Exon 46 specific phosphorothioate oligonucleotide,,11/18/2005,treatment of duchenne muscular dystrophy,Designated/Designation Withdrawn or Revoked,4/25/2014,Not FDA Approved for Orphan Indication,,,,,Prosensa Therapuetics BV,Einsteinweg 55,,Leiden,,' ' ,Netherlands,211905,muscular dystrophy,"""gard:0007922""",
2924,Exon 51 specific phosphorothioate oligonucleotide,,8/25/2009,treatment of duchenne muscular dystrophy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,' 94949 ' ,United States,287209,muscular dystrophy,"""gard:0007922""",
2925,Exon 52 specific phosphorothiate oligonucleotide,,1/23/2013,treatment of duchenne muscular dystrophy patients bearing mutations that can be corrected by skipping exon 52,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,' 94949 ' ,United States,384412,muscular dystrophy,"""gard:0007922""",
2926,exon 53 specific phosphorothioate oligonucleotide,,1/23/2013,treatment of duchenne muscular dystrophy patients bearing mutations that can be corrected by skipping exon 53,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,' 94949 ' ,United States,384612,muscular dystrophy,"""gard:0007922""",
2927,Exon 55 specific phosphorothioate oligonucleotide,,1/23/2013,treatment of duchenne muscular dystrophy patients bearing mutations that can be corrected by skipping exon 55,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,' 94949 ' ,United States,384312,muscular dystrophy,"""gard:0007922""",
2928,exosomes purified from primed human bone marrow derived mesenchymal stem cells and methacrylated hyaluronic acid,,7/5/2023,treatment of neurotrophic keratitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pandorum Technologies, Inc.","Pandorum International, MBC BioLabs, LLC",733 Industrial Road,San Carlos,California,' 94070 ' ,United States,917722,,,
2929,expanded allogeneic human dermal fibroblasts in hypothermosol(r)-FRS,,8/20/2009,treatment of dystrophic epidermolysis bullosa.,Designated,,Not FDA Approved for Orphan Indication,,,,,Intercytex Ltd.,St. John's Innovation Centre,,Cambridge,,' ' ,United Kingdom,287909,dystrophic epidermolysis bullosa,"""gard:0002150""",
2930,expanded human allogeneic mesenchymal adult stem cells extracted from adipose tissue,,10/18/2017,treatment of fistulizing crohn's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,373012,,,
2931,expanded human allogeneic neural retinal progenitor cells extracted from neural retina,,8/22/2013,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,ReNeuron Ltd,Pencoed Business Park,,Pencoed,Bridgend,' ' ,United Kingdom,402613,retinitis pigmentosa,"""gard:0005694""",
2932,"expanded human autologous chondrocytes in a biopolymer (sodium alginate, gellan gum) matrix",,3/25/2019,treatment of microtia (including anotia),Designated,,Not FDA Approved for Orphan Indication,,,,,Auregen BioTherapeutics SA,Avenue Giuseppe Motta 31-33,Case Postale 145 CH-1211,Geneva,,' ' ,Switzerland,681919,anotia,"""gard:0016835""",
2933,"Expanded, activated methylguanine methyltransferase (MGMT) gene-modified gamma-delta T cells drug resistant immunotherapy",,4/24/2023,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,IN8bio Inc.,"350 5th Avenue, Suite 5330",,New York,New York,' 10018 ' ,United States,934723,,,
2934,Explored Claudin 18.2 CAR T Cells,,1/19/2022,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nanjing Bioheng Biotech Co., Ltd.","Block B1-2, 73 Tanmi Road",,Pukou District,Nanjing,' 00000 ' ,China,857821,,,
2935,extracellular domain of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 fused to the Fc region of human IgG1,,6/11/2018,treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency (generalized arterial calcification of infancy and autosomal recessive hypophosphatemic rickets type 2),Designated,,Not FDA Approved for Orphan Indication,,,,,Inozyme Pharma Inc.,700 Technology Square,,Cambridge,Massachusetts,' 02139 ' ,United States,637918,autosomal recessive hypophosphatemic rickets,"""gard:0017320""",
2936,"Extract of sea cucumber, sea sponge, shark fin, sea urchin, and sargassum grass",,5/14/2012,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Unicorn Pacific Corporation,No. 1 Monmount Road,Bellevue Estate,Port Vila,,' ' ,Vanuatu,368612,multiple myeloma,"""gard:0007108""",
2937,extract of sorghum bicolor extract,,11/19/2012,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Invenux, LLC",1550 Main Street,Suite A3,Windsor,Colorado,' 80550 ' ,United States,358811,,,
2938,"Extracts of herbs Scutellaria baicalensis Geori, Glycyrrhiza uralensis Fisch, Paeonia lactiflora Pall, and Ziziphus jujuba Mill",,2/11/2019,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Yiviva Inc.,"447 Broadway, 2FL",,New York,New York,' 10013 ' ,United States,673718,,,
2939,ezatiostat hydrochloride,,1/9/2013,treatment of myelodysplastic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hessian Pharmaceuticals, Inc.","1111 Broadway, 3rd Floor",Suite 03-138,Oakland,California,' 94607 ' ,United States,382312,myelodysplastic syndrome,"""gard:0007132""",
2940,ezogabine,,6/21/2018,treatment of kcnq2 epileptic encephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Xenon Pharmaceuticals, Inc.",200-3650 Gilmore Way,,Burnaby,British Columbia,' V5G 4W8 ' ,Canada,639118,,,
2941,ezurpimtrostat,,9/7/2022,treatment of cholangiocarcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Genfit SA,"Parc Eurasanté, 885 Avenue Eugène Avinée",,Loos,,' 59120 ' ,France,897522,cholangiocarcinoma,"""gard:0009304""",
2942,F18-PARPi,,3/21/2022,diagnostic for the management of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,"Theragnostics, Inc.","150 Grossman Drive, Suite 306",,Braintree,Massachusetts,' 02184 ' ,United States,868221,glioblastoma,"""gard:0002491""",
2943,faceted gold nanocrystals,,5/8/2019,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Clene Nanomedicine, Inc.",3165 East Millrock Drive,Suite 325,Salt Lake City,Utah,' 84121 ' ,United States,682119,amyotrophic lateral sclerosis,"""gard:0005786""",
2944,Facilitated DNA Plasmid Vaccine,,3/8/1995,treatment of cutaneous t cell lymphoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Wyeth-Lederle Vaccines and Pediatrics,211 Bailey Rd.,,West Henrietta,New York,' 14586 ' ,United States,88295,lymphoma,"""gard:0020548""",
2945,factor XIII concentrate (human),Corifact,1/16/1985,treatment of congenital factor xiii deficiency,Designated/Approved,,,Indicated for routine prophylactic treatment and peri-operative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency.,1/24/2013,1/24/2020,Peri-operative management of surgical bleeding in adult and pediatric patients with congenital Factor XIII deficiency.,CSL Behring LLC,1020 First Ave.,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,4484,congenital factor xiii deficiency,"""gard:0010766""",
2946,factor XIII concentrate (human),Corifact,1/16/1985,treatment of congenital factor xiii deficiency,Designated/Approved,,,For the routine prophylactic treatment of congenital factor XIII deficiency,2/17/2011,2/17/2018,,CSL Behring LLC,1020 First Ave.,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,4484,congenital factor xiii deficiency,"""gard:0010766""",
2947,"Factor XIII [A2] homodimer, recombinant DNA origin",,5/21/2003,treatment of congenital fxiii deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk Pharmaceuticals, INc.",100 College Road West,,Princeton,New Jersey,' 08540 ' ,United States,168603,,,
2948,"Factor XIII, recombinant",,4/22/1993,treatment of congenital factor xiii deficiency.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Zymogenetics, Inc.",4225 Roosevelt Way,,Seattle,Washington,' 98105 ' ,United States,73993,congenital factor xiii deficiency,"""gard:0010766""",
2949,fam-trastuzumab deruxtecan-nxki,Enhertu,5/20/2020,"treatment of gastric cancer, including gastroesophageal junction cancer",Designated/Approved,,,treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen,1/15/2021,1/15/2028,treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen,"Daiichi Sankyo, Inc.",211 Mount Airy Road,,Basking Ridge,New Jersey,' 07920 ' ,United States,738420,,,
2950,Fampridine,,6/2/1997,"treatment of chronic, incomplete spinal cord injury.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Acorda Therapeutics, Inc.",15 Skyline Dr.,,Hawthorne,New York,' 10532 ' ,United States,104497,spinal cord injury,"""gard:0019109""",
2951,Fancalen (lentiviral vector containing the Fanconi anemia-A (FANCA) gene,,5/2/2016,treatment of fanconi anemia type a patients.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Rocket Pharmaceuticals, Inc.",The Empire State Building,"350 Fifth Avenue, Suite 7530",New York,New York,' 10118 ' ,United States,519316,fanconi anemia,"""gard:0006425""",
2952,farletuzumab,,6/16/2006,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.,200 Metro Blvd.,,Nutley,New Jersey,' 07110-6102 ' ,United States,204905,ovarian cancer,"""gard:0007295""",
2953,fast skeletal muscle troponin activator,,5/11/2017,treatment of spinal muscular atrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cytokinetics, Inc.",280 East Grand Avenue,,South San Francisco,California,' 94080 ' ,United States,516215,,,
2954,fasudil,,9/5/2019,treatment of subarachnoid hemorrhage,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aneuryst, Inc.",211 East 43rd Street,Suite 710,New York,New York,' 10017-8601 ' ,United States,700019,,,
2955,Fasudil,,9/9/2020,treatment of frontotemporal dementia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Woolsey Pharmaceuticals, Inc.Woolsey Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,' 10279 ' ,United States,761320,frontotemporal dementia,"""gard:0008436""",
2956,Fasudil,,12/21/2020,treatment of progressive supranuclear palsy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Woolsey Pharmaceuticals, Inc.","233 Broadway, Suite 1750",,New York,New York,' 10279 ' ,United States,787220,progressive supranuclear palsy,"""gard:0007471""",
2957,Fasudil,,1/15/2020,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Woolsey Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,' 10279 ' ,United States,719119,amyotrophic lateral sclerosis,"""gard:0005786""",
2958,fasudil HCL,,8/25/2020,treatment of huntington’s disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Woolsey Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,' 10279 ' ,United States,715919,,,
2959,Fasudil hydrochloride,,5/3/2023,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,"BioPharma Global, a division of Pace® Life Sciences",1934 Old Gallows Rd Suite 420,,Vienna,Virginia,' 22182 ' ,United States,936123,amyotrophic lateral sclerosis,"""gard:0005786""",
2960,Fasudil hydrochloride,,9/21/2021,treatment of 16p11.2 deletion syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Woolsey Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,' 10279 ' ,United States,815421,n syndrome,"""gard:0003902""",
2961,Fasudil hydrochloride,,1/7/2021,treatment of corticobasal syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Woolsey Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,' 10279 ' ,United States,792720,corticobasal syndrome,"""gard:0013168""",
2962,fatty acylated parathyroid (prodrug) hormone agonist,,7/25/2022,treatment of hypoparathyroidism,Designated,,Not FDA Approved for Orphan Indication,,,,,MBX Biosciences,"275 Medical Drive, Unit 3904",,Carmel,Indiana,' 46032 ' ,United States,862221,,,
2963,FC-fusion bispecific antibody targeting extracellular domains II and IV of HER 2 and FC-fusion bispecific IgG1 antibody inhibiting PD-L1 and CTLA-4,,12/21/2020,"treatment of gastric cancer, including cancer of the gastroesophageal junction",Designated,,Not FDA Approved for Orphan Indication,,,,,"Jiangsu Alphamab Biopharmaceuticals Co., Ltd.","Bldg. C23, 218 Xinghu Street",SIP,SuZhou,,' ' ,China,786920,,,
2964,"fecal microbiota spores, live-brpk",Vowst,8/19/2015,treatment of recurrent clostridium difficile infection (cdi),Designated/Approved,,,to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI),4/26/2023,4/26/2030,to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI),"Seres Therapeutics, Inc.",200 Sidney St.,,Cambridge,Massachusetts,' 02139 ' ,United States,466214,,,
2965,"fecal microbiota, live - jslm",Rebyota,3/10/2014,prevention of recurrent clostridium difficile infection (cdi) in individuals with recurrent clostridium difficile infection,Designated/Approved,,,prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI,11/30/2022,11/30/2029,prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI,"Ferring Pharmaceuticals, Inc.",100 Interpace Parkway,,Parsippany,New Jersey,' 07054 ' ,United States,421013,,,
2966,Fedratinib,,3/21/2013,treatment of polycythemia vera,Designated,,Not FDA Approved for Orphan Indication,,,,,Impact Biomedicines,12526 High Bluff Drive,Suite 260,San Diego,California,' 92130 ' ,United States,390913,polycythemia,"""gard:0019466""",
2967,Fedratinib,INREBIC,5/18/2009,treatment of secondary and primary myelofibrosis,Designated/Approved,,,INREBIC® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).,8/16/2019,8/16/2026,For the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).,"Impact Biomedicines, Inc. a wholly-owned subsidiary of Celgene Corporation",86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,279409,primary myelofibrosis,"""gard:0008618""",
2968,Felbamate,Felbatol,1/24/1989,treatment of lennox-gastaut syndrome.,Designated/Approved,,,As adjunctive therapy in the treatment of partial and generalized seizures associated with the Lennox-Gastaut syndrome in children.,7/29/1993,7/29/2000,,Wallace Laboratories,301B College Road East,,Princeton,New Jersey,' 08540 ' ,United States,33488,lennox-gastaut syndrome,"""gard:0009912""",
2969,felzartamab,,5/17/2023,treatment of membranous nephropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Human Immunology Biosciences,2 Tower Place,,South San Francisco,California,' 94080 ' ,United States,939423,,,
2970,felzartamab,,3/12/2024,treatment of antibody mediated rejection in kidney transplant recipients,Designated,,Not FDA Approved for Orphan Indication,,,,,"Human Immunology Biosciences, Inc.",6000 Shoreline Court,Suite 304,South San Francisco,California,' 94080 ' ,United States,992823,,,
2971,fenfluramine,Fintepla,6/19/2017,treatment of lennox-gastaut syndrome,Designated/Approved,,,Treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older,3/25/2022,3/25/2029,Treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older,"UCB, Inc.","1950 Lake Park Drive, Bldg 2100",,Smyrna,Georgia,' 30080 ' ,United States,584217,lennox-gastaut syndrome,"""gard:0009912""",
2972,fenfluramine HCI,Fintepla,12/20/2013,for the treatment of dravet syndrome,Designated/Approved,,,Fintepla (fenfluramine) is indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older.,6/25/2020,6/25/2027,For the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older.,"UCB, Inc.","1950 Lake Park Drive, Bldg 2100",,Smyrna,Georgia,' 30080 ' ,United States,414613,dravet syndrome,"""gard:0010430""",
2973,fenfluramine hydrochloride,,6/7/2022,treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder,Designated,,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.","1950 Lake Park Drive, Bldg 2100",,Smyrna,Georgia,' 30080 ' ,United States,880422,,,
2974,Fenobam hydrochloride,,11/20/2006,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neuropharm, Ltd.",87 Church Street,,"Crowthorne, Berkshire",,' ' ,United Kingdom,232406,fragile x syndrome,"""gard:0006464""",
2975,Fenretinide,,4/7/2010,treatment of pseudomonas aeruginosa lung infections in cystic fibrosis patients,Designated,,Not FDA Approved for Orphan Indication,,,,,McGill University,McGill University,,Montreal,,' ' ,Canada,303210,cystic fibrosis,"""gard:0006233""",
2976,Fenretinide,,10/5/2005,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,USC-CHLA Institute for Pediatric Clinical Research,Children's Hospital Los Angeles,MS 55,Los Angeles,California,' 90027 ' ,United States,209805,neuroblastoma,"""gard:0007185""",
2977,fenretinide,,12/22/2017,treatment of peripheral t-cell lymphoma (including follicular t-cell lymphoma),Designated,,Not FDA Approved for Orphan Indication,,,,,"SciTech Development, LLC",281 Kercheval Avenue,,Grosse Pointe Farms,Michigan,' 48236 ' ,United States,621117,lymphoma,"""gard:0020548""",
2978,fenretinide,,12/19/2017,treatment of cutaneous t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"SciTech Development, LLC",281 Kercheval Avenue,,Grosse Pointe Farms,Michigan,' 48236 ' ,United States,615217,lymphoma,"""gard:0020548""",
2979,fenretinide,,9/4/2013,treatment of cutaneous t-cell lymphoma,Designated/Designation Withdrawn or Revoked,12/13/2021,Not FDA Approved for Orphan Indication,,,,,"CerRx, Inc.",Reese Technology Center,"9801 Reese Blvd, Suite 104",Lubbock,Texas,' 79416 ' ,United States,409913,lymphoma,"""gard:0020548""",
2980,fenretinide,,9/4/2013,treatment of peripheral t-cell lymphoma,Designated/Designation Withdrawn or Revoked,12/13/2021,Not FDA Approved for Orphan Indication,,,,,"CerRx, Inc.",Reese Technology Center,"9801 Reese Blvd, Suite 104",Lubbock,Texas,' 79416 ' ,United States,404013,lymphoma,"""gard:0020548""",
2981,fenretinide,,2/1/2007,treatment of ewing's sarcoma family of tumors.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Cancer Research UK,61 Lincoln's Inn Fields,WC2A 3PX,London,,' ' ,United Kingdom,236106,,,
2982,"ferric hexacyanoferrate (II) ""Prussian Blue""",,6/26/2003,treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium,Designated,,Not FDA Approved for Orphan Indication,,,,,Degussa AG,Weissfrauenstr 9,,Frankfurt,,' ' ,Germany,173403,,,
2983,ferroportin inhibitor,,1/25/2021,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vifor Pharma, Inc.",200 Cardinal Way,,Redwood City,California,' 94063 ' ,United States,796320,,,
2984,ferumoxytol,,10/7/2011,for use in magnetic resonance imaging in brain metastases,Designated,,Not FDA Approved for Orphan Indication,,,,,Covis Pharma GmbH,Grafenauweg 12,,Zug,,' 6300 ' ,Switzerland,350111,,,
2985,ferumoxytol,,4/6/2012,"for use in magnetic resonance imaging to assess, and monitor treatment of solid tumor malignancies previously diagnosed in pediatric patients (age 16 years and younger)",Designated,,Not FDA Approved for Orphan Indication,,,,,"ArsNova Partners, LLC",38 Frederick Street,,Newton,Massachusetts,' 02460 ' ,United States,365212,,,
2986,ferumoxytol,,4/29/2011,for use in mr imaging for the mangement of brain tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,Covis Pharma GmbH,Grafenauweg 12,,Zug,,' 6300 ' ,Switzerland,338411,,,
2987,fexinidazole,,4/4/2016,treatment of human african trypanosomiasis (hat) or sleeping sickness,Designated/Approved,,,"Treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg. Limitations of use: Due to the decreased efficacy observed in patients with severe second stage HAT (cerebrospinal fluid white blood cell count (CSF-WBC) >100 cells/?L) due to T. brucei gambiense disease, Fexinidazole Tablets should only be used in these patients if there are no other available treatment options.",7/16/2021,7/16/2028,"Treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg. Limitations of use: Due to the decreased efficacy observed in patients with severe second stage HAT (cerebrospinal fluid white blood cell count (CSF-WBC) >100 cells/?L) due to T. brucei gambiense disease, Fexinidazole Tablets should only be used in these patients if there are no other available treatment options.","Sanofi US Services Inc., A SANOFI COMPANY",55 Corporate Drive,,Bridgewater,New Jersey,' 08807-5925 ' ,United States,513915,african trypanosomiasis,"""gard:0007826""",
2988,fialuridine,,7/24/1992,adjunctive treatment of chronic active hepatitis b.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Oclassen Pharmaceuticals, Inc.",100 Pelican Way,,San Rafael,California,' 94901 ' ,United States,67892,,,
2989,Fibrin-based agent containing a N-terminally modified parathyroid hormone fragment TGplPTH1-34,,2/1/2007,treatment of solitary (unicameral) bone cysts,Designated,,Not FDA Approved for Orphan Indication,,,,,Kuros Biosurgery AG,Technoparkstrasse 1,,Zurich,,' ' ,Switzerland,217905,,,
2990,Fibrinogen (human),,8/23/1995,for the control of bleeding and prophylactic treatment of patients deficient in fibrinogen.,Designated,,Not FDA Approved for Orphan Indication,,,,,Alpha Therapeutic Corporation,5555 Valley Boulevard,,Los Angeles,California,' 90032 ' ,United States,88595,,,
2991,fibrinogen-depleted human platelet lysate,,2/24/2020,treatment of ocular graft-versus-host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Cambium Medical Technologies LLC,1055 Brookhaven Walk Northeast,,Atlanta,Georgia,' 30319 ' ,United States,620817,,,
2992,Fibromun,,12/18/2018,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Philogen S.p.A.,La Lizza 7,I-53100 Siena,Siena,Tuscany,' ' ,Italy,662918,soft tissue sarcoma,"""gard:0004898""",
2993,Fibromun / Onfekafusp alfa,,10/7/2020,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Philogen S.p.A.,Località Bellaria 35,,Sovicille,,' I-53018 ' ,Italy,771020,,,
2994,Fibronectin (human plasma derived),,9/5/1988,treatment of non-healing corneal ulcers or epithelial defects which have been unresponsive to conventional therapy and the underlying cause has been eliminated.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Melville Biologics, Inc.",310 East 67th Street,,New York,New York,' 10021 ' ,United States,24987,,,
2995,Fibronectin (plasma derived),,12/5/1988,treatment of non-healing corneal ulcers or epithelial defects which are unresponsive to conventional therapy and for which any infectious cause of the defect has been eliminated.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Chiron Vision,9342 Jeronimo Road,,Irvine,California,' 92718 ' ,United States,24287,,,
2996,Fibronectin Peptide,,6/29/2011,"prevention of burn injury progression of acute, deep dermal burns in hospitalized patients.",Designated,,Not FDA Approved for Orphan Indication,,,,,"NeoMatrix Therapeutics, Inc.",Long Island High Tech Incubator,25 Health Sciences Drive,Stony Brook,New York,' 11790 ' ,United States,311510,,,
2997,fidanacogene elaparvovec-dzkt,Beqvez,9/21/2015,treatment of hemophilia b.,Designated/Approved,,,"treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who: Currently use factor IX prophylaxis therapy, or; Have current or historical life-threatening hemorrhage, or; Have repeated, serious spontaneous bleeding episodes, and; Do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by an FDA-approved test",4/25/2024,4/25/2031,"treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who: Currently use factor IX prophylaxis therapy, or; Have current or historical life-threatening hemorrhage, or; Have repeated, serious spontaneous bleeding episodes, and; Do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by an FDA-approved test",Pfizer Inc.,66 Hudson Boulevard East,,New York,New York,' 10001 ' ,United States,490715,hemophilia,"""gard:0010418""",
2998,fidaxomicin,Dificid,12/13/2010,treatment of pediatric clostridium difficile infection,Designated/Approved,,,DIFICID® is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).,1/24/2020,1/24/2027,Dificid (fidaxomicin) is indicated for pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).,"Cubist Pharmaceuticals LLC, a subsidiary of Merck Sharp & Dohme LLC",20 Weystrasse,,Luzern,Luzern,' ' ,Switzerland,325210,,,
2999,filanesib,,5/6/2014,treatment of multiple myeloma.,Designated/Designation Withdrawn or Revoked,12/14/2021,Not FDA Approved for Orphan Indication,,,,,"Array BioPharma, Inc.",3200 Walnut Street,,Boulder,Colorado,' 80301 ' ,United States,431114,multiple myeloma,"""gard:0007108""",
3000,filgotinib maleate,,10/5/2017,treatment of pediatric ulcerative colitis (uc),Designated/Designation Withdrawn or Revoked,1/31/2022,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 East Blaine Street,,Seattle,Washington,' 98102 ' ,United States,604517,,,
3001,filgotinib maleate,,7/18/2017,treatment of pediatric crohn's disease,Designated/Designation Withdrawn or Revoked,1/31/2022,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 East Blaine Street,,Seattle,Washington,' 98102 ' ,United States,588017,,,
3002,Filgrastim,Neupogen,11/7/1996,"reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia.",Designated/Approved,,,"Reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia.",4/2/1998,4/2/2005,,"Amgen, Inc.",One Amgen Center Dr.,,Thousand Oaks,California,' 91320 ' ,United States,101096,acute myeloid leukemia,"""gard:0012757""",
3003,Filgrastim,Neupogen,10/1/1990,treatment of neutropenia associated with bone marrow transplants.,Designated/Approved,,,Reduce the duration of neutropenia and neutropenia sequelae in patients with non-myeloid malignancies undergoing ablative chemotherapy followed by BMT.,6/15/1994,6/15/2001,,"Amgen, Inc.",1840 Dehavilland Drive,,Thousand Oaks,California,' 91320 ' ,United States,50090,,,
3004,filgrastim,Neupogen,11/20/2013,treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident,Designated/Approved,,,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).,3/30/2015,3/30/2022,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).,"Amgen, Inc.",One Amgen Center Drive,M/S 17-1-C,Thousand Oaks,California,' 91320 ' ,United States,413113,,,
3005,Filgrastim,,8/30/1990,treatment of myelodysplastic syndrome,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",1840 Dehavilland Drive,,Thousand Oaks,California,' 91320 ' ,United States,49090,myelodysplastic syndrome,"""gard:0007132""",
3006,Filgrastim,Neupogen,11/7/1990,treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).,Designated/Approved,,,Treatment of patients with severe chronic neutropenia.,12/19/1994,12/19/2001,,"Amgen, Inc.",1840 Dehavilland Drive,,Thousand Oaks,California,' 91320 ' ,United States,49390,,,
3007,Filgrastim,Neupogen,7/17/1995,for use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.,Designated/Approved,,,For use in the mobilization of hematopoietic progenitor cells into the peripheral blood collection by leukapheresis.,12/28/1995,12/28/2002,,"Amgen, Inc.",1840 Dehavilland Drive,,Thousand Oaks,California,' 91320 ' ,United States,89395,,,
3008,Filgrastim,,9/3/1991,"treatment of patients with aids who, in addition, are afflicted with cytomegalovirus retinitis and are being treated with ganciclovir",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Dr.,,Thousand Oaks,California,' 91320 ' ,United States,49990,,,
3009,filgrastim,,1/27/2015,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,Neurovision Pharma GmbH,Emil-Geis Str. 4,,Grunwald,,' ' ,Germany,461814,amyotrophic lateral sclerosis,"""gard:0005786""",
3010,filociclovir,,11/29/2010,treatment of active cytomegalovirus infections,Designated,,Not FDA Approved for Orphan Indication,,,,,"Microbiotix, Inc.",One Innovation Drive,,Worcester,Massachusetts,' 01605 ' ,United States,319010,,,
3011,fimaporfin,,9/27/2017,treatment of cholangiocarcinoma,Designated/Designation Withdrawn or Revoked,9/30/2022,Not FDA Approved for Orphan Indication,,,,,PCI Biotech AS,64 Ullernchausseen,,Ullern,Oslo,' ' ,Norway,574217,cholangiocarcinoma,"""gard:0009304""",
3012,fingolimod,,4/30/2010,treatment of chronic inflammatory demyelinating polyneuropathy,Designated/Designation Withdrawn or Revoked,12/9/2020,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceutical Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,305910,chronic inflammatory demyelinating polyneuropathy,"""gard:0006102""",
3013,firolimogene autotemcel,,8/31/2020,treatment x-linked severe combined immunodeficiency.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mustang Bio, Inc.",377 Plantation Street,,Worcester,Massachusetts,' 01605 ' ,United States,759720,severe combined immunodeficiency,"""gard:0007628""",
3014,firtecan pegol,,4/18/2011,treatment of neuroblastoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Enzon Pharmaceuticals, Inc.",20 Kingsbridge Road,,Piscataway,New Jersey,' 08854 ' ,United States,338311,neuroblastoma,"""gard:0007185""",
3015,fish oil triglycerides,Omegaven,2/27/2008,treatment of parenteral nutrition-associated liver disease,Designated/Approved,,,Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC),7/27/2018,7/27/2025,Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC),"Fresenius Kabi USA, LLC",3 Corporate Drive,,Lake Zurich,Illinois,' 60047 ' ,United States,251507,,,
3016,fixed combination of dimethyl fumarate and aspirin (162mg),,9/27/2018,treatment of multiple sclerosis in patients who experience dimethyl fumarate flushing,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vitalis, LLC",93 4th Avenue,#19,New York,New York,' 10003 ' ,United States,607917,,,
3017,fixed combination of diroximel fumarate and aspirin,,4/6/2020,treatment of patients with multiple sclerosis who experience the fumarate flush,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vitalis, LLC",93 4th Avenue,#19,New York,New York,' 10003 ' ,United States,724719,,,
3018,Fixed combination of monomethyl fumarate and aspirin,,4/6/2020,treatment of patients with multiple sclerosis who experience the fumarate flush,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vitalis, LLC",93 4th Avenue,#19,New York,New York,' 10003 ' ,United States,724619,,,
3019,fixed dose combination of methimazole and liothyronine,,3/6/2017,treatment of brain metastases in patients with primary lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Musli Thyropeutics Ltd.,6 Hagefen Street,P. O. Box 529,Zur Moshe,,' ' ,Israel,539116,,,
3020,fixed dose combination of modafinil and flecainide,,9/19/2016,treatment of narcolepsy,Designated/Designation Withdrawn or Revoked,3/15/2023,Not FDA Approved for Orphan Indication,,,,,Theranexus S.A,86 Rue de Paris,,Orsay,Île-de-France,' ' ,France,536716,narcolepsy,"""gard:0022460""",
3021,fixed dose combination of Pyronaridine and Benznidazole,,5/11/2020,treatment of chagas disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc.",840 Main Campus Drive,Lab 3510,Raleigh,North Carolina,' 27606 ' ,United States,719219,,,
3022,fixed dose combination of pyronaridine tetraphosphate and artesunate,,9/27/2018,treatment of malaria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shin Poong Pharmaceutical Co., Ltd.","161 Yoksam-Ro, Gangnam-Gu",,Seoul,Seoul,' ' ,South Korea,651218,malaria,"""gard:0006961""",
3023,Fixed dose combination of relatlimab and nivolumab,,6/18/2018,treatment of gastric cancer (gc) and gastro-esophageal junction cancer (gej).,Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co.,P. O. Box 4000,,Princeton,New Jersey,' 08543 ' ,United States,641718,,,
3024,"fixed set of four ribonucleic acid lipoplex (RNA-LPX) drug products (RBL001.3, RBL002.4, RBL003.3, RBL004.3) which code for four melanoma tumor-associated antigens",,9/15/2021,treatment of stage iib through iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,BioNTech SE,An der Goldgrube 12,,,Mainz,' 55131 ' ,Germany,837221,noma,"""gard:0004001""",
3025,fixed-dose combination of celecoxib and ciprofloxacin.,,1/8/2020,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,NeuroSense Therapeutics,85 Medinat Ha-Yehudim,,Herzliya,,' ' ,Israel,718519,amyotrophic lateral sclerosis,"""gard:0005786""",
3026,Fixed-dose combination of Donepezil hydrochloride and Nebivolol hydrochloride,,9/28/2023,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,"Dr. Noah Biotech, Inc.","[16229] #1208, 91, Changnyong-daero256beon-gil, Yeongtong-gu",,Suwon-si,Gyeonggi-do,' ' ,South Korea,963223,amyotrophic lateral sclerosis,"""gard:0005786""",
3027,fixed-dose combination of potassium citrate and potassium bicarbonate,,12/9/2022,treatment of primary/inherited distal renal tubular acidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Advicenne,262 rue du Faubourg Saint Honoré,,Paris,Paris,' 75008 ' ,France,913522,distal renal tubular acidosis,"""gard:0004667""",
3028,fixed-dosed combination of L-citrulline + allopurinol,,4/30/2024,treatment of duchenne muscular dystrophy (dmd),Designated,,Not FDA Approved for Orphan Indication,,,,,"Dr. Noah Biotech, Inc.","[16229] #1208, 91, Changnyong-daero256beon-gil",Yeongtong- gu,Suwon-si,Gyeonggi-do,' ' ,South Korea,1001124,muscular dystrophy,"""gard:0007922""",
3029,florbetaben F18,,4/7/2020,diagnostic for the management of amyloid light chain (al) amyloidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Life Molecular Imaging Ltd.,"First Floor, The Woods, Opus 40 Business Park",,Warwick,,' CV34 5AH ' ,United Kingdom,732420,amyloidosis,"""gard:0018676""",
3030,florilglutamic acid,,5/11/2016,diagnostic for the management of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Life Molecular Imaging Ltd.,"Iceni Centre, Warwick Technology Park",,Warwick,,' CV34 6DA ' ,United Kingdom,517616,,,
3031,flotetuzumab,,12/22/2016,treatment of acute myeloid leukemia (aml),Designated/Designation Withdrawn or Revoked,3/1/2023,Not FDA Approved for Orphan Indication,,,,,"MacroGenics, Inc.",9704 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,563516,acute myeloid leukemia,"""gard:0012757""",
3032,"Floxuridine, FUDR",,12/22/2004,intraperitoneal treatment of gastric cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Franco Muggia, M.D.",160 East 34th Street,,New York,New York,' 10016 ' ,United States,195104,,,
3033,fluasterone,,3/28/2018,"treatment of cushing syndrome (including hyperglycemia, nonalcoholic fatty liver disease, and nonalcoholic steatosis)",Designated,,Not FDA Approved for Orphan Indication,,,,,"Sterotherapeutics, LLC",3805 Old Easton Road,,Doylestown,Pennsylvania,' 18902 ' ,United States,527116,cushing syndrome,"""gard:0006224""",
3034,flubendazole,,1/23/2014,"treatment of lymphatic filariasis caused by nematodes of the family filariodidea, in children and adults.",Designated/Designation Withdrawn or Revoked,4/10/2017,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,' 08869 ' ,United States,399813,filariasis,"""gard:0018757""",
3035,flubendazole,,10/25/2013,treatment of onchocerciasis caused by onchocerca volvulus,Designated/Designation Withdrawn or Revoked,4/10/2017,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,' 08869 ' ,United States,396713,onchocerciasis,"""gard:0007252""",
3036,flubrobenguane (18F),,6/4/2019,diagnostic for the management of neuroendocrine tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"Lantheus Medical Imaging, Inc.",331 Treble Cove Road,,North Billerica,Massachusetts,' 01862 ' ,United States,695819,,,
3037,fluciclovine (18F),,3/17/2023,diagnostic for the management of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Blue Earth Diagnostics Ltd,"The Oxford Science Park, Magdalen Centre",Robert Robinson Avenue,Oxford,Oxfordshire,' OX4 4GA ' ,United Kingdom,929022,multiple myeloma,"""gard:0007108""",
3038,"fluciclovine (18F)(anti-1-amino-3-fluorocyclobutane-1-carboxylic acid, labelled with Fluorine-18)",,4/7/2015,for the diagnosis of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Blue Earth Diagnostics Ltd.,215 Euston Rd.,NW1 2BE,London,,' ' ,United Kingdom,465814,,,
3039,Flucytosine Injection for intravenous Infusion,,6/21/2023,treatment of cryptococcal meningitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Cipla Ltd.,"Cipla House, Peninsula Business Park","Ganpatrao Kadam Marg, Lower Parel",,Mumbai,' 400 013 ' ,India,883722,,,
3040,Fludarabine phosphate,,4/18/1989,treatment and management of patients with non-hodgkins lymphoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Berlex Laboratories, Inc.",15049 San Pablo Avenue,P.O. Box 4099,Richmond,California,' 94804 ' ,United States,35889,lymphoma,"""gard:0020548""",
3041,Fludarabine phosphate,Fludara,4/18/1989,"treatment of chronic lymphocytic leukemia (cll), including refractory cll.",Designated/Approved,,,,4/18/1991,4/18/1998,,"Berlex Laboratories, Inc.","15049 San Pablo Avenue, P.O. Box 4099",,Richmond,California,' 94804 ' ,United States,27688,,,
3042,Fludarabine phosphate oral tablets,,12/18/2007,treatment of b-cell chronic lymphocytic leukemia,Designated/Approved,,,Treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not responded to or has progressed during or after treatment with at least one standard alkylating-agent containing regimen,12/18/2008,12/18/2015,,"Sanofi-Aventis U.S., Inc.",55 Corproate Drive,P. O. Box 5925,Bridgewater,New Jersey,' 08807 ' ,United States,250607,b-cell chronic lymphocytic leukemia,"""gard:0006104""",
3043,Flumecinol,,1/15/1985,treatment of hyperbilirubinemia in newborn infants unresponsive to phototherapy.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Farmacon, Inc.","Post House, Suite 213",1720 Post Road East,Westport,Connecticut,' 06880 ' ,United States,2984,,,
3044,flunarizine,,1/6/1986,treatment of alternating hemiplegia.,Designated,,Not FDA Approved for Orphan Indication,,,,,Janssen Research Foundation,,P.O. Box 200,Titusville,New Jersey,' 08560 ' ,United States,9485,alternating hemiplegia,"""gard:0020446""",
3045,flunarizine,,1/19/2022,treatment of juvenile absence epilepsy (jae),Designated,,Not FDA Approved for Orphan Indication,,,,,Xenon Pharmaceuticals Inc.,200-3650 Gilmore Way,,Burnaby,British Columbia,' V5G 4W8 ' ,Canada,857721,juvenile absence epilepsy,"""gard:0002162""",
3046,flunarizine,,5/12/2021,treatment of childhood absence epilepsy,Designated,,Not FDA Approved for Orphan Indication,,,,,Xenon Pharmaceuticals Inc.,200-3650 Gilmore Way,,Burnaby,British Columbia,' V5G 4W8 ' ,Canada,823521,childhood absence epilepsy,"""gard:0016667""",
3047,flunarizine,,11/20/2018,treatment of alternating hemiplegia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Xenon Pharmaceuticals, Inc.",200-3650 Gilmore Way,,Burnaby,British Columbia,' V5G 4W8 ' ,Canada,665818,alternating hemiplegia,"""gard:0020446""",
3048,flunarizine,,6/24/2013,treatment of alternating hemiplegia,Designated/Designation Withdrawn or Revoked,4/13/2017,Not FDA Approved for Orphan Indication,,,,,"Marathon Pharmaceuticals, LLC",1033 Skokie Blvd.,Suite 600,Northbrook,Illinois,' 60062 ' ,United States,398513,alternating hemiplegia,"""gard:0020446""",
3049,flunarizine,,7/20/2016,treatment of hemiplegic migraine,Designated,,Not FDA Approved for Orphan Indication,,,,,"Xenon Pharmaceuticals, Inc.",200-3650 Gilmore Way,,Burnaby,British Columbia,' V5G 4W8 ' ,Canada,528116,,,
3050,Fluocinolone,Retisert,7/31/2000,treatment uveitis involving the posterior segment of the eye.,Designated/Approved,,,Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye,4/8/2005,4/8/2012,,"Bausch & Lomb Pharmaceuticals, Inc.",8500 Hidden River Parkway,,Tampa,Florida,' 33637 ' ,United States,132800,uveitis,"""gard:0019549""",
3051,Fluorouracil,,6/29/2000,treatment of glioblastoma multiforme.,Designated,,Not FDA Approved for Orphan Indication,,,,,Ethypharm SA,194 Bureaux de la Colline - Batiment D,,92213 Saint-Cloud Cedex,,' ' ,France,131799,glioblastoma,"""gard:0002491""",
3052,Fluorouracil,,4/18/1990,"for use in combination with interferon alpha-2a, recombinant, for the treatment of advanced colorectal carcinoma.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,42289,noma,"""gard:0004001""",
3053,Fluorouracil,,2/6/1989,for use in combination with leucovorin for therapy of metastatic adenocarcinoma of the colon and rectum.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Lederle Laboratories,Division of American Cyanamid Company,401 N. Middletown Road,Pearl River,New York,' 10965 ' ,United States,32088,noma,"""gard:0004001""",
3054,Fluorouracil,,10/27/1989,"for use in combination with interferon alpha-2a, recombinant, for the treatment of esophageal carcinoma.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,40589,noma,"""gard:0004001""",
3055,Fluoxetine,,4/30/1999,treatment of autism.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neuropharm, Ltd.",Felcham Park House,,Surrey,,' ' ,United Kingdom,123199,,,
3056,Fluoxetine,,4/14/2004,treatment of body dysmorphic disorder in children and adolescents,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hollander, Eric MD",The Mount Sinai School of Medicine,One Gustave L. Levy Place,New York,New York,' 10029 ' ,United States,183504,,,
3057,fluticasone propionate,,1/19/2011,treatment of pediatric and adult eosinophilic esophagitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Ellodi Pharmaceuticals,"325 Sentry Parkway, Building 5 West, Suite 200",,Blue Bell,Pennsylvania,' 19422 ' ,United States,319410,,,
3058,fluticasone propionate,,12/29/2015,treatment of eosinophilic esophagitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Banner Life Sciences, LLC",4125 Premier Drive,,High Point,North Carolina,' 27265 ' ,United States,499815,,,
3059,folate binding protein peptide: Glu-Ile-Trp-Thr-His-Ser-Tyr-Lys-Val,,6/8/2016,treatment (including prevention of recurrence) of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Galena Biopharma, Inc.",Crow Canyon Place,Suite 380,San Ramon,California,' 94583 ' ,United States,522416,ovarian cancer,"""gard:0007295""",
3060,Folate Binding Protein Peptide: Glu-Ile-Trp-Thr-Phe-Ser-Thr-Lys-Val,,6/8/2016,treatment (including prevention of recurrence) of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Galena Biopharma, Inc.",Crow Canyon Place,Suite 380,San Ramon,California,' 94583 ' ,United States,528616,ovarian cancer,"""gard:0007295""",
3061,Folate-TRPV6-peptide exatecan drug conjugate,,9/19/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Coherent Biophanna (Hefei) Co., Ltd.","22nd Floor, Building A","National Health Industrial Park, High-tech District,",Hefei,Anhui,' 230088 ' ,China,963323,,,
3062,Folate-TRPV6-peptide exatecan drug conjugate,,4/8/2024,treatment of esophageal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Coherent Biophanna (Hefei) Co., Ltd.","22nd Floor, Building A","National Health Industrial Park, High-tech District",Hefei,Anhui,' 230088 ' ,China,996424,,,
3063,Follistatin291-IgG2 Fc fusion protein,,7/3/2018,treatment of facioscapulohumeral muscular dystrophy,Designated/Designation Withdrawn or Revoked,10/4/2019,Not FDA Approved for Orphan Indication,,,,,Acceleron Pharma Inc.,128 Sidney Street,,Cambridge,Massachusetts,' 02139 ' ,United States,573617,muscular dystrophy,"""gard:0007922""",
3064,"Follitropin alfa, recombinant",Gonal-F,12/21/1998,for the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure,Designated/Approved,,,For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.,5/24/2000,5/24/2007,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,119398,,,
3065,Fomepizole,,3/2/2021,treatment of acetaminophen overdose,Designated,,Not FDA Approved for Orphan Indication,,,,,Denver Health - Rocky Mountain Poison & Drug Safety,777 Bannock St. MC 0180,,Denver,Colorado,' 80204 ' ,United States,801320,,,
3066,fomepizole,Antizole,12/22/1988,treatment of methanol or ethylene glycol poisoning.,Designated/Approved,,,"Use for suspected or confirmed methanol poisoning, either alone or in combination with hemodialysis",12/8/2000,12/8/2007,,"Par Pharmaceuticals, Inc",1 Ram Ridge Road,,Chestnut Ridge,New York,' 10977 ' ,United States,33388,ethylene glycol poisoning,"""gard:0018805""",
3067,fomepizole,Antizole,12/22/1988,treatment of methanol or ethylene glycol poisoning.,Designated/Approved,,,"As an antidote to ethylene glycol (antifreeze) poisoning, or for use in suspected ethylene glycol ingestion.",12/4/1997,12/4/2004,,"Par Pharmaceuticals, Inc",1 Ram Ridge Road,,Chestnut Ridge,New York,' 10977 ' ,United States,33388,ethylene glycol poisoning,"""gard:0018805""",
3068,fosbretabulin tromethamine,,12/29/2015,treatment of neuroendocrine tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mateon Therapeutics, Inc.",701 Gateway Blvd,Suite 210,South San Francisco,California,' 94080 ' ,United States,500715,,,
3069,fosbretabulin tromethamine,,6/8/2016,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mateon Therapeutics, Inc.",701 Gateway Boulevard,Suite 210,South San Francisco,California,' 94080 ' ,United States,524816,,,
3070,fosdenopterin,Nulibry,11/5/2009,treatment of molybdenum cofactor deficiency type a (mocd),Designated/Approved,,,to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A,2/26/2021,2/26/2028,to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A,"Origin Biosciences, Inc.",75 Park Plaza,,Boston,Massachusetts,' 02116 ' ,United States,291209,,,
3071,fosfomycin/tobramycin,,11/28/2008,treatment of pulmonary infections associated with cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"CURx Pharmaceuticals, Inc.",3210 Merryfield Row,,San Diego,California,' 92121 ' ,United States,271908,cystic fibrosis,"""gard:0006233""",
3072,fosgemcitabine palabenamide,,6/11/2019,treatment of biliary tract cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,NuCana plc,3 Lochside Way,,Edinburgh,Scotland,' ' ,United Kingdom,644618,,,
3073,fosmanogepix,,11/2/2016,"treatment of invasive rare mold infections caused by scedosporium spp., fusarium spp., and mucorales fungi (including mucor spp., and rhizopus spp.)",Designated,,Not FDA Approved for Orphan Indication,,,,,"Basilea Pharmaceutica Ltd, Allschwil",Hegenheimermattweg 167b,,Allschwil,,' 4123 ' ,Switzerland,554916,,,
3074,fosmanogepix,,11/3/2016,treatment of coccidioidomycosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Basilea Pharmaceutica Ltd, Allschwil",Hegenheimermattweg 167b,,Allschwil,,' 4123 ' ,Switzerland,555016,coccidioidomycosis,"""gard:0009525""",
3075,fosmanogepix,,1/22/2019,treatment of cryptococcosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Basilea Pharmaceutica Ltd, Allschwil",Hegenheimermattweg 167b,,Allschwil,,' 4123 ' ,Switzerland,667318,cryptococcosis,"""gard:0006218""",
3076,fosmanogepix,,10/19/2016,treatment of invasive candidiasis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Basilea Pharmaceutica Ltd, Allschwil",Hegenheimermattweg 167b,,Allschwil,,' 4123 ' ,Switzerland,538616,,,
3077,fosmanogepix,,10/26/2016,treatment of invasive aspergillosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Basilea Pharmaceutica Ltd, Allschwil",Hegenheimermattweg 167b,,Allschwil,,' 4123 ' ,Switzerland,551416,aspergillosis,"""gard:0005856""",
3078,Fosphenytoin,Cerebyx,6/4/1991,for the acute treatment of patients with status epilepticus of the grand mal type.,Designated/Approved,,,For the control of generalized convulsive status epilepticus.,8/5/1996,8/5/2003,,Warner-Lambert Company,2800 Plymouth Road,,Ann Arbor,Michigan,' 48106 ' ,United States,55790,,,
3079,fostamatinib disodium,,1/31/2018,treatment of autoimmune hemolytic anemia (aiha),Designated,,Not FDA Approved for Orphan Indication,,,,,"Rigel Pharmaceuticals, INc.",1180 Veterans Blvd,,South San Francisco,California,' 94080 ' ,United States,544516,autoimmune hemolytic anemia,"""gard:0005870""",
3080,fostamatinib disodium hexahydrate,,8/25/2015,treatment of immune thrombocytopenic purpura,Designated/Approved,,,TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.,4/17/2018,4/17/2025,TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.,"Rigel Pharmaceuticals, Inc.",1180 Veterans Boulevard,,South San Francisco,California,' 94080 ' ,United States,487715,,,
3081,fresolimumab,,10/21/2010,treatment of primary focal segmental glomerulosclerosis,Designated/Designation Withdrawn or Revoked,8/19/2015,Not FDA Approved for Orphan Indication,,,,,"Genzyme, a Sanofi Company",200 Crossing Boulevard,,Framingham,Massachusetts,' 01702 ' ,United States,313510,,,
3082,"Fructose-1,6-diphosphate",,5/29/1998,treatment of painful vaso-occlusive episodes associated with sickle cell disease.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Questcor Pharmaceuticals, Inc.",3260 Whipple Road,,Union City,California,' 94587 ' ,United States,112398,,,
3083,FTV1+GDP-fucose,,3/18/2011,to improve homing to bone (treatment of myeloablation) in patients receiving hematopoietic stem cell transplantation.,Designated,,Not FDA Approved for Orphan Indication,,,,,"America Stem Cell, Inc.",11014 Bar X Trail,,Helotes,Texas,' 78023 ' ,United States,321010,,,
3084,Full Phosphorothioate Antisense Oligonucleotide against EWS-Fli-1 nanoparticles,,9/22/2008,treatment of ewing's sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,The Cure Our Children Foundation,1730 Michael Lane,,Pacific Palisades,California,' 90272 ' ,United States,202505,,,
3085,Fully Human Anti-BCMA (B-Cell Maturation Antigen) Autologous Chimeric Antigen Receptor (CAR) T Cell,,8/28/2019,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,CARsgen Therapeutics Corporation,"6575 West Loop South, Suite 455",,Bellaire,Texas,' 77401 ' ,United States,699819,multiple myeloma,"""gard:0007108""",
3086,Fully human anti-galectin-9 IgG4 monoclonal antibody,,2/27/2024,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,PureTech Health LLC,"6 Tide Street, Suite 400",,Boston,Massachusetts,' 02210 ' ,United States,990323,acute myeloid leukemia,"""gard:0012757""",
3087,Fully human anti-galectin-9 IgG4 monoclonal antibody,,11/10/2021,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"PureTech Health, LLC.",6 Tide Street,,Boston,Massachusetts,' 02210 ' ,United States,845321,,,
3088,Fully human anti-human neonatal Fc receptor (hFcRn) IgG1 monoclonal antibody,,6/24/2021,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immunovant Sciences, GmbH",Viaduktstrasse 8,4051 Basel,Basel,Basel-Stadt,' 04501 ' ,Switzerland,809421,myasthenia gravis,"""gard:0007122""",
3089,fully human anti-proMyostatin monoclonal antibody of the IgG4/lambda isotype that binds to human pro- and latent myostatin with high affinity,,3/22/2018,treatment of spinal muscular atrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Scholar Rock,620 Memorial Drive,Suite E,Cambridge,Massachusetts,' 02139 ' ,United States,629218,,,
3090,Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A),,1/31/2022,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nanjing Iaso Biotherapeutics Co., Ltd.","10th floor, Building D, Phase II","Zhongdan Eco Life Science Industrial Park, No. 3-1 Xinjinhu Rd.","Jiangbei New District, Nanjing",Jiangsu,' 210000 ' ,China,842921,multiple myeloma,"""gard:0007108""",
3091,Fully Human CD19 / CD22 Dual Target Chimeric Antigen Receptor Autologous T Cell Injection,,11/24/2021,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nanjing IASO Biotherapeutics Co., Ltd.","10th floor, Building D, Phase II","Zhongdan Eco Life Science Industrial Park, No. 3-1 Xinjinhu Rd.","Jiangbei New District, Nanjing",Jiangsu,' 210000 ' ,China,848821,acute lymphoblastic leukemia,"""gard:0000522""",
3092,Fully human IgG1 antibody specific for CD33,,2/27/2017,treatment of myelodysplastic syndromes (mds),Designated/Designation Withdrawn or Revoked,6/12/2023,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,' 06877 ' ,United States,555316,myelodysplastic syndrome,"""gard:0007132""",
3093,fully human IgG2 monoclonal antibody that binds insulin receptors,,6/9/2015,treatment of congenital hyperinsulinism,Designated,,Not FDA Approved for Orphan Indication,,,,,"Rezolute, Inc.",201 Redwood Shores Parkway,,Redwood City,California,' 94065 ' ,United States,430714,,,
3094,Fully human immunoglobulin G1 monoclonal antibody that targets CD32b,,1/29/2019,treatment of mantle cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,BioInvent International AB,Ideon Science Park,,Lund,Skåne County,' ' ,Sweden,669218,lymphoma,"""gard:0020548""",
3095,fully human monoclonal IgG1 antibody against the type 2 isoform of human Claudin 18 protein (Claudin 18.2).,,4/6/2021,"treatment of gastric cancer, including cancer of gastroesophageal junction",Designated,,Not FDA Approved for Orphan Indication,,,,,"Leap Therapeutics, Inc.","47 Thorndike Street, Suite B-1",,Cambridge,Massachusetts,' 02141 ' ,United States,810021,,,
3096,fully human nicotine-specific monoclonal antibody,,8/22/2018,treatment of thromboangiitis obliterans (buerger’s disease),Designated,,Not FDA Approved for Orphan Indication,,,,,"Antidote Therapeutics, Inc.",708 Quince Orchard Rd.,Suite 250-C,Gaithersburg,Maryland,' 20878 ' ,United States,647218,,,
3097,"fully human, antagonistic IgG1 monoclonal antibody targeting IL-27 subunit alpha (p28)",,10/8/2020,treatment of hepatocellular carcinoma (hcc),Designated,,Not FDA Approved for Orphan Indication,,,,,"Coherus BioSciences, Inc.","333 Twin Dolphin drive, Suite 600",,Redwood City,California,' 94065 ' ,United States,771820,hepatocellular carcinoma,"""gard:0016773""",
3098,fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA,,3/27/2023,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,BioMarin Pharmaceutical Inc.,105 Digital Drive,,Novato,California,' 94949 ' ,United States,910722,muscular dystrophy,"""gard:0007922""",
3099,"Functionalized benzodihydropyran or chroman closely related to triphendiol, cantrixil and trilexium",,10/2/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Noxopharm Ltd,159 Ridgecrop Drive,Suite 71,Castle Hill,New South Whales,' 02154 ' ,Australia,963023,,,
3100,furmonertinib,,2/5/2024,treatment of non-small cell lung cancer with epidermal growth factor receptor (egfr) mutations or human epidermal growth factor receptor 2 (her2) mutations or her4 mutations.,Designated,,Not FDA Approved for Orphan Indication,,,,,"ArriVent Biopharma, Inc.","18 Campus Blvd, Suite 100",,Newtown Square,Pennsylvania,' 19073 ' ,United States,869122,small cell lung cancer,"""gard:0009344""",
3101,fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha,,3/9/2021,treatment of mucosal melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mural Oncology, Inc.",852 Winter Street,,Waltham,Massachusetts,' 02451-1420 ' ,United States,806020,noma,"""gard:0004001""",
3102,fusion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to a human single chain variable fragment with affinity for human CD38 cell surface protein,,12/19/2019,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Molecular Templates, Inc.",9301 Amberglen Blvd. Suite 100,,Austin,Texas,' 78729 ' ,United States,713819,multiple myeloma,"""gard:0007108""",
3103,Fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1,,1/11/2006,treatment of x-linked hypohidrotic ectodermal dysplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,Espoir XLHED Sarl,EPFL Innovation Park,15 avenue Secheron,Geneva,Geneva,' ' ,Switzerland,216005,x-linked hypohidrotic ectodermal dysplasia,"""gard:0010427""",
3104,Fusion protein linking human frataxin to a cell-penetrant peptide,,7/19/2017,treatment of friedreich's ataxia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Larimar Therapeutics, Inc.",Three Bala Plaza East,Suite 506,Bala Cynwyd,Pennsylvania,' 19004 ' ,United States,590617,,,
3105,futibatinib,Lytgobi,5/23/2018,treatment of cholangiocarcinoma (cca),Designated/Approved,,,"Treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements",9/30/2022,9/30/2029,"Treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements","Taiho Oncology, Inc.","101 Carnegie Center, Suite 101",,Princeton,New Jersey,' 08540 ' ,United States,635018,cholangiocarcinoma,"""gard:0009304""",
3106,G17DT Immunogen,,7/10/2002,treatment of adenocarcinoma of the pancreas,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cancer Advances, Inc.",Westpark Corporate Center,Suite 210,Durham,North Carolina,' 27713 ' ,United States,156902,noma,"""gard:0004001""",
3107,G17DT Immunogen,,7/18/2002,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cancer Advances, Inc.",Westpark Corporate Center,Suite 210,Durham,North Carolina,' 27713 ' ,United States,157002,,,
3108,gabapentin,Gralise,11/8/2010,management of postherpetic neuralgia,Designated/Approved,,,For the management of postherpetic neuralgia,1/28/2011,1/28/2018,,Golf Acquiror LLC,44 Whippany Road,Suite 300,Morristown,New Jersey,' 07960 ' ,United States,236506,,,
3109,gabapentin,,7/5/1995,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Warner-Lambert Company,Parke-Davis Pharmaceutical Research Division,2800 Plymouth Road,Ann Arbor,Michigan,' 48105 ' ,United States,88695,amyotrophic lateral sclerosis,"""gard:0005786""",
3110,gabapentin enacarbil,Horizant,6/7/2011,treatment of postherpetic neuralgia,Designated/Approved,,,Management of postherpetic neuralgia in adults.,6/6/2012,6/6/2019,,"Arbor Pharmaceuticals, LLC",6 Concourse Parkway,Suite 1800,Atlanta,Georgia,' 30328 ' ,United States,330710,,,
3111,Gabexate,,9/18/2020,treatment of anti-neutrophil cytoplasmic antibody (anca)-associated vasculitis,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenafly,New Jersey,' 07670 ' ,United States,764320,vasculitis,"""gard:0018844""",
3112,Gaboxadol,,10/3/2017,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Ovid Therapeutics,1460 Broadway,,New York,New York,' 10036 ' ,United States,605517,fragile x syndrome,"""gard:0006464""",
3113,Gadolinium-chelated polysiloxane based nanoparticles,,5/10/2021,radiosensitizer to be used during radiation treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,NH TherAguix,"29, Chemin de Vieux Chêne",,Meylan,,' 38240 ' ,France,816121,,,
3114,Gadolinium-chelated polysiloxane based nanoparticles,,2/25/2021,radiosensitizer to be used during radiation treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Nh TherAguix,"29, chemin du Vieux Chêne",,Meylan,,' 38240 ' ,France,803120,,,
3115,galinpepimut-S,,5/8/2018,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"SELLAS Life Sciences Group, Inc.",315 Madison Avenue,4th floor,New York,New York,' 10017 ' ,United States,636918,multiple myeloma,"""gard:0007108""",
3116,Gallium (68Ga) edotreotide,,7/1/2015,diagnostic for the clinical management of neuroendocrine tumors.,Designated/Designation Withdrawn or Revoked,12/9/2020,Not FDA Approved for Orphan Indication,,,,,"Advanced Accelerator Applications, USA",57 East Willow Street,,Millburn,New Jersey,' 07041 ' ,United States,483915,,,
3117,gallium citrate,,6/24/2019,treatment of lung infections in patients with cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aridis Pharmaceuticals, Inc.",5941 Optical Court,,San Jose,California,' 95138 ' ,United States,689419,cystic fibrosis,"""gard:0006233""",
3118,gallium maltolate,,10/5/2023,treatment of atypical teratoid/rhabdoid tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"Imaging Biometrics, LLC",13416 Watertown Plank Road,Suite 260,Elm Grove,Wisconsin,' 53122 ' ,United States,948023,rhabdoid tumor,"""gard:0007572""",
3119,Gallium maltolate,,2/27/2023,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Imaging Biometrics, LLC",13416 Watertown Plank Road,Suite 260,Elm Grove,Wisconsin,' 53122 ' ,United States,924822,glioblastoma,"""gard:0002491""",
3120,Gallium nitrate injection,Ganite,12/5/1988,treatment of hypercalcemia of malignancy.,Designated/Approved/Designation Withdrawn or Revoked,,,,1/17/1991,1/17/1998,,Solopak Pharmaceutical Co.,1845 Tonne Road,,Elk Grove Village,Illinois,' 60007 ' ,United States,24487,,,
3121,"Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide",NETSPOT,12/31/2013,diagnostic for the clinical management of neuroendocrine tumors,Designated/Approved,,,"For use after radiolabeling with Ga 68, with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.",6/1/2016,6/1/2023,A radioactive diagnostic agent indicated for use with with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.,"Advanced Accelerator Applications, USA",57 East Willow Street,,Millburn,New Jersey,' 07041 ' ,United States,413613,,,
3122,Gallium-68 (DOTA0-Phel-Tyr3)octreotide,,10/25/2013,the management of neuroendocrine tumors,Designated/Approved,,,Ga 68 DOTATOC Injection is indicated for use with positron emission tomography (PET) for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.,8/21/2019,,Exclusivity waived by sponsor,University of Iowa Hospital & Clinics,Department of Radiology/PET Imaging Center,200 Hawkins Drive,Iowa City,Iowa,' 52242 ' ,United States,409513,,,
3123,Gamma hydroxybutyrate,,12/3/1987,"treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations and automatic behavior.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Biocraft Laboratories, Inc.",18-01 River Road,,Fair Lawn,New Jersey,' 07410 ' ,United States,26387,narcolepsy,"""gard:0022460""",
3124,Gamma-hydroxybutyric acid,,1/22/1985,"treatment of narcolepsy and the auxiliary symptoms of cataplexy, sleep paralysis, hypnagogic hallucinations, and automatic behavior.",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Sigma Chemical Company,,,,,' ' ,,5384,narcolepsy,"""gard:0022460""",
3125,Gammalinolenic acid,,7/27/1994,treatment of juvenile rheumatoid arthritis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Zurier, Robert B. M.D.",University of Massachusetts Medical Center,55 Lake Avenue,Worcester,Massachusetts,' 01655 ' ,United States,82994,,,
3126,Ganaplacide and Lumefantrine fixed-dose combination,,8/15/2022,treatment of malaria,Designated,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936-1080 ' ,United States,895622,malaria,"""gard:0006961""",
3127,ganaxolone,,3/21/2023,treatment of lennox-gastaut syndrome (lgs),Designated,,Not FDA Approved for Orphan Indication,,,,,"Marinus Pharmaceuticals, Inc.",5 Radnor Corporate Center,"100 Matsonford Road, Suite 500",Radnor,Pennsylvania,' 19087 ' ,United States,929822,lennox-gastaut syndrome,"""gard:0009912""",
3128,ganaxolone,,3/24/2015,treatment of protocadherin 19 (pcdh19) female epilepsy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Marinus Pharmaceuticals, Inc.",3 Radnor Corporate Center,Suite 304,Radnor,Pennsylvania,' 19087 ' ,United States,473515,,,
3129,ganaxolone,Ztalmy,6/28/2017,treatment of cyclin-dependent kinase-like 5 (cdkl5) gene-related early-onset infantile epileptic encephalopathy,Designated/Approved,,,Treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older,6/1/2022,6/1/2029,Treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older,Marinus Pharmaceuticals,170 North Radnor Chester Road,Suite 250,Radnor,Pennsylvania,' 19087 ' ,United States,578017,,,
3130,Ganaxolone,,5/25/1994,treatment of infantile spasms.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Marinus Pharmaceuticals, Inc.",21 Business Park Drive,,Branford,Connecticut,' 06405 ' ,United States,81894,,,
3131,ganaxolone,,4/14/2016,treatment of status epilepticus.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Marinus Pharmaceuticals, Inc.",Three Radnor Corporate Center,100 Matsonford Road,Radnor,Pennsylvania,' 19087 ' ,United States,489215,,,
3132,ganaxolone,,12/28/2016,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Marinus Pharmaceuticals,170 North Radnor Chester Road,Suite 250,Radnor,Pennsylvania,' 19087 ' ,United States,547116,fragile x syndrome,"""gard:0006464""",
3133,ganaxolone,,8/12/2021,treatment of tuberous sclerosis complex,Designated,,Not FDA Approved for Orphan Indication,,,,,"Marinus Pharmaceuticals, Inc.",5 Radnor Corporate Center,,Radnor,Pennsylvania,' 19087 ' ,United States,833521,tuberous sclerosis complex,"""gard:0007830""",
3134,ganciclovir,Zirgan,3/22/2007,treatment of acute herpetic keratitis (dendritic and geographic ulcers),Designated/Approved,,,Treatment of acute herpetic keratitis (dendritic ulcers),9/15/2009,9/15/2016,,"Sirion Therapeutics, Inc.",9314 East Broadway Avenue,,Tampa,Florida,' 33619 ' ,United States,237607,,,
3135,Ganciclovir intravitreal implant,Vitrasert Implant,6/7/1995,treatment of cytomegalovirus retinitis.,Designated/Approved,,,Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome.,3/4/1996,3/4/2003,,"Bausch & Lomb Surgical, Chiron Vision Products",9342 Jeronimo Road,,Irvine,California,' 92718 ' ,United States,86494,,,
3136,Ganciclovir sodium,Cytovene,10/31/1985,treatment of cytomegalovirus retinitis in immunocompromised patients with aids.,Designated/Approved/Designation Withdrawn or Revoked,,,,6/23/1989,6/23/1996,,"Syntex (USA), Inc.",3401 Hillview Avenue,,Palo Alto,California,' 94304 ' ,United States,7985,,,
3137,Gancyclovir,,6/7/1985,treatment of severe human cytomegalovirus infections in specific immunosuppressed patient populations.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Burroughs Wellcome Company,3030 Cornwallis Road,P.O. Box 12700,Research Triangle Park,North Carolina,' 27709 ' ,United States,5885,,,
3138,Gangliosides as sodium salts,,11/17/1988,treatment of retinitis pigmentosa.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Fidia Pharmaceutical Corp.,"1401 Eye Street, N.W. Suite 900",,Washington,District of Columbia,' 20005 ' ,United States,31388,retinitis pigmentosa,"""gard:0005694""",
3139,ganitumab,,3/21/2017,treatment of ewing sarcoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"NantCell, Inc., a wholly-owned subsidiary of ImmunityBio, Inc.",9920 Jefferson Boulevard,,Culver City,California,' 90232 ' ,United States,578217,,,
3140,ganitumab,,11/23/2010,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"NantCell, Inc., a wholly-owned subsidiary of ImmunityBio, Inc.",9920 Jefferson Boulevard,,Culver City,California,' 90232 ' ,United States,321510,,,
3141,garadacimab,,4/30/2020,treatment of bradykinin-mediated angioedema,Designated,,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,715419,,,
3142,garadacimab,,8/16/2022,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,P.O. Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,870622,idiopathic pulmonary fibrosis,"""gard:0008609""",
3143,Gastrin 17C Diphtheria Toxoid Immunogen,,7/7/2009,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Astrimmune Ltd.,Mansfield i-cente,Hamilton Way,Mansfield,,' ' ,United Kingdom,256708,,,
3144,Gavilimomab,,11/20/2000,acute graft-versus-host disease (agvhd),Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Amgen,One Amgen Center Drive,Mail Stop 17-2-A,Thousand Oaks,California,' 91320 ' ,United States,136900,,,
3145,gavocabtagene autoleucel (gavo-cel),,9/1/2021,treatment of cholangiocarcinoma,Designated/Designation Withdrawn or Revoked,1/16/2024,Not FDA Approved for Orphan Indication,,,,,"TCR2 Therapeutics, Inc., a wholly owned","100 Binney Street, Suite 710",,Cambridge,Massachusetts,' 02142 ' ,United States,689519,cholangiocarcinoma,"""gard:0009304""",
3146,GCSF-mobilized autologous CD34 cells for intramuscular injection,,3/4/2021,treatment of buerger's disease (thromboangiitis obliterans),Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Lisata Therapeutics,110 Allen Road,Second Floor,Basking Ridge,New Jersey,' 07920 ' ,United States,805020,,,
3147,gefitinib,Iressa,8/26/2014,treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer,Designated/Approved,,,For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test,7/13/2015,7/13/2022,For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,' 19803 ' ,United States,443014,small cell lung cancer,"""gard:0009344""",
3148,gemcabene,,2/6/2014,treatment of homozygous familial hypercholesterolemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"NeuroBo Pharmaceuticals, Inc.",200 Berkeley Street,FL 19,Boston,Massachusetts,' 02116 ' ,United States,419313,homozygous familial hypercholesterolemia,"""gard:0010416""",
3149,gemcitabine,,12/30/2015,treatment of upper tract urothelial carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,TARIS Biomedical LLC,113 Hartwell Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,502015,upper tract urothelial carcinoma,"""gard:0009376""",
3150,Gemcitabine,,5/18/2020,treatment of cholangiocarcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,RenovoRx,4546 El Camino Real,Suite 203,Los Altos,California,' 94022 ' ,United States,737820,cholangiocarcinoma,"""gard:0009304""",
3151,gemcitabine,,1/11/2016,treatment of cholangiocarcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"InnoPharmax, Inc.","9F, No. 22, Lane 478",Rueiguang Road,Taipei,Neihu District,' ' ,Taiwan,504815,cholangiocarcinoma,"""gard:0009304""",
3152,gemcitabine intra-arterial infusion via the RenovoCath¿ RC120 catheter,,4/24/2018,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,RenovoRx,4546 El Camino Real,Suite 203,Los Altos,California,' 94022 ' ,United States,620917,,,
3153,gemcitabine ready-to-use,,6/24/2015,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,7/12/2021,Not FDA Approved for Orphan Indication,,,,,Sun Pharmaceutical Industries Ltd.,Acme Plaza,,"Andheri (East), Mumbai 400059",,' ' ,India,476915,,,
3154,gemcitabine ready-to-use,,6/24/2015,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,7/12/2021,Not FDA Approved for Orphan Indication,,,,,Sun Pharmaceutical Industries Ltd.,Acme Plaza,,"Andheri (East), Mumbai 400059",,' ' ,India,477015,ovarian cancer,"""gard:0007295""",
3155,Gemfibrozil,,8/30/2021,treatment of krabbe disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Polaryx Therapeutics, Inc.","140 E. Ridgewood Avenue, Suite 415, South Tower",,Paramus,New Jersey,' 07652 ' ,United States,834921,krabbe disease,"""gard:0006844""",
3156,gemfibrozil,,8/2/2017,treatment of neuronal ceroid lipofuscinoses,Designated,,Not FDA Approved for Orphan Indication,,,,,"Polaryx Therapeutics, Inc.",140 East Ridgewood Avenue,"Suite 415, South Tower",Paramus,New Jersey,' 07652 ' ,United States,591917,,,
3157,Gemfibrozil,,8/27/2021,treatment of gm2 gangliosidoses,Designated,,Not FDA Approved for Orphan Indication,,,,,"Polaryx Therapeutics, Inc.","140 E. Ridgewood Avenue, Suite 415, South Tower",,Paramus,New Jersey,' 07652 ' ,United States,834821,,,
3158,gemfibrozil and vitamin A,,12/6/2017,treatment of neuronal ceroid lipofuscinoses,Designated,,Not FDA Approved for Orphan Indication,,,,,"Polaryx Therapeutics, Inc.",140 East Ridgewood Avenue,"Suite 415, South Tower",Paramus,New Jersey,' 07652 ' ,United States,546216,,,
3159,Gemtuzumab ozogamicin,Mylotarg,11/24/1999,treatment of acute myeloid leukemia,Designated/Approved,,,Treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy,5/17/2000,5/17/2007,,"Wyeth Pharmaceuticals, Inc., a Pfizer Company",10646 Science Center Drive,,San Diego,California,' 92121 ' ,United States,127899,acute myeloid leukemia,"""gard:0012757""",
3160,Gemtuzumab ozogamicin,Mylotarg,11/24/1999,treatment of acute myeloid leukemia,Designated/Approved,,,Mylotarg¿ is indicated for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and pediatric patients 1 month and older and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older.,6/16/2020,6/16/2027,For the treatment of newly-diagnosed CD33-positive acute myeloid leukemia in pediatric patients 1 month and older,"Wyeth Pharmaceuticals, Inc., a Pfizer Company",10646 Science Center Drive,,San Diego,California,' 92121 ' ,United States,127899,acute myeloid leukemia,"""gard:0012757""",
3161,Gemtuzumab ozogamicin,Mylotarg,11/24/1999,treatment of acute myeloid leukemia,Designated/Approved,,,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older,9/1/2017,9/1/2024,Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older,"Wyeth Pharmaceuticals, Inc., a Pfizer Company",10646 Science Center Drive,,San Diego,California,' 92121 ' ,United States,127899,acute myeloid leukemia,"""gard:0012757""",
3162,gene encoding chimeric CD40 ligand,,2/4/2009,treatment of chronic lymphocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Memgen, LLC",402 W. Broadway,Suite 400,San Diego,California,' 92101 ' ,United States,273608,,,
3163,"generation 4 hydroxyl-terminated polyamidoamine dendrimer containing an ethylene diamine (EDA) core, amidoamine repate units, and 64 hydroxyl end groups",,3/22/2017,treatment of x-linked adrenoleukodystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Ashvattha Therapeutics,1235 Radio Road - Suite 200,,Redwood City,California,' 94065 ' ,United States,551316,leukodystrophy,"""gard:0006895""",
3164,"Genetically engineered (alpha-1,3-galactosyltransferase knock-out}, live cell porcine (Sus scrofa) xenotransplantation skin graft",,6/14/2021,"treatment of severe and extensive, deep partial and full-thickness burn wounds requiring hospitalization, surgical excision, and skin grafting.",Designated,,Not FDA Approved for Orphan Indication,,,,,"XenoTherapeutics, Inc.",359 Newbury St,Unit 526,Boston,Massachusetts,' 02115 ' ,United States,819421,,,
3165,genetically engineered herpes simplex virus,,5/9/2019,treatment of medulloblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aettis, Inc.",128 Penarth Road,,Bala Cynwyd,Pennsylvania,' 19004 ' ,United States,682419,medulloblastoma,"""gard:0007005""",
3166,genetically engineered herpes simplex virus,,5/9/2019,treatment of primitive neuroectodermal brain tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aettis, Inc.",128 Penarth Road,,Bala Cynwyd,Pennsylvania,' 19004 ' ,United States,692219,,,
3167,genetically engineered herpes simplex virus (G207),,4/29/2002,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aettis, Inc.",128 Penarth Road,,Bala Cynwyd,Pennsylvania,' 19004 ' ,United States,155202,,,
3168,Genetically engineered human recombinant IgG4 monoclonal antibody directed against human TNF alpha,,12/11/1997,treatment of crohn's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Celltech Chiroscience Limited,216 Bath Road,,Slough,Berkshire,' ' ,United Kingdom,108497,,,
3169,genetically modified allogeneic chimeric antigen receptor (CAR)-T cell therapy designed to target cell surface B-Cell Maturation Antigen,,3/12/2024,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Poseida Therapeutics, Inc.","9390 Towne Center Drive, Suite 200,",,San Diego,California,' 92121 ' ,United States,993023,multiple myeloma,"""gard:0007108""",
3170,Genetically modified human adenovirus encoding human PH20,,6/27/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Theriva Biologics S.L.,"Torrent de Can Ninou, naus 5-6",,Parets del Vallès,,' 08150 ' ,Spain,945723,,,
3171,Genetically modified human adenovirus encoding human PH20,,2/7/2022,treatment of retinoblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,VCN Biosciences S.L.,Avinguda de la Generalitat 152,Sant Cugat del Vallès,Barcelona,,' 08174 ' ,Spain,860321,retinoblastoma,"""gard:0007563""",
3172,"genetically modified, non-self replicating Adeno-Associated Virus serotype 9 expressing shRNA to knock down mutant PABP1 as well as a codon optimized, shRNA-insensitive, wildtype PABN1",,1/8/2018,treatment of oculopharyngeal muscular dystrophy (opmd),Designated,,Not FDA Approved for Orphan Indication,,,,,Benitec Biopharma Limited,"99 Mount Street,",Suit 1201,North Sydney,NSW,' ' ,Australia,617717,muscular dystrophy,"""gard:0007922""",
3173,"genetically recombinant, non-pathogenic polio:rhinovirus chimera with a tumor--specific conditional replication phenotype",,1/8/2021,treatment of stage iib-iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Istari Oncology, Inc.","430 Davis Drive, Suite 560",,Morrisville,North Carolina,' 27560 ' ,United States,793620,noma,"""gard:0004001""",
3174,Geneticin,,6/6/2005,treatment of amoebiasis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"ProcesScience, Inc. (PSI)",117 Woodberry Lane,,Fayetteville,New York,' 13066 ' ,United States,204605,,,
3175,gentamicin C2 congener,,3/29/2016,treatment of cystic fibrosis,Designated/Designation Withdrawn or Revoked,6/28/2019,Not FDA Approved for Orphan Indication,,,,,La Jolla Pharmaceuticals Company,10182 Telesis Court,Suite 600,San Diego,California,' 92121 ' ,United States,513215,cystic fibrosis,"""gard:0006233""",
3176,Gentamicin impregnated PMMA beads on surgical wire,,1/31/1991,"treatment of chronic osteomyelitis of post-traumatic, postoperative, or hematogenous origin.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Lipha Pharmaceuticals, Inc.",9 West 57th Street,Suite 3825,New York,New York,' 10019 ' ,United States,52090,,,
3177,Gentamicin liposome injection,,7/10/1990,treatment of disseminated mycobacterium avium-intracellulare infection.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Liposome Company, Inc.",One Research Way,,Princeton,New Jersey,' 08540 ' ,United States,47390,,,
3178,Gentulizumab,,10/12/2021,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Changchun GeneScience Pharmaceutical Co., Ltd.",No. 1718 Yueda Road,Changchun High-Tech Dev. Zone,Changchun City,Jilin Province,' 130012 ' ,China,841321,acute myeloid leukemia,"""gard:0012757""",
3179,geranylgeranylacetone,,6/26/2020,treatment of spinal and bulbar muscular atrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,' 07670 ' ,United States,744620,,,
3180,geranylgeranylacetone,,6/10/2020,prevention of acute radiation syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,' 07670 ' ,United States,743920,acute radiation syndrome,"""gard:0021896""",
3181,Geranylgeranylacetone,,6/16/2020,prevention of post-hepatectomy liver failure,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,' 07670 ' ,United States,742220,,,
3182,gevokizumab,,7/27/2010,treatment of behcet's disease,Designated/Designation Withdrawn or Revoked,6/14/2018,Not FDA Approved for Orphan Indication,,,,,XOMA (US) LLC,2910 Seventh St.,,Berkeley,California,' 94710 ' ,United States,310810,,,
3183,gevokizumab,,2/21/2014,treatment of pyoderma gangrenosum,Designated/Designation Withdrawn or Revoked,6/14/2018,Not FDA Approved for Orphan Indication,,,,,XOMA (US) LLC,2910 Seventh St.,,Berkeley,California,' 94710 ' ,United States,419113,pyoderma gangrenosum,"""gard:0007510""",
3184,gevokizumab,,8/20/2012,"treatment of non-infectious intermediate, posterior or pan uveitis, or chronic non-infectious anterior uveitis",Designated/Designation Withdrawn or Revoked,6/14/2018,Not FDA Approved for Orphan Indication,,,,,XOMA (US) LLC,2910 Seventh St.,,Berkeley,California,' 94710 ' ,United States,364512,non-infectious anterior uveitis,"""gard:0021260""",
3185,gilteritinib,XOSPATA,7/13/2017,treatment of acute myeloid leukemia (aml),Designated/Approved,,,XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.,11/28/2018,11/28/2025,XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.,"Astellas Pharma US, Inc.",1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,587217,acute myeloid leukemia,"""gard:0012757""",
3186,Girentuximab,,3/22/2001,treatment of renal cell carcinoma.,Designated/Designation Withdrawn or Revoked,4/29/2021,Not FDA Approved for Orphan Indication,,,,,Heidelberg Pharma AG,101 Schriesheimer Straße,,Ladenburg,Baden-Württemberg,' ' ,Germany,139000,renal cell carcinoma,"""gard:0013215""",
3187,Givinostat,,9/28/2017,treatment of polycythemia vera (pv),Designated,,Not FDA Approved for Orphan Indication,,,,,Italfarmaco SpA,54 Via dei Lavoratori,,Cinisello Balsamo,Lombardia,' ' ,Italy,604917,polycythemia,"""gard:0019466""",
3188,givinostat,Duvyzat,4/12/2013,treatment of duchenne muscular dystrophy and becker muscular dystrophy,Designated/Approved,,,treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older,3/21/2024,3/21/2031,treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older,Italfarmaco SpA,"Via dei Lavoratori, 54",,20092 Cinisello Balsamo,,' ' ,Italy,391613,muscular dystrophy,"""gard:0007922""",
3189,givosiran,GIVLAARI,8/29/2016,treatment of acute hepatic porphyria,Designated/Approved,,,GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP).,11/20/2019,11/20/2026,Indicated for the treatment of adults with acute hepatic porphyria (AHP).,"Alnylam Pharmaceuticals, Inc.",101 Main Street,,Cambridge,Massachusetts,' 02142 ' ,United States,535516,acute hepatic porphyria,"""gard:0019255""",
3190,Glasdegib,DAURISMO,6/28/2017,treatment of acute myeloid leukemia (aml),Designated/Approved,,,"DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.",11/21/2018,11/21/2025,"DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.","Pfizer, Inc.",445 Eastern Point Road,,Groton,Connecticut,' 06340 ' ,United States,585517,acute myeloid leukemia,"""gard:0012757""",
3191,glasdegib,,10/20/2017,treatment of myelodysplastic syndrome,Designated/Designation Withdrawn or Revoked,9/15/2021,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",445 Eastern Point Road,,Groton,Connecticut,' 06340 ' ,United States,608617,myelodysplastic syndrome,"""gard:0007132""",
3192,glatiramer acetate,Copaxone,11/9/1987,treatment of multiple sclerosis,Designated/Approved,,,For reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.,12/20/1996,12/20/2003,,Teva Pharmaceuticals USA,1510 Delp Drive,,Kulpsville,Pennsylvania,' 19443 ' ,United States,24087,,,
3193,glatiramer acetate,,11/14/2007,treatment of amyotrophic lateral sclerosis (als).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Teva Neurosciences, Inc.",P. O. Box 1005,,Horsham,Pennsylvania,' 19044 ' ,United States,247507,amyotrophic lateral sclerosis,"""gard:0005786""",
3194,Glatiramer acetate for injection,,6/5/2001,treatment of primary-progressive multiple sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Teva Pharmaceuticals USA,650 Cathill Rd.,,Sellersville,Pennsylvania,' 18960 ' ,United States,140500,,,
3195,glecaprevir and pibrentasvir,Mavyret,1/9/2017,treatment of pediatric patients with chronic hepatitis c virus infection,Designated/Approved,,,"treatment of adult and pediatric patients 3 years and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both",6/10/2021,6/10/2028,"treatment of pediatric patients 3 years of age to less than 12 years of age weighing less than 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and treatment of pediatric patients 3 years of age to less than 12 years of age weighing less than 45 kg with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both","AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,' 60044 ' ,United States,550516,,,
3196,glecaprevir and pibrentasvir,MAVYRET,1/9/2017,treatment of pediatric patients with chronic hepatitis c virus infection,Designated/Approved,,,"MAVYRET is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.",4/30/2019,4/30/2026,"For the treatment of pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A), and also for the treatment of pediatric patients 12 years and older or weighing at least 45 kg with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.","AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,' 60044 ' ,United States,550516,,,
3197,Glecirasib,,4/8/2024,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jacobio Pharmaceuticals Co., Ltd.","Building 8, No. 105 Jinghai 3rd Road, BDA",,Beijing,,' 101111 ' ,China,996924,,,
3198,Gleolan,,2/15/2024,"diagnostic for the management of ovarian, fallopian tube, and primary peritoneal cancer",Designated,,Not FDA Approved for Orphan Indication,,,,,NX Development Corp.,"870 Corporate Drive, Suite 403",,Lexington,Kentucky,' 40503 ' ,United States,919122,,,
3199,glepaglutide,,10/20/2017,treatment of short bowel syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Zealand Pharma A/S,36 Smedeland,,Glostrup,,' ' ,Denmark,539216,short bowel syndrome,"""gard:0001502""",
3200,glibentek (glibenclamide oral suspension),,6/8/2016,treatment of neonatal diabetes (monogenic forms of diabetes that present in infancy),Designated,,Not FDA Approved for Orphan Indication,,,,,AMMTeK,15 Rue Béranger,,Paris,Île-de-France,' ' ,France,518816,,,
3201,glioma derived cell lysates and irradiated cells,,1/12/2011,treatment of glioma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Epitopoietic Research Corp.,1055 E. Colorado Blvd,,Pasadena,California,' 91160 ' ,United States,329210,,,
3202,Glofitamab,,2/22/2022,treatment of mantle cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080-4990 ' ,United States,864121,lymphoma,"""gard:0020548""",
3203,glucagon,,12/5/2012,prevention of hypoglycemia in the congenital hyperinsulinism population,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biodel, Inc.",100 Saw Mill Road,,Danbury,Connecticut,' 06810 ' ,United States,366812,,,
3204,glucagon (ready-to-use),,1/24/2018,treatment of hyperinsulinemic hypoglycemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Xeris Pharmaceuticals, Inc.","1375 West Fulton Street, Suite 1300",,Chicago,Illinois,' 60607 ' ,United States,616317,,,
3205,glucagon analog conjugated with human immunoglobulin G4 fragment,,2/1/2018,treatment of congenital hyperinsulinism (chi),Designated,,Not FDA Approved for Orphan Indication,,,,,"Hanmi Pharmaceutical Company, Ltd.","14, Wiryeseong-daero,",Songpa-gu,Seoul,5545,' ' ,South Korea,620717,,,
3206,glucagon infusion,,9/25/2014,"prevention of chronic, severe hypoglycemia related to congential hyperinsulinism",Designated,,Not FDA Approved for Orphan Indication,,,,,"Xeris Pharmaceuticals, Inc.","1375 West Fulton Street, Suite 1300",,Chicago,Illinois,' 60607 ' ,United States,427514,,,
3207,Glucagon like peptide-1 (GLP-1) Elastin like peptide (ELP)-120 fusion protein,,3/29/2023,treatment of dermatomyositis (dm),Designated,,Not FDA Approved for Orphan Indication,,,,,"ImmunoForge Co., Ltd.","#1701~#1711, Ace Hansol Tower, 58 Gasan Digital 1-ro",Geumcheon-gu,Seoul,,' 08591 ' ,South Korea,931523,dermatomyositis,"""gard:0006263""",
3208,Glucagon like peptide-1 (GLP-1) Elastin like peptide (ELP)-120 fusion protein,,8/31/2021,treatment of polymyositis,Designated,,Not FDA Approved for Orphan Indication,,,,,"ImmunoForge Co., Ltd.","307-1, 105-1 Bldg, Seoul National University","1 Gwanak-ro, Gwanak-gu,",Seoul,,' ' ,South Korea,808321,polymyositis,"""gard:0007425""",
3209,Glucagon like peptide-1 Elastin like peptide-120 fusion protein,,12/30/2020,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"ImmunoForge Co., Ltd.","307-1, 105 Bldg., Seoul National University","1 Gwanak-ro, Gwanak-gu",Seoul,,' ' ,South Korea,789220,muscular dystrophy,"""gard:0007922""",
3210,Glucagon-Like Peptide 2 fused to hyFc,,10/11/2018,treatment of short bowel syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Genexine,700 Daewangpangyo-ro,Korea Bio Park Bldg. B,Seongnam-si,Gyeonggi-do,' ' ,South Korea,655218,short bowel syndrome,"""gard:0001502""",
3211,glucagon-like peptide-1/glucagon/gastric inhibitory polypeptide triple agonist linked to human IgG4 Fc fragment,,5/10/2021,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hanmi Pharmaceutical Co., Ltd.",14 Wiryeseong-daero,Songpa-gu,Seoul,,' 05545 ' ,South Korea,815521,idiopathic pulmonary fibrosis,"""gard:0008609""",
3212,Glucagon-like peptide-1/Glucagon/Gastric inhibitory polypeptide triple agonist linked to human IgG4 Fc fragment,,3/9/2020,treatment of primary biliary cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hanmi Pharmaceutical Company, Ltd.","14, Wiryeseong-daero",,Seoul,Songpa-gu,' ' ,South Korea,727919,primary biliary cholangitis,"""gard:0007459""",
3213,Glucagon-like peptide-1/Glucagon/Gastric inhibitory polypeptide triple agonist linked to human IgG4 Fc fragment,,3/4/2020,treatment of primary sclerosing cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hanmi Pharmaceutical Company, Ltd.","14, Wiryeseong-daero",,Seoul,Songpa-gu,' ' ,South Korea,728019,sclerosing cholangitis,"""gard:0021868""",
3214,glucarpidase,Voraxaze,8/19/2003,treatment of patients at risk of methotrexate toxicity,Designated/Approved,,,Treatment of toxic (>1 micromole/liter) plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function.,1/17/2012,1/17/2019,,BTG International Inc.,5214 Maryland Way,Suite 405,Brentwood,Tennessee,' 37027 ' ,United States,163702,methotrexate toxicity,"""gard:0022269""",
3215,Glucopyranosyl lipid A stable emulsion,,2/14/2017,treatment of follicular lymphoma,Designated/Designation Withdrawn or Revoked,8/13/2019,Not FDA Approved for Orphan Indication,,,,,Immune Design Corp.,1616 Eastlake Ave. E,Suite 310,Seattle,Washington,' 98102 ' ,United States,554616,lymphoma,"""gard:0020548""",
3216,glufosfamide,,9/18/2006,for treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,Eleison Pharmaceuticals LLC,103 Carnegie Center,Suite 300,Princeton,New Jersey,' 08540 ' ,United States,221606,,,
3217,glumetinib,,1/25/2022,treatment of non-small cell lung cancer (nsclc) with met genomic aberration,Designated,,Not FDA Approved for Orphan Indication,,,,,"Haihe Biopharma Co., Ltd.",No. 421 Newton Road,"Zhangjiang High-Tec Park, Pudong New District",Shanghai,,' 201203 ' ,China,858221,small cell lung cancer,"""gard:0009344""",
3218,Glutamine,NutreStore,3/6/1995,for use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).,Designated/Approved,,,Treatment of short bowel syndrome in patients receiving specialized nutritional support when used in conjunction with a recombinant human growth hormone that is approved for this indication.,6/10/2004,6/10/2011,,"Emmaus Medical, Inc.",20725 S. Western Avenue,Suite 136,Torrence,California,' 90501 ' ,United States,85794,short bowel syndrome,"""gard:0001502""",
3219,Glutathione pegylated liposomal doxorubicin hydrochloride,,8/16/2010,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,to-BBB technologies BV,Niels Bohrweg 11,,Leiden,,' ' ,Netherlands,311910,,,
3220,Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu- Gly-Pro-Pro-Pro-Ala-Leu-Ala-Leu-Ala-NH2,,5/24/2022,treatment of primary sclerosing cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sterotherapeutics, LLC",805 Old Easton Road,,Doylestown,Pennsylvania,' 18902 ' ,United States,878622,sclerosing cholangitis,"""gard:0021868""",
3221,Glyburide,,1/12/2017,treatment of severe cerebral edema in patients with acute ischemic stroke,Designated,,Not FDA Approved for Orphan Indication,,,,,"Remedy Pharmaceuticals, Inc.","233 Broadway, Suite 1750",,New York,New York,' 10279 ' ,United States,539316,,,
3222,glyburide,,9/29/2015,treatment of acute spinal cord injury,Designated,,Not FDA Approved for Orphan Indication,,,,,"Remedy Pharmaceuticals, Inc.","233 Broadway, Suite 1750",,New York,New York,' 10279 ' ,United States,491215,spinal cord injury,"""gard:0019109""",
3223,glyburide,,2/8/2016,treatment of acute subarachnoid hemorrhage,Designated,,Not FDA Approved for Orphan Indication,,,,,"Remedy Pharmaceuticals, Inc.","233 Broadway, Suite 1750",,New York,New York,' 10279 ' ,United States,502615,,,
3224,glycafilin,,8/22/2008,prevention of delayed graft function after solid organ transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,ProtAffin Biotechnologies AG,Impulszentrum Graz - West,Reininghaustrasse 13 A,Graz,,' ' ,Austria,264808,,,
3225,Glyceol,,2/22/1990,to decrease intracranial hypertension and/or alleviate cerebral edema in patients who may benefit from osmotherapy.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Chugai Pharmaceutical Co., Ltd.",,,,,' ' ,,28188,,,
3226,glycerol phenylbutyrate,RAVICTI,4/27/2009,maintenance treatment of patients with deficiencies in enzymes of the urea cycle,Designated/Approved,,,"Use as a nitrogen-binding agent for chronic management of adult and pediatric patients > or =2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (eg, essential amino acids, arginine, citrulline, protein-free calorie supplements).",2/1/2013,2/1/2020,"Use as a nitrogen-binding adjunctive therapy for chronic management of adult and pediatric patients at least 2 years of age with urea cycle disorders (UCDs) that cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (eg, essential amino acids, arginine, citrulline, protein-free calorie supplements).","Horizon Pharma USA, INc.",150 South Saunders Road,Suite 400,Lake Forest,Illinois,' 60045 ' ,United States,203505,,,
3227,glycerol phenylbutyrate,RAVICTI,4/27/2009,maintenance treatment of patients with deficiencies in enzymes of the urea cycle,Designated/Approved,,,For use as a nitrogen-binding agent for chronic management of patients 2 months of age and older with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.,4/28/2017,4/28/2024,For use as a nitrogen-binding agent for chronic management of pediatric patients > or =2 months and,"Horizon Pharma USA, INc.",150 South Saunders Road,Suite 400,Lake Forest,Illinois,' 60045 ' ,United States,203505,,,
3228,glycerol tribenzoate,,9/10/2019,treatment of huntington’s disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Forest Hills Partners Hong Kong Limited,7/F 80 Gloucester Road,,Wanchai,,' ' ,Hong Kong,703419,,,
3229,Glyceryl tri (4-phenylbutyrate),,5/24/2005,treatment of spinal muscular atrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ucyclyd Pharma, Inc",Subsidiary of Medicis Pharmaceutical Corporation,7720 N. Dobson Road,Scottsdale,Alaska,' 85256 ' ,United States,204205,,,
3230,glyceryl tribenzoate,,10/15/2019,treatment of nonketotic hyperglycinemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Liberyx Therapeutics Limited,7/F 80 Gloucester Road,,Wanchai,,' ' ,Hong Kong,705019,,,
3231,Glyceryl trioleate and glyceryl trierucate,,2/14/1995,treatment of adrenoleukodystrophy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Moser, Hugo W. M.D.",Johns Hopkins University,"Kennedy Krieger Institute, 707 North Broadway",Baltimore,Maryland,' 21205 ' ,United States,87594,leukodystrophy,"""gard:0006895""",
3232,"Glycine, L-prolyl-L-prolyl-L-leucyl-L-seryl-L-glutaminyl-L-alpha-glutamyl-L-threonyl-L-phenylalanyl-L-seryl-L-alpha-aspartyl-L-leucyl-L-tryptophyl-L-lysyl-L-leucyl-L-leucyl-L-lysyl-L-lysyl-L-tryptophyl-L-lysyl-L-methionyl-L-arginyl-L-arginyl-L-asparaginyl-L-glutaminyl-L-phenylalanyl-L-tryptophyl-L-valyl-L-lysyl-L-valyl-L-glutaminyl-L-arginyl-",,12/28/2023,treatment of osteosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Oncolyze, Inc.",845 UN Plaza,61b,New York City,New York,' 10017 ' ,United States,980923,osteosarcoma,"""gard:0007284""",
3233,"Glycine, L-prolyl-L-prolyl-L-leucyl-L-seryl-L-glutaminyl-L-alpha-glutamyl-L-threonyl-Lphenylalanyl- L-seryl-L-alpha-aspartyl-L-leucyl-L-tryptophyl-L-lysyl-L-leucyl-L-leucyl-L-lysyl-Llysyl- L-tryptophyl-L-lysyl-L-methionyl-L-arginyl-L-arginyl-L-asparaginyl-L-glutaminyl-Lphenylalanyl- L-tryptophyl-L-valyl-L-lysyl-L-valyl-L-glutaminyl-L-arginyl-",,1/3/2022,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Oncolyze, Inc.",845 UN Plaza,61b,New York City,New York,' 10017 ' ,United States,855021,acute myeloid leukemia,"""gard:0012757""",
3234,glycolate oxidase inhibitor,,9/10/2020,treatment of primary hyperoxaluria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cantero Therapeutics, Inc.","1800 Owens Street, Suite C-1200",,San Francisco,California,' 94158 ' ,United States,762420,primary hyperoxaluria,"""gard:0016530""",
3235,Glycolic acid and D-lactic acid,,4/19/2022,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Neurevo GmbH,Balantstr. 6,,München,Bavaria,' 81669 ' ,Germany,872422,amyotrophic lateral sclerosis,"""gard:0005786""",
3236,glycopyrrolate,Cuvposa,6/9/2006,treatment of pathologic (chronic moderate to severe) drooling in pediatric patients,Designated/Approved,,,To reduce chronic drooling in patients aged 3 - 16 with neurologic conditions associated with problem drooling (e.g. cerebral palsy),7/28/2010,7/28/2017,,"Shionogi, Inc.",300 Campus Drive,,Florham,New Jersey,' 07932 ' ,United States,204105,,,
3237,glycopyrrolate 2%,,6/17/2010,treatment of frey's syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Wellesley Therapeutics, Inc.","200 Gerrard St., East",,Toronto,,' ' ,Canada,309810,,,
3238,glycosylated recombinant human interleukin-7,,9/27/2012,treatment of progressive multifocal leukoencephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cytheris, Inc.",1700 Rockville Pike,Suite 230,Rockville,Maryland,' 20852 ' ,United States,379112,progressive multifocal leukoencephalopathy,"""gard:0007468""",
3239,Glyeraldehyde-3-phosphate dehydrogenase,,4/30/2010,treatment of pediatric multiple sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"BPT Pharmaceuticals, Inc.",743 North Sweetzer Avenue #103,,Los Angeles,California,' 90069 ' ,United States,304710,pediatric multiple sclerosis,"""gard:0010443""",
3240,GNE Lipoplex,,11/13/2008,treatment of hereditary inclusion body myopathy-2,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gradalis, Inc.",2545 Golden Bear Drive,,Carrollton,Texas,' 75006 ' ,United States,267108,,,
3241,GNE plasmid(H001),,3/26/2010,treatment of hereditary inclusion body myopathy type 2,Designated,,Not FDA Approved for Orphan Indication,,,,,HIBM Research Group,18341 Sherman Way #201A,,Reseda,California,' 91335 ' ,United States,303610,,,
3242,Golexanolone,,1/12/2023,treatment of primary biliary cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Umecrine Cognition AB,Fogdevreten 2,,Solna,Sweden,' SE-171 65 ' ,Sweden,871222,primary biliary cholangitis,"""gard:0007459""",
3243,golimumab,,5/21/2012,treatment of sarcoidosis,Designated/Designation Withdrawn or Revoked,5/7/2014,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.",200 Great Vallley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,368412,sarcoidosis,"""gard:0007607""",
3244,golimumab,,11/2/2004,treatment of chronic sarcoidosis,Designated/Designation Withdrawn or Revoked,9/17/2014,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,194204,sarcoidosis,"""gard:0007607""",
3245,golimumab,SIMPONI ARIA®,4/2/2015,treatment of polyarticular juvenile idiopathic arthritis in patients 0 through 18 years of age.,Designated/Approved,,,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older,9/29/2020,9/29/2027,treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 to 18 years of age,"Janssen Research & Development, LLC",1400 McKean Road,,Spring House,Pennsylvania,' 19477 ' ,United States,325610,polyarticular juvenile idiopathic arthritis,"""gard:0021729""",
3246,golimumab,,3/16/2012,treatment of pediatric ulcerative colitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.",1400 McKean Road,,Spring House,Pennsylvania,' 19477 ' ,United States,365112,,,
3247,golnerminogene pradenovec,,10/28/2009,treatment of pancreatic cancer.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"GenVec, Inc.",65 West Watkins Mill Road,,Gaithersburg,Maryland,' 20878 ' ,United States,294209,,,
3248,golodirsen,VYONDYS 53,5/22/2018,treatment of duchenne muscular dystrophy (dmd),Designated/Approved,,,VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.,12/12/2019,12/12/2026,Indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping,"Sarepta Therapeutics, Inc.",215 First Street,,Cambridge,Massachusetts,' 02142 ' ,United States,636818,muscular dystrophy,"""gard:0007922""",
3249,Gonadorelin acetate,Lutrepulse,4/22/1987,for induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous gnrh secretion.,Designated/Approved,,,,10/10/1989,10/10/1996,,"Ferring Laboratories, Inc.","400 Rella Boulevard, Suite 201",,Suffern,New York,' 10901 ' ,United States,17086,,,
3250,Gossypol,,10/22/1990,treatment of cancer of the adrenal cortex.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Reidenberg, Marcus M. M.D.",The New York Hospital - Cornell Medical Center,"525 East 68th Street, Box 70",New York,New York,' 10021 ' ,United States,46390,,,
3251,Gotistobart,,8/29/2023,treatment of adenoid cystic carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"OncoC4, Inc.",9640 Medical Center Dr.,,Rockville,Maryland,' 20850 ' ,United States,889722,noma,"""gard:0004001""",
3252,Gp100 adenoviral gene therapy,,3/25/1997,treatment of metastatic melanoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,104397,noma,"""gard:0004001""",
3253,granaticin B,,3/7/2018,treatment of acute lymphoblastic leukemia (all),Designated,,Not FDA Approved for Orphan Indication,,,,,Lin BioScience,3210 Merryfield Row,"12F., No.68, Sec.5, Zhongxiao E. Rd.","Xinyi Dist., Taipei City 110",,' ' ,Taiwan,625017,acute lymphoblastic leukemia,"""gard:0000522""",
3254,Granexin gel (aCTI peptide),,8/3/2017,treatment of cutaneous radiation injury due to radiation disaster,Designated,,Not FDA Approved for Orphan Indication,,,,,"Xequel Bio, Inc.",300 West Coleman Boulevard,Suite 203,Mount Pleasant,South Carolina,' 29464 ' ,United States,573217,,,
3255,Granulocyte colony-stimulating-factor (G-CSF),,6/3/2022,treatment of thromboangiitis obliterans (buerger’s disease),Designated,,Not FDA Approved for Orphan Indication,,,,,Vasogenesis Inc,32 Marshal Street,Suite 3,Brookline,Massachusetts,' 02446 ' ,United States,879722,,,
3256,granulocyte macrophage colony stimuling factor,,8/27/2008,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Savara Inc.,"1717 Langhorne Newtown Road, Suite 300",,Langhorne,Pennsylvania,' 19047 ' ,United States,264908,cystic fibrosis,"""gard:0006233""",
3257,Granulocyte macrophage-colony stimulating factor,,5/4/1990,treatment of chronic lymphocytic leukemia to increase granulocyte count.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,' 07033 ' ,United States,43289,,,
3258,Granulocyte macrophage-colony stimulating factor,,6/6/1989,treatment of severe thermal injuries in patients with greater than 40% full or partial thickness burns.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,' 07033 ' ,United States,27588,,,
3259,Granulocyte macrophage-colony stimulating factor,,12/12/1989,treatment of neutropenia associated with bone marrow transplants.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,' 07033 ' ,United States,41389,,,
3260,Granulocyte macrophage-colony stimulating factor,,5/3/1990,treatment of neutropenia due to hairy cell leukemia.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,' 07033 ' ,United States,41289,,,
3261,Granulocyte macrophage-colony stimulating factor,,8/7/1989,treatment of myelodysplastic syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,' 07033 ' ,United States,37889,myelodysplastic syndrome,"""gard:0007132""",
3262,"granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus, Ad5/3-D24-GMCSF",,7/24/2013,treatment of soft tissue sarcoma,Designated/Designation Withdrawn or Revoked,12/20/2023,Not FDA Approved for Orphan Indication,,,,,"Targovax Solutions AS, a subsidiary of Targovax ASA",Vollsveien 19,,Lysaker,,' 1366 ' ,Norway,399513,soft tissue sarcoma,"""gard:0004898""",
3263,GRObeta (a truncated form of the human CXC motif chemokine 2),,5/18/2020,mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent transplant,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ensoma, Inc.","451 D Street, Suite 600",,Boston,Massachusetts,' 02210 ' ,United States,738320,,,
3264,Group B streptococcus immune globulin,,5/8/1990,treatment of neonates for disseminated group b streptococcal infection.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"North American Biologicals, Inc.",12280 Wilkins Avenue,,Rockville,Maryland,' 20852 ' ,United States,44190,,,
3265,Growth hormone releasing factor,,8/7/1989,for the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,Designated,,Not FDA Approved for Orphan Indication,,,,,Valeant Pharmaceuticals North America,700 Route 202/206,,Bridgewater,New Jersey,' 08807 ' ,United States,37389,,,
3266,Growth Hormone Releasing Hormone (GHRH) 1-44 Human Amide and Arginine,,3/7/2022,diagnosis of growth hormone deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hollenbeck Pharmaceuticals, Inc.",P.O. Box 429,,Falls Village,Connecticut,' 06031 ' ,United States,785420,,,
3267,"growth hormone releasing hormone, 1-44 human amide",,2/23/2016,treatment of growth hormone deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hollenbeck Pharmaceuticals, Inc.",P. O. Box 429,,Falls Village,Connecticut,' 06031 ' ,United States,436814,,,
3268,guadecitabine,,9/29/2015,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,12/2/2020,Not FDA Approved for Orphan Indication,,,,,"Astex Pharmaceuticals, Inc.",4420 Rosewood Drive,Suite 200,Pleasanton,California,' 94588 ' ,United States,492515,acute myeloid leukemia,"""gard:0012757""",
3269,guadecitabine SC,,6/10/2020,treatment of myelodysplastic syndromes including chronic myelomonocytic leukemia,Designated/Designation Withdrawn or Revoked,12/2/2020,Not FDA Approved for Orphan Indication,,,,,"Astex Pharmaceuticals, Inc.",4420 Rosewood Drive,Suite 200,Pleasanton,California,' 94588 ' ,United States,627818,chronic myelomonocytic leukemia,"""gard:0008225""",
3270,Guanethidine monosulfate,,1/6/1986,treatment of moderate to severe reflex sympathetic dystrophy and causalgia.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,59 Route 10,,East Hanover,New Jersey,' 07936 ' ,United States,6385,,,
3271,guanfacine,,8/5/1999,treatment of fragile x syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Watson Laboratories, Inc.",311 Bonnie Circle,P.O. Box 1900,Corona,California,' 91718 ' ,United States,124199,fragile x syndrome,"""gard:0006464""",
3272,guanfacine and amphetamine,,3/17/2016,treatment of pediatric patients with tourette's syndrome (0 through 16 years of age),Designated,,Not FDA Approved for Orphan Indication,,,,,"KemPharm, Inc.",1180 Celebration Boulevard,Suite 103,Celebration,Florida,' 34747 ' ,United States,405313,,,
3273,gunagratinib,,6/7/2021,treatment of cholangiocarcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,InnoCare Pharma Inc.,"103 Carnegie Center, Suite 209",,Princeton,New Jersey,' 08540 ' ,United States,820521,cholangiocarcinoma,"""gard:0009304""",
3274,Gusperimus,,6/27/1996,treatment of acute renal graft rejection episodes.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Pharmaceutical Research Institute,5 Research Parkway,P.O. Box 5100,Wallingford,Connecticut,' 06492 ' ,United States,96896,,,
3275,gusperimus trihydrochloride,,6/29/2011,treatment of wegener's granulomatosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Nordic Group B.V.,Siriusdreef 22,,2132 WT Hoofdorp,,' ' ,Netherlands,342711,,,
3276,GVAX melanoma,,12/23/2010,treatment of stage iib to iv melanoma,Designated/Designation Withdrawn or Revoked,1/10/2019,Not FDA Approved for Orphan Indication,,,,,"Aduro BioTech, Inc.",740 Heinz Avenue,,Berkeley,California,' 94710 ' ,United States,313110,noma,"""gard:0004001""",
3277,gylceryl tri (4-pheynlybutyrate),,9/3/2009,for intermittent or chronic treatment of patients with cirrhosis and any grade hepatic encephalopathy.,Designated,,Not FDA Approved for Orphan Indication,,,,,Horizon Therapeutics,1 Horizon Way,,Deerfield,Illinois,' 60015 ' ,United States,269308,,,
3278,H-(4-amino-3-iodo)-D-Phe-c[Cys-(3-iodo)-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2,,11/3/2016,treatment of acromegaly,Designated,,Not FDA Approved for Orphan Indication,,,,,Amryt Research Ltd.,18 Fitzwilliam Place,,Dublin,Dublin,' ' ,Ireland,540916,acromegaly,"""gard:0005725""",
3279,H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminyl-(D)arginyl-(D)arginine acetate salt,,12/22/2011,for use in combination with cisplatin and pemetrexed for the treatment of patients with mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"CanBas Company, Ltd.",2-2-1 Otemachi,,Numazu City,Shizuoka,' ' ,Japan,358411,,,
3280,H-(D)p-Benzoylphenylalanyl-(D)seryl-(D)tryptophanyl-(D)seryl-(D)pentafluorophenylalanyl-(D)cyclohexylalanyl-(D)arginyl-(D)arginyl-(D)arginyl-(D)glutaminyl-(D)arginyl-(D)arginine acetate salt,,1/26/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"CanBas Co., Ltd.",2-2-1 Otemachi,,Numazu City,Shizuoka,' 410-0801 ' ,Japan,922322,,,
3281,H-Ala-Val-Ala-Glu-Ile-Gln-Leu-Met-His-Gln-Arg-Ala-Lys-Trp-Ile-Gln-Asp-Ala-Arg-Arg-Arg-Ala-Phe-Leu-His-Lys-Leu-Ile-Ala-Glu-Ile-His-Thr-Ala-Glu-Ile-OH,,12/14/2020,treatment of hypoparathyroidism,Designated,,Not FDA Approved for Orphan Indication,,,,,Amolyt Pharma SAS (formerly Alize Pharma III SAS),"15, chemin du Saquin, Espace Europeen",Building G,Ecully,,' 619 130 ' ,France,786220,,,
3282,H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-2Thi-Gly-Leu-Met(O2)-NH2-DOTA-225-actinium,,11/5/2021,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,NovaCurie AG,Spitalgasse 32,,Bern,,' 3011 ' ,Switzerland,820221,,,
3283,H-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-D-Arg-OH (acetate),,11/14/2023,treatment of hypoxic ischemic encephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Argenica Therapeutics Ltd.,4/117 Broadway Nedlands,,WA,,' 6009 ' ,Australia,969923,,,
3284,H-D-valyl1-D-alanyl-D-glutamyl-D-alanyl-D-arginyl5-D-glutamyl-D-glutamyl-D-leucyl-D-glutamyl-D-arginyl10-D-leucyl-D-glutamyl-D-alanyl-D-arginyl-D-leucyl15-glycyl-D-glutaminyl-D-alanyl-D-arginyl-glycyl20-D-glutamyl-D-leucyl-D-lysyl-D-lysyl-D-tryptophyl25-D-lysyl-D-methionyl-D-arginyl-D-arginyl-D-asparaginyl30-D-glutaminyl-D-phenylalanyl-D-tryptophyl-D-leucyl-D-lysyl35-D-leucyl-D-glutaminyl-D-arginine,,4/25/2022,treatment of stage iib-iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sapience Therapeutics, Inc.","500 Mamaroneck Ave, Suite 320",,Harrison,New York,' 10528 ' ,United States,871922,noma,"""gard:0004001""",
3285,H-L-tryphophanyl-L-seryl-glycyl-L-tryptophanyl-L-seryl-L-seryl-L-cysteinyl-L-seryl-L-arginyl-L-seryl-L-cysteinyl-glycyl-OH (disulfide bond),,10/20/2022,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,AXOLTIS Pharma,15-17 Rue du Pré la Reine,,Clermont-Ferrand,,' 63100 ' ,France,906122,amyotrophic lateral sclerosis,"""gard:0005786""",
3286,H-Leu-Pro-Pro-Ser-Arg-OH,,9/20/2012,treatment of kaposi sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immuno Tech, Inc.","6329 256th Street, NE",,Arlington,Washington,' 98223 ' ,United States,375312,kaposi sarcoma,"""gard:0006814""",
3287,H-Lys-Lys-Gly-Asp-Asn-Ile-Met-Val-Thr-Phe-Arg-Asn-Gln-Ala-Ser-Arg-Pro-Tyr-Gly-Lys-Lys-OH,,10/27/2022,treatment of hemophilia a,Designated,,Not FDA Approved for Orphan Indication,,,,,Worg Pharmaceuticals (Hangzhou) Co. Ltd,"Suite 801, Building#5, JiaBao Technology Innovation Center","No. 519, 2nd Avenue, Qiantang New District",Hangzhou,Zhejiang,' 310000 ' ,China,906922,hemophilia,"""gard:0010418""",
3288,H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-alys-aleu-Ser-Ser-Ile-Glu-Ser-Asp-Val-OH,,5/14/2013,treatment of subarachnoid hemorrhage,Designated,,Not FDA Approved for Orphan Indication,,,,,"NoNO, Inc.",399 Bathurst Street,,Toronto,,' ' ,Canada,377812,,,
3289,H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu- Ser-Asp-Val-OH,,4/11/2014,treatment of acute ischemic stroke patients presenting within 3 hours of symptom onset,Designated,,Not FDA Approved for Orphan Indication,,,,,"NoNO, Inc.",399 Bathurst Street,Suite 4W-435,Toronto,,' ' ,Canada,412713,,,
3290,half-life extended bispecific T-cell engager antibody construct targeting MUC17 and CD3,,6/2/2020,"treatment of gastric cancer, including cancer of gastroesophageal junction",Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,' 91320 ' ,United States,741120,,,
3291,Halofantrine,Halfan,11/4/1991,treatment of mild to moderate acute malaria caused by susceptible strains of p. falciparum and p. vivax.,Designated/Approved,,,Treatment of adults who can tolerate oral medication and who have mild to moderate malaria caused by Plasmodium falciparum or Plasmodium vivax.,7/24/1992,7/24/1999,,SmithKline Beecham Pharmaceuticals,One Franklin Plaza,P.O. Box 7929,Philadelphia,Pennsylvania,' 19101 ' ,United States,61791,malaria,"""gard:0006961""",
3292,Halofuginone,,2/7/2000,treatment of systemic sclerosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Collgard Biopharmaceuticals Ltd.,"Textile House, 2 Koifman St.",,Tel-Aviv,,' ' ,Israel,131699,systemic sclerosis,"""gard:0009748""",
3293,halofuginone hydrobromide,,10/13/2011,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Akashi Therapeutics, Inc.",245 First Street,18th Floor,Cambridge,Massachusetts,' 02142 ' ,United States,352711,muscular dystrophy,"""gard:0007922""",
3294,Hanferon,,3/9/2012,treatment of behcet's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"HanAll BioPharma Co., Ltd.",Jamsil I-Space Building 6F,138 420,Seoul,,' ' ,South Korea,362911,,,
3295,Hantaan virus and Puumala virus DNA vaccines,,11/13/2012,prevention of hemorrhagic fever with renal syndrome caused by hantaan virus and puumala virus,Designated,,Not FDA Approved for Orphan Indication,,,,,Surgeon General of the U. S. Army,1430 Veterans Drive,ATTN: USAMR and MC,Fort Detrick,Maryland,' 21702 ' ,United States,369312,,,
3296,"haptoglobin (Hp1-1), (Human)",,10/12/2021,treatment of subarachnoid hemorrhage,Designated,,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,' 19406-0901 ' ,United States,841121,,,
3297,HDF-LV-RTS-MMP1 (human dermal fibroblasts genetically modified with LV-RTS-MMP1) and Veledimex,,4/19/2016,treatment of localized scleroderma.,Designated/Designation Withdrawn or Revoked,7/8/2022,Not FDA Approved for Orphan Indication,,,,,"Castle Creek Biosciences, LLC",405 Eagleview Blvd,,Exton,Pennsylvania,' 19341 ' ,United States,493815,scleroderma,"""gard:0018705""",
3298,heat killed Mycobacterium w immunomodulator,,9/3/2004,active tuberculosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cadila Pharmaceuticals Limited, Inc.",9801 Washingtonian Blvd,Suite 220,Gaithersburg,Maryland,' 20878 ' ,United States,185304,tuberculosis,"""gard:0007827""",
3299,heat killed mycobacterium w immunomodulator,,11/21/2002,adjuvant to multi-drug therapy in the management of multibacillary leprosy,Designated,,Not FDA Approved for Orphan Indication,,,,,"CPL, Inc.",16020 Swingley Ridge Road,Suite 145,Chesterfield,Missouri,' 63017 ' ,United States,161202,leprosy,"""gard:0006886""",
3300,heat killed mycobacterium w immunomodulator,,7/31/2012,treatment of non-small cell lung cancers that express desmocollin-3,Designated,,Not FDA Approved for Orphan Indication,,,,,Cadila Pharmaceuticals Limited,"Sarkhej-Dholka Road, Bhat",Ahmedabad - 382210,Gujarat,,' ' ,India,349211,small cell lung cancer,"""gard:0009344""",
3301,heat killed whole cell mycobacterium obuense,,9/23/2014,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Immodulon Therapeutics Limited,6-9 The Square,Stockley Park,Uxbridge,,' UB11 1FW ' ,United Kingdom,446114,,,
3302,Heat Shock Protein (hsp60) antigen,,5/21/2012,for use in type 1 diabetic mellitus patients with residual beta-cell function,Designated/Designation Withdrawn or Revoked,6/13/2016,Not FDA Approved for Orphan Indication,,,,,"AndromedA Biotech, LTD",42 Hayarkon St.,,Yavne,,' ' ,Israel,337111,,,
3303,Heat Shock Protein 70,,3/18/2011,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"ALS Biopharma, LLC",3805 Old Easton Rd,,Doylestown,Pennsylvania,' 18902 ' ,United States,330410,amyotrophic lateral sclerosis,"""gard:0005786""",
3304,"Hematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1r, 4r)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",,4/2/2024,treatment to enhance cell engraftment and immune reconstitution in patients receiving hematopoietic stem cell transplant,Designated,,Not FDA Approved for Orphan Indication,,,,,Cordex Biologics Inc.,2950 chemin de Polytechnique,,Montreal,Quebec,' H3T 1J4 ' ,Canada,995724,,,
3305,hematopoietic stem cells modified with a lentiviral vector containing the CD18 (Integrin Beta 2) gene,,11/9/2016,treatment of leukocyte adhesion deficiency type i,Designated,,Not FDA Approved for Orphan Indication,,,,,"Rocket Pharmaceuticals, Inc.",The Empire State Building,"350 Fifth Avenue, Suite 7530",New York,New York,' 10118 ' ,United States,543016,leukocyte adhesion deficiency,"""gard:0016616""",
3306,Heme arginate,,3/1/1994,treatment of myelodysplastic syndromes.,Designated,,Not FDA Approved for Orphan Indication,,,,,Orphan Europe SARL,Immeuble Le Wilson,"70 avenue du General de Gaulle,",Puteaux,,' ' ,France,79893,myelodysplastic syndrome,"""gard:0007132""",
3307,Heme arginate,,3/10/1988,treatment of symptomatic stage of acute porphyria.,Designated,,Not FDA Approved for Orphan Indication,,,,,Orphan Europe SARL,Immeuble Le Wilson,70 avenue du General de Gaulle,Puteaux,,' ' ,France,9185,porphyria,"""gard:0010353""",
3308,"Hemi L-glutarate salt of 7-[(3R,4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1-ylmethyl]-3,5- dihydro-pyrrolo [3,2-d] pyrimidin-4-one",,12/14/2022,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Laevoroc Immunology,Boesch 37,,"Huenenberg,",Canton Zug,' 6331 ' ,Switzerland,899322,acute lymphoblastic leukemia,"""gard:0000522""",
3309,Hemin,Panhematin,3/16/1984,"amelioration of recurrent attacks of acute intermittent porphyria (aip) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with aip, porphyria variegata and hereditary coproporphyria.",Designated/Approved,,,,7/20/1983,7/20/1990,,Abbott Laboratories,Diagnostics Division,,Abbott Park,Illinois,' 60064 ' ,United States,683,porphyria,"""gard:0010353""",
3310,Hemin and zinc mesoporphyrin,,12/20/1993,treatment of acute porphyric syndromes.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Bonkovsky, Herbert L. M.D.",University Of Massachusetts Medical Center,55 Lake Avenue North,Worcester,Massachusetts,' 01655 ' ,United States,77393,c syndrome,"""gard:0005978""",
3311,Hemopexin (Human),,9/23/2020,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,768120,,,
3312,Hemoximer (pyridoxalated hemoglobin polyoxyethylene),,12/18/2007,treatment of cardiogenic shock,Designated,,Not FDA Approved for Orphan Indication,,,,,"Apex Bioscience, Inc.",109 Conner Drive,,Chapel Hill,North Carolina,' 27514 ' ,United States,249807,cardiogenic shock,"""gard:0019362""",
3313,heparan sulfate mimetic,,5/29/2014,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,3/25/2021,Not FDA Approved for Orphan Indication,,,,,"Momenta Pharmaceuticals, Inc.",675 West Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,433314,,,
3314,Heparin,,11/3/2005,treatment of cystic fibrosis,Designated/Designation Withdrawn or Revoked,1/16/2014,Not FDA Approved for Orphan Indication,,,,,"Vectura Group, Inc.",1 Prospect West,,Wiltshire,,' ' ,United Kingdom,211305,cystic fibrosis,"""gard:0006233""",
3315,heparin activated recombinant human fibroblast growth factor 1 (FGF1)in combination with a surgically implanted biodegradable device,,10/24/2011,treatment of patients with a confirmed traumatic complete spinal cord injury where no motor or sensory function is preserved below the injury(scale a),Designated/Designation Withdrawn or Revoked,11/17/2020,Not FDA Approved for Orphan Indication,,,,,BioArctic Neuroscience AB,Warfvinges vag 39,,Stockholm,,' ' ,Sweden,342111,spinal cord injury,"""gard:0019109""",
3316,Heparin sodium,,6/29/2006,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Ockham Biotech Limited,Manor Farm,,Swanwick,Hampshire,' ' ,United Kingdom,222106,cystic fibrosis,"""gard:0006233""",
3317,heparin sodium,,7/29/2019,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Vectura Limited,One Prospect West,Chippenham,Wiltshire,,' ' ,United Kingdom,694019,cystic fibrosis,"""gard:0006233""",
3318,Heparin-binding epidermal growth factor-like growth factor,,9/18/2006,"prevention and treatment of necrotizing enterocolitis (nec) in preterm infants with birth weight less than 1,500 grams",Designated,,Not FDA Approved for Orphan Indication,,,,,"Trillium Therapeutics, Inc.",96 Skyway Avenue,,Toronto,,' ' ,Canada,221506,necrotizing enterocolitis,"""gard:0009767""",
3319,hepatitis B immune globulin (human),HepaGam B,3/24/2008,prevention of hepatitis b recurrence following orthotopic liver transplant,Designated/Approved,,,Prevention of hepatitis B recurrence following liver transplantation in HBsAG-positive liver transplant patients,4/6/2007,4/6/2014,,Cangene Corporation,155 Innovation Drive,,Winnipeg,,' ' ,Canada,228506,,,
3320,Hepatitis B immune globulin intravenous (human),,3/8/1995,prophylaxis against hepatitis b virus reinfection in liver transplant patients.,Designated,,Not FDA Approved for Orphan Indication,,,,,Biotest Pharmaceuticals Corporation,"5800 Park of Commerce Blvd., NW",,Boca Raton,Florida,' 33487 ' ,United States,76093,,,
3321,hepatitis B virus neutralizing human monoclonal antibody,,5/6/2013,prevention of hepatitis b recurrence following liver transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,Green Cross Corp.,"303, Bojeong-Dong, Giheung-Gu",,"Gyunggi-Do, 446-770",,' ' ,South Korea,395113,,,
3322,Hepatitis C virus immune globulin (human),,11/14/2002,prophylaxis of hepatitis c infection in liver transplant recipients.,Designated/Designation Withdrawn or Revoked,1/12/2018,Not FDA Approved for Orphan Indication,,,,,"ADMA Biologics, Inc.",465 Route 17 South,,Ramsey,New Jersey,' 07446 ' ,United States,73193,,,
3323,hepcidin mimetic peptide,,3/1/2018,treatment of beta-thalassemia,Designated/Designation Withdrawn or Revoked,4/27/2022,Not FDA Approved for Orphan Indication,,,,,Protagonist Therapeutics,521 Cottonwood Drive,Suite 100,Milpitas,California,' 95035 ' ,United States,584117,beta-thalassemia,"""gard:0000871""",
3324,Hepcidin mimetic peptide,,6/12/2020,treatment of polycythemia vera,Designated,,Not FDA Approved for Orphan Indication,,,,,"Protagonist Therapeutics, Inc.","7707 Gateway Blvd, Suite 140",,Newark,California,' 94560 ' ,United States,715819,polycythemia,"""gard:0019466""",
3325,hepcortespenlisimut-L,,12/17/2014,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immunitor, Inc.",365-2906 West Broadway,,Vancouver,,' ' ,Canada,457714,hepatocellular carcinoma,"""gard:0016773""",
3326,HER2 targeted antibody-drug conjugate (ADC) consisting of a HER2 targeted antibody conjugated with a stimulator of interferon genes (STING) agonist payload,,5/17/2022,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mersana Therapeutics, Inc.",840 Memorial Drive - FL 5,,Cambridge,Massachusetts,' 02139 ' ,United States,877522,,,
3327,herpes simplex type 1 virus containing cellular B-myb gene as tumor-specific promoter,,12/23/2014,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Karcinolys S.A.S.,"16, rue des Pervenches",92500 Rueil-Mamaison,Rueil-Mamaison,,' ' ,France,456614,,,
3328,Herpes simplex virus gene,,10/16/1992,treatment of primary and metastatic brain tumors.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genetic Therapy, Inc.",938 Clopper Road,,Gaithersburg,Maryland,' 20878 ' ,United States,66892,,,
3329,heterocyclic small molecule kinase inhibitor of a Notch associated kinase that enhances satellite cell driven regeneration of muscle,,8/1/2023,treatment of duchenne muscular dystrophy (dmd),Designated,,Not FDA Approved for Orphan Indication,,,,,Satellos Bioscience Inc.,"79 Wellington St. West, Suite 3300",,Toronto,Ontario,' M5K 1N2 ' ,Canada,951323,muscular dystrophy,"""gard:0007922""",
3330,heterodimeric fusion protein that binds to IL-1 beta consisting of human extracellular domain of IL1 receptor and a mutant Fc fragment of human IgG1 and part of human IL1 receptor accessory protein,,10/15/2018,treatment of schnitzler syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,R-Pharm Overseas,505 Cost Boulevard South,Suite #102,San Diego,California,' 92037 ' ,United States,657018,schnitzler syndrome,"""gard:0012390""",
3331,Heterodimeric multi-specific IgG1 antibody targeting human epidermal growth factor receptor 2 (HER2) and NKG2D on natural killer (NK) and cytotoxic T-cells,,10/25/2021,treatment of esophageal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Dragonfly Therapeutics, Inc.",35 Gatehouse Drive,,Waltham,Massachusetts,' 02451 ' ,United States,844121,,,
3332,heterologous human adult liver derived progenitor cells (HHALPC),,1/13/2012,treatment of urea cycle disorders,Designated,,Not FDA Approved for Orphan Indication,,,,,Promethera Biosciences,Watson & Crick Hill,"Rue Granbonpre, 11",Mont-Saint-Guibert,,' ' ,Belgium,358011,,,
3333,heterologous human liver derived progenitor cells,,3/9/2012,treatment of crigler-najjar syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Promethera Biosciences,Watson & Crick Hill,"Rue Granbonpre, 11",Mont-Saint-Guibert,,' ' ,Belgium,341411,crigler-najjar syndrome,"""gard:0016526""",
3334,heterologous swine glyco-humanized polyclonal antibody against T lymphocytes,,8/7/2023,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Xenothera,21 rue la Nouë Bras de Fer,,Nantes,,' 44200 ' ,France,952723,lymphoma,"""gard:0020548""",
3335,hetrombopag,,6/13/2022,treatment for chemotherapy-induced thrombocytopenia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.",7 Kunlunshan Road,Economic & Technological Development Zone,Lianyungang,Jiangsu,' 222047 ' ,China,882322,,,
3336,hexasodium phytate,,12/2/2012,treatment of calciphylaxis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vifor Pharma, Inc.",200 Cardinal Way,,Redwood City,California,' 94063 ' ,United States,380412,calciphylaxis,"""gard:0005980""",
3337,"hexasodium salt of myo-inositol hexaphosphate (IP6, phytate) hexasodium phytate",,2/8/2021,treatment of peripheral arterial disease in patients with end-stage kidney disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vifor Pharma, Inc.",200 Cardinal Way,,Redwood City,California,' 94063 ' ,United States,799020,,,
3338,"high molecular weight multimer of E3-Fc, an endostatin C-terminus and IgG1-Fc fusion protein",,6/27/2016,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"iBio, Inc.",600 Madison Avenue,Suite 1601,New York,New York,' 10022 ' ,United States,526716,systemic sclerosis,"""gard:0009748""",
3339,Highly branched poly(beta-amino ester) complexed with a nanoplasmid containing the human COL7A1 gene,,12/21/2020,treatment of dystrophic epidermolysis bullosa,Designated,,Not FDA Approved for Orphan Indication,,,,,Amryt Genetics Limited,90 Harcourt Street,,Dublin,,"' 2, D02 CR98 ' ",Ireland,787820,dystrophic epidermolysis bullosa,"""gard:0002150""",
3340,HIRMAb-IDS,,5/15/2013,treatment of mucopolysaccharidosis type ii (hunter syndrome),Designated,,Not FDA Approved for Orphan Indication,,,,,"ArmaGen Technologies, Inc.",914 Colorado Avenue,,Santa Monica,California,' 90401 ' ,United States,396913,mucopolysaccharidosis,"""gard:0007065""",
3341,His-D-Trp-Ala-Trp-D-Phe-Lys NH2,,5/23/1990,for the long term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,SmithKline Beecham Pharmaceuticals,One Franklin Plaza,,Philadelphia,Pennsylvania,' 19101 ' ,United States,46190,,,
3342,His-His- Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr-NH2,,1/13/2016,treatment of retinal detachment,Designated,,Not FDA Approved for Orphan Indication,,,,,"ONL Therapeutics, Inc",1600 Huron Parkway,"NCRC Bldg. 520, 2nd Floor",Ann Arbor,Michigan,' 48109 ' ,United States,501215,,,
3343,His-His-Ile-Tyr-Leu-Gly-Ala-Val-Asn-Tyr-Ile-Tyr,,3/11/2013,treatment of retinal detachment,Designated,,Not FDA Approved for Orphan Indication,,,,,"ONL Therapeutics, Inc",1600 Huron Parkway,Second Floor,Ann Arbor,Michigan,' 48109 ' ,United States,390313,,,
3344,Histamine,,12/15/1999,adjunct to cytokine therapy in the treatment of acute myeloid leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,EpiCept Corporation,777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,127399,acute myeloid leukemia,"""gard:0012757""",
3345,Histamine,,2/1/2000,for use as an adjunct to cytokine therapy in the treatment of malignant melanoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,EpiCept Corporation,777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,127199,noma,"""gard:0004001""",
3346,Histrelin,,5/3/1991,"treatment of acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Anderson, Karl E., M.D.",University of Texas Medical Branch at Galveston,"Route J-09, 700 The Strand",Galveston,Texas,' 77550 ' ,United States,28488,porphyria,"""gard:0010353""",
3347,Histrelin,Supprelin LA,11/18/2005,treatment of central precocious puberty,Designated/Approved,,,Treatment of central precocious puberty,5/3/2007,5/3/2014,,"Endo Pharmaceuticals Solutions, Inc.",100 Endo Blvd,,Chadds Ford,Pennsylvania,' 19317 ' ,United States,212605,central precocious puberty,"""gard:0016546""",
3348,Histrelin acetate,Supprelin Injection,8/10/1988,treatment of central precocious puberty.,Designated/Approved,,,Treatment of central precocious puberty.,12/24/1991,12/24/1998,,Roberts Pharmaceutical Corp.,Meridian Center III,6 Industrial Way West,Eatontown,New Jersey,' 07724 ' ,United States,16986,central precocious puberty,"""gard:0016546""",
3349,HIV neutralizing antibodies,,3/24/1992,treatment of acquired immunodeficiency syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Hemacare Corporation,4954 Van Nuys Boulevard,,Sherman Oaks,California,' 91403 ' ,United States,61991,acquired immunodeficiency,"""gard:0021359""",
3350,HLA-B7/Beta2M DNA Lipid (DMRIE/DOPE) Complex,,9/30/1999,"treatment of invasive and metastatic melanoma (stages ii, iii, and iv).",Designated,,Not FDA Approved for Orphan Indication,,,,,Vical Incorporated,"9373 Towne Centre Dr., Suite 100",,San Diego,California,' 92121 ' ,United States,128199,noma,"""gard:0004001""",
3351,Homodimeric fragment crystallizable fusion protein comprised of the extracellular domain of the human transforming growth factor beta receptor type II linked to a human IgG1 Fc domain,,11/25/2020,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.",126 East Lincoln Avenue,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,782620,systemic sclerosis,"""gard:0009748""",
3352,homoharringtonine,,2/8/2002,treatment for chronic myelogenous leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"American BioScience, Inc.",2730 Wilshire Blvd. #110,,Santa Monica,California,' 90403 ' ,United States,152901,,,
3353,HPV-16 cancer therapeutic trojan peptide vaccine,,1/12/2009,treatment of hpv-16 expressing head and neck squamous cell carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gliknik, Inc.",801 W. Baltimore Street,,Baltimore,Maryland,' 21201 ' ,United States,273508,noma,"""gard:0004001""",
3354,HPV16 E6/E7 synthetic long peptides vaccine,,9/1/2011,treatment of epithelial neoplasias of the vulva positive for human papilloma virus type 16.,Designated,,Not FDA Approved for Orphan Indication,,,,,ISA Therapeutics BV,J.H. Oortweg 19,2333 CH Leiden,CH Leiden,,' ' ,Netherlands,324310,,,
3355,HSV-1-erasing lentivirus-like particle delivering gRNA-expressing cassette and SpCas9 mRNA,,6/24/2022,treatment of herpes simplex (hsv-1) infected keratitis (hsk),Designated,,Not FDA Approved for Orphan Indication,,,,,Shanghai BDgene Therapeutics Co. LTD,"301, 302, 303, 304, Unit B, Building 17",No.1699 Duhui Road,"Minhang District, Shanghai",,' ' ,China,885922,,,
3356,"Hu1D10, humanized monoclonal antibody",,11/28/2001,for use in the treatment of 1d10+ b cell non-hodgkin's lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"PDL BioPharma, Inc.",34801 Campus Drive,,Fremont,California,' 94555 ' ,United States,144701,lymphoma,"""gard:0020548""",
3357,"Human acid precursor alpha-glucosidase, recombinant",,9/10/1996,treatment of glycogen storage disease type ii.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Pharming/Genzyme LLC,1 Mountain Rd.,PO Box 9322,Framingham,Massachusetts,' 01701 ' ,United States,100496,glycogen storage disease,"""gard:0018973""",
3358,human allogeneic bone marrow derived osteoblastic cells,,11/9/2015,treatment of osteogenesis imperfecta.,Designated,,Not FDA Approved for Orphan Indication,,,,,Biosenic SA,Rue Granbonpré,"11, Batiment H, bte 24",Mont-Saint-Guibert,,' B-1435 ' ,Belgium,495015,osteogenesis imperfecta,"""gard:0001017""",
3359,human allogeneic bone marrow derived osteoblastic cells,,1/10/2014,treatment of osteonecrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Biosenic SA,Rue Granbonpré,"11, Batiment H, bte 24",Mont-Saint-Guibert,,' B-1435 ' ,Belgium,416813,osteonecrosis,"""gard:0021657""",
3360,"Human Allogeneic HLA-matched, Umbilical Cord Blood Hematopoietic Progenitor Cells Ex Vivo Expanded on Allogeneic Mesenchymal Precursor Cells",,9/12/2008,treatment of insufficient hematopoietic stem cell production in patients with hematologic malignancies who have failed treatment with conventional chemotherapy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mesoblast, Inc.",275 Madison Avenue,4th Floor,New York,New York,' 10016 ' ,United States,263308,,,
3361,Human allogeneic umbilical cord mesenchymal stromal cells-derived extracellular vesicles.,,10/25/2022,prevention of bronchopulmonary dysplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,Exo Biologics SA,Boulevard Gustave Kleyer 17,,Liege,Liege,' 4000 ' ,Belgium,906222,bronchopulmonary dysplasia,"""gard:0005962""",
3362,"Human alpha 2,6 sialyltransferase adenoviral gene therapy",,4/4/2005,"treatment of patients with invasive (malignant) brain and central nervous system tumors lacking alpha 2,6 sialyltransferase.",Designated,,Not FDA Approved for Orphan Indication,,,,,Falk Center for Molecular Therapeutics,1801 Maple Avenue,Suite 4300,Evanston,Illinois,' 60201 ' ,United States,201805,,,
3363,Human alpha-1-antitrypsin,,6/12/2017,treatment of acute graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Paul Maher, MD",10644 Weymouth Street,Suite 104,Bethesda,Maryland,' 20814 ' ,United States,576717,graft versus host disease,"""gard:0016642""",
3364,human Alpha1-Proteinase inhibitor,,7/30/2018,prevention of graft-versus-host disease (gvhd),Designated,,Not FDA Approved for Orphan Indication,,,,,CSL Behring LLC,1020 First Ave.,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,644118,,,
3365,Human Alpha1-proteinase inhibitor,,10/22/2019,treatment of graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,708519,graft versus host disease,"""gard:0016642""",
3366,Human anti-CD30 monoclonal antibody,,9/27/2004,treatment of hodgkin's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Bristol-Myers Squibb, Inc.",519 Route 173 West,,Bloomsbury,New Jersey,' 08804 ' ,United States,192904,,,
3367,human anti-CD4 monoclonal antibody,,8/13/2004,treatment of mycosis fungoides,Designated,,Not FDA Approved for Orphan Indication,,,,,"Emergent Product Development Seattle, LLC",,2401 Fourth Avenue,Seattle,Washington,' 98121 ' ,United States,188504,,,
3368,human anti-CD94 IgG1 monoclonal antibody (non-fucosylated),,5/9/2024,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Dren Bio, Inc",384 Foster City Blvd.,,Foster City,California,' 94404 ' ,United States,1001724,lymphoma,"""gard:0020548""",
3369,human anti-CD94 IgG1 monoclonal antibody (non-fucosylated),,3/23/2023,treatment of large granular lymphocyte leukemia (lgll),Designated,,Not FDA Approved for Orphan Indication,,,,,"Dren Bio, Inc",384 Foster City Blvd.,,Foster City,California,' 94404 ' ,United States,930622,large granular lymphocyte leukemia,"""gard:0022073""",
3370,human anti-cellular adhesion molecule-1 monoclonal antibody,,7/29/2008,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,BioInvent International AB,Solvegatan 41,,Lund,,' ' ,Sweden,258708,multiple myeloma,"""gard:0007108""",
3371,Human anti-integrin receptor av monoclonal antibody,,5/5/2005,treatment of patients with angiosarcoma,Designated/Designation Withdrawn or Revoked,7/16/2014,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring House,Pennsylvania,' 19477 ' ,United States,203605,angiosarcoma,"""gard:0020900""",
3372,human anti-integrin receptor avb3/avb5 monoclonal antibody,,12/1/2004,"treatment of patients with high-risk stage ii, stage iii, and stage iv malignant melanoma",Designated/Designation Withdrawn or Revoked,7/16/2014,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring House,Pennsylvania,' 19477 ' ,United States,173803,noma,"""gard:0004001""",
3373,human anti-LIGHT monoclonal antibody,,10/26/2021,treatment of pediatric crohn’s disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Cerecor Inc.,"540 Gaither Road, Suite 400",Suite 715,Rockville,Maryland,' 20850 ' ,United States,643018,,,
3374,human anti-transforming growth factor beta 1 monoclonal antibody,,1/11/2002,treatment of systemic sclerosis,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,One Kendall Square,,Cambridge,Massachusetts,' 02139 ' ,United States,151101,systemic sclerosis,"""gard:0009748""",
3375,"human anti-transforming growth factor-B1,2,3",,7/9/2004,treatment of idiopathic pulmonary fibrosis,Designated/Designation Withdrawn or Revoked,8/19/2015,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,187304,idiopathic pulmonary fibrosis,"""gard:0008609""",
3376,Human Anti-tumor Necrosis factor alpha monoclonal antibody,,1/16/2003,"treatment of uveitis of the posterior segment of non-infectious etiology, and uveitis of the anterior segment of non-infectious etiology and refractory to conventional therapy",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,159402,uveitis,"""gard:0019549""",
3377,human astrocytes derived from astrocyte progenitor cells originating from clincial-grade human embryonic stem cells,,11/1/2018,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kadimastem, Ltd.",7 Pinhas Sapir Street,Weizmann Science Park,Ness Ziona,Center District,' ' ,Israel,658618,amyotrophic lateral sclerosis,"""gard:0005786""",
3378,Human autologous bone-forming cell derived from bone marrow stem cells,,3/24/2008,treatment of osteonecrosis,Designated/Designation Withdrawn or Revoked,10/24/2019,Not FDA Approved for Orphan Indication,,,,,Bone Therapeutics S.A.,"Rue Auguste Piccard, 37",,Gosselies,,' ' ,Belgium,250207,osteonecrosis,"""gard:0021657""",
3379,Human autologous CD4+ and CD8+ T cells engineered ex vivo to express a T cell receptor that recognizes amino acids 11-19 of the human papillomavirus (HPV)16 E7 protein when bound to human leukocyte antigen-A*02:01,,12/1/2020,treatment of patients with human papillomavirus (hpv)+ cervical cancer who are human leukocyte antigen (hla)-a*02+,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kite Pharma, Inc.",2400 Broadway,,Santa Monica,California,' 90404 ' ,United States,784120,,,
3380,human coagulation factor VIII,,12/3/2012,immune tolerance induction in hemophilia a patients with inhibitors,Designated/Designation Withdrawn or Revoked,1/3/2020,Not FDA Approved for Orphan Indication,,,,,"OCTAPHARMA USA, Inc.",121 River Street,12th Floor,Hoboken,New Jersey,' 07030 ' ,United States,382812,hemophilia,"""gard:0010418""",
3381,human coagulation factor XI,,2/15/2018,treatment of congenital factor xi deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Bio Products Laboratory Limited,Dagger Lane,,Elstree,Hertfordshire,' ' ,United Kingdom,625417,congenital factor xi deficiency,"""gard:0009670""",
3382,human coagulation factor XI,,11/8/2007,treatment of severe congential factor xi deficiency.,Designated/Designation Withdrawn or Revoked,1/3/2017,Not FDA Approved for Orphan Indication,,,,,Laboratoire francais du Fractionnement et des Biot,3 Avenue des Tropiques,B.P. 305-Les Ulis,Courtaboeuf Cedex,,' ' ,France,229706,,,
3383,human cystic fibrosis transmembrane conductance regulator (hCFTR) messenger RNA (mRNA) complexed with branched polyethyleneimine (bPEI),,11/3/2015,treatment of patients with cystic fibrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Translate Bio,200 Sidney Street,Suite 310,Cambridge,Massachusetts,' 02139 ' ,United States,496215,cystic fibrosis,"""gard:0006233""",
3384,Human cytomegalovirus (HCMV) internal repeat short 1 (IRS1)-expressing oncolytic Herpes Simplex Virus,,5/9/2019,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Nationwide Children's Hospital,700 Children's Drive,Rm W210,Columbus,Ohio,' 43205 ' ,United States,683219,,,
3385,Human cytomegalovirus immunoglobulin,,12/20/2006,prevention of congenital cytomegalovirus (cmv) infection following primary cmv infection in pregnant women,Designated,,Not FDA Approved for Orphan Indication,,,,,Biotest Pharmaceuticals Corporation's (BPC),901 Yamato Road,Suite 101,Boca Raton,Florida,' 33431 ' ,United States,232806,,,
3386,"Human decorin, natural anti-fibrotic protein, fused to the C-terminal vascular homing peptide tCRK",,1/31/2023,treatment of epidermolysis bullosa (eb),Designated,,Not FDA Approved for Orphan Indication,,,,,Tampereen Korkeakoulusäätiö sr.,Arvo Ylpön katu 34,,Tampere University,,' FI-33014 ' ,Finland,922422,,,
3387,human donor hematopoietic stem and progenitor cells (HSPC) that have been treated ex vivo with TBX-4000,,6/2/2016,enhancement of cell engraftment in patients receiving hematopoietic stem cell transplant.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Taiga Biotechnologies, Inc.",12635 Montview Boulevard,Fitzsimmons BBioscience Park Center,Aurora,Colorado,' 80045 ' ,United States,507115,,,
3388,"Human Engrailed-1 homeoprotein, recombinant",,9/24/2020,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,BrainEver SAS,"74, Rue du Faubourg Saint Antoine",,PARIS,,' 75012 ' ,France,766620,amyotrophic lateral sclerosis,"""gard:0005786""",
3389,"human fibrinogen concentrate, pasteurized",RiaSTAP,3/13/2008,treatment of fibrinogen deficient patients.,Designated/Approved,,,Treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia),1/16/2009,1/16/2016,,"CSL Behring, LLC",1020 First Avenue,P.O. Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,245107,,,
3390,human fully IgG1 antibody specific for CD33,,6/19/2014,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,6/12/2023,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,' 06877 ' ,United States,435614,acute myeloid leukemia,"""gard:0012757""",
3391,human gammaglobulin,,9/16/2002,"treatment of gastrointestinal disturbances (to include constipation, diarrhea, and abdominal pain) associated with regression-onset autism in pediatric patients.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Latona Life Sciences, Inc.",10 Village St.,,Mills,Massachusetts,' 02054 ' ,United States,152101,,,
3392,human gammaglobulin,,11/14/2003,treatment of idiopathic inflammatory myopathies,Designated,,Not FDA Approved for Orphan Indication,,,,,"Latona Life Sciences, Inc.",10 Village St.,,Mills,Massachusetts,' 02054 ' ,United States,176003,,,
3393,human gammaglobulin,,5/25/2001,treatment for juvenile rheumatoid arthritis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Latona Life Sciences, Inc.",10 Village St.,,Mills,Massachusetts,' 02054 ' ,United States,142901,,,
3394,human glial restricted progenitor cells and their progeny,,9/11/2013,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Q Therapeutics, Inc.",615 Arapeen Drive,Suite 102,Salt Lake City,Utah,' 84108 ' ,United States,406513,amyotrophic lateral sclerosis,"""gard:0005786""",
3395,human glial restricted progenitor cells and their progeny,,4/11/2018,treatment of transverse myelitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Q Therapeutics, Inc.",417 Wakara Way,Ste. 3510,Salt Lake City,Utah,' 84108 ' ,United States,635118,,,
3396,human glucagon-like peptide-2 analogue linked to a human immunoglobulin Fc fragment (ready to use pre-filled syringe),,5/1/2019,treatment of short bowel syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Hanmi Pharmaceutical Co. Ltd.,"14, Wiryeseong-daero",,Songpa-gu,Seoul,' ' ,South Korea,658818,short bowel syndrome,"""gard:0001502""",
3397,human haptoglobin,,11/19/2013,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,BioProducts Laboratory Limited,"Dagger Lane, Elstree",,Herts,,' ' ,United Kingdom,359511,,,
3398,Human Hemin,,8/6/2013,prevention of ischemia reperfusion injury in patients undergoing solid organ transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,Borders Technology Management Ltd,2 Broomlee Mains Court,,Peeblesshire,Scotland,' ' ,United Kingdom,402413,,,
3399,human Hepatocarcinoma-Intestine-pancreas/pancreatitis associated protein,,5/11/2011,treatment of acute liver failure,Designated,,Not FDA Approved for Orphan Indication,,,,,Vivo Bioscience Company Limited,No. 501 East Daming Road,Room 5302,Hongkou District,,' ' ,China,340711,acute liver failure,"""gard:0019112""",
3400,human heterologous liver cells,,2/14/2011,treatment of urea cycle disorders,Designated,,Not FDA Approved for Orphan Indication,,,,,Promethera Biosciences,Watson & Crick Hill,Rue Granbonpre 11,Mont Saint Guibert,,' ' ,Belgium,331810,,,
3401,human IgG1 anti-human cytomegalovirus monoclonal antibodies LJP538 and LJP539,,10/18/2017,prevention of congenital cytomegalovirus (cmv) infection following primary cmv infection in pregnant women,Designated/Designation Withdrawn or Revoked,1/17/2024,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,35 Lichtstrasse,,Basel,Basel-Stadt,' ' ,Switzerland,533216,,,
3402,Human IgG1 monoclonal antibody to human CD38,,1/22/2019,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,667418,multiple myeloma,"""gard:0007108""",
3403,Human IgG1Fc- iMod domain (amino acids 2-60) of human HARS fusion protein,,1/5/2022,treatment of sarcoidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,aTyr Pharma,3545 John Hopkins Court,Suite 250,San Diego,California,' 92121 ' ,United States,708419,sarcoidosis,"""gard:0007607""",
3404,human IgG2 anti-monoclonal antibody directed against mucosal addressin cell adhesion molecule (MAdCAM),,11/16/2017,treatment of pediatric patients with ulcerative colitis (uc),Designated/Designation Withdrawn or Revoked,6/30/2020,Not FDA Approved for Orphan Indication,,,,,"Shire Human Genetic Therapies, Inc. (Shire)",300 Shire Way,,Lexington,Massachusetts,' 02421 ' ,United States,608217,,,
3405,human IgG2 monoclonal antibody directed against the mucosal addressin cell adhesion molecule,,2/7/2018,treatment of crohn’s disease (cd) in the pediatric population,Designated/Designation Withdrawn or Revoked,6/30/2020,Not FDA Approved for Orphan Indication,,,,,"Shire Human Genetic Therapies, Inc. (Shire)",300 Shire Way,,Lexington,Massachusetts,' 02421 ' ,United States,608117,,,
3406,human IgG4-based anti-CD20 x anti-CD3 bispecific monoclonal antibody,,6/6/2017,treatment of diffuse large b-cell lymphoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,569816,lymphoma,"""gard:0020548""",
3407,human IgG4-based anti-CD3 x anti-BCMA bispecific monoclonal antibody that binds to CD3 and BCMA,,6/6/2022,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,882022,multiple myeloma,"""gard:0007108""",
3408,Human IgM monoclonal antibody (C-58) To CMV,,8/7/1989,prophylaxis of cytomegalovirus infections in bone marrow transplant patients.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",244 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,33088,,,
3409,Human IgM monoclonal antibody (C-58) To CMV,,8/7/1989,treatment of cytomegalovirus infections in allogenic bone marrow transplant patients.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",244 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,32988,,,
3410,Human immune globulin,,3/29/2006,treatment of post-polio syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Instituto Grifols, S.A.","Can Guasch, 2",08150 Parets del Valles,Barcelona,,' ' ,Spain,219706,,,
3411,Human immunodeficiency virus immune globulin,,11/21/1989,treatment of aids.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,NABI,"5800 Park of Commerce Blvd., NW",,Boca Raton,Florida,' 33487 ' ,United States,37489,,,
3412,Human immunodeficiency virus immune globulin,,1/4/1995,treatment of hiv-infected pediatric patients.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,NABI,"5800 Park of Commerce Blvd., NW",,Boca Raton,Florida,' 33487 ' ,United States,85994,,,
3413,Human immunodeficiency virus immune globulin,,3/25/1992,treatment of hiv-infected pregnant women and infants of hiv-infected mothers.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,NABI,"5800 Park of Commerce Blvd., NW",,Boca Raton,Florida,' 33487 ' ,United States,63791,,,
3414,Human immunoglobin anti-CD30 monoclonal antibody,,1/10/2006,treatment of cd30+ t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb,519 Route 173 West,,Bloombury,New Jersey,' 08804 ' ,United States,215905,lymphoma,"""gard:0020548""",
3415,human immunoglobulin (IgG1K) monoclonal antibody that binds to interleukin 15,,4/10/2018,treatment of refractory celiac disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,1 Amgen Center Drive,,Thousand Oaks,California,' 91320 ' ,United States,574517,refractory celiac disease,"""gard:0021640""",
3416,Human induced pluripotent stem cell derived myogenic progenitor cells (GIVI-MPC),,10/3/2022,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,IPS Heart,14090 Southwest Fwy,Unit 300,Sugar Land,Texas,' 77478 ' ,United States,902022,muscular dystrophy,"""gard:0007922""",
3417,Human induced pluripotent stem cells (iPSC)-derived Photoreceptor Progenitor Cells,,3/20/2024,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"iRegene Therapeutics Co., Ltd","Room 301, Building 5, No. 9, 3rd Gao Ke Yuan Road","Precision Medicine Industrial Park, East Lake High-Tech Development Zone",Wuhan,Hubei,' 430074 ' ,China,994623,retinitis pigmentosa,"""gard:0005694""",
3418,human insulin (rDNA),,4/6/2015,treatment of short bowel syndrome (sbs).,Designated,,Not FDA Approved for Orphan Indication,,,,,ELGAN Pharma Ltd.,13 wadi el hadj,,Nazareth,,' 17111 ' ,Israel,469115,short bowel syndrome,"""gard:0001502""",
3419,Human Insulin (rDNA),,2/28/2022,prevention of retinopathy of prematurity (rop),Designated,,Not FDA Approved for Orphan Indication,,,,,"Elgan Pharma, Ltd.",Wadi El Haj 13,,Nazareth,Israel,' 16100 ' ,Israel,863821,retinopathy of prematurity,"""gard:0005695""",
3420,human insulin beta chain peptide with incomplete Freund's adjuvant vaccine,,2/11/2013,treatment of type 1 diabetes patients with residual beta cell function,Designated,,Not FDA Approved for Orphan Indication,,,,,"Orban Biotech, LLC",64 Aspinwall Avenue,,Brookline,Massachusetts,' 02446 ' ,United States,369912,,,
3421,human interleukin-3 genetically conjugated to diphtheria toxin protein,,2/18/2011,treatment of acute myeloid leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Stemline Therapeutics, Inc.",750 Lexington Avenue,,New York,New York,' 10022 ' ,United States,332811,acute myeloid leukemia,"""gard:0012757""",
3422,human laminin-111,,9/23/2011,treatment of merosin (laminin-alpha2) deficient congential muscular dystrophy type 1a.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Prothelia, Inc.",30 Haven Street,,Milford,Massachusetts,' 01757 ' ,United States,351811,muscular dystrophy,"""gard:0007922""",
3423,human leukocyte antigen-A2 restricted peptides,,1/26/2015,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Stemline Therapeutics, Inc.",750 Lexington Avenue,11 th Floor,New York,New York,' 10022 ' ,United States,433614,,,
3424,human leukocyte-derived cytokine mixture,,7/7/2005,neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck,Designated,,Not FDA Approved for Orphan Indication,,,,,"IRX Therapeutics, Inc.",Suite 2100,,Brooklyn,New York,' 11220 ' ,United States,199604,noma,"""gard:0004001""",
3425,Human major histocompatibility complex (MHC) non-restricted T-cell line 104,,4/17/2017,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Galileo Research srl,Via Paradiso 6,56019 Migliarino Pisano,Pisa,,' ' ,Italy,562016,multiple myeloma,"""gard:0007108""",
3426,human MHC non-restricted cytotoxic T-cell line,,7/6/2012,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Galileo Research srl,Via Paradiso 6,56019 Migliarino Pisano,Pisa,,' ' ,Italy,364812,ovarian cancer,"""gard:0007295""",
3427,human monoclonal anti-PA antibody,,10/21/2010,for post-exposure prophylaxis and treatment of inhalation anthrax.,Designated/Designation Withdrawn or Revoked,2/19/2016,Not FDA Approved for Orphan Indication,,,,,"Emergent Product Development Gaithersburg, Inc.",300 Professional Drive,,Gaithersburg,Maryland,' 20879 ' ,United States,317710,,,
3428,Human Monoclonal Antibody against Epidermal Growth Factor Receptor Linked to Monomethylauristatin F,,5/29/2014,treatment of glioblastoma multiforme,Designated/Designation Withdrawn or Revoked,2/18/2020,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,433214,glioblastoma,"""gard:0002491""",
3429,Human monoclonal antibody against phosphorylcholine,,6/15/2017,prevention of arteriovenous fistula or arteriovenous graft failure in patients with end stage renal disease receiving hemodialysis or preparing for hemodialysis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Athera Biotechnologies, AB",117 Sankt Eriksgatan,4th Floor,Norrmalm,Stockholms län,' ' ,Sweden,579717,,,
3430,Human monoclonal antibody against platelet-derived growth factor D,,11/2/2004,to slow the progression of iga nephropathy and delay kidney failure in patients affected by the disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,CuraGen Corporation,322 East Main Street,,Branford,Connecticut,' 06405 ' ,United States,194404,,,
3431,human monoclonal antibody againt human interleukin 13 (IL-13),,10/15/2013,treatment of eosinophilic esophagitis,Designated/Designation Withdrawn or Revoked,8/17/2022,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporaton,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,408513,,,
3432,human monoclonal antibody based on an IgG1 lambda framework against human interferon gamma,,9/1/2022,treatment of hemophagocytic lymphohistiocytosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Elixiron Immunotherapeutics (Hong Kong) Limited,15/F Boc Group Life Assurance Tower,126 Des Voeux Rd,"Central, Central, Hong Kong",,' N/A ' ,Hong Kong,871722,,,
3433,Human monoclonal antibody directed against human Activin A,,1/19/2017,treatment of fibrodysplasia ossificans progressiva,Designated,,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,547016,fibrodysplasia ossificans progressiva,"""gard:0006445""",
3434,Human monoclonal antibody directed against serotype 011 Pseudomonas aeruginosa,,9/18/2006,treatment of hospital acquired pneumonia caused by serotype 011 positive pseudomonas aeruginosa,Designated,,Not FDA Approved for Orphan Indication,,,,,Kenta Biotech Limited,Rehhagstrsase 79,,Berne,,' ' ,Switzerland,223706,,,
3435,human monoclonal antibody directed against serotype O1 Pseudomonas aeruginosa,,1/6/2010,treatment of pneumonia caused by serotype o1 positive pseudomonas aeruginosa,Designated,,Not FDA Approved for Orphan Indication,,,,,Kenta Biotech Limited,Rehhagstrasase 79,,Berne,,' ' ,Switzerland,297009,,,
3436,human monoclonal antibody inhibitor of mannan binding lectin-associated serine protease-2,,8/3/2017,treatment of immunoglobulin a nephropathy (igan),Designated,,Not FDA Approved for Orphan Indication,,,,,Omeros Corporation,201 Elliott Avenue West,,Seattle,Washington,' 98119 ' ,United States,561516,,,
3437,Human monoclonal antibody inhibitor of mannan binding lectin-associated serine protease-2 (MASP-2),,12/16/2013,prevention (inhibition) of complement-mediated thrombotic microangiopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Omeros Corporation,201 Elliott Avenue West,,Seattle,Washington,' 98119 ' ,United States,397813,thrombotic microangiopathy,"""gard:0019227""",
3438,human monoclonal antibody inhibitor of mannan binding lectin-associated serine protease-2 (MASP-2),,10/22/2018,treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Omeros Corporation,201 Elliott Avenue West,,Seattle,Washington,' 98119 ' ,United States,655418,thrombotic microangiopathy,"""gard:0019227""",
3439,Human monoclonal antibody targeting CC-chemokine ligand 2 (CNTO 888),,4/30/2010,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Ortho Biotech,200 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,306810,ovarian cancer,"""gard:0007295""",
3440,human monoclonal antibody targeting human sclerostin,,2/29/2016,treatment of osteogenesis imperfecta.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ultragenyx Pharmaceutical, Inc.",60 Leveroni Ct,,Novato,California,' 94949 ' ,United States,508615,osteogenesis imperfecta,"""gard:0001017""",
3441,Human monoclonal IgG1 antibody against the isoform 2 of human Claudin 18 protein (Claudin 18.2),,12/21/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shandong Boan Biotechnology Co., Ltd.","No.39 Keji Avenue, Yantai Hi-Tech Zone, Shandong Province, P.R. China",,,,' ' ,China,978523,,,
3442,Human monoclonal IgG1 antibody against the isoform 2 of human Claudin 18 protein (Claudin 18.2),,1/22/2024,"treatment of gastric cancer, including cancer of the gastroesophageal junction",Designated,,Not FDA Approved for Orphan Indication,,,,,"Shandong Boan Biotechnology Co., Ltd.","No.39 Keji Avenue,",,Yantai Hi-Tech Zone,Shandong Province,' ' ,China,983423,,,
3443,Human monoclonal IgG1 TREM2 agonist antibody,,7/27/2022,treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vigil Neuroscience, Inc.","One Broadway, Suite 07-300",,Cambridge,Massachusetts,' 02142 ' ,United States,831521,,,
3444,Human monoclonal IgG2 antibody against tissue factor pathway inhibitor,,6/25/2019,treatment of hemophilia b,Designated/Designation Withdrawn or Revoked,2/10/2020,Not FDA Approved for Orphan Indication,,,,,Bayer HealthCare LLC,100 Bayer Boulevard,P.O. Box 915,Hanover,New Jersey,' 07981 ' ,United States,685719,hemophilia,"""gard:0010418""",
3445,human monoclonal IgG2 antibody against tissue factor pathway inhibitor (TFPI),,3/25/2019,treatment of hemophilia a,Designated/Designation Withdrawn or Revoked,2/10/2020,Not FDA Approved for Orphan Indication,,,,,Bayer HealthCare LLC,100 Bayer Boulevard,P.O. Box 915,Hanover,New Jersey,' 07981 ' ,United States,678219,hemophilia,"""gard:0010418""",
3446,Human N-sulfoglucosamine sulfohydrolase fused to a humanised monoclonal antibody targeting human transferrin receptor,,12/12/2023,treatment of mucopolysaccharidosis type iiia (sanfilippo syndrome type a),Designated,,Not FDA Approved for Orphan Indication,,,,,"JCR Pharmaceuticals Co., Ltd.","3-19 Kasuga-cho,",,Ashiya,Hyogo,' 659-0021 ' ,Japan,933123,sanfilippo syndrome type a,"""gard:0007071""",
3447,Human Nuclear Hormone Receptor Subfamily 2 Group E Member 3 (hNR2E3),,12/15/2022,treatment of leber congenital amaurosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ocugen, Inc.",11 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,914622,leber congenital amaurosis,"""gard:0000634""",
3448,Human Nuclear Hormone Receptor Subfamily 2 Group E Member 3 (hNR2E3),,12/15/2022,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ocugen, Inc.",11 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,914522,retinitis pigmentosa,"""gard:0005694""",
3449,Human Placental Extract,,5/28/2020,prevention of necrotizing enterocolitis in early preterm infants (gestational age less than 34 weeks).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Plakous Therapeutics, Inc.",755 Highland Oaks Dr.,Suite 103,Winston-Salem,North Carolina,' 27103 ' ,United States,733520,necrotizing enterocolitis,"""gard:0009767""",
3450,Human plasma derived conagulation protein-Factor XI,,4/30/2014,for the treatment of congenital factor xi deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Cambryn Biologics,600Tallevast Rd,Unit 201,Sarasota,Florida,' 34243 ' ,United States,427214,congenital factor xi deficiency,"""gard:0009670""",
3451,human plasminogen,,6/7/2010,treatment of ligneous conjunctivitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kedrion, S.p.A.",Loc. ai Conti,55051 Castelvecchio Pascoli,Barga (Lucca),,' ' ,Italy,309210,,,
3452,human platelet antigen-1a immunoglobulin (anti-HPA-1a),,6/27/2013,prevention of fetal and neonatal alloimmune thrombocytopenia,Designated/Designation Withdrawn or Revoked,12/12/2023,Not FDA Approved for Orphan Indication,,,,,"Rallybio IPA, LLC",234 Church Street,Suite 1020,New Haven,Connecticut,' 06510 ' ,United States,398413,immune thrombocytopenia,"""gard:0005194""",
3453,human platelet derived hemostatic agent,,5/7/2020,treatment of acute radiation syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cellphire, Inc.","9430 Key West Avenue, Suite 250",,Rockville,Maryland,' 20850 ' ,United States,677219,acute radiation syndrome,"""gard:0021896""",
3454,Human pooled allogenic umbilical cord mesenchymal stromal cells,,11/22/2023,treatment of hypoxic ischemic encephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,ESPL Regulatory Consulting Limited,"Riverhouse, Unit 4D",Blackpool Retail Park,Cork,Munster,' T23 R5TF ' ,Ireland,971323,,,
3455,human recombinant bone morphogenetic protein 4,,5/4/2016,treatment of glioblastoma multiforme.,Designated,,Not FDA Approved for Orphan Indication,,,,,Stemgen Spa,"Piazza della Scienza, 2",,Milano,,' 20 126 ' ,Italy,520216,glioblastoma,"""gard:0002491""",
3456,human recombinant dual-variable domain immunoglobulin G1 monoclonal antibody that selectively neutralizes tumor necrosis factor-alpha and interkeukin-17A,,2/4/2016,treatment of pediatric patients 0 to,Designated/Designation Withdrawn or Revoked,2/22/2017,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,503715,,,
3457,"Human recombinant factor VIIa variant (P10Q, K32E, T106N, V253N), desialylated",,1/20/2022,treatment of postpartum hemorrhage,Designated,,Not FDA Approved for Orphan Indication,,,,,"Coagulant Therapeutics, Corp.",117-3 Hoegi-ro; Suite 402,"Seoul BioHub, Dongdaemun-gu",Seoul,,' 02455 ' ,South Korea,782420,,,
3458,"human recombinant mesencephalic, astrocyte derived neurotrophic factor",,12/22/2014,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"Amarantus BioScience Holdings, Inc.",655 Montgomery Street,Suite 900,San Francisco,California,' 94111 ' ,United States,457514,retinitis pigmentosa,"""gard:0005694""",
3459,"human recombinant, monoclonal antibody (mAb) of the IgG1 isotype against alpha-synuclein",,4/30/2024,treatment of multiple system atrophy (msa),Designated,,Not FDA Approved for Orphan Indication,,,,,Lundbeck Pharmaceuticals LLC,Six Parkway North,Suite 400,Deerfield,Illinois,' 60015 ' ,United States,794020,multiple system atrophy,"""gard:0007079""",
3460,Human Retinal Pigment Epithelial Cell Injection,,9/19/2023,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,Eyecure Therapeutics Inc.,"6 Junshan Road, Xinwu District",,Wuxi City,Jiangsu Province,' ' ,China,961523,retinitis pigmentosa,"""gard:0005694""",
3461,human retinal progenitor cells,,7/23/2012,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"jCyte, Inc.",42 Whitman Court,,Irvine,California,' 92617 ' ,United States,372712,retinitis pigmentosa,"""gard:0005694""",
3462,human single domain antibody-like protein inhibitor of the chemokine receptor type 4,,1/11/2017,treatment of idiopathic pulmonary fibrosis,Designated/Designation Withdrawn or Revoked,4/23/2021,Not FDA Approved for Orphan Indication,,,,,AdAlta Limited,15/2 Park Drive,,Bundoora,Victoria,' ' ,Australia,535816,idiopathic pulmonary fibrosis,"""gard:0008609""",
3463,human soluble receptor-Fc fusion protein that targets human activin A,,10/14/2015,treatment of ovarian cancer.,Designated/Designation Withdrawn or Revoked,12/15/2017,Not FDA Approved for Orphan Indication,,,,,Atara Biotherapeutics,4360 Park Terrace Drive,Suite 100,Westlake Village,California,' 91361 ' ,United States,489415,ovarian cancer,"""gard:0007295""",
3464,human spinal cord derived neural stem cells,,2/4/2011,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Seneca Biopharma, Inc.",20271 Goldenrod Lane,Suite 2024,Germantown,Maryland,' 20876 ' ,United States,329710,amyotrophic lateral sclerosis,"""gard:0005786""",
3465,human T-lymphoid progenitors derived from CD34+ hematopoietic stem and progenitor cells,,1/19/2021,treatment to enhance cell engraftment in patients receiving hematopoietic stem cell transplant,Designated,,Not FDA Approved for Orphan Indication,,,,,Smart Immune,67 rue de Seine,,Paris,,' 75006 ' ,France,774820,,,
3466,Human T-lymphotropic virus type III Gp160 antigens,,11/20/1989,treatment of aids.,Designated,,Not FDA Approved for Orphan Indication,,,,,"MicroGeneSys, Inc.",1000 Research Parkway,,Meriden,Connecticut,' 06450 ' ,United States,40989,,,
3467,Human telomerase reverse transcriptase peptide vaccine,,7/20/2006,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,GemVax A/S,Froyas Gate 1,273,Oslo,,' ' ,Norway,226306,,,
3468,Human transferrin 1 receptor (TfR1) targeting humanized IgG 1 kappa fragment antibody conjugated to an antisense oligonucleotide (ASO),,9/19/2023,treatment of myotonic dystrophy type i,Designated,,Not FDA Approved for Orphan Indication,,,,,"Dyne Therapeutics, Inc.",1560 Trapelo Road,,Waltham,Massachusetts,' 02541 ' ,United States,923922,myotonic dystrophy,"""gard:0010419""",
3469,human tumor necrosis factor coupled to the C terminus of CNGRCG peptide,,10/1/2009,treatment of liver cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Molecular Medicine S.p.A. (Molmed),Via Olgettina 58,,20132 Milano %i,,' ' ,Italy,204405,,,
3470,human umbilical cord blood-derived mesenchymal stem cells,,11/26/2013,prevention of bronchopulmonary dysplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,"MEDIPOST America, Inc.",9601 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,389713,bronchopulmonary dysplasia,"""gard:0005962""",
3471,human umbilical cord-derived mesenchymal stem cells,,8/9/2023,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Wuhan Optics Valley Vcanbiopharma Co., Ltd.","No. 2 Workshop, Floor 2, Building 14, Block B, Wuhan High-tech Medical Devices Park, No. 818, High-Tech Avenue",East Lake High-Tech Development Zone,Wuhan,Hubei,' 430206 ' ,China,952523,idiopathic pulmonary fibrosis,"""gard:0008609""",
3472,human umbilical tissue derived cells (hUTC),,5/10/2011,treatment of amyotrophic lateral sclerosis,Designated/Designation Withdrawn or Revoked,8/14/2013,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring House,Pennsylvania,' 19477 ' ,United States,339811,amyotrophic lateral sclerosis,"""gard:0005786""",
3473,Human umbilical tissue-derived cells,,3/13/2006,treatment of retinitis pigmentosa,Designated/Designation Withdrawn or Revoked,4/7/2014,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring House,Pennsylvania,' 19477 ' ,United States,219006,retinitis pigmentosa,"""gard:0005694""",
3474,Human wilms tumor protein 1 peptides,,2/23/2016,treatment of mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,SELLAS Life Sciences Group,75 Baarerstrasse,,Zug,,' ' ,Switzerland,508915,,,
3475,Human Wilms tumor protein 1 peptides,,12/23/2015,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,SELLAS Life Sciences Group,75 Baarerstrasse,,Zug,Zug,' ' ,Switzerland,500915,acute myeloid leukemia,"""gard:0012757""",
3476,Human/Murine Chimeric Monoclonal antibody to Endoglin,,1/20/2016,treatment of soft tissue sarcoma.,Designated/Designation Withdrawn or Revoked,5/10/2019,Not FDA Approved for Orphan Indication,,,,,"Tracon Pharmaceuticals, Inc.",4350 LaJolla Village Dr.,Suite 800,San Diego,California,' 92122 ' ,United States,504715,soft tissue sarcoma,"""gard:0004898""",
3477,Humanized afucosylated IgG1 monoclonal antibody binding to KLRG1,,7/7/2020,treatment of inclusion body myositis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Abcuro, Inc.","55 Chapel St., Suite 200",,Newton,Massachusetts,' 02458 ' ,United States,681119,inclusion body myositis,"""gard:0003896""",
3478,humanized anti CD20 monoclonal antibody,,6/11/2019,treatment of dermatomyositis,Designated/Designation Withdrawn or Revoked,6/15/2021,Not FDA Approved for Orphan Indication,,,,,Biocon Limited,"20th KM, Hosur Main Road",Electronics City,Bangalore,Karnataka,' ' ,India,642318,dermatomyositis,"""gard:0006263""",
3479,humanized anti-CD-47 mAb,,1/3/2022,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"ARCH Oncology, Inc.","2000 Sierra Point Parkway, Suite 700",,Brisbane,California,' 94005 ' ,United States,855321,multiple myeloma,"""gard:0007108""",
3480,"humanized anti-CD19, Fc engineered, monoclonal antibody with enhanced binding to FcyRIIb",,5/9/2017,treatment of immunoglobulin g4-related disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Zenas BioPharma (USA) LLC.,1000 Winter Street,"North Building, Suite 1200",Waltham,Massachusetts,' 02451 ' ,United States,566516,,,
3481,Humanized anti-CD2 monoclonal antibody,,11/13/1998,treatment of graft-versus-host disease.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"MedImmune, Inc.",35 West Watkins Mill Rd.,,Gaithersburg,Maryland,' 20878 ' ,United States,116498,,,
3482,Humanized Anti-claudin18.2 Autologous Chimeric Antigen Receptor (CAR) T Cells,,9/30/2020,treatment of gastric cancer including cancer of the gastroesophageal junction,Designated,,Not FDA Approved for Orphan Indication,,,,,CARsgen Therapeutics Corporation,6575 West Loop South,Suite 455,Bellaire,Texas,' 77401 ' ,United States,768620,,,
3483,Humanized anti-GD2 monoclonal antibody,,4/8/2024,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Renaissance Pharma, Ltd.",3rd Floor Ashley Road,,Altrincham,Cheshire,' WA142DT ' ,United Kingdom,980423,neuroblastoma,"""gard:0007185""",
3484,humanized anti-Globo H monoclonal antibody,,11/20/2018,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"OBI Pharma USA, Inc.","6020 Cornerstone Court W, Suite 200",,San Diego,California,' 92121 ' ,United States,661218,,,
3485,Humanized Anti-Globo H Monoclonal Antibody Monomethyl Auristatin E Conjugate,,1/15/2020,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"OBI Pharma USA, Inc.","6020 Cornerstone Court W, Suite 200",,San Diego,California,' 92121 ' ,United States,722619,,,
3486,Humanized Anti-Globo H Monoclonal Antibody Monomethyl Auristatin E Conjugate,,12/23/2019,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"OBI Pharma USA, Inc.","6020 Cornerstone Court W, Suite 200",,San Diego,California,' 92121 ' ,United States,716219,,,
3487,humanized anti-human CD16 monoclonal antibody,,3/21/2005,treatment of adult idiopathic thrombocytopenic purpura,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,199504,,,
3488,Humanized anti-human CD2 MAb,,9/17/1998,"for the induction of donor-specific immunologic unresponsiveness resulting in prophylaxis of organ rejection without the need for chronic immunosuppressive therapy, in patients receiving allogeneic renal transplants.",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Biotransplant, Inc.","Building 75, 3rd. Ave.",Charlestown Navy Yard,Charlestown,Massachusetts,' 02129 ' ,United States,107797,,,
3489,Humanized anti-tac,,3/5/1993,prevention of acute graft-vs-host disease following bone marrow transplantation.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,67792,,,
3490,humanized bi-specific XmAb(R) T cell recruiting antibody construct directed against CD3 and CD38,,11/14/2019,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,11/17/2023,Not FDA Approved for Orphan Indication,,,,,"Xencor, Inc.",111 W. Lemon Ave.,,Monrovia,California,' 91016 ' ,United States,648318,multiple myeloma,"""gard:0007108""",
3491,humanized bispecific anti-C5 minibody,,8/3/2023,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Blvd,,Boston,Massachusetts,' 02210 ' ,United States,877622,myasthenia gravis,"""gard:0007122""",
3492,humanized bispecific IgG1 antibody that can simultaneously bind to both programmed death-ligand 1 and cytotoxic T-lymphocyte-associated protein 4,,9/2/2020,treatment of thymic epithelial tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jiangsu Alphamab Biopharmaceuticals Co., Ltd.","Bldg. C23, 218 Xinghu Street,",SIP,SuZhou,Jiangsu,' ' ,China,759120,,,
3493,Humanized connexin 43 (hCx43) monoclonal antibody,,9/18/2019,treatment of osteosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"AlaMab Therapeutics, Inc.",11550 West Interstate 10,Suite 250,San Antonio,Texas,' 78230 ' ,United States,710019,osteosarcoma,"""gard:0007284""",
3494,humanized connexin 43 monoclonal antibody,,11/20/2018,treatment of acute spinal cord injury,Designated,,Not FDA Approved for Orphan Indication,,,,,"AlaMab Therapeutics, Inc.",11550 IH 10 West,Suite 250,San Antonio,Texas,' 78249 ' ,United States,611417,spinal cord injury,"""gard:0019109""",
3495,humanized Fc engineered monoclonal antibody against CD19,,4/29/2014,treatment of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,427914,lymphoma,"""gard:0020548""",
3496,humanized HER2 targeting monoclonal antibody conjugated to a cytotoxic tubulin inhibitor amberstatin,,1/14/2021,treatment of gastric cancer including cancer at the gastroesophageal junction,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ambrx, Inc.",10975 N. Torrey Pines Road,,La Jolla,California,' 92037 ' ,United States,794820,,,
3497,Humanized IgG-1 antibody targeting human transferrin receptor conjugated to human iduronate-2-sulfatase,,10/15/2018,treatment of mucopolysaccharidosis type ii (mps ii) or hunter syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"JCR Pharmaceuticals Co., Ltd.",2-4 Kasuga-cho,,Ashiya,Hyogo Prefecture,' ' ,Japan,652518,mucopolysaccharidosis,"""gard:0007065""",
3498,humanized IgG-like T cell engager (TcE) comprised of 2 polypeptide chains specific for human Delta-like 3 (DLL3) and human CD3 (BI 764532),,10/16/2023,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P.O. Box 368,Ridgefield,Connecticut,' 06877 ' ,United States,947323,small cell lung cancer,"""gard:0009344""",
3499,humanized IgG1 antibody specifific for the AXL tyrosine kinase conjugated to monomethyl auristatin E,,11/19/2018,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,BioAtla LLC,11085 Torreyana Road,Suite 100,San Diego,California,' 92121 ' ,United States,659718,,,
3500,humanized IgG1 low affinity allergic reactivity inhibiting (LARI) monoclonal antibody,,2/15/2018,treatment for mastocytosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Sixal Inc.,416 15th Street,,Santa Monica,California,' 90402 ' ,United States,613817,mastocytosis,"""gard:0006987""",
3501,humanized IgG1 monoclonal anti-CD20 antibody,,5/26/2011,treatment of follicular lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"MENTRIK Biotech, LLC",12400 Coit Rd,,Dallas,Texas,' 75251 ' ,United States,341111,lymphoma,"""gard:0020548""",
3502,Humanized IgG1 monoclonal antibody against annexin-A1,,9/15/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Medannex Ltd,1 Lochrin Square,Fountainbridge,Edinburgh,Scotland,' EH3 9QA ' ,United Kingdom,960423,,,
3503,humanized IgG1 monoclonal antibody against BCMA conjugated to synthetic amatoxin via a cathepsin B cleavable linker,,3/19/2024,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Heidelberg Pharma AG,Gregor-Mendel-Str. 22,,Ladenburg,,' 68526 ' ,Germany,950723,multiple myeloma,"""gard:0007108""",
3504,humanized IgG1 monoclonal antibody targeting KIR3DL2,,6/14/2017,treatment of cutaneous t-cell lymphoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Innate Pharma,117 Avenue de Luminy,BP 30191,Marseille,Provence-Alpes-Côte d'Azur,' ' ,France,574717,lymphoma,"""gard:0020548""",
3505,"humanized IgG1 monoclonal VpreB1 antibody conjugated to N-acetyl gamma-calicheamicin 1, 2-dimethyl hydrazine dichloride (NAc gamma-calicheamicin DMH) via an acid-labile 4-(4-acetylphenoxy) butanoic acid linker (acetyl butyrate)",,11/14/2023,treatment of acute lymphoblastic leukemia/acute lymphoblastic lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Children's Minnesota,2525 Chicago Avenue South,,Minneapolis,Minnesota,' 55404 ' ,United States,953223,lymphoma,"""gard:0020548""",
3506,humanized IgG1anti-AXL-antibody conjugated to monomethyl auristatin E,,3/1/2021,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioAtla, Inc.",11085 Torreyana Road,Suite 100,San Diego,California,' 92121 ' ,United States,802920,soft tissue sarcoma,"""gard:0004898""",
3507,humanized IgG1k monoclonal antibody against LAIR-1,,3/5/2024,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,"NextCure, Inc.",9000 Virginia Manor Road,Suite 200,Beltsville,Maryland,' 20705 ' ,United States,928122,acute myeloid leukemia,"""gard:0012757""",
3508,Humanized IgG1kappa monoclonal antibody (anti-HER2 antibody) conjugated to eribulin,,9/16/2022,treatment of gastric and gastroesophageal junction cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Bliss Biopharmaceutical (Hangzhou) Co., Ltd.","Building 7, Hexiang Technology Center, Qiantang New Area",,Hangzhou,Zhejiang,' ' ,China,899522,,,
3509,humanized IgG4 monoclonal antibody,,12/12/2011,prevention of ischemia/reperfusion injury associated with solid organ tranplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neuramedy Co., Ltd.","Rm408, Convergence Research Bldg",Seoul National University College of Medicine,Seoul,Jongro-gu,' ' ,South Korea,355311,,,
3510,"Humanized IgG4 monoclonal antibody against total complement component 1, subcomponent s",,3/28/2018,treatment of immune thrombocytopenia,Designated,,Not FDA Approved for Orphan Indication,,,,,Bioverativ USA Inc.,225 2nd Avenue,,Waltham,Massachusetts,' 02451 ' ,United States,614317,immune thrombocytopenia,"""gard:0005194""",
3511,"humanized IgG4 Monoclonal Antibody against total complement component 1, subcomponent s (C1s)",,8/17/2017,treatment of bullous pemphigoid (bp).,Designated,,Not FDA Approved for Orphan Indication,,,,,Bioverativ USA Inc.,225 Second Avenue,,Waltham,Massachusetts,' 02451 ' ,United States,597117,bullous pemphigoid,"""gard:0005972""",
3512,humanized IgG4 monoclonal antibody binding to human C1q,,1/19/2017,treatment of guillain-barre syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Annexon, Inc.",180 Kimball Way,,South San Francisco,California,' 94080 ' ,United States,550416,,,
3513,"humanized IgG4 monoclonal antibody optimized for neutralizing activity against DKK1, a secreted modulator of Wnt signaling",,6/10/2020,treatment of gastric and gastroesophageal junction cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Leap Therapeutics, Inc",47 Thorndike Street,Suite B-1,Cambridge,Massachusetts,' 02141 ' ,United States,744020,,,
3514,Humanized IgG4 monoclonal antibody that antagonizes endothelin-1 receptor subtype A,,6/6/2017,treatment of pulmonary arterial hypertension (pah),Designated,,Not FDA Approved for Orphan Indication,,,,,"GenThera, Inc.",3254 Bordero Lane,,Thousand Oaks,California,' 91362 ' ,United States,575717,pulmonary arterial hypertension,"""gard:0007501""",
3515,humanized IgG4 monoclonal antibody that binds to the SEMA4D antigen,,8/16/2016,treatment of huntington's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vaccinex, Inc.",1895 Mount Hope Avenue,,Rochester,New York,' 14620 ' ,United States,530916,,,
3516,humanized IgG4 monoclonal antibody to Toll-Like Receptor 2 (TLR2),,8/30/2016,treatment of myelodysplastic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"TLR Therapeutics, Inc.",902 Brigham Young Drive,,Claremont,California,' 91711 ' ,United States,455014,myelodysplastic syndrome,"""gard:0007132""",
3517,Humanized IgG4 S228P monoclonal antibody targeting the cis conformation of the phosphorylated Thr231-Pro232 motif in tau,,6/16/2020,treatment of progressive supranuclear palsy,Designated,,Not FDA Approved for Orphan Indication,,,,,Pinteon Therapeutics Inc.,1188 Centre Street,,Newton Centre,Massachusetts,' 02459 ' ,United States,720319,progressive supranuclear palsy,"""gard:0007471""",
3518,humanized IgG4-based anti-CD20 x anti-CD3 bispecific monoclonal antibody,,1/25/2018,treatment of follicular lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,623317,lymphoma,"""gard:0020548""",
3519,Humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against claudin 18.2 (CLDN18.2),,5/1/2023,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"TORL Biotherapeutics, LLC",6100 Bristol Parkway,,Culver,California,' 90230 ' ,United States,935823,,,
3520,humanized immunoglobulin G1 (IgG1) monoclonal antibody (mAb) directed against Claudin18.2 (CLDN18.2),,5/1/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"TORL Biotherapeutics, LLC",6100 Bristol Parkway,,Culver,California,' 90230 ' ,United States,935923,,,
3521,humanized immunoglobulin G1 (IgG1) T-cell bispecific (TCB) antibody targeting carcinoembryonic antigen (CEA),,1/22/2018,"treatment of gastric cancer, including gastroesophageal junction cancer",Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,MS 35-5E,South San Francisco,California,' 94080 ' ,United States,618817,,,
3522,humanized immunoglobulin G1 (IgG1) T-cell bispecific (TCB) antibody targeting carcinoembryonic antigen (CEA) and CD3 epsilon chain (CD3e) on T-cells,,7/27/2017,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,MS 35-5E,South San Francisco,California,' 94080 ' ,United States,589817,,,
3523,humanized immunoglobulin G1 anti-integrin beta-6 monoclonal antibody conjugated to monomethyl auristatin E,,2/13/2023,treatment of esophageal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Seagen Inc.,21823 30th Drive SE,,Bothell,Washington,' 98021 ' ,United States,924622,,,
3524,Humanized immunoglobulin G1 kappa monoclonal antibody targeting PAUF,,6/24/2020,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Prestige Biopharma Ltd,2 Science Park #04-13/14,Ascent Tower B,Science Park,,' ' ,Singapore,749620,,,
3525,Humanized immunoglobulin G4 monoclonal antibody directed against mannan-binding lectin-associated serine protease-3 (MASP-3),,7/28/2022,treatment of paroxysmal nocturnal hemoglobinuria,Designated,,Not FDA Approved for Orphan Indication,,,,,Omeros Corporation,201 Elliott Ave West,,Seattle,Washington,' 98119 ' ,United States,830121,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
3526,humanized immunoglobulin G4-variant monoclonal antibody directed against the p19 subunit of interleukin (IL)-23,,6/15/2017,treatment of ulcerative colitis in pediatric patients,Designated,,Not FDA Approved for Orphan Indication,,,,,Eli Lilly & Company,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,577817,,,
3527,humanized immunoglobulin G4-variant monoclonal antibody directed against the p19 subunit of interleukin (IL)-23,,7/6/2017,treatment of pediatric crohn's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Eli Lilly & Company,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,584617,,,
3528,Humanized MAb (IDEC-131) to CD40L,,2/9/1999,treatment of systemic lupus erythematosus.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Biogen IdecInc.,3030 Callan Rd.,,San Diego,California,' 92121 ' ,United States,119298,systemic lupus erythematosus,"""gard:0018695""",
3529,humanized monoclonal antibodies hu1B7 and hu11E6,,9/11/2014,treatment of bordetella pertussis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Synthetic Biologics, Inc.",155 Gibbs Street,Suite 412,Rockville,Maryland,' 20850 ' ,United States,442914,,,
3530,humanized monoclonal antibody against human integrin alphaVbeta6,,8/5/2010,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biogen Idec, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,' 02142 ' ,United States,311310,idiopathic pulmonary fibrosis,"""gard:0008609""",
3531,humanized monoclonal antibody against human PD-1,,6/8/2017,treatment of neuroendocrine tumors,Designated/Designation Withdrawn or Revoked,2/20/2024,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,"One Health Plaza, 315/5450A",,East Hanover,New Jersey,' 07936 ' ,United States,576417,,,
3532,humanized monoclonal antibody against Shiga-like toxin II,,9/12/2001,to prevent the development of or to decrease the incidence and severity of hemolytic uremic syndrome and associated sequelae of shiga-like toxin-producing e. coli.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Teijin America, Inc.",600 Alexander Park,Suite 304,Princeton,New Jersey,' 08540 ' ,United States,148101,hemolytic uremic syndrome,"""gard:0022233""",
3533,humanized monoclonal antibody of the IgG4 kappa isotype targeting CD47,,8/20/2015,treatment of acute myeloid (myelogenous) leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,488515,,,
3534,humanized monoclonal antibody targeting interleukin-15,,10/25/2018,treatment of eosinophilic esophagitis,Designated,,Not FDA Approved for Orphan Indication,,,,,CALYPSO BIOTECH BV,Gustav Mahlerplein 102,1082 MA Amsterdam,Amsterdam,North Holland,' ' ,Netherlands,655518,,,
3535,Humanized monoclonal antibody targeting tissue factor conjugated to monomethyl auristatin E payload,,5/29/2024,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nanolattix Biotechnology Co., Ltd.","Room 3501-3503, Floor 3, Building 4, Incubation Base, No.11","Kangshou Street, Tanghuai Industrial Park",Shanxi Transformation Comprehensive Reform Demonstration Zone,,' 86-0351-8230618 ' ,China,1004724,,,
3536,humanized monoclonal antibody that targets the a-subunit of the human IL-3 receptor also known as the CD123 antigen; (JNJ-56022473),,5/5/2015,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,6/23/2021,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,' 08869 ' ,United States,478715,acute myeloid leukemia,"""gard:0012757""",
3537,humanized monoclonal antibody to CCR5,,10/4/2017,prevention of graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"CytoDyn, Inc.",1111 Main Street,Suite 660,Vancouver,Washington,' 98660 ' ,United States,516516,graft versus host disease,"""gard:0016642""",
3538,humanized monoclonal antibody to tissue factor,,4/26/2011,treatment of pancreatic cancer.,Designated/Designation Withdrawn or Revoked,6/1/2018,Not FDA Approved for Orphan Indication,,,,,"Morphotek, Inc.",210 Welsh Pool Road,,Exton,Pennsylvania,' 19341 ' ,United States,340311,,,
3539,Humanized monoclonal antibody to TumorEndothelial Marker-1,,4/29/2011,treatment of soft tissue sarcoma,Designated/Designation Withdrawn or Revoked,10/22/2021,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.,155 Tice Boulevard,,Woodcliff Lake,New Jersey,' 07677 ' ,United States,337311,soft tissue sarcoma,"""gard:0004898""",
3540,Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through a protease cleavable valine-alanine linker,,6/8/2017,treatment of mantle cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,ADC Therapeutics SA,"Route de la Corniche, 3B",,Epalinges,Vaud,' ' ,Switzerland,572816,lymphoma,"""gard:0020548""",
3541,humanized monocloncal antibody against human integrin alphaVbeta6,,6/18/2008,treatment of fibrosis-associated chronic allograft nephropathy in kidney transplant patients.,Designated/Designation Withdrawn or Revoked,4/4/2014,Not FDA Approved for Orphan Indication,,,,,"Stromedix, Inc.",14 Cambridge Center,BIO 7-2,Cambridge,Massachusetts,' 02142 ' ,United States,258908,,,
3542,humanized non-fucosylated Anti-Siglec-8 Monoclonal Antibody (IgG1),,2/1/2018,treatment of eosinophilic gastroenteritis,Designated/Designation Withdrawn or Revoked,5/16/2024,Not FDA Approved for Orphan Indication,,,,,"Allakos, Inc.",75 Shoreway Road,Suite A,San Carlos,California,' 94070 ' ,United States,623017,eosinophilic gastroenteritis,"""gard:0009142""",
3543,humanized non-fucosylated anti-siglec-8 monoclonal antibody (IgG1),,2/1/2018,treatment of eosinophilic gastritis,Designated/Designation Withdrawn or Revoked,5/16/2024,Not FDA Approved for Orphan Indication,,,,,"Allakos, Inc.",75 Shoreway Road,Suite A,San Carlos,California,' 94070 ' ,United States,628417,,,
3544,humanized non-fucosylated anti-Siglec-8 monoclonal antibody (IgG1),,7/15/2019,treatment of mastocytosis,Designated/Designation Withdrawn or Revoked,5/16/2024,Not FDA Approved for Orphan Indication,,,,,Allakos Inc.,"975 Island Drive, Suite 201",,Redwood City,California,' 94065 ' ,United States,693519,mastocytosis,"""gard:0006987""",
3545,Humanized one-armed monoclonal antibody with high affinity for NMDA receptor,,12/29/2022,treatment of anti-n-methyl-d-aspartate (anti-nmda) receptor encephalitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Arialys Therapeutics, Inc.",11099 North Torrey Pines Rd.,Suite 290,La Jolla,California,' 92037 ' ,United States,919522,encephalitis,"""gard:0019357""",
3546,Humanized Recombinant Anti-Tumor Necrosis Factor ? Monoclonal Antibody,,11/24/2020,treatment of sarcoidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Xentria, Inc.","8700 W. Bryn Mawr, Suite 600S",,Chicago,Illinois,' 60631 ' ,United States,782020,sarcoidosis,"""gard:0007607""",
3547,Humanized Recombinant IgG4 Anti-PD-1 Monoclonal Antibody,,7/14/2020,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"CStone Pharmaceuticals (Suzhou) Co., Ltd.",1000 Zhangheng Road,Building 25,Shanghai,,' 201203 ' ,China,722919,hepatocellular carcinoma,"""gard:0016773""",
3548,humanized recombinant immunoglobulin G (IgG) 4 monoclonal antibody against C1q,,10/25/2021,treatment of huntington's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Annexon, Inc.",180 Kimball Way,"2nd Floor, Suite 200",South San Francisco,California,' 94080 ' ,United States,843121,,,
3549,humanized secreted frizzled-related protein-2 monoclonal antibody,,10/15/2020,treatment of osteosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Innova Therapeutics,10 Tabby Lane,,Isle of Palms,South Carolina,' 29451 ' ,United States,772620,osteosarcoma,"""gard:0007284""",
3550,humanized single chain monoclonal antibody(scFV: IgG1 hinge: IgG1 CH2 and CH3 domains),,11/17/2011,treatment of chronic lymphocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aptevo Therapeutics, Inc.",2401 Fourth Avenue,Suite 1050,Seattle,Washington,' 98121 ' ,United States,353411,,,
3551,"Humanized, Low-fucose Anti-Claudin 18.2 IgG1 Antibody",,3/23/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Suzhou Transcenta Therapeutics Co., Ltd.","218 Xinghu Street, Biobay, Building B6, Suite 501",,Suzhou,China,' ' ,China,930922,,,
3552,"Humanized, Low-fucose Anti-Claudin 18.2 IgG1 Antibody with Enhanced Antibody Dependent Cell-mediated Cytotoxicity",,7/26/2021,treatment of gastric cancer including cancer of gastroesophageal junction,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mabspace Biosciences (Suzhou) Co., Limited","218 Xinghu Street,Biobay, building B6-501",,Suzhou,Jiangsu,' 215123 ' ,China,824721,,,
3553,Huperzine A,,4/12/2017,treatment of dravet syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Supernus Pharmaceuticals, Inc.",9715 Key West Avenue,,Rockville,Maryland,' 20850 ' ,United States,559916,dravet syndrome,"""gard:0010430""",
3554,hyaluronic acid,,3/19/2002,treatment of emphysema in patients due to alpha-1 antitrypsin deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,CoTherix,5000 Shoreline Court,Suite 101,South San Francisco,California,' 94080 ' ,United States,153501,,,
3555,hyaluronic acid,,1/18/2017,treatment of emphysema due to alpha1-antitrypsin deficiency.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gerard M. Turino, MD","Division of Pulmonary, Critical Care & Sleep Medicine",Mt. Sinai Roosevelt Hospital Center,New York,New York,' 10019 ' ,United States,550716,,,
3556,Hyaluronic Acid-Paclitaxel Conjugate,,5/12/2021,treatment of malignant mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Fidia Farmaceutici S.p.A.,Via Ponte della Fabbrica 3/A,,Abano Terme,,' 35031 ' ,Italy,813721,,,
3557,Hydralazine,,4/9/2004,treatment of severe intrapartum hypertension (diastolic blood pressure greater than or equal to 110 or systolic blood pressure greater than or equal to 160) associated with severe preeclampsia/eclampsia of pregnancy,Designated,,Not FDA Approved for Orphan Indication,,,,,Bioniche Pharma USA LLC,272 E. Deerpath Road,Suite 304,Lake Forest,Illinois,' 60045 ' ,United States,166703,preeclampsia,"""gard:0012924""",
3558,hydralazine - magnesium valproate,,3/17/2011,treatment of myelodysplastic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Neolpharma S.A.DE C.V.,Boulevard de los Ferrocarriles 277,Azcapotalco,Mexico City,,' ' ,Mexico,334611,myelodysplastic syndrome,"""gard:0007132""",
3559,hydralazine - magnesium valproate,,3/17/2011,treatment of cutaneous t-cell lymphoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Neolpharma S.A.DE C.V.,Boulevard de los Ferrocarriles 277,Azcapotalco,Mexico City,,' ' ,Mexico,334411,lymphoma,"""gard:0020548""",
3560,hydrocinnamate-[Orn-Pro-dCha-Trp-Arg](CH3COO),,3/9/2015,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Alsonex Pty Ltd,210 Alice Street,"OLD, 4000",Brisbane,,' ' ,Australia,469014,amyotrophic lateral sclerosis,"""gard:0005786""",
3561,hydrocortisone,,5/13/2020,prevention of bronchopulmonary dysplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,LABORATOIRE AGUETTANT,"1, rue Alexander Fleming",,Lyon,,' ' ,France,716719,bronchopulmonary dysplasia,"""gard:0005962""",
3562,Hydrocortisone,ALKINDI® SPRINKLE,5/13/2015,treatment of pediatric adrenal insufficiency (0 through 16 years of age).,Designated/Approved,,,ALKINDI® SPRINKLE is indicated as replacement therapy in pediatric patients with adrenocortical insufficiency,9/29/2020,,,"Eton Pharmaceuticals, Inc.","21925 West Field Parkway, Suite 235",,Deer Park,Illinois,' 60010 ' ,United States,441614,,,
3563,hydrocortisone acetate,,6/27/2017,treatment of pediatric ulcerative colitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cristcot HCA, LLC",555 Virginia Road,Suite 202,Concord,Massachusetts,' 01742 ' ,United States,568616,,,
3564,hydrocortisone modified release capsules,,9/3/2015,treatment of adrenal insufficiency.,Designated,,Not FDA Approved for Orphan Indication,,,,,Diurnal Limited,Cardiff Medicentre,,Cardiff,,' ' ,United Kingdom,487515,,,
3565,hydrocortisone modified release capsules,,3/18/2015,treatment of congenital adrenal hyperpasia,Designated,,Not FDA Approved for Orphan Indication,,,,,Diurnal Limited,Cardiff Medicentre,,Cardiff,,' ' ,United Kingdom,467014,,,
3566,hydrocortisone modified release tabs,,6/18/2008,treatment of adrenal insufficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shire ViroPharma, Inc.",300 Shire Way,,Lexington,Massachusetts,' 02421 ' ,United States,234906,,,
3567,hydromethylthionine mesylate,,11/20/2018,treatment of frontotemporal dementia,Designated,,Not FDA Approved for Orphan Indication,,,,,TauRx Therapeutics Ltd,395 King Street,,Aberdeen,Scotland,' ' ,United Kingdom,661118,frontotemporal dementia,"""gard:0008436""",
3568,hydromorphone hydrochloride (intrathecal infusion),,6/16/2016,treatment of complex regional pain syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Piramal Critical Care, Inc.",3950 Schelden Circle,,Bethlehem,Pennsylvania,' 18017 ' ,United States,499415,complex regional pain syndrome,"""gard:0004647""",
3569,Hydroxocobalamin,,9/22/2000,treatment of acute cyanide poisoning,Designated,,Not FDA Approved for Orphan Indication,,,,,"Rare Disease Therapeutics, Inc.",12975 Brookprinter Pl,Suite 170,Poway,California,' 92064 ' ,United States,137600,cyanide poisoning,"""gard:0021938""",
3570,Hydroxocobalamin,Cyanokit,11/25/2003,treatment of acute cyanide poisoning,Designated/Approved,,,Treatment on known or suspected cyanide poisoning,12/15/2006,12/15/2013,,"SERB, S.A.",480 Avenue Louise,,Brussels,Brussels,' ' ,Belgium,177403,cyanide poisoning,"""gard:0021938""",
3571,Hydroxy-Propyl-Beta-Cyclodextrin,,5/17/2010,"treatment of niemann pick disease, type c",Designated,,Not FDA Approved for Orphan Indication,,,,,"Cyclo Therapeutics, Inc.","6714 NW 16th Street, Suite B",,Gainesville,Florida,' 32653-3975 ' ,United States,303910,,,
3572,hydroxycarbamide (hydroxyurea),Siklos,7/24/2013,treatment of sickle cell disease in patients under 18 years of age,Designated/Approved,,,"To reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises",12/21/2017,12/21/2024,"To reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises",Theravia Pharma,16 rue Montrosier,,Neuilly-sur-Seine,,' 992200 ' ,France,400413,,,
3573,Hydroxycobalamin/sodium thiosulfate,,10/4/1985,treatment of severe acute cyanide poisoning.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Hall, Alan H., M.D.",Mile 5.0 Pass Creek Road,PO Box 24,Elk Mountain,Wyoming,' 82324 ' ,United States,9585,cyanide poisoning,"""gard:0021938""",
3574,hydroxypioglitazone,,1/30/2017,treatment of x-linked adrenoleukodystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Minoryx Therapeutics S.L.,TecnoCampus Mataro-Maresme. TCM3 602,"Av. Ernest Lluch, 32.",Mataró,Catalunya,' ' ,Spain,552716,leukodystrophy,"""gard:0006895""",
3575,hydroxyprogesterone caproate,Makena,1/25/2007,prevention of preterm birth in singleton pregnancies,Designated/Approved,,,To reduce the risk of preterm birth in women with singleton pregnancy who have a history of singleton spontaneous preterm birth,2/3/2011,2/3/2018,,"AMAG Pharma USA, Inc.",1100 Winter Street,,Waltham,Massachusetts,' 02154 ' ,United States,218706,,,
3576,hydroxyprogesterone caproate,Makena,1/25/2007,prevention of preterm birth in singleton pregnancies,Designated/Approved,,,Makena auto-injector for subcutaneous injection is indicated to reduce the risk of preterm birth in women with singleton pregnancy who have a history of singleton spontaneous preterm birth.,2/14/2018,,,"AMAG Pharma USA, Inc.",1100 Winter Street,,Waltham,Massachusetts,' 02154 ' ,United States,218706,,,
3577,hydroxypropyl-B-cyclodextrin-panobinostat complex,,10/22/2019,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Biodexa Ltd.,1 Caspian Point,Caspian Way,Cardiff,,' CF10 4DQ ' ,United Kingdom,705919,,,
3578,hydroxyurea,,4/15/2005,treatment of pediatric patients with sickle cell anemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"UPM Pharmaceuticals, Inc.",6200 Seaforth Street,,Baltimore,Maryland,' 21224 ' ,United States,202605,sickle cell anemia,"""gard:0008614""",
3579,Hydroxyurea,Droxia,10/1/1990,treatment of patients with sickle cell anemia as shown by the presence of hemoglobin s.,Designated/Approved,,,To reduce the frequency of painful crises and to reduce the need for blood transfusions in adult patients with sickle cell anemia with recurrent moderate to severe painful crises (generally at least 3 during the preceding 12 months).,2/25/1998,2/25/2005,,Bristol-Myers Squibb Pharmaceutical Research Institute,P.O. Box 4000,,Princeton,New Jersey,' 08543 ' ,United States,49590,sickle cell anemia,"""gard:0008614""",
3580,hydroxyurea,,3/16/2015,"treatment of symptomatic sickle cell disease in pediatric patients, less than 17 years of age.",Designated,,Not FDA Approved for Orphan Indication,,,,,Ebelle D'Ebelle Pharmaceuticals LLC,5 Witherwood Drive,,Hamburg,New Jersey,' 07419 ' ,United States,463414,,,
3581,hydroxyurea,Xromi,3/2/2017,treatment of sickle cell anemia in pediatric patients,Designated/Approved,,,"to reduce the frequency of painful crises and reduce the need for blood transfusions in pediatric patients aged 6 months of age to less than 2 years, with sickle cell anemia with recurrent moderate to severe painful crises",4/4/2024,4/4/2031,"to reduce the frequency of painful crises and reduce the need for blood transfusions in pediatric patients aged 6 months of age to less than 2 years, with sickle cell anemia with recurrent moderate to severe painful crises",Nova Laboratories Limited,Martin House,Gloucester Crescent,Leicester,Wigston,' ' ,United Kingdom,555116,sickle cell anemia,"""gard:0008614""",
3582,Hydroxyurea methylacylfulvene,,8/20/2021,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Lantern Pharma, Inc.",1920 McKinney Avenue,,Dallas,Texas,' 75201 ' ,United States,833721,,,
3583,Hypericin,,9/2/2021,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.","29 Emmons Drive, Suite B-10",,Princeton,New Jersey,' 08054 ' ,United States,835521,lymphoma,"""gard:0020548""",
3584,Hypericin,,8/3/2000,treatment of glioblastoma multiforme.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.",29 Emmons Drive Suite B-10,,Princeton,New Jersey,' 08540 ' ,United States,131199,glioblastoma,"""gard:0002491""",
3585,hypericin,,2/7/2000,treatment of cutaneous t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.",29 Emmons Drive,Suite B-10,Princeton,New Jersey,' 08540 ' ,United States,131099,lymphoma,"""gard:0020548""",
3586,Hypothiocyanite and lactoferrin,,11/5/2009,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Alaxia Biotechnologies Sante,3-11 Rue de la Perlerie,,Vaulx-en-velin,,' ' ,France,294609,cystic fibrosis,"""gard:0006233""",
3587,"Hypotonic, acid oxidizing solution containing hypochlorous acid (HClO)",,11/26/2019,treatment of epidermolysis bullosa,Designated,,Not FDA Approved for Orphan Indication,,,,,APR Applied Pharma Research s.a.,Via Corti 5,,Balerna,,' ' ,Switzerland,711819,,,
3588,I(131)-TM-601 (chlorotoxin),,2/14/2002,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.,200 Metro Blvd.,,Nutley,New Jersey,' 07110-6102 ' ,United States,152201,,,
3589,iadademstat,,6/6/2022,treatment of small cell lung cancer (sclc),Designated,,Not FDA Approved for Orphan Indication,,,,,Oryzon Genomics S.A.,Sant Ferran 74,Cornellà de Llobregat,Barcelona,,' 08940 ' ,Spain,880122,small cell lung cancer,"""gard:0009344""",
3590,iadademstat,,2/10/2021,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Oryzon Genomics S.A.,"Carrera de San Jeronimo 15, 2ª planta",,Madrid,Spain,' 28014 ' ,Spain,800020,acute myeloid leukemia,"""gard:0012757""",
3591,ibalizumab,Trogarzo,10/20/2014,treatment of hiv-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of hiv-1 replication despite ongoing antiretroviral therapy,Designated/Approved,,,"TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.",3/6/2018,3/6/2025,"TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.",Theratechnologies Inc.,2015 Peel Street,5th Floor,Montreal,,' ' ,Canada,321910,,,
3592,iberdomide,,12/19/2018,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,665718,multiple myeloma,"""gard:0007108""",
3593,Iboctadekin,,6/3/2005,treatment of renal cell carcinoma,Designated/Designation Withdrawn or Revoked,2/7/2014,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline LLC,Corporation service Company,Suite 400,Wilmington,Delaware,' 19808 ' ,United States,193004,renal cell carcinoma,"""gard:0013215""",
3594,ibrexafungerp,,5/10/2016,"treatment of invasive candida infections, including candidemia",Designated,,Not FDA Approved for Orphan Indication,,,,,"SCYNEXIS, Inc.","One Evertrust Plaza, 13th Floor",,Jersey City,New Jersey,' 07302 ' ,United States,519616,,,
3595,ibrexafungerp,,8/22/2016,treatment of invasive aspergillus infections,Designated,,Not FDA Approved for Orphan Indication,,,,,"SCYNEXIS, Inc.","One Evertrust Plaza, 13th Floor",,Jersey City,New Jersey,' 07302 ' ,United States,531716,,,
3596,ibritumomab tiuxetan,Zevalin,9/6/1994,treatment of b-cell non-hodgkin's lymphoma.,Designated/Approved,,,"Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma",2/19/2002,2/19/2009,,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,' 08520 ' ,United States,84894,lymphoma,"""gard:0020548""",
3597,ibrutinib,,6/12/2017,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pharmacyclics, LLC",995 East Arques Avenue,,Sunnyvale,California,' 94085 ' ,United States,574317,,,
3598,ibrutinib,,5/16/2013,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,' 94085 ' ,United States,397313,multiple myeloma,"""gard:0007108""",
3599,ibrutinib,IMBRUVICA,5/30/2013,treatment of small lymphocytic lymphoma,Designated/Approved,,,Indicated for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and indicated for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) with 17p deletion.,5/6/2016,5/6/2023,For treatment of patients with small lymphocytic lymphoma (SLL),"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,' 94085 ' ,United States,395513,lymphoma,"""gard:0020548""",
3600,ibrutinib,Imbruvica,2/2/2016,treatment of patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [malt type] lymphoma),Designated/Approved,,,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy (indication withdrawn),1/18/2017,5/18/2023,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy (indication withdrawn),"Pharmacyclics, LLC",1000 Gateway Blvd,,South San Francisco,California,' 94080 ' ,United States,462114,lymphoma,"""gard:0020548""",
3601,ibrutinib,,2/1/2018,"treatment of gastric cancer, including gastroesophageal junction adenocarcinoma",Designated,,Not FDA Approved for Orphan Indication,,,,,"Pharmacyclics, LLC",995 East Arques Avenue,,Sunnyvale,California,' 94085 ' ,United States,622317,noma,"""gard:0004001""",
3602,ibrutinib,Imbruvica,6/23/2016,treatment of chronic graft versus host disease,Designated/Approved,,,Treatment of adult and pediatric patients age 1 year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy,8/24/2022,8/24/2029,Treatment of pediatric patients age 1 year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy,"Pharmacyclics, LLC",995 East Arques Avenue,,Sunnyvale,California,' 94085 ' ,United States,525616,graft versus host disease,"""gard:0016642""",
3603,ibrutinib,Imbruvica,6/23/2016,treatment of chronic graft versus host disease,Designated/Approved,,,Treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.,8/2/2017,8/2/2024,Treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.,"Pharmacyclics, LLC",995 East Arques Avenue,,Sunnyvale,California,' 94085 ' ,United States,525616,graft versus host disease,"""gard:0016642""",
3604,ibrutinib,Imbruvica,2/5/2015,treatment of nodal marginal zone lymphoma,Designated/Approved,,,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy (indication withdrawn),1/18/2017,5/18/2023,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy (indication withdrawn),"Pharmacyclics, LLC",1000 Gateway Blvd,,South San Francisco,California,' 94080 ' ,United States,462214,lymphoma,"""gard:0020548""",
3605,ibrutinib,Imbruvica,2/5/2015,treatment of splenic marginal zone lymphoma,Designated/Approved,,,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy (indication withdrawn),1/18/2017,5/18/2023,Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy (indication withdrawn),"Pharmacyclics, LLC",1000 Gateway Blvd,,South San Francisco,California,' 94080 ' ,United States,462314,lymphoma,"""gard:0020548""",
3606,ibrutinib,,10/23/2013,treatment of diffuse large b-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,' 94085 ' ,United States,409713,lymphoma,"""gard:0020548""",
3607,ibrutinib,Imbruvica,4/6/2012,treatment of chronic lymphocytic leukemia (cll),Designated/Approved,,,Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy,2/12/2014,2/12/2021,Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,' 94085 ' ,United States,368012,,,
3608,ibrutinib,Imbruvica,4/6/2012,treatment of chronic lymphocytic leukemia (cll),Designated/Approved,,,Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion,7/28/2014,7/28/2021,Treatment of chronic lymphocytic leukemia with 17p deletion who have not received at least one prior therapy,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,' 94085 ' ,United States,368012,,,
3609,ibrutinib,Imbruvica,4/6/2012,treatment of chronic lymphocytic leukemia (cll),Designated/Approved,,,Indicated for the treatment of patients with chronic lymphocytic leukemia,3/4/2016,3/4/2023,Indicated for the treatment of patients with chronic lymphocytic leukemia without 17p deletion who have not received at least one prior therapy (first line therapy).,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,' 94085 ' ,United States,368012,,,
3610,ibrutinib,,3/27/2012,treatment of chronic lymphocytic leukemia (cll).,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,' 94085 ' ,United States,366212,,,
3611,ibrutinib,Imbruvica,10/15/2013,treatment of waldenstrom's macroglobulinemia,Designated/Approved,,,Treatment of patients with Waldenstrom's macroglobulinemia,1/29/2015,1/29/2022,Treatment of patients with Waldenstrom's macroglobulinemia,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,' 94085 ' ,United States,407413,,,
3612,ibrutinib,Imbruvica,12/3/2012,treatment of mantle cell lymphoma,Designated/Approved,,,Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy,11/13/2013,11/13/2020,Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,' 94085 ' ,United States,383112,lymphoma,"""gard:0020548""",
3613,ibrutinib,,9/8/2014,treatment of follicular lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,' 94085 ' ,United States,444414,lymphoma,"""gard:0020548""",
3614,ibudilast,,10/6/2016,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"MediciNova, Inc.",4275 Executive Square,Suite 300,La Jolla,California,' 92037 ' ,United States,445814,amyotrophic lateral sclerosis,"""gard:0005786""",
3615,Ibudilast,,6/15/2022,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Healx Limited,"Charter House, 66-68 Hills Rd.",,Cambridge,,' CB2 1LA ' ,United Kingdom,889222,fragile x syndrome,"""gard:0006464""",
3616,ibudilast,,6/1/2015,treatment of krabbe disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"MediciNova, Inc.",4275 Executive Square,Suite 300,La Jolla,California,' 92037 ' ,United States,480015,krabbe disease,"""gard:0006844""",
3617,Ibudilast,,10/2/2018,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"MediciNova, Inc.",4275 Executive Square,Suite 300,La Jolla,California,' 92037 ' ,United States,587717,glioblastoma,"""gard:0002491""",
3618,Ibuprofen i.v. solution,,10/29/1996,prevention of patent ductus arteriosus.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Farmacon-IL, LLC",1720 Post Road East,Suite 213,Westport,Connecticut,' 06880 ' ,United States,100896,,,
3619,Ibuprofen lysine,NeoProfen,10/29/1996,treatment of patent ductus arteriosus,Designated/Approved,,,"For closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective",4/13/2006,4/13/2013,,"Lundbeck, Inc.",Four Parkway North,,Deerfield,Illinois,' 60015 ' ,United States,101496,,,
3620,ibutamoren mesylate,,6/15/2017,treatment of growth hormone deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Lumos Pharma,4200 Marathon Blvd.,Suite 200,Austin,Texas,' 78756 ' ,United States,579617,,,
3621,icatibant,Firazyr,11/25/2003,treatment of angioedema,Designated/Approved,,,Treatment of acute attacks of hereditary angioedema in adults 18 years of age and older,8/25/2011,8/25/2018,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,176203,,,
3622,icatibant,,5/5/2004,treatment of burn patients hospitalized with burn-induced edema,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Shire Human Genetic Therapies,700 Main Street,,Cambridge,Massachusetts,' 02139 ' ,United States,184804,,,
3623,icerguastat,,3/23/2022,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,Inflectis Bioscience,21 Rue la Noue Bras de Fer,,Nantes,,' F - 44200 ' ,France,868321,amyotrophic lateral sclerosis,"""gard:0005786""",
3624,ICG136:CD123-CD33cCAR T-cells,,9/19/2017,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,iCell Gene Therapeutics,25 Health Sciences Drive,Suite 118,Stony Brook,New York,' 11793 ' ,United States,603117,acute myeloid leukemia,"""gard:0012757""",
3625,"ICG140:CD19-CD123 cCAR T-cells, a chimeric antigen receptor (CAR) on the surface of T-cells directed against the target proteins CD19 and CD 123",,12/26/2017,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,iCell Gene Therapeutics,25 Health Sciences Drive,Suite 118,Stony Brook,New York,' 11793 ' ,United States,614017,acute lymphoblastic leukemia,"""gard:0000522""",
3626,iclaprim,,9/14/2017,treatment of staphylococus aureus lung infections in patients with cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Motif Bio PLC,330 Madison Avenue,6th Floor,New York,New York,' 10017 ' ,United States,514415,cystic fibrosis,"""gard:0006233""",
3627,Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution,Extraneal (with 7.5% Icodextrin) Peritoneal Dialysis Solutio,7/18/1997,treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.,Designated/Approved,,,For use as a single daily exchange for the long (8-16 hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of chronic renal failure.,12/20/2002,12/20/2009,,Baxter Healthcare Corporation,Renal Division,1620 Waukegan Road,McGaw Park,Illinois,' 60085 ' ,United States,105697,,,
3628,Idarubicin,,12/2/1992,treatment of chronic myelogenous leukemia.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Pharmacia & Upjohn,7000 Portage Road,Unit 0633-298-113,Kalamazoo,Michigan,' 49001 ' ,United States,70992,,,
3629,Idarubicin,,12/1/1992,treatment of myelodysplastic syndromes.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Pharmacia & Upjohn,7000 Portage Road,Unit 0633-298-113,Kalamazoo,Michigan,' 49001 ' ,United States,70892,myelodysplastic syndrome,"""gard:0007132""",
3630,Idarubicin HCl for injection,,2/12/1991,treatment of acute lymphoblastic leukemia in pediatric patients.,Designated/Designation Withdrawn or Revoked,2/20/2014,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",235 East 42nd Street,,New York,New York,' 10017 ' ,United States,55890,acute lymphoblastic leukemia,"""gard:0000522""",
3631,Idarubicin HCl for injection,Idamycin,7/25/1988,"treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",Designated/Approved,,,,9/27/1990,9/27/1997,,"Adria Laboratories, Inc.",P.O. Box 16529,,Columbus,Ohio,' 43216 ' ,United States,29388,,,
3632,idarucizumab,,5/28/2015,to reverse the anticoagulant effect of dabigatran due to uncontrolled life-threatening bleeding requiring urgent intervention or a need to undergo an emergency surgery/urgent invasive procedure,Designated/Approved,,,For use in patients treated with Pradaxa® when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding,10/16/2015,10/16/2022,For use in patients treated with Pradaxa® when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding,"Boehringer Ingelheim Pharmaceuticals, Inc.",PO Box 368,900 Ridgebury Road,Ridgefield,Connecticut,' 06877 ' ,United States,445714,,,
3633,idasanutlin,,11/29/2017,treatment of polycythemia vera,Designated/Designation Withdrawn or Revoked,2/7/2020,Not FDA Approved for Orphan Indication,,,,,Hoffmann-La Roche Inc.,430 East 29th Street,,New York,New York,' 10016 ' ,United States,615017,polycythemia,"""gard:0019466""",
3634,idebenone,,2/16/2007,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Chiesi Farmaceutici S.p.A.,Via Palermo 26/A,,"Parma, Emilia Romagna",,' ' ,Italy,231906,muscular dystrophy,"""gard:0007922""",
3635,idebenone,,3/25/2004,treatment of friedreich's ataxia,Designated,,Not FDA Approved for Orphan Indication,,,,,Chiesi Farmaceutici S.p.A.,Via Palermo 26/A,,Parma,Emilia Romagna,' 43122 ' ,Italy,178303,,,
3636,idebenone,,5/22/2009,"treatment of mitochondrial myopathy, encephalopathy, lactic acidosis with stroke-like episodes syndrome (melas)",Designated/Designation Withdrawn or Revoked,7/22/2019,Not FDA Approved for Orphan Indication,,,,,Santhera Pharmaceuticals (Switzerland) Ltd.,25 Hammerstrasse,,Liestal,Basel-Landschaft,' ' ,Switzerland,281909,mitochondrial myopathy,"""gard:0020371""",
3637,idebenone,,10/31/2006,treatment of leber's hereditary optic neuropathy.,Designated,,Not FDA Approved for Orphan Indication,,,,,Chiesi Farmaceutici S.p.A.,Via Palermo 26/A,,"Parma, Emilia Romagna",,' 43122 ' ,Italy,232006,hereditary optic neuropathy,"""gard:0019540""",
3638,idecabtagene vicleucel,Abecma,5/11/2016,treatment of multiple myeloma,Designated/Approved,,,"treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody",3/26/2021,3/26/2028,"treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody","Celgene Corporation, a Bristol-Myers Squibb Company",86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,520416,multiple myeloma,"""gard:0007108""",
3639,idecabtagene vicleucel,Abecma,5/11/2016,treatment of multiple myeloma,Designated/Approved,,,"treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody",4/4/2024,4/4/2031,"treatment of adult patients with relapsed or refractory multiple myeloma after two or three prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody","Celgene Corporation, a Bristol-Myers Squibb Company",86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,520416,multiple myeloma,"""gard:0007108""",
3640,idelalisib,,8/25/2011,treatment of chronic lymphocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 E. Blaine St.,,Seattle,Washington,' 98102 ' ,United States,347511,,,
3641,idelalisib,,9/26/2013,treatment of lymphoplasmacytic lymphoma with or without walenstrom's macroglobulinemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 E. Blaine St,,Seattle,Washington,' 98102 ' ,United States,405713,lymphoma,"""gard:0020548""",
3642,idelalisib,,10/15/2013,treatment of splenic marginal zone lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 E. Blaine St,,Seattle,Washington,' 98102 ' ,United States,412613,lymphoma,"""gard:0020548""",
3643,idelalisib,,10/15/2013,treatment of nodal marginal zone lymphoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 E. Blaine St,,Seattle,Washington,' 98102 ' ,United States,412513,lymphoma,"""gard:0020548""",
3644,idelalisib,,10/15/2013,treatment of extranodal marginal zone lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 E. Blaine St,,Seattle,Washington,' 98102 ' ,United States,405613,lymphoma,"""gard:0020548""",
3645,idelalisib,Zydelig,9/26/2013,treatment of follicular lymphoma,Designated/Approved,,,Zydelig is indicated for the treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least two prior systemic therapies.,7/23/2014,7/23/2021,Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients who have received at least two prior systemic therapies.,"Gilead Sciences, Inc.",199 E. Blaine St,,Seattle,Washington,' 98102 ' ,United States,405813,lymphoma,"""gard:0020548""",
3646,idelalisib,Zydelig,10/15/2013,treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma,Designated/Approved,,,"Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and Zydelig is indicated for the treatment of patients with relapsed small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.",7/23/2014,7/23/2021,"(1) Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and (2) Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies.","Gilead Sciences, Inc.",199 E. Blaine St,,Seattle,Washington,' 98102 ' ,United States,405913,lymphoma,"""gard:0020548""",
3647,Idoxuridine,,4/8/1996,treatment of nonparenchymatous sarcomas.,Designated,,Not FDA Approved for Orphan Indication,,,,,"NeoPharm, Inc.","225 East Deerpath, Suite 250",,Lake Forest,Illinois,' 60045 ' ,United States,95696,,,
3648,Idronoxil,,3/17/2022,treatment of soft tissue sarcomas (sts),Designated,,Not FDA Approved for Orphan Indication,,,,,Noxopharm Limited,"Level 20, Tower A, The Zenith",821 Pacific Hwy,Chatswood,NSW,' 2067 ' ,Australia,868622,soft tissue sarcoma,"""gard:0004898""",
3649,Idroxioleic acid,,10/26/2021,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Laminar Pharma Inc,"360 Massachusettes Avenue, Suite 203",,Acton,Massachusetts,' 01720 ' ,United States,844021,,,
3650,IDUA-HIRMAb fusion protein,,1/10/2008,treatment of mucopolysaccharidosis type 1 (mps),Designated,,Not FDA Approved for Orphan Indication,,,,,"ArmaGen Technologies, Inc.",914 Colorado Ave.,,Santa Monica,California,' 90401 ' ,United States,250907,mucopolysaccharidosis type 1,"""gard:0010335""",
3651,idursulfase,Elaprase,11/28/2001,long term enzyme replacement therapy for patients with mucopolysaccharidosis ii (hunter syndrome),Designated/Approved,,,"Indicated for patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Idursulfase has been shown to improve walking capacity in these patients",7/24/2006,7/24/2013,,"Takeda Pharmaceuticals U.S.A., Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,147301,mucopolysaccharidosis,"""gard:0007065""",
3652,idursulfase beta,,2/11/2013,treatment of hunter syndrome (mucopolysaccharidoses),Designated,,Not FDA Approved for Orphan Indication,,,,,Green Cross Corp.,"303 Bojeong-dong, Giheung-gu",,Gyunggi-Do 446-770,,' ' ,South Korea,385712,,,
3653,idursulfase IT,,9/3/2009,for treatment of neurocognitive symptoms associated with hunter syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Pharmaceuticals U.S.A., Inc.",95 Hayden Ave,,Lexington,Massachusetts,' 02421 ' ,United States,289709,,,
3654,iduvec,,1/21/2011,treatment of mucopolysaccharidosis type i,Designated,,Not FDA Approved for Orphan Indication,,,,,Zebraic Corporation,8837 Stratford Crossing,,Brooklyn Park,Minnesota,' 55443 ' ,United States,327110,mucopolysaccharidosis,"""gard:0007065""",
3655,ifenprodil,,12/1/2022,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Algernon Pharmaceuticals Inc.,Suite 400 - 601 West Broadway,,Vancouver,British Columbia,' V5Z 4C2 ' ,Canada,914122,idiopathic pulmonary fibrosis,"""gard:0008609""",
3656,iferanserin (S-MPEC),,12/13/2010,for use in pulmonary arterial hypertension.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sam Amer & Company, Inc.",P. O. Box 5685,,Montecito,California,' 93150 ' ,United States,315910,pulmonary arterial hypertension,"""gard:0007501""",
3657,Ifinatamab deruxtecan,,4/26/2023,treatment of small-cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Daiichi Sankyo, Inc.",211 Mt. Airy Road,,Basking Ridge,New Jersey,' 07920 ' ,United States,935123,,,
3658,Ifosfamide,Ifex,1/20/1987,treatment of testicular cancer.,Designated/Approved,,,"In combination with certain other approved antineoplastic agents, for third line chemotherapy in the treatment of germ cell testicular cancer.",12/30/1988,12/30/1995,,Bristol-Myers Squibb Pharmaceutical Research Institute,"5 Research Parkway, P.O. Box 5100",,Wallingford,Connecticut,' 06492 ' ,United States,17786,,,
3659,ifosfamide,,8/7/1985,treatment of soft tissue and bone sarcomas,Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,P.O. Box 4000,Mail Stop D12-02,Princeton,New Jersey,' 08543 ' ,United States,8585,bone sarcoma,"""gard:0020547""",
3660,IgG-like bispecific monoclonal antibody (mAb) composed of the anti-IL-1beta mAb canakinumab and the anti-IL-18 mAb CMK389,,12/20/2021,"treatment of nucleotide-binding oligomerization domain-like receptor family card domain-containing protein 4 - gain of function (nlrc4-gof), also described as autoinflammation with infantile enterocolitis (aifec)",Designated,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936-1080 ' ,United States,853521,,,
3661,IgG1 chimeric monoclonal antibody,,6/22/2011,treatment of multiple myeloma.,Designated,,Not FDA Approved for Orphan Indication,,,,,HaemaLogiX Pty Ltd.,"Cicada Innovations, Suite 145",4 Cornwallis Street,Eveleigh,,' NSW 2015 ' ,Australia,344411,multiple myeloma,"""gard:0007108""",
3662,IgG4 Fc linked recombinant human alpha-1 antitrypsin,,3/2/2022,treatment of alpha-1 antitrypsin deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Inhibrx Inc.,11025 North Torrey Pines Road,Suite 200,La Jolla,California,' 92037 ' ,United States,863521,,,
3663,IgG4 monoclonal antibody directed against protein S,,4/5/2023,treatment of von willebrand disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vega Therapeutics, Inc.","201 Haskins Way, 5th Floor",,South San Francisco,California,' 94080 ' ,United States,931923,von willebrand disease,"""gard:0007867""",
3664,IL-12 secreting dendritic cells loaded with autologous tumor lysate,,6/24/2013,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Activartis Biotech GmbH,Zimmermannplatz 10,,Vienna,,' ' ,Austria,377012,,,
3665,IL-4 Pseudomonas Toxin Fusion Protein (IL-4(38-37)-PE38KDEL),,4/6/2000,treatment of astrocytic glioma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Medicenna Therapeutics, Inc.",220-1075 West George Street,,Vancouver,,' ' ,Canada,132199,,,
3666,IL13 E13K mutation linked to portion of mutated pseudomonas exotoxin,,8/3/2021,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Targepeutics,475 W Governors Rd,,Hershey,Pennsylvania,' 17033 ' ,United States,829221,soft tissue sarcoma,"""gard:0004898""",
3667,IL13 E13K mutation linked to portion of pseudomonas exotoxin,,11/18/2020,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Targepeutics,"1214 Research Boulevard, Suite 1011",,Hummelstown,Pennsylvania,' 17036 ' ,United States,781820,,,
3668,Ilixadencel,,12/30/2020,treatment of hepatocellular carcinoma (hcc).,Designated,,Not FDA Approved for Orphan Indication,,,,,Mendus AB,Östermalmstorg 5,,Stockholm,,' SE-114 42 ' ,Sweden,788320,hepatocellular carcinoma,"""gard:0016773""",
3669,ilixadencel,,6/7/2022,treatment of gastrointestinal stromal tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,Mendus AB,Västra Trädgårdsgatan 15,,Stockholm,,' 11153 ' ,Sweden,864821,gastrointestinal stromal tumor,"""gard:0008598""",
3670,ilixadencel,,1/25/2021,treatment of soft tissue sarcoma (sts),Designated,,Not FDA Approved for Orphan Indication,,,,,Mendus AB,Östermalmstorg 5,,Stockholm,,' 114 42 ' ,Sweden,796120,soft tissue sarcoma,"""gard:0004898""",
3671,iloprost,,4/6/2012,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,"Algorithum Sciences, LLC",World Trade Center Delaware,702 West Street,Wilmington,Delaware,' 19801 ' ,United States,324610,pulmonary arterial hypertension,"""gard:0007501""",
3672,iloprost,Aurlumyn,6/29/2022,treatment of frostbite,Designated/Approved,,,treatment of severe frostbite in adults to reduce the risk of digit amputations,2/13/2024,2/13/2031,treatment of severe frostbite in adults to reduce the risk of digit amputations,"Eicos Sciences, Inc.",122 2nd Ave.,Suite 200,San Mateo,California,' 94401 ' ,United States,886722,,,
3673,Iloprost,,12/14/2023,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pharmosa Biopharm, Inc.","3F-3, No. 66, Sanchong Rd.",Nangang District,Taipei City,not applicable,' 11560 ' ,Taiwan,974823,systemic sclerosis,"""gard:0009748""",
3674,iloprost,,5/9/2019,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Eicos Sciences, Inc., a CiVi Biopharma, Inc. affiliated company",200 Four Falls Corporate Center,Suite 107,West Conshohocken,Pennsylvania,' 19528 ' ,United States,655118,systemic sclerosis,"""gard:0009748""",
3675,Iloprost inhalation solution,Ventavis,8/17/2004,treatment of pulmonary arterial hypertension,Designated/Approved,,,Treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms,12/29/2004,12/29/2011,,"CoTherix, Inc.",5000 Shoreline Court,,South San Francisco,California,' 94080 ' ,United States,186904,pulmonary arterial hypertension,"""gard:0007501""",
3676,Iloprost solution for infusion,,5/14/1990,treatment of heparin-associated thrombocytopenia.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Berlex Laboratories, Inc.",300 Fairfield Road,,Wayne,New Jersey,' 07470 ' ,United States,40089,,,
3677,Iloprost solution for infusion,,9/21/1989,treatment of raynaud's phenomenon secondary to systemic sclerosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Berlex Laboratories, Inc.",300 Fairfield Road,,Wayne,New Jersey,' 07470 ' ,United States,38789,systemic sclerosis,"""gard:0009748""",
3678,ilorasertib,,3/16/2012,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,8/16/2014,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,364212,ovarian cancer,"""gard:0007295""",
3679,imatinib,Gleevec,10/11/2005,treatment of philadelphia-positive acute lymphoblastic leukemia,Designated/Approved,,,Pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy,1/25/2013,1/25/2020,Treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy,Novartis Pharmaceuticals Corporation,One Health Plaza,Mail Code 105/1E870D,East Hanover,New Jersey,' 07936 ' ,United States,208905,acute lymphoblastic leukemia,"""gard:0000522""",
3680,Imatinib,Gleevec,1/31/2001,treatment of chronic myelogenous leukemia,Designated/Approved,,,"Treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy",5/10/2001,5/10/2008,,Novartis Pharmaceuticals Corporation,59 Route 10,,East Hanover,New Jersey,' 07936 ' ,United States,140100,,,
3681,imatinib,Gleevec,10/11/2005,treatment of philadelphia-positive acute lymphoblastic leukemia,Designated/Approved,,,Treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL),10/19/2006,10/19/2013,,Novartis Pharmaceuticals Corporation,One Health Plaza,Mail Code 105/1E870D,East Hanover,New Jersey,' 07936 ' ,United States,208905,acute lymphoblastic leukemia,"""gard:0000522""",
3682,Imatinib,,12/21/2020,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aerovate Therapeutics, Inc","200 Berkeley Street, Floor 18",,Boston,Massachusetts,' 02116 ' ,United States,787520,pulmonary arterial hypertension,"""gard:0007501""",
3683,imatinib,,7/26/2021,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,Aerami Therapeutics,"2520 Meridian Parkway, Suite 400",,Durham,North Carolina,' 27713 ' ,United States,831721,pulmonary arterial hypertension,"""gard:0007501""",
3684,imatinib,,4/7/2010,treatment of pulmonary arterial hypertension,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Novartis,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,303810,pulmonary arterial hypertension,"""gard:0007501""",
3685,imatinib mesylate,,6/15/2020,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,"PHPrecisionMed, LLC",3621 Grove Street,,Skokie,Illinois,' 60076 ' ,United States,741420,pulmonary arterial hypertension,"""gard:0007501""",
3686,imatinib mesylate,Gleevec,12/19/2005,treatment of dermatofibrosarcoma protuberans,Designated/Approved,,,"Treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)",10/19/2006,10/19/2013,,Novartis Pharmaceuticals Corporation,One Health Plaza,Mail Code 105/1E870D,East Hanover,New Jersey,' 07936 ' ,United States,208805,dermatofibrosarcoma protuberans,"""gard:0009569""",
3687,imatinib mesylate,Gleevec,11/1/2001,treatment of gastrointestinal stromal tumors,Designated/Approved,,,Treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST),2/1/2002,2/1/2009,,Novartis Pharmaceuticals Corp.,One Health Plaza,Mail Code 105/1E870D,East Hanover,New Jersey,' 07936 ' ,United States,149201,gastrointestinal stromal tumor,"""gard:0008598""",
3688,Imatinib mesylate,Gleevec,10/5/2005,treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements,Designated/Approved,,,Treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements,10/19/2006,10/19/2013,,Novartis Pharmaceuticals Corporation,One Health Plaza,Mail Code 105/1E870D,East Hanover,New Jersey,' 07936 ' ,United States,209105,myelodysplastic syndrome,"""gard:0007132""",
3689,Imatinib mesylate,Gleevec,8/25/2005,treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia,Designated/Approved,,,Treatment of adult patients with hypereosinophic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRÿ}ÿ± fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRÿ}ÿ± fusion kinase negative or unknown,10/19/2006,10/19/2013,,Novartis Pharmaceuticals Corporation,One Health Plaza,Mail Code 105/1E870D,East Hanover,New Jersey,' 07936 ' ,United States,209005,chronic eosinophilic leukemia,"""gard:0020104""",
3690,imatinib mesylate,Gleevec,11/1/2001,treatment of gastrointestinal stromal tumors,Designated/Approved,,,Adjuvant treatment of adult patients following complete resection Kit (CD 117) positive gastrointestinal stromal tumors (GIST).,12/19/2008,12/19/2015,,Novartis Pharmaceuticals Corp.,One Health Plaza,Mail Code 105/1E870D,East Hanover,New Jersey,' 07936 ' ,United States,149201,gastrointestinal stromal tumor,"""gard:0008598""",
3691,imatinib mesylate,,5/6/2014,treatment of progressive multifocal leukencephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Inhibikase Therapeutics, Inc.",3350 Riverwood Parkway,,Atlanta,Georgia,' 30339 ' ,United States,428914,,,
3692,Imatinib mesylate,Gleevec,9/9/2005,treatment of systemic mastocytosis without the d816v c-kit mutation,Designated/Approved,,,Treatment of adult patients with aggressive mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown,10/19/2006,10/19/2013,,Novartis Pharmaceuticals Corporation,One Health Plaza,Mail Code 105/1E870D,East Hanover,New Jersey,' 07936 ' ,United States,209205,systemic mastocytosis,"""gard:0008616""",
3693,Imciromab pentetate,,1/25/1989,detecting early necrosis as an indication of rejection of orthotopic cardiac transplants.,Designated/Designation Withdrawn or Revoked,6/7/2021,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",244 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,32888,,,
3694,imetelstat,,12/23/2015,treatment of myelodysplastic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Geron Corporation,"919 E. Hillsdale Blvd., Suite 250",,Foster City,California,' 94404 ' ,United States,501415,myelodysplastic syndrome,"""gard:0007132""",
3695,imetelstat,,6/11/2015,treatment of myelofibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Geron Corporation,"919 E. Hillsdale Blvd., Suite 250",,Foster City,California,' 94404 ' ,United States,481315,,,
3696,Imexon,,11/1/2003,treatment of pancreatic adenocarcinoma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,AmpliMed Corporation,4380 North Campbell Avenue,Suite 205,Tucson,Alaska,' 85718 ' ,United States,165903,noma,"""gard:0004001""",
3697,Imexon,,8/3/2001,treatment of metastatic malignant melanoma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,AmpliMed Corporation,2321 Camino La Zorrela,,Tucson,Alaska,' 85718 ' ,United States,142501,noma,"""gard:0004001""",
3698,imexon,,8/12/2005,treatment of ovarian cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,AmpliMed Corporation,4380 N. Campbell Ave.,,Tucson,Alaska,' 85718 ' ,United States,207205,ovarian cancer,"""gard:0007295""",
3699,Imexon,,11/8/1996,treatment of multiple myeloma.,Designated,,Not FDA Approved for Orphan Indication,,,,,AmpliMed Corporation,2321 Camino La Zorrela,,Tucson,Alaska,' 85718 ' ,United States,100996,multiple myeloma,"""gard:0007108""",
3700,imidazolyl ethanamide pentandioic acid,,9/17/2018,treatment of acute radiation syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Myelo Therapeutics GmbH,Rheinsberger Str. 7,,Berlin,Berlin,' ' ,Germany,650218,acute radiation syndrome,"""gard:0021896""",
3701,Imidazopyridine,,7/22/2019,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"1ST Biotherapeutics, Inc.",240 Pangyoyeok-ro A-306,Bundang-gu Seongnam-si,Gyeonggi-do,,' ' ,South Korea,699719,amyotrophic lateral sclerosis,"""gard:0005786""",
3702,Imiglucerase,Cerezyme,11/5/1991,"replacement therapy in patients with types i, ii, and iii gaucher's disease.",Designated/Approved,,,Enzyme replacement therapy in patients with type I Gaucher's disease.,5/23/1994,5/23/2001,,Genzyme Corporation,One Kendall Square,,Cambridge,Massachusetts,' 02139 ' ,United States,62491,,,
3703,Imiquimod,,12/8/2022,treatment of stage iib-iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Celista Pharmaceuticals LLC,5305 Kelsey Terrace,,Edina,Minnesota,' 55436 ' ,United States,881222,noma,"""gard:0004001""",
3704,Imiquimod,,12/3/2014,treatment of carcinoma in situ (cis) of the urinary bladder,Designated,,Not FDA Approved for Orphan Indication,,,,,UroGen Pharma Ltd,9 Ha'Ta'asiya Street,P. O. Box 2397,Ra'anana,,' ' ,Israel,425314,noma,"""gard:0004001""",
3705,imiquimod (IMQ)-ferulic acid (FA) co-crystal (IMQ API and FA coformer),,10/17/2022,treatment of vulvar intraepithelial neoplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,Celista Pharmaceuticals LLC,5305 Kelsey Terrace,,Edina,Minnesota,' 55436 ' ,United States,886422,vulvar intraepithelial neoplasia,"""gard:0019876""",
3706,Imiquimod-Ferulic Acid,,1/23/2024,treatment of cutaneous leishmaniasis,Designated,,Not FDA Approved for Orphan Indication,,,,,Celista Pharmaceuticals LLC,5305 Kelsey Terrace,,Edina,Minnesota,' 55436 ' ,United States,983823,leishmaniasis,"""gard:0006881""",
3707,Imlifidase,,7/3/2018,treatment of anti-glomerular basement membrane (anti-gbm) disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Hansa Medical AB,"Scheelevägen 22, P. O. Box 785",SE-220 07,Lund,,' ' ,Sweden,643118,,,
3708,imlifidase,,2/14/2018,treatment of guillain-barré syndrome (gbs),Designated,,Not FDA Approved for Orphan Indication,,,,,Hansa Medical AB,"Scheelevägen 22, P. O. Box 785",SE-220 07,Lund,,' ' ,Sweden,623817,guillain-barré syndrome,"""gard:0006554""",
3709,Immortalized human liver cells found in the extracorporeal liver assist device,,7/16/2004,treatment of fulminant hepatic failure (acute liver failure),Designated,,Not FDA Approved for Orphan Indication,,,,,"Vital Therapies, Inc.",15222 Avenue of Science,Suite C,San Diego,California,' 92128 ' ,United States,184104,acute liver failure,"""gard:0019112""",
3710,Immune Globulin (Human),,6/12/2023,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"CSL Behring, L.L.C.",1020 1st Ave,,King of Prussia,Pennsylvania,' 19406 ' ,United States,943023,systemic sclerosis,"""gard:0009748""",
3711,immune globulin (human),,3/2/2010,treatment of guillain-barre syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Octapharma USA, Inc.",121 River Street,Suite 1201,Hoboken,New Jersey,' 07030 ' ,United States,301110,,,
3712,immune globulin (human),,12/12/2016,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Grifols Therapeutics, Inc.",79 TW Alexander Drive,,Research Triangle Park,North Carolina,' 27709 ' ,United States,544616,myasthenia gravis,"""gard:0007122""",
3713,Immune Globulin (Human),Gamunex-C,7/27/2004,treatment of chronic inflammatory demyelinating polyneuropathy,Designated/Approved,,,Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse,9/12/2008,9/12/2015,,"Grifols Therapeutics, Inc.",8368 US 70 Busines Hwy West,,Clayton,North Carolina,' 27520 ' ,United States,185604,chronic inflammatory demyelinating polyneuropathy,"""gard:0006102""",
3714,Immune Globulin (Human) containing high titers of West Nile virus antibodies,,3/17/2004,treatment of the west nile virus infection,Designated,,Not FDA Approved for Orphan Indication,,,,,"OMRIX Biopharmaceuticals, Ltd.",Plasma Fractionation Institute,,Ramat Gan,,' ' ,Israel,181803,,,
3715,immune globulin infusion (human),Gammagard Liquid,7/20/2006,treatment of multifocal motor neuropathy,Designated/Approved,,,Maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).,6/22/2012,6/22/2019,,"Baxalta US, Inc.",One Baxter Way,,Westlake Village,California,' 91362 ' ,United States,224906,multifocal motor neuropathy,"""gard:0011011""",
3716,Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase,HyQvia,3/31/2016,treatment of chronic inflammatory demyelinating polyneuropathy,Designated/Approved,,,treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment in adults,1/12/2024,1/12/2031,treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment in adults,"Takeda Development Center Americas, Inc.",500 Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,514315,chronic inflammatory demyelinating polyneuropathy,"""gard:0006102""",
3717,immune globulin intravenous (human),Gammaplex,4/29/2011,treatment of idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia),Designated/Approved,,,Idiopathic thrombocytopenic purpura,3/8/2013,,,Bio Products Laboratory,Dagger Lane,Hertfordshire,England,,' ' ,United Kingdom,335211,immune thrombocytopenia,"""gard:0005194""",
3718,Immune Globulin Intravenous (human),,5/4/2004,treatment for guillain barre syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,ZLB Bioplasma AG,Wankdorfstrasse 10,,CH-3000 Bern 22,,' ' ,Switzerland,184704,,,
3719,Immune globulin intravenous (human),,11/22/1993,treatment of patients with acute myocarditis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Immuno Clinical Research Corp.,"750 Lexington Avenue, 19th Floor",,New York,New York,' 10022 ' ,United States,75893,,,
3720,Immune Globulin Intravenous (Human),,1/28/2020,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,720719,systemic sclerosis,"""gard:0009748""",
3721,Immune globulin intravenous (human),,12/16/1992,treatment of juvenile rheumatoid arthritis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Immuno Clinical Research Corp.,"750 Lexington Avenue, 19th Floor",,New York,New York,' 10022 ' ,United States,68892,,,
3722,Immune Globulin Intravenous (Human),Octagam 10%,4/19/2017,treatment of dermatomyositis,Designated/Approved,,,Treatment of dermatomyositis in adults,7/15/2021,7/15/2028,Treatment of dermatomyositis in adults,"OCTAPHARMA USA, Inc.",117 West Century Road,,Paramus,New Jersey,' 07652 ' ,United States,564716,dermatomyositis,"""gard:0006263""",
3723,Immune globulin intravenous (human),,10/13/1992,treatment of polymyositis/dermatomyositis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Immuno Clinical Research Corp.,155 East 56th Street,,New York,New York,' 10022 ' ,United States,68992,polymyositis,"""gard:0007425""",
3724,"Immune globulin intravenous, human",Gamimune N,2/18/1993,infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.,Designated/Approved,,,"For prophylaxis of children with clinical or immunologic evidence of human immunodeficiency virus to decrease the frequency of serious and minor bacterial infections and the frequency of hospitalization, and to increase the time free of serious bacterial infections.",12/27/1993,12/27/2000,,Bayer Corporation,"Pharmaceutical Division, Biological Products",400 Morgan Lane,New Haven,Connecticut,' 06516 ' ,United States,70592,,,
3725,Immune Globulin Subcutaneous (Human),,9/22/2004,treatment of patients with primary immune deficiency (pid) that are intolerant to immune globulin intravenous (igiv) due to severe adverse events or poor venous access,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,P.O. Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,180503,,,
3726,immune globulin subcutaneous (Human),,9/12/2018,treatment of dermatomyositis,Designated,,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,649518,dermatomyositis,"""gard:0006263""",
3727,"Immune Globulin Subcutaneous (Human), 20% Liquid",Hizentra,8/18/2014,treatment of chronic inflammatory demyelinating polyneuropathy (cidp),Designated/Approved,,,Indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.,3/15/2018,3/15/2025,Indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment,CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,439914,chronic inflammatory demyelinating polyneuropathy,"""gard:0006102""",
3728,immunoglobulin G (IgG) polyclonal antibody that binds to human T cells,,10/15/2020,prevention of graft rejection following solid organ transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,Xenothera,1 Rue Vauban,,Nantes,,' 44000 ' ,France,772520,,,
3729,immunoglobulin G degrading enzyme of Streptococcus pyogenes,,9/10/2015,prevention of antibody mediated organ rejection in solid organ transplant patients.,Designated,,Not FDA Approved for Orphan Indication,,,,,Hansa Medical AB,"Scheelevägen 22, P. O. Box 785",SE-220 07,Lund,,' ' ,Sweden,455114,,,
3730,"Immunoglobulin G [27-histidine,57-histidine,253-tyrosine,255- threonine,257-glutamic acid], anti-(human complement C5) (human monoclonal CAN106 hybrid y2-chain CH1-hinge region/y4-chain CH2- CH3 region), disulfide with human monoclonal CAN106 Kappa-chain, dimer",,11/8/2022,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,"CANbridge Pharmaceuticals, Inc.",4 Burlington Woods Dr,,Burlington,Massachusetts,' 01803 ' ,United States,889522,myasthenia gravis,"""gard:0007122""",
3731,"immunoglobulin VHH fragment-linker-VHH fragment, anti-CD1d and anti-[Vdelta2 T-cell receptor], humanized monoclonal antibody",,10/13/2021,treatment of chronic lymphocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,LAVA Therapeutics,"2929 Arch Street, Suite 1700",,Philadelphia,Pennsylvania,' 19104 ' ,United States,821821,,,
3732,immunologically active synthetic peptides,,6/1/2015,treatment of hemophilia a,Designated,,Not FDA Approved for Orphan Indication,,,,,Apitope International NV,"Agoralaan, Building A-bis",,Diepenbeek,,' ' ,Belgium,479315,hemophilia,"""gard:0010418""",
3733,immunomodulatory inhibitor of high mobility group box 1,,2/22/2024,treatment of idiopathic pulmonary fibrosis (ipf),Designated,,Not FDA Approved for Orphan Indication,,,,,"Spark Biopharma, Inc.","7F, 134, Gwanak - ro, Gwanak - gu",,Seoul,,' 08791 ' ,South Korea,989023,idiopathic pulmonary fibrosis,"""gard:0008609""",
3734,Immunotherapeutic vaccine consisting of (PAM)2-Lys-Ser-Ser-Gln-Tyr-Ile-Lys-Ala-Asn-Ser-Lys-Phe-Ile-Gly-Ile-Thr-Glu-Ala-Ala-Ala-Phe-Leu-Pro-Ser-Asp-Phe-Phe-Pro-Ser-Val,,3/16/1994,treatment of chronic active hepatitis b infection in hla-a2 positive patients.,Designated,,Not FDA Approved for Orphan Indication,,,,,Cytel Corporation,3525 John Hopkins Court,,San Diego,California,' 92121 ' ,United States,74893,,,
3735,"Immunotherapeutic vaccine consisting of pAc/emm55, a plasmid DNA (pDNA), which codes for a modified immunogenic, streptococcal Emm55 protein, complexed with in vivo-jetPEI® polymer-based reagent linear polyethylenimine)",,11/5/2020,treatment of stage iib to stage iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Morphogenesis, Inc.","10500 University Center Dr., Ste. 110",,Tampa,Florida,' 33612 ' ,United States,780520,noma,"""gard:0004001""",
3736,Implitapide,,8/13/2004,treatment of homozygous familial hypercholesterolemia,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Medical Research Laboratories International,2 Tesseneer Drive,,Highland Heights,Kentucky,' 41076 ' ,United States,188904,homozygous familial hypercholesterolemia,"""gard:0010416""",
3737,Implitapide,,8/19/2004,treatment of patients with fredrickson type i or v hyperlipoproteinemia,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Medical Research Laboratories International,2 Tesseneer Drive,,Highland Heights,Kentucky,' 41076 ' ,United States,188704,,,
3738,"Imported fire ant venom, allergenic extract",,5/12/1992,"for skin testing of victims of fire ant stings to confirm fire ant sensitivity and if positive, for use as immunotherapy for the prevention of ige-mediated anaphylactic reactions.",Designated,,Not FDA Approved for Orphan Indication,,,,,"ALK Laboratories, Inc.",Research Center,27 Village Lane,Wallingford,Connecticut,' 06492 ' ,United States,62691,,,
3739,imsidolimab,,7/7/2020,treatment of generalized pustular psoriasis,Designated,,Not FDA Approved for Orphan Indication,,,,,"AnaptysBio, Inc.",10421 Pacific Center Court,Suite 200,San Diego,California,' 92121 ' ,United States,673918,generalized pustular psoriasis,"""gard:0012819""",
3740,Imvotamab,,10/31/2022,treatment of follicular lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"IGM Biosciences, Inc.",325 East Middlefield Road,,Mountain View,California,' 94043 ' ,United States,907622,lymphoma,"""gard:0020548""",
3741,"Inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Poly I:C, kanamycin and calcium)",,12/29/2016,prevention of rabies virus infection including post-exposure prophylaxis (pep) for rabies,Designated,,Not FDA Approved for Orphan Indication,,,,,"Yisheng US Biopharma, Inc.",11 Firstfield Road,Suite A,Gaithersburg,Maryland,' 20878 ' ,United States,549316,rabies,"""gard:0007516""",
3742,"Inactivated purified rabies virus (IPRV) and the PIKA adjuvant (Polyinosinic-polycyidylic acid, kanamycin and calcium)",,2/15/2018,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Yisheng US Biopharma, Inc.",11 Firstfield Road,Suite A,Gaithersburg,Maryland,' 20878 ' ,United States,625117,,,
3743,Inalimarev and falimarev,,1/10/2006,treatment of adenocarcinoma of the pancreas,Designated,,Not FDA Approved for Orphan Indication,,,,,Therion Biologics Corporation,76 Rogers Street,,Cambridge,Massachusetts,' 02142 ' ,United States,215705,noma,"""gard:0004001""",
3744,inBreath airway transplant system,,9/4/2014,"to restore the structure and/or function of the trachea subsequent to tracheal damage due to cancer, injury or infection",Designated,,Not FDA Approved for Orphan Indication,,,,,"Biostage, Inc.",84 October Hill Road,Suite 11,Holliston,Massachusetts,' 01746 ' ,United States,419813,,,
3745,Inclacumab,,5/24/2022,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Global Blood Therapeutics, Inc.",181 Oyster Point Blvd,,South San Francisco,California,' 94080 ' ,United States,875522,,,
3746,inclisiran,,1/22/2018,treatment of homozygous familial hypercholesterolemia (hofh),Designated,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07932 ' ,United States,618017,homozygous familial hypercholesterolemia,"""gard:0010416""",
3747,incobotulinumtoxinA,,11/28/2022,treatment of hemifacial spasm,Designated,,Not FDA Approved for Orphan Indication,,,,,"Merz Pharmaceuticals, LLC",6601 Six Forks Road,Suite 430,Raleigh,North Carolina,' 27615 ' ,United States,911422,hemifacial spasm,"""gard:0017137""",
3748,Indium In 111 murine monoclonal antibody FAB to myosin,,8/7/1989,to aid in the diagnosis of myocarditis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",244 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,33788,,,
3749,Indium In-111 altumomab pentetate,,2/6/1990,detection of suspected and previously unidentified tumor foci of recurrent colorectal carcinoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Hybritech, Inc.",11095 Torreyanna Road,,San Diego,California,' 92196 ' ,United States,10085,noma,"""gard:0004001""",
3750,Indium-111 pentetreotide,,6/16/2006,treatment of neuroendocrine tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,RadioIsotope Therapy of America (RITA) Foundation,9701 Richmond Avenue,,Houston,Texas,' 77042 ' ,United States,224706,,,
3751,Indolino-benzodiazepine compound (sulfonated DGN462) conjugated to the humanized anti-CD33 monoclonal antibody (Z4681A) via the sulfo-SPDB linker,,5/2/2018,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,2/11/2022,Not FDA Approved for Orphan Indication,,,,,"ImmunoGen, Inc.",830 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,635518,acute myeloid leukemia,"""gard:0012757""",
3752,Indolino-benzodiazepine compound (sulfonated DGN549-C) conjugated to the humanized anti-CD123 monoclonal antibody (G4723A),,11/17/2020,treatment for blastic plasmacytoid dendritic cell neoplasm,Designated,,Not FDA Approved for Orphan Indication,,,,,"ImmunoGen, Inc.",830 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,781620,,,
3753,Indolino-benzodiazepine compound (sulfonated DGN549-C) conjugated to the humanized anti-CD123 monoclonal antibody (G4723A),,10/10/2018,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"ImmunoGen, Inc.",830 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,654018,acute myeloid leukemia,"""gard:0012757""",
3754,Indotecan,,10/31/2023,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gibson Oncology, LLC",7772 Fisher Island Drive,,Miami,Florida,' 33109 ' ,United States,968123,,,
3755,indoximod,,10/26/2017,treatment of stage iib to iv melanoma,Designated/Designation Withdrawn or Revoked,12/17/2021,Not FDA Approved for Orphan Indication,,,,,"Lumos Pharma, Inc.","2503 South Loop Drive, Suite 5100",,Ames,Iowa,' 50010 ' ,United States,608917,noma,"""gard:0004001""",
3756,indralin,,6/13/2018,prevention of acute radiation syndrome (ars),Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Innovative Partners, Inc.",7947 Brookside Court,,Lake Worth,Florida,' 33467 ' ,United States,636318,acute radiation syndrome,"""gard:0021896""",
3757,inebilizumab,Uplizna,2/10/2016,treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders,Designated/Approved,,,Uplizna is indicated for for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.,6/11/2020,6/11/2027,Indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.,Horizon Therapeutics Ireland DAC,70St. Stephen’s Green,,Dublin 2,,' D02 E2X4 ' ,Ireland,490415,neuromyelitis optica spectrum disorder,"""gard:0006267""",
3758,inebilizumab,,12/3/2009,treatment of scleroderma,Designated,,Not FDA Approved for Orphan Indication,,,,,Viela Bio,One MedImmune Way,,Gaithersburg,Maryland,' 20878 ' ,United States,295209,scleroderma,"""gard:0018705""",
3759,inecalcitol,,8/3/2015,treatment of acute myeloid leukemia.,Designated/Designation Withdrawn or Revoked,1/29/2019,Not FDA Approved for Orphan Indication,,,,,"Hybrigenics, S.A.",3-5 Impasse Reille,75014,Paris,,' ' ,France,479715,acute myeloid leukemia,"""gard:0012757""",
3760,Inecalcitol,,5/14/2014,treatment of chronic lymphocytic leukemia,Designated/Designation Withdrawn or Revoked,1/29/2019,Not FDA Approved for Orphan Indication,,,,,"Hybrigenics, S.A.",3-5 Impasse Reille,75014,Paris,,' ' ,France,432914,,,
3761,infigratinib,Truseltiq,9/11/2019,treatment of cholangiocarcinoma,Designated/Approved/Designation Withdrawn or Revoked,8/4/2023,,"Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.",5/28/2021,5/28/2028,,"QED Therapeutics, Inc.","1800 Owens Street, 12 Floor",,San Francisco,California,' 94148 ' ,United States,707019,cholangiocarcinoma,"""gard:0009304""",
3762,Infigratinib,,8/12/2021,treatment of achondroplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,"QED Therapeutics, Inc.",8000 Marina Blvd #400,,Brisbane,California,' 94005 ' ,United States,833221,achondroplasia,"""gard:0008173""",
3763,Infliximab,Remicade,11/12/2003,treatment of pediatric (0 to 16 years of age) crohn's disease,Designated/Approved,,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy,5/19/2006,5/19/2013,,"Centocor, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,175803,,,
3764,infliximab,Remicade,11/12/2003,treatment of pediatric (0 to 16 years of age) ulcerative colitis,Designated/Approved,,,For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy,9/23/2011,9/23/2018,,"Janssen Biotech, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,175903,,,
3765,infliximab,,10/23/2002,treatment of juvenile rheumatoid arthritis,Designated/Designation Withdrawn or Revoked,6/3/2021,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",,200 Great Valley Parkway,Malvern,Pennsylvania,' 19355 ' ,United States,160202,,,
3766,infliximab,,5/6/2003,treatment of giant cell arteritis,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,166303,giant cell arteritis,"""gard:0009615""",
3767,Infliximab,,5/21/2003,treatment of chronic sarcoidosis,Designated/Designation Withdrawn or Revoked,6/3/2021,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,168303,sarcoidosis,"""gard:0007607""",
3768,infliximab,Remicade,11/14/1995,treatment of crohn's disease,Designated/Approved,,,"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s).",8/24/1998,8/24/2005,,"Centocor, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,92495,,,
3769,inhibitor of microRNA-451,,2/4/2011,treatment of polycythemia vera,Designated/Designation Withdrawn or Revoked,12/5/2016,Not FDA Approved for Orphan Indication,,,,,"miRagen Therapeutics, Inc.",6200 Lookout Road,,Boulder,Colorado,' 80301 ' ,United States,316410,polycythemia,"""gard:0019466""",
3770,Inhibitor of Tissue Factor Pathway Inhibitor (TFPI),,1/29/2010,treatment of hemophilia a and hemophilia b.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Baxter Healthcare Corporation, Baxter BioScience",One Baxter Way,,Westlake Village,California,' 91362 ' ,United States,298409,hemophilia,"""gard:0010418""",
3771,Iniparib,,7/1/2021,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,TriAct Therapeutics,2717 Baker Street,,San Francisco,California,' 94123 ' ,United States,823921,,,
3772,Inobrodib,,6/21/2023,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,CellCentric Ltd.,Chesterford Research Park,,Cambridge,,' CB10 1XL ' ,United Kingdom,946123,multiple myeloma,"""gard:0007108""",
3773,inolimomab,,10/23/2002,treatment of graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,ElsaLys Biotech SAS,317 Avenue Jean Jaures,Batiment Accinov,Lyon,,' ' ,France,158602,graft versus host disease,"""gard:0016642""",
3774,Inosine pranobex,,9/20/1988,treatment of subacute sclerosing panencephalitis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Newport Pharmaceuticals,897 West Sixteenth Street,,Newport Beach,California,' 92663 ' ,United States,26888,encephalitis,"""gard:0019357""",
3775,Inotersen,TEGSEDI™,7/24/2012,treatment of transthyretin amyloidosis (attr amyloidosis),Designated/Approved,,,TEGSEDI¿ is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,10/5/2018,10/5/2025,TEGSEDI¿ is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,"Akcea Therapeutics, Inc.",22 Boston Wharf Road,9th Floor,Boston,Massachusetts,' 02210 ' ,United States,374512,amyloidosis,"""gard:0018676""",
3776,inotuzumab ozogamicin,Besponsa,3/25/2013,treatment of b-cell acute lymphoblastic leukemia,Designated/Approved,,,treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older,3/6/2024,3/6/2031,treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in pediatric patients 1 year and older,"Wyeth Pharmaceuticals, LLC",P.O. Box 8299,,Philadelphia,Pennsylvania,' 19101 ' ,United States,391413,acute lymphoblastic leukemia,"""gard:0000522""",
3777,inotuzumab ozogamicin,,3/25/2013,treatment of b-cell acute lymphoblastic leukemia,Designated/Approved,,,Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL),8/17/2017,8/17/2024,Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL),"Wyeth Pharmaceuticals, LLC",P.O. Box 8299,,Philadelphia,Pennsylvania,' 19101 ' ,United States,391413,acute lymphoblastic leukemia,"""gard:0000522""",
3778,insecticidal toxin derived from Bacillus thuringiensis,,9/5/2008,treatment of soil transmitted helminth infection strongyloidiasis,Designated,,Not FDA Approved for Orphan Indication,,,,,"University of California, San Diego","Aroian Laboratory, Div. of Biological Sciences",Department 0322,LaJolla,California,' 92093 ' ,United States,266408,strongyloidiasis,"""gard:0008195""",
3779,"Insulin producing cells (autologous liver cells transduced by Ad5-CMV-MafA, Ad5-CMV-NeuroD1, and Ad5-CMV-PDX1)",,6/11/2019,treatment of diabetes due to total pancreatectomy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Orgenesis, Ltd.",36 Harimon Street,,Ge'alya,Center District,' ' ,Israel,654218,,,
3780,insulin-like growth factor-1,,1/10/2022,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Sarcomed AB,Störtloppsvägen 25,,Stockholm,,' 12947 ' ,Sweden,856421,muscular dystrophy,"""gard:0007922""",
3781,Insulin-like Growth Factor-1,,6/21/2023,treatment of spinal bulbar muscular atrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Sarcomed AB,Störtloppsvägen 25,,Stockholm,,' 12947 ' ,Sweden,932423,,,
3782,Insulin-like Growth Factor-1,,4/11/2022,treatment of congenital muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Sarcomed AB,Störtloppsvägen 25,,Stockholm,,' 12947 ' ,Sweden,871322,congenital muscular dystrophy,"""gard:0009138""",
3783,inter-Alpha-Inhibitor-Proteins (IaIp) (Human),,2/13/2018,treatment of necrotizing enterocolitis (nec),Designated,,Not FDA Approved for Orphan Indication,,,,,"ProThera Biologics, Inc.",349 Eddy Street,,Providence,Rhode Island,' 02903 ' ,United States,626518,necrotizing enterocolitis,"""gard:0009767""",
3784,Interferon alfa-2a,Roferon A,6/6/1989,treatment of chronic myelogenous leukemia.,Designated/Approved,,,Treatment of chronic myelogenous leukemia.,10/19/1995,10/19/2002,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,36989,,,
3785,Interferon alfa-2a (recombinant),Roferon-A,12/14/1987,treatment of aids related kaposi's sarcoma.,Designated/Approved,,,,11/21/1988,11/21/1995,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,25987,,,
3786,Interferon alfa-2a (recombinant),,4/18/1988,treatment of renal cell carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,27488,renal cell carcinoma,"""gard:0013215""",
3787,Interferon alfa-2a (recombinant),,5/2/1990,for the concomitant administration with teceleukin for the treatment of metastatic renal cell carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,44590,renal cell carcinoma,"""gard:0013215""",
3788,Interferon alfa-2a (recombinant),,10/27/1989,for use in combination with fluorouracil for the treatment of esophageal carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,40889,noma,"""gard:0004001""",
3789,Interferon alfa-2a (recombinant),,5/11/1990,for the treatment of metastatic malignant melanoma in combination with teceleukin.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,44690,noma,"""gard:0004001""",
3790,Interferon alfa-2a (recombinant),,5/14/1990,for the concomitant administration with fluorouracil for the treatment of advanced colorectal cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,42389,,,
3791,Interferon alfa-2b (recombinant),,8/17/1988,treatment of laryngeal (respiratory) papillomatosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,' 07033 ' ,United States,21487,,,
3792,Interferon alfa-2b (recombinant),,5/13/1988,treatment of primary malignant brain tumors.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,' 07033 ' ,United States,21087,,,
3793,Interferon alfa-2b (recombinant),,8/10/1988,treatment of carcinoma in situ of the urinary bladder.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,' 07033 ' ,United States,20487,noma,"""gard:0004001""",
3794,Interferon alfa-2b (recombinant),,4/18/1988,treatment of invasive carcinoma of the cervix.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,' 07033 ' ,United States,20387,noma,"""gard:0004001""",
3795,Interferon alfa-2b (recombinant),,8/3/1987,treatment of ovarian carcinoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,' 07033 ' ,United States,20187,noma,"""gard:0004001""",
3796,Interferon alfa-2b (recombinant),,6/22/1987,treatment of chronic myelogenous leukemia.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,' 07033 ' ,United States,20087,,,
3797,Interferon alfa-2b (recombinant),,6/22/1987,treatment of metastatic renal cell carcinoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,' 07033 ' ,United States,19787,renal cell carcinoma,"""gard:0013215""",
3798,Interferon alfa-2b (recombinant),,11/17/1988,treatment of acute hepatitis b.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,' 07033 ' ,United States,26487,,,
3799,Interferon alfa-2b (recombinant),,5/4/1990,treatment of chronic delta hepatitis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,' 07033 ' ,United States,40289,,,
3800,Interferon alfa-2b (recombinant),Intron A,6/24/1987,treatment of aids-related kaposi's sarcoma.,Designated/Approved,,,Treatment of selected patients with AIDS-related Kaposi's sarcoma.,11/21/1988,11/21/1995,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,' 07033 ' ,United States,19187,,,
3801,Interferon alfa-nl,,8/25/1986,treatment of aids related kaposi's sarcoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Burroughs Wellcome Company,3030 Cornwallis Road,,Research Triangle Pk,North Carolina,' 27709 ' ,United States,12886,,,
3802,Interferon alfa-nl,,10/16/1987,treatment of human papillomavirus in patients with severe resistant/recurrent respiratory (laryngeal) papillomatosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,' 27709 ' ,United States,12986,,,
3803,Interferon beta (recombinant human),,1/13/1993,treatment of primary brain tumors.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Biogen Idec, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,' 02142 ' ,United States,69392,,,
3804,Interferon beta (recombinant),,4/18/1991,for the systemic treatment of cutaneous t-cell lymphoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,' 02142 ' ,United States,53390,lymphoma,"""gard:0020548""",
3805,Interferon beta (recombinant),,2/12/1991,for the systemic treatment of metastatic renal cell carcinoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,' 02142 ' ,United States,53890,renal cell carcinoma,"""gard:0013215""",
3806,Interferon beta (recombinant),,5/9/1991,for the intralesional and/or systemic treatment of aids-related kaposi's sarcoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,' 02142 ' ,United States,53590,,,
3807,"Interferon beta, recombinant human",,11/15/1988,treatment of acquired immunodeficiency syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Berlex Laboratories, Inc.",1401 Harbor Bay Parkway,,Alameda,California,' 94501 ' ,United States,31788,acquired immunodeficiency,"""gard:0021359""",
3808,Interferon beta-1a,,3/11/1996,treatment of patients with secondary progressive multiple sclerosis,Designated/Designation Withdrawn or Revoked,12/21/2017,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,95195,,,
3809,interferon Beta-1a,,10/14/1998,treatment of juvenile rheumatoid arthritis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,' 02142 ' ,United States,115498,,,
3810,Interferon beta-1a,Avonex,12/16/1991,treatment of multiple sclerosis.,Designated/Approved,,,Treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations.,5/17/1996,5/17/2003,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,' 02142 ' ,United States,62791,,,
3811,Interferon beta-1a (recombinant human),,1/7/1999,treatment of pulmonary fibrosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Biogen Idec, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,' 02142 ' ,United States,111598,,,
3812,Interferon beta-1a (recombinant human),,7/24/1992,"treatment of acute non-a, non-b hepatitis.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,' 02142 ' ,United States,62891,,,
3813,Interferon beta-1a (recombinant),,4/3/1991,for the systemic treatment of cutaneous malignant melanoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,' 02142 ' ,United States,53290,noma,"""gard:0004001""",
3814,Interferon beta-1a (recombinant),,12/2/1992,treatment of symptomatic patients with aids including all patients with cd4 t-cell counts less than 200 cells per mm3.,Designated/Designation Withdrawn or Revoked,12/21/2017,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,63391,,,
3815,Interferon beta-1b,Betaseron,11/17/1988,treatment of multiple sclerosis.,Designated/Approved,,,In ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations.,7/23/1993,7/23/2000,,Chiron Corp. & Berlex Laboratories,4560 Horton Street,,Emeryville,California,' 94608 ' ,United States,31888,,,
3816,Interferon gamma,,10/11/2007,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,mondoBIOTECH Laboratories AG,"Herrengasse 21, 9490 Vaduz",,Liechtenstein,,' ' ,Germany,246107,idiopathic pulmonary fibrosis,"""gard:0008609""",
3817,interferon gamma,,11/4/2011,treatment of friedreich's ataxia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Roberto Testi, MD",School of Medicine,via Michelini-Tocci 82,Rome,,' ' ,Italy,354711,,,
3818,Interferon gamma 1-b,Actimmune,9/30/1988,treatment of chronic granulomatous disease.,Designated/Approved,,,,12/20/1990,12/20/1997,,Horizon Therapeutic Ireland DAC,"Connaught House, 1st Floor",1 Burlington Road,Dublin 4,,' ' ,Ireland,29788,chronic granulomatous disease,"""gard:0006100""",
3819,interferon gamma-1b,,9/12/2002,treatment of idiopathic pulmonary fibrosis,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"InterMune, Inc.",3280 Bayshore Boulevard,,Brisbane,California,' 94005 ' ,United States,152301,idiopathic pulmonary fibrosis,"""gard:0008609""",
3820,Interferon gamma-1b,,12/4/1995,treatment of renal cell carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Horizon Therapeutic Ireland DAC,"Connaught House, 1st Floor",1 Burlington Road,Dublin 4,,' ' ,Ireland,93595,renal cell carcinoma,"""gard:0013215""",
3821,Interferon gamma-1b,Actimmune,9/30/1996,"delaying time to disease progression in patients with severe, malignant osteopetrosis.",Designated/Approved,,,"Delaying time to disease progression in patients with severe, malignant osteopetrosis.",2/10/2000,2/10/2007,,Horizon Therapeutic Ireland DAC,"Connaught House, 1st Floor",1 Burlington Road,Dublin 4,,' ' ,Ireland,98796,,,
3822,interferon gamma-1b,,10/1/2014,treatment of friedreich's ataxia,Designated,,Not FDA Approved for Orphan Indication,,,,,Horizon Therapeutic Ireland DAC,"Connaught House, 1st Floor",1 Burlington Road,Dublin 4,,' ' ,Ireland,445514,,,
3823,Interferon-alfa-1b,,4/17/2001,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Ernest C.Borden,Center for Cancer Drud Discovery and Development,9500 Euclid Avenue,Clevland,Ohio,' 44195 ' ,United States,142601,multiple myeloma,"""gard:0007108""",
3824,interferon-alpha secreting autologous micro-organ tissue converting into a biopump,,6/14/2012,treatment of chronic hepatitis d,Designated,,Not FDA Approved for Orphan Indication,,,,,"Medgenics, Inc.",555 California Street,Suite 365,San Francisco,California,' 94104 ' ,United States,370312,,,
3825,interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker,,3/23/2020,treatment of graft-versus-host-disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,1 Amgen Center Drive,,Thousand Oaks,California,' 91320 ' ,United States,620217,,,
3826,"Interleukin-1 alpha, human recombinant",,6/17/1991,for the promotion of early engraftment in bone marrow transplantation.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation,51 University Street,,Seattle,Washington,' 98101 ' ,United States,57191,,,
3827,"Interleukin-1 alpha, human recombinant",,6/17/1991,for hematopoietic potentiation in aplastic anemia.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation,51 University Street,,Seattle,Washington,' 98101 ' ,United States,57291,aplastic anemia,"""gard:0020234""",
3828,"interleukin-1 receptor antagonist (IL-1Ra, sequence-homologous anakinra)",,8/7/2018,treatment of bronchiolitis obliterans,Designated,,Not FDA Approved for Orphan Indication,,,,,"Onspira Therapeutics, Inc., a wholly owned subsidiary of Sumitomo Pharma America, Inc.",101 Lindenwood Drive,Suite 400,Malvern,Pennsylvania,' 19355 ' ,United States,636118,,,
3829,interleukin-1 receptor antagonist anakinra,,9/15/2015,treatment of still's disease including systemic juvenile idiopathic arithritis and adult-onset still's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Swedish Orphan Biovitrum AB,SE-112,75 Stockholm,Stockholm,,' ' ,Sweden,488715,,,
3830,"Interleukin-1 receptor antagonist, human recombinant",,10/16/1992,prevention and treatment of graft versus host disease in transplant recipients.,Designated,,Not FDA Approved for Orphan Indication,,,,,Swedish Orphan Biovitrum AB (publ) (SOBI),SE-112 76,,Stockholm,,' ' ,Sweden,65892,graft versus host disease,"""gard:0016642""",
3831,"Interleukin-1 receptor antagonist, human recombinant",,9/23/1991,treatment of juvenile rheumatoid arthritis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Swedish Orphan Biovitrum AB (publ) (SOBI),SE-112 76,,Stockholm,,' ' ,Sweden,59991,,,
3832,Interleukin-1 Trap,,4/4/2005,treatment of still's disease including juvenile rheumatoid arthritis and adult-onset still's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,197604,,,
3833,Interleukin-2,,2/5/1990,treatment of metastatic renal cell carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,36289,renal cell carcinoma,"""gard:0013215""",
3834,Interleukin-2,,2/6/1990,treatment of metastatic malignant melanoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,36389,noma,"""gard:0004001""",
3835,Interleukin-2,,5/11/1990,in combination with interferon alfa-2a for the treatment of metastatic malignant melanoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,44790,noma,"""gard:0004001""",
3836,Interleukin-2,,5/3/1990,in combination with interferon alfa-2a for the treatment of metastatic renal cell carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,44490,renal cell carcinoma,"""gard:0013215""",
3837,Interleukin-3 human (recombinant),,5/20/1991,promotion of erythropoiesis in diamond-blackfan anemia (congenital pure red cell aplasia).,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Immunex Corporation,51 University Street,,Seattle,Washington,' 98101 ' ,United States,53490,,,
3838,"Interleukin-3, human, recombinant",,9/30/1993,for sequential administration with sargramostim to accelerate neutrophil and platelet recovery in patients undergoing autologous bone marrow transplantation for the treatment of hodgkin's disease or non-hodgkin's lymphoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Sandoz Pharmaceuticals Corp.,59 Route 10,,East Hanover,New Jersey,' 07936 ' ,United States,74093,lymphoma,"""gard:0020548""",
3839,Intraoral fluoride releasing system,,7/31/2001,prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Digestive Care, Inc.",1120 Win Drive,,Bethlehem,Pennsylvania,' 18017 ' ,United States,143901,,,
3840,intravenous baclofen,,4/20/2020,prevention of baclofen withdrawal syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Allaysis, LLC",525 Route 73 North,Suite 104,Marlton,New Jersey,' 08503 ' ,United States,480215,,,
3841,intravenous carbamazepine,CARNEXIV,6/27/2013,treatment of epilepsy patients who cannot take anything by mouth (npo),Designated/Approved,,,"Replacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following seizure types: (1) Partial seizures with complex symptomology; (2)Generalized tonic-clonic seizures; and (3) Mixed seizure patterns which include the above or other partial or generalized seizures",10/7/2016,10/7/2023,"Replacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following seizure types: (1) Partial seizures with complex symptomology; (2)Generalized tonic-clonic seizures; and (3) Mixed seizure patterns which include the above or other partial or generalized seizures",Lundbeck LLC,"3530 Toringdon Way, Suite 200",,Charlotte,North Carolina,' 28277 ' ,United States,265508,,,
3842,Intravenous immune globulin,,7/26/2007,treatment of stage iib to iv malignant melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,GammaCan Ltd.,39 Jerusalem Street,,,,' ' ,Israel,243307,noma,"""gard:0004001""",
3843,Intravenous immune globulin (human) 10%,,7/31/2008,treatment of stiff-person syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Octapharma USA, Inc.",121 River Street,,Hoboken,New Jersey,' 07030 ' ,United States,264208,n syndrome,"""gard:0003902""",
3844,intraventricular nimodipine,,5/28/2015,treatment of subarachnoid hemorrhage,Designated,,Not FDA Approved for Orphan Indication,,,,,"Edge Therapeutics, Inc.",211 Warren Street,,Newark,New Jersey,' 07103 ' ,United States,343711,,,
3845,Iobenguane I 123,Adreview,12/1/2006,for the diagnosis of neuroblastomas,Designated/Approved,,,To be used in the detection of primary or metastatic pheochromocytomas or neuroblastomas as an adjunct to other diagnostic tests,9/19/2008,9/19/2015,,"GE Healthcare, Inc.",101 Carnegie Center,,Princeton,New Jersey,' 08540 ' ,United States,226406,neuroblastoma,"""gard:0007185""",
3846,Iobenguane I 123,AdreView,12/1/2006,for the diagnosis of pheochromocytomas,Designated/Approved,,,To be used in the detection of primary or metastatic pheochromocytomas or neuroblastomas as an adjunct to other diagnostic tests,9/19/2008,9/19/2015,,"GE Healthcare, Inc.",101 Carnegie Center,,Princeton,New Jersey,' 08540 ' ,United States,226506,pheochromocytoma,"""gard:0015105""",
3847,Iobenguane I 131,Azedra Ultratrace,1/18/2006,treatment of neuroendocrine tumors,Designated/Approved,,,"AZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.",7/30/2018,7/30/2025,"AZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.","Progenics Pharmaceuticals, Inc.",One World Trade Center.,"47th Floor, Suite J",New York,New York,' 10007 ' ,United States,216205,,,
3848,iobenguane I 131,,7/5/2007,treatment of neuroendocrine tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jubilant DraxImage, Inc.","Div. of Draxis Specialty Pharmaceuticals, Inc.",,Kirkland,,' ' ,Canada,241907,,,
3849,Iobenguane Sulfate I 131,,11/14/1984,for use as a diagnostic adjunct in patients with pheochromocytoma.,Designated/Approved/Designation Withdrawn or Revoked,,,Adjunctive diagnostic agent in the localization of primary or metastatic pheochromocytomas.,3/25/1994,3/25/2001,,University of Michigan,UH B1 H410/0028,1500 E. Medical Center Drive,Ann Arbor,Michigan,' 48109 ' ,United States,2284,pheochromocytoma,"""gard:0015105""",
3850,iobenguane sulfate I-123,,10/21/2005,"for the detection, localization, and staging of pheochromocytomas.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Brogan Pharmaceuticals, Inc.",9800 Connecticut Drive,c/o Purdue Technology Center,Crown Point,Indiana,' 46307 ' ,United States,208305,pheochromocytoma,"""gard:0015105""",
3851,Iobenguane Sulfate I-123,,10/17/2005,"for scintigraphic detection, localization and staging of neuroblastoma.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Brogan Pharmaceuticals, LLC",312 Lacebark Street,,Schererville,Indiana,' 46375 ' ,United States,208405,neuroblastoma,"""gard:0007185""",
3852,Iodine (I-124) evuzamitide,,7/26/2022,diagnostic for the management of transthyretin amyloidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Attralus, Inc.",50 Francisco Street,Suite 450,San Francisco,California,' 94133 ' ,United States,891522,amyloidosis,"""gard:0018676""",
3853,Iodine (I124) evuzamitide,,11/14/2022,diagnostic for the management of immunoglobulin light chain amyloidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Attralus, Inc.",50 Francisco Street,Suite 450,San Francisco,California,' 94133 ' ,United States,888422,amyloidosis,"""gard:0018676""",
3854,Iodine 131 6B-iodomethyl-19-norcholesterol,,8/1/1984,for use in adrenal cortical imaging.,Designated,,Not FDA Approved for Orphan Indication,,,,,"David E. Kuhl, M.D.",University of Michigan Medical Center/1500 E. Med.,B1G412 /0028 University Hospital,Ann Arbor,Michigan,' 48109 ' ,United States,2184,,,
3855,Iodine I 123 murine monoclonal antibody to alpha-fetoprotein,,9/30/1988,1. detection of hepatocellular carcinoma and hepatoblastoma 2. detection of alpha-fetoprotein producing germ cell tumors,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,25487,germ cell tumor,"""gard:0018797""",
3856,Iodine I 123 murine monoclonal antibody to hCG,,11/7/1988,detection of hcg producing tumors such as germ cell and trophoblastic cell tumors.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,25087,,,
3857,Iodine I 131 bis(indium-diethylenetriaminepentaacetic acid)tyrosyllysine/hMN-14 x m734 F(ab')2 bispecific monoclonal antibody,,2/22/2000,treatment of small-cell lung cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"IBC Pharmaceuticals, L.L.C.",300 American Rd.,,Morris Plains,New Jersey,' 07950 ' ,United States,132400,,,
3858,Iodine I 131 Lym-1 Monoclonal Antibody,,11/2/1987,treatment of b-cell lymphoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Lederle Laboratories Division,American Cyanamide Company,401 N. Middletown Road,Pearl River,New York,' 10965 ' ,United States,21887,lymphoma,"""gard:0020548""",
3859,Iodine I 131 murine monoclonal antibody IgG2a to B cell,,9/18/1989,treatment of b-cell leukemia and b-cell lymphoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,38289,lymphoma,"""gard:0020548""",
3860,Iodine I 131 murine monoclonal antibody to alpha-fetoprotein,,9/30/1988,1. treatment of hepatocellular carcinoma and hepatoblastoma 2. treatment of alpha-fetoprotein producing germ cell tumors,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,25687,germ cell tumor,"""gard:0018797""",
3861,Iodine I 131 murine monoclonal antibody to hCG,,11/7/1988,treatment of hcg producing tumors such as germ cell and trophoblastic cell tumors.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,25587,,,
3862,Iodine I-131 radiolabeled chimeric MAb tumor necrosis treatment (TNT-1B),,2/12/1999,treatment of glioblastoma multiforme and anaplastic astrocytoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Peregrine Pharmaceuticals, Inc.",14282 Franklin Ave.,,Tustin,California,' 92780 ' ,United States,119098,astrocytoma,"""gard:0012928""",
3863,Ipatasertib,,4/30/2014,for the treatment of gastric cancer including cancer of the gastro-esophageal junction.,Designated/Designation Withdrawn or Revoked,3/30/2016,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,429714,,,
3864,ipilimumab,Yervoy,10/9/2014,treatment of stage iib to stage iv melanoma,Designated/Approved,,,"as a single agent or in combination with nivolumab, for the treatment of unresectable or metastatic melanoma in adult and pediatric patients 12 years and older",2/15/2023,,,Bristol-Myers Squibb Company,5 Research Parkway,,Wallingford,Connecticut,' 06492 ' ,United States,445014,noma,"""gard:0004001""",
3865,ipilimumab,Yervoy,6/3/2004,"treatment of high risk stage ii, stage iii, and stage iv melanoma",Designated/Approved,,,treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older),7/21/2017,7/21/2024,treatment of unresectable or metastatic melanoma in pediatric patients (12 years and older).,Bristol-Myers Squibb Company,P.O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,177703,noma,"""gard:0004001""",
3866,ipilimumab,Yervoy,6/3/2004,"treatment of high risk stage ii, stage iii, and stage iv melanoma",Designated/Approved,,,"In combination with nivolumab, for the treatment of unresectable or metastatic melanoma in adult patients",5/25/2021,,,Bristol-Myers Squibb Company,P.O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,177703,noma,"""gard:0004001""",
3867,ipilimumab,Yervoy,6/3/2004,"treatment of high risk stage ii, stage iii, and stage iv melanoma",Designated/Approved,,,Treatment of unresectable or metastatic melanoma,3/25/2011,3/25/2018,,Bristol-Myers Squibb Company,P.O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,177703,noma,"""gard:0004001""",
3868,ipilimumab,Yervoy,6/3/2004,"treatment of high risk stage ii, stage iii, and stage iv melanoma",Designated/Approved,,,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.",10/28/2015,10/28/2022,"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy.",Bristol-Myers Squibb Company,P.O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,177703,noma,"""gard:0004001""",
3869,ipilimumab,,11/7/2018,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,P.O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,657418,small cell lung cancer,"""gard:0009344""",
3870,iptacopan,Fabhalta,7/31/2020,treatment of paroxysmal nocturnal hemoglobinuria,Designated/Approved,,,Treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH),12/5/2023,12/5/2030,Treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH),Novartis Pharmaceuticals Corporation,One Health Plaza,Bldg. 315/5150A,East Hanover,New Jersey,' 07936 ' ,United States,751920,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
3871,irinotecan liposome injection,Onivyde,7/21/2011,treatment of pancreatic cancer,Designated/Approved,,,"in combination with oxaliplatin, fluorouracil and leucovorin for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma",2/13/2024,2/13/2031,first-line treatment of adult patients with metastatic pancreatic adenocarcinoma,"Ipsen Biopharmaceuticals, Inc.",One Main Street,,Cambridge,Massachusetts,' 02142 ' ,United States,344311,,,
3872,irinotecan liposome injection,,5/24/2017,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ipsen Bioscience, Inc.",650 East Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,567516,small cell lung cancer,"""gard:0009344""",
3873,irinotecan liposome injection,,7/21/2011,treatment of pancreatic cancer,Designated/Approved,,,"For use in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas that has progressed following gemcitabine-based therapy",10/22/2015,10/22/2022,"For use in combination with 5-fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas that has progressed following gemcitabine-based therapy","Ipsen Biopharmaceuticals, Inc.",One Main Street,,Cambridge,Massachusetts,' 02142 ' ,United States,344311,,,
3874,irofulven,,7/27/1999,treatment of renal cell carcinoma.,Designated/Designation Withdrawn or Revoked,5/12/2014,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.",300 Tice Blvd,,Woodcliff Lake,New Jersey,' 07677 ' ,United States,125399,renal cell carcinoma,"""gard:0013215""",
3875,irofulven,,7/6/1999,treatment of ovarian cancer.,Designated/Designation Withdrawn or Revoked,5/12/2014,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.",300 Tice Blvd,,Woodcliff Lake,New Jersey,' 07677 ' ,United States,124399,ovarian cancer,"""gard:0007295""",
3876,iron(III)-hexacyanoferrate(II),Radiogardase,5/1/2003,treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium,Designated/Approved,,,Treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination,10/2/2003,10/2/2010,,"Heyl Chemisch-Pharmzeutische Fabrik GMBH & Co, KG",Goerzallee 253,D-14167,Berlin,,' ' ,Germany,169203,,,
3877,isatuximab-irfc,Sarclisa,5/22/2014,treatment of multiple myeloma,Designated/Approved,,,"SARCLISA is indicated, in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.",3/2/2020,3/2/2027,"Indicated in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.","Sanofi U.S. Services, Inc.",50 Binney St.,,Cambridge,Massachusetts,' 02142 ' ,United States,431914,multiple myeloma,"""gard:0007108""",
3878,isatuximab-irfc,Sarclisa,5/22/2014,treatment of multiple myeloma,Designated/Approved,,,"in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy",3/31/2021,3/31/2028,"treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 prior line of therapy, and for treatment of adult patients with relapsed or refractory multiple myeloma who have received 2 to 3 prior therapies excluding patients covered by the indication approved on March 2, 2020","Sanofi U.S. Services, Inc.",50 Binney St.,,Cambridge,Massachusetts,' 02142 ' ,United States,431914,multiple myeloma,"""gard:0007108""",
3879,isavuconazonium sulfate,Cresemba,5/6/2013,treatment of invasive aspergillosis,Designated/Approved,,,Treatment of invasive aspergillosis in patients 18 years of age and older,3/6/2015,3/6/2022,Treatment of invasive aspergillosis in patients 18 years of age and older,Astellas Pharma Global Development Inc.,1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,394913,aspergillosis,"""gard:0005856""",
3880,isavuconazonium sulfate,Cresemba,10/25/2013,treatment of zygomycosis,Designated/Approved,,,Treatment of invasive mucormycosis in patients 18 years of age and older,3/6/2015,3/6/2022,Treatment of invasive mucormycosis in patients 18 years of age and older,Astellas Pharma Global Development Inc.,1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,395013,zygomycosis,"""gard:0010224""",
3881,isavuconazonium sulfate,,10/20/2014,treatment of invasive candidiasis/candidemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,447814,,,
3882,isavuconazonium sulfate,Cresemba,10/25/2013,treatment of zygomycosis,Designated/Approved,,,treatment of invasive mucormycosis in adults and pediatric patients 1 year of age and older,12/8/2023,12/8/2030,treatment of invasive mucormycosis in pediatric patients 1 year of age and older,Astellas Pharma Global Development Inc.,1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,395013,zygomycosis,"""gard:0010224""",
3883,isavuconazonium sulfate,Cresemba,5/6/2013,treatment of invasive aspergillosis,Designated/Approved,,,treatment of invasive aspergillosis in adults and pediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater,12/8/2023,12/8/2030,treatment of invasive aspergillosis in pediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater,Astellas Pharma Global Development Inc.,1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,394913,aspergillosis,"""gard:0005856""",
3884,isavuconazonium sulfate,Cresemba,5/6/2013,treatment of invasive aspergillosis,Designated/Approved,,,treatment of invasive aspergillosis in adults and pediatric patients 1 year of age and older,12/8/2023,12/8/2030,treatment of invasive aspergillosis in pediatric patients 1 year of age and older,Astellas Pharma Global Development Inc.,1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,394913,aspergillosis,"""gard:0005856""",
3885,isavuconazonium sulfate,Cresemba,10/25/2013,treatment of zygomycosis,Designated/Approved,,,treatment of invasive mucormycosis in adults and pediatric patients 6 years of age and older who weigh 16 kg and greater,12/8/2023,12/8/2030,treatment of invasive mucormycosis in pediatric patients 6 years of age and older who weigh 16 kg and greater,Astellas Pharma Global Development Inc.,1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,395013,zygomycosis,"""gard:0010224""",
3886,Isobutyramide,,12/18/1992,treatment of beta-hemoglobinopathies and beta-thalassemia syndromes.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Perrine, Susan P., M.D.",Boston University,Cancer Research Center,Boston,Massachusetts,' 02118 ' ,United States,71792,beta-thalassemia,"""gard:0000871""",
3887,Isobutyramide,,5/25/1994,treatment of sickle cell disease and beta thalassemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,Alpha Therapeutic Corporation,5555 Valley Boulevard,,Los Angeles,California,' 90032 ' ,United States,82494,,,
3888,isofagomine tartrate,,1/10/2006,treatment of gaucher disease,Designated/Designation Withdrawn or Revoked,7/23/2018,Not FDA Approved for Orphan Indication,,,,,"Amicus Therapeutics, Inc.",1 Cedarbrook Drive,,Cranbury,New Jersey,' 08512 ' ,United States,215605,gaucher disease,"""gard:0008233""",
3889,"Isoindolin-1,3-Di Thione",,11/21/2016,treatment of frontotemporal dementia,Designated,,Not FDA Approved for Orphan Indication,,,,,"P2D, Inc.",10101 Alliance Road,Suite 105,Cincinnati,Ohio,' 45242 ' ,United States,542616,frontotemporal dementia,"""gard:0008436""",
3890,isotretinoin,,4/10/2014,treatment of congenital ichthyosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Timber Pharmaceuticals,50 Tice Blvd,Suite A35,Woodcliff Lake,New Jersey,' 07677 ' ,United States,424614,ichthyosis,"""gard:0018985""",
3891,Istiratumab,,10/22/2014,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Merrimack Pharmaceuticals, Inc.",One Kendall Square,Suite B7201,Cambridge,Massachusetts,' 02139 ' ,United States,450314,,,
3892,itacitinib,,4/17/2017,treatment of graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,562716,graft versus host disease,"""gard:0016642""",
3893,itolizumab,,2/5/2019,prevention of acute graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Equillium, Inc.",2223 Avenida De La Playa,Suite 108,San Diego,California,' 92037 ' ,United States,676618,graft versus host disease,"""gard:0016642""",
3894,itolizumab,,2/1/2019,treatment of acute graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Equillium, Inc.",2223 Avenida De La Playa,Suite 108,San Diego,California,' 92037 ' ,United States,646718,graft versus host disease,"""gard:0016642""",
3895,itraconazole,,11/17/2020,treatment of coccidioidomycosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Mayne Pharma International Pty Ltd. c/o Mayne Pharma Inc.,1240 Sugg Parkway,,Greenville,North Carolina,' 27834 ' ,United States,781320,coccidioidomycosis,"""gard:0009525""",
3896,Itraconazole,,5/19/2016,treatment of basal cell carcinoma nevus syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,Mayne Pharma LLC,1240 Sugg Parkway,,Greenville,North Carolina,' 27834 ' ,United States,473715,noma,"""gard:0004001""",
3897,itraconazole inhalation powder,,8/16/2016,treatment of pulmonary fungal infections in patients with cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pulmatrix, Inc",99 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,509515,cystic fibrosis,"""gard:0006233""",
3898,Itraconazole suspension,,10/30/2008,topical treatment of fungal otitis externa (otomycosis),Designated,,Not FDA Approved for Orphan Indication,,,,,"Fairfield Clinical Trials, LLC",200 Steep Hill Road,,Weston,Connecticut,' 06883 ' ,United States,257308,,,
3899,ivabradine,CORLANOR,3/23/2016,treatment of pediatric patients (0 through 16 years of age) with dilated cardiomyopathy.,Designated/Approved,,,"Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.",4/22/2019,4/22/2026,"Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate.","Amgen, Inc.,",1 Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,' 91320 ' ,United States,511915,dilated cardiomyopathy,"""gard:0000221""",
3900,ivabradine,,7/9/2018,treatment of post-cardiac transplant heart dysfunction,Designated/Designation Withdrawn or Revoked,7/22/2019,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.,",1 Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,' 91320 ' ,United States,631818,,,
3901,ivacaftor,Kalydeco,12/20/2006,treatment of patients with cystic fibrosis,Designated/Approved,,,"Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R; and treatment of CF in patients age 6 years and older who have an R117H mutation in the CFTR gene.",12/29/2014,12/29/2021,Treatment of cystic fibrosis (CF) in patients age 6 years and older who have an R117H mutation in the CFTR gene.,"Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,228306,cystic fibrosis,"""gard:0006233""",
3902,ivacaftor,Kalydeco,12/20/2006,treatment of patients with cystic fibrosis,Designated/Approved,,,"Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.",2/21/2014,2/21/2021,"Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.","Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,228306,cystic fibrosis,"""gard:0006233""",
3903,ivacaftor,Kalydeco,12/20/2006,treatment of patients with cystic fibrosis,Designated/Approved,,,"Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R ; and treatment of CF in patients age 2 years and older who have an R117H mutation in the CFTR gene.",3/17/2015,3/17/2022,"Treatment of cystic fibrosis (CF) in patients ages 2 to less than 6 years who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, and R117H.","Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,228306,cystic fibrosis,"""gard:0006233""",
3904,ivacaftor,Kalydeco,12/20/2006,treatment of patients with cystic fibrosis,Designated/Approved,,,Treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene.,1/31/2012,1/31/2019,,"Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,228306,cystic fibrosis,"""gard:0006233""",
3905,ivacaftor,Kalydeco,12/20/2006,treatment of patients with cystic fibrosis,Designated/Approved,,,Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.,5/17/2017,5/17/2024,"Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, and D1270N.","Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,228306,cystic fibrosis,"""gard:0006233""",
3906,ivacaftor,Kalydeco,12/20/2006,treatment of patients with cystic fibrosis,Designated/Approved,,,treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,12/21/2020,12/21/2027,"treatment of cystic fibrosis (CF) in patients age 4 months and older who have one of the additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that have been identified as responsive to ivacaftor potentiation based on in vitro data and identified in the approval on December 21, 2020.","Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,228306,cystic fibrosis,"""gard:0006233""",
3907,ivacaftor,Kalydeco,12/20/2006,treatment of patients with cystic fibrosis,Designated/Approved,,,KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,9/24/2020,9/24/2027,treatment of cystic fibrosis (CF) in patients age 4 months to less than 6 months who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,"Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,228306,cystic fibrosis,"""gard:0006233""",
3908,ivacaftor,Kalydeco,12/20/2006,treatment of patients with cystic fibrosis,Designated/Approved,,,treatment of cystic fibrosis (CF) in patients age 1 month and older who have at least one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,5/3/2023,5/3/2030,treatment of cystic fibrosis (CF) in patients 1 month to less than 4 months of age who have at least one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,"Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,228306,cystic fibrosis,"""gard:0006233""",
3909,ivacaftor,Kalydeco,12/20/2006,treatment of patients with cystic fibrosis,Designated/Approved,,,Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.,7/31/2017,7/31/2024,"Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: 711+3A G, E831X, 2789+5G A, 3272-26A G, and 3849+10kbC T.","Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,228306,cystic fibrosis,"""gard:0006233""",
3910,ivacaftor,Kalydeco,12/20/2006,treatment of patients with cystic fibrosis,Designated/Approved,,,Treatment of cystic fibrosis (CF) in patients age 12 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.,8/15/2018,8/15/2025,For the treatment of cystic fibrosis (CF) in patients age 12 months to less than 2 years who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,"Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,228306,cystic fibrosis,"""gard:0006233""",
3911,ivacaftor,Kalydeco,12/20/2006,treatment of patients with cystic fibrosis,Designated/Approved,,,KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,4/29/2019,4/29/2026,For the treatment of cystic fibrosis (CF) in patients age 6 months to less than 12 months who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data,"Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,228306,cystic fibrosis,"""gard:0006233""",
3912,Ivaltinostat,,1/3/2023,treatment of idiopathic pulmonary fibrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Machaon Biotherapeutics, Inc.","70 Osongsaengmyeong 6-ro,","Osong-eup, Heungdeok-gu,",Cheongju-si,Chungcheongbuk-do,' 28158 ' ,South Korea,919022,idiopathic pulmonary fibrosis,"""gard:0008609""",
3913,Ivaltinostat,,1/8/2021,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"CG Pharmaceuticals, Inc.","100-D, Bldg. D, Pine Grove Business Center",4 Orinda Way,Orinda,California,' 94563 ' ,United States,793520,acute myeloid leukemia,"""gard:0012757""",
3914,Ivaltinostat,,8/21/2020,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"CG Pharmaceuticals, Inc.","100-D, Bldg. D, Pine Grove Business Center",4 Orinda Way,Orinda,California,' 94563 ' ,United States,760420,hepatocellular carcinoma,"""gard:0016773""",
3915,Ivaltinostat,,11/4/2021,treatment of alport syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Machaon Biotherapeutics, Inc.",70 Osongsaengmyeong 6-ro,,Cheongju-si,Chungcheongbuk-do,' 28158 ' ,South Korea,846121,alport syndrome,"""gard:0005785""",
3916,ivosidenib,Tibsovo,6/9/2015,treatment of acute myeloid leukemia (aml),Designated/Approved,,,"In combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy",5/25/2022,,,Servier Pharmaceuticals LLC,200 Pier Four Blvd,,Boston,Massachusetts,' 02210 ' ,United States,481515,acute myeloid leukemia,"""gard:0012757""",
3917,ivosidenib,Tibsovo,4/26/2017,treatment of cholangiocarcinoma,Designated/Approved,,,"Treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test",8/25/2021,8/25/2028,"Treatment of adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test",Servier Pharmaceuticals LLC,200 Pier Four Blvd,,Boston,Massachusetts,' 02210 ' ,United States,562216,cholangiocarcinoma,"""gard:0009304""",
3918,ivosidenib,,5/1/2018,treatment of glioma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Servier Pharmaceuticals LLC,200 Pier Four Blvd,,Boston,Massachusetts,' 02210 ' ,United States,637718,,,
3919,ivosidenib,,5/17/2023,treatment of chondrosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Servier Pharmaceuticals,200 Pier 4 Blvd,,Boston,Massachusetts,' 02210 ' ,United States,938423,chondrosarcoma,"""gard:0006055""",
3920,ivosidenib,TIBSOVO,6/9/2015,treatment of acute myeloid leukemia (aml),Designated/Approved,,,TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.,7/20/2018,7/20/2025,Indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test,Servier Pharmaceuticals LLC,200 Pier Four Blvd,,Boston,Massachusetts,' 02210 ' ,United States,481515,acute myeloid leukemia,"""gard:0012757""",
3921,ivosidenib,Tibsovo,5/20/2020,treatment of myelodysplastic syndromes,Designated/Approved,,,Treatment of adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test,10/24/2023,10/24/2030,Treatment of adult patients with relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test,Servier Pharmaceuticals LLC,200 Pier Four Blvd,,Boston,Massachusetts,' 02210 ' ,United States,739720,myelodysplastic syndrome,"""gard:0007132""",
3922,ivosidenib,TIBSOVO,6/9/2015,treatment of acute myeloid leukemia (aml),Designated/Approved,,,TIBSOVO is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.,5/2/2019,5/2/2026,TIBSOVO is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.,Servier Pharmaceuticals LLC,200 Pier Four Blvd,,Boston,Massachusetts,' 02210 ' ,United States,481515,acute myeloid leukemia,"""gard:0012757""",
3923,ivospemin,,8/7/2014,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Panbela Therapeutics, Inc.",712 Vista Blvd,Suite 305,Waconia,Minnesota,' 55387 ' ,United States,441214,,,
3924,ixazomib citrate,Ninlaro,2/18/2011,treatment of multiple myeloma,Designated/Approved,,,Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy,11/20/2015,11/20/2022,Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,330510,multiple myeloma,"""gard:0007108""",
3925,ixmyelocel-T,,1/25/2007,treatment of dilated cardiomyopathy,Designated/Designation Withdrawn or Revoked,12/17/2021,Not FDA Approved for Orphan Indication,,,,,Vericel Corporation,64 Sidney Street,,Cambridge,Massachusetts,' 02139 ' ,United States,232606,dilated cardiomyopathy,"""gard:0000221""",
3926,Izaflortaucipir (proposed INN),,4/12/2021,diagnosis of corticobasal degeneration,Designated,,Not FDA Approved for Orphan Indication,,,,,Life Molecular Imaging Ltd.,25 Barnes Wallis Road,,Fareham,Hampshire,' PO15 5TT ' ,United Kingdom,763320,,,
3927,izaflortaucipir (proposed INN),,1/5/2021,1) in the initial diagnosis of progressive supranuclear palsy (psp) and 2) diagnostic in the clinical management of psp.,Designated,,Not FDA Approved for Orphan Indication,,,,,Life Molecular Imaging Ltd.,25 Barnes Wallis Road,,Fareham,Hampshire,' PO15 5TT ' ,United Kingdom,755520,progressive supranuclear palsy,"""gard:0007471""",
3928,Jaktinib,,12/14/2020,treatment of myelofibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Suzhou Zelgen Biopharmaceuticals Co., Ltd.","No. 209, Chenfeng Road",Kunshan,Suzhou,Jiangsu Province,' 215300 ' ,China,786020,,,
3929,"Japanese encephalitis vaccine (live, attenuated)",,5/19/1999,prevention of japanese encephalitis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Glovax Co., Ltd.","Room 307, Koryo Academytel, 437-3","Ahyun-Dong, Mapo-Gu,",Seoul 121-010,,' ' ,South Korea,120998,encephalitis,"""gard:0019357""",
3930,"Japanese encephalitis vaccine, inactivated, adsorbed",IXIARO,9/25/2012,prevention of japanese encephalitis virus in pediatric patients.,Designated/Approved,,,IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus (JEV). IXIARO is approved for use in individuals 2 months of age and older.,5/17/2013,5/17/2020,"To extend the age range to include infants, children, and adolescents 2 months to less than 17 years of age for active immunization for the prevention of disease caused by Japanese encephalitis virus.",Intercell AG,Campus Vienna Biocenter 3,A-1030,Vienna,,' ' ,Austria,376112,encephalitis,"""gard:0019357""",
3931,Kallikrein 7 and elastase 2 inhibitor,,6/25/2019,treatment of netherton syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"LifeMax Laboratories, Inc.","1731 Embarcadero Road, Suite 200",,Palo Alto,California,' 94303 ' ,United States,695519,netherton syndrome,"""gard:0007182""",
3932,ketamine,,5/10/2021,treatment of complex regional pain syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,iX Biopharma Ltd.,1 Kim Seng Promenade #14-01,Great World City East Tower,Singapore,,' 237994 ' ,Singapore,812221,complex regional pain syndrome,"""gard:0004647""",
3933,ketamine,,8/3/2021,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,PharmaTher Inc.,82 Richmond Street East,,Toronto,Ontario,' ' ,Canada,829921,amyotrophic lateral sclerosis,"""gard:0005786""",
3934,Ketamine,,6/6/2022,treatment of complex regional pain syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vitalis Analgesics, LLC",93 4th Avenue #19,,New York,New York,' 10003 ' ,United States,883122,complex regional pain syndrome,"""gard:0004647""",
3935,Ketamine,,2/1/2023,treatment of rett syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,PharmaTher Inc.,82 Richmond Street East,,Toronto,Ontario,' M5C 1P1 ' ,Canada,922622,rett syndrome,"""gard:0005696""",
3936,Ketamine,,10/12/2021,treatment of complex regional pain syndrome (crps),Designated,,Not FDA Approved for Orphan Indication,,,,,PharmaTher Inc.,82 Richmond Street East,,Toronto,Ontario,' ' ,Canada,840821,complex regional pain syndrome,"""gard:0004647""",
3937,ketamine,,2/1/2019,treatment of complex regional pain syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Bexson Biomedical, Inc.",856 Chelham Way,,Santa Barbara,California,' 93108 ' ,United States,669318,complex regional pain syndrome,"""gard:0004647""",
3938,Ketamine Hydrochloride,,1/31/2022,treatment of status epilepticus,Designated,,Not FDA Approved for Orphan Indication,,,,,PharmaTher Inc.,82 Richmond Street East,,Toronto,Ontario,' ' ,Canada,860021,,,
3939,ketamine hydrochloride,,12/14/2022,prevention of ischemia/reperfusion injury during solid organ transplantation.,Designated,,Not FDA Approved for Orphan Indication,,,,,PharmaTher Inc.,82 Richmond Street East,,Toronto,Ontario,' ' ,Canada,901422,,,
3940,Ketoconazole,,3/27/1991,for use with cyclosporine a to diminish the nephrotoxicity induced by cyclosporine in organ transplantation.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Pharmedic Company,28101 Ballard Road,,Lake Forest,Illinois,' 60045 ' ,United States,51990,,,
3941,ketotifen,,2/25/2015,treatment of mastocytosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Valcrest Pharmaceuticals, LLC",520 White Plains Road,Suite 500,Tarrytown,New York,' 10591 ' ,United States,464714,mastocytosis,"""gard:0006987""",
3942,KIT and PDGFR inhibitor,,8/7/2017,treatment of glioblastoma multiforme and anaplastic astrocytomas,Designated/Designation Withdrawn or Revoked,10/7/2020,Not FDA Approved for Orphan Indication,,,,,"Deciphera Pharmaceuticals, LLC",200 Smith Street,,Waltham,Massachusetts,' 02451 ' ,United States,597617,astrocytoma,"""gard:0012928""",
3943,Kre-Celazine,,4/1/2013,treatment of juvenile rheumatoid arthritis joint and related tissue inflammation in the pediatric population,Designated,,Not FDA Approved for Orphan Indication,,,,,All American Pharmaceutical & Natural Foods Corpor,2376 Main Street,,Billings,Montana,' 59105 ' ,United States,298309,,,
3944,L-2-oxothiazolidine-4-carboxylic acid,,6/14/1994,treatment of adult respiratory distress syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Transcend Therapeutics, Inc.","640 Memorial Drive, 3rd Floor West",,Cambridge,Massachusetts,' 02139 ' ,United States,81994,,,
3945,L-2-oxothiazolidine-4-carboxylic acid,,7/30/1996,treatment of amyotrophic lateral sclerosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Transcend Therapeutics, Inc.","640 Memorial Drive, 3rd Floor West",,Cambridge,Massachusetts,' 02139 ' ,United States,99296,amyotrophic lateral sclerosis,"""gard:0005786""",
3946,"L-3,4-Dihydroxy-6-[18F]fluorophenylalanine",,5/31/2017,diagnostic agent for the management of patients with aromatic l-amino acid decarboxylase deficiency (aadc).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,' 33467 ' ,United States,567816,aromatic l-amino acid decarboxylase deficiency,"""gard:0000770""",
3947,L-5 Hydroxytrytophan,,11/1/1984,treatment of postanoxic intention myoclonus.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Watson Laboratories, Inc.",33 Ralph Avenue,P.O. Box 30,Copiaque,New York,' 11726 ' ,United States,3984,,,
3948,L-5-hydroxytryptophan,,1/20/1999,treatment of tetrahydrobiopterin deficiency.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Watson Laboratories, Inc.",311 Bonnie Circle,P.O. Box 1900,Corona,California,' 91718 ' ,United States,118298,,,
3949,L-alanoyl-D-glutamate endopeptidase from Bacillus-infected bacteriophages,,6/21/2018,treatment of inhalational anthrax,Designated,,Not FDA Approved for Orphan Indication,,,,,"iNtRON Biotechnology, Inc.","137 Sagimakgol-ro, Seongnam-si",,,Gyeonggi-do,' ' ,South Korea,642118,inhalational anthrax,"""gard:0020657""",
3950,"L-amino acids, vitamins and minerals combined with omega-3 fatty acids",,1/12/2011,treatment of patients with pediatric crohn's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immunopath Profile, Inc.",325 Dunes Blvd - Suite 403 (zip code 34110),,Naples,Florida,' 34110 ' ,United States,285809,,,
3951,L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal,,1/18/2006,treatment of duchenne and becker muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,CepTor Corporation,200 International Circle,,Hunt Valley,Maryland,' 21030 ' ,United States,214405,duchenne and becker muscular dystrophy,"""gard:0018686""",
3952,l-arginine,,5/8/2024,treatment of sickle cell disease and its complications including pain; acute chest syndrome; vasculopathy; pulmonary hypertension; mitochondrial dysfunction; oxidative stress; leg ulcers; priapism; consequences of arginine deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Emory University,1760 Haygood Drive,,Atlanta,Georgia,' 30322 ' ,United States,984823,,,
3953,L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alanine-amide,,9/11/2013,treatment of acute radiation syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.",29 Emmons Drive,Suite B-10,Princeton,New Jersey,' 08540 ' ,United States,395913,acute radiation syndrome,"""gard:0021896""",
3954,L-asparaginase,,3/27/2014,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,ERYTECH Pharma S.A.,Batiment Adenine,"60, avenue Rockefeller",Lyon,,' ' ,France,424114,acute myeloid leukemia,"""gard:0012757""",
3955,L-asparaginase encapsulated in red blood cells,,1/6/2010,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Erytech Pharma,Batiment Adenine,"60, Avenue Rockfeller",LYON,,' ' ,France,239807,acute lymphoblastic leukemia,"""gard:0000522""",
3956,L-asparaginase encapsulated in red blood cells,,7/6/2012,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,ERYTECH Pharma,Batiment Adenine,60 Avenue Rockefeller,lyon,,' ' ,France,370712,,,
3957,L-baclofen,,7/13/1990,treatment of trigeminal neuralgia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Fromm, Gerhard M.D.",University Of Pittsburgh School of Medicine,,Pittsburgh,Pennsylvania,' 15261 ' ,United States,45690,trigeminal neuralgia,"""gard:0007805""",
3958,L-baclofen,,12/17/1991,treatment of spasticity associated with spinal cord injury or multiple sclerosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Osmotica Pharmaceutical Corp.,1205 Culbreth Dr.,Suite 200,Wilmington,North Carolina,' 28405 ' ,United States,57391,spinal cord injury,"""gard:0019109""",
3959,L-baclofen,,1/6/1998,treatment of trigeminal neuralgia,Designated,,Not FDA Approved for Orphan Indication,,,,,Osmotica Pharmaceutical Corp.,1205 Culbreth Dr.,Suite 200,Wilmington,North Carolina,' 28405 ' ,United States,109397,trigeminal neuralgia,"""gard:0007805""",
3960,L-baclofen,,1/30/1992,treatment of intractable spasticity in children with cerebral palsy.,Designated,,Not FDA Approved for Orphan Indication,,,,,Osmotica Pharmaceutical Corp.,1205 Culbreth Drive,Suite 200,Wilmington,North Carolina,' 28405 ' ,United States,65592,,,
3961,L-Citrulline,,11/3/2020,treatment of ornithine transcarbamylase deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Orpha Labs, AG",Haldenstrasse 5,,Baar,,' CH-6340 ' ,Switzerland,779420,ornithine transcarbamylase deficiency,"""gard:0008391""",
3962,L-citrulline,,1/9/2017,prevention of clinical sequelae of acute lung injury induced by cardiopulmonary bypass in pediatric patients,Designated,,Not FDA Approved for Orphan Indication,,,,,"Asklepion Pharmaceuticals, LLC",729 East Pratt Street,Suite 360,Baltimore,Maryland,' 21202 ' ,United States,544216,acute lung injury,"""gard:0020146""",
3963,L-citrulline,,10/7/2020,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Asklepion Pharmaceuticals, LLC",729 E. Pratt Street,Suite 360,Baltimore,Maryland,' 21202 ' ,United States,769820,,,
3964,L-cycloserine,,8/1/1989,treatment of gaucher's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Lev, Meir M.D.","The City College, City University Of NY Medical Sc",Convent Avenue at 138 Street,New York,New York,' 10031 ' ,United States,38489,,,
3965,L-cysteine,,5/16/1994,for the prevention and lessening of photosensitivity in erythropoietic protoporphyria.,Designated,,Not FDA Approved for Orphan Indication,,,,,Brigham and Women's Hospital,Channing Laboratory,181 Longwood Ave.,Boston,Massachusetts,' 02115 ' ,United States,79693,porphyria,"""gard:0010353""",
3966,L-cystine bis(N'-methylpiperazide),,6/4/2018,treatment of cystinuria.,Designated,,Not FDA Approved for Orphan Indication,,,,,PharmaKrysto Ltd,Rmt Accountants & Business Advisors Ltd.,Gosforth Park Avenue,,England,' ' ,United Kingdom,639418,cystinuria,"""gard:0006237""",
3967,L-Ergothioneine,,12/28/2022,treatment of cystinuria,Designated,,Not FDA Approved for Orphan Indication,,,,,AVEROA SAS,11 Avenue Paul Verlaine,,Grenoble,Dauphine,' 38100 ' ,France,918722,cystinuria,"""gard:0006237""",
3968,L-fucose,,1/14/2019,treatment of congenital disorder of glycosylation iic,Designated,,Not FDA Approved for Orphan Indication,,,,,"AUG Therapeutics, LLC",1 Broadway,,Cambridge,Massachusetts,' 02142 ' ,United States,667018,congenital disorder of glycosylation,"""gard:0010307""",
3969,L-fucose,,6/8/2020,treatment of leukocyte adhesion deficiency type- ii,Designated,,Not FDA Approved for Orphan Indication,,,,,"Orpha Labs, AG",Haldenstrasse 5,,Baar,Zug,' ' ,Switzerland,753120,leukocyte adhesion deficiency,"""gard:0016616""",
3970,L-glutamine,Endari,8/1/2001,treatment of sickle cell disease,Designated/Approved,,,To reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.,7/7/2017,7/7/2024,To reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.,"Emmaus Medical, Inc.","21250 Hawthorne Blvd., Suite 800",,Torrance,California,' 90503 ' ,United States,145901,,,
3971,L-glutamyl-L-tryptophan,,10/20/1999,treatment of aids-related kaposi's sarcoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Implicit Bioscience Pty Ltd,P. O. Box 2072.,Toowong Business Center,,,' ' ,Australia,126799,,,
3972,"L-Leucyl-L-prolyl-L-prolyl-L-leucyl-L-prolyl-L-tyrosyl-L-proline, acetate salt",,6/19/2019,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immunity Pharma, Ltd.","6 Rabbi Binyamin st,",,Jerusalem,,' ' ,Israel,689819,amyotrophic lateral sclerosis,"""gard:0005786""",
3973,"L-Lysinamide,N2,N6-bis(L-lysylglycyl-L-valyl-L-seryl-L-leucyl-L-seryl-L-tyrosyl-L-arginyl)-hexa-acetate salt",,9/18/2019,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,TCM Biotech International Corp.,"24F-8, No. 97","Sec. 1, Xintai 5th Rd., Xizhi Dist.",New Taipei City,Taiwan,' ' ,Taiwan,703719,hepatocellular carcinoma,"""gard:0016773""",
3974,L-ornithine phenylacetate,,4/7/2010,treatment of hyperammonemia and resultant hepatic encephalopathy (he) in patients with acute liver failure or acute on chronic liver disase,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ocera Therapeutics LLC, a Mallinckrodt Pharmaceuticals Company",440 Route 22 East,,Bridgewater,New Jersey,' 08807 ' ,United States,287309,acute liver failure,"""gard:0019112""",
3975,L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser,,9/13/2011,treatment of neuropathic pain in patients with sarcoidosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Araim Pharmaceuticals, Inc.",712 Kitchawan Raod,,Ossining,New York,' 10562 ' ,United States,349111,sarcoidosis,"""gard:0007607""",
3976,L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser,,6/13/2016,treatment to increase survival and improve functioning of pancreatic islets following transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,"Araim Pharmaceuticals, Inc.",580 White Plains Road,Suite 210,Tarrytown,New York,' 10591 ' ,United States,523116,,,
3977,L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser,,9/18/2009,prevention of delayed graft function following renal transplant,Designated,,Not FDA Approved for Orphan Indication,,,,,"Araim Pharmaceuticals, Inc.",712 Kitchawan Raod,,Ossining,New York,' 10562 ' ,United States,289609,,,
3978,L-pyr-L-glu-L-gln-L-leu-L-glu-L-arg-L-ala-L-leu-L-asn-L-ser-L-ser,,6/13/2016,treatment of sarcoidosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Araim Pharmaceuticals, Inc.",580 White Plains Road,Suite 210,Tarrytown,New York,' 10591 ' ,United States,523816,sarcoidosis,"""gard:0007607""",
3979,L-pyroglutamyl-L-asparaginyl-L-prolyl-D-tyrosyl-D-tryptophan amide,,1/19/2021,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Neuropath Therapeutics Limited,26 Upper Pembroke Street,Suite 2006,Dublin,,' 2 ' ,Ireland,796220,amyotrophic lateral sclerosis,"""gard:0005786""",
3980,L-S-(3-Amino-3-carboxypropyl)-S-methylsulfoximine,,11/2/2021,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"William S. Brusilow, Ph.D.",30 Rivard Blvd.,,Gross Pointe,Michigan,' 48230 ' ,United States,844521,amyotrophic lateral sclerosis,"""gard:0005786""",
3981,"L-serine, L-threonine, L-leucine, glycine, L-alanine, L-arginine, L-cysteine, L-glutamine, L-histidine, L-aspartic acid, L-proline, L-isoleucine, L-lysine, L-tryptophan, L-valine, L-methionine, L-tyrosine, carnitine and taurine",,3/23/2020,treatment of phenylketonuria,Designated,,Not FDA Approved for Orphan Indication,,,,,APR Applied Pharma Research,Via Corti 5,,Balerna,,' ' ,Switzerland,687719,phenylketonuria,"""gard:0007383""",
3982,L-threonine,,7/24/1992,treatment of spasticity associated with familial spastic paraparesis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Interneuron Pharmaceuticals, Inc.","99 Hayden Ave., Suite 200",,Lexington,Massachusetts,' 02421 ' ,United States,62191,,,
3983,L-threonine,,2/6/1989,treatment of amyotrophic lateral sclerosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Tyson And Associates,12832 Chadron Avenue,,Hawthorne,California,' 90250 ' ,United States,33888,amyotrophic lateral sclerosis,"""gard:0005786""",
3984,L-threonyl-L-prolyl-L-prolyl-L-threonine,,4/26/2005,treatment of neuropathic pain associated with spinal cord injury,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nyxis Neurotherapies, Inc.",1801 Maple Avenue,Suite 4300,Evanston,Illinois,' 60201 ' ,United States,199404,spinal cord injury,"""gard:0019109""",
3985,L-tyrosine-L-serine-L-leucine,,9/10/2004,treatment of hepatocellular carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,CMS Peptides Patent Holding Company Limited,"Unit 2106, 21st Floor, Island Place Tower",510 King's Rd,North Point,,' ' ,,190604,hepatocellular carcinoma,"""gard:0016773""",
3986,L. reuteri,,8/1/2013,"prevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams",Designated,,Not FDA Approved for Orphan Indication,,,,,Infant Bacterial Therapeutics,Kungsbroplan 3A,P. O. Box 3242,Stockholm,,' ' ,Sweden,393013,necrotizing enterocolitis,"""gard:0009767""",
3987,Lacnotuzumab,,8/19/2014,"treatment of pigmented villonodular synovitis, including giant cell tumor of the tendon sheath",Designated/Designation Withdrawn or Revoked,1/11/2024,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,439314,,,
3988,Lactic acid,,6/29/1999,"treatment of severe aphthous stomatitis in severely, terminally immunocompromised patients.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Frontier Pharmaceutical, Inc.",SUNY Farmingdale,Conklin Hall,Farmingdale,New York,' 11735 ' ,United States,122098,,,
3989,"lactic acid bacteria (Lactobacilli, Bifidobacteria, and Steptococci)",,1/15/2002,treatment of active chronic pouchitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"VSL Pharmaceuticals, Inc.",800 S. Frederick Ave.,,Gaithersburg,Maryland,' 20877 ' ,United States,145201,pouchitis,"""gard:0020510""",
3990,"lactic acid bacteria (Lactobacilli, Bifidobacteria, and Streptococcus species)",,1/15/2002,prevention of disease relapse in patients with chronic pouchitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"VSL Pharmaceuticals, Inc.",800 S. Frederick Ave.,,Gaithersburg,Maryland,' 20877 ' ,United States,154102,pouchitis,"""gard:0020510""",
3991,Lactobacillus acidophilus and Bifidobacterium animalis subsp. lactis,,3/24/2015,prevention of necrotizing enterocolitis (nec) in premature infants with very low birth weight less than or equal to 1500 grams,Designated,,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd.,Suite 500,Gaithersburg,Maryland,' 20878 ' ,United States,422414,necrotizing enterocolitis,"""gard:0009767""",
3992,lactobacillus brevis CD2,,10/4/2011,treatment behcet's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"VSL Pharmaceuticals, Inc.",100 West Road,,Towson,Maryland,' 21204 ' ,United States,351711,,,
3993,lactobacillus plantarum,,11/30/2016,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,"New Biotic, LLC",19546 Rogan Court,,Rowland Heights,California,' 91748 ' ,United States,550016,amyotrophic lateral sclerosis,"""gard:0005786""",
3994,Lactobacillus reuteri,,6/30/2023,treatment of gastroschisis,Designated,,Not FDA Approved for Orphan Indication,,,,,Infant Bacterial Therapeutics AB,Bryggargatan 10,Infant Bacterial Therapeutics,STOCKHOLM,Out-of-Country,' 11121 ' ,Sweden,899922,gastroschisis,"""gard:0008661""",
3995,Lactobin,,9/12/1990,treatment of aids-associated diarrhea unresponsive to initial antidiarrheal therapy.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Roxane Laboratories, Inc.",PO Box 16532,,Columbus,Ohio,' 43216 ' ,United States,46990,,,
3996,laminin-111 (human),,7/21/2011,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Prothelia, Inc.",30 Haven Street,,Milford,Massachusetts,' 01757 ' ,United States,337411,muscular dystrophy,"""gard:0007922""",
3997,Lamotrigine,Lamictal,8/23/1995,treatment of lennox-gastaut syndrome.,Designated/Approved,,,Adjunctive treatment of Lennox-Gastaut syndrome in pediatric and adult patients.,8/24/1998,8/24/2005,,Glaxo Wellcome Research and Development,5 Moore Drive,P.O. Box 13398,Research Triangle Park,North Carolina,' 27709 ' ,United States,91695,lennox-gastaut syndrome,"""gard:0009912""",
3998,lanadelumab-flyo,Takhzyro,11/26/2013,treatment of angioedema,Designated/Approved,,,prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older,2/3/2023,2/3/2030,prophylaxis to prevent attacks of hereditary angioedema (HAE) in pediatric patients aged 2 years to less than 12 years,"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,397213,,,
3999,lanadelumab-flyo,Takhzyro,11/26/2013,treatment of angioedema,Designated/Approved,,,Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older,8/23/2018,8/23/2025,Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older,"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,397213,,,
4000,lanraplenib,,1/29/2024,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,"Kronos Bio, Inc.",1300 S El Camino Real #400,,San Mateo,California,' 94402 ' ,United States,984723,acute myeloid leukemia,"""gard:0012757""",
4001,Lanreotide,Somatuline Depot,9/11/2000,treatment for acromegly,Designated/Approved,,,Long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy,8/30/2007,8/30/2014,,"IPSEN, Inc.",27 Maple Street,,Milford,Massachusetts,' 01757 ' ,United States,136300,,,
4002,lanreotide acetate,,9/8/2011,treatment of carcinoid syndrome,Designated/Approved,,,"treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy",9/15/2017,9/15/2024,"treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy","Ipsen Biopharmaceuticals, Inc.",106 Allen Road,,Basking Ridge,New Jersey,' 07920 ' ,United States,347111,carcinoid syndrome,"""gard:0005994""",
4003,lanreotide acetate,Somatuline Depot,8/25/2011,treatment of neuroendocrine tumors,Designated/Approved,,,"Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival",12/16/2014,12/16/2021,"Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival","Ipsen Biopharmaceuticals, Inc.",106 Allen Road,,Basking Ridge,New Jersey,' 07920 ' ,United States,347811,,,
4004,lapatinib,,5/29/2009,treatment of erbb2 positive gastric cancer,Designated/Designation Withdrawn or Revoked,6/8/2016,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,284209,,,
4005,lapatinib ditosylate hydrochloride,,5/29/2009,treatment of erbb2 positive esophageal cancer,Designated/Designation Withdrawn or Revoked,6/8/2016,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Hampshire,' 07936 ' ,United States,284309,,,
4006,laquinimod sodium,,1/31/2017,treatment of huntington's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Active Biotech AB,Scheelevagen 22,Box 724,Lund,Scania,' SE-220-07 ' ,Sweden,466114,,,
4007,Laromustine,,3/27/2014,treatment of acute myelogenous leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,NanoSHIFT LLC,10454 Northwest 132nd Drive,,Alachua,Florida,' 32615 ' ,United States,424014,,,
4008,laromustine,,10/21/2004,treatment of acute myelogenous leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vion Pharmaceuticals, Inc.",Four Science Park,,New Haven,Connecticut,' 06511 ' ,United States,194104,,,
4009,laronidase,Aldurazyme,9/24/1997,treatment of patients with mucopolysaccharidosis-i.,Designated/Approved,,,Treatment for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms,4/30/2003,4/30/2010,,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,' 94949 ' ,United States,106097,mucopolysaccharidosis,"""gard:0007065""",
4010,Larotrectinib,,8/31/2015,treatment of soft tissue sarcoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Bayer HealthCare Pharmaceuticals Inc.,100 Bayer Boulevard,,Whippany,New Jersey,' 07981 ' ,United States,490115,soft tissue sarcoma,"""gard:0004898""",
4011,larotrectinib,VITRAKVI,5/9/2017,treatment of solid tumors with ntrk-fusion proteins,Designated/Approved,,,VITRAKVI® is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have no satisfactory alternative treatments or that have progressed following treatment.,11/26/2018,11/26/2025,VITRAKVI® is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have no satisfactory alternative treatments or that have progressed following treatment.,Bayer HealthCare Pharmaceuticals Inc.,100 Bayer Boulevard,,Whippany,New Jersey,' 07981 ' ,United States,578317,,,
4012,late stage human motor neutron progenitors,,11/25/2009,treatment of spinal muscular atrophy,Designated/Designation Withdrawn or Revoked,11/22/2016,Not FDA Approved for Orphan Indication,,,,,Caladrius Biosciences,110 Allen Road,2nd Floor,Basking Ridge,New Jersey,' 07920 ' ,United States,293509,,,
4013,Latrodectus immune F(ab)2,,6/18/2001,treatment of black widow spider envenomations,Designated,,Not FDA Approved for Orphan Indication,,,,,"Instituto Bioclon, S.A. de C.V.","Tlalpan,",No. 4687 Colonia Toriello Guerra,Tlalpan,,' ' ,Mexico,144001,noma,"""gard:0004001""",
4014,Lead-212 DOTAMTATE,,10/11/2018,treatment of neuroendocrine tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"RadioMedix, Inc.",9701 Richmond Avenue,Suite 222,Houston,Texas,' 77042 ' ,United States,653318,,,
4015,lebrikizumab,,3/9/2015,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,381112,idiopathic pulmonary fibrosis,"""gard:0008609""",
4016,ledipasvir/sofosbuvir,Harvoni,10/12/2016,treatment of chronic hepatitis c virus (hcv) infection in pediatric patients,Designated/Approved,,,"Treatment of pediatric patients 12 years of age and older or weighing at least 35 kg with chronic hepatitis C virus genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis",4/7/2017,4/7/2024,"Treatment of pediatric patients 12 years of age and older or weighing at least 35 kg with chronic hepatitis C virus genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis","Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,535916,,,
4017,ledipasvir/sofosbuvir,Harvoni,10/12/2016,treatment of chronic hepatitis c virus (hcv) infection in pediatric patients,Designated/Approved,,,"HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin, and genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin",8/28/2019,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,535916,,,
4018,ledipasvir/sofosbuvir,Harvoni,10/12/2016,treatment of chronic hepatitis c virus (hcv) infection in pediatric patients,Designated/Approved,,,"HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin, and genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin",8/28/2019,8/28/2026,"For treatment of pediatric patients between 3 years of age and 12 years of age or weighing 35 kg with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis; (2) treatment of pediatric patients 3 years of age and older with chronic HCV genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin; and (3) treatment of pediatric patients 3 years of age and older with chronic HCV genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin","Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,535916,,,
4019,Leflunomide,,10/18/1996,prevention of acute and chronic rejection in patients who have received solid organ transplants.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Williams, MD, James W.","Rush-Presbyterian-St. Luke's Medical Ctr., Dept. o",1653 West Congress Parkway,Chicago,Illinois,' 60612 ' ,United States,100296,,,
4020,lenabasum,,7/18/2018,treatment of dermatomyositis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Corbus Pharmaceuticals, Inc.",500 River Ridge Drive,Second Floor,Norwood,Massachusetts,' 02062 ' ,United States,643618,dermatomyositis,"""gard:0006263""",
4021,lenadogene nolparvovec,,11/20/2013,treatment of leber hereditary optic neuropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Gensight Biologics,74 Rue du Faubourg Saint Antoine,,Paris,,' 75012 ' ,France,412013,hereditary optic neuropathy,"""gard:0019540""",
4022,lenalidomide,,1/17/2007,treatment of chronic lymphocytic leukemia,Designated/Designation Withdrawn or Revoked,5/15/2020,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,230606,,,
4023,lenalidomide,Revlimid,4/27/2009,treatment of mantle cell lymphoma,Designated/Approved,,,"Treatment of mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.",6/5/2013,6/5/2020,"Treatment of mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.",Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,278809,lymphoma,"""gard:0020548""",
4024,lenalidomide,Revlimid,9/20/2001,treatment of multiple myeloma,Designated/Approved,,,"Treatment of multiple myeloma (MM), as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)",2/22/2017,2/22/2024,"Treatment of multiple myeloma (MM), as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)",Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,147701,multiple myeloma,"""gard:0007108""",
4025,lenalidomide,Revlimid,9/20/2001,treatment of multiple myeloma,Designated/Approved,,,REVLIMID in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).,2/17/2015,2/17/2022,For use in combination with dexamethasone for the treatment of patients with multiple myeloma who have not received at least one prior therapy (first-line therapy).,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,147701,multiple myeloma,"""gard:0007108""",
4026,lenalidomide,Revlimid,9/20/2001,treatment of multiple myeloma,Designated/Approved,,,For use in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy,6/29/2006,6/29/2013,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,147701,multiple myeloma,"""gard:0007108""",
4027,lenalidomide,Revlimid,1/29/2004,treatment of myelodysplastic syndromes,Designated/Approved,,,Treatment of patients with transfusion dependant anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5 q cytogenetic abnormality with or without additional cytogenetic abnormalities,12/27/2005,12/27/2012,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,180303,myelodysplastic syndrome,"""gard:0007132""",
4028,lenalidomide,Revlimid,4/29/2015,treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue,Designated/Approved,,,"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).",5/28/2019,5/28/2026,In combination with a rituximab product for the treatment of adult patients with previously treated extranodal marginal zone lymphoma,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,476115,lymphoma,"""gard:0020548""",
4029,lenalidomide,Revlimid,1/4/2017,treatment of nodal marginal zone lymphoma,Designated/Approved,,,"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).",5/28/2019,5/28/2026,In combination with a rituximab product for the treatment of adult patients with previously treated nodal marginal zone lymphoma,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,476015,lymphoma,"""gard:0020548""",
4030,lenalidomide,Revlimid,1/4/2017,treatment of splenic marginal zone lymphoma,Designated/Approved,,,"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL).",5/28/2019,5/28/2026,In combination with a rituximab product for the treatment of adult patients with previously treated splenic marginal zone lymphoma,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,475915,lymphoma,"""gard:0020548""",
4031,lenalidomide,Revlimid,9/17/2013,treatment of follicular lymphoma,Designated/Approved,,,"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL).",5/28/2019,5/28/2026,In combination with a rituximab product for the treatment of adult patients with previously treated follicular lymphoma (FL).,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,390813,lymphoma,"""gard:0020548""",
4032,lenalidomide,,3/28/2011,treatment of diffuse large b-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,333811,lymphoma,"""gard:0020548""",
4033,leniolisib,Joenja,1/30/2018,"treatment of activated p13kdelta syndrome/p110delta-activating mutation causing senescent t cells, lymphadenopathy, and immunodeficiency",Designated/Approved,,,treatment of activated phosphoinositide 3-kinase delta (PI3K delta) syndrome (APDS) in adult and pediatric patients 12 years of age and older,3/24/2023,3/24/2030,treatment of activated phosphoinositide 3-kinase delta (PI3K delta) syndrome (APDS) in adult and pediatric patients 12 years of age and older,Pharming Technologies B.V.,Darwinweg 24,,Leiden,,' 2333CR ' ,Netherlands,504315,,,
4034,lentiviral transfected chimeric antigen receptor T-cells modified to target B-cell maturation antigen and CS1,,12/14/2017,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,iCell Gene Therapeutics,25 Health Sciences Drive,Suite 118,Stony Brook,New York,' 11793 ' ,United States,612717,multiple myeloma,"""gard:0007108""",
4035,lentiviral vector containing the human ABCA4 gene,,4/30/2010,treatment of stargardt disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Sanofi US Services Inc.,50 Binney Street,,Cambridge,Massachusetts,' 02142 ' ,United States,306610,stargardt disease,"""gard:0000181""",
4036,lentiviral vector containing the human liver and erythroid pyruvate kinase gene,,3/23/2016,treatment of pyruvate kinase deficiency.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Rocket Pharmaceuticals, Inc.",The Empire State Building,"350 Fifth Avenue, Suite 7530",New York,New York,' 10118 ' ,United States,516816,,,
4037,lentiviral vector containing the human MY07A gene,,5/17/2010,treatment of retinitis pigmentosa associated with usher syndrome 1b gene defect.,Designated,,Not FDA Approved for Orphan Indication,,,,,Sanofi US Services Inc.,50 Binney Street,,Cambridge,Massachusetts,' 02142 ' ,United States,306710,usher syndrome,"""gard:0007843""",
4038,Lentiviral vector encoded with a human beta-globin gene plasmid,,1/11/2006,treatment of beta-thalassemia major and beta-thalassemia intermedia,Designated,,Not FDA Approved for Orphan Indication,,,,,"San Rocco Therapeutics, LLC",308 East Emily Street,,Tampa,Florida,' 33603 ' ,United States,215505,beta-thalassemia intermedia,"""gard:0017163""",
4039,Lentiviral vector expressing human fumarylacetoacetate hydrolase,,8/8/2019,treatment of hereditary tyrosinemia type i,Designated,,Not FDA Approved for Orphan Indication,,,,,"Castle Creek Biosciences, LLC",405 Eagleview Blvd,,Exton,Pennsylvania,' 19341 ' ,United States,696319,,,
4040,lentiviral-transduced CD33-directed CAR-T cell therapy,,3/18/2024,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Vor Biopharma,100 Cambridgepark Dr.,Suite 101,Cambridge,Massachusetts,' 02140 ' ,United States,993523,acute myeloid leukemia,"""gard:0012757""",
4041,lenvatinib,Lenvima,12/27/2012,"treatment of follicullar, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer",Designated/Approved,,,"Treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer",2/13/2015,2/13/2022,"Treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer","Eisai, Inc.",200 Metro Blvd.,,Nutley,New Jersey,' 07110-6102 ' ,United States,378412,,,
4042,lenvatinib,LENVIMA,3/27/2014,treatment of hepatocellular carcinoma,Designated/Approved,,,LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC),8/15/2018,8/15/2025,LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC),Eisai Inc.,200 Metro Blvd.,,Nutley,New Jersey,' 07110-6102 ' ,United States,423714,hepatocellular carcinoma,"""gard:0016773""",
4043,lenvatinib,,3/26/2014,treatment of stage iib to stage iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Eisai, Inc.",200 Metro Blvd.,,Nutley,New Jersey,' 07110-6102 ' ,United States,423614,noma,"""gard:0004001""",
4044,lenzumestrocel,,8/1/2018,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Corestem, Inc.","2F, 24, Pangyo-ro 255 beon-gil",Bundang-gu,Seongnam-si,Gyeonggi-do,' ' ,South Korea,646618,amyotrophic lateral sclerosis,"""gard:0005786""",
4045,Lepirudin,Refluden,2/13/1997,treatment of heparin-associated thrombocytopenia type ii.,Designated/Approved,,,For anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease in order to prevent further thromboembolic complications.,3/6/1998,3/6/2005,,Hoechst Marion Roussel,Frankfurt am Main,P.O. Box 1140,Marburg,,' ' ,Germany,102796,,,
4046,leriglitazone,,8/1/2019,treatment of friedreich´s ataxia,Designated,,Not FDA Approved for Orphan Indication,,,,,Minoryx Therapeutics S.L.,TecnoCampus Mataro-Maresme. TCM3 602,"Av. Ernest Lluch, 32.",Mataró,Catalunya,' ' ,Spain,700919,,,
4047,lestaurtinib,,3/24/2006,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,5/14/2024,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,' 19380 ' ,United States,219406,acute myeloid leukemia,"""gard:0012757""",
4048,lestaurtinib,,9/3/2009,treatment of philadelphia-negative classic myeloproliferative disorders,Designated,,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,' 19380 ' ,United States,289109,,,
4049,letermovir,Prevymis,12/12/2011,prevention of human cytomegalovirus viremia and disease in at risk populations,Designated/Approved,,,prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]),6/5/2023,6/5/2030,prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]),Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,340211,,,
4050,letermovir,PREVYMIS,12/12/2011,prevention of human cytomegalovirus viremia and disease in at risk populations,Designated/Approved,,,Prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).,11/8/2017,11/8/2024,Prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,340211,,,
4051,letetresgene autoleucel,,3/28/2016,treatment of soft tissue sarcoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Adaptimmune, LLC",351 Rouse Blvd.,,Philadelphia,Pennsylvania,' 19112 ' ,United States,512315,soft tissue sarcoma,"""gard:0004898""",
4052,Leu-Lys-Gly-Gln-Leu-Arg-Cys-Ile,,8/7/2017,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kalos Therapeutics, Inc.",6351 W. Lone Cactus Drive,,Glendale,Alaska,' 85308 ' ,United States,593517,,,
4053,Leucovorin,Leucovorin calcium,8/17/1988,for rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.,Designated/Approved,,,,8/31/1988,8/31/1995,,Immunex Corporation,51 University Street,,Seattle,Washington,' 98101 ' ,United States,30588,osteosarcoma,"""gard:0007284""",
4054,Leucovorin,Leucovorin calcium,12/8/1986,for use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.,Designated/Approved,,,For use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.,12/12/1991,12/12/1998,,Immunex Corporation,51 University Street,,Seattle,Washington,' 98101 ' ,United States,16786,,,
4055,Leucovorin calcium,,6/23/1988,for use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Glaxo Wellcome Research and Development,5 Moore Drive,PO Box 13398,Research Triangle Park,North Carolina,' 27709 ' ,United States,29288,,,
4056,leukocyte interleukin,,5/4/2007,neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck,Designated,,Not FDA Approved for Orphan Indication,,,,,CEL-SCI Corporation,8229 Boone Blvd.,Suite 802,Vienna,Virginia,' 22182 ' ,United States,221706,noma,"""gard:0004001""",
4057,leukotriene A4 hydrolase inhibitor,,1/26/2015,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Celltaxis, LLC",3060 Peachtree Road,"NW, Suite 1425",Atlanta,Georgia,' 30305 ' ,United States,432114,cystic fibrosis,"""gard:0006233""",
4058,Leupeptin,,9/18/1990,for use as an adjunct to microsurgical peripheral nerve repair.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neuromuscular Adjuncts, Inc.",S.U.N.Y. at Stony Brook,H.S.C. T18-020,Stony Brook,New York,' 11794 ' ,United States,49690,,,
4059,Leuprolide acetate,Lupron Injection,7/25/1988,treatment of central precocious puberty,Designated/Approved,,,Treatment of children with central precocious puberty,4/16/1993,4/16/2000,,AbbVie Endocrine Inc.,1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,28688,central precocious puberty,"""gard:0016546""",
4060,Leuprolide acetate,Lupron Depot-Ped,7/25/1988,treatment of central precocious puberty,Designated/Approved,,,treatment of pediatric patients with central precocious puberty (CPP),4/14/2023,,,AbbVie Endocrine Inc.,1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,28688,central precocious puberty,"""gard:0016546""",
4061,levetiracetam,,4/30/2010,treatment of neonatal seizures,Designated,,Not FDA Approved for Orphan Indication,,,,,University of California,UCSD Medical Center 0935,,La Jolla,California,' 92093 ' ,United States,303310,,,
4062,Levocabastine HCl ophthalmic suspension 0.05%,,2/29/1988,treatment of vernal keratoconjunctivitis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Iolab Pharmaceuticals,500 Iolab Drive,,Claremont,California,' 91711 ' ,United States,24787,vernal keratoconjunctivitis,"""gard:0007854""",
4063,Levocarnitine,,11/24/1986,treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd,Suite 500,Gaithersburg,Maryland,' 20878 ' ,United States,17386,,,
4064,levocarnitine,,11/15/1989,1. prevention of secondary carnitine deficiency in valproic acid toxicity 2. treatment of secondary carnitine deficiency in valproic acid toxicity,Designated,,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd,Suite 500,Gaithersburg,Maryland,' 20878 ' ,United States,32488,,,
4065,Levocarnitine,,11/22/1993,treatment of pediatric cardiomyopathy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd,Suite 500,Gaithersburg,Maryland,' 20878 ' ,United States,76393,,,
4066,Levocarnitine,,4/7/1997,treatment of zidovudine-induced mitochondrial myopathy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.",9841 Washingtonian Boulevard,Suite 500,Gaithersburg,Maryland,' 20878 ' ,United States,103897,mitochondrial myopathy,"""gard:0020371""",
4067,Levocarnitine,Carnitor,9/6/1988,treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.,Designated/Approved,,,Prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis.,12/15/1999,12/15/2006,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd,Suite 500,Gaithersburg,Maryland,' 20878 ' ,United States,27888,,,
4068,Levocarnitine,Carnitor,7/26/1984,treatment of primary and secondary carnitine deficiency of genetic origin.,Designated/Approved,,,Treatment of primary systemic carnitine deficiency. (approved 12/27/85) Treatment of secondary carnitine deficiency. (approved 12/16/92),12/16/1992,12/16/1999,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd,Suite 500,Gaithersburg,Maryland,' 20878 ' ,United States,1584,,,
4069,Levocarnitine,Carnitor,2/28/1984,treatment of genetic carnitine deficiency.,Designated/Approved,,,,4/10/1986,4/10/1993,,"Leadiant Biosciences, Inc.",9841 Washingtonian Blvd,Suite 500,Gaithersburg,Maryland,' 20878 ' ,United States,1384,,,
4070,levodopa and carbidopa,Duopa,1/18/2000,treatment of late stage parkinson's disease,Designated/Approved,,,Treatment of motor flucuations in patients with advanced Parkinson's disease,1/9/2015,1/9/2022,Treatment of motor flucuations in patients with advanced Parkinson's disease,"AbbVie, Inc.",1 N. Waukegan Road,Building AP30-1,North Chicago,Illinois,' 60064 ' ,United States,129499,,,
4071,Levofloxacin,,2/27/2008,treatment of pulmonary infections due to pseudomonas aeruginosa and other bacteria in patients with cystic fibrosis patients,Designated,,Not FDA Approved for Orphan Indication,,,,,"Horizon Therapeutics USA, Inc.",150 S. Saunders Road,Suite 100,Lake Forest,Illinois,' 60045 ' ,United States,253707,cystic fibrosis,"""gard:0006233""",
4072,levoketoconazole,Recorlev,3/9/2012,treatment of endogenous cushing's syndrome,Designated/Approved,,,Treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome for whom surgery is not an option or has not been curative,12/30/2021,12/30/2028,Treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome for whom surgery is not an option or has not been curative,Strongbridge Dublin Limited,"Suite 206, Fitzwilliam Hall",,Dublin 2,,' D02 T292 ' ,Ireland,364412,,,
4073,levoleucovorin,Fusilev,12/18/1990,for use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum,Designated/Approved,,,For use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer,4/29/2011,4/29/2018,,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,' 08520 ' ,United States,48590,noma,"""gard:0004001""",
4074,Levoleucovorin,Fusilev,8/1/1991,for use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.,Designated/Approved,,,Levoleucovorin rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Levoleucovorin is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists,3/7/2008,3/7/2015,,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,' 08520 ' ,United States,48490,osteosarcoma,"""gard:0007284""",
4075,levomefolate calcium,,2/10/2015,treatment of megaloblastic anemia caused by folate deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Cox Biosciences LLC,"267 West 71st Street, #3F",,New York,New York,' 10023 ' ,United States,428514,,,
4076,Levomethadyl acetate hydrochloride,Orlaam,1/24/1985,treatment of heroin addicts suitable for maintenance on opiate agonists.,Designated/Approved,,,For the management of opiate dependence.,7/9/1993,7/9/2000,,Biodevelopment Corporation,"8180 Greensboro Drive, Suite 1000",,McLean,Virginia,' 22102 ' ,United States,4784,,,
4077,levosimendan,,4/10/2017,treatment of amyotrophic lateral sclerosis,Designated/Designation Withdrawn or Revoked,2/8/2021,Not FDA Approved for Orphan Indication,,,,,Orion Corporation,Orionintie 1,,Espoo,,' ' ,Finland,495515,amyotrophic lateral sclerosis,"""gard:0005786""",
4078,levothyroxine sodium,,4/26/2011,the preservation of organ function in brain-dead organ donors.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Fera Pharmaceuticals, LLC",134 Birch Hill Road,,Locust Valley,New York,' 11560 ' ,United States,334711,,,
4079,liarozole,,6/18/2004,treatment of congenital ichthyosis,Designated/Designation Withdrawn or Revoked,9/23/2015,Not FDA Approved for Orphan Indication,,,,,"Stiefel Laboratories, Inc.",20 T.W. Alexander Drive,P. O. Box 14910,Research Triangle Park,North Carolina,' 27709 ' ,United States,183904,ichthyosis,"""gard:0018985""",
4080,Lidocaine patch 5%,Lidoderm Patch,10/24/1995,"for relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia.",Designated/Approved,,,,3/19/1999,3/19/2006,,"Teikoku Pharma USA, Inc.",745-D Camden Ave.,,Campbell,California,' 95008 ' ,United States,92395,,,
4081,lifileucel,Amtagvi,6/9/2015,treatment of malignant melanoma stages iib to iv,Designated/Approved,,,"treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor",2/16/2024,2/16/2031,"treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor","Iovance Biotherapeutics, Inc.",825 Industrial Road,Suite 400,San Carlos,California,' 94070 ' ,United States,477215,noma,"""gard:0004001""",
4082,linerixibat,,9/18/2019,treatment of primary biliary cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline,1250 South Collegeville Road,"Building 4, Mail Stop 4400",Collegeville,Pennsylvania,' 19426 ' ,United States,701919,primary biliary cholangitis,"""gard:0007459""",
4083,linperlisib,,5/26/2021,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shanghai Yingli Pharmaceutical Co., Ltd.","Room 01, 4th Floor, Building A","2829 Jinke Road, Zhangjiang Hi-Tech Park, Pudong New Area",Shanghai,,' ' ,China,818221,lymphoma,"""gard:0020548""",
4084,linsitinib,,3/9/2012,treatment of adrenocortical carcinoma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,362311,noma,"""gard:0004001""",
4085,lintuzumab,,3/20/2007,treatment of myelodysplastic syndrome,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,238007,myelodysplastic syndrome,"""gard:0007132""",
4086,lintuzumab,,1/30/2007,treatment of acute myeloid leukemia.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,235106,acute myeloid leukemia,"""gard:0012757""",
4087,lintuzumab,,9/9/2002,treatment of acute myelogenous leukemia,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Protein Design Labs, Inc.",34801 Campus Drive,,Fremont,California,' 94555 ' ,United States,158502,,,
4088,Liothyronine sodium injection,Triostat,7/30/1990,treatment of myxedema coma/precoma.,Designated/Approved,,,Treatment of myxedema coma/precoma.,12/31/1991,12/31/1998,,SmithKline Beecham Pharmaceuticals,One Franklin Plaza,P.O. Box 7929,Philadelphia,Pennsylvania,' 19101 ' ,United States,46090,,,
4089,"lipase, amylase, and protease",,1/23/2002,treatment of pancreatic insufficiency,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Altus Biologics Inc.,625 Putnam Avenue,,Cambridge,Massachusetts,' 02139 ' ,United States,148501,,,
4090,lipid nanoparticle encapsulating single guide RNA (G012267) targeting the human KLKB1 gene and messenger RNA (mRNA000042) encoding Cas9,,9/1/2022,treatment of hereditary angioedema,Designated,,Not FDA Approved for Orphan Indication,,,,,"Intellia Therapeutics, Inc.",40 Erie Street,,Cambridge,Massachusetts,' 02139 ' ,United States,897622,hereditary angioedema,"""gard:0005979""",
4091,Lipid/DNA human cystic fibrosis gene,,4/8/1996,treatment of cystic fibrosis.,Designated/Designation Withdrawn or Revoked,5/21/2015,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,Metrowest Place,15 Pleasant St. Connector,Framingham,Massachusetts,' 01701 ' ,United States,90095,cystic fibrosis,"""gard:0006233""",
4092,lipophilic derivative of dimercaptosuccinic acid sulfur containing chelator,,12/27/2023,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,Pleco Therapeutics USA Inc.,26 Nottingham Rd,,Edison,New Jersey,' 08820 ' ,United States,979223,acute myeloid leukemia,"""gard:0012757""",
4093,liposomal amikacin,,3/9/2006,treatment of bronchopulmonary pseudomonas aeruginosa infections in cystic fibrosis patients,Designated/Designation Withdrawn or Revoked,8/16/2023,Not FDA Approved for Orphan Indication,,,,,"Insmed, Inc.",Princeton Corporate Plaza,"9 Deer Park Drive, Suite C",Monmouth Junction,New Jersey,' 08852 ' ,United States,217305,cystic fibrosis,"""gard:0006233""",
4094,liposomal amikacin,,8/25/2009,treatment of bronchiectasis in patients with pseudomonas aeruginosa or other susceptible microbial pathogens,Designated/Designation Withdrawn or Revoked,8/16/2023,Not FDA Approved for Orphan Indication,,,,,"Insmed, Inc.",Princeton Corpoarate Plaza,Suite C,Monmouth Junction,New Jersey,' 08852 ' ,United States,282109,,,
4095,liposomal amikacin,Arikayce,3/25/2013,treatment of infections caused by non-tuberculous mycobacteria,Designated/Approved,,,Treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy,9/28/2018,9/28/2025,Treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy,Insmed Incorporated,10 Finderne Avenue,Building 10,Bridgewater,New Jersey,' 08807 ' ,United States,342011,,,
4096,Liposomal amphotericin B,,12/10/1996,treatment of histoplasmosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Fujisawa USA, Inc.",3 Parkway North Center,,Deerfield,Illinois,' 60015 ' ,United States,99696,histoplasmosis,"""gard:0018692""",
4097,Liposomal amphotericin B,AmBisome,12/6/1996,treatment of visceral leishmaniasis.,Designated/Approved,,,Treatment of visceral leishmaniasis.,8/11/1997,8/11/2004,,"Fujisawa USA, Inc.",3 Parkway North Center,,Deerfield,Illinois,' 60015 ' ,United States,99596,leishmaniasis,"""gard:0006881""",
4098,Liposomal amphotericin B,AmBisome,12/10/1996,treatment of cryptococcal meningitis.,Designated/Approved,,,Treatment of disseminated cryptococcosis including meningitis.,8/11/1997,8/11/2004,,"Fujisawa USA, Inc.",3 Parkway North Center,,Deerfield,Illinois,' 60015 ' ,United States,99496,,,
4099,liposomal annamycin,,3/20/2017,treatment of acute myeloid leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Moleculin Biotech, Inc.",2575 West Bellfort Avenue,Suite 333,Houston,Texas,' 77054 ' ,United States,550116,acute myeloid leukemia,"""gard:0012757""",
4100,Liposomal annamycin,,6/17/2005,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Callisto Pharmaceuticals, Inc.",420 Lexington Avenue,,New York,New York,' 10170 ' ,United States,206205,acute lymphoblastic leukemia,"""gard:0000522""",
4101,Liposomal annamycin,,6/17/2005,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Callisto Pharmaceuticals, Inc.",420 Lexington Avenue,,New York,New York,' 10170 ' ,United States,206305,acute myeloid leukemia,"""gard:0012757""",
4102,liposomal annamycin,,12/28/2020,treatment of soft tissue sarcomas,Designated,,Not FDA Approved for Orphan Indication,,,,,"Moleculin Biotech, Inc.","5300 Memorial Drive, Suite 950",,Houston,Texas,' 77007 ' ,United States,787720,soft tissue sarcoma,"""gard:0004898""",
4103,liposomal busulfan,,6/24/2013,for use as a conditioning regimen for patients with malignancies undergoing autologous or allogeneic hematopoietic stem cell transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,Calliditas Therapeutics AB,Kungsbron 1,,Stockholm,,' SE-111 22 ' ,Sweden,394513,,,
4104,Liposomal ciprofloxacin for inhalation,,12/27/2006,management of bronchiectasis,Designated,,Not FDA Approved for Orphan Indication,,,,,Savara Inc.,"1717 Langhorne Newtown Road, Suite 300",,Langhorne,Pennsylvania,' 19047 ' ,United States,230806,,,
4105,liposomal ciprofloxacin for inhalation,,4/19/2006,management of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Savara Inc.,"1717 Langhorne Newtown Road, Suite 300",,Langhorne,Pennsylvania,' 19047 ' ,United States,216905,cystic fibrosis,"""gard:0006233""",
4106,liposomal ciprofloxacin plus ciprofloxacin,,6/1/2012,for the management of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Savara Inc.,"1717 Langhorne Newtown Road, Suite 300",,Langhorne,Pennsylvania,' 19047 ' ,United States,369812,cystic fibrosis,"""gard:0006233""",
4107,Liposomal cisplatin,,5/23/2006,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Eleison Pharmaceuticals LLC,103 Carnegie Center,Suite 300,Princeton,New Jersey,' 08540 ' ,United States,221906,ovarian cancer,"""gard:0007295""",
4108,Liposomal cyclosporin A,,4/30/1998,for aerosolized administration in the prevention and treatment of lung allograft rejection and pulmonary rejection events associated with bone marrow transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vernon Knight, M.D.","Baylor College of Medicine, Dept. of Molecular Phy",One Baylor Plaza,Houston,Texas,' 77030 ' ,United States,112798,,,
4109,liposomal cyclosporine,,5/11/2009,treatment of bronchiolitis obliterans,Designated,,Not FDA Approved for Orphan Indication,,,,,Zambon S.p.A.,Via Lillo del Duca 10,,Bresso,Ml,' 20091 ' ,Italy,252107,,,
4110,liposomal cyclosporine for inhalation,,6/24/2008,prevention of bronchiolitis obliterans.,Designated,,Not FDA Approved for Orphan Indication,,,,,Zambon S.p.A.,Via Lillo del Duca 10,,Bresso,MI,' 20091 ' ,Italy,252207,,,
4111,Liposomal doxorubicin hydrochloride,,12/27/2006,treatment of soft tissue sarcomas,Designated,,Not FDA Approved for Orphan Indication,,,,,GP-Pharm SA,"Pol. Ind. Els Vinyets els Fogars n 2,",Quinti de Mediona,Barcelona,,' ' ,Spain,229006,soft tissue sarcoma,"""gard:0004898""",
4112,liposomal encapsulated paclitaxel,,1/21/2015,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Benuvia Therapeutics, LLC",3950 N. Mays Street,,Round Rock,Texas,' 78665 ' ,United States,454114,ovarian cancer,"""gard:0007295""",
4113,liposomal gadodiamide,,11/12/2008,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"MedGenesis Therapeutix, Inc.",730-730 View Street,,Victoria,,' ' ,Canada,268408,,,
4114,liposomal glutathione,,5/18/2016,treatment of dengue virus infection.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Your Energy Systems, LLC",555 Bryant Street #305,,Palo Alto,California,' 94301 ' ,United States,519216,,,
4115,Liposomal Glutathione,,4/30/2010,support of glutathione deficiency in individuals with inborn errors of metabolism of glutathione (iemg),Designated,,Not FDA Approved for Orphan Indication,,,,,"Your Energy Systems, LLC",555 Bryant Street #305,,Palo Alto,California,' 94301 ' ,United States,303410,,,
4116,liposomal mannose-1-phosphate,,6/4/2018,treatment of phosphomannomutase 2-congenital disorder of glycosylation,Designated,,Not FDA Approved for Orphan Indication,,,,,"Glycomine, Inc.",QB3@953,953 Indiana Street,San Francisco,California,' 94107 ' ,United States,640318,congenital disorder of glycosylation,"""gard:0010307""",
4117,Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl,,6/10/1998,treatment of ewing's sarcoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Endorex Corp.,900 North Shore Drive,,Lake Bluff,Illinois,' 60044 ' ,United States,114898,,,
4118,Liposomal N-Acetylglucosminyl-N-Acetylmuramly-L-Ala-D-isoGln-L-Ala -gylcerolidpalmitoyl,,6/10/1998,treatment of osteosarcoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Endorex Corp.,900 North Shore Drive,,Lake Bluff,Illinois,' 60044 ' ,United States,114098,osteosarcoma,"""gard:0007284""",
4119,Liposomal nystatin,,6/13/2000,treatment of invasive fungal infections.,Designated,,Not FDA Approved for Orphan Indication,,,,,The University of Texas,M.D. Anderson Cancer Center,Unit 038,Houston,Texas,' 77030 ' ,United States,133800,,,
4120,liposomal oxaliplatin,,9/18/2017,treatment of pancreatic adenocarcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"KC Specialty Therapeutics, LLC",2002 West 39th Avenue,,Kansas City,Arkansas,' 66103 ' ,United States,560816,noma,"""gard:0004001""",
4121,liposomal oxaliplatin,,3/30/2017,treatment of cholangiocarcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"KC Specialty Therapeutics, LLC",2002 West 39th Avenue,,Kansas City,Arkansas,' 66103 ' ,United States,561716,cholangiocarcinoma,"""gard:0009304""",
4122,liposomal P-ethoxy growth factor receptor-bound protein 2 antisense oligonucleotide,,4/27/2015,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Bio-Path Holdings, Inc.",4710 Bellaire Blvd,Suite 210,Houston,Texas,' 77401 ' ,United States,472115,acute myeloid leukemia,"""gard:0012757""",
4123,liposomal p-ethoxy growth receptor bound protein-2 antisense product,,12/5/2003,treatment of chronic myelogenous leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Bio-Path, Inc.","3293 Harrison Blvd., Suite 230",,Ogden,Utah,' 84403 ' ,United States,179103,,,
4124,Liposomal prostaglandin E1 injection,,4/25/1996,treatment of acute respiratory distress syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Liposome Company, Inc.",One Research Way,,Princeton,New Jersey,' 08540 ' ,United States,95596,,,
4125,liposomal topotecan hydrochloride,,10/30/2008,treatment of gliomas,Designated,,Not FDA Approved for Orphan Indication,,,,,"MedGenesis Therapeutix, Inc.",730-730 View Street,,Victoria,,' ' ,Canada,268508,,,
4126,liposomal vinorelbine,,7/13/2017,treatment of soft tissue carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Taiwan Liposome Company, Ltd.",3 Yuanqu Street,,,Taipei City,' ' ,Taiwan,588417,noma,"""gard:0004001""",
4127,liposomal vinorelbine,,10/12/2016,treatment of cutaneous t-cell lymphoma (ctcl),Designated,,Not FDA Approved for Orphan Indication,,,,,"Taiwan Liposome Company, Ltd.","11F-1, No. 3, Yuanqu Street",,Taipei City,Nangang District,' ' ,Taiwan,540716,lymphoma,"""gard:0020548""",
4128,liposomal Ã}Â±-galactosylceramide,,9/28/2012,prevention of graft-versus-host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,REGiMMUNE Corporation,320 Logue Avenue,,Mountain View,California,' 94043 ' ,United States,370612,,,
4129,"Liposomal-cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane-Pt (II)",,9/1/1999,treatment of malignant mesothelioma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Antigenics Incorporated,3 Forbes Road,,Lexington,Massachusetts,' 02421 ' ,United States,126599,,,
4130,liposome encapsulated paclitaxel,,12/3/2014,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Benuvia Therapeutics, LLC",3950 N. Mays Street,,Round Rock,Texas,' 78665 ' ,United States,454014,,,
4131,Liposome encapsulated recombinant interleukin-2,,6/20/1994,treatment of cancers of the kidney and renal pelvis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Oncothyreon Canada, Inc.",2011 - 94th Street NW,,Edmonton,,' ' ,Canada,78493,,,
4132,Liposome encapsulated recombinant interleukin-2,,11/25/1991,treatment of brain and cns tumors.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Oncothyreon Canada, Inc.","2011-94 St., NW",Suite 200,Edmonston,,' ' ,Canada,62991,,,
4133,Lisavanbulin,,7/27/2021,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Basilea Pharmaceutical International Ltd.,Grenzacherstrasse 487,,Basel,BS,' 4058 ' ,Switzerland,828321,,,
4134,lisinopril oral solution,,10/14/2015,treatment of hypertension in pediatric patients 0 through 16 years of age.,Designated/Designation Withdrawn or Revoked,4/28/2016,Not FDA Approved for Orphan Indication,,,,,"Silvergate Pharmaceuticals, Inc.",6251 Greenwood Plaza Blvd.,Suite 101,Greenwood Village,Colorado,' 80111 ' ,United States,481915,,,
4135,lisinopril oral solution,,1/27/2015,treatment of primary hypertension with complications and secondary hypertension in pediatric patients (ages 0 through 16 years of age),Designated/Designation Withdrawn or Revoked,4/28/2016,Not FDA Approved for Orphan Indication,,,,,"BioRamo, LLC",5319 NW 35th Terrace,,Ft. Lauderdale,Florida,' 33309 ' ,United States,365512,,,
4136,lisocabtagene maraleucel,,4/17/2023,treatment of splenic marginal zone lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",400 Dexter Avenue N.,Suite 1200,Seattle,Washington,' 98109 ' ,United States,933623,lymphoma,"""gard:0020548""",
4137,lisocabtagene maraleucel,,4/17/2023,treatment of extranodal marginal zone lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",400 Dexter Avenue N.,Suite 1200,Seattle,Washington,' 98109 ' ,United States,933823,lymphoma,"""gard:0020548""",
4138,lisocabtagene maraleucel,Breyanzi,9/7/2017,treatment of follicular lymphoma (fl),Designated/Approved,,,treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received 2 or more prior lines of systemic therapy,5/15/2024,,,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",400 Dexter Avenue N,,Seattle,Washington,' 98109 ' ,United States,600517,lymphoma,"""gard:0020548""",
4139,lisocabtagene maraleucel,Breyanzi,10/4/2016,treatment of chronic lymphocytic leukemia,Designated/Approved,,,"treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy including, a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor",3/14/2024,3/14/2031,"treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least 2 prior lines of therapy including, a Bruton tyrosine kinase (BTK) inhibitor and a B-cell lymphoma 2 (BCL-2) inhibitor","Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",400 Dexter Avenue North,Suite 1200,Seattle,Washington,' 98109 ' ,United States,538816,,,
4140,lisocabtagene maraleucel,Breyanzi,4/1/2020,treatment of mantle cell lymphoma,Designated/Approved,,,"treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least 2 prior lines of systemic therapy, including a Bruton tyrosine kinase (BTK) inhibitor",5/30/2024,,,"Juno Therapeutics, Inc.",400 Dexter Avenue N,400 Dexter Avenue N,Seattle,Washington,' 98109 ' ,United States,730920,lymphoma,"""gard:0020548""",
4141,lisocabtagene maraleucel,,3/30/2023,treatment of nodal marginal zone lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",400 Dexter Avenue N.,Suite 1200,Seattle,Washington,' 98109 ' ,United States,933723,lymphoma,"""gard:0020548""",
4142,lisocabtagene maraleucel,Breyanzi,9/7/2017,treatment of follicular lymphoma (fl),Designated/Approved,,,"treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B",2/5/2021,2/5/2028,treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy; treatment of adult patients with relapsed or refractory primary mediastinal large B-cell lymphoma after two or more lines of systemic therapy; and treatment of adult patients with relapsed or refractory follicular lymphoma grade 3B after two or more lines of systemic therapy,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",400 Dexter Avenue N,,Seattle,Washington,' 98109 ' ,United States,600517,lymphoma,"""gard:0020548""",
4143,lisocabtagene maraleucel,Breyanzi,7/12/2018,treatment of primary mediastinal large b-cell lymphoma,Designated/Approved,,,"treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B",2/5/2021,2/5/2028,treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma) after two or more lines of systemic therapy; treatment of adult patients with relapsed or refractory primary mediastinal large B-cell lymphoma after two or more lines of systemic therapy; and treatment of adult patients with relapsed or refractory follicular lymphoma grade 3B after two or more lines of systemic therapy,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",400 Dexter Ave N,,Seattle,Washington,' 98109 ' ,United States,644018,lymphoma,"""gard:0020548""",
4144,lisocabtagene maraleucel,Breyanzi,4/27/2016,treatment of diffuse large b-cell lymphoma,Designated/Approved,,,"treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B",2/5/2021,2/5/2028,treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy; treatment of adult patients with relapsed or refractory primary mediastinal large B-cell lymphoma after two or more lines of systemic therapy; and treatment of adult patients with relapsed or refractory follicular lymphoma grade 3B after two or more lines of systemic therapy,"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",400 Dexter Avenue North,,Seattle,Washington,' 98109 ' ,United States,516115,lymphoma,"""gard:0020548""",
4145,lisocabtagene maraleucel,Breyanzi,7/12/2018,treatment of primary mediastinal large b-cell lymphoma,Designated/Approved,,,"Treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age. Limitations of Use: Breyanzi is not indicated for the treatment of patients with primary central nervous system (CNS) lymphoma.",6/24/2022,6/24/2029,"Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age (not including treatment of patients with primary central nervous system (CNS) lymphoma and excluding patients covered by the indication that received marketing approval on February 5, 2021 for Breyanzi)","Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",400 Dexter Ave N,,Seattle,Washington,' 98109 ' ,United States,644018,lymphoma,"""gard:0020548""",
4146,lisocabtagene maraleucel,Breyanzi,9/7/2017,treatment of follicular lymphoma (fl),Designated/Approved,,,"Treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age. Limitations of Use: Breyanzi is not indicated for the treatment of patients with primary central nervous system (CNS) lymphoma.",6/24/2022,6/24/2029,"Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age (not including treatment of patients with primary central nervous system (CNS) lymphoma and excluding patients covered by the indication that received marketing approval on February 5, 2021 for Breyanzi)","Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",400 Dexter Avenue N,,Seattle,Washington,' 98109 ' ,United States,600517,lymphoma,"""gard:0020548""",
4147,lisocabtagene maraleucel,Breyanzi,4/27/2016,treatment of diffuse large b-cell lymphoma,Designated/Approved,,,"Treatment of adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age. Limitations of Use: Breyanzi is not indicated for the treatment of patients with primary central nervous system (CNS) lymphoma.",6/24/2022,6/24/2029,"Treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) , primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who have refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation (HSCT) due to comorbidities or age (not including treatment of patients with primary central nervous system (CNS) lymphoma and excluding patients covered by the indication that received marketing approval on February 5, 2021 for Breyanzi)","Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",400 Dexter Avenue North,,Seattle,Washington,' 98109 ' ,United States,516115,lymphoma,"""gard:0020548""",
4148,Lisofylline,,6/10/1999,treatment of patients undergoing induction therapy for acute myeloid leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cell Therapeutics, Inc.",501 Elliott Avenue West,Suite 400,Seattle,Washington,' 98119 ' ,United States,124099,acute myeloid leukemia,"""gard:0012757""",
4149,listeria monocytogenes,,9/5/2013,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,1/29/2019,Not FDA Approved for Orphan Indication,,,,,"Aduro BioTech, Inc.",740 Heinz Avenue,,Berkeley,California,' 94710 ' ,United States,386212,,,
4150,lisuride,,1/17/2013,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,Sinoxa Pharma GmbH,Thomasiusstr.13,,Berlin,,' ' ,Germany,316610,pulmonary arterial hypertension,"""gard:0007501""",
4151,Lisuride Maleate,,10/24/2022,treatment of fragile x syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,NeuroVenti Inc.,"15, Seolleung-ro 121-gil",,Seoul,Gangnam-gu,' 06100 ' ,South Korea,906822,fragile x syndrome,"""gard:0006464""",
4152,lithium carbonate,,3/29/2021,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Lispiro LLC,4 Betsy Lane,,Dover,Massachusetts,' 02030 ' ,United States,808921,idiopathic pulmonary fibrosis,"""gard:0008609""",
4153,lithium citrate tetrahydrate (in reverse micelle formulation),,12/13/2010,treatment of huntington's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Medesis Pharma,L'Oree des Mas,,Baillargues,,' ' ,France,325510,,,
4154,live attenuated bioengineered Listeria monocytogenes immunotherapy,,5/21/2014,treatment of osteosarcoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,OS Therapies Incorporated,104 Tech Drive,,Cambridge,Massachusetts,' 21613 ' ,United States,437714,osteosarcoma,"""gard:0007284""",
4155,live attenuated bioengineered Listeria monocytogenes immunotherapy,,11/4/2013,treatment of human papilloma virus-associated head and neck cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ayala Pharmaceuticals, Inc.","9 Deer Park Drive, Suite K-1",,Monmouth Junction,New Jersey,' 08852 ' ,United States,403113,,,
4156,live attenuated E. Coli expressing Beta catenin shRNA,,12/20/2010,treatment of familial adenomatous polyposis,Designated,,Not FDA Approved for Orphan Indication,,,,,Marina Biotech,One Kendall Square,"Building 400, Suite B4401",Cambridge,Massachusetts,' 02139 ' ,United States,326210,familial adenomatous polyposis,"""gard:0006408""",
4157,Live attenuated Salmonella enterica Serovar Typhimurium (S. Typhimurium),,5/10/2022,treatment of schwannoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mulberry Biotherapeutics, Inc.",40 Walnut Street,Suite 301,Wellesley,Massachusetts,' 02481 ' ,United States,874522,noma,"""gard:0004001""",
4158,live bacterial product consisting of defined consortia of Clostridium clusters live bacterial product consisting of defined consortia of Clostridium clusters,,11/2/2017,prevention of recurrent clostridium difficile infection in individuals with prior recurrent clostridium difficile infection,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vedanta Biosciences, Inc.",19 Blackstone Street,Third Floor,Cambridge,Massachusetts,' 02139 ' ,United States,573717,,,
4159,live biotherapeutic consisting of metP and metDC genes which are incorporated into the genome of a probiotic strain of E. coli Nissie 1917,,11/22/2022,treatment of homocystinuria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Synlogic Operating Company, Inc.",301 Binney St.,,Cambridge,Massachusetts,' 02142 ' ,United States,876922,cystinuria,"""gard:0006237""",
4160,Live biotherapeutic product consisting of a single bacterial strain (Leuconostoc citreum [L. citreum]),,12/1/2022,treatment of primary sclerosing cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,LISCure Biosciences Inc.,"4F, 68, Pangyo-ro 255beon-gil, Bundang-gu,",,Seongnam-si,Gyeonggi-do,' 13486 ' ,South Korea,914722,sclerosing cholangitis,"""gard:0021868""",
4161,live E. coli Nissle bacterium modified to assimilate ammonia,,8/22/2016,treatment of urea cycle disorders,Designated,,Not FDA Approved for Orphan Indication,,,,,"Synlogic, Inc.",200 Sidney Street,#320,Cambridge,Massachusetts,' 02139 ' ,United States,529516,,,
4162,Live-attenuated Listeria monocytogenes actA/inlB/human mesothelin (hMeso) Strain hMeso38,,3/24/2015,treatment of mesothelioma.,Designated/Designation Withdrawn or Revoked,1/29/2019,Not FDA Approved for Orphan Indication,,,,,"Aduro BioTech, Inc.",740 Heinz Avenue,,Berkeley,California,' 94710 ' ,United States,468614,,,
4163,lixivaptan,,9/18/2017,treatment of autosomal dominant polycystic kidney disease (adpkd),Designated,,Not FDA Approved for Orphan Indication,,,,,"Palladio Biosciences, Inc.",12 Penns Trail,Unit A,Newtown,Pennsylvania,' 18940 ' ,United States,589617,autosomal dominant polycystic kidney disease,"""gard:0010413""",
4164,lixudebart,,5/24/2024,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Alentis Therapeutics AG,Hegenheimermattweg 167A,,Allschwil,,' 4123 ' ,Switzerland,1002824,idiopathic pulmonary fibrosis,"""gard:0008609""",
4165,lixumistat,,12/27/2023,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"ImmunoMet Therapeutics, Inc.",JLABS at TMC,2450 Holcombe Blvd.,"Houston,",Texas,' 77021 ' ,United States,979623,,,
4166,"LOAd703, a modified adenovirus 5/35 containing a CMV promoter-driven transgene cassette with the human transgenes for a membrane-bound CD40 ligand (TMZ-CD40L) and full length 4-1BBL",,5/4/2015,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Lokon Pharma AB,Dag Hammarskjoldsvag 40c,,Uppsala,,' ' ,Sweden,477315,,,
4167,Lodoxamide tromethamine,Alomide Ophthalmic Solution,10/16/1991,treatment of vernal keratoconjunctivitis.,Designated/Approved,,,"Treatment of ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, vernal keratitis.",9/23/1993,9/23/2000,,"Alcon Laboratories, Inc.",6201 South Freeway,,Fort Worth,Texas,' 76134 ' ,United States,59791,vernal keratoconjunctivitis,"""gard:0007854""",
4168,lomitapide,Juxtapid,10/23/2007,treatment of homozygous familial hypercholesterolemia,Designated/Approved,,,"Adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).",12/21/2012,12/21/2019,,Chiesi Farmaceutici S.p.A.,Via Palermo 26/A,,Parma,Emilia Romagna,' 43122 ' ,Italy,245907,homozygous familial hypercholesterolemia,"""gard:0010416""",
4169,lomitapide,,3/3/2011,treatment of familial chylomicronemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Chiesi Farmaceutici S.p.A.,Via Palermo 26/A,,Parma,Emilia Romagna,' 43122 ' ,Italy,332110,,,
4170,lonafarnib,,11/19/2013,treatment of hepatitis delta virus (hdv)infection,Designated,,Not FDA Approved for Orphan Indication,,,,,"Eiger Biopharmaceuticals, Inc.",PO Box 430,,San Carlos,California,' 94070 ' ,United States,411713,hepatitis delta,"""gard:0021716""",
4171,lonafarnib,ZOKINVY,4/18/2011,treatment of hutchinson-gilford progeria syndrome and progeroid laminopathies,Designated/Approved,,,in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above (1) to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS); and (2) for the treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations,11/20/2020,11/20/2027,in patients 12 months of age and older with a body surface area (BSA) of 0.39 m2 and above: (1) to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS); and (2) for the treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations,"Eiger BioPharmaceuticals, Inc.",2155 Park Boulevard,,Palo Alto,California,' 94306 ' ,United States,333411,hutchinson-gilford progeria syndrome,"""gard:0007467""",
4172,lonapegsomatropin-tcgd,Skytrofa,4/13/2020,treatment of growth hormone deficiency,Designated/Approved,,,Treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH),8/25/2021,,,Ascendis Pharma Endocrinology Division A/S,12 Tuborg Boulevard,,Hellerup,,' ' ,Denmark,654718,,,
4173,loncastuximab tesirine-lpyl,Zynlonta,6/8/2017,treatment of diffuse large b-cell lymphoma,Designated/Approved,,,"treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma",4/23/2021,4/23/2028,treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy,ADC Therapeutics SA,"Route de la Corniche, 3B",,Epalinges,Vaud,' ' ,Switzerland,572716,lymphoma,"""gard:0020548""",
4174,long acting recombinantFactor VIIa-CTP3,,2/27/2014,treatment and prophylaxis of bleeding episodes in patients with hemophilia a or b with inhibitors to factor viii or factor ix,Designated,,Not FDA Approved for Orphan Indication,,,,,"OPKO Biotech, Ltd",16 Ashlagan Street,,Kiryat Gat 8211804,,' ' ,Israel,417913,hemophilia,"""gard:0010418""",
4175,Lorcaserin,,8/31/2020,treatment of dravet syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.,100 Tice Boulevard,,Woodcliff Lake,New Jersey,' 07677 ' ,United States,758920,dravet syndrome,"""gard:0010430""",
4176,lorcaserin,,4/17/2017,treatment of dravet syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Epygenix Therapeutics, Inc.","630 W. Germantown Pike, Suite 215",,Plymouth Meeting,Pennsylvania,' 19462 ' ,United States,565816,dravet syndrome,"""gard:0010430""",
4177,Lorcaserin,,7/21/2021,treatment of lennox-gastaut syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Epygenix Therapeutics, Inc.",140 E Ridgewood Avenue,"Suite 415, South Tower",Paramus,New Jersey,' 07652 ' ,United States,828021,lennox-gastaut syndrome,"""gard:0009912""",
4178,Lorlatinib; lorlatinib,LORBRENA; Lorbrena,6/23/2015,treatment of anaplastic lymphoma kinase (alk)-positive or ros1-positive non-small cell lung cancer,Designated/Approved,,,treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.,3/3/2021,3/3/2028,"Treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test, excluding patients whose disease has progressed on crizotinib and at least one other ALK inhibitor; or alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.","Pfizer, Inc.",66 Hudson Boulevard East,,New York,New York,' 10001 ' ,United States,481015,lymphoma,"""gard:0020548""",
4179,Lorlatinib; lorlatinib,LORBRENA; Lorbrena,6/23/2015,treatment of anaplastic lymphoma kinase (alk)-positive or ros1-positive non-small cell lung cancer,Designated/Approved,,,LORBRENA® is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or alectinib as the first ALK inhibitor therapy for metastatic disease; or ceritinib as the first ALK inhibitor therapy for metastatic disease.,11/2/2018,11/2/2025,LORBRENA® is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or alectinib as the first ALK inhibitor therapy for metastatic disease; or ceritinib as the first ALK inhibitor therapy for metastatic disease.,"Pfizer, Inc.",66 Hudson Boulevard East,,New York,New York,' 10001 ' ,United States,481015,lymphoma,"""gard:0020548""",
4180,Losartan,,1/29/2019,treatment of epidermolysis bullosa,Designated,,Not FDA Approved for Orphan Indication,,,,,Crowd Pharma Losartan GmbH & Co. KG,Merkurstr. 8,,Dobel,Pforzheim,' 75179 ' ,Germany,668618,,,
4181,losartan,,12/12/2011,treatment of marfan syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,National Marfan Foundation,22 Manhhasset Avenue,,Port Washington,New York,' 11050 ' ,United States,357211,marfan syndrome,"""gard:0016535""",
4182,losmapimod,,1/27/2020,treatment of facioscapulohumeral muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Fulcrum Therapeutics, Inc.",26 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,721919,muscular dystrophy,"""gard:0007922""",
4183,lovotibeglogene autotemcel,Lyfgenia,2/26/2014,for the treatment of sickle cell disease,Designated/Approved,,,treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events,12/8/2023,12/8/2030,treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events,bluebird bio Inc.,60 Binney Street,,Cambridge,Massachusetts,' 02142 ' ,United States,420413,,,
4184,low molecular weight dextran sulfate,,7/6/2011,treatment to mobilze progenitor cells prior to stem cell transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,TikoMed AB,P.O. Box 81 (Karlsfaltsvagen 349),"SE-263 03, Viken",Viken,,' ' ,Sweden,344711,,,
4185,low molecular weight dextran sulfate,,10/20/2009,prevention of graft rejection during pancreatic islet transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,TikoMed AB,P.O. Box 81 (Karlsfaltsvagen 349),"SE-263 03, Viken",Viken,,' ' ,Sweden,292609,,,
4186,Low molecular weight dextran sulfate (LMW-DS),,7/28/2020,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,TikoMed AB,P.O. Box 81,Karlsfaltsvagen 349,Viken,,' ' ,Sweden,752220,amyotrophic lateral sclerosis,"""gard:0005786""",
4187,Loxoribine,,2/24/1992,treatment of common variable immunodeficiency.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,R. W. Johnson Pharmaceutical Research Institute,"Route 202, P.O. Box 300",,Raritan,New Jersey,' 08869 ' ,United States,54390,common variable immunodeficiency,"""gard:0006140""",
4188,"Lu-177(3+),2-[[5-(2,6-dimethoxyphenyl)-1-[2-isopropyl-4-[methyl-[3-[methyl-[3-[methyl-[2-[4,7,10- tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]propyl]amino]propyl]carbamoyl]phenyl]pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid",,10/28/2019,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Fusion Pharmaceuticals Inc.,"Two International Place, Ste 2310",,Boston,Massachusetts,' 02110 ' ,United States,708119,,,
4189,lucerastat,,10/29/2015,treatment of fabry disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Idorsia Pharmaceuticals US Inc.,1820 Chapel Avenue West,Suite 150,Cherry Hill,New Jersey,' 08002 ' ,United States,495815,fabry disease,"""gard:0006400""",
4190,Lucinactant,,10/21/2010,treatment of cystic fibrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Lee’s Pharmaceutical (HK) Limited,"1/F, Building 20E, Phase 3",Hong Kong Science Park,Shatin,,' ' ,Hong Kong,318910,cystic fibrosis,"""gard:0006233""",
4191,Lucinactant,,5/23/2006,prevention of bronchopulmonary dysplasia in premature infants,Designated,,Not FDA Approved for Orphan Indication,,,,,Lee’s Pharmaceutical (HK) Limited,"1/F, Building 20E, Phase 3",Hong Kong Science Park,Shatin,,' ' ,Hong Kong,211405,bronchopulmonary dysplasia,"""gard:0005962""",
4192,Lucinactant,,7/17/1995,treatment of acute respiratory distress syndrome in adults.,Designated,,Not FDA Approved for Orphan Indication,,,,,Lee’s Pharmaceutical (HK) Limited,"1/F, Building 20E, Phase 3",Hong Kong Science Park,Shatin,,' ' ,Hong Kong,89995,,,
4193,Lucinactant,,10/18/1995,treatment of respiratory distress syndrome in premature infants.,Designated,,Not FDA Approved for Orphan Indication,,,,,Lee’s Pharmaceutical (HK) Limited,"1/F, Building 20E, Phase 3",Hong Kong Science Park,Shatin,,' ' ,Hong Kong,91395,,,
4194,Lucinactant,,10/21/2005,treatment of bronchopulmonary dysplasia in premature infants.,Designated,,Not FDA Approved for Orphan Indication,,,,,Lee’s Pharmaceutical (HK) Limited,"1/F, Building 20E, Phase 3",Hong Kong Science Park,Shatin,,' ' ,Hong Kong,208705,bronchopulmonary dysplasia,"""gard:0005962""",
4195,Lucinactant,,7/30/1996,treatment of meconium aspiration syndrome in newborn infants,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Windtree Therapeutics, Inc.",2600 Kelly Road,Suite 100,Warrington,Pennsylvania,' 18976 ' ,United States,99796,meconium aspiration syndrome,"""gard:0010494""",
4196,Lumacaftor,,9/9/2020,treatment of subarachnoid hemorrhage,Designated,,Not FDA Approved for Orphan Indication,,,,,Qanatpharma AG,Alter Postplatz 2,,Stans,,' 6370 ' ,Switzerland,761720,,,
4197,lumacaftor and ivacaftor,Orkambi,6/30/2014,treatment of cystic fibrosis,Designated/Approved,,,Treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene,9/2/2022,9/2/2029,Treatment of cystic fibrosis (CF) in patients aged 1 year to less than 2 years who are homozygous for the F508del mutation in the CFTR gene,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,434814,cystic fibrosis,"""gard:0006233""",
4198,lumacaftor/ivacaftor,Orkambi,6/30/2014,treatment of cystic fibrosis,Designated/Approved,,,ORKAMBI is a combination of lumacaftor and ivacaftor indicated for the treatment of cystic fibrosis (CF) in patients age 2 years and older who are homozygous for the F508del mutation in the CFTR gene.,8/7/2018,8/7/2025,ORKAMBI (lumacaftor/ivacaftor) oral granules indicated for the treatment of cystic fibrosis (CF) in patients age 2 through 5 years old who are homozygous for the F508del mutation in the CFTR gene.,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,434814,cystic fibrosis,"""gard:0006233""",
4199,lumacaftor/ivacaftor,Orkambi,6/30/2014,treatment of cystic fibrosis,Designated/Approved,,,Treatment of cystic fibrosis in patients age 12 years and older who are homozygous for F508del mutation in the CFTR gene,7/2/2015,7/2/2022,Treatment of cystic fibrosis in patients age 12 years and older who are homozygous for F508del mutation in the CFTR gene,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,434814,cystic fibrosis,"""gard:0006233""",
4200,lumacaftor/ivacaftor,Orkambi,6/30/2014,treatment of cystic fibrosis,Designated/Approved,,,Treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene,9/28/2016,9/28/2023,Treatment of cystic fibrosis (CF) in patients age 6-11 years old who are homozygous for the F508del mutation in the CFTR gene,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,434814,cystic fibrosis,"""gard:0006233""",
4201,lumasiran,Oxlumo,2/8/2016,treatment of primary hyperoxaluria type 1,Designated/Approved,,,Treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients,10/6/2022,10/6/2029,Treatment of primary hyperoxaluria type 1 (PH1) to lower plasma oxalate levels in pediatric and adult patients,Alnylam Pharmaceuticals,300 Third Street,,Cambridge,Massachusetts,' 02142 ' ,United States,505315,primary hyperoxaluria,"""gard:0016530""",
4202,lumasiran,Oxlumo,2/8/2016,treatment of primary hyperoxaluria type 1,Designated/Approved,,,treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients,11/23/2020,11/23/2027,treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients,"Alnylam Pharmaceuticals, Inc.",300 Third Street,,Cambridge,Massachusetts,' 02142 ' ,United States,505315,primary hyperoxaluria,"""gard:0016530""",
4203,luminol monosodium,,5/1/2023,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,MetrioPharm AG,Europaallee 41,,Zurich,,' 8004 ' ,Switzerland,935523,muscular dystrophy,"""gard:0007922""",
4204,lurbinectedin,,8/20/2012,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"PharmaMar USA, Inc.",205 East 42nd St.,Suite 15003,New York,New York,' 10017 ' ,United States,376512,ovarian cancer,"""gard:0007295""",
4205,lurbinectedin,Zepzelca,8/1/2018,treatment of small cell lung cancer (sclc),Designated/Approved,,,Zepzelca (lurbinectedin) is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after prior platinum-based chemotherapy.,6/15/2020,6/15/2027,For the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.,Jazz Pharmaceuticals Ireland Limited,5th Floor Waterloo Exchange,Waterloo Road,Dublin,,' ' ,Ireland,646018,small cell lung cancer,"""gard:0009344""",
4206,luspatercept,,1/16/2020,treatment of myelofibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,718419,,,
4207,luspatercept,,9/21/2021,treatment of alpha-thalassemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Ave,,Summit,New Jersey,' 07901 ' ,United States,837321,alpha-thalassemia,"""gard:0000621""",
4208,luspatercept-aamt,Reblozyl,3/18/2013,treatment of myelodysplastic syndrome,Designated/Approved,,,treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naive) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions,8/28/2023,8/28/2030,treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naive) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions,"Celgene Corporation, a Bristol-Myers Squibb Company",86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,387112,myelodysplastic syndrome,"""gard:0007132""",
4209,Luspatercept-aamt,REBLOZYL,3/11/2013,treatment of b-thalassemia,Designated/Approved,,,REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.,11/8/2019,11/8/2026,Indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,389813,,,
4210,luspatercept-aamt,Reblozyl,3/18/2013,treatment of myelodysplastic syndrome,Designated/Approved,,,REBLOZYL is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).,4/3/2020,4/3/2027,For the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS),"Celgene Corporation, a Bristol-Myers Squibb Company",86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,387112,myelodysplastic syndrome,"""gard:0007132""",
4211,Lusvertikimab,,7/20/2023,treatment of acute lymphoblastic leukemia (all),Designated,,Not FDA Approved for Orphan Indication,,,,,OSE Immunotherapeutics,22 boulevard Benoni-Goullin,,Nantes,FRA,' 44200 ' ,France,949523,acute lymphoblastic leukemia,"""gard:0000522""",
4212,lutetium (177Lu)-edotreotide,,5/21/2015,treatment of gastro-entero-pancreatic neuroendocrine tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,ITM Solucin GmbH,Lichtenbergstrasse 1,,Garching,,' ' ,Germany,479215,,,
4213,lutetium Lu 177 dotatate,,1/12/2009,treatment of gastro-entero-pancreatic neuroendocrine tumors,Designated/Approved,,,"Treatment of somatostatin receptor positive GEP-NETs including foregut, midgut, and hindgut neuroendocrine tumors in adults",1/26/2018,1/26/2025,"Treatment of somatostatin receptor positive GEP-NETs including foregut, midgut, and hindgut neuroendocrine tumors in adults",Advanced Accelerator Applications,57 East Willow Street,,Millburn,New Jersey,' 07041 ' ,United States,271008,,,
4214,lutetium Lu 177 dotatate,Lutathera,1/12/2009,treatment of gastro-entero-pancreatic neuroendocrine tumors,Designated/Approved,,,"treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors",4/23/2024,4/23/2031,"treatment of pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors",Advanced Accelerator Applications,57 East Willow Street,,Millburn,New Jersey,' 07041 ' ,United States,271008,,,
4215,Lutetium-177 labeled humanized monoclonal antibody targeting leucine rich repeat containing 15 (LRRC15),,9/7/2022,treatment of osteosarcoma (os),Designated,,Not FDA Approved for Orphan Indication,,,,,"Radiopharm Theranostics, Inc.",C/O Vcorp Services LLC,701 S. Carson Street,Carson City,Nevada,' 89701 ' ,United States,905122,osteosarcoma,"""gard:0007284""",
4216,luveltamab tazevibulin,,12/7/2022,treatment of pediatric acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sutro Biopharma, Inc.",111 Oyster Point Blvd,,South San Francisco,California,' 94080 ' ,United States,915722,acute myeloid leukemia,"""gard:0012757""",
4217,"Lyophilized microbiota purified from the stool of screened, healthy human donors",,1/3/2023,treatment of pitt hopkins syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Gut-Brain Axis Therapeutics,1340 E. Vinedo Ln,,Tempe,Arizona,' 85284 ' ,United States,922722,,,
4218,Lysine acetylsalicylate injectable,,8/1/1989,treatment of pain and fever secondary to sickle cell disease crisis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,G.D. Searle & Company,4901 Searle Parkway,,Skokie,Illinois,' 60077 ' ,United States,33988,,,
4219,lyso-thermosensitive lipsomal doxorubicin,,3/17/2009,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Imunon,997 Lenox Drive,Suite 100,Lawrenceville,New Jersey,' 08648 ' ,United States,276009,hepatocellular carcinoma,"""gard:0016773""",
4220,lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase,,9/10/2008,treatment of mucopolysaccharidosis type iva (morquio syndrome),Designated,,Not FDA Approved for Orphan Indication,,,,,Vivendy Therapeutics LTD,Peter Merian -Strasse 45,,Basel,,' ' ,Switzerland,267708,mucopolysaccharidosis,"""gard:0007065""",
4221,MA09-hRPE cells,,2/2/2010,treatment of stargardt's macular dystrophy,Designated/Designation Withdrawn or Revoked,6/29/2023,Not FDA Approved for Orphan Indication,,,,,Astellas Pharma Global Development Inc.,1 Astellas Parkway,,Northbrook,Illinois,' 60062 ' ,United States,299409,,,
4222,macimorelin acetate,Macrelin,5/14/2007,diagnosis of growth hormone deficiency,Designated/Approved,,,For the diagnosis of adult growth hormone deficiency,12/20/2017,12/20/2024,For the diagnosis of adult growth hormone deficiency.,Aeterna Zentaris GmbH,WeismilllerstraBe 50,,Frankfurt am Main,,' 60314 ' ,Germany,225506,,,
4223,macitentan,Opsumit,9/3/2009,treatment of pulmonary arterial hypertension,Designated/Approved,,,"Treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). Opsumit also reduced hospitalization for PAH.",10/18/2013,10/18/2020,"Treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). Opsumit also reduced hospitalization for PAH.",Actelion Pharmaceuticals Ltd,Gewerbestrasse 16,,Allschwil,,' ' ,Switzerland,282209,pulmonary arterial hypertension,"""gard:0007501""",
4224,macitentan,,4/14/2009,treatment of idiopathic pulmonary fibrosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Actelion Pharmaceuticals Ltd,Gewerbestrasse 16,,Allschwil,,' ' ,Switzerland,279309,idiopathic pulmonary fibrosis,"""gard:0008609""",
4225,macitentan,,6/15/2017,treatment of chronic thromboembolic pulmonary hypertension (cteph),Designated,,Not FDA Approved for Orphan Indication,,,,,"Actelion Clinical Research, Inc.",1820 Chapel Avenue West,Suite 300,Cherry Hill,New Jersey,' 08002 ' ,United States,580117,chronic thromboembolic pulmonary hypertension,"""gard:0013124""",
4226,macitentan,,6/6/2017,treatment of fontan-palliated patients,Designated,,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1820 Chapel Avenue West,Suite 300,Cherry Hill,New Jersey,' 08002 ' ,United States,574917,,,
4227,macitentan and tadalafil,Opsynvi,10/19/2016,treatment of pulmonary arterial hypertension,Designated/Approved,,,"chronic treatment of adults with pulmonary arterial hypertension (PAH, WHO Group I and WHO Functional Class (FC) II-III)",3/22/2024,3/22/2031,"chronic treatment of adults with pulmonary arterial hypertension (PAH, WHO Group I and WHO Functional Class (FC) II-III)","Actelion Pharmaceuticals US, Inc.","1125 Trenton-Harbourton Road,",1st Floor/B-Wing,Titusville,New Jersey,' 08560 ' ,United States,509615,pulmonary arterial hypertension,"""gard:0007501""",
4228,macromolecular conjugate of heparin sodium on a polymer backbone,,5/2/2017,prevention of ischemia-reperfusion injury associated with solid organ tranplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,Corline Biomedical AB,Lefflersgatan 5,,Uppsala,,' SE-754 50 ' ,Sweden,506915,,,
4229,Mafenide acetate solution,Sulfamylon solution,7/18/1990,for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.,Designated/Approved,,,,6/5/1998,6/5/2005,,"Mylan Laboratories, Inc.",781 Chestnut Ridge Road,P.O. Box 4310,Morgantown,West Virginia,' 26504 ' ,United States,47890,,,
4230,Mafosfamide,,1/21/2003,treatment of neoplastic meningitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Baxter Healthcare Corporation,Route 120 & Wilson Road,,Round Lake,Illinois,' 60073 ' ,United States,162202,,,
4231,MAGE-A3 cancer therapeutic Trojan peptide vaccine,,11/24/2008,treatment of mage-a3 expressing head and neck squamous cell carcinoma,Designated/Designation Withdrawn or Revoked,1/25/2022,Not FDA Approved for Orphan Indication,,,,,"Gliknik, Inc.",801 W. Baltimore Street,Suite 501A,Baltimore,Maryland,' 21201 ' ,United States,269708,noma,"""gard:0004001""",
4232,magnesium lysinate bis eicosapentaenoate,,12/23/2015,treatment of familial adenomatous polyposis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Thetis Pharmaceuticals,167 Old Post Road,2nd Floor,Southport,Connecticut,' 06890 ' ,United States,501115,familial adenomatous polyposis,"""gard:0006408""",
4233,Magnesium lysinate bis Resolvin E1,,3/30/2020,treatment of pediatric ulcerative colitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Thetis Pharmaceuticals,23 Business Park Drive,,Branford,Connecticut,' 06405 ' ,United States,629818,,,
4234,magnesium lysinate-bis-resolvin E1,,7/20/2021,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Thetis Pharmaceuticals,"54 Danbury Rd., Suite 285",,Ridgefield,Connecticut,' 06877 ' ,United States,826721,,,
4235,Magnetic nanocarrier-conjugated small interfering RNA against programmed death ligand 1,,6/14/2022,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"TransCode Therapeutics, Inc",6 Liberty Square #2382,,Boston,Massachusetts,' 02109 ' ,United States,882122,,,
4236,Magrolimab,,12/18/2019,treatment of myelodysplastic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,716319,myelodysplastic syndrome,"""gard:0007132""",
4237,manganese (II) chloride tetrahydrate (with L-alanine and vitamin D3 as promoters of absorption),,9/26/2013,use as a targeted contrast agent for diagnostic mri for the detection and localization of focal liver lesions in patients where use of gadolinium based contrast agents may be medically inadvisable or where gadolinium based contrast agents cannot be admini,Designated,,Not FDA Approved for Orphan Indication,,,,,Ascelia Pharma AB,Scion DTU,DK-2800 Lyngby,Lund,,' ' ,Sweden,342911,,,
4238,Manganese butoxyethyl pyridyl porphyrin,,1/9/2020,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioMimetix JV, LLC",5340 South Quebec Street,Suite 345N,Greenwood Village,Colorado,' 80111 ' ,United States,717419,,,
4239,Manganese superoxide dismutase mimetic,,2/27/2008,prevention of radiation- or chemotherapy-induced oral mucositis in cancer patients,Designated,,Not FDA Approved for Orphan Indication,,,,,"Galera Therapeutics, LLC",2 West Liberty Blvd,Suite 110,Malvern,Pennsylvania,' 19355 ' ,United States,243907,,,
4240,MANNITOL,Bronchitol®,2/11/2005,for use to facilitate clearance of mucus in patients with bronchiectasis and in patients with cystic fibrosis at risk for bronchiectasis,Designated/Approved,,,as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use Bronchitol only for adults who have passed the Bronchitol Tolerance Test.,10/30/2020,10/30/2027,as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis and who have passed the Bronchitol Tolerance Test,"Chiesi Farmaceutici S.p.A (Chiesi USA, Inc.)",175 Regency Woods Place,Suite 600,Cary,North Carolina,' 27518 ' ,United States,198704,cystic fibrosis,"""gard:0006233""",
4241,mannopentaose phosphate sulfate,,4/27/2004,"treatment of high-risk stage ii, stage iii, and stage iv melanoma",Designated,,Not FDA Approved for Orphan Indication,,,,,Medigen Biotechnology Corp.,"14F, No. 3, Yuancyu St.",Nangang District,Taipei City 11503,,' ' ,Taiwan,179603,noma,"""gard:0004001""",
4242,maplirpacept,,12/6/2023,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,Pfizer Inc.,10646 Science Center Drive,,San Diego,California,' 92121 ' ,United States,954123,acute myeloid leukemia,"""gard:0012757""",
4243,maralixibat,Livmarli,9/4/2013,treatment of progressive familial intrahepatic cholestasis,Designated/Approved,,,treatment of cholestatic pruritus in patients 5 years of age and older with progressive familial intrahepatic cholestasis (PFIC),3/13/2024,3/13/2031,treatment of cholestatic pruritus in patients 5 years of age and older with progressive familial intrahepatic cholestasis (PFIC),"Mirum Pharmaceuticals, Inc.",950 Tower Lane,Suite 1050,Foster City,California,' 94404 ' ,United States,406013,familial intrahepatic cholestasis,"""gard:0021119""",
4244,maralixibat,,10/21/2020,treatment of biliary atresia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mirum Pharmaceuticals, Inc.",950 Tower Lane,Suite 1050,Foster City,California,' 94404 ' ,United States,705519,,,
4245,maralixibat,Livmarli,9/4/2013,treatment of alagille syndrome,Designated/Approved,,,Treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older,9/29/2021,9/29/2028,Treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older,"Mirum Pharmaceuticals, Inc.",950 Tower Lane,Suite 1050,Foster City,California,' 94404 ' ,United States,401513,alagille syndrome,"""gard:0000804""",
4246,maralixibat,Livmarli,9/4/2013,treatment of alagille syndrome,Designated/Approved,,,treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 3 months of age and older,3/13/2023,3/13/2030,treatment of cholestatic pruritus in patients 3 months of age to less than 1 year of age with Alagille syndrome (ALGS),"Mirum Pharmaceuticals, Inc.",950 Tower Lane,Suite 1050,Foster City,California,' 94404 ' ,United States,401513,alagille syndrome,"""gard:0000804""",
4247,margetuximab,,6/3/2020,treatment of gastric and gastroesophageal junction cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"MacroGenics, Inc.",9704 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,739820,,,
4248,maribavir,,2/1/2007,prevention of cytomegalovirus viremia and disease in the populations at risk.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Phrmaceuticals USA, Inc.",650 East Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,229906,,,
4249,maribavir,Livtencity,6/7/2011,treatment of clinically significant cytomegalovirus viremia and disease in at-risk patients.,Designated/Approved,,,"Treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet",11/23/2021,11/23/2028,"Treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet","Takeda Pharmaceuticals USA, Inc.",650 East Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,332210,,,
4250,Marijuana,,5/25/1999,treatment of hiv-associated wasting syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Multidisciplinary Association for Psychedelic Studies, Inc.",3 Francis St.,,Belmont,Massachusetts,' 02478 ' ,United States,105397,,,
4251,marizomib,,9/21/2015,treatment of malignant glioma.,Designated/Designation Withdrawn or Revoked,4/20/2023,Not FDA Approved for Orphan Indication,,,,,Celgene International II S?,Rue du Pre-Jorat 14,,Couvet,Neuchâtel,' ' ,Switzerland,490015,,,
4252,marizomib,,12/13/2013,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,4/20/2023,Not FDA Approved for Orphan Indication,,,,,Celgene International II S?,4 Rue des Moulins,,Couvet,Neuchâtel,' ' ,Switzerland,414313,multiple myeloma,"""gard:0007108""",
4253,marstacimab,,5/18/2016,"treatment of hemophilia a and hemophilia b patients with or without inhibitors, which includes routine prophylaxis to prevent or reduce the frequency of bleeding in hemophilia a and hemophilia b patients.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",66 Hudson Boulevard East,,New York,New York,' 10001 ' ,United States,521916,hemophilia,"""gard:0010418""",
4254,MART-1 adenoviral gene therapy for malignant melanoma,,3/28/1997,treatment of metastatic melanoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,One Mountain Road,P.O. Box 9322,Framingham,Massachusetts,' 01701 ' ,United States,103096,noma,"""gard:0004001""",
4255,marzeptacog alfa (activated),,11/30/2012,routine prophylaxis to prevent bleeding episodes in patients with hemophilia a and b patients with inhibitors,Designated,,Not FDA Approved for Orphan Indication,,,,,GC Biopharma Corp.,"107 Ihyeon-ro 30 beong-gil, Giheung-gu",,Yongin-si,Gyeonggi-do,' ' ,South Korea,377612,hemophilia,"""gard:0010418""",
4256,Marzeptacog alfa (activated),,9/27/2021,treatment of factor vii deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,GC Biopharma Corp.,"107 Ihyeon-ro 30 beong-gil, Giheung-gu",,Yongin-si,Gyeonggi-do,' ' ,South Korea,837721,,,
4257,Marzeptacog alfa (activated),,12/15/2021,"treatment of bleeding episodes in patients with hemophilia a or b, including those with inhibitors",Designated,,Not FDA Approved for Orphan Indication,,,,,GC Biopharma Corp.,"107 Ihyeon-ro 30 beong-gil, Giheung-gu",,Yongin-si,Gyeonggi-do,' ' ,South Korea,820721,hemophilia,"""gard:0010418""",
4258,masitinib,,7/21/2009,treatment of patients with pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,AB Science,"3, avenue George V",,"Paris,",,' ' ,France,285309,,,
4259,masitinib,,4/20/2005,treatment of malignant gastrointestinal stromal tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,AB Science,"3, avenue George V",,Paris,,' ' ,France,201005,gastrointestinal stromal tumor,"""gard:0008598""",
4260,masitinib,,9/14/2005,treatment of mastocytosis,Designated,,Not FDA Approved for Orphan Indication,,,,,AB Science,"3, avenue GeorgeV",75008,Paris,,' ' ,France,201505,mastocytosis,"""gard:0006987""",
4261,masitinib mesylate,,3/18/2015,treatment of amyotrophic lateral sclerosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,AB Science,"3, avenuve George V",75008,Paris,,' ' ,France,469415,amyotrophic lateral sclerosis,"""gard:0005786""",
4262,masitinib mesylate,,9/14/2015,treatment of gastric cancer including cancer of the gastroesophageal junction,Designated,,Not FDA Approved for Orphan Indication,,,,,AB Science,"3, avenue George V",,Paris,,' ' ,France,490815,,,
4263,Masked immunocytokine (MIC) comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a,,5/31/2022,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nammi Therapeutics, Inc","10940 Wilshire Blvd., STE 600",,Los Angeles,California,' 90024 ' ,United States,879622,,,
4264,Masked immunocytokine comprised of an anti-CD138 immunoglobulin G1 antibody fused to interferon alpha 2a,,5/31/2022,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nammi Therapeutics, Inc","10940 Wilshire Blvd., STE 600",,Los Angeles,California,' 90024 ' ,United States,879522,multiple myeloma,"""gard:0007108""",
4265,Matrix metalloproteinase inhibitor,,12/5/1991,treatment of corneal ulcers.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Glycomed, Inc",860 Atlantic Avenue,,Alameda,California,' 94501 ' ,United States,63991,,,
4266,mavacamten,Camzyos,4/27/2016,treatment of symptomatic hypertrophic cardiomyopathy,Designated/Approved,,,Treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms,4/28/2022,4/28/2029,Treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms,"MyoKardia, Inc. (A Wholly-Owned Subsidiary of Bristol Myers Squibb)",1000 Sierra Point Parkway,,Brisbane,California,' 94005 ' ,United States,515015,,,
4267,mavorixafor,Xolremdi,10/10/2018,"treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (whim) syndrome",Designated/Approved,,,"to increase the number of circulating mature neutrophils and lymphocytes in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis)",4/26/2024,4/26/2031,"to increase the number of circulating mature neutrophils and lymphocytes in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis)","X4 Pharmaceuticals, Inc.",1 Broadway,14th Floor,Cambridge,Massachusetts,' 02142 ' ,United States,500115,,,
4268,mavorixafor,,7/1/2022,treatment of waldenstrom’s macroglobulinemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"X4 Pharmaceuticals, Inc.",61 N Beacon St; 4th Floor,,Boston,Massachusetts,' 02134 ' ,United States,887322,,,
4269,mavrilimumab,,9/14/2020,treatment of giant cell arteritis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kiniksa Pharmaceuticals, GmbH",Grafenaustrasse 5,,Zug,,' CH-6300 ' ,Switzerland,764620,giant cell arteritis,"""gard:0009615""",
4270,MaxAdFVIII,,3/3/2003,treatment of hemophilia a,Designated,,Not FDA Approved for Orphan Indication,,,,,GenStar Therapeutics Corporation,10865 Altman Row,Suite 200,San Diego,California,' 92121 ' ,United States,164402,hemophilia,"""gard:0010418""",
4271,"Maytansine bound via linker to bacterial derived, negatively charged modified Gyrase inhibitor",,7/25/2023,treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,CyGenica Ltd.,"Unit 4 Joyce House, Barrack Square",,Ballincollig,County Cork,' P31 HW35 ' ,Ireland,950223,glioblastoma,"""gard:0002491""",
4272,Maytansinoid DM-1 Conjugated Humanized Monoclonal Antibody N901,,8/17/2010,treatment of small cell lung cancer.,Designated/Designation Withdrawn or Revoked,6/18/2014,Not FDA Approved for Orphan Indication,,,,,"ImmunoGen, Inc.",830 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,311010,small cell lung cancer,"""gard:0009344""",
4273,maytansinoid DM1-conjugated humanized monoclonal antibody N901,,3/2/2010,treatment of merkel cell carcinoma,Designated/Designation Withdrawn or Revoked,6/18/2014,Not FDA Approved for Orphan Indication,,,,,"ImmunoGen, Inc.",830 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,300309,noma,"""gard:0004001""",
4274,maytansinoid DM1-conjugated humanized monoclonal antibody N901,,11/29/2010,treatment of multiple myeloma.,Designated/Designation Withdrawn or Revoked,6/18/2014,Not FDA Approved for Orphan Indication,,,,,"ImmunoGen, Inc.",830 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,322610,multiple myeloma,"""gard:0007108""",
4275,Mazindol,,12/8/1986,treatment of duchenne muscular dystrophy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Collipp, Platon J. M.D.",176 Memorial Drive,,Jesup,Georgia,' 31545 ' ,United States,16186,muscular dystrophy,"""gard:0007922""",
4276,mazindol,,10/31/2022,treatment of idiopathic hypersomnia,Designated,,Not FDA Approved for Orphan Indication,,,,,NLS Pharmaceutics AG,Alter Postplatz 2,,Stans,NIDWALDO,' 6370 ' ,Switzerland,876822,idiopathic hypersomnia,"""gard:0008737""",
4277,mazindol,,7/6/2016,treatment of narcolepsy,Designated,,Not FDA Approved for Orphan Indication,,,,,NLS-0 Pharma AG,10 Breitenweg,CH-6370,Stans NW,Nidwalden,' ' ,Switzerland,526816,narcolepsy,"""gard:0022460""",
4278,MCMV5322A/MCMV3068A,,11/22/2011,prevention of maternal-fetal transmission of congenital cmv in pregnant women who acquire cmv infection during pregnancy,Designated/Designation Withdrawn or Revoked,10/7/2015,Not FDA Approved for Orphan Indication,,,,,Genentech,1 DNA Way,MS#241B,South San Francisco,California,' 94080 ' ,United States,355911,,,
4279,mebendazole,,11/22/2022,treatment of autosomal dominant polycystic kidney disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Healx Technology Limited,"Charter House, 66-68 Hills Road",,Cambridge,,' CB2 1LA ' ,United Kingdom,910922,autosomal dominant polycystic kidney disease,"""gard:0010413""",
4280,mebendazole,VERMOX 500 mg chewable tablets,9/3/2014,"treatment of single or mixed gastrointestinal infestations by trichuris trichiura (whipworm), ascaris lumbricoides (large roundworm), and ancylostoma duodenale and nectar americanus (hookworm).",Designated/Approved,,,treatment of patients one year of age and older withgastrointestinal infections caused by Ascaris lumbricoides (roundworm) and Trichuris trichiura (whipworm),10/19/2016,,,"Janssen Pharmaceutical Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,' 08869 ' ,United States,397013,,,
4281,Mecamylamine,,10/14/1998,treatment of tourette's syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Targacept, Inc.",200 East First St.,Suite 300,Winston-Salem,North Carolina,' 27101 ' ,United States,117598,,,
4282,Mecasermin,Increlex,12/12/1995,treatment of growth hormone insensitivity syndrome.,Designated/Approved,,,Long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.,8/30/2005,8/30/2012,,"Ipsen Biopharmaceuticals, Inc.",106 Allen Road,,Basking Ridge,New Jersey,' 07920 ' ,United States,93695,growth hormone insensitivity syndrome,"""gard:0003924""",
4283,mecasermin,,8/5/1991,treatment of amyotrophic lateral sclerosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",41 Moores Road,,Frazer,Pennsylvania,' 19355 ' ,United States,59191,amyotrophic lateral sclerosis,"""gard:0005786""",
4284,mecasermin,,12/3/2007,treatment of myotonic dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Insmed, Inc.",10 Finderne Avenue,Building 10,Bridgewater,New Jersey,' 08817 ' ,United States,249707,myotonic dystrophy,"""gard:0010419""",
4285,mecasermin rinfabate,Iplex,5/17/2002,treatment of growth hormone insensitivity syndrome (ghis),Designated/Approved,,,Treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone,12/12/2005,12/12/2012,,"Insmed, Inc.",10 Finderne Ave,Building 10,Bridgewater,New Jersey,' 08807 ' ,United States,156302,growth hormone insensitivity syndrome,"""gard:0003924""",
4286,mecasermin rinfabate,,7/7/2021,prevention of bronchopulmonary dysplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,OHB Neonatology Ltd,"3rd Floor, 1 Ashley Road",,Altrincham,Cheshire,' WA14 2DT ' ,United Kingdom,824321,bronchopulmonary dysplasia,"""gard:0005962""",
4287,mecasermin rinfabate,,3/21/2024,prevention of intraventricular hemorrhage in preterm infants less than 32 weeks gestational age,Designated,,Not FDA Approved for Orphan Indication,,,,,OHB Neonatology Ltd.,"1 Ashley Road, 3rd Floor",,Altrincham Cheshire,,' WA14 2DT ' ,United Kingdom,921322,,,
4288,mecasermin rinfabate,,9/20/2012,prevention of retinopathy of prematurity in premature infants born at risk for the disease,Designated,,Not FDA Approved for Orphan Indication,,,,,OHB Neonatology Ltd,"3rd Floor, 1 Ashley Road",,Altrincham,Cheshire,' WA14 2DT ' ,Uk,372612,retinopathy of prematurity,"""gard:0005695""",
4289,mecasermin rinfabate,,7/23/2012,treatment of amyotropic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"PCUT BioPartners, Inc.",2196 Glenkirk Drive,,San Jose,California,' 95124 ' ,United States,364312,,,
4290,"mecasermin, recombinant human insulin-like growth factor-1",,9/21/2015,treatment of rett syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences,535 Watson Drive,,Claremont,California,' 91711 ' ,United States,491915,rett syndrome,"""gard:0005696""",
4291,meclorethamine,Valchlor,8/17/2004,treatment of mycosis fungoides,Designated/Approved,,,Topical treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.,8/23/2013,8/23/2020,Topical treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.,Helsinn Birex Pharmaceuticals Ltd.,Damastown,,Mulhuddart,County Dublin,' ' ,Ireland,188404,,,
4292,Medroxyprogesterone acetate,,2/22/2001,treatment of immune thrombocytopenic purpura.,Designated,,Not FDA Approved for Orphan Indication,,,,,"ZaBeCor Pharmaceutical Company, LLC",821 Westview Street,,Philadelphia,Pennsylvania,' 19119 ' ,United States,141901,,,
4293,Mefloquine HCl,,7/22/1987,treatment and prevention of chloroquine-resistant falciparummalaria,Designated,,Not FDA Approved for Orphan Indication,,,,,Mepha AG,4143 Dornach,,Aesch Basel,,' ' ,Switzerland,18687,malaria,"""gard:0006961""",
4294,mefloquine HCL,Lariam,4/13/1988,"for use in the treatment of acute malaria due to plasmodium falciparum and plasmodium vivax, and for the prophylaxis of plasmodium falciparum malaria which is resistant to other available drugs",Designated/Approved,,,Treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax,5/2/1989,5/2/1996,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,26287,malaria,"""gard:0006961""",
4295,mefloquine HCL,Lariam,4/13/1988,"for use in the treatment of acute malaria due to plasmodium falciparum and plasmodium vivax, and for the prophylaxis of plasmodium falciparum malaria which is resistant to other available drugs",Designated/Approved,,,Prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs,5/3/1989,5/3/1996,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,26287,malaria,"""gard:0006961""",
4296,Mefuparib,,2/28/2023,treatment of biliary tract cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Convalife (Shanghai) Co., Ltd.","Room 41, No.780 Cailun Road","Zhangjiang Hi-Tech Park, Pudong New Area",Shanghai,,' 201203 ' ,China,926722,,,
4297,Megestrol acetate,Megace,4/13/1988,"treatment of patients with anorexia, cachexia, or significant weight loss (=/>10% of baseline body weight) and confirmed diagnosis of aids.",Designated/Approved,,,"Treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immune deficiency syndrome.",9/10/1993,9/10/2000,,Bristol-Myers Squibb Pharmaceutical Research Institute,2400 West Lloyd Expressway,,Evansville,Indiana,' 47721 ' ,United States,26187,,,
4298,Melanoma autologous dendritic cell vaccine,,9/6/2006,treatment of stage iiib through iv metastatic melanoma,Designated/Designation Withdrawn or Revoked,12/13/2018,Not FDA Approved for Orphan Indication,,,,,Caladrius Biosciences,110 Allen Road,2nd Floor,Basking Ridge,New Jersey,' 07920 ' ,United States,222706,noma,"""gard:0004001""",
4299,Melanoma cell vaccine,,10/13/1994,treatment of invasive melanoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,CancerVax Corporation,2110 Rutherford Road,,Carlsbad,California,' 92008 ' ,United States,84194,noma,"""gard:0004001""",
4300,Melanoma peptide vaccine,,3/29/2005,"treatment of hla-a2+ patients with stage iib, iic, iii, and iv malignant melanoma",Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Research Inst,5 Research Parkway,P. O. Box 5100,Wallingford,Connecticut,' 06492 ' ,United States,194604,noma,"""gard:0004001""",
4301,Melanoma vaccine,,12/20/1989,treatment of stage iii - iv melanoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ribi ImmunoChem Research, Inc.",533 Old Corvallis Road,,Hamilton,Montana,' 59840 ' ,United States,41589,noma,"""gard:0004001""",
4302,melarsoprol-hydroxypropylbetadex,,9/13/2013,treatment of human african trypanosomiasis (sleeping sickness),Designated,,Not FDA Approved for Orphan Indication,,,,,"Peter Kennedy, CBE, MD, PhD, DSc, FRCP FMedSci,",Glasgow University Department of Neurology,,Glasgow,,' ' ,United Kingdom,406613,african trypanosomiasis,"""gard:0007826""",
4303,melatonin,,10/22/2018,treatment of acute radiation syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,' ' ,Italy,644918,acute radiation syndrome,"""gard:0021896""",
4304,melatonin,,10/9/2019,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,' ' ,Italy,704519,,,
4305,melatonin,,3/28/2018,treatment of subarachnoid hemorrhage,Designated,,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,' ' ,Italy,600317,,,
4306,melatonin,,3/8/2018,treatment of perinatal asphyxia,Designated,,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,' ' ,Italy,628518,,,
4307,Melatonin,,5/10/2021,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,Via Malachia Marchesi de Taddei 21,,Milan,,' I-20146 ' ,Italy,816621,retinitis pigmentosa,"""gard:0005694""",
4308,melatonin,,4/12/2013,treatment of neonatal hypoxic ischemic encephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Scharper S.p.A.,Viale Ortles 12,,Milan,,' ' ,Italy,391313,,,
4309,Melatonin,,4/20/2020,prevention of retinopathy of prematurity,Designated,,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,' ' ,Italy,734420,retinopathy of prematurity,"""gard:0005695""",
4310,Melatonin,,4/20/2020,treatment of retinopathy of prematurity,Designated,,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,' ' ,Italy,734320,retinopathy of prematurity,"""gard:0005695""",
4311,melatonin,,1/25/2017,treatment of necrotizing enterocolitis,Designated,,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,' ' ,Italy,552016,necrotizing enterocolitis,"""gard:0009767""",
4312,Melatonin,,11/15/1993,treatment of circadian rhythm sleep disorders in blind people with no light perception.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sack, Robert, M.D.",Oregon Health Sciences University,3181 S.W. Sam Jackson Park Road,Portland,Oregon,' 97201 ' ,United States,77593,,,
4313,melatonin,,11/3/2016,treatment of smith-magenis syndrome in combination with a beta-blocker,Designated,,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,' ' ,Italy,541016,smith-magenis syndrome,"""gard:0008197""",
4314,melatonin,,2/28/2019,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,' ' ,Italy,677519,hepatocellular carcinoma,"""gard:0016773""",
4315,Melatonin,,9/21/2021,treatment of optic neuritis,Designated,,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,Via Malachia Marchesi de Taddei 21,,Milan,MI,' I-20146 ' ,Italy,845921,,,
4316,Melatonin,,1/22/2020,treatment of primary intracerebral hemorrhage,Designated,,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,' ' ,Italy,719519,,,
4317,Melatonin,,7/9/2004,treatment of non-24-hour sleep-wake disorder in blind individuals without light perception,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neurim Pharmaceuticals, Ltd.",8 Hanechoshet St.,,Tel-Aviv,,' ' ,Israel,181203,,,
4318,melatonin,,3/2/2017,treatment of acute acetaminophen overdose,Designated,,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,' ' ,Italy,557416,,,
4319,melatonin,,2/14/2017,treatment of short bowel syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,' ' ,Italy,551916,short bowel syndrome,"""gard:0001502""",
4320,Melatonin,,4/22/2019,treatment of heat stroke,Designated,,Not FDA Approved for Orphan Indication,,,,,WORPHMED Srl,"Via Malachia Marchesi de Taddei, 21",,Milan,Lombardy,' ' ,Italy,680719,,,
4321,Melatonin / ethanol,,7/7/2022,treatment of neonatal hypoxic ischemic encephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,ESPL Regulatory Consulting Limited,"River House, Unit 4D","Blackpool Retail Park, Blackpool, Co.",Cork,Cork,' ' ,Ireland,888822,,,
4322,meloxicam,Mobic,11/22/2002,treatment of juvenile rheumatoid arthritis,Designated/Approved,,,For relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age or older,8/11/2005,8/11/2012,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,' 06877 ' ,United States,160602,,,
4323,Melphalan,,3/3/1992,for use in hyperthermic regional limb perfusion to treat metastatic melanoma of the extremity.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Glaxo Wellcome Research and Development,5 Moore Drive,PO Box 13398,Research Triangle Park,North Carolina,' 27709 ' ,United States,64291,noma,"""gard:0004001""",
4324,Melphalan,Alkeran For Injection,2/24/1992,treatment of patients with multiple myeloma for whom oral therapy is inappropriate.,Designated/Approved,,,For the palliative treatment of patients with multiple myeloma for whom oral melphalan is not appropriate.,11/18/1992,11/18/1999,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,' 27709 ' ,United States,60991,multiple myeloma,"""gard:0007108""",
4325,melphalan,Hepzato,11/12/2008,treatment of patients with ocular (uveal) melanoma.,Designated/Approved,,,"as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation",8/14/2023,8/14/2030,"as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation","Delcath Systems, Inc.","1633 Broadway, 22nd Floor",,New York,New York,' 10019 ' ,United States,271708,noma,"""gard:0004001""",
4326,melphalan,,11/19/2012,treatment of retinoblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"EyePoint Pharmaceuticals, Inc.","480 Pleasant Street, B300",,Watertown,Massachusetts,' 02472 ' ,United States,378112,retinoblastoma,"""gard:0007563""",
4327,melphalan,,7/14/2015,treatment of cholangiocarcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Delcath Systems, Inc.",1633 Broadway,Suite 22C,New York,New York,' 10019 ' ,United States,485515,cholangiocarcinoma,"""gard:0009304""",
4328,melphalan,,11/19/2012,treatment of stage iib through iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"OncoTx, LLC",9 Brandeis Road,,Newton,Massachusetts,' 02459 ' ,United States,381412,noma,"""gard:0004001""",
4329,melphalan,EVOMELA,11/24/2008,high dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation,Designated/Approved,,,for high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma,3/10/2016,3/10/2023,for high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,' 08520 ' ,United States,270008,,,
4330,melphalan flufenamide,Pepaxto,3/16/2015,"treatment of plasma cell myeloma, also referred to as multiple myeloma",Designated/Approved,,,"Treatment, in combination with dexamethasone, of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody (Indication withdrawn)",2/26/2021,2/23/2024,"Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody (Indication withdrawn)",Oncopeptides AB,Vastra Tradgardsgatan 15,,Stockholm,,' ' ,Sweden,465314,multiple myeloma,"""gard:0007108""",
4331,melphalan hydrochloride,,11/12/2008,treatment of patients with cutaneous melanoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Delcath Systems, Inc.",1301 6th Avenue,43rd Floor,New York,New York,' 10019 ' ,United States,270508,noma,"""gard:0004001""",
4332,melphalan hydrochloride,,5/22/2009,treatment of neuroendocrine tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"Delcath Systems, Inc.",1301 6th Avenue,43rd Floor,New York,New York,' 10019 ' ,United States,281809,,,
4333,melphalan hydrochloride,,9/26/2013,treatment of patients with hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Delcath Systems, Inc.",1301 6th Avenue,43rd Floor,New York,New York,' 10019 ' ,United States,405413,hepatocellular carcinoma,"""gard:0016773""",
4334,Menadione Sodium Bisulfite,,5/14/2014,for the treatment of autosomal dominant polycystic kidney disease,Designated,,Not FDA Approved for Orphan Indication,,,,,IC-MedTech Corporation,9902 Indian Creek Lane,,El Cajon,California,' 92021 ' ,United States,429014,autosomal dominant polycystic kidney disease,"""gard:0010413""",
4335,menadione sodium bisulfite,,5/14/2014,treatment of autosomal dominant polycystic liver disease,Designated,,Not FDA Approved for Orphan Indication,,,,,IC-MedTech Corporation,9902 Indian Creek Lane,,El Cajon,California,' 92021 ' ,United States,430114,,,
4336,menaquinone,,9/4/2012,treatment of calciphylaxis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nu Science Trading, LLC",428 East Thunderbird Road,Suite 510,Phoenix,Alaska,' 85022 ' ,United States,357311,calciphylaxis,"""gard:0005980""",
4337,menatetrenone,,2/4/2011,treatment of myelodysplastic syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,' 59718 ' ,United States,319110,myelodysplastic syndrome,"""gard:0007132""",
4338,menatetrenone,,3/17/2011,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,' 59718 ' ,United States,319210,acute myeloid leukemia,"""gard:0012757""",
4339,menatetrenone,,11/2/2010,treatment of acute promyelocytic leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,' 59718 ' ,United States,320810,acute promyelocytic leukemia,"""gard:0000538""",
4340,menatetrenone,,11/2/2010,treatment of hepatocellular carcinoma (hcc).,Designated,,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,' 59718 ' ,United States,319910,hepatocellular carcinoma,"""gard:0016773""",
4341,menatetrenone and Vitamin D3,,8/22/2011,treatment of myelodysplastic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,' 59718 ' ,United States,348111,myelodysplastic syndrome,"""gard:0007132""",
4342,menin inhibitor,,6/29/2022,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Pharma America, Inc.",84 Waterford Drive,,Marlborough,Massachusetts,' 01752 ' ,United States,887822,acute myeloid leukemia,"""gard:0012757""",
4343,mepivacaine,,1/8/2007,treatment of postherpetic neuralgia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Relmada Therapeutics, Inc.",546 Fifth Avenue,14 Floor,New York,New York,' 10036 ' ,United States,206805,,,
4344,mepivacaine,,10/18/2006,treatment of painful hiv-associated neuropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Relmada Therapeutics, Inc.",750 3rd Avenue,9th Floor,New York,New York,' 10017 ' ,United States,206705,,,
4345,meplazumab,,3/15/2019,treatment of malaria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jiangsu Pacific-Meinuoke Bio-pharmaceutical Co., Ltd.","No. 128, Hehai West Rd",Xinbei District,Changzhou,Jiangsu,' ' ,China,676218,malaria,"""gard:0006961""",
4346,mepolizumab,NUCALA,7/14/2011,treatment of churg-strauss syndrome,Designated/Approved,,,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA),12/12/2017,12/12/2024,Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA),GlaxoSmithKline LLC,Corporation Service Company,1250 S. Collegeville Rd.,Collegeville,Pennsylvania,' 19426 ' ,United States,345111,,,
4347,mepolizumab,NUCALA®,5/28/2004,treatment of hypereosinophilic syndrome,Designated/Approved,,,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause,9/25/2020,9/25/2027,treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for > or = 6 months without an identifiable non-hematologic secondary cause,GlaxoSmithKline LLC,1250 S. Collegeville Road,,Collegeville,Pennsylvania,' 19426 ' ,United States,182103,c syndrome,"""gard:0005978""",
4348,mepolizumab,NUCALA,7/14/2011,treatment of churg-strauss syndrome,Designated/Approved,,,NUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).,6/6/2019,,,GlaxoSmithKline LLC,Corporation Service Company,1250 S. Collegeville Rd.,Collegeville,Pennsylvania,' 19426 ' ,United States,345111,,,
4349,mercaptopurine oral solution,Purixan,8/20/2012,treatment of acute lymphoblastic leukemia in pediatric patients,Designated/Approved,,,Treatment of patients with acute lymphoblastic leukemia as part of a combination regimen.,4/28/2014,4/28/2021,Treatment of patients with acute lymphoblastic leukemia as part of a combination regimen (in pediatric patients).,Nova Laboratories Limited,Martin House,,Leicester,Wigston,' ' ,United Kingdom,373512,acute lymphoblastic leukemia,"""gard:0000522""",
4350,merestinib,,4/10/2017,treatment of biliary tract cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,563316,,,
4351,meropenem,,7/20/2023,treatment of bacterial keratitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"IBIOTICA, LLC",206 Avondale Drive,,North Wales,Pennsylvania,' 19454 ' ,United States,948423,,,
4352,Meropenem,,4/27/2000,"management of acute pulmonary exacerbations, in cystic fibrosis patients, due to respiratory tract infection with susceptible organisms.",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals,1800 Concord Pike,PO Box 15437,Wilmington,Delaware,' 19850 ' ,United States,130799,cystic fibrosis,"""gard:0006233""",
4353,mesalamine,,1/19/2010,treatment of pediatric ulcerative colitis,Designated,,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 N Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,298109,,,
4354,mesalamine and N-acetycysteine,,9/10/2009,treatment of pediatric patients with ulcerative colitis (inclusive through age 16 years),Designated,,Not FDA Approved for Orphan Indication,,,,,"Altheus Therapeutics, Inc.",755 Research Parkway,Suite 435,Oklahoma City,Oklahoma,' 73104 ' ,United States,275909,,,
4355,mesalamine; 5-aminosalicylic acid,Lialda,2/27/2008,treatment of ulcerative colitis in pediatric patients (revised indication 10/21/2010).,Designated/Approved,,,Lialda (mesalamine) is indicated for the treatment of mildly to moderately active ulcerative colitis in pediatric patients weighing at least 24 kg.,6/26/2020,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,253607,,,
4356,"mesencephalic, astrocyte-derived neurotrophic factor",,9/10/2015,treatment of retinal artery occlusion.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Amarantus BioScience Holdings, Inc.",655 Montgomery Street,Suite 900,San Francisco,California,' 94111 ' ,United States,466314,,,
4357,Mesenchymal stem cell (MSC) derived small extracellular vesicles (EVs) loaded with short and modified interfering RNA (siRNA) against the phosphatase and tensin homolog (PTEN) protein,,10/26/2023,treatment of acute spinal cord injury,Designated,,Not FDA Approved for Orphan Indication,,,,,"NurExone Biologic, Ltd.","9 Mezada St. BSR 3 Tower, 30 Fl.",,Bnei-Brak,,' 5120109 ' ,Israel,940823,spinal cord injury,"""gard:0019109""",
4358,Mesenchymal Stem Cell-derived Extracellular Vesicles,,2/8/2021,prevention of bronchopulmonary dysplasia in neonates,Designated,,Not FDA Approved for Orphan Indication,,,,,"Stella Kourembanas, M.D.",Boston Children's Hospital,300 Longwood Avenue | Enders 961,Boston,Massachusetts,' 02115 ' ,United States,713919,bronchopulmonary dysplasia,"""gard:0005962""",
4359,Mesenchymal stem cells,,5/12/2022,treatment of acute graft-versus-host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ossium Health, Inc.",80 Tehama Street,,San Francisco,California,' 94105 ' ,United States,874222,,,
4360,Mesenchymal stem cells (MSCs) primed with interferon gamma (IFNgamma),,7/25/2022,prevention of acute graft-versus-host disease (gvhd),Designated,,Not FDA Approved for Orphan Indication,,,,,"Ossium Health, Inc.",80 Tehama Street,,San Francisco,California,' 94105 ' ,United States,873622,,,
4361,mesenchymal stromal cells secreting neurotrophic factors,,2/4/2011,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,BrainStorm Cell Therapeutics Ltd.,12 Bazel St.,,Kiryat Arie,,' ' ,Israel,331910,amyotrophic lateral sclerosis,"""gard:0005786""",
4362,Mesna,,12/16/1987,inhibition of the urotoxic effects induced by oxazaphosphorine compounds such as cyclophosphamide.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Asta Medica , Inc.",890 East St.,,Tewksbury,Massachusetts,' 01876 ' ,United States,24887,,,
4363,Mesna,Mesnex,11/14/1985,for use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.,Designated/Approved,,,,12/30/1988,12/30/1995,,Degussa Corporation,65 Challenger Road,,Ridgefield Park,New Jersey,' 07660 ' ,United States,8685,,,
4364,messanger ribonucleic acid (mRNA)-based therapeutic agent encoding human methylmalonyl-coenzyme A mutase,,3/7/2018,treatment of isolated methylmalonic academia (mma) due to methylmalonyl-coenzyme a mutase (mut) deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Moderna Therapeutics, Inc.",200 Technology Square,,Cambridge,Massachusetts,' 02139 ' ,United States,625717,,,
4365,messenger ribonucleic acid-based therapeutic agent encoding human propionyl-CoA carboxylase alpha and beta subunits,,12/5/2018,treatment of propionic acidemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Moderna Therapeutics, Inc.",200 Technology Square,,Cambridge,Massachusetts,' 02139 ' ,United States,668518,propionic acidemia,"""gard:0000467""",
4366,mesylate synthetic small molecule inhibitor of HDAC and PI3K,,9/6/2016,treatment of nuclear protein in testis (nut) midline carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Curis, Inc.",4 Maguire Road,,Lexington,Massachusetts,' 02421 ' ,United States,482415,noma,"""gard:0004001""",
4367,met-enkephalin; Met-N,,2/18/2011,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,' 59718 ' ,United States,333011,,,
4368,metadoxine,,12/16/2013,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alcobra, Inc.",2 Weizman Street,,Tel-Aviv,,' ' ,Israel,414513,fragile x syndrome,"""gard:0006464""",
4369,"metavert, N-hydroxy-4-(5-((4-methoxyphenyl)amino)-1,3,4-oxadiazol-2-yl)benzamide",,7/6/2016,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Avenzoar Pharmaceuticals, Inc.",662 Encinitas Blvd,Suite 248,Encinitas,California,' 92024 ' ,United States,526216,,,
4370,metformin,,12/14/2017,treatment of progressive myoclonus epilepsy type 2 (lafora disease),Designated,,Not FDA Approved for Orphan Indication,,,,,"Consorcio Centro de Investigación Biomédica en Red, M.P. (CIBER)",Monforte de Lemos,3-5 Pabellon 11,Madrid,Comunidad de Madrid,' ' ,Spain,616117,lafora disease,"""gard:0008214""",
4371,metformin,,5/29/2014,treatment of pediatric polycystic ovary syndrome,Designated/Designation Withdrawn or Revoked,3/19/2021,Not FDA Approved for Orphan Indication,,,,,EffRx Pharmaceuticals SA,Wolleraustrass 41 B,,8807 Freienbach (SZ),,' ' ,Switzerland,432214,,,
4372,Methanesulfonate-1-sec-butoxycarbonyloxymethyl-1-methyl-4-{4-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenylcarbamoyl]-benzyl}-piperazin-1-ium,,9/13/2018,treatment of chronic myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Inhibikase Therapeutics, Inc.",3350 Riverwood Parkway,,Atlanta,Georgia,' 30339 ' ,United States,591517,chronic myeloid leukemia,"""gard:0006105""",
4373,methimazole and liothyronine sodium,,6/2/2016,treatment of glioblastoma multiforme.,Designated,,Not FDA Approved for Orphan Indication,,,,,Musli Thyropeutics Ltd,6 HaGefen Street,,zur Moshe,Center District,' ' ,Israel,523216,glioblastoma,"""gard:0002491""",
4374,Methionine/L-methionine,,8/21/1996,treatment of aids myelopathy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genopia USA, Inc.","90 Gold Street, 6N",,New York,New York,' 10038 ' ,United States,91795,,,
4375,methotrexate,,8/23/1993,treatment of juvenile rheumatoid arthritis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Wyeth-Ayerst Laboratories,P.O. Box 8299,,Philadelphia,Pennsylvania,' 19101 ' ,United States,76693,,,
4376,methotrexate,,8/20/2009,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Orbona Pharma Ltd,Old Chambers,93-94 West Street,Farnham,Surrey,' ' ,United Kingdom,286409,acute lymphoblastic leukemia,"""gard:0000522""",
4377,Methotrexate,,8/28/2014,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,The Universtiy of Kanasa Medical Center,3901 Rainbow Blvd,MSN 2012,Kanasa City,Kansas,' 66160 ' ,United States,440314,myasthenia gravis,"""gard:0007122""",
4378,methotrexate,,3/25/2019,treatment of ectopic pregnancy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Antares Pharma, Inc",Princeton Crossroads Corporate Center,100 Princeton South Suite 300,"Ewing,",New Jersey,' 08628 ' ,United States,679019,,,
4379,Methotrexate,,7/21/2021,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aldeyra Therapeutics, Inc.","131 Hartwell Avenue, Suite 320",,Lexington,Massachusetts,' 02421 ' ,United States,829121,retinitis pigmentosa,"""gard:0005694""",
4380,methotrexate,,10/4/2023,"treatment of non-infectious intermediate, posterior, or pan uveitis or chronic non-infectious anterior uveitis",Designated,,Not FDA Approved for Orphan Indication,,,,,Nordic Group B.V.,Siriusdreef 41,,Hoofddorp,,' 2132 WT ' ,Netherlands,931023,non-infectious anterior uveitis,"""gard:0021260""",
4381,methotrexate,,4/11/2018,prevention of proliferative vitreoretinopathy (pvr),Designated,,Not FDA Approved for Orphan Indication,,,,,"Aldeyra Therapeutics, Inc.","131 Hartwell Avenue, Suite 320",,Lexington,Massachusetts,' 02421 ' ,United States,630518,vitreoretinopathy,"""gard:0019539""",
4382,methotrexate (intravitreal),,7/19/2021,treatment of primary vitreoretinal lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aldeyra Therapeutics, Inc.",131 Hartwell Avenue,Suite 320,Lexington,Massachusetts,' 02421 ' ,United States,754320,lymphoma,"""gard:0020548""",
4383,methotrexate oral liquid formulation,,3/18/2015,treatment of acute lymphoblastic leukemia in pediatric patients aged 0 through 16 years.,Designated,,Not FDA Approved for Orphan Indication,,,,,Chesapeake Therapeutics,1498-M Reistertown Road,Suite 313,Pikesville,Maryland,' 21208 ' ,United States,469315,acute lymphoblastic leukemia,"""gard:0000522""",
4384,methotrexate oral solution,Xatmep,8/27/2015,management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pjia) who are intolerant of or had an inadequate response to first-line therapy.,Designated/Approved,,,"Management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).",4/25/2017,4/25/2024,Management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who are intolerant or of had an inadequate response to first-line therapy.,"Silvergate Pharmaeuticals, Inc.",6251 Greenwood Plaza Blvd,Suite 101,Greenwood Village,Colorado,' 80111 ' ,United States,479515,polyarticular juvenile idiopathic arthritis,"""gard:0021729""",
4385,methotrexate oral solution,Xatmep,5/28/2015,treatment of acute lymphoblastic leukemia in pediatric patients (0 through 16 years of age),Designated/Approved,,,Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as a component of a combination chemotherapy maintenance regimen,4/25/2017,4/25/2024,Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as a component of a combination chemotherapy maintenance regimen,"Silvergate Pharmaceuticals, Inc.",6251 Greenwood Plaza Blvd.,Suite 101,Greenwood Village,Colorado,' 80111 ' ,United States,479615,acute lymphoblastic leukemia,"""gard:0000522""",
4386,Methotrexate sodium,Methotrexate,10/21/1985,treatment of osteogenic sarcoma.,Designated/Approved,,,For the use of high dose methotrexate with leucovorin rescue in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor.,4/7/1988,4/7/1995,,Lederle Laboratories,Division of American Cyanamid Company,401 N. Middletown Road,Pearl River,New York,' 10965 ' ,United States,9985,,,
4387,Methotrexate with laurocapram,,10/15/1990,topical treatment of mycosis fungoides.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Echo Therapeutics, Ltd.",8 Penn Center,1628 JFK Blvd,Philadelphia,Pennsylvania,' 19103 ' ,United States,43389,,,
4388,Methoxsalen,,10/14/1998,for use in conjunction with the uvar photopheresis system to treat graft versus host disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Mallinckrodt Hospital Products IP Limited,440 Route 22 East,,Bridgewater,New Jersey,' 08807 ' ,United States,117298,graft versus host disease,"""gard:0016642""",
4389,methoxsalen,,5/12/1994,for the prevention of acute rejection of cardiac allografts,Designated,,Not FDA Approved for Orphan Indication,,,,,Mallinckrodt Hospital Products IP Limited,440 Route 22 East,,Bridgewater,New Jersey,' 08807 ' ,United States,80594,,,
4390,Methoxyamine hydrochloride,,10/22/2020,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"TRACON Pharmaceuticals, Inc.","4350 La Jolla Village Dr., Suite 800",,San Diego,California,' 92122 ' ,United States,777120,,,
4391,"methyl (2R,3S)-3-[(methylsulfonyl)amino]-2-{[(cis-4-phenylcyclohexyl)oxy]methyl}piperidine-1-carboxylate",,12/19/2017,treatment of narcolepsy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,616717,narcolepsy,"""gard:0022460""",
4392,"methyl (R)-4-((3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-2-ylmethyl)amino)butyl)amino)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate",,5/12/2022,treatment of wilson's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,DepYmed Inc.,3 Bioscience Park Dr,,Farmingdale,New York,' 11735 ' ,United States,876122,,,
4393,"methyl (R)-4-((3S,5R,7R,8R,9S,10S,13R,14S,17R)-7-hydroxy-10,13-dimethyl-3-((4-((pyridin-3- ylmethyl)amino)butyl)amino)hexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoate",,4/19/2022,treatment of rett syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"DepYmed, Inc.",3 Bioscience Park Drive,,Farmingdale,New York,' 11735 ' ,United States,872122,rett syndrome,"""gard:0005696""",
4394,Methyl 4-{[2-(acetamino)ethyl]sulfanyl}-4-oxobutanoate,,4/14/2023,treatment of mitochondrial disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Abliva AB,Medicon Village,,Lund,,' 223 81 ' ,Sweden,933323,mitochondrial disease,"""gard:0018887""",
4395,"Methyl O-4-O-[2-[2-[2-[2-[[N-[(1R)-1-[[4-(aminoiminomethyl)phenyl]methyl]-2-oxo-2-(1-piperidinyl)ethyl]-N2-[(4-methoxy-2,3,6-trimethylphenyl)sulfonyl]-L-?-aspararginyl-4-aminobutanoyl-N6-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-L-lysyl]amino]ethoxy]ethoxy]ethoxy]ethyl]-2,3-di-O-methyl-6-O-sulfo-?-D-glucopyranosyl-(1?4)-O-2,3-di-O-methyl-?-D-glucopyranuronosyl-(1?4)-O-2,3,6-tri-O-sulfo- ?-D-glucopyranosyl-(1?4)-O-2,3-di-O-methyl- ?-L-idopyranuronosyl-(1?4)-3-O",,4/18/2011,prevention of ischemia reperfusion injury associated wth solid organ transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,Endotis Pharma,"102, avenue Gaston Roussel",,93230 Romainville,,' ' ,France,336211,,,
4396,methyldopa,,1/12/2017,treatment of type 1 diabetes in dq8 positive patients with residual beta cell function,Designated,,Not FDA Approved for Orphan Indication,,,,,IM Therapeutics LLC,11001 West 120th Avenue,Suite 400,Broomfield,Colorado,' 80021 ' ,United States,548616,,,
4397,methyldopa,,2/27/2024,prevention of retinopathy of prematurity,Designated,,Not FDA Approved for Orphan Indication,,,,,FELIQS Corporation,1-1 Hyakunenkoen,,Kurume Fukuoka,,' 8390864 ' ,Japan,989923,retinopathy of prematurity,"""gard:0005695""",
4398,methylene blue,,7/24/2012,treatment of methemoglobinemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Fera Pharmaceuticals, LLC",134 Birch Hill Road,,Locust Valley,New York,' 11560 ' ,United States,345711,,,
4399,methylene blue injection,,8/11/2012,treatment of congenital and acquired methemoglobinemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",One Luitpold Drive,P. O. Box 9001,Shirley,New York,' 11967 ' ,United States,357111,acquired methemoglobinemia,"""gard:0021930""",
4400,methylene blue0.5%,ProvayBlue,12/18/2012,treatment of hereditary and acquired methemoglobinemia,Designated/Approved,,,For treatment of pediatric and adult patients with acquired methemoglobinemia.,4/8/2016,4/8/2023,For treatment of pediatric and adult patients with acquired methemoglobinemia.,Provepharm SAS,Technopote de Chateau-Combert,,Marseille,,' ' ,France,385512,acquired methemoglobinemia,"""gard:0021930""",
4401,Methylnaltrexone,,6/17/1996,treatment of chronic opioid-induced constipation unresponsive to conventional therapy.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Progenics Pharmaceuticals, Inc.",765 Old Saw Mill River Rd.,,Tarrytown,New York,' 10591 ' ,United States,92195,,,
4402,methylparaben suberohydroxamic acid phenyl ester,,4/15/2013,treatment of cutaneous t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Medivir AB,Box 1086s,,Huddinge,,' ' ,Sweden,292109,lymphoma,"""gard:0020548""",
4403,methylprednisolone oral suspension,,9/19/2016,treatment of adrenal insufficiency in pediatric patients,Designated,,Not FDA Approved for Orphan Indication,,,,,Generic Specialty Pharma,"Unit 10, Block 3",City North Business Campus,Stamullin,Meath,' ' ,Ireland,531816,,,
4404,metreleptin,MYALEPT,8/22/2001,treatment of metabolic disorders secondary to lipodystrophy,Designated/Approved,,,Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.,2/24/2014,2/24/2021,Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.,Chiesi Farmaceutici S.p.A.,Via Palermo 26/A,,Parma,Emilia Romagna,' 43122 ' ,Italy,146701,,,
4405,metreleptin,,8/22/2001,treatment of leptin deficiency secondary to generalized lipodystrophy and partial familial lipodystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Chiesi Farmaceutici S.p.A.,Via Palermo 26/A,,Parma,Emilia Romagna,' 43122 ' ,Italy,144301,,,
4406,metronidazole,,4/5/2016,treatment of clostridium difficile infection in pediatric patients (0 through 16 years of age).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Appili Therapeutics, Inc.",1344 Summer Street,Suite 415,Halifax,,' ' ,Canada,514715,,,
4407,metronidazole,,4/26/2011,treatment of pouchitis,Designated,,Not FDA Approved for Orphan Indication,,,,,S.L.A. Pharma Limited (UK),Elite House,,"Watford, Hertfordshire.",,' ' ,United Kingdom,339111,pouchitis,"""gard:0020510""",
4408,metronidazole,,9/17/2008,treatment of pouchitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Avivia Project BV,Leeuwenhoekweg 12,,Schijndel,,' ' ,Netherlands,267008,pouchitis,"""gard:0020510""",
4409,Metronidazole,,10/24/1991,treatment of perioral dermatitis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Galderma Laboratories, Inc.",P.O. Box 331329,,Fort Worth,Texas,' 76163 ' ,United States,61891,,,
4410,Metronidazole (topical),Metrogel,10/22/1987,treatment of acne rosacea.,Designated/Approved,,,,11/22/1988,11/22/1995,,"Galderma Laboratories, Inc.",P.O. Box 331329,,Fort Worth,Texas,' 76163 ' ,United States,21687,,,
4411,Metronidazole (topical),,11/24/1987,"treatment of grade iii and iv, anaerobically infected, decubitus ulcers.",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Searle,4901 Searle Parkway,,Skokie,Illinois,' 60077 ' ,United States,17486,,,
4412,Metronidazole 10% ointment,,11/8/2007,topical treatment of active perianal crohn's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,SLA Pharma (UK) Ltd,Elite House,Hill Farm Industrial Estate,Watford WD25 7SA,,' ' ,United Kingdom,247907,,,
4413,metyrapone,,9/25/2012,treatment of cushing's syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,HRA Pharma Rare Diseases,"200, Avenue de Paris",,Chatillon,,' 92320 ' ,France,377212,,,
4414,metyrosine,,7/25/2008,treatment of velocardiofacial syndrome associated psychosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cerberus Princeton, LLC",c/o Cerberus Capital Management L.P.,875 Third Avenue,New York,New York,' 10022 ' ,United States,265008,velocardiofacial syndrome,"""gard:0015123""",
4415,mexiletine,,9/2/2010,treatment of nondystrophic myotonia,Designated,,Not FDA Approved for Orphan Indication,,,,,University of Rochester Medical Center,1351 Mt. Hope Ave.,Suite 203,Rochester,New York,' 14620 ' ,United States,314410,,,
4416,mexiletine,,3/16/2020,treatment of myotonic disorders,Designated,,Not FDA Approved for Orphan Indication,,,,,Lupin Europe GmbH,Hanauer Landstr. 139 -143,,Frankfurt am Main,,' ' ,Germany,728219,,,
4417,Mezagitamab,,10/17/2022,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,905822,myasthenia gravis,"""gard:0007122""",
4418,Mezagitamab,,8/9/2023,treatment of immune thrombocytopenia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,953823,immune thrombocytopenia,"""gard:0005194""",
4419,mibefradil,,8/25/2009,treatment of glioblastoma multiforme.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cavion, LLC",600 E. Water Street,Suite E,Charlottesville,Virginia,' 22902 ' ,United States,289209,glioblastoma,"""gard:0002491""",
4420,mibefradil,,10/16/2008,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cavion, LLC",600 E. Water Street,Suite E,Charlottesville,Virginia,' 22902 ' ,United States,268608,,,
4421,mibefradil,,6/15/2007,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cavion, LLC",600 E. Water Street,Suite E,Charlottesville,Virginia,' 22902 ' ,United States,224806,ovarian cancer,"""gard:0007295""",
4422,miconazole,,5/22/2014,treatment of fungal otitis externa (otomycosis),Designated,,Not FDA Approved for Orphan Indication,,,,,"Hill Dermaceuticals, Inc.",2650 S. Mellonville Ave.,,Sanford,Florida,' 32773 ' ,United States,406413,,,
4423,Microbubble contrast agent,,11/16/1990,intraoperative aid in the identification and localization of intracranial tumors.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cav-Con, Inc.",55 Knollwood Road,,Farmington,Connecticut,' 06032 ' ,United States,48790,,,
4424,Microencapsulated Interleukin-10,,9/5/2023,treatment of familial adenomatous polyposis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Therapyx, Inc.",1576 Sweet Home Rd,Suite 102A,Amherst,New York,' 14228 ' ,United States,958723,familial adenomatous polyposis,"""gard:0006408""",
4425,Microvesiculated modified glycosylated tissue factor,,10/11/2007,"treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in patients with von willebrand disease.",Designated,,Not FDA Approved for Orphan Indication,,,,,Thrombotargets Corp.,2530 Meridian Parkway,,Durham,North Carolina,' 27713 ' ,United States,246407,von willebrand disease,"""gard:0007867""",
4426,Microvesiculated modified glycosylated tissue factor,,1/25/2007,"treatment of non-life threatening, mild to severe bleeding episodes due to cutaneous injuries or dental procedures in hemophiliac patients",Designated,,Not FDA Approved for Orphan Indication,,,,,Thrombotargets Corp.,2530 Meridian Parkway,Suite 3023,Durham,North Carolina,' 27713 ' ,United States,234706,hemophilia,"""gard:0010418""",
4427,midazolam,NAYZILAM,10/20/2009,"rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. acute repetitive seizures, seizure clusters)",Designated/Approved,,,"NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient¿s usual seizure pattern in patients with epilepsy 12 years of age and older.",5/17/2019,5/17/2026,"NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient¿s usual seizure pattern in patients with epilepsy 12 years of age and older.","UCB, Inc.",1950 Lake Park Drive,Building 2100,Smyrna,Georgia,' 30080 ' ,United States,277809,,,
4428,midazolam,,7/24/2012,treatment of nerve agent-induced seizures,Designated,,Not FDA Approved for Orphan Indication,,,,,"Meridian Medical Technologies, Inc.","6350 Stevens Forest Rd, Suite 301",,Columbia,Maryland,' 21046 ' ,United States,373912,,,
4429,midazolam,,5/8/2006,treatment of bouts of increased seizure activity in selected refractory patients with epilepsy who are on stable regimens of anti-epileptic drugs and who require intermittent use of midazolam,Designated,,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc",1950 Lake Park rive,,Smyrna,Georgia,' 30080 ' ,United States,217405,,,
4430,midazolam,,1/30/2018,treatment of status epilepticus,Designated,,Not FDA Approved for Orphan Indication,,,,,Crossject SA,6 Rue Pauline Kergomard,,Dijon,Bourgogne Franche-Comté,' ' ,France,622817,,,
4431,midazolam,,2/18/2016,treatment of status epilepticus,Designated,,Not FDA Approved for Orphan Indication,,,,,"Laboratorios Lesvi, S.L.",Avda. Barcelona 69,,Sant Joan Despí,Barcelona,' 08970 ' ,Spain,514115,,,
4432,midazolam,SEIZALAM,2/4/2016,treatment of status epilepticus,Designated/Approved,,,SEIZALAM is indicated for the treatment of status epilepticus in adults.,9/14/2018,9/14/2025,SEIZALAM is indicated for the treatment of status epilepticus in adults.,Meridian Medical Technologies,6350 Stevens Forest Road,Suite 301,Columbia,Maryland,' 21046 ' ,United States,508215,,,
4433,midazolam,,2/8/2016,treatment of seizures induced by organophosporous insecticide poisoning.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Meridian Medical Technologies, Inc.","6350 Stevens Forest Rd, Suite 301",,Columbia,Maryland,' 21046 ' ,United States,507615,,,
4434,Midodrine HCl,Amatine,6/21/1985,treatment of patients with symptomatic orthostatic hypotension.,Designated/Approved,,,Treatment of symptomatic orthostatic hypotension.,9/6/1996,9/6/2003,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,7585,,,
4435,midostaurin,Rydapt,4/30/2010,treatment of mastocytosis,Designated/Approved,,,"Treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)",4/28/2017,4/28/2024,"Treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)",Novartis Pharmaceuticals Corporation,"One Health Plaza, 105/3W038",,East Hanover,New Jersey,' 07936 ' ,United States,306410,mastocytosis,"""gard:0006987""",
4436,midostaurin,Rydapt,7/7/2009,treatment of acute myeloid leukemia,Designated/Approved,,,"Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.",4/28/2017,4/28/2024,"Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.",Novartis Pharmaceuticals Corporation,"One Health Plaza, 105/3W038",,East Hanover,New Jersey,' 07936 ' ,United States,285909,acute myeloid leukemia,"""gard:0012757""",
4437,mifamuritide,,6/5/2001,treatment of osteosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,143401,osteosarcoma,"""gard:0007284""",
4438,Mifepristone,,2/7/2005,treatment of cushing's syndrome secondary to ectopic acth secretion,Designated/Designation Withdrawn or Revoked,2/2/2016,Not FDA Approved for Orphan Indication,,,,,HRA Pharma,"15 , rue Beranger",75003,Paris,,' ' ,France,196304,,,
4439,mifepristone,Korlym,7/5/2007,treatment of the clinical manifestations of endogenous cushing's syndrone,Designated/Approved,,,for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.,2/17/2012,2/17/2019,,"Corcept Therapeutics, Inc.",149 Commonwealth Drive,,Menlo Park,California,' 94025 ' ,United States,239507,,,
4440,mifepristone,,1/14/2016,treatment of ovarian cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Corcept Therapeutics, Inc.",149 Commonwealth Drive,,Menlo Park,California,' 94025 ' ,United States,506015,ovarian cancer,"""gard:0007295""",
4441,migalastat hydrochloride,GALAFOLD,2/25/2004,treatment of fabry disease,Designated/Approved,,,GALAFOLD¿ is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data,8/10/2018,8/10/2025,GALAFOLD¿ is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data,"Amicus Therapeutics, Inc.",1 Cedarbrook Drive,,Cranbury,New Jersey,' 08512 ' ,United States,180003,fabry disease,"""gard:0006400""",
4442,miglustat,,11/12/2008,"treatment of the neurological manifestations of niemann-pick disease,type c.",Designated/Designation Withdrawn or Revoked,12/7/2017,Not FDA Approved for Orphan Indication,,,,,Actelion Pharmaceuticals Ltd,Innovation Centre,,Allschwil,,' ' ,Switzerland,270708,,,
4443,Miglustat,,2/2/2021,treatment of niemann-pick disease type c,Designated,,Not FDA Approved for Orphan Indication,,,,,Edenbridge Pharmaceuticals LLC,"169 Lackawanna Ave, Suite 110",,Parsippany,New Jersey,' 07054 ' ,United States,798620,niemann-pick disease type c,"""gard:0007207""",
4444,miglustat,Zavesca,5/29/1998,treatment of gaucher disease.,Designated/Approved,,,"Treatment of mild to moderate Type I Gaucher disease in adults for whom enzyme replacement therapy is not a therapeutic option (e.g., due to constraints such as allergy, hypersensitivity, or poor venous access).",7/31/2003,7/31/2010,,IC-MedTech Corporation,9902 Indian Creek Lane,,San Diego,California,' 92021 ' ,United States,112598,gaucher disease,"""gard:0008233""",
4445,miglustat,,1/19/2021,treatment of cln batten disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Beyond Batten Disease Foundation,P.O. Box 50221,,Austin,Texas,' 78763 ' ,United States,795420,,,
4446,milademetan,,2/13/2017,treatment of liposarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Rain Oncology Inc.,"8000 Jarvis Rd., Suite 204",,Newark,California,' 94560 ' ,United States,555416,liposarcoma,"""gard:0006913""",
4447,milatuzumab,,3/10/2008,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,255807,multiple myeloma,"""gard:0007108""",
4448,milatuzumab,,6/24/2008,treatment of chronic lymphocytic leukemia.,Designated/Designation Withdrawn or Revoked,8/20/2019,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,256608,,,
4449,milciclib maleate,,9/20/2012,treatment of thymic epithelial tumors.,Designated/Designation Withdrawn or Revoked,3/15/2021,Not FDA Approved for Orphan Indication,,,,,Tiziana Life Sciences PLC,18 South Street,W1K 1DG,London,,' ' ,United Kingdom,375512,,,
4450,milrinone,,1/8/2018,treatment of right heart failure (rhf) in left ventricular assist device (lvad) patients,Designated,,Not FDA Approved for Orphan Indication,,,,,Hyloris Developments SA,1555 S Wasatch Dr.,,Salt Lake City,Utah,' 84108 ' ,United States,565916,,,
4451,miltefosine,,12/6/2016,treatment of acanthamoeba keratitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Profounda, Inc.",5790 Hoffner Avenue,Suite 507,Orlando,Florida,' 32822 ' ,United States,565016,,,
4452,miltefosine,,3/18/2009,topical treatment of cutaneous lymphoma encompassing cutaneous manifestations of t-cell lymphoma and b-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,ExperGen Drug Development GmbH,Hernalser,,Haupstrasse 24/16,,' ' ,Austria,275409,lymphoma,"""gard:0020548""",
4453,miltefosine,,6/19/2017,treatment of disseminated amebiasis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Profounda, Inc.",5790 Hoffner Avenue,Suite 507,Orlando,Florida,' 32822 ' ,United States,565216,,,
4454,miltefosine,,12/6/2016,treatment of primary amebic encephalitis (pam),Designated,,Not FDA Approved for Orphan Indication,,,,,"Profounda, Inc.",5790 Hoffner Avenue,Suite 507,Orlando,Florida,' 32822 ' ,United States,540216,encephalitis,"""gard:0019357""",
4455,Miltefosine,,11/1/2021,treatment invasive candidiasis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Profounda, lnc.",10501 S. Orange Ave,STE 124,Orlando,Florida,' 32824 ' ,United States,843921,,,
4456,miltefosine,,6/19/2017,treatment of granulomatous amebic encephalitis (gae),Designated,,Not FDA Approved for Orphan Indication,,,,,"Profounda, Inc.",5790 Hoffner Avenue,Suite 507,Orlando,Florida,' 32822 ' ,United States,565116,encephalitis,"""gard:0019357""",
4457,miltefosine,IMPAVIDO,10/10/2006,treatment of leishmaniasis.,Designated/Approved,,,"Treatment of visceral leishmaniasis due to Leishmania donovani; cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis; and mucosal leishmaniasis due to Leishmania braziliensis.",3/19/2014,3/19/2021,"Treatment of visceral leishmaniasis due to Leishmania donovani; cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis; and mucosal leishmaniasis due to Leishmania braziliensis.",Knight Therapeutics (USA),Corporation Trust Center,1209 Orange Street,Wilmington,Delaware,' 19801 ' ,United States,229406,leishmaniasis,"""gard:0006881""",
4458,miltefosine,,8/2/2017,treatment of schistosomiasis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Profounda, Inc.",5790 Hoffner Avenue,Suite 507,Orlando,Florida,' 32822 ' ,United States,590217,schistosomiasis,"""gard:0009687""",
4459,Minnelide,,2/18/2013,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Minneamrita Therapeutics, LLC",6 Hickory Court,,Rock Island,Illinois,' 61201 ' ,United States,388512,,,
4460,Minocycline HCl,,6/19/1992,treatment of chronic malignant pleural effusion.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Lederle Laboratories Division,Division of American Cyanamid Company,401 N. Middletown Road,Pearl River,New York,' 10965 ' ,United States,67092,,,
4461,Minocycline hydrochloride,,3/28/2006,treatment of sarcoidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Autoimmunity Research Foundation,"Autoimmunity Research, Inc.",,Thousand Oaks,California,' 91360 ' ,United States,213305,sarcoidosis,"""gard:0007607""",
4462,mipomersen,KYNAMRO,5/23/2006,treatment of homozygous familial hypercholesterolemia,Designated/Approved,,,"Adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).",1/29/2013,1/29/2020,"Adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).","Kastle Therapeutics, LLC",181 West Madison Street,Suite 3745,Chicago,Illinois,' 60602 ' ,United States,221406,homozygous familial hypercholesterolemia,"""gard:0010416""",
4463,mirvetuximab soravtansine-gynx,Elahere,7/14/2014,treatment of ovarian cancer,Designated/Approved,,,"treatment of adult patients with folate receptor-alpha (FR?) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.",11/14/2022,11/14/2029,"treatment of adult patients with folate receptor-alpha (FR?) positive, platinum-resistant epithelial ovarian cancer, as detected by an FDA-approved test, who have received one to three prior systemic treatment regimens","ImmunoGen, Inc.",830 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,435214,ovarian cancer,"""gard:0007295""",
4464,misoprostol,,1/10/2005,treatment of intrauterine fetal death not accompanied by complete expulsion of the products of conception in the second and third trimesters of pregnancy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gynuity Health Projects, LLC",15 East 26th Street,,New York,New York,' 10010 ' ,United States,186604,,,
4465,mitapivat,,11/12/2020,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Agios Pharmaceuticals, Inc.",88 Sidney Street,,Cambridge,Massachusetts,' 02139 ' ,United States,781120,,,
4466,mitapivat,Pyrukynd,3/24/2015,treatment of pyruvate kinase deficiency,Designated/Approved,,,Treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency,2/17/2022,2/17/2029,Treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency,"Agios Pharmaceuticals, Inc.",88 Sidney Street,,Cambridge,Massachusetts,' 02139 ' ,United States,442814,,,
4467,Mitapivat,,6/8/2020,treatment of thalassemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Agios Pharmaceuticals, Inc.",88 Sidney Street,,Cambridge,Massachusetts,' 02139 ' ,United States,739920,,,
4468,Mitazalimab,,5/17/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Alligator Biosciences AB,Medicon Village,Scheelevägen 2,Lund,Lund,' SE-223 81 ' ,Sweden,865221,,,
4469,Mitochondria,,7/10/2020,prevention of ischemia-reperfusion injury during solid organ transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,cellvie Inc.,4326B Scotland Street,,Houston,Texas,' 77007 ' ,United States,747420,,,
4470,mitogen-activated protein kinase / phosphatidylinositol 3-kinase / mammalian target of rapamycin inhibitor,,1/12/2024,treatment of myelofibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Lympharma LLC,8120 Main Street,,Dexter,Michigan,' 48130 ' ,United States,982023,,,
4471,Mitoguazone,,3/18/1994,"treatment of diffuse non-hodgkin's lymphoma, including aids-related diffuse non-hodgkin's lymphoma.",Designated,,Not FDA Approved for Orphan Indication,,,,,"ILEX Oncology, Inc.",4545 Horizon Hill Blvd.,,San Antonio,Texas,' 78229 ' ,United States,80094,lymphoma,"""gard:0020548""",
4472,Mitolactol,,7/12/1995,as adjuvant therapy in the treatment of primary brain tumors.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Targent, Inc.",155 Lambert Drive,,Princeton,New Jersey,' 08540 ' ,United States,90295,,,
4473,Mitolactol,,1/23/1989,treatment of invasive carcinoma of the uterine cervix,Designated,,Not FDA Approved for Orphan Indication,,,,,"Targent, Inc..",155 Lambert Drive,,Princeton,New Jersey,' 08540 ' ,United States,33188,noma,"""gard:0004001""",
4474,mitomycin,,6/1/2011,prevention of corneal sub-epithelial haze formation following surface ablation laser keratectomy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mobius Therapeutics, LLC",1141 South 7th Street,,St. Louis,Missouri,' 63104 ' ,United States,305610,,,
4475,mitomycin,,1/13/2011,prevention of recurrence of pterygium after its surgical excision.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mobius Therapeutics, LLC",4041 Forest Park Avenue,,St. Louis,Missouri,' 63108 ' ,United States,312510,,,
4476,mitomycin,Jelmyto,9/8/2014,treatment of upper tract urothelial cell cancers (transitional cell carcinoma of the renal pelvis and ureter),Designated/Approved,,,JELMYTO¿ is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC),4/15/2020,4/15/2027,Indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC).,"UroGen Pharma, Ltd.","9 Ha'Ta'asiya St., POB 2397",,Ra'anana,,' ' ,Israel,445114,noma,"""gard:0004001""",
4477,Mitomycin-C,,8/20/1993,treatment of refractory glaucoma as an adjunct to ab externo glaucoma surgery.,Designated,,Not FDA Approved for Orphan Indication,,,,,IOP Inc.,"3100 Airway Avenue, Suite 106",,Costa Mesa,California,' 92626 ' ,United States,73493,,,
4478,mitomycin-C,Mitosol,1/8/2008,treatment of refractory glaucoma as an adjunct to surgery,Designated/Approved,,,An adjunct to ab externo glaucoma surgery.,2/7/2012,2/7/2019,,"Mobius Therapeutics, LLC",1141 South 7th Street,,St. Louis,Missouri,' 63104 ' ,United States,251407,,,
4479,Mitoxantrone,Novantrone,8/13/1999,treatment of secondary-progressive multiple sclerosis.,Designated/Approved,,,"Reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly adnormal between relapses).",10/13/2000,10/13/2007,,"Serono, Inc.",One Technoloogy Place,,Rockland,Massachusetts,' 02370 ' ,United States,125199,,,
4480,Mitoxantrone,Novantrone,8/21/1996,treatment of hormone refractory prostate cancer.,Designated/Approved,,,In combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer.,11/13/1996,11/13/2003,,Serono,One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,96696,,,
4481,Mitoxantrone,Novantrone,8/13/1999,treatment of progressive-relapsing multiple sclerosis.,Designated/Approved,,,"Reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly adnormal between relapses).",10/13/2000,10/13/2007,,"Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,128499,,,
4482,Mitoxantrone HCl,Novantrone,7/13/1987,"treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",Designated/Approved,,,,12/23/1987,12/23/1994,,Lederle Laboratories,Division of American Cyanamid Company,401 N. Middletown Road,Pearl River,New York,' 10965 ' ,United States,19287,,,
4483,Mitoxantrone hydrochloride liposome,,9/20/2017,treatment of peripheral t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.","., a subsidiary company within CSPC Pharmaceutical Group, Ltd",226 Huanghe Avenue,Shijiazhuang Shi,Hebei Sheng,' ' ,China,602317,lymphoma,"""gard:0020548""",
4484,Mixture of 2 anti-rabies humanized monoclonal immunoglobulin (Ig)G1k antibodies,,10/7/2015,post-exposure prophylaxis against rabies virus infection,Designated,,Not FDA Approved for Orphan Indication,,,,,"Synermore Biologics Co., Ltd","6F, No 5-6, Aly 22, Ln 513 Ruiguang Rd.",Neihu Dist.,Taipei City 11492,,' ' ,Taiwan,489515,rabies,"""gard:0007516""",
4485,Mixture of delta 9-tetrahydrocannabinol glycosides,,8/9/2021,treatment of pediatric ulcerative colitis between the ages of 0-18 years,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vitality Biopharma, Inc.",1901 Avenue of the Stars,2nd Floor,Los Angeles,California,' 90067 ' ,United States,627218,,,
4486,Mizoribine,,11/9/2020,treatment of membranous nephropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,161 Jefferson Avenue,,Tenafly,New Jersey,' 07670 ' ,United States,780820,,,
4487,MLN4924-Inhibitor of Nedd8-activating enzyme (NAE),,2/4/2011,treatment of acute myelogenous leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,331510,,,
4488,MLN4924-Inhibitor of Nedd8-activating enzyme (NAE),,2/4/2011,treatment of myelodysplastic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,331310,myelodysplastic syndrome,"""gard:0007132""",
4489,MN14 monoclonal antibody to carcinoembryonic antigen,,11/24/1998,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,1/11/2018,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,117998,,,
4490,MN14 monoclonal antibody to carcinoembryonic antigen,,9/18/1998,treatment of small cell lung cancer,Designated/Designation Withdrawn or Revoked,9/27/2017,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,113498,small cell lung cancer,"""gard:0009344""",
4491,mobilized perioheral blood cells that have undergone ex-vivo negative functionial selection of GvHD-causing T-cells by short term incubation with Fas-ligand,,8/15/2017,prevention of graft versus host disease (gvhd),Designated,,Not FDA Approved for Orphan Indication,,,,,Cellect Biotherapeutics,23 Ha'Taas Street,P.O. Box 2442,Kfar Saba,Center District,' ' ,Israel,589217,graft versus host disease,"""gard:0016642""",
4492,"Mobilized peripheral blood-derived autologous CD34+ hematopoietic stem cells, that have been genetically modified, ex vivo, with self-inactivating lentiviral vector CL20-4i-EF1a-hyc-OPT containing a normal version of the coding region of the IL2RG gene.",,9/18/2020,treatment of severe combined immunodeficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mustang Bio, Inc.",377 Plantation Street,,Worcester,Massachusetts,' 01605 ' ,United States,765220,severe combined immunodeficiency,"""gard:0007628""",
4493,mobocertinib,Exkivity,12/17/2019,"treatment of non-small cell lung cancer with genetic alterations in egfr including egfr mutations and/or egfr gene amplifications, her2 mutations, or braf g466v mutations",Designated/Approved,,,"Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy",9/15/2021,9/15/2028,"Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy","Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,653018,small cell lung cancer,"""gard:0009344""",
4494,mocetinostat,,8/7/2014,treatment of diffuse large b-cell lymphoma,Designated/Designation Withdrawn or Revoked,3/21/2022,Not FDA Approved for Orphan Indication,,,,,"Mirati Therapeutics, Inc.",9363 Towne Center Drive,Suite 200,San Diego,California,' 92121 ' ,United States,441514,lymphoma,"""gard:0020548""",
4495,Mocetinostat,,6/12/2014,treatment of myelodysplastic syndrome,Designated/Designation Withdrawn or Revoked,3/21/2022,Not FDA Approved for Orphan Indication,,,,,"Mirati Therapeutics, Inc.",9363 Towne Center Drive,Suite 200,San Diego,California,' 92121 ' ,United States,435414,myelodysplastic syndrome,"""gard:0007132""",
4496,mocravimod,,10/27/2021,prevention of graft-versus-host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Priothera SAS,57 Avenue Général De Gaulle,,Saint-Louis,,' 68300 ' ,France,843321,,,
4497,mocravimod,,11/14/2023,treatment to improve outcome following hematopoietic stem cell transplantation in hematologic malignancies,Designated,,Not FDA Approved for Orphan Indication,,,,,Priothera SAS,57 Avenue Général De Gaulle,,Saint-Louis,,' 68300 ' ,France,969523,,,
4498,Modafinil,Provigil,3/15/1993,treatment of excessive daytime sleepiness in narcolepsy.,Designated/Approved,,,Improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy.,12/24/1998,12/24/2005,,"Cephalon, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,' 19380 ' ,United States,73793,narcolepsy,"""gard:0022460""",
4499,modakafusp alfa,,2/28/2019,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,675518,multiple myeloma,"""gard:0007108""",
4500,modified a-cobratoxin,,9/1/2015,treatment of pediatric multiple sclerosis (0 through 16 years of age).,Designated,,Not FDA Approved for Orphan Indication,,,,,Nutra Pharma Corporation,12502 W. Atlantic Blvd,,Coral Springs,Florida,' 33071 ' ,United States,489115,pediatric multiple sclerosis,"""gard:0010443""",
4501,Modified cholera toxin,,2/7/2017,treatment of gaucher disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"ERAD Therapeutics, Inc.",11500 Dahlia Terrace,,Potomac,Maryland,' 20854 ' ,United States,552816,gaucher disease,"""gard:0008233""",
4502,modified human papillomavirus capsid protein conjugated to a near infrared dye,,4/8/2015,treatment of uveal melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aura Biosciences, Inc.",85 Bolton Street,,Cambridge,Massachusetts,' 02140 ' ,United States,472515,uveal melanoma,"""gard:0008621""",
4503,"modified mRNA encoding UGT1A1 protein, formulated in lipid nanoparticles",,7/5/2016,treatment of crigler-najjar syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Moderna Therapeutics, Inc.",200 Technology Square,,Cambridge,Massachusetts,' 02139 ' ,United States,526616,crigler-najjar syndrome,"""gard:0016526""",
4504,Modified mRNA that encodes human glucose-6-phosphatase-alpha,,8/27/2021,treatment of glycogen storage disease type 1a (gsd1a),Designated,,Not FDA Approved for Orphan Indication,,,,,"ModernaTX, Inc.",200 Technology Square,,"Cambridge,",Massachusetts,' 02139 ' ,United States,833921,glycogen storage disease,"""gard:0018973""",
4505,"Modified Recombinant adeno-associated virus (rAAV) serotype 2 vector, AAV.IVT18, expressing human retinoschisis gene RS1 driven by RS1 and CMV chimeric promoter",,2/8/2024,treatment of x-linked retinoschisis,Designated,,Not FDA Approved for Orphan Indication,,,,,InnoVec Biotherapeutics Inc.,"9 Yongteng North Road, Building 9, Haidian District",,Beijing,,' 100094 ' ,China,986923,x-linked retinoschisis,"""gard:0004690""",
4506,modified recombinant human Factor VIIa (rFVIIa) molecule,,5/30/2013,treatment of bleeding episodes in hemophilia a or b subjects with inhibitors,Designated/Designation Withdrawn or Revoked,12/22/2015,Not FDA Approved for Orphan Indication,,,,,"Bayer Healthcare Pharmaceuticals, Inc.",100 Bayer Boulevard,,Whippany,New Jersey,' 07981 ' ,United States,396213,hemophilia,"""gard:0010418""",
4507,modified recombinant mitochondrial transcription factor A (TFAM) containing the mitochondrial transduction domain,,8/20/2012,treatment of inherited mitochondrial respiratory chain disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Gencia Corporation,200 Garrett Street,Suite H,Charlottesville,Virginia,' 22902 ' ,United States,375012,,,
4508,modified vitamin D binding protein,,4/17/2017,treatment of recurrent respiratory papillomatosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Efranat, Ltd.",7 Oppenheimer Street,,Rehovot,,' ' ,Israel,577017,recurrent respiratory papillomatosis,"""gard:0000111""",
4509,mogamulizumab,,7/14/2011,treatment of adult t-cell leukemia/lymphoma (atll).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kyowa Kirin Pharmaceutical Development, Inc.",212 Carnegie Center,Suite 101,Princeton,New Jersey,' 08540 ' ,United States,345311,lymphoma,"""gard:0020548""",
4510,mogamulizumab,,11/2/2010,treatment of peripheral t-cell lymphoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kyowa Kirin Pharmaceutical Development, Inc.",212 Carnegie Center #101,,Princeton,New Jersey,' 08540 ' ,United States,313710,lymphoma,"""gard:0020548""",
4511,mogamulizumab,POTELIGEO,11/2/2010,treatment of patients with cutaneous t-cell lymphoma.,Designated/Approved,,,POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.,8/8/2018,8/8/2025,POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.,Kyowa Kirin Pharmaceutical Development Inc.,212 Carnegie Center # 101,,Princeton,New Jersey,' 08540 ' ,United States,322010,lymphoma,"""gard:0020548""",
4512,Molgramostim,,9/25/1989,treatment of aplastic anemia.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,' 07033 ' ,United States,39989,aplastic anemia,"""gard:0020234""",
4513,Molgramostim,,1/24/1989,"treatment of aids patients with neutropenia due to the disease, aztor ganciclovir.",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,' 07033 ' ,United States,34188,,,
4514,momelotinib,Ojjaara,8/5/2010,treatment of myelofibrosis,Designated/Approved,,,"treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia",9/15/2023,9/15/2030,"treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia",GlaxoSmithKline,23 rue François Jacob,,Rueil-Malmaison,,' 92500 ' ,France,311610,,,
4515,mometasone furoate,,6/26/2019,treatment of eosinophilic esophagitis,Designated,,Not FDA Approved for Orphan Indication,,,,,EsoCap AG,Malzgasse 9,,Basel,,' ' ,Switzerland,691019,,,
4516,monarsen,,11/14/2003,treatment of myasthenia gravis,Designated/Designation Withdrawn or Revoked,12/7/2016,Not FDA Approved for Orphan Indication,,,,,"Bioline Rx, Ltd.",19 Hartum Street,P. O. Box 45158,Jerusalem,,' ' ,Israel,173903,myasthenia gravis,"""gard:0007122""",
4517,monepantel,,5/16/2024,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,PharmAust Limited,"1 Kyle Way, Suite 116",,Claremont,Western Australia,' 6010 ' ,Australia,984623,amyotrophic lateral sclerosis,"""gard:0005786""",
4518,mongersen,,7/20/2015,treatment of pediatric crohn's disease,Designated/Designation Withdrawn or Revoked,8/1/2018,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,484215,,,
4519,monobenzone and imiquimod,,10/28/2019,treatment of stage iib-iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Learmont Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,' 10279 ' ,United States,707519,noma,"""gard:0004001""",
4520,Monoclonal Ab(murine) anti-idiotype melanoma-associated antigen,,9/19/1994,treatment of invasive cutaneous melanoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,IDEC Pharmaceuticals Corporation,3030 Callan Road,,San Diego,California,' 92121 ' ,United States,84094,noma,"""gard:0004001""",
4521,Monoclonal anti-IL-7R alpha antibody,,4/15/2020,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Allterum Therapeutics,"3900 Essex Lane, Suite 575",,Houston,Texas,' 77027 ' ,United States,656018,acute lymphoblastic leukemia,"""gard:0000522""",
4522,Monoclonal antibodies (murine or human) to B-cell lymphoma,,5/6/1986,treatment of b-cell lymphoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,IDEC Pharmaceuticals Corporation,11011 Torreyana Road,,San Diego,California,' 92121 ' ,United States,7085,lymphoma,"""gard:0020548""",
4523,Monoclonal antibodies PM-81 and AML-2-23,,3/12/1990,for the exogenous depletion of cd14 and cd15 positive acute myeloid leukemic bone marrow cells from patients undergoing bone marrow transplantation.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Medarex, Inc.",67 Beaver Avenue,,Annandale,New Jersey,' 08801 ' ,United States,39689,,,
4524,monoclonal antibody,,1/21/2011,prevention of congential cytomegalovirus (cmv)infection following primary cmv infection in pregnant women.,Designated/Designation Withdrawn or Revoked,5/16/2016,Not FDA Approved for Orphan Indication,,,,,Theraclone Sciences,1124 Columbia Street,,Seattle,Washington,' 98104 ' ,United States,325710,,,
4525,Monoclonal antibody -81,,6/27/1991,adjunctive treatment of acute myelogenous leukemia.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Medarex, Inc.",67 Beaver Avenue,,Annandale,New Jersey,' 08801 ' ,United States,58791,,,
4526,monoclonal antibody 11-1F4,,12/11/2009,for use as a therapeutic agent for patients al amyloidosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Caelum Biosciences, Inc.",2 Gansevoort Street,9th Floor,New York,New York,' 10014 ' ,United States,290309,amyloidosis,"""gard:0018676""",
4527,monoclonal antibody 11-1F4,,12/7/2009,for use as a radioimmaging agent in amyloidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Caelum Biosciences, Inc.",2 Gansevoort Street,9th Floor,New York,New York,' 10014 ' ,United States,293709,amyloidosis,"""gard:0018676""",
4528,Monoclonal antibody 17-1a,,4/4/1988,treatment of pancreatic cancer.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,27388,,,
4529,monoclonal antibody 3F8,,10/16/2008,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,United Therapeutics Corporation,55 TW Alexander Drive,P. O. Box 14186,Research Triangle Park,North Carolina,' 27709 ' ,United States,268808,neuroblastoma,"""gard:0007185""",
4530,"monoclonal antibody consisting of three mouse/human chimeric IgG1 monoclonal antibodies (c2G4, c4G7, and c13C6) that target Ebola virus",,8/25/2014,treatment of ebola virus infection,Designated/Designation Withdrawn or Revoked,3/4/2021,Not FDA Approved for Orphan Indication,,,,,"LeafBio, Inc.",6160 Lusk Blvd.,Suite C105,San Diego,California,' 90121 ' ,United States,440914,,,
4531,monoclonal antibody directed at hepatitis C virus E2 glycoprotein,,11/4/2013,prevention of hepatitis c recurrence in patients receiving liver transplantation,Designated/Designation Withdrawn or Revoked,8/14/2018,Not FDA Approved for Orphan Indication,,,,,MassBiologics-University of MA Medical School,460 Walk HIll Street,,Boston,Massachusetts,' 02126 ' ,United States,407013,,,
4532,Monoclonal antibody for immunization against lupus nephritis,,1/7/1993,treatment of lupus nephritis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"VivoRx Autoimmune, Inc.","2825 Santa Monica Blvd., Suite 200",,Santa Monica,California,' 90404 ' ,United States,71992,,,
4533,monoclonal antibody Hu3F8,,1/10/2014,treatment of osteosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Y-mAbs Therapeutics A/S,Agern Allé 11,,Hørsholm,,' 2970 ' ,Denmark,416313,osteosarcoma,"""gard:0007284""",
4534,Monoclonal antibody targeting CCL24,,10/11/2018,treatment of primary sclerosing cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"ChemomAb, Ltd.",6 Hanehoset St.,,Tel Aviv,,' ' ,Israel,618317,sclerosing cholangitis,"""gard:0021868""",
4535,monoclonal antibody targeting eotaxin-2,,10/29/2015,treatment of idiopathic pulmonary fibrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"ChemomAb, Ltd.",6 Hanehoset St.,,Tel Aviv,,' ' ,Israel,494615,idiopathic pulmonary fibrosis,"""gard:0008609""",
4536,monoclonal antibody targeting eotaxin-2,,1/6/2015,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"ChemomAb, Ltd.",6 Hanehoset St.,,Tel Aviv,,' ' ,Israel,442214,systemic sclerosis,"""gard:0009748""",
4537,Monoclonal antibody to cytomegalovirus (human),,11/15/1991,treatment of cytomegalovirus retinitis in patients with aids.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Protein Design Labs, Inc.",2375 Garcia Avenue,,Mountain View,California,' 94043 ' ,United States,59591,,,
4538,Monoclonal antibody to cytomegalovirus (human),,9/13/1991,prophylaxis of cytomegalovirus disease in patients undergoing solid organ transplantation.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Protein Design Labs, Inc.",2375 Garcia Avenue,,Mountain View,California,' 94043 ' ,United States,59491,,,
4539,Monoclonal antibody to hepatitis B virus (human),,6/17/1991,prophylaxis of hepatitis b reinfection in patients undergoing liver transplantation secondary to end-stage chronic hepatitis b infection.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Protein Design Labs, Inc.",34801 Campus Dr.,,Fremont,California,' 94555 ' ,United States,58391,,,
4540,Monoclonal antibody-B43.13,,11/25/1996,treatment of epithelial ovarian cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,CanariaBio Inc.,29 Jungang-ro,,Pyeongtaek-si,Gyeonggi-do,' ' ,South Korea,101396,ovarian cancer,"""gard:0007295""",
4541,Monoclonal antiendotoxin antibody XMMEn-0e5,,11/4/1985,treatment of patients with gram-negative sepsis which has progressed to shock.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",235 East 42nd Street,,New York,New York,' 10017 ' ,United States,6885,,,
4542,Monolaurin,,4/29/1993,treatment of congenital primary ichthyosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Glaxo Wellcome Inc.,5 Moore Drive,PO Box 13398,Research Triangle Park,North Carolina,' 27709 ' ,United States,71892,ichthyosis,"""gard:0018985""",
4543,monomethoxypolyethylene glycol recombinant adenosine deaminase,,6/15/2017,treatment of systemic sclerosis,Designated/Designation Withdrawn or Revoked,8/15/2022,Not FDA Approved for Orphan Indication,,,,,Chiesi USA Inc.,175 Regency Woods Place,Suite 600,Cary,North Carolina,' 27518 ' ,United States,570316,systemic sclerosis,"""gard:0009748""",
4544,monomethyl auristatin E conjugated to a monoclonal antibody which targets guanylyl cyclase C,,7/29/2014,treatment of pancreatic cancer.,Designated/Designation Withdrawn or Revoked,9/20/2016,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,438014,,,
4545,Mononuclear enriched fraction of human umbilical cord blood,,9/15/2015,treatment of amyotrophic lateral sclerosis (als).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Saneron CCEL Therapeutics, Inc.",13014 North Dale Mabry Highway,Suite 266,Tampa,Florida,' 33618 ' ,United States,491515,amyotrophic lateral sclerosis,"""gard:0005786""",
4546,Monooctanoin,Moctanin,5/30/1984,for dissolution of cholesterol gallstones retained in the common bile duct.,Designated/Approved,,,,10/31/1985,10/31/1992,,"Ethitek Pharmaceuticals, Inc.","7855 Gross Point Road, Unit L",,Skokie,Illinois,' 60077 ' ,United States,2484,,,
4547,monosialotetrahexosylganglioside,,3/9/2021,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Innomedica Schweiz AG,Gesellschaftsstrasse 16,,Bern,,' CH- 3012 ' ,Switzerland,805620,amyotrophic lateral sclerosis,"""gard:0005786""",
4548,monosialotetrahexosylganglioside,,8/7/2018,treatment of huntington’s disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Qilu Pharmaceutical Co., Ltd.",243 Gong Ye Bei Road Jinan,,,Shandong,' ' ,China,648018,,,
4549,"Monovalent replication-incompetent adenovirus serotype 26 (Ad26) vaccine, AD26.ZEBOV in combination with multivalent replication-defective Modified Vaccinia Ankara (MVA)-Bavarian Nordic (BN) vaccine, MVA-mBN226B",,1/11/2017,pre-exposure prophylaxis of ebola virus disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Janssen Vaccines and Prevention B.V.,Archimedesweg 4-6,,Leiden,Zuid-Holland,' ' ,Netherlands,490615,,,
4550,Morphine sulfate concentrate (preservative free),Infumorph,7/12/1990,for use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.,Designated/Approved,,,For intrathecal or epidural infusion in the treatment of tractable chronic pain. It was developed for use in continuous microinfusion devices and may require dilution before use as directed.,7/19/1991,7/19/1998,,"Elkins-Sinn, Inc.",2 Esterbrook Lane,,Cherry Hill,New Jersey,' 08003 ' ,United States,18587,,,
4551,mosedipimod,,12/19/2017,treatment of acute radiation syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Enzychem Lifesciences Corporation,"59, Bio valley-ro",,Jecheon-si,Chungcheongbuk-do,' ' ,South Korea,616517,acute radiation syndrome,"""gard:0021896""",
4552,mosunetuzumab-axgb,Lunsumio,12/17/2018,treatment of follicular lymphoma,Designated/Approved,,,treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy,12/22/2022,12/22/2029,treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,663418,lymphoma,"""gard:0020548""",
4553,motexafin gadolinium,,1/27/2003,for use in conjunction with whole brain radiation for the treatment of brain metastases arising from solid tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pharmacyclics, LLC",995 E. Arques Avenue,,Sunnyvale,California,' 94085 ' ,United States,152401,,,
4554,motixafortide,,9/5/2013,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioLineRx, Ltd.",Modi’in Technology Park,2 HaMa’ayan Street,Modi’in,,' ' ,Israel,403213,acute myeloid leukemia,"""gard:0012757""",
4555,motixafortide,,2/1/2019,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioLineRx, Ltd.",Modi’in Technology Park,2 HaMa’ayan Street,Modi’in,,' ' ,Israel,669818,,,
4556,motixafortide,Aphexda,7/6/2012,for use to mobilize hematopoietic stem cells (hscs) from the marrow to peripheral blood for collection for autologous or allogeneic transplantation,Designated/Approved,,,in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma,9/8/2023,9/8/2030,to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma,"BioLineRx, Ltd.",Modi'in Technology Park,2 HaMa'ayan Street,Modi'in,,' ' ,Israel,371912,,,
4557,"mouse-human chimeric antibody of the IgG1 isotype, directed against human CD37",,3/24/2015,treatment of chronic lymphocytic leukemia (cll).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.","900 Ridgebury Rd., PO Box 368",,Ridgefield,Connecticut,' 06877 ' ,United States,451514,,,
4558,mouse-human chimeric monoclonal anti-GD2 IgG1 antibody,,9/20/2012,treatment of neuroblastoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,EUSA Pharma (UK) Limited,Breakspear Park,Breakspear Way,,England,' ' ,United Kingdom,377712,neuroblastoma,"""gard:0007185""",
4559,moxetumomab pasudotox,,11/15/2007,treatment of cd22-positive chronic lymphocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike PO Box 8355,,Wilmington,Delaware,' 19803-8355 ' ,United States,248807,,,
4560,moxetumomab pasudotox,,6/28/2013,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike PO Box 8355,,Wilmington,Delaware,' 19803-8355 ' ,United States,396813,acute lymphoblastic leukemia,"""gard:0000522""",
4561,moxetumomab pasudotox-tdfk,LUMOXITI,11/15/2007,treatment of hairy cell leukemia,Designated/Approved,,,"LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).",9/13/2018,9/13/2025,"LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).",AstraZeneca Pharmaceuticals LP,1800 Concord Pike PO Box 8355,,Wilmington,Delaware,' 19803-8355 ' ,United States,248707,,,
4562,moxidectin,,9/29/2010,treatment of onchocerciasis volvulus in children and adults,Designated/Approved,,,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older,6/13/2018,6/13/2025,Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older,Medicines Development Limited,"Level 1, 18 Kevanagh Street",Southbank VIC 3006,Melbourne,,' ' ,Australia,316510,onchocerciasis,"""gard:0007252""",
4563,moxifloxacin hydrochloride,,4/30/2014,treatment of tuberculosis,Designated/Designation Withdrawn or Revoked,5/13/2014,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Boulevard,P. O. Box 915,Whippany,New Jersey,' 07981 ' ,United States,428014,tuberculosis,"""gard:0007827""",
4564,mPEG-r-crisantaspase,,2/1/2010,treatment of acute lymphoblastic leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jazz Pharmaceuticals, Inc.",3180 Porter Drive,,Palo Alto,California,' 94304 ' ,United States,299609,acute lymphoblastic leukemia,"""gard:0000522""",
4565,MRG-106 oligonucleotide inhibitor of microRNA miR-155-5p,,3/30/2017,treatment of mycosis fungoides,Designated,,Not FDA Approved for Orphan Indication,,,,,"miRagen Therapeutics, Inc.",6200 Lookout Road,Suite 100,Boulder,Colorado,' 80301 ' ,United States,560316,,,
4566,mRNA encoding human argininosuccinate lyase,,9/18/2017,treatment of argininosuccinate lyase deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"PhaseRx, Inc.",410 West Harrison Street,Suite 300,Seattle,Washington,' 98119 ' ,United States,605617,,,
4567,mRNA encoding human ornithine transcarbamylase,,11/23/2016,treatment of ornithine transcarbamylase deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"PhaseRx, Inc.",410 West Harrison Street,Suite 300,Seattle,Washington,' 98119 ' ,United States,542216,ornithine transcarbamylase deficiency,"""gard:0008391""",
4568,mRNA encoding the ciliary protein CCDC40,,9/26/2023,treatment of primary ciliary dyskinesia,Designated,,Not FDA Approved for Orphan Indication,,,,,Ethris GmbH,Semmeweisstrasse 3,,Planegg,Bavaria,' 82152 ' ,Germany,962723,primary ciliary dyskinesia,"""gard:0004484""",
4569,mRNA encoding the human glycogen debranching enzyme,,6/24/2021,treatment of glycogen storage disease type iii,Designated,,Not FDA Approved for Orphan Indication,,,,,Ultragenyx Pharmaceutical Inc.,60 Leveroni Court,,Novato,California,' 94949 ' ,United States,821921,glycogen storage disease,"""gard:0018973""",
4570,mRNA plus Lysate-Loaded Dendritic Cell Vaccine,,11/27/2023,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Joseph Georges, D.O., Ph.D.","Three Cooper Plaza, Suite 320",,Camden,New Jersey,' 08103 ' ,United States,972023,,,
4571,MTC-DOX for Injection,,1/3/2001,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,FeRx Incorporated,4330 La Jolla Village Drive,Suite #250,San Diego,California,' 92122 ' ,United States,139800,hepatocellular carcinoma,"""gard:0016773""",
4572,mTOR kinase inhibitor (CC-223),,10/16/2013,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,407913,hepatocellular carcinoma,"""gard:0016773""",
4573,Mucoid exopolysaccharide Pseudomonas hyperimmune globulin,,1/9/1991,treatment of pulmonary infections due to pseudomonas aeruginosa in patients with cystic fibrosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"North American Biologicals, Inc.",12280 Wilkins Avenue,,Rockville,Maryland,' 20852 ' ,United States,50590,cystic fibrosis,"""gard:0006233""",
4574,Mucoid exopolysaccharide Pseudomonas hyperimmune globulin,,11/7/1990,prevention of pulmonary infections due to pseudomonas aeruginosa in patients with cystic fibrosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"North American Biologicals, Inc.",12280 Wilkins Avenue,,Rockville,Maryland,' 20852 ' ,United States,50490,cystic fibrosis,"""gard:0006233""",
4575,multi-epitope folate receptor alpha peptide vaccine with GM-CSF adjuvant (TPIV200),,12/7/2015,treatment of ovarian cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Marker Therapeutics, Inc. (formerly Tapimmune, Inc.)",3200 Southwest Freeway,Suite 2240,Houston,Texas,' 77027 ' ,United States,498915,ovarian cancer,"""gard:0007295""",
4576,Multi-ligand somatostatin analog,,7/27/2004,"treatment of patients with functional gastroenteropancreatic (gep) neuroendocrine tumors (specifically, carcinoid, insulinoma, gastrinoma, somastatinoma, grfoma, vipoma and glucagonoma.",Designated/Designation Withdrawn or Revoked,7/20/2017,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,Office 337 A13.5B,East Hanover,New Jersey,' 07936 ' ,United States,188804,grfoma,"""gard:0019356""",
4577,Multi-peptide cancer vaccine,,6/23/2013,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"OncoPep, Inc.",520 Boston Street,,North Andover,Massachusetts,' 01845 ' ,United States,392313,multiple myeloma,"""gard:0007108""",
4578,Multi-vitamin infusion (neonatal formula),,12/12/1989,for establishment and maintenance of total parenteral nutrition in very low birth weight infants.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Astra Pharmaceuticals, L.P.",725 Chesterbrook Blvd.,,Wayne,Pennsylvania,' 19087 ' ,United States,41789,,,
4579,multi-vitamin infusion without vitamin K,M.V.I.-12,3/8/2004,prevention of vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type anticoagulant therapy,Designated/Approved,,,Prevention of vitamin deficiency and thrombormbolic complications in people receiving home parenteral nutrition who also receive warfarin-type anticoagulant therapy,9/9/2004,9/9/2011,,Mayne Pharma (USA) Inc.,Mack-Cali Centre II,Second Floor,Paramus,New Jersey,' 07652 ' ,United States,182003,,,
4580,Multicyclic 2-aminothiazole carboxamide that inhibits tubulin polymerization,,10/31/2023,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Reglagene, Inc.","3320 N Campbell Ave, Suite 200",,Tucson,Arizona,' 85719 ' ,United States,967923,glioblastoma,"""gard:0002491""",
4581,Multistem,,9/15/2010,prophylaxis of graft vs host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Athersys, Inc.",3201 Carnegie Avenue,,Cleveland,Ohio,' 44115 ' ,United States,314710,,,
4582,Murine double minute-2 (MDM2) or Human double minute-2 (HDM2),,11/24/2020,treatment of retinoblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,' 20850 ' ,United States,784720,retinoblastoma,"""gard:0007563""",
4583,Murine IgG1 monoclonal antibody binding to site II on G protein of rabies virus envelope and murine IgG2b monoclonal antibody binding to site III on G protein of rabies virus envelope,,5/15/2019,post-exposure prophylaxis against rabies virus infection.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cadila Healthcare Limited, India",Zydus Tower,Satellite Cross Roads,Ahmedabad,,' ' ,India,684319,rabies,"""gard:0007516""",
4584,murine IgG1(kappa) subtype monoclonal antibody MAb-AR20.5 that binds to MUC1,,8/10/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,CanariaBio Inc.,29 Jungang-ro,,Pyeongtaek-si,Gyeonggi-do,' ' ,South Korea,954923,,,
4585,Murine MAb (Lym-1) and Iodine 131-I radiolabeled murine MAb (Lym-1) to human B-cell lymphoma,,11/27/1998,treatment of b-cell non-hodgkin's lymphoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Peregrine Pharmaceuticals, Inc.",14272 Franklin Ave.,Suite 100,Tustin,California,' 92780 ' ,United States,118198,lymphoma,"""gard:0020548""",
4586,"Murine MAb to polymorphic epithelial mucin, human milk fat globule 1",,3/22/1999,adjuvant treatment of ovarian cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,Antisoma plc,West Africa House,Hanger Lane Ealing,London,,' ' ,United Kingdom,118098,ovarian cancer,"""gard:0007295""",
4587,murine monoclonal antibody against CD26,,2/18/2011,treatment of graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,ADIENNE S.A.,"Via Zurigo, 46",,Lugano,,' ' ,Switzerland,332510,graft versus host disease,"""gard:0016642""",
4588,Mutated form of human acetylcholine receptor a1 extracellular domain subunit,,3/16/2017,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,Toleranzia AB,Arvid Wallgrens backe 20,,Gothenburg,Västra Götalands län,' ' ,Sweden,561116,myasthenia gravis,"""gard:0007122""",
4589,"MV-NB-02, its bivalent ganglioside vaccine consisting of GD2-lactone and GD3-lactone each covalently conjugated to keyhole hemocyanin",,9/23/2014,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Y-mAbs Therapeutics, Inc.",230 Park Avenue,,New York,New York,' 10169 ' ,United States,445914,neuroblastoma,"""gard:0007185""",
4590,Mx-dnG1,,6/24/2008,treatment of osteosarcoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Epeius Biotechnologies Corporation,475 Huntington Drive,,San Marino,California,' 91108 ' ,United States,261208,osteosarcoma,"""gard:0007284""",
4591,Mx-dnG1,,6/24/2008,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Epeius Biotechnologies Corporation,475 Huntington Drive,,San Marino,California,' 91108 ' ,United States,262108,soft tissue sarcoma,"""gard:0004898""",
4592,Mx-dnG1 or Rexin-G retroviral vector,,8/15/2003,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Epeius Biotechnologies Corporation,"345 Pioneer Drive, 1803W",,Glendale,California,' 91203 ' ,United States,171703,,,
4593,Mycobacterium avium sensitin RS-10,,10/11/1995,for use in the diagnosis of invasive mycobacterium avium disease in immunocompetent individuals.,Designated,,Not FDA Approved for Orphan Indication,,,,,Statens Seruminstitut,5 Artillerivej,,DK-2300 Copenhagen S,,' ' ,Sweden,90495,,,
4594,mycobacterium vaccae,,8/20/2010,treatment of tuberculosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Immodulon Therapeutics Ltd,6-9 The Square,Stockley Park,Uxbridge,,' UB11 1FW ' ,United Kingdom,312710,tuberculosis,"""gard:0007827""",
4595,mycobacterium vaccae,,8/6/2010,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,11/26/2014,Not FDA Approved for Orphan Indication,,,,,Immodulon Therapeutics Ltd.,22 Devonshire Place,,London,,' ' ,United Kingdom,312810,,,
4596,Mycobacterium vaccae,,12/23/2019,treatment of tuberculosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Immunitor Inc.,365-2912 West Broadway,,Vancouver,,' ' ,Canada,714519,tuberculosis,"""gard:0007827""",
4597,Mycophenolate mofetil,,12/19/2005,treatment of myasthenia gravis,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Hoffman-LaRoche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,215405,myasthenia gravis,"""gard:0007122""",
4598,Mycophenolate mofetil,,5/26/2006,treatment of pemphigus vulgaris,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Hoffman-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,223106,pemphigus vulgaris,"""gard:0007355""",
4599,Myelin,,6/27/1991,treatment of multiple sclerosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"AutoImmune, Inc.",128 Spring Street,,Lexington,Massachusetts,' 02173 ' ,United States,57791,,,
4600,myo-inositol,,4/7/2005,prevention of retinopathy of prematurity in preterm infants at risk for developing retinopathy of prematurity,Designated,,Not FDA Approved for Orphan Indication,,,,,Abbott Nutrition,Abbott Laboratories,625 Cleveland Ave.,Columbus,Ohio,' 43215 ' ,United States,202105,retinopathy of prematurity,"""gard:0005695""",
4601,myristoylated recombinant SCR1-3 of human complement reseptor type I,,5/21/2003,prevention of delayed graft function in solid organ transplant,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Orexo AB,Box 303,Virdings alle 32 A,Uppsala,,' ' ,Sweden,166903,,,
4602,"N'-(7-Chloroquinolin-4-yl)-N,N-diethyl-propane-1,3-diamine",,10/29/2015,treatment of malaria.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Donald J. Krogstad, MD","1430 Tulane Ave., #8317",J.B. Johnson Building,New Orleans,Louisiana,' 70112 ' ,United States,494715,malaria,"""gard:0006961""",
4603,"N( 4{[ 5fluoro7( 2methoxyethoxy) 4quinazolinyl] amino}phenyl)2( 4isopropyl1H1,2,3triazol1yl) acetamide 4-methylbenzenesulfonate (1:1)",,9/13/2023,treatment of gastrointestinal stromal tumors (gist),Designated,,Not FDA Approved for Orphan Indication,,,,,"Ningbo NewBay Technology Development Co., Ltd.","Room 301, Blg.1, 39th Qiyuan Road, Hangzhou Bay New Zone",,Ningbo,Zhejiang,' 315336 ' ,China,959723,gastrointestinal stromal tumor,"""gard:0008598""",
4604,"N,N-dimethyl-N-(2-{[(2R,3R,4S,5R,6R)-3,4,5-tris(acetyloxy)-6-[(acetyloxy)methyl]oxan-2-yl]oxy}ethyl)cyclopropylammonium",,7/7/2020,treatment of trimethylaminuria,Designated/Designation Withdrawn or Revoked,8/17/2021,Not FDA Approved for Orphan Indication,,,,,"Kintai Therapeutics, Inc.",26 Landsdowne St,Suite 450,Cambridge,Massachusetts,' 02139 ' ,United States,761020,,,
4605,"N-((2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-2-(4-nitrophenoxy)tetrahydro-2H-pyran-3-yl)acetamide",,1/18/2021,prevention of bronchopulmonary dysplasia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"AyuVis Research, Inc.","1120 South Fwy, #121",,Fort Worth,Texas,' 76104 ' ,United States,723619,bronchopulmonary dysplasia,"""gard:0005962""",
4606,"N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline",,6/14/2017,treatment of hepatocellular carcinoma,Designated/Designation Withdrawn or Revoked,6/29/2023,Not FDA Approved for Orphan Indication,,,,,"MedPacto, Inc.",145 Gwanggyo-ro,Advanced Institutes of Convergence Technology,Suwon,Gyeonggi-do,' ' ,South Korea,575617,hepatocellular carcinoma,"""gard:0016773""",
4607,"N-(1¿,2-dihydroxy-[1,2¿-binapthalen]-4¿-yl)-4-methoxybenzenesulfonamide",,4/19/2022,treatment of pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tvardi Therapeutics, Inc.",2450 Holcombe Blvd. Suite X,,Houston,Texas,' 77021 ' ,United States,872022,,,
4608,"N-(2,3-dihydro-3,3-dimethyl-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide, phosphate (1:2)",,1/13/2005,treatment of gastrointestinal stromal tumors,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,' 91320 ' ,United States,197104,gastrointestinal stromal tumor,"""gard:0008598""",
4609,"N-(2,6-diethyphenyl)-8-({4-[4-(dimethylamino)piperidin-1-yl]-2- methoxyphenyl}amino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide phosphate",,1/11/2024,treatment of hepatocellular carcinoma (hcc),Designated,,Not FDA Approved for Orphan Indication,,,,,Nerviano Medical Sciences S.r.l.,"Viale Pasteur, 10",,Nerviano,MI,' 20014 ' ,Italy,982523,hepatocellular carcinoma,"""gard:0016773""",
4610,"N-(2-(4-Fluorophenyl)-5,7-dimethyl-1,2,3,4-tetrahydro isoquinolin-6-yl)-2-(1-methylcyclopropyl) acetamide",,10/18/2023,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shanghai Zhimeng Biopharma, Inc.","1976 Gaoke Middle Rd, Suite A-302",,"Pudong , Shanghai",,' 201210 ' ,China,967023,amyotrophic lateral sclerosis,"""gard:0005786""",
4611,N-(2-amino-2-oxoethyl)-2-(2-((4-fluorophenethyl)amino)-N-isobutylacetamido)-N-(3-(2-oxopyrrolidin-1-yl)propyl)acetamide N-({Carbamoylmethyl-[3-(2-oxo-pyrrolidin-1-yl)propyl}-carbamoyl}-methyl)-2-[2-(2-fluorophenyl)-ethylamino]-N-isobutyl-acetamide,,11/17/2014,treatment of optic neuritis,Designated,,Not FDA Approved for Orphan Indication,,,,,Bionure Farma SL,Dalmases 27,,Barcelona,,' ' ,Spain,440014,,,
4612,N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide,,8/8/2007,treatment of hodgkin's lymphoma,Designated/Designation Withdrawn or Revoked,3/21/2022,Not FDA Approved for Orphan Indication,,,,,"Mirati Therapeutics, Inc.",9363 Towne Center Drive,Suite 200,San Diego,California,' 92121 ' ,United States,244307,lymphoma,"""gard:0020548""",
4613,N-(2-amino-phenyl)-4-[(4-pyridin-3-yl-pyrimidin-2-ylamino)-methyl] benzamide dihydrobromide,,2/1/2008,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,3/21/2022,Not FDA Approved for Orphan Indication,,,,,"Mirati Therapeutics, Inc.",9363 Towne Center Drive,Suite 200,San Diego,California,' 92121 ' ,United States,253007,acute myeloid leukemia,"""gard:0012757""",
4614,"N-(2-chloro-3-((3,4-dihydro-2H-pyrimido[1,2-c] quinazolin-10- yl) oxy) phenyl) propane-1-sulfonamide hydrochloride",,7/26/2023,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,ABM Therapeutics Corporation,"4445 Eastgate Mall, , Suite 200",,San Diego,California,' 92121 ' ,United States,950923,,,
4615,"N-(2-chloro-6-propoxypyridin-4-yl)-2-(2-hydroxyethyl)-2-(4-isopropyl-1,3-dimethyl-1H-pyrazolo[3,4-b]pyridin-6-yl)hydrazinecarboxamide",,5/23/2018,treatment of idiopathic pulmonary fibrosis (ipf),Designated,,Not FDA Approved for Orphan Indication,,,,,"Arroyo Biosciences, LLC",1812 Pelling Court,,Silver Spring,Maryland,' 20905 ' ,United States,618717,idiopathic pulmonary fibrosis,"""gard:0008609""",
4616,"N-(2-Methoxyethyl)-6-methyl-N-[(3-methyl-2-thienyl)methyl]-2-oxo-1,2-dihydropyridine-4-carboxamide",,8/9/2023,treatment of glycogen storage disease type iv (gsd-iv),Designated,,Not FDA Approved for Orphan Indication,,,,,"Golden Heart Flower, Ltd.",2 Hamal Street,Industrial Park North,Afula,,' 1857107 ' ,Israel,953523,glycogen storage disease,"""gard:0018973""",
4617,"N-(3,4-dihydroxyphenyl)-3,4-dihydroxybenzamide",,10/15/2014,treatment of al amyloidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"ProtaMed, Inc.","14241 Woodinville Duvall Road, Suite # 370",,Woodinville,Washington,' 98072 ' ,United States,434014,amyloidosis,"""gard:0018676""",
4618,"N-(3-(2-(2,3-difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenylamino)quinazolin-8-yl)phenyl)acrylamide",,9/5/2017,treatment of epidermal growth factor receptor (egfr) mutation-positive non-small cell lung cancer (nsclc),Designated,,Not FDA Approved for Orphan Indication,,,,,"Checkpoint Therapeutics, Inc.",2 Gansevoort Street,9th Floor,New York,New York,' 10014 ' ,United States,599817,small cell lung cancer,"""gard:0009344""",
4619,"N-(3-(2-cyanopropan-2-yl)-5-(4-methyl-1H-imidazol-1-yl)phenyl)-2-fluoro-4-methyl-5-((8-((1-methyl-1H-pyrazol-4-yl)amino)imidazo[1,2-a]pyridin-3-yl)ethynyl)benzamide dihydrochloride",,1/12/2023,treatment of chronic myeloid leukemia (cml),Designated,,Not FDA Approved for Orphan Indication,,,,,"ImmunoForge Co., Ltd.","#1701~#1711, Ace Hansol Tower, 58 Gasan Digital 1-ro",Geumcheon-gu,Seoul,,' 08591 ' ,South Korea,873522,chronic myeloid leukemia,"""gard:0006105""",
4620,N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine disulphate salt,,3/20/2017,treatment of progressive supranuclear palsy,Designated,,Not FDA Approved for Orphan Indication,,,,,Alzprotect sas,85C Rue Nelson Mandela,Parc Eurasanté – Le Galénis,Loos,Hauts-de-France,' ' ,France,504115,progressive supranuclear palsy,"""gard:0007471""",
4621,N-(3-fluorobenzyl)-2-(5-(4-morpholinophenyl) pyridin-2-yl) Acetamide Besylate,,11/26/2013,treatment of gliomas,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kinex Pharmaceuticals, Inc.",701 Ellicott Street,,Buffalo,New York,' 14203 ' ,United States,413513,,,
4622,"N-(4,4-difluorocyclohexyl)-2-(3-methyl-1H-pyrazol-1-yl)-6-morpholinopyrimidin-4-amine",,5/22/2019,treatment of spinocerebellar ataxia,Designated,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,Building 337/03/A13L1-22,East Hanover,New Jersey,' 07936 ' ,United States,686219,,,
4623,N-(4-((2-aminopyrimidin-5-yl)ethynyl)-3-fluoropyridin-2-yl)-5-chloro-2-methoxypyridine-3-sulfonamide,,4/11/2024,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Apollo Therapeutics Inc.,"33 Arch Street, 17th Floor",,Boston,Massachusetts,' 02110 ' ,United States,997424,acute myeloid leukemia,"""gard:0012757""",
4624,"N-(4-(1-cyclopropyl-4-fluoro-2-methyl-1H-benzo[d]imidazol-6-yl)-5-fluoropyrimidin-2-yl)-6-(2-(dimethylamino)ethyl-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine maleate",,3/21/2023,treatment of liposarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Shanghai Pharma Biotherapeutics USA Inc.,"3545 John Hopkins Ct., Ste 160",,San Diego,California,' 92121 ' ,United States,930522,liposarcoma,"""gard:0006913""",
4625,"N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide hydrochloride",,1/27/2022,treatment of cholangiocarcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Relay Therapeutics Inc.,399 Binney Street,2nd Floor,Cambridge,Massachusetts,' 02139 ' ,United States,859021,cholangiocarcinoma,"""gard:0009304""",
4626,"N-(4-amino-3,4-dioxo-1-phenylbutan-2-yl)-4-(2-fluorophenyl)-2-methyloxazole-5-carboxamide",,7/22/2019,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Blade Therapeutics, Inc.",442 Littlefield Avenue,,South San Francisco,California,' 94080 ' ,United States,698719,idiopathic pulmonary fibrosis,"""gard:0008609""",
4627,"N-(4-Methoxyphenyl)-N,2,6-trimethylfuro[2,3-d] pyrimidin-4-amine",,2/18/2016,treatment of glioma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Flag Therapeutics, Inc.",9168 Wooden Road,,Raleigh,North Carolina,' 27617 ' ,United States,509015,,,
4628,N-(4-Methyl-3-(4-(5-(4-methylisoxazol-5-yl)pyridine-3-yl)pyrimidin-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide succinate,,10/3/2023,treatment of multiple system atrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Inhibikase Theapeutics, Inc.",3350 Riverwood Pkwy SE,Ste 1900,Atlanta,Georgia,' 30339 ' ,United States,941223,multiple system atrophy,"""gard:0007079""",
4629,"N-(4-methyl-3-(7-methyl-2-((6-methylpyridin-3-yl)amino)-8-oxo-7,8-dihydropyrido[3,4-d]pyrimidin-6-yl)phenyl)-3-(trifluoromethyl)benzamide",,11/8/2021,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pharos iBio Co., Ltd.","1407 & 1408, 38, Heungan-daero 427 beon-gil",,Anyang,Gyeonggi,' N/a ' ,South Korea,847921,acute myeloid leukemia,"""gard:0012757""",
4630,N-(4-{3-(2-aminopyrimidin-4-yl)pyridin-2-yl]oxy}phenyl)-4-(4-methylthiophen-2-yl)phthalazin-1-amine bis-mesylate dihydrate,,10/21/2014,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,11/6/2019,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,Mail Stop 17-2-B,Thousand Oaks,California,' 91320 ' ,United States,450414,ovarian cancer,"""gard:0007295""",
4631,"N-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(3,3-dimethylpiperazin-1-yl)benzamide hydrochloride",,10/11/2022,treatment of cholangiocarcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"3D Medicines (Beijing) Co., Ltd","7 Liangshuihe 1st Street, Building 3-6","Hongkun Park, BDA",Beijing,,' 100176 ' ,China,904422,cholangiocarcinoma,"""gard:0009304""",
4632,"N-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-4-(3,3-dimethylpiperazin-1-yl)benzamide hydrochloride",,1/12/2023,treatment of gastric cancer and gastro-esophageal junction cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"3D Medicines (Beijing) Co., Ltd",7 Liangshuihe 1st Street,"Building 3-6, Hongkun Park, BDA,",Beijing,,' 100176 ' ,China,921122,,,
4633,N-(6-2-aminophenylamino)-6-oxohexyl)-4-methylbenzamide,,5/17/2010,treatment of friedreich's ataxia.,Designated/Designation Withdrawn or Revoked,11/16/2013,Not FDA Approved for Orphan Indication,,,,,Repligen Corporation,"Building 1, Suite 100",,Waltham,Massachusetts,' 02453 ' ,United States,306110,,,
4634,N-(9-methoxynonyl)-1-deoxynojirimycin hydrochloride,,11/17/2014,"treatment of acute dengue illness (inclusive of acute dengue illness, dengue fever, dengue hemorrhagic fever, and dengue shock syndrome)",Designated/Designation Withdrawn or Revoked,9/25/2018,Not FDA Approved for Orphan Indication,,,,,"Emergent Virology, LLC",400 Professional Drive,,Gaithersburg,Maryland,' 20879 ' ,United States,442714,ck syndrome,"""gard:0017210""",
4635,"N-(bromoacetyl)-3,3-dinitroazetidine",,6/15/2017,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"EpicentRx, Inc.",4445 Eastgate Mall,Suite 200,San Diego,California,' 92121 ' ,United States,577317,small cell lung cancer,"""gard:0009344""",
4636,"N-(bromoacetyl)-3,3-dinitroazetidine",,6/15/2017,treatment of neuroendocrine tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"EpicentRx, Inc.",4445 Eastgate Mall,Suite 200,San Diego,California,' 92121 ' ,United States,579817,,,
4637,"N-(bromoacetyl)-3,3-dinitroazetidine",,1/16/2019,treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,EpicentRx Inc.,"11099 North Torrey Pines Road, Suite 160",La Jolla,San Diego,California,' 92037 ' ,United States,666718,glioblastoma,"""gard:0002491""",
4638,"N-(bromoacetyl)-3,3-dinitroazetidine",,4/15/2020,prevention of acute radiation syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"EpicentRx, Inc.",11099 North Torrey Pines Rd,Suite 160,La Jolla,California,' 92037 ' ,United States,737520,acute radiation syndrome,"""gard:0021896""",
4639,N-(methyl-diazacyclohexyl-methylbenzamide)-azaphenyl-aminothiopyrrole) mesylate,,10/17/2005,treatment of multiple myeloma.,Designated,,Not FDA Approved for Orphan Indication,,,,,AB Science,"3, avenue GeorgeV",75008,Paris,,' ' ,France,210505,multiple myeloma,"""gard:0007108""",
4640,N-(N-(4-(trifluoromethoxy)phenyl) carbamimidoyl)pyrrolidine-1-carboximidamide acetate (Or N1-(4-trifluoromethoxy)phenyl-N5-pyrrolidine biguanide acetate),,2/1/2021,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,ImmunoMet Therapeutics Inc.,2450 Holcombe,,Houston,Texas,' 77021 ' ,United States,796920,idiopathic pulmonary fibrosis,"""gard:0008609""",
4641,"N-(tert-butylcarbamoyl)-5-cyano-2-((4'-(difluoromethoxy)-[1,1'-biphenyl]-3-yl)oxy)benzenesulfonamide",,3/1/2018,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,ATXA Therapeutics Limited,75 Avoca Avenue,Avoca Avenue,Blackrock,County Dublin,' ' ,Ireland,628618,pulmonary arterial hypertension,"""gard:0007501""",
4642,"N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide",,3/7/2018,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Proteostasis Therapeutics, Inc.",200 Technology Square,,Cambridge,Massachusetts,' 02139 ' ,United States,544916,cystic fibrosis,"""gard:0006233""",
4643,N-acetyl cysteine amide,,12/31/2013,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nacuity Pharmaceuticals, Inc.",Fort Worth Club Building,306 W 17th Street,Fort Worth,Texas,' 76106 ' ,United States,417513,retinitis pigmentosa,"""gard:0005694""",
4644,N-acetyl-DL-leucine,,6/6/2018,treatment of spinocerebellar ataxia (sca),Designated,,Not FDA Approved for Orphan Indication,,,,,IntraBio Inc.,270 Devon Road,,Tenafly,New Jersey,' 07670 ' ,United States,640818,,,
4645,N-acetyl-DL-leucine,,3/26/2018,treatment of gm2 gangliosidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,IntraBio Inc.,270 Devon Road,,Tenafly,New Jersey,' 07670 ' ,United States,631918,gm2 gangliosidosis,"""gard:0021323""",
4646,N-acetyl-DL-leucine,,2/22/2018,"treatment of niemann-pick disease, type c",Designated,,Not FDA Approved for Orphan Indication,,,,,IntraBio Inc.,270 Devon Road,,Tenafly,New Jersey,' 07670 ' ,United States,626218,,,
4647,N-acetyl-glucosamine thiazoline,,2/6/2006,treatment of adult tay-sachs disease,Designated,,Not FDA Approved for Orphan Indication,,,,,ExSAR Corporation,11 Deer Park Drive,,Monmouth Junction,New Jersey,' 08852 ' ,United States,216805,tay-sachs disease,"""gard:0007737""",
4648,N-acetyl-L-leucine,,1/11/2022,treatment of gm2 gangliosidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,IntraBio Inc.,270 Devon Road,,Tenafly,New Jersey,' 07670 ' ,United States,855721,gm2 gangliosidosis,"""gard:0021323""",
4649,N-acetyl-L-leucine,,9/8/2021,"treatment of niemann-pick disease, type c",Designated,,Not FDA Approved for Orphan Indication,,,,,IntraBio Inc.,270 Devon Road,,Tenafly,New Jersey,' 07670 ' ,United States,836121,,,
4650,N-Acetyl-Leucine,,4/13/2022,treatment of gm1 gangliosidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,IntraBio Inc.,270 Devon Road,,Tenafly,New Jersey,' 07670 ' ,United States,870222,gangliosidosis,"""gard:0012510""",
4651,N-Acetyl-Leucine,,3/14/2023,treatment of ataxia-oculomotor apraxia-4 (aoa4),Designated,,Not FDA Approved for Orphan Indication,,,,,IntraBio Inc.,270 Devon Road,,Tenafly,New Jersey,' 07670 ' ,United States,914022,oculomotor apraxia,"""gard:0019547""",
4652,N-Acetyl-Leucine,,10/2/2018,treatment of ataxia telangiectasia,Designated,,Not FDA Approved for Orphan Indication,,,,,IntraBio Inc.,270 Devon Road,,Tenafly,New Jersey,' 07670 ' ,United States,653218,,,
4653,N-Acetyl-Leucine,,9/13/2023,treatment of multiple systems atrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,IntraBio Inc.,270 Devon Road,,Tenafly,New Jersey,' 07670 ' ,United States,959823,,,
4654,N-acetyl-procainamide,,12/10/1996,prevention of life-threatening ventricular arrhythmias in patients with documented procainamide-induced lupus.,Designated,,Not FDA Approved for Orphan Indication,,,,,NAPA of the Bahamas,"3560 Pennsylvania Avenue, Suite 7",,Dubuque,Iowa,' 52002 ' ,United States,99196,,,
4655,N-acetyl-sarcosyl-glycyl-L-valyl-D-alloisoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl_L-prolylethylaminde acetate,,12/9/2003,treatment of soft tissue sarcoma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,177803,soft tissue sarcoma,"""gard:0004898""",
4656,N-acetylcysteinate Lysine,,12/27/2000,for the management of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Galephar Pharmaceutical Research, Inc.","Road 198, No. 100 km. 14.7",Juncos Industrial Park,Juncos,,' ' ,United States,139200,cystic fibrosis,"""gard:0006233""",
4657,N-acetylcysteine,,10/21/2010,treatment of apnea of prematurity,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Galleon Pharmaceuticals,213 Witmer Road,,Horsham,Pennsylvania,' 19044 ' ,United States,309110,apnea of prematurity,"""gard:0019722""",
4658,N-acetylcysteine,,9/9/2002,treatment of acute liver failure,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cumberland Pharmaceuticals, Inc.",2525 West End Ave.,Suite 950,Nashville,Tennessee,' 37203 ' ,United States,158102,acute liver failure,"""gard:0019112""",
4659,N-acetylcysteine,,7/19/2012,prevention of ototoxicity caused by platinum-based chemotherapeutic agents used to treat pediatric cancers,Designated,,Not FDA Approved for Orphan Indication,,,,,"Edward A. Neuwelt, MD",3181 SW Sam Jackson Park Road,,Portland,Oregon,' 97239 ' ,United States,370012,,,
4660,N-acetylcysteine amide,,9/7/2021,treatment of cystinosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nacuity Pharmaceuticals, Inc.","306 W. 7th Street, Suite 310",,Fort Worth,Texas,' 76102 ' ,United States,768820,cystinosis,"""gard:0006236""",
4661,N-acetylcysteine amide,,9/27/2021,"treatment for gain-of-function mutation in acox1, mitchell’s syndrome.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Nacuity Pharmaceuticals, Inc.","306 W 7th St., Ste 310",,Fort Worth,Texas,' 76102 ' ,United States,771920,,,
4662,N-acetylcysteine and sodium thiosulfate,,8/31/2015,prevention of platinum-induced toxicities in pediatric patients (0 through 16 years of age).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Edward A. Neuwelt, MD",3181 SW Sam Jackson Park Road,,Portland,Oregon,' 97239 ' ,United States,479415,,,
4663,"N-acetylgalactosamine-4-sulfatase, recombinant human",Naglazyme,2/17/1999,treatment of mucopolysaccharidosis type vi (maroteaux-lamy syndrome).,Designated/Approved,,,For patients with mucopolysaccharidosis VI. Galsulfase has been shown to improve walking and stair-climbing capacity.,5/31/2005,5/31/2012,,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,' 94949 ' ,United States,119898,mucopolysaccharidosis,"""gard:0007065""",
4664,N-Acetylglucosamine,,9/23/2020,treatment for duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Wellesley Therapeutics, Inc.","200 Gerrard St., East",,Toronto,Ontario,' M5A 2E6 ' ,Canada,767420,muscular dystrophy,"""gard:0007922""",
4665,N-Acetylmannosamine (ManNAc),,4/5/2010,treatment of gne myopathy (hereditary inclusion body myopathy type 2),Designated,,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.","9841 Washingtonian Blvd, Suite 500",,Gaithersburg,Maryland,' 20878 ' ,United States,303510,gne myopathy,"""gard:0009493""",
4666,N-acetylprocainamide,,3/23/1990,to lower the defibrillation energy requirement sufficiently to allow automatic implantable cardioverter defibrillator therapy in those patients who could otherwise not use the device.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Medco Research, Inc.",8455 Beverly Blvd.,Suite 308,Los Angeles,California,' 90048 ' ,United States,35989,,,
4667,N-adamantanyl-N'-Geranyl-ethylenediamine,,10/16/2007,treatment of tuberculosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sequella, Inc.",9610 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,247307,tuberculosis,"""gard:0007827""",
4668,N-Benzothiazol-2-yl-4-(2-hydroxy-3-methoxy-benzylamino)-bezenesulfonamide,,12/30/2020,prophylaxis of thrombosis in patients with heparin-induced thrombocytopenia,Designated,,Not FDA Approved for Orphan Indication,,,,,Veralox Therapeutics,4539 Metropolitan Ct.,,Frederick,Maryland,' 21704 ' ,United States,736720,heparin-induced thrombocytopenia,"""gard:0002650""",
4669,"N-hydroxy-4-((4-((((1R,2S)-2-phenylcyclopropyl) amino)methyl)-1H-pyrazol-1-yl)methyl)benzamide hydrogen bromide",,12/27/2022,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Jubilant Therapeutics Inc.,"1430 US Highway 206, Suite 110",,Bedminster,New Jersey,' 07921 ' ,United States,916922,small cell lung cancer,"""gard:0009344""",
4670,"N-hydroxy-4-((4-((((1R,2S)-2-phenylcyclopropyl) amino)methyl)-1H-pyrazol-1-yl)methyl)benzamide hydrogen bromide.",,10/24/2022,treatment of the acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,Jubilant Therapeutics Inc.,"1430 US Highway 206, Suite 110",,Bedminster,New Jersey,' 07921 ' ,United States,906522,acute myeloid leukemia,"""gard:0012757""",
4671,N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide,,1/13/2012,treatment of schwannoma of the central nervous system,Designated,,Not FDA Approved for Orphan Indication,,,,,Recursion Pharmaceuticals Inc.,41 S. Rio Grande Street,,Salt Lake City,Utah,' 84101 ' ,United States,355611,noma,"""gard:0004001""",
4672,N-Hydroxy-4-(3-methyl-2-(S)phenyl-butyrylamino)benzamide,,1/13/2012,treatment of meningioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Recursion Pharmaceuticals Inc.,41 S. Rio Grande Street,,Salt Lake City,Utah,' 84101 ' ,United States,355511,meningioma,"""gard:0007015""",
4673,N-hydroxy-N-(methylacylfulvene)urea,,12/14/2021,treatment of atypical teratoid/rhabdoid tumor (atrt),Designated,,Not FDA Approved for Orphan Indication,,,,,Lantern Pharma Inc.,1920 MCKINNEY AVE,7TH FLOOR,Dallas,Texas,' 75201-2483 ' ,United States,850721,rhabdoid tumor,"""gard:0007572""",
4674,N-hydroxy-N-(methylacylfulvene)urea,,8/9/2021,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Lantern Pharma, Inc.",1920 MCKINNEY AVE,7TH FLOOR,DALLAS,Texas,' 75201 ' ,United States,832821,,,
4675,N-Methanocarbathymidine,,10/15/2014,treatment of neonatal herpes,Designated,,Not FDA Approved for Orphan Indication,,,,,"N & N Pharmaceuticals, Inc.",2400 Research Blvd,Suite 310,Rockville,Maryland,' 20850 ' ,United States,426014,,,
4676,N-Methyl-2-[3-[((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]benzamide,,5/4/2007,"treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer.",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",10646 Science Center Drive,,San Diego,California,' 92121 ' ,United States,230706,thyroid carcinoma,"""gard:0019763""",
4677,N-methyl-3-(1-methyl-1H-imidazol-4-yl)-4-((4-(trifluoromethyl)benzyl)amino)benzenesulfonamide,,12/14/2023,treatment of epithelioid hemangioendothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Ikena Oncology,"645 Summer St., Suite 101",,Boston,Massachusetts,' 02210 ' ,United States,975223,epithelioid hemangioendothelioma,"""gard:0020014""",
4678,N-methyl-4-({4-[({3-methyl(methylsulfonyl)amino]pyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride,,7/18/2013,treatment of mesothelioma,Designated/Designation Withdrawn or Revoked,9/15/2023,Not FDA Approved for Orphan Indication,,,,,"Verastem, Inc.",117 Kendrick Street,Suite 500,Needham,Massachusetts,' 02494 ' ,United States,393313,,,
4679,N-myristoylated -Glu-Ala-Val-Ser-Leu-Lys-Pro-Thr,,5/31/2023,prevention of ischemia/reperfusion injury in kidney transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,"Young Therapeutics, LLC",1715 Stanwood Street,,Philadelphia,Pennsylvania,' 19152 ' ,United States,617017,,,
4680,N-sulfoglucosamine sulfohydrolase,,2/20/2024,treatment of mucopolysaccharidosis type iiia (mps iiia; sanfilippo syndrome type a),Designated,,Not FDA Approved for Orphan Indication,,,,,Denali Therapeutics Inc.,161 Oyster Point Blvd,,South San Francisco,California,' 94080 ' ,United States,989323,sanfilippo syndrome type a,"""gard:0007071""",
4681,N-t-butylhydroxylamine,,5/12/2015,treatment of infantile neuronal ceroid lipofuscinosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Andrew Lim,California Institute of Technology,1200 East California Blvd.,Pasadena,California,' 91125 ' ,United States,478615,neuronal ceroid lipofuscinosis,"""gard:0010739""",
4682,"N-[(1R,2R)-2-(3-chloro-4-cyclopropoxyphenyl)-2-hydroxy-1-(pyrrolidinylmethyl)ethyl]-2-(6-chloro(2-naphthyl))-2-(hydroxyimino)acetamide.",,9/1/2022,treatment of fabry disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"AceLink Therapeutics, Inc.","39600 Eureka Drive, Suite 151",,Newark,California,' 94560 ' ,United States,898722,fabry disease,"""gard:0006400""",
4683,"N-[(1S)-1-(4- fluorophenyl)ethyl]-4-(1-methyl-1H-pyrazol-4-yl)-N'-(pyrazin-2-yl)pyridine-2,6- diamine maleate",,12/7/2022,treatment of myelofibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"NS Pharma, Inc.",140 East Ridgewood Avenue,Suite 280S,Paramus,New Jersey,' 07652 ' ,United States,916522,,,
4684,"N-[(1S)-1-[3-chloro-5-fluoro-2-({[2-methyl-4-(1-methyl-1H-1,2,4-triazol-5-yl)quinolin-8-yl]oxy}methyl)phenyl](1-2H)ethyl]-2-(difluoromethoxy)acetamide",,3/18/2022,treatment of bradykinin-mediated angioedema,Designated,,Not FDA Approved for Orphan Indication,,,,,Pharvaris Inc.,"303 Wyman Street, Suite 300",,Waltham,Massachusetts,' 02451 ' ,United States,809521,,,
4685,"N-[(2R)-2,3 dihydroxypropoxyl]-3,4 difluro-2 -[(2-fluoro-4-iodophenyl)amino] benzamide",,10/30/2018,treatment of neurofibromatosis type i,Designated,,Not FDA Approved for Orphan Indication,,,,,"SpringWorks Therapeutics, Inc.","575 5th Avenue, 16th Floor",,New York,New York,' 10017 ' ,United States,655618,neurofibroma,"""gard:0007191""",
4686,"N-[(2S)-2,3-dihydroxypropyl]-3-[(2-fluoro-4-iodophenyl)amino] isonicotinamide hydrochloride",,1/12/2011,treatment of acute myeloid leukemia (aml).,Designated/Designation Withdrawn or Revoked,5/15/2020,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,328110,acute myeloid leukemia,"""gard:0012757""",
4687,"N-[(3-fluoro-4-methoxypyridin-2-yl) methyl]-3-(methoxymethyl)-1-({4-[(2-oxo-1,2-dihydropyridin-1-yl) methyl]phenyl}methyl)-1H-pyrazole-4-carboxamide",,9/7/2021,treatment of bradykinin-mediated angioedema,Designated,,Not FDA Approved for Orphan Indication,,,,,KalVista Pharmaceuticals Ltd,Porton Science Park Bybrook Road,Porton Down,Salisbury,,' SP4 0BF ' ,United Kingdom,770420,,,
4688,N-[1-(5-Cyano-pyridin-2-ylmethyl)-1H-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl-phenyl]-acetamide,,4/8/2021,treatment of epileptic encephalopathy with continuous spike-wave discharges during sleep (eecsws),Designated,,Not FDA Approved for Orphan Indication,,,,,Neurocrine Biosciences Inc.,12780 El Camino Real,,San Diego,California,' 92130 ' ,United States,808621,,,
4689,"N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-[4-(dimethylamino)phenyl]cyclopentyl]methyl]urea, hydrochloride salt",,1/7/2015,for the treatment of cushing's syndrome,Designated/Designation Withdrawn or Revoked,1/4/2021,Not FDA Approved for Orphan Indication,,,,,"Millendo Therapeutics, Inc.",301 North Main St.,Suite 100,"Ann Arbor,",Michigan,' 48104 ' ,United States,414913,,,
4690,N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide,,9/30/2004,treatment of neuroblastoma,Designated/Designation Withdrawn or Revoked,7/10/2015,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,188604,neuroblastoma,"""gard:0007185""",
4691,"N-[3-(4',5'-bipyrimidin-2-ylamino)-4-methylphenyl]-4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]methyl}-3-(trifluoromethyl)benzamide",,12/27/2006,treatment of philadelphia chromosome-positive chronic myelogenous leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,CytRx Corporation,11726 San Vicente Blvd.,,Los Angeles,California,' 90049 ' ,United States,233206,,,
4692,"N-[3-[2-[(1R)-1-Hydroxypropan-2-ylamino]-6-(4- morpholinyl)-4-pyridinyl]-4-methylphenyl]-(3S)-3-(2,2,2-trifluoroethyl)-1- pyrrolidine carboxamide hydrochloride.",,5/19/2022,treatment of braf mutation-positive stage iib-iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Pierre Fabre Medicament,Les Cauquillous,,Lavaur,,' 81500 ' ,France,854521,noma,"""gard:0004001""",
4693,N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea,,10/23/2007,treatment of acute myelogenous leukemia,Designated/Designation Withdrawn or Revoked,8/15/2014,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,248007,,,
4694,N-[4-(3-amino1H-indazol-4-yl)phenyl]-N1-(2-fluoro-5-methylphenyl)urea,,5/23/2007,treatment of hepatocellular carcinoma,Designated/Designation Withdrawn or Revoked,8/16/2014,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,240807,hepatocellular carcinoma,"""gard:0016773""",
4695,"N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide",,8/13/2004,treatment of stages iib-iv melanoma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",50 Pequot,6025-A3106,New London,Connecticut,' 06320 ' ,United States,176603,noma,"""gard:0004001""",
4696,"N-[4-(4-amino-2-ethyl-lH-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide",,3/24/2006,treatment of cutaneous t-cell lymphoma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",50 Pequot Avenue,6025-A3106,New London,Connecticut,' 06320 ' ,United States,218105,lymphoma,"""gard:0020548""",
4697,N-[4-(trifluoromethyl)phenyl] 5 methylisoxazole-4-carboxamide,,5/25/1995,treatment of malignant glioma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sugen, Inc.",230 East Grand Ave.,,South San Francisco,California,' 94080 ' ,United States,89895,,,
4698,N-[4-(trifluoromethyl)phenyl]-5-methylisoxazole-4-carboxamide,,3/12/1996,treatment of ovarian cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sugen, Inc.",230 East Grand Ave.,,South San Francisco,California,' 94080 ' ,United States,95095,ovarian cancer,"""gard:0007295""",
4699,"N-[4-bromo-2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-N'-[3,5-bis(trifluoromethyl)phenyl]urea",,5/13/2002,treatment of sickle cell disease,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,NeuroSearch A/S,93 Pederstrupvej,,DK-2750 Ballerup,,' ' ,Denmark,153901,,,
4700,"N-[5-(2,3-Dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl]-2-[(4-ethylpiperazin-1-yl)methyl]quinoline-6-carboxamide",,8/16/2023,treatment of cholangiocarcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nuvectis Pharma, Inc.",1 Bridge Plaza N.,,Fort Lee,New Jersey,' 07024 ' ,United States,955523,cholangiocarcinoma,"""gard:0009304""",
4701,"N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methylpiperazin-1yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzamide",,2/12/2015,"treatment of trka-positive, trkb-positive, trkc-positive, ros1-positive, or alk-positive colorectal cancer",Designated/Designation Withdrawn or Revoked,1/7/2020,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,MS#241A,South San Francisco,California,' 94080 ' ,United States,463014,,,
4702,N-[5-(6-fluoro-8-{[4-(2-hydroxypropan-2-yl) piperidin-1-yl]methyl}-2-morpholinoquinazolin-4-yl)-2-methoxypyridin-3-]methanesulfonamide,,10/11/2018,treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shanghai Yingli Pharmaceutical Co., Ltd.","No.1 Building, 998 Halei Road","Zhangiiang Hi-tech Park, Pudong New Area",Shanghai,Shanghai,' ' ,China,654418,lymphoma,"""gard:0020548""",
4703,N-[5-(6-fluoro-8-{[4-(2-hydroxypropan-2-yl)piperidin-1-yl]methyl}-2-morpholinoquinazolin-4-yl)-2-methoxypyridin-3-yl]methanesulfonamide,,10/10/2018,treatment follicular lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shanghai Yingli Pharmaceutical Co., Ltd.","No.1 Building, 998 Halei Road","Zhangiiang Hi-tech Park, Pudong New Area",Shanghai,Shanghai,' ' ,China,654518,lymphoma,"""gard:0020548""",
4704,"N-[[(1,2,3,5,6,7-hexahydro-s-indacen-4-yl) amino]carbonyl]-1-(1-methylethyl)-1H-Pyrazole-3-sulfonamide",,7/7/2020,treatment of cryopyrin-associated periodic syndromes,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc., a Member of the Roche Group",1 DNA Way,,South San Francisco,California,' 94080-4990 ' ,United States,757720,cryopyrin-associated periodic syndrome,"""gard:0010927""",
4705,N-{2-[4-(2-Amino-5-chloropyridin-3-yl)phenoxy]pyrimidin-5-yl}-N'-[2-(methanesulfonyl)-5-(trifluoromethyl)phenyl]urea mono-4-toluenesulfonate,,9/13/2017,treatment of tropomyosin receptor kinase (trk) gene fusion-positive cancer,Designated/Designation Withdrawn or Revoked,10/3/2018,Not FDA Approved for Orphan Indication,,,,,Ono Pharmaceuticals Co. Ltd.,"8-2, Kyutaromachi l-chome",,Chuo-ku,Osaka-fu,' ' ,Japan,599717,,,
4706,N-{2-[N-((3S)(3-piperidyl))carbamoyl]-5-[2-(3-fluorophenyl)ethynyl](3-thienyl)}aminoamide,,4/29/2019,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pharos iBio Co., Ltd.","#1408, 38, Heungan-daero 427 beon-gil","Gwanyang-dong, Sungji Starwith),",Dongan-gu,Anyang-si Gyeonggi-do,' ' ,South Korea,681819,acute myeloid leukemia,"""gard:0012757""",
4707,"N-{[(5S)-3-(3-fluoro-4-thiomorpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide",,2/4/2011,treatment of tuberculosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sequella, Inc.",9610 Medical Center Drive,Suite 200,Rockville,Maryland,' 20820 ' ,United States,328210,tuberculosis,"""gard:0007827""",
4708,N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-Maystansine-Conjugated Humanized C242 Monoclonal Antibody,,12/7/2000,for pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,SmithKline Beecham Pharmaceuticals,1250 S. Collegeville Road,,Collegeville,Pennsylvania,' 19426 ' ,United States,138400,,,
4709,N2'-Deacetyl-N2'-[4-methyl-4-(oxobuthyldithio)-1-oxopentyl]-maytansine-chimerized anti-CD138 IgG4 Monoclonal Antibody,,2/27/2008,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,11/6/2019,Not FDA Approved for Orphan Indication,,,,,Biotest AG,5 Landsteinerstraße,,Dreieich,Hessen,' ' ,Germany,255407,multiple myeloma,"""gard:0007108""",
4710,nabumetone,,5/5/2008,treatment of pediatric juvenile rheumatoid arthritis,Designated,,Not FDA Approved for Orphan Indication,,,,,Cook Pharma,109 Graylyn Drive,,Chapel Hill,North Carolina,' 27516 ' ,United States,255207,,,
4711,Nadofaragene firadenovec,,7/7/2020,treatment of malignant mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Trizell Ltd,Sanderum House,"Oakley Road, Chinnor",Oxon,,' ' ,United Kingdom,748120,,,
4712,nadunolimab,,9/21/2021,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Cantargia AB,Scheelevägen 27,,Lund,,' SE-223 63 ' ,Sweden,815221,,,
4713,Nafamostat,,5/11/2020,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,' 07670 ' ,United States,742120,,,
4714,Nafamostat,,9/1/2021,treatment of dengue fever,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR Biomedical inc,161 Jefferson Ave.,,tenafly,New Jersey,' 07670 ' ,United States,835721,dengue fever,"""gard:0006254""",
4715,Nafarelin acetate,Synarel Nasal Solution,7/20/1988,treatment of central precocious puberty.,Designated/Approved,,,Treatment of central precocious puberty (gonadotropin-dependent precocious puberty) in children of both sexes.,2/26/1992,2/26/1999,,"Syntex (USA), Inc.",3401 Hillview Avenue,,Palo Alto,California,' 94303 ' ,United States,29888,central precocious puberty,"""gard:0016546""",
4716,naloxone,,11/23/2010,topical treatment of pruritus associated with mycosis fungoides,Designated,,Not FDA Approved for Orphan Indication,,,,,"Elorac, Inc.",100 Fairway Drive,,Vernon Hills,Illinois,' 60061 ' ,United States,280209,,,
4717,Naltrexone,,6/14/2021,treatment of complex regional pain syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Soin Theraputics,10601 Sunderland Woods CT,,Dayton,Ohio,' 45458 ' ,United States,819621,complex regional pain syndrome,"""gard:0004647""",
4718,naltrexone,,2/23/2015,treatment of postherpetic neuralgia,Designated,,Not FDA Approved for Orphan Indication,,,,,Allodynic Therapeutics LLC,1785 NE 123rd Street,,North Miami,Florida,' 33181 ' ,United States,465614,,,
4719,naltrexone,,1/19/2010,treatment of crohn's disease in pediatric patients,Designated,,Not FDA Approved for Orphan Indication,,,,,"Statera BioPharma, Inc.",2537 Research Boulevard,Suite 201,Ft. Collins,Colorado,' 80526 ' ,United States,296909,,,
4720,naltrexone,,1/13/2015,treatment of autoimmune hepatitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"TaiwanJ Pharmaceuticals Co., Ltd.","Room 204 A, Bldg 53","195 Chung Hsing Rd., Sec 4","Chutung, Hsinchu",,' ' ,Taiwan,460314,autoimmune hepatitis,"""gard:0005871""",
4721,Naltrexone HCl,Trexan,3/11/1985,for blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.,Designated/Approved,,,,11/30/1984,11/30/1991,,DuPont Pharmaceuticals,E.I. Du Pont De Nemours & Co.,,Wilmington,Delaware,' 19880 ' ,United States,6085,,,
4722,naltrexone/clonidine combination,,4/14/2014,treatment of postherpetic neuralgia,Designated,,Not FDA Approved for Orphan Indication,,,,,Allodynic Therapeutics LLC,1785 NE 123rd Street,,North Miami,Florida,' 33181 ' ,United States,425614,,,
4723,nanatinostat and valganciclovir,,2/28/2019,treatment of plasmablastic lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Viracta Therapeutics, Inc.",2533 South Coast Highway,Suite 210,Cardiff,California,' 92007 ' ,United States,676118,lymphoma,"""gard:0020548""",
4724,nanatinostat and valganciclovir,,6/22/2020,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Viracta Therapeutics, Inc.",2533 South Coast Highway,Suite 210,Cardiff,California,' 92007 ' ,United States,733420,lymphoma,"""gard:0020548""",
4725,nanatinostat and valganciclovir,,3/15/2019,treatment of angioimmunoblastic t-cell lymphoma,Designated/Designation Withdrawn or Revoked,7/7/2020,Not FDA Approved for Orphan Indication,,,,,"Viracta Therapeutics, Inc.",2533 South Coast Highway,Suite 210,Cardiff,California,' 92007 ' ,United States,675818,lymphoma,"""gard:0020548""",
4726,nanatinostat and valganciclovir,,2/28/2019,treatment of post-transplant lymphoproliferative disorder,Designated,,Not FDA Approved for Orphan Indication,,,,,"Viracta Therapeutics, Inc.",2533 South Coast Highway,Suite 210,Cardiff,California,' 92007 ' ,United States,676018,,,
4727,Nanatinostat and valganciclovir combination,,12/11/2023,treatment of nasopharyngeal carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Viracta Therapeutics, Inc.",2533 S. Coast Hwy 101,Suite 210,Cardiff,California,' 92007 ' ,United States,974223,nasopharyngeal carcinoma,"""gard:0007163""",
4728,nandrolone,,1/6/2022,treatment of facioscapulohumeral muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Sarcomed AB,Störtloppsvägen,25,Hägersten,Select...,' 12947 ' ,Sweden,855521,muscular dystrophy,"""gard:0007922""",
4729,nandrolone,,6/13/2017,treatment of duchenne and becker muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Sarcomed AB,25 Störtloppsvägen,,Hägersten-Liljeholmen,Stockholms län,' ' ,Sweden,569116,duchenne and becker muscular dystrophy,"""gard:0018686""",
4730,nandrolone,,12/4/2019,treatment of limb-girdle muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Sarcomed AB,25 Störtloppsvägen,,Hägersten-Liljeholmen,Stockholms län,' ' ,Sweden,712219,muscular dystrophy,"""gard:0007922""",
4731,nano-diamino-tetraiodothyroacetic acid,,10/28/2015,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"NanoPharmaceuticals, LLC",1 Discovery Place,,Rensselaer,New York,' 12144 ' ,United States,493715,,,
4732,nano-diamino-tetraiodothyroacetic acid,,7/9/2015,treatment of glioblastoma multiforme (gbm),Designated,,Not FDA Approved for Orphan Indication,,,,,"NanoPharmaceuticals, LLC",1 Discovery Place,,Rensselaer,New York,' 12144 ' ,United States,485115,glioblastoma,"""gard:0002491""",
4733,Nanocomplex consisting of a small interfering RNA that targets the human EV11 oncogenic transcription factor and an elastin-like polypeptide drug carrier.,,5/23/2016,treatment of ovarian cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,PeptiMed,922 Walsh Road,Suite 208,Madison,Wisconsin,' 53714 ' ,United States,523316,ovarian cancer,"""gard:0007295""",
4734,NanoDTPA(tm),,6/17/2011,"treatment of known or suspected cases of internal contamination with plutonium, americium, or curium",Designated,,Not FDA Approved for Orphan Indication,,,,,NanoSHIFT LLC,10454 Northwest 132nd Drive,,Alachua,Florida,' 32615 ' ,United States,335511,,,
4735,Nanoparticle suspension containing biosynthetic codon-optimized human ornithine transcarbamylase messenger RNA,,3/28/2018,treatment of ornithine transcarbamylase (otc) deficiency,Designated/Designation Withdrawn or Revoked,12/20/2021,Not FDA Approved for Orphan Indication,,,,,"Translate Bio, Inc.",29 Hartwell Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,632618,,,
4736,nanoparticles containing Zoledronic acid,,11/29/2016,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Laboratorio Italiano Biochimico Farmaceutico Lisapharma SpA,Via Licinio 11,,Erba (CO),Lombardia,' ' ,Italy,543616,,,
4737,nanoparticulate paclitaxel,,10/6/2015,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"NanOlogy, LLC",231 Bonetti Drive,,San Luis Obispo,California,' 93401 ' ,United States,482015,ovarian cancer,"""gard:0007295""",
4738,nanovesicle containing Saposin C and dioleoylphosphatidylserine,,4/28/2020,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Bexion Pharmaceuticals, Inc",632 Russell St,,Covington,Kentucky,' 41011 ' ,United States,735720,,,
4739,Nanvuranlat,,4/19/2022,treatment of biliary tract cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"J-Pharma Co., Ltd.",Leading Venture Plaza 1,75-1 Onocho,"Tsurumi, Yokohama",Kanagawa,' 230-0046 ' ,Japan,872522,,,
4740,napabucasin,,10/25/2016,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,8/30/2021,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Dainippon Pharma Oncology, Inc.",640 Memorial Drive,,Cambridge,Massachusetts,' 02139 ' ,United States,542316,,,
4741,napabucasin,,6/20/2016,treatment of gastric cancer including gastroesophageal junction cancer.,Designated/Designation Withdrawn or Revoked,8/22/2018,Not FDA Approved for Orphan Indication,,,,,"Boston Biomedical, Inc.",640 Memorial Drive,,Cambridge,Massachusetts,' 02139 ' ,United States,526116,,,
4742,naproxcinod,,2/28/2022,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Fera Pharmaceuticals, LLC",134 Birch Hill Road,,Locust Valley,New York,' 11560 ' ,United States,742820,,,
4743,naproxcinod,,3/16/2015,treatment of duchenne muscular dystrophy.,Designated,,Not FDA Approved for Orphan Indication,,,,,Nicox SA,2105 route des Dolines,Drakkar bat D-CS 10313,Valbonne,,' ' ,France,467414,muscular dystrophy,"""gard:0007922""",
4744,Naratuximab emtansine,,5/12/2016,treatment of diffuse large b-cell lymphoma,Designated/Designation Withdrawn or Revoked,7/6/2022,Not FDA Approved for Orphan Indication,,,,,Debiopharm International S.A.,"Forum ""apres-demain""","Chemin Messidor 5-7, CP 5911",,,' ' ,Switzerland,518016,lymphoma,"""gard:0020548""",
4745,Natural human lymphoblastoid interferon-alpha,,8/10/2000,treatment of papillomavirus warts in the oral cavity of hiv positive patients.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Amarillo Biosciences, Inc.",4134 Business Park Drive,,Amarillo,Texas,' 79110 ' ,United States,136000,,,
4746,natural human lymphoblastoid interferon-alpha,,11/18/2002,treatment of polycythemia vera,Designated,,Not FDA Approved for Orphan Indication,,,,,"Amarillo Biosciences, Inc.",4134 Business Park Drive,,Amarillo,Texas,' 79110 ' ,United States,159602,polycythemia,"""gard:0019466""",
4747,Natural human lymphoblastoid interferon-alpha,,1/18/2000,treatment of behcet's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Amarillo Biosciences, Inc.",4134 Business Park Drive,,Amarillo,Texas,' 79110 ' ,United States,131299,,,
4748,"Natural Regulatory T Cells (T-Regs), Expanded with Interleukin-2, ExpAct Beads (CD3/CD28; Miltenyi), Rapamycin and Transforming Growth Factor-beta",,12/23/2019,prevention of graft rejection following solid organ transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,"TRACT Therapeutics, Inc.",212 W. Superior Street,Suite 130,Chicago,Illinois,' 60654 ' ,United States,715719,,,
4749,navitoclax,,11/18/2019,treatment of myelofibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,"Dept #PA72, Bldg. AP30-4",North Chicago,Illinois,' 60064 ' ,United States,709319,,,
4750,navtemadlin,,4/8/2020,treatment of merkel cell carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kartos Therapeutics, Inc.",275 Shoreline Drive,,Redwood City,California,' 94065 ' ,United States,735120,noma,"""gard:0004001""",
4751,naxitamab-gqgk,DANYELZA®,6/24/2013,treatment of neuroblastoma,Designated/Approved,,,"in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy",11/25/2020,11/25/2027,"treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy","Y-mAbs Therapeutics, Inc.",750 3rd Avenue,9th Floor,New York,New York,' 10017 ' ,United States,399613,neuroblastoma,"""gard:0007185""",
4752,NDX-peptides,,12/14/2010,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,NeoDiagnostic Research Ltd,Sheraton House 1st Floor,Chorleywood,Herts,,' ' ,United Kingdom,326010,amyotrophic lateral sclerosis,"""gard:0005786""",
4753,Near-infrared monoamine oxidase inhibitor (conjugate of clorgyline and cyanine dye MHI-148),,4/15/2020,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jean C. Shih, Ph.D.",Department of Pharmacology and Pharmaceutical Sciences,University of Southern California,Los Angeles,California,' 90089 ' ,United States,740420,,,
4754,Nebacumab,,10/1/1986,treatment of patients with gram-negative bacteremia which has progressed to endotoxin shock.,Designated/Designation Withdrawn or Revoked,8/19/2021,Not FDA Approved for Orphan Indication,,,,,"Centocor, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,14186,,,
4755,necitumumab,,11/20/2015,treatment of squamous non-small cell lung cancer,Designated/Approved,,,"Use in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic, squamous, non-small cell lung cancer. Limitation of Use: PORTRAZZA is not indicated for treatment of non-squamous non-small cell lung cancer.",11/24/2015,11/24/2022,"Use in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic, squamous, non-small cell lung cancer. PORTRAZZA is not indicated for treatment of non-squamous, non-small cell lung cancer",Eli Lilly and Company,33 ImClone Drive,,Branchburg,New Jersey,' 08876 ' ,United States,418213,small cell lung cancer,"""gard:0009344""",
4756,nedaplatin,,8/31/2020,treatment of esophageal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenafly,New Jersey,' 07670 ' ,United States,747220,,,
4757,Nedaplatin,,8/5/2020,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,' 07670 ' ,United States,753320,small cell lung cancer,"""gard:0009344""",
4758,nedosiran,Rivfloza,5/15/2018,treatment of primary hyperoxaluria,Designated/Approved,,,"to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR greater than or equal to 30 mL/min/1.73 m2",9/29/2023,9/29/2030,"to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR greater than or equal to 30 mL/min/1.73 m2","Dicerna Pharmaceuticals, Inc. (a wholly owned subsidiary of Novo Nordisk)",75 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,635418,primary hyperoxaluria,"""gard:0016530""",
4759,neihulizumab,,1/25/2018,treatment of acute graft-versus-host disease (agvhd),Designated,,Not FDA Approved for Orphan Indication,,,,,"AltruBio Inc. (formerly AbGenomics International, Inc.)",5050 El Camino Real,Suite #105,Los Altos,California,' 94022 ' ,United States,622617,,,
4760,nelarabine,Arranon,8/10/2004,treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma,Designated/Approved,,,Treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens,10/28/2005,10/28/2012,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,184404,lymphoma,"""gard:0020548""",
4761,nelarabine,,9/2/1999,treatment of chronic lymphocytic leukemia.,Designated/Designation Withdrawn or Revoked,7/15/2021,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,125999,,,
4762,nelatimotide and adegramotide (DSP-7888 dosing emulsion),,9/18/2017,treatment of brain cancer,Designated/Designation Withdrawn or Revoked,6/23/2023,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Pharma Oncology, Inc.",84 Waterford Drive,,Marlborough,Massachusetts,' 01752 ' ,United States,603617,,,
4763,NELATIMOTIDE AND ADEGRAMOTIDE combination,,6/19/2017,treatment of myelodysplastic syndrome.,Designated/Designation Withdrawn or Revoked,6/23/2023,Not FDA Approved for Orphan Indication,,,,,"Sumitomo Pharma Oncology, Inc.",84 Waterford Drive,,Marlborough,Massachusetts,' 01752 ' ,United States,571516,myelodysplastic syndrome,"""gard:0007132""",
4764,nelfinavir,,2/14/2017,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,3/10/2021,Not FDA Approved for Orphan Indication,,,,,Swiss Group for Clinical Cancer Research (SAKK),Effingerstrasse 33,,Bern,Bern,' ' ,Switzerland,554316,multiple myeloma,"""gard:0007108""",
4765,neostigmine,,3/18/2013,treatment of acute colonic pseudo-obstruction,Designated,,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",One Luitpold Drive,P. O. Box 9001,Shirley,New York,' 11967 ' ,United States,388812,,,
4766,neostigmine methylsulfate,,2/17/2012,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",1000 Madison Ave,,Norristown,Pennsylvania,' 19403 ' ,United States,359611,myasthenia gravis,"""gard:0007122""",
4767,neratinib,,3/25/2024,treatment of gastric cancer (including gastroesophageal junction cancer),Designated,,Not FDA Approved for Orphan Indication,,,,,"Convalife (Shanghai) CO., Ltd.","Room 518, Building 21, No.1-28,","Lane 588, Tianxiong Road, Pudong New District",,Shanghai,' ' ,China,995024,,,
4768,neratinib,,8/26/2019,treatment of breast cancer patients with brain metastases,Designated/Designation Withdrawn or Revoked,4/27/2023,Not FDA Approved for Orphan Indication,,,,,Puma Biotechnology Inc.,"10880 Wilshire Blvd., Suite 2150",,Los Angeles,California,' 90024 ' ,United States,699119,,,
4769,neridronate,,3/25/2013,"treatment of complex regional pain syndrome (crps-1, crps-ii, crps-nos)",Designated,,Not FDA Approved for Orphan Indication,,,,,"NovaPharm, LLC",526 Park Ridge Drive,,Wayne,Pennsylvania,' 19087 ' ,United States,372412,complex regional pain syndrome,"""gard:0004647""",
4770,netazepide,,9/10/2009,treatment of gastric carcinoids,Designated,,Not FDA Approved for Orphan Indication,,,,,Trio Medicines Ltd.,Pavillion View,19 New Road,Brighton,,' ' ,United Kingdom,243207,,,
4771,Neurotrophin-1,,9/13/1994,treatment of motor neuron disease/amyotrophic lateral sclerosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ericsson, Arthur Dale, M.D.","6560 Fannin, Scurlock Tower, Suite 720",,Houston,Texas,' 77303 ' ,United States,84594,motor neuron disease,"""gard:0019477""",
4772,neutralizing equine anti-Stx hyperimmune immunoglobulin F(ab')2 fragment,,8/19/2019,treatment of shiga-toxin producing bacterial infection as it relates to the prevention of hemolytic uremic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Inmunova SA,"Av. 25 de Mayo 1021, San Martin (1650)",,Buenos Aires,Buenos Aires,' ' ,Argentina,644418,hemolytic uremic syndrome,"""gard:0022233""",
4773,Neutrophil-endothelial interaction inhibitor,,12/22/1993,treatment of post-ischemic pulmonary reperfusion edema following surgical treatment for chronic thromboembolic pulmonary hypertension.,Designated,,Not FDA Approved for Orphan Indication,,,,,Cytel Corporation,3525 John Hopkins Court,,San Diego,California,' 92121 ' ,United States,77693,chronic thromboembolic pulmonary hypertension,"""gard:0013124""",
4774,nevanimibe HCL,,3/9/2012,treatment of adrenocortical carcinoma,Designated/Designation Withdrawn or Revoked,1/4/2021,Not FDA Approved for Orphan Indication,,,,,"Millendo Therapeutics, Inc.",301 North Main Street,Suite 100,Ann Arbor,Michigan,' 48104 ' ,United States,364712,noma,"""gard:0004001""",
4775,nevanimibe HCL,,8/17/2017,treatment of congenital adrenal hyperplasia,Designated/Designation Withdrawn or Revoked,1/4/2021,Not FDA Approved for Orphan Indication,,,,,"Millendo Therapeutics, Inc.",301 North Main Street,Suite 100,Ann Arbor,Michigan,' 48104 ' ,United States,497315,congenital adrenal hyperplasia,"""gard:0001467""",
4776,nevirapine,,11/25/2009,prevention of hiv infection in pediatric patients under the age of 16 years,Designated,,Not FDA Approved for Orphan Indication,,,,,Auritec Pharmaceuticals,1434 6th Street,,Santa Monica,California,' 90401 ' ,United States,293409,,,
4777,nicardipine,,11/26/2019,treatment of pitt-hopkins syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc.","5616 Hilltop Needmore Rd,",,Fuquay Varina,North Carolina,' 27526 ' ,United States,712819,pitt-hopkins syndrome,"""gard:0004372""",
4778,NiCord (cord blood-derived exvivo expanded CD34+ cells and the non-expanded cell fraction of the same cord blood unit),,11/9/2016,treatment of chronic myelogenous leukemia (cml),Designated/Designation Withdrawn or Revoked,10/10/2018,Not FDA Approved for Orphan Indication,,,,,Gamida Cell Ltd.,P. O. Box 34670,,Jerusalem,,' ' ,Israel,544116,,,
4779,nicotinamide riboside,,1/25/2017,"treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome (melas)",Designated,,Not FDA Approved for Orphan Indication,,,,,Rejuvenation Therapeutics,774 Mays Boulevard,10-509 PMB,Incline Village,Nevada,' 89451 ' ,United States,548716,melas,"""gard:0007009""",
4780,nicotinamide riboside and pterostilbene,,3/19/2018,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Elysium Health Inc.,434 Broadway,Floor 2,New York,New York,' 10013 ' ,United States,628218,amyotrophic lateral sclerosis,"""gard:0005786""",
4781,Nicotinamide riboside chloride,,6/3/2024,treatment of ataxia telangiectasia,Designated,,Not FDA Approved for Orphan Indication,,,,,"ChromaDex, Inc.","10900 Wilshire Blvd., Suite 600",,Los Angeles,California,' 90024 ' ,United States,1004624,,,
4782,Nifedipine,,6/13/1991,treatment of interstitial cystitis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Fleischmann, Jonathan M.D.",MetroHealth Medical Center,3395 Scranton Road,Cleveland,Ohio,' 44109 ' ,United States,57991,interstitial cystitis,"""gard:0018825""",
4783,nifurtimox,,12/31/2013,treatment of chagas disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"MetronomX Therapeutics, LLC",7000 Fannin Street,Suite 1960,Houston,Texas,' 77030 ' ,United States,419213,,,
4784,nifurtimox,LAMPIT,8/5/2010,treatment of chagas disease (american typanosomiasis)caused by t. cruzi,Designated/Approved,,,"LAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi",8/6/2020,8/6/2027,indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi,"Bayer HealthCare Pharmaceuticals, Inc.",100 BAYER BLVD,,WHIPPANY,New Jersey,' 07981 ' ,United States,310110,,,
4785,Nikkomycin Z,,2/14/2006,treatment of coccidioidomycosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Valley Fever Center for Excellence (1-111 INF),University of Arizona,,Tucson,Alaska,' 85723 ' ,United States,217505,coccidioidomycosis,"""gard:0009525""",
4786,nilotinib,Tasigna,4/27/2006,treatment of chronic myelogenous leukemia,Designated/Approved,,,Treatment of pediatric patients greater than or equal to 1 year of age with chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy,9/23/2021,9/23/2028,Treatment of pediatric patients greater than or equal to 1 year of age with accelerated phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,220806,,,
4787,nilotinib,Tasigna,4/27/2006,treatment of chronic myelogenous leukemia,Designated/Approved,,,For the use for chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior therapy that included imatinib.,10/29/2007,10/29/2014,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,220806,,,
4788,nilotinib,Tasigna,4/27/2006,treatment of chronic myelogenous leukemia,Designated/Approved,,,TASIGNA® (nilotinib) is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase and pediatric patients greater than or equal to 1 year of age with chronic phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy.,3/22/2018,3/22/2025,TASIGNA® (nilotinib) is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase and pediatric patients greater than or equal to 1 year of age with chronic phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy.,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,220806,,,
4789,nilotinib,,3/20/2007,treatment of gastrointestinal stromal tumors.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaeuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,237307,gastrointestinal stromal tumor,"""gard:0008598""",
4790,Nilotinib ONCORE,,12/23/2020,treatment of chronic myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Handa Oncology, LLC","1732 N. First Street, Suite 200",,San Jose,California,' 95112 ' ,United States,786820,chronic myeloid leukemia,"""gard:0006105""",
4791,nilotinib oral formulation,,12/28/2020,treatment of chronic myeloid leukemia (cml).,Designated,,Not FDA Approved for Orphan Indication,,,,,Xspray Pharma AB,Råsundavägen 12,,Solna,,' 16967 ' ,Sweden,788520,chronic myeloid leukemia,"""gard:0006105""",
4792,nilotinib oral tablets,,5/28/2020,treatment of chronic myelogenous leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nanocopoeia, LLC",1246 West University Avenue,Suite 463,St. Paul,Minnesota,' 55104 ' ,United States,743720,,,
4793,nimodipine,NYMALIZE,9/16/2011,treatment of subarachnoid hemorrhage.,Designated/Approved,,,"Improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V).",5/10/2013,5/10/2020,"Improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V).","Arbor Pharmaceuticals, Inc.",6 Concourse Parkway,Suite 1800,Atlanta,Georgia,' 30328 ' ,United States,338611,,,
4794,nimodipine intravenous,,8/10/2017,treatment of subarachnoid hemorrhage,Designated,,Not FDA Approved for Orphan Indication,,,,,Acasti Pharma Inc.,"103 Carnegie Center Drive, Suite 300",,Princeton,New Jersey,' 08540 ' ,United States,566016,,,
4795,nimodipine intravenous,,8/1/2023,treatment of subarachnoid hemorrhage,Designated,,Not FDA Approved for Orphan Indication,,,,,Cipla Ltd.,"Cipla House, Peninsula Business Park",Ganpatrao Kadam Marg,Lower Parel Mumbai,,' 400 013 ' ,India,951423,,,
4796,nimotuzumab,,9/8/2015,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,InnoCIMab Pte Ltd,21 Bukit Batok Crescent,,WCEGA Tower #14-78,,' ' ,Singapore,487915,,,
4797,Nimotuzumab,,11/17/2004,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,InnoKeys PTE Ltd.,26 Bukit Batok East Avenue 2,,#03-10,,' ' ,Singapore,192504,,,
4798,Nine amino acid polypeptide derived from proteinase 3,,9/3/2004,treatment of chronic myelogenous leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,The Vaccine Company,P. O. Box 93921,,Carmel,California,' 93921 ' ,United States,187704,,,
4799,Nine amino acid polypeptide derived from proteinase 3,,9/3/2004,treatment of myelodysplastic syndromes requiring therapy,Designated,,Not FDA Approved for Orphan Indication,,,,,The Vaccine Company,P. O. Box 93921,,Carmel,California,' 93921 ' ,United States,187904,myelodysplastic syndrome,"""gard:0007132""",
4800,Nine amino acid polypeptide derived from proteinase 3,,9/3/2004,treatment of acute myelogenous leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,The Vaccine Company,P. O. Box 93921,,Carmel,California,' 93921 ' ,United States,187804,,,
4801,nintedanib,OFEV,6/29/2011,treatment of patients with idiopathic pulmonary fibrosis.,Designated/Approved,,,Treatment of idiopathic pulmonary fibrosis,10/15/2014,10/15/2021,Treatment of idiopathic pulmonary fibrosis,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,' 06877 ' ,United States,344511,idiopathic pulmonary fibrosis,"""gard:0008609""",
4802,Nintedanib,,12/12/2016,treatment of mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,' 06877 ' ,United States,547916,,,
4803,nintedanib,OFEV,7/6/2016,treatment of systemic sclerosis (including the associated interstitial lung disease).,Designated/Approved,,,OFEV is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD).,9/6/2019,9/6/2026,Indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,' 06877 ' ,United States,528516,interstitial lung disease,"""gard:0020244""",
4804,nipocalimab,,10/14/2021,treatment of chronic inflammatory demyelinating polyneuropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1125 Trenton-Harbourton Road,,Titusville,New Jersey,' 08560 ' ,United States,840221,chronic inflammatory demyelinating polyneuropathy,"""gard:0006102""",
4805,nipocalimab,,12/14/2023,prevention of fetal and neonatal alloimmune thrombocytopenia (fnait),Designated,,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,,Spring House,Pennsylvania,' 19477 ' ,United States,952223,immune thrombocytopenia,"""gard:0005194""",
4806,nipocalimab,,2/11/2021,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1125 Trenton-Harbourton Road,,Titusville,New Jersey,' 08560 ' ,United States,799320,myasthenia gravis,"""gard:0007122""",
4807,nipocalimab,,12/5/2019,treatment of autoimmune hemolytic anemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC","Welsh & McKean Roads, P.O. Box 776",,Spring House,Pennsylvania,' 19477 ' ,United States,711519,autoimmune hemolytic anemia,"""gard:0005870""",
4808,nipocalimab,,6/26/2020,prevention of hemolytic disease of the fetus and newborn,Designated,,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC","Welsh & McKean Roads, P.O. Box 776",,Spring House,Pennsylvania,' 19477 ' ,United States,712419,,,
4809,niprisan,,8/15/2003,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Xechem International, Inc.",379 Thornall Street,,Edison,New Jersey,' 08837 ' ,United States,169703,,,
4810,niraparib,Zejula,4/30/2010,treatment of ovarian cancer,Designated/Approved,,,"Indicated for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy",3/27/2017,3/27/2024,Indicated for maintenance treatment of adult patients with recurrent epithelial ovarian cancer who are in a complete or partial response to platinum-based chemotherapy,"GlaxoSmithKline, LLC.",1000 Winter St.,Suite 3300,Waltham,Massachusetts,' 02451 ' ,United States,306510,ovarian cancer,"""gard:0007295""",
4811,niraparib,Zejula,4/30/2010,treatment of ovarian cancer,Designated/Approved,,,"ZEJULA is indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy",4/29/2020,4/29/2027,Indicated for the maintenance treatment of adult patients with advanced epithelial ovarian cancer who are in a complete or partial response to first-line platinum-based chemotherapy.,"GlaxoSmithKline, LLC.",1000 Winter St.,Suite 3300,Waltham,Massachusetts,' 02451 ' ,United States,306510,ovarian cancer,"""gard:0007295""",
4812,niraparib,Zejula,4/30/2010,treatment of ovarian cancer,Designated/Approved,,,"ZEJULA? is indicated for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either, (1) a deleterious or suspected deleterious BRCA mutation, or (2) genomic instability and who have progressed more than six months after response to the last platinum-based chemotherapy (Indication withdrawn)",10/23/2019,9/14/2022,"Indicated for the treatment of adult patients with advanced ovarian cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation, or genomic instability and who have progressed more than six months after response to the last platinum-based chemotherapy (Indication withdrawn)","GlaxoSmithKline, LLC.",1000 Winter St.,Suite 3300,Waltham,Massachusetts,' 02451 ' ,United States,306510,ovarian cancer,"""gard:0007295""",
4813,nirogacestat,Ogsiveo,6/7/2018,treatment of desmoid tumor (aggressive fibromatosis),Designated/Approved,,,for adult patients with progressing desmoid tumors who require systemic treatment,11/27/2023,11/27/2030,for adult patients with progressing desmoid tumors who require systemic treatment,"SpringWorks Therapeutics, Inc.",100 Washington Boulevard,,Stamford,Connecticut,' 06902 ' ,United States,636518,desmoid tumor,"""gard:0001820""",
4814,Nitazoxanide,Alinia,12/12/1996,treatment of cryptosporidiosis.,Designated/Approved,,,Treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia,11/22/2002,11/22/2009,,"Romark Laboratories, L.C.",6200 Courtney Campbell Causeway,Suite 880,Tampa,Florida,' 33607 ' ,United States,91895,,,
4815,nitazoxanide,,10/23/2001,treatment for intestinal amebiasis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Romark Laboratories, L.C.",6200 Courtney Campbell Causeway,Suite 880,Tampa,Florida,' 33607 ' ,United States,150501,,,
4816,nitazoxanide,Alinia,2/14/2002,treatment of intestinal giardiasis,Designated/Approved,,,Treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia,11/22/2002,11/22/2009,,"Romark Laboratories, L.C.",6200 Courtney Campbell Causeway,Suite 880,Tampa,Florida,' 33607 ' ,United States,150401,,,
4817,nitisinone,,10/19/2001,treatment of alkaptonuria,Designated,,Not FDA Approved for Orphan Indication,,,,,Swedish Orphan Biovitrum AB (publ),Tomtebodavägen 23A,,Stockholm,,' SE-11276 ' ,Sweden,148701,alkaptonuria,"""gard:0005775""",
4818,nitisinone,,6/12/2023,treatment of alkaptonuria,Designated,,Not FDA Approved for Orphan Indication,,,,,Cycle Pharmaceuticals Ltd.,"The Broers Building, 21 JJ Thomson Ave.",,Cambridge,,' CB3 0FA ' ,United Kingdom,942723,alkaptonuria,"""gard:0005775""",
4819,Nitisinone; Nitisinone,Orfadin; Orfadin,5/16/1995,treatment of tyrosinemia type 1.,Designated/Approved,,,Treatment of hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.,4/22/2016,,,Swedish Orphan Biovitrum AB (publ),Tomtebodavägen 23A,,Stockholm,,' SE-11276 ' ,Sweden,89095,tyrosinemia type 1,"""gard:0002658""",
4820,Nitisinone; Nitisinone,Orfadin; Orfadin,5/16/1995,treatment of tyrosinemia type 1.,Designated/Approved,,,Adjunctive therapy to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1,1/18/2002,1/18/2009,,Swedish Orphan Biovitrum AB (publ),Tomtebodavägen 23A,,Stockholm,,' SE-11276 ' ,Sweden,89095,tyrosinemia type 1,"""gard:0002658""",
4821,nitric oxide,,9/11/2013,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Novoteris, LLC",7245 Garden Grove Blvd.,Suite C,Garden Grove,California,' 92841 ' ,United States,403613,cystic fibrosis,"""gard:0006233""",
4822,Nitric Oxide,,11/8/2022,to selectively reduce pulmonary arterial pressures in patients at elevated risk for developing hemodynamically unstable pulmonary hypertension after cardiovascular surgery,Designated,,Not FDA Approved for Orphan Indication,,,,,Mallinckrodt Pharmaceuticals,90 Washington Valley Road,,Bedminster,New Jersey,' 07921 ' ,United States,756820,mody,"""gard:0003697""",
4823,nitric oxide,,9/5/2008,use in combination with a drug delivery device for acute treatment of sickle cell vaso-occlusive crisis (pain crises),Designated,,Not FDA Approved for Orphan Indication,,,,,Mallinckrodt Pharmaceuticals Ireland Ltd.,College Business & Technology Park,Cruiserath Road,Blanchardstown,Dublin,' D15 TX2V ' ,Ireland,265708,,,
4824,Nitric oxide,INOmax,6/22/1993,treatment of persistent pulmonary hypertension in the newborn.,Designated/Approved,,,"In conjunction with ventilatory support and other appropriate agents, in the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.",12/23/1999,12/23/2006,,Mallinckrodt Hospital Products,1425 U.S. 206,,Bedminster Township,New Jersey,' 07921 ' ,United States,74493,,,
4825,nitric oxide,,12/28/2011,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,Bellerophon Therapeutics,53 Frontage Road,Suite 301,Hampton,New Jersey,' 08827 ' ,United States,340811,pulmonary arterial hypertension,"""gard:0007501""",
4826,Nitric oxide,,2/16/2005,diagnosis of sarcoidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,SensorMedics Corporation,22705 Savi Ranch Parkway,,Yorba Linda,California,' 92887 ' ,United States,193304,sarcoidosis,"""gard:0007607""",
4827,Nitric oxide,,9/26/2017,treatment of non-tuberculosis mycobacterial (ntm) infections,Designated,,Not FDA Approved for Orphan Indication,,,,,Advanced Inhalation Therapies Ltd.,2 Ilan Ramon Street,Ness Ziona,,,' ' ,Israel,603917,tuberculosis,"""gard:0007827""",
4828,nitric oxide,,1/25/2017,treatment of pulmonary arterial hypertension excluding persistent pulmonary hypertension of the newborn,Designated,,Not FDA Approved for Orphan Indication,,,,,"GeNo, LLC",2941 Oxbow Circle,,Cocoa,Florida,' 32926 ' ,United States,551616,pulmonary arterial hypertension,"""gard:0007501""",
4829,Nitric oxide,,9/27/2004,to reduce the risk of chronic lung disease in premature neonates,Designated,,Not FDA Approved for Orphan Indication,,,,,Mallinckrodt Pharmaceuticals Ireland Ltd.,College Business & Technology Park,Cruiserath Road,Blanchardstown,Dublin,' D15 TX2V ' ,Ireland,192104,,,
4830,nitric oxide,,9/23/2014,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Inhalation Therapies, Ltd.",2 Ilan Ramon Street,,Ness Ziyona,,' ' ,Israel,443914,cystic fibrosis,"""gard:0006233""",
4831,Nitric oxide,,7/10/1995,treatment of acute respiratory distress syndrome in adults.,Designated,,Not FDA Approved for Orphan Indication,,,,,Mallinckrodt Hopspital Products,1425 U.S. 206,,Bedminster Township,New Jersey,' 07921 ' ,United States,90595,,,
4832,nitric oxide,,1/31/2017,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,VERO Biotech,387 Technology Circle,Suite 125,Atlanta,Georgia,' 30313 ' ,United States,551716,idiopathic pulmonary fibrosis,"""gard:0008609""",
4833,nitric oxide,,6/5/2018,treatment of non-tuberculous mycobacterial lung disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Novoteris, LLC",7245 Garden Grove Blvd.,Suite C,Garden Grove,California,' 92841 ' ,United States,638918,,,
4834,nitric oxide,,6/18/2012,treatment of persistent pulmonary hypertension in newborns,Designated/Approved,,,GENOSYL® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.,12/20/2019,,,VERO BIOTECH,"387 Technology Circle, Suite 125",,Atlanta,Georgia,' 30313 ' ,United States,368512,,,
4835,Nitroprusside,,2/21/2001,treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Thomas, MD, Jeffrey Evan",Thomas Jefferson University and Wills Neurosensory,"834 Walnut Street, Suite 650",Philadelphia,Pennsylvania,' 19107 ' ,United States,112498,,,
4836,Nitroxoline,,7/17/2023,treatment of neurofibromatosis type 1 (nf1),Designated,,Not FDA Approved for Orphan Indication,,,,,Healx Limited,"Charter House, 66-68 Hills Road",,Cambridge,,' CB2 1LA ' ,United Kingdom,948823,neurofibromatosis type 1,"""gard:0007866""",
4837,Nivatrotamab,,9/25/2020,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Y-mAbs Therapeutics, Inc.","230 Park Avenue, Suite 3350",,New York,New York,' 10169 ' ,United States,767020,neuroblastoma,"""gard:0007185""",
4838,nivolumab,OPDIVO,8/7/2014,treatment of hodgkin lymphoma,Designated/Approved,,,Treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin; or 3 or more lines of systemic therapy that includes autologous HSCT.,4/25/2017,4/25/2024,"Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after 3 or more lines of systemic therapy that includes autologous HSCT, not including any overlap with the orphan exclusivity awarded for the 2016 marketing approval of nivolumab for the treatment of adult patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin.",Bristol-Myers Squibb Company,Route 206 & Province Line Road,P. O. Box 4000,Princeton,New Jersey,' 08543 ' ,United States,442614,lymphoma,"""gard:0020548""",
4839,nivolumab,OPDIVO,9/15/2015,treatment of small cell lung cancer.,Designated/Approved,,,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy. (Indication withdrawn),8/16/2018,12/29/2020,For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy. (Indication withdrawn),Bristol-Myers Squibb Company,5 Research Parkway,,Wallingford,Connecticut,' 06492 ' ,United States,491415,small cell lung cancer,"""gard:0009344""",
4840,nivolumab,Opdivo,1/23/2013,treatment of stage iib to iv melanoma,Designated/Approved,,,"adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma",10/13/2023,10/13/2030,adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB or Stage IIC melanoma,Bristol-Myers Squibb Co.,P. O. Box 4000,,Princeton,New Jersey,' 08543 ' ,United States,387612,noma,"""gard:0004001""",
4841,nivolumab,,2/1/2019,treatment of primary mediastinal b-cell lymphoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,P.O. Box 4000,,Princeton,New Jersey,' 08543 ' ,United States,670918,lymphoma,"""gard:0020548""",
4842,nivolumab,Opdivo,8/22/2016,treatment of esophageal cancer,Designated/Approved,,,"in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma",4/16/2021,4/16/2028,"treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma",Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,531016,,,
4843,nivolumab,,8/16/2017,treatment of mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,595817,,,
4844,nivolumab,Opdivo,8/22/2016,treatment of esophageal cancer,Designated/Approved,,,"Opdivo (nivolumab) indicated for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.",6/10/2020,6/10/2027,"For the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.",Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,531016,,,
4845,nivolumab,Opdivo,1/23/2013,treatment of stage iib to iv melanoma,Designated/Approved,,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor",12/22/2014,12/22/2021,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor",Bristol-Myers Squibb Co.,P. O. Box 4000,,Princeton,New Jersey,' 08543 ' ,United States,387612,noma,"""gard:0004001""",
4846,nivolumab,Opdivo,1/23/2013,treatment of stage iib to iv melanoma,Designated/Approved,,,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,12/20/2017,12/20/2024,Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,Bristol-Myers Squibb Co.,P. O. Box 4000,,Princeton,New Jersey,' 08543 ' ,United States,387612,noma,"""gard:0004001""",
4847,nivolumab,Opdivo,1/23/2013,treatment of stage iib to iv melanoma,Designated/Approved,,,"As a single agent or in combination with ipilimumab, for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma",2/15/2023,2/15/2030,Treatment of pediatric patients 12 years and older with unresectable or metastatic melanoma,Bristol-Myers Squibb Co.,P. O. Box 4000,,Princeton,New Jersey,' 08543 ' ,United States,387612,noma,"""gard:0004001""",
4848,nivolumab,Opdivo,1/23/2013,treatment of stage iib to iv melanoma,Designated/Approved,,,adjuvant treatment of adult and pediatric patients 12 years and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,2/15/2023,2/15/2030,adjuvant treatment of pediatric patients 12 years and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection,Bristol-Myers Squibb Co.,P. O. Box 4000,,Princeton,New Jersey,' 08543 ' ,United States,387612,noma,"""gard:0004001""",
4849,nivolumab,Opdivo,12/20/2016,treatment of gastric cancer and gastro-esophageal junction cancer,Designated/Approved,,,"in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma",4/16/2021,4/16/2028,"treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma",Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,545016,,,
4850,nivolumab,Opdivo,8/22/2016,treatment of esophageal cancer,Designated/Approved,,,adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT),5/20/2021,5/20/2028,adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT),Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,531016,,,
4851,nivolumab,,8/7/2017,treatment of anal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,591617,,,
4852,nivolumab,,8/27/2015,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Co,P. O. Box 4000,,Princeton,New Jersey,' 08543 ' ,United States,469615,glioblastoma,"""gard:0002491""",
4853,nivolumab,Opdivo,10/9/2014,treatment of stage iib to stage iv melanoma,Designated/Approved,,,"as a single agent or in combination with ipilimumab, for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma",2/15/2023,,,Bristol-Myers Squibb Company,5 Research Parkway,,Wallingford,Connecticut,' 06492 ' ,United States,445014,noma,"""gard:0004001""",
4854,nivolumab,Opdivo,12/20/2016,treatment of gastric cancer and gastro-esophageal junction cancer,Designated/Approved,,,adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT),5/20/2021,5/20/2028,adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT),Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,545016,,,
4855,nivolumab,Opdivo,8/22/2016,treatment of esophageal cancer,Designated/Approved,,,"In combination with ipilimumab, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC)",5/27/2022,5/27/2029,First-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC),Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,531016,,,
4856,nivolumab,Opdivo,8/22/2016,treatment of esophageal cancer,Designated/Approved,,,"In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC)",5/27/2022,5/27/2029,First-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC),Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,531016,,,
4857,nivolumab,OPDIVO,8/7/2014,treatment of hodgkin lymphoma,Designated/Approved,,,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin,5/17/2016,5/17/2023,Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin,Bristol-Myers Squibb Company,Route 206 & Province Line Road,P. O. Box 4000,Princeton,New Jersey,' 08543 ' ,United States,442614,lymphoma,"""gard:0020548""",
4858,nivolumab and ipilimumab,OPDIVO® and YERVOY®,8/16/2017,treatment of mesothelioma,Designated/Approved,,,"OPDIVO, in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.",10/2/2020,10/2/2027,OPDIVO (nivolumab) for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma,Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,595917,,,
4859,nivolumab and ipilimumab,OPDIVO® and YERVOY®,8/16/2017,treatment of mesothelioma,Designated/Approved,,,"YERVOY® (ipilimumab), in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.",10/2/2020,10/2/2027,YERVOY® (ipilimumab) for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma,Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,595917,,,
4860,Nivolumab and Ipilimumab,,12/20/2016,treatment of gastric cancer and gastric-esophageal junction cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,' 08543 ' ,United States,545116,,,
4861,nivolumab and relatlimab-rmbw,Opdualag,8/18/2017,treatment of stage iib to iv melanoma,Designated/Approved,,,Treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma,3/18/2022,3/18/2029,Treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma,Bristol-Myers Squibb Company,P.O. Box 5326,,Princeton,New Jersey,' 08543-5326 ' ,United States,595017,noma,"""gard:0004001""",
4862,nivolumab; nivolumab,OPDIVO; OPDIVO,9/2/2015,treatment of hepatocellular carcinoma,Designated/Approved,,,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (Indication withdrawn),9/22/2017,7/23/2021,Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib (Indication withdrawn),Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,' 08543-5326 ' ,United States,489915,hepatocellular carcinoma,"""gard:0016773""",
4863,nivolumab; nivolumab,OPDIVO; OPDIVO,9/2/2015,treatment of hepatocellular carcinoma,Designated/Approved,,,"OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.",3/10/2020,,,Bristol-Myers Squibb Company,P. O. Box 5326,,Princeton,New Jersey,' 08543-5326 ' ,United States,489915,hepatocellular carcinoma,"""gard:0016773""",
4864,nolatrexed,,10/18/2001,treatment of hepatocellular carcinoma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,EXIMIAS Pharmaceutical Corporation,1055 Westlakes Drive,Suite 200,Berwyn,Pennsylvania,' 19312 ' ,United States,148801,hepatocellular carcinoma,"""gard:0016773""",
4865,nomacopan,,9/12/2019,treatment of bullous pemphigoid,Designated,,Not FDA Approved for Orphan Indication,,,,,Akari Therapeutics Plc,24 West 40th Street,8th Floor,New York,New York,' 10018 ' ,United States,669018,bullous pemphigoid,"""gard:0005972""",
4866,nomacopan,,8/28/2019,treatment of hematopoietic stem cell transplantation-associated thrombotic microangiopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Akari Therapeutics Plc,24 West 40th Street,8th Floor,New York,New York,' 10018 ' ,United States,698219,thrombotic microangiopathy,"""gard:0019227""",
4867,non-peptide small molecule orally available agonist of the parathyroid hormone receptor type I,,12/15/2014,treatment of hypoparathyroidism,Designated,,Not FDA Approved for Orphan Indication,,,,,"Chugai Pharma USA, LLC",300 Connell Drive,Suite 300,Berkeley Heights,New Jersey,' 07922 ' ,United States,455914,,,
4868,non-replicating AAV-based gene therapy vector with a single stranded DNA genome engineered to carry an expression cassette encoding for human cardiac myosin binding protein-C (cMyBP-C; hMYBPC3 transgene),,9/26/2023,treatment of patients with hypertrophic cardiomyopathy (hcm) with a mutation in the mybpc3 gene,Designated,,Not FDA Approved for Orphan Indication,,,,,BioMarin Pharmaceutical Inc.,105 Digital Drive,,"Novato,",California,' 94949 ' ,United States,963623,,,
4869,"non-replicating adeno-associated viral vector, serotype 8, expressing human myotubularin gene",,12/3/2014,treatment of x-linked myotubular myopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Astellas Gene Therapies, Inc.",480 Forbes Blvd.,,South San Francisco,California,' 94080 ' ,United States,453814,,,
4870,"non-replicating recombinant adeno associated viral vector, serotype 9, designed to promote increased transcription of SCN1A gene",,5/14/2020,treatment of dravet syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,Encoded Therapeutics,341 Oyster Point Blvd.,Suite 100,South San Francisco,California,' 94080 ' ,United States,744920,dravet syndrome,"""gard:0010430""",
4871,Non-replicating recombinant adeno-associated viral vector expressing the human acid alpha-glucosidase gene,,1/11/2017,treatment of pompe disease,Designated/Designation Withdrawn or Revoked,8/7/2023,Not FDA Approved for Orphan Indication,,,,,"Asklepios Biopharmaceutics, Inc","20 T.W. Alexander Drive, Suite 110",,Research Triangle Park,North Carolina,' 27709 ' ,United States,547316,,,
4872,"non-replicating recombinant adeno-associated viral vector, serotype 8, expressing the 1A1 isoform of the bilirubin-uridine diphosphate glucuronosyltransferase gene",,5/24/2016,treatment of crigler najjar syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Audentes Therapeutics, Inc.",600 California Street,17th Floor,San Francisco,California,' 94109 ' ,United States,529416,,,
4873,non-replicating recombinant adeno-associated virus (AAV) vector of serotype 9 expressing human iduronate-2-sulfatase,,12/8/2015,treatment of mucopolysaccharidosis type ii,Designated,,Not FDA Approved for Orphan Indication,,,,,"REGENXBIO, Inc.",9712 Medical Center Drive,Suite 100,Rockville,Maryland,' 20850 ' ,United States,501815,mucopolysaccharidosis,"""gard:0007065""",
4874,Non-replicating recombinant adeno-associated virus serotype 1 vector delivering human GRN gene encoding the protein progranulin,,1/7/2021,treatment of frontotemporal dementia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Passage Bio, Inc.",Commerce Square Two,2001 Market Street,Philadelphia,Pennsylvania,' 19103 ' ,United States,793020,frontotemporal dementia,"""gard:0008436""",
4875,Non-replicating recombinant adeno-associated virus serotype 9 containing the progranulin gene,,12/5/2019,treatment of frontotemporal dementia,Designated,,Not FDA Approved for Orphan Indication,,,,,Prevail Therapeutics,430 East 29th Street,Suite 940,New York,New York,' 10016 ' ,United States,712719,frontotemporal dementia,"""gard:0008436""",
4876,"non-replicating recombinant adeno-associated virus serotype hu68 vector, which contains human GLB1 transgene encoding the galactosidase beta 1 enzyme",,4/16/2020,treatment of gm1 gangliosidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Passage Bio, Inc.",Commerce Square Two,2001 Market Street,Philadelphia,Pennsylvania,' 19103 ' ,United States,742720,gangliosidosis,"""gard:0012510""",
4877,non-replicating recombinant adeno-associated virus serotype rh79 (AAVrh.79) vectors: AAVrh79.TBG.M2PCSK9.WPRE.bGH and AAVrh79.hHDR.TBG.hOTCco.bGH,,9/1/2022,treatment of ornithine transcarbamylase deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"iECURE, Inc.",620 West Germantown Pike Suite 220,,Plymouth Meeting,Pennsylvania,' 19462 ' ,United States,900222,ornithine transcarbamylase deficiency,"""gard:0008391""",
4878,non-replicating recombinant adeno-associated virus vector containing 4 antisense sequences designed to target exon 2 in the human DMD gene under the control of U7 small nuclear non-coding RNA,,9/19/2017,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Nationwide Children's Hospital,Drug and Device Development Services,700 Children's Drive,Columbus,Ohio,' 43205 ' ,United States,603217,muscular dystrophy,"""gard:0007922""",
4879,non-replicating recombinant adeno-associated virus vector containing a fragment of the gene encoding channelrhodopsin-2 protein,,10/20/2014,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"Allergan, Inc.",2525 Dupont Drive,P.O. Box 19534,Irvine,California,' 92623 ' ,United States,447714,retinitis pigmentosa,"""gard:0005694""",
4880,"Non-replicating recombinant, self-complementary adeno-associated virus serotype 9 containing the human CLN3 gene",,11/26/2019,treatment of cln3 batten disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Nationwide Children's Hospital,700 Children's Drive,,Columbus,Ohio,' 43205 ' ,United States,713119,,,
4881,"Non-replicating recombinant, self-complementary adeno-associated virus serotype 9 containing the human CLN6 gene",,11/27/2019,treatment of cln6 batten disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Nationwide Children's Hospital,700 Children's Drive,,Columbus,Ohio,' 43205 ' ,United States,714419,,,
4882,"non-replicating, recombinant adeno-associated virus (AAV) serotype 9 (AAV9) vector containing an hCLN2 expression cassette encoding for the soluble lysosomal enzyme tripeptidyl peptidase I (TPP1)",,10/25/2018,treatment of neuronal ceroid lipofuscinosis type 2 (cln2) disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,REGENXBIO Inc. (REGENXBIO),9600 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,663718,neuronal ceroid lipofuscinosis,"""gard:0010739""",
4883,"non-replicating, recombinant adeno-associated virus serotype 9 (AAV9) containing the short hairpin RNA (shRNA) sequence against human SOD1 under the H1 promoter",,7/1/2019,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"AveXis, Inc.",2275 Half Day Road,,Bannockburn,Illinois,' 60015 ' ,United States,691719,amyotrophic lateral sclerosis,"""gard:0005786""",
4884,Nonfucosylated humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting B-cell maturation antigen (SEA-BCMA),,12/16/2021,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Seagen Inc.,21823 30th Drive SE,,Bothell,Washington,' 98021 ' ,United States,852321,multiple myeloma,"""gard:0007108""",
4885,NorLeu3-Angiontensin(1-7)) [NorLeu3-A(1-7)],,12/31/2013,treatment of leakage from the surgical site following penetrating keratoplasty,Designated,,Not FDA Approved for Orphan Indication,,,,,"US Biotest, Inc.",231 Bonetti Drive,,San Luis Obispo,California,' 93401 ' ,United States,414813,,,
4886,NorLeu3-Angiotensin(1-7) [NorLeu3-A(1-7)],,1/31/2014,treatment of dermal injury due to nuclear/radiation incident,Designated,,Not FDA Approved for Orphan Indication,,,,,"US Biotest, Inc.",231 Bonetti Drive,,San Luis Obispo,California,' 93401 ' ,United States,414713,,,
4887,Norrin-derived growth factor,,1/19/2022,treatment of familial exudative vitreoretinopathy (fevr),Designated,,Not FDA Approved for Orphan Indication,,,,,"Caeregen Therapeutics, LLC",510 Meadowmont Village Cir Suite 303,,Chapel Hill,North Carolina,' 27517 ' ,United States,839821,vitreoretinopathy,"""gard:0019539""",
4888,Norucholic acid,,6/24/2021,treatment of primary sclerosing cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Dr. Falk Pharma GmbH,Leinenweberstrasse 5,79108 Freiburg,Freiburg,,' ' ,Germany,821121,sclerosing cholangitis,"""gard:0021868""",
4889,noscapine,,12/29/2015,treatment of amyotrophic lateral sclerosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,KineMed Inc.,5980 Horton Street,Suite 470,Emeryville,California,' 94608 ' ,United States,500615,amyotrophic lateral sclerosis,"""gard:0005786""",
4890,Novel Acting Thrombolytic (NAT),,1/26/2001,treatment of peripheral arterial occlusion (pao),Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Nuvelo, Inc. Inc.",201 Industrial Road,Suite 310,San Carlos,California,' 94070 ' ,United States,137700,,,
4891,NP-CSIC002,,12/26/2017,treatment of anterior ischemic optic neuropathy (aion),Designated,,Not FDA Approved for Orphan Indication,,,,,Neurizon Pharma,15 Paul-Ehrlich-Straße,,Tübingen,Baden-Württemberg,' ' ,Germany,618617,,,
4892,Nucleic acid aptamer binding to tumor cell nucleolin,,8/17/2004,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Antisoma Research Ltd.,Hanger Lane,,London,,' ' ,United Kingdom,189604,,,
4893,Nucleic acid aptamer binding to tumor cell nucleolin,,9/10/2009,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Antisoma, Inc.",300 Technology Square,,Cambridge,Massachusetts,' 02139 ' ,United States,291609,acute myeloid leukemia,"""gard:0012757""",
4894,Nucleic acid aptamer binding to tumor cell nucleon,,7/28/2005,treatment of renal cell carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Antisoma Inc.,300 Technology Square,,Cambridge,Massachusetts,' ' ,United States,207105,renal cell carcinoma,"""gard:0013215""",
4895,nusinersen,Spinraza,4/18/2011,treatment of spinal muscular atrophy,Designated/Approved,,,Treatment of spinal muscular atrophy in pediatric and adult patients,12/23/2016,12/23/2023,Treatment of spinal muscular atrophy in pediatric and adult patients,"Biogen, Inc",225 Binney Street,,Cambridge,Massachusetts,' 02142 ' ,United States,336711,,,
4896,"O,O'-Bis({4-[3,5-diiodo-4-(1-methylene-1,2,3-triazol-4-ylmethoxy)phenoxy]-3,5-diiodophenyl}acetic acid)polyethylene glycol",,8/18/2017,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"NanoPharmaceuticals, LLC",1 Discovery Place,,Rensselaer,New York,' 12144 ' ,United States,598917,,,
4897,"O,O'-Bis({4-[3,5-diiodo-4-(1-methylene-1,2,3-triazol-4-ylmethoxy)phenoxy]-3,5-diiodophenyl}acetic acid)polyethylene glycol",,6/28/2017,treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,"NanoPharmaceuticals, LLC",1 Discovery Place,,Rensselaer,New York,' 12144 ' ,United States,582117,glioblastoma,"""gard:0002491""",
4898,O-(2-[18F]fluoroethyl)-L-tyrosine,,4/20/2023,diagnostic for the management of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,UCSF Radiopharmaceutical Facility,185 Berry Street,Suite 350,San Francisco,California,' 94107 ' ,United States,934623,,,
4899,O-(3-piperidino-2-hydroxy-1-propyl)-nicotinic acid amidoxime dihydrochloride,,10/8/2020,treatment of familial dysautonomia,Designated,,Not FDA Approved for Orphan Indication,,,,,Mitochon Technologies Kft.,Rizling út 3,,,Balatonvilágos,' 8171 ' ,Hungary,769720,familial dysautonomia,"""gard:0007581""",
4900,O-(3-piperidino-2-hydroxyl-1-propyl)-nicotinic acid amidoxime hydrochloride,,1/15/2013,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Vudbenk Life Science Kft.,Rizling utca 3,,Balatonvilagos,,' 8171 ' ,Hungary,386512,muscular dystrophy,"""gard:0007922""",
4901,O-18F-fluoroethyl-L-tyrosine,,5/8/2019,diagnostic for the management of malignant rhabdoid tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,' 33467 ' ,United States,683619,rhabdoid tumor,"""gard:0007572""",
4902,"O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate",,3/16/2012,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"JSK Therapeutics, Inc.",1567 W. Silver Springs Road,,Park City,Utah,' 84098 ' ,United States,363412,acute myeloid leukemia,"""gard:0012757""",
4903,"O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1yl]diazen-1-ium-1,2-diolate",,12/13/2013,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"JSK Therapeutics, Inc.",85 Fort Douglas Boulevard,P.O. Box 58986,Salt Lake City,Utah,' 84158 ' ,United States,414013,multiple myeloma,"""gard:0007108""",
4904,obatoclax mesylate,,10/8/2004,treatment of chronic lymphocytic leukemia,Designated/Designation Withdrawn or Revoked,9/13/2013,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Products R&D, Inc.",41 Moores Road,P. O. Box 4011,Frazer,Pennsylvania,' 19355 ' ,United States,193804,,,
4905,Obatoclax mesylate,,12/1/2006,treatment of myelofibrosis,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Gemin X Pharmaceuticals US, Inc.",400 Chesterfield Pkwy.,Suite 100,Malvern,Pennsylvania,' 19355 ' ,United States,233006,,,
4906,Obatoclax mesylate,,11/6/2006,treatment of myelodysplastic syndrome,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Gemin X, Inc.",400 Chesterfield Parkway,Suite 100,Malvern,Pennsylvania,' 19355 ' ,United States,232106,myelodysplastic syndrome,"""gard:0007132""",
4907,obeticholic acid,OCALIVA,4/9/2008,treatment of primary biliary cirrhosis,Designated/Approved,,,"Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA",5/27/2016,5/27/2023,"Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA","Intercept Pharmaceuticals, Inc.",4760 Eastgate Mall,,San Diego,California,' 92122 ' ,United States,253207,,,
4908,Obeticholic Acid; Bezafibrate,,5/16/2023,treatment of primary biliary cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Intercept Pharmaceuticals, Inc.",305 Madison Avenue,,Morristown,New Jersey,' 07960 ' ,United States,937523,primary biliary cholangitis,"""gard:0007459""",
4909,obiltoxaximab,Anthim,6/9/2006,treatment of exposure to b. anthracis spores,Designated/Approved,,,Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax due to B. anthracis when alternative therapies are not available or are not appropriate.,3/18/2016,3/18/2023,"1) Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and (2) for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.","Elusys Therapeutics, Inc.",25 Riverside Drive,P.O. Box 102,Pine Brook,New Jersey,' 07058 ' ,United States,224306,,,
4910,obinutuzumab,GAZYVA,2/17/2012,treatment of chronic lymphocytic leukemia,Designated/Approved,,,"GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).",11/1/2013,11/1/2020,Treatment of patients with previously untreated chronic lymphocytic leukemia in combination with chlorambucil.,"Genentech Inc., a member of the Roche Group",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,359911,,,
4911,obinutuzumab,GAZYVA,4/15/2015,treatment of follicular lymphoma,Designated/Approved,,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen",2/26/2016,2/26/2023,"in combination with bendamustine followed by Gazyva monotherapy, indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen.","Genentech Inc., a member of the Roche Group",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,473415,lymphoma,"""gard:0020548""",
4912,obinutuzumab,,6/8/2020,treatment of membranous nephropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc., A Member of the Roche Group",1 DNA Way,MS# 241B,South San Francisco,California,' 94080 ' ,United States,727719,,,
4913,obinutuzumab,,2/17/2012,treatment of diffuse large b cell lymphoma,Designated/Designation Withdrawn or Revoked,7/16/2018,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group",1 DNA Way,MS #355e,South San Francisco,California,' 94080 ' ,United States,360011,lymphoma,"""gard:0020548""",
4914,obinutuzumab,,6/11/2015,treatment of splenic marginal zone lymphoma,Designated/Designation Withdrawn or Revoked,7/14/2016,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,MS# 214A,South San Francisco,California,' 94080 ' ,United States,473315,lymphoma,"""gard:0020548""",
4915,obinutuzumab,,11/22/2021,"treatment of childhood-onset idiopathic nephrotic syndrome (ns), defined as steroid dependent or frequently relapsing ns.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080-4990 ' ,United States,824921,idiopathic nephrotic syndrome,"""gard:0021539""",
4916,obinutuzumab,GAZYVA,4/15/2015,treatment of follicular lymphoma,Designated/Approved,,,"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen; and in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma",11/16/2017,11/16/2024,"In combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.","Genentech Inc., a member of the Roche Group",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,473415,lymphoma,"""gard:0020548""",
4917,obinutuzumab,,8/17/2017,treatment of splenic marginal zone lymphoma,Designated/Designation Withdrawn or Revoked,7/16/2018,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., a member of the Roche Group",1 DNA Way,MS #355e,South San Francisco,California,' 94080 ' ,United States,592717,lymphoma,"""gard:0020548""",
4918,oblimersen,,8/28/2001,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genta, Inc.",200 Connell Drive,,Berkeley Heights,New Jersey,' 07922 ' ,United States,145601,multiple myeloma,"""gard:0007108""",
4919,oblimersen,,8/28/2001,treatment of chronic lymphocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genta, Inc.",200 Connell Drive,,Berkeley Heights,New Jersey,' 07922 ' ,United States,145501,,,
4920,oblimersen,,8/28/2001,treatment of acute myelocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genta, Inc.",200 Connell Drive,,Berkeley Heights,New Jersey,' 07922 ' ,United States,144901,,,
4921,oblimersen,,7/31/2000,"treatment of advanced malignant melanoma (stages ii,iii, iv).",Designated,,Not FDA Approved for Orphan Indication,,,,,"Genta, Inc.",200 Connell Drive,,Berkeley Heights,New Jersey,' 07922 ' ,United States,134600,noma,"""gard:0004001""",
4922,ocifisertib,,1/29/2024,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,Treadwell Therapeutics,"PO Box 309, Ugland House",,George Town,,' KY1-1104 ' ,Cayman Islands,985023,acute myeloid leukemia,"""gard:0012757""",
4923,octavalent Psuedomonas aeruginosa O-polysaccaharide-toxin A conjugate,,5/16/2002,prevention of psuedomonas aeruginosa infections in patients with cystic fibrosis,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Berna Biotech Ltd.,Rehhagstrass 79,CH-3018,Berna,,' ' ,Switzerland,155702,cystic fibrosis,"""gard:0006233""",
4924,Octreotide,Sandostatin LAR,8/24/1998,treatment of diarrhea associated with vasoactive intestinal peptide tumors (vipoma).,Designated/Approved,,,Treatment of profuse watery diarrhea associated with VIPoma.,11/25/1998,11/25/2005,,Novartis Pharmaceuticals Corporation,59 Route 10,,East Hanover,New Jersey,' 07936 ' ,United States,116898,vipoma,"""gard:0003787""",
4925,Octreotide,Sandostatin LAR,8/24/1998,treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.,Designated/Approved,,,Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome.,11/25/1998,11/25/2005,,Novartis Pharmaceuticals Corporation,59 Route 10,,East Hanover,New Jersey,' 07936 ' ,United States,114698,,,
4926,octreotide,,8/5/2010,treatment of neuroendocrine tumors,Designated/Designation Withdrawn or Revoked,7/12/2021,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health laza,,East Hanover,New Jersey,' 07936 ' ,United States,310710,,,
4927,Octreotide,Sandostatin LAR,8/24/1998,treatment of acromegaly.,Designated/Approved,,,Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly.,11/25/1998,11/25/2005,,Novartis Pharmaceuticals Corporation,59 Route 10,,East Hanover,New Jersey,' 07936 ' ,United States,114598,acromegaly,"""gard:0005725""",
4928,octreotide,,9/15/2021,treatment of autosomal dominant polycystic liver disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Camurus AB,Ideon Science Park,,Lund,,' SE-223 70 ' ,Sweden,836621,,,
4929,Octreotide (acetate),,6/30/2022,treatment of carcinoid syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Chiesi USA, Inc.","175 Regency Woods Place, Suite 600",,Cary,North Carolina,' 27518 ' ,United States,886622,carcinoid syndrome,"""gard:0005994""",
4930,octreotide (oral),MYCAPSSA (formerly Octreolin),6/17/2010,for the oral treatment of acromegaly,Designated/Approved,,,Mycapssa (octreotide) is indicated for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.,6/26/2020,6/26/2027,long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide,"Chiesi USA, Inc.",175 Regency Woods Place. Suite 600,,Cary,North Carolina,' 27518 ' ,United States,309310,acromegaly,"""gard:0005725""",
4931,Octreotide Acetate,,7/19/2021,treatment of idiopathic intracranial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,NBO Pharma LLC,64 Quarry Lane,,Bedford,New York,' 10506 ' ,United States,826221,idiopathic intracranial hypertension,"""gard:0004561""",
4932,octreotide acetate (intranasal),,1/23/2018,treatment of acromegaly,Designated/Designation Withdrawn or Revoked,8/8/2019,Not FDA Approved for Orphan Indication,,,,,"Dauntless Pharmaceuticals, Inc.",12390 El Camino Real,Suite 170,San Diego,California,' 92130 ' ,United States,606217,acromegaly,"""gard:0005725""",
4933,octreotide acetate subcutaneous implant,,12/7/2009,treatment of acromegaly,Designated,,Not FDA Approved for Orphan Indication,,,,,"Endo Pharmaceuticals Solutions, Inc.",100 Endo Blvd,,Chadds Ford,Pennsylvania,' 19317 ' ,United States,286509,acromegaly,"""gard:0005725""",
4934,odevixibat,Bylvay,10/15/2018,treatment of alagille syndrome,Designated/Approved,,,treatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS),6/13/2023,6/13/2030,treatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS),"Ipsen Biopharmaceuticals, Inc.","One Main Street, 7th Floor",,Cambridge,Massachusetts,' 02142 ' ,United States,370812,alagille syndrome,"""gard:0000804""",
4935,odevixibat,Bylvay,10/31/2012,treatment of progressive familial intrahepatic cholestasis,Designated/Approved,,,Treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). Limitations of use: BYLVAY may not be effective in PFIC type 2 patients with ABCB11 variants resulting in nonfunctional or complete absence of bile salt export pump protein (BSEP-3),7/20/2021,7/20/2028,Treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). Limitations of use: BYLVAY may not be effective in PFIC type 2 patients with ABCB11 variants resulting in nonfunctional or complete absence of bile salt export pump protein (BSEP-3),"Ipsen Biopharmaceuticals, Inc.","One Main Street, 7th Floor",,Cambridge,Massachusetts,' 02142 ' ,United States,370912,familial intrahepatic cholestasis,"""gard:0021119""",
4936,odevixibat,,1/16/2019,treatment of biliary atresia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharmaceuticals, Inc.","One Main Street, 7th Floor",,Cambridge,Massachusetts,' 02142 ' ,United States,658118,,,
4937,odiparcil,,8/3/2017,treatment of mucopolysaccharidosis type vi (maroteaux-lamy syndrome),Designated,,Not FDA Approved for Orphan Indication,,,,,Inventiva SA,50 rue de Dijon,,Daix,,' 21121 ' ,France,592317,mucopolysaccharidosis,"""gard:0007065""",
4938,ofatumumab,ARZERRA,3/10/2009,treatment of chronic lymphocytic leukemia,Designated/Approved,,,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.,1/19/2016,1/19/2023,For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,275809,,,
4939,ofatumumab,ARZERRA,3/10/2009,treatment of chronic lymphocytic leukemia,Designated/Approved,,,"ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",4/17/2014,4/17/2021,"Ofatumumab in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.",Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,275809,,,
4940,ofatumumab,ARZERRA,3/10/2009,treatment of chronic lymphocytic leukemia,Designated/Approved,,,Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine,10/26/2009,10/26/2016,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,275809,,,
4941,ofatumumab,ARZERRA,3/10/2009,treatment of chronic lymphocytic leukemia,Designated/Approved,,,Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).,8/30/2016,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,275809,,,
4942,Ofloxacin,Ocuflox Ophthalmic Solution,4/18/1991,treatment of bacterial corneal ulcers.,Designated/Approved,,,Treatment of bacterial corneal ulcers.,5/22/1996,5/22/2003,,"Allergan, Inc.",2525 Dupont Drive,P.O. Box 19534,Irvine,California,' 92713 ' ,United States,56791,,,
4943,oglufanide disodium,,9/24/2001,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Implicit Bioscience Pty Ltd,P. O. Box 2072,Toowong Business Center,Brisbane,Queensland,' ' ,Australia,147901,ovarian cancer,"""gard:0007295""",
4944,olaparib,Lynparza,10/16/2013,treatment of ovarian cancer,Designated/Approved,,,"Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",5/8/2020,5/8/2027,"LYNPARZA® is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by genomic instability.",AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,' 19803 ' ,United States,409213,ovarian cancer,"""gard:0007295""",
4945,olaparib,Lynparza,5/15/2018,treatment of primary peritoneal cancer,Designated/Approved,,,"Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza.",12/19/2018,12/19/2025,Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy.,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,' 19803 ' ,United States,419013,,,
4946,olaparib,Lynparza,5/15/2018,treatment of fallopian tube cancer,Designated/Approved,,,"Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza.",12/19/2018,12/19/2025,Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced fallopian tube cancer who are in complete or partial response to first-line platinum based chemotherapy.,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,' 19803 ' ,United States,417613,,,
4947,olaparib,Lynparza,10/16/2013,treatment of ovarian cancer,Designated/Approved,,,"Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza.",12/19/2018,12/19/2025,Lynparza® is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian cancer who are in complete or partial response to first-line platinum based chemotherapy.,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,' 19803 ' ,United States,409213,ovarian cancer,"""gard:0007295""",
4948,olaparib,Lynparza,5/15/2018,treatment of fallopian tube cancer,Designated/Approved,,,"Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; and treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.",8/17/2017,8/17/2024,Maintenance treatment of adult patients with recurrent fallopian tube cancer who are in a complete or partial response to platinum-based chemotherapy.,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,' 19803 ' ,United States,417613,,,
4949,olaparib,Lynparza,5/15/2018,treatment of primary peritoneal cancer,Designated/Approved,,,"Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; and treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.",8/17/2017,8/17/2024,Maintenance treatment of adult patients with recurrent primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,' 19803 ' ,United States,419013,,,
4950,olaparib,Lynparza,5/15/2018,treatment of primary peritoneal cancer,Designated/Approved,,,"Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",5/8/2020,5/8/2027,"LYNPARZA® is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by genomic instability.",AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,' 19803 ' ,United States,419013,,,
4951,olaparib,Lynparza,10/16/2013,treatment of ovarian cancer,Designated/Approved,,,"Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.",8/17/2017,8/17/2024,"Maintenance treatment of adult patients with recurrent epithelial ovarian cancer, who are in a complete or partial response to platinum-based chemotherapy.",AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,' 19803 ' ,United States,409213,ovarian cancer,"""gard:0007295""",
4952,olaparib,Lynparza,5/15/2018,treatment of fallopian tube cancer,Designated/Approved,,,"Lynparza is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either: a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.",5/8/2020,5/8/2027,"LYNPARZA® is indicated in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinumbased chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by genomic instability.",AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,' 19803 ' ,United States,417613,,,
4953,olaparib,Lynparza,10/11/2018,treatment of pancreatic cancer,Designated/Approved,,,Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,12/27/2019,12/27/2026,Indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P.O. Box 8355,Wilmington,Delaware,' 19803 ' ,United States,655318,,,
4954,olaparib,Lynparza,10/16/2013,treatment of ovarian cancer,Designated/Approved,,,Indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy,12/19/2014,12/19/2021,Use as monotherapy for patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,' 19803 ' ,United States,409213,ovarian cancer,"""gard:0007295""",
4955,olaptesed pegol,,8/19/2014,treatment of glioblastoma in conjunction with radiotherapy.,Designated,,Not FDA Approved for Orphan Indication,,,,,Noxxon Pharma AG,Max-Dohrn0Strasse,,Berlin,,' ' ,Germany,443114,glioblastoma,"""gard:0002491""",
4956,olaratumab,Lartruvo,10/9/2014,treatment of soft tissue sarcoma,Designated/Approved,,,"In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. (Indication withdrawn)",10/19/2016,2/25/2020,"In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery. (Indication withdrawn)",Eli Lilly and Company,"Lilly Corporate Center, Drop Code 2543",,Indianapolis,Indiana,' 46285 ' ,United States,448414,soft tissue sarcoma,"""gard:0004898""",
4957,Oleoylethanolamide,,6/8/2017,treatment of prader-willi syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"NutriForward, LLC","1520 Luna Road, # 120",,Carrollton,Texas,' 75006 ' ,United States,577117,prader-willi syndrome,"""gard:0005575""",
4958,oleylphosphocholine,,10/25/2013,treatment of leishmaniasis,Designated,,Not FDA Approved for Orphan Indication,,,,,Oblita Therapeutics bvba,Rogendijk 40,,Zoersel,,' ' ,Belgium,410313,leishmaniasis,"""gard:0006881""",
4959,olezarsen,,2/14/2024,treatment of familial chylomicronemia syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Ionis Pharmaceuticals,2855 Gazelle Court,,Carlsbad,California,' 92010 ' ,United States,953423,familial chylomicronemia syndrome,"""gard:0006414""",
4960,oligodendrocyte progenitor cells,,2/2/2016,treatment of acute spinal cord injury,Designated,,Not FDA Approved for Orphan Indication,,,,,"Lineage Cell Therapeutics, Inc.","2173 Salk Avenue, Suite 200",,Carlsbad,California,' 92008 ' ,United States,500815,spinal cord injury,"""gard:0019109""",
4961,oligopeptide containing 6 amino acids (H-Phe-Ser-Arg-Tyr-Ala-Arg-OH),,2/27/2014,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genervon Biopharmaceuticals, LLC",1055 E. Colorado Blvd,Suite 500,Pasadena,California,' 91106 ' ,United States,424714,amyotrophic lateral sclerosis,"""gard:0005786""",
4962,olinciguat,,6/4/2018,treatment of sickle cell disease,Designated/Designation Withdrawn or Revoked,12/13/2021,Not FDA Approved for Orphan Indication,,,,,"Cyclerion Therapeutics, Inc.",245 First Street,"Riverview II, 18th Floor",Cambridge,Massachusetts,' 02142 ' ,United States,639718,,,
4963,olipudase alfa-rpcp,Xenpozyme,8/3/2000,treatment of acid sphingomyelinase deficiency (niemann-pick disease),Designated/Approved,,,Treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients,8/31/2022,8/31/2029,Treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients,Genzyme Corporation,55 Corporate Drive,,Bridgewater,New Jersey,' 08807 ' ,United States,132900,acid sphingomyelinase deficiency,"""gard:0022457""",
4964,olorofim,,4/27/2021,treatment of invasive scopulariopsis/microascus,Designated,,Not FDA Approved for Orphan Indication,,,,,F2G Limited,Lankro Way Eccles,,Manchester,Manchester,' M30 OLX ' ,United Kingdom,814021,,,
4965,olorofim,,3/11/2020,treatment of coccidioidomycosis,Designated,,Not FDA Approved for Orphan Indication,,,,,F2G Limited,Lankro Way,Eccles,Manchester,,' ' ,United Kingdom,721719,coccidioidomycosis,"""gard:0009525""",
4966,Olorofim,,1/15/2020,treatment of lomentospora/scedosporium infections,Designated,,Not FDA Approved for Orphan Indication,,,,,F2G Limited,Lankro Way,Eccles,Manchester,,' ' ,United Kingdom,704219,,,
4967,olorofim,,1/16/2020,treatment of invasive aspergillosis,Designated,,Not FDA Approved for Orphan Indication,,,,,F2G Limited,Lankro Way,Eccles,Manchester,,' ' ,United Kingdom,702219,aspergillosis,"""gard:0005856""",
4968,Olorofim,,8/3/2021,treatment of invasive fusariosis,Designated,,Not FDA Approved for Orphan Indication,,,,,F2G Limited,Lankro Way Eccles,,Manchester,Manchester,' M30 OLX ' ,United Kingdom,829821,fusariosis,"""gard:0020570""",
4969,olutasidenib,Rezlidhia,4/27/2017,treatment of acute myeloid leukemia,Designated/Approved,,,treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test,12/1/2022,12/1/2029,treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test,"Rigel Pharmaceuticals, Inc.",611 Gateway Boulevard,Suite 900,South San Francisco,California,' 94080 ' ,United States,565716,acute myeloid leukemia,"""gard:0012757""",
4970,olverembatinib,,3/8/2022,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"800 King Farm Blvd., Suite 300",,Rockville,Maryland,' 20850 ' ,United States,864921,acute lymphoblastic leukemia,"""gard:0000522""",
4971,olverembatinib,,4/22/2020,treatment of chronic myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,' 20850 ' ,United States,735620,chronic myeloid leukemia,"""gard:0006105""",
4972,olverembatinib,,12/14/2021,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,' 20850 ' ,United States,852921,acute myeloid leukemia,"""gard:0012757""",
4973,Olverembatinib,,9/29/2022,treatment of gastrointestinal stromal tumor (gist),Designated,,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,' 20850 ' ,United States,903622,gastrointestinal stromal tumor,"""gard:0008598""",
4974,omacetaine mepesuccinate,,1/12/2009,treatment of myelodysplastic syndromes,Designated,,Not FDA Approved for Orphan Indication,,,,,IVAX International GmbH,Alpenstrasse 2,8640 Rapperswil,Frazer,,' ' ,Switzerland,272608,myelodysplastic syndrome,"""gard:0007132""",
4975,omacetaxine mepesuccinate,Synribo,3/10/2006,treatment of chronic myelogenous leukemia,Designated/Approved,,,Treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI),10/26/2012,10/26/2019,,IVAX International GmbH,Alpenstrasse 2,8640 Rapperswil,Frazer,,' ' ,Switzerland,218205,,,
4976,omadacycline,,8/18/2021,treatment of infections caused by nontuberculous mycobacteria (ntm),Designated,,Not FDA Approved for Orphan Indication,,,,,"Paratek Pharmaceuticals, Inc.",75 Park Plaza,4th floor,Boston,Massachusetts,' 02116 ' ,United States,741020,,,
4977,omaveloxolone,,9/5/2017,treatment of stage iib through iv malignant melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Reata Pharmaceuticals, Inc.",2801 Gateway Dr.,Suite 150,Irving,Texas,' 75063 ' ,United States,461114,noma,"""gard:0004001""",
4978,omaveloxolone,Skyclarys,6/19/2017,treatment of friedreich's ataxia,Designated/Approved,,,treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older,2/28/2023,2/28/2030,treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older,"Reata Phamaceuticals, Inc.",5320 Legacy Drive,,Plano,Texas,' 75024 ' ,United States,461214,,,
4979,Ombitasvir/Paritaprevir/Ritonavir,,2/24/2016,treatment of pediatric patients with chronic hepatitis c virus infection,Designated/Designation Withdrawn or Revoked,5/15/2020,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,509215,,,
4980,ombitasvir/paritaprevir/ritonavir and dasabuvir,,7/16/2015,treatment of pediatric patients with hepatitis c virus infection (0 through 16 years of age),Designated,,Not FDA Approved for Orphan Indication,,,,,"Abbvie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,484715,,,
4981,"ombrabulin; N-{2-methoxy-5-[(Z)-2-(3,4,5-trimethozyphenyl)vinyl]phenyl}-L-serinamide hydrochloride",,3/3/2011,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sanofi-Aventis U.S., Inc.",55 Corporate Drive,,Bridgewater,New Jersey,' 08807 ' ,United States,334511,soft tissue sarcoma,"""gard:0004898""",
4982,Omega-3 (n-3) polyunsaturated fatty acid with all double bonds in the cis configuration,,11/22/1995,prevention of organ graft rejection.,Designated,,Not FDA Approved for Orphan Indication,,,,,Research Triangle Pharmaceuticals,4364 South Alston Avenue,,Durham,North Carolina,' 27713 ' ,United States,93195,,,
4983,Omega-3 (n-3) polyunsaturated fatty acids,,5/4/2000,treatment of iga nephropathy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pronova Biocare, AS",PO Box 420,,Lysaker,,' ' ,Norway,128799,,,
4984,omeprazole-lansoprazole with buffer,,2/10/2015,treatment of esophageal ulcers,Designated,,Not FDA Approved for Orphan Indication,,,,,"Effexus Pharmaceuticals, LLC",10901 Granada Lane,Suite 101,Leawood,Kansas,' 66211 ' ,United States,446014,,,
4985,omidubicel-onlv,Omisirge,5/23/2018,enhancement of cell engraftment and immune reconstitution in patients receiving hematopoietic stem cell transplant,Designated/Approved,,,for use in adults and pediatric patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection,4/17/2023,4/17/2030,for use in adults and pediatric patients 12 years and older with hematologic malignancies who are planned for umbilical cord blood transplantation following myeloablative conditioning to reduce the time to neutrophil recovery and the incidence of infection,Gamida Cell Ltd.,P. O. Box 34670,,Jerusalem,,' ' ,Israel,637518,,,
4986,omigapil,,6/24/2008,treatment of congenital muscular dystrophy.,Designated,,Not FDA Approved for Orphan Indication,,,,,Santhera Pharmaceuticals (Switzerland) Limited,Hammerstrass 49,CH-4410 Liestal,Liestal,,' ' ,Switzerland,260508,congenital muscular dystrophy,"""gard:0009138""",
4987,onartuzumab,,1/23/2013,treatment of gastric cancer including gastroesophageal cancer,Designated/Designation Withdrawn or Revoked,4/29/2015,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,MS# 241B,South San Francisco,California,' 94080 ' ,United States,387712,,,
4988,onartuzumab (MetMab),,12/16/2013,treatment of hepatocellular carcinoma,Designated/Designation Withdrawn or Revoked,4/29/2015,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,417113,hepatocellular carcinoma,"""gard:0016773""",
4989,onasemnogene abeparvovec,ZOLGENSMA,9/30/2014,treatment of spinal muscular atrophy,Designated/Approved,,,Indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.,5/24/2019,5/24/2026,Indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.,"AveXis, Inc.",2275 Half Day Road,Suite 200,Bannockburn,Illinois,' 60015 ' ,United States,444714,,,
4990,Oncolytic adenovirus coding for granulocyte macrophage colony stimulating factor (ONCOS-102),,12/22/2014,treatment of malignant mesothelioma,Designated/Designation Withdrawn or Revoked,12/20/2023,Not FDA Approved for Orphan Indication,,,,,"Targovax Solutions AS, a subsidiary of Targovax ASA",Vollsveien 19,,Lysaker,,' 1366 ' ,Norway,457314,,,
4991,Oncolytic Herpes Simplex Virus Expressing IL-12 - M032,,12/11/2019,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,University of Alabama at Birmingham,1720 2nd Avenue South,Suite 1170 AB,Birmingham,Alabama,' 35294 ' ,United States,712319,,,
4992,Oncolytic Type 1 Herpes Simplex Virus (HSV-1) Expressing Human Cytokine Interleukin 12 (IL-12) and Fab Fragment of Anti-PD-1 Antibody,,8/1/2022,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"ImmVira Pharma Co., Limited",Unit 417 4/F Lippo Centre Tower Two,No.89 Queensway Admiralty,Hong Kong,,' ' ,Hong Kong,893322,,,
4993,oncophage,,4/14/2009,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Agenus, Inc.",3 Forbes Road,,Lexington,Massachusetts,' 02421 ' ,United States,274208,,,
4994,ondansetron inhalation powder,,10/14/2015,prevention of chemotherapy-induced nausea and vomiting due to highly emetogenic chemotherapy in pediatric patients (0 through 16 years of age) .,Designated,,Not FDA Approved for Orphan Indication,,,,,"Luxena Pharmaceuticals, Inc.",1400 Coleman Avenue,Suite D27,Santa Clara,California,' 95050 ' ,United States,491115,,,
4995,"One, two, three, or four antisense oligonucleotides of Phosphorodiamidate morpholino oligomer combination that skips exons 4, 5, 6, and 7 of the gamma sarcoglycan (SGCG) gene",,7/18/2017,"treatment of limb-girdle muscular dystrophy type 2c that have mutations or deletions in exons 4, 5, 6, or 7of gamma sarcoglycan gene",Designated,,Not FDA Approved for Orphan Indication,,,,,Kurt+Peter Foundation,P. O. Box 691,,Menlo Park,California,' 94025 ' ,United States,587017,muscular dystrophy,"""gard:0007922""",
4996,opelconazole,,7/1/2021,treatment of invasive aspergillosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Pulmocide Inc.,177 Huntington Ave Ste 1703,PBM 58659,Boston,Massachusetts,' 02115-3153 ' ,United States,824121,aspergillosis,"""gard:0005856""",
4997,opioid growth factor,,4/16/2013,treatment of liver and intrahepatic bile duct cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Primocure Pharma, Inc.",1732 1st Avenue,#23222,New York,New York,' 10128 ' ,United States,392213,,,
4998,opium tincture,,12/2/2011,treatment of chronic diarrhea in short bowel syndrome patients with an inadequate response to anti-diarrheal treatment,Designated,,Not FDA Approved for Orphan Indication,,,,,"Valeant Pharmaceuticals International, Inc.",400 Somerset Corporate Blvd,,Bridgewater,New Jersey,' 08807 ' ,United States,307710,short bowel syndrome,"""gard:0001502""",
4999,Oprelvekin,Neumega,12/17/1996,prevention of severe chemotherapy-induced thrombocytopenia.,Designated/Approved,,,,11/25/1997,11/25/2004,,"Genetics Institute, Inc.",87 Cambridge Park Drive,,Cambridge,Massachusetts,' 02140 ' ,United States,96796,,,
5000,oprozomib,,8/25/2014,treatment of waldenstrom's macroglobulinemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Onyx Therapeutics, Inc.",249 E. Grand Avenue,,South San Francisco,California,' 94080 ' ,United States,443614,,,
5001,oprozomib,,10/28/2014,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Onyx Therapeutics, Inc.",249 E. Grand Avenue,,South San Francisco,California,' 94080 ' ,United States,449614,multiple myeloma,"""gard:0007108""",
5002,optimized human tissue-type plasminogen activator,,10/21/2021,treatment of intracerebral hemorrhage,Designated,,Not FDA Approved for Orphan Indication,,,,,Op2Lysis SAS,117 Avenue,,Victore Hugo,Boulogne-Billancourt,' 92100 ' ,France,841221,,,
5003,oral melanocortin 4 receptor agonist,,6/6/2022,treatment for pro-opiomelanocortin (pomc) deficiency.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Rhythm Pharmaceuticals, Inc.","222 Berkeley Street, Suite 1200",,Boston,Massachusetts,' 02116 ' ,United States,765820,,,
5004,oral potent and selective antagonist,,2/18/2011,treatment of patients with chondrosarcoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Infinity Pharmaceuticals, Inc.",780 Memorial Drive,,Cambridge,Massachusetts,' 02139 ' ,United States,333511,chondrosarcoma,"""gard:0006055""",
5005,oral testosterone,,6/2/2016,treatment of constitutional delay of growth and puberty in adolescent boys 14 to 17 years of age.,Designated,,Not FDA Approved for Orphan Indication,,,,,"TesoRx Pharma, LLC",3670 West Temple Avenue,Suite 270,Pomona,California,' 91768 ' ,United States,523916,,,
5006,oral tyrosine kinase inhibitor,,6/28/2017,treatment of chronic myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Fusion Pharma, LLC",Territory of the Skolkovo innovation center,Nobelya St. 7,,Moscow,' ' ,Russia,585217,chronic myeloid leukemia,"""gard:0006105""",
5007,oral unfractionated heparin,,1/29/2004,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"TRF Technologies, Inc.","863 Mitten Road, Suite 101",,Burlingame,California,' 94010 ' ,United States,178103,,,
5008,Oraxol,,4/16/2018,treatment of angiosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Health Hope Pharma,726 Exchange Street Suite 1006,,Buffalo,New York,' 14210 ' ,United States,594217,angiosarcoma,"""gard:0020900""",
5009,Orelabrutinib,,12/30/2020,treatment of mantle cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,InnoCare Pharma Inc.,"103 Carnegie Center, Suite 209",,Princeton,New Jersey,' 08540 ' ,United States,788920,lymphoma,"""gard:0020548""",
5010,Orgotein for injection,,12/22/1994,"treatment of familial amyotrophic lateral sclerosis associated with a mutation of the gene (on chromosome 21q) for copper, zinc superoxide dismutase.",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Oxis International, Inc.","6040 N. Cutter Circle, Suite 317",,Portland,Oregon,' 97217 ' ,United States,87294,amyotrophic lateral sclerosis,"""gard:0005786""",
5011,orilanolimab,,9/10/2018,treatment of pemphigus,Designated/Designation Withdrawn or Revoked,3/15/2022,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Blvd.,,Boston,Massachusetts,' 02210 ' ,United States,649018,,,
5012,Ornithine transcarbamylase messenger RNA,,6/26/2019,treatment of ornithine transcarbamylase deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Arcturus Therapeutics, Inc.",10628 Science Center Drive,Suite 250,San Diego,California,' 92121 ' ,United States,690819,ornithine transcarbamylase deficiency,"""gard:0008391""",
5013,osilodrostat,Isturisa,9/13/2013,treatment of cushing's disease,Designated/Approved,,,ISTURISA is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing¿s disease for whom pituitary surgery is not an option or has not been curative.,3/6/2020,3/6/2027,For the treatment of adult patients with Cushing¿s disease for whom pituitary surgery is not an option or has not been curative.,"Recordati Rare Diseases, Inc",100 Corporate Drive,,Lebanon,New Jersey,' 08833 ' ,United States,405113,,,
5014,osilodrostat,,4/29/2024,treatment of endogenous cushing's syndrome excluding cushing's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Recordati Rare Diseases Inc.,440 Route 22 East,,Bridgewater,New Jersey,' 08807 ' ,United States,980023,,,
5015,osimertinib,Tagrisso,9/4/2014,treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer,Designated/Approved,,,"in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test",2/16/2024,,,AstraZeneca Pharmaceuticals LP,P. O. Box 8355,1800 Concord Pike,Wilmington,Delaware,' 19803 ' ,United States,445214,small cell lung cancer,"""gard:0009344""",
5016,osimertinib,Tagrisso,9/4/2014,treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer,Designated/Approved,,,"adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test",12/18/2020,12/18/2027,"adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test",AstraZeneca Pharmaceuticals LP,P. O. Box 8355,1800 Concord Pike,Wilmington,Delaware,' 19803 ' ,United States,445214,small cell lung cancer,"""gard:0009344""",
5017,osimertinib,Tagrisso,9/4/2014,treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer,Designated/Approved,,,"For treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy",11/13/2015,11/13/2022,"For treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy",AstraZeneca Pharmaceuticals LP,P. O. Box 8355,1800 Concord Pike,Wilmington,Delaware,' 19803 ' ,United States,445214,small cell lung cancer,"""gard:0009344""",
5018,osimertinib,Tagrisso,9/4/2014,treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer,Designated/Approved,,,"TAGRISSO® is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test",4/18/2018,4/18/2025,"TAGRISSO® is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test",AstraZeneca Pharmaceuticals LP,P. O. Box 8355,1800 Concord Pike,Wilmington,Delaware,' 19803 ' ,United States,445214,small cell lung cancer,"""gard:0009344""",
5019,otelixizumab,,2/6/2006,treatment of new-onset type i diabetes mellitus,Designated/Designation Withdrawn or Revoked,7/22/2020,Not FDA Approved for Orphan Indication,,,,,GlaxoSmithKline,2301 Renaissance Blvd (RN0420),P. O. Box 61540,King of Prussia,Pennsylvania,' 19406 ' ,United States,216605,,,
5020,Oxaliplatin,,10/6/1992,treatment of ovarian cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,Debiopharm S.A.,17 Rue des Terreaux,,Lausanne,,' ' ,Switzerland,69492,ovarian cancer,"""gard:0007295""",
5021,oxaloacetate,,7/24/2012,treatment of gliomas,Designated,,Not FDA Approved for Orphan Indication,,,,,Terra Biological LLC,3830 Valley Centre Drive,Suite 705-561,San Diego,California,' 92130 ' ,United States,370412,,,
5022,oxaloacetic acid,,11/18/2015,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Terra Biological LLC,3830 Valley Centre Drive,Suite 705-561,San Diego,California,' 92130 ' ,United States,488015,amyotrophic lateral sclerosis,"""gard:0005786""",
5023,Oxalobacter formigenes,,3/29/2006,treatment of primary hyperoxaluria,Designated,,Not FDA Approved for Orphan Indication,,,,,OxThera Inc.,Regeringsgatan 111,,Stockholm,,' ' ,Sweden,219206,primary hyperoxaluria,"""gard:0016530""",
5024,Oxandrolone,,4/22/1997,treatment of patients with duchenne's muscular dystrophy and becker's muscular dystrophy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Savient Pharmaceuticals, Inc.","One Tower Center Boulevard, 12th floor",,East Brunswick,New Jersey,' 08816 ' ,United States,103797,muscular dystrophy,"""gard:0007922""",
5025,Oxandrolone,,3/18/1994,treatment of moderate/severe acute alcoholic hepatitis in the presence of moderate protein calorie malnutrition.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Bio-Technology General Corp.,"One Tower Center Boulevard, 12 th floor",,East Brunswick,New Jersey,' 08816 ' ,United States,75793,,,
5026,Oxandrolone,,7/5/1990,treatment of short stature associated with turner's syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Bio-Technology General Corp.,"70 Wood Avenue, South",,Iselin,New Jersey,' 08830 ' ,United States,45590,,,
5027,Oxandrolone,,10/5/1990,treatment of constitutional delay of growth and puberty.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Bio-Technology General Corp.,"70 Wood Avenue, South",,Iselin,New Jersey,' 08830 ' ,United States,45790,,,
5028,Oxandrolone,,9/6/1991,adjunctive therapy for aids patients suffering from hiv-wasting syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,Bio-Technology General Corp.,"One Tower Center Boulevard, 12 th floor",,East Brunswick,New Jersey,' 08816 ' ,United States,59091,,,
5029,oxfendazole,,8/7/2017,treatment of cysticercosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Oxfendazole Development Group,736 Cathcart Road,,Blue Bell,Pennsylvania,' 19422 ' ,United States,597217,cysticercosis,"""gard:0008194""",
5030,oxfendazole,,7/14/2014,treatment of cysticercosis (including neurocysticercosis),Designated,,Not FDA Approved for Orphan Indication,,,,,"Robert H. Gilman, MD, DTMH and",Johns Hopkins School of Public Health,"615 N. Wolfe St, Room W5515",Baltimore,Maryland,' 21205 ' ,United States,435514,cysticercosis,"""gard:0008194""",
5031,oxoindoline carboxamide compound,,12/12/2023,treatment of alpha-1 antitrypsin deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,BioMarin Pharmaceutical Inc.,105 Digital Drive,,Novato,California,' 94949 ' ,United States,974923,,,
5032,Oxymorphone,,3/19/1985,for relief of severe intractable pain in narcotic-tolerant patients.,Designated,,Not FDA Approved for Orphan Indication,,,,,DuPont Merck Pharmaceutical Company,P.O. Box 80027,,Wilmington,Delaware,' 19880 ' ,United States,6185,,,
5033,Oxypurinol,,11/9/1998,treatment of hyperuricemia in patients intolerant to allopurinol.,Designated,,Not FDA Approved for Orphan Indication,,,,,Cardiome Pharma Corp.,3650 Westbrook Mall,,Vancouver,,' ' ,Canada,115798,,,
5034,oxypurinol,,4/20/2023,treatment of autosomal dominant polycystic kidney disease,Designated,,Not FDA Approved for Orphan Indication,,,,,XORTX Therapeutics Inc.,3710 33rd Street NW,,Calgary,AB,' T2L 2M1 ' ,Canada,934023,autosomal dominant polycystic kidney disease,"""gard:0010413""",
5035,Oxytocin,,3/1/2022,treatment of prader-willi syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tonix Pharmaceuticals, Inc.","26 Main Street, Suite 101",,Chatham,New Jersey,' 07928 ' ,United States,864421,prader-willi syndrome,"""gard:0005575""",
5036,oxytocin,,6/15/2017,treatment of prader-willi syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Eric Hollander, MD",Montefiore Medical Center,Univ. Hosp for Albert Einstein College of Medicine,Bronx,New York,' 10467 ' ,United States,582717,prader-willi syndrome,"""gard:0005575""",
5037,oxytocin,,11/24/2014,treatment of prader-willi syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,OT4B,109 Avenue de Lespinet,,Toulouse,,' 31400 ' ,France,453614,prader-willi syndrome,"""gard:0005575""",
5038,ozanimod,,12/29/2015,treatment of pediatric (0 through 16 years of age) ulcerative colitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,3033 Science Park Road,Suite 300,San Diego,California,' 92121 ' ,United States,499515,,,
5039,ozanimod,,11/1/2017,treatment of pediatric crohn’s disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene International II Sarl,4 Rue des Moulins,,Val-de-Travers,Neuchâtel,' ' ,Switzerland,611517,,,
5040,"P1, P4-Di(uridine 5'-tetraphosphate), tetrasodium salt",,10/27/1998,treatment of cystic fibrosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Inspire Pharmaceuticals, Inc.","4222 Emperor Blvd., Suite 470",,Durham,North Carolina,' 27703 ' ,United States,116998,cystic fibrosis,"""gard:0006233""",
5041,"p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt",,3/7/2001,for the treatment of cystic fibrosis,Designated/Designation Withdrawn or Revoked,10/3/2016,Not FDA Approved for Orphan Indication,,,,,"Inspire Pharmaceuticals, Inc.",4222 Emperor Blvd.,Suite 200,Durham,North Carolina,' 27703 ' ,United States,139400,cystic fibrosis,"""gard:0006233""",
5042,P140K MGMT transduced human CD34 cells,,1/9/2013,for bone marrow protection in the treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,Lentigen Corporation,910 Clopper Road,Suite 200 South Building,Gaithersburg,Maryland,' 20878 ' ,United States,385212,glioblastoma,"""gard:0002491""",
5043,p38 mitogen-activated kinase inhibitor,,5/27/2014,"treatment of dilated cardiomyopathy, including dilated cardiomyopathy secondary to lamin a/c gene mutations",Designated/Designation Withdrawn or Revoked,1/9/2023,Not FDA Approved for Orphan Indication,,,,,"Array BioPharma, Inc.",3200 Walnut Street,,Boulder,Colorado,' 80301 ' ,United States,431714,dilated cardiomyopathy,"""gard:0000221""",
5044,Paclitaxel,Taxol,3/25/1997,treatment of aids-related kaposi's sarcoma.,Designated/Approved,,,For the second line treatment of AIDS-related Kaposi's sarcoma.,8/4/1997,8/4/2004,,Bristol-Myers Squibb Pharmaceutical Research Institute,5 Research Parkway,P.O. Box 5100,Wallingford,Connecticut,' 06492 ' ,United States,103497,,,
5045,Paclitaxel,,4/15/1997,treatment of aids-related kaposi's sarcoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Baker Norton Pharmaceuticals, Inc.",4400 Biscayne Boulevard,,Miami,Florida,' 33137 ' ,United States,104797,,,
5046,paclitaxel,,5/1/2009,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,9/5/2023,Not FDA Approved for Orphan Indication,,,,,"SynCore Biotechnology Co., Ltd.",No. 84 Chung Shan Rd,Tung-Shan Shine I-Lan 269,,,' ' ,Taiwan,280409,,,
5047,paclitaxel,,12/22/2004,treatment of non-superficial urothelial cancer,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Sonus Pharmaceuticals, Inc.",22026 20th Avenue SE,,Bothell,Washington,' 98021 ' ,United States,186404,,,
5048,paclitaxel aqueous gel,,2/1/2008,treatment of esophageal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"BTG International, Inc.",5214 Maryland Way,Suite 405,Brentwood,Tennessee,' 37027 ' ,United States,252907,,,
5049,paclitaxel aqueous gel,,12/23/2008,treatment of brain cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,BTG International Inc.,5214 Maryland Way,Suite 405,Brentwood,Tennessee,' 37027 ' ,United States,270208,,,
5050,paclitaxel nanoparticles,,1/2/2013,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"CIRJ Co., Ltd.",1800 Loma Vista Street,,Pasadena,California,' 91104 ' ,United States,384912,,,
5051,paclitaxel poliglumex,,9/20/2012,treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,CTI BioPharma Corporation,3101 Western Ave,Suite 600,Seattle,Washington,' 98119 ' ,United States,377312,glioblastoma,"""gard:0002491""",
5052,paclitaxel protein-bound particles,Abraxane,9/3/2009,treatment of pancreatic cancer.,Designated/Approved,,,"Treatment of metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.",9/6/2013,9/6/2020,"Treatment of metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine.","Abraxis BioScience, LLC","9225 Indian Creek Parkway, Suite 900",,Overland Park,Kansas,' 66210 ' ,United States,291009,,,
5053,Paclitaxel protein-bound particles for injection suspension,,10/1/2009,treatment of stage iib to iv melanoma,Designated/Designation Withdrawn or Revoked,6/19/2015,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,400 Connell Drive,Suite 7000,Berkeley Heights,New Jersey,' 07922 ' ,United States,290709,noma,"""gard:0004001""",
5054,"paclitaxel, micellar",,4/3/2009,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Elevar Therapeutics, Inc.",2825 E Cottonwood Parkway,Suite 180,Salt Lake City,Utah,' 84121 ' ,United States,278309,ovarian cancer,"""gard:0007295""",
5055,paclitaxel-coated buttress,,7/15/2014,for use as local administration at the time of curative surgery in the treatment of stage 0 to iii non-small cell lung cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,Cook Biotech Incorporated,1425 Innovation Place,,West Lafayette,Indiana,' 47906 ' ,United States,394813,small cell lung cancer,"""gard:0009344""",
5056,Paclitaxel/Polyoligo(ethylene glycol)methacrylate-co-poly(vinylbenzyldithiodibutyric acid-gemcitabine) fixed-dose combination,,7/25/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,DUO Oncology,4165 Blair St.,,Pittsburgh,Pennsylvania,' 15207 ' ,United States,950623,,,
5057,pacritinib,Vonjo,3/13/2008,"treatment of primary myelofibrosis (mf), post-polycythemia vera mf, and post-essential thrombocythemia mf",Designated/Approved,,,Treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 x 109/L,2/28/2022,2/28/2029,Treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 x 109/L,CTI BioPharma Corporation,3101 Western Avenue,Suite 800,Seattle,Washington,' 98121 ' ,United States,245607,polycythemia,"""gard:0019466""",
5058,padeliporfin,,3/2/2021,treatment of upper tract urothelial cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Steba Biotech S.A,7 Place du Théâtre,,,Luxembourg,' L-2613 ' ,Luxembourg,803320,,,
5059,Padeliporfin,,4/5/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,IMPACT Biotech Ltd,"16 Einstein St., Kiryat Weizmann Science Park",P.O. Box 4052,Ness Ziona,Ness Ziona,' 7403620 ' ,Israel,932523,,,
5060,pafolacianine,Cytalux,12/23/2014,detecting folic receptor alpha positive lesions in ovarian cancer patients (diagnostic for the management of ovarian cancer),Designated/Approved,,,As an adjunct for intraoperative identification of malignant lesions in adult patients with ovarian cancer,11/29/2021,11/29/2028,As an adjunct for intraoperative identification of malignant lesions in adult patients with ovarian cancer,"On Target Laboratories, LLC",1282 Win Hentschel Blvd,,West Lafayette,Indiana,' 47906 ' ,United States,458714,ovarian cancer,"""gard:0007295""",
5061,Pafuramidine maleate,,8/31/2007,treatment of human african trypanosomiasis (sleeping sickness),Designated,,Not FDA Approved for Orphan Indication,,,,,"Immtech Pharmaceuticals, Inc.",150 Fairway Drive,Suite 150,Vernon Hills,Illinois,' 60061 ' ,United States,244507,african trypanosomiasis,"""gard:0007826""",
5062,pafuramidine maleate,,11/17/2006,treatment of pneumocystis jiroveci pneumonia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immtech Pharmaceuticals, Inc.",150 Fairway Drive,Suite 150,Vernon Hills,Illinois,' 60061 ' ,United States,220706,,,
5063,Pafuramidine maleate,,5/14/2007,treatment of malaria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immtech Pharmaceuticsl, Inc.",150 Fairway Drive,,Vernon Hills,Illinois,' 60061 ' ,United States,241207,malaria,"""gard:0006961""",
5064,Palifosfamide,,5/5/2008,treatment of soft tissue sarcomas,Designated/Designation Withdrawn or Revoked,6/8/2015,Not FDA Approved for Orphan Indication,,,,,"ZIOPHARM Oncology, Inc.","One First Avenue, Parris Building #34",Navy Yard Plaza,Boston,Massachusetts,' 02129 ' ,United States,257508,soft tissue sarcoma,"""gard:0004898""",
5065,palm tocotrienol complex,,6/13/2017,treatment of cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (cadasil),Designated,,Not FDA Approved for Orphan Indication,,,,,Hovid Berhad,121 Jalan Tunku Abdul Rahman,,Ipoh,Perak,' ' ,Malaysia,576117,,,
5066,palovarotene,,11/6/2017,treatment of multiple osteochondromas,Designated/Designation Withdrawn or Revoked,9/9/2021,Not FDA Approved for Orphan Indication,,,,,"Clementia Pharmaceuticals, Inc.","1000 De La Gauchetiere West, Suite 1200",,Montreal,,' ' ,Canada,612117,multiple osteochondromas,"""gard:0007035""",
5067,palovarotene,Sohonos,7/21/2014,treatment of fibrodysplasia ossificans progressiva,Designated/Approved,,,for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP),8/16/2023,8/16/2030,for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP),"Ipsen Biopharmaceuticals, Inc.","One Main Street, 7th Floor",,Cambridge,Massachusetts,' 02142 ' ,United States,438714,fibrodysplasia ossificans progressiva,"""gard:0006445""",
5068,Paltusotine,,7/7/2020,treatment of acromegaly,Designated,,Not FDA Approved for Orphan Indication,,,,,"Crinetics Pharmaceuticals, Inc.",6197 Cornerstone Court East,,San Diego,California,' 92121 ' ,United States,576617,acromegaly,"""gard:0005725""",
5069,pamrevlumab,,4/11/2019,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"FibroGen, Inc.",409 Illinois Street,,San Francisco,California,' 94158 ' ,United States,680319,muscular dystrophy,"""gard:0007922""",
5070,pamrevlumab,,7/6/2012,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"FibroGen, Inc.",409 Illinois Street,,San Francisco,California,' 94158 ' ,United States,351211,idiopathic pulmonary fibrosis,"""gard:0008609""",
5071,pamrevlumab,,6/19/2017,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"FibroGen, Inc.",409 Illinois Street,,San Francisco,California,' 94158 ' ,United States,581617,,,
5072,panobinostat,,9/18/2009,treatment of hodgkin's lymphoma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,"One Health Plaza, 105/3W038",,East Hanover,New Jersey,' 07936 ' ,United States,291509,lymphoma,"""gard:0020548""",
5073,panobinostat,Farydak,8/20/2012,treatment of multiple myeloma,Designated/Approved,,,"FARYDAK (panobinostat) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent",2/23/2015,2/23/2022,"FARYDAK (panobinostat) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent",zr pharma& GmbH,Rauhensteingasse 10/14,,Wien,,' 1010 ' ,Austria,376212,multiple myeloma,"""gard:0007108""",
5074,Panobinostat,,9/26/2007,treatment of cutaneous t-cell lymphoma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,"One Health Plaza, 105/3W038",,East Hanover,New Jersey,' 07936 ' ,United States,244407,lymphoma,"""gard:0020548""",
5075,pantothenate phosphate,,5/4/2015,treatment of pantothenate kinase associated neurodegeneration (pkan).,Designated/Designation Withdrawn or Revoked,3/6/2020,Not FDA Approved for Orphan Indication,,,,,"Retrophin, Inc.",777 Third Avenue,22nd Floor,New York,New York,' 10017 ' ,United States,427114,,,
5076,"Papain, trypsin, and chymotrypsin",,12/21/1998,treatment of multiple myeloma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Marlyn Nutraceuticals, Inc.",14851 N. Scottsdale Rd.,,Scottsdale,Alaska,' 85254 ' ,United States,117498,multiple myeloma,"""gard:0007108""",
5077,papaverine,,8/3/2017,treatment of mesenteric ischemia,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,161 Jefferson Avenue,,Tenafly,New Jersey,' 07670 ' ,United States,581417,,,
5078,Papaverine topical gel,,2/6/1992,treatment of sexual dysfunction in spinal cord injury patients.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Pharmedic Company,417 Harvester Court,,Wheeling,Illinois,' 60090 ' ,United States,64991,spinal cord injury,"""gard:0019109""",
5079,paquinimod,,1/17/2014,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Active Biotech AB,Scheelevagen 22,SE-220 07,LUND,,' ' ,Sweden,356911,systemic sclerosis,"""gard:0009748""",
5080,Para-toluenesulfonamide,,1/30/2017,treatment of adenoid cystic carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,PTS International Inc.,2211 Newoak Pk,,San Antonio,Texas,' 78230 ' ,United States,553516,noma,"""gard:0004001""",
5081,parathyroid hormone,Natpara,8/31/2007,treatment of hypoparathyroidism,Designated/Approved,,,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism,1/23/2015,1/23/2022,An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism,"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,246707,,,
5082,Parathyroid Hormone Inverse Agonist (PTH-IA),,3/16/2023,treatment of patients with jansen’s metaphyseal chondrodysplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,"National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH)",9800 Medical Center Dr.,,Rockville,Maryland,' 20850 ' ,United States,929322,,,
5083,paricalcitol,Zemplar,10/27/2015,treatment of pediatric hyperparathyroidism,Designated/Approved,,,Indicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 and CKD Stage 5 in patients on hemodialysis or peritoneal dialysis,10/18/2016,10/18/2023,Indicated in pediatric patients ages 10 -16 years for treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 and pediatric patients ages 10-16 years for treatment of secondary hyperparathyroidism associated with CKD Stage 5.,"Abbvie, inc.",1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,492815,,,
5084,paromomycin,,2/11/2015,treatment of cutaneous leishmaniasis (old world and new world),Designated,,Not FDA Approved for Orphan Indication,,,,,Appili Therapeutics Inc.,21-1344 Summer Street,,Halifax,Nova Scotia,' B3H 0A8 ' ,Canada,464314,leishmaniasis,"""gard:0006881""",
5085,paromomycin sulfate/gentamicin sulfate,,1/18/2008,treatment of all uncomplicated cutaneous leishmaniasis (both new world and old world),Designated,,Not FDA Approved for Orphan Indication,,,,,Appili Therapeutics Inc.,21-1344 Summer Street,,Halifax,Nova Scotia,' B3H 0A8 ' ,Canada,231206,leishmaniasis,"""gard:0006881""",
5086,parsaclisib,,9/10/2019,treatment of splenic marginal zone lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,688319,lymphoma,"""gard:0020548""",
5087,parsaclisib,,6/12/2019,treatment of mantle cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,688519,lymphoma,"""gard:0020548""",
5088,parsaclisib,,7/28/2020,treatment of autoimmune hemolytic anemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,758420,autoimmune hemolytic anemia,"""gard:0005870""",
5089,Parsaclisib,,9/25/2019,treatment of follicular lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,703919,lymphoma,"""gard:0020548""",
5090,parsaclisib,,10/9/2019,treatment of extranodal marginal zone lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,707419,lymphoma,"""gard:0020548""",
5091,parsaclisib,,10/7/2019,treatment of nodal marginal zone lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,707319,lymphoma,"""gard:0020548""",
5092,parsaclisib and ruxolitinib,,3/27/2023,treatment of myelofibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,932023,,,
5093,Partial agonist at the opioid receptor-like 1 receptor with amino acid sequence Ac-Arg-Tyr-Tyr-Arg-Trp-Lys-Lys-Lys-Lys-Lys-Lys-Lys-NH2,,10/19/2016,treatment of pulmonary arterial hypertension,Designated/Designation Withdrawn or Revoked,1/28/2019,Not FDA Approved for Orphan Indication,,,,,Serodus ASA,Gaustadalléen 21,,Oslo,Oslo,' ' ,Norway,541316,pulmonary arterial hypertension,"""gard:0007501""",
5094,partial myostatin antigen displayed on the surface of Lactobacillus casei,,12/28/2017,treatment of duchenne muscular dystrophy (dmd),Designated,,Not FDA Approved for Orphan Indication,,,,,BioLeaders Corporation,"7F, U-Tower, 767, Sinsu-ro, Suji-gu",,Yongin-si,Gyeonggi-do,' ' ,South Korea,619017,muscular dystrophy,"""gard:0007922""",
5095,"Particles comprised ofmethacrylic acid based co-polymer, cross-linked with a bi-functional cross-linker, purified to bind L-phenylalanine and L-phenylalanine containing peptides",,2/27/2020,treatment of hyperphenylalaninemia,Designated,,Not FDA Approved for Orphan Indication,,,,,MipSalus ApS,AgemAlle 3,,Hørsholm,,' ' ,Denmark,726119,,,
5096,Parvovirus B19 (recombinant VP1 and VP2; S.frugiperda cells) vaccine,,5/7/1999,prevention of transient aplastic crisis in patients with sickle cell anemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"MedImmune, Inc.",35 West Watkins Mill Rd.,,Gaithersburg,Maryland,' 20878 ' ,United States,123699,sickle cell anemia,"""gard:0008614""",
5097,pasireotide,Signifor,7/24/2009,treatment of cushing's disease,Designated/Approved,,,Treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative,12/14/2012,12/14/2019,,Novartis Pharmaceuticals Corporation,One Health Plaza,"Bldg 104, 3K28",East Hanover,New Jersey,' 07936 ' ,United States,288709,,,
5098,pasireotide,,8/25/2009,treatment of acromegaly,Designated/Approved,,,Treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option,12/15/2014,12/15/2021,Treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option,Novartis Pharmaceuticals Corporation,One Health Plaza,"Bldg 104, 3K28",East Hanover,New Jersey,' 07936 ' ,United States,288609,acromegaly,"""gard:0005725""",
5099,pasireotide,Signifor,7/24/2009,treatment of cushing's disease,Designated/Approved,,,SIGNIFOR® LAR is indicated for the treatment of patients with Cushing¿s disease for whom pituitary surgery is not an option or has not been curative.,6/29/2018,6/29/2025,Indicated for treatment of patients with Cushing¿s disease for whom pituitary surgery is not an option or has not been curative.,Novartis Pharmaceuticals Corporation,One Health Plaza,"Bldg 104, 3K28",East Hanover,New Jersey,' 07936 ' ,United States,288709,,,
5100,patidegib,,7/19/2017,treatment of nevoid basal cell carcinoma syndrome (gorlin syndrome),Designated,,Not FDA Approved for Orphan Indication,,,,,"Sol-Gel Technologies, Ltd.",7 Golda Meir St.,,Weizmann Scíence Park,Ness-Ziona,' 7403650 ' ,Israel,587917,gorlin syndrome,"""gard:0007166""",
5101,patisiran,ONPATTRO,6/14/2012,treatment of transthyretin-mediated amyloidosis,Designated/Approved,,,ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,8/10/2018,8/10/2025,ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,"Alnylam Pharmaceuticals, Inc.",300 Third Street,,Cambridge,Maryland,' 02142 ' ,United States,371112,amyloidosis,"""gard:0018676""",
5102,Patupilone,,10/4/2005,treatment of ovarian cancer.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceutical Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,210205,ovarian cancer,"""gard:0007295""",
5103,patupilone,,2/2/2010,treatment of primary pertitoneal cancer.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,298909,,,
5104,patupilone,,2/2/2010,treatment of primary fallopian tube cancer.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,298809,,,
5105,Pax7+ Satellite Stem Cell Therapy,,7/21/2020,treatment of duchenne muscular dystrophy.,Designated,,Not FDA Approved for Orphan Indication,,,,,Vita Therapeutics,1812 Ashland Street,Suite 110,Baltimore,Maryland,' 21205 ' ,United States,749920,muscular dystrophy,"""gard:0007922""",
5106,Paxalisib,,8/21/2020,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Kazia Therapeutics Limited,ACN 063 259 754,"Level 24, 300 Barangaroo Avenue",Sydney,NSW,' 2000 ' ,Australia,759220,,,
5107,Paxalisib (INN and USAN),,6/15/2022,treatment of atypical teratoid/rhabdoid tumors (at/rt),Designated,,Not FDA Approved for Orphan Indication,,,,,Kazia Therapeutics Limited,ACN 063 259 754,"Level 24, 300 Barangaroo Avenue",Sydney,New South Whales,' 02000 ' ,Australia,892422,rhabdoid tumor,"""gard:0007572""",
5108,pazopanib,,10/9/2019,treatment of hereditary hemorrhagic telangiectasia,Designated,,Not FDA Approved for Orphan Indication,,,,,HHT Foundation International (d/b/a Cure HHT),8 Henderson Hill Ct,,Monkton,Maryland,' 21111 ' ,United States,705819,hereditary hemorrhagic telangiectasia,"""gard:0006626""",
5109,pazopanib,Votrient,10/20/2009,treatment of soft tissue sarcomas,Designated/Approved,,,Advanced soft tissue sarcoma (STS) who have received prior chemotherapy,4/26/2012,4/26/2019,,Novartis Pharmaceuticals Corp,1 Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,293809,soft tissue sarcoma,"""gard:0004898""",
5110,pazopanib,,5/6/2013,treatment of ovarian cancer.,Designated/Designation Withdrawn or Revoked,6/19/2020,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,"One Health Plaza, 337/B17.5F",,East Hanover,New Jersey,' 07936 ' ,United States,383912,ovarian cancer,"""gard:0007295""",
5111,"PEG-b-PLA micelles containing (1) paclitaxel, (2) sirolimus (rapamycin) and (3) tanespimycin (17-AAG)(also known as: triolimus)",,4/2/2015,treatment of angiosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Co-D Therapeutics, Inc.",1625 Kings Mill Way,Suite 205,Madison,Wisconsin,' 53718 ' ,United States,469915,angiosarcoma,"""gard:0020900""",
5112,PEG-glucocerebrosidase,,12/9/1992,for use as chronic enzyme replacement therapy in patients with gaucher's disease who are deficient in glucocerebrosidase.,Designated,,Not FDA Approved for Orphan Indication,,,,,"National Institute of Mental Health, NIH",49 Convent Dr. MSC4405,"Bldg. 49, Room B1EE16",Bethesda,Maryland,' 20892 ' ,United States,71492,,,
5113,PEG-interleukin-2,,2/1/1990,treatment of primary immunodeficiencies associated with t-cell defects.,Designated,,Not FDA Approved for Orphan Indication,,,,,Chiron Corporation,4560 Horton Street,,Emeryville,California,' 94608 ' ,United States,42589,,,
5114,Pegademase bovine,Adagen,5/29/1984,for enzyme replacement therapy for ada deficiency in patients with severe combined immunodeficiency.,Designated/Approved,,,,3/21/1990,3/21/1997,,"Sigma-tau Pharmaceuticals, Inc.",9841 Washingtonian Blvd,Suite 500,Gaithersburg,Maryland,' 20878 ' ,United States,2084,severe combined immunodeficiency,"""gard:0007628""",
5115,pegargiminase,,7/21/2014,treatment of mesothelioma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Polaris Group,"10675 Sorrento Valley Road, Suite 200",,San Diego,California,' 92121 ' ,United States,437014,,,
5116,PEGASEMP¿(doxorubicin hydrochloride in a lipid-based pegylated nanoparticle modified with a 31 aminoacid peptide targeting nucleolin),,3/15/2018,treatment of mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"TREAT U, S.A.",Parque Industrial de Taveiro,Lote 44,Taveiro,Coimbra,' ' ,Portugal,628318,,,
5117,Pegaspargase,Oncaspar; Asparlas,10/20/1989,treatment of acute lymphocytic leukemia.,Designated/Approved,,,Combination chemotherapy for the treatment of patients with acute lymphoblastic leukemia who are hypersensitive to native forms of L-asparaginase.,2/1/1994,2/1/2001,,Servier Pharmaceuticals LLC,200 Pier Four Blvd,,Boston,Massachusetts,' 02210 ' ,United States,39589,,,
5118,Pegaspargase,Oncaspar; Asparlas,10/20/1989,treatment of acute lymphocytic leukemia.,Designated/Approved,,,ASPARLAS is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.,12/20/2018,,,Servier Pharmaceuticals LLC,200 Pier Four Blvd,,Boston,Massachusetts,' 02210 ' ,United States,39589,,,
5119,pegcetacoplan,,12/19/2018,treatment of c3 glomerulopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Apellis Pharmaceuticals, Inc.",6400 Westwind Way,Suite A,Crestwood,Kentucky,' 40014 ' ,United States,633418,c3 glomerulopathy,"""gard:0017507""",
5120,pegcetacoplan,,6/7/2022,treatment of immune complex-membranoproliferative glomerulonephritis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Apellis Pharmaceuticals, Inc.",100 5th Ave,3rd floor,Waltham,Massachusetts,' 02451 ' ,United States,799620,,,
5121,Pegcetacoplan,,4/24/2023,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Apellis Pharmaceuticals, Inc.",100 5th Ave,3rd floor,Waltham,Massachusetts,' 02451 ' ,United States,817321,amyotrophic lateral sclerosis,"""gard:0005786""",
5122,pegcetacoplan,Empaveli,4/20/2014,treatment of paroxysmal nocturnal hemoglobinuria,Designated/Approved,,,Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH),5/14/2021,5/14/2028,Treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH),"Apellis Pharmaceuticals, Inc.",100 Fifth Avenue,,Waltham,Massachusetts,' 02451 ' ,United States,427614,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
5123,pegcetacoplan,,2/1/2019,treatment of autoimmune hemolytic anemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Apellis Pharmaceuticals, Inc.","100 Fifth Avenue, 3rd Floor",,Waltham,Massachusetts,' 02451 ' ,United States,627018,autoimmune hemolytic anemia,"""gard:0005870""",
5124,Pegfilgrastim,Neulasta,11/20/2013,treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident,Designated/Approved,,,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome),11/13/2015,11/13/2022,To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome),"Amgen, Inc.",One Amgen Center Drive,M/S 17-1-C,Thousand Oaks,California,' 91320 ' ,United States,413013,,,
5125,Peginterferon alfa-2a,,7/13/1998,treatment of renal cell carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Hoffman-La Roche Inc.,340 Kingsland St.,,Nutley,New Jersey,' 07110 ' ,United States,113898,renal cell carcinoma,"""gard:0013215""",
5126,Peginterferon alfa-2a,,9/30/1999,treatment of chronic myelogenous leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,Hoffman-La Roche Inc.,340 Kingsland St.,,Nutley,New Jersey,' 07110 ' ,United States,125299,,,
5127,peginterferon alfa-2b,Sylatron,4/9/2008,treatment of malignant melanoma stages iib through iv.,Designated/Approved,,,Adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy,3/29/2011,,,"Merck, Sharpe & Dohme Corp.",1 Merck Drive,,Whitehouse Station,New Jersey,' 08889 ' ,United States,249507,noma,"""gard:0004001""",
5128,Peginterferon lambda-1a,,8/25/2017,treatment of hepatitis delta virus infection,Designated,,Not FDA Approved for Orphan Indication,,,,,"Eiger BioPharmaceuticals, Inc.",350 Cambridge Avenue,Suite 350,Palo Alto,California,' 94306 ' ,United States,594817,hepatitis delta,"""gard:0021716""",
5129,pegloticase,Krystexxa,2/21/2001,to control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective,Designated/Approved,,,Treatment of chronic gout in adult patients refractory to conventional treatment,9/14/2010,9/14/2017,,Horizon Therapeutics Ireland DAC,70 St. Stephen’s Green,,Dublin,,' 2 D02 E2X4 ' ,Ireland,135600,,,
5130,pegloticase,Krystexxa,2/21/2001,to control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.,Designated/Approved,,,Treatment of chronic gout in adult patients refractory to conventional therapy,7/7/2022,,,Horizon Therapeutics Ireland DAC,70 St. Stephen’s Green,,Dublin,,' 2 D02 E2X4 ' ,Ireland,135600,,,
5131,pegsitacase,,12/3/2009,treatment of lesch-nyhan syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,Swedish Orphan Biovitrum AB,Tomtebodavägen 23A,,Solna,,' ' ,Sweden,296309,lesch-nyhan syndrome,"""gard:0007226""",
5132,pegvaliase-pqpz,PALYNZIQ,3/8/1995,treatment of hyperphenylalaninemia,Designated/Approved,,,Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management,5/24/2018,5/24/2025,Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management,BioMarin Pharmaceutical Inc.,105 Digital Drive,,Novato,California,' 94949 ' ,United States,88195,,,
5133,Pegvisomant,Somavert,6/24/1997,treatment of acromegaly.,Designated/Approved,,,"Treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate",3/25/2003,3/25/2010,,Sensus Corporation,"Suite 430,",98 San Jacinto Boulevard,Austin,Texas,' 78701 ' ,United States,105097,acromegaly,"""gard:0005725""",
5134,"PEGylated 24-amino acid peptide inhibitor of Interleukin-2, Interleukin-9 and Interleukin-15",,7/15/2019,treatment of cutaneous t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Equillium, Inc.",2223 Avenida de la Playa,Suite 108,La Jolla,California,' 92037 ' ,United States,693019,lymphoma,"""gard:0020548""",
5135,PEGylated aptamer targeting Von Willebrand Factor A1 domain,,9/27/2021,treatment of von willebrand disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Band Therapeutics, LLC",101 Hartwell Ave,Suite #2,Lexington,Massachusetts,' 02421 ' ,United States,838021,von willebrand disease,"""gard:0007867""",
5136,PEGylated aptamer targeting Von Willebrand Factor A1 domain,,12/27/2021,treatment of hemophilia a,Designated,,Not FDA Approved for Orphan Indication,,,,,"Band Therapeutics, LLC",101 Hartwell Ave,Suite #2,Lexington,Massachusetts,' 02421 ' ,United States,853621,hemophilia,"""gard:0010418""",
5137,pegylated arginine deiminase,,3/26/1999,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Polaris Pharmaceuticals, Inc.",A Polaris Group Company,6370 Nancy Ridge Drive,San Diego,California,' 92121 ' ,United States,118398,hepatocellular carcinoma,"""gard:0016773""",
5138,Pegylated arginine deiminase,,4/12/1999,treatment of invasive malignant melanoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Polaris Pharmaceuticals, Inc.",A Polaris Group Company,Suite 106,San Diego,California,' 92121 ' ,United States,120898,noma,"""gard:0004001""",
5139,pegylated carboxyhemoglobin,,10/21/2010,treatment of acute painful sickling crises in patients with sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sangart, Inc.",6175 Lusk Blvd,,San Diego,California,' 92121 ' ,United States,315210,,,
5140,pegylated carboxyhemoglobin bovine,,1/15/2015,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Prolong Pharmaceuticals, LLC",300 B Corporate Court,,South Plainfield,New Jersey,' 07080 ' ,United States,407713,,,
5141,Pegylated Glucagon Receptor Agonist,,5/17/2021,treatment of congenital hyperinsulinism,Designated,,Not FDA Approved for Orphan Indication,,,,,Pegbio Co. Ltd.,"Suite 420, Building A3","Biobay, 218 Xing Hu Street",Suzhou,Jiangsu,' 215123 ' ,China,815621,,,
5142,pegylated granulocyte colony stimulating factor,,4/30/2014,treatment of patients at risk of developing myelosuppression following a radiological or nuclear incident,Designated,,Not FDA Approved for Orphan Indication,,,,,PharmaEssentia,"13 F, No.3, YuanQu Street",,Taipei,,' ' ,Taiwan,426514,,,
5143,Pegylated Iron Oxide Nanoparticles,,6/26/2023,as a diagnostic for the management of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"MegaPro Biomedical Company, Ltd.","10F-1, No. 66, Shengyi 5th RD.",,Zhubei City,Hsinchu,' 302 ' ,Taiwan,945123,hepatocellular carcinoma,"""gard:0016773""",
5144,Pegylated Liposomal Alendronate with Doxorubicin,,11/8/2021,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,LEVCO Pharmaceuticals Ltd.,Shlomo Momo Halevi St. 5,,Jerusalem,Israel,' 9777019 ' ,Israel,844921,soft tissue sarcoma,"""gard:0004898""",
5145,pegylated proline interferon alpha-2b,,4/10/2014,treatment of myelofibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,PharmaEssentia,"13F, No 3, YuanQu Street",,Taipei,,' ' ,Taiwan,424414,,,
5146,pegylated proline interferon alpha-2b,,4/11/2014,treatment of essential thrombocythemia,Designated,,Not FDA Approved for Orphan Indication,,,,,PharmaEssentia,"13F, No 3, YuanQu Street",,Taipei,,' ' ,Taiwan,424514,essential thrombocythemia,"""gard:0006594""",
5147,PEGylated recombinant anti-Pseudomonas aeruginosa PcrV Fab' antibody,,10/25/2013,treatment of cystic fibrosis patients with pseudomonas aeruginosa lung infections,Designated,,Not FDA Approved for Orphan Indication,,,,,"KaloBios Pharmaceuticals, Inc.",442 Littlefield Avenue,,South San Francisco,California,' 94080 ' ,United States,398013,cystic fibrosis,"""gard:0006233""",
5148,PEGylated recombinant human hyaluronidase PH20,,10/1/2014,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Halozyme Therapeutics, Inc.",11388 Sorrento Valley Road,,San Diego,California,' 92121 ' ,United States,447914,,,
5149,pegylated recombinant human interleukin-10,,7/18/2016,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,9/21/2023,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,528416,,,
5150,Pegylated recombinant human megakaryocyte growth and development factor,,10/20/1997,for reducing the period of thrombocytopenia in patients undergoing hematopoietic stem cell transplantation.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Dr.,,Thousand Oaks,California,' 91320 ' ,United States,107097,,,
5151,PEGylated recombinant human tumor necrosis factor-related apoptosis inducing ligand,,5/20/2020,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Theraly Fibrosis, Inc.","20271 Goldenrod Lane, Suite 2046",,Germantown,Maryland,' 20876 ' ,United States,737920,systemic sclerosis,"""gard:0009748""",
5152,PEGylated recombinant human tumor necrosis factor-related apoptosis inducing ligand,,9/5/2019,treatment of chronic pancreatitis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Theraly Fibrosis, Inc.","20271 Goldenrod Lane, Suite 2046",,Germantown,Maryland,' 20876 ' ,United States,699619,,,
5153,"PEGylated, Engineered, Human Cystathionine gamma-Lyase",,10/22/2020,treatment of homocystinuria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Spyre Therapeutics, Inc.",221 Crescent Street,"Building 17, Suite 102B",Waltham,Massachusetts,' 02453 ' ,United States,774220,cystinuria,"""gard:0006237""",
5154,pegzilarginase,,3/16/2015,treatment of arginase i deficiency (hyperargininemia).,Designated,,Not FDA Approved for Orphan Indication,,,,,Immedica Pharma AB,Solnavägen 3H,,Stockholm,,' 113 63 ' ,Sweden,466614,argininemia,"""gard:0005840""",
5155,pelareorep,,2/24/2015,treatment of fallopian tube cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.","210, 1167 Kensington Crescent NW",,Calgary,,' ' ,Canada,470115,,,
5156,pelareorep,,2/24/2015,treatment of primary peritoneal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.","210, 1167 Kensington Crescent NW",,Calgary,,' ' ,Canada,470215,,,
5157,pelareorep,,4/15/2015,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.","210, 1167 Kensington Crescent NW",,Calgary,,' ' ,Canada,472915,,,
5158,pelareorep,,5/4/2015,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.","210, 1167 Kensington Crescent NW",,Calgary,,' ' ,Canada,478315,,,
5159,pelareorep,,2/10/2015,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.","210, 1167 Kensington Crescent NW",,Calgary,,' ' ,Canada,464414,ovarian cancer,"""gard:0007295""",
5160,pelareorep,,2/11/2015,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Oncolytics Biotech, Inc.","210, 1167 Kensington Crescent NW",,Calgary,,' ' ,Canada,464514,,,
5161,Pelcitoclax,,9/23/2020,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,' 20850 ' ,United States,766320,small cell lung cancer,"""gard:0009344""",
5162,Peldesine,,10/5/1993,treatment of cutaneous t-cell lymphoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioCryst Pharmaceuticals, Inc.",2190 Parkway Lake Drive,,Birmingham,Alabama,' 35244 ' ,United States,76293,lymphoma,"""gard:0020548""",
5163,Pemafibrate,,4/20/2023,treatment of primary biliary cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kowa Research Institute, Inc.","430 Davis Drive, Suite 200",,Morrisville,North Carolina,' 27560 ' ,United States,934223,primary biliary cholangitis,"""gard:0007459""",
5164,pembrolizumab,Keytruda,10/9/2019,treatment of biliary tract carcinoma,Designated/Approved,,,"in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC)",10/31/2023,10/31/2030,treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC),"Merck Sharp & Dohme, LLC",126 East Lincoln Avenue,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,705319,noma,"""gard:0004001""",
5165,pembrolizumab,Keytruda,6/16/2015,"treatment of gastric cancer, including gastroesophageal junction adenocarcinoma",Designated/Approved,,,"in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma",11/16/2023,11/16/2030,"for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma, excluding patients covered by Keytruda's previous indications for gastric or GEJ adenocarcinoma",Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,481715,noma,"""gard:0004001""",
5166,pembrolizumab,,6/6/2017,treatment of follicular lymphoma.,Designated/Designation Withdrawn or Revoked,2/4/2022,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp",1 Merck Access Road,,Whitehouse Station,New Jersey,' 08889 ' ,United States,570816,lymphoma,"""gard:0020548""",
5167,pembrolizumab,Keytruda,6/15/2017,treatment of esophageal carcinoma,Designated/Approved,,,"treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation, in combination with platinum- and fluoropyrimidine-based chemotherapy",3/22/2021,3/22/2028,"treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation, excluding patients covered by Keytruda¿s previously approved indication for esophageal cancer","Merck Sharp & Dohme, LLC",126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,578717,noma,"""gard:0004001""",
5168,pembrolizumab,Keytruda,6/12/2017,treatment of hepatocellular carcinoma (hcc),Designated/Approved,,,treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen,1/25/2024,1/25/2031,treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen and other than sorafenib,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,576917,hepatocellular carcinoma,"""gard:0016773""",
5169,pembrolizumab,Keytruda,6/12/2017,treatment of hepatocellular carcinoma (hcc),Designated/Approved,,,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,11/9/2018,11/9/2025,KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,576917,hepatocellular carcinoma,"""gard:0016773""",
5170,pembrolizumab,,2/17/2016,treatment of multiple myeloma.,Designated/Designation Withdrawn or Revoked,2/4/2022,Not FDA Approved for Orphan Indication,,,,,"Merck, Sharp & Dohme Corp.",One Merck Drive,,Whitehouse Station,New Jersey,' 08889 ' ,United States,513115,multiple myeloma,"""gard:0007108""",
5171,pembrolizumab,Keytruda,11/19/2012,treatment of stage iib through iv malignant melanoma,Designated/Approved,,,"adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection",12/3/2021,12/3/2028,"adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma following complete resection, and adjuvant treatment of pediatric (12 years and older) patients with Stage III melanoma following complete resection",Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,381012,noma,"""gard:0004001""",
5172,pembrolizumab,Keytruda,11/19/2012,treatment of stage iib through iv malignant melanoma,Designated/Approved,,,Treatment of patients with unresectable or metastatic melanoma.,12/18/2015,12/18/2022,Initial treatment of patients with unresectable or metastatic melanoma,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,381012,noma,"""gard:0004001""",
5173,pembrolizumab,,10/11/2016,treatment of nasopharyngeal carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,511715,nasopharyngeal carcinoma,"""gard:0007163""",
5174,pembrolizumab,Keytruda,6/15/2017,treatment of esophageal carcinoma,Designated/Approved,,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.",7/30/2019,7/30/2026,"Indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (Combined Positive Score [CPS] =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.","Merck Sharp & Dohme, LLC",126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,578717,noma,"""gard:0004001""",
5175,pembrolizumab,Keytruda,11/19/2012,treatment of stage iib through iv malignant melanoma,Designated/Approved,,,"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.",9/4/2014,9/4/2021,,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,381012,noma,"""gard:0004001""",
5176,pembrolizumab,Keytruda,11/19/2012,treatment of stage iib through iv malignant melanoma,Designated/Approved,,,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.,2/15/2019,2/15/2026,KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,381012,noma,"""gard:0004001""",
5177,pembrolizumab,Keytruda,6/16/2015,"treatment of gastric cancer, including gastroesophageal junction adenocarcinoma",Designated/Approved,,,"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy (Indication withdrawn)",9/22/2017,2/4/2022,"Treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) >or =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu targeted therapy excluding microsatellite instability-high or mismatch repair deficient gastric or gastroesophageal adenocarcinomas that have progressed and have no satisfactory alternative treatment options (Indication withdrawn)",Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,481715,noma,"""gard:0004001""",
5178,pembrolizumab,Keytruda,6/16/2015,"treatment of gastric cancer, including gastroesophageal junction adenocarcinoma",Designated/Approved,,,"in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma",5/5/2021,5/5/2028,"for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma, excluding patients covered by Keytruda's previous indication for gastric or GEJ adenocarcinoma approved on September 22, 2017",Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,481715,noma,"""gard:0004001""",
5179,pembrolizumab,KEYTRUDA,12/30/2015,treatment of hodgkin lymphoma.,Designated/Approved,,,"Treatment for adult and pediatric patients with refractory classical Hodgkin Lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy.",3/14/2017,3/14/2024,"Treatment of adult and pediatric patients with refractory classical Hodgkin Lymphoma, or who have relapsed after 3 or more prior lines of therapy.",Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rathway,Pennsylvania,' 07065 ' ,United States,502415,lymphoma,"""gard:0020548""",
5180,pembrolizumab,Keytruda,1/14/2016,treatment of primary mediastinal b cell lymphoma.,Designated/Approved,,,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy",6/13/2018,6/13/2025,"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy",Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,495415,lymphoma,"""gard:0020548""",
5181,pembrolizumab,Keytruda,12/28/2016,treatment of merkel cell carcinoma,Designated/Approved,,,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma,12/19/2018,12/19/2025,KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,548216,noma,"""gard:0004001""",
5182,pembrolizumab,Keytruda,10/3/2017,treatment of small cell lung cancer,Designated/Approved,,,KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. (Indication withdrawn),6/17/2019,3/30/2021,Indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. (Indication withdrawn),"Merck Sharp & Dohme, LLC",126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,605417,small cell lung cancer,"""gard:0009344""",
5183,pemetrexed disodium,Alimta,8/28/2001,treatment of malignant pleural mesothelioma,Designated/Approved,,,Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery,2/4/2004,2/4/2011,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,145101,pleural mesothelioma,"""gard:0007026""",
5184,pemigatinib,Pemazyre,8/21/2019,"treatment of myeloid/lymphoid neoplasms with eosinophilia and rearrangement of pdgfra, pdgfrb, or fgfr1, or with pcm1-jak2",Designated/Approved,,,Treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement,8/26/2022,8/26/2029,Treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,696419,,,
5185,Pemigatinib,PEMAZYRE,3/12/2018,treatment of cholangiocarcinoma,Designated/Approved,,,"PEMAZYRE is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test",4/17/2020,4/17/2027,"For the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.",Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,624117,cholangiocarcinoma,"""gard:0009304""",
5186,Penpulimab,,2/23/2021,treatment of nasopharyngeal carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Akeso Biopharma, Inc.","6 Shennong Road, Torch Development Zone",,Zhongshan,Guangdong,' 528437 ' ,China,802020,nasopharyngeal carcinoma,"""gard:0007163""",
5187,pentagastrin,,4/21/2020,diagnostic for the management of medullary thyroid cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Exela Pharma Sciences, LLC",1245 Blowing Rock Blvd.,,Lenoir,North Carolina,' 28645 ' ,United States,689719,,,
5188,pentagastrin,,5/29/2009,to aid in the diagnosis of medullary thyroid carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,AOP Orphan IP AG,Staedtle 28,P.O. Box 838,Vaduz,,' ' ,Liechtenstein,277509,thyroid carcinoma,"""gard:0019763""",
5189,pentamidine,,8/12/2013,treatment of liver and intrahepatic bile duct cancer,Designated/Designation Withdrawn or Revoked,7/28/2015,Not FDA Approved for Orphan Indication,,,,,"Verlyx Pharma, Inc.","555 Rene-Levesque West, 9th Floor",,Montreal,,' ' ,Canada,389312,,,
5190,pentamidine,,9/13/2010,treatment of pancreatic cancer.,Designated/Designation Withdrawn or Revoked,10/14/2014,Not FDA Approved for Orphan Indication,,,,,"Oncozyme Pharma, Inc.",555 Rene-Levesque West - 9th Floor,,Montreal,,' ' ,Canada,279709,,,
5191,pentamidine,,8/12/2013,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,10/14/2014,Not FDA Approved for Orphan Indication,,,,,"Oncozyme Pharma, Inc.",555 Rene-Levesque West,,Montreal,,' ' ,Canada,389212,ovarian cancer,"""gard:0007295""",
5192,Pentamidine isethionate,,10/29/1984,treatment of pneumocystis carinii pneumonia.,Designated,,Not FDA Approved for Orphan Indication,,,,,Aventis Behring L.L.C.,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,3784,,,
5193,Pentamidine isethionate,Pentam 300,2/28/1984,treatment of pneumocystis carinii pneumonia.,Designated/Approved,,,,10/16/1984,10/16/1991,,"Fujisawa USA, Inc.",3 Parkway North Center,,Deerfield,Illinois,' 60015 ' ,United States,1083,,,
5194,Pentamidine isethionate,Nebupent,1/12/1988,prevention of pneumocystis carinii pneumonia in patients at high risk of developing this disease.,Designated/Approved,,,,6/15/1989,6/15/1996,,"Fujisawa USA, Inc.",3 Parkway North Center,,Deerfield,Illinois,' 60015 ' ,United States,25887,,,
5195,Pentamidine isethionate (inhalation),,10/5/1987,prevention of pneumocystis carinii pneumonia in patients at high risk of developing this disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Fisons Corporation,"755 Jefferson Rd., P.O. Box 1710",,Rochester,New York,' 14603 ' ,United States,21187,,,
5196,pentapeptide with sequence Ac-VSRRR-NH2,,1/13/2015,treatment of intracerebral hemorrhage,Designated,,Not FDA Approved for Orphan Indication,,,,,"AegisCN, LLKC",3105 Cone Manor Lane,Suite B,Raleigh,North Carolina,' 27613 ' ,United States,449014,,,
5197,"Pentasaccharide ethyl glycoside consisting of one alpha-D-sialylosyl residue as a sodium salt, two beta-D-galactopyranosyl residues, one 2-acetamido-beta-D-glucopyranosyl unit, and one alpha-L-fucopyranosyl unit",,7/18/1997,treatment of neonates and infants undergoing cardiopulmonary bypass during surgical repair of congenital heart lesions.,Designated,,Not FDA Approved for Orphan Indication,,,,,Cytel Corporation,3525 John Hopkins Court,,San Diego,California,' 92121 ' ,United States,106297,,,
5198,Pentastarch,Pentaspan,8/28/1985,as an adjunct in leukapheresis to improve the harvesting and increase the yield of leukocytes by centrifugal means.,Designated/Approved,,,,5/19/1987,5/19/1994,,DuPont Pharmaceuticals,E.I. Du Pont De Nemours & Co.,,Wilmington,Delaware,' 19880 ' ,United States,8085,,,
5199,pentetate trisodium,,4/12/2004,"treatment of patients with known or suspected internal contamination with plutonium, americium, or curium.",Designated,,Not FDA Approved for Orphan Indication,,,,,Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG,Goerzallee 253,,Berlin,,' ' ,Germany,183004,,,
5200,pentetrazol,,3/16/2017,treatment of narcolepsy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Balance Therapeutics, Inc.",533 Airport Blvd.,Suite 400,Burlingame,California,' 94010 ' ,United States,558716,narcolepsy,"""gard:0022460""",
5201,pentetrazol,,9/9/2015,treatment of idiopathic hypersomnia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Balance Therapeutics, Inc.",1250 Bayhill Drive,Suite 125,San Bruno,California,' 94066 ' ,United States,488815,idiopathic hypersomnia,"""gard:0008737""",
5202,pentosan polysulfate,,4/28/2020,treatment of mucopolysaccharidosis type 1,Designated,,Not FDA Approved for Orphan Indication,,,,,Paradigm Biopharmaceuticals Ltd.,"Level 2, 517 Flinders Lane",,Melbourne,Victoria,' ' ,Australia,741920,mucopolysaccharidosis type 1,"""gard:0010335""",
5203,Pentosan polysulfate sodium,Elmiron,8/7/1985,treatment of interstitial cystitis.,Designated/Approved,,,Relief of bladder pain or discomfort associated with interstitial cystitis.,9/26/1996,9/26/2003,,Alza Corporation,950 Page Mill Rd.,PO Box 10950,Palo Alto,California,' 94303 ' ,United States,1784,interstitial cystitis,"""gard:0018825""",
5204,pentosan polysulfate sodium,,9/16/2011,treatment of sickle cell disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vanguard Therapeutics, Inc.",108 Eagle Trace Drive,,Half Moon Bay,California,' 94019 ' ,United States,352311,,,
5205,pentosan polysulfate sodium,,11/21/2008,treatment of sickle cell disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"TRF Pharma, Inc.",863 Mitten Road,,Burlingame,California,' 94010 ' ,United States,251607,,,
5206,pentosan polysulfate sodium,,1/5/2015,treatment of mucopolysaccharidosis (mps) type vi,Designated,,Not FDA Approved for Orphan Indication,,,,,Paradigm Biopharmaceuticals Ltd.,"Level 15, 500 Collins Street",,Melbourne,Victoria,' ' ,Australia,458614,mucopolysaccharidosis,"""gard:0007065""",
5207,Pentostatin,,1/29/1991,treatment of patients with chronic lymphocytic leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,' 94568 ' ,United States,50390,,,
5208,Pentostatin,,3/27/1998,treatment of cutaneous t-cell lymphoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,' 94568 ' ,United States,111998,lymphoma,"""gard:0020548""",
5209,Pentostatin,,11/24/1999,treatment of peripheral t-cell lymphomas.,Designated,,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,' 94568 ' ,United States,123899,lymphoma,"""gard:0020548""",
5210,pentostatin for injection,Nipent,9/10/1987,treatment of hairy cell leukemia,Designated/Approved,,,Single agent treatment for adult patients with alpha-interferon-refractory hairy cell leukemia.,10/11/1991,10/11/1998,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,' 94568 ' ,United States,21287,,,
5211,pentoxifylline,,6/14/2012,treatment of behcet's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Silk Road Therapeutics,641 S Street Northwest,3rd Floor,Washington,District of Columbia,' 20001 ' ,United States,369712,,,
5212,peptide 144 TGF beta-1 inhibitor,,4/27/2006,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Digna Biotech, S.L.",Calloe ORENSE No. 85,2nd Floor,Madrid,,' ' ,Spain,219506,systemic sclerosis,"""gard:0009748""",
5213,Peptide 144 TGF beta-1-inhibitor,,4/26/2006,treatment of localized scleroderma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Digna Biotech, S.L.",Calloe ORENSE No. 85,2nd Floor,Madrid,,' ' ,Spain,221006,scleroderma,"""gard:0018705""",
5214,peptide conjugated phosphorodiamidate morpholino oligomer,,11/12/2020,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sarepta Therapeutics, Inc.",215 First Street,,Cambridge,Massachusetts,' 02142 ' ,United States,745120,muscular dystrophy,"""gard:0007922""",
5215,peptide conjugated phosphorodiamidate morpholino oligomer,,9/8/2020,treatment for hutchinson-gilford progeria syndrome and progeroid laminopathies,Designated,,Not FDA Approved for Orphan Indication,,,,,,,,,,' ' ,,768520,hutchinson-gilford progeria syndrome,"""gard:0007467""",
5216,Peptide consisting of L-amino acids with the sequence H-lys-glu-phe-leu-his-pro-ser-lys-val-asp-leu-pro-arg-OH,,6/29/2016,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Soricimed Biopharma, Inc.",18 Botsford Street,Suite 201,Moncton,,' ' ,Canada,526016,,,
5217,peptide fraction derived from porcine brain protein,,4/5/2016,"treatment of frontotemporal dementia, including all subvariants",Designated,,Not FDA Approved for Orphan Indication,,,,,EVER Neuro Pharma GmbH,3 Oberburgau,,4866 Unterach,Salzburg,' ' ,Austria,513315,frontotemporal dementia,"""gard:0008436""",
5218,peptide fraction derived from porcine brain protein,,5/8/2018,treatment of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (cadasil),Designated,,Not FDA Approved for Orphan Indication,,,,,EVER Neuro Pharma GmbH,3 Oberburgau,,4866 Unterach,Salzburg,' ' ,Austria,582617,,,
5219,Peptide inhibiting murine double minute 2 (MDM2) and murine double minute X (MDMX),,4/19/2017,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aileron Therapeutics, Inc.",81 Albany Street,,Cambridge,Massachusetts,' 02139 ' ,United States,565316,acute myeloid leukemia,"""gard:0012757""",
5220,Peptide Inhibitor of Complement C1,,1/29/2020,treatment of neonatal hypoxic-ischemic encephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"ReAlta Life Sciences, Inc.","4211 Monarch Way, Suite 102",,Norfolk,Virginia,' 23508 ' ,United States,722719,,,
5221,Peptide that inhibits mechanosensitive ion channel (MSC) activity,,9/15/2010,treatment of duchenne muscular dystrophy (dmd.),Designated,,Not FDA Approved for Orphan Indication,,,,,Rose Pharmaceuticals,8210 Godlen Oak Circle,,Williamsville,New York,' 14221 ' ,United States,315710,muscular dystrophy,"""gard:0007922""",
5222,peptide YY,,4/18/2011,treatment of hepatocellular carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Mondobiotech Laboratories AG,Herrengasse 21,,Furstentum Liechtenstein,,' ' ,Germany,338911,hepatocellular carcinoma,"""gard:0016773""",
5223,peptide-based vaccine targeting telomerase reverse transcriptase,,2/20/2009,treatment of telomerase reverse transcriptase (tert) positive non-small cell lung cancer in hla-a*0201 positive patients,Designated,,Not FDA Approved for Orphan Indication,,,,,VAXON-Biotech,3 Rue de l'Arrivée,,Paris,Île-de-France,' ' ,France,272108,small cell lung cancer,"""gard:0009344""",
5224,peptide-conjugated phosporodiamidate morpholino oligomer (PPMO),,9/3/2009,"treatment of duchenne muscular dystrophy in patients with a deletion, duplication or frame shift mutation correctable by skipping of exon 50 of the dystrophin gene to allow restoration of the reading frame (including mutations within exons 51, 51-53, or 5",Designated/Designation Withdrawn or Revoked,2/14/2020,Not FDA Approved for Orphan Indication,,,,,"Sarepta Therapeutics, Inc.",215 First Street,,Cambridge,Massachusetts,' 02142 ' ,United States,286009,muscular dystrophy,"""gard:0007922""",
5225,"peptide-drug conjugate combining [(Tyr3,Cys8) octreotate amide] and N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl) maytansine",,11/20/2018,treatment of neuroendocrine tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tarveda Therapeutics, Inc.",134 Coolidge Ave.,,Watertown,Massachusetts,' 02472 ' ,United States,630018,,,
5226,"peptide-drug conjugate combining [(Tyr3,Cys8) octreotate amide] and N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl) maytansine",,2/15/2019,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tarveda Therapeutics, Inc.",134 Coolidge Ave.,,Watertown,Massachusetts,' 02472 ' ,United States,673318,small cell lung cancer,"""gard:0009344""",
5227,peptides mimicking antigen receptors on autoimmune B cells and autoimmune T cells associated with myasthenia gravis,,2/4/2011,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,CuraVac Europe SA,Avenue de Villefranche,,Rixensart,,' ' ,Belgium,332610,myasthenia gravis,"""gard:0007122""",
5228,perampanel,,12/7/2012,treatment of lennox-gastaut syndrome,Designated/Designation Withdrawn or Revoked,5/1/2024,Not FDA Approved for Orphan Indication,,,,,Eisai Inc.,200 Metro Blvd.,,Nutley,New Jersey,' 07110-6102 ' ,United States,380912,lennox-gastaut syndrome,"""gard:0009912""",
5229,peretinoin,,9/23/2011,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Kowa Pharmaceutical Europe GmbH,Duiburger Landstassa,,Dusseldorf,,' ' ,Germany,352011,hepatocellular carcinoma,"""gard:0016773""",
5230,Perflubron,,4/26/2001,treatment of acute respiratory distress disease (ards) in adults,Designated,,Not FDA Approved for Orphan Indication,,,,,PFC Development/New Alliance Pharmaceutical,15021 Venture Blvd,,Sherman Oaks,California,' 91403 ' ,United States,141100,,,
5231,perfluorooctyl-bromide,,8/8/2019,treatment of congenital pulmonary hypoplasia in infancy,Designated,,Not FDA Approved for Orphan Indication,,,,,Children’s Hospital of Pennsylvania,Clinical Research Support,"Colket Translational Research Building, 11th Floor, Room 11101",Philadelphia,Pennsylvania,' 19104 ' ,United States,630718,,,
5232,perfluorooctyl-bromide (PFOB),,3/22/2018,treatment of respiratory distress syndrome (rds),Designated,,Not FDA Approved for Orphan Indication,,,,,Children’s Hospital of Pennsylvania,Clinical Research Support,"Colket Translational Research Building, 11th Floor, Room 11101",Philadelphia,Pennsylvania,' 19104 ' ,United States,631018,,,
5233,Perfosfamide,,12/4/1989,"for use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia.",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Scios Nova, Inc.",2450 Bayshore Parkway,,Mountain View,California,' 94043 ' ,United States,37789,,,
5234,Pergolide,,11/20/1997,treatment of tourette's syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Sallee, Floyd R. M.D., Ph.D.",Cincinnati Children's Hospital Medical Center,3333 Burnet Ave.,Cincinnati,Ohio,' 45229 ' ,United States,108197,,,
5235,perhexiline maleate,,6/14/2012,treatment of moderate to severe symptomatic hypertrophic cardiomyopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Heart Metabolics, Limited.",88 Harcourt Street,,Dublin,,' ' ,Ireland,360211,,,
5236,perifosine,,9/3/2009,treatment of multiple myeloma.,Designated/Designation Withdrawn or Revoked,12/20/2013,Not FDA Approved for Orphan Indication,,,,,Aeterna Zentaris GmbH,Weismuellerstrasse 50,,Frankfurt,,' ' ,Germany,290909,multiple myeloma,"""gard:0007108""",
5237,perifosine,,7/9/2010,treatment of neuroblastoma,Designated/Designation Withdrawn or Revoked,3/10/2017,Not FDA Approved for Orphan Indication,,,,,Aeterna Zentaris GmbH,Weismuellerstrasse 50,D-60314 Frankfurt Am Main,Frankfurt Am Main,,' ' ,Germany,310010,neuroblastoma,"""gard:0007185""",
5238,perillyl alcohol,,4/18/2011,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"NeOnc Technologies, Inc.",10524 South La Cienega Blvd.,,Inglewood,California,' 90304 ' ,United States,340411,,,
5239,peritoneal dialysis solution containing combination of D-glucose and L-carnitine,,2/21/2019,treatment of patients with end stage renal disease who require peritoneal dialysis,Designated,,Not FDA Approved for Orphan Indication,,,,,CoreQuest Sagl,Stabile Suglio Via Cantonale 18,,Manno TI,Tessin,' ' ,Switzerland,599517,,,
5240,"peritoneal dialysis solution containing combination of D-xylitol, D-glucose, L-carnitine",,11/9/2020,treatment of patients with end stage renal disease who are undergoing peritoneal dialysis,Designated,,Not FDA Approved for Orphan Indication,,,,,CoreQuest Sagl,"Stabile Suglio, Via Cantonale 18",,Manno,,' CH-6928 ' ,Switzerland,780220,,,
5241,personalized neoantigen peptide vaccine comprised of 7-25 linear peptides (each peptide containing 20-30 amino acids on average) and poly IC:LC,,2/23/2022,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Anda Biology Medicine Development (Shenzhen) Co., Ltd.","419, R&D Building, Founder Technology Industrial Park","North of Songbai Highway, Shiyan Street, Baoan District,",Shenzhen,People’s Republic of China,' ' ,China,873922,,,
5242,pertuzumab,,6/8/2009,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,6/6/2017,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,MS # 355C,South San Francisco,California,' 94080 ' ,United States,284409,ovarian cancer,"""gard:0007295""",
5243,pertuzumab,,7/12/2013,"treatment of gastric cancer, including gastroesophageal junction cancer",Designated/Designation Withdrawn or Revoked,6/5/2018,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,400713,,,
5244,Pexastimogene Devacirepvec,,9/14/2020,treatment of stage iib-iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"SillaJen, Inc.","6F, 111, Hyoyeol-ro",Suite 200,Buk-gu,Busan,' ' ,South Korea,762820,noma,"""gard:0004001""",
5245,pexastimogene devacirepvec,,5/6/2013,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"SillaJen Biotherapeutics, Inc.",450 Sansome Street,Suite 200,San Francisco,California,' 94111 ' ,United States,394213,hepatocellular carcinoma,"""gard:0016773""",
5246,pexidartinib,TURALIO,2/14/2014,treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath,Designated/Approved,,,TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.,8/2/2019,8/2/2026,For the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery,"Daiichi Sankyo, Inc.",211 Mount Airy Road,,Basking Ridge,New Jersey,' 07920 ' ,United States,419913,,,
5247,PG2 (Astragalus polysaccharides extracted and purified from the dry root of Astragalus membranaceus),,7/5/2012,treatment of idiopathic thrombocytopenic purpura,Designated,,Not FDA Approved for Orphan Indication,,,,,PhytoHealth Corporation,Fl. 5 No. 167,,Taipei,,' ' ,Taiwan,365912,,,
5248,PGC-C12E-terlipressin,,12/27/2012,treatment of ascites due to all etiologies except for cancer,Designated/Designation Withdrawn or Revoked,1/27/2023,Not FDA Approved for Orphan Indication,,,,,PharmaIN Corporation,19805 N. Creek Pkwy,Suite 200,Bothell,Washington,' 98011 ' ,United States,374812,,,
5249,"Phage-derived, non-replicative delivery vector carrying a DNA payload encoding an RNA-guided nuclease that targets stx genes of Shiga toxin-producing Escherichia coli (STEC)",,3/17/2022,treatment of shiga-toxin producing escherichia coli infection as it relates to the prevention of hemolytic uremic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Eligo Bioscience SA,29 rue du Faubourg Saint-Jacques,,Paris,,' 75014 ' ,France,842821,hemolytic uremic syndrome,"""gard:0022233""",
5250,phenobarbital,,10/25/2017,treatment of neonatal seizures,Designated/Designation Withdrawn or Revoked,9/12/2019,Not FDA Approved for Orphan Indication,,,,,"Renaissance SSA, LLC",411 South State Street,Suite E100,Newtown,Pennsylvania,' 18940 ' ,United States,601717,,,
5251,Phenobarbital,,2/26/2020,treatment of neonatal seizures,Designated,,Not FDA Approved for Orphan Indication,,,,,Accord Healthcare Inc.,"1009 Slater Road, Suite 210-B",,Durham,North Carolina,' 27703 ' ,United States,725519,,,
5252,phenobarbital sodium,Sezaby,10/2/2019,treatment of neonatal seizures,Designated/Approved,,,treatment of neonatal seizures in term and preterm infants,11/17/2022,11/17/2029,treatment of neonatal seizures in term and preterm infants,Sun Pharma Advanced Research Company Ltd.,"17/B, Mahal Industrial Estate",,Andheri (E),Mumbai,' ' ,India,703819,,,
5253,Phenobarbital sodium,,3/28/2018,treatment of neonatal seizures,Designated,,Not FDA Approved for Orphan Indication,,,,,Genus Lifesciences,514 North 12th Street,,Allentown,Pennsylvania,' 18102 ' ,United States,633118,,,
5254,Phenobarbital Sodium,,9/30/2020,treatment of neonatal seizures,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hikma Pharmaceuticals USA, Inc.",2 Esterbrook Lane,,Cherry Hill,New Jersey,' 08003 ' ,United States,768420,,,
5255,phenobarbital sodium,,2/26/2020,treatment of status epilepticus,Designated,,Not FDA Approved for Orphan Indication,,,,,Accord Healthcare Inc.,"1009 Slater Road, Suite 210-B",,Durham,North Carolina,' 27703 ' ,United States,725419,,,
5256,phenobarbital sodium,,2/27/2020,treatment of neonatal seizures,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nivagen Pharmaceuticals, Inc.","3050 Fite Circle, Suite 100",,Sacramento,California,' 95827 ' ,United States,725819,,,
5257,phenobarbitol sodium injection,,10/23/2013,treatment of hypoxic-ischemic encephalopathy to prevent siezures in neonates,Designated,,Not FDA Approved for Orphan Indication,,,,,"Fera Pharmaceuticals, LLC",134 Birch Hill Road,,Locust Valley,New York,' 11560 ' ,United States,408413,,,
5258,"phenol, 4-[2-(aminomethyl)-4-thiazolyl]-2,6-bis (1,1-dimethyethyl) monohydrochloride",,3/16/2015,treatment of huntington's disease.,Designated/Designation Withdrawn or Revoked,8/4/2017,Not FDA Approved for Orphan Indication,,,,,"Ipsen Biopharmaceuticals, Inc.",106 Allen Road,3rd Floor,Basking Ridge,New Jersey,' 07920 ' ,United States,468314,,,
5259,Phenylacetate,,3/6/1998,"for use as an adjunct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Elan Drug Delivery, Inc.",1300 Gould Dr.,,Gainesville,Georgia,' 30504 ' ,United States,110698,,,
5260,Phenylbutyrate,,1/19/2000,treatment of acute promyelocytic leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Elan Drug Delivery, Inc.",1300 Gould Dr.,,Gainesville,Georgia,' 30504 ' ,United States,126199,acute promyelocytic leukemia,"""gard:0000538""",
5261,phenylephrine,,2/14/2002,treatment of ileal pouch anal anastomosis related fecal incontinence,Designated,,Not FDA Approved for Orphan Indication,,,,,S.L.A. Pharma,"Unit 3, Hill Farm Industrial Estate",,"Leavesden, Watford",,' ' ,United Kingdom,147201,,,
5262,phenylephrine,,1/31/2012,treatment of tetralogy of fallot,Designated,,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",One Luitpold Drive,P. O. Box 9001,Shirley,New York,' 11967 ' ,United States,359011,tetralogy of fallot,"""gard:0002245""",
5263,"Phosphatidylinositol 3-Kinase ""PI3K"" Inhibitor",,11/2/2010,treatment of chronic lymphocytic leukemia (cll),Designated,,Not FDA Approved for Orphan Indication,,,,,Semafore Pharmaceuticals,17338 Westfield Park Road,Suite 3,Westfield,Indiana,' 46074 ' ,United States,313910,,,
5264,Phosphocysteamine,,9/12/1988,treatment of cystinosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Medea Research Laboratories,Port Jefferson Business Center,"200 Wilson Street, Building D-6",Port Jefferson,New York,' 11776 ' ,United States,29588,cystinosis,"""gard:0006236""",
5265,Phosphorodiamidate morpholino oligomer (5¿- CTATATATAGTTATTCAACA -3¿),,3/4/2020,treatment of spinal muscular atrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shift Pharmaceuticals Holdings, Inc.",8318 West 102nd Street,,Overland Park,Kansas,' 66212 ' ,United States,727019,,,
5266,phosphorothioate antisense olignucleotide against EWS-Fli-1,,9/22/2008,treatment of ewing's sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,The Cure Our Children Foundation,1730 Michael Lane,,Pacific Palisades,California,' 90272 ' ,United States,268208,,,
5267,phosphorothioate oligonucleotide,,11/9/2007,treatment of amyotrophic lateral sclerosis,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Ionis Pharmaceuticals, Inc.",2855 Gazelle Court,,Carlsbad,California,' 92010 ' ,United States,226706,amyotrophic lateral sclerosis,"""gard:0005786""",
5268,photochlor,,5/24/2018,treatment of esophageal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ami Onco-Theranostics, LLC",701 Ellicott Street,Center of Excellence,Buffalo,New York,' 14203 ' ,United States,640418,,,
5269,phoxillum,,2/14/2014,for use as a replacement solution in patients undergoing continuous renal replacement therapy,Designated/Approved,,,As a replacement solution in Continuous Renal Replacement Therapy (CRRT) and in case of drug poisoning when CRRT is used to remove dialzable substances,1/13/2015,1/13/2022,As a replacement solution in Continuous Renal Replacement Therapy (CRRT) and in case of drug poisoning when CRRT is used to remove dialzable substances,"Gambro Renal Products, Inc.",1845 Mason Avenue,,Daytona Beach,Florida,' 32117 ' ,United States,382012,,,
5270,physostigmine salicylatephysostigmine salicylate,,1/16/1985,treatment of friedreich's and other inherited ataxias.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Forest Pharmaceuticals.3-.3-.30 6,150 East 58th Street,,New York,New York,' 10155 ' ,United States,183,,,
5271,picibanil,,3/17/2011,treatment of lymphatic malformations,Designated,,Not FDA Approved for Orphan Indication,,,,,Protara Therapeutics Inc.,"345 Park Avenue South, 3rd Floor",,New York,New York,' 10010 ' ,United States,335811,,,
5272,picibanil,,5/15/2009,treatment of patients with lymphatic malformations,Designated,,Not FDA Approved for Orphan Indication,,,,,"Royds Pharmaceuticals, Inc.",4365 Route 1 South,,Princeton,New Jersey,' 08540 ' ,United States,282009,,,
5273,Picoplatin,,11/2/2005,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Poniard Pharmaceuticals,300 Elliott Avenue West,,Seattle,Washington,' 98119 ' ,United States,212305,small cell lung cancer,"""gard:0009344""",
5274,Picropodophyllin,,7/27/2017,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,MAX Kemikonsult AB,c/o Magnus Axelson,"Hanna Nilssons vag 6, Lgh 1301",Jarfalla,Stockholms län,' SE-176 68 ' ,Sweden,593617,,,
5275,Pigment Epithelium Derived Factor derived short peptide (Ac-Ser-Leu-Gly-Ala-Glu-Gln-Arg-Thr-Glu-Ser-Ile-Ile-His-Arg-Ala- Leu-Tyr-Tyr-Asp-Leu-Ile-Ser-Ser-Pro-Asp-Ile-His-Gly-Thr-NH2),,11/28/2022,treatment of neurotrophic keratitis,Designated,,Not FDA Approved for Orphan Indication,,,,,BRIM Biotechnology,"8F, No.1, Alley 30, Lane 358,","Ruiguang Rd., Neihu Dist.",Taipei,,' 11492 ' ,Taiwan,838321,,,
5276,PIKFYVE antisense oligonucleotide,,10/11/2023,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Takeda Development Centers America,95 Hayden Avenue,,Lexington,Massachusetts,' 02471 ' ,United States,965923,amyotrophic lateral sclerosis,"""gard:0005786""",
5277,Pilocarpine,Salagen,9/24/1990,treatment of xerostomia induced by radiation therapy for head and neck cancer.,Designated/Approved,,,Treatment of symptoms of xerostomia from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck.,3/22/1994,3/22/2001,,"MGI Pharma, Inc.",5775 West Old Shakoppe Rd.,Suite 100,Bloomington,Minnesota,' 55437 ' ,United States,45990,,,
5278,Pilocarpine HCl,Salagen,2/28/1992,treatment of xerostomia and keratoconjunctivitis sicca in sjogren's syndrome patients.,Designated/Approved,,,Treatment of dry mouth in patients with Sjogren's syndrome.,2/11/1998,2/11/2005,,"MGI Pharma, Inc.",5775 West Old Shakoppe Rd.,Suite 100,Bloomington,Minnesota,' 55437 ' ,United States,62091,,,
5279,pimasertib,,1/29/2010,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,5/15/2020,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,297909,,,
5280,pioglitazone,,12/12/2019,treatment of sudden sensorineural hearing loss,Designated,,Not FDA Approved for Orphan Indication,,,,,Strekin AG,60C Hochbergerstrasse,,Basel,Basel-Stadt,' ' ,Switzerland,583017,,,
5281,Pioglitazone hydrochloride,,7/20/2022,treatment of childhood onset idiopathic nephrotic syndrome (defined as steroid dependent or frequently relapsing ns).,Designated,,Not FDA Approved for Orphan Indication,,,,,"NephKey Therapeutics, Inc.","15100 Weston Parkway, Suite 101",,Cary,North Carolina,' 27513 ' ,United States,890822,idiopathic nephrotic syndrome,"""gard:0021539""",
5282,Piperidine-containing autotaxin inhibitor,,1/19/2023,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,NextGen Bioscience,3F Elentec-dong 17,"Pangyo-ro 228 Beon-gil,","Bundang-gu, Seongnam-si",Gyeonggi-do,' ' ,South Korea,920222,idiopathic pulmonary fibrosis,"""gard:0008609""",
5283,Piperlongumine (PL) Hydrogel,,9/19/2023,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,TargTex S.A.,"Avenida Tenente Valadim, N17, 2F",,Torres Vedras,,' 2560-275 ' ,Portugal,960723,,,
5284,Piracetam,,10/2/1987,treatment of myoclonus.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"UCB Pharma, Inc.",1950 Lake Park Drive,,Smyrna,Georgia,' 30080 ' ,United States,20987,,,
5285,Pirarubicin,,10/29/2020,treatment of osteosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hillstream BioPharma, Inc.",245 Main Street,Suite 204,Chester,New Jersey,' 07930 ' ,United States,778820,osteosarcoma,"""gard:0007284""",
5286,pirfenidone,,3/11/2020,treatment of unclassifiable-interstitial lung disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech Inc., A Member of the Roche Group",1 DNA Way,MS# 355F,South San Francisco,California,' 94080 ' ,United States,727219,interstitial lung disease,"""gard:0020244""",
5287,pirfenidone,,7/31/2014,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Avalyn Pharma, Inc.",701 Pike Street,Suite 1500,Seattle,Washington,' 98101 ' ,United States,436914,idiopathic pulmonary fibrosis,"""gard:0008609""",
5288,pirfenidone,ESBRIET,3/5/2004,treatment of idiopathic pulmonary fibrosis,Designated/Approved,,,Treatment of idiopathic pulmonary fibrosis,10/15/2014,10/15/2021,Treatment of idiopathic pulmonary fibrosis,Genentech,1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,177903,idiopathic pulmonary fibrosis,"""gard:0008609""",
5289,pirfenidone,,11/19/2013,treatment of systemic sclerosis (including the associated interstitial lung disease),Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,411113,interstitial lung disease,"""gard:0020244""",
5290,Piritrexim isethionate,,6/13/1988,"treatment of infections caused by pneumocystis carinii, toxoplasma gondii, and mycobacterium avium-intracellulare.",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Burroughs Wellcome Company,3030 Cornwallis Road,P.O. Box 12700,Research Triangle Park,North Carolina,' 27709 ' ,United States,29188,,,
5291,pirtobrutinib,Jaypirca,9/14/2020,treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma,Designated/Approved,,,"treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor",12/1/2023,12/1/2030,"treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor","Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company",701 Gateway Boulevard,Suite 420,South San Francisco,California,' 94080 ' ,United States,763420,lymphoma,"""gard:0020548""",
5292,pirtobrutinib,Jaypirca,8/28/2020,treatment of mantle cell lymphoma,Designated/Approved,,,"treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor",1/27/2023,1/27/2030,"treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor","Loxo Oncology, Inc.","201 Haskins Way, Suite 400",,South San Francisco,California,' 94080 ' ,United States,758120,lymphoma,"""gard:0020548""",
5293,Pitolisant,WAKIX,5/17/2010,treatment of narcolepsy,Designated/Approved,,,WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy,8/14/2019,8/14/2026,For the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy,"Harmony Biosciences, LLC",630 W Germantown Pike,Suite 215,Plymouth Meeting,Pennsylvania,' 19462 ' ,United States,307210,narcolepsy,"""gard:0022460""",
5294,pitolisant,,2/12/2024,treatment of prader-willi syndrome (pws),Designated,,Not FDA Approved for Orphan Indication,,,,,"Harmony Biosciences, LLC",630 W Germantown Pike,Suite 215,Plymouth Meeting,Pennsylvania,' 19462 ' ,United States,819721,prader-willi syndrome,"""gard:0005575""",
5295,pitolisant,,9/5/2023,treatment of idiopathic hypersomnia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Harmony Biosciences, LLC",630 W Germantown Pike,Suite 215,Plymouth Meeting,Pennsylvania,' 19462 ' ,United States,958123,idiopathic hypersomnia,"""gard:0008737""",
5296,pitolisant,WAKIX®,5/17/2010,treatment of narcolepsy,Designated/Approved,,,treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy,10/13/2020,10/13/2027,treatment of cataplexy in adult patients with narcolepsy,"Harmony Biosciences, LLC",630 W Germantown Pike,Suite 215,Plymouth Meeting,Pennsylvania,' 19462 ' ,United States,307210,narcolepsy,"""gard:0022460""",
5297,Placenta-Derived Decidua Stromal Cells,,12/9/2019,treatment of graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"ASC Therapeutics, Inc.",521 Cottonwood Dr.,,Milpitas,California,' 95035 ' ,United States,711919,graft versus host disease,"""gard:0016642""",
5298,plasmid DNA encoding the human cystic fibrosis transmembrane conductance regulator gene complexed with a nonviral cationic lipid based gene transfer agent,,6/30/2014,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Imperial Innovations Limited,52 Princess Gate,,London,,' ' ,United Kingdom,437314,cystic fibrosis,"""gard:0006233""",
5299,Plasmid DNA vector expressing cystic fibrosis transmembrane gene,,3/29/2005,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Copernicus Therapeutics, Inc.",11000 Cedar Avenue,,Cleveland,Ohio,' 44106 ' ,United States,202205,cystic fibrosis,"""gard:0006233""",
5300,plasmin (human),,3/30/2009,treatment of acute peripheral arterial occlusion,Designated/Designation Withdrawn or Revoked,2/8/2018,Not FDA Approved for Orphan Indication,,,,,"Grifols Therapeutics, Inc.",8368 US 70 Busines Hwy West,,Clayton,North Carolina,' 27520 ' ,United States,275308,acute peripheral arterial occlusion,"""gard:0019113""",
5301,plasminogen (Human),,12/14/2017,treatment of idiopathic pulmonary fibrosis (ipf),Designated,,Not FDA Approved for Orphan Indication,,,,,Kedrion Biopharma Inc.,"Parker Plaza, 400 Kelby Street",,Fort Lee,New Jersey,' 07024 ' ,United States,609317,idiopathic pulmonary fibrosis,"""gard:0008609""",
5302,"plasminogen, human-tvmh",Ryplazim,3/5/2013,"treatment of hypoplasminogenemia, or type i plasminogen deficiency",Designated/Approved,,,Treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia).,6/4/2021,6/4/2028,Treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia),"ProMetic BioTherapeutics, Inc.",1330 Piccard Drive,Suite 201,Rockville,Maryland,' 20850 ' ,United States,389112,hypoplasminogenemia,"""gard:0004380""",
5303,pleconaril,,12/22/2014,treatment of symptomatic enteroviral infection in the neonate,Designated,,Not FDA Approved for Orphan Indication,,,,,"NES Therapeutics, Inc.",7 Ardsley Ct.,,Princeton,New Jersey,' 08550 ' ,United States,457214,,,
5304,plerixafor,Mozobil (r),7/10/2003,for use to improve the yield of progentor cells in the apheresis product for subsequest stem cell transplantation following myelosuppressive or myeloablative chemotherapy,Designated/Approved,,,To enhance mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma,12/15/2008,12/15/2015,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,167903,,,
5305,plerixafor,,7/28/2011,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,11/20/2013,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,346111,acute myeloid leukemia,"""gard:0012757""",
5306,Plevitrexed,,5/29/2007,treatment of gastric (stomach cancer,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,BTG International Ltd,10 Fleet Place,EC4M 7SB,London,,' ' ,United Kingdom,240207,,,
5307,Plevitrexed,,5/14/2007,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,BTG International Ltd,10 Fleet Place,EC4M 7SB,London,,' ' ,United Kingdom,240307,ovarian cancer,"""gard:0007295""",
5308,Plitidepsin,,6/18/2004,treatment of acute lymphoblastic leukemia,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"PharmaMar USA, Inc",University Park at M.I.T.,Sidney Street,Cambridge,Massachusetts,' 02139 ' ,United States,187404,acute lymphoblastic leukemia,"""gard:0000522""",
5309,plitidepsin,,9/30/2004,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"PharmaMar USA, Inc.",205 East 42nd St.,Suite 15003,New York,New York,' 10017 ' ,United States,191604,multiple myeloma,"""gard:0007108""",
5310,Pociredir,,2/10/2022,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Fulcrum Therapeutics, Inc.",26 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,862121,,,
5311,polatuzumab vedotin-piiq,POLIVY,12/12/2016,treatment of diffuse large b-cell lymphoma,Designated/Approved,,,"POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.",6/10/2019,6/10/2026,"In combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.","Genentech, Inc.",1 DNA Way,MS# 40?N8?5,South San Francisco,California,' 94080-4990 ' ,United States,547416,lymphoma,"""gard:0020548""",
5312,polatuzumab vedotin-piiq,Polivy,12/12/2016,treatment of diffuse large b-cell lymphoma,Designated/Approved,,,"in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater",4/19/2023,4/19/2030,"treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) and who have an International Prognostic Index score of 2 or greater","Genentech, Inc.",1 DNA Way,MS# 40?N8?5,South San Francisco,California,' 94080-4990 ' ,United States,547416,lymphoma,"""gard:0020548""",
5313,polidocanol,,2/19/2015,treatment of congenital venous malformations,Designated,,Not FDA Approved for Orphan Indication,,,,,Provensis Ltd,5 Fleet Place,,London,,' ' ,United Kingdom,464614,,,
5314,polifeprosan 20 with carmustine,Gliadel,12/13/1989,treatment of malignant glioma.,Designated/Approved,,,Expanding the indication to include patients with malignant glioma undergoing primary surgical resection.,2/25/2003,2/25/2010,,"Guilford Pharmaceuticals, Inc.",6611 Tributary Street,,Baltimore,Maryland,' 21224 ' ,United States,37089,,,
5315,polifeprosan 20 with carmustine,Gliadel,12/13/1989,treatment of malignant glioma.,Designated/Approved,,,As an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated,9/23/1996,9/23/2003,,"Guilford Pharmaceuticals, Inc.",6611 Tributary Street,,Baltimore,Maryland,' 21224 ' ,United States,37089,,,
5316,Polihexanide,,2/11/2022,treatment of fungal keratitis infection,Designated,,Not FDA Approved for Orphan Indication,,,,,SIFI SpA,"Via Ercole Patti, 36",,Aci Sat'Antonio,CT,' 95025 ' ,Italy,861321,fungal keratitis,"""gard:0022134""",
5317,poloxamer 188,,11/8/2013,treatment of acute limb ischemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Mast Therapeutics Inc.,3611 Valley Centre rive,Suite 500,San Diego,California,' 92130 ' ,United States,408113,,,
5318,Poloxamer 188,,8/5/1997,treatment of vasospasm in subarachnoid hemorrhage patients following surgical repair of a ruptured cerebral aneurysm.,Designated,,Not FDA Approved for Orphan Indication,,,,,CytRx Corporation,154 Technology Parkway,,Norcross,Georgia,' 30092 ' ,United States,102696,,,
5319,Poloxamer 188,,2/22/1990,treatment of severe burns requiring hospitalization.,Designated,,Not FDA Approved for Orphan Indication,,,,,CytRx Corporation,154 Technology Parkway,,Norcross,Georgia,' 30092 ' ,United States,40389,,,
5320,poloxamer 188 (purified),,6/27/1989,treatment of sickle cell disease (this includes the treatment and prevention of complications of sickle cell disease),Designated,,Not FDA Approved for Orphan Indication,,,,,Mast Therapeutics Inc.,3611 Valley Centre rive,Suite 500,San Diego,California,' 92130 ' ,United States,38189,,,
5321,Poloxamer 331,,3/21/1991,initial therapy of toxoplasmosis in patients with aids.,Designated,,Not FDA Approved for Orphan Indication,,,,,CytRx Corporation,154 Technology Parkway,,Norcross,Georgia,' 30092 ' ,United States,55990,,,
5322,poloxamer-188 NF,,1/19/2010,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Phrixus Pharmaceuticals, Inc.",300 N. Fifth Avenue,,Ann Arbor,Michigan,' 48104 ' ,United States,296409,muscular dystrophy,"""gard:0007922""",
5323,"poly (acetyl, arginyl) glucosamine",,10/2/2018,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Synedgen, Inc.",1420 North Claremont Boulevard,Suite 105D,Claremont,California,' 91711 ' ,United States,492115,cystic fibrosis,"""gard:0006233""",
5324,poly (lactide-co-glycolide)-polyethylene glycol nanoparticles encapsulating quercetin,,12/17/2018,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Cancer Research and Life Foundation,2015 Placentia Ave.,,Costa Mesa,California,' 92627 ' ,United States,664018,glioblastoma,"""gard:0002491""",
5325,Poly (Phenyl Sulfoglucuronate Galactoside),,5/14/2020,treatment of anti-myelin-associated glycoprotein (mag) neuropathy,Designated/Designation Withdrawn or Revoked,10/29/2021,Not FDA Approved for Orphan Indication,,,,,Polyneuron Pharmaceuticals AG,c/o Basel Inkubator,Hochbergerstrasse 60C,Basel,Basel City,' ' ,Switzerland,641918,,,
5326,Poly I: poly C12U,,12/9/1993,"treatment of invasive metastatic melanoma (stage iib, iii, iv).",Designated,,Not FDA Approved for Orphan Indication,,,,,AIM ImmunoTech Inc.,783 Jersey Avenue,,New Brunswick,New Jersey,' 08901 ' ,United States,76893,noma,"""gard:0004001""",
5327,Poly I: poly C12U,,5/20/1991,treatment of renal cell carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,AIM ImmunoTech Inc.,783 Jersey Avenue,,New Brunswick,New Jersey,' 08901 ' ,United States,57091,renal cell carcinoma,"""gard:0013215""",
5328,Poly I: poly C12U,,12/9/1993,treatment of chronic fatigue syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,AIM ImmunoTech Inc.,783 Jersey Avenue,,New Brunswick,New Jersey,' 08901 ' ,United States,75993,,,
5329,poly(lactide-co-glycolide) carboxylated microparticle,,9/13/2016,treatment of malaria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cour Pharmaceutical Development Company, Inc.",428 S. Hillside Avenue,,Elmhurst,Illinois,' 60126 ' ,United States,534816,malaria,"""gard:0006961""",
5330,poly(lactide-co-glycolide) carboxylated microparticle,,10/25/2013,treatment of acute encephalitis syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cour Pharmaceutical Development Company, Inc.",428 S. Hillside Avenue,,Elmhurst,Illinois,' 60126 ' ,United States,410413,encephalitis,"""gard:0019357""",
5331,poly-CD-PEG-camptothecin,,5/21/2015,treatment of ovarian cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ellipses Pharma, Ltd.",10 Stratton Street,,London,,' ' ,United Kingdom,479915,ovarian cancer,"""gard:0007295""",
5332,Poly-ICLC,,3/17/1997,treatment of primary brain tumors.,Designated,,Not FDA Approved for Orphan Indication,,,,,Oncovir,3202 Cleveland Avenue N.W.,,Washington,District of Columbia,' 20008 ' ,United States,103197,,,
5333,"poly-N,N'-hexamethyleneguanidine-poly-N1,N4-hexamethyleneaminoguanidine",,4/5/2016,"treatment of pulmonary infections in patients with cystic fibrosis including infections due to pseudomonas aeruginosa,burkholderia cepacia and other bacteria",Designated,,Not FDA Approved for Orphan Indication,,,,,"TGV-Inhalonix, Inc.",303 5th Avenue,Suite 2012,New York,New York,' 10016 ' ,United States,511215,cystic fibrosis,"""gard:0006233""",
5334,polyethylene glycol modified recombinant C-terminal truncate of human cystathionine beta-synthase,,3/17/2015,treatment of homocystinuria,Designated,,Not FDA Approved for Orphan Indication,,,,,Travere Therapeutics Switzerland GmbH,Zentrum Sonnenhof,Zürcherstrasse 6,San Diego,Rapperswil-Jona,' 8640 ' ,Switzerland,469715,cystinuria,"""gard:0006237""",
5335,polyethylene glycol-3350,,1/11/2024,treatment of peripheral nerve injury requiring repair,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neuraptive Therapeutics, Inc.","851 Duportail Road, Suite 200",,Chesterbrook,Pennsylvania,' 19087 ' ,United States,824021,,,
5336,Polyethylene glycol-modified uricase,,12/21/1998,treatment of tumor lysis syndrome in cancer patients undergoing chemotherapy.,Designated,,Not FDA Approved for Orphan Indication,,,,,Swedish Orphan Biovitrum AB,Tomtebodavägen 23A,,Solna,,' ' ,Sweden,117798,,,
5337,Polyethylene glycol-modified uricase,,9/14/1999,prophylaxis of hyperuricemia in cancer patients prone to develop tumor lysis syndrome during chemotherapy.,Designated,,Not FDA Approved for Orphan Indication,,,,,Swedish Orphan Biovitrum AB,Tomtebodavägen 23A,,Solna,,' ' ,Sweden,118598,,,
5338,Polyethylene glycol-modified uricase,,6/6/2005,treatment of hyperuricemia in patients with gout refractory to conventional therapy or in whom conventional therapy is contraindicated,Designated,,Not FDA Approved for Orphan Indication,,,,,Swedish Orphan Biovitrum AB,Tomtebodavägen 23A,,Solna,,' ' ,Sweden,118698,,,
5339,polyhexanide,,11/6/2017,treatment of acanthamoeba keratitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Società Industria Farmaceutica Italiana S.p.A.,36 Via Ercole Patti,,Lavinaio,Sicilia,' ' ,Italy,610317,,,
5340,polyinosinic-polycytidilic acid,,3/3/2003,"treatment of flavivirus infections including those due to west nile, japanese encephalitis, dengue, st. louis encephalitis, yellow fever, murray valley, and banzai viruses",Designated,,Not FDA Approved for Orphan Indication,,,,,Oncovir,"3203 Cleveland Ave., NW",,Washington,District of Columbia,' 20008 ' ,United States,163302,encephalitis,"""gard:0019357""",
5341,polyinosinic-polycytidilic acid,,8/2/2002,as an adjuvant to smallpox vaccination,Designated,,Not FDA Approved for Orphan Indication,,,,,Oncovir,"3203 Cleveland Ave., NW",,Washington,District of Columbia,' 20008 ' ,United States,157802,,,
5342,polyinosinic-polycytidilic acid (Poly-ICLC),,11/19/2002,treatment for orthopox virus infections,Designated,,Not FDA Approved for Orphan Indication,,,,,Oncovir,"3203 Cleveland Ave., NW",,Washington,District of Columbia,' 20008 ' ,United States,157702,,,
5343,polyinosinic:polycytidylic acid,,9/27/2022,treatment of stage iib-iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Highlight Therapeutics,Parc Científic Universitat de Valencia,"C/ Catedrático Agustín Escardino, 9",Paterna (Valencia),,' 46980 ' ,Spain,901722,noma,"""gard:0004001""",
5344,Polymeric oxygen,,3/25/1992,treatment of sickle cell anemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,Capmed USA,P.O. Box 14,,Bryn Mawr,Pennsylvania,' 19010 ' ,United States,31188,sickle cell anemia,"""gard:0008614""",
5345,Polymeric polyethylene glycol-phosphatidyl ethanolamine (PEG-PE) micelles containing Curcumin C3 complex (CUR) and doxorubicin hydrochloride (DOX),,9/27/2021,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immix Biopharma, Inc",10573 W. Pico Blve,#58,Los Angeles,California,' 90064 ' ,United States,808221,soft tissue sarcoma,"""gard:0004898""",
5346,polyphenon E,,7/17/2008,treatment of chronic lymphocytic leukemia,Designated/Designation Withdrawn or Revoked,7/13/2017,Not FDA Approved for Orphan Indication,,,,,"Mitsui Norin Co., Ltd",223-1 Miyabara,426-0133,Fujieda City,,' ' ,Japan,260208,,,
5347,Polyribonucleotide; Polyribo-inosinic/-cyclidylic/-uridylic acid,,7/19/1988,treatment of aids,Designated,,Not FDA Approved for Orphan Indication,,,,,AIM ImmunoTech Inc.,783 Jersey Avenue,,New Brunswick,New Jersey,' 08901 ' ,United States,11685,,,
5348,"Polyvalent, shed-antigen melanoma vaccine",,6/9/2006,treatment of stage iib to stage iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Polynoma LLC,11622 El Camino Real #100,,San Diego,California,' 92130 ' ,United States,223206,noma,"""gard:0004001""",
5349,pomalidomide,Pomalyst,1/15/2003,treatment of multiple myeloma,Designated/Approved,,,Treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.,2/8/2013,2/8/2020,Treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,161402,multiple myeloma,"""gard:0007108""",
5350,pomalidomide,POMALYST®,4/4/2018,treatment of kaposi sarcoma,Designated/Approved,,,POMALYST (pomalidomide) is indicated for the treatment of adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART); and for the treatment of Kaposi sarcoma (KS) in adult patients who are HIV-negative.,5/14/2020,5/14/2027,Indicated for the treatment of adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART); and for the treatment of Kaposi sarcoma (KS) in adult patients who are HIV-negative.,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,635818,kaposi sarcoma,"""gard:0006814""",
5351,pomalidomide,,8/22/2013,treatment of systemic sclerosis,Designated/Designation Withdrawn or Revoked,5/21/2015,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,363212,systemic sclerosis,"""gard:0009748""",
5352,pomalidomide,,9/21/2010,treatment of persons with myeloproliferative neoplasm-associated myelofibrosis and anemia who are red blood cell tranfusion dependent.,Designated/Designation Withdrawn or Revoked,1/17/2017,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,308610,myeloproliferative neoplasm,"""gard:0009319""",
5353,ponatinib,,3/12/2015,treatment of gastrointestinal stromal tumors (gist).,Designated/Designation Withdrawn or Revoked,5/15/2017,Not FDA Approved for Orphan Indication,,,,,"ARIAD Pharmaceuticals, Inc.",26 Landsdowne Street,,Cambridge,Massachusetts,' 02339 ' ,United States,466714,gastrointestinal stromal tumor,"""gard:0008598""",
5354,ponatinib,Iclusig,11/20/2009,treatment of chronic myeloid leukemia,Designated/Approved,,,"Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.",12/14/2012,12/14/2019,,ARIAD Pharmaceuticals Inc.,26 Landsdowne Steet,,Cambridge,Massachusetts,' 02139 ' ,United States,294709,chronic myeloid leukemia,"""gard:0006105""",
5355,ponatinib,Iclusig,11/20/2009,treatment of philadelphia chromosome-positive acute lymphoblastic leukemia (ph+all),Designated/Approved,,,treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy,3/19/2024,3/19/2031,treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL),"Takeda Pharmaceuticals U.S.A., Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,294809,acute lymphoblastic leukemia,"""gard:0000522""",
5356,ponatinib,Iclusig,11/20/2009,treatment of philadelphia chromosome-positive acute lymphoblastic leukemia (ph+all),Designated/Approved,,,Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.,12/14/2012,12/14/2019,,"Takeda Pharmaceuticals U.S.A., Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,294809,acute lymphoblastic leukemia,"""gard:0000522""",
5357,Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation,,12/17/1996,treatment of hoehn and yahr stage 4 and 5 parkinson's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Diacrin/Genzyme LLC,One Kendall Square,,Cambridge,Massachusetts,' 02139 ' ,United States,102596,,,
5358,Porcine fetal neural dopaminergic cells and/or precursors aseptically prepared for intracerebral implantation.,,12/17/1996,treatment of hoehn and yahr stage 4 and 5 parkinson's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Diacrin/Genzyme LLC,One Kendall Square,,Cambridge,Massachusetts,' 02139 ' ,United States,93395,,,
5359,Porcine fetal neural gabaergic cells and/or precursors aseptically prepared and coated with anti-MHC-1 Ab for intracerebral implantation,,12/10/1996,treatment of huntington's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Diacrin/Genzyme LLC,One Kendall Square,,Cambridge,Massachusetts,' 02139 ' ,United States,102896,,,
5360,Porcine fetal neural gabaergic cells and/or precursors aseptically prepared for intracerebral implantation for Huntington's disease.,,12/10/1996,treatment of huntington's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Diacrin/Genzyme LLC,One Kendall Square,,Cambridge,Massachusetts,' 02139 ' ,United States,93295,,,
5361,porcine GM1 ganglioside,,12/3/2012,treatment of acute spinal cord injury,Designated,,Not FDA Approved for Orphan Indication,,,,,TRB Chemedica International S.A.,Rue Michel-Servet 12,,Geneva 12,,' ' ,Switzerland,374412,spinal cord injury,"""gard:0019109""",
5362,Porcine Sertoli cells aseptically prepared for intracerebral co-implantation with fetal neural tissue,,6/24/1997,treatment of hoehn and yahr stage four and five parkinson's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Titan Pharmaceuticals, Inc.",Post Office Plaza,"50 Division Street, Suite 503",Somerville,New Jersey,' 08876 ' ,United States,104697,,,
5363,porfimer,Photofrin,10/19/2001,for the ablation of high-grade dysplasia in barrett's esophagus in patients who are not considered to be candidates for esophagectomy,Designated/Approved,,,For the ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy,8/1/2003,8/1/2010,,Axcan Scandipharm Inc.,22 Inverness Parkway,Suite 310,Birmingham,Alabama,' 35242 ' ,United States,146601,,,
5364,porfimer sodium,,12/2/2011,treatment of malignant mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Concordia Laboratories, Inc., Sarl",8-10 Avenue de la Gare - L-1610,,Luxembourg,Grand Duchy of Luxembourg,' ' ,Luxembourg,357011,,,
5365,Porfimer sodium,,11/15/1989,for the photodynamic therapy of patients with transitional cell carcinoma in situ of the urinary bladder.,Designated,,Not FDA Approved for Orphan Indication,,,,,"QLT Phototherapeutics, Inc.",Lederle Laboratories,401 North Middletown Road,Pearl River,New York,' 10965 ' ,United States,39489,noma,"""gard:0004001""",
5366,Porfimer sodium,,11/18/2004,treatment of cholangiocarcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Concordia Laboratories, Inc., Sarl",8-10 Avenue de la Gare - L-1610,,Luxembourg,Grand Duchy of Luxembourg,' ' ,Luxembourg,191904,cholangiocarcinoma,"""gard:0009304""",
5367,Porfimer sodium,Photofrin,6/6/1989,for the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.,Designated/Approved,,,"Photodynamic therapy with PHOTOFRIN for the palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who cannot be satisfactorily treated with Nd:YAG laser therapy.",12/27/1995,12/27/2002,,"QLT Phototherapeutics, Inc.",Lederle Laboratories,401 North Middletown Road,Pearl River,New York,' 10965 ' ,United States,35589,noma,"""gard:0004001""",
5368,Porfiromycin,,3/13/1997,treatment of cervical cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,' 06877 ' ,United States,103597,,,
5369,Porfiromycin,,9/19/1995,treatment of head and neck cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,' 06877 ' ,United States,91495,,,
5370,posaconazole,,7/16/2004,treatment of zygomycosis,Designated/Designation Withdrawn or Revoked,3/16/2023,Not FDA Approved for Orphan Indication,,,,,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,187604,zygomycosis,"""gard:0010224""",
5371,posaconazole,Noxafil,10/4/2016,treatment of invasive aspergillosis,Designated/Approved,,,Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older,6/17/2021,6/17/2028,Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,539016,aspergillosis,"""gard:0005856""",
5372,Posaconazole,,12/13/2021,treatment of mucormycosis (previously called zygomycosis),Designated,,Not FDA Approved for Orphan Indication,,,,,"AET Pharma US, Inc.",9841 Washingtonian Boulevard,Suite 200,Gaithersburg,Maryland,' 20878 ' ,United States,850521,zygomycosis,"""gard:0010224""",
5373,Positive transcription elongation factor b (PTEFb) inhibitor,,10/12/2022,treatment of diffuse large b-cell lymphoma/high grade b-cell lymphoma with myc and bcl2 rearrangements,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vincerx Pharma, Inc.",260 Sheridan Avenue,Suite 400,Palo Alto,California,' 94306 ' ,United States,903722,lymphoma,"""gard:0020548""",
5374,"potassium (benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide/tezacaftor/ivacaftor",,5/23/2018,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,638618,cystic fibrosis,"""gard:0006233""",
5375,"potassium 2-chloro-3-(1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-6-oxo- 5-phenyl-6,7-dihydrothieno[2, 3-b]pyridin-4-olate hydrate",,5/12/2022,treatment of x-linked adrenoleukodystrophy (ald),Designated,,Not FDA Approved for Orphan Indication,,,,,Poxel S.A.,259/261 Avenue Jean Jaures,,Lyon,,' F-69007 ' ,France,875822,leukodystrophy,"""gard:0006895""",
5376,"potassium 2-chloro-3-(1-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-6-oxo- 5-phenyl-6,7-dihydrothieno[2, 3-b]pyridin-4-olate hydrate",,9/14/2022,treatment of autosomal dominant polycystic kidney disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Poxel S.A.,259/261 Avenue Jean Jaures,,Lyon,,' F-69007 ' ,France,898922,autosomal dominant polycystic kidney disease,"""gard:0010413""",
5377,Potassium citrate,Urocit-K,11/1/1984,prevention of uric acid nephrolithiasis.,Designated/Approved,,,,8/30/1985,8/30/1992,,University of Texas Health Science Center at Dallas,5323 Harry Hines Blvd,,Dallas,Texas,' 75235 ' ,United States,2784,,,
5378,Potassium citrate,Urocit-K,11/1/1984,1. prevention of calcium renal stones in patients with hypocitraturia 2. for avoidance of the complication of calcium stone formation in patients with uric lithiasis.,Designated/Approved,,,Prevention of recurring calcium conating stines associated with a deficiency in the urine.,8/7/1985,8/7/1992,,University of Texas Health Science Center at Dallas,5323 Harry Hines Blvd,,Dallas,Texas,' 75235 ' ,United States,9685,,,
5379,Potassium citrate and citric acid,,2/14/1986,for the dissolution and control of uric acid and cysteine calculi in the urinary tract.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Willen Drug Company,,,,,' ' ,,9785,,,
5380,Potassium citrate and potassium bicarbonate,,3/21/2024,treatment of cystinuria,Designated,,Not FDA Approved for Orphan Indication,,,,,Advicenne S.A.,22 rue de la Paix,,Paris,,' 75002 ' ,France,817521,cystinuria,"""gard:0006237""",
5381,Potassium Iodide Oral Solution,ThyroShield,11/17/2004,for use as a thyroid blocking agent in pediatric patients exposed to radiactive iodine,Designated/Approved,,,For use as a thyroid blocking agent in pediatric patients exposed to radiactive iodine,1/12/2005,,,"Fleming & Company, Pharmaceuticals",1733 Gilsinn Lane,,Fenton,Missouri,' 63026 ' ,United States,190304,,,
5382,potassium sodium aluminosilicate,,1/8/2007,for treatment of poisoning by or exposure to cesium.,Designated,,Not FDA Approved for Orphan Indication,,,,,Westhaven Therapeutics Corporation,1825 K Street Northwest,Suite 510,Washington,District of Columbia,' 20006 ' ,United States,232306,,,
5383,povidone iodine,,11/30/2018,treatment of endophthalmitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Cumulus Pharmaceutical LLC,1712 Pioneer Avenue,Suite 1377,Cheyenne,Wyoming,' 82001 ' ,United States,647518,endophthalmitis,"""gard:0020333""",
5384,povidone-iodine 0.5% (w/w) in dimethylsulfoxide 44% (w/w),,5/11/2017,treatment of microbial keratitis (which includes acanthamoeba keratitis).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Veloce BioPharma, LLC",7315 Wisconsin Avenue,Suite 400W,Chevy Chase,Maryland,' 20815 ' ,United States,566216,,,
5385,"Powdered extracts of the herbs Scutellaria baicalensis Geori, Glycyrrhiza uralensis Fisch, Paeonia lactiflora Pall, and Ziziphus jujuba Mill",,3/22/2018,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Yiviva Inc.,"447 Broadway, 2FL",,New York,New York,' 10013 ' ,United States,624817,hepatocellular carcinoma,"""gard:0016773""",
5386,pozelimab,,7/22/2019,treatment of paroxysmal nocturnal hemoglobinuria,Designated,,Not FDA Approved for Orphan Indication,,,,,Regeneron Pharmaceuticals Inc,777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,660518,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
5387,pozelimab and cemdisiran combiantion,,8/28/2023,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,828121,myasthenia gravis,"""gard:0007122""",
5388,pozelimab-bbfg,Veopoz,4/13/2020,treatment of cd55-deficient protein-losing enteropathy,Designated/Approved,,,"treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease",8/18/2023,8/18/2030,"treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease","Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Rd.,,Tarrytown,New York,' 10591-6707 ' ,United States,736820,,,
5389,Pozelimab/Cemdisiran Combination,,9/8/2020,treatment of paroxysmal nocturnal hemoglobinuria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharamecuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,760920,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
5390,Pr-122 (redox-phenytoin),,7/5/1990,"for the emergency rescue treatment of status epilepticus, grand mal type.",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Pharmos,2 Innovation Drive,,Alachua,Florida,' 32615 ' ,United States,43490,,,
5391,PR-225 (redox-acyclovir),,5/29/1990,treatment of herpes simplex encephalitis in individuals afflicted with aids.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Pharmos,2 Innovation Drive,,Alachua,Florida,' 32615 ' ,United States,37589,encephalitis,"""gard:0019357""",
5392,PR-239 (redox penicillin G),,5/23/1990,treatment of aids associated neurosyphilis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Pharmos,2 Innovation Drive,,Alachua,Florida,' 32615 ' ,United States,37689,,,
5393,Pr-320 (molecusol-carbamazepine),,7/20/1990,"for the emergency rescue treatment of status epilepticus, grand mal type.",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Pharmos,2 Innovation Drive,,Alachua,Florida,' 32615 ' ,United States,43590,,,
5394,pracinostat,,2/27/2014,treatment of acute myeloid leulemia,Designated/Designation Withdrawn or Revoked,1/26/2022,Not FDA Approved for Orphan Indication,,,,,Helsinn Healthcare SA,P.O. Box 357,,Pambio-Noranco,Lugano,' 6915 ' ,Switzerland,421313,,,
5395,pralatrexate,,10/20/2008,treatment of diffuse large b-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,' 08520 ' ,United States,268308,lymphoma,"""gard:0020548""",
5396,pralatrexate,,10/20/2008,treatment of follicular lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,' 08520 ' ,United States,269008,lymphoma,"""gard:0020548""",
5397,pralatrexate,Folotyn,7/20/2006,treatment of t-cell lymphoma,Designated/Approved,,,Treatment of patients with relapsed or refractory peripheral T-cell lymphoma,9/24/2009,9/24/2016,,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,' 08520 ' ,United States,225306,lymphoma,"""gard:0020548""",
5398,pralatrexate,,5/3/2010,treatment of advanced or metastatic transitional cell carcinoma of the urinary bladder,Designated,,Not FDA Approved for Orphan Indication,,,,,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,' 08520 ' ,United States,260708,noma,"""gard:0004001""",
5399,pralmorelin hydrochloride,,10/18/2012,as a diagnostic agent for the detection of growth hormone deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sella Pharmaceuticals, Inc.",412 Wister Road,,Wynnewood,Pennsylvania,' 19096 ' ,United States,372912,,,
5400,pralsetinib,Gavreto,5/26/2020,"treatment of ret-fusion, ret-mutation, and trkc-positive poorly differentiated thyroid cancer, undifferentiated or anaplastic thyroid cancer, medullary thyroid cancer, and locally advanced or metastatic follicular or papillary thyroid cancer",Designated/Approved,,,Treatment of (1) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; and; (2) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate),12/1/2020,12/1/2027,Treatment of (1) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; and; (2) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate),Blueprint Medicines Corporation,45 Sidney Street,,Cambridge,Massachusetts,' 02139 ' ,United States,728519,,,
5401,pralsetinib,GAVRETO™,4/11/2018,"treatment of rearranged during transfection (ret)-rearranged non-small cell lung cancer (nsclc), jak1/2-positive nsclc, or trkc-positive nsclc.",Designated/Approved,,,treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test,9/4/2020,9/4/2027,treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test,Blueprint Medicines Corporation,45 Sidney Street,,Cambridge,Massachusetts,' 02139 ' ,United States,634318,small cell lung cancer,"""gard:0009344""",
5402,Pralsetinib,,2/22/2022,treatment of metastatic ret fusion-positive solid tumors,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,840321,,,
5403,pramipexole,,1/31/2008,treatment of tourette's syndrome in pediatric patients,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Boehringer-Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,,Ridgefield,Connecticut,' 06877 ' ,United States,252007,,,
5404,Pramiracetam Sulfate,,11/4/1991,for the management of cognitive dysfunction and enhancement of antidepressant activity associated with electroconvulsive therapy.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Cambridge Neuroscience, Inc.","1 Kendall Square, Bldg. 700",,Cambridge,Massachusetts,' 02139 ' ,United States,61691,,,
5405,prasugrel hydrochloride,,5/26/2015,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Eli Lilly,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,473015,,,
5406,pravibismane,,12/7/2023,treatment of non-tuberculous mycobacterial (ntm) infections,Designated,,Not FDA Approved for Orphan Indication,,,,,Microbion Corporation,"5 West Mendenhall Street, Suite 202",,Bozeman,Montana,' 59715 ' ,United States,924522,,,
5407,Praziquantel,,4/18/1988,treatment of neurocysticercosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"EM Pharmaceuticals, Inc.",,,,,' ' ,,19487,cysticercosis,"""gard:0008194""",
5408,Pre-Morula Stem Cells,,10/8/2020,treatment for amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,ReoStem L.L.C.,8 The Green,Suite #10862,Dover,Delaware,' 19901 ' ,United States,769420,amyotrophic lateral sclerosis,"""gard:0005786""",
5409,Pre-Morula Stem Cells,,5/10/2021,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,ReoStem L.L.C.,8 The Green,Suite #10862,Dover,Delaware,' 19901 ' ,United States,816521,muscular dystrophy,"""gard:0007922""",
5410,Prednimustine,,6/17/1985,treatment of malignant non-hodgkin's lymphomas.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Pharmacia Inc.,P.O. Box 16529,,Columbus,Ohio,' 43216 ' ,United States,6685,lymphoma,"""gard:0020548""",
5411,Prednisone,,3/5/2024,treatment of limb-girdle muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Sarcomed AB,Störtloppsvägen 25,,Stockholm,,' 12947 ' ,Sweden,991023,muscular dystrophy,"""gard:0007922""",
5412,Prednisone,,7/13/2022,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Sarcomed AB,Störtloppsvägen 25,,Stockholm,,' 12947 ' ,Sweden,889122,muscular dystrophy,"""gard:0007922""",
5413,prednisone,,3/12/2024,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,Sarcomed AB,Störtloppsvägen 25,,Stockholm,,' 12947 ' ,Sweden,993223,myasthenia gravis,"""gard:0007122""",
5414,prednisone,,3/20/2024,treatment of chronic inflammatory demyelinating polyneuropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Sarcomed AB,Stortloppsvagen 25,,Stockholm,,' 12947 ' ,Sweden,994523,chronic inflammatory demyelinating polyneuropathy,"""gard:0006102""",
5415,Pretomanid,Pretomanid,7/5/2007,treatment of tuberculosis,Designated/Approved,,,"Pretomanid tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).",8/14/2019,8/14/2026,As part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).,Global Alliance for TB Drug Development,40 Wall Street,24th Floor,New York,New York,' 10005 ' ,United States,243107,tuberculosis,"""gard:0007827""",
5416,Pridopidine,,7/7/2021,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Prilenia Neurotherapeutics LTD,"10 Hamenofim St, #317-318",,Herzliya,Merkaz,' 4672561 ' ,Israel,824621,amyotrophic lateral sclerosis,"""gard:0005786""",
5417,priliximab,,9/18/2017,treatment of mycosis fungoides (mf),Designated,,Not FDA Approved for Orphan Indication,,,,,"Onco Therapies, Inc.",2265 East Foothill Boulevard,,Pasadena,California,' 91107 ' ,United States,600717,,,
5418,Primaquine phosphate,,7/23/1993,for use in combination with clindamycin hydrochloride in the treatment of pneumocystis carinii pneumonia associated with aids.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sanofi Winthrop, Inc.",90 Park Avenue,,New York,New York,' 10016 ' ,United States,74793,,,
5419,Primary Human Satellite cell-derived muscle stem cells,,7/13/2023,treatment of exstrophy-epispadias complex,Designated,,Not FDA Approved for Orphan Indication,,,,,MyoPax Denmark ApS,C/O Bioinnovation Institute Fond,Ole Maaløes Vej 3,København N,,' 2200 ' ,Denmark,948123,exstrophy-epispadias complex,"""gard:0002207""",
5420,Prime edited CD34+ cell-based drug product targeting the delGT mutation in the NCF1 gene,,1/19/2024,treatment of chronic granulomatous disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Prime Medicine,21 Erie Street,,Cambridge,Massachusetts,' 02139 ' ,United States,959423,chronic granulomatous disease,"""gard:0006100""",
5421,Prismocitrate 18,,9/19/2017,use as replacement solution (includes regional anticoagulation of the extracorporeal circuit) in patients undergoing continuous renal replacement therapy (crrt),Designated,,Not FDA Approved for Orphan Indication,,,,,Baxter Healthcare Corporation,32650 Wilson Road,WG1-3,Round Lake,Illinois,' 60073 ' ,United States,561316,,,
5422,pritumumab,,4/6/2016,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nascent Biotech, Inc.",8400 Miramar Road,Suite 247,San Diego,California,' 92126 ' ,United States,476615,,,
5423,pritumumab,,10/28/2014,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nascent Biotech, Inc.",10246 Parkdale Avenue,,San Diego,California,' 92126 ' ,United States,448514,,,
5424,Pro-Pro-Thr-Val-Pro-Thr-Arg,,7/27/2017,treatment of xeroderma pigmentosum,Designated/Designation Withdrawn or Revoked,1/28/2022,Not FDA Approved for Orphan Indication,,,,,ProGeLife S.A.S,8 Rue Sainte-Barbe,,Marseille,Provence-Alpes-Côte d'Azur,' ' ,France,587417,xeroderma pigmentosum,"""gard:0007910""",
5425,Procarbazine HCl,,8/8/2006,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Leadiant Biosciences, Inc.",9841 Washingtonian Boulevard,Suite 500,Gaithersburg,Maryland,' 20878 ' ,United States,217005,,,
5426,procaspase-activating compound 1,,7/23/2015,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vanquish Oncology, Inc.",2001 S. First Street,Suite 201,Champaign,Illinois,' 61820 ' ,United States,486615,,,
5427,Progerinin,,2/5/2020,treatment of werner syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"PRG S&T Co., Ltd.",306 Hyowon Industry-Cooperation Bldg.,Pusan National University,Geumjeong-gu,Busan,' ' ,South Korea,661818,werner syndrome,"""gard:0007885""",
5428,progerinin,,10/2/2018,treatment of hutchinson-gilford progeria syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"PRG S&T Co., Ltd.",306 Hyowon Industry-Cooperation Bldg.,Pusan National University,Geumjeong-gu,Busan,' ' ,South Korea,653718,hutchinson-gilford progeria syndrome,"""gard:0007467""",
5429,progesterone,,12/22/1994,establishment and maintenance of pregnancy in women undergoing in vitro fertilization or embryo transfer procedures.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Watson Laboratories, Inc.",311 Bonnie Circle,,Corona,California,' 91720 ' ,United States,82694,,,
5430,progesterone,,9/3/2009,for early intervention in the treatment of moderate to severe closed-head traumatic brain injury,Designated/Designation Withdrawn or Revoked,6/10/2014,Not FDA Approved for Orphan Indication,,,,,"BHR Pharma, LLC",607 Herndon Parkway,Suite 110,Herndon,Virginia,' 20170 ' ,United States,284809,,,
5431,progesterone,,6/3/2020,treatment of ocular graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"GLIA, LLC",134 Saint Botolph Street,,Boston,Massachusetts,' 02115 ' ,United States,664818,graft versus host disease,"""gard:0016642""",
5432,Proglumide,,7/23/2020,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,' 07670 ' ,United States,756620,,,
5433,Proglumide,,9/9/2020,treatment of chronic pancreatitis,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,' 07670 ' ,United States,762120,,,
5434,Proglumide,,6/16/2020,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jill P Smith, MD","Department of Medicine, Georgetown University",Building D Room 338,Washington,District of Columbia,' 20007 ' ,United States,743020,,,
5435,Proglumide,,3/13/2024,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"CCKr Therapeutics, Inc.",4364 S. Alston Ave.,,Durham,North Carolina,' 27713 ' ,United States,993423,hepatocellular carcinoma,"""gard:0016773""",
5436,Progranulin,,2/10/2020,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alpha Cognition, Inc.",439 Helmcken Street,,Vancouver,BC,' V6B 2E6 ' ,Canada,725319,amyotrophic lateral sclerosis,"""gard:0005786""",
5437,prolactin receptor antagonist,,4/15/2013,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Oncolix, Inc.",14405 Walters Road,Suite 780,Houston,Texas,' 77014 ' ,United States,392613,ovarian cancer,"""gard:0007295""",
5438,Proliferation arrested myelomonocytic leukemic cell line-derived cells with a mature dendritic cell phenotype,,10/30/2019,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Mendus BV,Emmy Noetherweg 2K,,Leiden,,' 2333 BK ' ,Netherlands,709019,acute myeloid leukemia,"""gard:0012757""",
5439,propagermanium and irbesartan,,12/9/2015,treatment of focal segmental glomerulosclerosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Dimerix Bioscience Ltd.,"Level 2, 25 Flinders Lane",,Melbourne,Victoria,' ' ,Australia,496715,,,
5440,Propamidine isethionate 0.1% ophthalmic solution,,3/10/1988,treatment of acanthamoeba keratitis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Bausch & Lomb,Pharmaceuticals Division,8500 Hidden River Parkway,Tampa,Florida,' 33637 ' ,United States,27288,,,
5441,propofol hemisuccinate,,8/19/2016,treatment of acute repetitive seizures,Designated,,Not FDA Approved for Orphan Indication,,,,,EpaleX Corporation,305 Lytton Avenue,,Palo Alto,California,' 94301 ' ,United States,530016,,,
5442,Propranolol,,8/23/2019,treatment of retinopathy of prematurity,Designated,,Not FDA Approved for Orphan Indication,,,,,"Recordati Rare Diseases, SARL","Immeuble le ""Wilson""",70 Avenue du General de Gaulle,Puteaux,,' ' ,France,703319,retinopathy of prematurity,"""gard:0005695""",
5443,propranolol,HEMANGEOL,9/5/2008,treatment of proliferating infantile hemangiomas requiring systemic therapy,Designated/Approved,,,Treatment of proliferating infantile hemangioma requiring systemic therapy.,3/14/2014,3/14/2021,Treatment of proliferating infantile hemangioma requiring systemic therapy.,Pierre Fabre Dermatologie,"8 Campus Drive, 2nd Floor",,Parsippany,New Jersey,' 07054 ' ,United States,266708,,,
5444,propranolol and etodolac,,7/8/2015,treatment of malignant glioma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vicus Therapeutics, LLC",55 Madison Avenue,Suite 400,Morristown,New Jersey,' 07960 ' ,United States,484315,,,
5445,propranolol and etodolac,,4/27/2015,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vicus Therapeutics, LLC",55 Madison Avenue,Suite 400,Morristown,New Jersey,' 07960 ' ,United States,475715,,,
5446,propranolol hydrochloride and etodolac,,2/24/2015,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vicus Therapeutics, LLC",55 Madison Avenue,Suite 400,Morristown,New Jersey,' 07960 ' ,United States,454614,hepatocellular carcinoma,"""gard:0016773""",
5447,Prosetin,,8/4/2020,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Project ALS,"801 Riverside Drive, Suite 6G",,New York,New York,' 10032 ' ,United States,754220,amyotrophic lateral sclerosis,"""gard:0005786""",
5448,Prostaglandin E1 enol ester (AS-013),,6/12/1998,treatment of fontaine stage iv chronic critical limb ischemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"LTT Baio-Pharma Co., Ltd",Research & Development Division,2-5-1 Atago,Minato-ku,Tokyo,' ' ,Japan,112898,,,
5449,Prostaglandin E1 in lipid emulsion,,9/10/1996,treatment of ischemic ulceration of the lower limbs due to peripheral arterial disease.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Alpha Therapeutic Corporation,5555 Valley Boulevard,,Los Angeles,California,' 90032 ' ,United States,88795,,,
5450,Protaxel,,5/21/2003,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biophysica, Inc.",2159 Avenida de la Playa,Suite B,La Jolla,California,' 92037 ' ,United States,168203,ovarian cancer,"""gard:0007295""",
5451,Protein C concentrate,,4/22/1993,for use in the prevention and treatment of purpura fulminans in meningococcemia.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Immuno Clinical Research Corp.,"750 Lexington Avenue, 19th Floor",,New York,New York,' 10022 ' ,United States,65292,,,
5452,Protein C concentrate,Ceprotin,6/23/1992,"for replacement therapy in congenital protein c deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans.",Designated/Approved,,,Prevention and treatment of venous thrombosis and purpura fulminans,3/30/2007,3/30/2014,,"Baxalta US, Inc.",One Baxter Way,,West Lake Village,California,' 91362 ' ,United States,65392,,,
5453,Protein C concentrate,,6/19/1992,for replacement therapy in patients with congenital or acquired protein c deficiency for the prevention and treatment of warfarin-induced skin necrosis during oral anticoagulation.,Designated,,Not FDA Approved for Orphan Indication,,,,,Immuno Clinical Research Corp.,"750 Lexington Avenue, 19th Floor",,New York,New York,' 10022 ' ,United States,65192,,,
5454,prothrombin complex concentrate (human),Kcentra,12/27/2012,treatment of patients needing urgent reversal of vitamin k antagonist therapy for treatment of major bleeding and/or surgical procedures,Designated/Approved,,,"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or need for an urgent surgery/invasive procedure.",12/13/2013,12/13/2020,"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy (VKA, e.g., warfarin) in adult patients with the need for urgent surgery/invasive procedure.",CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,305310,,,
5455,prothrombin complex concentrate (human),Kcentra,12/27/2012,treatment of patients needing urgent reversal of vitamin k antagonist therapy for treatment of major bleeding and/or surgical procedures,Designated/Approved,,,"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.",4/29/2013,4/29/2020,"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.",CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,305310,,,
5456,"prothrombin complex concentrate, human-lans",Balfaxar,2/1/2008,reversal of anticoagulation therapy in patients needing treatment of serious or life threatening bleeding and/or needing urgent surgery or invasive procedures,Designated/Approved,,,"urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for an urgent surgery/invasive procedure",7/21/2023,,,"Octapharma USA, Inc.",121 River Street,12th Floor,Hoboken,New Jersey,' 07030 ' ,United States,225806,,,
5457,Protirelin,,8/24/1993,prevention of infant respiratory distress syndrome associated with prematurity.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"UCB Pharma, Inc.",1950 Lake Park Drive,,Smyrna,Georgia,' 30080 ' ,United States,75093,,,
5458,Protirelin injection,,1/10/1985,treatment of amyotrophic lateral sclerosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Abbott Laboratories,200 Abbott Park Road,,Abbott Park,Illinois,' ' ,United States,5184,amyotrophic lateral sclerosis,"""gard:0005786""",
5459,ProTmune (ex vivo Programmed Mobilized Peripheral Blood),,9/19/2016,prevention of graft-versus-host disease in patients undergoing allogenic hematopoietic cell transplantation,Designated/Designation Withdrawn or Revoked,8/8/2022,Not FDA Approved for Orphan Indication,,,,,Fate Therapeutics,3535 General Atomics Court,Suite 200,San Diego,California,' 92121 ' ,United States,535616,,,
5460,"protoplasmic protein matrix, omega-3 fatty oils, vitamins, minerals and trace elements, cell membrane matrix phospholipid, entracellular matrix, lipids, medium chain triglycerides, longer chain triglycerides, carbohydrates, probiotic, and phytonutrients",,1/11/2017,treatment of juvenile rheumatoid arthritis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Leonard S. Girsh, MD","Immunopath Profile, Ind.",P. O. Box 770805,Naples,Florida,' 34107 ' ,United States,393713,,,
5461,"Pseudomonas aeruginosa-specific Bacteriophage Mixture, Live consisting of 3 bacteriophages (IHMA-2121771-1, IHMA-2121771-2, IHMA-2121908-1)",,12/27/2023,treatment of chronic pulmonary infection caused by pseudomonas aeruginosa in patients with cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,BiomX Inc.,22 Einstein St.,,Nes Ziona,Israel,' ' ,Israel,979123,cystic fibrosis,"""gard:0006233""",
5462,Psilocybin,,10/25/2021,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Nova Mentis Life Science Corp.,700-838 West Hasting Street,,Vancouver,British Columbia,' V6C 0A6 ' ,Canada,843421,fragile x syndrome,"""gard:0006464""",
5463,PTH(1-34)-Cys(succinimido-PEG-vitamin D) amide (human) acetate salt,,5/25/2022,treatment of hypoparathyroidism,Designated,,Not FDA Approved for Orphan Indication,,,,,Extend Biosciences Inc.,90 Bridge St.,Suite 100,Newton,Massachusetts,' 02459 ' ,United States,879122,,,
5464,Pulmonary surfactant replacement,,12/5/1988,prevention and treatment of infant respiratory distress syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Scios Nova, Inc.",2450 Bayshore Parkway,,Mountain View,California,' 94043 ' ,United States,30988,,,
5465,"Pulmonary surfactant replacement, porcine",Curosurf,8/2/1993,for the treatment and prevention of respiratory distress syndrome in premature infants.,Designated/Approved,,,Treatment (rescue) of respiratory distress syndrome in premature infants.,11/18/1999,,,"Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,' 27518 ' ,United States,71192,,,
5466,Purified Allogeneic Human Pancreatic Islets of Langerhans,,5/1/2019,treatment of brittle type 1 diabetes,Designated,,Not FDA Approved for Orphan Indication,,,,,University of Chicago,"5801 S Ellis Ave, Suite 619",,Chicago,Illinois,' 60637 ' ,United States,687819,,,
5467,purified autologous type 1 regulatory T lymphocytes specific for human type II collagen,,9/1/2015,treatment of chronic non-infectious uveitis,Designated/Designation Withdrawn or Revoked,8/28/2018,Not FDA Approved for Orphan Indication,,,,,TxCell SA,Allee de la Nertiere,,Valbonne,Sophia-Antipolis,' ' ,France,457814,uveitis,"""gard:0019549""",
5468,purified bovine type collagen,,4/27/2009,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Magnolia Therapeutics LLC,"605 Crescent Blvd., Suite 200",,Ridgeland,Mississippi,' 39157 ' ,United States,280609,idiopathic pulmonary fibrosis,"""gard:0008609""",
5469,Purified bovine Type V Collagen,,11/20/2019,prevention of primary graft dysfunction in lung transplant patients.,Designated,,Not FDA Approved for Orphan Indication,,,,,Magnolia Therapeutics LLC,"605 Crescent Blvd., Suite 200",,Ridgeland,Mississippi,' 39157 ' ,United States,710119,,,
5470,Purified extract of Pseudomonas aeruginosa,,9/22/1997,treatment of immune thrombocytopenia purpura where it is required to increase platelet counts.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Able Laboratories, Inc.",200 Highland Avenue,Suite 30,Needham,Massachusetts,' 02494 ' ,United States,106697,immune thrombocytopenia,"""gard:0005194""",
5471,Purified Human Allogeneic Pancreatic Islets of Langerhans,,3/9/2020,treatment of brittle type 1 diabetes,Designated,,Not FDA Approved for Orphan Indication,,,,,University of Minnesota,"420 Delaware Street, S.E.",MMC 195,Minneapolis,Minnesota,' 55455 ' ,United States,672918,,,
5472,Purified type II collagen,,2/9/1995,treatment of juvenile rheumatoid arthritis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"AutoImmune, Inc.",128 Spring Street,,Lexington,Massachusetts,' 02421 ' ,United States,87494,,,
5473,pVGI.1(VEGF2),,11/9/1999,treatment of thromboangiitis obliterans.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Corautus Genetics, Inc.","75 Fifth St., NW",Suite 700,Atlanta,Georgia,' 30308 ' ,United States,124599,,,
5474,PyNTTTTGT class of oligodeoxynucleotide with a 24-base single chain composed of nucleotide sequence 5'TCATCATTTTGTCATTTTGTCATT 3',,11/24/2014,treatment of rabies virus infections,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mid-Atlantic BioTherapeutics, Inc.",3805 Old Easton Rd.,,Doylestown,Pennsylvania,' 18902 ' ,United States,451914,rabies,"""gard:0007516""",
5475,Pyridine derivative containing pyridazine that inhibits lysophospholipase,,11/8/2023,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,,Ridgefield,Connecticut,' 06877 ' ,United States,968823,idiopathic pulmonary fibrosis,"""gard:0008609""",
5476,pyridine derivative containing pyridazine that inhibits lysophospholipase,,3/21/2024,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Rd,,Ridgefield,Connecticut,' 06877 ' ,United States,977323,systemic sclerosis,"""gard:0009748""",
5477,pyridoxal-5¿ phosphate monohydrate (P5P),,1/4/2017,treatment of seizures associated with pyridox(am)ine 5'-phosphate oxidase (pnpo) deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Medicure International Inc.,2-1250 Waverley Street,,Winnipeg,,' ' ,Canada,557116,,,
5478,pyridoxine; vitamin B6,,3/3/2011,treatment of pyridoxine dependent seizures.,Designated,,Not FDA Approved for Orphan Indication,,,,,"NBI Pharmaceuticals, Inc.",1087 Stoneridge Drive,,Bozeman,Montana,' 59718 ' ,United States,334311,,,
5479,pyrimethamine,,8/16/2011,treatment of gm-2 gangliosidoses (tay-sachs disease and sandhoff disease).,Designated,,Not FDA Approved for Orphan Indication,,,,,ExSAR Corporation,11 Deer Park Drive,,Monmouth Junction,New Jersey,' 08852 ' ,United States,232206,tay-sachs disease,"""gard:0007737""",
5480,pyrindinyl benzaldehyde,,1/7/2021,treatment of sickle cell disease,Designated/Designation Withdrawn or Revoked,10/23/2023,Not FDA Approved for Orphan Indication,,,,,"Illexcor Therapeutics, LLC","800 East Leigh Street, Suite 19",,Richmond,Virginia,' 23219 ' ,United States,791020,,,
5481,Pyronaridine,,10/21/2019,treatment of chagas disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc.","5616 Hilltop Needmore Rd,",,Fuquay Varina,North Carolina,' 27526 ' ,United States,696919,,,
5482,pyronaridine tetraphosphate,,2/28/2019,treatment of ebola infection,Designated,,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc.","5616 Hilltop Needmore Rd,",,Fuquay Varina,North Carolina,' 27526 ' ,United States,677019,,,
5483,Pyronaridine tetraphosphate,,2/11/2020,treatment of malaria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc.","5616 Hilltop Needmore Rd,",,Fuquay Varina,North Carolina,' 27526 ' ,United States,723819,malaria,"""gard:0006961""",
5484,Pyruvate,,2/21/2001,treatment of interstitial lung disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cellular Sciences, Inc",84 park Avenue,P.O. Box 968,Flemington,New Jersey,' 08822 ' ,United States,140900,interstitial lung disease,"""gard:0020244""",
5485,pyrvinium,,1/5/2015,treatment of familial adenomatous polyposis,Designated,,Not FDA Approved for Orphan Indication,,,,,"StemSynergy Therapeutics, Inc.",1951 NW 7th Avenue,Suite 300,Miami,Florida,' 33136 ' ,United States,458314,familial adenomatous polyposis,"""gard:0006408""",
5486,quaratusugene ozeplasmid,,8/9/2023,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genprex, Inc.","3300 Bee Cave Road, #650-227",,Austin,Texas,' 78746 ' ,United States,953123,small cell lung cancer,"""gard:0009344""",
5487,quinacrine,,6/7/2021,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,Pulmosim Therapeutics,1 Sansome Street,Suite 3500,San Francisco,California,' 94104 ' ,United States,820321,pulmonary arterial hypertension,"""gard:0007501""",
5488,quinacrine,,9/28/2012,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cleveland BioLabs, Inc & Incuron, LLC Joint Ventur",73 High Street,,Buffalo,New York,' 14203 ' ,United States,379912,hepatocellular carcinoma,"""gard:0016773""",
5489,quinacrine,,9/10/2019,treatment of ebola infection,Designated,,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc.","5616 Hilltop Needmore Rd,",,Fuquay Varina,North Carolina,' 27526 ' ,United States,701119,,,
5490,Quinacrine hydrochloride,,10/17/1984,for prevention of recurrence of pneumothorax in patients at high risk of recurrence.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Lyphomed, Inc.",,,,,' ' ,,4184,,,
5491,quinine sulfate,,12/2/2008,treatment of malaria excluding plasmodium faliparum,Designated,,Not FDA Approved for Orphan Indication,,,,,"Zydus Pharmaceuticals, Inc.",210 Carnegie Center,,Princeton,New Jersey,' 08540 ' ,United States,272008,malaria,"""gard:0006961""",
5492,quinine Sulfate,,6/3/2004,treatment of malaria,Designated/Approved,,,Treatment of uncomplicated Plasmodium falciparum malaria,8/12/2005,8/12/2012,,"AR Holding Company, Inc.",1100 Orthodox Street,,Philadelphia,Pennsylvania,' 19124 ' ,United States,185004,malaria,"""gard:0006961""",
5493,quizartinib,Vanflyta,3/18/2009,treatment of acute myeloid leukemia,Designated/Approved,,,"in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test",7/20/2023,7/20/2030,"in combination with standard induction and consolidation, and as maintenance therapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test","Daiichi Sankyo, Inc.",211 Mount Airy Road,,Basking Ridge,New Jersey,' 07920 ' ,United States,277109,acute myeloid leukemia,"""gard:0012757""",
5494,R-(-)-gossypol,,10/24/2006,treatment of chronic lymphocytic leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ascenta Therapeutics, Inc.",101 Lindenwood Drive,Suite 405,Malvern,Pennsylvania,' 19355 ' ,United States,230206,,,
5495,R-4-amino-3-(4-chlorophenyl)butanoic acid,,11/28/2008,treatment of the behavorial abnormalities associated with fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Clinical Research Associates, LLC",160 Fifth Avenue,7th Floor,New York,New York,' 10010 ' ,United States,271808,fragile x syndrome,"""gard:0006464""",
5496,R-etodolac,,12/9/2002,treatment of chronic lymphocytic leukemia,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Cephalon, Inc.",41 Moores Road,,Frazer,Pennsylvania,' 19355 ' ,United States,162702,,,
5497,rAAV2-CB-hRPE65,,2/11/2005,treatment of type ii leber's congenital amaurosis,Designated/Designation Withdrawn or Revoked,3/25/2019,Not FDA Approved for Orphan Indication,,,,,Applied Genetic Technologies Corp.,11801 Research Drive,Suite D,Alachua,Florida,' 32615 ' ,United States,197404,,,
5498,Rabbit anti-human thymocyte globulin (rATG),,9/26/2006,induction treatment to prevent rejection and to minimize maintenance immunosupression in pediatric liver transplant recipients,Designated,,Not FDA Approved for Orphan Indication,,,,,Children's Hospital of Pittsburgh,University of Pittsburgh,,Pittsburgh,Pennsylvania,' 15213 ' ,United States,226006,,,
5499,racecadotril,,4/13/2020,treatment of microvillus inclusion disease,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,' 07670 ' ,United States,732920,microvillus inclusion disease,"""gard:0007039""",
5500,Racemetyrosine,,7/31/2020,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tyme Technologies, Inc.",17 State Street,7th Floor,New York,New York,' 10004 ' ,United States,677819,,,
5501,radgocitabine,,11/28/2022,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,"Delta-Fly Pharma, Inc.",37-5 Nishikino Miyajima Kawauchi-cho,,Tokushima,,' 771-0116 ' ,Japan,912822,acute myeloid leukemia,"""gard:0012757""",
5502,radiolabeled somastatin analog,,12/31/2013,diagnostic for the management of neuroendocrine tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"RadioMedix, Inc.",9701 Richmond Avenue,Suite 222,Houston,Texas,' 77042 ' ,United States,404813,,,
5503,raloxifene,Evista,7/14/2005,reduction of the risk of breast cancer in postmenopausal women,Designated/Approved,,,Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer,9/13/2007,9/13/2014,,Eli Lilly and Company,Lilly Corporate Center,Drop Code 1853,Indianapolis,Indiana,' 46285 ' ,United States,197504,,,
5504,raloxifene hydrochloride,,8/20/2010,treatment of hereditary hemorrhagic telangiectasia,Designated,,Not FDA Approved for Orphan Indication,,,,,Consejo Superior de Investigaciones Cientificas,C/ Serrano 142,,Madrid,,' ' ,Spain,309910,hereditary hemorrhagic telangiectasia,"""gard:0006626""",
5505,ramucirumab,CYRAMZA,11/4/2011,treatment of hepatocellular carcinoma,Designated/Approved,,,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.",5/10/2019,5/10/2026,"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib.",Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,353911,hepatocellular carcinoma,"""gard:0016773""",
5506,ramucirumab,CYRAMZA,2/16/2012,treatment of gastric cancer,Designated/Approved,,,"CYRAMZA as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.",4/21/2014,4/21/2021,"Treatment of advanced gastric cancer or gastro-esophageal junction adenocarcinoma, as a single-agent after prior fluoropyrimidine-or platinum-containing therapy.",Eli Lilly and Company,33 ImClone Drive,,Branchburg,New Jersey,' 08876 ' ,United States,359711,,,
5507,ramucirumab,CYRAMZA,2/16/2012,treatment of gastric cancer,Designated/Approved,,,"Treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after prior fluoropyrimidine- or platinium-containing chemotherapy.",11/5/2014,,,Eli Lilly and Company,33 ImClone Drive,,Branchburg,New Jersey,' 08876 ' ,United States,359711,,,
5508,ranagengliotucel-L,,5/29/2009,treatment of astrocytic tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,NovaRx Corporation,6828 Nancy Ridge Drive,,San Diego,California,' 92121 ' ,United States,280009,,,
5509,Ranpirnase,,7/14/2017,treatment of ebola virus disease (evd),Designated,,Not FDA Approved for Orphan Indication,,,,,"Tamir Biotechnology, Inc.",51 John F Kennedy Parkway,1st Floor West,Short Hills,New Jersey,' 07078 ' ,United States,596317,,,
5510,ranprinase,,1/25/2007,treatment of malignant mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Alfacell Corporation,225 Belleville Ave.,,Bloomfield,New Jersey,' 07003 ' ,United States,236206,,,
5511,rapamycin,,3/20/2007,treatment of tuberous sclerosis complex,Designated,,Not FDA Approved for Orphan Indication,,,,,"OncoImmune, Inc.",333 Parkland Plaza,Suite 1000,Ann Arbor,Michigan,' 48103 ' ,United States,237007,tuberous sclerosis complex,"""gard:0007830""",
5512,rapamycin,,2/24/2016,treatment of facial angiofibromas (fa) associated with tuberous sclerosis complex (tsc).,Designated,,Not FDA Approved for Orphan Indication,,,,,AFT Pharmaceuticals Ltd.,129 Hurstmere Road,"Level 1, Nielsen Building",Takapuna,Auckland,' ' ,New Zealand,508515,tuberous sclerosis complex,"""gard:0007830""",
5513,rapamycin,,10/20/2016,treatment of pulmonary arterial hypertention,Designated,,Not FDA Approved for Orphan Indication,,,,,Lam Therapeutics,530 Old Whitfield Street,,Guilford,Connecticut,' 06437 ' ,United States,540516,,,
5514,Rapamycin (mTOR) inhibitor,,8/9/2005,treatment of bone sarcoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Merck Sharp & Dohme Corp.,"S Merck & Co., Inc. Subsidiary","P. O. Box 1000, UG-2C50",North Wales,Pennsylvania,' 19454 ' ,United States,207705,bone sarcoma,"""gard:0020547""",
5515,Rapamycin-resistant Autologous Th1/Tc1 T cells,,8/5/2021,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Rapa Therapeutics LLC,12712 Rock Creek Mill Road,Suite 5B,ROCKVILLE,Maryland,' 20852 ' ,United States,830821,multiple myeloma,"""gard:0007108""",
5516,rasburicase,Elitek,10/11/2000,treatment of malignancy-associated or chemotherapy-induced hyperuricemia.,Designated/Approved,,,"Initial management of plasma uric acid levels in pediatric patients with leukemia,lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.",7/12/2002,7/12/2009,,Sanofi-Synthelabo Research,9 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,131499,,,
5517,Ravulizumab,,11/25/2020,treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,783320,thrombotic microangiopathy,"""gard:0019227""",
5518,ravulizumab-cwvz,Ultomiris,10/27/2017,treatment of atypical hemolytic uremic syndrome (ahus),Designated/Approved,,,Treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA),7/22/2022,,,"Alexion Pharmaceuticals, Inc.",100 College Street,,New Haven,Connecticut,' 06510 ' ,United States,606917,hemolytic uremic syndrome,"""gard:0022233""",
5519,ravulizumab-cwvz,Ultomiris,6/12/2014,treatment of myasthenia gravis,Designated/Approved,,,Treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive,4/27/2022,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,434214,myasthenia gravis,"""gard:0007122""",
5520,ravulizumab-cwvz,Ultomiris,1/4/2017,treatment of paroxysmal nocturnal hemoglobinuria,Designated/Approved,,,Treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH),6/7/2021,6/7/2028,Treatment of pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH),"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,513015,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
5521,ravulizumab-cwvz,Ultomiris,1/4/2017,treatment of paroxysmal nocturnal hemoglobinuria,Designated/Approved,,,ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).,12/21/2018,12/21/2025,ULTOMIRIS¿ is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,513015,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
5522,ravulizumab-cwvz,Ultomiris,1/4/2017,treatment of paroxysmal nocturnal hemoglobinuria,Designated/Approved,,,Treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH),7/22/2022,,,"Alexion Pharmaceuticals, Inc.",100 College Street,,New Haven,Connecticut,' 06510 ' ,United States,513015,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
5523,ravulizumab-cwvz,Ultomiris,1/4/2017,treatment of paroxysmal nocturnal hemoglobinuria,Designated/Approved,,,ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).,10/9/2020,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,513015,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
5524,ravulizumab-cwvz,Ultomiris,6/24/2013,treatment of neuromyelitis optica,Designated/Approved,,,treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive,3/22/2024,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,398713,,,
5525,raxibacumab,ABthraxTM,11/12/2003,treatment of anthrax,Designated/Approved,,,"Treatment of inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs,",12/14/2012,12/14/2019,,"Human Genome Sciences, Inc.",14200 Shady Grove Road,,Rockville,Maryland,' 20850 ' ,United States,175503,,,
5526,RCH4 synthesized dimer peptide that links a lipid raft receptor to the extracellular matrix,,5/19/2021,treatment of amyotrophic lateral sclerosis (als) also known as motor neurone disease (mnd),Designated,,Not FDA Approved for Orphan Indication,,,,,R. Curran (a.k.a. The RC Charity),"56, Amanda Close",,Chigwell,Essex,' IG7 5JG ' ,United Kingdom,795520,amyotrophic lateral sclerosis,"""gard:0005786""",
5527,Re188 P2045 somatostatin analog,,2/6/2014,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Andarix Pharmaceuticals,"141 Powderhouse Blvd, Suite 1",,Somerville,Massachusetts,' 02144 ' ,United States,403013,small cell lung cancer,"""gard:0009344""",
5528,Re188 P2045 somatostatin peptide analogue,,6/19/2014,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Andarix Pharmaceuticals, Inc.",141 Powderhouse Blvd,Suite 1,Somerville,Massachusetts,' 02144 ' ,United States,434914,,,
5529,Ready-to-use vigabatrin oral liquid,,10/12/2022,treatment of infantile spasms,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pyros Pharmaceuticals, Inc.","2001 Route 46, Suite 310",,Parsippany,New Jersey,' 07054 ' ,United States,905322,,,
5530,Rebastinib,,9/3/2009,treatment of philadelphia chromosome positive chronic myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Deciphera Pharmaceuticals, LLC",643 Massachusetts,,Lawrence,Kansas,' 66044 ' ,United States,290509,chronic myeloid leukemia,"""gard:0006105""",
5531,rebastinib,,5/23/2018,treatment of facioscapulohumeral muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Genea Biocells US Inc.,11099 North Torrey Pines Road,,San Diego,California,' 92037 ' ,United States,637018,muscular dystrophy,"""gard:0007922""",
5532,reboxetine,,10/15/2018,treatment of narcolepsy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Axsome Therapeutics, Inc.","25 Broadway, 9th Floor",Suite 2000,New York,New York,' 10004 ' ,United States,656118,narcolepsy,"""gard:0022460""",
5533,recilisib sodium,,9/4/2012,treatment of acute radiation syndrome,Designated/Designation Withdrawn or Revoked,5/2/2018,Not FDA Approved for Orphan Indication,,,,,"Onconova Therapeutics, Inc.",375 Pheasant Run,,Newton,Pennsylvania,' 18940 ' ,United States,350411,acute radiation syndrome,"""gard:0021896""",
5534,recilisib sodium,,6/1/2012,prevention of acute radiation syndrome,Designated/Designation Withdrawn or Revoked,1/13/2021,Not FDA Approved for Orphan Indication,,,,,"Onconova Therapeutics, Inc.",375 Pheasant Run,,Newtown,Pennsylvania,' 18940 ' ,United States,350311,acute radiation syndrome,"""gard:0021896""",
5535,"Recombinant humanized, non-fucosylated IgG1 anti-Siglec-8 monoclonal antibody",,10/30/2019,treatment of eosinophilic esophagitis,Designated/Designation Withdrawn or Revoked,5/16/2024,Not FDA Approved for Orphan Indication,,,,,"Allakos, Inc.",75 Shoreway Road,Suite A,San Carlos,California,' 94070 ' ,United States,668818,,,
5536,recombinant AAV8 that contains a vector genome encoding a miniaturized dystrophin protein (microdystrophin),,11/8/2021,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,REGENXBIO Inc.,9804 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,847521,muscular dystrophy,"""gard:0007922""",
5537,Recombinant AAV9 expressing human alpha-N-acetylglucosaminidase,,4/30/2014,mucopolysaccharidosis iii-b (sanfilippo syndrome type b),Designated,,Not FDA Approved for Orphan Indication,,,,,The Research Institute at Nationwide Children's Hospital,700 Children's Drive-Rm WA3011,,Columbus,Ohio,' 43205 ' ,United States,433814,sanfilippo syndrome type b,"""gard:0007072""",
5538,recombinant AAV9 expressing human sulfoglucosamine sulfohydrolase,,4/29/2014,treatment of mucopolysaccharidosis type iii-a (sanfilippo syndrome type a),Designated,,Not FDA Approved for Orphan Indication,,,,,Ultragenyx Pharmaceutical Inc.,60 Leveroni Court,,Novato,California,' 94949 ' ,United States,433714,sanfilippo syndrome type a,"""gard:0007071""",
5539,Recombinant AAV9 vector encoding the human progranulin (PGRN) gene,,11/24/2021,treatment of frontotemporal dementia (ftd),Designated,,Not FDA Approved for Orphan Indication,,,,,AviadoBio Ltd.,86 Hatton Garden,Floor 5,London,London,' EC1N 8QQ ' ,United Kingdom,847621,frontotemporal dementia,"""gard:0008436""",
5540,"Recombinant AAV9 viral vector containing the transgene encoding the human WW domain-containing oxidoreductase (WWOX) protein, under the control of a human Synapsin I promoter",,12/5/2023,treatment of ww domain-containing oxidoreductase (wwox)-related developmental and epileptic encephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Mahzi Therapeutics,470 Noor Avenue,STE B #1036,South San Francisco,California,' 94080 ' ,United States,973923,,,
5541,recombinant activated Factor X variant,,3/3/2015,treatment of intracerebral hemorrhage,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",66 Hudson Boulevard East,,New York,New York,' 10001 ' ,United States,439014,,,
5542,Recombinant adeno associated virus vector targeting human PHD 2 protein,,10/10/2023,treatment of rhodopsin and pde6-associated retinopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Trustees of Columbia University in the city of New York,"Edward S. Harkness Eye Institute, Research Annex, Room 513",635 West 165th Street,New York,New York,' 10032 ' ,United States,919922,,,
5543,recombinant adeno- associated virus vector AAV2/rh8 expressing human B-hexosaminidase A and B subunits,,3/25/2013,for the treatment of sandhoff disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Nat'l Tay-Sachs & Allied Diseases Association,2001 Beacon Street,Suite 204,Boston,Massachusetts,' 02135 ' ,United States,392713,sandhoff disease,"""gard:0002521""",
5544,recombinant adeno-associated viral (AAV) vector that contains a bio-engineered capsid (AAV-Spark100) and a codon-optimized expression cassette to drive expression of a secretable form of human acid a-glucosidase (GAA),,2/1/2019,treatment of pompe disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Spark Therapeutics, Inc.",3737 Market Street,Suite 1300,Philadelphia,Pennsylvania,' 19104 ' ,United States,674118,,,
5545,recombinant adeno-associated viral (AAV) vector that contains a bioengineered capsid (AAV-Spark200) and a codon-optimized expression cassette to drive expression of the SQ form of a B-domain deleted human coagulation factor VIII (hFVIII),,1/16/2018,treatment of hemophilia a,Designated,,Not FDA Approved for Orphan Indication,,,,,"Spark Therapeutics, Inc.",3737 Market Street,Suite 1300,Philadelphia,Pennsylvania,' 19104 ' ,United States,569916,hemophilia,"""gard:0010418""",
5546,recombinant adeno-associated viral vector containing a single-stranded transgene encoding a codon-optimized human SMN1 complementary deoxyribonucleic acid under the control of the chicken beta actin promoter,,7/16/2018,treatment of spinal muscular atrophy,Designated/Designation Withdrawn or Revoked,12/9/2020,Not FDA Approved for Orphan Indication,,,,,Biogen Inc.,225 Binney Street,,Cambridge,Massachusetts,' 02142 ' ,United States,644718,,,
5547,recombinant adeno-associated viral vector serotype 8 encoding human acid alpha-glucosidase,,12/31/2019,treatment of pompe disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Astellas Gene Therapies, Inc.",480 Forbes Blvd.,,San Francisco,California,' 94080 ' ,United States,717119,,,
5548,recombinant adeno-associated viral vector serotype HSC expressing human phenylalanine hydroxylase,,7/19/2017,treatment of phenylalanine hydroxylase deficiency,Designated/Designation Withdrawn or Revoked,8/4/2023,Not FDA Approved for Orphan Indication,,,,,"Homology Medicines, Inc.",45 Wiggins Avenue,,Bedford,Massachusetts,' 01730 ' ,United States,588217,,,
5549,"Recombinant adeno-associated viral vector serotype HSC15, containing homology arms targeting the human phenylalanine hydroxylase genomic locus, and expressing human phenylalanine hydroxylase",,5/27/2022,treatment of phenylalanine hydroxylase deficiency,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Homology Medicines, Inc.",1 Patriots Park,,Bedford,Massachusetts,' 01730 ' ,United States,879022,,,
5550,Recombinant adeno-associated viral vector serotype S3 containing codon optimised expression cassette encoding human beta-glucocerebrosidase variant,,8/11/2021,treatment of gaucher disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Freeline Therapeutics, Inc.","915 Broadway, Suite 1005",,New York,New York,' 10014-4606 ' ,United States,831121,gaucher disease,"""gard:0008233""",
5551,recombinant adeno-associated viral vector serotype S3 containing codon-optimized expression cassette encoding human coagulation factor IX variant,,2/15/2019,treatment of hemophilia b,Designated/Designation Withdrawn or Revoked,9/29/2023,Not FDA Approved for Orphan Indication,,,,,Freeline Therapeutics Limited,Stevenage Bioscience Catalyst,Gunnels Wood Road,Stevenage,Hertfordshire,' ' ,United Kingdom,672318,hemophilia,"""gard:0010418""",
5552,Recombinant adeno-associated viral vector serotype S3 containing DNA encoding for human alpha-galactosidase A,,4/22/2020,treatment of fabry disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Freeline Therapeutics Limited,Stevenage Bioscience Catalyst,Gunnels Wood Road,Stevenage,Herts,' ' ,United Kingdom,734220,fabry disease,"""gard:0006400""",
5553,recombinant adeno-associated viral vector with human methylmalonyl-COA mutase (MUT) gene,,4/22/2019,treatment of methylmalonic acidemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"LogicBio Therapeutics, Inc.",610 Main St,,Cambridge,Massachusetts,' 02139 ' ,United States,681419,,,
5554,"Recombinant adeno-associated viral vector, AAV2 serotype 6 (rAAv2/6), expressing human factor 8 (hf8) cDNA",,5/3/2017,treatment of hemophilia a,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",66 Hudson Boulevard East,,New York,New York,' 10001 ' ,United States,562616,hemophilia,"""gard:0010418""",
5555,Recombinant adeno-associated virus (AAV) serotype HSC15 (rAAVHSC15) encoding human iduronate-2-sulfatase (hIDS),,7/14/2022,"treatment of mucopolysaccharidosis type ii (mps ii), also known as hunter syndrome",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Homology Medicines, Inc","Homology Medicines, Inc.",1 Patriots Park,Bedford,Massachusetts,' 01730 ' ,United States,892022,mucopolysaccharidosis,"""gard:0007065""",
5556,recombinant adeno-associated virus (AAV) vector based on the AAV serotype hu37 containing a single stranded DNA genome encoding a form of human Factor VIII,,11/20/2018,treatment of hemophilia a,Designated/Designation Withdrawn or Revoked,1/16/2024,Not FDA Approved for Orphan Indication,,,,,Bayer HealthCare LLC,100 Bayer Boulevard,P.O. Box 915,Hanover,New Jersey,' 07981 ' ,United States,659618,hemophilia,"""gard:0010418""",
5557,Recombinant adeno-associated virus (rAAV) vector expressing human retinoschisis protein RS1,,11/15/2022,treatment of juvenile x-linked retinoschisis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Langxin Qisheng (Suzhou) Biopharmaceutical Co., Ltd.","Room 101/201/301, Building C31, Bio-bay, No. 218, Xinghu Street",,Suzhou Industrial Park,Jiangsu Province,' ' ,China,909822,x-linked retinoschisis,"""gard:0004690""",
5558,Recombinant adeno-associated virus (serotype 2) (rAAV2) gene transfer agent expressing RPE65,,5/11/2009,treatment of leber's congential amaurosis,Designated,,Not FDA Approved for Orphan Indication,,,,,AmpliPhi Biosciences Corporation,601 Union St.,Suite 4200,Seattle,Washington,' 98111 ' ,United States,279209,,,
5559,recombinant adeno-associated virus alpha 1-antitrypsin vector,,1/27/2003,treatment of alpha1-antitrypsin deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,University of Massachusetts Medical School,55 Lake Avenue North,Suite S1-340,Worcester,Massachusetts,' 01655 ' ,United States,164302,,,
5560,recombinant adeno-associated virus containing human ASPA cDNA (rAAV-Olig001-ASPA),,2/17/2022,treatment of canavan disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Myrtelle, Inc.","17 State Street, Floor 3, Suite 350",,New York,New York,' 10004 ' ,United States,863321,canavan disease,"""gard:0005984""",
5561,recombinant adeno-associated virus encoded gene for X-linked mammalian inhibitor of apoptosis protein (XIAP),,8/25/2009,treatment of huntington's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neurologix, Inc.","One Bridge Plaza, North",,Fort Lee,New Jersey,' 07024 ' ,United States,287409,,,
5562,Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2,,6/24/2008,treatment of leber congenital amaurosis due to rpe65 mutations.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Spark Therapeutics, Inc.",3737 Market Street,Suite 1300,Philadelphia,Pennsylvania,' 19104 ' ,United States,259308,leber congenital amaurosis,"""gard:0000634""",
5563,recombinant adeno-associated virus serotype 2 containing human mitochondrial ND1 codon optimized gene (rAAV2-ND1),,1/13/2022,treatment of leber's hereditary optic neuropathy (lhon),Designated,,Not FDA Approved for Orphan Indication,,,,,"Neurophth Therapeutics, Inc.","6042 Cornerstone Ct W, Suite D",,San Diego,California,' 92121 ' ,United States,856321,hereditary optic neuropathy,"""gard:0019540""",
5564,recombinant adeno-associated virus serotype 2 vector encoding human cytochrome P450 family 4 subfamily V member 2 (CYP4V2),,4/24/2024,treatment of bietti crystalline corneoretinal dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"NGGT (Suzhou) Biotechnology Co., Ltd.","Building 5, Zone A, Phase III Suzhou BioBAY",,SuZhou,Jiangsu,' 215125 ' ,China,923122,,,
5565,Recombinant adeno-associated virus serotype 2/1 vector encoding human beta-hexosaminidase alpha & beta subunits (rAAV2/1 Hex alpha & beta),,11/14/2017,treatment of gm2 gangliosidosis (tay-sachs & sandhoff diseases),Designated,,Not FDA Approved for Orphan Indication,,,,,University of Cambridge,Hills Road,Addenbroke's Hospital,Cambridge,England,' ' ,United Kingdom,614617,gm2 gangliosidosis,"""gard:0021323""",
5566,Recombinant adeno-associated virus serotype 8 (rAAV2/8) vector expressing bioengineered B domain deleted liver-codon-optimized human factor VIII,,1/27/2020,treatment of hemophilia a,Designated,,Not FDA Approved for Orphan Indication,,,,,"ASC Therapeutics, Inc.",521 Cottonwood Dr.,,Milpitas,California,' 95035 ' ,United States,720819,hemophilia,"""gard:0010418""",
5567,recombinant adeno-associated virus serotype 8 vector encoding human glucose-6-phosphatase-alpha (G6Pase or G6PC),,9/28/2016,treatment of glycogen storage disease type ia (von gierke disease),Designated,,Not FDA Approved for Orphan Indication,,,,,"Ultragenyx Pharmaceutical, Inc.",60 Leveroni Court,,Novato,California,' 94949 ' ,United States,536016,glycogen storage disease,"""gard:0018973""",
5568,recombinant adeno-associated virus serotype 8 vector encoding human phenylalanine hydroxylase (PAH),,1/9/2023,treatment of phenylketonuria (pku),Designated,,Not FDA Approved for Orphan Indication,,,,,NGGT INC.,3166 Linda Vista Ln.,,Lafayette,California,' 94549-4111 ' ,United States,918222,phenylketonuria,"""gard:0007383""",
5569,recombinant adeno-associated virus serotype 9 constitutively expressing codon optimized coding sequence of human GBA1,,1/27/2020,treatment of gaucher disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Prevail Therapeutics,430 East 29th Street,Suite 940,New York,New York,' 10016 ' ,United States,726019,gaucher disease,"""gard:0008233""",
5570,"recombinant adeno-associated virus serotype 9 vector carrying high-fidelity Cas13Y (hfCas13Y), an RNA editor, gene expression cassette, and guide RNAs targeting human MECP2",,10/30/2023,treatment of methyl-cpg binding protein 2 (mecp2) duplication syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cholgene Therapeutics, Inc.","54 Old Highway 22, Suite 220",,Clinton,New Jersey,' 08809 ' ,United States,967623,n syndrome,"""gard:0003902""",
5571,recombinant adeno-associated virus serotype 9 vector containing the codon optimized human alpha-N-acetylglucosaminidase (NAGLU) gene,,8/1/2023,"treatment of mucopolysaccharidosis (mps) iiib, also called sanfilippo syndrome b",Designated,,Not FDA Approved for Orphan Indication,,,,,"NeuroGT, Inc.",510 Meadowmont Village Circle #135,,Chapel Hill,North Carolina,' 27517 ' ,United States,951923,mucopolysaccharidosis,"""gard:0007065""",
5572,recombinant adeno-associated virus serotype 9 vector containing the transgene UBE3A encoding for ubiquitin protein ligase E3A/E6-AP,,10/29/2015,treatment of angelman syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",500 Warren Corporate Center Drive,,Warren,New Jersey,' 07059 ' ,United States,494815,angelman syndrome,"""gard:0005810""",
5573,Recombinant adeno-associated virus serotype 9 vector expressing codon-optimized miniaturized version of DMD gene,,5/22/2017,treatment of duchenne muscular dystrophy (dmd),Designated,,Not FDA Approved for Orphan Indication,,,,,"Bamboo Therapeutics, w wholly owned subsidiary of Pfizer",Worldwide Safety & Regulatory,Pfizer Inc.,Groton,Connecticut,' 06340 ' ,United States,583117,muscular dystrophy,"""gard:0007922""",
5574,recombinant adeno-associated virus serotype AAV8 vector encoding human ornithine transcarbamylase,,12/29/2015,treatment of ornithine transcarbamylase deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Dimension Therapeutics,840 Memorial Drive,,Cambridge,Massachusetts,' 02139 ' ,United States,499315,ornithine transcarbamylase deficiency,"""gard:0008391""",
5575,"recombinant adeno-associated virus serotype rhesus 74 (rh74) expressing the human CT GalNac transferase (GALGT2) gene, also called the Sda or Cad GAlNac transferase or b4Galnt2, under control of the muscle creatine kinase (MCK) promoter",,6/16/2015,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Nationwide Children's Hospital,700 Children's Drive,Rm W213,Columbus,Ohio,' 43205 ' ,United States,482515,muscular dystrophy,"""gard:0007922""",
5576,recombinant adeno-associated virus serotype rhesus 74 expressing the human dysferin gene (AAVrh74.MHCK7.DYSF.DV),,9/19/2016,treatment of limb girdle muscular dystrophy type 2b,Designated,,Not FDA Approved for Orphan Indication,,,,,Sarepta Therapeutics,"215 First Street, Suite 415",,Cambridge,Massachusetts,' 02142 ' ,United States,537616,muscular dystrophy,"""gard:0007922""",
5577,Recombinant adeno-associated virus type 5 vector containing codon optimized human RPGR^ORF15 protein coding gene (rAAV5-hRPGR^ORF15),,1/22/2024,treatment of retinal dystrophies due to defects in the rpgr gene,Designated,,Not FDA Approved for Orphan Indication,,,,,"Frontera Therapeutics, Inc",One Patriots Park,,Bedford,Massachusetts,' 01730 ' ,United States,983623,,,
5578,Recombinant adeno-associated virus vector carrying human CYP4V2 gene,,8/9/2021,treatment of bietti crystalline dystrophy (bcd),Designated,,Not FDA Approved for Orphan Indication,,,,,"Chigenovo Co., Ltd.","402, Building 1, Yard 9, Shengshengyuan Road","Zhongguancun Life Science Park, Changping Distric",Beijing,,' ' ,China,831621,bietti crystalline dystrophy,"""gard:0010050""",
5579,recombinant adeno-associated virus vector containing DNA encoding INT41 intrabody,,11/30/2018,treatment of huntington’s disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Vybion Inc.,584 Oak Street,,Monterey,California,' 93940 ' ,United States,662518,,,
5580,Recombinant adeno-associated virus vector containing the active biological substance AAV-GTX-hUBE3A,,10/22/2020,treatment of angelman syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",500 Warren Corporate Center Drive,,Warren,New Jersey,' 07059 ' ,United States,777420,angelman syndrome,"""gard:0005810""",
5581,recombinant adeno-associated virus vector encoding human CYP4V2 protein,,6/21/2018,treatment of bietti's crystalline dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Reflection Biotechnologies Limited,"Unit 601, 6/F, Core Building 1",No. 1 Science Park East Avenue,Pak Shek Kok,New Territories,' ' ,,609917,,,
5582,recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel alpha subunit (CNGA3),,11/16/2015,treatment of achromatopsia caused by mutations in the cnga3 gene,Designated,,Not FDA Approved for Orphan Indication,,,,,Beacon Therapeutics,14193 NW 119th Terrace,Suite 10,Alachua,Florida,' 32615 ' ,United States,496615,achromatopsia,"""gard:0015015""",
5583,recombinant adeno-associated virus vector expressing the cyclic nucleotide gated channel beta subunit (rAAV-CNGB3),,2/4/2011,treatment of achromatopsia caused by mutations in the cngb3 gene.,Designated,,Not FDA Approved for Orphan Indication,,,,,Beacon Therapeutics,14193 NW 119th Terrace,Suite 10,Alachua,Florida,' 32615 ' ,United States,332310,achromatopsia,"""gard:0015015""",
5584,recombinant adeno-associated virus vector expressing the retinitis pigmentosa GTPase regulator,,7/31/2017,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,Beacon Therapeutics,14193 NW 119th Terrace,Suite 10,Alachua,Florida,' 32615 ' ,United States,524616,retinitis pigmentosa,"""gard:0005694""",
5585,Recombinant adeno-associated virus vector serotype 5 (AAV5) harboring a codon-optimized human GLA transgene,,2/15/2024,treatment of fabry disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sichuan Real&Best Biotech Co., Ltd.","D2-10, Chengdu Tianfu international Bio-town",,"Chengdu City,Sichuan Province",,' ' ,China,988423,fabry disease,"""gard:0006400""",
5586,recombinant adeno-associated virus vector serotype 8 carrying the coding sequence of human GBA1 gene,,10/5/2023,treatment of gaucher disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Lingyi Biotech Co. Ltd.,"Room1506, 15F, Transfar Science & Technology Building",Xiaoshan Innovation Polis Hangzhou,,,' 311231 ' ,China,964923,gaucher disease,"""gard:0008233""",
5587,recombinant adeno-associated virus vector serotype 9 expressing human iduronate-2-sulfatase,,9/1/2016,"treatment of mucopolysaccharidosis ii, also called hunter syndrome a.",Designated,,Not FDA Approved for Orphan Indication,,,,,University of North Carolina at Chapel Hill,"Division of Genetics and Metabolism, CB#7487, Department of Pediatrics",,Chapel Hill,North Carolina,' 27599 ' ,United States,534016,mucopolysaccharidosis,"""gard:0007065""",
5588,recombinant adeno-associated virus vector serotype 9 expressing human N-Sulfoglucosamine Sulfohydrolase,,9/1/2016,"treatment of mucopolysaccharidosis type iii a, also called sanfilippo syndrome a",Designated,,Not FDA Approved for Orphan Indication,,,,,Research Institute at Nationwide Children's Hospital,Center for Gene Therapy,700 Childrens Drive,Columbus,Ohio,' 43205 ' ,United States,534116,mucopolysaccharidosis,"""gard:0007065""",
5589,recombinant adeno-associated virus vector that contains a bioengineered capsid (AAV-Spark100) and a codon-optimized expression cassette to drive expression of a secretable form of alpha-galactosidase A,,8/11/2023,treatment of fabry disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Spark Therapeutics, Inc.","3737 Market Street, Suite 1300",,Philadelphia,Pennsylvania,' 19104 ' ,United States,953623,fabry disease,"""gard:0006400""",
5590,Recombinant adeno-associated virus vector-based gene therapy expressing the methylmalonyl-CoA mutase (MMUT) transgene,,10/26/2020,treatment of methylmalonic acidemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Selecta Biosciences, Inc.",65 Grove Street,,Watertown,Massachusetts,' 02472 ' ,United States,775520,,,
5591,"recombinant adeno-associated virus, serotype 1, containing a transgene that encodes a microRNA targeting huntingtin messenger RNA",,3/15/2019,treatment of huntington’s disease.,Designated/Designation Withdrawn or Revoked,5/13/2022,Not FDA Approved for Orphan Indication,,,,,Voyager Therapeutics,75 Sidney Street,,Cambridge,Massachusetts,' 02139 ' ,United States,678519,,,
5592,Recombinant adenovirus carrying the cDNA coding sequence for the human interferon gamma gene,,7/19/2017,"treatment of basal cell carcinomas in individuals with basal cell nevus syndrome (bcns), also known as gorlin syndrome",Designated,,Not FDA Approved for Orphan Indication,,,,,Ascend Biopharmaceuticals Ltd,"Level 1, 159 Dorcas Street",,South Melbourne,Victoria,' ' ,Australia,589517,gorlin syndrome,"""gard:0007166""",
5593,recombinant adenovirus vector AAV2/rh8 expressing human B-hexosaminidase A & B subunits,,3/25/2013,treatment of tay-sachs disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Na't Tay-Sachs & Allied Diseases Association,2001 Beacon Street,Suite 204,Boston,Massachusetts,' 02135 ' ,United States,392813,tay-sachs disease,"""gard:0007737""",
5594,Recombinant anti-CD-40 monoclonal antibody,,1/25/2006,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceutical Corporation,Oncology Business Unit,"One Health Plaza, Bldg 104",East Hanover,New Jersey,' 07936 ' ,United States,214505,multiple myeloma,"""gard:0007108""",
5595,Recombinant anti-CD40 monoclonal antibody,,8/12/2005,treatment of chronic lymphocytic leukemia,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceutical Corporation,Oncology Business Unit,"One Health Plaza, Bldg 104",East Hanover,New Jersey,' 07936 ' ,United States,207605,,,
5596,Recombinant anti-claudin 18.2 monoclonal antibody,,8/3/2021,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hengenix Biotech, Inc.",430 N. McCarthy Blvd.,,Milpitas,California,' 95035 ' ,United States,829321,,,
5597,recombinant anti-human activated protein C humanized monoclonal antibody,,5/30/2023,treatment of hemophilia a and b,Designated,,Not FDA Approved for Orphan Indication,,,,,Equilibra Bioscience LLC,"13915 Old Coast RD, Unit 1905",,Naples,Florida,' 34110 ' ,United States,940023,hemophilia,"""gard:0010418""",
5598,Recombinant anti-SIRPalpha humanized monoclonal antibody,,1/4/2024,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,BioRay Pharmaceutical Corp.,10239 Flanders Court,Suite 102,San Diego,California,' 92121 ' ,United States,980723,,,
5599,Recombinant antibody construct against human CD30 and CD16A,,8/20/2009,treatment of hodgkin lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Affimed GmbH,Technologiepark,Im Neuenheimer Feld 582,Heidelberg,,' ' ,Germany,288109,lymphoma,"""gard:0020548""",
5600,Recombinant bactericidal/permeability-increasing protein,,6/22/1998,treatment of severe meningococcal disease.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Xoma (US) LLC,2910 Seventh Street,,Berkeley,California,' 94710 ' ,United States,112298,,,
5601,Recombinant Bispecific antibody targeting CD123 and CD3,,11/26/2019,treatment of acute myelogenous leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Aptevo Research and Development,2401 Fourth Avenue,Suite 1050,Seattle,Washington,' 98121 ' ,United States,711019,,,
5602,recombinant bispecific human IgG4 antibody which functionally mimics the procoagulant properties of activated FVIII,,5/10/2021,treatment of hemophilia a,Designated,,Not FDA Approved for Orphan Indication,,,,,"Novo Nordisk, Inc.",800 Scudders Mill Rd.,,Plainsboro,New Jersey,' 08536 ' ,United States,814121,hemophilia,"""gard:0010418""",
5603,recombinant bispecific humanized anti-programmed cell death 1 (PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody,,2/18/2021,treatment of stage ia2-iv cervical cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Akeso Biopharma, Inc.","6 Shennong Road, Torch Development Zone",,Zhongshan,Guangdong,' ' ,China,729219,,,
5604,recombinant botulinum vaccine A/B,,2/26/2019,"prevention of botulism caused by inhalational intoxication with botulinum neurotoxin (bont) serotype a, subtype a1, and bont serotype b, subtype b1.",Designated,,Not FDA Approved for Orphan Indication,,,,,"The Surgeon General, Department of the Army",Medical Research and Materiel Command 1430 Veterans Drive,,Fort Detrick,Maryland,' 21702-5009 ' ,United States,652618,botulism,"""gard:0000943""",
5605,Recombinant coagulation factor VIIa,,4/26/2006,treatment of diffuse alveolar hemorrhage,Designated/Designation Withdrawn or Revoked,8/24/2021,Not FDA Approved for Orphan Indication,,,,,Savara Inc.,900 S. Capital Texas Highway,Suite 150,Austin,Texas,' 78746 ' ,United States,213005,diffuse alveolar hemorrhage,"""gard:0019110""",
5606,Recombinant complement-specific multimerized human IgG1 Fc,,10/21/2019,treatment of autoimmune hemolytic anemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gliknik, Inc.",801 W. Baltimore Street,Suite 501A,Baltimore,Maryland,' 21201 ' ,United States,705619,autoimmune hemolytic anemia,"""gard:0005870""",
5607,recombinant deriative of C3 transferase,,11/18/2005,treatment of acute spinal cord injury,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vertex Pharmaceuticals, Inc.",50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,213505,spinal cord injury,"""gard:0019109""",
5608,recombinant DNA plasmid,,1/31/2014,"treatment of stage iib, iic, iii and iv melanoma.",Designated,,Not FDA Approved for Orphan Indication,,,,,Scancell Ltd.,"Bellhouse Building, Sanders Road, Oxford Science Park",,Oxford,,' OX4 4GD ' ,United Kingdom,417313,noma,"""gard:0004001""",
5609,recombinant elafin,,3/18/2013,prevention of inflammatory complications of transthoracic esophagectomy,Designated,,Not FDA Approved for Orphan Indication,,,,,tiakis Biotech AG,Sophienblatt 40,,Kiel,,' D-24103 ' ,Germany,364612,,,
5610,Recombinant Epstein-Barr virus gp350 glycoprotein vaccine,,8/18/2005,prevention of post-transplantation lymphoproliferative disorders in pediatric recipients of solid-organ transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,Henogen S.A.,"Rue des Professeurs Jenner et Brachet, 12",B-6041-Gosselies,Charleroi,,' ' ,Belgium,148001,,,
5611,recombinant fragment human surfactant protein-D,,11/1/2017,prevention of bronchopulmonary dysplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,Trimunocor Ltd.,2 Victoria Road,,Hertfordshire,England,' ' ,United Kingdom,588317,bronchopulmonary dysplasia,"""gard:0005962""",
5612,Recombinant fully human monoclonal antibody to anthrax protective antigen,,2/16/2006,treatment of anthrax infection,Designated/Designation Withdrawn or Revoked,1/26/2023,Not FDA Approved for Orphan Indication,,,,,"Altimmune, Inc.","910 Clopper Road, Suite 201",,Gaithersburg,Maryland,' 20878 ' ,United States,218005,,,
5613,Recombinant fully humanized anti-IL 6 monoclonal antibody,,8/15/2022,treatment of uveitic macular edema,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,857221,,,
5614,Recombinant Fusion Protein,,7/24/2012,treatment of myelodysplastic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Apogenix GmbH,Im Neuenheimer Feld 584,,Heidelberg,,' ' ,Germany,371612,myelodysplastic syndrome,"""gard:0007132""",
5615,recombinant fusion protein (biologic) made by linking human serum albumin to a human Insulin-like growth factor 2 sequence,,11/27/2023,treatment of myotonic dystrophy type 1,Designated,,Not FDA Approved for Orphan Indication,,,,,"Juvena Therapeutics, Inc.",640 Galveston Drive,,Redwood City,California,' 94063 ' ,United States,972623,myotonic dystrophy,"""gard:0010419""",
5616,recombinant fusion protein composed of a recombinant human arylsulfatase A (rhARSA) fused with a variable domain of the heavy chain of heavy chain-only antibody fragment targeting human transferrin,,12/15/2023,treatment of metachromatic leukodystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Linno Pharmaceuticals, Inc.","Suite 503, Building #2, 720 Cailun Road, Zhangjiang High-Tech Park, Pudong New District",,Shanghai,Shanghai,' 201203 ' ,China,975123,leukodystrophy,"""gard:0006895""",
5617,recombinant fusion protein comprising exenatide and XTEN,,10/7/2015,treatment of short bowel syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"9 Meters Biopharma, Inc.","8480 Honeycutt Road, Suite 120",,Raleigh,North Carolina,' 27615 ' ,United States,489615,short bowel syndrome,"""gard:0001502""",
5618,Recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG,,1/20/2022,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Trillium Therapeutics Inc.,2488 Dunwin Drive,,Mississauga,Ontario,' L5L1J9 ' ,Canada,858521,multiple myeloma,"""gard:0007108""",
5619,recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP),Idelvion,4/27/2012,treatment of patients with congenital factor ix deficiency (hemophilia b).,Designated/Approved,,,"Indicated in children and adults with hemophilia B (congenital Factor IX deficiency) for the (1) on-demand control and prevention of bleeding episodes, (2) perioperative management of bleeding, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes.",3/4/2016,3/4/2023,"Indicated for the (1) on-demand control and prevention of bleeding episodes, (2) perioperative management of bleeding, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes.","CSL Behring, LLC",1020 First Avenue,P.O. Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,366712,hemophilia,"""gard:0010418""",
5620,recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP),,5/6/2013,treatment of congenital factor vii deficiency which includes treatment and prophylaxis of bleeding episodes in patients with congenital factor vii deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,PO Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,396313,congenital factor vii deficiency,"""gard:0002238""",
5621,Recombinant fusion protein of human alpha-L-iduronidase (IDUA) and Fab fragment of a humanized monoclonal antibody targeting human transferrin receptor (hTfR).,,2/8/2021,treatment of mucopolysaccharidosis type i (mps i),Designated,,Not FDA Approved for Orphan Indication,,,,,"JCR Pharmaceuticals Co., Ltd.","3-19 Kasuga-cho Ashiya,",,Hyogo,,' 659-0021 ' ,Japan,798120,mucopolysaccharidosis,"""gard:0007065""",
5622,Recombinant fusion protein of Mycobacterium bovis BCG Hsp65 and HPV16 E7,,3/19/2001,treatment of recurrent respiratory papillomatosis (rrp),Designated,,Not FDA Approved for Orphan Indication,,,,,"StressGen Biotechnologies, Inc. is now Nventa",Nventa Biopharmaceuticals Corporation,6055 Lusk Boulevard,San Diego,California,' 19426 ' ,United States,141200,recurrent respiratory papillomatosis,"""gard:0000111""",
5623,recombinant fusion protein with a truncated form of the cytotoxic protein Pseudomonas exotoxin,,1/28/2005,treatment of ep-cam-positive squamous cell carcinoma of the head and neck,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sesen Bio, Inc. (Sesen Bio)",2929 Arch Street,17th Floor,Philadelphia,Pennsylvania,' 19104 ' ,United States,195304,noma,"""gard:0004001""",
5624,Recombinant fusion protein-extracellular portion of CD95 fused to the Fc part of human IgG1,,10/13/2009,treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,Apogenix GmbH,Im Neuenheimer Feld 584,,Heidelberg,,' ' ,Germany,293009,glioblastoma,"""gard:0002491""",
5625,recombinant growth hormone fused to hyFc,,11/9/2016,treatment of growth hormone deficiency.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genexine, Inc.",700 Daewangpangyo-ro,"Korea Bio Pk Bldg B, Bundang-gu",Gyeonggi-do,,' ' ,South Korea,523716,,,
5626,Recombinant human acid alpha-glucosidase; alglucosidase alfa,1. Myozyme 2. Lumizyme,8/19/1997,treatment of glycogen storage disease type ii.,Designated/Approved,,,(Lumizyme) Patients with Pompe disease (acid alpha-glucosidase (GAA deficiency)).,8/1/2014,,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,106597,glycogen storage disease,"""gard:0018973""",
5627,Recombinant human acid alpha-glucosidase; alglucosidase alfa,1. Myozyme 2. Lumizyme,8/19/1997,treatment of glycogen storage disease type ii.,Designated/Approved,,,"Myozyme for use in patients with Pompe disease (GAA deficiency). Alglucosidase alfa has been shown to improve ventilator-free survival in patients with infantile onset Pompe disease as compared to an untreated historical control, whereas use of Alphaglucosidase in patients with other forms of Pompe disease has not been adequately studied to assure safety and efficacy.",4/28/2006,4/28/2013,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,106597,glycogen storage disease,"""gard:0018973""",
5628,Recombinant human acid alpha-glucosidase; alglucosidase alfa,1. Myozyme 2. Lumizyme,8/19/1997,treatment of glycogen storage disease type ii.,Designated/Approved,,,"Lumizyme for patients 8 years and older with late (non-infantile) onset Pompe disease (GAA deficiency) who do not have evidence of cardiac hypertrophy. The safety and efficacy of Lumizyme (alglucosidase alfa) have not been evaluated in controlled clinical trials in infantile-onset patients, or in late (non-infantile) onset patients less than 8 years of age",5/24/2010,,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,106597,glycogen storage disease,"""gard:0018973""",
5629,recombinant human acid ceramidase,,12/24/2013,treatment of farber disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aceragen, Inc.",15 TW Alexander Drive,,Durham,North Carolina,' 27709 ' ,United States,415313,farber disease,"""gard:0006426""",
5630,Recombinant Human Adeno-Associated Virus Serotype 2 Containing Human Mitochondrial ND4 gene (rAAV2-ND4),,9/22/2020,treatment of leber's hereditary optic neuropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neurophth Therapeutics, Inc.",200 Continental Drive,"Suite 401, Room 411",New Castle,Delaware,' 19713 ' ,United States,765420,hereditary optic neuropathy,"""gard:0019540""",
5631,recombinant human alkaline phosphatase,,5/13/2015,treatment of hypophosphatasia.,Designated,,Not FDA Approved for Orphan Indication,,,,,#NAME?,Rumpsterweg 6,,Bunnik,,' ' ,Netherlands,476815,hypophosphatasia,"""gard:0006734""",
5632,Recombinant human alpha 1-antitrypsin,,4/28/2005,prevention of bronchopulmonary dysplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Arriva Pharmaceuticals, Inc.",1010 Atlantic Avenue,,Alameda,California,' 94501 ' ,United States,203705,bronchopulmonary dysplasia,"""gard:0005962""",
5633,recombinant human alpha 1-antitrypsin (rAAT),,11/20/2001,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,AiroMedica LLC,6114 LaSalle Avenue,Suite 141,Oakland,California,' 94611 ' ,United States,149301,cystic fibrosis,"""gard:0006233""",
5634,recombinant human alpha-1 antitrypsin,,3/6/1998,treatment of cystic fibrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,PPL Therapeutics (Scotland) Limited,Roslin,,Edinburgh,Scotland,' ' ,United Kingdom,111098,cystic fibrosis,"""gard:0006233""",
5635,recombinant human alpha-1 antitrypsin (rAAT),,8/28/2001,to delay progression of chronic obstructive pulmonary disease resulting from aat deficiency-mediated emphysema and bronchiectasis,Designated,,Not FDA Approved for Orphan Indication,,,,,AiroMedica LLC,6114 LaSalle Avenue,Suite 141,Oakland,California,' 94611 ' ,United States,147601,,,
5636,Recombinant human alpha-1 antitrypsin from Oryza sativa,,2/19/2020,treatment of alpha-1 antitrypsin deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,Wuhan Healthgen Biotechnology Corporation,"D3-2, #666, Gaoxin Avenue",East Lake High-Tech Development Zone,Wuhan,Hubei,' ' ,China,724219,,,
5637,Recombinant Human Alpha-Fetoprotein (rhAFP),,2/22/2001,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alpha Cancer Technologies, Inc.","MaRS Discovery District, South Tower",200-101 College St.,Toronto,,' ' ,Canada,140300,myasthenia gravis,"""gard:0007122""",
5638,recombinant human alpha-galactosidase A fused in-frame to the aglycosylated human IgG4 Fc mutein,,5/24/2024,treatment of fabry disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hanmi Pharmaceutical. Co., Ltd.","14 Wiryeseong-daero,",,Songpa-gu,Seoul,' 05545 ' ,South Korea,1003324,fabry disease,"""gard:0006400""",
5639,recombinant human alpha-N-acetylglucosaminidase,,4/15/2013,treatment of mucopolysaccharidosis iiib (sanfilippo b syndrome),Designated/Designation Withdrawn or Revoked,9/11/2017,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",100 College Street,,Hew Haven,Connecticut,' 06510 ' ,United States,394113,mucopolysaccharidosis,"""gard:0007065""",
5640,recombinant human anti-ATTR-immunoglobulin G1 monoclonal antibody,,10/2/2023,treatment of transthyretin amyloidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,963923,amyloidosis,"""gard:0018676""",
5641,Recombinant human anti-GDF-8 (growth and differentiation factor-8) antibody,,2/16/2005,treatment of duchenne and becker muscular dystrophies,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Wyeth Pharmaceuticals, Inc.",P. O. Box 8299,,Philadelphia,Pennsylvania,' 19101 ' ,United States,199104,,,
5642,recombinant human anti-GDF-8 monoclonal antibody,,7/24/2012,treatment of duchenne muscular dystrophy.,Designated/Designation Withdrawn or Revoked,4/12/2021,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",500 Arcola Road,,Collegeville,Pennsylvania,' 19426 ' ,United States,373412,muscular dystrophy,"""gard:0007922""",
5643,"recombinant human anti-human sortilin (SORT1) IgG1 G1m17,1 [or G1m (z,a)] kappa monoclonal antibody",,7/22/2019,treatment of frontotemporal dementia,Designated/Designation Withdrawn or Revoked,9/5/2023,Not FDA Approved for Orphan Indication,,,,,"Alector, Inc.","131 Oyster Point Boulevard, Suite 300",,South San Francisco,California,' 94080 ' ,United States,680219,frontotemporal dementia,"""gard:0008436""",
5644,"recombinant human anti-human Sortilin (SORT1) monoclonal IgG1 G1m17,1 [or G1m (z,a)] kappa monoclonal antibody",,6/18/2018,treatment of frontotemporal dementia,Designated,,Not FDA Approved for Orphan Indication,,,,,Alector,151 Oyster Point Boulevard,Suite 300,South San Francisco,California,' 94080 ' ,United States,605817,frontotemporal dementia,"""gard:0008436""",
5645,"recombinant human anti-TGFBeta IgG2 monoclonal antibody that belongs to the IgG2/Gamma isotype subclass and binds TGFBeta1 and TGFBeta2 with high affinity and, to a lesser extent, TGFBeta3",,7/21/2021,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hannover,New Jersey,' 07936 ' ,United States,828421,,,
5646,Recombinant human antibody directed against human misfolded superoxide dismutase 1,,8/10/2017,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,AL-S Pharma SA,13 Wagistrasse,,Schlieren,Zürich,' ' ,Switzerland,596417,amyotrophic lateral sclerosis,"""gard:0005786""",
5647,recombinant human antithrombin,ATryn,12/7/2007,"treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures",Designated/Approved,,,"Prevention of peri-operative and peri-partum thromboembolic events, in hereditary antithrombin deficient patients.",2/6/2009,2/6/2016,,"GTC Biotherapeutics, Inc.",175 Crossing Blvd,,Framingham,Massachusetts,' 01702 ' ,United States,246807,,,
5648,Recombinant human antithrombin III,,4/6/2000,treatment of antithrombin iii dependent heparin resistance requiring anticoagulation.,Designated,,Not FDA Approved for Orphan Indication,,,,,AT III LLC,c/o Genzyme Corporation,"15 Pleasant St. Connector, P.O. Box 9322",Framingham,Massachusetts,' 01701 ' ,United States,118798,,,
5649,Recombinant human apolipoprotein A-I/phospholipid complexes,,1/10/2022,treatment of lecithin-cholesterol acyltransferase (lcat) deficiency including familial lcat deficiency and fisheye disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Abionyx Pharma,33-43 avenue Georges Pompidou,Batiment D2,Balma,FRANCE,' 31130 ' ,France,856021,lcat deficiency,"""gard:0016539""",
5650,recombinant human arylsulphatase A,,4/11/2008,treatment of metachromatic leukodystrophy (mld).,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Shire Human Genetic Therapies,300 Patriot Way,,Lexington,Massachusetts,' 02421 ' ,United States,170903,leukodystrophy,"""gard:0006895""",
5651,recombinant human biglycan,,7/13/2016,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tivorsan Pharmaceuticals, Inc.",3 Davol Square,A340,Providence,Rhode Island,' 02903 ' ,United States,526416,muscular dystrophy,"""gard:0007922""",
5652,Recombinant human C1 inhibitor,,6/9/2006,prevention and/or treatment of delayed graft function after solid organ transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,Pharming Group N.V.,P. O. Box 451 Darwinweg 24,,Leiden,,' ' ,Netherlands,218306,,,
5653,Recombinant human C1 inhibitor,,6/9/2006,treatment of capillary leakage syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Pharming Group N.V.,P. O. Box 451 Darwinweg 24,,Leiden,,' ' ,Netherlands,218406,,,
5654,Recombinant human C1-esterase inhibitor,,2/23/1999,prophylactic treatment of angioedema caused by hereditary or acquired c1-esterase inhibitor deficiency.,Designated,,Not FDA Approved for Orphan Indication,,,,,Pharming Group N.V.,P. O. Box 451 Darwinweg 24,,Leiden,,' ' ,Netherlands,122498,,,
5655,recombinant human CD24FcIg (humanized fusion protein consisting of the extracellular domain of CD24 linked to IgG1 Fc domain,,6/9/2015,prevention of graft-versus-host disease,Designated/Designation Withdrawn or Revoked,5/1/2024,Not FDA Approved for Orphan Indication,,,,,Merck Sharp & Dohme LLC,126 East Lincoln Ave.,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,478915,,,
5656,Recombinant human CD4 immunoglobulin G,,8/30/1990,treatment of aids resulting from infection with hiv-1.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",460 Point San Bruno Boulevard,,South San Francisco,California,' 94080 ' ,United States,44090,,,
5657,recombinant human cerebral dopamine neurotrophic factor,,6/8/2016,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Herantis Pharma Plc,4 Viikinkaari,,Helsinki,,' ' ,Finland,515515,amyotrophic lateral sclerosis,"""gard:0005786""",
5658,Recombinant human Clara Cell 10kDa protein,,7/13/1998,prevention of neonatal bronchopulmonary dysplasia in premature neonates with respiratory distress syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Trove Therapeutics, Inc.",9430 Key West Avenue,,Rockville,Maryland,' 20850 ' ,United States,113998,bronchopulmonary dysplasia,"""gard:0005962""",
5659,recombinant human club cell protein,,4/10/2017,treatment of bronchiolitis obliterans,Designated,,Not FDA Approved for Orphan Indication,,,,,"Trove Therapeutics, Inc.",9430 Key West Avenue,,Rockville,Maryland,' 20850 ' ,United States,550216,,,
5660,recombinant human collagen alpha-1 (VII) chain homo-trimer (rC7),,3/17/2014,treatment of dystrophic epidermolysis bullosa,Designated,,Not FDA Approved for Orphan Indication,,,,,Phoenix Tissue Repair,P. O. Box 370,,Andover,Massachusetts,' 01810 ' ,United States,422514,dystrophic epidermolysis bullosa,"""gard:0002150""",
5661,recombinant human deoxyribonuclease I,,8/18/2014,treatment of graft-vs-host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"CLS Therapeutics, Inc.",180 Varick Street,,New York,New York,' 10014 ' ,United States,447114,,,
5662,recombinant human deoxyribonuclease I (DNase I),,8/18/2014,prevention of graft-vs-host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"CLS Therapeutics, Inc.",180 Varick Street,,New York,New York,' 10014 ' ,United States,439614,,,
5663,Recombinant human ectonucleotide pyrophosphatase/phosphodiesterase 1 fused to the Fc fragment of IgG1,,2/4/2021,treatment of adenosine triphosphate binding cassette subfamily c member 6 deficiency (abcc6 deficiency),Designated,,Not FDA Approved for Orphan Indication,,,,,"Inozyme Pharma, Inc.","321 Summer Street, Suite 400",,Boston,Massachusetts,' 02210 ' ,United States,660118,,,
5664,recombinant human endostatin protein,,2/21/2002,treatment of metastatic melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"EntreMed, Inc.",9640 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,153101,noma,"""gard:0004001""",
5665,Recombinant human endostatin protein,,8/13/2001,treatment of neuroendocrine tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"EntreMed, Inc.",9640 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,146301,,,
5666,recombinant human erythropoietin (rHuEPO),,5/26/2011,treatment of mutliple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"XTL Biopharmaceuticals, Ltd",85 Medinat Hayehudim St.,,Herzliya Pituach 46766,,' ' ,Israel,341711,,,
5667,recombinant human fibrinogen,,10/4/2007,treatment of bleeding in patients deficient in fibrinogen,Designated,,Not FDA Approved for Orphan Indication,,,,,Pharming Technologies B.V.,Darwinweg 24,,Leiden,CR,' ' ,Netherlands,230906,,,
5668,Recombinant human fibroblast growth factor receptor 3,,6/2/2017,treatment of achondroplasia.,Designated/Designation Withdrawn or Revoked,3/21/2023,Not FDA Approved for Orphan Indication,,,,,Pfizer Inc.,235 East 42nd Street,,New York,New York,' 10017 ' ,United States,567916,achondroplasia,"""gard:0008173""",
5669,recombinant human fibroblast growth factor-20,,1/29/2004,treatment of radiation induced oral mucositis,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,CuraGen Corporation,322 East Main Street,,Branford,Connecticut,' 06405 ' ,United States,179203,,,
5670,recombinant human fucosyltransferase VI [ FTVI ] + GDP-fucose,,1/27/2015,to increase the activity of regulatory t-cells (tregs) used in the prevention of graft versus host disease in patients undergoing hematopoietic stem cell transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,"TargaZyme, Inc.",2100 Palomar Airport Road,Suite 214-219,Carlsbad,California,' 92011 ' ,United States,459214,graft versus host disease,"""gard:0016642""",
5671,recombinant human galactocerebrosidase (rhGALC);,,12/12/2011,treatment of globoid cell leukodystrophy (krabbe disease),Designated/Designation Withdrawn or Revoked,4/7/2021,Not FDA Approved for Orphan Indication,,,,,"Chiesi USA, Inc.",175 Regency Woods Place,Ste. 600,Cary,North Carolina,' 27518 ' ,United States,357711,leukodystrophy,"""gard:0006895""",
5672,Recombinant human gelsolin,,1/12/1994,treatment of the respiratory symptoms of cystic fibrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioAegis Therapeutics, Inc.",6 East Cove Lane,,Morristown,New Jersey,' 07960 ' ,United States,78393,cystic fibrosis,"""gard:0006233""",
5673,Recombinant human gelsolin,,3/6/1995,treatment of acute and chronic respiratory symptoms of bronchiectasis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioAgeis, Therapeutics, Inc.",6 East Cove Lane,,Morristown,New Jersey,' 07960 ' ,United States,85394,,,
5674,Recombinant human glutamic acid decarboxylase 65KDa isoform,,3/22/2010,treatment of type i diabetes with residual beta cell function,Designated,,Not FDA Approved for Orphan Indication,,,,,Diamyd Therapeutics AB,Linnegatan 89B,,Stockholm,,' ' ,Sweden,274508,,,
5675,"recombinant human GM-CSF, molgramostim",,10/31/2012,treatment of pulmonary alveolar proteinosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Savara Inc.,One Summit Square,"1717 Langhorne Newtown Road, Suite 300",Langhorne,Pennsylvania,' 19047 ' ,United States,377912,,,
5676,recombinant human gowth hormone in an ocular delivery system,,12/3/2012,treatment of persistent corneal epithelial defects,Designated,,Not FDA Approved for Orphan Indication,,,,,Jade Therapeutics LLC,7585 Ranch Club Trail,,Park City,Utah,' 84098 ' ,United States,384012,,,
5677,Recombinant human granulocyte colony stimulating factor,,7/24/2006,prevention of implantation failure and unexplained recurrent miscarriage,Designated/Designation Withdrawn or Revoked,6/22/2016,Not FDA Approved for Orphan Indication,,,,,"Nora Therapeutics, Inc.",530 Lytton Avenue,2nd Floor,Palo Alto,California,' 94301 ' ,United States,219606,,,
5678,recombinant human growth hormone fused to alpha1-antitrypsin variant,,12/19/2019,treatment of growth hormone deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alteogen, Inc.",62 Yuseong-daero 1628 beon-gil,Yuseong-gu,Daejeon,Daejeon,' ' ,South Korea,713719,,,
5679,Recombinant Human Heparan N-sulfatase (rhHNS),,1/24/2023,treatment of mucopolysaccharidosis type iiia (mps iiia),Designated,,Not FDA Approved for Orphan Indication,,,,,GC Biopharma Corp.,"107 Ihyeon-ro 30-beongil, Giheung-gu,",,Yongin-si,Gyeonggi-do,' 16924 ' ,South Korea,921622,mucopolysaccharidosis,"""gard:0007065""",
5680,Recombinant human highly phosphorylated acid alpha-glucosidase,,9/20/2000,"for enzyme replacement therapy in patients with all subtypes of glycogen storage disease type ii (gsdii, pompe disease)",Designated,,Not FDA Approved for Orphan Indication,,,,,"Novazyme Pharmaceuticals, Inc.",800 Research Parkway,Suite 200,Oklahoma City,Oklahoma,' 73104 ' ,United States,137800,glycogen storage disease,"""gard:0018973""",
5681,Recombinant human highly phosphorylated alpha-L-iduronidase (rhHP-IDUA),,4/11/2001,enzyme replacement therapy in patients with all subtypes of mucopolysaccharidosis i.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Novazyme Pharmaceuticals, Inc.",800 Research Parkway,Suite 200,Oklahoma City,Oklahoma,' 73104 ' ,United States,141801,mucopolysaccharidosis,"""gard:0007065""",
5682,recombinant human histidyl tRNA synthetase,,4/22/2015,treatment of facioscapulohumeral muscular dystrophy,Designated/Designation Withdrawn or Revoked,3/6/2020,Not FDA Approved for Orphan Indication,,,,,"aTyr Pharma, Inc.",3545 John Hopkins Court,Suite 250,San Diego,California,' 92121 ' ,United States,474215,muscular dystrophy,"""gard:0007922""",
5683,Recombinant human histidyl-tRNA synthetase,,2/23/2017,treatment of patients with limb girdle muscular dystrophy,Designated/Designation Withdrawn or Revoked,3/6/2020,Not FDA Approved for Orphan Indication,,,,,aTyr Pharma,3545 John Hopkins Court,Suite 250,San Diego,California,' 92121 ' ,United States,548416,muscular dystrophy,"""gard:0007922""",
5684,recombinant human histone H1.3; recombinant human N-bis-met-histone H1.3,,10/20/2008,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Xenetic Biosciences Plc,London Bioscience Innovation Centre,2 Royal College Street,London,,' ' ,United Kingdom,267508,acute myeloid leukemia,"""gard:0012757""",
5685,recombinant human IgG monoclonal HPA-1a antibody,,7/1/2020,prevention of fetal and neonatal alloimmune thrombocytopenia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Rallybio IPA, LLC",234 Church Street,Suite 1020,New Haven,Connecticut,' 06510 ' ,United States,735020,immune thrombocytopenia,"""gard:0005194""",
5686,Recombinant human IgG1 anti-B7H3 monoclonal antibody conjugated to topoisomerase I inhibitor YL0010014,,11/16/2023,treatment of esophageal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,MediLink Therapeutics,"Unit 101, North Block B3","BioBAY, No. 218, Xinghu Street",Suzhou,Jiangsu,' 215000 ' ,China,969723,,,
5687,recombinant human IgG1 neutralizing monoclonal antibody (mAb) that recognizes the dengue virus (DENV) envelope (E) protein,,6/21/2023,treatment of dengue,Designated,,Not FDA Approved for Orphan Indication,,,,,AbViro LLC,"4800 Hampden Lane, Suite 200",,Bethesda,Maryland,' 20814 ' ,United States,944423,,,
5688,Recombinant human IgG4 monoclonal antibody against FGF19,,2/29/2024,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Huahui Health Ltd.,"Floor 7-8, Building 5, No.9, YiKe Road","Life Science Park, Changping District",Beijing,,' ' ,China,990723,hepatocellular carcinoma,"""gard:0016773""",
5689,recombinant human IL12/15-PDL1B HSV-1 oncolytic virus injection,,1/23/2023,"treatment of intrahepatic cholangiocarcinoma (icc, icca)",Designated,,Not FDA Approved for Orphan Indication,,,,,Virogin Biotech Canada Ltd,150-13511 Commerce Parkway,,Richmond,BC,' V6V 2JB ' ,Canada,920822,cholangiocarcinoma,"""gard:0009304""",
5690,recombinant human insulin,,9/21/2022,treatment of intestinal malabsorption in preterm infants,Designated,,Not FDA Approved for Orphan Indication,,,,,"Elgan Pharma, Ltd.",Wadi El Haj 13,,Nazareth,Nazareth,' 16100 ' ,Israel,900422,,,
5691,Recombinant human insulin receptor monoclonal antibody-N-heparan sulfamidase fusion protein,,7/12/2018,"treatment of mucopolysaccharidosis type iiia, sanfilippo a syndrome",Designated,,Not FDA Approved for Orphan Indication,,,,,"ArmaGen, Inc.","26679 Agoura Road, Suite #100",,Calabasas,California,' 91302 ' ,United States,643818,mucopolysaccharidosis,"""gard:0007065""",
5692,Recombinant human insulin-like growth factor 1,,6/7/1995,treatment of growth hormone receptor deficiency.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Pharmacia & Upjohn,7000 Portage Road,,Kalamazoo,Michigan,' 49001 ' ,United States,89795,,,
5693,Recombinant human insulin-like growth factor 1,,6/7/1995,treatment of antibody-mediated growth hormone resistance in patients with isolated growth hormone deficiency ia.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Pharmacia & Upjohn,7000 Portage Road,,Kalamazoo,Michigan,' 49001 ' ,United States,90895,,,
5694,Recombinant human insulin-like growth factor-I,,10/13/1995,treatment of post-poliomyelitis syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Teva Branded Pharmaceutical Product R&D, Inc.",41 Moores Road,,Frazer,Pennsylvania,' 19355 ' ,United States,91995,poliomyelitis,"""gard:0007413""",
5695,Recombinant human insulin-like growth factor-I,,2/16/2000,treatment of short-bowel syndrome as a result of resection of the small bowel or as a result of congenital dysfunction of the intestines.,Designated,,Not FDA Approved for Orphan Indication,,,,,GroPep Pty Ltd.,"Gate 11, Victoria Dr.",Adelaide SA 5000,,,' ' ,Australia,128999,,,
5696,Recombinant human insulin-like growth factor-I/insulin-like growth factor binding protein-3,,6/15/1999,treatment of major burns that require hospitalization.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Insmed, Inc.",10 Finderne Ave,Building 10,Bridgewater,New Jersey,' 08807 ' ,United States,114298,,,
5697,recombinant human interleukin 12,,12/5/2018,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,TherapyX Inc.,108 Biomedical Research Building,3435 Main Street,Buffalo,New York,' 14214 ' ,United States,663218,,,
5698,recombinant human interleukin 22-human immunoglobulin Fc fusion protein,,10/21/2019,treatment of acute graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Generon (Shanghai) Corporation Ltd.,"Building 9, 787 Kangqiao Road",,Pudong Xinqu,Shanghai Shi,' ' ,China,581117,graft versus host disease,"""gard:0016642""",
5699,recombinant human interleukin-10 fusion protein,,11/8/2022,treatment of pouchitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Applied Molecular Transport, Inc.","1 Tower Place, Suite 850",,South San Francisco,California,' 94080 ' ,United States,784420,pouchitis,"""gard:0020510""",
5700,Recombinant human interleukin-12,,10/20/1997,treatment of renal cell carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genetics Institute, Inc.",87 Cambridge Park Drive,,Cambridge,Massachusetts,' 02140 ' ,United States,107597,renal cell carcinoma,"""gard:0013215""",
5701,recombinant human interleukin-12,,8/22/2016,treatment of acute radiation syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neumedicines, Inc.",133 Altadena Drive,Suite 133,Pasadena,California,' 91107 ' ,United States,531916,acute radiation syndrome,"""gard:0021896""",
5702,Recombinant human interleukin-15/IL-15 receptor alpha complex with linked integrin binding motif,,10/12/2021,treatment of cholangiocarcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,BJ Bioscience Inc.,1500 Wenyi West Road,"Floor 15, Building 4",Hangzhou,Zhejiang,' ' ,China,749420,cholangiocarcinoma,"""gard:0009304""",
5703,Recombinant Human Interleukin-21 (rIL-21),,10/4/2005,"treatment of stage ii (t4), iii or iv malignant melanoma.",Designated/Designation Withdrawn or Revoked,6/24/2016,Not FDA Approved for Orphan Indication,,,,,"Zymo Genetics, Inc",1201 Eastlake Avenue East,,Seattle,Washington,' 98102 ' ,United States,208005,noma,"""gard:0004001""",
5704,Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc),,11/14/2023,treatment of acute radiation syndrome (ars),Designated,,Not FDA Approved for Orphan Indication,,,,,"NeoImmuneTech, Inc.",2400 Research Blvd,Suite 250,Rockville,Maryland,' 20850 ' ,United States,969823,acute radiation syndrome,"""gard:0021896""",
5705,Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc),,4/11/2019,treatment of idiopathic cd4+ lymphocytopenia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"NeoImmuneTech, Inc.",2400 Research Boulevard,Suite 250,Rockville,Maryland,' 20850 ' ,United States,666218,,,
5706,Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc),,7/11/2022,treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,NeoImmuneTech,2400 Research Blvd,Suite 250,Rockville,Maryland,' 20850 ' ,United States,890122,glioblastoma,"""gard:0002491""",
5707,Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc).,,6/11/2020,treatment of progressive multifocal leukoencephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"NeoImmuneTech, Inc.",2400 Research Boulevard,Suite 250,Rockville,Maryland,' 20850 ' ,United States,741620,progressive multifocal leukoencephalopathy,"""gard:0007468""",
5708,Recombinant human keratinocyte growth factor,,12/20/1999,reducing the incidence and severity of radiation-induced xerostomia.,Designated,,Not FDA Approved for Orphan Indication,,,,,Swedish Orphan Biovitrum AB (publ) (SOBI),SE-112 76,,Stockholm,,' ' ,Sweden,130699,,,
5709,recombinant human lecithin:cholesterol acyltransferase (rhLCAT),,9/2/2010,treatment of familial lecithin-cholesterol acyltransferase deficiency (fld).,Designated,,Not FDA Approved for Orphan Indication,,,,,MedImmune,1 Medimmune Way,,Gaithersburg,Maryland,' 20878 ' ,United States,314010,,,
5710,Recombinant human luteinizing hormone,Luveris,10/7/1994,for use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.,Designated/Approved,,,"Luveris (lutropin alfa for injection), concomitantly administered with Gonal-f (follitropin alfa for injection), is indicated for stimulation of follicular development in infertile hypogonadotropic hypogonadal women with profound LH deficiency (LH (less than) 1.2 IU/L).",10/8/2004,10/8/2011,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,80292,,,
5711,Recombinant human lysosomal acid lipase or cholesteryl ester hydrolase,,7/14/2005,"treatment of lipase deficiencies, including wolman disease and cholesteryl ester storage disease",Designated,,Not FDA Approved for Orphan Indication,,,,,"Lysosomal Acid Lipase, LLC","Subsidiary of Kentucky BioProcessing, LLC",3700 Airpark Drive,Owensboro,Kentucky,' 42301 ' ,United States,205805,cholesteryl ester storage disease,"""gard:0012099""",
5712,Recombinant human microplasmin,,1/23/2006,treatment of peripheral arterial occlusion,Designated/Designation Withdrawn or Revoked,10/23/2020,Not FDA Approved for Orphan Indication,,,,,ThromboGenics Ltd,"Unit 14, Bridgecourt Office Park",,Dublin,,' ' ,Ireland,215805,,,
5713,recombinant human minibody against complement component,,6/7/2011,treatment of atypical hemolytic uremic syndrome associated with an inherited abnormality of the complement system.,Designated/Designation Withdrawn or Revoked,4/4/2019,Not FDA Approved for Orphan Indication,,,,,ADIENNE S.A,Via Zurigo 46,6900 Lugano,,,' ' ,Switzerland,269908,hemolytic uremic syndrome,"""gard:0022233""",
5714,recombinant human minibody against complement component C5,,2/4/2009,treatment of primary membranoproliferative glomerulonephritis,Designated/Designation Withdrawn or Revoked,4/4/2019,Not FDA Approved for Orphan Indication,,,,,ADIENNE S.A.,Via Zurigo 46,6900,Lugno,,' ' ,Switzerland,270908,primary membranoproliferative glomerulonephritis,"""gard:0011982""",
5715,recombinant human minibody against complement component C5 fused with RGD-motif,,2/4/2009,prevention of ischemia/reperfusion injury associated with solid organ transplantation.,Designated/Designation Withdrawn or Revoked,4/4/2019,Not FDA Approved for Orphan Indication,,,,,ADIENNE S.A.,Via Zurigo 46,6900,Lugno,,' ' ,Switzerland,270308,,,
5716,Recombinant human monoclonal antibody against human complement component C5a,,10/6/2016,treatment of acute graft versus host disease,Designated/Designation Withdrawn or Revoked,9/21/2017,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",100 College Street,,New Haven,Connecticut,' 06510 ' ,United States,539416,graft versus host disease,"""gard:0016642""",
5717,recombinant human monoclonal antibody of the IgG1 kappa class against prostate stem cell antigen,,12/3/2012,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,2/20/2014,Not FDA Approved for Orphan Indication,,,,,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,383812,,,
5718,recombinant human monoclonal antibody to hsp90,,9/16/2002,treatment of invasive candidiasis,Designated/Designation Withdrawn or Revoked,3/27/2018,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,' ' ,United Kingdom,158402,,,
5719,Recombinant Human Monoclonal Antibody To Vascular Endothelial Growth Factor Receptor-2,,3/8/2018,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,PharmAbcine Inc.,"#307, Daedeok Tech-Biz Center","593, Daedeok-daero",Yuseong-gu,Daejeon,' ' ,South Korea,628118,glioblastoma,"""gard:0002491""",
5720,recombinant human monoclonal IgM antibody targeting glucose regulated protein 78,,10/25/2013,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Patrys Ltd.,"Suite 614, Level 6, Equitable House",,Melbourne,Victoria,' ' ,Australia,410013,multiple myeloma,"""gard:0007108""",
5721,recombinant human N-acetylglucosamine-6-sulfatase enzyme (rhGNS),,1/16/2024,treatment of sanfilippo syndrome type d (also known as mucopolysaccharidosis mps iiid),Designated,,Not FDA Approved for Orphan Indication,,,,,Phoenix Nest Inc.,254 36th St.,,Brooklyn,New York,' 11232 ' ,United States,982323,sanfilippo syndrome type d,"""gard:0007074""",
5722,recombinant human Naglu- insulin-like growth factor II,,3/5/2013,treatment of mucopolysaccharidosis type iiib (sanfilippo syndrome type b),Designated/Designation Withdrawn or Revoked,10/17/2022,Not FDA Approved for Orphan Indication,,,,,"Shire Human Genetic Therapies, Inc.",300 Shire Way,,Lexington,Massachusetts,' 02421 ' ,United States,388712,sanfilippo syndrome type b,"""gard:0007072""",
5723,recombinant human nerve growth factor,,8/8/2013,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,Dompe S.p.A.,Via S. Martino 12-12/A,,Milan,,' ' ,Italy,402013,retinitis pigmentosa,"""gard:0005694""",
5724,Recombinant human nerve growth factor,,4/16/1999,treatment of hiv-associated sensory neuropathy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",460 Point San Bruno Boulevard,,South San Francisco,California,' 94080 ' ,United States,110898,,,
5725,recombinant human neutrophil inhibitor (hNE),,12/9/2003,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Dyax Corporation,300 Technology Square,,Cambridge,Massachusetts,' 02139 ' ,United States,173503,cystic fibrosis,"""gard:0006233""",
5726,recombinant human palmitoyl-protein thioeserase-1 (rhPPT1),,6/5/2017,treatment of ppt1-deficient neuronal ceroid lipofuscinoses,Designated,,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc.",840 Main Campus Drive,Lab 3510,Raleigh,North Carolina,' 27606 ' ,United States,570116,,,
5727,recombinant human Pentraxin-2,,8/26/2014,treatment of myelofibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,MS 241B,South San Francisco,California,' 94080 ' ,United States,416013,,,
5728,recombinant human Pentraxin-2; recombinant human Serum Amyloid P,,2/17/2012,treatment of idiopathic pulmonary fibrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,Building 45,South San Francisco,California,' 94080 ' ,United States,361111,idiopathic pulmonary fibrosis,"""gard:0008609""",
5729,Recombinant human placental growth factor,,3/16/2017,treatment of severe preeclampsia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aggamin, LLC",3960 Broadway,Suite 330B,New York,New York,' 10032 ' ,United States,559716,preeclampsia,"""gard:0012924""",
5730,Recombinant human platelet derived growth factor BB,,2/1/2007,treatment of osteonecrosis of the jaws,Designated,,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",800 Adams Avenue,Suite 100,Norristown,Pennsylvania,' 19403 ' ,United States,233106,osteonecrosis of the jaw,"""gard:0021663""",
5731,recombinant human platelet derived growth factor-BB,,8/6/2010,treatment of osteochondritis dissecans,Designated/Designation Withdrawn or Revoked,9/2/2016,Not FDA Approved for Orphan Indication,,,,,"Biomimetic Therapeutics, Inc.",389-A Nichol Mill Lane,,Franklin,Tennessee,' 37067 ' ,United States,310410,osteochondritis dissecans,"""gard:0012703""",
5732,recombinant human porphobilinogen deaminase,,9/9/2002,treatment of acute intermittent porphyria attacks,Designated/Designation Withdrawn or Revoked,4/7/2021,Not FDA Approved for Orphan Indication,,,,,"Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,' 27518 ' ,United States,157202,porphyria,"""gard:0010353""",
5733,"recombinant human porphobilinogen deaminase, erythropoetic form",,7/11/2002,treatment of acute intermittent porphyria preventing attacks,Designated/Designation Withdrawn or Revoked,4/7/2021,Not FDA Approved for Orphan Indication,,,,,"Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,' 27518 ' ,United States,157302,porphyria,"""gard:0010353""",
5734,recombinant human proinsulin (Including rhPI-Methionine),,12/10/2008,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"ProRetina Therapeutics, S.L.",Centro de Empresas de Pozuelo,,Pozuelo de Alarcon,,' ' ,Spain,271408,retinitis pigmentosa,"""gard:0005694""",
5735,Recombinant human relaxin,,11/3/1995,treatment of progressive systemic sclerosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Connetics Corporation,3400 West Bayshore Road,,Palo Alto,California,' 94303 ' ,United States,92995,systemic sclerosis,"""gard:0009748""",
5736,recombinant human rod-derived cone viability factor,,1/7/2008,treatment of retinitis pigmentosa,Designated/Designation Withdrawn or Revoked,8/1/2014,Not FDA Approved for Orphan Indication,,,,,Fovea Pharmaceuticals,12 Rue Jean Antoine de Baif,,Paris,,' ' ,France,251007,retinitis pigmentosa,"""gard:0005694""",
5737,recombinant human serum albumin human growth hormone,,1/13/2016,treatment of growth hormone deficiency,Designated/Designation Withdrawn or Revoked,3/12/2024,Not FDA Approved for Orphan Indication,,,,,"TEVA Branded Pharmaceutical Products R&D, Inc.",145 Brandywine Parkway,,West Chester,Pennsylvania,' 19380 ' ,United States,410513,,,
5738,Recombinant human signal regulating protein alpha (SIRPalpha) fragment crystallizable (Fc)-fusion protein,,11/7/2023,treatment of chronic myelomonocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,ImmuneOnco Biopharmaceuticals (Shanghai) Inc.,"Building 15, Lane 1000, Zhangheng Road",Free Trade Zone,Shanghai,,' 201203 ' ,China,969123,chronic myelomonocytic leukemia,"""gard:0008225""",
5739,Recombinant Human soluble Fc-gamma Receptor IIb,,3/22/2010,treatment of idiopathic thrombocytopenic purpura,Designated/Designation Withdrawn or Revoked,9/27/2019,Not FDA Approved for Orphan Indication,,,,,"Baxalta US Inc., now part of Shire Plc",650 Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,287709,,,
5740,Recombinant human superoxide dismutase,,4/18/1991,prevention of bronchopulmonary dysplasia in premature neonates weighing less than 1500 grams.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Savient Pharmaceuticals, Inc.","One Tower Center Boulevard, 12th floor",,East Brunswick,New Jersey,' 08816 ' ,United States,54990,bronchopulmonary dysplasia,"""gard:0005962""",
5741,recombinant human surfactant protein D,,6/23/2014,prevention of bronchopulmonary dysplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,Airway Therapeutics LLC,11804 Conrey Road,Suite 175,Cincinnati,Ohio,' 45249 ' ,United States,347011,bronchopulmonary dysplasia,"""gard:0005962""",
5742,Recombinant human thrombopoietin,,9/29/1997,for use in accelerating platelet recovery in patients undergoing hematopoietic stem cell transplantation.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,106897,,,
5743,recombinant human type VII collagen,,6/18/2008,treatment of hereditary dystrophic epidermolysis bullosa (deb),Designated,,Not FDA Approved for Orphan Indication,,,,,"David T. Woodley, MD and Mei Chen, MD","USC Department of Dermatology, Cancer Research Lab",1303 North Mission Road,Los Angeles,California,' 90033 ' ,United States,258208,dystrophic epidermolysis bullosa,"""gard:0002150""",
5744,recombinant human vascular endothelial growth factor,,6/7/2010,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,NeuroNova AB,Fiskartorpsvagen 15 A-D,,Stockholm,,' ' ,Sweden,309010,amyotrophic lateral sclerosis,"""gard:0005786""",
5745,recombinant humanized anti-CD3/CD19 bispecific antibody,,4/22/2024,treatment of follicular lymphoma (fl),Designated,,Not FDA Approved for Orphan Indication,,,,,"Curon Biopharmaceutical (Shanghai) Co., Limited","Room 103, No. 6, Lane 898 Halei Road, Pilot Free Trade Zone, Shanghai",,Shanghai,Shanghai,' 201210 ' ,China,998724,lymphoma,"""gard:0020548""",
5746,recombinant humanized anti-complement component 5 monoclonal antibody,,9/5/2017,treatment of paroxysmal nocturnal hemoglobinuria (pnh),Designated,,Not FDA Approved for Orphan Indication,,,,,Genentech Inc.,1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,590717,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
5747,Recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated to monomethyl auristatin E,,9/20/2022,treatment of patients with nasopharyngeal carcinoma (npc),Designated,,Not FDA Approved for Orphan Indication,,,,,Shanghai Miracogen Inc.,"Building 3, Suite 4E, No. 1238 Zhangjiang Rd.",Pudong District,Shanghai,,' 201203 ' ,China,899622,nasopharyngeal carcinoma,"""gard:0007163""",
5748,recombinant humanized anti-human tissue factor monoclonal antibody conjugated with a cytotoxic small molecule MMAE,,12/12/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Shanghai Miracogen Inc.,"1238 Zhangjiang Road, Building 3, Suite 4E","Pudong District, Shanghai, 201203",Shanghai,,' 201203 ' ,China,974523,,,
5749,recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody,,2/11/2015,treatment of eosinophilic esophagitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,3033 Science Park Road,Suite 300,San Diego,California,' 92121 ' ,United States,443314,,,
5750,recombinant humanized anti-interleukin 36R monoclonal antibody,,10/16/2023,treatment of generalized pustular psoriasis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shanghai Huaota Biopharmaceutical Co., Ltd.","No.538 Cailun Road, Zhangjiang High-tech. Park",,Shanghai,Shanghai,' 201203 ' ,China,951723,generalized pustular psoriasis,"""gard:0012819""",
5751,Recombinant humanized anti-LOXL2 monoclonal antibody,,4/18/2011,treatment of idiopathic pulmonary fibrosis,Designated/Designation Withdrawn or Revoked,2/1/2016,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 East Blaine St.,,Seattle,Washington,' 98102 ' ,United States,336611,idiopathic pulmonary fibrosis,"""gard:0008609""",
5752,"recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)",,5/17/2011,treatment of pancreatic cancer.,Designated/Designation Withdrawn or Revoked,5/27/2015,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 E. Blaine St.,,Seattle,Washington,' 98102 ' ,United States,339311,,,
5753,"Recombinant humanized anti-LOXL2 monoclonal antibody, IgG4(S241P)",,6/1/2011,treatment of myelofibrosis,Designated/Designation Withdrawn or Revoked,6/19/2015,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 E. Blaine St.,,Seattle,Washington,' 98102 ' ,United States,340511,,,
5754,recombinant humanized anti-matrix metalloprotein 9 (MMP9) monoclonal antibody IgG4,,7/16/2015,treatment of gastric cancer,Designated/Designation Withdrawn or Revoked,5/14/2019,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",199 E. Blaine St.,,Seattle,Washington,' 98102 ' ,United States,473815,,,
5755,Recombinant humanized anti-MSLN monoclonal antibody- monomethyl auristatin E conjugate,,5/22/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"RemeGen Co., Ltd.","58 Middle Beijing Road, Yantai Development Area",,Yantai,ShanDong,' 264006 ' ,China,938823,,,
5756,recombinant humanized anti-tau antibody,,1/22/2015,treatment of progressive supranuclear palsy,Designated,,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,460914,progressive supranuclear palsy,"""gard:0007471""",
5757,recombinant humanized anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody,,3/14/2024,treatment of hemophilia a,Designated,,Not FDA Approved for Orphan Indication,,,,,"Suzhou Alphamab Co., Ltd.","Bldg. C23, 218 Xinghu Street, Suzhou Industrial Park",,SuZhou,Jiang Su,' 215125 ' ,China,994023,hemophilia,"""gard:0010418""",
5758,Recombinant humanized anti-transforming growth factor (TGF) beta 3 antibody,,10/17/2022,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,839521,systemic sclerosis,"""gard:0009748""",
5759,Recombinant humanized IgG1 anti-Claudin18.2 monoclonal antibody conjugated to MMAE,,12/1/2022,"treatment of gastric cancer (gc), including cancer of the gastroesophageal junction (gej)",Designated,,Not FDA Approved for Orphan Indication,,,,,"RemeGen Co., Ltd.","58 Middle Beijing Road, Yantai Development Area",,Yantai,ShangDong,' 264006 ' ,China,913822,,,
5760,Recombinant humanized IgG1 anti-Claudin18.2 monoclonal antibody conjugated to MMAE,,12/1/2022,treatment of pancreatic cancer (pc),Designated,,Not FDA Approved for Orphan Indication,,,,,"RemeGen Co., Ltd.","58 Middle Beijing Road, Yantai Development Area",,Yantai,ShangDong,' 264006 ' ,China,913922,,,
5761,Recombinant humanized IgG1 anti-HER2 monoclonal antibody conjugated to Duostatin-5,,6/7/2018,treatment of gastric cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Klus Pharma, Inc.",8 Clarke Drive,Suite 4,Cranbury Township,New Jersey,' 08512 ' ,United States,641118,,,
5762,recombinant humanized IgG1-based monoclonal antibody which binds to human latent myostatin in a pH dependent manner,,12/7/2021,treatment of spinal muscular atrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Genentech Inc.,1 DNA Way,,South San Francisco,California,' 94080-4990 ' ,United States,850121,,,
5763,recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR),,4/12/2013,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"NKT Therapeutics, Inc.",880 Winter Street,Suite 350,Waltham,Massachusetts,' 02451 ' ,United States,391513,,,
5764,recombinant humanized IgG4 monoclonal antibody against pHERV-W Envelope protein,,2/14/2018,treatment of chronic inflammatory demyelinating polyradiculoneuropathy/polyneuropathy (cidp),Designated,,Not FDA Approved for Orphan Indication,,,,,GeNeuro S.A.,3 Chemin du Pré-Fleuri,,Plan-les-Ouates,Genèva,' ' ,Switzerland,625517,,,
5765,recombinant humanized IgG4P monoclonal antibody with specificity for human tau,,9/5/2017,treatment of progressive supranuclear palsy (psp),Designated,,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.",1950 Lake Park Drive,,Smyrna,Georgia,' 30080 ' ,United States,598117,progressive supranuclear palsy,"""gard:0007471""",
5766,Recombinant humanized immunoglobulin gamma 1 monoclonal antibody (mAb) directed against the CemX segment of human membrane-bound immunoglobulin E (mIgE),,9/28/2017,treatment of hyperimmunoglobulin e syndrome (hies),Designated,,Not FDA Approved for Orphan Indication,,,,,"Oneness Biotech Co., Ltd.","11F., No.236, Sec 4","Xinyi Road, Da'an District","Taipei City 106, Taiwan",,' ' ,Taiwan,606617,,,
5767,Recombinant humanized MAb 5c8,,3/22/1999,prevention of rejection of pancreatic islet cell transplants.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,' 02142 ' ,United States,123499,,,
5768,Recombinant humanized MAb 5c8,,10/14/1998,prevention and treatment of factor viii/factor ix inhibitors in patients with hemophilia a or b.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,' 02142 ' ,United States,113798,hemophilia,"""gard:0010418""",
5769,Recombinant humanized MAb 5c8,,3/22/1999,prevention of rejection of solid organ transplants.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,' 02142 ' ,United States,120098,,,
5770,Recombinant humanized monclonal antibody 5c8,,2/3/1998,treatment of immune thrombocytopenic purpura.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,' 02142 ' ,United States,109897,,,
5771,"Recombinant humanized monoclonal antibody (immunoglobulin gamma-1 with kappa light chains, IgG1kappa) directed against human soluble cytokine interferon beta.",,11/5/2020,ttreatment of dm (including improvements in cutaneous and muscle manifestations of the disease) in adult and adolescent (aged >/=12 to,Designated,,Not FDA Approved for Orphan Indication,,,,,Pfizer Inc.,66 Hudson Boulevard East,,New York,New York,' 10001 ' ,United States,779620,,,
5772,Recombinant humanized monoclonal antibody 5c8,,2/18/1998,treatment of systemic lupus erythematosus.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,' 02142 ' ,United States,111298,systemic lupus erythematosus,"""gard:0018695""",
5773,Recombinant humanized monoclonal antibody directed against an epidermal growth factor receptor,,2/17/2012,treatment of glioblastoma multiforme,Designated/Designation Withdrawn or Revoked,11/25/2014,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,361811,glioblastoma,"""gard:0002491""",
5774,recombinant humanized monoclonal antibody of the immunoglobulin G1 subclass directed against colony stimulating factor-1 receptor expressed on macrophages,,5/14/2014,treatment of pigmented villonodular synovitis and tenosynovial giant cell tumor,Designated/Designation Withdrawn or Revoked,4/21/2017,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,431614,tenosynovial giant cell tumor,"""gard:0007396""",
5775,recombinant humanized monoclonal antibody targeting the anti-müllerian hormone receptor II,,1/30/2018,treatment of anti -mullerian hormone receptor ii (amhrii)-expressing ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Exelixis, Inc.",1851 Harbor Bay Parkway,,Alameda,California,' 94502 ' ,United States,578617,ovarian cancer,"""gard:0007295""",
5776,recombinant humanized monoclonal antibody targeting transmembrane serine protease matripase-6,,2/8/2024,treatment of polycythemia vera,Designated,,Not FDA Approved for Orphan Indication,,,,,"Disc Medicine, Inc.","321 Arsenal Street, Suite 101",,Watertown,Massachusetts,' 02472 ' ,United States,987023,polycythemia,"""gard:0019466""",
5777,recombinant IgA protease of bacterium Heamophilus influenzae,,4/18/2011,"treatment of immunoglobulin a nephropathy (igan, berger's disease).",Designated,,Not FDA Approved for Orphan Indication,,,,,Shire Human Genetics Therapies,300 Shire Way,,Lexington,Massachusetts,' 02421 ' ,United States,339411,,,
5778,Recombinant IgG-fusion protein containing a humanized anti-C5 monoclonal antibody fused with a truncated human complement FH to the heavy chain C-terminus,,7/20/2022,treatment of paroxysmal nocturnal hemoglobinuria (pnh),Designated,,Not FDA Approved for Orphan Indication,,,,,"Kira Pharmaceuticals, LLC",245 Main Street,,Cambridge,Massachusetts,' 02142 ' ,United States,834521,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
5779,Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin,,2/11/2002,treatment of malignant mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,National Institutes of Health,Cancer Therapy Evaluation Program/DCTD/NCI,Suite 7111,Rockville,Maryland,' 20852 ' ,United States,151801,,,
5780,Recombinant immunotoxin combining the functional components of antibody against mesothelin and the enzymatic activity of a pseudomonas exotoxin,,2/11/2002,treatment of epithelial ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,National Institutes of Health,Cancer Therapy Evaluation Program/DCTD/NCI,Suite 7111,Rockville,Maryland,' 20852 ' ,United States,150801,ovarian cancer,"""gard:0007295""",
5781,recombinant kallikrein inhibitor,,11/23/2010,treatment of netherton syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,Dermadis SA,Batiment Le Forum,,Archamps,,' ' ,France,323710,netherton syndrome,"""gard:0007182""",
5782,recombinant lens epithelium derived growth factor 1-326,,5/19/2014,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ocugen, Inc.",5 Great Valley Parkway,Suite 160,Malvern,Pennsylvania,' 19355 ' ,United States,432314,retinitis pigmentosa,"""gard:0005694""",
5783,recombinant lentivirus vector expressing the human phenylalanine hydroxylase (PAH) gene under control of a liver-specific promoter,,10/15/2018,treatment of phenylketonuria,Designated,,Not FDA Approved for Orphan Indication,,,,,American Gene Technologies International Inc.,9640 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,657218,phenylketonuria,"""gard:0007383""",
5784,Recombinant methionyl brain-derived neurotrophic factor,,11/28/1994,treatment of amyotrophic lateral sclerosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Dr.,M/S: 17-2-B,Thousand Oaks,California,' 91320 ' ,United States,86394,amyotrophic lateral sclerosis,"""gard:0005786""",
5785,Recombinant methionyl human stem cell factor,,11/22/1995,treatment of primary bone marrow failure.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,' 91320 ' ,United States,88395,,,
5786,recombinant Mitsugumin 53,,1/17/2019,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Axolo Pharma, Inc.",6425 Nieman Road,,Shawnee,Arkansas,' 66203 ' ,United States,667618,muscular dystrophy,"""gard:0007922""",
5787,recombinant monoclonal antibody to human serum amyloid P component,,2/10/2015,treatment of al amyloidosis,Designated/Designation Withdrawn or Revoked,2/14/2019,Not FDA Approved for Orphan Indication,,,,,"Glaxo Group Limited, England d/b/a GlaxoSmithKline",980 Great West Road,,"Middlesex, TW8, 9GS",,' ' ,United Kingdom,462714,amyloidosis,"""gard:0018676""",
5788,recombinant multimerized human IgG1 Fc,,7/14/2015,treatment of chronic inflammatory demyelinating polyneuropathy (cidp).,Designated,,Not FDA Approved for Orphan Indication,,,,,Gliknik Inc.,801 W. Baltimore Street,Suite 501A,Baltimore,Maryland,' 21201 ' ,United States,484815,chronic inflammatory demyelinating polyneuropathy,"""gard:0006102""",
5789,recombinant nematode anticoagulant protein c2 (rNAPc2),,12/8/2014,treatment of viral hemorrhagic fever post-exposure to ebola virus (treatment of ebola),Designated,,Not FDA Approved for Orphan Indication,,,,,"ARCA Biopharma, Inc.",11080 Circle Point Rd.,Suite 140,Westminster,Colorado,' 80020 ' ,United States,329810,viral hemorrhagic fever,"""gard:0005494""",
5790,recombinant neuroglobin (rNgb) containing mutations H64Q/C46G/C55S/C120S,,11/17/2014,treatment of patients with carbon monoxide poisoning,Designated,,Not FDA Approved for Orphan Indication,,,,,University of Pittsburgh,4200 Fifth Ave.,,Pittsburgh,Pennsylvania,' 15260 ' ,United States,451314,,,
5791,recombinant NY-ESO-1 protein mixed with glucopyranosyl lipid A,,1/6/2016,treatment of soft tissue sarcoma.,Designated/Designation Withdrawn or Revoked,8/13/2019,Not FDA Approved for Orphan Indication,,,,,Immune Design Corp.,1616 Eastlake Ave. E,Suite 310,Seattle,Washington,' 98102 ' ,United States,497815,soft tissue sarcoma,"""gard:0004898""",
5792,Recombinant Oncolytic Herpes Simplex Virus Type II (OH2) Therapeutic Injection (Vero Cell) for Human Use (rHSV2hGM-CSF),,2/12/2024,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Binhui Biopharmaceutical Co., Ltd.",High-tech 3rd Road,"D3-4 OUV, Gedian E&T Development Zone",Ezhou,hubei,' 436070 ' ,China,987223,,,
5793,Recombinant Oncolytic Herpes Simplex Virus Type II (OH2) Therapeutic Injection (Vero Cell) for Human Use (rHSV2hGM-CSF),,7/28/2022,treatment of stage iib to iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Binhui Biopharmaceutical Co., Ltd.",High-tech 3rd Road,"D3-4 OUV, Gedian E&T Development Zone",Ezhou,Hubei,' 436070 ' ,China,894322,noma,"""gard:0004001""",
5794,Recombinant oncolytic virus based on the backbone of Alphavirus M1,,9/12/2022,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Guangzhou Virotech Pharmaceutical Co., Ltd.","Guangzhou International Business Incubator, No. 3 Lanyue Road",Science City of Guangzhou High-tech Industrial Development Zone,Guangzhou,Guangdong,' 510663 ' ,China,897922,,,
5795,Recombinant oncolytic virus M1-c6v1,,9/7/2022,treatment of primary liver cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Guangzhou Virotech Pharmaceutical Co., Ltd.","Guangzhou International Business Incubator, No. 3 Lanyue Road",Science City of Guangzhou High-tech Industrial Development Zone,Guangzhou,Guangdong,' 510663 ' ,China,898022,,,
5796,recombinant ovine interferon tau,,1/25/2007,treatment of pediatric multiple sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,PEPGEN Corporation,1301 Harbor Bay Parkway,,Alameda,California,' 94502 ' ,United States,235306,pediatric multiple sclerosis,"""gard:0010443""",
5797,Recombinant P-Selectin glycoprotein ligand,,3/29/2006,prevention of delayed graft function in renal transplant patients,Designated,,Not FDA Approved for Orphan Indication,,,,,"Y's Therapeutics, Inc.",1111 Bayhill Drive,Suite 405,San Bruno,California,' 94066 ' ,United States,215305,,,
5798,Recombinant P-selectin glycoprotein ligand-immunoglobulin Ig,,7/26/2007,prevention of ischemia reperfusion injury in all solid organ transplants,Designated,,Not FDA Approved for Orphan Indication,,,,,"Y's Therapeutics, Inc.",1539 Granger Way,,Redwood City,California,' 94061 ' ,United States,243407,,,
5799,Recombinant protein inhibitor of complement factor 5,,5/10/2016,treatment of guillain-barre syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,Akari Therapeutics Plc,24 West 40th Street,8th Floor,New York,New York,' 10018 ' ,United States,520316,,,
5800,Recombinant replication deficient adenovirus vector carrying human p53 gene,,4/12/1999,treatment of primary ovarian cancer.,Designated/Designation Withdrawn or Revoked,9/2/2017,Not FDA Approved for Orphan Indication,,,,,Schering Corporation,2000 Galloping Hill Rd.,,Kenilworth,New Jersey,' 07033 ' ,United States,122398,ovarian cancer,"""gard:0007295""",
5801,Recombinant retroviral vector - glucocerebrosidase,,11/15/1993,"for use as enzyme replacement therapy for patients with types i, ii, or iii gaucher disease.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Genetic Therapy, Inc.",938 Clopper Road,,Gaithersburg,Maryland,' 20878 ' ,United States,74393,gaucher disease,"""gard:0008233""",
5802,Recombinant secretory leucocyte protease inhibitor,,3/29/1991,treatment of congenital alpha-1 antitrypsin deficiency.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,3200 Walnut Street,,Boulder,Colorado,' 80301 ' ,United States,55490,,,
5803,Recombinant secretory leucocyte protease inhibitor,,3/29/1991,treatment of cystic fibrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",3200 Walnut Street,,Boulder,Colorado,' 80301 ' ,United States,55590,cystic fibrosis,"""gard:0006233""",
5804,recombinant self-complementary adeno-associated virus9 gene therapy expressing codon-optimized human N-Sulfoglucosamine Sulfohydrolase gene,,4/26/2023,treatment of mucopolysaccharidosis (mps) iiia,Designated,,Not FDA Approved for Orphan Indication,,,,,"NeuroGT, Inc.",510 Meadowmont Village Circle #289,,Chapel Hill,North Carolina,' 27517 ' ,United States,935323,mucopolysaccharidosis,"""gard:0007065""",
5805,"Recombinant serotype 9 adeno-associated virus (AAV) encoding an intron encoding a miRNA generating sequence, complementary miRNA binding sites and a full-length human methyl cytosine binding protein 2 (MECP2)",,2/27/2023,treatment of rett syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Neurogene Inc.,"535 W 24th St, 5th Floor",,New York,New York,' 10011 ' ,United States,926322,rett syndrome,"""gard:0005696""",
5806,Recombinant serotype 9 adeno-associated virus encoding a codon-optimized human galactosylceramidase (GALC) transgene (hGALCopt2),,2/10/2022,treatment of krabbe disease,Designated/Designation Withdrawn or Revoked,3/22/2024,Not FDA Approved for Orphan Indication,,,,,Neurogene Inc.,"535 W 24th St, 5th Floor",,New York,New York,' 10011 ' ,United States,861621,krabbe disease,"""gard:0006844""",
5807,Recombinant soluble human CD4,,11/20/1989,treatment of acquired immunodeficiency syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",14 Cambridge Center,,Cambridge,Massachusetts,' 02142 ' ,United States,38989,acquired immunodeficiency,"""gard:0021359""",
5808,Recombinant soluble human CD4 (rCD4),,3/23/1989,treatment of aids in patients infected with hiv virus.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",460 Point San Bruno Boulevard,,South San Francisco,California,' 94080 ' ,United States,34889,,,
5809,Recombinant T-cell receptor ligand,,5/2/2003,treatment of multiple sclerosis patients who are both hla-dr2 positive and autoreactive to myelin oligodendrocyte glycoprotein residues 35-55,Designated,,Not FDA Approved for Orphan Indication,,,,,"Artielle ImmunoTherapeutics, Inc.",9020 SW Washington Square Road,Suite 450,"Tigard,",Oregon,' 97223 ' ,United States,163102,,,
5810,recombinant thymidine phosphorylase encapsulated with autologous erythrocytes,,12/13/2010,treatment of mitochondrial neurogastrointestinal encephalomyopathydue to thymidine phosphorylase deficiency.,Designated,,Not FDA Approved for Orphan Indication,,,,,St. George's University of London,Joint Research Office,,London,,' ' ,United Kingdom,324810,mitochondrial neurogastrointestinal encephalomyopathy,"""gard:0009920""",
5811,Recombinant truncated SPINT2 protease inhibitor,,6/24/2005,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aerovance, Inc.",2929 Seventh Street,,Berkeley,California,' 94710 ' ,United States,205905,cystic fibrosis,"""gard:0006233""",
5812,Recombinant urate oxidase,,10/11/2000,prophylaxis of chemotherapy-induced hyperuricemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,Sanofi-Synthelabo Research,9 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,131599,,,
5813,Recombinant vaccinia (human papillomavirus),,8/24/1994,treatment of cervical cancer.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Xenova Research Limited,310 Cambridge Science Park,,Cambridge,,' ' ,United Kingdom,84394,,,
5814,recombinant von Willebrand factor (rhVWF),,11/23/2010,treatment of von willebrand disease,Designated/Approved,,,Indicated for on-demand treatment and control of bleeding episodes in adults (age 18 and older) diagnosed with von Willebrand disease (VWD),12/8/2015,12/8/2022,Indicated for on-demand treatment and control of bleeding episodes in adults diagnosed with von Willebrand disease (VWD),"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,322210,von willebrand disease,"""gard:0007867""",
5815,recombinant von Willebrand factor (rhVWF),,11/23/2010,treatment of von willebrand disease,Designated/Approved,,,Indicated for use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for perioperative management of bleeding,4/13/2018,4/13/2025,Indicated for use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for perioperative management of bleeding,"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,322210,von willebrand disease,"""gard:0007867""",
5816,recombinant von Willebrand factor (rhVWF),Vonvendi,11/23/2010,treatment of von willebrand disease,Designated/Approved,,,For use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 VWD receiving on-demand therapy,1/28/2022,1/28/2029,For use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 VWD receiving on-demand therapy,"Takeda Pharmaceuticals USA, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,322210,von willebrand disease,"""gard:0007867""",
5817,"recombinant, adeno-associated virus serotype 5 vector, containing the transgene, which encodes for the human protein, frataxin",,7/25/2016,treatment of friedreich's ataxia,Designated,,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",500 Warren Corporate Center Drive,,Warren,New Jersey,' 07059 ' ,United States,498515,,,
5818,"recombinant, fully-human, IgG4 immunoglobulin with antigen-binding specificity for human vascular adhesion protein-1 (VAP-1)",,8/25/2016,treatment of primary sclerosing cholangitis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Acorda Therapeutics, Inc.",420 Saw Mill River Road,,Ardsley,New York,' 10502 ' ,United States,531516,sclerosing cholangitis,"""gard:0021868""",
5819,"recombinant, glycoenfineered humanized IgG1 kappa monoclonal antibody directed against Fibroblast Growth Factor Receptor 2b",,6/29/2016,treatment of gastric cancer including cancer of the gastroesophageal junction.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Five Prime Therapeutics, Inc.",2 Corporate Drive,,South San Francisco,California,' 94080 ' ,United States,527716,,,
5820,"recombinant, humanized immunoglobulin G1 monoclonal antibody that targets the leukocyte immunoglobulin-like receptor subfamily B4",,2/8/2024,treatment of chronic myelomonocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Immune-Onc Therapeutics,795 San Antonio Road,,Palo Alto,California,' 94303 ' ,United States,854821,chronic myelomonocytic leukemia,"""gard:0008225""",
5821,"Recombinant, Humanized, aglycosylated, IgG1 Kappa Anti-Properdin Monoclonal Antibody",,10/5/2022,treatment of paroxysmal nocturnal hemoglobinuria,Designated,,Not FDA Approved for Orphan Indication,,,,,"NovelMed Therapeutics, Inc.",11000 Cedar Avenue 135,,Cleveland,Ohio,' 44106 ' ,United States,835921,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
5822,"Recombinant, Humanized, Aglycosylated, Immunoglobulin G1 kappa Anti-Factor Bb Monoclonal Antibody",,12/20/2023,treatment of paroxysmal nocturnal hemoglobinuria,Designated,,Not FDA Approved for Orphan Indication,,,,,"NovelMed Therapeutics, Inc.",11000 Cedar Avenue,,Cleveland,Ohio,' 44106 ' ,United States,627318,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
5823,"recombinant, non-pathogenic poliovirus:rhinovirus chimera that consists of the genome of the live attenuated poliovirus serotype 1 vaccine with its cognate IRES element replaced with that of HRV2",,5/26/2016,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Istari Oncology, Inc.",Duke University Medical Center,"177 MSRB, Box 3156",Durham,North Carolina,' 27710 ' ,United States,521816,,,
5824,Red blood cell-derived microparticles,,2/9/2023,treatment of intracerebral hemorrhage,Designated,,Not FDA Approved for Orphan Indication,,,,,"RxMP Therapeutics, Inc.","790 North-West 107th Avenue, Suite 215",,Miami,Florida,' 33172 ' ,United States,923422,,,
5825,Redaporfin,,4/12/2017,treatment of cholangiocarcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Luzitin, S.A.",Edificio Bluepharma,S Martinho do Bispo,Coimbra,Coimbra District,' ' ,Portugal,556616,cholangiocarcinoma,"""gard:0009304""",
5826,Reduced L-glutathione,,2/14/1994,treatment of aids-associated cachexia.,Designated,,Not FDA Approved for Orphan Indication,,,,,Telluride Pharmaceutical Corporation,146 Flanders Drive,,Hillsborough,New Jersey,' 08876 ' ,United States,77493,,,
5827,refanalin,,5/25/2010,to improve renal function and prevent delayed graft function following renal transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,Angion Biomedica Corporation,1050 Stewart Avenue,,Garden City,New York,' 11530 ' ,United States,307510,,,
5828,regorafenib,Stivarga,6/4/2015,treatment of hepatocellular carcinoma,Designated/Approved,,,Treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with sorafenib.,4/27/2017,4/27/2024,Treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with sorafenib.,"Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Blvd,P. O. Box 915,Whippany,New Jersey,' 07981 ' ,United States,478015,hepatocellular carcinoma,"""gard:0016773""",
5829,Regorafenib,,7/1/2019,treatment of glioblastoma multiforme,Designated/Designation Withdrawn or Revoked,12/13/2022,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Boulevard,P.O. Box 915,Whippany,New Jersey,' 07981 ' ,United States,690619,glioblastoma,"""gard:0002491""",
5830,regorafenib,Stivarga,1/12/2011,treatment gastrointestinal stromal tumors,Designated/Approved,,,"Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.",2/25/2013,2/25/2020,"Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.","Bayer HealthCare Pharmaceuticals, Inc.",P. O. Box 1000,,Montvale,New Jersey,' 07045 ' ,United States,329410,gastrointestinal stromal tumor,"""gard:0008598""",
5831,regulatory T cell activating peptide,,1/19/2024,treatment of eosinophilic esophagitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Revolo Biotherapeutics,900 Camp Street,,New Orleans,Louisiana,' 70130 ' ,United States,819821,,,
5832,relacorilant,,9/27/2018,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Corcept Therapeutics, Inc.",149 Commonwealth Drive,,Menlo Park,California,' 94025 ' ,United States,652118,,,
5833,relacorilant,,10/15/2018,treatment of endogenous cushing syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Corcept Therapeutics, Inc.",149 Commonwealth Drive,,Menlo Park,California,' 94025 ' ,United States,656518,cushing syndrome,"""gard:0006224""",
5834,Reldesemtiv,,12/11/2019,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cytokinetics, Inc.",280 East Grand Avenue,,South San Francisco,California,' 94080 ' ,United States,712519,amyotrophic lateral sclerosis,"""gard:0005786""",
5835,reltecimod,,10/12/2011,treatment of necrotizing soft tissue infections (nsti),Designated,,Not FDA Approved for Orphan Indication,,,,,"Atox Bio, Inc.",3 Golda Meir St.,,Ness Ziona,,' ' ,Israel,352211,necrotizing soft tissue infection,"""gard:0021839""",
5836,Remacemide,,3/6/2000,treatment of huntington's disease.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,AstraZeneca LP,725 Chesterbrook Blvd.,,Wayne,Pennsylvania,' 19087 ' ,United States,130599,,,
5837,Remdesivir,,9/18/2015,treatment of ebola virus disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,490515,,,
5838,remdesivir,,3/23/2020,treatment of coronavirus disease 2019 (covid-19),Designated/Designation Withdrawn or Revoked,3/25/2020,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,739020,,,
5839,REMUNE HIV 1,,2/14/2014,treatment of pediatric hiv/aids (age through 16 years),Designated,,Not FDA Approved for Orphan Indication,,,,,"Immune Response BioPharma, Inc.",1801 Atlantic Avenue,Suite 8352,Atlantic City,New Jersey,' 08401 ' ,United States,420113,,,
5840,rencofilstat,,6/17/2022,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hepion Pharmaceuticals, Inc.","399 Thornall Street, First Floor",,Edison,New Jersey,' 08837 ' ,United States,885822,hepatocellular carcinoma,"""gard:0016773""",
5841,reparixin,,9/25/2012,prevention of graft loss in pancreatic islet transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,Dompe S.p.A.,Via Campo di Pile,,L'Aquila,,' ' ,Italy,373312,,,
5842,reparixin,,1/27/2003,prevention of delayed graft function in solid organ transplant,Designated,,Not FDA Approved for Orphan Indication,,,,,Dompe S.p.A.,Via Campo di Pile,,L'Aquila,,' ' ,Italy,162802,,,
5843,Replication defective recombinant adenovirus serotype 5 vector carrying the p53 gene in its E1 deleted region,,1/27/2003,treatment of head and neck cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Introgen Therapeutics, Inc.",,2250 Holcombe Blvd,Houston,Texas,' 77030 ' ,United States,160302,,,
5844,"replication-competent oncolytic herpes simplex virus (oHSV), engineered by removing the two endogenous copies of infected cell protein 34.5 (ICP34.5) and re-inserting one copy of the ICP34.5 gene under transcriptional control mediated by the promoter-enhancer elements of nestin",,5/21/2024,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Brigham and Women's Hospital,75 Francis Street,,Boston,Massachusetts,' 02115 ' ,United States,1003924,,,
5845,replication-deficient recombinant serotype 2 adeno-associated viral vector containing hAQP1 cDNA,,5/3/2013,treatment of symptoms of grade 2 and grade 3 late xerostomia from parotid gland hypofunction caused by radiotherapy for cancer of the oral cavity.,Designated,,Not FDA Approved for Orphan Indication,,,,,"MeiraGTx, LLC",450 East 29th Street,15th Floor,New York,New York,' 10016 ' ,United States,365012,,,
5846,replication-incompetent adeno-associated virus serotype 9 vector encoding the human fragile x mental retardation 1 gene,,6/16/2022,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Forge Biologics, Inc.",3900 Gantz Road,,Grove City,Ohio,' 42123 ' ,United States,889322,fragile x syndrome,"""gard:0006464""",
5847,Replication-incompetent GM-CSF-expressing gene-modified allogeneic acute myeloid leukemia cancer cell lines,,3/2/2010,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,1/10/2019,Not FDA Approved for Orphan Indication,,,,,"Aduro BioTech, Inc.",740 Heinz Avenue,,Berkeley,California,' 94710 ' ,United States,300710,acute myeloid leukemia,"""gard:0012757""",
5848,Replication-incompetent GM-CSF-expressing gene-modified allogeneic chronic myeloid leukemia cancer cell lines,,4/30/2010,treatment of chronic myeloid leukemia,Designated/Designation Withdrawn or Revoked,1/10/2019,Not FDA Approved for Orphan Indication,,,,,"Aduro BioTech, Inc.",740 Heinz Avenue,,Berkeley,California,' 94710 ' ,United States,300810,chronic myeloid leukemia,"""gard:0006105""",
5849,Replication-incompetent GM-CSF-expressing gene-modified allogeneic pancreatic cancer cell lines,,3/1/2010,treatment of pancreatic cancer.,Designated/Designation Withdrawn or Revoked,1/28/2019,Not FDA Approved for Orphan Indication,,,,,"Aduro BioTech, Inc.",740 Heinz Avenue,,Berkeley,California,' 94710 ' ,United States,299709,,,
5850,"replication-incompetent human mastadenovirus C serotype 5, with E1 and partial E3 deletions that encodes a hTERT RNA-targeting trans-splicing ribozyme with HSVtk transgene",,1/18/2024,treatment of hepatocellular carcinoma (hcc),Designated,,Not FDA Approved for Orphan Indication,,,,,Rznomics,"#801, C Building","Pangyo Innovalley, 253","Pangyo-ro, Bundang-gu",Seongnam,' 13486 ' ,South Korea,982823,hepatocellular carcinoma,"""gard:0016773""",
5851,repository corticortropin injection,,6/28/2013,treatment of amyotrophic lateral sclerosis,Designated/Designation Withdrawn or Revoked,1/29/2021,Not FDA Approved for Orphan Indication,,,,,"Mallinckrodt Pharmaceuticals, Inc.",Perryville III Corporate Park,P. O. Box 9001,Hampton,New Jersey,' 08827 ' ,United States,399113,amyotrophic lateral sclerosis,"""gard:0005786""",
5852,repository corticotropin or adrenocorticotropic hormone,H.P. Acthar Gel,5/21/2003,treatment of infantile spasms,Designated/Approved,,,To treat infantile spasms,10/15/2010,10/15/2017,,"Questcor Pharmaceuticals, Inc.",26118 Research Road,,Hayward,California,' 94545 ' ,United States,168103,,,
5853,repotrectinib,,3/12/2024,treatment of ntrk fusion-positive solid tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,P.O. Box 4000,,Princeton,New Jersey,' 08543 ' ,United States,992623,,,
5854,repotrectinib,Augtyro,6/22/2017,treatment of non-small cell lung cancer with adenocarcinoma histology,Designated/Approved,,,treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC),11/15/2023,11/15/2030,treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) with adenocarcinoma histology,Bristol Myers Squibb Company,3401 Princeton Pike,,Lawrenceville,New Jersey,' 08648 ' ,United States,573517,small cell lung cancer,"""gard:0009344""",
5855,resatorvid,,1/2/2018,treatment of acute-on-chronic liver failure,Designated/Designation Withdrawn or Revoked,11/28/2022,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",One Takeda Parkway,,Deerfield,Illinois,' 60015 ' ,United States,503515,,,
5856,resiniferatoxin,,5/13/2003,treatment of intractable pain at end-stage disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sorrento Theraeputics, Inc.",9380 Judicial Drive,,San Diego,California,' 92121 ' ,United States,164802,,,
5857,resiquimod,,5/24/2017,treatment of cutaneous t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Galderma Research and Development, LLC",14501 North Freeway,,Fort Worth,Texas,' 76177 ' ,United States,569016,lymphoma,"""gard:0020548""",
5858,reslizumab,,12/19/2007,treatment of children with eosinophilic esophagitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Teva Respiratory, LLC",145 Brandywine Pkwy.,,West Chester,Pennsylvania,' 19380 ' ,United States,237507,,,
5859,reslizumab,,1/12/2011,treatment of hypereosinophilic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Teva Respiratory, LLC",145 Brandywine Pkwy.,,West Chester,Pennsylvania,' 19380 ' ,United States,328510,c syndrome,"""gard:0005978""",
5860,resminostat,,6/29/2011,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,4SC AG,Am Klopferspitz 19a,,Martinsried,,' ' ,Germany,345511,hepatocellular carcinoma,"""gard:0016773""",
5861,resminostat,,9/16/2011,treatment of hodgkin's lymphoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,4SC AG,Am Klopferspitz 19a,,Martinsried,,' ' ,Germany,351411,lymphoma,"""gard:0020548""",
5862,resminostat mesilate,,9/22/2023,treatment of cutaneous t-cell lymphoma (ctcl),Designated,,Not FDA Approved for Orphan Indication,,,,,4SC AG,Fraunhoferstrasse 22,,Planegg-Martinsried,,' 82152 ' ,Germany,926922,lymphoma,"""gard:0020548""",
5863,Respiratory syncytial virus immune globulin (Human),Respigam,9/27/1990,prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of rsv disease.,Designated/Approved,,,For the prevention of serious lower respiratory tract infections caused by RSV in children less than 24 months of age with bronchopulmonary dysplasia or a history of prematurity (less than or equal to 35 weeks gestation).,1/18/1996,1/18/2003,,MedImmune & Massachussetts Public Health Biologics Labs.,35 West Watkins Mill Road,,Gaithersburg,Maryland,' 20878 ' ,United States,51190,,,
5864,Respiratory Syncytial Virus Immune Globulin (human),,9/27/1990,treatment of respiratory syncytial virus lower respiratory tract infections in hospitalized infants and young children.,Designated,,Not FDA Approved for Orphan Indication,,,,,"MedImmune, Inc.",35 West Watkins Mill Road,,Gaithersburg,Maryland,' 20878 ' ,United States,51290,,,
5865,retaspimycin,,8/31/2007,treatment for gastrointestinal stromal tumor,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Infinity Pharmaceuticals, Inc.",780 Memorial Drive,,Cambridge,Massachusetts,' 02139 ' ,United States,242907,gastrointestinal stromal tumor,"""gard:0008598""",
5866,retaspimycin hydrochloride,,6/24/2008,treatment of melanoma stages iib through iv.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,P. O. Box 8355,1800 Concord Pike,Wilmington,Delaware,' 19803 ' ,United States,260608,noma,"""gard:0004001""",
5867,retifanlimab,,3/24/2020,treatment of anal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,691419,,,
5868,retifanlimab-dlwr,Zynyz,10/26/2020,treatment of merkel cell carcinoma,Designated/Approved,,,treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC),3/22/2023,3/22/2030,treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC),Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,695719,noma,"""gard:0004001""",
5869,Retinol palmitate,,8/8/2016,prevention of bronchopulmonary dysplasia.,Designated,,Not FDA Approved for Orphan Indication,,,,,Orphanix GmbH,41 Peter-Rosegger-Straße,,Ried im Innkreis,Oberösterreich,' ' ,Austria,525116,bronchopulmonary dysplasia,"""gard:0005962""",
5870,retinol palmitate (vitamin A palmitate),,6/28/2017,prevention of retinopathy of prematurity (rop),Designated,,Not FDA Approved for Orphan Indication,,,,,orphanix GmbH,41 Peter-Rosegger-Straße,,Ried im Innkreis,Oberösterreich,' ' ,Austria,583417,retinopathy of prematurity,"""gard:0005695""",
5871,"Retinyl Palmitate, Alisitol (herbal extract), Zn Gluconate",,3/18/2021,treatment of microvillus inclusion disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Dmitry V. Kravtsov, M.D.","925 Sherman Avenue, Hamden, CT 06514, USA",,Hamden,Connecticut,' 06514 ' ,United States,805420,microvillus inclusion disease,"""gard:0007039""",
5872,retroviral gamma-c cDNA containing vector,,4/29/2002,treatment of x linked severe combined immune deficiency disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"AVAX technologies, Inc.",9200 Indian Creek Parkway,"Building 9, Suite 200",Overland Park,Kansas,' 66210 ' ,United States,151601,,,
5873,"Retroviral vector, R-GC and GC gene 1750",,5/6/1997,treatment of gaucher disease.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,One Mountain Road,P.O. Box 9322,Framingham,Massachusetts,' 01701 ' ,United States,102396,gaucher disease,"""gard:0008233""",
5874,reveglucosidase alfa,,8/20/2010,treatment of pompe disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,' 94949 ' ,United States,308310,,,
5875,reversal agent linked to chloroquine-like moiety,,3/26/2010,treatment of malaria,Designated,,Not FDA Approved for Orphan Indication,,,,,DesignMedix,2828 SW Corbett Avenue,,Portland,Oregon,' 97201 ' ,United States,303710,malaria,"""gard:0006961""",
5876,Revimmune,,2/18/2011,treatment of autoimmune hemolytic anemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,Accentia Biopharmaceuticals,324 South Hyde Park Avenue #350,,Tampa,Florida,' 33606 ' ,United States,333711,autoimmune hemolytic anemia,"""gard:0005870""",
5877,Reviparin sodium,,6/18/2001,long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients,Designated,,Not FDA Approved for Orphan Indication,,,,,Abbott,"Abbott Laboratories, Dept. 389, Bldg. J-45",200 Abbott Park Rd.,Abbott Park,Illinois,' 60064 ' ,United States,143501,,,
5878,Reviparin sodium,,6/18/2001,treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients,Designated,,Not FDA Approved for Orphan Indication,,,,,Abbott,"Abbott Laboratories, Dept. 389, Bldg. J-45",200 Abbott Park Rd.,Abbott Park,Illinois,' 60064 ' ,United States,143601,,,
5879,revusiran,,5/18/2015,treatment of transthyretin amyloidosis,Designated/Designation Withdrawn or Revoked,4/4/2017,Not FDA Approved for Orphan Indication,,,,,"Alnylam Pharmaceuticals, Inc.",300 Third Street,,Cambridge,Massachusetts,' 02142 ' ,United States,477615,amyloidosis,"""gard:0018676""",
5880,rexlemestrocel-L,,6/19/2019,prevention of post-lvad (left ventricular assist device) implantation mucosal bleeding,Designated,,Not FDA Approved for Orphan Indication,,,,,Mesoblast,505 5th Avenue,3rd Floor,New York,New York,' 10017 ' ,United States,661518,,,
5881,rexlemestrocel-L,,2/14/2024,treatment of hypoplastic left heart syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Mesoblast, Inc.",505 Fifth Avenue,Third Floor,New York,New York,' 10017 ' ,United States,988023,hypoplastic left heart syndrome,"""gard:0006739""",
5882,rezafungin,Rezzayo,2/8/2016,treatment of candidemia and invasive candidiasis infections caused by susceptible candida spp.,Designated/Approved,,,in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis,3/22/2023,3/22/2030,in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis,"Cidara Therapeutics, Inc.","6310 Nancy Ridge Drive, Suite 101",,San Diego,California,' 92121 ' ,United States,507215,,,
5883,"RGG0853, E1A lipid complex",,9/15/1995,treatment of ovarian cancer.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Targeted Genetics Corporation,"1100 Olive Way, Suite 100",,Seattle,Washington,' 98101 ' ,United States,90995,ovarian cancer,"""gard:0007295""",
5884,"rh-microplasmin, ocriplasmin",,3/16/2004,adjunct to surgery in cases of pediatric vitrectomy,Designated/Designation Withdrawn or Revoked,10/23/2020,Not FDA Approved for Orphan Indication,,,,,ThromboGenics Inc.,Unit 14,Walkinstown Avenue,Dublin 12,,' ' ,Ireland,180703,,,
5885,rhIGF-I/rhIGFBP-3,,12/9/2003,"treatment of extreme insulin resistance syndromes (type a, rabson-mendenhall syndrome, leprechaunism, type b syndrome)",Designated,,Not FDA Approved for Orphan Indication,,,,,"Insmed, Inc.",10 Finderne Ave,Building 10,Bridgewater,New Jersey,' 08807 ' ,United States,168903,leprechaunism,"""gard:0006885""",
5886,Rho (D) immune globulin intravenous (human),WinRho SD,11/9/1993,treatment of immune thrombocytopenic purpura.,Designated/Approved,,,Treatment of adults and children with chronic and acute immune thrombocytopenic purpura.,3/24/1995,3/24/2002,,"Rh Pharmaceuticals, Inc.",104 Chancellor Matheson Road,U of Manitoba,Winnipeg,,' ' ,Canada,74993,,,
5887,ribavirin,REBETOL,4/4/2003,treatment of chronic hepatitis c in pediatric patients,Designated/Approved,,,Treatment of chronic hepatitis C among previously untreated pediatric patients at least three years of age or older.,7/29/2003,7/29/2010,,Schering Corporation,2000 Galloping Hill Road,,Kenilworth,New Jersey,' 07033 ' ,United States,162402,,,
5888,ribavirin,,4/12/1991,treatment of hemorrhagic fever with renal syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Valeant Pharmaceuticals International,3300 Hyland Avenue,,Costa Mesa,California,' 92626 ' ,United States,57491,,,
5889,ribavirin elaidate,,9/2/2011,"treatment of follicular, medullary, and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer",Designated,,Not FDA Approved for Orphan Indication,,,,,"Translational Therapeutics, Inc.",163 Scituate Street,,Arlington,Massachusetts,' 02476 ' ,United States,344011,thyroid carcinoma,"""gard:0019763""",
5890,ribitol,,1/16/2019,treatment of limb-girdle muscular dystrophy type 2i,Designated,,Not FDA Approved for Orphan Indication,,,,,"ML Bio Solutions, Inc.","1800 Owens Street, Suite C-1200",,San Francisco,California,' 94158 ' ,United States,666518,muscular dystrophy,"""gard:0007922""",
5891,ribociclib,,11/25/2022,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936-1080 ' ,United States,912722,neuroblastoma,"""gard:0007185""",
5892,riboflavin 5'-phosphate sodium,,9/21/2021,treatment of corneal ulcers,Designated,,Not FDA Approved for Orphan Indication,,,,,Glaukos Corporation,229 Avenida Fabricante,,San Clemente,California,' 92672 ' ,United States,812721,,,
5893,riboflavin ophthalmic solution & ultraviolet A,Photrexa Viscous,9/2/2011,treatment of keratoconus,Designated/Approved,,,Indicated for use in corneal collagen crosslinking in combination with the KXL¿ System for the treatment of progressive keratoconus,4/15/2016,4/15/2023,Treatment of progressive keratoconus,"Avedro, Inc.",230 Third Avenue,,Waltham,Massachusetts,' 02451 ' ,United States,344911,,,
5894,riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation,Photrexa Viscous,12/2/2011,treatment of corneal ectasia following refractive surgery,Designated/Approved,,,Treatment of corneal ectasia following refractive surgery,7/15/2016,7/15/2023,Treatment of corneal ectasia following refractive surgery,"Avedro, Inc.",230 Third Avenue,,Waltham,Massachusetts,' 02451 ' ,United States,352511,,,
5895,riboflavin-vitamin E-TPGS topical solution,,11/8/2016,treatment of keratoconus in patients undergoing crosslinking procedure,Designated,,Not FDA Approved for Orphan Indication,,,,,Institute of Refractive & Ophthalmic Surgery,"Via Andrea D'Isernia 31,",,Napoli,,' ' ,Italy,468414,,,
5896,Ricin (blocked) conjugated murine mca (anti-b4),,1/24/1991,for the ex-vivo purging of leukemic cells from the bone marrow of non-t cell acute lymphocytic leukemia patients who are in complete remission.,Designated/Designation Withdrawn or Revoked,12/9/2014,Not FDA Approved for Orphan Indication,,,,,"ImmunoGen, Inc.",830 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,49190,,,
5897,Ricin (blocked) conjugated murine MCA (anti-B4),,11/17/1988,treatment of b-cell leukemia and b-cell lymphoma.,Designated/Designation Withdrawn or Revoked,12/8/2014,Not FDA Approved for Orphan Indication,,,,,"ImmunoGen, Inc.",148 Sidney Street,,Cambridge,Massachusetts,' 02139 ' ,United States,30288,lymphoma,"""gard:0020548""",
5898,Ricin (blocked) conjugated murine MCA (anti-my9),,2/1/1990,for use in the ex-vivo treatment of autologous bone marrow and subsequent reinfusion in patients with acute myelogenous leukemia.,Designated/Designation Withdrawn or Revoked,12/9/2014,Not FDA Approved for Orphan Indication,,,,,"ImmunoGen, Inc.",830 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,42489,,,
5899,Ricin (blocked) conjugated murine MCA (anti-my9),,8/3/1989,"treatment of myeloid leukemia, including aml, and blast crisis of cml.",Designated/Designation Withdrawn or Revoked,12/9/2014,Not FDA Approved for Orphan Indication,,,,,"ImmunoGen, Inc.",830 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,38389,,,
5900,Ricin (blocked) conjugated murine MCA (n901),,1/25/1991,treatment of small cell lung cancer,Designated/Designation Withdrawn or Revoked,12/8/2014,Not FDA Approved for Orphan Indication,,,,,"ImmunoGen, Inc.",830 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,52490,small cell lung cancer,"""gard:0009344""",
5901,Ricin (blocked) conjugated murine monoclonal antibody (CD6),,9/6/1994,"treatment of cutaneous t-cell lymphomas, acute t-cell leukemia-lymphoma, and related mature t-cell malignancies.",Designated/Designation Withdrawn or Revoked,12/8/2014,Not FDA Approved for Orphan Indication,,,,,"ImmunoGen, Inc.",830 Winter Street,,Waltham,Massachusetts,' 02451 ' ,United States,77093,lymphoma,"""gard:0020548""",
5902,Ricin Immune Fab,,11/16/2023,treatment of ricin poisoning,Designated,,Not FDA Approved for Orphan Indication,,,,,BTG International Inc,"300 Four Falls Corporate Center,","300 Conshohocken State Road, Suite 300",West Conshohocken,Pennsylvania,' 19428 ' ,United States,970423,ricin poisoning,"""gard:0022311""",
5903,ricin vaccine,,1/7/2011,prevention of ricin intoxication.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.",29 Emmons Drive,Suite B-10,Princeton,New Jersey,' 08540 ' ,United States,329110,,,
5904,ridaforolimus,,8/12/2005,treatment of soft tissue sarcoma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Merck Sharp & Dohme Corp.,"Merck & Co., Inc. Subsidiary","P. Box 1000, UG-2C50",North Wales,Oregon,' 19454 ' ,United States,207805,soft tissue sarcoma,"""gard:0004898""",
5905,Rifabutin,Mycobutin,12/18/1989,prevention of disseminated mycobacterium avium complex disease in patients with advanced hiv infection.,Designated/Approved,,,Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections.,12/23/1992,12/23/1999,,"Adria Laboratories, Inc.",P.O. Box 16529,,Columbus,Ohio,' 43216 ' ,United States,41989,,,
5906,Rifabutin,,12/18/1989,treatment of disseminated mycobacterium avium complex disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Pfizer Inc.,235 East 42nd Street,,New York,New York,' 10017 ' ,United States,41889,,,
5907,Rifalazil,,4/13/1999,treatment of pulmonary tuberculosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,PathoGenesis Corporation,201 Elliott Avenue West,Suite 150,Seattle,Washington,' 98119 ' ,United States,122699,tuberculosis,"""gard:0007827""",
5908,Rifampin,,3/7/2023,treatment of frontotemporal dementia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Medilabo RFP, Inc.",Sanjo CHOJU building 4F,"24 Umeda-cho, Nakagyo-ku,",Kyoto,,' 604-8136 ' ,Japan,928022,frontotemporal dementia,"""gard:0008436""",
5909,Rifampin,Rifadin I.V.,12/9/1985,for antituberculosis treatment where use of the oral form of the drug is not feasible.,Designated/Approved,,,,5/25/1989,5/25/1996,,Hoechst Marion Roussel,P.O. Box 9627,,Kansas City,Missouri,' 64134 ' ,United States,7685,tuberculosis,"""gard:0007827""",
5910,"Rifampin, isoniazid, pyrazinamide",Rifater,9/12/1985,for the short-course treatment of tuberculosis.,Designated/Approved,,,Short-course treatment of tuberculosis.,5/31/1994,5/31/2001,,Hoechst Marion Roussel,P.O. Box 9627,,Kansas City,Missouri,' 64134 ' ,United States,6585,tuberculosis,"""gard:0007827""",
5911,Rifamycin,,10/18/2022,treatment of pouchitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cosmo Technologies, Ltd.",Riverside II,Sir John Rogerson’s Quay,Dublin,Dublin,' 2 ' ,Ireland,853821,pouchitis,"""gard:0020510""",
5912,Rifapentine,,6/9/1995,treatment of mycobacterium avium complex in patients with aids.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hoechst Marion Roussel , Inc.",P.O. Box 9627,Mail Station: H3-M2516,Kansas City,Missouri,' 64134 ' ,United States,89595,,,
5913,Rifapentine,,3/12/1996,prophylactic treatment of mycobacterium avium complex in patients with aids and a cd4+ count less than or equal to 75/mm3.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hoechst Marion Roussel, Inc.",P.O. Box 9627,Mail Station: H3-M2516,Kansas City,Missouri,' 64134 ' ,United States,89695,,,
5914,Rifapentine,Priftin,6/9/1995,treatment of pulmonary tuberculosis.,Designated/Approved,,,,6/22/1998,6/22/2005,,Hoechst Marion Roussel,P.O. Box 9627,Mail Station: H3-M2516,Kansas City,Missouri,' 64134 ' ,United States,89495,tuberculosis,"""gard:0007827""",
5915,rifaximin,Xifaxan,2/10/1998,treatment of hepatic encephalopathy,Designated/Approved,,,Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age,3/24/2010,3/24/2017,,"Salix Pharmaceuticals, Inc.",400 Somerset Corporate Blvd,,Somerset,New Jersey,' 08807 ' ,United States,109497,,,
5916,Rifaximin,,10/28/2020,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Salix Pharmaceuticals, Inc. (a division of Bausch Health US, LLC)",400 Somerset Corporate Boulevard,,Bridgewater,New Jersey,' 08807 ' ,United States,778520,,,
5917,rigosertib,,3/16/2012,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,5/2/2018,Not FDA Approved for Orphan Indication,,,,,"Onconova Therapeutics, Inc.",375 Pheasant Run,,Newton,Pennsylvania,' 18940 ' ,United States,366412,ovarian cancer,"""gard:0007295""",
5918,rigosertib,,3/18/2011,treatment of pancreatic cancer.,Designated/Designation Withdrawn or Revoked,5/2/2018,Not FDA Approved for Orphan Indication,,,,,"Onconova Therapeutics, Inc",375 Pheasant Run,,Newtown,Pennsylvania,' 18940 ' ,United States,333611,,,
5919,rigosertib,,9/3/2009,treatment of myelodysplastic syndromes,Designated/Designation Withdrawn or Revoked,10/29/2021,Not FDA Approved for Orphan Indication,,,,,"Onconova Therapeutics, Inc.",375 Pheasant Run,,Newtown,Pennsylvania,' 18940 ' ,United States,289409,myelodysplastic syndrome,"""gard:0007132""",
5920,RII retinamide,,5/6/1993,treatment of myelodysplastic syndromes.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sparta Pharmaceuticals, Inc.",111 Rock Road,,Horsham,Pennsylvania,' 19044 ' ,United States,74193,myelodysplastic syndrome,"""gard:0007132""",
5921,rilonacept,Arcalyst,7/14/2020,treatment of pericarditis,Designated/Approved,,,Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older,3/18/2021,3/18/2028,Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older,"Kiniksa Pharmaceuticals, Ltd.",c/o Kiniksa Pharmaceuticals Corp.,100 Hayden Avenue,Lexington,Massachusetts,' 02421 ' ,United States,649718,,,
5922,rilonacept,,5/9/2017,treatment of deficiency of interleukin-1 receptor antagonist (dira),Designated,,Not FDA Approved for Orphan Indication,,,,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,561616,,,
5923,rilonacept,,1/9/2013,treatment of familial mediterranean fever,Designated,,Not FDA Approved for Orphan Indication,,,,,"Philip J Hashkes, MD, MSc.","Head, Section of Pediatric Rheumatology",9500 Euclid Avenue,Cleveland,Ohio,' 044195 ' ,United States,292509,familial mediterranean fever,"""gard:0006421""",
5924,Rilonacept,Arcalyst,12/20/2004,treatment of cias1-associated periodic syndromes,Designated/Approved,,,Treatment of Cryopyrin-Assisted Periodic Syndromes (CAPS),2/27/2008,2/27/2015,,"Regeneron Pharmaceuticals, Inc.",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,196904,c syndrome,"""gard:0005978""",
5925,rilotumumab,,6/18/2012,treatment of gastric cancer including gastroesophageal junction adenocarcinoma,Designated/Designation Withdrawn or Revoked,1/17/2017,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,M/S 17-2-B,Thousand Oaks,California,' 91320 ' ,United States,369412,noma,"""gard:0004001""",
5926,Rilpivirine,,1/19/2022,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Aptorum International Limited,4T.07 17 Hanover Square,,London,not applicable,' W1S 1BN ' ,United Kingdom,858321,neuroblastoma,"""gard:0007185""",
5927,Riluzole,,10/15/1996,treatment of huntington's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Rhone-Poulenc Rorer Pharmaceuticals, Inc.",500 Arcola Road,PO Box 5096,Collegeville,Pennsylvania,' 19426 ' ,United States,100796,,,
5928,Riluzole,Rilutek,3/16/1993,treatment of amyotrophic lateral sclerosis.,Designated/Approved,,,Treatment of patients with amyotrophic lateral sclerosis. Riluzole extends survival and/or time to tracheostomy.,12/12/1995,12/12/2002,,"Rhone-Poulenc Rorer Pharmaceuticals, Inc.","500 Arcola Road, P.O. Box 1200",,Collegeville,Pennsylvania,' 19426 ' ,United States,72792,amyotrophic lateral sclerosis,"""gard:0005786""",
5929,riluzole,,2/23/2016,treatment of spinocereballar ataxia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biohaven Pharmaceutical Holding Company, Ltd.",215 Church Street,,New Haven,Connecticut,' 06510 ' ,United States,510015,,,
5930,riluzole oral film,EXSERVAN,1/23/2018,treatment of amyotrophic lateral sclerosis (als),Designated/Approved,,,EXSERVAN is indicated for the treatment of amyotrophic lateral sclerosis (ALS).,11/22/2019,,,Aquestive Therapeutics,30 Technology Drive South,,Warren,New Jersey,' 07059 ' ,United States,563216,amyotrophic lateral sclerosis,"""gard:0005786""",
5931,riluzole oral suspension,Tiglutik,9/15/2016,treatment of amyotrophic lateral sclerosis (als).,Designated/Approved,,,TIGLUTIK is indicated for the treatment of amyotrophic lateral sclerosis (ALS).,12/13/2019,,,Italfarmaco SpA,54 Via dei Lavoratori,,Cinisello Balsamo,Lombardia,' 20092 ' ,Italy,508715,amyotrophic lateral sclerosis,"""gard:0005786""",
5932,riluzole oral suspension,Tiglutik,9/15/2016,treatment of amyotrophic lateral sclerosis (als).,Designated/Approved,,,TIGLUTIK is indicated for the treatment of amyotrophic lateral sclerosis (ALS).,9/5/2018,,,Italfarmaco SpA,54 Via dei Lavoratori,,Cinisello Balsamo,Lombardia,' 20092 ' ,Italy,508715,amyotrophic lateral sclerosis,"""gard:0005786""",
5933,riluzole orally disolving tablet,,11/30/2016,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,"Biohaven Pharmaceutical Holding Company, Ltd",215 Church Street,,New Haven,Connecticut,' 06510 ' ,United States,509415,amyotrophic lateral sclerosis,"""gard:0005786""",
5934,rilzabrutinib,,10/15/2018,treatment of immune thrombocytopenic purpura (itp),Designated,,Not FDA Approved for Orphan Indication,,,,,Principia Biopharma Inc.,400 East Jamie Court,,South San Francisco,California,' 94080 ' ,United States,605717,,,
5935,rimeporide,,9/19/2017,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,EspeRare Foundation,"14, Ch des Aulx",,Plan-les-Ouates,Genève,' ' ,Switzerland,602717,muscular dystrophy,"""gard:0007922""",
5936,rindopepimut,,11/19/2007,treatment of egfrviii-expressing glioblastoma multiforme,Designated/Designation Withdrawn or Revoked,1/21/2022,Not FDA Approved for Orphan Indication,,,,,"Celldex Therapeutics, Inc.",119 Fourth Avenue,,Needham,Massachusetts,' 02494 ' ,United States,249207,glioblastoma,"""gard:0002491""",
5937,Rintatolimod,,12/17/2020,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,AIM ImmunoTech Inc.,2117 SW Highway 484,,Ocala,Florida,' 34473 ' ,United States,785520,,,
5938,Rintatolimod,,10/31/2022,treatment of ebola virus disease,Designated,,Not FDA Approved for Orphan Indication,,,,,AIM ImmunoTech Inc.,2117 SW Highway 484,,Ocala,Florida,' 34473 ' ,United States,907922,,,
5939,riociguat,Adempas,9/19/2013,treatment of chronic thromboembolic pulmonary hypertension,Designated/Approved,,,"Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) WHO Group 4, after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class",10/8/2013,10/8/2020,"Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) WHO Group 4, after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class","Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Blvd.,,Whippany,New Jersey,' 07981 ' ,United States,406913,chronic thromboembolic pulmonary hypertension,"""gard:0013124""",
5940,riociguat,,6/26/2019,treatment of fontan-palliated patients,Designated/Designation Withdrawn or Revoked,2/10/2020,Not FDA Approved for Orphan Indication,,,,,Bayer U.S. LLC,100 Bayer Boulevard,P.O. Box 915,Hanover,New Jersey,' 07981 ' ,United States,669718,,,
5941,riociguat,,7/24/2014,treatment of systemic sclerosis,Designated/Designation Withdrawn or Revoked,1/15/2019,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Blvd,P. O. Box 915,Whippany,New Jersey,' 07981 ' ,United States,439514,systemic sclerosis,"""gard:0009748""",
5942,riociguat,Adempas,9/19/2013,treatment of pulmonary arterial hypertension.,Designated/Approved,,,"Treatment of adults with pulmonary arterial hypertension (PAH) WHO Group 1, to improve exercise capacity, WHO functional class and to delay clinical worsening.",10/8/2013,10/8/2020,"Treatment of adults with pulmonary arterial hypertension (PAH) WHO Group 1, to improve exercise capacity, WHO functional class and to delay clinical worsening.","Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Blvd.,,Whippany,New Jersey,' 07981 ' ,United States,392113,pulmonary arterial hypertension,"""gard:0007501""",
5943,Ripretinib,,10/2/2014,treatment of gastrointestinal stromal tumors (gist),Designated/Approved,,,"QINLOCK (ripretinib) is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.",5/15/2020,5/15/2027,"Indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.","Deciphera Pharmaceuticals, LLC",200 Smith Street,,Waltham,Massachusetts,' 02451 ' ,United States,447414,gastrointestinal stromal tumor,"""gard:0008598""",
5944,risankizumab,,11/29/2016,treatment of pediatric crohn's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,Regulatory Affair,1 North Waukegan Road,North Chicago,Illinois,' 60044 ' ,United States,544716,,,
5945,risdiplam,Evrysdi,1/4/2017,treatment of spinal muscular atrophy,Designated/Approved,,,treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older,8/7/2020,8/7/2027,treatment of spinal muscular atrophy (SMA) in patients 2 months of age and older.,"Genentech, Inc., a Member of the Roche Group",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,548116,,,
5946,risdiplam,Evrysdi,1/4/2017,treatment of spinal muscular atrophy,Designated/Approved,,,Treatment of spinal muscular atrophy (SMA) in pediatric and adult patients,5/27/2022,5/27/2029,Treatment of spinal muscular atrophy (SMA) in pediatric patients between birth and 2 months of age,"Genentech, Inc., a Member of the Roche Group",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,548116,,,
5947,risedronate sodium,,12/18/2006,treatment of patients with osteogenesis imperfecta,Designated/Designation Withdrawn or Revoked,5/22/2014,Not FDA Approved for Orphan Indication,,,,,Warner Chilcott Pharmaceuticals,100 Enterprise Drive,,Roakaway,New Jersey,' 07866 ' ,United States,229106,osteogenesis imperfecta,"""gard:0001017""",
5948,Ritanserin,,5/11/2017,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,The University of Virginia/Benjamin Purow,1215 Lee Street,,Charlottesville,Virginia,' 22908 ' ,United States,575017,glioblastoma,"""gard:0002491""",
5949,Ritonavir powder for oral suspension,Norvir Powder for Oral Suspension,1/11/2017,use with other antiretroviral agents for the treatment of pediatric hiv-1 infection,Designated/Approved/Designation Withdrawn or Revoked,4/3/2020,,Used in combination with other antiretroviral agents for the treatment of patients with HIV-1 infection,6/7/2017,,,AbbVie Inc.,Regulatory Affairs,1 Waukegan Road,North Chicago,Illinois,' 60044 ' ,United States,549816,,,
5950,rituximab,,11/12/2020,treatment of autoimmune hemolytic anemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Taxon Therapeutics Ltd.,"122 Bar Kokhva St,",,Herzliya,,' 4600728 ' ,Israel,781520,autoimmune hemolytic anemia,"""gard:0005870""",
5951,rituximab,,11/9/2016,treatment of rasmussen's encephalitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Keck Graduate Institute of Applied Life Sciences,535 Watson Drive,,Claremont,California,' 91711 ' ,United States,542416,encephalitis,"""gard:0019357""",
5952,Rituximab,,10/12/2021,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,Taxon Therapeutics Ltd.,122 Bar Kokhva St.,,Herzliya 4600728,Herzliya,' 4600728 ' ,Israel,840621,myasthenia gravis,"""gard:0007122""",
5953,rituximab,Rituxan(r); MabThera(r),2/23/2015,treatment of pemphigus vulgaris.,Designated/Approved,,,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,6/7/2018,6/7/2025,RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,465014,pemphigus vulgaris,"""gard:0007355""",
5954,rituximab,,2/7/2023,treatment of autoimmune hemolytic anemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Mabion S.A.,Langiewicza 60 Str.,,Konstantynow Lodzki,,' 95-050 ' ,Poland,923822,autoimmune hemolytic anemia,"""gard:0005870""",
5955,rituximab,Rituxan,6/13/1994,treatment of non-hodgkin's b-cell lymphoma,Designated/Approved,,,"treatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy",12/2/2021,12/2/2028,"treatment of pediatric patients aged 6 months and older with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL)","Genentech, Inc.","1 DNA Way, MS 242",,South San Francisco,California,' 94080 ' ,United States,79793,lymphoma,"""gard:0020548""",
5956,rituximab,Rituxan,2/14/2006,"treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (wegener's granulomatosis, microscopic polyangiitis, and churg-strauss syndrome)",Designated/Approved,,,"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegener?s Granulomatosis) and Microscopic Polyangiitis (MPA)",9/27/2019,9/27/2026,"indicated in combination with glucocorticoids, for the treatment of pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA)","Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,216305,vasculitis,"""gard:0018844""",
5957,rituximab,,3/12/2002,treatment of immune thrombocytopenic purpura,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,155102,,,
5958,rituximab,Rituxan,2/14/2006,"treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (wegener's granulomatosis, microscopic polyangiitis, and churg-strauss syndrome)",Designated/Approved,,,For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). ),4/19/2011,4/19/2018,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,216305,vasculitis,"""gard:0018844""",
5959,rituximab,Rituxan,1/29/2004,treatment of chronic lymphocytic leukemia,Designated/Approved,,,Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide,2/18/2010,2/18/2017,,"Genentech, Inc.",1DNA Way,MS 241A,South San Francisco,California,' 94080 ' ,United States,177603,,,
5960,rituximab,Rituxan,6/13/1994,treatment of non-hodgkin's b-cell lymphoma,Designated/Approved,,,"Treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin's lymphoma",11/26/1997,11/26/2004,,"Genentech, Inc.","1 DNA Way, MS 242",,South San Francisco,California,' 94080 ' ,United States,79793,lymphoma,"""gard:0020548""",
5961,rituximab,,1/26/2023,treatment of membranous nephropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Mabion S.A.,Langiewicza 60 Str.,,Lodzki,Konstantynow,' 95-050 ' ,Poland,922222,,,
5962,rituximab and recombinant human hyaluronidase,Rituxan SC,8/22/2016,treatment of chronic lymphocytic leukemia (cll),Designated/Approved,,,Treatment of adult patients with previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide,6/22/2017,6/22/2024,Treatment of adult patients with previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,545616,,,
5963,rituximab and recombinant human hyaluronidase,Rituxan SC,9/7/2016,treatment of diffuse large b-cell lymphoma,Designated/Approved,,,"Treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens",6/22/2017,6/22/2024,"Treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens","Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,546516,lymphoma,"""gard:0020548""",
5964,rituximab and recombinant human hyaluronidase,Rituxan SC,8/22/2016,treatment of follicular lymphoma,Designated/Approved,,,"Treatment of adult patients with relapsed or refractory, follicular lymphoma as a single agent; previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy; and non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.",6/22/2017,6/22/2024,"Treatment of adult patients with relapsed or refractory, follicular lymphoma as a single agent; previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therap; and non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.","Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,529816,lymphoma,"""gard:0020548""",
5965,Rivoceranib,,2/2/2021,treatment of adenoid cystic carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Elevar Therapeutics, Inc.","2825 E Cottonwood Pkwy, Suite 180",,Salt Lake City,Utah,' 84121 ' ,United States,798720,noma,"""gard:0004001""",
5966,rivoceranib,,11/4/2021,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Elevar Therapeutics, Inc.",2825 E. Cottonwood Pkwy. Ste 180,,Salt Lake City,Utah,' 84121 ' ,United States,682618,hepatocellular carcinoma,"""gard:0016773""",
5967,rociletinib,,5/14/2013,treatment of non-small cell lung cancer and mutations in the epidermal growth factor receptor,Designated,,Not FDA Approved for Orphan Indication,,,,,"Clovis Oncology, Inc.",5500 Flatiron Parkway,Suite 100,Boulder,Colorado,' 80301 ' ,United States,380212,small cell lung cancer,"""gard:0009344""",
5968,rodatristat ethyl,,10/6/2015,treatment of pulmonary arterial hypertension (pah).,Designated,,Not FDA Approved for Orphan Indication,,,,,Altavant Sciences GmbH,8 Viaduktstrasse,,Basel,Basel-Stadt,' ' ,Switzerland,492715,pulmonary arterial hypertension,"""gard:0007501""",
5969,rofecoxib,,3/16/2004,treatment of juvenile rheumatoid arthritis,Designated,,Not FDA Approved for Orphan Indication,,,,,"MERCK & Co., Inc.",126 East Lincoln Ave.,,Rahway,New Jersey,' 07065 ' ,United States,181703,,,
5970,rofecoxib,,9/26/2017,treatment of hemophilic arthropathy (ha),Designated,,Not FDA Approved for Orphan Indication,,,,,"Tremeau Pharmaceuticals, Inc.",1 Broadway,14th Floor,Cambridge,Massachusetts,' 02142 ' ,United States,601917,,,
5971,romidepsin,Istodax,9/30/2004,treatment of non-hodgkin t-cell lymphomas,Designated/Approved,,,Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy,11/5/2009,11/5/2016,,Celgene Corporation,One Broadway,14th Floor,Cambridge,Massachusetts,' 02142 ' ,United States,193404,lymphoma,"""gard:0020548""",
5972,romidepsin,Istodax,9/30/2004,treatment of non-hodgkin t-cell lymphomas,Designated/Approved,,,Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy,6/16/2011,6/16/2018,,Celgene Corporation,One Broadway,14th Floor,Cambridge,Massachusetts,' 02142 ' ,United States,193404,lymphoma,"""gard:0020548""",
5973,Romilkimab,,8/21/2019,treatment of systemic sclerosis,Designated/Designation Withdrawn or Revoked,5/11/2021,Not FDA Approved for Orphan Indication,,,,,Sanofi U.S. Service Inc.,55 Corporate Drive,Mail Stop: 55C-300,Bridgewater,New Jersey,' 08807 ' ,United States,629518,systemic sclerosis,"""gard:0009748""",
5974,Romiplostim,,11/27/2019,treatment of aplastic anemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,' 91320 ' ,United States,712019,aplastic anemia,"""gard:0020234""",
5975,romiplostim,Nplate,5/24/2018,treatment of patients acutely exposed to myelosuppressive doses of radiation following radiological/nuclear incident,Designated/Approved,,,to increase survival in adults and pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]),1/28/2021,1/28/2028,to increase survival in adults and pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]),Amgen Inc.,1 Amgen Center Drive,,Thousand Oaks,California,' 91320 ' ,United States,639818,,,
5976,romiplostim,,1/25/2021,treatment of chemotherapy-induced thrombocytopenia,Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,' 91320 ' ,United States,751320,,,
5977,romiplostim,Nplate,3/27/2003,treatment of immune thrombocytopenic purpura,Designated/Approved,,,"Nplate is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.",12/14/2018,12/14/2025,"Nplate is indicated for the treatment of pediatric patients 1 year of age and older with immune thrombocytopenia (ITP) for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.",One Amgen Center Drive,Mail Stop: 27-2-D,Thousand Oaks,California,' 91320 ' ,United States,165402,,,
5978,romiplostim,Nplate,3/27/2003,treatment of immune thrombocytopenic purpura,Designated/Approved,,,"Nplate is indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy",10/17/2019,10/17/2026,"For the treatment of thrombocytopenia in adult patients with non-chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.","Amgen, Inc.",One Amgen Center Drive,Mail Stop: 27-2-D,Thousand Oaks,California,' 91320 ' ,United States,165402,,,
5979,romiplostim,Nplate,3/27/2003,treatment of immune thrombocytopenic purpura,Designated/Approved,,,"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy",8/22/2008,8/22/2015,,"Amgen, Inc.",One Amgen Center Drive,Mail Stop: 27-2-D,Thousand Oaks,California,' 91320 ' ,United States,165402,,,
5980,romiplostim,,10/31/2007,treatment of thrombocytopenia associated with myelodysplasia syndrome,Designated/Designation Withdrawn or Revoked,10/3/2022,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,,Thousand Oaks,California,' 91320 ' ,United States,234506,,,
5981,romosozumab,,5/10/2021,treatment of osteogenesis imperfecta,Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop: 27-2-D,Thousand Oaks,California,' 91320-1799 ' ,United States,816321,osteogenesis imperfecta,"""gard:0001017""",
5982,roneparstat,,3/19/2015,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,3/24/2022,Not FDA Approved for Orphan Indication,,,,,Leadiant Biosciences S.p.A,Via Sudafrica 20,,Roma,,' ' ,Italy,468914,multiple myeloma,"""gard:0007108""",
5983,ropeginterferon alfa-2b-njft,Besremi,4/2/2012,treatment of polycythemia vera,Designated/Approved,,,Treatment of adults with polycythemia vera,11/12/2021,11/12/2028,Treatment of adults with polycythemia vera,PharmaEssentia,"13F, No. 3, YuanQu St.",,Taipei,Taiwan,' ' ,Taiwan,367012,polycythemia,"""gard:0019466""",
5984,ropidoxuridine,,5/19/2016,radiosensitizer to be used during radiation treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"EMEK, Inc.",196 Channel View,,Warwick,Rhode Island,' 02889 ' ,United States,519016,,,
5985,Roquinimex,,7/1/1993,to prolong time to relapse in leukemia patients who have undergone autologous bone marrow transplantation.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Pharmacia & Upjohn,7000 Portage Road,,Kalamazoo,Michigan,' 49001 ' ,United States,72893,,,
5986,rose bengal disodium,,2/11/2019,treatment of ocular melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Provectus BioPharmaceuticals, Inc.",10025 Investment Drive,Suite 250,Knoxville,Tennessee,' 37932 ' ,United States,670618,noma,"""gard:0004001""",
5987,rose bengal disodium,,4/18/2011,treatment of hepatocellular carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Provectus BioPharmaceuticals, Inc.",10025 Investment Drive,Suite 250,Knoxville,Tennessee,' 37932 ' ,United States,339611,hepatocellular carcinoma,"""gard:0016773""",
5988,Rose Bengal Disodium,,12/21/2006,treatment of metastatic melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Provectus BioPharmaceuticals, Inc.",10025 Investment Drive,Suite 250,Knoxville,Tennessee,' 37932 ' ,United States,233706,noma,"""gard:0004001""",
5989,Rose bengal disodium,,11/2/2018,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Provectus BioPharmaceuticals, Inc.",10025 Investment Drive,Suite 250,Knoxville,Tennessee,' 37932 ' ,United States,657518,neuroblastoma,"""gard:0007185""",
5990,Roseburia hominis,,8/4/2014,treatment of ulcerative colitis in pediatric patients age 0 through 16 years,Designated/Designation Withdrawn or Revoked,4/21/2023,Not FDA Approved for Orphan Indication,,,,,4D Pharma Research Ltd,Life Sciences Innovation Bldg,Cornhill Road,Scotland,,' ' ,United Kingdom,439114,,,
5991,Rosomidnar,,3/10/2016,treatment of diffuse large b-cell lymphoma.,Designated/Designation Withdrawn or Revoked,7/20/2016,Not FDA Approved for Orphan Indication,,,,,"ProNAi Therapeutics, Inc.",46701 Commerce Center Drive,,Plymouth,Michigan,' 48170 ' ,United States,512415,lymphoma,"""gard:0020548""",
5992,rosuvastatin,Crestor,2/14/2014,for the treatment of pediatric homozygous familial hypercholesterolemia,Designated/Approved,,,"An adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., LDL apheresis).",5/27/2016,5/27/2023,"An adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., LDL apheresis).","iPR Pharmaceuticals, Inc.",1 MedImmune Way,,Gaithersburg,Maryland,' 20878 ' ,United States,420513,homozygous familial hypercholesterolemia,"""gard:0010416""",
5993,rovalpituzumab tesirine,,12/22/2015,treatment of small cell lung cancer,Designated/Designation Withdrawn or Revoked,5/15/2020,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,500315,small cell lung cancer,"""gard:0009344""",
5994,Rovatirelin,,8/15/2022,treatment of spinocerebellar ataxia,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioPharma Global, a division of Pace Life Sciences","2665 Long Lake Road, Suite 300",,Roseville,Minnesota,' 55113 ' ,United States,895422,,,
5995,Rozanolixizumab,,4/30/2018,treatment of immune thrombocytopenic purpura (itp),Designated,,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.",1950 Lake Park Drive Building 2100,,Smyrna,Georgia,' 30080 ' ,United States,636618,,,
5996,rozanolixizumab-noli,Rystiggo,2/1/2019,treatment of myasthenia gravis,Designated/Approved,,,treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive,6/26/2023,6/26/2030,treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive,"UCB, Inc.","1950 Lake Park Drive, Building 2100",,Smyrna,Georgia,' 30080 ' ,United States,669918,myasthenia gravis,"""gard:0007122""",
5997,rozrolimupab,,9/13/2010,treatment of primary immune thrombocytopenia.,Designated,,Not FDA Approved for Orphan Indication,,,,,Symphogen A/S,Pederstrupvej 93,,Ballerup,,' ' ,Denmark,312610,immune thrombocytopenia,"""gard:0005194""",
5998,rsATP7A cDNA,,1/10/2014,treatment of menkes disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cyprium Therapeutics, Inc.",2 Gansevoort Street,9th Floor,New York,New York,' 10014 ' ,United States,416413,menkes disease,"""gard:0001521""",
5999,rSP-C lung surfactant,,4/3/2000,treatment of adult respiratory distress syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,Byk Gulden Pharmaceuticals,Byk-Gulden StraBe 2,,Konstanz,,' ' ,Germany,119198,,,
6000,rSP-C surfactant,,9/18/2006,"for use in patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygen impairment",Designated,,Not FDA Approved for Orphan Indication,,,,,Altana Pharma,220 Park avenue,,Florham Park,New Jersey,' 07932 ' ,United States,224406,,,
6001,rubitecan,,7/17/2002,treatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"SuperGen, Inc.",4140 Dublin Blvd.,Suite 200,Dublin,California,' 94568 ' ,United States,156602,acquired immunodeficiency,"""gard:0021359""",
6002,rucaparib,Rubraca,7/31/2012,treatment of ovarian cancer,Designated/Approved,,,"For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.",4/6/2018,4/6/2025,For the maintenance treatment of adult patients with recurrent epithelial ovarian cancer who are in complete or partial response to platinum-based chemotherapy.,"Clovis Oncology, Inc.",5500 Flatiron Parkway,Suite 100,Boulder,Colorado,' 80301 ' ,United States,374712,ovarian cancer,"""gard:0007295""",
6003,rucaparib,Rubraca,7/31/2012,treatment of ovarian cancer,Designated/Approved,,,As monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies (Indication withdrawn),12/19/2016,6/10/2022,As monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies (Indication withdrawn),"Clovis Oncology, Inc.",5500 Flatiron Parkway,Suite 100,Boulder,Colorado,' 80301 ' ,United States,374712,ovarian cancer,"""gard:0007295""",
6004,Rucosopasem manganese,,5/17/2023,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Galera Therapeutics, Inc.","2 West Liberty Boulevard, Suite 100",,Malvern,Pennsylvania,' 19355 ' ,United States,939023,,,
6005,rufinamide,Banzel,10/8/2004,treatment of lennox-gastaut syndrome.,Designated/Approved,,,Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome.,11/14/2008,11/14/2015,,"Eisai, Inc.",300 Tice Blvd,,Woodcliff Lake,New Jersey,' 07677 ' ,United States,193504,lennox-gastaut syndrome,"""gard:0009912""",
6006,rusalatide acetate,,9/7/2017,treatment of acute radiation syndrome (ars),Designated,,Not FDA Approved for Orphan Indication,,,,,"Chrysalis BioTherapeutics, Inc.",2200 Market Street,Suite 609,Galveston,Texas,' 77550 ' ,United States,601417,acute radiation syndrome,"""gard:0021896""",
6007,ruxolitinib,JAKAFI,11/3/2016,treatment of graft versus host disease,Designated/Approved,,,Treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.,5/24/2019,5/24/2026,Treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,542716,graft versus host disease,"""gard:0016642""",
6008,Ruxolitinib,,7/18/2016,treatment of acute lymphoblastic leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-off,,Wilmington,Delaware,' 19803 ' ,United States,529116,acute lymphoblastic leukemia,"""gard:0000522""",
6009,ruxolitinib,Jakafi,11/3/2016,treatment of graft versus host disease,Designated/Approved,,,Treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older,9/22/2021,9/22/2028,Treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,542716,graft versus host disease,"""gard:0016642""",
6010,ruxolitinib,,8/16/2013,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,400613,,,
6011,ruxolitinib,Jakafi,3/26/2010,treatment of polycythemia vera,Designated/Approved,,,Treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.,12/4/2014,12/4/2021,Treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,302310,polycythemia,"""gard:0019466""",
6012,ruxolitinib phosphate,,3/22/2010,treatment of essential thrombocythemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,302510,essential thrombocythemia,"""gard:0006594""",
6013,ruxolitinib phosphate,Jakafi,9/5/2008,treatment of myelofibrosis,Designated/Approved,,,"Treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis",11/16/2011,11/16/2018,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,265308,,,
6014,rVIIa-FP,,12/22/2011,treatment and prophyllaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor viii or ix,Designated,,Not FDA Approved for Orphan Indication,,,,,CSL Behring,1020 First Avenue,P. O. Box 61501,King of Prussia,Pennsylvania,' 19406 ' ,United States,356111,hemophilia,"""gard:0010418""",
6015,S(-)-3-[3-amino-phthalimido]-glutaramide,,3/14/2002,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,EntreMed Incorporated,9640 Medical Center Dr.,,Rockville,Maryland,' 20850 ' ,United States,151701,multiple myeloma,"""gard:0007108""",
6016,S-59 treated FFP (plasma treated with amotosalen hydrochloride & ultraviolet A light,,2/14/2011,treatment of thrombotic thrombocytopenic purpura,Designated,,Not FDA Approved for Orphan Indication,,,,,Cerus Corporation,2550 Stanwell Drive,,Concord,California,' 94520 ' ,United States,331710,thrombotic thrombocytopenic purpura,"""gard:0016659""",
6017,S-adenosylmethionine,,4/30/1998,treatment of aids-myelopathy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genopia USA, Inc.","90 Gold Street, 6N",,New York,New York,' 10038 ' ,United States,111498,,,
6018,S-ethylisothiourea diethylphosphate,,8/29/2016,"treatment of symptomatic intradialytic hypotension, including symptomatic hypotension in the immediate post-dialytic period.",Designated,,Not FDA Approved for Orphan Indication,,,,,"TrioxBio, Inc.",P. O. Box 1000,,Wilmington,Delaware,' 19801 ' ,United States,514615,,,
6019,S-nitrosoglutathione,,5/12/2009,management of cystic fibrosis patients to improve airway clearance and to improve or stabilize pulmonary function,Designated,,Not FDA Approved for Orphan Indication,,,,,"N30 PHARMAceuticals, LLC",3122 Sterling Circle,,Boulder,Colorado,' 80301 ' ,United States,281609,cystic fibrosis,"""gard:0006233""",
6020,S-nitrosoglutathione,,12/28/2012,treatment of severe preeclampsia,Designated,,Not FDA Approved for Orphan Indication,,,,,Salupont Consulting Ltd,"The Old Quarters, Hazells Hall","Everton Road, Sandy",Bedfordshire SG19 2DD,,' ' ,United Kingdom,358511,preeclampsia,"""gard:0012924""",
6021,S-[+]-apomorphine,,10/2/2018,treatment of amyotrophic lateral sclerosis (als).,Designated,,Not FDA Approved for Orphan Indication,,,,,Aclipse One Inc,170 North Radnor Chester Road,Suite 350,Wayne,Pennsylvania,' 19087 ' ,United States,652718,amyotrophic lateral sclerosis,"""gard:0005786""",
6022,"S-[2,3-bispalmitoyloxy-(2R)-propyl]-cysteinly-GNNDESNISFKEK",,10/20/2009,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,MBiotec GmBH,Hohenweg 13,,Seefeld,,' ' ,Germany,292809,,,
6023,"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide",,11/16/2015,treatment of c3 glomerulopathy.,Designated,,Not FDA Approved for Orphan Indication,,,,,Amyndas Pharmaceuticals S.A,Kyprou 27,,Glyfada,,' 16675 ' ,Greece,494915,c3 glomerulopathy,"""gard:0017507""",
6024,"S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide)",,10/9/2014,treatment of paroxysmal nocturnal hemoglobinuria (pnh),Designated,,Not FDA Approved for Orphan Indication,,,,,Amyndas Pharmaceuticals,Kyprou 27,,Glyfada,,' 16675 ' ,Greece,446714,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
6025,sacituzumab govitecan,,5/29/2014,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,433514,,,
6026,sacituzumab govitecan,,11/27/2013,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,415413,small cell lung cancer,"""gard:0009344""",
6027,sacituzumab govitecan (SG),,10/8/2020,treatment for adult and pediatric patients with glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,769520,glioblastoma,"""gard:0002491""",
6028,Sacrosidase,Sucraid,12/10/1993,treatment of congenital sucrase-isomaltase deficiency,Designated/Approved,,,"Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrease-isomaltase deficiency.",4/9/1998,4/9/2005,,"QOL Medical, LLC","4445 North Highway A1A, 241",,Vero Beach,Florida,' 32963 ' ,United States,78693,congenital sucrase-isomaltase deficiency,"""gard:0007710""",
6029,Safusidenib erbumine,,3/14/2024,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,AnHeart Therapeutics Inc.,"777 Third Avenue, Suite 1704",,New York,New York,' 10017 ' ,United States,993323,,,
6030,salicylic acid 6%,,2/17/2012,treatment of rare congenital ichthyoses.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Orenova Group, LLC",10 New King Street,Suite 106,White Plains,New York,' 10604 ' ,United States,359211,,,
6031,Salinomycin,,12/12/2019,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hillstream Biopharma, Inc.",245 Main Street,Suite 204,Chester,New Jersey,' 07930 ' ,United States,713219,small cell lung cancer,"""gard:0009344""",
6032,salinomycin,,2/15/2022,treatment of uveal melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hillstream Biopharma, Inc.","245 Main Street, Suite 204",,Chester,New Jersey,' 07930 ' ,United States,862721,uveal melanoma,"""gard:0008621""",
6033,salirasib,,12/18/2006,treatment of pancreatic cancer.,Designated/Designation Withdrawn or Revoked,8/8/2017,Not FDA Approved for Orphan Indication,,,,,"Kadmon Corporation, LLC",450 East 29th Street,5th Floor,New York,New York,' 10016 ' ,United States,231306,,,
6034,salmeterol xinafoate/fluticasone propionate,,10/29/2009,treatment of symptomatic exophthalmos associated with thyroid related eye disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Lithera, Inc.",9191 Towne Center Drive,,San Diego,California,' 92122 ' ,United States,273208,,,
6035,Salmonella Typhi strain Ty21a transfected with a plasmid vector encoding for the human vascular endothelial growth factor receptor 2,,8/31/2017,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Vaximm GmbH,1 Julius-Hatry-Straße,,Mannheim,Baden-Württemberg,' ' ,Germany,596117,,,
6036,"Samarium (Sm-153) chelate of DOTMP (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methylenephophonate))",,8/11/2021,treatment of osteosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"QSAM Therapeutics, Inc.","9442 N Capital of Texas Hwy, Plaza One, Suite 500",,Austin,Texas,' 78759-7228 ' ,United States,773120,osteosarcoma,"""gard:0007284""",
6037,saposin C,,2/3/2015,treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,"Bexion Pharmaceuticals, LLC",632 Russell St.,,Covington,Kentucky,' 41011 ' ,United States,463814,glioblastoma,"""gard:0002491""",
6038,sapropterin,Kuvan,1/29/2004,treatment of hyperphenylalaninemia,Designated/Approved,,,Indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.,12/13/2007,12/13/2014,,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,' 94949 ' ,United States,181503,,,
6039,"Sar9, Met(O2)11-Substance P",,3/16/2011,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,New Amsterdam Sciences,"14358 N. Frank Llyod Wright Blvd., Suite 3",,Scottsdale,Alaska,' 85260 ' ,United States,304110,idiopathic pulmonary fibrosis,"""gard:0008609""",
6040,saracatinib,,3/11/2019,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"AstraZeneca Pharmaceuticals, LP","Emerging Innovations, AstraZeneca, R&D Boston",35 Gatehouse Drive,Waltham,Massachusetts,' 02451 ' ,United States,674218,idiopathic pulmonary fibrosis,"""gard:0008609""",
6041,sarcosine,,10/12/2011,treatment of obsessive compulsive disorder in pediatric patients (0 to 16 years of age),Designated,,Not FDA Approved for Orphan Indication,,,,,"Guochuan Emil Tsai, MD, PhD","David Geffen School of Medicine, UCLA","1000 W., Carson St.",Torrance,California,' 90502 ' ,United States,346611,,,
6042,Sargramostim,Leukine,3/6/1995,to reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.,Designated/Approved,,,Following induction chemotherapy in older adult patients with acute myelogenous leukemia to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death.,9/15/1995,9/15/2002,,Immunex Corporation,51 University Street,,Seattle,Washington,' 98101 ' ,United States,81494,,,
6043,sargramostim,,8/8/2019,treatment of stage iib-iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.",19 Muzzey Street,,Lexington,Massachusetts,' 02421 ' ,United States,674618,noma,"""gard:0004001""",
6044,sargramostim,,10/22/2018,treatment of pulmonary alveolar proteinosis (pap).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Partner Therapeutics, Inc.",19 Muzzey Street,,Lexington,Massachusetts,' 02421 ' ,United States,654318,,,
6045,sargramostim,Leukine,11/9/2016,treatment of individuals acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome),Designated/Approved,,,LEUKINE® is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]).,3/29/2018,3/29/2025,to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]),"Partner Therapeutics, Inc.",19 Muzzey Street,,Lexington,Massachusetts,' 02421 ' ,United States,541816,acute radiation syndrome,"""gard:0021896""",
6046,sargramostim,Leukine,5/3/1990,"treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment.",Designated/Approved,,,,3/5/1991,3/5/1998,,Immunex Corporation,51 University Street,,Seattle,Washington,' 98101 ' ,United States,44290,,,
6047,sarizotan,,7/7/2015,treatment of rett syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Newron Pharmaceuticals US, Inc.",89 Headquarter Plaza North,Suite 1438,Morristown,New Jersey,' 07960 ' ,United States,484015,rett syndrome,"""gard:0005696""",
6048,saroglitazar magnesium,,1/26/2021,treatment of primary biliary cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Zydus Discovery DMCC,"Unit no 909, Armada 2","Plot no : JLT-PH2-P2A,",Dubai,,' ' ,United Arab Emirates,686819,primary biliary cholangitis,"""gard:0007459""",
6049,sarsasapogenin,,6/18/2004,treatment of amyotrophic lateral sclerosis (als),Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Phytopharm plc,Corpus Christi House,,Godmanchester,Cambridgeshire,' ' ,United Kingdom,185704,amyotrophic lateral sclerosis,"""gard:0005786""",
6050,satoreotide tetraxetan,,9/24/2014,management of gastroenteropancreatic neuroendocrine tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,SatoSea Oncology GmbH,c/o LSP Services Deutschland GmbH,Dachauer Str. 65,München,,' 80335 ' ,Germany,449514,,,
6051,satralizumab-mwge,,10/26/2021,treatment of myelin oligodendrocyte glycoprotein antibody-associated disease (mogad),Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080-4990 ' ,United States,824521,,,
6052,satralizumab-mwge,Enspryng,6/30/2014,treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder,Designated/Approved,,,treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,8/14/2020,8/14/2027,treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,"Genentech, Inc.",1 DNA WAY,,SOUTH SAN FRANCISCO,California,' 94080 ' ,United States,436114,neuromyelitis optica spectrum disorder,"""gard:0006267""",
6053,satralizumab-mwge,,7/18/2022,treatment of n-methyl-d-asparatate receptor (nmdar) antibody autoimmune encephalitis (aie),Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080-4990 ' ,United States,822921,encephalitis,"""gard:0019357""",
6054,satralizumab-mwge,,2/23/2021,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080-4990 ' ,United States,802720,myasthenia gravis,"""gard:0007122""",
6055,Satumomab pendetide,Oncoscint CR/OV,9/25/1989,detection of ovarian carcinoma.,Designated/Approved,,,For determining the extent and location of extraphepatic malignant disease in patients with known colorectal and ovarian cancer.,12/29/1992,12/29/1999,,Cytogen Corporation,600 College Road East,,Princeton,New Jersey,' 08540 ' ,United States,36789,noma,"""gard:0004001""",
6056,SC-1 monoclonal antibody,,11/12/2003,treatment of patients with cd55 (sc-1) positive gastric tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,Patrys Ltd.,"Suite 614, Level 6, Equitable House",,Melbourne,Victoria,' ' ,Australia,175703,,,
6057,"scAAV9.MeCP2.hCLN3, a self-complementary AAV serotype 9 expressing human CLN3 (hCLN3)",,6/27/2017,treatment of neuronal ceroid lipofuscinosis type 3 (cln3),Designated,,Not FDA Approved for Orphan Indication,,,,,UNeMed Corporation,986099 Nebraska Medical Center,,Omaha,Nebraska,' 68198-6099 ' ,United States,570016,neuronal ceroid lipofuscinosis,"""gard:0010739""",
6058,SCN2A mRNA knockdown antisense oligonucleotide,,1/5/2021,treatment of scn2a developmental and epileptic encephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Praxis Precision Medicines, Inc.","One Broadway, 16th Floor",,Cambridge,Massachusetts,' 02142 ' ,United States,789720,,,
6059,SDF-1 (108) Lysine Dlmer,,7/7/2005,treatment of osteogenic sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Chemokine Therapeutics Corporation,190 Agronomy Road (UBC),Suite 405,Vancouver,,' ' ,Canada,182403,,,
6060,sdTD-K6a.513a.12; small interfering RNA composed of 2 strands of hybridized RNAs,,4/15/2013,treatment of pachyonychia congenita,Designated,,Not FDA Approved for Orphan Indication,,,,,"TransDerm, Inc.",2161 Delaware Avenue,,Santa Cruz,,' 95060 ' ,United States,387912,pachyonychia congenita,"""gard:0010753""",
6061,sebelipase alfa,Kanuma,7/1/2010,treatment of lysosomal acid lipase deficiency,Designated/Approved,,,Indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency,12/8/2015,12/8/2022,Indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency,Alexion Pharmaceuticals,100 College Street,,New Haven,Connecticut,' 06510 ' ,United States,309410,lysosomal acid lipase deficiency,"""gard:0012097""",
6062,Secalciferol,,7/26/1993,treatment of familial hypophosphatemic rickets.,Designated,,Not FDA Approved for Orphan Indication,,,,,Teva Pharmaceuticals USA,650 Cathill Rd.,,Sellersville,Pennsylvania,' 18960 ' ,United States,75193,hypophosphatemic rickets,"""gard:0006735""",
6063,Secretory leukocyte protease inhibitor,,6/30/1992,treatment of bronchopulmonary dysplasia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Synergen, Inc.",1885 33rd Street,,Boulder,Colorado,' 80301 ' ,United States,68292,bronchopulmonary dysplasia,"""gard:0005962""",
6064,secukinumab,,3/26/2010,adjunctive treatment of chronic non-infectious uveitis requiring systemic immunosuppression,Designated/Designation Withdrawn or Revoked,11/28/2014,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceutical Corporation,One Health Plaza,Bldg 404/470,East Hanover,New Jersey,' 07936 ' ,United States,281309,uveitis,"""gard:0019549""",
6065,seladelpar,,11/7/2016,treatment of primary biliary cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,CymaBay Therapeutics,7999 Gateway Boulevard,Suite 130,Newark,California,' 94560 ' ,United States,543416,primary biliary cholangitis,"""gard:0007459""",
6066,Selective Colony Stimulating Factor-1 Receptor kinase inhibitor,,7/27/2022,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Elixiron Immunotherapeutics Inc.,"17F, No.3, Park St.",,Taipei City,Nangang District,' 11503 ' ,Taiwan,893122,idiopathic pulmonary fibrosis,"""gard:0008609""",
6067,selective deacylglycerol acyltransferase 1 inhibitor,,3/28/2011,"treatment of hypertriglyceridemia in the setting of type i hyperlipoproteinemia, also known as familial chylomicronemia syndrome",Designated/Designation Withdrawn or Revoked,11/27/2018,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,335711,familial chylomicronemia syndrome,"""gard:0006414""",
6068,selective gamma secretase inhibitor of Notch-mediated signaling,,11/2/2023,treatment of desmoid tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,Ayala Pharmaceuticals Inc.,c/o MWE Corporate Services,"1007 North Orange Street, 4th Floor,",Wilmington,Delaware,' 19801 ' ,United States,968423,desmoid tumor,"""gard:0001820""",
6069,selective inhibitor of fungal CYP51,,3/3/2016,treatment of coccidioidomycosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"NQP 1598, Ltd.","P.O. Box 309, Ugland House",,Grand Cayman,KYl-1004,' ' ,Cayman Islands,511515,coccidioidomycosis,"""gard:0009525""",
6070,selective inhibitor of fungal lanosterol demethylase,,8/19/2014,treatment of cryptococcal meningitis,Designated/Designation Withdrawn or Revoked,11/5/2018,Not FDA Approved for Orphan Indication,,,,,"Viamet Pharmaceuticals, Inc.",4505 Emperor Blvd,Suit 300,Durham,North Carolina,' 27703 ' ,United States,439214,,,
6071,selective inhibitor of GYS1,,8/12/2022,treatment of pompe disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Shionogi Inc.,400 Campus Drive,,Florham Park,New Jersey,' 07932 ' ,United States,894222,,,
6072,selective inhibitor of mechanistic target of rapamycin complex 1,,12/18/2023,treatment of autosomal dominant polycystic kidney disease (adpkd),Designated,,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC","920 U.S. Highway 202, P.O. Box 300",,Raritan,New Jersey,' 08869 ' ,United States,976323,autosomal dominant polycystic kidney disease,"""gard:0010413""",
6073,Selective inhibitor of polymorphonuclear leukocyte (PMN) elastase,,6/4/1996,therapeutic management of patients with lung disease attributable to cystic fibrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,DuPont Pharmaceuticals Company,"Chestnut Run, Maple Run",Centre Rd.,Wilmington,Delaware,' 19805 ' ,United States,96496,cystic fibrosis,"""gard:0006233""",
6074,Selective KIT Inhibitor,,7/1/2022,treatment of mastocytosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Blueprint Medicines,45 Sidney Street,,Cambridge,Massachusetts,' 02139 ' ,United States,890922,mastocytosis,"""gard:0006987""",
6075,selective rapidly accelerated fibrosarcoma (RAF) murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor,,3/17/2023,treatment of primary brain and cns malignancies,Designated,,Not FDA Approved for Orphan Indication,,,,,Fore Biotherapeutics U.S. Inc.,3675 Market Street,Suite 200,Philadelphia,Pennsylvania,' 19104 ' ,United States,929622,,,
6076,selective small molecular inhibitor of fibroblast growth factor receptor 4,,4/22/2024,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Abbisko Therapeutics Co., Ltd.","Building 3, Lane 898, Halei Road Pudong New Area",,Shanghai,,' 201203 ' ,China,997924,hepatocellular carcinoma,"""gard:0016773""",
6077,selective small molecule messenger RNA (mRNA) degrader of MYB,,4/24/2024,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,Remix Therapeutics,"100 Forge Rd., Suite 400",,Watertown,Massachusetts,' 02472 ' ,United States,998424,acute myeloid leukemia,"""gard:0012757""",
6078,Selegiline HCl,Eldepryl,11/7/1984,"as an adjuvant to levodopa and carbidopa treatment of idiopathic parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism.",Designated/Approved,,,,6/5/1989,6/5/1996,,"Somerset Pharmaceuticals, Inc.","400 Morris Ave., Suite 7s",,Denville,New Jersey,' 07834 ' ,United States,583,postencephalitic parkinsonism,"""gard:0019370""",
6079,seletalisib,,8/3/2017,treatment of activated phosphoinositide 3-kinase delta syndrome (apds),Designated/Designation Withdrawn or Revoked,9/16/2021,Not FDA Approved for Orphan Indication,,,,,"UCB, Inc.",1950 Lake Park Drive,,Smyrna,Georgia,' 30080 ' ,United States,579917,,,
6080,selexipag,Uptravi,4/30/2010,treatment of pulmonary arterial hypertension,Designated/Approved,,,"For treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH",12/21/2015,12/21/2022,"For treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH",Actelion Pharmaceuticals Ltd,Gewerbestrasse 16,,Allschwil,,' ' ,Switzerland,304810,pulmonary arterial hypertension,"""gard:0007501""",
6081,selexipag,Uptravi,4/30/2010,treatment of pulmonary arterial hypertension,Designated/Approved,,,"Treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH",7/29/2021,,,Actelion Pharmaceuticals Ltd,Gewerbestrasse 16,,Allschwil,,' ' ,Switzerland,304810,pulmonary arterial hypertension,"""gard:0007501""",
6082,selexipag,,10/2/2018,treatment of chronic thromboembolic pulmonary hypertension,Designated/Designation Withdrawn or Revoked,2/16/2023,Not FDA Approved for Orphan Indication,,,,,Janssen Research & Development LLC,1820 Chapel Ave West,Suite 300,Cherry Hill,New Jersey,' 08002 ' ,United States,652018,chronic thromboembolic pulmonary hypertension,"""gard:0013124""",
6083,Self complimentary adeno-associated virus serotype 9 expressing human aspartoacylase transgene,,12/23/2019,treatment of canavan disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aspa Therapeutics, Inc.",421 Kipling Street,,Palo Alto,California,' 94301 ' ,United States,715219,canavan disease,"""gard:0005984""",
6084,self-complementary adeno-associated virus 9 containing human methyl-CpG binding protein 2,,3/11/2024,treatment of rett syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Genecombio Ltd.,"Building 17, Lane 388, Shengrong Road, Pudong New Area",,Shanghai,,' ' ,China,991823,rett syndrome,"""gard:0005696""",
6085,Self-complementary adeno-associated virus serotype 9 vector harboring a miniaturized codon-optimized human IDUA gene,,4/8/2024,treatment of mucopolysaccharidosis type i,Designated,,Not FDA Approved for Orphan Indication,,,,,"NeuroGT, Inc.",510 Meadowmont Village Circle #172,,Chapel Hill,North Carolina,' 27517 ' ,United States,996724,mucopolysaccharidosis,"""gard:0007065""",
6086,"self-complementary non-replicating, recombinant adeno-associated virus serotype rhesus 74 (rh 74) expressing the human beta-sarcoglycan gene under the control of the muscle creatine kinase (MHCK7) promoter",,2/15/2018,treatment of limb girdle muscular dystrophy type 2e (lgmd2e),Designated,,Not FDA Approved for Orphan Indication,,,,,Sarepta Therapeutics,"215 First Street, Suite 415",,Cambrige,Massachusetts,' 02142 ' ,United States,625818,muscular dystrophy,"""gard:0007922""",
6087,"self-complementary non-replicating, recombinant adeno-associated virus serotype rhesus 74 expressing the human alpha-sarcoglycan gene under a triple E-box muscle creatine kinase muscle specific promoter (scAAVrh74.tMCK.hSGCA)",,12/5/2018,treatment of limb girdle muscular dystrophy type 2d,Designated,,Not FDA Approved for Orphan Indication,,,,,Sarepta Therapeutics,215 First Street,,Cambridge,Massachusetts,' 02142 ' ,United States,668418,muscular dystrophy,"""gard:0007922""",
6088,Self-complimentary adeno-associated virus 9 gene therapy containing codon optimized human AP4M1,,12/1/2022,treatment of patients with spastic paraplegia type 50 (spg50) caused by the ap4m1 gene mutation,Designated,,Not FDA Approved for Orphan Indication,,,,,CureSPG50,6 Topham Road,,Toronto,Ontario,' M4B3K2 ' ,Canada,774020,,,
6089,"self-complimentary adeno-associated virus vector, serotype 9, packaging the full lenght GAN gene in the viral capsid",,9/27/2013,treatment of giant axonal neuropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"The National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH)",9000 Rockville Pike,"Building 10, Suite 2A23",Bethesda,Maryland,' 20892 ' ,United States,408813,giant axonal neuropathy,"""gard:0006500""",
6090,selinexor,Xpovio,1/5/2015,treatment of multiple myeloma,Designated/Approved,,,in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy,12/18/2020,12/18/2027,"for the treatment of adult patients with multiple myeloma who have received at least one prior therapy, excluding adult patients covered by Xpovio's previous indication for multiple myeloma approved on July 3, 2019","Karyopharm Therapeutics, Inc.","85 Wells Avenue, Suite 210",,Newton,Massachusetts,' 02459 ' ,United States,459014,multiple myeloma,"""gard:0007108""",
6091,selinexor,,7/7/2016,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Karyopharm Therapeutics, Inc.",85 Wells Avenue,,Newton,Massachusetts,' 02459 ' ,United States,527816,soft tissue sarcoma,"""gard:0004898""",
6092,selinexor,Xpovio,5/14/2014,treatment of diffuse large b-cell lymphoma,Designated/Approved,,,"XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.",6/22/2020,6/22/2027,"For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy","Karyopharm Therapeutics, Inc.",2 Mercer Road,,Natick,Massachusetts,' 01760 ' ,United States,436414,lymphoma,"""gard:0020548""",
6093,selinexor,,12/2/2021,treatment of glioblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Karyopharm Therapeutics, Inc.",85 Wells Avenue,,Newton,Massachusetts,' 02459 ' ,United States,825721,glioblastoma,"""gard:0002491""",
6094,selinexor,XPOVIO,1/5/2015,treatment of multiple myeloma,Designated/Approved,,,"XPOVIO is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.",7/3/2019,7/3/2026,"Indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.","Karyopharm Therapeutics, Inc.","85 Wells Avenue, Suite 210",,Newton,Massachusetts,' 02459 ' ,United States,459014,multiple myeloma,"""gard:0007108""",
6095,Selinexor,,5/26/2022,treatment of myelofibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Karyopharm Therapeutics, Inc.","85 Wells Ave,",,Newton,Massachusetts,' 02459 ' ,United States,880222,,,
6096,selinexor,,5/14/2014,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Karyopharm Therapeutics, Inc.",85 Wells Avenue,,Newton,Massachusetts,' 02459 ' ,United States,432414,acute myeloid leukemia,"""gard:0012757""",
6097,selisistat,,12/7/2009,treatment of huntington's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,AOP Orphan Pharmaceuticals AG,91/llf Wilhelminenstraße,,Wien,Wien,' ' ,Austria,295709,,,
6098,selpercatinib,Retevmo,10/30/2019,treatment of ret-fusion-positive non-small cell lung cancer,Designated/Approved,,,"Treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test",9/21/2022,9/21/2029,"treatment of adult patients with locally advanced non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test","Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company","701 Gateway Boulevard, Suite 420",,South San Francisco,California,' 94080 ' ,United States,675218,small cell lung cancer,"""gard:0009344""",
6099,selpercatinib,Retevmo,11/21/2019,"treatment of ret fusion-positive or ret mutant thyroid cancers including poorly differentiated thyroid cancer, undifferentiated or anaplastic thyroid cancer, medullary thyroid cancer, and locally advanced or metastatic follicular or papillary thyroid canc",Designated/Approved,,,"treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy; and treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate)",5/29/2024,,,"Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company","701 Gateway Boulevard, Suite 420",,South San Francisco,California,' 94080 ' ,United States,653118,,,
6100,selpercatinib,RETEVMO,11/21/2019,"treatment of ret fusion-positive or ret mutant thyroid cancers including poorly differentiated thyroid cancer, undifferentiated or anaplastic thyroid cancer, medullary thyroid cancer, and locally advanced or metastatic follicular or papillary thyroid canc",Designated/Approved,,,RETEVMO is indicated for the treatment of: ¿ Adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; ¿ Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate),5/8/2020,5/8/2027,"For the treatment of: adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; and, adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).","Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company","701 Gateway Boulevard, Suite 420",,South San Francisco,California,' 94080 ' ,United States,653118,,,
6101,selpercatinib,Retevmo,5/19/2022,treatment of tissue-agnostic ret fusion-positive tumors,Designated/Approved,,,Treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options,9/21/2022,9/21/2029,Treatment of adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options,"Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company",Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,849621,,,
6102,selpercatinib,Retevmo,5/19/2022,treatment of tissue-agnostic ret fusion-positive solid tumors,Designated/Approved,,,"treatment of adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options",5/29/2024,,,"Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company",Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,849621,,,
6103,selpercatinib,RETEVMO,10/30/2019,treatment of ret-fusion-positive non-small cell lung cancer,Designated/Approved,,,RETEVMO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC),5/8/2020,5/8/2027,For the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC),Loxo Oncolocy at Lilly,"701 Gateway Boulevard, Suite 420",,South San Francisco,California,' 94080 ' ,United States,675218,small cell lung cancer,"""gard:0009344""",
6104,selumetinib,,11/21/2023,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alexion Pharmaceuticals, Inc.",121 Seaport Boulevard,,Boston,Massachusetts,' 02210 ' ,United States,970623,,,
6105,selumetinib,,4/15/2015,treatment of uveal melanoma.,Designated/Designation Withdrawn or Revoked,12/15/2015,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P. O. Box 8355,Wilmington,Delaware,' 19803 ' ,United States,471015,uveal melanoma,"""gard:0008621""",
6106,selumetinib,,2/14/2018,treatment of neurofibromatosis type 1,Designated/Approved,,,"KOSELUGO is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)",4/10/2020,4/10/2027,"Indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).",AstraZeneca Pharmaceuticals LP,1800 Concord Pike,,Wilmington,Delaware,' 19803 ' ,United States,624017,neurofibromatosis type 1,"""gard:0007866""",
6107,selumetinib,,5/10/2016,adjuvant treatment of patients with stage iii or stage iv differentiated thyroid cancer.,Designated/Designation Withdrawn or Revoked,5/30/2019,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P.O. Box 8355,Wilmington,Delaware,' 19803 ' ,United States,475815,,,
6108,Seneca Valley virus,,8/22/2008,treatment of neuroendocrine tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"Seneca Therapeutics, Inc.",202 St. Andrews Court,,Blue Bell,Pennsylvania,' 19422 ' ,United States,266008,,,
6109,Sepantronium Bromide,,12/7/2023,treatment of burkitt lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cothera Bioscience, Inc.","155 Bovet Road, Suite 660",,San Mateo,California,' 94402 ' ,United States,950523,lymphoma,"""gard:0020548""",
6110,sepiapterin,,2/19/2020,treatment of primary tetrahydrobiopterin deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc. (PTC)",500 Warren Corporate Center Drive,,Warren,New Jersey,' 07059 ' ,United States,729519,,,
6111,Sepiapterin,,3/4/2021,treatment of hyperphenylalaninemia (hpa),Designated,,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",500 Warren Corporate Center Drive,,Warren,New Jersey,' 07059 ' ,United States,805320,,,
6112,serdexmethylphenidate,,11/17/2022,treatment of idiopathic hypersomnia,Designated,,Not FDA Approved for Orphan Indication,,,,,KemPharm Inc.,1180 Celebration Blvd.,,Celebration,Florida,' 34747 ' ,United States,878522,idiopathic hypersomnia,"""gard:0008737""",
6113,seribantumab,,10/25/2017,treatment of heregulin-positive non-small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Elevation Oncology, Inc.",888 7th Avenue,Suite 30,New York,New York,' 10106 ' ,United States,545516,small cell lung cancer,"""gard:0009344""",
6114,Sermorelin acetate,,2/13/1990,adjunct to gonadotropin therapy in the induction of ovulation in women with anovulatory or oligo-ovulatory infertility who fail to ovulate in response to adequate treatment with clomiphene citrate alone and gonadotropin therapy alone.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,31988,,,
6115,Sermorelin acetate,Geref,9/14/1988,treatment of idiopathic or organic growth hormone deficiency in children with growth failure.,Designated/Approved,,,,9/26/1997,9/26/2004,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,24687,,,
6116,Sermorelin acetate,,12/5/1991,treatment of aids-associated catabolism/weight loss.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,61491,,,
6117,serplulimab,,3/31/2022,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hengenix Biotech, Inc.",430 N. McCarthy Blvd.,"Milpitas, CA 95035",Milpitas,California,' 95035 ' ,United States,869822,small cell lung cancer,"""gard:0009344""",
6118,Serratia marcescens extract (polyribosomes),,9/7/1988,treatment of primary brain malignancies.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cell Technology, Inc.",1668 Valtec Lane,,Boulder,Colorado,' 80306 ' ,United States,30188,,,
6119,setanaxib,,9/26/2023,treatment of alport syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Calliditas Therapeutics Suisse SA,Chemin des Aulx 16,1228 Plan-les-Ouates,Geneva,1228 Plan-les-Ouates,' 1228 ' ,Switzerland,962823,alport syndrome,"""gard:0005785""",
6120,Setanaxib,,10/16/2020,treatment of primary biliary cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Calliditas Therapeutics Suisse SA,Chemin des Aulx 16,,Plan-les-Ouates,,' 1228 ' ,Switzerland,773220,primary biliary cholangitis,"""gard:0007459""",
6121,setmelanotide,Imcivree,11/27/2017,treatment of leptin receptor deficiency,Designated/Approved,,,"Chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).",11/25/2020,11/25/2027,"Chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).","Rhythm Pharmaceuticals, Inc.",222 Berkeley St. Suite 1200,,Boston,Massachusetts,' 02116 ' ,United States,613717,,,
6122,setmelanotide,,3/4/2020,treatment of alström syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Rhythm Pharmaceuticals, Inc",222 Berkeley Street,Suite 1200,Boston,Massachusetts,' 02116 ' ,United States,726419,alström syndrome,"""gard:0005787""",
6123,setmelanotide,Imcivree,9/19/2019,treatment of bardet-biedl syndrome,Designated/Approved,,,For chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to Bardet-Biedl syndrome (BBS),6/16/2022,6/16/2029,For chronic weight management in adult and pediatric patients 6 years of age and older with monogenic or syndromic obesity due to Bardet-Biedl syndrome (BBS),"Rhythm Pharmaceuticals, Inc.",222 Berkeley Street,Suite 1200,Boston,Massachusetts,' 02116 ' ,United States,700719,bardet-biedl syndrome,"""gard:0006866""",
6124,setmelanotide,,9/21/2015,treatment of prader-willi syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Rhythm Metabolics, Inc.",855 Boylston Street,11th Floor,Boston,Massachusetts,' 02116 ' ,United States,480615,prader-willi syndrome,"""gard:0005575""",
6125,setmelanotide,Imcivree,4/4/2016,treatment of pro-opiomelanocortin (pomc) deficiency due to mutations in the pomc gene,Designated/Approved,,,"chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).",11/25/2020,11/25/2027,"chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).","Rhythm Pharmaceuticals, Inc.",222 Berkeley St. Suite 1200,,Boston,Massachusetts,' 02116 ' ,United States,514815,,,
6126,sevuparin,,3/17/2015,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Modus Therapeutics,Sankt Eriksgatan 117,SE-113 43,Stockholm,,' ' ,Sweden,467314,,,
6127,SF-RI-1 bovine surfactant for inhalation,,1/23/2018,treatment of respiratory distress syndrome (rds),Designated,,Not FDA Approved for Orphan Indication,,,,,Aerogen Pharma Corporation,1660 South Amphlett Boulevard,,San Mateo,California,' 94402 ' ,United States,593817,,,
6128,Short chain fatty acid enema,,8/19/1997,treatment of chronic radiation proctitis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Richard I. Breuer, M.D.","1000 Central Street, Suite 615",,Evanston,Illinois,' 60201 ' ,United States,106397,radiation proctitis,"""gard:0018900""",
6129,Short chain fatty acid solution,,5/29/1990,treatment of the active phase of ulcerative colitis with involvement restricted to the left side of the colon.,Designated,,Not FDA Approved for Orphan Indication,,,,,Richard I. Breuer,"1000 Central Street, Suite 615",,Evanston,Illinois,' 60201 ' ,United States,44890,,,
6130,Signal regulatory protein alpha (SIRPalpha)-Exosome,,1/25/2024,treatment of acute liver failure regardless of etiology,Designated,,Not FDA Approved for Orphan Indication,,,,,SHIFTBIO INC.,"76 Hwarang-ro, Unit 102, 103 (1st Floor)",Seongbuk-gu,Seoul,,' ' ,South Korea,931123,acute liver failure,"""gard:0019112""",
6131,sildenafil,Revatio,7/28/2011,treatment of pediatric (defined as children less than 17 years of age) pulmonary arterial hypertension,Designated/Approved,,,"treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in pediatric patients 1 to 17 years old to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, pulmonary hemodynamics thought to underly improvements in exercise",1/31/2023,1/31/2030,"treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in pediatric patients 1 to 17 years old to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, pulmonary hemodynamics thought to underly improvements in exercise",Viatris Specialty LLC,3711 Collins Ferry Road,,Morgantown,West Virginia,' 26505 ' ,United States,344211,pulmonary arterial hypertension,"""gard:0007501""",
6132,sildenafil,Revatio,7/28/2011,treatment of pediatric (defined as children less than 17 years of age) pulmonary arterial hypertension,Designated/Approved,,,"treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in pediatric patients (1 to 17 years old) to improve exercise ability and, in pediatric patients too young to perform standardized exercise testing, pulmonary hemodynamics thought to underlie improvements in exercise",3/3/2023,,,Viatris Specialty LLC,3711 Collins Ferry Road,,Morgantown,West Virginia,' 26505 ' ,United States,344211,pulmonary arterial hypertension,"""gard:0007501""",
6133,"silibinin-C-2',3-dihydrogensuccinate, disodium salt",,9/11/2014,"treatment of amatoxin poisoning, which includes the prevention and treatment of amatoxin induced hepatic failure",Designated,,Not FDA Approved for Orphan Indication,,,,,Mylan Specialty LP,781 Chestnut Ridge Road,P. O. Box 4310,Morgantown,West Virginia,' 26504 ' ,United States,444214,,,
6134,"Silibinin-C-2',3-dihydrogensuccinate, disodium salt",,2/17/2012,prevention of recurrent hepatitis c in liver transplant patients,Designated,,Not FDA Approved for Orphan Indication,,,,,Mylan Specialty LP,781 Chestnut Ridge Road,P. O. Box 4310,Morgantown,West Virginia,' 26505 ' ,United States,362811,,,
6135,Silmitasertib,,1/19/2022,treatment of biliary tract cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Senhwa Biosciences, Inc.","10F, NO. 225, Sec. 3, Peihsin Road",,Hsintien District,New Taipei City,' 23143 ' ,Taiwan,856821,,,
6136,silmitasertib,,12/15/2021,treatment of medulloblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Senhwa Biosciences, Inc.","10F, No. 225, Sec. 3, Peihsin Road",,Hsintien District,New Taipei City,' 23143 ' ,Taiwan,851021,medulloblastoma,"""gard:0007005""",
6137,Silmitasertib,,12/22/2016,treatment of cholangiocarcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Senhwa Biosciences, Inc.","No. 205-1, Peihsin Road",Section 3,New Taipei City,Hsintien District,' ' ,Taiwan,548516,cholangiocarcinoma,"""gard:0009304""",
6138,siltuximab,,10/11/2005,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,7/10/2014,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring House,Pennsylvania,' 19477 ' ,United States,200505,multiple myeloma,"""gard:0007108""",
6139,siltuximab,SYLVANT,5/26/2006,treatment of castleman's disease,Designated/Approved,,,Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.,4/23/2014,4/23/2021,Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.,EUSA Pharma (UK) Ltd.,Breakspear Park,Breakspear Way,Hertfordshire,,' ' ,United Kingdom,200605,,,
6140,Silver sulfadiazine and cerium nitrate,,11/17/1999,treatment of patients with severe dermal burns,Designated,,Not FDA Approved for Orphan Indication,,,,,Alliance Pharmaceuticals Ltd,Avonbridge House,"Bath Road, Chippenham",Wiltshire,,' ' ,United Kingdom,110798,,,
6141,simtuzumab,,1/5/2015,treatment of primary sclerosing cholangitis,Designated/Designation Withdrawn or Revoked,7/26/2017,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,458214,sclerosing cholangitis,"""gard:0021868""",
6142,single chain recombinant trispecific killer engager consistent of anti-CD16 scFV spliced to anti-CD33 scFV with a modified IL-15 linker,,10/12/2021,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,2/2/2022,Not FDA Approved for Orphan Indication,,,,,"GT Biopharma, Inc.","9350 Wilshire Blvd, Suite 203",,Beverly Hills,California,' 90212 ' ,United States,840921,acute myeloid leukemia,"""gard:0012757""",
6143,Single Protein Encapsulated Doxorubicin,,11/15/2022,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Sunstate Biosciences LLC,870 S. Myrtle Ave,,Monrovia,California,' 91016 ' ,United States,808521,soft tissue sarcoma,"""gard:0004898""",
6144,Single stranded adeno-associated virus vector encoding beta-galactosidase-1,,11/14/2019,treatment of gm1 gangliosidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Axovant Sciences,"11 Times Square, 33rd Floor",,"New York,",New York,' 10036 ' ,United States,714719,gangliosidosis,"""gard:0012510""",
6145,"single stranded, chemically modified oligonucleotide that binds to and inhibits the function of micro RNA-21",,7/17/2014,treatment of alport syndrome,Designated/Designation Withdrawn or Revoked,7/5/2023,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,55 Corporate Drive,Mail Stop: 55C-300,Bridgewater,New Jersey,' 08807 ' ,United States,438614,alport syndrome,"""gard:0005785""",
6146,"single stranded, synthetic, hybrid RNA/DNA antisense oligonucleotide (ASO) gapmer targeting the TUBB4A gene",,12/1/2022,treatment of hypomyelination with atrophy of the basal ganglia and cerebellum (h-abc),Designated,,Not FDA Approved for Orphan Indication,,,,,SynaptixBio Ltd.,"9400 Garsington Road, Oxford Business Park",,Oxford,,' OX4 2HN ' ,United Kingdom,913722,,,
6147,"single-stranded mRNA consisting of a 5 cap, a 5 untranslated region (UTR), reading frame of the transgene encoding for the human CFTR (hCFTR), the 3 UTR, and poly A tail",,11/21/2023,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Arcturus Therapeutics, Inc.","10628 Science Center Drive, Suite 250",,San Diego,California,' 92121 ' ,United States,971723,cystic fibrosis,"""gard:0006233""",
6148,"Single-stranded, non-replicating recombinant adeno-associated viral vector serotype 9 containing the human immunoglobulin u-binding protein 2 cDNA",,11/24/2020,treatment for spinal muscular atrophy with respiratory distress type 1 (smard1),Designated,,Not FDA Approved for Orphan Indication,,,,,"Abigail Wexner Research Institute, Nationwide Children’s Hospital",700 Children's Drive Room W175,,Columbus,Ohio,' 43205 ' ,United States,783220,spinal muscular atrophy with respiratory distress type 1,"""gard:0008592""",
6149,Sintilimab,,4/14/2020,treatment of esophageal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Innovent Biologics (Suzhou) Co. Ltd,168 Dongping Street,,Suzhou Industrial Park,Jiangsu Province,' ' ,China,737320,,,
6150,sintilimab,,3/24/2020,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Innovent Biologics (Suzhou) Co. Ltd,168 Dongping Street,,Suzhou Industrial Park,Jiangsu Province,' ' ,China,733120,lymphoma,"""gard:0020548""",
6151,siplizumab,,7/15/2003,treatment of t-cell lymphomas,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC",One MedImmune Way,,Gaithersburg,Maryland,' 20878 ' ,United States,170603,lymphoma,"""gard:0020548""",
6152,Siplizumab,,2/15/2018,prevention of solid organ transplant rejection,Designated,,Not FDA Approved for Orphan Indication,,,,,ITB-MED AB,15 Västra Trädgårdsgatan,,Norrmalm,Stockholms län,' ' ,Sweden,623917,,,
6153,Siponimod,,11/26/2013,treatment of polymyositis,Designated/Designation Withdrawn or Revoked,4/24/2018,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,413413,polymyositis,"""gard:0007425""",
6154,siponimod,,7/10/2014,treatment of dermatomyositis,Designated/Designation Withdrawn or Revoked,4/24/2018,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,437614,dermatomyositis,"""gard:0006263""",
6155,siRNA oligonucleotide designed to target and knockdown the expression of SOD1,,3/1/2023,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,Ractigen Therapeutics,"Bldg.18, Rudong Life & Health Industry Park","888 Zhujiang Rd., Rudong",Nantong,Jiangsu Province,' 226400 ' ,China,928822,amyotrophic lateral sclerosis,"""gard:0005786""",
6156,sirolimus,,6/25/2014,treatment of lymphangioleiomyomatosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"LAM Therapeutics, Inc.",530 Old Whitfield Street,,Guilford,Connecticut,' 06437 ' ,United States,434114,lymphangioleiomyomatosis,"""gard:0003319""",
6157,sirolimus,,11/17/2014,treatment of lymphangioleiomyomatosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cote Orphan Consulting, LLC","8630 Fenton St., #222",,Silver Spring,Maryland,' 20910 ' ,United States,453114,lymphangioleiomyomatosis,"""gard:0003319""",
6158,Sirolimus,,12/21/2021,treatment of bronchiolitis obliterans syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"AI Therapeutics, Inc.",530 Old Whitfield Street,,Guilford,Connecticut,' 06437 ' ,United States,833821,,,
6159,sirolimus,,3/18/2013,treatment of pachyonychia congenita,Designated,,Not FDA Approved for Orphan Indication,,,,,"Palvella Therapeutics, Inc.",125 Strafford Avenue,Suite #360,Wayne,Pennsylvania,' 19087 ' ,United States,391013,pachyonychia congenita,"""gard:0010753""",
6160,sirolimus,,6/21/2016,treatment of beta-thalassemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,Rare Partners srl Impresa Sociale,31 Corso Magenta,,Milano,Lombardia,' ' ,Italy,524916,beta-thalassemia,"""gard:0000871""",
6161,sirolimus,,8/26/2019,treatment of tuberous sclerosis complex,Designated,,Not FDA Approved for Orphan Indication,,,,,"AI Therapeutics, Inc.",530 Old Whitfield Street,,Guilford,Connecticut,' 06437 ' ,United States,698619,tuberous sclerosis complex,"""gard:0007830""",
6162,sirolimus,Rapamune,10/31/2012,treatment of lymphangioleiomyomatosis,Designated/Approved,,,Treatment of lymphangioleiomyomatosis (LAM),5/28/2015,5/28/2022,Treatment of lymphangioleiomyomatosis (LAM),"Pfizer, Inc.",500 Arcola Road,,Collegeville,Pennsylvania,' 19426 ' ,United States,379312,lymphangioleiomyomatosis,"""gard:0003319""",
6163,Sirolimus,,7/27/2021,treatment of sarcoidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,AI Therapeutics,530 Old Whitfield Street,,Guildord,Connecticut,' 06437 ' ,United States,828521,sarcoidosis,"""gard:0007607""",
6164,sirolimus,,8/3/2021,treatment of lymphatic malformations,Designated,,Not FDA Approved for Orphan Indication,,,,,"Palvella Therapeutics, Inc.","125 Stafford Ave., Suite 360",,Wayne,Pennsylvania,' 19087 ' ,United States,829421,,,
6165,sirolimus,,3/13/2018,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Rare Partners srl Impresa Sociale,31 Corso Magenta,,Milano,Lombardia,' ' ,Italy,628918,,,
6166,sirolimus,Hyftor,5/17/2017,treatment of angiofibroma associated with tuberous sclerosis,Designated/Approved,,,treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older,3/22/2022,3/22/2029,treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older,"NobelPharma Co., LTD",12-10 Nihonbashi-kobunacho,,Chuo-ku,Tokyo-to,' ' ,Japan,568416,,,
6167,sirolimus,,11/4/2011,"treatment of chronic/refractory anterior noninfectious uveitis, noninfectious intermediate uveitis, noninfectious panuveitis and non-infectious, uveitis affecting the posterior of the eye (nicups).",Designated,,Not FDA Approved for Orphan Indication,,,,,Santen Inc.,"6401 Hollis Street, Suite 125",,Emeryville,California,' 94608 ' ,United States,327210,infectious panuveitis,"""gard:0021068""",
6168,sirolimus,,2/13/2017,treatment of tuberous sclerosis complex-related facial angiofibromas,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aucta Pharmaceuticals, Inc.",675 US Highway One,,North Brunswick,New Jersey,' 08902 ' ,United States,555516,tuberous sclerosis complex,"""gard:0007830""",
6169,sirolimus in an implantable collagen matrix,,5/10/2012,"prevention of arteriovenous(av) fistula or av graft failure in patients with end stage renal disease, receiving hemodialysis or preparing for hemodialysis",Designated,,Not FDA Approved for Orphan Indication,,,,,"Vascular Therapies, LLC",105 Union Avenue,,Cresskill,New Jersey,' 07626 ' ,United States,184304,,,
6170,sirolimus protein-bound particles for injectable suspension (albumin-bound),Fyarro,12/21/2017,treatment of perivascular epithelioid cell tumors (pecoma),Designated/Approved,,,treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa),11/22/2021,11/22/2028,treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa),"Aadi Bioscience, Inc.","17383 Sunset Blvd, A250",,Pacific Palisades,California,' 90272 ' ,United States,616217,,,
6171,sirpiglenastat,,2/20/2024,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Dracen Pharmaceuticals, Inc",9276 Scranton Rd. Suite 500,,San Diego,California,' 92121 ' ,United States,989123,hepatocellular carcinoma,"""gard:0016773""",
6172,sirukumab,,7/3/2017,treatment of juvenile idiopathic arthritis (jia) in pediatric patients,Designated/Designation Withdrawn or Revoked,7/26/2021,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring House,Pennsylvania,' 19477 ' ,United States,575217,juvenile idiopathic arthritis,"""gard:0018677""",
6173,Sitaxentan (also known as sitaxsentan),,1/11/2021,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Timber Pharmaceuticals, Inc.","50 Tice Boulevard, Suite A26",,Woodcliff Lake,New Jersey,' 07677 ' ,United States,793420,systemic sclerosis,"""gard:0009748""",
6174,Sitaxsentan Sodium,,11/2/2004,for the treatment of pulmonary arterial hypertension in the absence of chronic obstructive pulmonary disease or congestive heart failure.,Designated,,Not FDA Approved for Orphan Indication,,,,,Pfizer Global Research and Development,50 Pequot Avenue 6025-B4137,,New London,Connecticut,' 06320 ' ,United States,180803,pulmonary arterial hypertension,"""gard:0007501""",
6175,sitimagene ceradenovec,,7/31/2001,use with gancyclovir in the treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gliotherapy, Ltd.",Sanderum House,Oakley Road,London,,' ' ,United Kingdom,145801,,,
6176,Sivelestat,,8/26/2021,treatment of myelodysplastic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR Biomedical inc,161 Jefferson Ave.,,tenafly,New Jersey,' 07670 ' ,United States,813321,myelodysplastic syndrome,"""gard:0007132""",
6177,sivelestat,,6/5/2020,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,' 07670 ' ,United States,746220,,,
6178,Sivelestat,,1/27/2021,treatment of acute radiation syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical,c/o Noa Avtalion,161 Jefferson Avenue,Tenafly,New Jersey,' 07670-1627 ' ,United States,796020,acute radiation syndrome,"""gard:0021896""",
6179,Sivelestat,,6/9/2021,treatment of elane gene related neutropenia,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR Biomedical inc,161 Jefferson Ave.,,tenafly,New Jersey,' 07670 ' ,United States,812921,,,
6180,Sleeping Beauty Transposon-Engineered Autologous Plasmablasts for Expression and Delivery of Alpha-L-Iduronidase,,3/19/2018,treatment of mucopolysaccharidosis type i (mps i),Designated,,Not FDA Approved for Orphan Indication,,,,,Immusoft Corporation,454 North 34th Street,,Seattle,Washington,' 98103 ' ,United States,626918,mucopolysaccharidosis,"""gard:0007065""",
6181,small interfering RNA agent that targets human transforming growth factor-Eszett1 messenger RNA,,12/19/2018,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Toray Industries, Inc.","1-1, Nihonbashi-muromachi 2-chome, Chuo-ku",,Tokyo,,' 103-8666 ' ,Japan,663918,idiopathic pulmonary fibrosis,"""gard:0008609""",
6182,small interfering RNA targeting TGF-Beta1 and COX-2 mRNA,,2/5/2020,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sirnaomics, Inc.",401 Professional Drive,Suite 280,Gaithersburg,Maryland,' 20879 ' ,United States,726219,hepatocellular carcinoma,"""gard:0016773""",
6183,"Small molecular inhibitor of fibroblast growth factor receptor (FGFR)-1,2 and 3 tyrosine kinases",,3/1/2022,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Abbisko Therapeutics Co.,Ltd","Building 3, Lane 898, Halei Road, Zhangjiang High-Tech Park",,Shanghai,Shanghai,' 201210 ' ,China,863921,,,
6184,Small molecule activator of pantothenate kinases,,8/14/2020,treatment of propionic acidemia,Designated,,Not FDA Approved for Orphan Indication,,,,,CoA Therapeutics,21 Kipling Street,,Palo Alto,California,' 94301 ' ,United States,770620,propionic acidemia,"""gard:0000467""",
6185,Small molecule activator of pantothenate kinases,,10/7/2020,treatment for pantothenate kinase-associated neurodegeneration,Designated,,Not FDA Approved for Orphan Indication,,,,,CoA Therapeutics,421 Kipling Street,,Palo Alto,California,' 94301 ' ,United States,770320,pantothenate kinase-associated neurodegeneration,"""gard:0006564""",
6186,small molecule agonist of 5-hydroxytryptamine serotonergic receptors,,7/27/2022,treatment of dravet syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Xenon Pharmaceuticals Inc.,200-3650 Gilmore Way,,Burnaby,British Columbia,' V5G 4W8 ' ,Canada,896522,dravet syndrome,"""gard:0010430""",
6187,Small molecule allosteric inhibitor of the phosphodiesterase-4D enzyme,,3/26/2018,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tetra Discovery Partners, Inc.",38 Fulton Street West,Suite 303,Grand Rapids,Michigan,' 49503 ' ,United States,631618,fragile x syndrome,"""gard:0006464""",
6188,Small Molecule Bruton's Agammaglobulinemia Tyrosine Kinase (BKT) Inhibitor,,6/29/2017,treatment of pemphigus vulgaris,Designated/Designation Withdrawn or Revoked,10/19/2021,Not FDA Approved for Orphan Indication,,,,,Principia Biopharma Inc.,400 East Jamie Court,,South San Francisco,California,' 94080 ' ,United States,582517,pemphigus vulgaris,"""gard:0007355""",
6189,Small molecule chaperone to stabilize and rescue the activity of dysfunctional phenylalanine variants,,12/27/2023,treatment of phenylketonuria,Designated,,Not FDA Approved for Orphan Indication,,,,,Pluvia AS,Thormohlensgate 51,,Bergen,,' 5006 ' ,Norway,979323,phenylketonuria,"""gard:0007383""",
6190,"small molecule composed of a ligand binding moiety to BRD9, a chemical linker, and a ligand binding moiety to the cereblon (CRBN) E3 ligase",,3/8/2022,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"C4 Therapeutics, Inc.",490 Arsenal Way,Suite 200,Watertown,Massachusetts,' 02742 ' ,United States,865121,soft tissue sarcoma,"""gard:0004898""",
6191,Small molecule Ewing Sarcoma breakpoint region 1/Friend leukemia virus integration 1 fusion protein inhibitor,,6/30/2016,treatment of ewing sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Oncternal Therapeutics, Inc",12230 El Camino Real,Suite 300,San Diego,California,' 92130 ' ,United States,525716,,,
6192,small molecule FGFR4 inhibitor,,9/14/2015,treatment of hepatocellular cancer (hcc).,Designated,,Not FDA Approved for Orphan Indication,,,,,Blueprint Medicines Corporation,38 Sidney Street,Suite 200,Cambridge,Massachusetts,' 02139 ' ,United States,490915,,,
6193,Small molecule fibroblast growth factor receptor 3 selective tyrosine kinase inhibitor,,7/25/2023,treatment of achondroplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,Tyra Biosciences,2656 State Street,,Carlsbad,California,' 92008 ' ,United States,950323,achondroplasia,"""gard:0008173""",
6194,"small molecule inhibitor of AAK1, a protein kinase member of the Notch pathway",,4/23/2024,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Satellos Bioscience Inc.,RBC Plaza – South Tower,"200 Bay Street, Suite 2800",Toronto,ON,' M5J-2J1 ' ,Canada,997524,muscular dystrophy,"""gard:0007922""",
6195,small molecule inhibitor of histone methyltransferase DOT1L,,8/15/2013,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Epizyme Inc.,"400 Technology Square, 4th Floor",,Cambridge,Massachusetts,' 02139 ' ,United States,402113,acute myeloid leukemia,"""gard:0012757""",
6196,small molecule inhibitor of histone methyltransferase DOT1L,,8/8/2013,treatment of acute lymphoblastic leukemia (all),Designated,,Not FDA Approved for Orphan Indication,,,,,Epizyme Inc.,"400 Technology Square, 4th Floor",,Cambridge,Massachusetts,' 02139 ' ,United States,402213,acute lymphoblastic leukemia,"""gard:0000522""",
6197,small molecule inhibitor of hyaluronan synthesis,,4/9/2024,treatment of primary sclerosing cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Halo Biosciences, Inc.","125 University Ave, Suite 140",,Palo Alto,California,' 94301 ' ,United States,996624,sclerosing cholangitis,"""gard:0021868""",
6198,small molecule inhibitor of integrins avb6 and avb1,,8/1/2018,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pliant Therapeutics, Inc.",260 Littlefield Avenue,,South San Francisco,California,' 94080 ' ,United States,646518,idiopathic pulmonary fibrosis,"""gard:0008609""",
6199,small molecule inhibitor of integrins avß6 and avß1,,11/19/2018,treatment of primary sclerosing cholangitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pliant Therapeutics, Inc.",260 Littlefield Avenue,,South San Francisco,California,' 94080 ' ,United States,660718,sclerosing cholangitis,"""gard:0021868""",
6200,Small molecule inhibitor of kinase mediators of the Wnt pathway,,4/16/2021,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"Endogena Therapeutics, Inc,",111 Pine Street,,San Francisco,California,' 94111 ' ,United States,812321,retinitis pigmentosa,"""gard:0005694""",
6201,Small molecule inhibitor of non-muscle myosin II (NMII) A and B,,2/20/2024,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Myosin Therapeutics Inc.,130 Scripps Way 3B3,,Jupiter,Florida,' 33458 ' ,United States,966423,,,
6202,small molecule inhibitor of phosphodiesterase 10,,9/26/2013,treatment of huntington's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Omeros Corporation,201 Elliott Avenue West,,Seattle,Washington,' 98119 ' ,United States,400213,,,
6203,Small molecule inhibitor of PRMT5 (protein arginine methyl transferase 5),,12/5/2022,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tango Therapeutics, Inc.","201 Brookline Avenue, Suite 901",,Boston,Massachusetts,' 02115 ' ,United States,913422,,,
6204,Small molecule inhibitor of PRMT5 (protein arginine methyl transferase 5),,7/25/2022,treatment of malignant peripheral nerve sheath tumor,Designated,,Not FDA Approved for Orphan Indication,,,,,Tango Therapeutics,"100 Binney Street, Suite 700",,Cambridge,Massachusetts,' 02142 ' ,United States,893222,malignant peripheral nerve sheath tumor,"""gard:0010872""",
6205,small molecule inhibitor of protein arginine methyltransferase 5 (PRMT5),,12/21/2023,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tango Therapeutics, Inc.","201 Brookline Avenue, Suite 901",,Boston,Massachusetts,' 02215 ' ,United States,978323,soft tissue sarcoma,"""gard:0004898""",
6206,small molecule inhibitor of the B-Raf protein,,2/8/2024,treatment of epidermal growth factor receptor inhibitor (egfri) and mitogen-activated extracellular signal-regulated kinase inhibitor (meki) induced acneiform rash,Designated,,Not FDA Approved for Orphan Indication,,,,,Lutris Pharma Ltd.,27 Habarzel St.,,Tel Aviv,,' ' ,Israel,749720,,,
6207,Small molecule inhibitor of the bcr-abl tyrosine kinase,,3/7/2024,treatment of chronic myelogenous leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Terns, Inc.",1065 E. Hillsdale Blvd.,Suite 100,Foster City,California,' 94404 ' ,United States,991723,,,
6208,"Small molecule inhibitor of the enzymatic activity of Su(var), Enhancer-of-zeste, Trithorax domain containing 2 (SETD2)",,1/19/2022,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Epizyme, Inc.",400 Technology Square 4th Floor,,Cambridge,Massachusetts,' 02139 ' ,United States,857121,multiple myeloma,"""gard:0007108""",
6209,small molecule inhibitor of the pro-survival protein Myeloid Cell Leukemia sequence 1 (MCL 1),,2/28/2019,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,' 91320-1799 ' ,United States,674818,multiple myeloma,"""gard:0007108""",
6210,small molecule inhibitor of the pro-survival protein Myeloid Cell Leukemia sequence 1 (MCL1),,8/21/2019,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,Mail Stop 27-2-D,Thousand Oaks,California,' 91320-1799 ' ,United States,698019,multiple myeloma,"""gard:0007108""",
6211,small molecule inhibitor of the Wnt pathway,,6/6/2017,treatment of idiopathic pulmonary fibrosis (ipf).,Designated/Designation Withdrawn or Revoked,8/5/2021,Not FDA Approved for Orphan Indication,,,,,"Biosplice Therapeutics, Inc.",9360 Towne Centre Drive,,San Diego,California,' 92121 ' ,United States,568516,idiopathic pulmonary fibrosis,"""gard:0008609""",
6212,Small molecule kinase inhibitor,,7/26/2022,treatment of gastrointestinal stromal tumors (gist),Designated,,Not FDA Approved for Orphan Indication,,,,,"IDRX, Inc.",52A Court Street,,Plymouth,Massachusetts,' 02360 ' ,United States,892122,gastrointestinal stromal tumor,"""gard:0008598""",
6213,small molecule Mas receptor agonist,,4/25/2017,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Capacity Bio, Inc.",3175 Hanover Street,,Palo Alto,California,' 94304 ' ,United States,557916,muscular dystrophy,"""gard:0007922""",
6214,Small molecule melanocortin 4 receptor agonist,,9/21/2020,treatment for leptin receptor deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Rhythm Pharmaceuticals, Inc.","222 Berkeley Street, Suite 1200",,Boston,Massachusetts,' 02116 ' ,United States,765720,,,
6215,small molecule normalizing the p53 function,,6/12/2014,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Critical Outcome Technologies, Inc.",700 Collip Circle,Suite 213,London,,' ' ,Canada,434314,ovarian cancer,"""gard:0007295""",
6216,small molecule PRMT5/MTA cooperative inhibitor,,11/28/2023,treatment of biliary tract cancers,Designated,,Not FDA Approved for Orphan Indication,,,,,Amgen Inc.,One Amgen Center Drive,,Thousand Oaks,California,' 91320-1799 ' ,United States,926222,,,
6217,small molecule selective inhibitor of c-Jun N-terminal kinase,,6/27/2018,treatment of idiopathic pulmonary fibrosis,Designated/Designation Withdrawn or Revoked,7/19/2022,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,573116,idiopathic pulmonary fibrosis,"""gard:0008609""",
6218,"Small molecule, non-isoform selective NaV persistent current inhibitor",,4/27/2021,treatment of scn2a developmental and epileptic encephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Praxis Precision Medicines, Inc.","One Broadway, 16th Floor",,Cambridge,Massachusetts,' 02142 ' ,United States,789420,,,
6219,"Small molecule, non-isoform selective NaV persistent current inhibitor",,4/8/2021,treatment of scn8a developmental and epileptic encephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Praxis Precision Medicines, Inc.","One Broadway, 16th Floor",,Cambridge,Massachusetts,' 02142 ' ,United States,789620,,,
6220,"small synthetic peptide based on a sequence found in the human endogenous protein, central coordination network protein 3",,3/21/2024,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,BLR Bio LLC,313 54th Street,,Kenosha,Wisconsin,' 53140 ' ,United States,992423,systemic sclerosis,"""gard:0009748""",
6221,Small-molecule oral KIT inhibitor targeting activating mutations and resistance mutations,,1/28/2022,treatment of gastrointestinal stromal tumors (gist),Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Theseus Pharmaceuticals, Inc.",210 Broadway Street,,Cambridge,Massachusetts,' 02139 ' ,United States,858721,gastrointestinal stromal tumor,"""gard:0008598""",
6222,smilagenin,,7/21/2011,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Junaxo, Inc.",First Canadian Place,Suite 5600,Toronto,,' ' ,Canada,345811,amyotrophic lateral sclerosis,"""gard:0005786""",
6223,sobetirome,,4/29/2011,treatment of x-linked adrenoleukodystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Naftali Kaminski, MD","Department of Medicine, Yale School of Medicine",300 Cedar Street,New Haven,Connecticut,' 06520 ' ,United States,334811,leukodystrophy,"""gard:0006895""",
6224,"Sodium (1-hydroxy-4-(((2-((4-(2-(pyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinolin-7-yl)oxy)ethoxy)carbonyl)amino)butane-1,1-diyl)bis(hydrogen phosphonate)",,9/1/2022,treatment of camurati-engelmann disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Brise Pharmaceuticals Co., Ltd.","1976 Middle Gaoke Road, Building A, Suite A108",Pudong New District,Shanghai,Shanghai,' 201210 ' ,China,898222,camurati-engelmann disease,"""gard:0001072""",
6225,Sodium (4-{(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-yl-prop-1ynyl)phenyl]allyloxy}-2-methylphenoxy)acetate,,6/2/2020,treatment of primary mitochondrial myopathy,Designated/Designation Withdrawn or Revoked,1/8/2024,Not FDA Approved for Orphan Indication,,,,,Reneo Pharmaceuticals Inc.,12230 El Camino Real,Suite 230,San Diego,California,' 92130 ' ,United States,740220,mitochondrial myopathy,"""gard:0020371""",
6226,Sodium (4-{(E)-3-(4-fluorophenyl)-3-[4-(3-morpholin-4-yl-prop-1ynyl)phenyl]allyloxy}-2-methylphenoxy)acetate,,7/22/2019,treatment of fatty acid oxidation disorders,Designated/Designation Withdrawn or Revoked,1/8/2024,Not FDA Approved for Orphan Indication,,,,,Reneo Pharma Ltd,"Innovation House, Office 12B","Discovery Park, Ramsgate Road",Sandwich,Kent,' ' ,United Kingdom,693819,,,
6227,"Sodium (4Z,7Z,10R,11E,13E,15Z,17S,19Z) 10,17-dihydroxy-docosa-4,7,11,13,15,19-hexaenoate",,3/30/2020,prevention of retinopathy of prematurity,Designated,,Not FDA Approved for Orphan Indication,,,,,Anida Pharma Inc.,"155 Brookline Street, Suite 005",,Cambridge,Massachusetts,' 02139 ' ,United States,731720,retinopathy of prematurity,"""gard:0005695""",
6228,Sodium (R)-2-(5-(2-(3-ethylureido)-5-fluoro-4-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)propan-2-yl hydrogen phosphate,,3/9/2020,treatment of nontuberculous mycobacteria infection,Designated,,Not FDA Approved for Orphan Indication,,,,,"Spero Therapeutics, Inc.","675 Massachusetts Ave., 14th Floor",,Cambridge,Massachusetts,' 02139 ' ,United States,727819,,,
6229,"Sodium ({(2S)-1,4-bis[2-(4-chloro-3- fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2- yl}oxy)methyl hydrogen phosphate - 2-amino-2- (hydroxymethyl)propane-1,3-diol (1/1/1)",,9/27/2022,treatment of vanishing white matter disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Calico Life Sciences LLC,1170 Veterans Blvd.,,South San Francisco,California,' 94080 ' ,United States,901322,,,
6230,"sodium 2, 2 dimethylbutyrate",,7/25/2008,treatment of sickle cell disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"HemaQuest Pharmaceuticals, Inc.",1001 Fourth Avenue,Suite 3317,Seattle,Washington,' 98154 ' ,United States,265108,,,
6231,sodium 2-hydroxylinoleate,,8/25/2015,treatment of neuroblastoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ability Pharmaceuticals, SL","Edifici Eureka, Campus de la UAB",,Bellaterra,,' 08193 ' ,Spain,489315,neuroblastoma,"""gard:0007185""",
6232,sodium 2-hydroxylinoleate,,11/23/2016,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ability Pharmaceuticals, SL",Edifici Eureka,Campus de la UAB,Bellaterra,,' 08193 ' ,Spain,543816,,,
6233,sodium 2-hydroxylinoleate,,9/27/2018,treatment of biliary tract cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ability Pharmaceuticals, SL",Edifici Eureka,Campus de la UAB,Bellaterra,,' ' ,Spain,652418,,,
6234,Sodium 4-amino-3- [6-( 4-fluoro-2-methylphenyl)pyridine-3-ylazo] naphthalene-1-sulfonate dihydrate,,5/3/2022,treatment of retinal artery occlusion (rao).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kyoto Drug Discovery & Development Co., Ltd.","8F, Sakaisuji Satellite Building 1-6-9",,"Awaji-Machi, Chuo-ku",,' 541-0047 ' ,Japan,873422,,,
6235,sodium 4-phenylbutyrate,,10/18/2011,treatment of spinal muscular atrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,GMP-Orphan SAS,"7, rue du Pasteur Wagner",F-75011,Paris,,' ' ,France,354011,,,
6236,"sodium 4-{ [9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-d] [2] benzazepin-2-yl]-2-methoxybenzoate",,4/3/2009,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,6/14/2016,Not FDA Approved for Orphan Indication,,,,,"Millennium Pharmaceuticals, Inc.",40 Landsdowne Street,,Cambridge,Massachusetts,' 02139 ' ,United States,276309,ovarian cancer,"""gard:0007295""",
6237,sodium alginate oligosaccharide,,2/24/2016,treatment of cystic fibrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,AlgiPharma AS,Industriveien 33,N-1337,Sandvika,,' ' ,Norway,320110,cystic fibrosis,"""gard:0006233""",
6238,Sodium aluminosilicate,,3/4/2005,treatment of chronic hepatic encephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Westhaven Therapeutics Corporation,1825 K Street Northwest,Suite 510,Washington,District of Columbia,' 20006 ' ,United States,192704,,,
6239,sodium ascorbate and menadione sodium bisulfite,,4/15/2013,treatment of autosomal dominant polycystic liver disease,Designated,,Not FDA Approved for Orphan Indication,,,,,IC-Medtech Corporation,9902 Indian Creek Lane,,El Cajon,California,' 92021 ' ,United States,395413,,,
6240,Sodium ascorbate and menadione sodium bisulfite,,7/31/2007,treatment of metastatic or locally advanced inoperable transitional cell carcinoma of the urothelium (stage iii and iv bladder cancer),Designated,,Not FDA Approved for Orphan Indication,,,,,IC-MedTech Corporation,9902 Indian Creek Lane,,San Diego,California,' 92021 ' ,United States,236606,noma,"""gard:0004001""",
6241,sodium ascorbate and menadione sodium bisulfite,,4/15/2013,treatment of autosomal dominant polycystic kidney disease,Designated,,Not FDA Approved for Orphan Indication,,,,,IC-MedTech Corporation,9902 Indian Creek Lane,,El Cajon,California,' 92021 ' ,United States,394313,autosomal dominant polycystic kidney disease,"""gard:0010413""",
6242,sodium ascorbate and menadione sodium bisulfite,,4/9/2015,treatment of noninfected painful total joint without mechanical complication,Designated,,Not FDA Approved for Orphan Indication,,,,,IC-MedTech Corporation,9902 Indian Creek Lane,,El Cajon,California,' 92021 ' ,United States,392513,,,
6243,sodium benzoate and clozapine,,12/22/2011,treatment of treatment-resistant schizophrenia,Designated,,Not FDA Approved for Orphan Indication,,,,,SyneuRx International Corp.,"20F-9 99 Section 1, Xintaiwu Road",Xizhi District,New Taipei City,,' ' ,Taiwan,357411,,,
6244,sodium bispiperidine-carboxamido-dimethylpenatnamido-methoxycarbonyl-indol-propanamidohexanoate,,3/28/2019,treatment of malignant melanoma stages iib to iv,Designated,,Not FDA Approved for Orphan Indication,,,,,"ENB Therapeutics, INC","Alexandria Center for Life Sciences, Launch Labs","430 E 29th St, 14th Floor",New York,New York,' 10016 ' ,United States,679519,noma,"""gard:0004001""",
6245,sodium bispiperidine-carboxamido-dimethylpenatnamido-methoxycarbonyl-indol-propanamidohexanoate,,4/19/2022,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"ENB Therapeutics, Inc.","Alexandria Center for Life Sciences, Launch Labs","430 E 29th St, 14th Floor",New York,New York,' 10016 ' ,United States,871622,,,
6246,sodium chlorite,,8/22/2011,for slowing the progression of amyotrophic lateral sclerosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neuraltus Pharmaceuticals, Inc.",1111 Bayhill Drive,Suite 210,San Bruno,California,' 94066 ' ,United States,343311,amyotrophic lateral sclerosis,"""gard:0005786""",
6247,Sodium dichloroacetate,,6/11/1990,treatment of homozygous familial hypercholesterolemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Stacpoole, Peter W. M.D., Ph.D.",University of Florida,P.O. Box 100277,Gainesville,Florida,' 32610 ' ,United States,45390,homozygous familial hypercholesterolemia,"""gard:0010416""",
6248,sodium dichloroacetate,,7/3/2003,use as an antidote in the management of systemic monochloroacetic acid poisoning,Designated,,Not FDA Approved for Orphan Indication,,,,,EBD Group,2032 Corte del Nogal,Suite 120,Carlsbad,California,' 92011 ' ,United States,169803,,,
6249,sodium dichloroacetate,,11/29/2010,for pulmonary arterial hypertension.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Peter W. Stackpoole, PhD, MD",University of FL College of Medicine,P. O. Box 100226,Gainesville,Florida,' 32611 ' ,United States,313010,pulmonary arterial hypertension,"""gard:0007501""",
6250,Sodium dichloroacetate,,11/10/1994,treatment of lactic acidosis in patients with severe malaria.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Stacpoole, Peter W. M.D., Ph.D.",University of Florida,P.O. Box 100277,Gainesville,Florida,' 32610 ' ,United States,83694,malaria,"""gard:0006961""",
6251,Sodium dichloroacetate,,6/11/1990,treatment of congenital lactic acidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Saol Therapeutics Inc.,"Ground Floor, 9 Windsor Place",,Dublin 2,,' D02 YF30 ' ,Ireland,45290,,,
6252,Sodium dichloroacetate,,6/14/1999,treatment of severe head injury.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Questcor Pharmaceuticals, Inc.",3260 Whipple Rd.,,Union City,California,' 94587 ' ,United States,114798,,,
6253,Sodium dichloroacetate,,12/31/1997,treatment of congenital lactic acidosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Questcor Pharmaceuticals, Inc.",3260 Whipple Rd.,,Union City,California,' 94587 ' ,United States,108797,,,
6254,sodium fusidate,,10/23/2013,treatment of patients with prosthetic joint infections,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cempra Pharmaceuticals, Inc.",6340 Quadrangle Drive,Suite 100,Chapel Hill,North Carolina,' 27517 ' ,United States,400513,,,
6255,sodium fusidate,,2/13/2020,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Arnasi LLC,"12 Gill Street, Suite 4350",,Woburn,Massachusetts,' 01801 ' ,United States,723519,cystic fibrosis,"""gard:0006233""",
6256,Sodium Hypochlorite,,1/31/2024,treatment of walled-off pancreatic necrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Johns Hopkins University School of Medicine,"600 N. Wolfe Street, Blalock 411",,BALTIMORE,Maryland,' 21205 ' ,United States,932923,,,
6257,Sodium meta-arsenite,,7/1/2021,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Komipharm International Australia Pty Ltd.,11 Monterey Road,Dandenong South,Victoria,,' 3175 ' ,Australia,823621,,,
6258,Sodium monomercaptoundecahydro-closo-dodecaborate,,12/18/1984,for use in conjunction with a thermal or epithermal neutron beam in boron nuclear capture therapy of glioblastoma multiforme.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Theragenics Corporation,,,,,' ' ,,4284,glioblastoma,"""gard:0002491""",
6259,Sodium Monomercaptoundecahydro-closo-dodecaborate,,4/15/1992,for use in boron neutron capture therapy (bnct) in the treatment of glioblastoma multiforme.,Designated,,Not FDA Approved for Orphan Indication,,,,,Neutron Technology Corp.& Neutron R&D Partner,"877 Main Street, Suite 402",,Boise,Idaho,' 83702 ' ,United States,65692,glioblastoma,"""gard:0002491""",
6260,Sodium Nitrite,,3/25/2020,treatment of sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,AdimaBio LLC,19 Garrison Road,,Wellesley,Massachusetts,' 02482 ' ,United States,729719,,,
6261,sodium nitrite,,9/3/2009,prevention of ischemia reperfusion injury to donor organ tissue associated with solid organ transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd St.,Suite 125,Scottsdale,Alaska,' 85260 ' ,United States,288209,,,
6262,sodium nitrite,,1/9/2012,treatment of chlorine gas poisoning,Designated,,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd St.,Suite 125,Scottsdale,Alaska,' 85260 ' ,United States,359111,,,
6263,sodium nitrite,,4/18/2007,treatment of cyanide poisoning,Designated,,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd Street,Suite 125,Scottsdale,Alaska,' 85260 ' ,United States,233806,cyanide poisoning,"""gard:0021938""",
6264,sodium nitrite,,1/17/2007,prevention of vasospasm associated with subarachnoid hemorrhage,Designated,,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd St.,Suite 125,Scottsdale,Alaska,' 85260 ' ,United States,233906,,,
6265,sodium nitrite,,7/8/2008,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,"Airess Pharmaceuticals, Inc.","(subsidiary of Mast Therapeutics, Inc)",3611 Valley Centre Drive,San Diego,California,' 92130 ' ,United States,252707,pulmonary arterial hypertension,"""gard:0007501""",
6266,sodium nitrite,,4/2/2007,treatment of vaso-occlusive crisis associated with sickle cell disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd St.,Suite 125,Scottsdale,Alaska,' 85260 ' ,United States,238707,,,
6267,sodium nitrite and EDTA,,11/10/2015,treatment of pseudomonas aeruginosa pulmonary infections in patients with cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Arch Biopartners, Inc.",27 Saint Clair Avenue East,P. O. Box 305,Toronto,,' ' ,Canada,495615,cystic fibrosis,"""gard:0006233""",
6268,sodium nitrite and sodium thiosulfate,Nithiodote,4/9/2008,treatment of known or suspected cyanide poisoning,Designated/Approved,,,For sequential use for the treatment of cyanide poisoning that is judged to be life-threatening,1/14/2011,1/14/2018,,Hope Pharmaceuticals,16416 North 92nd Street,Suite 125,Scottsdale,Arizona,' 85260 ' ,United States,244207,cyanide poisoning,"""gard:0021938""",
6269,Sodium nitrite/sodium thiosulfate,,3/23/2007,treatment of cyanide poisoning,Designated,,Not FDA Approved for Orphan Indication,,,,,"Keystone Pharmaceuticals, Inc.",26072 Merit Circle,,Laguna Hills,California,' 92653 ' ,United States,239207,cyanide poisoning,"""gard:0021938""",
6270,sodium oxybate,Xyrem,11/7/1994,treatment of narcolepsy.,Designated/Approved,,,Xyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.,10/26/2018,10/26/2025,Xyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in pediatric patients 7 years of age and older with narcolepsy.,Jazz Pharmaceuticals Ireland Limited,5th Floor Waterloo Exchange,Waterloo Road,Dublin 4,,' D04 E5W7 ' ,Ireland,85894,narcolepsy,"""gard:0022460""",
6271,sodium oxybate,Lumryz,1/8/2018,treatment of narcolepsy,Designated/Approved,,,Treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy,5/1/2023,5/1/2030,Treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy,Flamel Ireland Limited dba Avadel Ireland,10 Earlsfort Terrace,,Dublin,Dublin,' ' ,Ireland,530216,narcolepsy,"""gard:0022460""",
6272,sodium oxybate,Xyrem,11/7/1994,treatment of narcolepsy.,Designated/Approved,,,Treatment of excessive daytime sleepiness in patients with narcolepsy,11/18/2005,11/18/2012,,Jazz Pharmaceuticals Ireland Limited,5th Floor Waterloo Exchange,Waterloo Road,Dublin 4,,' D04 E5W7 ' ,Ireland,85894,narcolepsy,"""gard:0022460""",
6273,sodium oxybate,Xyrem,11/7/1994,treatment of narcolepsy.,Designated/Approved,,,Treatment of cataplexy associated with narcolepsy,7/17/2002,7/17/2009,,Jazz Pharmaceuticals Ireland Limited,5th Floor Waterloo Exchange,Waterloo Road,Dublin 4,,' D04 E5W7 ' ,Ireland,85894,narcolepsy,"""gard:0022460""",
6274,Sodium phenylacetate/sodium benzoate 10%/10% Injection,,6/3/2005,treatment of grade iii and iv hepatic encephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ucyclyd Pharma, Inc.",7720 N. Dobson Road,,Scottsdale,Alaska,' 85256 ' ,United States,197804,,,
6275,sodium phenylbutyrate,Pheburane,6/6/2013,treatment of urea cycle disorders,Designated/Approved,,,"As adjunctive therapy to standard of care, which includes dietary management, for the chronic management of adult and pediatric patients with urea cycle disorders (UCDs), involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinic acid synthetase (AS)",6/17/2022,,,Medunik Canada Inc,950 Boulevard Michèle-Bohec,,Blainville,,' ' ,Canada,372112,,,
6276,sodium phenylbutyrate,Buphenyl,11/22/1993,"treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency.",Designated/Approved,,,"Adjunctive therapy in the chronic managment of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase.",4/30/1996,4/30/2003,,Medicis Pharmaceutical Corp.,8125 N. Hayden Road,,Scottsdale,Alaska,' 85258 ' ,United States,77893,ornithine transcarbamylase deficiency,"""gard:0008391""",
6277,sodium phenylbutyrate,,7/2/1992,"treatment for sickling disorders, which include s-s hemoglobinopathy, s-c hemoglobinopathy, and s-thalassemia hemoglobinopathy.",Designated,,Not FDA Approved for Orphan Indication,,,,,Medicis Pharmaceutical Corp.,8125 N. Hayden Road,,Scottsdale,Alaska,' 85258 ' ,United States,68192,hemoglobinopathy,"""gard:0018883""",
6278,Sodium phenylbutyrate,,4/24/1998,"for use as an adjuct to surgery, radiation therapy and chemotherapy for the treatment of patients with primary or recurrent malignant glioma.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Elan Drug Delivery, Inc.",1300 Gould Dr.,,Gainesville,Georgia,' 30504 ' ,United States,110598,,,
6279,Sodium phenylbutyrate,,3/20/2007,treatment of spinal muscular atrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tikvah Therapeutics, Inc.","75 5th Street, NW.",,Atlanta,Georgia,' 30308 ' ,United States,236907,,,
6280,sodium phenylbutyrate,,1/19/2010,treatment of urea cycle disorder.,Designated,,Not FDA Approved for Orphan Indication,,,,,Navinta LLC,1499 Lower Ferry Road,,Ewing,New Jersey,' 08618 ' ,United States,293309,,,
6281,Sodium phenylbutyrate,,1/25/2007,treatment of spinal muscular atrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"OrphaMed, Inc.",7720 N. Dobson Road,subsidiary of Medicis Pharmaceutical Corp.,Scottsdale,Alaska,' 85256 ' ,United States,235806,,,
6282,sodium phenylbutyrate,,8/19/2014,treatment of maple syrup urine disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Acer Therapeutics, Inc.",One Gateway Center,"300 Washington Street, Suite 351",Newton,Massachusetts,' 02458 ' ,United States,439714,maple syrup urine disease,"""gard:0003228""",
6283,Sodium phenylbutyrate and tauroursodeoxycholic acid dihydrate,,9/30/2020,treatment of wolfram syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Amylyx Pharmaceuticals Inc.,43 Thorndike Street,,Cambridge,Massachusetts,' 02139 ' ,United States,767720,wolfram syndrome,"""gard:0007898""",
6284,sodium phenylbutyrate and taurursodiol,Relyvrio,7/27/2017,treatment of amyotrophic lateral sclerosis (als),Designated/Approved,,,Treatment of amyotrophic lateral sclerosis (ALS) in adults,9/29/2022,9/29/2029,Treatment of amyotrophic lateral sclerosis (ALS) in adults,"Amylyx Pharmaceuticals, Inc.",43 Thorndike St.,,Cambridge,Massachusetts,' 02141 ' ,United States,588117,amyotrophic lateral sclerosis,"""gard:0005786""",
6285,Sodium pyruvate,,3/31/2003,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cellular Sciences, Inc",84 park Avenue,P.O. Box 968,Flemington,New Jersey,' 08822 ' ,United States,165602,cystic fibrosis,"""gard:0006233""",
6286,sodium salt of 19-bp single stranded RNA uniformly modified 2¿-O-(2-methoxyethyl) phosphorothioate Antisense Oligonucleotide (ASO) consisting of 19 nucleotide residues with the sequence 5'-5MeC-5MeU-G-5MeC-A-A-5MeC-A-G-A-5MeU-G-G-A-A-G-A-5MeC-5MeU-3¿,,11/10/2021,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,SpliSense Ltd.,"Biohouse Labs Jerusalem Bio Park, 1st Floor",Haddasah Ein Kerem,Jerusalem,Israel,' 9112101 ' ,Israel,845221,cystic fibrosis,"""gard:0006233""",
6287,Sodium stibogluconate,,6/16/2006,treatment of cutaneous leishmaniasis,Designated,,Not FDA Approved for Orphan Indication,,,,,"VioQuest Pharmaceuticals, Inc.",180 Mt. Airy Road,Suite 102,Basking Ridge,New Jersey,' 07920 ' ,United States,225906,leishmaniasis,"""gard:0006881""",
6288,sodium stibogluconate,,10/28/2009,treatment of cutaneous leishmaniasis,Designated/Designation Withdrawn or Revoked,9/11/2023,Not FDA Approved for Orphan Indication,,,,,Surgeon General of the US Army,US Army Medical Research & Materiel Command,1430 Veterans Drive,Ft. Detrick,Maryland,' 21702 ' ,United States,293609,leishmaniasis,"""gard:0006881""",
6289,Sodium Stibogluconate,,6/5/2017,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,BioXcel Corporation,780 East Main Street,Suite 2,Branford,Connecticut,' 06405 ' ,United States,572516,acute myeloid leukemia,"""gard:0012757""",
6290,"sodium sulfate, magnesium sulfate, potassium chloride",,12/19/2017,for the cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in pediatric patients,Designated,,Not FDA Approved for Orphan Indication,,,,,"Braintree Laboratories, Inc.",60 Columbian Street West,P.O. Box 850929,Braintree,Massachusetts,' 02185 ' ,United States,616817,,,
6291,"sodium sulfate, potassium sulfate, and magnesium sulfate",SUPREP Bowel Prep Kit,10/31/2012,for cleansing of the colon in preparation for colonoscopic diagnosis of colonic disease in children and adolescents,Designated/Approved,,,for cleansing of the colon as a preparation for colonoscopy in adult and pediatric patients 12 years of age and older,8/5/2020,8/5/2027,for cleansing of the colon as a preparation for colonoscopy in pediatric patients 12 years of age and older.,"Braintree Laboratories, Inc.",60 Columbian Street West,PO Box 850929,Braintree,Massachusetts,' 02185 ' ,United States,379212,,,
6292,"sodium sulfate, potassium sulfate, and magnesium sulfate; PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride",,9/4/2013,for use in cleansing of the colon in preparation for colonoscopy in children and adolescents,Designated,,Not FDA Approved for Orphan Indication,,,,,"Braintree Laboratories, Inc.",60 Columbian Street West,P.O. Box 850929,Braintree,Massachusetts,' 02185 ' ,United States,403513,,,
6293,Sodium tetradecyl sulfate,,6/10/1986,treatment of bleeding esophageal varices.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Elkins-Sinn, Inc.",2 Esterbrook Lane,,Cherry Hill,New Jersey,' 08003 ' ,United States,12786,,,
6294,sodium thiosulfate,,12/2/2010,treatment of extravasation of meclorethamine hydrochloride into subcutaneous tissues.,Designated,,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd St.,Suite 125,Scottsdale,Alaska,' 85260 ' ,United States,322410,,,
6295,sodium thiosulfate,,10/13/2011,prevention of platinum-induced ototoxicity in pediatric patients,Designated,,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd St.,Suite 125,Scottsdale,Alaska,' 85260 ' ,United States,353311,,,
6296,sodium thiosulfate,,11/9/2011,treatment of uremic and non-uremic calciphylaxis,Designated,,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd St.,Suite 125,Scottsdale,Alaska,' 85260 ' ,United States,352611,calciphylaxis,"""gard:0005980""",
6297,sodium thiosulfate,,3/3/2011,treatment of sulfur mustard poisoning,Designated,,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd St.,Suite 125,Scottsdale,Alaska,' 85260 ' ,United States,335311,,,
6298,sodium thiosulfate,,10/28/2014,treatment of dermatomyositis,Designated,,Not FDA Approved for Orphan Indication,,,,,Hope Pharmaceuticals,16416 North 92nd St.,Suite 125,Scottsdale,Alaska,' 85260 ' ,United States,450114,dermatomyositis,"""gard:0006263""",
6299,sodium thiosulfate,,11/19/2012,treatment of calciphylaxis,Designated,,Not FDA Approved for Orphan Indication,,,,,Edinburg BioQuarter,University Medical School 47,EH16 4TJ,Edinburgh,,' ' ,United Kingdom,381912,calciphylaxis,"""gard:0005980""",
6300,sodium thiosulfate,Pedmark,3/17/2004,prevention of platinum-induced ototoxicity in pediatric patients,Designated/Approved,,,"To reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors",9/20/2022,9/20/2029,"To reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors","Fennec Pharmaceuticals, Inc.",PO Box 13628,68 T.W. Alexander Drive,Research Triangle Park,North Carolina,' 27709 ' ,United States,177303,,,
6301,Sodium Thiosulfate,,2/16/2012,treatment of uremic and non-uremic calciphylaxis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Luitpold Pharmaceuticals, Inc.",800 Adams Avenue,Suite 100,Norristown,Pennsylvania,' 19403 ' ,United States,356511,calciphylaxis,"""gard:0005980""",
6302,Sodium thiosulfate and sodium nitrite,,12/18/2006,treatment of cyanide poisoning,Designated,,Not FDA Approved for Orphan Indication,,,,,"Akorn, Inc.",2500 Millbrook Drive,,Buffalo Grove,Illinois,' 60089 ' ,United States,233306,cyanide poisoning,"""gard:0021938""",
6303,"Sodium thiosulfate, sodium nitrite, amyl nitrite",,6/16/2006,treatment of cyanide poisoning,Designated,,Not FDA Approved for Orphan Indication,,,,,"Keystone Pharmaceuticals, Inc.",26072 Merit Circle,,Laguna Hills,California,' 92653 ' ,United States,225606,cyanide poisoning,"""gard:0021938""",
6304,Sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)],,4/27/2021,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Bold Therapeutics, Inc.","170 - 422 Richards Street,",,Vancouver,BC,' V6B 2Z4 ' ,Canada,813421,,,
6305,sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)],,6/8/2017,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Bold Therapeutics Inc.,170 - 422 Richards St.,,Vancouver,British Columbia,' V6B 2Z4 ' ,Canada,573817,,,
6306,sodium valproate,,8/5/2015,treatment of wolfram syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,The University of Birmingham,Birmingham Research Park - Vincent Drive,,Birmingham,,' ' ,United Kingdom,486515,wolfram syndrome,"""gard:0007898""",
6307,sodium valproate,,3/9/2020,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,Cereno Scientific AB,Pepparedsleden 1,,Mölndal,,' ' ,Sweden,729920,pulmonary arterial hypertension,"""gard:0007501""",
6308,"Sodium-3-((2,6-dichloro-7-fluoro-1-(1-propyl-1H-pyrazol-4-yl)-1H-indol-3-yl)thio)-2-fluorobenzoate",,2/23/2021,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Blade Therapeutics, Inc.",442 Littlefield Avenue,,South San Francisco,California,' 94080 ' ,United States,801820,idiopathic pulmonary fibrosis,"""gard:0008609""",
6309,sofosbuvir,Sovaldi,10/25/2016,treatment of pediatric chronic hepatitis c virus infection,Designated/Approved,,,Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin,4/7/2017,4/7/2024,Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,541716,,,
6310,sofosbuvir,Sovaldi,10/25/2016,treatment of pediatric chronic hepatitis c virus infection,Designated/Approved,,,SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin,8/28/2019,8/28/2026,For the treatment of chronic hepatitis C virus (HCV) genotype 2 or 3 infection in pediatric patients between 3 years of age and 12 years of age or weighing 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,541716,,,
6311,sofosbuvir,Sovaldi,10/25/2016,treatment of pediatric chronic hepatitis c virus infection,Designated/Approved,,,SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin,8/28/2019,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,541716,,,
6312,sofosbuvir and velpatasvir,Epclusa,2/22/2017,treatment of pediatric chronic hepatitis c virus (hcv) infection,Designated/Approved,,,"EPCLUSA is indicated for the treatment of adults and pediatric patients 6 years of age and older or weighing at least 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection: without cirrhosis or with compensated cirrhosis; or with decompensated cirrhosis for use in combination with ribavirin.",3/19/2020,3/19/2027,"For the treatment of pediatric patients 6 years of age and older or weighing at least 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection: without cirrhosis or with compensated cirrhosis; or with decompensated cirrhosis for use in combination with ribavirin.","Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,554816,,,
6313,sofosbuvir and velpatasvir,Epclusa,2/22/2017,treatment of pediatric chronic hepatitis c virus (hcv) infection,Designated/Approved,,,"treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or with decompensated cirrhosis for use in combination with ribavirin",6/10/2021,6/10/2028,"treatment of pediatric patients 3 years of age to less than 6 years of age weighing less than 17 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection: without cirrhosis or with compensated cirrhosis; or with decompensated cirrhosis for use in combination with ribavirin","Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,554816,,,
6314,"soidum (5-(3-cyanopyrazolo[1,5-a]pyridin-5-yl)-2-methoxypyridin-3-yl)((2,4-difluorophenyl)sulfonyl)amide",,7/9/2018,treatment of idiopathic pulmonary fibrosis (ipf),Designated,,Not FDA Approved for Orphan Indication,,,,,"Sunshine Lake Pharma Co., Ltd",Northern Industry Road #1,Song Shan Lake,Dongguan,Guangdong,' ' ,China,642518,idiopathic pulmonary fibrosis,"""gard:0008609""",
6315,Solasonine and solamargine,,11/2/2005,treatment of renal cell carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Solbec Pharmaceuticals Limited,P. O. Box 2142,,WA 6018,,' ' ,Australia,211805,renal cell carcinoma,"""gard:0013215""",
6316,Solasonine and solamargine,,2/6/2006,"treaatment of high risk stage ii, stage iii and stage iv melanoma",Designated,,Not FDA Approved for Orphan Indication,,,,,Solbec Pharmaceuticals Limited,P. O. Box 2142,"Osbourne Park, Western Australia 6017",,,' ' ,Australia,211705,noma,"""gard:0004001""",
6317,solnatide,,2/8/2016,treatment of generalized systemic pseudohypoaldosteronism type 1 (also known as autosomal recessive pha-i or pha-ib),Designated,,Not FDA Approved for Orphan Indication,,,,,Apeptico Forschung und Entwicklung GmbH (APEPTICO),Mariahilferstrabe 136,Top 1150,Vienna,,' ' ,Austria,504515,pseudohypoaldosteronism,"""gard:0021861""",
6318,solnatide,,2/4/2016,treatment of primary graft dysfunction following lung transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,Apeptico Forschung und Entwicklung GmbH,c/o mingo bueros,,Vienna,,' ' ,Austria,504415,,,
6319,Solriamfetol,Sunosi,8/20/2012,treatment of narcolepsy,Designated/Approved,,,SUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy,6/17/2019,6/17/2026,To improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy,"Axsome Malta, Ltd.","78 Mill Street, Zone 5, Central Business District",,Qormi,,' CBD 5090 ' ,Malta,375112,narcolepsy,"""gard:0022460""",
6320,Soluble complement receptor type 1,,3/6/2000,prevention of post-cardiopulmonary bypass syndrome in children undergoing cardiopulmonary bypass.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Avant Immunotherapeutics, Inc.",119 Fourth Ave.,,Needham,Massachusetts,' 02494 ' ,United States,131899,,,
6321,Soluble recombinant human complement receptor type 1,,11/21/1994,prevention or reduction of adult respiratory distress syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"T Cell Sciences, Inc.",119 Fourth Avenue,,Needham Heights,Massachusetts,' 02194 ' ,United States,82894,,,
6322,solution of protein-free hemodialysate of calf blood,,7/6/2022,treatment of cutaneous sulfur mustard-induced injury,Designated,,Not FDA Approved for Orphan Indication,,,,,"DermDefense, Inc.",13020 Jacob Lane,,Kearney,Missouri,' 64060 ' ,United States,888622,,,
6323,solution stable glucagon analog,,4/20/2020,treatment of congenital hyperinsulinism,Designated,,Not FDA Approved for Orphan Indication,,,,,AmideBio,331 South 104th Street,,Louisville,Colorado,' 80027 ' ,United States,716419,,,
6324,solvent/detergent treated non-blood-group specific human coagulation active plasma,,12/12/2005,treatment of thrombotic thrombocytopenic purpura,Designated/Designation Withdrawn or Revoked,1/11/2019,Not FDA Approved for Orphan Indication,,,,,"Octapharma USA, Inc.",121 River Street,12th Floor,Hoboken,New Jersey,' 07030 ' ,United States,211605,thrombotic thrombocytopenic purpura,"""gard:0016659""",
6325,somapacitan-beco,Sogroya,7/10/1987,1. treatment of growth failure in children due to inadequate growth hormone secretion 2. treatment of short stature associated with turner's syndrome,Designated/Approved,,,Treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH),4/28/2023,,,Novo Nordisk Pharmaceuticals,100 Overlook Center,Suite 200,Princeton,New Jersey,' 08540 ' ,United States,13386,,,
6326,"somatic cell therapy product containing hematopoietic progenitor cells (HPC), Facilitating Cells (FC), and alpha beta T cells.",,2/4/2016,prevention of organ rejection in living donor kidney transplant recipients,Designated,,Not FDA Approved for Orphan Indication,,,,,Regenerex LLC,570 South Preston Street,Suite 404,Louisville,Kentucky,' 40202 ' ,United States,507015,,,
6327,somatorelin,,8/8/1989,diagnostic measure of the capacity of the pituitary gland to release growth hormone.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ferring Laboratories, Inc.","400 Rella Boulevard, Suite 201",,Suffern,New York,' 10901 ' ,United States,36689,,,
6328,Somatostatin,,12/22/1994,treatment of bleeding esophageal varices.,Designated,,Not FDA Approved for Orphan Indication,,,,,Eumedica Pharmaceuticals A.G. (Schweiz),Arnold Bocklin-Strasse 1,CH-4051,BASEL,,' ' ,Switzerland,86094,,,
6329,Somatostatin,,6/20/1988,"adjunct to the non-operative management of secreting cutaneous fistulas of the stomach, duodenum, small intestine (jejunum and ileum), or pancreas.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Ferring Laboratories, Inc.","400 Rella Boulevard, Suite 201",,Suffern,New York,' 10901 ' ,United States,21587,,,
6330,Somatrem for injection,Protropin,12/9/1985,"1. long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion (prevalence 15,000) 2. treatment of short stature associated with turner's syndrome (prevalence 8000).",Designated/Approved,,,,10/17/1985,10/17/1992,,"Genentech, Inc.",460 Point San Bruno Boulevard,,South San Francisco,California,' 94080 ' ,United States,10785,,,
6331,somatrogon-ghla,Ngenla,9/29/2010,treatment of growth hormone deficiency,Designated/Approved,,,treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone,6/27/2023,6/27/2030,treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone,Pfizer Ireland Pharmaceuticals,Operations Support Group Building,,Ringaskiddy,Co. Cork,' ' ,Ireland,313410,,,
6332,Somatropin,Genotropin,9/6/1994,treatment of adults with growth hormone deficiency.,Designated/Approved,,,,10/31/1997,10/31/2004,,Pharmacia & Upjohn,7000 Portage Road,,Kalamazoo,Michigan,' 49001 ' ,United States,83594,,,
6333,Somatropin,Norditropin,8/9/2006,treatment of short stature in patients with noonan syndrome,Designated/Approved,,,Treatment of short stature in patients with Noonan syndrome,5/31/2007,5/31/2014,,Novo Nordisk Inc.,100 College Road West,,Princeton,New Jersey,' 08540 ' ,United States,226606,noonan syndrome,"""gard:0010955""",
6334,Somatropin,,3/16/2004,treatment of patients with hiv-associated adipose redistribution syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,169403,n syndrome,"""gard:0003902""",
6335,Somatropin,Humatrope,5/8/1990,treatment of short stature associated with turner syndrome.,Designated/Approved,,,Treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed.,12/30/1996,12/30/2003,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,45090,turner syndrome,"""gard:0007831""",
6336,Somatropin,Nutropin,3/6/1987,for use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,Designated/Approved,,,,10/17/1985,10/17/1992,,"Genentech, Inc.",460 Point San Bruno Boulevard,,South San Francisco,California,' 94080 ' ,United States,12586,,,
6337,Somatropin,,2/12/1993,treatment of cachexia associated with aids.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Bio-Technology General Corp.,"70 Wood Avenue, South",,Iselin,New Jersey,' 08830 ' ,United States,71592,,,
6338,Somatropin,,9/1/1987,"adjunct for the induction of ovulation in women with infertility due to hypogonadotropic hypogonadism or bilateral tubal occlusion or unexplained infertility, who are undergoing in vivo or in vitro fertilization procedures.",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Novo Nordisk Pharmaceuticals,100 Overlook Center,Suite 200,Princeton,New Jersey,' 08540 ' ,United States,21787,,,
6339,Somatropin,Humatrope,12/15/2005,treatment of short stature in pediatric patients with short stature homeobox-containing gene (shox) deficiency,Designated/Approved,,,Treatment of short stature or growth failure in children with SHOX (short stature homeobox-containing gene) deficiency whose epiphyses are not closed,11/1/2006,11/1/2013,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,211205,,,
6340,Somatropin (rDNA),,5/3/1989,for the enhancement of nitrogen retention in hospitalized patients suffering from severe burns.,Designated,,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,24587,,,
6341,Somatropin (r-DNA),Zorbtive,3/6/1995,for use alone or in combination with glutamine in the treatment of short bowel syndrome.,Designated/Approved,,,Treatment of short bowel syndrome in patients receiving specialized nutritional support,12/1/2003,12/1/2010,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,80394,short bowel syndrome,"""gard:0001502""",
6342,Somatropin (r-DNA) for injection,,3/26/1996,treatment of children with aids-associated failure-to-thrive including aids-associated wasting.,Designated,,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,94695,,,
6343,Somatropin (rDNA origin),Nutropin Depot,10/28/1999,long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.,Designated/Approved,,,Long-term treatment of growth failure due to a lack of adequate endogenous growth hormone secetion for once- or twice-a-month administration.,12/22/1999,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,115098,,,
6344,Somatropin (rDNA origin),Saizen,3/6/1987,treatment of idiopathic or organic growth hormone deficiency in children with growth failure.,Designated/Approved,,,Long term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.,10/8/1996,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,15486,,,
6345,Somatropin (rDNA origin) injection,Norditropin,7/10/1987,1. treatment of growth failure in children due to inadequate growth hormone secretion 2. treatment of short stature associated with turner's syndrome,Designated/Approved,,,Long-term treatment of children who have growth failure due to inadequate secretion of endogenous growth hormone.,6/20/2000,,,Novo Nordisk Pharmaceuticals,100 Overlook Center,Suite 200,Princeton,New Jersey,' 08540 ' ,United States,13386,,,
6346,Somatropin for injection,Nutropin,11/18/1996,as replacement therapy for growth hormone deficiency in adults after epiphyseal closure.,Designated/Approved,,,,12/15/1997,12/15/2004,,"Genentech, Inc.",460 Point San Bruno Boulevard,,South San Francisco,California,' 94080 ' ,United States,100396,,,
6347,Somatropin for injection,Humatrope,6/12/1986,for the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.,Designated/Approved,,,,3/8/1987,3/8/1994,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,11285,,,
6348,Somatropin for injection,Nutropin,8/4/1989,treatment of growth retardation associated with chronic renal failure.,Designated/Approved,,,Treatment of children with growth failure associated with chronic renal insufficency.,11/17/1993,11/17/2000,,"Genentech, Inc.",460 Point San Bruno Boulevard,,South San Francisco,California,' 94080 ' ,United States,34989,,,
6349,Somatropin for injection,Nutropin,3/23/1989,treatment of short stature associated with turner's syndrome.,Designated/Approved,,,Treatment of growth failure associated with Turner syndrome.,12/30/1996,12/30/2003,,"Genentech, Inc.",460 Point San Bruno Boulevard,,South San Francisco,California,' 94080 ' ,United States,12686,,,
6350,Somatropin for injection,Serostim,11/15/1991,treatment of aids-associated catabolism/weight loss.,Designated/Approved,,,Treatment of AIDS wasting or cachexia.,8/23/1996,8/23/2003,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,60491,,,
6351,Somatropin [rDNA],Genotropin,7/6/1999,treatment of short stature in patients with prader-willi syndrome.,Designated/Approved,,,Long-term treatment of pediatric patients who have growth failure due to Prader-Willi syndrome (PWS).,6/20/2000,6/20/2007,,Pharmacia & Upjohn,7000 Portage Rd.,0633-298-113,Kalamazoo,Michigan,' 49001 ' ,United States,124799,prader-willi syndrome,"""gard:0005575""",
6352,somatropin [rDNA],Genotropin,12/27/2000,treatment of growth failure in children who were born small for gestational age.,Designated/Approved,,,For long-term treatment of growth failure in children born small for gestational age who fail to manifest catch-up growth by two years of age.,7/25/2001,7/25/2008,,Pharmacia and Upjohn Company,7000 Portage Road,,Kalamazoo,Michigan,' 49001 ' ,United States,135400,,,
6353,somavaratan,,10/16/2013,treatment of growth hormone deficiency,Designated,,Not FDA Approved for Orphan Indication,,,,,"Versartis, Inc.",275 Shoreline Drive,Suite 450,Redwood City,,' 94065 ' ,United States,379412,,,
6354,sonidegib,,3/23/2015,treatment of medulloblastoma,Designated/Designation Withdrawn or Revoked,3/15/2023,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,468814,medulloblastoma,"""gard:0007005""",
6355,Sonrotoclax,,11/21/2023,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc","1840 Gateway Drive, 3rd floor,",,San Mateo,California,' 94404 ' ,United States,971223,multiple myeloma,"""gard:0007108""",
6356,Sonrotoclax,,12/21/2023,treatment of mantle cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc","1840 Gateway Drive, 3rd floor",,San Mateo,California,' 94404 ' ,United States,978423,lymphoma,"""gard:0020548""",
6357,sonrotoclax,,12/19/2023,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc","1840 Gateway Drive, 3rd Floor",,San Mateo,California,' 94404 ' ,United States,977623,acute myeloid leukemia,"""gard:0012757""",
6358,Sonrotoclax,,12/14/2023,treatment of waldenstrom macroglobulinemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc.","1840 Gateway Drive, 3rd floor",,San Mateo,California,' 94404 ' ,United States,975323,,,
6359,Soquelitinib,,2/7/2024,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Corvus Pharmaceuticals, Inc.","863 Mitten Road, Suite 102",,Burlingame,California,' 94010 ' ,United States,986723,lymphoma,"""gard:0020548""",
6360,Sorafenib,,9/29/2006,treatment of stage iib through stage iv melanoma,Designated/Designation Withdrawn or Revoked,3/11/2014,Not FDA Approved for Orphan Indication,,,,,Bayer Pharmaceuticals Corp.,100 Bayer Blvd,P. O. Box 915,Whippany,New Jersey,' 07981 ' ,United States,229206,noma,"""gard:0004001""",
6361,sorafenib,Nexavar,12/12/2011,"treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer",Designated/Approved,,,"Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment.",11/22/2013,11/22/2020,"Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment.","Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Blvd.,PO Box 915,Whippany,New Jersey,' 07981 ' ,United States,320310,,,
6362,Sorafenib,Nexavar,4/20/2006,treatment of hepatocellular carcinoma,Designated/Approved,,,Treatment of unresectable hepatocellular carcinoma,11/16/2007,11/16/2014,,Bayer Pharmaceuticals Corporation,400 Morgan Lane,,West Haven,Connecticut,' 06516 ' ,United States,220206,hepatocellular carcinoma,"""gard:0016773""",
6363,sorafenib,,2/28/2019,treatment of desmoid tumors/aggressive fibromatosis,Designated/Designation Withdrawn or Revoked,4/22/2022,Not FDA Approved for Orphan Indication,,,,,"Bayer HealthCare Pharmaceuticals, Inc.",100 Bayer Boulevard,P.O. Box 915,Whippany,New Jersey,' 07981 ' ,United States,675918,desmoid tumor,"""gard:0001820""",
6364,Sorafenib,Nexavar,10/8/2004,treatment of renal cell carcinoma.,Designated/Approved,,,Treatment of patients with advanced renal cell carcinoma,12/20/2005,12/20/2012,,Bayer Pharmaceutical Corporation,400 Morgan Lane,,West Haven,Connecticut,' 06516 ' ,United States,185204,renal cell carcinoma,"""gard:0013215""",
6365,soraprazan,,12/22/2017,treatment of stargardt disease (std),Designated,,Not FDA Approved for Orphan Indication,,,,,Katairo GmbH,21 Lederstraße,,Kusterdingen,Baden-Württemberg,' ' ,Germany,617617,stargardt disease,"""gard:0000181""",
6366,Sorivudine,,11/9/1995,treatment of herpes zoster (shingles) in immunocompromised patients,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb,5 Research Parkway,P.O. Box 5100,Wallingford,Connecticut,' 06492 ' ,United States,92295,,,
6367,sotalol (IV),So-Aqueous,7/25/2008,"for ventricular tachycardia, ventricular fibrillation, or the maintenance of sinus rhythm in patients converted from atrial fibrillation or atrial flutter when oral administration is not possible.",Designated/Approved,,,"For use as a substitute for oral sotalol in patients who are unable to take sotalol orally [oral sotalol is indicated for maintenance of normal sinus rhythm in patients with history of highly symptomatic atrial fibrillation /flutter, and for treatment of documented life-threatening ventricular arrhythmias]",7/2/2009,7/2/2016,,AltaThera Pharmaceuticals LLC,311 South Wacker Drive,Suite 2275A,Chicago,Illinois,' 60606 ' ,United States,247707,,,
6368,Sotalol HCl,Betapace,9/23/1988,1. treatment of life-threatening ventricular tachyarrhythmias 2. prevention of life treatening ventricular tachyarrhythmias,Designated/Approved,,,Treatment of life-threatening ventricular tachyarrhythmias,10/30/1992,10/30/1999,,"Berlex Laboratories, Inc.",300 Fairfield Road,,Wayne,New Jersey,' 07470 ' ,United States,30088,,,
6369,sotalol hydrochloride,,2/10/2014,treatment of life-threatening ventricular arrhythmias in pediatric patients,Designated,,Not FDA Approved for Orphan Indication,,,,,"Arbor Pharmaceuticals, LLC",980 Hammond Drive,"Bldg Two, Suite 1250",Atlanta,Georgia,' 30328 ' ,United States,397613,,,
6370,sotatercept,,12/5/2013,treatment of beta-thalassemia intermedia and major,Designated/Designation Withdrawn or Revoked,1/31/2019,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,413713,beta-thalassemia intermedia,"""gard:0017163""",
6371,sotatercept,,4/28/2014,treatment of anemias associated with myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasms.,Designated/Designation Withdrawn or Revoked,5/2/2018,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,428614,myeloproliferative neoplasm,"""gard:0009319""",
6372,sotatercept-csrk,Winrevair,9/5/2019,treatment of pulmonary arterial hypertension,Designated/Approved,,,"treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events",3/26/2024,3/26/2031,"treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events",Merck Sharp & Dohme LLC,126 East Lincoln Avenue,P.O. Box 2000,Rahway,New Jersey,' 07065 ' ,United States,700219,pulmonary arterial hypertension,"""gard:0007501""",
6373,sotigalimab,,3/9/2020,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pyxis Oncology, Inc.",321 Harrison Avenue,"11th Floor, Suite 1",Boston,Massachusetts,' 02118 ' ,United States,726619,,,
6374,sotorasib,Lumakras,5/1/2019,treatment of kras p.g12c-positive non-small cell lung cancer,Designated/Approved,,,"Treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.",5/28/2021,5/28/2028,"Treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.",Amgen Inc.,1 Amgen Center Drive,Mail Stop 27-3-A,Thousand Oaks,California,' 91320 ' ,United States,653818,small cell lung cancer,"""gard:0009344""",
6375,sotuletinib,,8/16/2022,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936-1080 ' ,United States,897222,amyotrophic lateral sclerosis,"""gard:0005786""",
6376,Spanlecortemlocel,,8/27/2014,hematopoietic support in patients with acute lymphoblastic leukemia (all),Designated/Designation Withdrawn or Revoked,6/1/2022,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,443514,acute lymphoblastic leukemia,"""gard:0000522""",
6377,sparsentan,,1/5/2015,treatment of focal segmental glomerulosclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Travere Therapeutics, Inc.","3611 Valley Centre Drive, Suite 300",,San Diego,California,' 92130 ' ,United States,410113,,,
6378,sparsentan,Filspari,1/11/2021,treatment of immunoglobulin a (iga) nephropathy,Designated/Approved,,,"to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) greater than or equal to 1.5 g/g",2/17/2023,2/17/2030,"to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) greater than or equal to 1.5 g/g","Travere Therapeutics, Inc.","3611 Valley Centre Drive, Suite 300",,San Diego,California,' 92130 ' ,United States,614417,,,
6379,spartalizumab,,10/18/2018,treatment of stage iib-iv melanoma,Designated/Designation Withdrawn or Revoked,3/7/2024,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,Office 337 A13.5B,East Hanover,New Jersey,' 07936 ' ,United States,653418,noma,"""gard:0004001""",
6380,spartalizumab,,3/24/2021,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936-1080 ' ,United States,819321,,,
6381,Specific Peptide Enhanced Affinity Receptor T cell product comprised of autologous CD4 and CD8 positive T cells genetically engineered with an affinity-enhanced T cell receptor to target cancer-testis antigen MAGE-A4,,8/26/2019,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Adaptimmune, LLC",351 Rouse Blvd,,Philadelphia,Pennsylvania,' 19112 ' ,United States,666018,soft tissue sarcoma,"""gard:0004898""",
6382,Sperm Protein-17 oral microparticle vaccine,,6/21/2016,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kiromic, LLC",2707 Fannin Street,Fannin St. Professional Building,Houston,Texas,' 77002 ' ,United States,523416,ovarian cancer,"""gard:0007295""",
6383,spesolimab-sbzo,Spevigo,10/3/2018,treatment of generalized pustular psoriasis,Designated/Approved,,,Treatment of generalized pustular psoriasis (GPP) flares in adults,9/1/2022,9/1/2029,Treatment of generalized pustular psoriasis (GPP) flares in adults,"Boehringer Ingelheim Pharmaceuticals, Inc. (BI)",900 Ridgebury Road,P.O. Box 368,Ridgefield,Connecticut,' 06877 ' ,United States,651618,generalized pustular psoriasis,"""gard:0012819""",
6384,spesolimab-sbzo,Spevigo,10/3/2018,treatment of generalized pustular psoriasis,Designated/Approved,,,treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg,3/18/2024,3/18/2031,"treatment of generalized pustular psoriasis (GPP) flares in pediatric patients 12 years of age and older and weighing at least 40 kg, and treatment of GPP in adults and pediatric patients 12 years of age and older and weighing at least 40 kg who are not experiencing a flare","Boehringer Ingelheim Pharmaceuticals, Inc. (BI)",900 Ridgebury Road,P.O. Box 368,Ridgefield,Connecticut,' 06877 ' ,United States,651618,generalized pustular psoriasis,"""gard:0012819""",
6385,Spesolimab-sbzo,,2/20/2024,treatment of netherton syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc",900 Ridgebury Road,Boehringer Ingelheim,Ridgefield,Connecticut,' 06877 ' ,United States,988323,netherton syndrome,"""gard:0007182""",
6386,spherical carbon absorbent,,5/5/2020,treatment of urea cycle disorders,Designated,,Not FDA Approved for Orphan Indication,,,,,"CT Development One, LLC","187 Pavilion Parkway, Suite 200",,Newport,Kentucky,' 41071 ' ,United States,727419,,,
6387,spherical carbon adsorbent,,12/19/2007,treatment of chronic pouchitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ocera Therapeutics, Inc.",12651 High Bluff Drive,,San Diego,California,' 92130 ' ,United States,249007,pouchitis,"""gard:0020510""",
6388,Spiramycin,,10/17/1984,for symptomatic relief and parasitic cure of chronic cryptosporidiosis in patients with immunodeficiency.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Rhone-Poulenc Rorer Pharmaceuticals,500 Arcola Road,,Collegeville,Pennsylvania,' 19426 ' ,United States,3684,,,
6389,"Spiro[3H-Indole-3,2¿-pyrrolidin]-2(1H)-one derivative",,6/24/2022,treatment of soft tissue sarcoma (sts).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,PO Box 368,Ridgefield,Connecticut,' 06877 ' ,United States,885622,soft tissue sarcoma,"""gard:0004898""",
6390,"Spiro[3H-Indole-3,2¿-pyrrolidin]-2(1H)-one derivative",,6/8/2023,treatment of biliary tract cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,,Ridgefield,Connecticut,' 06877 ' ,United States,942623,,,
6391,spironolactone,,5/22/2014,use in pediatric patients with primary hyperaldosteronism,Designated,,Not FDA Approved for Orphan Indication,,,,,"CMP Pharma, Inc.",PO Box 147,8026 US Highway 264A,Farmville,North Carolina,' 27828 ' ,United States,430614,,,
6392,squalamine lactate,,5/11/2001,treatment of ovarian cancer refractory or resistant to standard chemotherapy,Designated,,Not FDA Approved for Orphan Indication,,,,,Genaera Corporation,5110 Campus Drive,,Plymouth Meeting,Pennsylvania,' 19462 ' ,United States,143101,ovarian cancer,"""gard:0007295""",
6393,Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor,,9/18/2020,treatment of esophageal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jacobio Pharmaceuticals Co., Ltd.","Bld-F2, No 88, 6th Kechuang St, BDA",,Beijing,,' 101111 ' ,China,764720,,,
6394,src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) inhibitor JAB-3068,,2/28/2019,treatment of esophageal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jacobio Pharmaceuticals Co., Ltd.","Bld-F2, No 88, 6th Kechuang St, BDA",,Beijing,,' ' ,China,676318,,,
6395,ST1-RTA immunotoxin (SR 44163),,8/12/1987,1. prevention of acute graft versus host disease in allogenic bone marrow transplantation 2. treatment of patients with b-chronic lymphocytic leukemia,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Sanofi Winthrop, Inc.",9 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,16886,graft versus host disease,"""gard:0016642""",
6396,stabilized sulforaphane,,8/22/2016,treatment of subarachnoid hemorrhage,Designated,,Not FDA Approved for Orphan Indication,,,,,Evgen Pharma PLC,146 Brownlow Hill,,Liverpool,,' ' ,United Kingdom,530616,,,
6397,Stabilized sulforaphane,,9/1/2021,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Evgen Pharma plc,"Liverpool Science Park, Innovation Centre 2",146 Brownlow Hill,Liverpool,,' L3 5RF ' ,United Kingdom,836021,,,
6398,staphylococcal aureus protein A,,6/10/2015,treatment of immune thrombocytopenic purpura,Designated,,Not FDA Approved for Orphan Indication,,,,,"Protalex, Inc.",131 Columbia Turnpike,Suite 1,Florham Park,New Jersey,' 07932 ' ,United States,427714,,,
6399,Staphylococcal immunoglobulin (human),,6/13/2001,reduction (prevention) of nosocomial bacteremia caused by staphylococci in very low birth weight infants.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Inhibitex, Inc.",8995 Westside Parkway,Suite 150,Alpharetta,Georgia,' 30004 ' ,United States,144501,,,
6400,Staphylococcus aureus Immune Globulin (Human),,1/29/2004,prophylaxis against staphylococcus aureus infections in low birth weight neonates,Designated,,Not FDA Approved for Orphan Indication,,,,,Biotest Pharmaceuticals Corporation,"5800 Park of Commerce Blvd, NW",,Boca Raton,Florida,' 33487 ' ,United States,178703,,,
6401,Stem and progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood,,3/4/2005,for use as hematopoietic support in patients with relapsed or refractory hematologic malignancies who are receiving high-dose therapy,Designated/Designation Withdrawn or Revoked,12/9/2014,Not FDA Approved for Orphan Indication,,,,,Gamida Cell Ltd - Teva Joint Venture,"5, Nahum Hafzadi St.",P. O. Box 34670,Jerusalem,,' ' ,Israel,195204,,,
6402,stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells,,4/28/2014,for the treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,10/10/2018,Not FDA Approved for Orphan Indication,,,,,Gamida Cell Ltd,PO Box 34670,,Jerusalem,,' ' ,Israel,426814,acute myeloid leukemia,"""gard:0012757""",
6403,stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells,,11/13/2014,treatment of hodgkin lymphoma.,Designated/Designation Withdrawn or Revoked,10/10/2018,Not FDA Approved for Orphan Indication,,,,,Gamida Cell Ltd.,P. O. Box 34670,,Jerusalem,,' ' ,Israel,454514,lymphoma,"""gard:0020548""",
6404,stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells,,11/13/2014,treatment of myelodysplastic syndrome.,Designated/Designation Withdrawn or Revoked,10/10/2018,Not FDA Approved for Orphan Indication,,,,,Gamida Cell Ltd.,P. O. Box 34670,,Jerusalem,,' ' ,Israel,455314,myelodysplastic syndrome,"""gard:0007132""",
6405,stem/progenitor cells derived from ex vivo expanded allogeneic umbilical cord blood cells,,11/13/2014,treatment of acute lymphoblastic leukemia.,Designated/Designation Withdrawn or Revoked,10/10/2018,Not FDA Approved for Orphan Indication,,,,,Gamida Cell Ltd.,P. O. Box 34670,,Jerusalem,,' ' ,Israel,454414,acute lymphoblastic leukemia,"""gard:0000522""",
6406,stemchymal,,12/16/2015,treatment of polyqlutamine spinocerebellar ataxia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Steminent Biotherapeutics, Inc.",No. 16 Wenhu Street,Neihu Dist.,Taipei City,,' ' ,Taiwan,498615,,,
6407,"Sterile Bicarbonate Infusate, Hemofiltration, Hemodiafiltration, and Hemopdialysis Solution",,5/29/2009,for use as a replacement solution in adults and children during continous renal replacement therapy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nikkiso America, Inc.",5910 Pacific Center Blvd,Suite 110,San Diego,California,' 92121 ' ,United States,276609,,,
6408,Sterile talc,Steritalc,12/8/1997,treatment of pneumothorax,Designated/Approved,,,Steritalc is indicated in adults to decrease the recurrence of pneumothorax.,5/1/2017,5/1/2024,To decrease the recurrence of pneumothorax in adults.,Novatech SA,Z.I. Athelia III,,La Ciotat,CEDEX,' ' ,France,109297,,,
6409,Sterile talc,Steritalc,12/8/1997,treatment of malignant pleural effusion,Designated/Approved,,,To decrease the recurrence of malignant pleural effusions in symptomatic patients following maximal drainage of the pleural effusion.,5/1/2017,5/1/2024,To decrease the recurrence of malignant pleural effusions in symptomatic patients following maximal drainage of the pleural effusion.,Novatech SA,Z.I. Athelia III,,La Ciotat,CEDEX,' ' ,France,106797,,,
6410,Sterile talc powder,Sclerosol Intrapleural Aerosol,9/18/1995,treatment of malignant pleural effusion.,Designated/Approved,,,Prevention of recurrence of malignant pleural effusions in symptomatic patients.,12/24/1997,12/24/2004,,"Sciarra Laboratories, Inc.",485-09 South Broadway,,Hicksville,New York,' 11801 ' ,United States,91595,,,
6411,Stiripentol,,2/22/2021,treatment of primary hyperoxaluria,Designated,,Not FDA Approved for Orphan Indication,,,,,Biocodex,7 avenue Gallieni,,Gentilly,Gentilly,' 94250 ' ,France,800820,primary hyperoxaluria,"""gard:0016530""",
6412,stiripentol,Diacomit,10/30/2008,treatment of dravet syndrome,Designated/Approved,,,Treatment of seizures associated with Dravet syndrome (DS) in patients taking clobazam who are 6 months of age and older and weighing 7 kg or more,7/14/2022,7/14/2029,Treatment of seizures associated with Dravet syndrome (DS) in patients taking clobazam who are 6 months to less than 2 years of age and weighing 7 kg or more,Biocodex,"7, avenue Gallieni",94250,Gentilly,,' ' ,France,266108,dravet syndrome,"""gard:0010430""",
6413,stiripentol,Diacomit,10/30/2008,treatment of dravet syndrome,Designated/Approved,,,DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older taking clobazam.,8/20/2018,8/20/2025,DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older taking clobazam.,Biocodex,"7, avenue Gallieni",94250,Gentilly,,' ' ,France,266108,dravet syndrome,"""gard:0010430""",
6414,substituted benzaldehyde that binds to the oxy-conformation of Hb between amino terminal residues of the alpha-subunits,,10/23/1987,treatment of sickle cell disease.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Burroughs Wellcome Company,3030 Cornwallis Road,,Research Triangle Pk,North Carolina,' 27709 ' ,United States,22087,,,
6415,Substituted imidazopyridine amide,,12/22/2015,treatment of active tuberculosis (tb).,Designated,,Not FDA Approved for Orphan Indication,,,,,"The Global Alliance for TB Drug Development, Inc.","80 Pine Street, 20th Floor",,New York,New York,' 10005 ' ,United States,499015,tuberculosis,"""gard:0007827""",
6416,"Subunit protein vaccine of recombinantly expressed Marburg Marburgvirus glycoprotein (MARV GP, MarVax)",,4/8/2024,prevention (which includes post-exposure prophylaxis) against marburg marburgvirus infection,Designated,,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.","29 Emmons Drive, Suite B-10",,Princeton,New Jersey,' 08054 ' ,United States,977423,,,
6417,subunit protein vaccine of recombinantly expressed Sudan Ebola virus glycoprotein,,4/8/2024,prevention (which includes post-exposure prophylaxis) against sudan ebola virus (sudv) infection,Designated,,Not FDA Approved for Orphan Indication,,,,,"Soligenix, Inc.","29 Emmons Drive, Suite B-10",,Princeton,New Jersey,' 08054 ' ,United States,976823,,,
6418,Succimer,,3/22/1991,treatment of mercury intoxication.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sanofi Winthrop, Inc.",90 Park Avenue,,New York,New York,' 10016 ' ,United States,50890,,,
6419,Succimer,Chemet capsules,5/9/1984,treatment of lead poisoning in children.,Designated/Approved,,,,1/30/1991,1/30/1998,,Bock Pharmacal Company,P.O. Box 419056,,Saint Louis,Missouri,' 63141 ' ,United States,1984,lead poisoning,"""gard:0021503""",
6420,Succimer,,11/5/1990,prevention of cystine kidney stone formation in patients with homozygous cystinuria who are prone to stone development.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sanofi Winthrop, Inc.",90 Park Avenue,,New York,New York,' 10016 ' ,United States,50790,cystinuria,"""gard:0006237""",
6421,Sucralfate,,7/15/1993,treatment of oral mucositis and stomatitis following radiation therapy for head and neck cancer.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Fuisz Technologies, Ltd.",14555 Avion at Lakeside,,Chantilly,Virginia,' 20151 ' ,United States,73893,,,
6422,Sucralfate suspension,,3/12/1990,treatment of oral complications of chemotherapy in bone marrow transplant patients.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Darby Pharmaceuticals, Inc.",100 Banks Avenue,,Rockville Centre,New York,' 11570 ' ,United States,41089,,,
6423,Sucralfate suspension,,3/4/1991,treatment of oral ulcerations and dysphagia in patients with epidermolysis bullosa.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Darby Pharmaceuticals, Inc.",100 Banks Avenue,,Rockville Centre,New York,' 11570 ' ,United States,47090,,,
6424,sugemalimab,,10/8/2020,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"CStone Pharmaceuticals (Suzhou) Co., Ltd.","399 West Haiyang Road, New Bund Times Square, 21/F",,Shanghai,,' 200126 ' ,China,772220,lymphoma,"""gard:0020548""",
6425,Sulfadiazine,,3/14/1994,for use in combination with pyrimethamine for the treatment of toxoplasma gondii encephalitis in patients with and without aids,Designated/Approved,,,"Toxoplasmosis, as adjunctive with pyrimethamine",7/29/1994,7/29/2001,,"Eon Labs Manufacturing, Inc.",227-15 North Conduit Avenue,,Laurelton,New York,' 11413 ' ,United States,78093,encephalitis,"""gard:0019357""",
6426,sulfamidase,,5/22/2008,for treatment of sanfilippo syndrome (mps iiia),Designated/Designation Withdrawn or Revoked,10/17/2022,Not FDA Approved for Orphan Indication,,,,,"Shire Human Genetic Therapies, Inc.",300 Shire Way,,Lexington,Massachusetts,' 02421 ' ,United States,258408,,,
6427,Sulfapyridine,,9/10/1990,treatment of dermatitis herpetiformis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Jacobus Pharmaceutical Company,37 Cleveland Lane,P.O. Box 5290,Princeton,New Jersey,' 08540 ' ,United States,51090,dermatitis herpetiformis,"""gard:0001917""",
6428,sulfo butyl ether beta-cyclodextrin,,10/8/2020,treatment of stargardt disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"reVision Therapeutics, Inc.",Attention: Paul Fehlner,125 Brookside Avenue,Ridgewood,New Jersey,' 07450 ' ,United States,771720,stargardt disease,"""gard:0000181""",
6429,sulfonated monophosphorylated mannose oligosaccharide,,2/17/2012,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Cellxpert Biotechnologies Corporation,"3th Floor, Building 8, No. 78,","West Fourth Ring Middle Road, Fengtai District",Beijing,,' 100039 ' ,China,360111,hepatocellular carcinoma,"""gard:0016773""",
6430,Sulindac,,5/10/2021,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Healx Limited,"Charter House, 66-68 Hills Rd",,Cambridge,,' CB2 1LA ' ,United Kingdom,818421,fragile x syndrome,"""gard:0006464""",
6431,sulindac,,8/4/2020,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"Prolindox, Inc.",8008 Desmond Dr.,,Boynton Beach,Florida,' 33472 ' ,United States,752620,retinitis pigmentosa,"""gard:0005694""",
6432,sulthiame,,7/25/2013,treatment of patients with benign epilepsy of childhood with centrotemporal spikes (bects) also known as rolandic epilepsy,Designated/Designation Withdrawn or Revoked,4/13/2017,Not FDA Approved for Orphan Indication,,,,,"Marathon Pharmaceuticals, LLC","1033 Skokie Blvd.,",Suite 600,Northbrook,Illinois,' 60062 ' ,United States,401213,rolandic epilepsy,"""gard:0010287""",
6433,Superoxide dismutase (human),,3/6/1985,"for protection of donor organ tissue from damage or injury mediated by oxygen-derived free radicals that are generated during the necessary periods of ischemia (hypoxia, anoxia), and especially reperfusion, associated with the operative procedure.",Designated,,Not FDA Approved for Orphan Indication,,,,,Pharmacia-Chiron Partnership,4560 Horton Street,,Emeryville,California,' 94608 ' ,United States,5985,,,
6434,Superoxide dismutase (recombinant human),,5/17/1988,prevention of reperfusion injury to donor organ tissue.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Bio-Technology General Corp.,"70 Wood Avenue, South",,Iselin,New Jersey,' 08830 ' ,United States,27188,,,
6435,"superoxide dismutase, gliadin",,4/30/2010,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Verius Limited,Chartwell House,,Cambridge,,' ' ,United Kingdom,302110,amyotrophic lateral sclerosis,"""gard:0005786""",
6436,Suramin,,5/6/1997,treatment of hormone-refractory prostate cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,Warner-Lambert Company,Parke-Davis Pharmaceutical Research Division,2800 Plymouth Road,Ann Arbor,Michigan,' 48105 ' ,United States,104897,,,
6437,suramin,,1/25/2021,treatment of human african trypanosomiasis,Designated,,Not FDA Approved for Orphan Indication,,,,,"PaxMedica, Inc.","50 Tice Blvd., Suite A26",,Woodcliff Lake,New Jersey,' 07677 ' ,United States,797220,african trypanosomiasis,"""gard:0007826""",
6438,Surfactant (human) (amniotic fluid derived),,3/25/1987,prevention and treatment of neonatal respiratory distress syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Merritt, T. Allen M.D.",2516 Stockton Boulevard,,Sacramento,California,' 95817 ' ,United States,16586,,,
6439,surufatinib,,11/21/2019,treatment of pancreatic neuroendocrine tumors,Designated/Designation Withdrawn or Revoked,1/19/2024,Not FDA Approved for Orphan Indication,,,,,Hutchison MediPharma Ltd.,"Building 4, 720 Cailun Road",Zhangjiang Hi-Tech Park,Shanghai,,' ' ,China,710319,,,
6440,sutimlimab-jome,Enjaymo,7/27/2016,treatment of autoimmune hemolytic anemia,Designated/Approved,,,treatment of hemolysis in adults with cold agglutinin disease (CAD),1/25/2023,,,Bioverativ USA Inc. (a fully owned subsidiary of Sanofi),951 Gateway Boulevard,,South San Francisco,California,' 94080 ' ,United States,506115,autoimmune hemolytic anemia,"""gard:0005870""",
6441,sutimlimab-jome,Enjaymo,7/27/2016,treatment of autoimmune hemolytic anemia,Designated/Approved,,,To decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD),2/4/2022,2/4/2029,To decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD),Bioverativ USA Inc. (a fully owned subsidiary of Sanofi),951 Gateway Boulevard,,South San Francisco,California,' 94080 ' ,United States,506115,autoimmune hemolytic anemia,"""gard:0005870""",
6442,Synsorb Pk,,7/17/1995,treatment of verocytotoxogenic e. coli infections.,Designated,,Not FDA Approved for Orphan Indication,,,,,Synsorb Biotech Inc.,"201, 1204 Kensington Road, N.W.",,Calgary,,' ' ,Canada,90395,,,
6443,Synthesized peptide of the L-amino acids with the sequence H-Lys-Glu-Phe-Leu-His-Pro-Ser-Lys-Val-Asp-Leu-Pro-Arg-OH,,2/4/2016,treatment of ovarian cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,Soricimed Biopharma Inc.,18 Botsford Street,Suite 201,Moncton,,' ' ,Canada,505215,ovarian cancer,"""gard:0007295""",
6444,synthetic 14-mer phosphorothioate antisense oligonucleotide directed against TGF-beta2 mRNA,,6/4/2015,prevention of scarring post glaucoma filtration surgery,Designated,,Not FDA Approved for Orphan Indication,,,,,Isarna Therapeutics GmbH,Leopoldstrasse 254-256,D-80807 Munich,Munich,,' ' ,Germany,475215,,,
6445,Synthetic 15-amino-acid macrocyclic peptide acylated with a ethyleneglycol palmitoylated linker,,7/19/2017,treatment of paroxysmal nocturnal hemoglobinuria (pnh),Designated,,Not FDA Approved for Orphan Indication,,,,,"Ra Pharmaceuticals, Inc.",87 Cambridge Park Drive,,Cambridge,Massachusetts,' 02140 ' ,United States,589717,paroxysmal nocturnal hemoglobinuria,"""gard:0007337""",
6446,synthetic 2'-O-methoxyethyl phosphorothioate oligoribonucleotide sodium salt consisting of 19 nucleotide residues with the sequence 5'-MeCMeUGMeUGGAAGMeUGAGGGMeCMeCAG-3',,5/31/2023,"treatment of charcot-marie-tooth disease, axonal, type 2s (cmt2s)",Designated,,Not FDA Approved for Orphan Indication,,,,,Vanda Pharmaceuticals Inc.,2200 Pennsylvania,,Washington DC,District of Columbia,' 20037 ' ,United States,924922,,,
6447,synthetic 23 amino acid peptide AASSGVSTPGSAGHDIITEQPRS derived from the Huntingtin protein,,11/4/2021,treatment of huntington’s disease,Designated,,Not FDA Approved for Orphan Indication,,,,,centre national de la recherche scientifique,4101 Reservoir Rd NW,,Washington,District of Columbia,' 20007 ' ,United States,847121,,,
6448,"synthetic 2?-O-(2-methoxyethyl)-modified antisense oligonucleotide linked to a tri-antennary cluster of N-acetyl galactosamine (GalNAc3) sugars targeting transmembrane protease, serine 6 messenger ribonucleic acid",,10/15/2020,treatment of beta-thalassemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ionis Pharmaceuticals, Inc.",2855 Gazelle Court,,Carlsbad,California,' 92010 ' ,United States,772120,beta-thalassemia,"""gard:0000871""",
6449,Synthetic adrenocorticotropic hormone,,9/25/2020,treatment of infantile spasms,Designated,,Not FDA Approved for Orphan Indication,,,,,Amzell B.V.,Siriusdreef 41,,2132 WT Hoofddorp,,' ' ,Netherlands,740820,,,
6450,Synthetic analogue of cyclic Glycine-Proline,,9/2/2021,treatment of prader-willi syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neuren Pharmaceuticals, Ltd.","Ste 201, 697 Burke Rd",,Camberwell,VIC3124,' xxxxx ' ,Australia,835121,prader-willi syndrome,"""gard:0005575""",
6451,synthetic cyclic 8 amino acid analog of human unacylated ghrelin,,10/12/2017,treatment of prader-willi syndrome (pws),Designated,,Not FDA Approved for Orphan Indication,,,,,"Millendo Therapeutics, Inc.",301 North Main Street,Suite 100,Ann Arbor,Michigan,' 48104 ' ,United States,603317,prader-willi syndrome,"""gard:0005575""",
6452,"Synthetic derivative of 16-hydroxy-9Z, 12Z, 14E-octadecatrienoic acid",,10/24/1991,prophylactic treatment of sickle cell disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Omex International, Inc.","6001 Savoy, Suite 110",,Houston,Texas,' 77036 ' ,United States,32288,,,
6453,Synthetic DNA aptamer-nucleoside drug conjugate targeting nucleolin-expression cancer cells,,3/31/2021,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Samjin Pharmaceutical Co., Ltd.","121 Wausan-ro, Mapo-gu",,Seoul,Republic of Korea,' 04054 ' ,South Korea,809821,acute myeloid leukemia,"""gard:0012757""",
6454,synthetic double-strand small interfering ribonucleic acid (siRNA) oligonucleotide drug directed against C3 messenger RNA,,11/22/2022,treatment of c3 glomerulopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Silence Therapeutics plc,72 Hammersmith Rd. W14 8th,,London,England,' ' ,United Kingdom,853121,c3 glomerulopathy,"""gard:0017507""",
6455,synthetic double-stranded (hybridized duplex) ribonucleic acid oligonucleotide specific to hydroxyacid oxidase 1 gene,,4/22/2015,treatment of primary hyperoxaluria type 1,Designated,,Not FDA Approved for Orphan Indication,,,,,"Dicerna Pharmaceuticals, Inc.",87 Cambridgepark Drive,,Cambridge,Massachusetts,' 02140 ' ,United States,473915,primary hyperoxaluria,"""gard:0016530""",
6456,synthetic double-stranded siRNA oligonucleotide against antithrombin (AT) mRNA,,8/16/2013,treatment of hemophilia a,Designated,,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,402813,hemophilia,"""gard:0010418""",
6457,synthetic double-stranded siRNA oligonucleotide against antithrombin mRNA,,8/12/2013,treatment of hemophilia b,Designated,,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,402913,hemophilia,"""gard:0010418""",
6458,synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA,,9/25/2012,treatment of ischemic optic neuropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Quark Pharmaceuticals, Inc.","7999 Gateway Boulevard, Suite 310",,Newark,California,' 94560 ' ,United States,317410,,,
6459,Synthetic double-stranded siRNA oligonucleotide directed against TMPRSS6 mRNA and covalently linked to a ligand containing 3 N-acetylgalactosamine residues,,2/24/2022,treatment of polycythemia vera (pv),Designated,,Not FDA Approved for Orphan Indication,,,,,Silence Therapeutics plc,72 Hammersmith Rd. W14 8th,,London,England,' ' ,United Kingdom,863021,polycythemia,"""gard:0019466""",
6460,Synthetic double-stranded siRNA oligonucleotide directed against TMPRSS6 mRNA and covalently linked to a ligand containing 3 N-acetylgalactosamine residues,,6/26/2020,treatment of ß-thalassemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Silence Therapeutics GmbH,Robert-Rossle-Str. 10,,Berlin,,' ' ,Germany,709119,,,
6461,synthetic double-stranded small interfering RNA (siRNA) oligonucleotide directed against TMPRSS6 mRNA,,4/6/2020,treatment of myelodysplastic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Silence Therapeutics GmbH,Robert-Rossle-Str. 10,,Berlin,,' ' ,Germany,709619,myelodysplastic syndrome,"""gard:0007132""",
6462,Synthetic Human Parathyroid Hormone 1-34,,1/26/2001,treatment of hypoparathyroidism,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Rare Disease Therapeutics, Inc.",2550 Meridian Blvd,,Nashville,Tennessee,' 37217 ' ,United States,138100,,,
6463,Synthetic human secretin,,9/18/2006,for use in conjunction with diagnostic procedures (excluding ercp) for pancreatic disorders to increase pancreatic fluid secretion,Designated,,Not FDA Approved for Orphan Indication,,,,,"Innovate Biopharmaceuticals, Inc.",8601 Six Forks Road,Suite 400,Raleigh,North Carolina,' 27615 ' ,United States,219906,,,
6464,Synthetic human secretin,,6/16/1999,for use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"ChiRhoClin, Inc.",15500 Gallaudet Ave.,,Silver Spring,Maryland,' 20905 ' ,United States,120698,noma,"""gard:0004001""",
6465,Synthetic human secretin,,6/16/1999,for use in the evaluation of exocrine pancreas function.,Designated,,Not FDA Approved for Orphan Indication,,,,,"ChiRhoClin, Inc.",15500 Gallaudet Ave.,,Silver Spring,Maryland,' 20905 ' ,United States,120598,,,
6466,Synthetic human secretin,Chirostim,6/16/1999,for use in the diagnosis of gastrinoma associated with zollinger-ellison syndrome.,Designated/Approved,,,"Stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction, stimulation of gastrin secretion to aid in the diagnosis of gastrinoma, and stimulation of pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography",4/9/2004,,,"ChiRhoClin, Inc.",15500 Gallaudet Ave.,,Silver Spring,Maryland,' 20905 ' ,United States,120798,zollinger-ellison syndrome,"""gard:0007918""",
6467,Synthetic human secretin,,3/7/2000,"for use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion",Designated,,Not FDA Approved for Orphan Indication,,,,,"ChiRhoClin, Inc.",15500 Gallaudet Ave.,,Silver Spring,Maryland,' 20905 ' ,United States,130199,,,
6468,synthetic oligomer of 16 nucleotides,,1/13/2015,treatment of myotonic dystrophy type i,Designated/Designation Withdrawn or Revoked,2/26/2018,Not FDA Approved for Orphan Indication,,,,,"Ionis Pharmaceuticals, Inc.",2855 Gazelle Ct.,,Carlsbad,California,' 92010 ' ,United States,457914,myotonic dystrophy,"""gard:0010419""",
6469,synthetic peptide; cyclo-Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-ALA-Lys-Pro-Trp-Tyr-Cys,,1/16/2013,treatment of high altitude pulmonary edema,Designated,,Not FDA Approved for Orphan Indication,,,,,Apeptico Forschung und Entwicklung GmbH,c/o mingo bueros,,Vienna,,' ' ,Austria,382912,high altitude pulmonary edema,"""gard:0021502""",
6470,synthetic polymer PEG conjugated to a phospholipid anchor (2-dipalmitoyl-sn-glycerol-3-phosphatidylethanolamine),,10/17/2022,prevention of ischemia reperfusion injury during solid organ transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,iCoat Medical AB,"WeWork, c/o iCoat Medical AB",Malmskillnadsgatan 32,Stockholm,,' 111 51 ' ,Sweden,905622,,,
6471,Synthetic porcine secretin,,6/18/1999,for use in obtaining desquamated pancreatic cells for cytopathologic examination in pancreatic carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"ChiRhoClin, Inc.",15500 Gallaudet Ave.,,Silver Spring,Maryland,' 20905 ' ,United States,120398,noma,"""gard:0004001""",
6472,Synthetic porcine secretin,Secreflo,6/18/1999,for use in the diagnosis of gastrinoma associated with zollinger-ellison syndrome.,Designated/Approved,,,Use in secretin stimulation testing for stimulation of gastrin secretion to aid in the diagnosis of gastrinoma,4/4/2002,4/4/2009,,"ChiRhoClin, Inc.",15500 Gallaudet Ave.,,Silver Spring,Maryland,' 20905 ' ,United States,120498,zollinger-ellison syndrome,"""gard:0007918""",
6473,Synthetic porcine secretin,Secreflo,6/18/1999,for use in the evaluation of exocrine pancreas function.,Designated/Approved,,,For use in secretin stimulation testing for: Stimulation of pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangio-pancreatography (ERCP),11/1/2002,11/1/2009,,"ChiRhoClin, Inc.",15500 Gallaudet Ave.,,Silver Spring,Maryland,' 20905 ' ,United States,120298,,,
6474,Synthetic porcine secretin,Secreflo,3/7/2000,"for use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion",Designated/Approved,,,"Use in secretin stimulation testing for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction",4/4/2002,4/4/2009,,"ChiRhoClin, Inc.",15500 Gallaudet Ave.,,Silver Spring,Maryland,' 20905 ' ,United States,130299,,,
6475,Synthetic PreImplantation Factor,,12/19/2018,treatment of acute radiation syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioIncept, LLC",140 East 40th Street,Suite 11E,New York,New York,' 10016 ' ,United States,664918,acute radiation syndrome,"""gard:0021896""",
6476,synthetic preImplantation factor,,5/8/2018,prevention of graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioIncept, LLC",140 East 40th Street,Suite 11E,New York,New York,' 10016 ' ,United States,622517,graft versus host disease,"""gard:0016642""",
6477,Synthetic PreImplantation Factor (H-Met-Val-Arg-Ile-Lys-Pro-Gly-Ser-Ala-Asn-Lys-Pro-Ser-Asp-Asp-OH,,11/22/2017,treatment of autoimmune hepatitis (aih),Designated,,Not FDA Approved for Orphan Indication,,,,,"BioIncept, LLC",140 East 40th Street,Suite 11E,New York,New York,' 10016 ' ,United States,613417,autoimmune hepatitis,"""gard:0005871""",
6478,synthetic signal peptide of human mucin-1 (amino acids 1-21),,6/16/2015,treatment of multiple myeloma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Vaxil Bio Therapeutics Ltd.,"13 Einstein St., Building 13A",,Nes-Ziona,,' ' ,Israel,482115,multiple myeloma,"""gard:0007108""",
6479,Synthetic stereopure antisense oligonucleotide specific for human dystrophin pre-messenger ribonucleic acid (mRNA),,8/7/2018,treatment of duchenne muscular dystrophy,Designated/Designation Withdrawn or Revoked,12/31/2019,Not FDA Approved for Orphan Indication,,,,,Wave Life Sciences Ltd.,733 Concord Avenue,,Cambridge,Massachusetts,' 02138 ' ,United States,602417,muscular dystrophy,"""gard:0007922""",
6480,synthetic stereopure antisense oligonucleotide specific to the mutant huntingtin mRNA transcript at the U variant of single nucleotide polymorphism rs326331,,9/5/2017,treatment of huntington's disease,Designated/Designation Withdrawn or Revoked,8/9/2021,Not FDA Approved for Orphan Indication,,,,,Wave Life Sciences Ltd.,733 Concord Avenue,,Cambridge,Massachusetts,' 02138 ' ,United States,598817,,,
6481,"synthetic surfactant comprised of DPPC, POPG Na, synthetic SP-C analogue and synthetic SP-B analogue",,3/16/2012,treatment of preterm neonatal respiratory distress syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,' 27518 ' ,United States,360811,,,
6482,synthetic survivin peptide SVN53-67/M57-keyhole limpet hemocyanin,,8/2/2017,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"MimiVax, LLC",Elm & Carlton Streets,,Buffalo,New York,' 14263 ' ,United States,594717,,,
6483,"synthetic, single stranded, fully phosphorothioated 2¿-OMethyl-RNA and DNA mixmer oligonucleotide-based compound targeted against natural antisense transcripts (NATs)",,3/16/2017,treatment of dravet syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Camp4 Therapeutics,"1 Kendall Square, Building 1400 West, 3rd Floor",,Cambridge,Massachusetts,' 02139 ' ,United States,557616,dravet syndrome,"""gard:0010430""",
6484,"T cell receptor (TCR) peptide (BV5S2, BV6S5, BV13S1) vaccine",,2/6/2014,treatment of pediatric multiple sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immune Response BioPharma, Inc.",244 5th Avenue,Suite 1727,New York,New York,' 10001 ' ,United States,385412,pediatric multiple sclerosis,"""gard:0010443""",
6485,T cell therapeutic product obtained from transduction of chimeric T cell receptor synthetic T cell receptor and antigen receptor (STAR),,12/15/2022,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Bristar Immunotech Limited,"Building 4, Medical and Pharma Tech Center","Life Science Park, Changping District",Beijing,,' 102206 ' ,China,916622,acute myeloid leukemia,"""gard:0012757""",
6486,T regulatory cells,,6/30/2021,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Coya Therapeutics, Inc.","5850 San Felipe St., Suite 500",,Houston,Texas,' 77057 ' ,United States,823321,amyotrophic lateral sclerosis,"""gard:0005786""",
6487,T-cell depleted stem cell enriched cellular product from peripheal b lood stem cells,,11/1/2001,treatment of chronic granulomatous disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Nexell Therapeutics Inc.,9 Parker,,Irvine,California,' 92618 ' ,United States,149001,chronic granulomatous disease,"""gard:0006100""",
6488,"T4 endonuclease V, liposome encapsulated",,6/27/1989,to prevent cutaneous neoplasms and other skin abnormalities in xeroderma pigmentosum.,Designated,,Not FDA Approved for Orphan Indication,,,,,AGI Dermatics,205 Buffalo Avenue,,Freeport,New York,' 11520 ' ,United States,38589,xeroderma pigmentosum,"""gard:0007910""",
6489,tabalumab,,11/19/2012,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,1/14/2016,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,381612,multiple myeloma,"""gard:0007108""",
6490,tabelecleucel,,2/4/2016,treatment of epstein-barr virus-positive post-transplant lymphoproliferative disorders,Designated,,Not FDA Approved for Orphan Indication,,,,,"ATARA Biotherapeutics, Inc.",4360 Park Terrace Drive,Suite 100,Westlake Village,California,' 91361 ' ,United States,487015,,,
6491,taberminogene vadenovec,,10/24/2000,prevention of complications due to neointimal hyperplasia disease in certain vascular anastomoses.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Finvector Vision Therapies, Ltd.",1 Fitzroy Mews,,London,,' ' ,United Kingdom,123299,,,
6492,Tacrolimus,,4/6/1998,prophylaxis of graft-versus-host-disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Fujisawa USA, Inc.",3 Parkway North Center,,Deerfield,Illinois,' 60015 ' ,United States,111398,,,
6493,Tacrolimus,Prograf,6/6/2005,prophylaxis of organ rejection in patients receiving heart transplants.,Designated/Approved,,,Prophylaxis of organ rejection in patients receiving allogenic heart transplants.,3/29/2006,3/29/2013,,"Astellas Pharma US, Inc.",Three Parkway North,,Deerfield,Illinois,' 60015 ' ,United States,203305,,,
6494,tacrolimus,,5/4/2015,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,Stanford University School of Medicine,300 Pasteur Drive,Room H3143,Stanford,California,' 94305 ' ,United States,472815,pulmonary arterial hypertension,"""gard:0007501""",
6495,tacrolimus,,3/16/2015,treatment of pulmonary arterial hypertension.,Designated,,Not FDA Approved for Orphan Indication,,,,,"VIVUS, Inc.",900 East Hamilton Avenue,Suite 550,Campbell,California,' 95008 ' ,United States,468214,pulmonary arterial hypertension,"""gard:0007501""",
6496,tacrolimus,Envarsus XR,12/20/2013,prophylaxis of organ rejection in patients receiving allogeneic kidney transplant,Designated/Approved,,,ENVARSUS XR is indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants.,12/19/2018,,,"Veloxis Pharmaceuticals, Inc.",1001 Winstead Drive,Suite 310,Cary,North Carolina,' 27513 ' ,United States,407113,,,
6497,tacrolimus,Envarsus XR,12/20/2013,prophylaxis of organ rejection in patients receiving allogeneic kidney transplant,Designated/Approved,,,Prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants,7/10/2015,7/10/2022,Prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants,"Veloxis Pharmaceuticals, Inc.",1001 Winstead Drive,Suite 310,Cary,North Carolina,' 27513 ' ,United States,407113,,,
6498,tacrolimus,,7/6/2012,treatment of hemorrhagic cystitis,Designated,,Not FDA Approved for Orphan Indication,,,,,Lipella Pharmaceuticals Inc.,"400 N. Lexington Ave, LL105",,Pittsburgh,Pennsylvania,' 15208 ' ,United States,314310,,,
6499,tacrolimus,Prograf,10/4/2016,"prevention of rejection in kidney, liver or heart transplant in pediatric patients",Designated/Approved,,,"For the prophylaxis of organ rejection, in patients receiving allogeneic kidney transplant, liver transplants and heart transplant, in combination with other immunosuppressants.",5/24/2018,5/24/2025,For the prophylaxis of organ rejection in pediatric patients receiving allogeneic liver transplants in combination with other immunosuppressants.,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,534516,,,
6500,tacrolimus,Prograf,10/4/2016,"prevention of rejection in kidney, liver or heart transplant in pediatric patients",Designated/Approved,,,"For the prophylaxis of organ rejection, in patients receiving allogeneic kidney transplant, liver transplants and heart transplant, in combination with other immunosuppressants.",5/24/2018,5/24/2025,"For the prophylaxis of organ rejection in pediatric patients receiving allogeneic kidney transplant and heart transplant, in combination with other immunosuppressants.","Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,534516,,,
6501,tacrolimus,Prograf,10/4/2016,"prevention of rejection in kidney, liver or heart transplant in pediatric patients",Designated/Approved,,,"For the prophylaxis of organ rejection, in patients receiving allogeneic kidney transplant, liver transplants and heart transplant, in combination with other immunosuppressants.",5/24/2018,5/24/2025,"For the prophylaxis of organ rejection in pediatric patients receiving allogeneic kidney transplant and heart transplant, in combination with other immunosuppressants.","Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,534516,,,
6502,tacrolimus,Prograf,9/12/2019,prevention of rejection in lung transplantation,Designated/Approved,,,"Prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic kidney transplant, liver transplant, heart transplant, or lung transplant in combination with other immunosuppressants",7/16/2021,7/16/2028,Prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic lung transplant,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,701319,,,
6503,tacrolimus,,6/16/2020,prophylaxis of lung allograft rejection,Designated,,Not FDA Approved for Orphan Indication,,,,,"TFF Pharmaceuticals, Inc.","1751 River Run, Suite 400",,Fort Worth,Texas,' 76107 ' ,United States,743220,,,
6504,Tacrolimus,,11/8/2023,treatment of graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Lipella Pharmaceuticals, Inc.",7800 Susquehananna St,Suite 505,Pittsburgh,Pennsylvania,' 15208 ' ,United States,969323,graft versus host disease,"""gard:0016642""",
6505,Tacrolimus,,6/3/2020,treatment of vernal keratoconjunctivitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"CN2 Therapeutics, Inc.",2764 Treasure Cove Circle,,Fort Lauderdale,Florida,' 33312 ' ,United States,753620,vernal keratoconjunctivitis,"""gard:0007854""",
6506,tacrolimus,,12/7/2021,"treatment of non-infectious intermediate, posterior, pan, and chronic anterior uveitis",Designated,,Not FDA Approved for Orphan Indication,,,,,BioNanoSim Ltd.,Minrav Building,Hadassah ein Kerem Campus,Jerusalem,Jerusalem,' 9112101 ' ,Israel,849321,uveitis,"""gard:0019549""",
6507,tacrolimus extended-release capsules,Astagraf XL,10/4/2016,"prevention of rejection in kidney, liver or heart transplant in pediatric patients",Designated/Approved,,,prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants in adult and pediatric patients.,11/29/2018,,,"Astellas Pharma Global Development, Inc.",1 Astellas Way,,Northbrook,Illinois,' 60062 ' ,United States,534516,,,
6508,tadalafil,,5/4/2015,treatment of duchenne muscular dystrophy (dmd),Designated,,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,476415,muscular dystrophy,"""gard:0007922""",
6509,tadalafil,Adcirca,12/18/2006,treatment of pulmonary arterial hypertension,Designated/Approved,,,Treatment of pulmonary arterial hypertension (WHO Group I) to improve exercise ability,5/22/2009,5/22/2016,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,228206,pulmonary arterial hypertension,"""gard:0007501""",
6510,tadekinig alfa,,7/3/2017,"treatment of still's disease, including adult-onset still's disease (aosd) and systemic juvenile idiopathic arthritis (sjia)",Designated,,Not FDA Approved for Orphan Indication,,,,,AB2 Bio Ltd,EPFL Innovation Park,Building B,Lausanne,Vaud,' ' ,Switzerland,585017,juvenile idiopathic arthritis,"""gard:0018677""",
6511,tadekinig alfa,,1/12/2017,treatment of hemophagocytic lymphohistiocytosis,Designated,,Not FDA Approved for Orphan Indication,,,,,AB2 Bio Ltd,EPFL Innovation Park,Building B,Lausanne,Vaud,' ' ,Switzerland,543916,,,
6512,tafamidis,,5/23/2006,treatment of familial amyloid polyneuropathy,Designated/Designation Withdrawn or Revoked,11/16/2021,Not FDA Approved for Orphan Indication,,,,,"Pfizer, Inc.",P. O. Box 8299,,Philadelphia,Pennsylvania,' 19101 ' ,United States,220606,,,
6513,tafamidis meglumine,VYNDAQEL; VYNDAMAX,2/17/2012,treatment of symptomatic transthyretin (ttr) amyloid cardiomyopathy.,Designated/Approved,,,VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.,5/3/2019,5/3/2026,VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.,"FoldRx Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.",445 Eastern Point Road,,Groton,Connecticut,' 06340 ' ,United States,363312,,,
6514,tafasitamab,MONJUVI,12/1/2014,treatment of diffuse large b-cell lymphoma,Designated/Approved,,,"MONJUVI® is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)",7/31/2020,7/31/2027,"indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)",Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,456014,lymphoma,"""gard:0020548""",
6515,tafasitamab-cxix,,1/7/2021,treatment of patients with follicular lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Incyte Corporation,1801 Augustine Cut-Off,,Wilmington,Delaware,' 19803 ' ,United States,790920,lymphoma,"""gard:0020548""",
6516,tafenoquine,Krintafel,1/15/2013,treatment of malaria,Designated/Approved,,,KRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.,7/20/2018,7/20/2025,KRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.,GlaxoSmithKline Intellectual Property Development Ltd. England,980 Great West Road,,"Brentford, Middlesex",England,' ' ,United Kingdom,385812,malaria,"""gard:0006961""",
6517,Tafenoquine,,6/5/2024,treatment of babesiosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"60 Degrees Pharmaceuticals, Inc.","1025 Connecticut Avenue, NW, Suite 1000",,Washington,District of Columbia,' 20036 ' ,United States,1004924,babesiosis,"""gard:0005878""",
6518,Tagraxofusp-erzs,ELZONRIS,6/6/2013,treatment of blastic plasmacytoid dendritic cell neoplasm,Designated/Approved,,,ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.,12/21/2018,12/21/2025,ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.,"Stemline Therapeutics, Inc.",750 Lexington Avenue,11th floor,New York,New York,' 10022 ' ,United States,397413,,,
6519,Talabostat,,1/26/2021,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,BioXcel Therapeutics,"555 Long Wharf Drive, 5th Floor",,New Haven,Connecticut,' 06511 ' ,United States,796720,soft tissue sarcoma,"""gard:0004898""",
6520,Talabostat,,3/16/2017,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,BioXcel Corporation,780 East Main Street,Suite 2,Branford,Connecticut,' 06405 ' ,United States,559616,,,
6521,Talabostat,,3/20/2017,treatment of stages iib through iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,BioXcel Corporation,780 East Main Street,Suite 2,Branford,Connecticut,' 06405 ' ,United States,559416,noma,"""gard:0004001""",
6522,Talabostat,,8/21/2019,treatment of acute myelogenous leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioXcel Therapeutics, Inc.",555 Long Wharf Drive,5th Floor,New Haven,Connecticut,' 06511 ' ,United States,697119,,,
6523,Talactoferrin alfa,,8/8/2007,treatment of stage iii/iv non-small cell lung cancer,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.",8 Greenway Plaza,Suite 910,Houston,Texas,' 77046 ' ,United States,236707,small cell lung cancer,"""gard:0009344""",
6524,talactoferrin alfa,,9/29/2006,treatment of renal cell carcinoma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.",8 Greenway Plaza,Suite 910,Houston,Texas,' 77046 ' ,United States,182203,renal cell carcinoma,"""gard:0013215""",
6525,talactoferrin alfa,,8/20/2003,for the prevention of graft-versus-host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.",8 Greenway Plaza,Suite 910,Houston,Texas,' 77046 ' ,United States,162102,,,
6526,talactoferrin alfa,,8/20/2003,for the treatment of graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Agennix, Inc.",8 Greenway Plaza,Suite 910,Houston,Texas,' 77046 ' ,United States,165703,graft versus host disease,"""gard:0016642""",
6527,talampanel,,2/17/2009,treatment of glioma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"TEVA Neuroscience, Inc.",425 Privet Road,,Horsham,Pennsylvania,' 19044 ' ,United States,274408,,,
6528,talampanel,,3/24/2008,treatment of amyotrophic lateral sclerosis,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,TEVA Neuroscience,P. O. Box 1005,425 Privet Road,Horsham,Pennsylvania,' 19044 ' ,United States,256007,amyotrophic lateral sclerosis,"""gard:0005786""",
6529,talarazole,,3/16/2012,treatment of congenital ichthyosis,Designated/Designation Withdrawn or Revoked,12/15/2015,Not FDA Approved for Orphan Indication,,,,,"Stiefel Laboratories, Inc.",20 T.W. Alexander Drive,,Research Triangle Park,North Carolina,' 27709 ' ,United States,365412,ichthyosis,"""gard:0018985""",
6530,Taldefgrobep Alfa,,12/16/2022,treatment of spinal muscular atrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biohaven Pharmaceuticals, Inc.",215 Church Street,,New Haven,Connecticut,' 06510 ' ,United States,918122,,,
6531,Taliglucerase alfa,ELELYSO for injection,9/3/2009,treatment of gaucher's disease,Designated/Approved,,,Use as long-term enzyme replacement therapy in patients with Type 1 Gaucher disease,5/1/2012,,,"Pfizer, Inc.",235 East 42nd Street,,New York,New York,' 10017 ' ,United States,191004,,,
6532,talimogene laherparepvec,IMLYGIC,3/14/2011,treatment of stage iib-stage iv melanoma,Designated/Approved,,,"Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery",10/27/2015,10/27/2022,"Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery","BioVex, Inc. (subsidiary of Amgen)",Amgen,Mail Stop 17-2-B,Thousand Oaks,California,' 91320 ' ,United States,334011,noma,"""gard:0004001""",
6533,Talotrexin,,5/8/2006,treatment of acute lymphoblastic leukemia,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Hana Biosciences, Inc.",7000 Shoreline Court,Suite 370,South San Francisco,California,' 94080 ' ,United States,221306,acute lymphoblastic leukemia,"""gard:0000522""",
6534,talquetamab-tgvs,Talvey,5/3/2021,treatment of multiple myeloma,Designated/Approved,,,"treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody",8/9/2023,8/9/2030,"treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody","Janssen Biotech, inc.",800/850 Ridgeview Dr.,,Horsham,Pennsylvania,' 19044 ' ,United States,814921,multiple myeloma,"""gard:0007108""",
6535,tamibarotene,,8/16/2017,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,"Syros Pharmaceuticals, Inc.",620 Memorial Drive,Suite 300,Cambridge,Massachusetts,' 02139 ' ,United States,596017,acute myeloid leukemia,"""gard:0012757""",
6536,tamibarotene,,2/1/2022,treatment of myelodysplastic syndrome (mds),Designated,,Not FDA Approved for Orphan Indication,,,,,Syros Pharmaceuticals,35 Cambridgepark Drive,Level 4,Cambridge,Massachusetts,' 02140 ' ,United States,861221,myelodysplastic syndrome,"""gard:0007132""",
6537,Tamibarotene,,10/11/2007,treatment of acute promyelocytic leukemia (apl).,Designated,,Not FDA Approved for Orphan Indication,,,,,CytRx Corporation,11726 San Vicente Blvd.,,Los Angeles,California,' 90049 ' ,United States,247007,acute promyelocytic leukemia,"""gard:0000538""",
6538,Tanespimycin,,9/9/2004,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb,5 Research Parkway,P.O. Box 5100,Wallingford,Connecticut,' 06492 ' ,United States,191504,multiple myeloma,"""gard:0007108""",
6539,taniraleucel,,4/6/2021,treatment of malignant glioma,Designated/Designation Withdrawn or Revoked,4/12/2023,Not FDA Approved for Orphan Indication,,,,,Celularity Inc.,170 Park Avenue,,Florham Park,New Jersey,' 07932 ' ,United States,809021,,,
6540,tarextumab,,1/26/2015,treatment of small cell lung cancer,Designated/Designation Withdrawn or Revoked,9/2/2017,Not FDA Approved for Orphan Indication,,,,,"OncoMed Pharmaceuticals, Inc.",800 Chesapeake Drive,,Redwood City,California,' 94063 ' ,United States,461314,small cell lung cancer,"""gard:0009344""",
6541,tarextumab,,1/26/2015,treatment of pancreatic cancer,Designated/Designation Withdrawn or Revoked,9/1/2017,Not FDA Approved for Orphan Indication,,,,,"OncoMed Pharmaceuticals, Inc.",800 Chesapeake Drive,,Redwood City,California,' 94063 ' ,United States,461414,,,
6542,"Targeted antigen-loaded liposomes (TALL) comprised of a neutral stealth liposome, encapsulated synthetic immunogenic HLA class I restricted peptide (H250) derived from measles virus and a tumor-targeting peptide",,4/29/2024,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,SRI International,333 Ravenswood Ave.,,Menlo Park,California,' 94025 ' ,United States,1000824,,,
6543,Targeted Gastrin 17 Complexed Peptide,,5/14/2014,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Tyg Oncology Ltd,"Synergy House, 7 Acorn Business Park",Nottinghamshire NG18 1 EX,,,' ' ,United Kingdom,431314,,,
6544,tarlatamab-dlle,Imdelltra,12/27/2018,treatment of small cell lung cancer (sclc),Designated/Approved,,,treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy,5/16/2024,,,Amgen Inc.,1 Amgen Center Drive,,Thousand Oaks,California,' 91320 ' ,United States,665418,small cell lung cancer,"""gard:0009344""",
6545,tasimelteon,HETLIOZ,1/19/2010,non-24-hour sleepwake disorder in blind individuals without light perception,Designated/Approved,,,Treatment of non-24-hour sleep-wake disorder,1/31/2014,1/31/2021,Treatment of non-24-hour sleep-wake disorder,"Vanda Pharmaceuticals, Inc.","2200 Penn. Ave., NW",Suite 300 E,Washington,District of Columbia,' 20037 ' ,United States,297409,,,
6546,tasimelteon,Hetlioz LQ,4/30/2010,treatment of sleep disorder in smith-magenis syndrome associated with diurnal melatonin secretion,Designated/Approved,,,Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in pediatric patients 3 to 15 years of age,12/1/2020,12/1/2027,Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in pediatric patients 3 to 15 years of age,"Vanda Pharmaceuticals, Inc.",9605 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,301410,smith-magenis syndrome,"""gard:0008197""",
6547,tasimelteon,Hetlioz,4/30/2010,treatment of sleep disorder in smith-magenis syndrome associated with diurnal melatonin secretion,Designated/Approved,,,Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older,12/1/2020,12/1/2027,Treatment of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) in patients 16 years of age and older.,"Vanda Pharmaceuticals, Inc.",9605 Medical Center Drive,,Rockville,Maryland,' 20850 ' ,United States,301410,smith-magenis syndrome,"""gard:0008197""",
6548,tasisulam sodium,,9/3/2009,treatment of melanoma stages iib through iv,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,289909,noma,"""gard:0004001""",
6549,Tasquinimod,,4/10/2017,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Active Biotech AB,Scheelevägen 22,P.O. Box 724,Lund,Skåne län,' ' ,Sweden,561916,multiple myeloma,"""gard:0007108""",
6550,Tasquinimod,,5/16/2022,treatment of myelofibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Active Biotech AB,Scheelevagen 22,,Lund,Lund,' xxxxx ' ,Sweden,877022,,,
6551,taurine,,3/22/2010,treatment of cystathionine beta-synthase deficient homocystinuria,Designated,,Not FDA Approved for Orphan Indication,,,,,"Johan L. Van Hove, MD, PhD",Department of Pediatrics/University of Colorado De,"13121 E. 17th Ave., P. O. Box 6508",Aurora,Colorado,' 80045 ' ,United States,298709,cystinuria,"""gard:0006237""",
6552,taurolidine,,5/16/2016,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Geistlich Pharma NA, Inc.",202 Carnegie Center Drive,,Princeton,New Jersey,' 08540 ' ,United States,500015,,,
6553,taurolidine,,2/22/2018,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"CorMedix, Inc.",1430 U.S. 206,Suite 200,Bedminster Township,New Jersey,' 07921 ' ,United States,528816,neuroblastoma,"""gard:0007185""",
6554,Taxol isolated from Taxus brevifolia,,10/15/1990,treatment of ovarian cancer.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb,5 Research Parkway,P.O. Box 5100,Wallingford,Connecticut,' 06492 ' ,United States,50190,ovarian cancer,"""gard:0007295""",
6555,tazemetostat,,9/28/2017,treatment of mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Epizyme Inc.,400 Technology Square,4th Floor,Cambridge,Massachusetts,' 02139 ' ,United States,544416,,,
6556,tazemetostat,Tazverik,11/14/2017,treatment of follicular lymphoma,Designated/Approved,,,TAZVERIK (tazemetostat) is indicated for: the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies; and the treatment of adult patients with R/R FL who have no satisfactory alternative treatment options.,6/18/2020,6/18/2027,"For the treatment of adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for the treatment of adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options","Epizyme, Inc.",400 Technology Square,4th Floor,Cambridge,Massachusetts,' 02139 ' ,United States,607017,lymphoma,"""gard:0020548""",
6557,tazemetostat,,6/15/2017,treatment of soft tissue sarcoma,Designated/Approved,,,TAZVERIK is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.,1/23/2020,1/23/2027,,"Epizyme, Inc.",400 Technology Square,4th Floor,Cambridge,Massachusetts,' 02139 ' ,United States,578417,soft tissue sarcoma,"""gard:0004898""",
6558,tazemetostat,,5/23/2018,treatment of chordoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Epizyme, Inc.",400 Technology Square,4th Floor,Cambridge,Massachusetts,' 02139 ' ,United States,637118,chordoma,"""gard:0001303""",
6559,tazemetostat,,2/4/2016,treatment of malignant rhabdoid tumors (mrts),Designated,,Not FDA Approved for Orphan Indication,,,,,Epizyme Inc.,400 Technology Square,4th Floor,Cambridge,Massachusetts,' 02139 ' ,United States,508415,rhabdoid tumor,"""gard:0007572""",
6560,tbo-filgrastim,,7/10/2017,for the mobilization of peripheral blood progenitor cells (pbpcs) in healthy donors prior to allogeneic pbpc transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,Sicor Biotech UAB,5 Moletu pl. 5,,Vilnius,Vilniaus apskritis,' ' ,Lithuania,577617,,,
6561,TD-K6a.513a.12,,6/15/2006,treatment of pachyonychia congenita,Designated,,Not FDA Approved for Orphan Indication,,,,,"TransDerm, Inc.",2161 Delaware Aenue,,Santa Cruz,California,' 95060 ' ,United States,222806,pachyonychia congenita,"""gard:0010753""",
6562,tebentafusp-tebn,Kimmtrak,1/21/2016,treatment of uveal melanoma,Designated/Approved,,,treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma,1/25/2022,1/25/2029,treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma,Immunocore Ltd,Milton Park,90 Park Drive,Milton,,' ' ,United Kingdom,503615,uveal melanoma,"""gard:0008621""",
6563,tecarfarin,,3/7/2019,prevention of systemic thromboembolism of cardiac origin in patients with end stage renal disease and atrial fibrillation,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cadrenal Therapeutics, Inc.",830 North A1A #196,,Ponte Vedra,Florida,' 32082 ' ,United States,659818,,,
6564,tecarfarin,,4/8/2024,"prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device (left ventricular assist device, right ventricular assist device, biventricular assist device, total artificial heart)",Designated,,Not FDA Approved for Orphan Indication,,,,,Cadrenal Therapeutics,822 North A1A,,Ponte Vedra,Florida,' 32082 ' ,United States,956823,,,
6565,technetium Tc 99m tilmanocept,LYMPHOSEEK,9/17/2014,"use in sentinel lymph node detection (sln) with a hand-held gamma-counter, with scintigraphic imaging, in patients with cancer of the head and neck",Designated/Approved,,,"Guiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.",6/13/2014,6/13/2021,"Guiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.","Cardinal Health 414, LLC",7200 Cardinal Pl,,Dublin,Ohio,' 43017 ' ,United States,427814,,,
6566,Technetium Tc99m anti-melanoma murine monoclonal antibody,,6/2/1987,"for use in detecting, by imaging, metastases of malignant melanoma.",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,NeoRx Corporation,410 West Harrison,,Seattle,Washington,' 98119 ' ,United States,18387,noma,"""gard:0004001""",
6567,Technetium Tc99m murine monoclonal antibody (IgG2a) to B cell,,4/7/1992,"diagnostic imaging in the evaluation of the extent of disease in patients with histologically confirmed diagnosis of non-hodgkin's b-cell lymphoma, acute b-cell lymphoblastic leukemia (in children and adults), and chronic b-cell lymphocytic leukemia.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,65492,lymphoma,"""gard:0020548""",
6568,Technetium Tc99m murine monoclonal antibody to hCG,,8/7/1989,detection of hcg producing tumors such as germ cell and trophoblastic cell tumors.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,35689,,,
6569,Technetium Tc99m murine monoclonal antibody to human AFP,,8/1/1989,detection of alpha-fetoprotein producing germ cell tumors.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,35489,germ cell tumor,"""gard:0018797""",
6570,Technetium Tc99m murine monoclonal antibody to human alpha-fetoprotein,,8/1/1989,detection of hepatocellular carcinoma and hepatoblastoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,35389,hepatocellular carcinoma,"""gard:0016773""",
6571,Technetium Tc99m rh-Annexin V,,11/3/2000,"diagnosis or assessment of rejection status in heart, heart-lung, single lung, or bilateral lung transplants.",Designated,,Not FDA Approved for Orphan Indication,,,,,Theseus Imaging Corporation,124 Mount Auburn Street,Suite 200 North,Cambridge,Massachusetts,' 02138 ' ,United States,135500,,,
6572,"Technetium Tc99m sulfur colloid injection, lyophilized",Technetium Tc99m Sulfur Colloi,3/17/2009,for localization of sentinel lymph nodes in patients with melanoma,Designated/Approved,,,Localization of lymph nodes draining a primary tumor in patients with melanoma when used with a hand-held gamma counter,8/13/2012,8/13/2019,,"Pharmalucence, Inc.",10 DeAngelo Drive,,Bedford,Massachusetts,' 01730 ' ,United States,271608,noma,"""gard:0004001""",
6573,technetium-99m radiolabeled heparin,,3/25/2020,diagnostic for the management of eosinophilic esophagitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"NexEos Diagnostics, Inc.","640 Lee Road, Suite 115",,Wayne,Pennsylvania,' 19087 ' ,United States,730020,,,
6574,teclistamab-cqyv,Tecvayli,11/24/2020,treatment of multiple myeloma,Designated/Approved,,,"Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody",10/25/2022,10/25/2029,"Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody","Janssen Biotech, Inc.",920 Route 202,,Raritan,New Jersey,' 08869 ' ,United States,782920,multiple myeloma,"""gard:0007108""",
6575,tecovirimat,,12/18/2006,post exposure prophylaxis against smallpox,Designated,,Not FDA Approved for Orphan Indication,,,,,"SIGA Technologies, Inc.",4575 SW Research Way,Suite 230,Corvallis,Oregon,' 97333 ' ,United States,233506,,,
6576,tecovirimat,TPOXX,12/27/2006,treatment of smallpox,Designated/Approved,,,Treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 3 kg,5/18/2022,,,"SIGA Technologies, Inc.",4575 SW Research Way,Suite 230,Corvallis,Oregon,' 97333 ' ,United States,229806,,,
6577,tecovirimat,TPOXX,12/27/2006,treatment of smallpox,Designated/Approved,,,TPOXX® is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg.,7/13/2018,7/13/2025,TPOXX® is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg.,"SIGA Technologies, Inc.",4575 SW Research Way,Suite 230,Corvallis,Oregon,' 97333 ' ,United States,229806,,,
6578,tecovirimat,,9/29/2010,treatment of orthopoxvirus infections.,Designated,,Not FDA Approved for Orphan Indication,,,,,"SIGA Technologies, Inc.",4575 SW Research Way,,Corvallis,Oregon,' 97333 ' ,United States,316210,,,
6579,Teduglutide,,12/8/2020,prevention of acute graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,9 Meters Biopharma Inc.,"8480 Honeycutt Road, Suite 120",,Raleigh,North Carolina,' 27615 ' ,United States,784820,graft versus host disease,"""gard:0016642""",
6580,teduglutide [rDNA origin]; teduglutide [rDNA origin],GATTEX; GATTEX,6/29/2000,treatment of short bowel syndrome.,Designated/Approved,,,GATTEX® is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support.,5/16/2019,5/16/2026,Treatment of pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support.,"Takeda Pharmaceuticals U.S.A., Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,126999,short bowel syndrome,"""gard:0001502""",
6581,teduglutide [rDNA origin]; teduglutide [rDNA origin],GATTEX; GATTEX,6/29/2000,treatment of short bowel syndrome.,Designated/Approved,,,Treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support,12/21/2012,12/21/2019,,"Takeda Pharmaceuticals U.S.A., Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,126999,short bowel syndrome,"""gard:0001502""",
6582,Tegafur/gimeracil/oteracil,,7/20/2006,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Taiho Oncology, Inc.",101 Carnegie Center,Suite 101,Princeton,New Jersey,' 08540 ' ,United States,225006,,,
6583,Tegavivint,,12/20/2022,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Iterion Therapeutics,2450 Holcombe Blvd. East,Suite X,Houston,Texas,' 77021 ' ,United States,923322,hepatocellular carcinoma,"""gard:0016773""",
6584,tegavivint,,11/22/2022,treatment of osteosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Iterion Therapeutics, Inc",2450 West Holcombe Boulevard,,Houston,Texas,' 77021 ' ,United States,912222,osteosarcoma,"""gard:0007284""",
6585,tegavivint,,4/11/2018,treatment of desmoid tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,Beta Cat Pharmaceuticals,"2450 Holcombe Blvd, Suite J606",,Houston,Texas,' 77021 ' ,United States,634118,desmoid tumor,"""gard:0001820""",
6586,tegoprubart,,6/7/2022,prevention of allograft rejection in pancreatic islet cell transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,"Eledon Pharmaceuticals, Inc.",19900 MacArthur Blvd.,Suite 550,Irvine,California,' 92612 ' ,United States,881622,,,
6587,tegoprubart,,4/4/2018,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,"Eledon Pharmaceuticals, Inc.",19900 MacArthur Blvd,Suite 550,Irvine,California,' 92612 ' ,United States,633818,amyotrophic lateral sclerosis,"""gard:0005786""",
6588,teicoplanin,,5/24/2018,treatment of staphylococcus aureus lung infections in patients with cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Neupharma srl,8 Piazza del Duomo,,Imola,Emilia-Romagna,' ' ,Italy,631418,cystic fibrosis,"""gard:0006233""",
6589,Telacebec,,1/13/2021,treatment of buruli ulcer,Designated,,Not FDA Approved for Orphan Indication,,,,,"The Global Alliance for TB Drug Development, Inc.","80 Pine Street, 20th Floor",,New York,New York,' 10005 ' ,United States,793920,,,
6590,telatinib,,5/17/2010,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,ACT Biotech Inc.,717 market St #650,Suite 650,San Francisco,California,' 94103 ' ,United States,307410,,,
6591,telitacicept,,9/27/2022,treatment of myasthenia gravis,Designated,,Not FDA Approved for Orphan Indication,,,,,"RemeGen Co., Ltd.","58 Middle Beijing Road, Yantai Development Area",,Yantai,ShangDong,' 264006 ' ,China,901522,myasthenia gravis,"""gard:0007122""",
6592,Telomerase Specific Replication-competent Oncolytic Adenovirus,,6/1/2020,treatment of esophageal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Oncolys BioPharma Inc.,4-1-28 Toranomon,Minato-ku,Tokyo,,' ' ,Japan,694719,,,
6593,telotristat etiprate,Xermelo,3/9/2012,treatment of carcinoid syndrome in patients with neuroendocrine tumors,Designated/Approved,,,Treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.,2/28/2017,2/28/2024,Treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.,"TerSera Therapeutics, LLC","520 Lake Cook Road, Suite 500",,Deerfield,Illinois,' 60015 ' ,United States,266308,carcinoid syndrome,"""gard:0005994""",
6594,temocillin sodium,,4/21/2004,treatment of pulmonary infections caused by burkholderia cepacia,Designated,,Not FDA Approved for Orphan Indication,,,,,Belpharma S.A.,"5, Rue de Bonnevoie",L-2160,Luxembourg,,' ' ,Germany,182903,,,
6595,Temoporfin,,10/28/1999,"palliative treatment of recurrent, refractory or second primary squamous cell carcinomas of the head and neck in patients considered to be incurable with surgery or radiotherapy.",Designated,,Not FDA Approved for Orphan Indication,,,,,Biolitec Pharma Ireland Ltd.,United Drug House,,Dublin,,' ' ,Ireland,128899,noma,"""gard:0004001""",
6596,Temozolomide,,10/14/1998,treatment of advanced metastatic melanoma.,Designated/Designation Withdrawn or Revoked,6/20/2017,Not FDA Approved for Orphan Indication,,,,,Merck & Company,2000 Galloping Hill Rd.,,Kenilworth,New Jersey,' 07033 ' ,United States,117198,noma,"""gard:0004001""",
6597,temozolomide,,11/25/2015,treatment glioblastoma multiforme in pediatric patients,Designated,,Not FDA Approved for Orphan Indication,,,,,"AmpliPharm Pharmaceuticals, LLC",970 Peachtree Industrial Boulevard,Suite 100,Suwanee,Georgia,' 30024 ' ,United States,497215,glioblastoma,"""gard:0002491""",
6598,Temozolomide,,8/1/2019,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,ORPHELIA Pharma,85 Blvd Saint-Michel,,Paris,,' ' ,France,698519,neuroblastoma,"""gard:0007185""",
6599,Temozolomide,,10/18/2004,treatment of newly diagnosed high grade glioma,Designated/Designation Withdrawn or Revoked,6/20/2017,Not FDA Approved for Orphan Indication,,,,,Merck & Company,2000 Galloping Hill Road,,Kenilworth,New Jersey,' 07033 ' ,United States,193904,,,
6600,temozolomide,Temodar,10/5/1998,treatment of recurrent malignant glioma.,Designated/Approved,,,"Treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse who have experienced disease progression on a drug regimen containing a nitrosourea and procarbazine",8/11/1999,8/11/2006,,Schering-Plough Research Institute,2000 Galloping Hill Rd.,,Kenilworth,New Jersey,' 07033 ' ,United States,116798,,,
6601,temozolomide,Temodar,10/5/1998,treatment of recurrent malignant glioma.,Designated/Approved,,,Treatment of adult patients with newly diagnosed glioblastoma multiforme concomitatly with radiotherapy and then as maintenance treatment,3/15/2005,3/15/2012,,Schering-Plough Research Institute,2000 Galloping Hill Rd.,,Kenilworth,New Jersey,' 07033 ' ,United States,116798,,,
6602,Tempol,,7/21/2021,treatment of ataxia telangiectasia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Matrix Biomed, Inc.",2600 Michelson Dr.,Suite 1700,Irvine,California,' 92612 ' ,United States,827721,,,
6603,Temsirolimus,Torisel,12/16/2004,treatment of renal cell carcinoma,Designated/Approved,,,Treatment of advanced renal cell carcinoma,5/30/2007,5/30/2014,,"Wyeth Pharmaceuticals, Inc.",P. O. Box 8299,,Phildelphia,Pennsylvania,' 19101 ' ,United States,196404,renal cell carcinoma,"""gard:0013215""",
6604,tenalisib,,4/4/2018,treatment of cutaneous t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Rhizen Pharmaceuticals SA,40 Rue Fritz-Courvoisier,,La Chaux-de-Fonds,Neuchâtel,' ' ,Switzerland,630618,lymphoma,"""gard:0020548""",
6605,tenapanor hydrochloride,,11/14/2023,treatment of pediatric hyperphosphatemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ardelyx, Inc.","400 Fifth Avenue, Suite 210",,Waltham,Massachusetts,' 02451 ' ,United States,632118,,,
6606,tenecteplase,,5/15/2009,restore function to hemodialysis catheters,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,276709,,,
6607,Teniposide,Vumon for injection,11/1/1984,treatment of refractory childhood acute lymphocytic leukemia.,Designated/Approved,,,Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.,7/14/1992,7/14/1999,,Bristol-Myers Squibb Pharmaceutical Research Institute,5 Research Parkway,P.O. Box 5100,Wallingford,Connecticut,' 06492 ' ,United States,883,,,
6608,tenofovir,Viread,3/17/2009,treatment of pediatric hiv infection.,Designated/Approved,,,Treatment of HIV infection in combination with other antiretroviral agents in patients 12 to less than 18 years of age,3/24/2010,3/24/2017,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster city,California,' 94404 ' ,United States,276209,,,
6609,tenofovir disoproxil fumarate,,9/27/2016,prevention of mother to child transmission of hepatitis b virus,Designated/Designation Withdrawn or Revoked,9/12/2019,Not FDA Approved for Orphan Indication,,,,,"Gilead Sciences, Inc.",333 Lakeside Drive,,Foster City,California,' 94404 ' ,United States,538416,,,
6610,tenofovir exalidex,,2/20/2018,treatment of pediatric chronic hepatitis b infection (age 0 through 11 years of age),Designated,,Not FDA Approved for Orphan Indication,,,,,"ContraVir Pharmaceuticals, Inc.",399 Thornall Street,First Floor,Edison,New Jersey,' 08837 ' ,United States,583917,,,
6611,teplizumab,,9/29/2006,treatment of recent-onset type i diabetes,Designated,,Not FDA Approved for Orphan Indication,,,,,"Provention Bio, Inc.",Box 666,,Oldwick,New Jersey,' 08858 ' ,United States,229606,,,
6612,tepotinib,Tepmetko,10/26/2020,treatment of non-small cell lung cancer with met genomic tumor aberrations,Designated/Approved,,,treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations,2/3/2021,2/3/2028,treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,679719,small cell lung cancer,"""gard:0009344""",
6613,Teprasiran,,12/23/2009,prophylaxis of delayed graft function in renal transplant patients,Designated,,Not FDA Approved for Orphan Indication,,,,,"Quark Pharmaceuticals, Inc.","7999 Gateway Boulevard, Suite 310",,Newark,California,' 94560 ' ,United States,296509,,,
6614,teprotumumab,,5/6/2013,treatment of active thyroid eye disease,Designated/Approved,,,TEPEZZA is indicated for the treatment of Thyroid Eye Disease.,1/21/2020,1/21/2027,For the treatment of active Thyroid Eye Disease,Horizon Therapeutics Ireland DAC,"Connaught House, 1st Floor",1 Burlington Road,Dublin,Ireland,' DO4 C5Y6 ' ,Ireland,387812,,,
6615,terguride,,5/2/2008,treatment of pulmonary arterial hypertension,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,ErgoNex Pharma GmbH,Ruetistr. 20,,CH-9050 Appenzell,,' ' ,Switzerland,255007,pulmonary arterial hypertension,"""gard:0007501""",
6616,terguride,,5/17/2013,treatment of systemic sclerosis,Designated/Designation Withdrawn or Revoked,10/13/2020,Not FDA Approved for Orphan Indication,,,,,Medac GmbH,TheaterstraBe 6+,,Wedel,,' ' ,Germany,380512,systemic sclerosis,"""gard:0009748""",
6617,Teriparatide,,10/28/1999,treatment of idiopathic osteoporosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biomeasure, Inc.",27 Maple St.,,Milford,Massachusetts,' 01757 ' ,United States,127099,,,
6618,teriparatide,,4/18/2014,treatment of hypoparathyroidism,Designated,,Not FDA Approved for Orphan Indication,,,,,"Entera Bio, Ltd.","Kiryat Hadassah Minrav Bldg, 5th Floor",P. O. Box 12117,Jeusalem,,' ' ,Israel,425814,,,
6619,Teriparatide,Parathar,1/9/1987,diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.,Designated/Approved,,,,12/23/1987,12/23/1994,,"Rhone-Poulenc Rorer Pharmaceuticals, Inc.",500 Arcola Road,,Collegeville,Pennsylvania,' 19426 ' ,United States,14486,pseudohypoparathyroidism,"""gard:0010758""",
6620,terlipressin,,9/8/2016,treatment of ascites due to all etiologies except cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Bio Vie Inc.,100 Cummings Center,Suite 247-C,Beverly,Massachusetts,' 01915 ' ,United States,534216,,,
6621,Terlipressin,,3/6/1986,treatment of bleeding esophageal varices.,Designated,,Not FDA Approved for Orphan Indication,,,,,Ferring Pharmaceuticals Inc.,100 Interpace Parkway,,Parsippany-Troy Hills,New Jersey,' 07054 ' ,United States,11785,,,
6622,terlipressin,Terlivaz,10/29/2004,treatment of hepatorenal syndrome,Designated/Approved,,,To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function,9/14/2022,9/14/2029,To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function,Mallinckrodt Pharmaceuticals Ireland Ltd,College Business & Technology Park,Cruiserath Road,"Blanchardstown, Dublin, Ireland D15 TX2V",,' ' ,Ireland,191804,,,
6623,terlipressin,,11/21/2018,treatment of hepatorenal syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,BioVie Inc.,100 Cummings Center,Suite 247-C,Beverly,Massachusetts,' 01915 ' ,United States,580417,,,
6624,tesetaxel,,12/22/2008,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Genta Inc.,200 Connell Drive,,Berkeley Heights,New Jersey,' 07922 ' ,United States,272508,,,
6625,tesetaxel,,11/21/2008,"treatment of stages iib, iic, iii, and stage iv melanoma",Designated,,Not FDA Approved for Orphan Indication,,,,,"Genta, Inc.",200 Connell Drive,,Berkley Heights,New Jersey,' 07922 ' ,United States,269108,noma,"""gard:0004001""",
6626,Tesevatinib,,3/1/2016,treatment of patients with autosomal recessive polycystic kidney disease (arpkd),Designated,,Not FDA Approved for Orphan Indication,,,,,"Kadmon Corporation, LLC",450 East 29th Street,,New York,New York,' 10016 ' ,United States,506715,autosomal recessive polycystic kidney disease,"""gard:0008378""",
6627,tesevatinib,,5/26/2021,treatment of autosomal dominant polycystic kidney disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Kadmon Corporation,450 East 29th Street,,New York,New York,' 10016 ' ,United States,802420,autosomal dominant polycystic kidney disease,"""gard:0010413""",
6628,tesevatinib,,8/3/2017,treatment of non-small cell lung cancer with epithelial growth factor receptor-activating mutations,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kadmon Corporation, LLC",450 East 29th Street,,New York,New York,' 10016 ' ,United States,584917,small cell lung cancer,"""gard:0009344""",
6629,Tesofensine plus metoprolol in a fixed-dose combination,,7/21/2021,treatment of hypothalamic obesity,Designated,,Not FDA Approved for Orphan Indication,,,,,Saniona S/A,Smedeland 26B,,Glostrup,,' DK-2600 ' ,Denmark,804220,,,
6630,Tesofensine plus metoprolol in a fixed-dose combination,,3/2/2021,treatment of prader-willi syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Saniona S/A,Smedeland 26B,,Glostrup,,' DK-2600 ' ,Denmark,804320,prader-willi syndrome,"""gard:0005575""",
6631,Testosterone,,2/5/1996,treatment of weight loss in aids patients with hiv-associated wasting.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Unimed Pharmaceuticals, Inc.",901 Sawyer Rd.,,Marietta,Georgia,' 30062 ' ,United States,94595,,,
6632,Testosterone,,9/22/1997,for use as physiologic testosterone replacement in androgen deficient hiv+ patients with an associated weight loss.,Designated,,Not FDA Approved for Orphan Indication,,,,,Watson Laboratories,Research Park,417 Wakara Way,Salt Lake City,Utah,' 84108 ' ,United States,104197,,,
6633,testosterone,,1/12/2022,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Sarcomed AB,Störtloppsvägen 25,,Stockholm,,' 12947 ' ,Sweden,855921,muscular dystrophy,"""gard:0007922""",
6634,Testosterone propionate ointment 2%,,7/31/1991,treatment of vulvar dystrophies.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Star Pharmaceuticals, Inc.",1990 N.W. 44th Street,,Pompano Beach,Florida,' 33064 ' ,United States,57691,,,
6635,Testosterone sublingual,,1/16/1991,treatment of constitutional delay of growth and puberty in boys.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Bio-Technology General Corp.,"70 Wood Avenue, South",,Iselin,New Jersey,' 08830 ' ,United States,52590,,,
6636,testosterone undecanoate (oral),,2/13/2013,treatment of constitutional delay in growth and puberty in adolescent boys (14-17 yrs of age),Designated,,Not FDA Approved for Orphan Indication,,,,,"Marius Pharmaceuticals, LLC",8601 Six Forks Road,Suite 630,Raleigh,North Carolina,' 27615 ' ,United States,366012,,,
6637,tetra substituted prophyrin derivative containing manganese (III),,1/17/2014,for use in patients exposed to radiation following a nuclear accident or detonation in order to treat or mitigate acute radiation syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aeolus Pharmaceuticals, Inc.",26361 Crown Valley Parkway,Suite 150,Mission Viejo,California,' 92691 ' ,United States,354611,acute radiation syndrome,"""gard:0021896""",
6638,tetra-substituted porphyrin derivative containing manganese (III),,3/16/2015,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Aeolus Pharmaceuticals,26361 Crown Valley Parkway,Suite 150,Mission Viejo,California,' 92691 ' ,United States,465414,idiopathic pulmonary fibrosis,"""gard:0008609""",
6639,tetrabenazine,,7/1/2009,"treatment of tourette's syndrome in school-age children, ages 5-16",Designated,,Not FDA Approved for Orphan Indication,,,,,Valeant International (Barbados) SRL,Welches Christ Church,,Barbados,,' ' ,Barbados,278109,,,
6640,Tetrabenazine,,5/12/1998,treatment of moderate/severe tardive dyskinesia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Prestwick Pharmaceuticals, Inc.","1825 K Street, NW",Suite 1475,Washington,District of Columbia,' 20006 ' ,United States,109797,,,
6641,Tetrabenazine,Xenazine,12/11/1997,treatment of huntington's disease,Designated/Approved,,,Treatment of chorea associated with Huntington's disease,8/15/2008,8/15/2015,,"Prestwick Pharmaceuticals, Inc",1825 K Street NW,Suite 1475,Washington,District of Columbia,' 20006 ' ,United States,108897,,,
6642,tetracosactide hexaacetate (beta 1-24-corticotrophin),,10/31/2012,treatment of infantile spasms,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cerium Pharmaceuticals, Inc.",817-B Linsdale Street,,Gaithersburg,Maryland,' 20878 ' ,United States,378212,,,
6643,"Tetrahydro-2H-pyran-4-yl 7-(2-(cyclopropanecarboxamido)- imidazo[1,2-a]pyridin-6-yl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-1-carboxylate hydrochloride",,12/11/2023,treatment of acute graft-versus-host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Accro Bioscience (Suzhou) Limited,"Unit 708, Building B1, No.218, Xinghu Street, Suzhou Industrial Park",,Suzhou,Jiangsu,' 215123 ' ,China,973723,,,
6644,"tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride",,6/20/2016,treatment of infantile spasms,Designated,,Not FDA Approved for Orphan Indication,,,,,Anavex Life Sciences Corp.,51 West 52nd Street,7th Floor,New York,New York,' 10019 ' ,United States,524416,,,
6645,Tetrahydronaphthyl urea based selective TRPV1 antagonist,,7/13/2022,treatment of erythromelalgia,Designated,,Not FDA Approved for Orphan Indication,,,,,Pila Pharma AB,Västergatan 1,,Malmö,,' 211 21 ' ,Sweden,890622,,,
6646,Tetraiodothyroacetic acid,,5/1/2000,suppression of thyroid stimulating hormone in patients with well-differentiated cancer of the thyroid gland.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Danforth, Jr., MD, Elliot",University of Vermont,84 Beartown Rd.,Underhill,Vermont,' 05489 ' ,United States,133100,,,
6647,tetrandrine,,12/13/2016,treatment of acute myeloid leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Escend Pharmaceuticals, Inc.",3475 Edison Way,Suite R,Menlo Park,California,' 94025 ' ,United States,545716,acute myeloid leukemia,"""gard:0012757""",
6648,tetrandrine,,5/19/2016,treatment of chronic myeloid leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Escend Pharmaceuticals, Inc.",3475 Edison Way,Suite R,Menlo Park,California,' 94025 ' ,United States,518916,chronic myeloid leukemia,"""gard:0006105""",
6649,tetravalent bispecific chimeric anti-human CD30 x anti-human CD16A recombinant antibody construct,,4/1/2020,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Affimed GmbH,Im Neuenheimer Feld 582,,Heidelberg,,' ' ,Germany,736120,lymphoma,"""gard:0020548""",
6650,Tetravalent recombinant humanized IgG1 agonist antibody targeting the human TRAIL death receptor 5 (DR5).,,11/24/2021,treatment of chondrosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Inhibrx, Inc.",11025 North Torrey Pines Road,Suite 140,La Jolla,California,' 92037 ' ,United States,848721,chondrosarcoma,"""gard:0006055""",
6651,tetravalent tandem diabody binding both CD3 and CD33,,8/17/2017,treatment of patients with acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,"Amphivena Therapeutics, Inc.",601 Gateway Boulevard,Suite 350,South San Francisco,California,' 94080 ' ,United States,593317,acute myeloid leukemia,"""gard:0012757""",
6652,Tezacaftor,,4/24/2014,treatment of cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,427414,cystic fibrosis,"""gard:0006233""",
6653,tezacaftor/ivacaftor; ivacaftor,Symdeko,6/15/2017,treatment of cystic fibrosis (cf),Designated/Approved,,,treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence,12/21/2020,12/21/2027,"treatment of cystic fibrosis (CF) in patients age 6 years and older who have at least one of the additional mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that have been identified as responsive to tezacaftor/ivacaftor based on in vitro data and identified in the approval on December 21, 2020",Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,577517,cystic fibrosis,"""gard:0006233""",
6654,tezacaftor/ivacaftor; ivacaftor,Symdeko,6/15/2017,treatment of cystic fibrosis (cf),Designated/Approved,,,SYMDEKO? is indicated for the treatment of patients with cystic fibrosis (CF) age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.,6/21/2019,6/21/2026,For the treatment of patients with cystic fibrosis (CF) age 6 years to less than 12 years who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence,Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,577517,cystic fibrosis,"""gard:0006233""",
6655,tezacaftor/ivacaftor; ivacaftor,Symdeko,6/15/2017,treatment of cystic fibrosis (cf),Designated/Approved,,,"SYMDEKO a combination of tezacaftor and ivacaftor, is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence",2/12/2018,2/12/2025,"SYMDEKO a combination of tezacaftor and ivacaftor, is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence",Vertex Pharmaceuticals Inc.,50 Northern Avenue,,Boston,Massachusetts,' 02210 ' ,United States,577517,cystic fibrosis,"""gard:0006233""",
6656,Tezacitabine,,1/27/2003,treatment of adenocarcinoma of the esophagus and stomach,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sanofi-Aventis US, Inc.",9 Great valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,164002,adenocarcinoma of the esophagus,"""gard:0016927""",
6657,tezepelumab,,10/7/2021,treatment of eosinophilic esophagitis,Designated,,Not FDA Approved for Orphan Indication,,,,,AstraZeneca Pharmaceuticals LP,1800 Concord Pike,P.O. Box 8355,Wilmington,Delaware,' 19803 ' ,United States,839721,,,
6658,"TGTX-102, an adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human SURF1 protein.",,10/20/2020,treatment of surf1-associated leigh syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Taysha Gene Therapies, Inc.",BioCenter at UT Southwestern,2280 Inwood Road,Dallas,Texas,' 75235 ' ,United States,773520,h syndrome,"""gard:0010239""",
6659,Thalidomide,,3/5/1990,treatment of graft versus host disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Andrulis Research Corporation,"11800 Baltimore Avenue, Suite 113",,Beltsville,Maryland,' 20705 ' ,United States,43790,graft versus host disease,"""gard:0016642""",
6660,Thalidomide,,5/15/1995,"treatment and prevention of recurrent aphthous ulcers in severely, terminally immunocompromised patients.",Designated,,Not FDA Approved for Orphan Indication,,,,,Andrulis Research Corporation,"11800 Baltimore Avenue, Suite 113",,Beltsville,Maryland,' 20705 ' ,United States,82594,,,
6661,Thalidomide,,11/15/1988,treatment and maintenance of reactional lepromatous leprosy.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pediatric Pharmaceuticals, Inc.",718 Bradford Avenue,,Westfield,New Jersey,' 07090 ' ,United States,32188,leprosy,"""gard:0006886""",
6662,thalidomide,,9/19/1988,1. treatment of graft versus host disease in patients receiving bone marrow transplantation 2. prevention of graft versus host disease in patients receiving bone marrow transplantation,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pediatric Pharmaceuticals, Inc.",718 Bradford Avenue,,Westfield,New Jersey,' 07090 ' ,United States,30788,graft versus host disease,"""gard:0016642""",
6663,Thalidomide,,5/1/1995,"treatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients.",Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,P.O. Box 4914,7 Powder Horn Srive,Warren,New Jersey,' 07059 ' ,United States,80194,,,
6664,Thalidomide,,1/12/1993,treatment of the clinical manifestations of mycobacterial infection caused by mycobacterium tuberculosis and non-tuberculous mycobacteria.,Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,P.O. Box 4914,7 Powder Horn Srive,Warren,New Jersey,' 07059 ' ,United States,72092,tuberculosis,"""gard:0007827""",
6665,Thalidomide,thalomid,10/14/1998,treatment of multiple myeloma,Designated/Approved,,,Treatment of patients with newly diagnosed multiple myeloma,5/25/2006,5/25/2013,,Celgene Corporation,P.O. Box 4914,7 Powder Horn Srive,Warren,New Jersey,' 07059 ' ,United States,115598,multiple myeloma,"""gard:0007108""",
6666,Thalidomide,,7/29/1998,treatment of kaposi's sarcoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,P.O. Box 4914,7 Powder Horn Srive,Warren,New Jersey,' 07059 ' ,United States,114998,,,
6667,Thalidomide,,4/6/1999,treatment of crohn's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,P.O. Box 4914,7 Powder Horn Srive,Warren,New Jersey,' 07059 ' ,United States,121898,,,
6668,Thalidomide,Thalomid,7/26/1995,treatment of erythema nodosum leprosum.,Designated/Approved,,,Acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences.,7/16/1998,7/16/2005,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,90795,,,
6669,Thalidomide,,3/11/1996,treatment of hiv-associated wasting syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,P.O. Box 4914,7 Powder Horn Srive,Warren,New Jersey,' 07059 ' ,United States,94995,,,
6670,Thalidomide,,3/5/1990,prevention of graft versus host disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,Andrulis Research Corporation,"11800 Baltimore Avenue, Suite 113",,Beltsville,Maryland,' 20705 ' ,United States,43890,graft versus host disease,"""gard:0016642""",
6671,Thalidomide,,2/27/1998,treatment of primary brain malignancies.,Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,P.O. Box 4914,7 Powder Horn Srive,Warren,New Jersey,' 07059 ' ,United States,110197,,,
6672,thalidomide,,9/27/2004,treatment of myelodysplastic syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,187204,myelodysplastic syndrome,"""gard:0007132""",
6673,thalidomide,,7/19/2017,treatment of hereditary hemorrhagic telangiectasia,Designated,,Not FDA Approved for Orphan Indication,,,,,PlumeStars s.r.l.,Via Lago Scuro11,,Parma,,' ' ,Italy,585417,hereditary hemorrhagic telangiectasia,"""gard:0006626""",
6674,Thawed donor matched banked umbilical cord blood enriched by cell sorting to produce a subpopulation expressing high levels of intracellular aldehyde dehydrogenase,,10/23/2008,to improve patient outcomes by decreasing time to platlet and neutrophil engraftment in patients with inherited metabolic diseases (imd) undergoing umbilical cord blood transplantation.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aldagen, Inc.",2810 Meridian Parkway,,Durham,North Carolina,' 27713 ' ,United States,259908,,,
6675,Theranost 68 Ga RGD,,10/1/2014,a diagnostic for the management of moyamoya disease (mmd),Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC (AIP)",3651 FAU Blvd.,,Boca Raton,Florida,' 33467 ' ,United States,452214,moyamoya disease,"""gard:0007064""",
6676,Theranost 68Ga RGD,,1/26/2015,diagnostic for the clinical management of patients with tuberculosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",3651 FAU Blvd.,,Boca Raton,Florida,' 33467 ' ,United States,461514,tuberculosis,"""gard:0007827""",
6677,theranost 68Ga-RGD,,12/8/2014,diagnostic for clinical management of patients with neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",Florida Atlantic University Research Park,3651 FAU Blvd,Boca Raton,Florida,' 33431 ' ,United States,454814,neuroblastoma,"""gard:0007185""",
6678,Therapeutic Inducers of Natural Killer cell Killing Immunotherapy expanded from cord blood-derived hematopoietic progenitors,,1/12/2023,treatment of acute lymphoblastic leukemia (all),Designated,,Not FDA Approved for Orphan Indication,,,,,Centre Hospitalier Universitaire Sainte-Justine,"3175, chemin de la Côte-Sainte-Catherine",,Montreal,QC,' H3T 1C5 ' ,Canada,920422,acute lymphoblastic leukemia,"""gard:0000522""",
6679,"THIOMAB antibody drug conjugate comprised of humanized IgG1 anti-C-type lectin-like molecule-1 monoclonal antibody and DNA alkylating cross-linking agent pyrrolo [2,1-c][1,4] benzodiazepine dimer",,10/24/2017,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,"mail stop: B-35, 355d",South San Francisco,California,' 94080 ' ,United States,609217,acute myeloid leukemia,"""gard:0012757""",
6680,thiostrepton,,12/14/2021,treatment of mesothelioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"RS Oncology, LLC","One Broadway, 14th Floor",,Cambridge,Massachusetts,' 02142 ' ,United States,851321,,,
6681,Thiotepa,Tepadina,4/2/2007,conditioning treatment prior to hematopoietic stem cell transplantation,Designated/Approved,,,Indicated for reducing the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogenic hematopoietic progenitor (stem) cell transplantation for pediatric patients with class 3 beta-thalassemia,1/26/2017,1/26/2024,Indicated for reducing the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogenic hematopoietic progenitor (stem) cell transplantation for pediatric patients with class 3 beta-thalassemia,ADIENNE S.A.,"Via Zurigo, 46",,Lugano,,' ' ,Switzerland,237807,,,
6682,thioureidobutyronitrile,,11/17/2015,treatment of retinoblastoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Innovation Pharmaceuticals, Inc.",100 Cummings Center,Suite 151-B,Beverly,Massachusetts,' 01915 ' ,United States,502515,retinoblastoma,"""gard:0007563""",
6683,thioureidobutyronitrile,,7/14/2015,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Innovation Pharmaceuticals, Inc.",100 Cummings Center,Suite 151-B,Beverly,Massachusetts,' 01915 ' ,United States,485615,ovarian cancer,"""gard:0007295""",
6684,thioureidobutyronitrile,,1/20/2016,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Innovation Pharmaceuticals, Inc.",100 Cummings Center,Suite 151-B,Beverly,Massachusetts,' 01915 ' ,United States,503815,,,
6685,three-dimensional bioprinted therapeutic liver tissue,,12/21/2017,treatment of alpha-1 antitrypsin deficiency,Designated/Designation Withdrawn or Revoked,11/22/2019,Not FDA Approved for Orphan Indication,,,,,Organovo Inc.,6275 Nancy Ridge Drive,,San Diego,California,' 92121 ' ,United States,617317,,,
6686,Thrombin-preconditioned allogeneic Wharton's Jelly-derived mesenchymal stem cells,,12/28/2023,treatment of neonatal hypoxic ischemic encephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Medinno Inc.,"Room 820, The Reason Valley","66 Gasan-ro-9-gil, Geumcheon-gu",Seoul,,' ' ,South Korea,980223,,,
6687,Thrombin-preconditioned allogeneic Wharton's Jelly-derived mesenchymal stem cells,,1/11/2024,treatment of neonatal intraventricular hemorrhage (ivh),Designated,,Not FDA Approved for Orphan Indication,,,,,Medinno Inc.,"Room 820, The Reason Valley,","66 Gasan-ro-9-gil, Geumcheon-gu,",Seoul,,' ' ,South Korea,982623,,,
6688,Thymalfasin,,3/6/2000,treatment of hepatocellular carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"SciClone Pharmaceuticals, Inc.",950 Tower Lane,Suite 900,Foster city,California,' 94404 ' ,United States,132600,hepatocellular carcinoma,"""gard:0016773""",
6689,Thymalfasin,,1/8/1998,treatment of digeorge anomaly with immune defects.,Designated,,Not FDA Approved for Orphan Indication,,,,,"SciClone Pharmaceuticals, Inc.",901 Mariner's Island Blvd.,,San Mateo,California,' 94404 ' ,United States,109597,noma,"""gard:0004001""",
6690,thymalfasin,,5/3/1991,treatment of chronic active hepatitis b,Designated,,Not FDA Approved for Orphan Indication,,,,,"SciClone Pharmaceuticals, Inc.",950 Tower Lane,Suite 900,Foster City,California,' 94404 ' ,United States,52990,,,
6691,Thymalfasin,,3/13/2006,treatment of stage iib through stage iv malignant melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"SciClone Pharmaceuticals, Inc.",950 Tower Lane,Suite 900,Foster City,California,' 94404 ' ,United States,218806,noma,"""gard:0004001""",
6692,Thymidine phosphorylase-cCPP-PEG,,3/30/2020,treatment of mitochondrial neurogastrointestinal encephalomyopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pierrepont Therapeutics, Inc.",Downstate Technology Center,"760 Parkside Avenue, Suite 327A",Brooklyn,New York,' 11203 ' ,United States,730220,mitochondrial neurogastrointestinal encephalomyopathy,"""gard:0009920""",
6693,thymopentin,,2/4/2011,treatment of sarcoidosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,Mondobiotech Laboratories AG,Herrengasse 21,,Furstentum Liechtenstein,,' ' ,Germany,330010,sarcoidosis,"""gard:0007607""",
6694,Thymosin beta 4,,5/28/2004,treatment of epidermolysis bullosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"HLB Therapeutics Co., Ltd","22nd FL, Parkview Tower","248 Jungjail-ro, Bundang-gu,",Seongnam-si,Gyeonggi-do,' ' ,South Korea,165302,,,
6695,thymosin beta 4,,12/31/2013,treatment of patients with neurotrophic keratopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"ReGenTree, LLC",116 Village Blvd,Suite 200,Princeton,New Jersey,' 08540 ' ,United States,416613,neurotrophic keratopathy,"""gard:0019878""",
6696,Thymoxamine HCl,,11/16/1987,reversal of phenylephrine-induced mydriasis in patients who have narrow anterior angles and are at risk of developing an acute attack of angle-closure glaucoma following mydriasis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Iolab Pharmaceuticals,500 Iolab Drive,,Claremont,California,' 91711 ' ,United States,19887,,,
6697,Thyrotropin alfa,Thyrogen,8/3/2001,"treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid",Designated/Approved,,,For use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer,12/14/2007,12/14/2014,,Genzyme Corporation,One Kendall Square,,Cambridge,Massachusetts,' 02139 ' ,United States,142301,noma,"""gard:0004001""",
6698,Thyrotropin alpha,Thyrogen,2/24/1992,as an adjunct in the diagnosis of thyroid cancer.,Designated/Approved,,,As an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with thyroid cancer.,11/30/1998,11/30/2005,,Genzyme Corporation,One Kendall Square,,Cambridge,Massachusetts,' 02139 ' ,United States,63191,,,
6699,tianeptine,,3/8/2018,treatment of rett syndrome (rtt),Designated,,Not FDA Approved for Orphan Indication,,,,,AMO Pharma Ltd.,"Braeburn, Grove Road",,Godalming,Surrey,' GU7 1RE ' ,United Kingdom,627918,rett syndrome,"""gard:0005696""",
6700,Tiapride,,4/21/1998,treatment of tourette's syndrome.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Sanofi-Synthelabo, Inc.",9 Great Valley Parkway,PO Box 3026,Malvern,Pennsylvania,' 19355 ' ,United States,111798,,,
6701,Tiazofurin (2-Beta-D-ribofuranosyl-4-thiazolecarboxamide),,12/27/2000,chronic myelogenous leukemia (cml),Designated,,Not FDA Approved for Orphan Indication,,,,,Valeant Pharmaceuticals North America,3300 Hyland Avenue,,Costa Mesa,California,' 92626 ' ,United States,139500,,,
6702,Tideglusib,,6/19/2017,treatment of myotonic dystrophy type 1 (dm1),Designated,,Not FDA Approved for Orphan Indication,,,,,AMO Pharma Ltd.,Braebum,Grove Road,Godalming,Surrey,' GU7 IRE ' ,United Kingdom,577417,myotonic dystrophy,"""gard:0010419""",
6703,tigecycline,,10/23/2013,treatment of acute myeloid leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Trillium Therapeutics, Inc.",96 Skyway Avenue,,Toronto,,' ' ,Canada,406313,acute myeloid leukemia,"""gard:0012757""",
6704,Tigilanol Tiglate,,2/8/2024,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,QBiotics Group Limited,"Level 1, 165 Moggill Road",,Taringa,Queensland,' 4068 ' ,Australia,987123,soft tissue sarcoma,"""gard:0004898""",
6705,Tilarginine acetate,,4/11/2005,treatment of cardiogenic shock,Designated,,Not FDA Approved for Orphan Indication,,,,,"Arginox Pharmceuticals, Inc.",120 Constitution Drive,,Menlo Park,California,' 94025 ' ,United States,198804,cardiogenic shock,"""gard:0019362""",
6706,tilorone dihydrochloride,,2/7/2018,treatment of ebola infection,Designated,,Not FDA Approved for Orphan Indication,,,,,"Collaborations Pharmaceuticals, Inc.",840 Main Campus Drive,Lab 3510,Raleigh,North Carolina,' 27606 ' ,United States,624717,,,
6707,tilsotolimod sodium,,6/21/2017,treatment of melanoma stages iib-iv.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Idera Pharmaceuticals, Inc.",505 Eagleview Boulevard,Suite 212,Exton,Pennsylvania,' 19341 ' ,United States,571016,noma,"""gard:0004001""",
6708,tin ethyl etiopurpurin,,11/4/2003,prevention of access graft disease in hemodialysis patients,Designated,,Not FDA Approved for Orphan Indication,,,,,Miravant Medical Technologies,336 Bollay Drive,,Goleta,California,' 93117 ' ,United States,168703,,,
6709,tin ethyl etiopurpurin,,1/16/2018,treatment of basal cell carcinoma nevus syndrome (bccns),Designated,,Not FDA Approved for Orphan Indication,,,,,"Adgero Biopharmaceuticals, Inc",4365 US Highway 1,Suite 211,Princeton,New Jersey,' 08540 ' ,United States,620517,noma,"""gard:0004001""",
6710,Tinidazole,Tindamax,8/20/2003,treatment of amebiasis,Designated/Approved,,,Treatment of intestinal amebiasis and amebic liver abcess caused by E. histolytica in both adults and pediatric patients older than three years of age. It is not indicated for the treatment of asymptomatic cyst passage.,5/17/2004,5/17/2011,,"Presutti Laboratories, Inc.",1607 N. Douglas Ave.,,Arlington Heights,Illinois,' 60004 ' ,United States,173603,,,
6711,tinidazole,Tindamax,4/18/2002,treatment of giardiasis,Designated/Approved,,,Treatment of giardiasis caused by G. duodenalis (also termed G. lamblia) in both adults and pediatric patients older than three years of age,5/17/2004,5/17/2011,,"Presutti Laboratories, Inc.",1607 N. Douglas Ave.,,Arlington Heights,Illinois,' 60004 ' ,United States,155402,,,
6712,tinostamustine hydrochloride,,3/15/2019,treatment of t-cell prolymphocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Mundipharma EDO GmbH,St. Alban-Rheinweg 74,,Basel,Basel City,' ' ,Switzerland,636418,t-cell prolymphocytic leukemia,"""gard:0013731""",
6713,tinostamustine hydrochloride,,4/2/2018,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,12/19/2023,Not FDA Approved for Orphan Indication,,,,,Mundipharma EDO GmbH,74 Sankt Alban-Rheinweg,,Basel,Basel-Stadt,' ' ,Switzerland,634018,multiple myeloma,"""gard:0007108""",
6714,Tiopronin,Thiola,1/17/1986,prevention of cystine nephrolithiasis in patients with homozygous cystinuria.,Designated/Approved,,,"THIOLA EC is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone.",6/28/2019,6/28/2026,,Mission Pharmacal Company,P.O. Box 786099,,San Antonio,Texas,' 78278 ' ,United States,12386,cystinuria,"""gard:0006237""",
6715,Tiopronin,Thiola,1/17/1986,prevention of cystine nephrolithiasis in patients with homozygous cystinuria.,Designated/Approved,,,"Indicated for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification or who have adverse reactions to d-penicillamine.",8/11/1988,8/11/1995,,Mission Pharmacal Company,P.O. Box 786099,,San Antonio,Texas,' 78278 ' ,United States,12386,cystinuria,"""gard:0006237""",
6716,Tiopronin,Thiola,1/17/1986,prevention of cystine nephrolithiasis in patients with homozygous cystinuria.,Designated/Approved,,,"THIOLA is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone.",6/28/2019,6/28/2026,"Indicated in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in pediatric patients between 20 kg and 9 years of age with severe homozygous cystinuria, who are not responsive to these measures alone",Mission Pharmacal Company,P.O. Box 786099,,San Antonio,Texas,' 78278 ' ,United States,12386,cystinuria,"""gard:0006237""",
6717,Tiotropium bromide,,1/8/2008,to improve pulmonary function in conjunction with standard therapy in the management of patients with cystic fibrosis,Designated/Designation Withdrawn or Revoked,5/23/2019,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",P. O. Box 368,900 Ridgebury Road,Ridgefield,Connecticut,' 06877 ' ,United States,241507,cystic fibrosis,"""gard:0006233""",
6718,tipelukast,,10/20/2014,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"MediciNova, Inc.",4275 Executive Square,Suite 300,La Jolla,California,' 92037 ' ,United States,448914,idiopathic pulmonary fibrosis,"""gard:0008609""",
6719,tipifarnib,,6/22/2017,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Paul Maher, MD",10644 Weymouth Street,Suite 104,Bethesda,Maryland,' 20814 ' ,United States,585317,multiple myeloma,"""gard:0007108""",
6720,Tipifarnib,,7/6/2004,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Johnson & Johnson Pharmaceutical Research & Dev.,920 U.S. Highway 202,,Raritan,New Jersey,' 08869 ' ,United States,187104,acute myeloid leukemia,"""gard:0012757""",
6721,tipifarnib,,4/6/2020,treatment of t-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kura Oncology, Inc.","12730 High Bluff Drive, Suite 400",,San Diego,California,' 92130 ' ,United States,730720,lymphoma,"""gard:0020548""",
6722,tiprelestat,,12/28/2012,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,tiakis Biotech AG,Sophienblatt 40,,Kiel,,' D-24103 ' ,Germany,241007,pulmonary arterial hypertension,"""gard:0007501""",
6723,tirabrutinib,,3/21/2023,treatment of primary central nervous system lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ono Pharma USA, Inc",One Main Street,Suite 1050,Cambridge,Massachusetts,' 02142 ' ,United States,930322,lymphoma,"""gard:0020548""",
6724,Tiragolumab,,1/7/2021,treatment of esophageal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Genentech Inc.,"1 DNA Way, MS #45-1A",,South San Francisco,California,' 94080-4990 ' ,United States,792420,,,
6725,tirapazamine,,10/23/2002,treatment of head and neck cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sanofi-Aventis US, Inc.",11 Great Valley Parkway,P. O. Box 3026,Malvern,Pennsylvania,' 19355 ' ,United States,155502,,,
6726,tirapazamine,,11/30/2015,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Teclison Limited,28 Baltusrol Way,,Short Hills,New Jersey,' 07078 ' ,United States,498815,hepatocellular carcinoma,"""gard:0016773""",
6727,tirasemtiv,,3/2/2010,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,Cytokinetics Inc.,280 East Grand Avenue,,South San Francisco,California,' 94080 ' ,United States,301710,amyotrophic lateral sclerosis,"""gard:0005786""",
6728,tiratricol,,1/16/2019,treatment of monocarboxylate 8 transporter (mct8) deficiency (allan-herndon-dudley-syndrome),Designated,,Not FDA Approved for Orphan Indication,,,,,Rare Thyroid Therapeutics,3 Teatergatan,SE-111 48,Stockholm,,' ' ,Sweden,666618,,,
6729,Tiratricol,,8/13/1991,for use in combination with levo-thyroxine to suppress thyroid stimulating hormone in patients with well-differentiated thyroid cancer who are intolerant to adequate doses of levo-thyroxine alone.,Designated,,Not FDA Approved for Orphan Indication,,,,,Laphal Laboratoires,"48 Bis, Rue des Belles-Feuilles",,Paris,,' ' ,France,46890,,,
6730,tiratricol,,2/17/2022,treatment of resistance to thyroid hormone type beta (rth-beta),Designated,,Not FDA Approved for Orphan Indication,,,,,Rare Thyroid Therapeutics International AB,Klara Norra Kyrkogata 26,,Stockhholm,,' SE-111 22 ' ,Sweden,862421,,,
6731,tisagenlecleucel,Kymriah,9/16/2020,treatment of follicular lymphoma,Designated/Approved,,,Treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy,5/27/2022,5/27/2029,Treatment of adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two or more lines of systemic therapy,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,765120,lymphoma,"""gard:0020548""",
6732,Tisagenlecleucel,,3/14/2014,treatment of chronic lymphocytic leukemia,Designated/Designation Withdrawn or Revoked,5/8/2020,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,"One Health Plaza,",Bldg 315 - Room 3650B,East Hanover,New Jersey,' 07936 ' ,United States,422013,,,
6733,tisagenlecleucel-T,Kymriah,2/3/2015,treatment of diffuse large b-cell lymphoma,Designated/Approved,,,"KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma",5/1/2018,5/1/2025,For treatment of adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma after two or more lines of systemic therapy.,Novartis Pharmaceuticals Corporation,"One Health Plaza,",Bldg 315 - Room 3650B,East Hanover,New Jersey,' 07936 ' ,United States,463114,lymphoma,"""gard:0020548""",
6734,Tislelizumab,,3/2/2022,treatment of nasopharyngeal carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc.","1840 Gateway Dr, 3rd Floor",,San Mateo,California,' 94404 ' ,United States,863721,nasopharyngeal carcinoma,"""gard:0007163""",
6735,tislelizumab,,5/14/2020,"treatment of gastric cancer, including cancer of the gastroesophageal junction",Designated,,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc.","1840 Gateway Dr, 3rd Floor",,San Mateo,California,' 94404 ' ,United States,738120,,,
6736,Tislelizumab,,11/20/2019,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc.","1840 Gateway Dr, 3rd Floor",,San Mateo,California,' 94404 ' ,United States,709919,hepatocellular carcinoma,"""gard:0016773""",
6737,tislelizumab-jsgr,Tevimbra,11/6/2019,treatment of esophageal cancer,Designated/Approved,,,"as a single agent, for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor",3/13/2024,3/13/2031,treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor,"BeiGene USA, Inc.",2955 Campus Drive,Suite 200,San Mateo,California,' 94403 ' ,United States,708919,,,
6738,Tissue Plasminogen activator,,4/18/2011,treatment of acute ischemic stroke (ais) in children age 16 years and younger.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Catherine Amlie-Lefond, MD",University of Washington,4800 Sand Point Way NE - M/S B5552,Seattle,Washington,' 98105 ' ,United States,331410,,,
6739,Tissue repair cells obtained from autologous bone marrow expanded ex vivo with a cell production system,,3/13/2006,treatment of osteonecrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aastrom Biosciences, Inc.","Domino's Farms, Lobby K",24 Frank Lloyd Wright Drive,Ann Arbor,Michigan,' 48105 ' ,United States,218906,osteonecrosis,"""gard:0021657""",
6740,Titanium dioxide and bisoctrizole,,5/25/2005,"for the secondary prevention (prevention of lesional induction) of disorders with uv-a and visible light-induced photosensitivity, specifically actinic prurigo, hydroa vacciniforme, solar urticara (su), chronic actinic dermatitis (cad), the cutaneous prop",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Orfagen,CRDPF - LANGLADE,,Toulouse,Cedex,' ' ,France,199204,chronic actinic dermatitis,"""gard:0021506""",
6741,tivantinib,,10/16/2013,treatment of hepatocellular carcinoma,Designated/Designation Withdrawn or Revoked,12/15/2017,Not FDA Approved for Orphan Indication,,,,,Daiichi Sankyo Pharma Development,399 Thornall Street,,Edison,New Jersey,' 08837 ' ,United States,407513,hepatocellular carcinoma,"""gard:0016773""",
6742,Tizanidine HCl,,1/31/1994,treatment of spasticity associated with multiple sclerosis and spinal cord injury.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Athena Neurosciences, Inc.",800 Gateway Boulevard,,South San Francisco,California,' 94080 ' ,United States,79193,spinal cord injury,"""gard:0019109""",
6743,Tobramycin,,6/18/1999,treatment of bronchiectasis patients infected with pseudomonas aeruginosa.,Designated,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corp.,One Health Plaza,Office 315,East Hanover,New Jersey,' 07936 ' ,United States,121098,,,
6744,Tobramycin for inhalation,TOBI,10/13/1994,treatment of bronchopulmonary infections of pseudomonas aeruginosa in cystic fibrosis patients.,Designated/Approved,,,Management of cystic fibrosis patients with P.aeruginosa.,12/22/1997,12/22/2004,,Mylan Specialty LP,781 Chestnut Ridge Road,Regulatory Affairs-Greenbag Road,Morgantown,West Virginia,' 26505 ' ,United States,84494,cystic fibrosis,"""gard:0006233""",
6745,tobramycin liposomal,,5/11/2009,treatment of pulmonary infection due to burkholderia cepacia complex pathogens in cystic fibrosis patients,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Axentis Pharma AG,138 Limmatquai,,Zurich,,' ' ,Switzerland,281709,cystic fibrosis,"""gard:0006233""",
6746,tobramycin liposomal for inhalation,,4/14/2009,treatment of chronic pulmonary infection due to p. aeruginosa in cystic fibrosis patients,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Axentis Pharma AG,138 Limmatquai,,Zurich,,' ' ,Switzerland,278009,cystic fibrosis,"""gard:0006233""",
6747,tocilizumab,Actemra,7/31/2012,treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,Designated/Approved,,,ACTEMRA® (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older,5/11/2018,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,367812,juvenile idiopathic arthritis,"""gard:0018677""",
6748,tocilizumab,Actemra,7/31/2012,treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis,Designated/Approved,,,ACTEMRA® (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older,4/29/2013,4/29/2020,Treatment of active polyarticular juvenile idiopathic arthritis in patients 2 through 16 years of age.,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,367812,juvenile idiopathic arthritis,"""gard:0018677""",
6749,tocilizumab,Actemra,8/1/2017,treatment of chimeric antigen receptor (car) t cell-induced cytokine release syndrome,Designated/Approved,,,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older,8/30/2017,8/30/2024,Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older,"Genentech Inc., a member of the Roche Group",1 DNA Way,MS #355e,South San Francisco,California,' 94080 ' ,United States,589317,,,
6750,tocilizumab,Actemra,4/17/2013,treatment of systemic sclerosis,Designated/Approved,,,slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease,3/4/2021,3/4/2028,slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,381212,systemic sclerosis,"""gard:0009748""",
6751,Tocophersolan oral solution (vitamin E-tpgs),,4/15/1988,treatment of vitamin e deficiency resulting from malabsorption due to prolonged cholestatic hepatobiliary disease.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Sterling Winthrop,9 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,22687,,,
6752,tofersen,Qalsody,9/19/2016,treatment of amyotrophic lateral sclerosis,Designated/Approved,,,treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene,4/25/2023,4/25/2030,treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene,Biogen Inc.,225 Binney St.,,Cambridge,Massachusetts,' 02142 ' ,United States,537216,amyotrophic lateral sclerosis,"""gard:0005786""",
6753,Tolcapone,,12/24/2013,treatment of transthyretin amyloidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Corino Therapeutics, Inc.",57 West 57th Street,18th Floor,New York,New York,' 10019 ' ,United States,413913,amyloidosis,"""gard:0018676""",
6754,tolerogen,,2/5/2015,treatment of myasthenia gravis,Designated/Designation Withdrawn or Revoked,3/11/2019,Not FDA Approved for Orphan Indication,,,,,Toleranzia AB,Arvid Wallgrens backe 20,,Gothenburg,,' ' ,Sweden,462514,myasthenia gravis,"""gard:0007122""",
6755,tolfenamic acid,,7/13/2016,treatment of progressive supranuclear palsy,Designated,,Not FDA Approved for Orphan Indication,,,,,Nasser H. Zawia,83 Castle Rocks Road,,Warwick,Rhode Island,' 02886 ' ,United States,517916,progressive supranuclear palsy,"""gard:0007471""",
6756,tolfenamic acid,,7/13/2016,treatment of frontotemporal dementia,Designated,,Not FDA Approved for Orphan Indication,,,,,Nasser H. Zawia,83 Castle Rocks Road,,Warwick,Rhode Island,' 02886 ' ,United States,517816,frontotemporal dementia,"""gard:0008436""",
6757,tolvaptan,Jynarque,4/6/2012,treatment of autosomal dominant polycystic kidney disease,Designated/Approved,,,JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD),4/23/2018,4/23/2025,JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD),"Otsuka Pharmaceutical Company, Ltd.","2-9, Kanda-Tsukasamachi",,Tokyo,,' ' ,Japan,347311,autosomal dominant polycystic kidney disease,"""gard:0010413""",
6758,Tominersen,,12/29/2015,treatment of huntington's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,499215,,,
6759,topiramate,,2/28/2024,treatment of neonatal seizures,Designated,,Not FDA Approved for Orphan Indication,,,,,PrevEP Inc.,"6410 Rockledge Drive, Suite 610",,Bethesda,Maryland,' 20817 ' ,United States,990623,,,
6760,Topiramate,Topamax,11/25/1992,treatment of lennox-gastaut syndrome.,Designated/Approved,,,As adjunctive therapy in patients two years and older with siezures associated with Lennox-Gastaut syndrome.,8/28/2001,8/28/2008,,"Johnson & Johnson Pharmaceutical R & D, LLC","Route 202, P.O. Box 300",,Raritan,New Jersey,' 08869 ' ,United States,70792,lennox-gastaut syndrome,"""gard:0009912""",
6761,topiramate injection,,7/24/2013,treatment of partial onset or primary generalized tonic-clonic seizures for hospitalized epilepsy patients or epilepsy patients being treated in an emergency care setting who are unable to take oral topiramate,Designated,,Not FDA Approved for Orphan Indication,,,,,"CURx Pharmaceuticals, Inc.",3210 Merryfield Row,,San Diego,California,' 92121 ' ,United States,283909,,,
6762,topotecan liposome injection,,3/21/2024,treatment of merkel cell carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Fujifilm Pharmaceuticals U.S.A., Inc.",One Broadway,,Cambridge,Massachusetts,' 02142 ' ,United States,994323,noma,"""gard:0004001""",
6763,toralizumab,,3/14/2002,treatment of immune thrombocytopenic purpura,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Biogen IDEC Inc.,3030 Callan Road,,San Diego,California,' 92121 ' ,United States,154302,,,
6764,Toremifene,,8/17/1993,treatment of desmoid tumors.,Designated,,Not FDA Approved for Orphan Indication,,,,,Orion Corporation,Orionintie 1,,Espoo,,' ' ,Finland,75393,desmoid tumor,"""gard:0001820""",
6765,Toremifene,Fareston,9/19/1991,hormonal therapy of metastatic carcinoma of the breast.,Designated/Approved,,,Treatment of metastatic breast cancer in postmenopausal women with estrogen positive or receptor unknown tumors.,5/29/1997,5/29/2004,,Orion Corporation,Orionintie 1,,Espoo,,' ' ,Finland,60291,noma,"""gard:0004001""",
6766,Toripalimab,,4/11/2022,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"TopAlliance Biosciences, Inc","9430 Key West Ave, Suite 125",,Rockville,Maryland,' 20850 ' ,United States,869622,small cell lung cancer,"""gard:0009344""",
6767,Toripalimab,,9/15/2020,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"TopAlliance Biosciences, Inc.",9430 Key West Ave,Suite 125,Rockville,Maryland,' 20850 ' ,United States,762720,soft tissue sarcoma,"""gard:0004898""",
6768,Toripalimab,,11/8/2021,treatment of esophageal cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"TopAlliance Biosciences, Inc.","9430 Key West Ave, Suite 125",,Rockville,Maryland,' 20850 ' ,United States,836421,,,
6769,toripalimab in combination with axitinib,,3/25/2020,treatment of mucosal melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"TopAlliance Biosciences, Inc.","9430 Key West Ave, Suite 125",,Rockville,Maryland,' 20850 ' ,United States,730120,noma,"""gard:0004001""",
6770,toripalimab-tpzi,Loqtorzi,5/18/2020,treatment of nasopharyngeal carcinoma,Designated/Approved,,,"In combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC); and as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy",10/27/2023,10/27/2030,"first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC); and for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy","Coherus BioSciences, Inc.","333 Twin Dolphin Drive, Suite 600",,Redwood City,California,' 94065 ' ,United States,738620,nasopharyngeal carcinoma,"""gard:0007163""",
6771,Tosedostat,,12/10/2008,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,2/6/2019,Not FDA Approved for Orphan Indication,,,,,CTI BioPharma Corporation,3101 Western Avenue,Suite 600,Seattle,Washington,' 98121 ' ,United States,272408,acute myeloid leukemia,"""gard:0012757""",
6772,Tositumomab and iodine I 131 tositumomab,Bexxar,5/16/1994,treatment of non-hodgkin's b-cell lymphoma.,Designated/Approved,,,"Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy",6/27/2003,6/27/2010,,GlaxoSmithKline LLC,Corporation Service Company,"2711 Centerville Road, Suite 400",Wilmington,Delaware,' 19808 ' ,United States,79493,lymphoma,"""gard:0020548""",
6773,tovorafenib,Ojemda,9/24/2020,treatment of malignant glioma,Designated/Approved,,,"treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation",4/23/2024,4/23/2031,"treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation","Day One Biopharmaceuticals, Inc.",2000 Sierra Point Parkway,Suite 501,Brisbane,California,' 94005 ' ,United States,768320,,,
6774,trabectedin,,3/29/2005,treatment of patients with ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,' 08869 ' ,United States,199004,ovarian cancer,"""gard:0007295""",
6775,trabectedin,Yondelis,9/30/2004,treatment of soft tissue sarcoma,Designated/Approved,,,For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen,10/23/2015,10/23/2022,For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen,"Janssen Research & Development, LLC",920 Route 202 South,,Raritan,New Jersey,' 08869 ' ,United States,193604,soft tissue sarcoma,"""gard:0004898""",
6776,trabedersen,,6/5/2002,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Oncotelic Inc.,29397 Agoura Road,Suite 107,Agoura Hills,California,' 91301 ' ,United States,155602,,,
6777,trabedersen,,7/21/2009,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,Oncotelic Inc.,29397 Agoura Road,Suite 107,Agoura Hills,California,' 91301 ' ,United States,286709,,,
6778,trabedersen,,8/22/2011,treatment of stage iib through stage iv malignant melanoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Oncotelic Inc.,29397 Agoura Road,Suite 107,Agoura Hills,California,' 91301 ' ,United States,346011,noma,"""gard:0004001""",
6779,trafermin in combination with plasma and platelet rich plasma,,12/21/2017,treatment of alopecia areata in pediatric patients,Designated,,Not FDA Approved for Orphan Indication,,,,,"HCell, Inc.",314 East Highland Mall Boulevard,Suite 406,Austin,Texas,' 78752 ' ,United States,595317,alopecia,"""gard:0018995""",
6780,tralokinumab,,7/24/2012,treatment of idiopathic pulmonary fibrosis,Designated/Designation Withdrawn or Revoked,8/5/2016,Not FDA Approved for Orphan Indication,,,,,MedImmune Ltd.,Milstein Building,Granta Park,Cambridge,,' ' ,United Kingdom,373812,idiopathic pulmonary fibrosis,"""gard:0008609""",
6781,Tramadol hydrochloride,,4/26/2005,management of postherpetic neuralgia,Designated,,Not FDA Approved for Orphan Indication,,,,,"TheraQuest Biosciences, LLC",146 Medinah Drive,,Blue Bell,Pennsylvania,' 19422 ' ,United States,192804,,,
6782,Tramadol hydrochloride,,1/28/2005,treatment of painful hiv-associated neuropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"TheraQuest Biosciences, LLC",146 Medinah Drive,,Blue Bell,Pennsylvania,' 19422 ' ,United States,197004,,,
6783,trametinib,MEKINIST,12/20/2010,treatment of stage iib through stage iv melanoma,Designated/Approved,,,Treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.,5/29/2013,5/29/2020,Treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.,Novartis Pharmaceuticals Corp.,One Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,325410,noma,"""gard:0004001""",
6784,trametinib,Mekinist,6/24/2022,treatment of malignant glioma with braf v600 mutation,Designated/Approved,,,"in combination with dabrafenib, for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy",3/16/2023,3/16/2030,treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy,Novartis Pharmaceuticals Corporation,One Health Plaza,,East Hanover,New Jersey,' 07936-1080 ' ,United States,882722,,,
6785,trametinib and dabrafenib,MEKINIST and TAFINLAR,9/20/2012,treatment of stage iib through iv melanoma.,Designated/Approved,,,MEKINIST (trametinib) in combination with dabrafenib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for MEKINIST in combination with dabrafenib.,1/8/2014,1/8/2021,MEKINIST (trametinib) in combination with dabrafenib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for MEKINIST in combination with dabrafenib.,Novartis Pharmaceuticals Corporation,One Health Plaza,Office 337 A13.5B,East Hanover,New Jersey,' 07936 ' ,United States,376812,noma,"""gard:0004001""",
6786,trametinib and dabrafenib,MEKINIST and TAFINLAR,9/20/2012,treatment of stage iib through iv melanoma.,Designated/Approved,,,"TAFINLAR is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection",4/30/2018,4/30/2025,"MEKINIST (trametinib) and TAFINLAR (dabrafenib) indicated in combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection",Novartis Pharmaceuticals Corporation,One Health Plaza,Office 337 A13.5B,East Hanover,New Jersey,' 07936 ' ,United States,376812,noma,"""gard:0004001""",
6787,trametinib and dabrafenib,MEKINIST and TAFINLAR,9/20/2012,treatment of stage iib through iv melanoma.,Designated/Approved,,,"MEKINIST is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection",4/30/2018,4/30/2025,"MEKINIST (trametinib) and TAFINLAR (dabrafenib) indicated in combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection",Novartis Pharmaceuticals Corporation,One Health Plaza,Office 337 A13.5B,East Hanover,New Jersey,' 07936 ' ,United States,376812,noma,"""gard:0004001""",
6788,trametinib and dabrafenib,MEKINIST and TAFINLAR,9/20/2012,treatment of stage iib through iv melanoma.,Designated/Approved,,,TAFINLAR (dabrafenib) in combination with trametinib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for TAFINLAR in combination with trametinib.,1/8/2014,1/8/2021,TAFINLAR (dabrafenib) in combination with trametinib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for TAFINLAR in combination with trametinib.,Novartis Pharmaceuticals Corporation,One Health Plaza,Office 337 A13.5B,East Hanover,New Jersey,' 07936 ' ,United States,376812,noma,"""gard:0004001""",
6789,tranexamic acid,Cyklokapron,12/3/1985,"for use in patients with congenital coagulopathies undergoing surgical procedures, e.g. dental extractions",Designated/Approved/Designation Withdrawn or Revoked,,,Treatment of patients with hemophilia for short term use (2 to 8 days) before and after tooth extraction to reduce or prevent hemorrhage abd reduce the need for replacement therapy,12/30/1986,12/30/1993,,Pharmacia Inc.,P.O. Box 16529,,Columbus,Ohio,' 43216 ' ,United States,8885,,,
6790,tranilast,,12/23/2010,prevention of scarring following glaucoma filtration surgery,Designated,,Not FDA Approved for Orphan Indication,,,,,Esperante Development B.V.,Tolweg 15,,Baarn,,' 3741 LM ' ,Netherlands,311810,,,
6791,Tranilast,,12/2/2003,for the treatment of maligant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Angiogen Pharmaceuticals, Pty. Ltd.","Level 31, ABN AMRO Tower",88 Phillip Street,Sydney,,' ' ,Australia,176803,,,
6792,"trans N-ethyl-2-((4-(7-((4-(ethylsulfonamido)cyclohexyl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)pyrimidin-5-yl)oxy)-5-fluoro-N-isopropylbenzamide sesquifumarate salt",,4/20/2020,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Syndax Pharmaceuticals, Inc.",35 Gatehouse Drive,,Waltham,Massachusetts,' 02451 ' ,United States,734520,acute myeloid leukemia,"""gard:0012757""",
6793,trans sodium crocetinate,,7/21/2011,treatment of glioblastoma in conjunction with radiotherapy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Diffusion Pharmaceuticals, LLC",2020 Avon Court,Suite 4,Charlottesville,Virginia,' 22902 ' ,United States,345911,glioblastoma,"""gard:0002491""",
6794,trans sodium crocetinate,,12/3/2012,treatment of brain metastasis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Diffusion Pharmaceuticals, LLC",1317 Carlton Ave,Suite 200,Charlottesville,Virginia,' 22902 ' ,United States,378312,,,
6795,"trans-4-({2-(aminocarbonyl)-5-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazol-1-yl]phenyl}amino)cyclohexyl glycinate mesylate",,5/23/2018,treatment of neuroendocrine tumors (nets).,Designated,,Not FDA Approved for Orphan Indication,,,,,Esanex Inc.,115 West Washington Street,South Tower Suite 1680,Indianapolis,Indiana,' 46240 ' ,United States,637818,,,
6796,"trans-4-[4-Amino-5-(7-methoxy-1H-indol-2-yl)-imidazo[5,1-f][1,2,4]triazine-7-yl]-cyclohexanecarboxylic acid, tromethamine salt",,7/30/2020,treatment of lymphatic malformations,Designated,,Not FDA Approved for Orphan Indication,,,,,"Avalo Therapeutics, Inc.",1500 Liberty Ridge Drive,Suite 321,Wayne,Pennsylvania,' 19087 ' ,United States,759820,,,
6797,Trans-Cinnamic Acid,,11/24/2020,treatment for niemann-pick disease type a and type b,Designated,,Not FDA Approved for Orphan Indication,,,,,"Polaryx Therapeutics, Inc.",140 E. Ridgewood Avenue,"Suite 415, South Tower",Paramus,New Jersey,' 07652 ' ,United States,783920,,,
6798,Trans-Cinnamic Acid,,11/24/2020,treatment of gm2 gangliosidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Polaryx Therapeutics, Inc.","140 E. Ridgewood Avenue, Suite 415, South Tower",,Paramus,New Jersey,' 07652 ' ,United States,782820,gm2 gangliosidosis,"""gard:0021323""",
6799,Trans-Cinnamic Acid,,2/3/2021,treatment of krabbe disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Polaryx Therapeutics, Inc.","140 E. Ridgewood Avenue, Suite 415, South Tower",,Paramus,New Jersey,' 07652 ' ,United States,802320,krabbe disease,"""gard:0006844""",
6800,trans-resveratrol,,8/16/2017,treatment of friedreich’s ataxia (frda),Designated,,Not FDA Approved for Orphan Indication,,,,,Jupiter Orphan Therapeutics,601 Heritage Drive,,Jupiter,Florida,' 33458 ' ,United States,597817,,,
6801,TransCon Parathyroid Hormone (mPEG conjugated parathyroid hormone 1-34),,6/4/2018,treatment of hypoparathyroidism,Designated,,Not FDA Approved for Orphan Indication,,,,,Ascendis Pharma Bone Diseases A/S,Tuborg Boulevard 5,DK-2900,Hellerup,,' ' ,Denmark,638818,,,
6802,transforming growth factor beta trap/anti-programmed death ligand-1 antibody bifunctional fusion protein,,12/7/2018,treatment of biliary tract cancer,Designated/Designation Withdrawn or Revoked,1/12/2022,Not FDA Approved for Orphan Indication,,,,,"EMD Serono Research & Development Institute, Inc.",45 Middlesex Turnpike,,Billerica,Massachusetts,' 01821 ' ,United States,663818,,,
6803,Transforming growth factor-beta 2,,12/18/1992,treatment of full thickness macular holes.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Celtrix Pharmaceuticals, Inc.",3055 Patrick Henry Drive,,Santa Clara,California,' 95054 ' ,United States,71092,,,
6804,transforming growth factor-beta receptor 1 kinase inhibitor,,4/1/2013,treatment of hepatocellular carcinoma,Designated/Designation Withdrawn or Revoked,3/15/2019,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,378712,hepatocellular carcinoma,"""gard:0016773""",
6805,transforming growth factor-beta receptor 1 kinase inhibitor,,3/11/2013,treatment of glioma,Designated/Designation Withdrawn or Revoked,3/15/2019,Not FDA Approved for Orphan Indication,,,,,Eli Lilly and Company,Lilly Corporate Center,,Indianapolis,Indiana,' 46285 ' ,United States,389412,,,
6806,Transgenic human alpha 1 antitrypsin,,5/19/1999,treatment of emphysema secondary to alpha 1 antitrypsin deficiency.,Designated,,Not FDA Approved for Orphan Indication,,,,,PPL Therapeutics (Scotland) Limited,Roslin,,Edinburgh,Scotland,' ' ,United Kingdom,122899,,,
6807,trastuzumab,,12/14/1999,treatment of patients with pancreatic cancer that overexpress p185her2.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,129399,,,
6808,trastuzumab,Herceptin,10/13/2009,"treatment of her2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction",Designated/Approved,,,"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease",10/20/2010,10/20/2017,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,292409,noma,"""gard:0004001""",
6809,trastuzumab biosimilar conjugated with TLR7/8 via a non-cleavable linker,,9/22/2023,"treatment of gastric cancer, including gastroesophageal junction cancer",Designated,,Not FDA Approved for Orphan Indication,,,,,Bolt Biotherapeutics,900 Chesapeake Drive,,"Redwood City, CA 94063",California,' 94063 ' ,United States,962423,,,
6810,trastuzumab emtansine,,10/25/2013,for the treatment of gastric cancer including gastroesophageal junction cancer.,Designated/Designation Withdrawn or Revoked,5/12/2016,Not FDA Approved for Orphan Indication,,,,,"Genethech, Inc.",1 DNA Way,,south San Francisco,California,' 94080 ' ,United States,412213,,,
6811,Trastuzumab vedotin,,8/29/2022,treatment of patients with gastric cancer (gc) and gastroesophageal junction (gej) cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Shanghai Miracogen Inc.,"1238 Zhangjiang Road, Building 3, Suite 4E",Pudong District,Shanghai,,' 201203 ' ,China,898822,,,
6812,trastuzumab-rezetecan,,12/14/2023,treatment of biliary tract cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","7 Kunlunshan Road,",Economic and Technological Development Zone,Lianyungang,Jiangsu,' 222047 ' ,China,976423,,,
6813,trazodone,,8/18/2017,treatment of dravet syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Epygenix Therapeutics, Inc.",140 E. Ridgewood Avenue,Suite 415 South Tower,Paramus,New Jersey,' 07652 ' ,United States,593917,dravet syndrome,"""gard:0010430""",
6814,trebananib,,8/30/2013,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,8/2/2022,Not FDA Approved for Orphan Indication,,,,,"Amgen, Inc.",One Amgen Center Drive,,Thousand Oaks,California,' 91320 ' ,United States,403313,ovarian cancer,"""gard:0007295""",
6815,tregalizumab,,8/31/2023,prevention of acute graft versus host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,T-Balance Therapeutics GmbH,Waldfriedstrasse 4,,Frankfurt,Hesse,' 60528 ' ,Germany,957323,graft versus host disease,"""gard:0016642""",
6816,trehalose,,11/17/2014,treatment of spinal cerebellar ataxia type 3 (also known as sca3 or machado joseph disease),Designated,,Not FDA Approved for Orphan Indication,,,,,"Seelos Therapeutics, Inc.",300 Park Avenue,,New York,New York,' 10022 ' ,United States,442014,,,
6817,Trehalose,,10/21/2020,treatment of cln batten disease,Designated/Designation Withdrawn or Revoked,4/11/2024,Not FDA Approved for Orphan Indication,,,,,Beyond Batten Disease Foundation,P.O. Box 50221,,Austin,Texas,' 78763 ' ,United States,774620,,,
6818,trehalose,,10/25/2013,treatment of occulopharyngeal muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Seelos Therapeutics,300 Park Avenue,,New York,New York,' 10022 ' ,United States,410713,muscular dystrophy,"""gard:0007922""",
6819,trehalose,,11/18/2020,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Seelos Therapeutics, Inc.","300 Park Avenue, 12th Floor",,New York,New York,' 10022 ' ,United States,781920,amyotrophic lateral sclerosis,"""gard:0005786""",
6820,Trehalose,,4/29/2020,"treatment of mucopolysaccharidosis type iii (mps iii), or sanfilippo syndrome",Designated,,Not FDA Approved for Orphan Indication,,,,,"Seelos Therapeutics, Inc.","300 Park Avenue, 12th Floor",,New York,New York,' 10022 ' ,United States,740920,mucopolysaccharidosis,"""gard:0007065""",
6821,Trehalose + miglustat,,8/10/2020,treatment of cln batten disease,Designated/Designation Withdrawn or Revoked,4/11/2024,Not FDA Approved for Orphan Indication,,,,,Beyond Batten Disease Foundation,P.O. Box 50221,,Austin,Texas,' 78763 ' ,United States,756020,,,
6822,tremelimumab,,3/18/2015,treatment of malignant mesothelioma,Designated/Designation Withdrawn or Revoked,11/29/2022,Not FDA Approved for Orphan Indication,,,,,"MedImmune, LLC",One MedImmune Way,,Gaithersburg,Maryland,' 20878 ' ,United States,466014,,,
6823,tremelimumab,,9/18/2006,treatment of stage iib to stage iv metastatic melanoma,Designated/Designation Withdrawn or Revoked,11/29/2022,Not FDA Approved for Orphan Indication,,,,,MedImmune,One Medimmune Way,,Gaithersburg,Maryland,' 20878 ' ,United States,227306,noma,"""gard:0004001""",
6824,tremelimumab-actl,Imjudo,1/15/2020,treatment of hepatocellular carcinoma,Designated/Approved,,,In combination with durvalumab for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC),10/21/2022,10/21/2029,treatment of adult patients with unresectable hepatocellular carcinoma (uHCC),AstraZeneca Pharmaceuticals LP,1800 Concord Pike,,Wilmington,Delaware,' 19803 ' ,United States,721419,hepatocellular carcinoma,"""gard:0016773""",
6825,Treosulfan,,5/16/1994,treatment of ovarian cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,Medac GmbH,Fehlandtstrasse 3,,Hamburg,,' ' ,Germany,81294,ovarian cancer,"""gard:0007295""",
6826,treosulfan,,4/8/2015,conditioning treatment prior to hematopoietic stem cell transplantation (hsct) in malignant and non-malignant diseases in adults and pediatric patients.,Designated,,Not FDA Approved for Orphan Indication,,,,,Medac GmbH,TheaterstraBe 6,,Wedel,,' ' ,Germany,468014,,,
6827,treprostinil,,6/8/2020,treatment of systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"LutaFlo Therapeutics, LLC","102 N Water St, Suite 612",,Milwaukee,Wisconsin,' 53202 ' ,United States,711319,systemic sclerosis,"""gard:0009748""",
6828,treprostinil,Remodulin;Orenitram,6/4/1997,treatment of pulmonary arterial hypertension.,Designated/Approved,,,Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity.,12/20/2013,12/20/2020,For treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity.,United Therapeutics Corp.,55 T.W. Alexander Dr.,,Research Triangle Park,North Carolina,' 27709 ' ,United States,105197,pulmonary arterial hypertension,"""gard:0007501""",
6829,treprostinil,Remodulin;Orenitram,6/4/1997,treatment of pulmonary arterial hypertension.,Designated/Approved,,,Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity.,10/18/2019,10/18/2026,Indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression.,United Therapeutics Corp.,55 T.W. Alexander Dr.,,Research Triangle Park,North Carolina,' 27709 ' ,United States,105197,pulmonary arterial hypertension,"""gard:0007501""",
6830,Treprostinil,,12/7/2020,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,United Therapeutics Corporation,55 T.W. Alexander Drive,PO Box 14186,Research Triangle Park,North Carolina,' 27709 ' ,United States,787620,idiopathic pulmonary fibrosis,"""gard:0008609""",
6831,treprostinil,Remodulin;Orenitram,6/4/1997,treatment of pulmonary arterial hypertension.,Designated/Approved,,,Treatment of pulmonary arterial hypertension.,5/21/2002,5/21/2009,,United Therapeutics Corp.,55 T.W. Alexander Dr.,,Research Triangle Park,North Carolina,' 27709 ' ,United States,105197,pulmonary arterial hypertension,"""gard:0007501""",
6832,treprostinil inhalation powder,Tyvaso DPI,6/17/2010,treatment of pulmonary arterial hypertension,Designated/Approved,,,Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability,5/23/2022,,,United Therapeutics Corporation,PO Box 14186,55 TW Alexander Drive,Research Triangle Park,North Carolina,' 27709 ' ,United States,189104,pulmonary arterial hypertension,"""gard:0007501""",
6833,treprostinil inhalation solution,Tyvaso,6/17/2010,treatment of pulmonary arterial hypertension,Designated/Approved,,,"Treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III symptoms, to increase walk distance",7/30/2009,7/30/2016,,United Therapeutics Corporation,PO Box 14186,55 TW Alexander Drive,Research Triangle Park,North Carolina,' 27709 ' ,United States,189104,pulmonary arterial hypertension,"""gard:0007501""",
6834,"treprostinil sodium solution enclosed within a pre-filled, pre-programmed, single-use, electronically-controlled infusion pump",,12/29/2015,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,SteadyMed Therapeutics,2603 Camino Ramon,Suite 350,San Ramon,California,' 94583 ' ,United States,478815,pulmonary arterial hypertension,"""gard:0007501""",
6835,Tretinoin,,4/11/2003,treatment of t-cell non-hodgkin's lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Antigenics, Inc.",3 Forbes Road,,Lexington,Massachusetts,' 02421 ' ,United States,165802,lymphoma,"""gard:0020548""",
6836,Tretinoin,,1/14/1993,treatment of acute and chronic leukemia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Antigenics, Inc.",3 Forbes Road,,Lexington,Massachusetts,' 02421 ' ,United States,71692,,,
6837,Tretinoin,Vesanoid,10/24/1990,treatment of acute promyelocytic leukemia.,Designated/Approved,,,Induction of remission in patients with acute promyelocytic leukemia who are refractory to or unable to tolerate anthracycline based cytotoxic chemotherapeutic regimens.,11/22/1995,11/22/2002,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,50990,acute promyelocytic leukemia,"""gard:0000538""",
6838,Tretinoin,,4/15/1985,treatment of squamous metaplasia of the ocular surface epithelia (conjunctiva and/or cornea) with mucous deficiency and keratinization.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hannan Ophthalmic Marketing Services, Inc",34 Sherrill Rd.,,Marshfield,Massachusetts,' 02050 ' ,United States,5785,,,
6839,tri-antennary glycotripeptide derivative of 5-fluorodeoxyuridine monophosphate,,11/23/2001,treatment for hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Cell Works Inc.,6200 Seaforth Street,,Baltimore,Maryland,' 21224 ' ,United States,150301,hepatocellular carcinoma,"""gard:0016773""",
6840,"Tri-specific T cell activating construct targeting DLL3, HSA, and CD3e",,3/1/2022,treatment of small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.","126 E. Lincoln Avenue, PO Box 2000",RY34B-332,Rahway,New Jersey,' 07065-0900 ' ,United States,864721,small cell lung cancer,"""gard:0009344""",
6841,tricaprilin,,10/27/2020,treatment of infantile spasms also known as west's syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cerecin, Inc.","44 Cook Street, Suite 100-71",,Denver,Colorado,' 80206 ' ,United States,777020,,,
6842,triciribine,,2/1/2008,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"VioQuest Pharmaceuticals, Inc.",180 Mt. Airy Road,,Basking Ridge,New Jersey,' 07920 ' ,United States,249907,multiple myeloma,"""gard:0007108""",
6843,Triciribine phosphate,,4/24/2017,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Prescient Therapeutics LTD,2644 North Kitty Hawk Drive,,Palm Springs,California,' 92262 ' ,United States,558516,acute myeloid leukemia,"""gard:0012757""",
6844,triclabendazole,Egaten,4/17/2017,treatment of fascioliasis,Designated/Approved,,,EGATEN¿ is indicated for the treatment of fascioliasis in patients 6 years of age and older.,2/13/2019,2/13/2026,EGATEN¿ is indicated for the treatment of fascioliasis in patients 6 years of age and older.,Novartis Pharmaceuticals Corporation,1 Health Plaza,,East Hanover,New Jersey,' 07936 ' ,United States,564216,,,
6845,triclabendazole,,6/27/2016,treatment of fascioliasis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tropicalis Pharmaceuticals, LLC",22345 Bracketts Road,,Excelsior,Minnesota,' 55331 ' ,United States,525416,,,
6846,Trientine HCl,Syprine,12/24/1984,"treatment of patients with wilson's disease who are intolerant, or inadequately responsive to penicillamine.",Designated/Approved,,,,11/8/1985,11/8/1992,,Merck Sharp & Dohme Research,Division Of Merck And Company,,West Point,Pennsylvania,' 19486 ' ,United States,4884,,,
6847,trientine hydrochloride,,11/2/2010,treatment of manganism,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cerberus Princeton, LLC",c/o Cerberus Capital Management L.P.,875 Third Avenue,New York,New York,' 10022 ' ,United States,301210,,,
6848,trientine tetrahydrochloride,Cuvrior,3/10/2016,treatment of wilson's disease excluding patients intolerant to penicillamine,Designated/Approved,,,Treatment of adult patients with stable Wilson¿s disease who are de-coppered and tolerant to penicillamine,4/28/2022,4/28/2029,Treatment of adult patients with stable Wilson¿s disease who are de-coppered and tolerant to penicillamine,Orphalan,226 boulevard Voltaire,,Paris,,' 75011 ' ,France,492915,,,
6849,trifarotene,,6/6/2014,treatment of congenital ichthyosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Mayne Pharma LLC.,1240 Sugg Parkway,,Greenville,North Carolina,' 27834 ' ,United States,431014,ichthyosis,"""gard:0018985""",
6850,trifluridine/tipiracil,LONSURF,4/17/2017,treatment of gastric cancer including cancer of the gastroesophageal junction,Designated/Approved,,,"LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.",2/22/2019,2/22/2026,"LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.","Taiho Oncology, Inc.",101 Carnegie Center,Suite 101,Princeton,New Jersey,' 08540 ' ,United States,564116,,,
6851,triheptanoin,Dojolvi,4/15/2015,treatment of fatty acid oxidation disorders,Designated/Approved,,,DOJOLVI is indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).,6/30/2020,6/30/2027,Indicated as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).,"Ultragenyx Pharmaceutical, Inc.",60 Leveroni Court,,Novato,California,' 94949 ' ,United States,474015,,,
6852,Triheptanoin,,5/26/2006,treatment of fatty acid disorders,Designated,,Not FDA Approved for Orphan Indication,,,,,Baylor Research Institute,Institute of Metabolic Disease,3812 Elm Street,Dallas,Texas,' 75226 ' ,United States,220306,,,
6853,Triheptanoin,,2/1/2008,treatment of glycogen storage disorder ii (pompe disease),Designated,,Not FDA Approved for Orphan Indication,,,,,Baylor Research Institute,3330 Live Oak Blvd,,Dallas,Texas,' 75204 ' ,United States,220406,,,
6854,triheptanoin,,10/21/2014,treatment of glucose transporter type-1 deficiency syndrome,Designated/Designation Withdrawn or Revoked,1/3/2020,Not FDA Approved for Orphan Indication,,,,,"Ultragenyx Pharmaceutical, Inc.",60 Leveroni Court,,Novato,California,' 94949 ' ,United States,426414,,,
6855,Trimetazidine,,3/15/2018,treatment of acute-on-chronic liver failure,Designated,,Not FDA Approved for Orphan Indication,,,,,"Martin Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,' 10279 ' ,United States,629618,,,
6856,trimetazidine,,8/7/2018,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,"Martin Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,' 10279 ' ,United States,642918,pulmonary arterial hypertension,"""gard:0007501""",
6857,trimetazidine,,10/30/2018,treatment of dilated cardiomyopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Martin Pharmaceuticals, Inc.",233 Broadway,Suite 1750,New York,New York,' 10279 ' ,United States,658318,dilated cardiomyopathy,"""gard:0000221""",
6858,Trimetrexate,,8/10/2000,treatment of metastatic osteogenic sarcoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Medimmune Oncology, Inc.",One MedImmune Way,,Gaithersburg,Maryland,' 20878 ' ,United States,132299,,,
6859,Trimetrexate glucuronate,,1/13/1988,treatment of patients with advanced non-small cell carcinoma of the lung.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Medimmune Oncology, Inc.",One MedImmune Way,,Gaithersburg,Maryland,' 20878 ' ,United States,14686,noma,"""gard:0004001""",
6860,Trimetrexate glucuronate,,7/25/1985,treatment of pancreatic adenocarcinoma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Medimmune Oncology, Inc.",One MedImmune Way,,Gaithersburg,Maryland,' 20878 ' ,United States,8385,noma,"""gard:0004001""",
6861,Trimetrexate glucuronate,Neutrexin,5/15/1986,treatment of pneumocystis carinii pneumonia in aids patients.,Designated/Approved,,,"Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients who are intolerant of, or are refractory to, trimethoprim sulfamethoxazole.",12/17/1993,12/17/2000,,"Medimmune Oncology, Inc.",One Tower Bridge,"100 Front Street, Suite 400",West Conshohocken,Pennsylvania,' 19428 ' ,United States,14286,,,
6862,Trineumin,,1/9/2023,treatment of neurofibromatosis type 2,Designated,,Not FDA Approved for Orphan Indication,,,,,"PRG S&T Co., Ltd","9F, Sejung Tower, 252, Geumjeong-ro, Geumjeong-gu",,Busan,Busan,' 46274 ' ,South Korea,918422,neurofibromatosis type 2,"""gard:0007193""",
6863,triptorelin pamoate,Triptodur,8/20/2012,treatment of central precocious puberty,Designated/Approved,,,Treatment of pediatric patients 2 years of age and older with central precocious puberty,6/29/2017,6/29/2024,Treatment of pediatric patients 2 years of age and older with central precocious puberty,"Arbor Pharmaceuticals, LLC",6 Concourse Parkway,Suite 1800,Atlanta,Georgia,' 30328 ' ,United States,376012,central precocious puberty,"""gard:0016546""",
6864,Triptorelin pamoate,,8/10/1990,for use in the palliative treatment of advanced ovarian carcinoma of epithelial origin.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Debio R.A. Inc.,"7929 Westpark Drive, Suite 400",,Mclean,Virginia,' 22102 ' ,United States,34688,noma,"""gard:0004001""",
6865,Trisaccharides A and B,,4/20/1987,"for use in abo-incompatible solid organ transplantation, including kidney, heart, liver and pancreas.",Designated,,Not FDA Approved for Orphan Indication,,,,,"Chembiomed, Ltd.",P.O. Box 8050,T6H 4NP,,,' ' ,Canada,18887,,,
6866,Trisaccharides A and B,,8/3/1987,"treatment of moderate to very severe clinical forms of transfusion reactions arising from abo incompatible transfusions of blood, blood products, and blood derivatives.",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Chembiomed, Ltd.",P.O. Box 8050,T6H 4NP,,,' ' ,Canada,20287,,,
6867,Trisaccharides A and B,,4/15/1988,prevention of abo medical hemolytic reactions arising from abo-incompatible bone marrow transplantation.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Chembiomed, Ltd.","P.O. Box 8050, Station F",T6H 4NP,,,' ' ,Canada,27988,,,
6868,Trisaccharides A and B,,4/12/1987,treatment of moderate to severe clinical forms of hemolytic disease of the newborn arising from placental transfer of antibodies against blood group substances a and b.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Chembiomed, Ltd.","P.O. Box 8050, Station F",T6H 4NP,,,' ' ,Canada,18086,,,
6869,Trisodium citrate concentration,,6/15/1995,for use in leukapheresis procedures.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Hemotec Medical Products, Inc.",Box 19255,,Johnston,Rhode Island,' 02919 ' ,United States,87094,,,
6870,Trisodium zinc Diethylenetriaminepentaacetate,,2/27/2004,"treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rate of elimination.",Designated,,Not FDA Approved for Orphan Indication,,,,,CustomCare Pharmacy,5710 Hoover Blvd,,Tampa,Florida,' 33634 ' ,United States,181003,,,
6871,Trispecific antibody targeting tumor associated antigens CD38 and BCMA and CD3 on human T cells,,6/28/2023,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,Ichnos Sciences SA,"Chemin de la Combeta, 5",,"La Chaux-de-Fonds, Neuchatel",,' 02300 ' ,Switzerland,946623,multiple myeloma,"""gard:0007108""",
6872,"Trispecific T cell activating construct targeting BCMA, HSA, and CD3",,1/8/2021,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Merck & Co., Inc.","126 E. Lincoln Avenue, PO Box 2000",RY34-A2014,Rahway,New Jersey,' 07065-0900 ' ,United States,793820,multiple myeloma,"""gard:0007108""",
6873,triterpenoid saponin,,7/23/2014,treatment of mantle cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Avicin Therapeutics, Ltd.",Westpark Corporate Center,4364 S. Alston Avenue,Durham,North Carolina,' 27713 ' ,United States,435314,lymphoma,"""gard:0020548""",
6874,Trodusquemine HCl,,2/19/2021,treatment of dystrophinopathies,Designated,,Not FDA Approved for Orphan Indication,,,,,Revidia Therapeutics. Inc.,415 Water Street,,Ellsworth,Maine,' 04605 ' ,United States,800120,,,
6875,Trofinetide,,10/23/2013,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,ACADIA Pharmaceuticals Inc.,3611 Valley Centre Drive,Suite 300,San Diego,California,' 92130 ' ,United States,409013,fragile x syndrome,"""gard:0006464""",
6876,trofinetide,Daybue,2/11/2015,treatment of rett syndrome,Designated/Approved,,,treatment of Rett syndrome in adults and pediatric patients 2 years of age and older,3/10/2023,3/10/2030,treatment of Rett syndrome in adults and pediatric patients 2 years of age and older,Acadia Pharmaceuticals Inc.,3611 Valley Centre Drive,Suite 300,San Diego,California,' 92130 ' ,United States,363111,rett syndrome,"""gard:0005696""",
6877,Troleandomycin,,9/21/1989,treatment of severe steroid-requiring asthma.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Szefler, Stanley M. M.D.",National Jewish Center for Immunology and Respirat,1400 Jackson Street,Denver,Colorado,' 80206 ' ,United States,39089,,,
6878,Troxacitabine,,4/4/2005,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Structural GenomiX, Inc. (SGX)",10505 Roselle Street,,San Diego,California,' 92121 ' ,United States,202005,acute myeloid leukemia,"""gard:0012757""",
6879,Trypan blue,MembraneBlue,8/2/2006,selectively staining epiretinal membranes during ophthalmic surgical vitrectomy procedures,Designated/Approved,,,"For use as an aid in ophthalmic surgery by staining the epiretinal membranes during ophthalmic surgical vitrectomy procedures, facilitating removal of the tissue",2/20/2009,2/20/2016,,Dutch Ophthalmic Research Center International BV,P.O. Box 43,,Zuidland,,' ' ,Netherlands,207505,,,
6880,Trypan Blue and Brilliant Blue G Ophthalmic Solution,,4/26/2023,to selectively stain the epiretinal membrane and internal limiting membrane,Designated,,Not FDA Approved for Orphan Indication,,,,,D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.,Scheijdelveweg 2,,Zuidland,ZUID-HOLLAND,' 3214 VN ' ,Netherlands,876222,,,
6881,Trypan Blue Ophthalmic Solution,,7/8/2022,for use as an aid in ophthalmic surgery by staining the descemet membrane during descemet membrane endothelial keratoplasty (dmek),Designated,,Not FDA Approved for Orphan Indication,,,,,D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.,Scheijdelveweg 2,,Zuidland,ZUID-HOLLAND,' 3214 VN ' ,Netherlands,889622,,,
6882,Trypsinogen/Chymotrypsinogen,,6/19/2017,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Propanc Pty Ltd.,302/6 Butler Street,,Camberwell,Victoria,' ' ,Australia,575917,,,
6883,tubimod,,4/10/2017,treatment of active tuberculosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immunitor, Inc.",365-2906 West Broadway,,Vancouver,,' ' ,Canada,563716,tuberculosis,"""gard:0007827""",
6884,tucatinib,,6/5/2017,treatment of breast cancer patients with brain metastases.,Designated/Approved,,,"TUKYSA is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.",4/17/2020,4/17/2027,"For use in combination with trastuzumab and capecitabine for treatment of adult patients with metastatic HER2-positive breast cancer and brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.",Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,570716,,,
6885,tucatinib,Tukysa,9/18/2017,treatment of her2+ colorectal cancer,Designated/Approved,,,"in combination with trastuzumab for the treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy",1/19/2023,1/19/2030,"treatment of adult patients with RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy",Seagen Inc.,21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,571216,,,
6886,tucidinostat,,8/26/2022,treatment of patients with of stage iib-iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"HUYABIO International, LLC","12531 High Bluff Drive, Suite 138",,San Diego,California,' 92130 ' ,United States,867121,noma,"""gard:0004001""",
6887,Tumor necrosis factor-binding protein 1,,1/6/1993,treatment of symptomatic patients with aids including all patients with cd4 counts less than 200 cells per mm3.,Designated,,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,63491,,,
6888,Tumor necrosis factor-binding protein II,,1/6/1993,treatment of symptomatic patients with the aids including all patients with cd4 t-cell counts less than 200 cells per mm3.,Designated,,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,64691,,,
6889,"Two AAV vectors, the first expressing the N- and the second expressing the C-region of the ATP-binding cassette subfamily A member 4 (ABCA4) protein fused to N- or C-terminal split-intein sequences",,4/8/2024,treatment of patients with confirmed abca4 gene mutation-associated inherited retinal dystrophy (ird),Designated,,Not FDA Approved for Orphan Indication,,,,,SpliceBio S.L.,Barcelona Science Park,"Baldiri Reixac, 10-12",Barcelona,Barcelona,' 08028 ' ,Spain,928722,,,
6890,Two immunoglobulin subclass 1 (IgG1) human monoclonal antibodies that target the Sudan ebolavirus glycoprotein,,6/3/2022,"treatment of ebolavirus disease caused by sudan ebolavirus (sudv) infection, otherwise termed sudan virus disease",Designated,,Not FDA Approved for Orphan Indication,,,,,"Mapp Biopharmaceutical, Inc.","4921 Directors Place, Suite 100",,San Diego,California,' 92121 ' ,United States,880322,,,
6891,TXA127,,10/25/2013,treament of acute radiation syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"US Biotest, Inc.",231 Bonetti Drive,,San Luis Obispo,California,' 93401 ' ,United States,411813,acute radiation syndrome,"""gard:0021896""",
6892,Tyloxapol,,3/8/1995,treatment of cystic fibrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kennedy & Hoidal, M.D.'s",University of Utah Health Sciences Center,"50 North Medical Drive, Room 4R240",Salt Lake City,Utah,' 84132 ' ,United States,87994,cystic fibrosis,"""gard:0006233""",
6893,Type 1 native bovine skin collagen,,2/1/2008,treatment of diffuse systemic sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"arGentis Pharmaceuticals, LLC",20 South Dudley Street,,Memphis,Tennessee,' 38139 ' ,United States,253407,systemic sclerosis,"""gard:0009748""",
6894,type II fast skeletal myosin inhibitor,,11/29/2023,treatment of duchenne and becker muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,Edgewise Therapeutics,1715 38th Street,,Boulder,Colorado,' 80301 ' ,United States,972823,duchenne and becker muscular dystrophy,"""gard:0018686""",
6895,UBE3A antisense oligonucleotide with locked nucleic acids (UBE3A-ATS-LNA),,11/24/2020,treatment of angelman syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080-4990 ' ,United States,783120,angelman syndrome,"""gard:0005810""",
6896,ubenimex,,11/19/2015,treatment of pulmonary arterial hypertension.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Eiger BioPharmaceuticals, Inc.",350 Cambridge Avenue,Suite 350,Palo Alto,California,' 94306 ' ,United States,498115,pulmonary arterial hypertension,"""gard:0007501""",
6897,Ubenimex,,3/8/2021,treatment of chronic myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical inc,161 Jefferson Ave.,,tenafly,New Jersey,' 07670 ' ,United States,806720,chronic myeloid leukemia,"""gard:0006105""",
6898,Ubenimex,,6/12/2020,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,' 07670 ' ,United States,749020,hepatocellular carcinoma,"""gard:0016773""",
6899,Ubenimex,,8/7/2020,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenafly,New Jersey,' 07670 ' ,United States,755720,acute myeloid leukemia,"""gard:0012757""",
6900,ubidecarenone,,4/16/2018,treatment of epidermolysis bullosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"BPGbio, Inc",Headquarters & Innovation Center,"500 Old Connecticut Path, Building B",Framingham,Massachusetts,' 01701 ' ,United States,635318,,,
6901,Ubidecarenone,,6/24/2021,treatment of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"BPGbio, Inc",Headquarters & Innovation Center,"500 Old Connecticut Path, Building B",Framingham,Massachusetts,' 01701 ' ,United States,822521,,,
6902,ubidecarenone,,11/8/2017,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"BPGbio, Inc",Headquarters & Innovation Center,"500 Old Connecticut Path, Building B",Framingham,Massachusetts,' 01701 ' ,United States,610717,,,
6903,ubiquinol,,4/12/2004,treatment of huntington's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gel-Tec, Division of Tishcon Corp.",30 New York Avenue,P. O. Box 331,Westbury,New York,' 11590 ' ,United States,179403,,,
6904,"Ubiquinol, coenzyme Q10, ubiquinone",,4/12/2004,treatment of pediatric congestive heart failure,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gel-Tec, Division of Tishcon Corporation",30 New York Avenue,P. O. Box 331,Westbury,New York,' 11590 ' ,United States,174603,,,
6905,Ubiquinone,,12/14/1999,treatment of mitochondrial cytopathies.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Gel-Tec, Division of Tishcon Corp.",30 New York Avenue,P. O. Box 331,Westbury,New York,' 11590 ' ,United States,125099,,,
6906,ublituximab,,9/5/2013,"treatment of extranodal marginal zone lymphoma (mucosa-associated lymphatic tissue, malt)",Designated/Designation Withdrawn or Revoked,8/18/2023,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.","343 Thornall Street, Suite 740",,Edison,New York,' 08837 ' ,United States,403813,lymphoma,"""gard:0020548""",
6907,ublituximab,,8/6/2010,treatment of chronic lymphocytic leukemia,Designated/Designation Withdrawn or Revoked,8/18/2023,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.","343 Thornall Street, Suite 740",,Edison,New Jersey,' 08837 ' ,United States,296609,,,
6908,ublituximab,,8/25/2016,treatment of neuromyelitis optica and neuromyelitis optica spectrum disorder,Designated,,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.","343 Thornall Street, Suite 740",,Edison,New Jersey,' 08837 ' ,United States,533116,neuromyelitis optica spectrum disorder,"""gard:0006267""",
6909,ublituximab,,9/5/2013,treatment of nodal marginal zone lymphoma,Designated/Designation Withdrawn or Revoked,8/18/2023,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.","343 Thornall Street, Suite 740",,Edison,New Jersey,' 08837 ' ,United States,410913,lymphoma,"""gard:0020548""",
6910,UCART cells targeting CD7,,5/25/2021,treatment of acute lymphoblastic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Nanjing Bioheng Biotech Co., Ltd","Block B1-2, 73 Tanmi Road,",,Nanjing,Pukou District,' 00000 ' ,China,817921,acute lymphoblastic leukemia,"""gard:0000522""",
6911,udenafil,,8/31/2015,treatment of single ventricle congenital heart disease with fontan physiology,Designated,,Not FDA Approved for Orphan Indication,,,,,Mezzion Pharma Co. Ltd.,3rd Floor C & H Building,Gangnam-gu 135-879,Seoul,,' ' ,South Korea,449714,,,
6912,Ulefnersen,,8/15/2023,treatment of amyotrophic lateral sclerosis (als),Designated,,Not FDA Approved for Orphan Indication,,,,,"Ionis Pharmaceuticals, Inc.",2855 Gazelle Court,,Carlsbad,California,' 92010 ' ,United States,954623,amyotrophic lateral sclerosis,"""gard:0005786""",
6913,Ulinastatin,,6/28/2021,treatment of acute radiation syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR Biomedical inc,161 Jefferson Ave.,,tenafly,New Jersey,' 07670 ' ,United States,822421,acute radiation syndrome,"""gard:0021896""",
6914,Ulinastatin,,6/12/2020,treatment of kawasaki disease,Designated,,Not FDA Approved for Orphan Indication,,,,,RNR BioMedical Inc.,c/o Noa Avtalion,161 Jefferson Av,Tenefly,New Jersey,' 07670 ' ,United States,742320,kawasaki disease,"""gard:0006816""",
6915,Ulinastatin,,10/2/2023,treatment of phosgene inhalation,Designated,,Not FDA Approved for Orphan Indication,,,,,"RNR Biomedical, Inc.",161 Jefferson Ave.,,Tenafly,New Jersey,' 07670 ' ,United States,964423,,,
6916,Ulixertinib,,6/24/2013,treatment of stage iib through stage iv braf mutant melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"BioMed Valley Discoveries, Inc.",4435 Main Street,Suite 550,Kansas City,Missouri,' 64111 ' ,United States,398213,noma,"""gard:0004001""",
6917,ulocuplumab,,1/12/2015,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Bristol-Myers Squibb Company,"3401 Princeton Pike, B-3043C",,Lawrence Township,New Jersey,' 08648 ' ,United States,457414,acute myeloid leukemia,"""gard:0012757""",
6918,umbilical cord mesenchymal stem cell secretome,,4/26/2022,treatment of sarcoidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,NRG Sciences LLC,11496 Luna Road,Suite 1100,Farmers Branch,Texas,' 75234 ' ,United States,735320,sarcoidosis,"""gard:0007607""",
6919,Umbilical Cord Mesenchymal Stem Cells,,1/28/2020,treatment of huntington’s disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Acen Regenerative Medicine Sci-Tech Co., Ltd.","No.8 Building, No. 14 Jinhui Road, Pingshan District",,Shenzhen,Guangdong,' ' ,China,720619,,,
6920,umbralisib,,8/23/2016,treatment of chronic lymphocytic leukemia,Designated/Designation Withdrawn or Revoked,8/18/2023,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.","343 Thornall Street, Suite 740",,Edison,New Jersey,' 08837 ' ,United States,533016,,,
6921,umbralisib,Ukoniq,4/11/2019,treatment of nodal marginal zone lymphoma,Designated/Approved,,,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn),2/5/2021,5/31/2022,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn),"TG Therapeutics, Inc.",3020 Carrington Mill Blvd. Suite 475,,Morrisville,North Carolina,' 27560 ' ,United States,687519,lymphoma,"""gard:0020548""",
6922,umbralisib,Ukoniq,4/11/2019,treatment of extranodal marginal zone lymphoma,Designated/Approved,,,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn),2/5/2021,5/31/2022,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn),"TG Therapeutics, Inc.",3020 Carrington Mill Blvd. Suite 475,,Morrisville,North Carolina,' 27560 ' ,United States,687419,lymphoma,"""gard:0020548""",
6923,umbralisib,Ukoniq,4/11/2019,treatment of splenic marginal zone lymphoma,Designated/Approved,,,treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn),2/5/2021,5/31/2022,treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen (Indication withdrawn),"TG Therapeutics, Inc.",3020 Carrington Mill Blvd. Suite 475,,Morrisville,North Carolina,' 27560 ' ,United States,680019,lymphoma,"""gard:0020548""",
6924,umbralisib,Ukoniq,3/4/2020,treatment of follicular lymphoma,Designated/Approved,,,Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy (Indication withdrawn),2/5/2021,5/31/2022,Treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy (Indication withdrawn),"TG Therapeutics, Inc.",3020 Carrington Mill Blvd. Suite 475,,Morrisville,North Carolina,' 27560 ' ,United States,726819,lymphoma,"""gard:0020548""",
6925,umbralisib in combination with ublituximab,,1/19/2017,treatment of diffuse large b-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.","343 Thornall Street, Suite 740",,Edison,New Jersey,' 08837 ' ,United States,552216,lymphoma,"""gard:0020548""",
6926,umbralisib in combination with ublituximab,,1/5/2017,treatment of chronic lymphocytic leukemia,Designated/Designation Withdrawn or Revoked,8/18/2023,Not FDA Approved for Orphan Indication,,,,,"TG Therapeutics, Inc.","343 Thornall Street, Suite 740",,Edison,New Jersey,' 08837 ' ,United States,554216,,,
6927,unoprostone isopropyl,,9/16/2010,treatment of retinitis pigmentosa,Designated/Designation Withdrawn or Revoked,9/2/2016,Not FDA Approved for Orphan Indication,,,,,"R-Tech Ueno, Ltd.","Kobe Hybrid Business Center, 3F",Chuo-ku,Kobe City,Hyogo,' ' ,Japan,314810,retinitis pigmentosa,"""gard:0005694""",
6928,upadacitinib,,8/16/2017,treatment of pediatric systemic juvenile idiopathic arthritis,Designated,,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,522916,juvenile idiopathic arthritis,"""gard:0018677""",
6929,upadacitinib,,12/30/2019,treatment of pediatric ulcerative colitis,Designated,,Not FDA Approved for Orphan Indication,,,,,AbbVie,1 North Waukegan Road,,North Chicago,Illinois,' 60044 ' ,United States,524116,,,
6930,upadacitinib,Rinvoq,9/18/2015,treatment of pediatric (aged 0 through 16 years) juvenile idiopathic arthritis (jia) ilar categories excluding systemic jia,Designated/Approved,,,"treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers, and for the treatment of pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers",4/26/2024,4/26/2031,"treatment of pediatric patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers, and for the treatment of pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers","AbbVie, Inc.",1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,485415,juvenile idiopathic arthritis,"""gard:0018677""",
6931,upamostat,,10/16/2017,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,RedHill Biopharma Ltd.,21 Ha'arba'a Street,,Tel Aviv-Yafo,Tel Aviv District,' ' ,Israel,608417,,,
6932,urea,,11/7/2011,"treatment of rare congenital ichthyoses (child syndrome, collodion baby, congenital ichthyosform erythroderma, conradi-flunermann, epidermolytic hyperkeratosis, erythrokeratoderma variabilis, harlequin ichthyosis, kid syndrome, lamellar ichthyosis, netherton syndrome, neutral lipid storage disease, sjorgren-larsson syndrome, trichothiodystrophy, x-linked ichthyosis).",Designated,,Not FDA Approved for Orphan Indication,,,,,"Orenova Group, LLC",10 New King Street,Suite 106,White Plains,New York,' 10604 ' ,United States,346211,erythrokeratoderma,"""gard:0018986""",
6933,Urea for intravitreal injection,,12/14/2005,treatment of retinitis pigmentosa,Designated,,Not FDA Approved for Orphan Indication,,,,,"Vitreo Retinal Techologies, Inc",2 Venture Plaza,,Irvine,California,' 92618 ' ,United States,192204,retinitis pigmentosa,"""gard:0005694""",
6934,"Urea, N-[4-[2,3-dihydro-7-(5-methyl-1H-imidazol-2-yl)-1-oxo-1H-isoindol-4-yl]-3-fluorophenyl]-N¿-(2,4,6-trifluorophenyl)-",,12/22/2017,treatment of acute myeloid leukemia (aml),Designated,,Not FDA Approved for Orphan Indication,,,,,"Aptose Biosciences, Inc.",12770 High Bluff Drive,Suite 120,San Diego,California,' 92130 ' ,United States,618417,acute myeloid leukemia,"""gard:0012757""",
6935,Uridine 5'-triphosphate,,12/4/1995,treatment of cystic fibrosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Inspire Pharmaceuticals, Inc.","4222 Emperor Boulevard, Suite 470",,Durham,North Carolina,' 27703 ' ,United States,93495,cystic fibrosis,"""gard:0006233""",
6936,Uridine 5'-triphosphate,,6/26/1996,to facilitate the removal of lung secretions in the treatment of patients with primary ciliary dyskinesia.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Inspire Pharmaceuticals, Inc.","4222 Emperor Boulevard, Suite 470",,Durham,North Carolina,' 27703 ' ,United States,99096,primary ciliary dyskinesia,"""gard:0004484""",
6937,uridine triacetate,,9/3/2009,treatment of mitchondrial disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Pharma Cinq, LLC",160 I Research Boulevard,,Rockville,Maryland,' 20850 ' ,United States,290009,,,
6938,uridine triacetate,,8/9/2013,treatment of hereditary orotic aciduria,Designated/Approved,,,Treatment of hereditary orotic aciduria,9/4/2015,9/4/2022,Treatment of hereditary orotic aciduria,BTG International Inc.,"300 Four Falls Corporate Center, 300 Conshohocken State Road",Suite 300,West Conshohocken,Pennsylvania,' 19428 ' ,United States,401013,hereditary orotic aciduria,"""gard:0005429""",
6939,uridine triacetate,,5/1/2009,an antidote in the treatment of 5-fluorouracil or capecitabine poisoning,Designated/Approved,,,"For the emergency treatment of adult and pediatric patients following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration",12/11/2015,12/11/2022,"For the emergency treatment of adult and pediatric patients following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration",BTG International Inc.,"300 Four Falls Corporate Center, 300 Conshohocken State Road",Suite 300,West Conshohocken,Pennsylvania,' 19428 ' ,United States,273808,,,
6940,Urinary-derived human chorionic gonadotropin and epidermal growth factor,,8/12/2020,treatment of acute graft-versus-host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,University of Minnesota,"420 Delaware Street, MMC 480",MMC 195,Minneapolis,Minnesota,' 55455 ' ,United States,735420,,,
6941,Urofollitropin,,12/5/1997,"for the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism.",Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,107397,,,
6942,Urofollitropin,Metrodin,11/25/1987,for induction of ovulation in patients with polycystic ovarian disease who have an elevated lh/fsh ratio and who have failed to respond to adequate clomiphene citrate therapy.,Designated/Approved,,,,9/18/1986,9/18/1993,,"EMD Serono, Inc.",One Technology Place,,Rockland,Massachusetts,' 02370 ' ,United States,14086,,,
6943,Urogastrone,,11/1/1984,for acceleration of corneal epithelial regeneration and healing of stromal incisions from corneal transplant surgery.,Designated,,Not FDA Approved for Orphan Indication,,,,,Chiron Vision,500 Iolab Drive,,Claremont,California,' 91711 ' ,United States,1684,,,
6944,Urokinase plasminogen activator receptor binding peptide attached to fluorophore indocyanine green,,10/2/2023,diagnostic for the management of malignant glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Fluoguide A/S,Ole Maaløes Vej 3,,Copenhagen,N,' DK-2200 ' ,Denmark,960223,,,
6945,Ursodeoxycholic acid,,4/26/2018,"treatment of niemann-pick disease, type c",Designated,,Not FDA Approved for Orphan Indication,,,,,IntraBio Inc.,270 Devon Road,,Tenafly,New Jersey,' 07670 ' ,United States,636718,,,
6946,Ursodiol,,2/19/1991,management of the clinical signs and symptoms associated with primary biliary cirrhosis.,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Novartis Pharmaceuticals Corporation,59 Route 10,,East Hanover,New Jersey,' 07936 ' ,United States,55390,,,
6947,Ursodiol,URSO 250,6/20/1991,treatment of patients with primary biliary cirrhosis,Designated/Approved,,,,12/10/1997,12/10/2004,,"Aptalis Pharma US, Inc.",100 Somerset corporate Blvd,,Bridgewater,New Jersey,' 08807 ' ,United States,22187,,,
6948,ursodiol,,10/23/2007,treatment of cystic fibrosis liver disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Asklepion Pharmaceuticals, LLC",5200 Maryland Way,,Brentwood,Tennessee,' 37027 ' ,United States,242607,cystic fibrosis,"""gard:0006233""",
6949,ustekinumab,,2/22/2017,treatment of pediatric ulcerative colitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.",1400 McKean Road,,Spring House,Pennsylvania,' 19477 ' ,United States,537516,,,
6950,ustekinumab,,5/18/2016,treatment of pediatric crohn's disease (0 through 16 years of age),Designated,,Not FDA Approved for Orphan Indication,,,,,"Janssen Research & Development, LLC",1400 McKean Road,P.O. Box 776,Spring House,Pennsylvania,' 19477 ' ,United States,520916,,,
6951,ustekinumab,,12/28/2011,treatment of chronic sarcoidosis,Designated/Designation Withdrawn or Revoked,3/27/2014,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.",800 & 850 Ridgeview Drive,,Horsham,Pennsylvania,' 19044 ' ,United States,358111,sarcoidosis,"""gard:0007607""",
6952,ustekinumab,,11/29/2010,treatment of type 1 diabetes mellitus patients with residual beta-cell function.,Designated/Designation Withdrawn or Revoked,6/7/2021,Not FDA Approved for Orphan Indication,,,,,Johnson & Johnson Pharmaceutical & Development LLC,902 Route 202 South,Room 1654,Raritan,New Jersey,' 08869 ' ,United States,314510,,,
6953,ustekinumab,,7/18/2017,treatment of pediatric systemic lupus erythematosus,Designated/Designation Withdrawn or Revoked,9/4/2020,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.",800 & 850 Ridgeview Drive,,Horsham,Pennsylvania,' 19044 ' ,United States,586217,pediatric systemic lupus erythematosus,"""gard:0019219""",
6954,ustekinumab; human monocloncal antibody to interkeukin 12p40,,12/22/2011,treatment of primary biliary cirrhosis,Designated/Designation Withdrawn or Revoked,3/27/2014,Not FDA Approved for Orphan Indication,,,,,"Janssen Biotech, Inc.",200 Great Valley Parkway,,Malvern,Pennsylvania,' 19355 ' ,United States,343811,,,
6955,utidelone,,3/21/2024,treatment of breast cancer brain metastases,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biostar Pharma, Inc.","1633 Old Bayshore HWY, Suite 280",,Burlingame,California,' 94010 ' ,United States,977123,,,
6956,Utidelone,,3/12/2024,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biostar Pharma, Inc.","1633 Old Bayshore HWY, Suite 280",,Burlingame,California,' 94010 ' ,United States,992923,,,
6957,uttroside B,,1/19/2021,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Q BioMed,366 Madison Ave,,New York,New York,' 10017 ' ,United States,795820,hepatocellular carcinoma,"""gard:0016773""",
6958,Vaccinia Immune Globulin (Human) Intravenous,,6/18/2004,treatment of severe complications from the smallpox vaccine,Designated/Approved,,,"Treatment and modification of aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard; eczema vaccinatum; progressive vaccinia; severe generalized vaccinia, and vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions",2/18/2005,2/18/2012,,DynPort Vaccine Company LLC,64 Thomas Johnson Drive,,Frederick,Maryland,' 21702 ' ,United States,184204,,,
6959,Vaccinia Immune Globulin (Human) Intravenous,CNJ-016,6/18/2004,treatment of complications of vaccinia vaccination,Designated/Approved,,,"treatment and/or modification of the following conditions, which are complications resulting from smallpox vaccination: Eczema vaccinatum Progressive vaccinia Severe generalized vaccinia Vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions Aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard.",5/2/2005,,,Cangene Corporation,104 Chancellor Matheson Road,,Winnipeg,,' ' ,Canada,179303,,,
6960,Vactosertib,,9/28/2020,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"MedPacto, Inc",145 Gwanggyo-ro,"Advanced Institutes of Convergence Technology, Building C, Room 506",Suwon,Gyeonggi-do,' 16229 ' ,Republic of Korea,767320,,,
6961,vactosertib,,8/27/2021,treatment of osteosarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"MedPacto, Inc.",92 Myeongdal-ro Seocho-Gu,,Seoul,Republic of Korea,' 06668 ' ,South Korea,834121,osteosarcoma,"""gard:0007284""",
6962,Vactosertib,,7/20/2021,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"MedPacto, Inc.","92 Myeongdal-ro, Seocho-Gu",,Seoul,,' 06668 ' ,South Korea,827321,,,
6963,vadastuximab talirine,,11/10/2015,treatment of acute myeloid leukemia.,Designated/Designation Withdrawn or Revoked,2/27/2019,Not FDA Approved for Orphan Indication,,,,,"Seattle Genetics, Inc.",21823 30th Drive Southeast,,Bothell,Washington,' 98021 ' ,United States,494515,acute myeloid leukemia,"""gard:0012757""",
6964,valbenazine,,10/19/2017,treatment of pediatric patients with tourette syndrome (ts).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neurocrine Biosciences, Inc.",12780 El Camino Real,,San Diego,California,' 92130 ' ,United States,608317,,,
6965,valbenazine,Ingrezza,5/10/2022,treatment of huntington disease,Designated/Approved,,,treatment of adults with chorea associated with Huntington's disease,8/18/2023,8/18/2030,treatment of adults with chorea associated with Huntington's disease,Neurocrine Biosciences Inc.,12780 El Camino Real,,San Diego,California,' 92130 ' ,United States,875022,huntington disease,"""gard:0006677""",
6966,valbenazine,Ingrezza,5/10/2022,treatment of huntington disease,Designated/Approved,,,treatment of adults with chorea associated with Huntington's disease,4/30/2024,,,Neurocrine Biosciences Inc.,12780 El Camino Real,,San Diego,California,' 92130 ' ,United States,875022,huntington disease,"""gard:0006677""",
6967,Valemetostat tosylate,,12/1/2021,treatment of peripheral t-cell lymphoma (ptcl),Designated,,Not FDA Approved for Orphan Indication,,,,,"Daiichi Sankyo, Inc.",211 Mount Airy Road,,Basking Ridge,New Jersey,' 07920-2311 ' ,United States,850021,lymphoma,"""gard:0020548""",
6968,"Valine, isoleucine and leucine",,1/5/1996,treatment of hyperphenylalaninemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Leas Research Products,78 Fallon Drive,,North Haven,Connecticut,' 06473 ' ,United States,93095,,,
6969,valine-valine-ganciclovir,,5/21/2007,treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to hsv1 and hsv2.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Verenta Pharmaceuticals, Inc.",10901 Granada Lane,Suite 101,Leawood,Kansas,' 66211 ' ,United States,239007,,,
6970,valoctocogene roxaparvovec-rvox,Roctavian,2/29/2016,treatment of hemophilia a.,Designated/Approved,,,treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity less than 1 IU/dL) without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test,6/29/2023,6/29/2030,treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity less than 1 IU/dL) without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,' 94949 ' ,United States,510915,hemophilia,"""gard:0010418""",
6971,Valproate,,5/5/2008,treatment of fragile x syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Neuropharm Ltd,",Fetcham Park House,,Surrey,,' ' ,United Kingdom,256908,fragile x syndrome,"""gard:0006464""",
6972,Valproic acid,,3/30/2017,treatment of diffuse large b-cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Valcuria AB,Scheelevägen 2,,Lund,Skåne län,' ' ,Sweden,563116,lymphoma,"""gard:0020548""",
6973,"Valproic acid, sodium",,6/24/2005,treatment of familial adenomatous polyposis,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Topotarget A/S,Fruebjergvej 3,DK-2100,Copenhagen,,' ' ,Denmark,200705,familial adenomatous polyposis,"""gard:0006408""",
6974,Valrubicin,Valstar,5/23/1994,treatment of carcinoma in situ of the urinary bladder.,Designated/Approved,,,For intravesical therapy of BCG-refractory carcinoma in situ of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.,9/25/1998,9/25/2005,,"Anthra Pharmaceuticals, Inc.","103 Carnegie Center, Suite 102",,Princeton,New Jersey,' 08540 ' ,United States,82194,noma,"""gard:0004001""",
6975,valsartan oral solution,,10/28/2015,treatment of hypertension in pediatric patients 0 through 16 years of age,Designated/Designation Withdrawn or Revoked,4/28/2016,Not FDA Approved for Orphan Indication,,,,,Carmel Biosciences,5673 Peachtree Dunwoody Road,Suite 440,Atlanta,Georgia,' 30342 ' ,United States,494115,,,
6976,vamorolone,,12/18/2023,treatment of becker muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,ReveraGen BioPharma Inc.,"155 Gibbs Street, Suite 433",,Rockville,Maryland,' 20850 ' ,United States,977023,muscular dystrophy,"""gard:0007922""",
6977,vamorolone,Agamree,12/2/2011,treatment of duchenne muscular dystrophy,Designated/Approved,,,Treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older,10/26/2023,10/26/2030,Treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older,"Catalyst Pharmaceuticals, Inc.","355 Alhambra Circle, Suite 801",,Coral Gables,Florida,' 33134 ' ,United States,343111,muscular dystrophy,"""gard:0007922""",
6978,Vancomycin,,3/17/2022,treatment of periprosthetic joint infection,Designated,,Not FDA Approved for Orphan Indication,,,,,"Osteal Therapeutics, Inc.",PO BOX 140740,,Dallas,Texas,' 75214 ' ,United States,867521,,,
6979,vancomycin,,12/27/2012,treatment of endophthalmitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Fera Pharmaceuticals, LLC",134 Birch Hill Road,,Locust Valley,New York,' 11560 ' ,United States,361211,endophthalmitis,"""gard:0020333""",
6980,vancomycin,,6/22/2023,treatment of periprosthetic joint infection,Designated,,Not FDA Approved for Orphan Indication,,,,,"ForCast Orthopedics, Inc.",11 S. Fairfax St.,,Denver,Colorado,' 80246 ' ,United States,919822,,,
6981,Vancomycin HCL and Tobramycin sulfate multi-pack component of the Joint Purification Systems X7 Spacer,,1/9/2017,treatment of periprosthetic joint infection,Designated,,Not FDA Approved for Orphan Indication,,,,,Joint Purification Systems LLC,c/o Cor Medical Ventures LLC,215 S. Highway 101,Solana Beach,California,' 92075 ' ,United States,536416,,,
6982,vancomycin hydrochloride (inhalational),,9/20/2012,treatment of persistent methicillin-resistant s. aureus lung infection in patients with cystic fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Savara Pharmaceuticals, Inc.","1717 Langhorne Newtown Road, Suite 300",,Langhorne,Pennsylvania,' 19047 ' ,United States,374212,cystic fibrosis,"""gard:0006233""",
6983,vandetanib,CAPRELSA(r),10/21/2005,"treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma",Designated/Approved,,,Treatment of asymptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease,4/6/2011,4/6/2018,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,211005,thyroid carcinoma,"""gard:0019763""",
6984,vapreotide,,1/10/2000,treatment of esophageal variceal hemorrhage patients with portal hypertension.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Debiovision, Inc.",666 Sherbrooke Street West,Suite 1400,Montreal,,' ' ,Canada,129899,,,
6985,vapreotide,,1/10/2000,treatment of gastrointestinal and pancreatic fistulas.,Designated,,Not FDA Approved for Orphan Indication,,,,,Debiopharm S.A.,17 rue des Terreaux,,Lausanne,,' ' ,Switzerland,129599,,,
6986,Vapreotide,,4/6/2004,treatment of symptomatic carcinoid tumors,Designated,,Not FDA Approved for Orphan Indication,,,,,"H3 Pharma, Inc.",666 Sherbrooke Street West,Suite 1400,Montreal,,' ' ,Canada,175403,,,
6987,vapreotide,,3/6/2000,prevention of early postoperative complications following pancreatic resection.,Designated,,Not FDA Approved for Orphan Indication,,,,,Debiopharm S.A.,17 rue des Terreaux,,Lausanne,,' ' ,Switzerland,129699,,,
6988,vapreotide,,11/4/2003,treatment of acromegaly,Designated,,Not FDA Approved for Orphan Indication,,,,,"H3 Pharma, Inc.","666 Sherbrooke Street West,",Suite 1400,Montreal,,' ' ,Canada,175203,acromegaly,"""gard:0005725""",
6989,Varbulin,,11/5/2009,treatment of glioblastoma multiforme.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Myrexis, Inc.",305 Chipeta Way,,Salt Lake City,Utah,' 84108 ' ,United States,290809,glioblastoma,"""gard:0002491""",
6990,vardenafil,,4/22/2019,treatment of pulmonary arterial hypertension,Designated,,Not FDA Approved for Orphan Indication,,,,,"Respira Therapeutics, Inc",5901 Indian School Road NE,#107,Albuquerque,New Mexico,' 87110 ' ,United States,679319,pulmonary arterial hypertension,"""gard:0007501""",
6991,Varespladib,,3/25/2019,treatment of snakebite,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ophirex, Inc.",5643 Paradise Dr #2,,Corte Madera,California,' 94925 ' ,United States,677919,,,
6992,varespladib sodium,,11/19/2007,prevention of acute chest syndrome in at-risk patients with sickle cell disease,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Anthera Pharmaceuticals, Inc.",25801 Industrial Blvd.,Suite B,Hayward,California,' 94545 ' ,United States,240107,,,
6993,Varicella Zoster Immune Globulin (Human),VARIZIG,11/7/2006,"passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella",Designated/Approved,,,Post exposure prophylaxis of varicella in high risk individuals to reduce the severity of varicella,12/20/2012,12/20/2019,,"Cangene bioPharma, Inc.",155 Innovation Drive,,Winnipeg,,' ' ,Canada,228006,,,
6994,varlitinib,,6/20/2016,treatment of gastric cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,ASLAN Pharmaceuticals,10A Bukit Pasoh Road,,,,' ' ,Singapore,524216,,,
6995,varlitinib,,8/5/2015,treatment of biliary tract cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"ASLAN Pharmaceuticals Pte, Ltd.",83 Clemenceau Avenue,#12-03,Singapore,,' ' ,Singapore,485915,,,
6996,vascular endothelial growth factor 165b,,6/24/2008,treatment of advanced melanoma stages iib through iv.,Designated,,Not FDA Approved for Orphan Indication,,,,,"PhiloGene, Inc.",174 Summit Avenue,,Summit,New Jersey,' 07901 ' ,United States,261108,noma,"""gard:0004001""",
6997,Vasoactive intestinal peptide,,3/9/2001,treatment of acute respiratory distress syndrome.,Designated,,Not FDA Approved for Orphan Indication,,,,,mondoBIOTECH,Europark,FL - 9490 Vaduz,Liechtenstein,,' ' ,Switzerland,142001,,,
6998,vasoactive intestinal peptide (VIP)-elastin-like peptide (ELP) fusion protein,,5/13/2014,"treatment of pulmonary arterial hypertension, who group 1",Designated,,Not FDA Approved for Orphan Indication,,,,,ImmunoForge Co. Ltd.,"#1704, Ace Hansol Tower, 58, Gasan Digital 1-ro",Geumcheon-gu,Seoul,,' ' ,South Korea,397513,pulmonary arterial hypertension,"""gard:0007501""",
6999,Vasoactive intestinal polypeptide,,6/23/1993,treatment of acute esophageal food impaction.,Designated,,Not FDA Approved for Orphan Indication,,,,,Research Triangle Pharmaceuticals,200 Westpark Corporate Center,4364 South Alston Avenue,Durham,North Carolina,' 27713 ' ,United States,72192,,,
7000,Vasomera,,11/19/2015,"treatment of cardiomyopathy associated with dystrophinopathies; duchenne muscular dystrophy (dmd), becker muscular dystrophy bmd), and x-linked dilated cardiomyopathy (xl-dcmp).",Designated,,Not FDA Approved for Orphan Indication,,,,,ImmunoForge Co. Ltd.,"#1704, Ace Hansol Tower, 58, Gasan Digital 1-ro",Geumcheon-gu,Seoul,,' ' ,South Korea,492215,muscular dystrophy,"""gard:0007922""",
7001,vasopressin 1a receptor antagonist,,10/30/2019,treatment of huntington's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Azevan Pharmaceuticals, Inc.",116 Research Drive,,Bethlehem,Pennsylvania,' 18015 ' ,United States,532016,,,
7002,vatiquinone,,1/31/2014,treatment of friedreich's ataxia,Designated,,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",500 Warren Corporate Center Drive,,South Plainfield,New Jersey,' 07080 ' ,United States,418413,,,
7003,vatiquinone,,6/4/2014,treatment of leigh syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",500 Warren Corporate Center Drive,,Warren,New Jersey,' 07059 ' ,United States,435014,h syndrome,"""gard:0010239""",
7004,vatiquinone,,11/17/2014,treatment of rett syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",500 Warren Corporate Center Drive,,Warren,New Jersey,' 07059 ' ,United States,453014,rett syndrome,"""gard:0005696""",
7005,vatiquinone,,8/10/2020,treatment of seizures in patients with mitochondrial disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",500 Warren Corporate Center Drive,,Warren,New Jersey,' 07059 ' ,United States,759620,mitochondrial disease,"""gard:0018887""",
7006,vatiquinone,,10/18/2017,treatment of pontocerebellar hypoplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,"PTC Therapeutics, Inc.",500 Warren Corporate Center Drive,,Warren,New Jersey,' 07059 ' ,United States,606317,,,
7007,vebreltinib,,8/16/2022,treatment of non-small cell lung cancer with met genomic tumor aberrations,Designated,,Not FDA Approved for Orphan Indication,,,,,"Apollomics, Inc.","989 E. Hillsdale Blvd, Suite 220",,Foster City,California,' 94404 ' ,United States,878722,small cell lung cancer,"""gard:0009344""",
7008,vedolizumab,,3/15/2021,treatment of pouchitis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,804920,pouchitis,"""gard:0020510""",
7009,vedolizumab,,8/4/2016,prevention of graft versus host disease.,Designated/Designation Withdrawn or Revoked,10/4/2023,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,523516,graft versus host disease,"""gard:0016642""",
7010,Vedolizumab,,3/21/2017,treatment of graft versus host disease,Designated/Designation Withdrawn or Revoked,10/4/2023,Not FDA Approved for Orphan Indication,,,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,558216,graft versus host disease,"""gard:0016642""",
7011,velaglucerase-alfa,VPRIV,6/8/2009,treatment of gaucher disease,Designated/Approved,,,Treatment of Type I Gaucher Disease,2/26/2010,,,"Takeda Development Center Americas, Inc.",95 Hayden Avenue,,Lexington,Massachusetts,' 02421 ' ,United States,283509,gaucher disease,"""gard:0008233""",
7012,veliparib,,11/20/2009,treatment of hepatocellular carcinoma in combination with dna-damaging agents,Designated/Designation Withdrawn or Revoked,3/23/2022,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,295509,hepatocellular carcinoma,"""gard:0016773""",
7013,veliparib,,9/3/2009,treatment of epithelial ovarian cancer in combination with dna-damaging agents,Designated/Designation Withdrawn or Revoked,12/5/2023,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,290209,ovarian cancer,"""gard:0007295""",
7014,veliparib,,11/3/2016,treatment of squamous non-small cell lung cancer,Designated/Designation Withdrawn or Revoked,3/23/2022,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,542916,small cell lung cancer,"""gard:0009344""",
7015,veliparib,,12/17/2014,treatment of brain metastases when used in combination with dna-damaging agents,Designated/Designation Withdrawn or Revoked,3/23/2022,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,456514,,,
7016,veliparib,,5/9/2008,treatment of glioblastoma multiforme when used in combination with dna-damaging agents,Designated/Designation Withdrawn or Revoked,12/5/2023,Not FDA Approved for Orphan Indication,,,,,"AbbVie, Inc.",1 N. Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,257108,glioblastoma,"""gard:0002491""",
7017,velmanase alfa-tycv,Lamzede,2/2/2006,treatment of alpha-mannosidosis,Designated/Approved,,,treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients,2/16/2023,2/16/2030,treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients,"Chiesi USA, Inc.",175 Regency Woods Place,Suite 600,Cary,North Carolina,' 27518 ' ,United States,212005,alpha-mannosidosis,"""gard:0006968""",
7018,veltuzumab,,7/28/2015,treatment of immune thrombocytopenic purpura.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,486915,,,
7019,veltuzumab,,11/17/2014,treatment of pemphigus,Designated/Designation Withdrawn or Revoked,12/9/2019,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 The American Rd.,,Morris Plains,New Jersey,' 07950 ' ,United States,454714,,,
7020,veltuzumab,,8/28/2008,treatment of chronic lymphocytic leukemia,Designated/Designation Withdrawn or Revoked,9/20/2019,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,261308,,,
7021,Velusetrag,,10/4/2022,treatment of chronic intestinal pseudo-obstruction,Designated,,Not FDA Approved for Orphan Indication,,,,,ALFASIGMA S.P.A.,VIA RAGAZZI DEL '99 - 5,,BOLOGNA,BO,' CAP 40133 ' ,Italy,902622,,,
7022,vemurafenib,,9/8/2014,treatment of patients with non-small cell lung cancer (nsclc) with braf v600 mutation,Designated/Designation Withdrawn or Revoked,4/30/2018,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,444314,small cell lung cancer,"""gard:0009344""",
7023,vemurafenib,,8/26/2014,treatment of hairy cell leukemia (hcl).,Designated/Designation Withdrawn or Revoked,4/30/2018,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,M/S 241B,South San Francisco,California,' 94080 ' ,United States,444114,,,
7024,vemurafenib,Zelboraf,12/20/2010,treatment of patients with iib to stage iv melanoma positive for the braf(v600) mutation,Designated/Approved,,,Treatment of unresectable or metastatic melanoma with the BRAFV600E mutation as detected by an FDA-approved test.,8/17/2011,8/17/2018,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,325310,noma,"""gard:0004001""",
7025,vemurafenib,,11/26/2013,treatment of anaplastic thyroid carcinoma and advanced papillary thyroid cancer whose tumors harbor a braf v600 mutation,Designated/Designation Withdrawn or Revoked,4/30/2018,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,M/S 241B,South San Francisco,California,' 94080 ' ,United States,399213,thyroid carcinoma,"""gard:0019763""",
7026,vemurafenib,Zelboraf,8/2/2016,treatment of erdheim-chester disease,Designated/Approved,,,Treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation,11/6/2017,11/6/2024,Treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080 ' ,United States,529616,erdheim-chester disease,"""gard:0006369""",
7027,Venadaparib,,8/5/2022,treatment of gastric cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Idience Co., Ltd.","2, Baumoe-ro 27-gil, Seocho-gu",,Seoul,Seoul,' 06752 ' ,South Korea,816221,,,
7028,Venetoclax,,11/5/2020,treatment for small cell lung cancer,Designated/Designation Withdrawn or Revoked,9/15/2021,Not FDA Approved for Orphan Indication,,,,,"Genentech, Inc.",1 DNA Way,,South San Francisco,California,' 94080-4990 ' ,United States,780920,small cell lung cancer,"""gard:0009344""",
7029,venetoclax,,8/31/2017,treatment of mantle cell lymphoma,Designated,,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,600117,lymphoma,"""gard:0020548""",
7030,venetoclax,,8/29/2016,treatment of multiple myeloma,Designated,,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,Regualtory Affairs,1 North Waukegan Road,North Chicago,Illinois,' 60064 ' ,United States,536116,multiple myeloma,"""gard:0007108""",
7031,venetoclax,,3/27/2014,treatment of diffuse large b-cell lymphoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,AbbVie,Research and Development,1 North Waukegan Road,North Chicago,Illinois,' 60064 ' ,United States,423814,lymphoma,"""gard:0020548""",
7032,Venetoclax,,10/26/2020,treatment of acute lymphoblastic leukemia,Designated/Designation Withdrawn or Revoked,4/16/2024,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,,North Chicago,Illinois,' 60064 ' ,United States,777520,acute lymphoblastic leukemia,"""gard:0000522""",
7033,venetoclax,VENCLEXTA,2/4/2016,treatment of acute myeloid leukemia.,Designated/Approved,,,"VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",11/21/2018,11/21/2025,"VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",AbbVie Inc.,1 North Waukegan Road,"Dept PA72, Bldg. AP30-4",North Chicago,Illinois,' 60064 ' ,United States,506815,acute myeloid leukemia,"""gard:0012757""",
7034,venetoclax,VENCLEXTA,9/20/2012,treatment of chronic lymphocytic leukemia,Designated/Approved,,,"VENCLEXTA® (venetoclax) indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.",6/8/2018,6/8/2025,"For treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), without 17p deletion, who have received at least one prior therapy.","AbbVie, Inc",1 North Waukegan Road,"Dept. PA72, Bldg. AP30",North Chicago,Illinois,' 60064 ' ,United States,375612,,,
7035,venetoclax,VENCLEXTA,9/20/2012,treatment of chronic lymphocytic leukemia,Designated/Approved,,,VENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).,5/15/2019,5/15/2026,Treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),"AbbVie, Inc",1 North Waukegan Road,"Dept. PA72, Bldg. AP30",North Chicago,Illinois,' 60064 ' ,United States,375612,,,
7036,venetoclax,VENCLEXTA,9/20/2012,treatment of chronic lymphocytic leukemia,Designated/Approved,,,"Treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy",4/11/2016,4/11/2023,"Treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy","AbbVie, Inc",1 North Waukegan Road,"Dept. PA72, Bldg. AP30",North Chicago,Illinois,' 60064 ' ,United States,375612,,,
7037,Venetoclax,,6/12/2019,treatment of myelodysplastic syndromes,Designated,,Not FDA Approved for Orphan Indication,,,,,AbbVie Inc.,1 North Waukegan Road,"Dept #PA72, Bldg. AP30-4",North Chicago,Illinois,' 60064 ' ,United States,689119,myelodysplastic syndrome,"""gard:0007132""",
7038,venetoclax + idasanutlin,,12/17/2018,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Genentech Inc. (A Member of the Roche Group),1 DNA Way,MS# 355d,South San Francisco,California,' 94080 ' ,United States,664118,acute myeloid leukemia,"""gard:0012757""",
7039,venglustat,,9/11/2014,treatment of gaucher disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Genzyme,500 Kendall Street,,Cambridge,Massachusetts,' 02142 ' ,United States,443414,gaucher disease,"""gard:0008233""",
7040,venglustat,,5/1/2018,treatment of autosomal dominant polycystic kidney disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genzyme Corporation, a SANOFI COMPANY",50 Binney Street,,Cambridge,Massachusetts,' 02142 ' ,United States,637218,autosomal dominant polycystic kidney disease,"""gard:0010413""",
7041,Venglustat,,8/26/2014,treatment of fabry's disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Genzyme Corporation,500 Kendall Street,,Cambridge,Massachusetts,' 01242 ' ,United States,439814,,,
7042,venglustat malate,,8/13/2020,treatment of gm2 gangliosidosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Genzyme Corporation, a SANOFI COMPANY",50 Binney Street,,Cambridge,Massachusetts,' 02142 ' ,United States,755820,gm2 gangliosidosis,"""gard:0021323""",
7043,vepafestinib,,3/30/2023,treatment of ret alteration-positive non-small cell lung cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Helsinn Healthcare SA,Via Pian Scairolo 9,,Pazzallo (Lugano),,' 6912 ' ,Switzerland,857521,small cell lung cancer,"""gard:0009344""",
7044,verdiperstat,,2/15/2019,treatment of multiple system atrophy (msa).,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biohaven Pharmaceuticals, Inc.",215 Church Street,,New Haven,Connecticut,' 06510 ' ,United States,671418,multiple system atrophy,"""gard:0007079""",
7045,verteporfin,,3/9/2012,treatment of chronic or recurrent central serous chorioretinopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Valeant Pharmaceuticals North America LLC,700 Route 202/206 North,,Bridgewater,New Jersey,' 08807 ' ,United States,350511,central serous chorioretinopathy,"""gard:0000200""",
7046,vestronidase alfa-vjbk,Mepsevii,2/16/2012,"treatment of mucopolysaccharidosis vii (mps vii, sly syndrome)",Designated/Approved,,,"Indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (PMS VII, Sly syndrome).",11/15/2017,11/15/2024,"Indicated in pediatric and adult patients for the treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome).","Ultragenyx Pharmaceutical, Inc.",60 Leveroni Court,,Novato,California,' 94949 ' ,United States,359811,mucopolysaccharidosis,"""gard:0007065""",
7047,vibostolimab and pembrolizumab,,11/8/2022,treatment of small cell lung cancer (sclc),Designated,,Not FDA Approved for Orphan Indication,,,,,"Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc.",126 East Lincoln Ave,P.O.Box 2000,Rahway,New Jersey,' 07065 ' ,United States,893722,small cell lung cancer,"""gard:0009344""",
7048,Vibrio alginolyticus collagenase,,10/12/2016,treatment of advanced dupuytren's disease (dupuytren's contracture),Designated,,Not FDA Approved for Orphan Indication,,,,,Fidia Farmaceutici S.p.A.,"Via Ponte della Fabbrica, 3/A",,Abano Terme PD,,' ' ,Italy,539616,,,
7049,vibriolysin,,6/16/2006,"debridement of severe, deep dermal burns in hospitalized patients",Designated,,Not FDA Approved for Orphan Indication,,,,,BioMarin Pharmaceutical Inc.,105 Digital Drive,,Novato,California,' 94949 ' ,United States,128599,,,
7050,vidutolimod,,2/26/2020,treatment of stage iib to iv melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Regeneron Pharmaceuticals Inc.,777 Old Saw Mill River Rd.,,Tarrytown,New York,' 10591 ' ,United States,724819,noma,"""gard:0004001""",
7051,vigabatrin,Sabril,6/12/2000,treatment of infantile spasms.,Designated/Approved,,,For infantile spasms (IS) - 1 month to 2 years of age.,8/21/2009,8/21/2016,,H. Lundbeck A/S,Four Parkway North,,Deerfield,Illinois,' 60015 ' ,United States,135100,,,
7052,vigabatrin and cosyntropin,,11/1/2017,treatment of infantile spasms,Designated,,Not FDA Approved for Orphan Indication,,,,,"West Therapeutic Development, LLC",540 Ziegler Drive,,Grayslake,Illinois,' 60030 ' ,United States,609817,,,
7053,Vilobelimab,,6/27/2022,treatment of pyoderma gangrenosum,Designated,,Not FDA Approved for Orphan Indication,,,,,InflaRx N.V.,Winzerlaer Str. 2,,Jena,,' 07745 ' ,Germany,884822,pyoderma gangrenosum,"""gard:0007510""",
7054,viloxazine HCL,,6/11/1984,treatment of cataplexy and narcolepsy,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Stuart Pharmaceuticals,Division of ICI Americas,,Wilmington,Delaware,' 19897 ' ,United States,2384,narcolepsy,"""gard:0022460""",
7055,viltolarsen,VILTEPSO,1/12/2017,treatment of duchenne muscular dystrophy,Designated/Approved,,,VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping,8/12/2020,8/12/2027,VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping,"NS Pharma, Inc.","140 East Ridgewood Avenue, Suite 280S",,Paramus,New Jersey,' 07652 ' ,United States,565616,muscular dystrophy,"""gard:0007922""",
7056,Vinblastine N-Oxide,,10/12/2022,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cascade Prodrug, Inc.",P.O. Box 13020,,Eugene,Oregon,' 97440 ' ,United States,904922,,,
7057,vinCRIStine sulfate LIPOSOME injection,Marqibo,1/8/2007,treatment of acute lymphoblastic leukemia,Designated/Approved,,,Treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.,8/9/2012,8/9/2019,,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,' 08520 ' ,United States,234406,acute lymphoblastic leukemia,"""gard:0000522""",
7058,vincristine sulfate liposomes,,6/24/2008,treatment of metastatic uveal melanoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,Acrotech Biopharma LLC,279 Princeton Hightstown Road,,East Windsor,New Jersey,' 08520 ' ,United States,259108,uveal melanoma,"""gard:0008621""",
7059,vintafolide,,12/16/2013,treatment of ovarian cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Endocyte, Inc.",3000 Kent Avenue,Suite A1-100,West Lafayette,Indiana,' 47906 ' ,United States,415513,ovarian cancer,"""gard:0007295""",
7060,Virulizin,,2/1/2001,treatment of pancreatic cancer.,Designated,,Not FDA Approved for Orphan Indication,,,,,"ZOR Pharmaceuticals, LLC",100-A Eastwood Center Drive,Suite 118,Wilmington,North Carolina,' 28403 ' ,United States,139600,,,
7061,Virus-like particle containing Cas9/gRNA ribonucleoprotein targeting the human HTT gene,,10/5/2023,treatment of huntington’s disease,Designated,,Not FDA Approved for Orphan Indication,,,,,"Shanghai BDgene Co., Ltd.","301, 302, 303, 304, Unit B, Building 17",No.1699 Duhui Road,Minhang District,Shanghai,' 201108 ' ,China,964823,,,
7062,vitamin A palmitate,,7/14/2015,prevention of bronchopulmonary dysplasia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advent Therapeutics, Inc.",6500 Old Carversville Road,,Lumberville,Pennsylvania,' 18933 ' ,United States,483315,bronchopulmonary dysplasia,"""gard:0005962""",
7063,vixotrigine,,7/24/2013,treatment of trigeminal neuralgia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",300 Binney Street,,Cambridge,Massachusetts,' 02142 ' ,United States,401613,trigeminal neuralgia,"""gard:0007805""",
7064,vixotrigine,,1/30/2017,treatment of erythromelalgia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biogen, Inc.",300 Binney Street,,Cambridge,Massachusetts,' 02142 ' ,United States,553016,,,
7065,VLA-4 and LFA-1 integrin activator,,11/8/2017,treatment of malignant melanoma stages iib to iv,Designated,,Not FDA Approved for Orphan Indication,,,,,"7 Hills Pharma, LLC",8285 El Rio Street,Suite 130,Houston,Texas,' 77054 ' ,United States,611917,noma,"""gard:0004001""",
7066,vocimagene amiretrorepvec and flucytosine,,1/12/2011,treatment of malignant glioma in addition to glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tocagen, Inc.",4242 Campus Point Court,Suite 500,San Diego,California,' 92121 ' ,United States,327910,glioblastoma,"""gard:0002491""",
7067,"volanesorsen sodium, apolipotrotein C-III antisense oligonucleotide",,6/23/2015,treatment of familial chylomicronemia syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Akcea Therapeutics, Inc.",22 Boston Wharf Road,9th Floor,Boston,Massachusetts,' 02210 ' ,United States,480815,familial chylomicronemia syndrome,"""gard:0006414""",
7068,volasertib,,4/14/2014,treatment of acute myeloid leukemia,Designated/Designation Withdrawn or Revoked,6/19/2019,Not FDA Approved for Orphan Indication,,,,,"Boehringer Ingelheim Pharmaceuticals, Inc.",900 Ridgebury Road,P. O. Box 368,Ridgefield,Connecticut,' 06877 ' ,United States,415913,acute myeloid leukemia,"""gard:0012757""",
7069,Volasertib,,10/8/2020,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Oncoheroes Biosciences Inc.,"43 Kent Street, #1",,Brookline,Massachusetts,' 02445 ' ,United States,771420,soft tissue sarcoma,"""gard:0004898""",
7070,von Willebrand Factor Human Concentrate,,5/29/2014,treatment of von willebrand disease,Designated/Designation Withdrawn or Revoked,7/18/2023,Not FDA Approved for Orphan Indication,,,,,"LFB USA, Inc.",175 Crossing Blvd,,Framingham,Massachusetts,' 01702 ' ,United States,424814,von willebrand disease,"""gard:0007867""",
7071,von Willebrand Factor/Coagulation Factor VIII Complex (Human),Wilate,4/18/2007,treatment of von willebrand disease except for surgical and/or invasive procedures in patients with von willebrand disease in whom desmopressin is either ineffective or contraindicated,Designated/Approved,,,Treatment of spontaneous or trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated,12/4/2009,,,"Octapharma USA, Inc.",117 West Century Road,,Paramus,New Jersey,' 07652 ' ,United States,234106,von willebrand disease,"""gard:0007867""",
7072,von Willebrand Factor/Coagulation Factor VIII Complex (Human),Wilate,4/18/2007,treatment of von willebrand disease except for surgical and/or invasive procedures in patients with von willebrand disease in whom desmopressin is either ineffective or contraindicated,Designated/Approved,,,Routine prophylaxis to reduce the frequency of bleeding episodes in children 6 years of age and older and adults with von Willebrand disease,12/1/2023,12/1/2030,Routine prophylaxis to reduce the frequency of bleeding episodes in children 6 years of age and older and adults with von Willebrand disease,"Octapharma USA, Inc.",117 West Century Road,,Paramus,New Jersey,' 07652 ' ,United States,234106,von willebrand disease,"""gard:0007867""",
7073,Vonafexor,,8/9/2023,treatment of alport syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,ENYO Pharma,60 avenue Rockefeller,,LYON,Bâtiment Bioserra B,' 69008 ' ,France,953323,alport syndrome,"""gard:0005785""",
7074,vonapanitase,,4/3/2009,prevention of arteriovenous fistula and arteriovenous graft failure in patients with chronic kidney disease (ckd) who are receiving hemodialysis or preparing for hemodialysis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Proteon Therapeutics, Inc.",200 West Street,,Waltham,Massachusetts,' 02451 ' ,United States,273908,,,
7075,vorasidenib,,9/10/2018,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,Servier Pharmaceuticals LLC,200 Pier Four Blvd,,Boston,Massachusetts,' 02210 ' ,United States,649318,,,
7076,voretigene neparvovec-rzyl,LUXTURNA,3/18/2015,treatment of inherited retinal dystrophy due to biallelic rpe65 gene mutations,Designated/Approved,,,an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells determined by a treating physician,12/19/2017,12/19/2024,Treatment of patients with confirmed biallelic RPE65 mutation-associated retinal distrophy. Patients must have viable retinal cells determined by a treating physician.,"Spark Therapeutics, Inc.",3737 Market Street,Suite 1300,Philadelphia,Pennsylvania,' 19104 ' ,United States,466414,,,
7077,vorinostat,Zolinza,3/16/2004,treatment of t-cell non-hodgkin's lymphoma,Designated/Approved,,,"Treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistant or recurrent disease on or following two systemic therapies.",10/6/2006,10/6/2013,,"Merck & Co., Inc.","P. O. Box 2000, RY 32-605",,Rahway,New Jersey,' 07065 ' ,United States,174203,lymphoma,"""gard:0020548""",
7078,vorinostat,,5/24/2024,treatment of rett syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Unravel Biosciences, Inc.",UMass-Boston Venture Development Center,100 Morrisey Boulevard,Boston,Massachusetts,' 02125 ' ,United States,1003224,rett syndrome,"""gard:0005696""",
7079,vorinostat,,3/17/2004,treatment of mesothelioma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,"Merck & Co., Inc.","P. O. Box 2000, RY 32-605",,Rahway,New Jersey,' 07065 ' ,United States,177203,,,
7080,vorinostat,,6/12/2003,treatment of multiple myeloma,Designated/Designation Withdrawn or Revoked,,Not FDA Approved for Orphan Indication,,,,,Merck Research Laboratories,"Merck & Co., Inc.","P. O. Box 2000, RY 33-212",Rahway,New Jersey,' 07065 ' ,United States,169503,multiple myeloma,"""gard:0007108""",
7081,vorinostat,,10/13/2016,"treatment of advanced melanoma (stages iib, iic, iii, and iv)",Designated,,Not FDA Approved for Orphan Indication,,,,,Qameleon Therapeutics,Moslaan 32,1433 WJ,Kudelstaart,Noord-Holland,' ' ,Netherlands,540116,noma,"""gard:0004001""",
7082,vosaroxin,,10/28/2009,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sunesis Pharmaceuticals, Inc.",395 Oyster Point Blvd,Suite 400,South San Francisco,California,' 94080 ' ,United States,294509,acute myeloid leukemia,"""gard:0012757""",
7083,vosoritide,,8/1/2023,treatment of hypochondroplasia,Designated,,Not FDA Approved for Orphan Indication,,,,,BioMarin Pharmaceutical Inc.,105 Digital Drive,,Novato,California,' 94949 ' ,United States,951623,hypochondroplasia,"""gard:0006724""",
7084,vosoritide,Voxzogo,1/17/2013,treatment of achondroplasia,Designated/Approved,,,to increase linear growth in pediatric patients with achondroplasia with open epiphyses,10/20/2023,10/20/2030,to increase linear growth in pediatric patients less than 5 years of age with achondroplasia with open epiphyses,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,' 94949 ' ,United States,386012,achondroplasia,"""gard:0008173""",
7085,vosoritide,Voxzogo,1/17/2013,treatment of achondroplasia,Designated/Approved,,,To increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses,11/19/2021,11/19/2028,To increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses,"BioMarin Pharmaceutical, Inc.",105 Digital Drive,,Novato,California,' 94949 ' ,United States,386012,achondroplasia,"""gard:0008173""",
7086,voxelotor,Oxbryta,12/29/2015,treatment of sickle cell disease,Designated/Approved,,,OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.,11/25/2019,11/25/2026,Indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.,"Global Blood Therapeutics, Inc.",181 Oyster Point Blvd,,South San Francisco,California,' 94080 ' ,United States,499715,,,
7087,voxelotor,Oxbryta,12/29/2015,treatment of sickle cell disease,Designated/Approved,,,treatment of sickle cell disease (SCD) in adults and pediatric patients 4 years of age and older,12/17/2021,12/17/2028,treatment of sickle cell disease (SCD) in pediatric patients 4 years of age to less than 12 years of age,"Global Blood Therapeutics, Inc.",181 Oyster Point Blvd,,South San Francisco,California,' 94080 ' ,United States,499715,,,
7088,vutrisiran,Amvuttra,5/25/2018,treatment of transthyretin-mediated amyloidosis (attr amyloidosis),Designated/Approved,,,Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults,6/13/2022,6/13/2029,Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults,Alnylam Pharmaceuticals,300 Third Street,,Cambridge,Massachusetts,' 02142 ' ,United States,637618,amyloidosis,"""gard:0018676""",
7089,Water-miscible vitamin A palmitate,,3/26/2010,prevention of bronchopulmonary dysplasia.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Fox Pharma, Inc.",6097 Hidden Valley Drive,,Doylestown,Pennsylvania,' 18902 ' ,United States,295109,bronchopulmonary dysplasia,"""gard:0005962""",
7090,Wharton's jelly mesenchymal stem cells,,9/27/2016,treatment of graft-versus-host disease,Designated,,Not FDA Approved for Orphan Indication,,,,,Midwest Stem Cell Therapy Center,University of Kansas Medical Center,3901 Rainbow Boulevard,Kansas City,Kansas,' 66160 ' ,United States,535016,,,
7091,Xenogeneic hepatocytes,,11/27/1998,treatment of severe liver failure.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Circe Biomedical, Inc.",99 Hayden Ave.,,Lexington,Massachusetts,' 02421 ' ,United States,117098,,,
7092,xenon gas,,5/18/2015,to improve neurological outcome in hospitalized cardiac arrest patients.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Invero Pharma, Inc.",103 Highland Drive,,Buffalo,New York,' 14221 ' ,United States,461914,,,
7093,xenon gas,,12/3/2014,treatment of hypoxic ischemic encephalopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Neuroprotexeon,Imperial Innovations,London SW7 2PG,London,,' ' ,United Kingdom,455714,,,
7094,Yersinia pestis plague recombinant antigen (rF1V; F1 capsular protein fused to V antigen; E. coli) vaccine with aluminum hydroxide,,11/30/2016,prevention of plague (yersinia pestis),Designated,,Not FDA Approved for Orphan Indication,,,,,"The Surgeon General, Department of the Army",Medical Research and Materiel Command 1430 Veterans Drive,,Fort Detrick,Maryland,' 21702-5009 ' ,United States,491615,plague,"""gard:0018702""",
7095,yinfenidone,,8/10/2017,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Sunshine Lake Pharma Co., Ltd",Northern Industry Road #1,Song Shan Lake,Dongguan,Guangdong,' ' ,China,594517,idiopathic pulmonary fibrosis,"""gard:0008609""",
7096,Yttrium (90Y) antiferritin polyclonal antibodies,,9/18/2006,treatment of hodgkin's disease.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Alissa Pharma, LLC",341 North Woodland St.,,Englewood,New Jersey,' 07631 ' ,United States,228606,,,
7097,Yttrium(90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10,,12/3/2012,treatment of soft tissue sarcoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"OncoTherapy Science, Inc.",Kanagawa Science Park R & D D-6F,,Kawasaki-shi,Kanagawa,' ' ,Japan,383012,soft tissue sarcoma,"""gard:0004898""",
7098,Yttrium-90 radiolabeled humanized monoclonal anti-carcinoembroyonic antigen IgG antibody,,8/3/1999,treatment of ovarian carcinoma.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Immunomedics, Inc.",300 American Road,,Morris Plains,New Jersey,' 07950 ' ,United States,124499,noma,"""gard:0004001""",
7099,zagociguat,,3/23/2023,treatment of mitochondrial diseases,Designated,,Not FDA Approved for Orphan Indication,,,,,"Tisento Therapeutics, Inc.","245 First Street, Riverview II, 18th Floor",,Cambridge,Massachusetts,' 02142 ' ,United States,931423,mitochondrial disease,"""gard:0018887""",
7100,Zalcitabine,,12/9/1986,treatment of aids.,Designated,,Not FDA Approved for Orphan Indication,,,,,"National Cancer Institute, DCT","NIH, Executive Plaza North, Room 7-18",,Bethesda,Maryland,' 20892 ' ,United States,17586,,,
7101,Zalcitabine,Hivid,6/28/1988,treatment of aids.,Designated/Approved,,,Combination therapy with zidovudine is indicated for the treatment of adult patients with advanced HIV infection (CD4 count < 300) who have demonstrated malignant clinical or immunologic deterioration.,6/19/1992,6/19/1999,,"Hoffmann-La Roche, Inc.",340 Kingsland Street,,Nutley,New Jersey,' 07110 ' ,United States,28388,,,
7102,Zamicastat,,7/15/2019,treatment of pulmonary arterial hypertension (pah) (pulmonary hypertension who group 1),Designated/Designation Withdrawn or Revoked,9/22/2022,Not FDA Approved for Orphan Indication,,,,,"Bial-Portela & Cª., S.A.",À Av. da Siderurgia Nacional,4745-457 S. Mamede do Coronado,Coronado,,' ' ,Portugal,693619,pulmonary arterial hypertension,"""gard:0007501""",
7103,Zandelisib,,11/9/2021,treatment of follicular lymphoma,Designated/Designation Withdrawn or Revoked,6/12/2023,Not FDA Approved for Orphan Indication,,,,,"MEI Pharma, Inc.",11455 El Camino Real,Suite 250,San Diego,California,' 92130 ' ,United States,849021,lymphoma,"""gard:0020548""",
7104,zanidatamab,,12/18/2019,treatment of biliary tract cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Jazz Pharmaceuticals Ireland Limited,3170 Porter Drive,,Palo Alto,California,' 94304 ' ,United States,715119,,,
7105,zanubrutinib,Brukinsa,8/24/2020,treatment of splenic marginal zone lymphoma,Designated/Approved,,,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen,9/14/2021,9/14/2028,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen,"BeiGene USA, Inc.",2955 Campus Drive,Suite 200,San Mateo,California,' 94403 ' ,United States,757020,lymphoma,"""gard:0020548""",
7106,zanubrutinib,,5/20/2024,treatment of membranous nephropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,"BeiGene USA, Inc.",1840 Gateway Drive,3rd Floor,San Mateo,California,' 94404 ' ,United States,1002924,,,
7107,zanubrutinib,Brukinsa,11/8/2022,treatment of follicular lymphoma,Designated/Approved,,,"treatment of adult patients with relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy",3/7/2024,3/7/2031,"treatment of adult patients with relapsed or refractory follicular lymphoma (FL), after two or more lines of systemic therapy","BeiGene, Ltd., c/o BeiGene USA, Inc.","1840 Gateway Drive, 3rd Floor",,San Mateo,California,' 94404 ' ,United States,889422,lymphoma,"""gard:0020548""",
7108,zanubrutinib,BRUKINSA,6/23/2016,treatment of mantle cell lymphoma,Designated/Approved,,,BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.,11/14/2019,11/14/2026,Indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.,"BeiGene USA, Inc.",2955 Campus Drive,Suite 200,San Mateo,California,' 94403 ' ,United States,527416,lymphoma,"""gard:0020548""",
7109,zanubrutinib,Brukinsa,6/29/2016,treatment of waldenstrom's macroglobulinemia,Designated/Approved,,,Treatment of adult patients with Waldenstrom¿s macroglobulinemia (WM),8/31/2021,8/31/2028,Treatment of adult patients with Waldenstrom¿s macroglobulinemia (WM),"BeiGene USA, Inc.",2955 Campus Drive,Suite 200,San Mateo,California,' 94403 ' ,United States,527616,,,
7110,zanubrutinib,Brukinsa,8/24/2020,treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue,Designated/Approved,,,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen,9/14/2021,9/14/2028,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen,"BeiGene USA, Inc.",2955 Campus Drive,Suite 200,San Mateo,California,' 94403 ' ,United States,756920,lymphoma,"""gard:0020548""",
7111,zanubrutinib,Brukinsa,8/24/2020,treatment of nodal marginal zone lymphoma,Designated/Approved,,,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen,9/14/2021,9/14/2028,Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen,"BeiGene USA, Inc.",2955 Campus Drive,Suite 200,San Mateo,California,' 94403 ' ,United States,757120,lymphoma,"""gard:0020548""",
7112,zanubrutinib,Brukinsa,7/20/2016,treatment of chronic lymphocytic leukemia,Designated/Approved,,,treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),1/19/2023,1/19/2030,treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),"BeiGene USA, Inc.","1840 Gateway Drive, 3rd floor",,San Mateo,California,' 94404 ' ,United States,527516,,,
7113,zapnometinib,,12/28/2021,treatment of hantavirus infection,Designated,,Not FDA Approved for Orphan Indication,,,,,Atriva Therapeutics GmbH,Eisenbahnstr. 1,,Tübingen,,' 72072 ' ,Germany,853921,,,
7114,zelasudil,,8/14/2023,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,Redx Pharma Plc,Block 33,"Mereside, Alderley Park",Macclesfield,Cheshire,' SK10 4TG ' ,United Kingdom,953723,idiopathic pulmonary fibrosis,"""gard:0008609""",
7115,Zenocutuzumab,,7/22/2020,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Merus N.V.,139 Main Street,,Cambridge,Massachusetts,' 02142 ' ,United States,750020,,,
7116,zidovudine,Retrovir,7/17/1985,treatment of aids,Designated/Approved,,,Management of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed Pneumocytis carinii pneumonia (PCP) or an absolute CD4 (T4 helper/induccer) lymphocyte count of less than 200/mm in the peripheral blood before therapy is begun,3/19/1987,3/19/1994,,Glaxo Wellcome Inc.,5 Moore Drive,,Research Triangle Park,North Carolina,' 27709 ' ,United States,8185,,,
7117,zildistrogene varoparvovec,,8/31/2016,treatment of duchenne muscular dystrophy,Designated,,Not FDA Approved for Orphan Indication,,,,,"Solid Biosciences, Inc.","500 Rutherford Ave, 3rd Floor",,Charlestown,Massachusetts,' 02129 ' ,United States,518216,muscular dystrophy,"""gard:0007922""",
7118,zilucoplan,Zilbrysq,8/26/2019,treatment of myasthenia gravis,Designated/Approved,,,Treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive,10/17/2023,10/17/2030,Treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive,"UCB, Inc.","1950 Lake Park Drive, Bldg. 2100",,Smyrna,Georgia,' 30080 ' ,United States,699319,myasthenia gravis,"""gard:0007122""",
7119,"Zinc (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate and (3S,9aS)-3-(1H-imidazol-5-ylmethyl)-octahydro-1H-pyrido[1,2-a]piperazine-1,4-dione",,5/30/2024,treatment of idiopathic pulmonary fibrosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"NovMetaPharma Co., Ltd.","727, Eonju-ro, Gangnam-gu",,"Seoul, Republic of Korea",,' ' ,South Korea,981123,idiopathic pulmonary fibrosis,"""gard:0008609""",
7120,Zinc acetate,Galzin,11/6/1985,treatment of wilson's disease.,Designated/Approved,,,For maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent.,1/28/1997,1/28/2004,,Lemmon Company,1510 Delp Drive,,Kulpsville,Pennsylvania,' 19443 ' ,United States,11185,,,
7121,zinflavonoids,,1/7/2021,treatment of anatomical sites of squamous cell carcinoma of oral cavity and oropharynx accessible for local and topical administration,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aveta Biomics, Inc.",110 Great Road,Suite 302,Bedford,Massachusetts,' 01730 ' ,United States,740720,noma,"""gard:0004001""",
7122,Ziritaxestat,,1/27/2020,treatment of systemic sclerosis,Designated/Designation Withdrawn or Revoked,3/30/2021,Not FDA Approved for Orphan Indication,,,,,Galapagos NV,Generaal De Wittelaan,L11 A3,Mechelen,,' ' ,Belgium,723919,systemic sclerosis,"""gard:0009748""",
7123,Zoledronate,"Zometa, Zabel",8/18/2000,treatment of tumor induced hypercalcemia.,Designated/Approved,,,Treatment of hypercalcemia of malignancy.,8/20/2001,8/20/2008,,Novartis Pharmaceuticals Corp.,59 Route 10,,East Hanover,New Jersey,' 07936 ' ,United States,130899,,,
7124,"zoledronate D,L-lysine monohydrate (ZLM)",,4/15/2015,treatment of complex regional pain syndrome (crps),Designated,,Not FDA Approved for Orphan Indication,,,,,"Thar Pharma, LLC",150 Gamma Dr.,,Pittsburgh,Pennsylvania,' 15238 ' ,United States,461014,complex regional pain syndrome,"""gard:0004647""",
7125,zoledronic acid,,5/6/2013,treatment of complex regional pain syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Axsome Therapeutics, Inc.","25 Broadway, 9th Floor",Suite 2000,New York,New York,' 10004 ' ,United States,374112,complex regional pain syndrome,"""gard:0004647""",
7126,Zosuquidar trihydrochloride,,12/15/2005,treatment of acute myeloid leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kanisa Pharmaceuticals, Inc.",12264 El Camino Real,,San Diego,California,' 02130 ' ,United States,212805,acute myeloid leukemia,"""gard:0012757""",
7127,zotiraciclib,,11/21/2019,treatment of glioma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Cothera Bioscience, Inc.","2929 Campus Drive, Suite 230",,San Mateo,California,' 94403 ' ,United States,710719,,,
7128,zuretinol acetate,,12/2/2010,treatment of retinitis pigmentosa,Designated/Designation Withdrawn or Revoked,4/1/2020,Not FDA Approved for Orphan Indication,,,,,Retinagenix LLC,1815 Purdy Avenue,,Miami Beach,Florida,' 33139 ' ,United States,324410,retinitis pigmentosa,"""gard:0005694""",
7129,zuretinol acetate,,12/2/2010,treatment of inherited retinal dystrophies caused by confirmed biallelic rpe65 or lrat mutations,Designated,,Not FDA Approved for Orphan Indication,,,,,"Eluminex Biosciences, Inc.","611 Gateway Boulevard, Suite 120",,South San Francisco,California,' 94080 ' ,United States,320410,,,
7130,"[(1S,2S,5S)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-6,6-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]methanol",,4/13/2020,prevention of proliferative vitreoretinopathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Tetra Bio-Pharma Inc.,365 St.-Jean Street,Suite 122,Longueuil,,' ' ,Canada,734920,vitreoretinopathy,"""gard:0019539""",
7131,[(4-benzylpiperazin-1-yl)(2-(isopentylamino)pyridin-3-yl)methanone]-phosphate,,8/7/2018,treatment of angelman syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Seneca Biopharma, Inc.",20271 Goldenrod Lane,Suite 2024,Germantown,Maryland,' 20876 ' ,United States,647018,angelman syndrome,"""gard:0005810""",
7132,[(S)-1-(L-valyl)-N_((S)-1-phenyl-2-(pyridin-2-yl)ethyl)pyrrolidine-2-carboxamide fumarate],,6/22/2017,treatment of rett syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Biohaven Pharmaceutical Holding Company, Ltd.",215 Church Street,,New Haven,Connecticut,' 06511 ' ,United States,582217,rett syndrome,"""gard:0005696""",
7133,"[10-(4,5-dimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)decyl](triphenyl)phosphonium bromide",,11/4/2021,treatment of leber hereditary optic neuropathy,Designated,,Not FDA Approved for Orphan Indication,,,,,Mitotech S.A.,42 rue de la Vallee,,Luxembourg,Luxembourg,' 2661 ' ,Luxembourg,846221,hereditary optic neuropathy,"""gard:0019540""",
7134,[11C]Acetic Acid,,2/28/2019,diagnostic for the management of hepatoblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Advanced Imaging Projects, LLC",7947 Brookside Ct.,,Lake Worth,Florida,' 33467 ' ,United States,662018,hepatoblastoma,"""gard:0002657""",
7135,[131I]-N-(2-(diethylamino) ethyl-4-(4 flurobenzamido)-5-(iodo)-2-methoxybenzamide,,9/17/2008,"treatment of metastatic melanoma, stages iib, iic, iii and iv",Designated,,Not FDA Approved for Orphan Indication,,,,,"Molecular Insight Pharmaceuticals, Inc. (Progenics Subsidiary)",777 Old Saw Mill River Road,,Tarrytown,New York,' 10591 ' ,United States,268008,noma,"""gard:0004001""",
7136,"[4,4'-(((dodecylazanediyl)bis(ethane-2,1-diyl))bis(azanediyl))bis(7-chloroquinoline 1-oxide)]",,2/8/2024,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Theranostec Inc.,2700 Stockton Blvd.,,Sacramento,California,' 95817 ' ,United States,987323,,,
7137,"[4-(4-{1-[2-(2-{2-[2-(2-{2-[2-(4-guanidinomethyl-phenoxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-ethoxy}-ethoxy)-ethyl]-1H-[1,2,3]triazol-4-ylmethoxy}-3,5-diiodo-phenoxy)-3,5-diiodo-phenyl]-acetic acid",,10/17/2018,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"NanoPharmaceuticals, LLC",1 Discovery Place,,Rensselaer,New York,' 12144 ' ,United States,655018,neuroblastoma,"""gard:0007185""",
7138,"[4-[(2R)-3-(3,4-dihydro-1H-isoquinolin-2-yl)-2-hydroxy-propyl]-8-[(1-methyl-4-piperidyl)oxy]-2,3-dihydro-1,4-benzoxazepin-5-one]",,11/22/2022,treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,SK Life Science Inc.,461 From Road,5th floor,Paramus,New Jersey,' 07652 ' ,United States,911122,glioblastoma,"""gard:0002491""",
7139,"[5,10,15,20-tetrakis(1,3-diethylimidazolium-2-yl)porphyrinato] manganese(III)pentachloride",,11/4/2003,treatment of amyotrophic lateral sclerosis,Designated,,Not FDA Approved for Orphan Indication,,,,,"Aeolus Pharmaceuticals, Inc.",PO Box 14287; 79 T.W. Alexander Dr.,Suite 200,Research Triangle Park,North Carolina,' 27709 ' ,United States,176703,amyotrophic lateral sclerosis,"""gard:0005786""",
7140,"[5-Amino-1-(4-fluoro-phenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxy-propoxy)-phenyl]-methanone",,10/20/2014,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,Synovo GmbH,Paul-Ehrlich-Str. 15,,D-72076 Tubingen,,' ' ,Germany,449814,,,
7141,"[6-(4-Chlorophenyl)-spiro[3.5]non-6-en-7-yl]methyl}-piperazin-1-yl}-N-{{3-nitro-4-[((2S)-1,4-dioxan-2-ylmethyl)amino]phenyl}sulfonyl}-2-(1H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide",,8/28/2020,treatment of chronic lymphocytic leukemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,' 20850 ' ,United States,757920,,,
7142,"[6-(4-Chlorophenyl)-spiro[3.5]non-6-en-7-yl]methyl}-piperazin-1-yl}-N-{{3-nitro-4-[((2S)-1,4-dioxan-2-ylmethyl)amino]phenyl}sulfonyl}-2-(1H- pyrrolo[2,3-b]pyridin-5-yloxy)benzamide",,7/1/2020,treatment of waldenström macroglobulinemia,Designated,,Not FDA Approved for Orphan Indication,,,,,Ascentage Pharma Group Inc.,"700 King Farm Blvd., Suite 510",,Rockville,Maryland,' 20850 ' ,United States,745620,waldenström macroglobulinemia,"""gard:0007872""",
7143,"[6-Fluoro-1-(4-morpholin-4-ylmethyl-phenyl)-5,5-dioxo-4,5-dihydro-1H-5Lambda6-thiochromeno[4,3-c]pyrazol-3-yl]-morpholin-4-yl-methanone hemi-fumarate",,11/1/2022,treatment of uveal melanoma,Designated,,Not FDA Approved for Orphan Indication,,,,,iOnctura SA,"Avenue de Sécheron, 15",,Geneva,,' CH-1202 ' ,Switzerland,908222,uveal melanoma,"""gard:0008621""",
7144,[64Cu]Cu-[MeCOSar0-Tyr3]-octreotate,,5/6/2020,diagnostic for the clinical management of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Clarity Pharmaceuticals Ltd.,National Innovation Centre,4 Cornwallis Street,Eveleigh Sydney,NSW,' ' ,Australia,737720,neuroblastoma,"""gard:0007185""",
7145,[67Cu]Cu-[MeCOSar0-Tyr3]-octreotate,,4/14/2020,treatment of neuroblastoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Clarity Pharmaceuticals Ltd.,National Innovation Centre,4 Cornwallis Street,Eveleigh Sydney,NSW,' ' ,Australia,718619,neuroblastoma,"""gard:0007185""",
7146,[68Ga]FAPI-46,,12/5/2023,diagnostic for the management of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,SOFIE Co. dba SOFIE,21000 Atlantic Blvd.,,Dulles,Virginia,' 20166 ' ,United States,956223,,,
7147,[a-N-(2'succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[epsilon-N-(2'succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr,,5/14/2014,treatment of glioblastoma multiforme,Designated,,Not FDA Approved for Orphan Indication,,,,,"Angiochem, Inc.",201 President-Kennedy Avenue,,Montreal,,' ' ,Canada,432514,glioblastoma,"""gard:0002491""",
7148,[F18] florilglutamic acid,,7/13/2016,for the diagnosis of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Life Molecular Imaging Ltd.,"Iceni Centre, Warwick Technology Park",,Warwick,,' CV34 6DA ' ,United Kingdom,517516,hepatocellular carcinoma,"""gard:0016773""",
7149,[F18] florilglutamic acid,,7/13/2016,diagnostic for the management of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,Life Molecular Imaging Ltd.,"Iceni Centre, Warwick Technology Park",,Warwick,,' CV34 6DA ' ,United Kingdom,538716,hepatocellular carcinoma,"""gard:0016773""",
7150,[met5]-enkephalin,,1/24/2013,treatment of pancreatic cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Statera BioPharma, Inc.",2537 Research Boulevard,Suite 201,Ft. Collins,Colorado,' 80526 ' ,United States,388312,,,
7151,"[P-deoxy-P-(dimethylamino)](2',3'-dideoxy-2',3'-imino-2',3'-seco), 5'-[Hydroxymethyl] (5' ->3')(C-A-A-C-C-A-C-T-T-T-A-C-C-C-T-T-T-C-T-A-G-G-C) [3¿-[N2-acetyl-D-arginyl-D-alanyl-D-seryl-D-alanyl-D-arginyl-D-arginyl-D-alanyl-D-seryl-D-alanyl-D-arginyl-D-arginyl-D-alanyl-D-asparagyl-D-alanyl-D-arginyl-D-arginyl-D-alanyl-D-asparagyl-D-alanyl-D-arginyl-D-arginyl-D-seryl-glycyl-glycyl-D-arginyl-glycyl-D-alanyl-D-seryl-glycyl-glycyl-D-alanyl-D-seryl-glycyl],Deca-acetate",,5/22/2024,treatment of opa1-associated vision loss.,Designated,,Not FDA Approved for Orphan Indication,,,,,"PYC Therapeutics, LLC","112 S French Street, Suite 105",,Wilmington,Delaware,' 19801 ' ,United States,1004124,,,
7152,"[Phe^2,Ile^3,Dab(PhAc-D-Tyr(Me)-Phe-Gln-Asn-Ala-Pro-Arg-iGln-Lys(Ac)-Epsilon-Lys)^8]vasopressin",,12/14/2023,treatment of ascites due to all etiologies except cancer,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ocelot Bio, Inc.",12670 High Bluff Drive,,San Diego,California,' 92130 ' ,United States,942823,,,
7153,"[Phe^2,Ile^3,Dab(PhAc-D-Tyr(Me)-Phe-Gln-Asn-Ala-Pro-Arg-iGln-Lys(Ac)-Epsilon-Lys)^8]vasopressin",,7/26/2022,treatment of hepatorenal syndrome,Designated,,Not FDA Approved for Orphan Indication,,,,,"Ocelot Bio, Inc",12670 High Bluff Drive,,San Diego,California,' 92130 ' ,United States,780020,,,
7154,[Î±â¿¿N-(2â¿¿succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[Îµâ¿¿N-(2â¿¿succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[Îµâ¿¿N-(2â¿¿succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr,,4/15/2015,treatment of breast cancer patients with brain metastases,Designated,,Not FDA Approved for Orphan Indication,,,,,"Angiochem, Inc.",201 President Kennedy,,Montreal,,' ' ,Canada,446614,,,
7155,"{(3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-[ (2S)-3 -methyl-1-(propan-2- ylsulfonyl)butan-2-yl]-2-oxopiperidin-3-yl}acetic acid",,5/13/2020,treatment of myelofibrosis.,Designated,,Not FDA Approved for Orphan Indication,,,,,"Kartos Therapeutics, Inc.",275 Shoreline Drive,,Redwood City,California,' 94065 ' ,United States,737220,,,
7156,"{2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl](3H-benzo[f]azepin-4-yl)}-N,N-dipropycarboxamide",,4/10/2014,treatment of ovarian cancer,Designated/Designation Withdrawn or Revoked,6/2/2017,Not FDA Approved for Orphan Indication,,,,,Celgene Corporation,86 Morris Avenue,,Summit,New Jersey,' 07901 ' ,United States,425014,ovarian cancer,"""gard:0007295""",
7157,{PEG2}-Val1-Leu2-Thr3-Thr4-Gly5-Leu6-Pro7-Ala8-Leu9-Ile10Ser11Trp12-Ile13- Lys14Arg15-Lys16-Arg17-Gln18-Gln19-Gly20-Gly21-Gly22-Gly23-Ser24-dLys25-dLeu26-,,10/23/2023,treatment of hepatocellular carcinoma,Designated,,Not FDA Approved for Orphan Indication,,,,,"Twinpig Biolab, Inc.","Rm 607, (old) College of Natural Sciences, 23 Kyungheedae- ro, Dongdaemun-gu",,Seoul,,' ' ,South Korea,967223,hepatocellular carcinoma,"""gard:0016773""",
7158,Note: Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.,,,,,,,,,,,,,,,,,,,,,
7159,Note: Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.,,,,,,,,,,,,,,,,,,,,,
